{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/anthonyrajecki-doyle/Documents/GitHub/de-case/.venv/lib/python3.9/site-packages/urllib3/__init__.py:35: NotOpenSSLWarning: urllib3 v2 only supports OpenSSL 1.1.1+, currently the 'ssl' module is compiled with 'LibreSSL 2.8.3'. See: https://github.com/urllib3/urllib3/issues/3020\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "\"\"\"Basic utilities module\"\"\"\n",
    "import requests\n",
    "import csv\n",
    "import re\n",
    "from io import StringIO\n",
    "import pandas as pd\n",
    "\n",
    "\n",
    "def request_ct(url):\n",
    "    \"\"\"Performs a get request that provides a (somewhat) useful error message.\"\"\"\n",
    "    try:\n",
    "        response = requests.get(url)\n",
    "        response.raise_for_status()\n",
    "    except requests.HTTPError as ex:\n",
    "        raise ex\n",
    "    except ImportError:\n",
    "        raise ImportError(\n",
    "            \"Couldn't retrieve the data, check your search expression or try again later.\"\n",
    "        )\n",
    "    else:\n",
    "        return response\n",
    "\n",
    "def json_handler(url):\n",
    "    \"\"\"Returns request in JSON (dict) format\"\"\"\n",
    "    return request_ct(url).json()\n",
    "\n",
    "def csv_handler(url):\n",
    "    \"\"\"Returns request in CSV (list of records) format\"\"\"\n",
    "\n",
    "    response = request_ct(url)\n",
    "    decoded_content = response.content.decode(\"utf-8\")\n",
    "\n",
    "    cr = csv.reader(decoded_content.splitlines(), delimiter=\",\")\n",
    "    records = list(cr)\n",
    "\n",
    "    return records\n",
    "\n",
    "filepath = 'src/pytrialsV2/study_fields.csv'\n",
    "\n",
    "def study_fields(file_path):\n",
    "    \"\"\"List of all study fields you can use in your query.\"\"\"\n",
    "\n",
    "    csv_fields = []\n",
    "    json_fields = []\n",
    "    with open(file_path, \"r\") as f:\n",
    "        reader = csv.DictReader(f)\n",
    "        for row in reader:\n",
    "            csv_fields.append(row[\"Column Name\"])\n",
    "            json_fields.append(row[\"Included Data Fields\"].split(\"|\"))\n",
    "\n",
    "    return {\n",
    "        \"csv\": csv_fields,\n",
    "        \"json\": [item for sublist in json_fields for item in sublist],\n",
    "    }\n",
    "\n",
    "study_fields(\"src/pytrialsV2/study_fields.csv\")\n",
    "\n",
    "def get_full_studies(search_expr, max_studies=50, fmt=\"json\"):\n",
    "    if fmt == \"json\":\n",
    "        format = \"format=json\"\n",
    "        handler = json_handler\n",
    "    elif fmt == \"csv\":\n",
    "        format = \"format=csv\"\n",
    "        handler = csv_handler\n",
    "    else:\n",
    "        raise ValueError(\"Format argument has to be 'json\")\n",
    "\n",
    "    if max_studies < 1:\n",
    "        raise ValueError(\"The number of studies can only be greater than 0\")\n",
    "\n",
    "    all_studies = []\n",
    "    pageToken = None\n",
    "    while len(all_studies) < max_studies:\n",
    "        req = f\"studies?{format}&markupFormat=legacy&query.term={search_expr}&pageSize={max_studies}\"\n",
    "        if pageToken:\n",
    "            req += f\"&pageToken={pageToken}\"\n",
    "        if fmt == \"json\":\n",
    "            response = json_handler(f\"https://clinicaltrials.gov/api/v2/{req}\")\n",
    "            full_studies = response['studies']\n",
    "            if 'nextPageToken' in response:\n",
    "                pageToken = response['nextPageToken']\n",
    "        else:  # fmt == \"csv\"\n",
    "            response = requests.get(f\"https://clinicaltrials.gov/api/v2/{req}\")\n",
    "            csv_reader = csv.reader(StringIO(response.text))\n",
    "            full_studies = list(csv_reader)\n",
    "            pageToken = response.headers.get('x-next-page-token')\n",
    "        all_studies.extend(full_studies)\n",
    "        if not pageToken:\n",
    "            break\n",
    "    return all_studies[:max_studies]\n",
    "\n",
    "def get_study_fields(search_expr, fields, max_studies=50, fmt=\"csv\"):\n",
    "    if fmt == \"json\":\n",
    "        format = \"format=json\"\n",
    "        handler = json_handler\n",
    "    elif fmt == \"csv\":\n",
    "        format = \"format=csv\"\n",
    "        handler = csv_handler\n",
    "    else:\n",
    "        raise ValueError(\"Format argument has to be either 'csv' or 'json\")\n",
    "\n",
    "    if not set(fields).issubset(study_fields(\"src/pytrialsV2/study_fields.csv\")[fmt]):\n",
    "        raise ValueError(\n",
    "            \"One of the fields is not valid!\"\n",
    "            \"Check the study_fields attribute for a list of valid ones.\"\n",
    "            \"They are different depending on the return format, json or csv.\"\n",
    "        )\n",
    "\n",
    "    all_studies = []\n",
    "    pageToken = None\n",
    "    while len(all_studies) < max_studies:\n",
    "        concat_fields = \"|\".join(fields)\n",
    "        req = f\"&query.term={search_expr}&markupFormat=legacy&fields={concat_fields}&pageSize={max_studies}\"\n",
    "        if pageToken:\n",
    "            req += f\"&pageToken={pageToken}\"\n",
    "        url = f\"https://clinicaltrials.gov/api/v2/studies?{format}{req}\"\n",
    "        response = handler(url)\n",
    "        if fmt == \"json\":\n",
    "            response = json_handler(f\"https://clinicaltrials.gov/api/v2/{format}{req}\")\n",
    "            full_studies = response['studies']\n",
    "            if 'nextPageToken' in response:\n",
    "                pageToken = response['nextPageToken']\n",
    "        else:  # fmt == \"csv\"\n",
    "            response = requests.get(f\"https://clinicaltrials.gov/api/v2/{format}{req}\")\n",
    "            csv_reader = csv.reader(StringIO(response.text))\n",
    "            full_studies = list(csv_reader)\n",
    "            pageToken = response.headers.get('x-next-page-token')\n",
    "        all_studies.extend(full_studies)\n",
    "        if not pageToken:\n",
    "            break\n",
    "\n",
    "    return all_studies[:max_studies]\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Pull all data for all trials in last 5 years"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index(['protocolSection', 'derivedSection', 'hasResults'], dtype='object')\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection</th>\n",
       "      <th>derivedSection</th>\n",
       "      <th>hasResults</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>{'identificationModule': {'nctId': 'NCT0643567...</td>\n",
       "      <td>{'miscInfoModule': {'versionHolder': '2024-05-...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>{'identificationModule': {'nctId': 'NCT0610027...</td>\n",
       "      <td>{'miscInfoModule': {'versionHolder': '2024-05-...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>{'identificationModule': {'nctId': 'NCT0621808...</td>\n",
       "      <td>{'miscInfoModule': {'versionHolder': '2024-05-...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>{'identificationModule': {'nctId': 'NCT0643107...</td>\n",
       "      <td>{'miscInfoModule': {'versionHolder': '2024-05-...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>{'identificationModule': {'nctId': 'NCT0627776...</td>\n",
       "      <td>{'miscInfoModule': {'versionHolder': '2024-05-...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     protocolSection  \\\n",
       "0  {'identificationModule': {'nctId': 'NCT0643567...   \n",
       "1  {'identificationModule': {'nctId': 'NCT0610027...   \n",
       "2  {'identificationModule': {'nctId': 'NCT0621808...   \n",
       "3  {'identificationModule': {'nctId': 'NCT0643107...   \n",
       "4  {'identificationModule': {'nctId': 'NCT0627776...   \n",
       "\n",
       "                                      derivedSection  hasResults  \n",
       "0  {'miscInfoModule': {'versionHolder': '2024-05-...       False  \n",
       "1  {'miscInfoModule': {'versionHolder': '2024-05-...       False  \n",
       "2  {'miscInfoModule': {'versionHolder': '2024-05-...       False  \n",
       "3  {'miscInfoModule': {'versionHolder': '2024-05-...       False  \n",
       "4  {'miscInfoModule': {'versionHolder': '2024-05-...       False  "
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from datetime import datetime, timedelta\n",
    "\n",
    "# Calculate the start date (one year ago)\n",
    "start_date = (datetime.now() - timedelta(days=int(1))).strftime('%Y-%m-%d')\n",
    "\n",
    "today = datetime.now().strftime('%Y-%m-%d')\n",
    "\n",
    "last_five_years = get_full_studies(search_expr=f\"AREA[StartDate]RANGE[{start_date}, {today}]\", max_studies=500000, fmt=\"json\")\n",
    "\n",
    "df = pd.DataFrame.from_records(last_five_years[1:], columns=last_five_years[0])\n",
    "\n",
    "print(df.columns)\n",
    "\n",
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'protocolSection': {'identificationModule': {'nctId': 'NCT06432127',\n",
       "    'orgStudyIdInfo': {'id': '256/2024'},\n",
       "    'organization': {'fullName': 'Mahidol University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis',\n",
       "    'officialTitle': 'Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis in Patients With Failed Oral Prophylaxis Medication : A Randomized Controlled Study in Thailand'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-15',\n",
       "    'studyFirstSubmitQcDate': '2024-05-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Mahidol University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this randomized controlled study in Thailand. is to find if there is a role\\r\\nof local anesthetic greater occipital nerve block at Cervical spine level 2 under\\r\\nultrasound guide in prophylaxis of episodic migraine and chronic migraine in patients\\r\\nwith failed oral prophylaxis medication.\\r\\n\\r\\nAccording to guidelines of the International Headache Society for controlled trials of\\r\\npreventive treatment of migraine attacks in episodic and chronic migraine,the primary and\\r\\nsecondary outcome were monitoring followed by these research guideline\\r\\n\\r\\nAfter informed consent, volunteer will be stratified random into 2 groups of injection\\r\\nagent at unilateral greater occipital nerve block on headache site under US guide by pain\\r\\nphysician\\r\\n\\r\\n  -  Normal saline\\r\\n\\r\\n  -  0.5% bupivacaine the injection was done 2 times between Week 0 and week 4 as to wean\\r\\n     off placebo effect the volunteer will be monitor by pain diary at 1 month before\\r\\n     intervention at week 0,4,8,12 and follow up at week 24 for Migraine Disability\\r\\n     Assessment Test (MIDAS) ,Thai Hospital-Anxiety-depression index(Thai-HADS)',\n",
       "    'detailedDescription': '  -  Neurologist screening candidate volunteers for this study, following the inclusion\\r\\n     and exclusion criteria\\r\\n\\r\\n  -  Candidate volunteers attended pain clinic for he protocol detail about this research\\r\\n     and informed consent\\r\\n\\r\\n  -  After signing consent, Volunteers would be stratified randomization into 2 groups\\r\\n     between Normal saline and bupivacaine\\r\\n\\r\\n  -  Volunteers would be done base line headache diary for 1 month before performing the\\r\\n     procedure (Week -4 to week0)\\r\\n\\r\\n  -  At Week 0, Volunteers would be applied local anesthetic cream at skin injection site\\r\\n     before done the procedure\\r\\n\\r\\n  -  According to stratified randomization, Pain interventionist and also volunteers\\r\\n     would be blinded to the group\\r\\n\\r\\n  -  First Unilateral greater occipital nerve block at Cervical spine level 2 (C2) was\\r\\n     done under ultrasound guide (Week0)\\r\\n\\r\\n  -  Telemedicine Follow up at week 2\\r\\n\\r\\n  -  Second Unilateral greater occipital nerve block at C2 level was done under\\r\\n     ultrasound guide (Week4)\\r\\n\\r\\n  -  Volunteers would be follow up via telemedicine and done headache diary until 3\\r\\n     months after 1st injection\\r\\n\\r\\n  -  Volunteers would be follow up according to outcome monitoring protocol in Week\\r\\n     0,4,8,12,24'},\n",
       "   'conditionsModule': {'conditions': ['Migraine Disorders']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 108, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Use Normal saline 3 ml as the injection agent',\n",
       "      'interventionNames': ['Drug: Placebo']},\n",
       "     {'label': 'Bupivacaine',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Use 0.5% Bupivacaine 3ml as the injection agent',\n",
       "      'interventionNames': ['Drug: Bupivacaine']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle\\r\\nin plane technique during ultrasound using normal saline 3 mL',\n",
       "      'armGroupLabels': ['Placebo']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Bupivacaine',\n",
       "      'description': 'Unilateral Greater occipital nerve block at C2 level under ultrasound guide with needle\\r\\nin plane technique during ultrasound using 0.5% Bupivacaine 3 mL',\n",
       "      'armGroupLabels': ['Bupivacaine']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'change of Frequency headache day /month',\n",
       "      'description': 'by using headache diary',\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'},\n",
       "     {'measure': 'change of migraine attack day /month from headache diary',\n",
       "      'description': 'by using headache diary',\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'}],\n",
       "    'secondaryOutcomes': [{'measure': 'change in severity of headache day per month (decrease of moderate-severe pain)',\n",
       "      'description': 'decrease of moderate-severe pain day per month compare to baseline by using headache\\r\\ndiary',\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'},\n",
       "     {'measure': 'Thai-Migraine Disability Assessment',\n",
       "      'description': 'Thai-Migraine Disability Assessment (MIDAS) ,Score 0 to 21+ ( 0-5 marks = little or no\\r\\ndisability and more than 21+ =severe disability',\n",
       "      'timeFrame': 'at Week 12,24 compare to baseline'},\n",
       "     {'measure': 'Thai-Hospital Anxiety and Depression Scale',\n",
       "      'description': 'Thai-Hospital Anxiety and Depression Scale (Thai HADS) , divided into anxiety and\\r\\ndepression part ,if either of the score in each depression or anxiety more than 11 mean\\r\\nabnormal',\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'},\n",
       "     {'measure': 'Healthcare outcomes/quality of life',\n",
       "      'description': 'by EuroQoL- (EQ-5D) measured health-related quality of life with 5 dimension (mobility,\\r\\nhealth care, usual activity, Pain, Anxiety/depression and in each of them had 5 grading\\r\\n1-5 by 1 means no problem and 5 means extreme problem) after having score in each\\r\\ndimension, calculated utility score would be done',\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'},\n",
       "     {'measure': \"Patient's reported outcome measurement (PGI-C)\",\n",
       "      'description': \"Patient's reported outcome measurement (PGI-C), score grading 1-7 by 1 very much worse to\\r\\nvery much improved , 7 means very much worse\",\n",
       "      'timeFrame': 'at Week 0,4,8,12,24 compared to base line at 1 months before injection procedure'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Age 18 -65 years old\\r\\n\\r\\n  2. Diagnosis as episodic migraine or chronic migraine and had indication to use\\r\\n     migraine prophylaxis\\r\\n\\r\\n  3. Volunteer prefer to use research procedure as first choice of migraine prophylaxis\\r\\n\\r\\n  4. Volunteer already had migraine prophylaxis treatment but still has the one of these\\r\\n     following problem 4.1 Frequency of migraine attack more than 4 times/month 4.2\\r\\n     Severe migraine headache & disturb daily life in spite of using migraine prophylaxis\\r\\n     4.3 Having migraine medication side effect, either from prophylaxis or acute attack\\r\\n     medication and cannot titration medication dosage 4.4 migraine attack not improved\\r\\n     as using many migraine prophylaxis medications 4.5 Having contra-indication to use\\r\\n     prophylaxis migraine medication or standard prophylaxis procedure such as botulinum\\r\\n     toxin 4.6 Cannot take prophylaxis medication daily (low compliance) 4.7 Had\\r\\n     financial problems in using standard prophylaxis migraine medication or procedure\\r\\n     4.8 Medication overuse headache\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Had these type of headache in combination with migraine\\r\\n\\r\\n       -  cervicogenic headache\\r\\n\\r\\n       -  occipital neuralgia\\r\\n\\r\\n       -  secondary headache\\r\\n\\r\\n  2. Had contraindication on greater occipital nerve block injection at cervical spine\\r\\n     level 2 under ultrasound-guided such as skin infection in needle site\\r\\n\\r\\n  3. Allergy to local anesthetic\\r\\n\\r\\n  4. Uncontrolled psychiatric disorder in 3 months before attending research\\r\\n\\r\\n  5. Cannot understand or reading, writing Thai language',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'RAVIWON ATISOOK, M.D.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+66819140784',\n",
       "      'email': 'raviwon.ati@gmail.com'}],\n",
       "    'overallOfficials': [{'name': 'RAVIWON ATISOOK, M.D.',\n",
       "      'affiliation': 'Siriraj Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Raviwon Atisook',\n",
       "      'city': 'Bangkok',\n",
       "      'zip': '10700',\n",
       "      'country': 'Thailand',\n",
       "      'contacts': [{'name': 'Raviwon Atisook, M.D',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+66819140784',\n",
       "        'email': 'raviwon.ati@gmail.com'}],\n",
       "      'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "    'description': 'will be consider again after data collection'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008881',\n",
       "      'term': 'Migraine Disorders'},\n",
       "     {'id': 'D000006261', 'term': 'Headache'}],\n",
       "    'ancestors': [{'id': 'D000051270', 'term': 'Headache Disorders, Primary'},\n",
       "     {'id': 'D000020773', 'term': 'Headache Disorders'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M9351',\n",
       "      'name': 'Headache',\n",
       "      'asFound': 'Headache',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11852',\n",
       "      'name': 'Migraine Disorders',\n",
       "      'asFound': 'Migraine',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22529', 'name': 'Headache Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M26657',\n",
       "      'name': 'Headache Disorders, Primary',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000002045',\n",
       "      'term': 'Bupivacaine'}],\n",
       "    'ancestors': [{'id': 'D000000779', 'term': 'Anesthetics, Local'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'}],\n",
       "    'browseLeaves': [{'id': 'M5315',\n",
       "      'name': 'Bupivacaine',\n",
       "      'asFound': 'Following',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4109', 'name': 'Anesthetics, Local', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06435676',\n",
       "    'orgStudyIdInfo': {'id': 'HRS9531-T-101'},\n",
       "    'organization': {'fullName': 'Fujian Shengdi Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects',\n",
       "    'officialTitle': 'A Phase I Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of HRS9531 Tablets in Healthy Subjects'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-24',\n",
       "    'studyFirstSubmitQcDate': '2024-05-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-30', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-26',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Fujian Shengdi Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and\\r\\npharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.'},\n",
       "   'conditionsModule': {'conditions': ['Overweight or Obesity; Type 2 Diabetes']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'randomized, double-blind, placebo-controlled',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 92, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'SAD Stage: HRS9531',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Administered po once',\n",
       "      'interventionNames': ['Drug: HRS9531']},\n",
       "     {'label': 'SAD Stage: placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Administered po once',\n",
       "      'interventionNames': ['Drug: Placebo']},\n",
       "     {'label': 'MAD Stage: HRS9531',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Administered po for multiple dose',\n",
       "      'interventionNames': ['Drug: HRS9531']},\n",
       "     {'label': 'MAD Stage: placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Administered po for multiple dose',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HRS9531',\n",
       "      'description': 'Single dose escalation of HRS9531 tablets in healthy subjects',\n",
       "      'armGroupLabels': ['SAD Stage: HRS9531']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Single dose of placebo in healthy adults',\n",
       "      'armGroupLabels': ['SAD Stage: placebo']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'HRS9531',\n",
       "      'description': 'Multiple dose escalation of HRS9531 tablets in healthy subjects',\n",
       "      'armGroupLabels': ['MAD Stage: HRS9531']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Multiple dose of placebo in healthy adults',\n",
       "      'armGroupLabels': ['MAD Stage: placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'SAD Stage: Number of Adverse Events',\n",
       "      'timeFrame': '36 days'},\n",
       "     {'measure': 'MAD Stage: Number of Adverse Events',\n",
       "      'timeFrame': '63 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Plasma Concentration-Time to Peak (Tmax) of HRS9531',\n",
       "      'description': 'Tmax of a single dose of HRS9531 tablets',\n",
       "      'timeFrame': '36 days'},\n",
       "     {'measure': 'Area Under the Plasma Concentration-Time Curve (AUC) of HRS9531',\n",
       "      'description': 'AUC of a single dose of HRS9531 tablets',\n",
       "      'timeFrame': '36 days'},\n",
       "     {'measure': 'Immunogenicity qualitative',\n",
       "      'description': 'anti-HRS9531 antibody',\n",
       "      'timeFrame': '36 days'},\n",
       "     {'measure': 'Plasma Concentration-Time to Peak (Tmax) of HRS9531',\n",
       "      'description': 'Tmax of multiple dose of HRS9531 tablets',\n",
       "      'timeFrame': '63 days'},\n",
       "     {'measure': 'Area Under the Plasma Concentration-Time Curve (AUC) of HRS9531',\n",
       "      'description': 'AUC of multiple dose of HRS9531 tablets',\n",
       "      'timeFrame': '63 days'},\n",
       "     {'measure': 'Glucose',\n",
       "      'description': 'fasting plasma glucose',\n",
       "      'timeFrame': '35 days'},\n",
       "     {'measure': 'Immunogenicity qualitative',\n",
       "      'description': 'anti-HRS9531 antibody',\n",
       "      'timeFrame': '63 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Ability to understand the trial procedures, be able and willing to provide a written\\r\\n     informed consent.\\r\\n\\r\\n  2. 18-55 years of age at the time of signing informed consent.\\r\\n\\r\\n  3. SAD stage: Body weight ≥50 kg,19.0 ≤BMI≤ 35.0 kg/m2 at screening visit. MAD stage:\\r\\n     24.0 ≤BMI≤ 35.0 kg/m2 at screening visit.\\r\\n\\r\\n  4. Subjects with good general health, no clinically significant abnormalities.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Known or suspected hypersensitivity to trial product(s) or related products.\\r\\n\\r\\n  2. With previous major organ diseases, including but not limited to neuropsychiatric,\\r\\n     cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other\\r\\n     diseases, are judged by researchers to be unsuitable for the study.\\r\\n\\r\\n  3. Abnormal and clinically significant blood pressure at screening.\\r\\n\\r\\n  4. Blood donation within 1 month prior to screening, or blood donation ≥400 mL or blood\\r\\n     loss ≥400 mL within 3 months prior to screening.\\r\\n\\r\\n  5. Participation in other clinical trials.\\r\\n\\r\\n  6. Presence of any clinically significant results in examination at screening visit.\\r\\n\\r\\n  7. Hepatitis B surface antigen (HBsAg), HIV antibody detection, treponema pallidum\\r\\n     specific antibody detection, hepatitis C virus antibody (HCVAb) positive.\\r\\n\\r\\n  8. Presence of - clinically significant ECG results.\\r\\n\\r\\n  9. Known or suspected history of drug abuse or drug abuse, or urine drug screening test\\r\\n     during the screening periodThose who are positive.\\r\\n\\r\\n 10. Addiction to tobacco and alcohol.\\r\\n\\r\\n 11. In the opinion of the investigator, there are any other conditions that interfere\\r\\n     with the evaluation of the results of the trial or are not suitable for\\r\\n     participation of this study.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '55 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Hongcheng Hu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0518-82342973',\n",
       "      'email': 'hongcheng.hu@hengrui.com'},\n",
       "     {'name': 'Jianting Han',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '15620796974',\n",
       "      'email': 'jianting.han.jh27@hengrui.com'}],\n",
       "    'locations': [{'facility': 'The Second Hospital Of Anhui medical University',\n",
       "      'city': 'Hefei',\n",
       "      'state': 'Anhui',\n",
       "      'zip': '230601',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Wei Hu, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86+13856086475',\n",
       "        'email': 'hwgcp@ayefy.com'},\n",
       "       {'name': 'Yijun Du, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86+13866700016',\n",
       "        'email': '2460679232@qq.com'}],\n",
       "      'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000050177',\n",
       "      'term': 'Overweight'}],\n",
       "    'ancestors': [{'id': 'D000044343', 'term': 'Overnutrition'},\n",
       "     {'id': 'D000009748', 'term': 'Nutrition Disorders'},\n",
       "     {'id': 'D000001835', 'term': 'Body Weight'}],\n",
       "    'browseLeaves': [{'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'},\n",
       "     {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'},\n",
       "     {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'},\n",
       "     {'id': 'M26186',\n",
       "      'name': 'Overweight',\n",
       "      'asFound': 'Overweight',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'},\n",
       "     {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06100276',\n",
       "    'orgStudyIdInfo': {'id': 'AMT-162-001'},\n",
       "    'organization': {'fullName': 'UniQure Biopharma B.V.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)',\n",
       "    'officialTitle': 'A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2031-03-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-20',\n",
       "    'studyFirstSubmitQcDate': '2023-10-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'UniQure Biopharma B.V.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate\\r\\nthe safety, tolerability, and exploratory efficacy of intrathecally administered gene\\r\\ntherapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.',\n",
       "    'detailedDescription': 'AMT-162 is an investigational gene therapy that encodes an artificial microribonucleic\\r\\nacid (microRNA or miRNA) targeting the SOD1 gene. This clinical study will test the\\r\\nsafety of AMT-162 and explore the hypothesis that it will silence expression of mutant\\r\\ncytosolic SOD1 and thereby ameliorate the course of ALS caused by this mutant gene.'},\n",
       "   'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'],\n",
       "    'keywords': ['Gene Therapy',\n",
       "     'AAV (adeno-associated virus)',\n",
       "     'ALS',\n",
       "     'SOD1']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': '3 single Ascending Dose Levels',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The study will be open-label with an initial plan to explore 3 dose levels of AMT-162 in\\r\\napproximately 6 to 12 Participants in total. Each Participant will receive a single dose\\r\\nof AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5\\r\\nyears after AMT-162 administration..',\n",
       "      'interventionNames': ['Drug: AMT-162']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'AMT-162',\n",
       "      'description': 'AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted,\\r\\nself-complementary Recombinant adeno-associated virus (rAAV) vector based on\\r\\nadeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic\\r\\nacid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.',\n",
       "      'armGroupLabels': ['3 single Ascending Dose Levels']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate the safety and tolerability of ascending doses of intrathecally administered AMT-162 in Participants with SOD1-ALS',\n",
       "      'description': 'Occurrence of TEAEs upon administration of ascending doses of AMT-162',\n",
       "      'timeFrame': 'up to 5 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Characterization of Immune Response to AMT-162 and Shedding of intrathecally administered AMT-162.',\n",
       "      'description': 'Any positive results in shedding samples will be summarized at each timepoint.\\r\\nImmunogenicity parameters will be summarized for each visit.',\n",
       "      'timeFrame': 'up to 5 years'},\n",
       "     {'measure': 'Characterization of the Effect of intrathecally administered AMT-162',\n",
       "      'description': 'Change from Baseline in Slow Vital Capacity (SVC) percent of predict value, Hand-held\\r\\ndynamometry (HHD) scores, and Neurofilament light chain (NfL) protein levels in serum.\\r\\n\\r\\nImmunogenicity parameters will be summarized for each visit.',\n",
       "      'timeFrame': 'up to 5 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Confirmed clinical and genetic diagnosis of SOD1-mediated ALS (SOD1-ALS)\\r\\n     experiencing signs and/or symptoms of lower motor neuron dysfunction (weakness,\\r\\n     atrophy, cramps, fasciculations), with or without upper motor neuron symptoms\\r\\n     (weakness, bring reflexes, spasticity).\\r\\n\\r\\n  2. ALSFRS-R score ≥ 25 at Screening.\\r\\n\\r\\n  3. Slow vital capacity (SVC) ≥65% of predicted normal value.\\r\\n\\r\\n  4. Capable of providing informed consent and complying with trial procedures,\\r\\n     including: medically able to undergo lumbar puncture and has a responsible caregiver\\r\\n     able to attend all clinic visit with the Participant.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. SOD1 pathogenic or likely pathogenic variants in amino acid regions 43-47.\\r\\n\\r\\n  2. Pathogenic repeat expansion in the C9orf72 gene\\r\\n\\r\\n  3. Any of the following prior or concomitant treatments:\\r\\n\\r\\n       1. Any prior SOD1 suppression therapy with viral microRNA mediators\\r\\n\\r\\n       2. Prior SOD suppression therapy with antisense oligonucleotide (ASO) mediators\\r\\n          such as tofersen (QALSODY™). Exception: Patient who previously received\\r\\n          tofersen may be enrolled if the last dose of tofersen was received at least 20\\r\\n          weeks prior to the first Screening assessment and if there were no previous\\r\\n          tofersen-related serious adverse events or ongoing tofersen-related adverse\\r\\n          events\\r\\n\\r\\n       3. Other ALS medications riluzole (RILUTEK®, TIGLUTIK®), edaravone (RADICAVA®),\\r\\n          and sodium phenylbutyrate and taururosdiol combination (RELYVRIO) or\\r\\n          bioequivalents are allowed if dose is stable for 30 days prior to\\r\\n          immunosuppression.\\r\\n\\r\\n       4. Any prior administration of an AAV gene therapy.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Director, Clinical Operations',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+1 339 970 7000',\n",
       "      'email': 'amt162_clinical_trials@uniqure.com'}],\n",
       "    'overallOfficials': [{'name': 'Executive Director, Clinical Development',\n",
       "      'affiliation': 'UniQure Biopharma B.V.',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'University of California Irvine',\n",
       "      'city': 'Irvine',\n",
       "      'state': 'California',\n",
       "      'zip': '92697',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 33.66946, 'lon': -117.82311}},\n",
       "     {'facility': 'California Pacific Medical Center',\n",
       "      'city': 'San Francisco',\n",
       "      'state': 'California',\n",
       "      'zip': '94109',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Daniela Sanchez',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '415-600-1764',\n",
       "        'email': 'daniela.sanchez@sutterhealth.org'},\n",
       "       {'name': 'Mackenzie Kenneally',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '415-600-0484',\n",
       "        'email': 'mackenzie.kenneally@sutterhealth.org'},\n",
       "       {'name': 'Jonathan S Katz, MD', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Liberty Jenkins, MD', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 37.77493, 'lon': -122.41942}},\n",
       "     {'facility': 'Northwestern University Feinberg School of Medicine',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60611',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "     {'facility': 'Massachusetts General Hospital, Sean M. Healey and AMG Center for ALS Research',\n",
       "      'city': 'Boston',\n",
       "      'state': 'Massachusetts',\n",
       "      'zip': '02114',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "     {'facility': 'Columbia University Irving Medical Center',\n",
       "      'city': 'New York',\n",
       "      'state': 'New York',\n",
       "      'zip': '10032',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.71427, 'lon': -74.00597}},\n",
       "     {'facility': 'University of Pensylvania School of Medicine',\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19104',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "      'term': 'Motor Neuron Disease'},\n",
       "     {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "     {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "     {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M15415',\n",
       "      'name': 'Sclerosis',\n",
       "      'asFound': 'Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18879',\n",
       "      'name': 'Motor Neuron Disease',\n",
       "      'asFound': 'Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4024',\n",
       "      'name': 'Amyotrophic Lateral Sclerosis',\n",
       "      'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T349',\n",
       "      'name': 'Amyotrophic Lateral Sclerosis',\n",
       "      'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4699',\n",
       "      'name': 'Primary Lateral Sclerosis',\n",
       "      'asFound': 'Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06218082',\n",
       "    'orgStudyIdInfo': {'id': '2022DER127'},\n",
       "    'organization': {'fullName': 'The Royal Wolverhampton Hospitals NHS Trust',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'briefTitle': 'Vitiligo Registry for Adults and Children in the UK',\n",
       "    'officialTitle': 'Vitiligo Registry for Adults and Children in the UK (VIRTUAL-UK)',\n",
       "    'acronym': 'VIRTUAL-UK'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-03', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-03', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-11-15',\n",
       "    'studyFirstSubmitQcDate': '2024-01-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-09', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'The Royal Wolverhampton Hospitals NHS Trust',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'collaborators': [{'name': 'Incyte Biosciences International Sàrl',\n",
       "      'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Vitiligo is the most common depigmentation disorder affecting around 1% of the population\\r\\nworldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around\\r\\n80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in\\r\\nchildhood and tends to be a lifelong disease, requiring prolonged courses of\\r\\nphototherapy.\\r\\n\\r\\nCurrently no national or international registry for patients with vitiligo exists.\\r\\nIndividual dermatologists maintain a database of such patients, however no coordinated\\r\\nefforts have been made to combine these individual registries into a broader national\\r\\nregistry. Finally, recently published British Association of Dermatologists (BAD)\\r\\nguideline for the management of vitiligo, recommended the development of a national\\r\\nregistry for people with vitiligo undergoing systemic or light therapy to identify\\r\\noutcomes and safety.',\n",
       "    'detailedDescription': 'Vitiligo is the most common depigmentation disorder affecting around 1% of the population\\r\\nworldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around\\r\\n80% develop vitiligo before the age of 30 years old. Vitiligo often presents in childhood\\r\\nand tends to be a lifelong disease, requiring prolonged courses of phototherapy.\\r\\n\\r\\nVitiligo is an autoimmune skin disorder and is often associated with multiple other\\r\\nautoimmune disorders such as thyroid disorders, diabetes, IBS, pernicious anemia,\\r\\nalopecia areata amongst others. Current treatments include topical corticosteroids and\\r\\ncalcineurin inhibitors, phototherapy, combination of phototherapy with oral\\r\\ncorticosteroids, laser and surgical interventions. Other treatment modalities such as\\r\\nMethotrexate have also been trialed. Currently available treatments are being used off\\r\\nlicense with uncertain therapeutic success.\\r\\n\\r\\nPreviously, it has been shown that vitiligo has an inverse relationship with melanoma,\\r\\nwhich means that people with vitiligo are less likely to develop melanoma. A recent\\r\\nsystematic review and meta-analysis looking into the risk of skin cancer in people with\\r\\nvitiligo showed that compared with people without vitiligo, people with vitiligo had a\\r\\nsignificantly lower risk of nonmelanoma skin cancer. The same pattern occurred for\\r\\nmelanoma (but was not statistically significant). However, this review was limited by the\\r\\nsmall number of included studies and high heterogeneity due to methodological and\\r\\nclinical differences between the included studies. In addition, there is lack of data on\\r\\nthe skin cancer risk for vitiligo patients who receive prolonged phototherapy courses,\\r\\nespecially regarding high cumulative exposures in children with less deeply pigmented\\r\\nskin. This is especially important when NB-UVB is combined with topical tacrolimus\\r\\ntreatment, due to theoretical increased risk of skin cancer.\\r\\n\\r\\nIn addition, there is an urgent need for new, effective and licensed treatment for\\r\\nvitiligo. In the dawn on new therapeutic era of new emerging treatments such as topical\\r\\nand oral JAK inhibitors, evidence will be needed on the effectiveness, safety and cost\\r\\neffectiveness of such therapies compared to other treatments. In order to gather evidence\\r\\non clinical effectiveness of vitiligo treatments and to assist with updating of clinical\\r\\nguidance pathway, as well as to gather information on possible risk factors, adverse\\r\\nevents, maintenance regime and assist with conduction of post marketing studies,\\r\\nprospective multicentre registry is needed for vitiligo patients who are treated with\\r\\nphototherapy, combination treatments (with phototherapy), oral agents (such as oral\\r\\ncorticosteroids) including new emerging JAK inhibitors (once there are available in the\\r\\nUK).\\r\\n\\r\\nOral corticosteroids combined with phototherapy are recommended by the recently published\\r\\nBAD guidelines for cases of rapidly progressive vitiligo. Case reports were published on\\r\\ninitiation of methotrexate and oral JAK inhibitors for the treatment of vitiligo.\\r\\n\\r\\nIn addition, there is no firm data on disease progression and especially predictors of\\r\\nrapidly progressive vitiligo are largely unknown, which is a challenging scenario for the\\r\\npatient and their clinician.\\r\\n\\r\\nCurrently no national or international registry for patients with vitiligo exists.\\r\\nIndividual dermatologists maintain a database of such patients, however no coordinated\\r\\nefforts have been made to combine these individual registries into a broader national\\r\\nregistry. Finally, recently published British Association of Dermatologists (BAD)\\r\\nguideline for the management of vitiligo, recommended the development of a national\\r\\nregistry for people with vitiligo undergoing systemic or light therapy to identify\\r\\noutcomes and safety.2\\r\\n\\r\\nAs an initial, preliminary step for the development of the online UK registry for\\r\\nvitiligo patients, development of a pilot multi-centred registry in the UK is needed. In\\r\\naddition, such registry will be co-ordinated with a pilot multi-centred registry in\\r\\nFrance and the USA. Each registry will be developed separately (country-specific) and\\r\\nthere will be no data sharing between the registries, however there will be co-ordination\\r\\nbetween the CIs of the registries with regards to the outcomes collected.\\r\\n\\r\\nAnother challenge in vitiligo has been consistency in the use of core outcome domains and\\r\\nmeasures instruments to define treatment success or failure. The international Initiative\\r\\nfor Outcomes for vitiligo (INFO) has previously addressed this heterogeneity and defined\\r\\n3 outcome domains as being essential: repigmentation, side effects/harms and maintenance\\r\\nof gained repigmentation. Four items were further recommended for inclusion but were not\\r\\nconsidered to be essential: cosmetic acceptability of the results, quality of life,\\r\\ncessation of spreading of vitiligo and tolerability or burden of treatment.5 INFO has\\r\\nsubsequently published recommendations on how to measure repigmentation in target lesion.\\r\\nPercentage of repigmentation in quartiles (0-25%, 26-50%, 51-79%, 80-100%) should be\\r\\nmeasured as well as cosmetic acceptability of results should be assessed using the\\r\\nVitiligo Noticeability Scale.6 There are also several other established instruments exist\\r\\n(such as VASI, VIPs, VITs) to measure these domains and these are suitable for use in a\\r\\nregistry.\\r\\n\\r\\nA long-term safety data will be vital to provide pharmacovigilance, particularly\\r\\nregarding rare or delayed adverse effects of treatment. Hence a prospective multicentre\\r\\nregistry study is greatly needed to evaluate the real-world use of phototherapy\\r\\n(including combination treatments with phototherapy), topical JAK inhibitors, systemic\\r\\nimmuno-modulatory therapies in adults and children undergoing treatment for vitiligo to\\r\\nprovide effectiveness and safety data beyond the confines of short-term randomised\\r\\ncontrolled trials (RCTs). Such a registry will ultimately inform treatment guidelines,\\r\\nprovide pharmacogenetic and pharmacodynamic research data, and help to identify those\\r\\npatients likely to experience rapid disease progression, ultimately improving and\\r\\npersonalising patient care. With novel topical and oral immunomodulatory therapies having\\r\\njust entering vitiligo clinical practice, the timing is ideal to harness the high-quality\\r\\ndata collection offered by the UK NHS.'},\n",
       "   'conditionsModule': {'conditions': ['Dermatologic Disease', 'Vitiligo']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '1 Year',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Multi-centred registry will be developed, with an aim to establish short- and long-term safety (pharmacovigilance) and effectiveness of vitiligo therapies',\n",
       "      'description': 'VIRTUAL-UK is a small registry and in collaboration with the BAD, aims to utilize and\\r\\nmodify one of the existing platforms (software), in order to assist the end user (i.e.\\r\\nDermatologists) in accessing the platform and reducing the time needed for training and\\r\\ndata input.',\n",
       "      'timeFrame': '12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'To document the clinical and socio-demographic characteristics, co-morbidities including cancers, previous treatments of patients included in the cohort as assessed by the case report forms (CRFs).',\n",
       "      'description': 'To document the clinical and socio-demographic characteristics, co-morbidities including\\r\\ncancers, previous treatments of patients included in the cohort as assessed by the case\\r\\nreport forms (CRFs).',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To describe the clinical and socio-demographic characteristics, co-morbidities including cancers, previous treatments of patients included in the cohort',\n",
       "      'description': 'To describe the clinical and socio-demographic characteristics, co-morbidities including\\r\\ncancers, previous treatments of patients included in the cohort',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To assess short- and long-term safety (pharmacovigilance) of these therapies',\n",
       "      'description': 'To assess short- and long-term safety (pharmacovigilance) of these therapies',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To evaluate the efficacy and safety of currently used therapies for vitiligo (including combination therapies), providing a basis for better shared decision making and guidelines.',\n",
       "      'description': 'To evaluate the efficacy and safety of currently used therapies for vitiligo (including\\r\\ncombination therapies), providing a basis for better shared decision making and\\r\\nguidelines.',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': \"To evaluate the impact of these therapies on vitiligo patients' quality of life\",\n",
       "      'description': \"To evaluate the impact of these therapies on vitiligo patients' quality of life\",\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To attempt to identify risk factors associated with treatment failure',\n",
       "      'description': 'To attempt to identify risk factors associated with treatment failure',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To document disease trajectory and its relationship to demographic, phenotypic and treatment factors',\n",
       "      'description': 'To document disease trajectory and its relationship to demographic, phenotypic and\\r\\ntreatment factors',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To develop predictors of rapidly progressive vitiligo',\n",
       "      'description': 'To develop predictors of rapidly progressive vitiligo',\n",
       "      'timeFrame': '12 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Paediatric and adult patients with vitiligo under management in secondary care.\\r\\n\\r\\n  2. Written informed consent for study participation obtained from the patient or\\r\\n     parents / legal guardian, with assent as appropriate by the patient, depending on\\r\\n     the level of understanding.\\r\\n\\r\\n  3. Participants consent to participate in long-term follow up and access to all\\r\\n     relevant medical records as needed by the study team\\r\\n\\r\\n  4. Clinical diagnosis of vitiligo made by a dermatologist\\r\\n\\r\\n  5. Willingness to comply with all study requirements.\\r\\n\\r\\n  6. Competent use of English language, according to patient's age (capable of\\r\\n     understanding patient questionnaires).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Insufficient understanding of the study by the patient and/or parent/guardian.\\r\\n\\r\\n  2. Patients with vitiligo/their parents or guardians, who do not provide consent for\\r\\n     participation.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': \"All consecutive patients (adults and children) seen at various hospitals in the UK and\\r\\nwho are diagnosed with vitiligo will be included. Vitiligo patients who receive therapy\\r\\nwith systemic steroids, phototherapy including laser, surgical treatments, new\\r\\nimmunomodulators (e.g. topical or oral JAK inhibitor) once they enter UK market and any\\r\\ncombination therapies of the above will be eligible to be included in the registry.\\r\\n\\r\\nThere is no upper or lower age limit for participation. The decision to therapy or switch\\r\\nto another systemic agent will be the result of the treating dermatology consultant's\\r\\ndecision, following discussion with the patient/parent/legal guardian, without using a\\r\\npre-specified severity score cut off. It is the treating physician's responsibility to\\r\\nensure that patients are suitable for the therapy, and that any standard of care\\r\\ntreatment or assessments are provided alongside participation in the study as per local\\r\\nrequirements.\",\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Viktoria Eleftheriadou',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01902307999',\n",
       "      'email': 'viktoria.eleftheriadou@nhs.net'}],\n",
       "    'overallOfficials': [{'name': 'Viktoria Eleftheriadou',\n",
       "      'affiliation': 'The Royal Wolverhampton NHS Trust',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'The Royal Wolverhampton NHS Trust',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Wolverhampton',\n",
       "      'zip': 'WV10 0QP',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Viktoria Eleftheriadou',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'viktoria.eleftheriadou@nhs.net'},\n",
       "       {'name': 'Lorraine Jacques',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'lorraine.jacques@nhs.net'}],\n",
       "      'geoPoint': {'lat': 52.58547, 'lon': -2.12296}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000014820',\n",
       "      'term': 'Vitiligo'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'ancestors': [{'id': 'D000017496', 'term': 'Hypopigmentation'},\n",
       "     {'id': 'D000010859', 'term': 'Pigmentation Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M15674',\n",
       "      'name': 'Skin Diseases',\n",
       "      'asFound': 'Dermatologic Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17563',\n",
       "      'name': 'Vitiligo',\n",
       "      'asFound': 'Vitiligo',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19761', 'name': 'Hypopigmentation', 'relevance': 'LOW'},\n",
       "     {'id': 'M13754', 'name': 'Pigmentation Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'T2945', 'name': 'Hypomelanotic Disorder', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06431074',\n",
       "    'orgStudyIdInfo': {'id': 'RADX-P-2402'},\n",
       "    'organization': {'fullName': 'Radicle Science', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Radicle Calm 24: A Study of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes',\n",
       "    'officialTitle': 'Radicle Calm™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Feelings of Anxiety and Related Health Outcomes'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-17',\n",
       "    'studyFirstSubmitQcDate': '2024-05-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Radicle Science', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A randomized, double-blind, placebo-controlled study assessing the impact of health and\\r\\nwellness products on feelings of anxiety and related health outcomes',\n",
       "    'detailedDescription': 'This is a randomized, double-blind, placebo-controlled study conducted with adult\\r\\nparticipants, residing in the United States.\\r\\n\\r\\nEligible participants will (1) endorse a desire for less feelings of anxiety (2) have the\\r\\nopportunity for meaningful improvement (at least 30%) in their primary health outcome,\\r\\nand (3) express acceptance in taking a product and not knowing its formulation until the\\r\\nend of the study.\\r\\n\\r\\nParticipants that report a known cardiac dysfunction, liver or kidney disease may be\\r\\nexcluded. Participants that report a known contraindication or with well-established,\\r\\nsignificant safety concerns due to illness will be excluded. Heavy drinkers and those who\\r\\nreport they are pregnant, trying to become pregnant, or breastfeeding will be excluded.\\r\\nParticipants that report taking medications with a known contraindication or with\\r\\nwell-established, significant safety concerns will be excluded.\\r\\n\\r\\nSelf-reported data are collected electronically from eligible participants over 7 weeks.\\r\\nParticipant reports of health indicators will be collected at baseline, throughout the\\r\\nactive period of study product use, and in a final survey. All study assessments will be\\r\\nelectronic; there are no in-person visits or assessments for this real-world evidence\\r\\nstudy.'},\n",
       "   'conditionsModule': {'conditions': ['Anxiety', 'Stress']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Participants will be stratified based on gender at birth, then randomized to one of the\\r\\nstudy arms',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'maskingDescription': \"The investigator is blinded to the participants' study product assignment. Participants\\r\\nare blinded to the study product they are assigned.\",\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Placebo Control 1',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Calm Product Form 1 - control',\n",
       "      'interventionNames': ['Dietary Supplement: Placebo Control Form 1']},\n",
       "     {'label': 'Active Product 1.1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Calm Product Form 1 - active product 1',\n",
       "      'interventionNames': ['Dietary Supplement: Calm Active Study Product 1.1 Usage']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Placebo Control Form 1',\n",
       "      'description': 'Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.',\n",
       "      'armGroupLabels': ['Placebo Control 1']},\n",
       "     {'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Calm Active Study Product 1.1 Usage',\n",
       "      'description': 'Participants will use their Radicle Calm Active Study Product 1.1 as directed for a\\r\\nperiod of 6 weeks.',\n",
       "      'armGroupLabels': ['Active Product 1.1']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in feelings of anxiety',\n",
       "      'description': 'Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome\\r\\nMeasurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less\\r\\nfeelings of anxiety)',\n",
       "      'timeFrame': '6 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change in stress',\n",
       "      'description': 'Mean difference in stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale\\r\\n0-16; where lower scores correspond to less stress)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Change in sleep',\n",
       "      'description': 'Mean difference in sleep score as assessed by Patient Reported Outcome Measurement System\\r\\n(PROMIS) Sleep Disturbance 4A (scale 4-20; where lower scores correspond to better sleep\\r\\nquality/less sleep disturbance)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Change in mood (emotional distress)',\n",
       "      'description': 'Mean difference in mood score as assessed by Patient Reported Outcome Measurement System\\r\\n(PROMIS) Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to\\r\\nlower levels of emotional distress)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Minimal clinically important difference (MCID) in feelings of anxiety',\n",
       "      'description': 'Likelihood of achieving a MCID in sleep disturbance, as measured by Patient Reported\\r\\nOutcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond\\r\\nto less feelings of anxiety)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Minimal clinically important difference (MCID) in stress',\n",
       "      'description': 'Likelihood of experiencing minimal clinically important difference in stress score as\\r\\nassessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond\\r\\nto less stress)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Minimal clinically important difference (MCID) in sleep',\n",
       "      'description': 'Likelihood of experiencing minimal clinically important difference in sleep score as\\r\\nassessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance 4A\\r\\n(scale 4-20; where lower scores correspond to better sleep quality/less sleep\\r\\ndisturbance)',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Minimal clinically important difference (MCID) in mood (emotional distress)',\n",
       "      'description': 'Likelihood of experiencing minimal clinically important difference in mood score as\\r\\nassessed by Patient Reported Outcome Measurement System (PROMIS) Emotional\\r\\nDistress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of\\r\\nemotional distress)',\n",
       "      'timeFrame': '6 weeks'}],\n",
       "    'otherOutcomes': [{'measure': 'Change in concentration of at-home (direct-to-consumer) specimen assay (saliva)',\n",
       "      'description': 'Mean difference in specimen assays as surrogates and/or markers for health outcomes.\\r\\n(Optional; among consented participants only). Potentially include saliva-based\\r\\nbiomarkers (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol,\\r\\nMelatonin, CRP).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Change in concentration of at-home (direct-to-consumer) specimen assay (blood)',\n",
       "      'description': 'Mean difference in specimen assays as surrogates and/or markers for health outcomes.\\r\\n(Optional; among consented participants only). Potentially include blood-based biomarkers\\r\\n(1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S,\\r\\nTestosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Optional Change in concentration of at-home (direct-to-consumer) specimen assays (stool)',\n",
       "      'description': 'Mean difference in specimen assays as surrogates and/or markers for health outcomes.\\r\\n(Optional; among consented participants only). Potentially include stool sample\\r\\n(microbial diversity). Units of measure will vary depending upon biospecimen collected.',\n",
       "      'timeFrame': '6 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adults, at least 21 years of age and older at the time of electronic consent,\\r\\n     inclusive of all ethnicities, races, genders and/or gender identities. Assigned sex\\r\\n     at birth will determine sex-specific recruitment and surveys (male vs female)\\r\\n     employed, when needed\\r\\n\\r\\n  -  Resides in the United States\\r\\n\\r\\n  -  Endorses less anxiety as a primary desire\\r\\n\\r\\n  -  Has the opportunity for at least 20% improvement in their primary health outcome\\r\\n\\r\\n  -  Expresses a willingness to take a study product and not know the product identity\\r\\n     (active or placebo) until the end of the study\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Reports being pregnant, trying to become pregnant, or breastfeeding\\r\\n\\r\\n  -  Unable to provide a valid US shipping address and mobile phone number\\r\\n\\r\\n  -  Reports current enrollment in another clinical trial\\r\\n\\r\\n  -  Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per\\r\\n     day)\\r\\n\\r\\n  -  Unable to read and understand English\\r\\n\\r\\n  -  Reports a current and/or recent (up to 3 months ago) major illness and/or surgery\\r\\n     that poses a known, significant safety risk.\\r\\n\\r\\n  -  Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a\\r\\n     known contraindication and/or a significant safety risk with any of the study\\r\\n     product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive\\r\\n     heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage\\r\\n     liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\\r\\n\\r\\n  -  Reports taking medications that have a well-established moderate or severe\\r\\n     interaction, posing a substantial safety risk with any of the study product\\r\\n     ingredients. Anticoagulants, antihypertensive, anxiolytics, antidepressants,\\r\\n     chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications\\r\\n     that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg\\r\\n     per day, diabetic medications, oral anti-infectives (antibiotics, antifungals,\\r\\n     antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase\\r\\n     inhibitors), or thyroid products\\r\\n\\r\\n  -  Reports current use of the primary ingredient(s) and/or similar product(s) to the\\r\\n     active study product(s)\\r\\n\\r\\n  -  Lack of reliable daily access to the internet',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '21 Years',\n",
       "    'maximumAge': '105 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Study Manager',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '760-281-3898',\n",
       "      'email': 'studymgmt@radiclescience.com'}],\n",
       "    'overallOfficials': [{'name': 'Emily K. Pauli, PharmD',\n",
       "      'affiliation': 'Radicle Science, Inc',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Radicle Science, Inc',\n",
       "      'city': 'Del Mar',\n",
       "      'state': 'California',\n",
       "      'zip': '92014',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 32.95949, 'lon': -117.26531}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Radicle Science, Inc',\n",
       "      'url': 'http://radiclescience.com'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'Data will not be shared with researchers outside of Radicle Collaborators on this study.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001008',\n",
       "      'term': 'Anxiety Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M4324',\n",
       "      'name': 'Anxiety Disorders',\n",
       "      'asFound': 'Anxiety',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06277765',\n",
       "    'orgStudyIdInfo': {'id': 'CM310-101212'},\n",
       "    'organization': {'fullName': 'Keymed Biosciences Co.Ltd',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis',\n",
       "    'officialTitle': 'A Randomized, Double Blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CM310 in Adolescent Patients With Moderate-to-severe Atopic Dermatitis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-18',\n",
       "    'studyFirstSubmitQcDate': '2024-02-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-18',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-26', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Keymed Biosciences Co.Ltd', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to\\r\\nevaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in children patients\\r\\nwith moderate-to-severe atopic dermatitis.'},\n",
       "   'conditionsModule': {'conditions': ['Atopic Dermatitis']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 180, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'CM310 group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Biological: CM310']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'interventionNames': ['Other: placebo']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'CM310',\n",
       "      'description': 'IL-4Rα monoclonal antibody',\n",
       "      'armGroupLabels': ['CM310 group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'placebo',\n",
       "      'description': 'Placebo',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of subjects achieving EASI-75 at week 18',\n",
       "      'description': 'The EASI is a composite index with scores ranging from 0 to 72. Four AD disease\\r\\ncharacteristics (erythema, edema/papulation, excoriation, lichenification) will each be\\r\\nassessed for severity by the investigator on a scale of \"0\" (none) through \"3\" (severe).',\n",
       "      'timeFrame': 'Up to week 18'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Have the ability to understand the study and voluntarily sign a written informed\\r\\n     consent form (ICF).\\r\\n\\r\\n  -  With Atopic Dermatitis.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Not enough washing-out period for previous therapies.\\r\\n\\r\\n  -  Any major surgery planned during the research period.\\r\\n\\r\\n  -  With intestinal parasitic infection within the 6 months before screening.\\r\\n\\r\\n  -  With any circumstance that is not suitable to participate in this study.\\r\\n\\r\\n  -  Major surgeries are planned during the study period.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '12 Years',\n",
       "    'maximumAge': '18 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Qian Jia',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '028-88610620',\n",
       "      'email': 'qianjia@keymedbio.com'}],\n",
       "    'overallOfficials': [{'name': 'jianzhong Zhang',\n",
       "      'affiliation': \"Peking University People's Hospital\",\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': \"Peking University People's hospital\",\n",
       "      'city': 'Beijing',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003876',\n",
       "      'term': 'Dermatitis, Atopic'},\n",
       "     {'id': 'D000003872', 'term': 'Dermatitis'},\n",
       "     {'id': 'D000004485', 'term': 'Eczema'}],\n",
       "    'ancestors': [{'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000012873', 'term': 'Skin Diseases, Genetic'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000017443', 'term': 'Skin Diseases, Eczematous'},\n",
       "     {'id': 'D000006969', 'term': 'Hypersensitivity, Immediate'},\n",
       "     {'id': 'D000006967', 'term': 'Hypersensitivity'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7067',\n",
       "      'name': 'Dermatitis',\n",
       "      'asFound': 'Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7071',\n",
       "      'name': 'Dermatitis, Atopic',\n",
       "      'asFound': 'Atopic Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7655',\n",
       "      'name': 'Eczema',\n",
       "      'asFound': 'Atopic Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15676', 'name': 'Skin Diseases, Genetic', 'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M19712', 'name': 'Skin Diseases, Eczematous', 'relevance': 'LOW'},\n",
       "     {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'},\n",
       "     {'id': 'M10020',\n",
       "      'name': 'Hypersensitivity, Immediate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4225',\n",
       "      'name': 'Antibodies',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06195540',\n",
       "    'orgStudyIdInfo': {'id': '49RC21_0376'},\n",
       "    'organization': {'fullName': 'University Hospital, Angers',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'briefTitle': 'RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing',\n",
       "    'officialTitle': 'RIVACAST : RIVAroxaban Versus Low-molecular Weight Heparinin Patients With Lower Limb Trauma Requiring Brace or CASTing',\n",
       "    'acronym': 'RIVACAST'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-08-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-22',\n",
       "    'studyFirstSubmitQcDate': '2023-12-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-01-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-01-31', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University Hospital, Angers',\n",
       "     'class': 'OTHER_GOV'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': \"Lower limb trauma requiring immobilization is a very frequent condition that is\\r\\nassociated with an increased risk of developing venous thromboembolism (VTE). The\\r\\nTRiP(cast) score has been developed to provide individual VTE risk stratification and\\r\\nhelp in thromboprophylactic anticoagulation decision. The recent CASTING study had\\r\\nconfirmed that patients with a TRiP(cast) score <7 have a very low risk of VTE and could\\r\\nbe safely manage without prophylactic treatment. Conversely, patients with a score ≥ 7\\r\\nhave a high-risk of VTE and require a prophylactic anticoagulant treatment. Low molecular\\r\\nweight heparins (LMWH) have been shown to be effective in this indication. However, in\\r\\nthe CASTING study, the 3-month symptomatic VTE rate was 2.6% in this subgroup despite\\r\\nLMWH prophylactic treatment. This result suggests that LMWH are not sufficiently\\r\\neffective in this particular subgroup of high-risk patients. Direct oral anticoagulants,\\r\\nand in particular rivaroxaban, may be an effective and safe alternative to LMWH. In the\\r\\nPRONOMOS study, comparing LMWH with rivaroxaban in patients who had undergone non-major\\r\\nlower limb surgery, the relative risk of symptomatic VTE was 0.25 (95% CI = 0.09 - 0.75)\\r\\nin favor of rivaroxaban 10mg. No significant increase in bleeding was found. In addition,\\r\\nas LMWH treatment requires subcutaneous daily injections, the use of rivaroxaban may\\r\\npositively impact patients' quality of life as well as being effective in medico-economic\\r\\nterms.\\r\\n\\r\\nThe aims of this study are to demonstrate that rivaroxaban is at least as effective,\\r\\neasier to use and more efficient than LMWH in patients with trauma to the lower limb\\r\\nrequiring immobilisation and deemed to be at risk of venous thromboembolism (TRiP(cast)\\r\\nscore ≥ 7). High-risk patients are randomized to receive either rivaroxaban or LMWH. They\\r\\nare followed up at 45 days and 90 days to assess the occurrence of thrombotic events or\\r\\nbleeding, as well as their satisfaction with the treatment received.\"},\n",
       "   'conditionsModule': {'conditions': ['Venous Thromboembolism',\n",
       "     'Deep Vein Thrombosis',\n",
       "     'Pulmonary Embolism',\n",
       "     'Lower Limb Trauma',\n",
       "     'Thromboprophylaxis',\n",
       "     'Immobilisation'],\n",
       "    'keywords': ['Emergency department',\n",
       "     'direct oral anticoagulant',\n",
       "     'rivaroxaban',\n",
       "     'Low-Molecular-weight heparin',\n",
       "     'randomized control trial',\n",
       "     'Prevent VTE']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': \"Open label with blind assessment of study's outcomes\",\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 1424, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Rivaroxaban arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: Rivaroxaban 10 MG']},\n",
       "     {'label': 'Low-molecular-weight heparin arm',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Treatment with LMWH is the standard-of-care in this population of lower limb trauma\\r\\npatients at risk of thrombosis.\\r\\n\\r\\nThe control group is therefore the group of patients who receive prophylactic\\r\\nanticoagulant treatment with LMWH for the duration of immobilization (i.e. until full\\r\\nmobilization with weight-bearing).',\n",
       "      'interventionNames': ['Drug: Low Heparin Molecular Weight']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Rivaroxaban 10 MG',\n",
       "      'description': \"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in\\r\\npatients with trauma to a lower limb.\\r\\n\\r\\nConsecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for\\r\\npossible participation in the study. At the inclusion visit, if the patient meets the\\r\\nstudy's selection criteria, the investigator provides oral and written information\\r\\n(information letter written in a language the patient can understand) and answers any\\r\\nquestions the patient may have. Depending on randomisation, the patient will receive\\r\\neither LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage\\r\\nadjustment).\\r\\n\\r\\nTreatment is started in the emergency department and continued at home for the duration\\r\\nof the immobilisation (i.e. until mobilisation with weight-bearing). The duration of\\r\\ntreatment will be determined by the physician.\",\n",
       "      'armGroupLabels': ['Rivaroxaban arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Low Heparin Molecular Weight',\n",
       "      'description': \"Administration of standard prophylactic anticoagulant treatment with LMWH for the\\r\\nduration of immobilisation (i.e. until full mobilisation with weight-bearing).\\r\\nConsecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for\\r\\npossible participation in the study. At the inclusion visit, if the patient meets the\\r\\nstudy's selection criteria, the investigator provides oral and written information\\r\\n(information letter written in a language the patient can understand) and answers any\\r\\nquestions the patient may have. Depending on randomisation, the patient will receive\\r\\neither LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices\\r\\nand national recommendations.\\r\\n\\r\\nTreatment is started in the emergency department and continued at home for the duration\\r\\nof the immobilisation (i.e. until mobilisation with weight-bearing). The duration of\\r\\ntreatment will be determined by the physician.\",\n",
       "      'armGroupLabels': ['Low-molecular-weight heparin arm']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of symptomatic venous thromboembolic events (45 days non-inferiority)',\n",
       "      'description': \"The primary endpoint is the rate of symptomatic venous thromboembolic events (including\\r\\ndeep vein thrombosis and/or pulmonary embolism and/or PE-related death) within 45 days\\r\\n(+/- 5 days) of inclusion.\\r\\n\\r\\nSymptomatic VTE is defined as follows:\\r\\n\\r\\n  -  Deep venous thrombosis (DVT) of the lower limbs: DVT confirmed by a non-compressible\\r\\n     venous segment on compression ultrasound or by a filling defect on CT venography.\\r\\n     Symptomatic proximal and distal DVTs will be taken into account.\\r\\n\\r\\n  -  Symptomatic pulmonary embolism documented by thoracic angioscan, high probability\\r\\n     planar lung scan, SPECT scan, pulmonary angiography or by the combination of\\r\\n     documented proximal deep vein thrombosis and thoracic symptomatology suggestive of\\r\\n     pulmonary embolism.\\r\\n\\r\\n  -  PE-related deaths according to the ISTH (International Society of Thrombosis and\\r\\n     Haemostasis) definition All events will need to be confirmed by the randomisation\\r\\n     group's blinded clinical events adjudication committee.\",\n",
       "      'timeFrame': '45 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Patient self reported treatment satisfaction',\n",
       "      'description': 'The outcome is patient self-reported treatment satisfaction using the Anti-Clot Treatment\\r\\nScales (ACTS) assessed at 45 days (+/- 5 days).',\n",
       "      'timeFrame': '45 days'},\n",
       "     {'measure': 'Rate of symptomatic venous thromboembolic events (90 days superiority)',\n",
       "      'description': 'This secondary outcome is the cumulative rate of symptomatic venous thromboembolism\\r\\n(i.e., deep venous thrombosis and/or pulmonary embolism) within the 90 days (± 7 days)\\r\\nafter the inclusion.\\r\\n\\r\\nThe definition of symptomatic VTE is the same as the primary outcome.',\n",
       "      'timeFrame': '90 days'},\n",
       "     {'measure': 'Cumulative rates of major bleeding and of non-major clinically relevant bleeding (90 days)',\n",
       "      'description': 'The cumulative rates of major bleeding and of non-major clinically relevant bleeding at\\r\\n90 days (± 7 days).\\r\\n\\r\\nMajor bleeding is defined according to the International Society of Thrombosis and\\r\\nHaemostasis (ISTH) criteria and includes:\\r\\n\\r\\n  -  Any bleeding resulting in death\\r\\n\\r\\n  -  Symptomatic bleeding in a critical organ including intracranial, intraspinal,\\r\\n     intraocular, retroperitoneal, intra-articular, pericardial bleeding and muscle\\r\\n     bleeding resulting in compartment syndrome,\\r\\n\\r\\n  -  Symptomatic bleeding resulting in a decrease in the haemoglobin concentration of at\\r\\n     least 2g/dL or resulting in the transfusion of at least two packs of blood red\\r\\n     cells.\\r\\n\\r\\nClinically Relevant Non-Major Bleeding is defined as:\\r\\n\\r\\n  -  Any bleeding requiring hospitalisation or a medical intervention including temporary\\r\\n     withholding of anticoagulant treatment to stop the bleeding.',\n",
       "      'timeFrame': '90 days'},\n",
       "     {'measure': 'Incremental cost-utility ratio (rivaroxaban efficiency 45 days)',\n",
       "      'description': 'The incremental cost-utility ratio (costs per quality-adjusted life year (QALY) gained)\\r\\nassessed at 45 days after inclusion. Health-related quality of life will be collected\\r\\nusing EQ-5D-5L self-administered questionnaires at each scheduled follow-up at 45 days (±\\r\\n5). Resources consumed will be taken from french national Health Data System.',\n",
       "      'timeFrame': '45 days'},\n",
       "     {'measure': 'Incremental cost-utility ratio (rivaroxaban efficiency 90 days)',\n",
       "      'description': 'The incremental cost-utility ratio (costs per quality-adjusted life year [QALY] gained)\\r\\nassessed at 90 days after inclusion. Health-related quality of life will be collected\\r\\nusing EQ-5D-5L self-administered questionnaires at each scheduled follow-up at at 90 days\\r\\n(± 7). Resources consumed will be taken from french national Health Data System.',\n",
       "      'timeFrame': '90 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patient aged 18 or over ;\\r\\n\\r\\n  -  Consultation in an emergency department of a participating centre;\\r\\n\\r\\n  -  Trauma to the lower limb requiring rigid or semi-rigid orthopaedic immobilisation;\\r\\n\\r\\n  -  Expected duration of orthopaedic immobilisation of at least 2 weeks;\\r\\n\\r\\n  -  Expected hospital stay of less than or equal to 72 hours;\\r\\n\\r\\n  -  TRiP(cast) score ≥ 7 ;\\r\\n\\r\\n  -  Patient affiliated to or benefiting from a social security scheme;\\r\\n\\r\\n  -  Patient with prior informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Active bleeding or high risk of bleeding,\\r\\n\\r\\n  -  Known contraindication to rivaroxaban or LMWH;\\r\\n\\r\\n  -  Taking any anticoagulant or antiplatelet agent before the trauma (only\\r\\n     antithrombotic authorised: aspirin < 325mg/d);\\r\\n\\r\\n  -  Pregnant or breastfeeding woman;\\r\\n\\r\\n  -  Any factor making 3-month follow-up impossible; 6. Patient subject to a legal\\r\\n     protection measure, Imprisonment 7. Participation in any interventional study which\\r\\n     modifies patient care or could influence study evaluation criteria',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Delphine Douillet, Doctor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0241353637',\n",
       "      'email': 'Delphine.Douillet@chu-angers.fr'},\n",
       "     {'name': 'Cindy Augereau, Mrs',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0241354143',\n",
       "      'email': 'Cindy.Augereau@chu-angers.fr'}],\n",
       "    'overallOfficials': [{'name': 'Delphine Douillet, Doctor',\n",
       "      'affiliation': 'Angers University Hospital',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Angers University Hospital, Emergency department',\n",
       "      'city': 'Angers',\n",
       "      'zip': '49000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Delphine Douillet, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0241353637',\n",
       "        'email': 'Delphine.Douillet@chu-angers.fr'}],\n",
       "      'geoPoint': {'lat': 47.46667, 'lon': -0.55}},\n",
       "     {'facility': 'Argenteuil hospital, Emergency department',\n",
       "      'city': 'Argenteuil',\n",
       "      'zip': '95100',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Catherine Le Gall, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0134232425',\n",
       "        'email': 'catherine.legall@ch-argenteuil.fr'}],\n",
       "      'geoPoint': {'lat': 48.95, 'lon': 2.25}},\n",
       "     {'facility': 'Caen University hospital, Emergency department',\n",
       "      'city': 'Caen',\n",
       "      'zip': '14000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Richard Macrez, Professor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0231064817',\n",
       "        'email': 'macrez-r@chu-caen.fr'}],\n",
       "      'geoPoint': {'lat': 49.18585, 'lon': -0.35912}},\n",
       "     {'facility': 'Tours University Hospital, Emergency department',\n",
       "      'city': 'Chambray-lès-Tours',\n",
       "      'zip': '37170',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Thomas Moumneh, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0247474747',\n",
       "        'email': 'moumneh_thomas@hotmail.fr'}],\n",
       "      'geoPoint': {'lat': 47.33537, 'lon': 0.70286}},\n",
       "     {'facility': 'Cholet Hospital, Emergency department',\n",
       "      'city': 'Cholet',\n",
       "      'zip': '49300',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Caroline Soulie, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0241496985',\n",
       "        'email': 'caroline.soulie-chavignon@ch-cholet.fr'}],\n",
       "      'geoPoint': {'lat': 47.06667, 'lon': -0.88333}},\n",
       "     {'facility': 'Clermont-Ferrand University Hospital, Emergency department',\n",
       "      'city': 'Clermont-Ferrand',\n",
       "      'zip': '63000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Romain Durif, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0473751940',\n",
       "        'email': 'rdurif@chu-clermontferrand.fr'}],\n",
       "      'geoPoint': {'lat': 45.77966, 'lon': 3.08628}},\n",
       "     {'facility': 'Grenoble University Hospital, Emergency Department',\n",
       "      'city': 'Grenoble',\n",
       "      'zip': '38000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Damien Viglino, Professor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0476766784',\n",
       "        'email': 'dviglino@chu-grenoble.fr'}],\n",
       "      'geoPoint': {'lat': 45.16667, 'lon': 5.71667}},\n",
       "     {'facility': 'Le Mans Hospital, Emergency department',\n",
       "      'city': 'Le Mans',\n",
       "      'zip': '72000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Cyrielle Houalard, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0243434343',\n",
       "        'email': 'cyrielle.houalard@gmail.com'}],\n",
       "      'geoPoint': {'lat': 48.0, 'lon': 0.2}},\n",
       "     {'facility': 'Limoges University hospital, Emergency department',\n",
       "      'city': 'Limoges',\n",
       "      'zip': '87000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Thomas Lafon, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0555056254',\n",
       "        'email': 'thomas.LAFON@chu-limoges.fr'}],\n",
       "      'geoPoint': {'lat': 45.83153, 'lon': 1.25781}},\n",
       "     {'facility': 'Edouard Herriot University Hospital, Emergency Department',\n",
       "      'city': 'Lyon',\n",
       "      'zip': '69000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Karim Tazarourte, Professor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0472110040',\n",
       "        'email': 'karim.tazarourte@chu-lyon.fr'}],\n",
       "      'geoPoint': {'lat': 45.74848, 'lon': 4.84669}},\n",
       "     {'facility': 'Montpellier University Hospital, emergency department',\n",
       "      'city': 'Montpellier',\n",
       "      'zip': '34000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Mustapha Sebbane, Professor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0467337974',\n",
       "        'email': 'm-sebbane@chu-montpellier.fr'}],\n",
       "      'geoPoint': {'lat': 43.61092, 'lon': 3.87723}},\n",
       "     {'facility': 'Nantes University Hospital, Emergency department',\n",
       "      'city': 'Nantes',\n",
       "      'zip': '44000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'François Javaudin, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0240083333',\n",
       "        'email': 'Francois.JAVAUDIN@chu-nantes.fr'}],\n",
       "      'geoPoint': {'lat': 47.21725, 'lon': -1.55336}},\n",
       "     {'facility': 'Nice University Hospital, Emergency department',\n",
       "      'city': 'Nice',\n",
       "      'zip': '06000',\n",
       "      'country': 'France',\n",
       "      'geoPoint': {'lat': 43.70313, 'lon': 7.26608}},\n",
       "     {'facility': 'Niort Hospital, Emergency Department',\n",
       "      'city': 'Niort',\n",
       "      'zip': '79000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Elodie Abguillerm, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0549783015',\n",
       "        'email': 'abgelodie@gmail.com'}],\n",
       "      'geoPoint': {'lat': 46.32313, 'lon': -0.45877}},\n",
       "     {'facility': 'Lariboisière hospital, emergency department',\n",
       "      'city': 'Paris',\n",
       "      'zip': '75010',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Anthony Chauvin, Professor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0149956565',\n",
       "        'email': 'anthony.chauvin@aphp.fr'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "     {'facility': 'Saint-Antoine Hospital, Emergency department',\n",
       "      'city': 'Paris',\n",
       "      'zip': '75012',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Pierre-Clément Thiebault, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0149282743',\n",
       "        'email': 'pierre-clement.thiebaud@aphp.fr'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "     {'facility': 'La Pitié-Salpétrière Hospital, Emergency Department',\n",
       "      'city': 'Paris',\n",
       "      'zip': '75013',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Karine Alame, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0142177242',\n",
       "        'email': 'alame.karine@gmail.com'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "     {'facility': 'Cochin Hospital, Emergency department',\n",
       "      'city': 'Paris',\n",
       "      'zip': '75014',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Florence Dumas, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0158412707',\n",
       "        'email': 'florence.dumas@aphp.fr'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "     {'facility': 'HEGP, Emergency Department',\n",
       "      'city': 'Paris',\n",
       "      'zip': '75015',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Richard Chocron, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0156095876',\n",
       "        'email': 'richard.chocron@gmail.com'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}},\n",
       "     {'facility': 'South Lyon University Hospital, Emergency department',\n",
       "      'city': 'Pierre-Bénite',\n",
       "      'zip': '69495',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Marion Douplat, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0478862854',\n",
       "        'email': 'marion.douplat@chu-lyon.fr'}],\n",
       "      'geoPoint': {'lat': 45.7009, 'lon': 4.82511}},\n",
       "     {'facility': 'Poitiers University Hospital, Emergency department',\n",
       "      'city': 'Poitiers',\n",
       "      'zip': '86000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Jérémy Guenezan, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0549444444',\n",
       "        'email': 'jeremy.guenezan@chu-poitiers.fr'}],\n",
       "      'geoPoint': {'lat': 46.58333, 'lon': 0.33333}},\n",
       "     {'facility': 'Rennes University Hospital, Emergency department',\n",
       "      'city': 'Rennes',\n",
       "      'zip': '35000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Vincent Levrel, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0299284321',\n",
       "        'email': 'Vincent.LEVREL@chu-rennes.fr'}],\n",
       "      'geoPoint': {'lat': 48.11198, 'lon': -1.67429}},\n",
       "     {'facility': 'Rouen University Hospital',\n",
       "      'city': 'Rouen',\n",
       "      'zip': '76000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Mélanie Roussel, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0232881879',\n",
       "        'email': 'melanie.roussel@chu-rouen.fr'}],\n",
       "      'geoPoint': {'lat': 49.44313, 'lon': 1.09932}},\n",
       "     {'facility': 'Strasbourg University Hospital, Emergency Department',\n",
       "      'city': 'Strasbourg',\n",
       "      'zip': '67000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Pierrick Le Borgne, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0388128690',\n",
       "        'email': 'pierrick.leborgne@chru-strasbourg.fr'}],\n",
       "      'geoPoint': {'lat': 48.58392, 'lon': 7.74553}},\n",
       "     {'facility': 'Toulouse University Hospital, Emergency Department',\n",
       "      'city': 'Toulouse',\n",
       "      'zip': '31000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Xavier Dubucs, Doctor',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0561775919',\n",
       "        'email': 'xavier.dubucs@gmail.com'}],\n",
       "      'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011655',\n",
       "      'term': 'Pulmonary Embolism'},\n",
       "     {'id': 'D000013927', 'term': 'Thrombosis'},\n",
       "     {'id': 'D000004617', 'term': 'Embolism'},\n",
       "     {'id': 'D000013923', 'term': 'Thromboembolism'},\n",
       "     {'id': 'D000054556', 'term': 'Venous Thromboembolism'},\n",
       "     {'id': 'D000020246', 'term': 'Venous Thrombosis'},\n",
       "     {'id': 'D000014947', 'term': 'Wounds and Injuries'}],\n",
       "    'ancestors': [{'id': 'D000016769', 'term': 'Embolism and Thrombosis'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M17685',\n",
       "      'name': 'Wounds and Injuries',\n",
       "      'asFound': 'Trauma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7796', 'name': 'Emergencies', 'relevance': 'LOW'},\n",
       "     {'id': 'M16686',\n",
       "      'name': 'Thrombosis',\n",
       "      'asFound': 'Thrombosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14509',\n",
       "      'name': 'Pulmonary Embolism',\n",
       "      'asFound': 'Pulmonary Embolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7784',\n",
       "      'name': 'Embolism',\n",
       "      'asFound': 'Embolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'},\n",
       "     {'id': 'M16682',\n",
       "      'name': 'Thromboembolism',\n",
       "      'asFound': 'Thromboembolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M27780',\n",
       "      'name': 'Venous Thromboembolism',\n",
       "      'asFound': 'Venous Thromboembolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22071',\n",
       "      'name': 'Venous Thrombosis',\n",
       "      'asFound': 'Deep Vein Thrombosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19128', 'name': 'Embolism and Thrombosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC26', 'name': 'Wounds and Injuries'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000006493',\n",
       "      'term': 'Heparin'},\n",
       "     {'id': 'D000006495', 'term': 'Heparin, Low-Molecular-Weight'},\n",
       "     {'id': 'D000017985', 'term': 'Dalteparin'},\n",
       "     {'id': 'D000069552', 'term': 'Rivaroxaban'}],\n",
       "    'ancestors': [{'id': 'D000000925', 'term': 'Anticoagulants'},\n",
       "     {'id': 'D000005343', 'term': 'Fibrinolytic Agents'},\n",
       "     {'id': 'D000050299', 'term': 'Fibrin Modulating Agents'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000065427', 'term': 'Factor Xa Inhibitors'},\n",
       "     {'id': 'D000000991', 'term': 'Antithrombins'},\n",
       "     {'id': 'D000015842', 'term': 'Serine Proteinase Inhibitors'},\n",
       "     {'id': 'D000011480', 'term': 'Protease Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M9579',\n",
       "      'name': 'Heparin',\n",
       "      'asFound': 'Obesity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4244', 'name': 'Anticoagulants', 'relevance': 'LOW'},\n",
       "     {'id': 'M463',\n",
       "      'name': 'Rivaroxaban',\n",
       "      'asFound': 'Benefit',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M46053', 'name': 'Calcium heparin', 'relevance': 'LOW'},\n",
       "     {'id': 'M9581',\n",
       "      'name': 'Heparin, Low-Molecular-Weight',\n",
       "      'asFound': 'Calcinosis Cutis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1943', 'name': 'Tinzaparin', 'relevance': 'LOW'},\n",
       "     {'id': 'M20153',\n",
       "      'name': 'Dalteparin',\n",
       "      'asFound': 'Calcinosis Cutis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8473', 'name': 'Fibrinolytic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M30513', 'name': 'Factor Xa Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4307', 'name': 'Antithrombins', 'relevance': 'LOW'},\n",
       "     {'id': 'M4306', 'name': 'Antithrombin III', 'relevance': 'LOW'},\n",
       "     {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M18391',\n",
       "      'name': 'Serine Proteinase Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T18', 'name': 'Serine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'FiAg', 'name': 'Fibrinolytic Agents'},\n",
       "     {'abbrev': 'AnCoag', 'name': 'Anticoagulants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06375044',\n",
       "    'orgStudyIdInfo': {'id': 'SIM0500-101'},\n",
       "    'organization': {'fullName': 'Jiangsu Simcere Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma',\n",
       "    'officialTitle': 'A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-16',\n",
       "    'studyFirstSubmitQcDate': '2024-04-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-19', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-19', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Jiangsu Simcere Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'Shanghai Xianxiang Medical Technology Co., Ltd.',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and\\r\\ntolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with\\r\\nRelapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part\\r\\n1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be\\r\\nadministered until disease progression, intolerable toxicity, withdraw of consent or end\\r\\nof trial.'},\n",
       "   'conditionsModule': {'conditions': ['Relapsed or Refractory Multiple Myeloma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 130, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'SIM0500',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: SIM0500']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'SIM0500',\n",
       "      'description': 'Participants will receive SIM0500 in a 28-day cycle until disease progression,\\r\\nintolerable toxicity, or until the participant voluntarily withdraws from trial\\r\\nintervention, or end of study, whichever comes first.',\n",
       "      'armGroupLabels': ['SIM0500']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose-limiting toxicity (DLT)',\n",
       "      'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Voluntary participation and signature of informed consent form.\\r\\n\\r\\n  2. ≥18 years of age.\\r\\n\\r\\n  3. Have documented diagnosis of relapsed or refractory multiple myeloma according to\\r\\n     Criteria for Response to Multiple Myeloma Treatment(IMWG)diagnostic criteria who\\r\\n     have failed all established standard of care.\\r\\n\\r\\n  4. Life expectancy ≥12 weeks.\\r\\n\\r\\n  5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.\\r\\n\\r\\n  6. Adequate hematologic, hepatic, and renal function.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Toxicities from previous anticancer therapies should have resolved to baseline\\r\\n     levels or to Grade 1 or less except for alopecia or peripheral neuropathy.\\r\\n\\r\\n  2. Active hepatitis B (HBsAg positive and HBV DNA ≥ 1×104 copies/mL or ≥ 2,000\\r\\n     international unit [IU]/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN)\\r\\n     infection; participant with HBsAg positive or detective HBV-DNA at screening should\\r\\n     receive antiviral treatment as per local practice during the trial.\\r\\n\\r\\n  3. Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency\\r\\n     syndrome (AIDS).\\r\\n\\r\\n  4. Participant is pregnant or breastfeeding, or expecting to conceive or father\\r\\n     children within the projected duration of the trial.\\r\\n\\r\\n  5. Active known or suspected autoimmune disease. Participants with vitiligo, residual\\r\\n     hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic\\r\\n     treatment or conditions not expected to recur in the absence of an external trigger,\\r\\n     type 1 diabetes mellitus (blood glucose can be controlled by insulin therapy) can be\\r\\n     included.\\r\\n\\r\\n  6. Current or previous other malignancy within 3 years of study entry, except basal or\\r\\n     squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the\\r\\n     prostate, cervix or breast.\\r\\n\\r\\n  7. Known active central nervous system (CNS) involvement or exhibits clinical signs of\\r\\n     meningeal involvement of multiple myeloma.\\r\\n\\r\\n  8. Participants with known active infection within 14 days prior to the first SIM0500.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Juan Wen Wang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '18630999743',\n",
       "      'email': 'wangwenjuan4@zaiming.com'}],\n",
       "    'locations': [{'facility': 'Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences',\n",
       "      'city': 'Tianjin',\n",
       "      'state': 'Tianjin',\n",
       "      'zip': '300000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Yan Xu',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'xuyan1@ihcams.ac.cn'}],\n",
       "      'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009101',\n",
       "      'term': 'Multiple Myeloma'},\n",
       "     {'id': 'D000054219', 'term': 'Neoplasms, Plasma Cell'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000020141', 'term': 'Hemostatic Disorders'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000010265', 'term': 'Paraproteinemias'},\n",
       "     {'id': 'D000001796', 'term': 'Blood Protein Disorders'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000006474', 'term': 'Hemorrhagic Disorders'},\n",
       "     {'id': 'D000008232', 'term': 'Lymphoproliferative Disorders'},\n",
       "     {'id': 'D000007160', 'term': 'Immunoproliferative Disorders'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12058',\n",
       "      'name': 'Multiple Myeloma',\n",
       "      'asFound': 'Multiple Myeloma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M27588',\n",
       "      'name': 'Neoplasms, Plasma Cell',\n",
       "      'asFound': 'Multiple Myeloma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21977', 'name': 'Hemostatic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5059',\n",
       "      'name': 'Blood Coagulation Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M13178', 'name': 'Paraproteinemias', 'relevance': 'LOW'},\n",
       "     {'id': 'M5077', 'name': 'Blood Protein Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9560', 'name': 'Hemorrhagic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M11225',\n",
       "      'name': 'Lymphoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10206',\n",
       "      'name': 'Immunoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3947',\n",
       "      'name': 'Multiple Myeloma',\n",
       "      'asFound': 'Multiple Myeloma',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4225',\n",
       "      'name': 'Antibodies',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06073873',\n",
       "    'orgStudyIdInfo': {'id': 'IM047-024'},\n",
       "    'organization': {'fullName': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea',\n",
       "    'officialTitle': 'Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-04-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-04-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-03',\n",
       "    'studyFirstSubmitQcDate': '2023-10-03',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this observational study is to assess the real-world safety of ozanimod in\\r\\nKorean participants with moderate to severe active ulcerative colitis.'},\n",
       "   'conditionsModule': {'conditions': ['Ulcerative Colitis']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 3000, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Participants with moderate to severe active ulcerative colitis treated with ozanimod',\n",
       "      'interventionNames': ['Drug: Ozanimod']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Ozanimod',\n",
       "      'description': 'According to local product label',\n",
       "      'armGroupLabels': ['Participants with moderate to severe active ulcerative colitis treated with ozanimod']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse events',\n",
       "      'description': 'The type, frequency, seriousness and severity of adverse events (AEs), and relationship\\r\\nof AEs for ozanimod',\n",
       "      'timeFrame': 'Up to 52 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adult participants 19 years of age or older\\r\\n\\r\\n  -  Participants who will receive ozanimod according to the approved label after\\r\\n     enrollment\\r\\n\\r\\n  -  Participants who sign the informed consent form voluntarily\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Participants who are prescribed ozanimod for therapeutic indications not approved in\\r\\n     Korea\\r\\n\\r\\n  -  Participants for whom ozanimod is contraindicated as clarified in Korean prescribing\\r\\n     information approved by Ministry of Food and Drug Safety',\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '19 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'The study population will consist of participants with moderately to severely active\\r\\nulcerative colitis who will receive at least 1 dose of ozanimod according to local\\r\\nproduct label. Moderate to severe disease will be defined as a Mayo score of 6 to 12 and\\r\\nan endoscopic sub-score of 2 or higher. Participants will be eligible if they had an\\r\\ninadequate response, lost response, or were intolerant to conventional therapy\\r\\n(5-aminosalicylic acid, corticosteroids, immunosuppressants) or biologic agents.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'BMS Study Connect Contact Center www.BMSStudyConnect.com',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '855-907-3286',\n",
       "      'email': 'Clinical.Trials@bms.com'},\n",
       "     {'name': 'First line of the email MUST contain NCT # and Site #.',\n",
       "      'role': 'CONTACT'}],\n",
       "    'overallOfficials': [{'name': 'Bristol-Myers Squibb',\n",
       "      'affiliation': 'Bristol-Myers Squibb',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Bristol-Myers Squibb YH',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Seoul',\n",
       "      'zip': '06178',\n",
       "      'country': 'Korea, Republic of',\n",
       "      'contacts': [{'name': 'Hyunho Kim',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Hyunho.kim@bms.com'}],\n",
       "      'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'BMS Clinical Trial Information',\n",
       "      'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html'},\n",
       "     {'label': 'FDA Safety Alerts and Recalls',\n",
       "      'url': 'https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003092',\n",
       "      'term': 'Colitis'},\n",
       "     {'id': 'D000003093', 'term': 'Colitis, Ulcerative'},\n",
       "     {'id': 'D000014456', 'term': 'Ulcer'}],\n",
       "    'ancestors': [{'id': 'D000005759', 'term': 'Gastroenteritis'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000003108', 'term': 'Colonic Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000015212', 'term': 'Inflammatory Bowel Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M17206',\n",
       "      'name': 'Ulcer',\n",
       "      'asFound': 'Ulcerative',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6320',\n",
       "      'name': 'Colitis',\n",
       "      'asFound': 'Colitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6321',\n",
       "      'name': 'Colitis, Ulcerative',\n",
       "      'asFound': 'Ulcerative Colitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8875', 'name': 'Gastroenteritis', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6336', 'name': 'Colonic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17917',\n",
       "      'name': 'Inflammatory Bowel Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000607776',\n",
       "      'term': 'Ozanimod'}],\n",
       "    'ancestors': [{'id': 'D000081243',\n",
       "      'term': 'Sphingosine 1 Phosphate Receptor Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M216548',\n",
       "      'name': 'Ozanimod',\n",
       "      'asFound': 'Patient Safety',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06399172',\n",
       "    'orgStudyIdInfo': {'id': 'OSPRItaly01'},\n",
       "    'organization': {'fullName': 'OncoSil Medical Limited',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy',\n",
       "    'officialTitle': 'OncoSil Pancreatic Cancer Post-marketing Clinical Registry Italy',\n",
       "    'acronym': 'OSPRItaly'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-10-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-23',\n",
       "    'studyFirstSubmitQcDate': '2024-05-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'OncoSil Medical Limited', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The OSPRItaly Patient Registry has been developed to assess the performance and safety of\\r\\nthe OncoSil™ device when used within the approved indication of unresectable, locally\\r\\nadvanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a\\r\\nreal-world observational registry.'},\n",
       "   'conditionsModule': {'conditions': ['Locally Advanced Pancreatic Adenocarcinoma']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '1 Year',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'OncoSil',\n",
       "      'description': 'Intra-tumoural implantation'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety and tolerability',\n",
       "      'description': 'The analysis for safety within the real-world setting will be performed. The safety of\\r\\nOncoSil™ is defined by the Adverse Event profile. All safety summaries will be produced\\r\\nfor the Intention-To-Treat (ITT) population. Adverse Device Effects will be coded using\\r\\nMedical Dictionary for Regulatory Activities (MedDRA). All Adverse Device Effects\\r\\nrecorded during the Registry will be listed.\\r\\n\\r\\nSummary tables will be produced for Treatment Emergent Adverse Device Effects (TEADEs).\\r\\nThe number and percentage of patients with device-related Adverse Events by system organ\\r\\nclass (SOC) and preferred term will be tabulated. Similar summaries will be produced by\\r\\nseverity of event (both mild, moderate or severe, CTCAE grade 1-4) and device\\r\\nrelationship.\\r\\n\\r\\nIn addition, summary tables will be produced for serious TEADEs and TEADEs associated\\r\\nwith special interest acute/late radiation effects and or withdrawal.',\n",
       "      'timeFrame': 'Followed to death or to 24-months after the date of the last enrolled patient.'},\n",
       "     {'measure': 'Tumour response',\n",
       "      'description': 'Target (implanted) tumour response (local and distant)',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Device implantation Performance',\n",
       "      'description': 'Safety of the implantation of OncoSil™ within the target tumour will be measured by means\\r\\nof procedure-related Adverse Events. Ease of administration and implantation related data\\r\\nfrom user questionnaires will be assessed.',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Overall Survival',\n",
       "      'description': 'Overall survival (OS) is defined as the time from enrolment to the date of death from any\\r\\ncause. Patients who are alive or permanently lost to follow-up at the cut-off date for\\r\\nthe analysis will be censored at the last date the patient was known to be alive.',\n",
       "      'timeFrame': 'Followed to death or to 24-months after the date of the last enrolled patient'},\n",
       "     {'measure': 'Resection Rates',\n",
       "      'description': 'Surgical resection rates and outcome',\n",
       "      'timeFrame': 'Followed to death or 24 months after the date of the last enrolled patient'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Patients who are eligible for and undergo OncoSil™ implantation at an eligible\\r\\n     treatment facility according to the approved OncoSil™ System Instructions for Use\\r\\n     (IFU), as part of their clinical care.\\r\\n\\r\\n  2. Patients who have completed and signed the Patient Informed Consent Form (PICF) for\\r\\n     the OSPRItaly Patient Registry.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patients participating in an interventional clinical study (company or\\r\\n     investigator-sponsored).\\r\\n\\r\\n  2. Use of an investigational agent at the time of enrolment.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'In the participating institutions every patient who is intended to undergo implantation\\r\\nof the OncoSil™ device when used within the approved indication of unresectable, locally\\r\\nadvanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, in the\\r\\ncommercial (sales) setting will be approached by the Principal Investigator (or delegate)\\r\\nto consent to participate in the OSPRItaly Patient Registry.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M13110',\n",
       "      'name': 'Pancreatic Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T4387',\n",
       "      'name': 'Pancreatic Cancer',\n",
       "      'asFound': 'Pancreatic Cancer',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06430372',\n",
       "    'orgStudyIdInfo': {'id': 'NIR-II-ENDO'},\n",
       "    'organization': {'fullName': 'Institute of Automation, Chinese Academy of Sciences',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract',\n",
       "    'officialTitle': 'Study of Vascular Endothelial Growth Factor A Targeting NIR-II Fluorescence in the Endoscopy of Gastrointestinal Tract'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-21',\n",
       "    'studyFirstSubmitQcDate': '2024-05-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Zhenhua Hu',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'Institute of Automation, Chinese Academy of Sciences'},\n",
       "    'leadSponsor': {'name': 'Institute of Automation, Chinese Academy of Sciences',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'In this study, the investigators are studying new ways to look for abnormal tissues of\\r\\nthe gastrointestinal tract during an endoscopy. We are using a VEGF-A targeting\\r\\nfluorescent probe and a NIR-II fluorescent endoscope to help detect abnormal tissues that\\r\\nare hard to see by the naked eye.\\r\\n\\r\\nThe main purposes of this study include:\\r\\n\\r\\n  1. To translate the NIR-II approach into the endoscopy, and understand its advantages\\r\\n     and limitations on detecting abnormal tissues in gastrointestinal.\\r\\n\\r\\n  2. To validate whether topical administration of a targeting probe can stick to\\r\\n     abnormal tissues and be detected by the NIR-II endoscope.\\r\\n\\r\\n  3. To validate the safety and effectiveness of the topical administration of VEGF-A\\r\\n     targeting probes for clinical application.'},\n",
       "   'conditionsModule': {'conditions': ['Gastrointestinal Carcinoma',\n",
       "     'Dysplasia',\n",
       "     'Gastrointestinal Polyp']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Bev-ICG NIR-II Endoscopy',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The patients will receive a topical administration of probe (Bev-ICG) during the\\r\\nendoscopy. Then fluorescence imaging will be performed to guide the detection.',\n",
       "      'interventionNames': ['Drug: Bev-ICG',\n",
       "       'Device: NIR-II fluorescence endoscopy platform']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Bev-ICG',\n",
       "      'description': 'Probe targeting VEGF-A that is topically administrated during the endoscopy',\n",
       "      'armGroupLabels': ['Bev-ICG NIR-II Endoscopy']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'NIR-II fluorescence endoscopy platform',\n",
       "      'description': 'An endoscopic detection device which can detect and visualize NIR-II fluorescent signal\\r\\nduring the endoscopy',\n",
       "      'armGroupLabels': ['Bev-ICG NIR-II Endoscopy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Validation of NIR-II endoscope and probe targeting VEGF-A',\n",
       "      'description': 'Demonstrate the feasibility of using the NIR-II endoscope and VEGF-A targeting\\r\\nfluorescent probe to image abnormal tissues of the gastrointestinal tract.',\n",
       "      'timeFrame': 'During endoscopy'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Known or suspected gastrointestinal lesions.\\r\\n\\r\\n  -  Scheduled for a clinically-indicated endoscopy.\\r\\n\\r\\n  -  Mentally competent person, 18 years or older.\\r\\n\\r\\n  -  Approved to sign the informed consent.\\r\\n\\r\\n  -  Adequate potential for follow-up.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Subjects with known allergy or negative reaction to ICG or derivatives.\\r\\n\\r\\n  -  Undesirable function of heart, lung, kidney, or any other organs.\\r\\n\\r\\n  -  Enrolled in other trials in the past 3 months.\\r\\n\\r\\n  -  Pregnant or trying to conceive.\\r\\n\\r\\n  -  Unable to tolerate an endoscopy.\\r\\n\\r\\n  -  Medical or psychiatric conditions that compromise the patient's ability to give\\r\\n     informed consent.\\r\\n\\r\\n  -  The researchers considered inappropriate to be included.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Lidan Fu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '17754927702',\n",
       "      'email': 'fulidan2021@ia.ac.cn'}],\n",
       "    'locations': [{'facility': 'Lidan Fu',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Beijing',\n",
       "      'state': 'Beijing',\n",
       "      'zip': '100190',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Lidan Fu',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '17754927702',\n",
       "        'email': 'fulidan2021@ia.ac.cn'}],\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M5534',\n",
       "      'name': 'Carcinoma',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14011', 'name': 'Polyps', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M18681',\n",
       "      'name': 'Endothelial Growth Factors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05959304',\n",
       "    'orgStudyIdInfo': {'id': 'CRTH258BIN01'},\n",
       "    'organization': {'fullName': 'Novartis', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.',\n",
       "    'officialTitle': 'A Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Diabetic Macular Edema (DME).'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-26', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-06-26', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-17',\n",
       "    'studyFirstSubmitQcDate': '2023-07-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-03',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-04', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to generate additional safety and effectiveness data in\\r\\nIndian Diabetic macular edema (DME) patients that more closely resemble the real-world\\r\\npopulation intended to be treated with Brolucizumab. This study is being conducted as\\r\\npart of the post-marketing regulatory commitment to the Indian Health authority.',\n",
       "    'detailedDescription': \"This study is a prospective, non-interventional, open-label, single-arm, multi-center\\r\\nphase IV study to evaluate safety and effectiveness of intravitreal injections (IVI) of\\r\\nbrolucizumab in patients with diabetic macular edema (DME) for whom a decision has\\r\\nalready been made to be treated with brolucizumab, irrespective of the trial\\r\\nparticipation. The study period for each patient will be 40 weeks from the informed\\r\\nconsent and enrolment in the study.\\r\\n\\r\\nAssessments/investigations shall be performed in accordance to the local clinical\\r\\npractice and the Investigator's assessed response will be collected in the database. Any\\r\\npatient who suffers from intraocular inflammation (IOI) during the study, treatment with\\r\\nbrolucizumab will be discontinued.\\r\\n\\r\\nData originating from assessments and evaluations performed at routine patient visits\\r\\nwill be collected from the patient's medical records at Baseline, i.e., the start of\\r\\nbrolucizumab treatment, and approximately at Week 6, Week 12, Week 18, Week 24, Week 32,\\r\\nWeek 36, and at Week 40. Safety data (AEs and SAEs) from any time point during the\\r\\nduration of the study.\"},\n",
       "   'conditionsModule': {'conditions': ['Diabetic Macular Edema'],\n",
       "    'keywords': ['Vision Loss', 'Macular Edema', 'Metamorphopsia']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 66, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'brolucizumab 6 mg',\n",
       "      'description': 'brolucizumab 6 mg intravitreal injection',\n",
       "      'interventionNames': ['Other: brolucizumab']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'brolucizumab',\n",
       "      'description': 'There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection\\r\\nwill be based on the local label/clinical practice.',\n",
       "      'armGroupLabels': ['brolucizumab 6 mg']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and characteristics of treatment-emergent adverse events during the 40 weeks of treatment with Brolucizumab.',\n",
       "      'description': 'To evaluate ocular & non-ocular safety of intravitreal brolucizumab in real-world\\r\\npatients with Diabetic Macular Edema (DME).',\n",
       "      'timeFrame': '40 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Mean change in BCVA from Baseline to Week 40 as measured by ETDRS letters.',\n",
       "      'description': 'To evaluate the effectiveness of brolucizumab in the management of DME in terms of change\\r\\nin best-corrected visual acuity (BCVA) from Baseline to Week 40 as measured by Early\\r\\nTreatment Diabetic Retinopathy Study (ETDRS) letters.\\r\\n\\r\\nMin and max possible scores are 0-100 letters read respectively. A higher score\\r\\nrepresents better visual functioning.',\n",
       "      'timeFrame': 'Baseline, week 40'},\n",
       "     {'measure': 'Percentage of patients with presence/absence of IRF and SRF at Week 40 compared to Baseline.',\n",
       "      'description': 'To evaluate the effectiveness of brolucizumab on fluid [intraretinal fluid (IRF) and\\r\\nsubretinal fluid (SRF)] from Baseline to Week 40.',\n",
       "      'timeFrame': 'Baseline, week 40'},\n",
       "     {'measure': 'Mean change in CRT as assessed by Optical Coherence Tomography (OCT) from Baseline to Week 40.',\n",
       "      'description': 'To evaluate the effectiveness of brolucizumab on central retinal thickness (CRT) from\\r\\nBaseline to Week 40.',\n",
       "      'timeFrame': 'Baseline, week 40'},\n",
       "     {'measure': 'Number of brolucizumab injections administered to the patients during 40 weeks of treatment with brolucizumab.',\n",
       "      'description': 'To characterize the number of anti-VEGF injections during the 40 weeks of treatment with\\r\\nbrolucizumab in the study.',\n",
       "      'timeFrame': '40 weeks'},\n",
       "     {'measure': 'Number of non-injection visits during 40 weeks of treatment with brolucizumab.',\n",
       "      'description': 'To characterize the number of non-injection visits during the 40 weeks of treatment with\\r\\nbrolucizumab in the study.',\n",
       "      'timeFrame': '40 weeks'},\n",
       "     {'measure': 'Total number of visits during 40 weeks of treatment with brolucizumab.',\n",
       "      'description': 'To characterize the total number of visits during the 40 weeks of treatment with\\r\\nbrolucizumab in the study.',\n",
       "      'timeFrame': '40 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Male and female patients ≥ 18 years old with visual impairment due to DME involving\\r\\n     the center of the macula.\\r\\n\\r\\n  2. Patients with type 1 or type 2 diabetes mellitus.\\r\\n\\r\\n  3. Patient or legally acceptable representative (LAR) must provide signed informed\\r\\n     consent for participation in the study.\\r\\n\\r\\n       -  Exclusion Criteria:\\r\\n\\r\\n  1. Concomitant conditions or ocular disorders in the study eye at screening or Baseline\\r\\n     which could, in the opinion of the Investigator, prevent response to study treatment\\r\\n     or may confound interpretation of study results, compromise visual acuity or require\\r\\n     medical or surgical intervention during the study period (e.g., cataract, vitreous\\r\\n     hemorrhage, retinal vascular occlusion, retinal detachment, macular hole, or\\r\\n     choroidal neovascularization of any cause).\\r\\n\\r\\n  2. Patient with existing or suspected ocular or periocular infection in the study eye.\\r\\n\\r\\n  3. Patient with an existing intraocular inflammation (IOI) in the study eye.\\r\\n\\r\\n  4. Patient who has undergone intraocular surgery including laser photocoagulation in\\r\\n     the study eye within 3 months prior to enrollment in this study.\\r\\n\\r\\n  5. Patient with uncontrolled glaucoma defined as intraocular pressure > 25 mmHg despite\\r\\n     treatment with anti-glaucoma medication, or according to Investigator's judgment.\\r\\n\\r\\n  6. Patient having scar, fibrosis, and atrophy involving the center of the fovea in the\\r\\n     study eye.\\r\\n\\r\\n  7. Active proliferative diabetic retinopathy in the study eye as per Investigator.\\r\\n\\r\\n  8. Patient having history of cardiac or cerebral ischemia in last 6 months prior to\\r\\n     enrollment in this study.\\r\\n\\r\\n  9. Previous treatment with any anti-VEGF drugs, steroids (dexamethasone intravitreal\\r\\n     implant or triamcinolone acetonide) or other investigational drugs in the study eye.\\r\\n\\r\\n 10. Pregnant or nursing (lactating) women at screening, where pregnancy is defined as\\r\\n     the state of a female after conception and until the termination of gestation,\\r\\n     confirmed by a positive hCG pregnancy test.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '100 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'The study population will consist of adult male and female patients aged 18 years and\\r\\nabove, diagnosed with DME for whom the Investigator prescribes treatment with\\r\\nbrolucizumab 6 mg injection in adherence to local Prescribing Information (PI).',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Novartis Pharmaceuticals',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+41613241111',\n",
       "      'email': 'novartis.email@novartis.com'},\n",
       "     {'name': 'Novartis Pharmaceuticals', 'role': 'CONTACT'}],\n",
       "    'overallOfficials': [{'name': 'Novartis Pharmaceuticals',\n",
       "      'affiliation': 'Novartis Pharmaceuticals',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008269',\n",
       "      'term': 'Macular Edema'},\n",
       "     {'id': 'D000004487', 'term': 'Edema'}],\n",
       "    'ancestors': [{'id': 'D000008268', 'term': 'Macular Degeneration'},\n",
       "     {'id': 'D000012162', 'term': 'Retinal Degeneration'},\n",
       "     {'id': 'D000012164', 'term': 'Retinal Diseases'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11261',\n",
       "      'name': 'Macular Edema',\n",
       "      'asFound': 'Macular Edema',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7657', 'name': 'Edema', 'asFound': 'Edema', 'relevance': 'HIGH'},\n",
       "     {'id': 'M11260', 'name': 'Macular Degeneration', 'relevance': 'LOW'},\n",
       "     {'id': 'M14997', 'name': 'Retinal Degeneration', 'relevance': 'LOW'},\n",
       "     {'id': 'M14999', 'name': 'Retinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06267872',\n",
       "    'orgStudyIdInfo': {'id': 'HVTN 309'},\n",
       "    'organization': {'fullName': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "     'class': 'NIH'},\n",
       "    'briefTitle': 'A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum',\n",
       "    'officialTitle': 'A Phase 1 Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-02',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-12', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-07-11', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-12',\n",
       "    'studyFirstSubmitQcDate': '2024-02-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "     'class': 'NIH'},\n",
       "    'collaborators': [{'name': 'National Institutes of Health (NIH)',\n",
       "      'class': 'NIH'},\n",
       "     {'name': 'Department of Health and Human Services', 'class': 'FED'},\n",
       "     {'name': 'Duke University', 'class': 'OTHER'},\n",
       "     {'name': 'Access to Advanced Health Institute (AAHI)',\n",
       "      'class': 'OTHER'}]},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a multicenter, open-label, phase 1 clinical trial to test two human\\r\\nimmunodeficiency virus (HIV) vaccines with two adjuvants. An adjuvant is an ingredient\\r\\nused with some vaccines that may help people make an immune response. HIV is the virus\\r\\nthat causes acquired immunodeficiency syndrome (AIDS).\\r\\n\\r\\nAbout 42 people will take part in the HVTN 309 clinical trial. This clinical trial will\\r\\ntake place at multiple sites in the US and South Africa and the clinical trial is divided\\r\\ninto 3 parts: Part A, Part B and Part C. About 3 people will participate in Part A of\\r\\nthis study. After results from Part A are reviewed, it will be determined whether or not\\r\\nPart B and Part C of the clinical trial will proceed.'},\n",
       "   'conditionsModule': {'conditions': ['HIV']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 42, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Part A - Group 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '• 60 mcg of CD4BS CH505M5 Pr-NP1, to be administered as two 0.5 mL doses intramuscularly\\r\\nat months 0, 2, and 4.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1']},\n",
       "     {'label': 'Part B - Group 2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be\\r\\n     administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 1.0 mcg of ACU-026-001-1\\r\\n     adjuvant to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: ACU-026-001-1 (labeled as empty LNP)']},\n",
       "     {'label': 'Part B - Group 3',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-1 adjuvant to be\\r\\n     administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1\\r\\n     adjuvant to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: ACU-026-001-1 (labeled as empty LNP)']},\n",
       "     {'label': 'Part B - Group 4',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  60 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with\\r\\n     500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0,\\r\\n     2, and 4\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant\\r\\n     along with 500 mcg of Alum to be administered to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: 3M-052-AF (labeled as AP 60-702)',\n",
       "       'Biological: Aluminum Hydroxide Suspension (Alum)']},\n",
       "     {'label': 'Part C - Group 5',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Low dose:\\r\\n\\r\\n  -  100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 1.0 mg of ACU-026-001-1 adjuvant to be\\r\\n     administered as two 0.5 mL doses intramuscularly at months 0, 2, and 4,\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 1mg empty LNP adjuvant to be\\r\\n     administered at months 6 and 8.\\r\\n\\r\\nOR,\\r\\n\\r\\nHigh Dose:\\r\\n\\r\\n  -  100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 2.0 mg of ACU-026-001-01 adjuvant to\\r\\n     be administered as two 0.5 mL doses intramuscularly at month 0, 2, and 4,\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 2.0 mg of ACU-026-001-1\\r\\n     adjuvant to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: ACU-026-001-1 (labeled as empty LNP)']},\n",
       "     {'label': 'Part C - Group 6',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 3 mcg of 3M-052-AF adjuvant along with\\r\\n     500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0,\\r\\n     2, and 4,\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 3 mcg of 3M-052-AF adjuvant\\r\\n     along with 500 mcg of Alum to be administered to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: 3M-052-AF (labeled as AP 60-702)',\n",
       "       'Biological: Aluminum Hydroxide Suspension (Alum)']},\n",
       "     {'label': 'Part C - Group 7',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  100 mcg of CD4BS CH505M5 Pr-NP1, admixed with 5 mcg of 3M-052-AF adjuvant along with\\r\\n     500 mcg of Alum to be administered as two 0.5 mL doses intramuscularly at months 0,\\r\\n     2, and 4\\r\\n\\r\\n  -  Followed by 300 mcg of CH505TF chTrimer, admixed with 5 mcg of 3M-052-AF adjuvant\\r\\n     along with 500 mcg of Alum to be administered to be administered at months 6 and 8.',\n",
       "      'interventionNames': ['Biological: CD4BS CH505M5 Pr-NP1',\n",
       "       'Biological: CH505TF chTrimer',\n",
       "       'Biological: 3M-052-AF (labeled as AP 60-702)',\n",
       "       'Biological: Aluminum Hydroxide Suspension (Alum)']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'CD4BS CH505M5 Pr-NP1',\n",
       "      'description': 'A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered\\r\\nintramuscularly (IM).',\n",
       "      'armGroupLabels': ['Part A - Group 1',\n",
       "       'Part B - Group 2',\n",
       "       'Part B - Group 3',\n",
       "       'Part B - Group 4',\n",
       "       'Part C - Group 5',\n",
       "       'Part C - Group 6',\n",
       "       'Part C - Group 7']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'CH505TF chTrimer',\n",
       "      'description': 'A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF\\r\\ngp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.',\n",
       "      'armGroupLabels': ['Part B - Group 2',\n",
       "       'Part B - Group 3',\n",
       "       'Part B - Group 4',\n",
       "       'Part C - Group 5',\n",
       "       'Part C - Group 6',\n",
       "       'Part C - Group 7']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': '3M-052-AF (labeled as AP 60-702)',\n",
       "      'description': 'An aqueous formulation (AF) of the small molecule imidazoquinoline immune response\\r\\nmodifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.',\n",
       "      'armGroupLabels': ['Part B - Group 4',\n",
       "       'Part C - Group 6',\n",
       "       'Part C - Group 7']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'Aluminum Hydroxide Suspension (Alum)',\n",
       "      'description': 'Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg)\\r\\nalong with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.',\n",
       "      'armGroupLabels': ['Part B - Group 4',\n",
       "       'Part C - Group 6',\n",
       "       'Part C - Group 7'],\n",
       "      'otherNames': ['Alhydrogel']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'ACU-026-001-1 (labeled as empty LNP)',\n",
       "      'description': 'An AF consisting of 4 lipid components.',\n",
       "      'armGroupLabels': ['Part B - Group 2',\n",
       "       'Part B - Group 3',\n",
       "       'Part C - Group 5']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency of local reactogenicity signs and symptoms after receipt of any study vaccine',\n",
       "      'timeFrame': 'Part A: Day 15, 71, and 127; Part B: Day 15, 71, 127, 183, and 239; Part C: 15, 71, 127, 183, and 239 (14 days following receipt of any study vaccine)'},\n",
       "     {'measure': 'Frequency of systemic reactogenicity signs and symptoms after receipt of any study vaccine',\n",
       "      'timeFrame': 'Part A: Day 15, 71, and 127; Part B: Day 15, 71, 127, 183, and 239; Part C: 15, 71, 127, 183, and 239 (14 days following receipt of any study vaccine)'},\n",
       "     {'measure': 'Number of serious adverse events (SAEs) leading to early participant withdrawal or permanent discontinuation',\n",
       "      'timeFrame': '31 months'},\n",
       "     {'measure': 'Number of medically attended adverse events (MAAEs) leading to early participant withdrawal or permanent discontinuation',\n",
       "      'timeFrame': '31 months'},\n",
       "     {'measure': 'Number of adverse events of special interest (AESIs) leading to early participant withdrawal or permanent discontinuation',\n",
       "      'timeFrame': '31 months'},\n",
       "     {'measure': 'Number of adverse events (AEs) leading to early participant withdrawal or permanent discontinuation',\n",
       "      'timeFrame': '31 months'},\n",
       "     {'measure': 'Part C only: Frequency of the CD4BS and CH505M5, G458Y, GNT1-specific, N280D KO IgG+ memory B cells, as assessed by flow cytometry',\n",
       "      'timeFrame': 'Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'},\n",
       "     {'measure': 'Part C only: Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'},\n",
       "     {'measure': 'Part C only: Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Parts B and C: Response rate of serum IgG binding Abs to autologous and heterologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Magnitude of serum IgG binding Abs to autologous and heterologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Part B only: Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by the TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'},\n",
       "     {'measure': 'Part B only: Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by the TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'},\n",
       "     {'measure': 'Parts B and C: Response rate of differential serum Ab neutralization of precursor detection virus and corresponding epitope KO virus, as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Magnitude of differential serum Ab neutralization of precursor detection virus and corresponding epitope KO virus, as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Response rate of serum Ab neutralization of heterologous HIV-1 strains, as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Magnitude of serum Ab neutralization of heterologous HIV-1 strains, as measured by TZM-bl assay',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Response rate of CD4+ and CD8+ T-cell responses, as measured by flow cytometry',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Parts B and C: Magnitude of CD4+ and CD8+ T-cell responses, as measured by flow cytometry',\n",
       "      'timeFrame': 'Part B: Day 127 and 239; Part C: Day 127 and 239 (2 weeks after the third and fifth vaccinations, respectively, in each part)'},\n",
       "     {'measure': 'Part B only: Frequency of the CD4BS and CH505M5, G458Y, GNT1-specific, N280D KO IgG+ memory B cells, as assessed by flow cytometry',\n",
       "      'timeFrame': 'Part B: Day 127 and 239 (2 weeks after the third and fifth vaccinations respectively)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Able and willing to complete the informed consent process, including an Assessment\\r\\n     of Understanding (AoU): Volunteer demonstrates an understanding of this study and\\r\\n     completes a questionnaire prior to first vaccination with verbal demonstration of\\r\\n     understanding of questionnaire items that were answered incorrectly.\\r\\n\\r\\n  2. 18 to 55 years old, inclusive, on day of enrollment.\\r\\n\\r\\n  3. Available for clinic follow-up through the last clinic visit, willing to undergo FNA\\r\\n     and leukapheresis (for Part C only), and willing to be contacted 12 months after the\\r\\n     last study-product administration.\\r\\n\\r\\n  4. Agrees not to enroll in another study of an investigational agent during\\r\\n     participation in the trial. If a potential participant is already enrolled in\\r\\n     another clinical trial, approvals from the other trial sponsor and the HVTN 309 PSRT\\r\\n     are required prior to enrollment into HVTN 309.\\r\\n\\r\\n  5. In good general health according to the clinical judgment of the site investigator.\\r\\n\\r\\n  6. Physical examination and laboratory results without clinically significant findings\\r\\n     that would interfere with assessment of safety or reactogenicity in the clinical\\r\\n     judgement of the site investigator.\\r\\n\\r\\n  7. Assessed by clinical staff as having a low likelihood of acquiring HIV per\\r\\n     guidelines and agrees to discuss their potential for HIV acquisition, agrees to\\r\\n     risk-reduction counseling, and agrees to avoid behaviors associated with a higher\\r\\n     likelihood of acquiring HIV through the final study visit. Low likelihood may\\r\\n     include persons stably taking pre-exposure prophylaxis (PrEP).\\r\\n\\r\\n  8. Hemoglobin (Hgb):\\r\\n\\r\\n       -  ≥ 11.0 g/dL for AFAB volunteers\\r\\n\\r\\n       -  ≥ 13.0 g/dL for cisgender AMAB volunteers and for transgender men who have been\\r\\n          on hormone therapy for more than 6 consecutive months\\r\\n\\r\\n       -  ≥ 12.0 g/dL for transgender women who have been on hormone therapy for more\\r\\n          than 6 consecutive months\\r\\n\\r\\n       -  For transgender volunteers who have been on hormone therapy for less than 6\\r\\n          consecutive months, determine Hgb eligibility based on their sex assigned at\\r\\n          birth.\\r\\n\\r\\n  9. WBC count = 2,500 to 12,000/mm3 (WBC over 12,000/mm3 is not exclusionary if further\\r\\n     evaluation shows general good health and if PSRT approval is granted).\\r\\n\\r\\n 10. Platelets = 125,000 to 550,000/mm3.\\r\\n\\r\\n 11. ALT < 2.5 x upper limit of normal (ULN) based on the institutional normal range.\\r\\n\\r\\n 12. Serum creatinine ≤ 1.1 x ULN based on the institutional normal range.\\r\\n\\r\\n 13. For Part C, total serum calcium level of > 8.5 mg/dL.\\r\\n\\r\\n 14. Systolic blood pressure of 90 to <140 mmHg and diastolic blood pressure of 50 to <90\\r\\n     mmHg at screening visit. The average blood pressure between the screening visit and\\r\\n     the enrollment visit must be below 140 mmHg systolic and 90 mmHg diastolic. A single\\r\\n     measurement greater than or equal to 160 systolic mmHg or 100 mmHg diastolic during\\r\\n     the current study evaluation is exclusionary.\\r\\n\\r\\n 15. Negative HIV test results by one of the following options:\\r\\n\\r\\n     For US volunteers:\\r\\n\\r\\n       -  US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA)\\r\\n\\r\\n       -  Chemiluminescent microparticle immunoassay (CMIA)\\r\\n\\r\\n       -  Two negative results on HIV rapid tests (one of which must be FDA-approved\\r\\n          CMIA)\\r\\n\\r\\n     For non-US volunteers:\\r\\n\\r\\n       -  A negative European Conformity (CE)-marked EIA\\r\\n\\r\\n       -  A CMIA\\r\\n\\r\\n       -  A negative result on two HIV rapid tests (one of these rapid tests must be\\r\\n          CE-marked)\\r\\n\\r\\n 16. Negative for anti-Hepatitis C virus (HCV) Abs (anti-HCV) or negative HCV nucleic\\r\\n     acid test (NAT) if anti-HCV Abs are detected.\\r\\n\\r\\n 17. Negative for Hepatitis B surface Ag.\\r\\n\\r\\n 18. For AFAB volunteers or volunteers who were intersex at birth and are capable of\\r\\n     becoming pregnant (hereafter referred to as \"persons of pregnancy potential\"):\\r\\n\\r\\n       -  Must agree to use effective means of contraception from at least 21 days prior\\r\\n          to enrollment through 8 weeks after their last scheduled vaccination timepoint.\\r\\n\\r\\n       -  Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test\\r\\n          (urine or serum) on day of enrollment.\\r\\n\\r\\n 19. AFAB volunteers or volunteers who were intersex at birth must agree to not seek\\r\\n     pregnancy through alternative methods, such as oocyte retrieval, artificial\\r\\n     insemination, or in vitro fertilization from at least 21 days prior to enrollment\\r\\n     through 8 weeks after their last scheduled vaccination timepoint.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Volunteer who is breastfeeding or pregnant.\\r\\n\\r\\n  2. Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site\\r\\n     investigator assesses are in good health, may be considered by PSRT approval.\\r\\n\\r\\n  3. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by\\r\\n     HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes\\r\\n     are not exclusionary. Enrollment of individuals with Type 2 DM that is well\\r\\n     controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case\\r\\n     basis, provided that the HgbA1c is ≤ 8% within the last 6 months (sites may draw\\r\\n     these at screening).\\r\\n\\r\\n  4. Previous or current recipient of an investigational HIV vaccine (previous placebo/\\r\\n     control recipients are not excluded).\\r\\n\\r\\n  5. Receipt of non-HIV experimental vaccine(s) received within the last 1 year.\\r\\n     Exceptions include vaccines that have subsequently undergone licensure or Emergency\\r\\n     Use Authorization (EUA) by the FDA or World Health Organization (WHO) Emergency Use\\r\\n     Listing (EUL), or if outside the US, by the national regulatory authority (RA)\\r\\n     authorizing this clinical trial.\\r\\n\\r\\n  6. Congenital or acquired immunodeficiency, including systemic medication use likely to\\r\\n     impair immune response to vaccine in the opinion of the site investigator, such as\\r\\n     glucocorticoid use, equal to or greater than prednisone 10 mg/day within 3 months\\r\\n     prior to enrollment.\\r\\n\\r\\n  7. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of\\r\\n     immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.\\r\\n\\r\\n  8. History of myocarditis and/or pericarditis.\\r\\n\\r\\n  9. Receipt of any vaccine within 4 weeks prior to enrollment.\\r\\n\\r\\n 10. Initiation of Ag-based immunotherapy for allergies within the previous year (stable\\r\\n     immunotherapy is not exclusionary); inclusion of participants who initiated\\r\\n     immunotherapy within the previous year requires PSRT approval.\\r\\n\\r\\n 11. Receipt of investigational research agents with a half-life of 7 or fewer days\\r\\n     within 4 weeks prior to enrollment. If a potential participant has received\\r\\n     investigational agents with a half-life of greater than 7 days (or unknown\\r\\n     half-life) within the past year, PSRT approval is required for enrollment.\\r\\n\\r\\n 12. History of serious reaction (eg, hypersensitivity, anaphylaxis) to any related\\r\\n     vaccine or component of the study-vaccine regimen. Of note, the study proposed\\r\\n     vaccine regimen includes components similar to components of the licensed COMIRNATY\\r\\n     (Pfizer) and SPIKEVAX (Moderna) mRNA vaccines; severe reaction to these vaccines is\\r\\n     therefore exclusionary.\\r\\n\\r\\n 13. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.\\r\\n\\r\\n 14. Idiopathic urticaria within the past year.\\r\\n\\r\\n 15. Bleeding disorder diagnosed by a clinician which would make study procedures a\\r\\n     contraindication.\\r\\n\\r\\n 16. Seizure disorder; febrile seizures as a child or seizures secondary to alcohol\\r\\n     withdrawal more than 5 years ago are not exclusionary.\\r\\n\\r\\n 17. Asplenia or functional asplenia.\\r\\n\\r\\n 18. Active duty and reserve US military personnel.\\r\\n\\r\\n 19. Any other chronic or clinically significant condition that, in the clinical judgment\\r\\n     of the investigator, would jeopardize the safety or rights of the study participant,\\r\\n     including but not limited to: clinically significant forms of substance use or\\r\\n     alcohol use disorder(s), serious psychiatric disorders, persons with any suicide\\r\\n     attempt within the past 1 year (if between 1 and 2 years, consult PSRT for\\r\\n     approval), or cancer that, in the clinical judgement of the site investigator, has\\r\\n     potential for recurrence (excluding basal cell carcinoma).\\r\\n\\r\\n 20. Asthma is excluded if the participant has ANY of the following:\\r\\n\\r\\n       -  Required either oral or parenteral corticosteroids for an exacerbation 2 or\\r\\n          more times within the past year; OR\\r\\n\\r\\n       -  Needed emergency care, urgent care, hospitalization, or intubation for an acute\\r\\n          asthma exacerbation within the past year (eg, would NOT exclude individuals\\r\\n          with asthma who meet all other criteria but sought urgent/emergent care solely\\r\\n          for asthma medication refills or coexisting conditions unrelated to asthma); OR\\r\\n\\r\\n       -  Uses a short-acting rescue inhaler more than 2 days/week for acute asthma\\r\\n          symptoms (ie, not for preventive treatment prior to athletic activity); OR\\r\\n\\r\\n       -  Uses medium- to high-dose inhaled corticosteroids (greater than 250 mcg\\r\\n          fluticasone or therapeutic equivalent per day), whether in single-therapy or\\r\\n          dual-therapy inhalers (ie, with a long-acting beta agonist [LABA]); OR\\r\\n\\r\\n       -  Uses more than 1 medication for maintenance therapy daily. Inclusion of anyone\\r\\n          on a stable dose of more than 1 medication for maintenance therapy daily for\\r\\n          greater than 2 years requires PSRT approval.\\r\\n\\r\\n 21. A participant with a history of a potential immune-mediated medical condition\\r\\n     (PIMMC), either active or remote. Not exclusionary: 1) Remote history of Bell\\'s\\r\\n     palsy (> 2 years ago) not associated with other neurologic symptoms and 2) Mild\\r\\n     psoriasis or other mild, uncomplicated, localized or dermatologic condition that\\r\\n     does not require ongoing systemic treatment.\\r\\n\\r\\n 22. History of allergy to local anesthetic (Novocaine, Lidocaine).\\r\\n\\r\\n 23. Investigator concern for difficulty with venous access based on clinical history and\\r\\n     physical examination. For example, persons with a history of intravenous drug use or\\r\\n     substantial difficulty with previous blood draws.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '55 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Alabama CRS (Site ID: 31788)',\n",
       "      'city': 'Birmingham',\n",
       "      'state': 'Alabama',\n",
       "      'zip': '35222',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Heather Logan, A.N.P.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '205-873-8686',\n",
       "        'email': 'heatherlogan@uabmc.edu'}],\n",
       "      'geoPoint': {'lat': 33.52066, 'lon': -86.80249}},\n",
       "     {'facility': 'The Ponce de Leon Center CRS (Site ID: 5802)',\n",
       "      'city': 'Atlanta',\n",
       "      'state': 'Georgia',\n",
       "      'zip': '30308',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Ericka Patrick, M.S.N',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '404-616-6313',\n",
       "        'email': 'erpatri@emory.edu'}],\n",
       "      'geoPoint': {'lat': 33.749, 'lon': -84.38798}},\n",
       "     {'facility': 'Vanderbilt Vaccine (VV) CRS (Site ID: 30352)',\n",
       "      'city': 'Nashville',\n",
       "      'state': 'Tennessee',\n",
       "      'zip': '37232',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Shonda E. Sumner, B.S.N.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '615-343-6906',\n",
       "        'email': 'Shonda.sumner@vumc.org'}],\n",
       "      'geoPoint': {'lat': 36.16589, 'lon': -86.78444}},\n",
       "     {'facility': 'Setshaba Research Centre CRS (Site ID: 31829)',\n",
       "      'city': 'Soshanguve',\n",
       "      'state': 'Gauteng',\n",
       "      'zip': '0152',\n",
       "      'country': 'South Africa',\n",
       "      'contacts': [{'name': 'Magdeline K. Molapo',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '27-12-7992422',\n",
       "        'email': 'KMolapo@setshaba.org.za'}]},\n",
       "     {'facility': 'Isipingo CRS (Site ID: 31635)',\n",
       "      'city': 'Isipingo',\n",
       "      'state': 'Kwa Zulu Natal',\n",
       "      'zip': '4110',\n",
       "      'country': 'South Africa',\n",
       "      'contacts': [{'name': 'Girisha Kistnasami, B.Sc., D.P.M.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '27-31-2423600',\n",
       "        'email': 'girisha.kistnasami@mrc.ac.za'}],\n",
       "      'geoPoint': {'lat': -29.98639, 'lon': 30.91853}},\n",
       "     {'facility': 'Klerksdorp CRS (Site ID: 30325)',\n",
       "      'city': 'Klerksdorp',\n",
       "      'state': 'North West Province',\n",
       "      'zip': '2571',\n",
       "      'country': 'South Africa',\n",
       "      'contacts': [{'name': 'Olebogeng Jonkane',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': 'None Listed',\n",
       "        'email': 'ojonkane@auruminstitute.org'}],\n",
       "      'geoPoint': {'lat': -26.85213, 'lon': 26.66672}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M3522',\n",
       "      'name': 'Acquired Immunodeficiency Syndrome',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M18250', 'name': 'HIV Infections', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000000536',\n",
       "      'term': 'Aluminum Hydroxide'},\n",
       "     {'id': 'C000626991', 'term': 'MEDI9197'}],\n",
       "    'ancestors': [{'id': 'D000000276', 'term': 'Adjuvants, Immunologic'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000863', 'term': 'Antacids'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000005765', 'term': 'Gastrointestinal Agents'}],\n",
       "    'browseLeaves': [{'id': 'M255432',\n",
       "      'name': 'MEDI9197',\n",
       "      'asFound': 'ARC-520',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3877',\n",
       "      'name': 'Aluminum Hydroxide',\n",
       "      'asFound': 'Concomitantly with',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M257732', 'name': 'Aluminum sulfate', 'relevance': 'LOW'},\n",
       "     {'id': 'M3628', 'name': 'Adjuvants, Immunologic', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4188', 'name': 'Antacids', 'relevance': 'LOW'},\n",
       "     {'id': 'M4219', 'name': 'Anti-Ulcer Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06430476',\n",
       "    'orgStudyIdInfo': {'id': 'EMI_depression'},\n",
       "    'organization': {'fullName': 'The University of Hong Kong',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'EMI Therapy for Depression in Hong Kong',\n",
       "    'officialTitle': 'Ecological Momentary Intervention (EMI) as Augmentative Therapy for Depression in Clinical Sample in Hong Kong'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-14',\n",
       "    'studyFirstSubmitQcDate': '2024-05-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'The University of Hong Kong', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'To determine if a two-week ecological momentary intervention (two EMA + one EMI daily) as\\r\\naugmentation to treatment as usual would reduce depressive symptoms, rumination levels,\\r\\nand functioning in subjects with mild to moderate depression, as compared to active\\r\\ncontrols receiving three EMA prompts daily.',\n",
       "    'detailedDescription': 'Background:\\r\\n\\r\\nMajor Depressive Disorder (MDD) is the leading contributors to disability-adjusted life\\r\\nyears, with a burden comparable to that of cardiovascular disease. Among the core\\r\\nsymptoms of MDD, rumination stands out as a particularly pernicious factor. Rumination is\\r\\ndysfunctional disturbing thinking; a maladaptive pattern of regulating thoughts and\\r\\nemotions characterized by a repetitive focus on negative thoughts, such as dwelling on\\r\\nnegative memories and analyzing events without taking actions. Rumination amplifies\\r\\nnegative cognitions and attenuates the effect of adapting problem-solving strategy,\\r\\ndecreasing the motivation of patients to cope with stressful encounters and become more\\r\\nvulnerable to momentary low mood. Interventional strategies (such as Cognitive Bias\\r\\nModification) targeting rumination involves increases one\\'s ability to become aware of\\r\\ntheir own rumination and supporting them to adapt alternative thinking habits.\\r\\nComplementary techniques such as mindfulness and relaxation do not involve the reframing\\r\\nof negative thoughts but rather promote the acceptance of these thoughts, in this way, it\\r\\nallows one become more aware of distractions and repetitive past or future thinking\\r\\nevents. The ESM, a structured self-report diary technique several times a day over a\\r\\nnumber of days using mobile devices zooming in on the micro-level of experience and\\r\\nbehavior, presents a novel and promising approach to accurately track symptoms and\\r\\nexperience by minimizing recall bias and capturing the natural fluctuations of symptom on\\r\\na more immediate, granular level. The ESM-derived intervention (ESM-I), uses personalized\\r\\nmobile feedback to effectively treat depressive symptoms. Importantly, increasing\\r\\nevidence from randomised controlled trials (RCTs) have shown ESM-I as effective means to\\r\\naugment interventions in depression. While improving rumination is key the core\\r\\ndepression symptom, ESM-I has yet to specifically target rumination, and the mechanisms\\r\\nby which ESM-I exert therapeutic effects warrant further investigation.\\r\\n\\r\\nObjectives:\\r\\n\\r\\nOur study aims to investigate the efficacy of a newly developed smartphone based 2-week\\r\\nEcological Momentary Intervention (EMI) in comparison with an active control group\\r\\nreceiving only ESM, as an innovative, online-based, accessible, and augmentative\\r\\ntreatment for depression. This intervention is designed to be both timely and adaptive,\\r\\ntargeting the core symptom of anhedonia in a clinical sample within Hong Kong.\\r\\n\\r\\nDesign:\\r\\n\\r\\nThis is a single-center, randomized, double-blind, sham-controlled trial with three\\r\\nassessment time points: Baseline (T0), post-intervention (T1) and 1-month\\r\\npost-intervention (T2).\\r\\n\\r\\nEcological Momentary Assessment (EMA): After providing informed consent, participants\\r\\nwill install the \"m-path\" smartphone-based application, which is an open-source ESM\\r\\nprogram developed by KU Leuven. Following a briefing and practise run, participants will\\r\\nbe randomly prompted within designated 3-hour blocks three times daily to complete a\\r\\n5-minute questionnaire assessing their momentary affect, rumination levels, and\\r\\nsuicidality, using visual analogue scales ranging from 0 (lowest) to 100 (highest). There\\r\\nwill be 14 EMA questions covering affect (8 questions), suicidality (2 questions), and\\r\\nrumination (4 questions).\\r\\n\\r\\nEcological Momentary Intervention (EMI): Embedded within the last EMA survey, the EMI arm\\r\\nwill include interactive tasks when a participant\\'s computed rumination score (i.e., mean\\r\\nscore of the four EMA rumination questions) reaches above the 80th percentile of their\\r\\nown cumulative score, or if the raw rumination score reach above 70 out of 100 (15). The\\r\\nintervention comprises of short exercises (most can be completed within 1-3 minutes)\\r\\nrooted in cognitive bias modification (CBM) techniques. Participants will interact with\\r\\ninstructions and multimedia formats based on CBM module framework based on reflection /\\r\\nbrooding. Participants will continue treatment with their psychiatrists who will be\\r\\nblinded to group allocation.\\r\\n\\r\\nVariables:\\r\\n\\r\\n  -  Hamilton Depression Rating Scale (HDRS)\\r\\n\\r\\n  -  Montgomery-Åsberg Depression Rating Scale (MADRS)\\r\\n\\r\\n  -  Social and Occupational Functioning Assessment scale (SOFAS) (Morosini et al., 2000)\\r\\n\\r\\n  -  Role Functioning Scale (RFS)\\r\\n\\r\\n  -  Global Functioning: Social Scale and Role Scale\\r\\n\\r\\n  -  Short Form Health Survey (SF-12)\\r\\n\\r\\n  -  General Self Efficacy Scale\\r\\n\\r\\n  -  Rumination Response Scale (RRS)\\r\\n\\r\\n  -  System Usability Scale - Chinese version\\r\\n\\r\\n  -  Beck Scale for Suicidal Ideation'},\n",
       "   'conditionsModule': {'conditions': ['Mild to Moderate Depression'],\n",
       "    'keywords': ['Depression',\n",
       "     'Ecological momentary intervention',\n",
       "     'Rumination',\n",
       "     'Hong Kong']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'EMA arm: participants will receive three ecological momentary assessment (EMA) prompts\\r\\ndaily with the prompts spread out throughout the day. Within each prompt, participants\\r\\nwill answer 14 questions regarding affect, suicidality, and rumination. Afterwards, they\\r\\nwill be shown a video clip extracted from a popular and longstanding soap opera in\\r\\nChinese that lasts between three to four minutes. Each prompt would take around 8 minutes\\r\\nto complete. In total, participants will complete 70 EMA prompts during the intervention\\r\\nperiod.\\r\\n\\r\\nEMI arm: participants will receive two EMA prompts and one EMI prompt daily. The EMA\\r\\nprompts would be identical to the ones in the EMA arm without the video clip at the end.\\r\\nThe EMI prompt would contain an interactive task designed to counter ruminative thoughts.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'maskingDescription': 'masking: Participants will be notified that they would engage in a diary recording\\r\\nactivity for two weeks, but would be blinded to whether they were receiving the\\r\\nintervention or active control version. Trained research assistents would assess outcomes\\r\\nand the principal investigator would randomise participants to the two conditions based\\r\\non anonymised IDs. Treatment provided to participants as usual by their usual care\\r\\nproviders (e.g., doctors) would not be notified about the randomisation conditions.',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'EMA',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Ecological momentary assessment (EMA) arm: participants will receive three ecological\\r\\nmomentary assessment (EMA) prompts daily within three time blocks spread out throughout\\r\\nthe day. Within each prompt, participants will answer 14 questions regarding affect,\\r\\nsuicidality, and rumination. Afterwards, they will be shown a video clip extracted from a\\r\\npopular and longstanding soap opera in Chinese that lasts between three to four minutes.\\r\\nEach prompt would take around 8 minutes to complete. In total, participants will complete\\r\\n70 EMA prompts during the intervention period.',\n",
       "      'interventionNames': ['Other: EMI']},\n",
       "     {'label': 'EMI',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'EMI arm: participants in this arm will receive two ecological momentary assessment (EMA)\\r\\nprompts and one econological momentary intervention (EMI) prompt daily. The EMA prompts\\r\\nwould be identical to the ones in the EMA arm without the video clip at the end. The EMI\\r\\nprompt would contain an interactive task designed to counter ruminative thoughts.\\r\\nExamples of the interactive tasks include: mindfulness exercises (mindful walking),\\r\\ncognitive reappriasal, strengths recognition, etc. Each EMI prompt would last around 3-5\\r\\nminutes.',\n",
       "      'interventionNames': ['Other: EMI']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'EMI',\n",
       "      'description': 'A phone-based intervention carried out on an experience sampling platform m-Path',\n",
       "      'armGroupLabels': ['EMA', 'EMI']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Hamilton Depression Rating Scale (HDRS) - 17 items',\n",
       "      'description': 'Gold standard for measuring depressive symptoms, score ranges from 0 (minimum) to 53\\r\\n(maximum); higher score indicates more severe depressive symptoms.',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Montgomery-Åsberg Depression Rating Scale (MADRS)',\n",
       "      'description': 'Measuring change in depressive symptoms; score ranges from 0 (minimum) to 60 (maximum);\\r\\nhigher score indicates more severe depressive symptoms.',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Social and Occupational Functioning Assessment scale (SOFAS)',\n",
       "      'description': 'Reference (Morosini et al., 2000); measures social and occupational functioning across\\r\\nwork functioning, independent functioning, immediate and extended social network\\r\\nfunctioning; score ranges from 0 (minimum) to 100 (maximum), higher score indicates\\r\\nhigher social and occupational functioning ability.',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Role Functioning Scale (RFS)',\n",
       "      'description': 'Measures role functioning in four areas: work productivity, independent living, immediate\\r\\nand extended social network relationships; score ranges from 0 (minimum) to 7 (maximum)\\r\\non each aspect, higher score indicates better role functioning',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Global Functioning: Social Scale and Role Scale',\n",
       "      'description': 'Measures social and role functioning; score ranges from 1 (minimum) to 10 (maximum);\\r\\nhigher score indicates better social/role functioning',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Short Form Health Survey (SF-12)',\n",
       "      'description': \"Measures impacts of overall physical and emotional health on individuals' day to day\\r\\nliving; score ranges from 0 (minimum) to 100 (maximum), higher score indicates better\\r\\nphysical and mental health functioning\",\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'General Self Efficacy Scale',\n",
       "      'description': 'Measures self-reported self-efficacy; score ranges from 10 (minimum) to 40 (maximum),\\r\\nwith higher scores indicating more self-efficacy',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Rumination Response Scale (RRS)',\n",
       "      'description': 'Measures self-reported rumination responses; score ranges from 10 (minimum) to 40\\r\\n(maximum), with higher scores indicating higher levels of ruminative responses styles.',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Beck Scale for Suicidal Ideation',\n",
       "      'description': 'Measures self-reported suicidal ideation; score ranges from 0 (minimum) to 38 (maximum),\\r\\nwith higher scores indicating a greater risk of suicide.',\n",
       "      'timeFrame': 'T0 (baseline); T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'System Usability Scale - Chinese version',\n",
       "      'description': 'Reference: (Wang et al., 2019); to assess acceptability and feedback regarding conducting\\r\\nEMA and EMI on mPath platform; scores ranges from 10 (minimum) to 50 (maximum), with\\r\\nhigher scores indicating higher perceived usability of the systems involved.',\n",
       "      'timeFrame': 'T1 (immedately after intervention); T2 (one-month after intervention follow-up)'},\n",
       "     {'measure': 'Clinical Global Impression Scale',\n",
       "      'description': 'Measures the severity of illness and global improvement following an intervention; scores\\r\\nranges from 1 (normal/very much improved) to 7 (most severely ill/very much worse), with\\r\\nhigher scores indicating worse outcome.',\n",
       "      'timeFrame': 'T1 (immedately after intervention); T2 (one-month after intervention follow-up)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Aged 16-65 years\\r\\n\\r\\n  -  Cantonese-speaking ethnic Chinese\\r\\n\\r\\n  -  Diagnosis of major depressive episode (MDE) established by the Structured Clinical\\r\\n     Interview for Diagnostic and Statistical Manual of Mental Disorder 5th Edition\\r\\n     (DSM-V)\\r\\n\\r\\n  -  17-item Hamilton Depression Rating Scale (HDRS) ≥ 14 at screening and at baseline\\r\\n     (i.e. moderate to severe depression)\\r\\n\\r\\n  -  Having a smartphone with Internet access and iOS or Android operating system.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients who could not read Chinese, are unable to provide informed consents\\r\\n\\r\\n  -  Comorbid with other Axis I diagnoses (especially schizoaffective disorder)\\r\\n\\r\\n  -  With an unstable medical condition or current substance abuse\\r\\n\\r\\n  -  Have a score of ≥4 on any one of the three items on Positive and Negative Syndrome\\r\\n     Scale (P1 Delusion, P2 Conceptual disorganization, P3 Hallucination)\\r\\n\\r\\n  -  Marked risk of self-harm or suicide that could not be safely managed in an\\r\\n     outpatient clinic setting\\r\\n\\r\\n  -  Currently receiving any other weekly psychosocial therapy\\r\\n\\r\\n  -  Unable to use a smartphone-based application due to cognitive impairment or learning\\r\\n     disability or inadequate vision.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '16 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'University of Hong Kong',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Hong Kong',\n",
       "      'country': 'Hong Kong',\n",
       "      'contacts': [{'name': 'Ka Ying Heidi Lo',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '2255 4486',\n",
       "        'email': 'lokaying@hku.hk'},\n",
       "       {'role': 'CONTACT', 'phone': '2255 4486', 'email': 'lokaying@hku.hk'}],\n",
       "      'geoPoint': {'lat': 22.27832, 'lon': 114.17469}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003863',\n",
       "      'term': 'Depression'},\n",
       "     {'id': 'D000003866', 'term': 'Depressive Disorder'}],\n",
       "    'ancestors': [{'id': 'D000001526', 'term': 'Behavioral Symptoms'},\n",
       "     {'id': 'D000019964', 'term': 'Mood Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M7058',\n",
       "      'name': 'Depression',\n",
       "      'asFound': 'Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7061',\n",
       "      'name': 'Depressive Disorder',\n",
       "      'asFound': 'Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2062', 'name': 'Rumination Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'},\n",
       "     {'id': 'M21835', 'name': 'Mood Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'T5077', 'name': 'Rumination Disorder', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06401044',\n",
       "    'orgStudyIdInfo': {'id': '20230302'},\n",
       "    'organization': {'fullName': 'Amgen', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease',\n",
       "    'officialTitle': 'A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-06-16', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-06-16', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-02',\n",
       "    'studyFirstSubmitQcDate': '2024-05-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-02',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Amgen', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The primary objective of this study is to investigate the safety and tolerability of AMG\\r\\n732 after single subcutaneous (SC) doses.'},\n",
       "   'conditionsModule': {'conditions': ['Thyroid Eye Disease'],\n",
       "    'keywords': ['AMG 732', 'Thyroid Eye Disease (TED)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Part A: AMG 732',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants in 5 cohorts will receive either AMG 732 or placebo in Single Ascending\\r\\nDoses (SAD).',\n",
       "      'interventionNames': ['Drug: AMG 732']},\n",
       "     {'label': 'Part A: Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Participants in 5 cohorts will receive either AMG 732 or placebo in Single Ascending\\r\\nDoses (SAD).',\n",
       "      'interventionNames': ['Other: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'AMG 732',\n",
       "      'description': 'SC injection',\n",
       "      'armGroupLabels': ['Part A: AMG 732']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'SC injection',\n",
       "      'armGroupLabels': ['Part A: Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Part A: Number of Participants With Treatment-emergent Adverse Events',\n",
       "      'timeFrame': 'Day 1 through Week 36 (End of Study)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Part A: Maximum Observed Plasma Concentration (Cmax) of AMG 732',\n",
       "      'timeFrame': 'Up to Week 36'},\n",
       "     {'measure': 'Part A: Time to Cmax (Tmax) of AMG 732',\n",
       "      'timeFrame': 'Up to Week 36'},\n",
       "     {'measure': 'Part A: Area Under the Plasma Concentration-time Curve (AUC) of AMG 732',\n",
       "      'timeFrame': 'Up to Week 36'},\n",
       "     {'measure': 'Part A: Half-life (t1/2) of AMG 732',\n",
       "      'timeFrame': 'Up to Week 36'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion:\\r\\n\\r\\n  -  Participant has provided informed consent before initiation of any study-specific\\r\\n     activities/procedures.\\r\\n\\r\\n  -  Male or female aged 18 to 55 years\\r\\n\\r\\n  -  Female participants must be of non-childbearing potential.\\r\\n\\r\\n  -  Body mass index (BMI) between 18 and 30 kg/m^2, inclusive, at screening.\\r\\n\\r\\n  -  The participant has adequate venous access and can receive intravenous (IV) therapy.\\r\\n\\r\\n  -  The participant is considered by the investigator or designee to be in good general\\r\\n     health as determined by medical history, clinical laboratory test results, vital\\r\\n     sign measurements, 12-lead ECG results, and physical examination findings at\\r\\n     screening.\\r\\n\\r\\n  -  Healthy Japanese participants in cohort 4 only. Japanese participants must meet all\\r\\n     the following as confirmed by interview: Descendants of 4 ethnic Japanese\\r\\n     grandparents who were born in Japan; Both parents are ethnic Japanese who were born\\r\\n     in Japan; Hold a Japanese passport or identity papers; Have lived outside Japan for\\r\\n     less than 10 years at the time of screening and lifestyle including diet has not\\r\\n     changed significantly since leaving Japan.\\r\\n\\r\\nExclusion:\\r\\n\\r\\n  -  Malignant condition in the past 12 months (except successfully treated\\r\\n     basal/squamous cell carcinoma of the skin or cervical cancer in situ).\\r\\n\\r\\n  -  Active liver disease or hepatic dysfunction at screening, as determined by ALT\\r\\n     (alanine aminotransferase) or aspartate aminotransferase (AST) levels > 1.5 times\\r\\n     upper limit of normal (ULN).\\r\\n\\r\\n  -  Positive test for hepatitis B serology at screening defined as: (1) positive for\\r\\n     hepatitis B surface antigen (HBsAg); OR (2) positive for hepatitis B core antibody\\r\\n     (HBcAb). Participants HBsAg negative, hepatitis B surface antibody (HBsAb) positive\\r\\n     and HBcAb negative due to vaccination are eligible for the study. Participants HBsAg\\r\\n     negative and HBsAb positive for which the cause cannot be determined as vaccination\\r\\n     will be considered ineligible for the study.\\r\\n\\r\\n  -  Positive test for hepatitis C virus (HCV) antibody at screening or within the last\\r\\n     12 months. Participants successfully treated for an HCV infection are allowed to\\r\\n     participate if a sustained virologic response was achieved, defined as aviremia 24\\r\\n     weeks after completion of the antiviral therapy.\\r\\n\\r\\n  -  Glycated hemoglobin (HbA1c) > 6.5% and/or fasting glucose levels (after at least an\\r\\n     8-hour fast) > 126 mg/dL (> 7 mmol/L) at screening.\\r\\n\\r\\n  -  History of substance abuse (ie, alcohol, licit or illicit drugs) within 12 months\\r\\n     before screening.\\r\\n\\r\\n  -  The participant has a major surgery within 8 weeks prior to screening or plans to\\r\\n     have an elective surgery from screening through end of study.\\r\\n\\r\\n  -  Donated blood, or had significant blood loss, or received a transfusion of any blood\\r\\n     or blood products within 60 days prior to day 1 dosing or received a plasma donation\\r\\n     within 7 days prior to day 1 dosing.\\r\\n\\r\\n  -  The participant has a seated resting blood pressure of < 90/40 mmHg or > 140/90\\r\\n     mmHg, or a seated pulse rate of < 40 beats per minute (bpm) or > 99 bpm or is\\r\\n     considered clinically significant at screening. One additional measurement can be\\r\\n     taken if blood pressure and pulse rate are outside the specified limits.\\r\\n\\r\\n  -  The participant has clinically significant 12-lead ECG abnormalities at screening\\r\\n     and check-in or in the opinion of the investigator has a second- or third-degree\\r\\n     atrioventricular block, or has any of the following: QRS > 120 msec; QT interval\\r\\n     corrected for heart rate using Fridericia's formula (QTcF) > 450 msec (males) or >\\r\\n     470 msec (females); PR interval > 220 msec.\\r\\n\\r\\n  -  Use of any steroid (IV, oral, steroid eye drops) within 3 weeks prior to screening.\\r\\n     Steroids cannot be initiated during the trial. Exceptions include topical and\\r\\n     inhaled steroids and steroids used to treat injection site reactions.\\r\\n\\r\\n  -  Any previous treatment or enrollment in clinical trials with an IGF-1R inhibitor,\\r\\n     such as TEPEZZA (teprotumumab-trbw).\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '55 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Amgen Call Center',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '866-572-6436',\n",
       "      'email': 'medinfo@amgen.com'}],\n",
       "    'overallOfficials': [{'name': 'MD',\n",
       "      'affiliation': 'Amgen',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'AmgenTrials clinical trials website',\n",
       "      'url': 'http://www.amgentrials.com'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'De-identified individual patient data for variables necessary to address the specific\\r\\nresearch question in an approved data sharing request.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "    'timeFrame': 'Data sharing requests relating to this study will be considered beginning 18 months after\\r\\nthe study has ended and either 1) the product and indication have been granted marketing\\r\\nauthorization in both the US and Europe or 2) clinical development for the product and/or\\r\\nindication discontinues and the data will not be submitted to regulatory authorities.\\r\\nThere is no end date for eligibility to submit a data sharing request for this study.',\n",
       "    'accessCriteria': 'Qualified researchers may submit a request containing the research objectives, the Amgen\\r\\nproduct(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical\\r\\nanalysis plan, data requirements, publication plan, and qualifications of the\\r\\nresearcher(s). In general, Amgen does not grant external requests for individual patient\\r\\ndata for the purpose of re-evaluating safety and efficacy issues already addressed in the\\r\\nproduct labelling. Requests are reviewed by a committee of internal advisors. If not\\r\\napproved, a Data Sharing Independent Review Panel will arbitrate and make the final\\r\\ndecision. Upon approval, information necessary to address the research question will be\\r\\nprovided under the terms of a data sharing agreement. This may include anonymized\\r\\nindividual patient data and/or available supporting documents, containing fragments of\\r\\nanalysis code where provided in analysis specifications. Further details are available at\\r\\nthe URL below.',\n",
       "    'url': 'http://www.amgen.com/datasharing'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005128',\n",
       "      'term': 'Eye Diseases'},\n",
       "     {'id': 'D000049970', 'term': 'Graves Ophthalmopathy'},\n",
       "     {'id': 'D000013959', 'term': 'Thyroid Diseases'}],\n",
       "    'ancestors': [{'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000015785', 'term': 'Eye Diseases, Hereditary'},\n",
       "     {'id': 'D000006111', 'term': 'Graves Disease'},\n",
       "     {'id': 'D000005094', 'term': 'Exophthalmos'},\n",
       "     {'id': 'D000009916', 'term': 'Orbital Diseases'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000006042', 'term': 'Goiter'},\n",
       "     {'id': 'D000006980', 'term': 'Hyperthyroidism'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M16718',\n",
       "      'name': 'Thyroid Diseases',\n",
       "      'asFound': 'Thyroid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8271',\n",
       "      'name': 'Eye Diseases',\n",
       "      'asFound': 'Eye Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26148',\n",
       "      'name': 'Graves Ophthalmopathy',\n",
       "      'asFound': 'Thyroid Eye Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M18339', 'name': 'Eye Diseases, Hereditary', 'relevance': 'LOW'},\n",
       "     {'id': 'M9214', 'name': 'Graves Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M8237', 'name': 'Exophthalmos', 'relevance': 'LOW'},\n",
       "     {'id': 'M12845', 'name': 'Orbital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M9147', 'name': 'Goiter', 'relevance': 'LOW'},\n",
       "     {'id': 'M10031', 'name': 'Hyperthyroidism', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC19',\n",
       "      'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06345729',\n",
       "    'orgStudyIdInfo': {'id': '1084-004'},\n",
       "    'secondaryIdInfos': [{'id': 'MK-1084-004',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Merck'},\n",
       "     {'id': 'U1111-1296-8093', 'type': 'OTHER', 'domain': 'UTN'},\n",
       "     {'id': '2023-507776-42', 'type': 'REGISTRY', 'domain': 'EU CT'}],\n",
       "    'organization': {'fullName': 'Merck Sharp & Dohme LLC',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)',\n",
       "    'officialTitle': 'A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-02-19', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2031-02-18', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-28',\n",
       "    'studyFirstSubmitQcDate': '2024-03-28',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as\\r\\nfirst-line treatment in participants with metastatic non-small cell lung cancer (NSCLC)\\r\\nwith identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and\\r\\nprogrammed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two\\r\\nprimary study hypotheses:\\r\\n\\r\\nHypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus\\r\\npembrolizumab with respect to progression free survival (PFS) per Response Evaluation\\r\\nCriteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review\\r\\n(BICR).\\r\\n\\r\\nHypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus\\r\\npembrolizumab with respect to overall survival (OS).'},\n",
       "   'conditionsModule': {'conditions': ['Non-small Cell Lung Cancer'],\n",
       "    'keywords': ['Programmed Cell Death-1 (PD1, PD-1)',\n",
       "     'Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)',\n",
       "     'Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)',\n",
       "     'Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 600, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'MK-1084 with Pembrolizumab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each\\r\\n21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets once daily until\\r\\ndiscontinuation criterion is met.',\n",
       "      'interventionNames': ['Drug: MK-1084', 'Biological: Pembrolizumab']},\n",
       "     {'label': 'Placebo with Pembrolizumab',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each\\r\\n21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until\\r\\ndiscontinuation criterion is met.',\n",
       "      'interventionNames': ['Other: Placebo', 'Biological: Pembrolizumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'MK-1084',\n",
       "      'description': 'Oral tablets',\n",
       "      'armGroupLabels': ['MK-1084 with Pembrolizumab']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Oral tablets',\n",
       "      'armGroupLabels': ['Placebo with Pembrolizumab']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'description': 'IV infusion',\n",
       "      'armGroupLabels': ['MK-1084 with Pembrolizumab',\n",
       "       'Placebo with Pembrolizumab'],\n",
       "      'otherNames': ['MK-3475', 'KEYTRUDA ®']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival (PFS)',\n",
       "      'description': 'PFS is defined as the time from randomization until either documented disease progression\\r\\nper Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) or death due to any cause,\\r\\nwhichever occurs first. PFS as determined by blinded independent central review (BICR)\\r\\nwill be presented.',\n",
       "      'timeFrame': 'Up to approximately 57 months'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'OS is defined as the time from randomization to death due to any cause.',\n",
       "      'timeFrame': 'Up to approximately 57 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)',\n",
       "      'description': 'ORR is defined as the percentage of participants with Complete Response or Partial\\r\\nResponse per RECIST1.1. The percentage of participants who experience CR or PR as\\r\\nassessed by BICR will be presented.',\n",
       "      'timeFrame': 'Up to approximately 57 months'},\n",
       "     {'measure': 'Duration of Response (DOR)',\n",
       "      'description': 'For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR,\\r\\nduration of response is defined as the time from the first documented evidence of CR or\\r\\nPR until disease progression or death due to any cause, whichever occurs first.',\n",
       "      'timeFrame': 'Up to approximately 57 months'},\n",
       "     {'measure': 'Number of Participants Who Experience One or More Adverse Event (AEs)',\n",
       "      'description': \"An AE is any unfavorable and unintended sign, symptom, or disease temporally associated\\r\\nwith the use of a medicinal product or protocol-specified procedure, whether or not\\r\\nconsidered related to the medicinal product or protocol-specified procedure. Any\\r\\nworsening of a preexisting condition that is temporally associated with the use of the\\r\\nSponsor's product, is also an AE. The number of participants who experience an AE will be\\r\\npresented.\",\n",
       "      'timeFrame': 'Up to approximately 57 months'},\n",
       "     {'measure': 'Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)',\n",
       "      'description': \"An AE is any unfavorable and unintended sign, symptom, or disease temporally associated\\r\\nwith the use of a medicinal product or protocol-specified procedure, whether or not\\r\\nconsidered related to the medicinal product or protocol-specified procedure. Any\\r\\nworsening of a preexisting condition that is temporally associated with the use of the\\r\\nSponsor's product, is also an AE. The number of participants who discontinue study\\r\\ntreatment due to an AE will be presented.\",\n",
       "      'timeFrame': 'Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score',\n",
       "      'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant responses to the questions \"How would you rate your overall health\\r\\nduring the past week?\" and \"How would you rate your overall quality of life during the\\r\\npast week?\" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear\\r\\ntransformation, raw scores are standardized, so that scores range from 0 to 100. The\\r\\nchange from baseline in the score of EORTC QLQ-C30 Items 29 and 30 will be presented.\\r\\nHigher scores indicate a better overall health status.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score',\n",
       "      'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant responses to 5 questions about their physical functioning are\\r\\nscored on a 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the\\r\\nscore of EORTC QLQ-C30 Items 1-5 will be presented. Higher scores indicate a better level\\r\\nof functioning.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score',\n",
       "      'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant responses to 2 questions about their role functioning are scored on\\r\\na 4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of\\r\\nEORTC QLQ-C30 Items 6-7 will be presented. Higher scores indicate a better level of\\r\\nfunctioning.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score',\n",
       "      'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant response to the question \"Were you short of breath?\" is scored on a\\r\\n4-point scale (1=Not at All to 4=Very Much). The change from baseline in the score of\\r\\nEORTC QLQ-C30 Item 8 will be presented. A higher score indicates a worse level of\\r\\ndyspnea.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score',\n",
       "      'description': 'The EORTC QLQ-C13 is a lung cancer-specific supplemental questionnaire used in\\r\\ncombination with the EORTC QLQ-C30. Participant response to the question \"Have you\\r\\ncoughed?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from\\r\\nbaseline in the score of EORTC QLQ-C13 Item 31 will be presented. A higher score\\r\\nindicates more frequent coughing.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-LC13) Chest pain (Item 40) Score',\n",
       "      'description': 'The EORTC QLQ-C13 is lung cancer-specific supplemental questionnaire used in combination\\r\\nwith the EORTC QLQ-C30. Participant response to the question \"Have you had pain in your\\r\\nchest?\" is scored on a 4-point scale (1=Not at All to 4=Very Much). The change from\\r\\nbaseline in the score of EORTC QLQ-C13 Item 40 will be presented. A higher score\\r\\nindicates a worse level of chest pain.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in global health status (GHS) and quality of life (QoL)\\r\\n(EORTC QLQ-C30 Items 29 and 30) score. Participant responses to the questions \"How would\\r\\nyou rate your overall health during the past week?\" and \"How would you rate your overall\\r\\nquality of life during the past week?\" are scored on a 7-point scale (1= Very poor to\\r\\n7=Excellent). Using linear transformation, raw scores are standardized, so that scores\\r\\nrange from 0 to 100. The TTD, as assessed based on a ≥10 point negative change (decrease)\\r\\nfrom baseline in GHS and QoL, will be presented. A longer TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Functioning (Items 1-5) Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score.\\r\\nThe EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant responses to 5 questions about their physical functioning are\\r\\nscored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw\\r\\nscores are standardized, so that scores range from 0 to 100. The TTD, as assessed based\\r\\non a ≥10 point negative change (decrease) from baseline in physical functioning score,\\r\\nwill be presented. A longer TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Role Functioning (Items 6 and 7) Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in role functioning (EORTC QLQ-C30 Items 6 and 7) score.\\r\\nThe EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer\\r\\npatients. Participant responses to 2 questions about their role functioning are scored on\\r\\na 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores\\r\\nare standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10\\r\\npoint negative change (decrease) from baseline in role functioning score, will be\\r\\npresented. A longer TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in dyspnea (EORTC QLQ-C30 Item 8) score. The EORTC\\r\\nQLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients.\\r\\nParticipant response to the question \"Were you short of breath?\" is scored on a 4-point\\r\\nscale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are\\r\\nstandardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10\\r\\npoint negative change (decrease) from baseline in dyspnea score, will be presented. A\\r\\nlonger TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Cough (Item 31) Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in cough (EORTC QLQ-C13 Item 31) score. The EORTC QLQ-C13\\r\\nis lung cancer-specific supplemental questionnaire used in combination with the EORTC\\r\\nQLQ-C30. Participant response to the question \"Have you coughed?\" is scored on a 4-point\\r\\nscale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are\\r\\nstandardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10\\r\\npoint negative change (decrease) from baseline in cough score, will be presented. A\\r\\nlonger TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'},\n",
       "     {'measure': 'Time to Deterioration (TTD) in European Organization for Research and Treatment of Cancer Quality of Life Lung Cancer-Specific Questionnaire Module (EORTC QLQ-C13) Chest pain (Item 40) Score',\n",
       "      'description': 'TTD is defined as the time from baseline to the first onset of a ≥10-point negative\\r\\nchange (decrease) from baseline in chest pain (EORTC QLQ-C13 Item 40) score. The EORTC\\r\\nQLQ-C13 is lung cancer-specific supplemental questionnaire used in combination with the\\r\\nEORTC QLQ-C30. Participant response to the question \"Have you had pain in your chest?\" is\\r\\nscored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw\\r\\nscores are standardized, so that scores range from 0 to 100. The TTD, as assessed based\\r\\non a ≥10 point negative change (decrease) from baseline chest pain score, will be\\r\\npresented. A longer TTD indicates a better outcome.',\n",
       "      'timeFrame': 'Baseline and Up to approximately 57 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"The main inclusion and exclusion criteria include but are not limited to the following:\\r\\n\\r\\nInclusion Criteria:\\r\\n\\r\\n  -  Has a histologically or cytologically confirmed diagnosis of NSCLC\\r\\n\\r\\n  -  Has newly diagnosed Stage IV NSCLC by American Joint Committee on Cancer (AJCC)\\r\\n     Staging Manual, Version 8\\r\\n\\r\\n  -  Has measurable disease based on RECIST 1.1\\r\\n\\r\\n  -  Has provided tumor tissue that demonstrates PD-L1 expression in ≥50% of tumor cells\\r\\n\\r\\n  -  Has provided tumor tissue that demonstrates presence of KRAS G12C mutation\\r\\n\\r\\n  -  Has life expectancy of at least 3 months\\r\\n\\r\\n  -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed\\r\\n     within 7 days before randomization\\r\\n\\r\\n  -  For participant assigned male sex at birth: If capable of producing sperm,\\r\\n     participant must agree to the following during the study treatment period and for at\\r\\n     least 10 days after the last dose of oral intervention: Either be abstinent or must\\r\\n     agree to use male condom plus additional contraceptive method.\\r\\n\\r\\n  -  For participant assigned female sex at birth: Either be a person of nonchildbearing\\r\\n     potential (PONCBP) or must agree to follow contraceptive guidance during the study\\r\\n     treatment period and for at least 10 days after the last dose of oral intervention\\r\\n     and 120 days after the last dose of pembrolizumab. Must abstain from breastfeeding\\r\\n     during the study intervention period and for at least 120 days after study\\r\\n     intervention.\\r\\n\\r\\n  -  Human immunodeficiency virus (HIV)-infected participants must have well controlled\\r\\n     HIV on antiretroviral therapy (ART).\\r\\n\\r\\n  -  Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if\\r\\n     they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks\\r\\n     and have undetectable HBV viral load before randomization\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Diagnosis of small cell lung cancer\\r\\n\\r\\n  -  Has active inflammatory bowel disease requiring immunosuppressive medication or\\r\\n     previous clear history of inflammatory bowel disease\\r\\n\\r\\n  -  Has a known history of, or active, neurologic paraneoplastic syndrome\\r\\n\\r\\n  -  Has an active infection requiring systemic therapy\\r\\n\\r\\n  -  Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\\r\\n     including New York Heart Association Class III or IV congestive heart failure,\\r\\n     unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia,\\r\\n     prolongation of QT interval corrected for heart rate by Fridericia's formula (QTcF)\\r\\n     interval to >470 ms, and/or other serious cardiovascular and cerebrovascular\\r\\n     diseases within the 6 months preceding study intervention\\r\\n\\r\\n  -  Is considered a poor medical risk due to a serious, uncontrolled medical disorder or\\r\\n     nonmalignant systemic disease. Examples include, but are not limited to,\\r\\n     uncontrolled major seizure disorder, unstable spinal cord compression, or superior\\r\\n     vena cava syndrome.\\r\\n\\r\\n  -  Has one or more of the following ophthalmological findings/conditions: intraocular\\r\\n     diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery\\r\\n     occlusion, diagnosis of retinal degenerative disease pressure >21 mm Hg and/or any\\r\\n     diagnosis of glaucoma\\r\\n\\r\\n  -  Is unable to swallow orally administered medication, or has a gastrointestinal\\r\\n     disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, or\\r\\n     malabsorption)\\r\\n\\r\\n  -  Received prior systemic anticancer therapy for their metastatic NSCLC\\r\\n\\r\\n  -  Received prior therapy with an anti-programmed cell death-1 (anti-PD-1),\\r\\n     anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent, or with an\\r\\n     agent directed to another stimulatory or coinhibitory T-cell receptor within 12\\r\\n     months before diagnosis of metastatic NSCLC\\r\\n\\r\\n  -  Has received radiotherapy within 2 weeks of start of study intervention\\r\\n\\r\\n  -  Has received a live or live-attenuated vaccine within 30 days before the first dose\\r\\n     of study intervention. Administration of killed vaccines is allowed.\\r\\n\\r\\n  -  Has received an investigational agent or has used an investigational device within 4\\r\\n     weeks prior to study intervention administration\\r\\n\\r\\n  -  Has known active central nervous system (CNS) metastases and/or carcinomatous\\r\\n     meningitis.\\r\\n\\r\\n  -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in\\r\\n     dosing exceeding 10 mg daily of prednisone equivalent) or any other form of\\r\\n     immunosuppressive therapy within 7 days prior to the first dose of study\\r\\n     intervention\\r\\n\\r\\n  -  Active autoimmune disease that has required systemic treatment in the past 2 years\\r\\n\\r\\n  -  History of (noninfectious) pneumonitis/interstitial lung disease that required\\r\\n     steroids or has current pneumonitis/interstitial lung disease\\r\\n\\r\\n  -  HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric\\r\\n     Castleman's Disease\\r\\n\\r\\n  -  History of allogeneic tissue/solid organ transplant\\r\\n\\r\\n  -  Has not fully recovered from any effects of major surgical procedure. Surgical\\r\\n     procedures that required general anesthesia must be completed at least 2 weeks\\r\\n     before first study intervention administration.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Toll Free Number',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '1-888-577-8839',\n",
       "      'email': 'Trialsites@merck.com'}],\n",
       "    'overallOfficials': [{'name': 'Medical Director',\n",
       "      'affiliation': 'Merck Sharp & Dohme LLC',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'St. Vincent Frontier Cancer Center-Research ( Site 0105)',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Billings',\n",
       "      'state': 'Montana',\n",
       "      'zip': '59102',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Study Coordinator',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '406-238-6290'}],\n",
       "      'geoPoint': {'lat': 45.78329, 'lon': -108.50069}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Merck Clinical Trials Information',\n",
       "      'url': 'https://www.merckclinicaltrials.com/'},\n",
       "     {'label': 'Plain Language Summary',\n",
       "      'url': 'https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=1084-004&&kw=1084-004'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf',\n",
       "    'url': 'http://engagezone.msd.com/ds_documentation.php'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008175',\n",
       "      'term': 'Lung Neoplasms'},\n",
       "     {'id': 'D000002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}],\n",
       "    'ancestors': [{'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000002283', 'term': 'Carcinoma, Bronchogenic'},\n",
       "     {'id': 'D000001984', 'term': 'Bronchial Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M5546',\n",
       "      'name': 'Carcinoma, Non-Small-Cell Lung',\n",
       "      'asFound': 'Non-Small Cell Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11172',\n",
       "      'name': 'Lung Neoplasms',\n",
       "      'asFound': 'Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15327', 'name': 'Sarcoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M6845', 'name': 'Death', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'},\n",
       "     {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'T5284', 'name': 'Soft Tissue Sarcoma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000582435',\n",
       "      'term': 'Pembrolizumab'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M349416',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'asFound': 'Blind',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2342',\n",
       "      'name': 'Immune Checkpoint Inhibitors',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06260774',\n",
       "    'orgStudyIdInfo': {'id': 'TTX-MC138-002'},\n",
       "    'organization': {'fullName': 'TransCode Therapeutics',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study of TTX-MC138 in Subjects With Advanced Solid Tumors',\n",
       "    'officialTitle': 'A Phase 1/2 Multicenter, Open-Label, Dose-escalation and Expansion Study of TTX-MC138 in Subjects With Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-02-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-02-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-12',\n",
       "    'studyFirstSubmitQcDate': '2024-02-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-15', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'TransCode Therapeutics', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in\\r\\nSubjects with Advanced Solid Tumors',\n",
       "    'detailedDescription': 'The study will consist of 2 phases, dose escalation and dose expansion, with 3 study\\r\\nperiods: Screening (up to 28 days), Treatment (28-day treatment cycles, with dosing on\\r\\nDay 1), and Survival Follow-up (every 3 months). Each 28-day cycle is comprised of 1 dose\\r\\nof study drug administered as an intravenous (IV) infusion on Day 1.\\r\\n\\r\\nA subject will continue on treatment until a dose limiting toxicity (DLT) is observed,\\r\\nother adverse event (AE) leading to unacceptable toxicity as assessed by the\\r\\nInvestigator, progression of disease, or withdrawal of consent.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'interventionModelDescription': 'Dose Escalation Study Design',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Dose level 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '0.4 mg/kg of TTX-MC138',\n",
       "      'interventionNames': ['Drug: TTX-MC138']},\n",
       "     {'label': 'Dose level 2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '0.8 mg/kg of TTX-MC138',\n",
       "      'interventionNames': ['Drug: TTX-MC138']},\n",
       "     {'label': 'Dose level 3',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '3.2 mg/kg of TTX-MC138',\n",
       "      'interventionNames': ['Drug: TTX-MC138']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'TTX-MC138',\n",
       "      'description': 'The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be\\r\\nincreased incrementally in subsequent cohorts until maximum tolerated dose (MTD)\\r\\ndetermination.',\n",
       "      'armGroupLabels': ['Dose level 1', 'Dose level 2', 'Dose level 3']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose Escalation - Adverse Events',\n",
       "      'description': 'The safety and tolerability of escalating dose levels of TTX-MC138 to determine incidence\\r\\nof treatment-emergent adverse events (TEAEs).',\n",
       "      'timeFrame': 'Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year'},\n",
       "     {'measure': 'Dose Escalation - Overall Response Rate (ORR)',\n",
       "      'description': 'proportion of subjects with a best response of CR, PR, or stable disease for at least 8\\r\\nweeks per RECIST version 1.1.',\n",
       "      'timeFrame': 'Throughout study treatment for 18 subjects, for average of 3 months and post treatment for survival follow-up through study completion, an average of 1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Have histologically or cytologically confirmed diagnosis of relapsed/refractory\\r\\n     metastatic or locally advanced solid tumor where no standard therapy exists,\\r\\n     standard therapy has failed and have no available therapies with known clinical\\r\\n     benefit.\\r\\n\\r\\n  2. Must have measurable or evaluable disease per RECIST version 1.1.\\r\\n\\r\\n  3. ≥18 years at the time of informed consent.\\r\\n\\r\\n  4. Life expectancy of ≥3 months\\r\\n\\r\\n  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or\\r\\n     equal to 2.\\r\\n\\r\\n  6. Have adequate organ function defined as:\\r\\n\\r\\n       1. Platelet count ≥75×109/L with no platelet transfusions in the past 7 days\\r\\n\\r\\n       2. Absolute neutrophil count ≥1.0×109/L\\r\\n\\r\\n       3. Hemoglobin ≥8 g/dL (red blood cell transfusion may be used to reach 8 g/dL but\\r\\n          must have been administered at least 1 week prior to the administration of the\\r\\n          study drug)\\r\\n\\r\\n       4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5× the\\r\\n          upper limit of normal (ULN) if no hepatic metastases are present; <5× ULN if\\r\\n          hepatic metastases are present\\r\\n\\r\\n       5. Total bilirubin <1.5× ULN; <3 X ULN in the presence of Gilbert's disease\\r\\n\\r\\n       6. Estimated (Cockcroft-Gault formula) or measured creatinine clearance ≥60 mL/min\\r\\n\\r\\n       7. International normalized ratio (INR) ≤1.5× ULN unless participant is receiving\\r\\n          anticoagulant therapy as long as the prothrombin time (PT) or activated partial\\r\\n          thromboplastin time (aPTT) is within therapeutic range of intended use of\\r\\n          anticoagulants\\r\\n\\r\\n  7. If female of childbearing potential, either abstain from sexual intercourse or\\r\\n     employ highly effective contraception measures during the study and for ≥30 days\\r\\n     after the administration of the study drug. Highly effective measures include 2\\r\\n     forms of contraception. Postmenopausal or surgically sterile women (ie,\\r\\n     hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) are eligible.\\r\\n     Postmenopausal status is defined as either: amenorrheic for ≥12 months following\\r\\n     cessation of exogenous hormonal treatments and without an alternative medical cause;\\r\\n     luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal\\r\\n     range for women <50 years of age; radiation-induced ovarian ablation with last\\r\\n     menses ≥1 year ago; or chemotherapy-induced menopause with a ≥1-year interval since\\r\\n     last menses. Female subjects must refrain from donating or banking eggs (ova,\\r\\n     oocytes) and retrieving eggs for use during study treatment and for 30 days after\\r\\n     the administration of the study drug.\\r\\n\\r\\n  8. For male subjects not surgically sterile, must either abstain from sexual\\r\\n     intercourse or employ highly effective contraception (condoms or other barrier forms\\r\\n     of contraception) during the study and for at least 30 days after the administration\\r\\n     of the study drug. Male subjects should also avoid semen donation or providing semen\\r\\n     for in vitro fertilization during the above-mentioned duration.\\r\\n\\r\\n  9. Able to understand and willing to provide informed consent and able to comply with\\r\\n     the study procedures, including biopsy, and restrictions.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Unwilling or unable to comply with scheduled visits, study drug administration plan,\\r\\n     laboratory tests, or other study procedures and study restrictions.\\r\\n\\r\\n  2. Have received anticancer therapy (including both systemic therapy and radiotherapy,\\r\\n     but not including immunotherapy or other antibody therapies) within 14 days or 5\\r\\n     half-lives (whichever is shorter) of study drug administration or;\\r\\n\\r\\n     a. received antibody therapy within 30 days before the start of study drug\\r\\n     administration.\\r\\n\\r\\n  3. Have a history of a second primary malignancy that has been diagnosed or required\\r\\n     active therapy within the past year.\\r\\n\\r\\n     a. Note: The following prior malignancies are not exclusionary: completely resected\\r\\n     basal cell and squamous cell skin cancer, curatively treated localized prostate or\\r\\n     breast cancer, curatively treated localized thyroid cancer, and completely resected\\r\\n     carcinoma in situ of any site.\\r\\n\\r\\n  4. Have central nervous system (CNS) metastases or primary CNS tumor that is associated\\r\\n     with progressive neurologic symptoms or requires ongoing corticosteroids to control\\r\\n     the CNS disease. Subjects must have a stable neurologic status without steroid\\r\\n     support for ≥2 weeks before the start of study drug administration. Subjects with\\r\\n     stable or asymptomatic CNS metastases or primary CNS are eligible.\\r\\n\\r\\n  5. Require treatment with traditional/herbal medicines or their preparations indicated\\r\\n     for tumors or with adjuvant anti-tumor effects that cannot be discontinued during\\r\\n     the study.\\r\\n\\r\\n  6. Have clinically significant, uncontrolled cardiovascular disease including\\r\\n     congestive heart failure Class III or Class IV according to the New York Heart\\r\\n     Association classification; myocardial infarction or unstable angina within the\\r\\n     previous 6 months; uncontrolled hypertension (Grade ≥3); or clinically significant,\\r\\n     uncontrolled arrhythmia, including bradyarrhythmia that may cause QT prolongation\\r\\n     (eg, Type II second-degree heart block or third-degree heart block).\\r\\n\\r\\n  7. Have QT interval corrected using Fridericia's formula >480 msec. Unless the subject\\r\\n     has a history of prolonged QT syndrome or torsade de pointes or a familial history\\r\\n     of prolonged QT syndrome.\\r\\n\\r\\n  8. Have a history of acute ischemic stroke, diagnosed by imaging (CT or MRI) or\\r\\n     clinical diagnosis within 6 months prior to screening.\\r\\n\\r\\n  9. Have any severe or uncontrolled systemic disease or condition per clinical\\r\\n     judgement, including: (i) uncontrolled hypertension or diabetes; (ii) serious\\r\\n     cardiac, pulmonary, or renal conditions; (iii) active bleeding diatheses; (iv) any\\r\\n     active type of bacterial, viral, fungal, or other infection that would pose a\\r\\n     significant risk to the subject in the opinion of the Investigator; (v)\\r\\n     cerebrovascular accident within the last 6 months before administration of study\\r\\n     drug.\\r\\n\\r\\n 10. Have received a major surgical procedure within 28 days before the start of study\\r\\n     drug administration (procedures such as central venous catheter placement and tumor\\r\\n     needle biopsy are not considered major surgical procedures). The study center should\\r\\n     discuss other minor surgeries with the sponsor.\\r\\n\\r\\n 11. Clinical diagnosis of hemochromatosis or secondary iron overload,\\r\\n\\r\\n 12. Have known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C\\r\\n     virus infection that is not well-controlled and meets any of the following exclusion\\r\\n     criteria:\\r\\n\\r\\n       1. Documented detectable HIV RNA within 4 weeks of study drug administration,\\r\\n\\r\\n       2. Acquired immunodeficiency syndrome defining opportunistic infections within the\\r\\n          past 12 months prior to study enrollment, and\\r\\n\\r\\n       3. Is not on antiretroviral therapy for at least 4 weeks prior to study\\r\\n          enrollment.\\r\\n\\r\\n 13. Have clinical signs or symptoms consistent with COVID-19 infection or confirmed\\r\\n     infection by appropriate laboratory test (done at the discretion of Investigator or\\r\\n     per local regulation) within the last 2 weeks before the administration of the study\\r\\n     drug. In case of confirmed COVID-19 infection before screening, documentation of\\r\\n     resolution of infection by appropriate laboratory test is required.\\r\\n\\r\\n 14. Have received or are planning to receive a COVID-19 vaccination within 2 weeks\\r\\n     before or after the administration of the study drug. However, COVID-19 vaccinations\\r\\n     received >2 weeks before or after the administration of the study drug are\\r\\n     permitted.\\r\\n\\r\\n 15. Have received a live or live attenuated vaccines within 30 days before the\\r\\n     administration of the study drug.\\r\\n\\r\\n 16. Have any unresolved clinically relevant toxicities from prior therapy, greater than\\r\\n     NCI CTCAE Grade 1 at the time of starting study treatment, except for alopecia.\\r\\n\\r\\n 17. Have a history of hypersensitivity to active or inactive excipients of the study\\r\\n     drug or drugs with a similar chemical structure or class to the study drug,\\r\\n     including ferumoxytol (Feraheme®).\\r\\n\\r\\n 18. Have an active autoimmune disease (eg, rheumatoid arthritis, systemic lupus\\r\\n     erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, ankylosing\\r\\n     spondylitis, thyroiditis) requiring continuing immune suppressive therapy, including\\r\\n     >10 mg prednisone per day or equivalent.\\r\\n\\r\\n 19. Pregnant or breastfeeding at the time of screening or on Day 1 before TTX-MC138 as\\r\\n     documented by a serum beta human chorionic gonadotropin pregnancy test consistent\\r\\n     with pregnancy.\\r\\n\\r\\n 20. Known current drug or alcohol abuse.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Susan Duggan',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '8578373099',\n",
       "      'email': 'susan.duggan@transcodetherapeutics.com'}],\n",
       "    'locations': [{'facility': 'Mary Crowley Cancer Center',\n",
       "      'city': 'Dallas',\n",
       "      'state': 'Texas',\n",
       "      'zip': '75230',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Minal Barve, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'referral@MaryCrowley.org'},\n",
       "       {'name': 'Minal Barve, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 32.78306, 'lon': -96.80667}},\n",
       "     {'facility': 'MD Anderson Cancer Center',\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77230',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Ashabari Sprenger, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'amukherjee1@mdanderson.org'},\n",
       "       {'name': 'Siqing Fu, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': 'Next Oncology',\n",
       "      'city': 'Fairfax',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '22031',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Amanda Betancourt, BS, M.Jur',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'abetancourt@nextoncology.com'},\n",
       "       {'name': 'Alex Spira, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06367374',\n",
       "    'orgStudyIdInfo': {'id': 'BGB-11417-2002-IIT；BDH-CLL-004'},\n",
       "    'organization': {'fullName': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL',\n",
       "    'officialTitle': 'A Single Arm, Open-label Study of MRD-Guided Zanubrutinib in Combination With Sonrotoclax in Adult Patients With Treatment Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2030-02-28', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2030-07-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-20',\n",
       "    'studyFirstSubmitQcDate': '2024-04-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-11',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Qiu Lugui',\n",
       "     'investigatorTitle': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "     'investigatorAffiliation': 'Institute of Hematology & Blood Diseases Hospital, China'},\n",
       "    'leadSponsor': {'name': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a single-arm, open-label study of sonrotoclax plus zanubrutinib with MRD-driven\\r\\ntreatment duration in patients with previously untreated Chronic Lymphocytic Leukemia\\r\\n(CLL) or Small Lymphocytic Lymphoma (SLL).\\r\\n\\r\\nThe primary goal of this study is to evaluate the efficacy of MRD-guided zanubrutinib\\r\\nplus sonrotoclax for first-line CLL/SLL treatment.',\n",
       "    'detailedDescription': \"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are often\\r\\nconsidered different variations of the same disease due to their many similarities. There\\r\\nis an urgent need for new treatments to improve patients' quality of life, prolong\\r\\nsurvival, and manage disease-related symptoms.\\r\\n\\r\\nThere are several different methods for treating front-line therapy, including\\r\\nChemoimmunotherapy (CIT), Bruton tyrosine kinase inhibitors (BTKis), and BCL-2 inhibitors\\r\\n(BCL2is). Continuous treatment with BTK inhibitors is necessary for the treatment of CLL\\r\\nor SLL. However, younger patients may need to limit their therapeutic duration. The\\r\\ncombination of BTK inhibitors and BCL-2 inhibitors is believed to be an optimizing\\r\\nregimen that provides a limited duration of therapy.\\r\\n\\r\\nThe main aim of this study is to assess whether MRD-guided zanubrutinib, in combination\\r\\nwith sonrotoclax, can be an effective first-line treatment option for adult patients with\\r\\ntreatment-naïve CLL or SLL. The goal is to achieve long-lasting and more profound\\r\\nresponses, which could allow for the possibility of discontinuing treatment.\"},\n",
       "   'conditionsModule': {'conditions': ['Chronic Lymphocytic Leukemia',\n",
       "     'Small Lymphocytic Lymphoma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 66, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Sonrotoclax Plus Zanubrutinib',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Participants will receive from the start of Cycle 1 a standard dose of zanubrutinib\\r\\n     twice daily orally for three cycles and in combination with sonrotoclax starting\\r\\n     from Cycle 4 onwards at increasing doses twice a week until the target dose is\\r\\n     reached from Cycle 5 and continuing until the end of Cycle 15 (each cycle is 28\\r\\n     days). Patients with a measurable minimal residual disease (MRD) will receive\\r\\n     another 12 cycles of Zanubrutinib in combination with sonrotoclax until their MRD is\\r\\n     undetectable.\\r\\n\\r\\n  -  Interventions:\\r\\n\\r\\n       -  Drug: Sonrotoclax\\r\\n\\r\\n       -  Drug: Zanubrutinib',\n",
       "      'interventionNames': ['Drug: Sonrotoclax', 'Drug: Zanubrutinib']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Sonrotoclax',\n",
       "      'description': 'Participants receive zanubrutinib orally 160mg bid from start of Cycle 1, and in\\r\\ncombination with sonrotoclax (SZ) from Cycle 4 onwards at increasing doses until 320mg\\r\\ndaily target dose is reached and continuing for at least 12 cycles (each cycle is 28\\r\\ndays).\\r\\n\\r\\nParticipants with uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others\\r\\nwill continue to receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.\\r\\n\\r\\nParticipants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those\\r\\nwith MRD-positive by then.',\n",
       "      'armGroupLabels': ['Sonrotoclax Plus Zanubrutinib'],\n",
       "      'otherNames': ['BGB-11417']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Zanubrutinib',\n",
       "      'description': 'Participants receive zanubrutinib orally 160mg bid from start of Cycle 1,Participants\\r\\nwith uMRD and PR/CR by the end of Cycle 15 will stop SZ treatment, others will continue\\r\\nto receive SZ for another 12 cycles and stop SZ if uMRD and PR/CR.\\r\\n\\r\\nParticipants will receive sonrotoclax up to 2 years, and receive zanubrutinib for those\\r\\nwith MRD-positive by then.',\n",
       "      'armGroupLabels': ['Sonrotoclax Plus Zanubrutinib'],\n",
       "      'otherNames': ['BGB- 3111']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': '4-Year Progressive Free Survival (PFS) Rate',\n",
       "      'description': 'PFS is defined as the time from the date of enrollment to the date of first confirmed\\r\\ndisease progression or death due to any cause, whichever occurs first, as determined by\\r\\ninvestigators',\n",
       "      'timeFrame': '4 years after enrollment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Rate of peripheral blood (PB) and Bone marrow (BM) undetectable minimal residual disease (uMRD)',\n",
       "      'description': 'Rate of PB and BM uMRD is defined as proportion of participants achieving remission based\\r\\non flow cytometry (FCM) result of < 1 CLL cell per 100,000 leukocytes (< 10 ^-4 ), after\\r\\ncompletion of 12 and 24 cycles of sonrotoclax treatment.',\n",
       "      'timeFrame': 'At screening, the end of Cycle 14 and Cycle 26 (each cycle is 28 days)'},\n",
       "     {'measure': 'Complete Response Rate (CRR; Complete Response/Complete Response with Incomplete Blood Count Recovery [CR/CRi]) Rate',\n",
       "      'description': 'CR/CRi rate is defined as the percentage of participants achieving a response of complete\\r\\nresponse (CR), CR with incomplete blood count recovery (CRi) per 2018 IWCLL criteria, as\\r\\ndetermined by investigators',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Overall Response Rate (ORR)',\n",
       "      'description': 'ORR is defined as the percentage of participants achieving a response of complete\\r\\nresponse (CR), CR with incomplete blood count recovery (CRi), nodular partial response\\r\\n(nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated under the 2018\\r\\nIWCLL criteria, as determined byinvestigators',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Duration of Response (DOR)',\n",
       "      'description': 'DOR was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2018\\r\\nIWCLL response criteria in CLL or a response (PR or better) based on 2014 Lugano response\\r\\ncriteria and defined as the interval between the date of initial documentation of a\\r\\nresponse mentioned above until disease progression (PD) or death from any cause,\\r\\nwhichever occurred first',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Progression Free Survival (PFS)',\n",
       "      'description': 'PFS is defined as the time from the date of enrollment to the date of first confirmed\\r\\ndisease progression or death due to any cause, whichever occurs first, as determined by\\r\\ninvestigators',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'OS is defined as time from the date of enrollment to the date of death because of any\\r\\ncause',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Time to Next Therapy (TTNT)',\n",
       "      'description': 'Time to next CLL or SLL therapy is defined as the time from the first administration of\\r\\nstudy drugs to the first administration of the next CLL/SLL treatment, as determined by\\r\\ninvestigators',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Overall survival rate',\n",
       "      'description': 'Number, time frame and seriousness of participants with Treatment-Emergent Adverse Events\\r\\n(NCI-TEAE v5.0)',\n",
       "      'timeFrame': 'Up to 4 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Treatment naïve adult patients with diagnosis of CLL/SLL requiring treatment\\r\\n     according to iwCLL guidelines 2018\\r\\n\\r\\n  2. Measurable nodal disease by CT/MRI.\\r\\n\\r\\n  3. Adequate hematologic function\\r\\n\\r\\n  4. Adequate hepatic and renal function\\r\\n\\r\\n  5. Eastern Cooperative Oncology Group\\r\\n\\r\\n  6. (ECOG) performance status of 0-2\\r\\n\\r\\n  7. Expected survival period > 6 months\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Any prior systemic therapy used for treatment of CLL/SLL\\r\\n\\r\\n  2. With history of prolymphocytic leukemia, known or currently suspected Richter's\\r\\n     transformation\\r\\n\\r\\n  3. Known central nervous system involvement by leukemia or lymphoma\\r\\n\\r\\n  4. Confirmed progressive multifocal leukoencephalopathy (PML)\\r\\n\\r\\n  5. Severe or debilitating pulmonary disease\\r\\n\\r\\n  6. Clinically significant cardiovascular disease\\r\\n\\r\\n  7. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura\\r\\n     requiring treatment\\r\\n\\r\\n  8. History of other malignancies\\r\\n\\r\\n  9. Prior therapy with study drugs within 4 weeks before screening\\r\\n\\r\\n 10. Active fungal, bacterial, and/or viral infection requiring systemic therapy\\r\\n\\r\\n 11. Known allergy to zanubrutinib or sonrotoclax or any pharmaceutical excipients\\r\\n\\r\\n 12. Pregnant or lactating women\\r\\n\\r\\n 13. Vaccinated with live vaccines within 28 days prior to enrollment\\r\\n\\r\\n 14. Serologically positive of human immunodeficiency virus (HIVAb), or active infection\\r\\n     with hepatitis B virus (HBV) or hepatitis C virus (HCV)\\r\\n\\r\\n 15. History of stroke or intracranial hemorrhage within 6 months\\r\\n\\r\\n 16. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Shuhua Yi',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '15900265415',\n",
       "      'email': 'yishuhua@ihcams.ac.cn'},\n",
       "     {'name': 'Yexiang Wang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '13810279737',\n",
       "      'email': 'yexiang.wang@ashermed.com'}],\n",
       "    'overallOfficials': [{'name': 'Lugui Qiu',\n",
       "      'affiliation': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008223',\n",
       "      'term': 'Lymphoma'},\n",
       "     {'id': 'D000007938', 'term': 'Leukemia'},\n",
       "     {'id': 'D000007945', 'term': 'Leukemia, Lymphoid'},\n",
       "     {'id': 'D000015451', 'term': 'Leukemia, Lymphocytic, Chronic, B-Cell'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008232', 'term': 'Lymphoproliferative Disorders'},\n",
       "     {'id': 'D000008206', 'term': 'Lymphatic Diseases'},\n",
       "     {'id': 'D000007160', 'term': 'Immunoproliferative Disorders'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000015448', 'term': 'Leukemia, B-Cell'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M11220',\n",
       "      'name': 'Lymphoma',\n",
       "      'asFound': 'Lymphoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10951',\n",
       "      'name': 'Leukemia, Lymphoid',\n",
       "      'asFound': 'Lymphocytic Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18116',\n",
       "      'name': 'Leukemia, Lymphocytic, Chronic, B-Cell',\n",
       "      'asFound': 'Small lymphocytic lymphoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11225',\n",
       "      'name': 'Lymphoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10206',\n",
       "      'name': 'Immunoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M18115', 'name': 'Leukemia, B-Cell', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T3543', 'name': 'Lymphosarcoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T1308',\n",
       "      'name': 'Chronic Lymphocytic Leukemia',\n",
       "      'asFound': 'Chronic Lymphocytic Leukemia',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000629551',\n",
       "      'term': 'Zanubrutinib'}],\n",
       "    'ancestors': [{'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M42199',\n",
       "      'name': 'Zanubrutinib',\n",
       "      'asFound': 'Allowing',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06414525',\n",
       "    'orgStudyIdInfo': {'id': 'constipation'},\n",
       "    'organization': {'fullName': 'Cairo University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Effect of Abdominal Massage Versus Visceral Manipulation on Constipation',\n",
       "    'officialTitle': 'Effect of Abdominal Massage Versus Visceral Manipulation on Constipation Status and Quality of Life in Adults'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-06',\n",
       "    'studyFirstSubmitQcDate': '2024-05-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Mennat Allah Mohamed Ali Ahmed',\n",
       "     'investigatorTitle': 'head of department of physical therapy AboKhalefa hospital',\n",
       "     'investigatorAffiliation': 'Cairo University'},\n",
       "    'leadSponsor': {'name': 'Cairo University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The study compares the effect of abdominal massage vs. visceral manipulation on\\r\\nconstipation status and quality of life in adults.\\r\\n\\r\\nChronic idiopathic constipation (CIC) is considered a common functional bowel disorder\\r\\ncharacterized by difficult, infrequent, and/or incomplete defecation. It has a great\\r\\nimpact on the quality of life and on the healthcare system and represents an important\\r\\nfinancial strain .'},\n",
       "   'conditionsModule': {'conditions': ['Constipation Chronic Idiopathic'],\n",
       "    'keywords': ['chronic idiopathic constipation',\n",
       "     'abdominal massage',\n",
       "     'visceral manipulation',\n",
       "     'quality of life']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Abdominal massage',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The technique involves stroking and kneading the abdomen in a consistent pattern.',\n",
       "      'interventionNames': ['Other: abdominal massage']},\n",
       "     {'label': 'visceral manipulation',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The technique involves visceral connective tissue manipulation.',\n",
       "      'interventionNames': ['Other: visceral manipulation']},\n",
       "     {'label': 'control',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'instructions on daily, dietary, toilet, and physical activity habits',\n",
       "      'interventionNames': ['Other: instructions on daily, dietary , toilet , and physical activity habits']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'abdominal massage',\n",
       "      'description': 'It will include patients that will receive abdominal massage; the frequency and duration\\r\\nof the massage will be arranged as 3 sessions per week, with each session lasting an\\r\\naverage of 20-25 minutes for 6 weeks.',\n",
       "      'armGroupLabels': ['Abdominal massage']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'visceral manipulation',\n",
       "      'description': 'It will include patients that will receive visceral manipulation; the frequency and\\r\\nduration of the technique will be arranged as 3 sessions per week, with each session\\r\\nlasting an average of 20-25 minutes for 6 weeks.',\n",
       "      'armGroupLabels': ['visceral manipulation']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'instructions on daily, dietary , toilet , and physical activity habits',\n",
       "      'description': 'It will include patients that will receive behavioral therapy: defecation mechanism and\\r\\ninforming about negative attitudes and behaviors towards defecation), lifestyle advice\\r\\n(diet, water consumption, fiber food, etc.), teaching effective defecation posture, and\\r\\ntimed toilet training.',\n",
       "      'armGroupLabels': ['control']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Constipation Severity Instrument (CSI)',\n",
       "      'description': 'Constipation Severity Instrument (CSI) will be used to evaluate the severity of the\\r\\nconstipation. The Constipation Severity Instrument is a 16-item patient-reported outcome\\r\\nmeasure that investigates symptoms of constipation based on frequency, severity, and\\r\\nbother of symptoms. CSI consists of three subscales: obstructive defecation, colonic\\r\\ninertia, and pain.\\r\\n\\r\\nHigher scores of CSI indicate more severe constipation.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Constipation Assessment Scale',\n",
       "      'description': 'Constipation assessment scale will be used to evaluate the severity of the constipation.\\r\\nThe constipation assessment scale is a eight-item scale that assess the presence and\\r\\nseverity of constipation.\\r\\n\\r\\nThe patient rates each constipation item on a three-point scale (no problem to severe\\r\\nproblem). Total scores range from 0 (no constipation) to 16 (worst possible\\r\\nconstipation).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Patient Assessment of Constipation- Quality of Life (PAC-QOL) Questionnaire',\n",
       "      'description': 'Patient Assessment of Constipation Quality of Life Questionnaire (PAC-QOL) will be used\\r\\nto evaluate quality of life. PAC-QOL consists a total of 28 items in four subscales:\\r\\nworries and concerns (11 items), physical discomfort (4 items), psychosocial discomfort\\r\\n(8 items), and satisfaction (5 items). Higher scores of PAC-QOL indicate more negative\\r\\neffects of constipation on the quality of life.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Bowel Function Index',\n",
       "      'description': '(Scale 0 - 100), will be calculated as the mean of three variables (ease of defecation,\\r\\nfeeling of incomplete bowel evacuation, and personal judgement of constipation) was\\r\\ndeveloped to evaluate bowel function.',\n",
       "      'timeFrame': '6 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patients of both sex with age ranges (20-40) years old.\\r\\n\\r\\n  -  having a diagnosis of functional constipation according to Rome IV criteria onset of\\r\\n     constipation symptoms from 6-12 months .\\r\\n\\r\\n  -  having body mass index 18.5-29.9 kg/m2 , waist height ratio </=0.5\\r\\n\\r\\n  -  Subjects bothered by their constipation\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Pregnancy.\\r\\n\\r\\n  -  Having comorbidities (chronic pelvic pain, neurological (Parkinson's, multiple\\r\\n     sclerosis, spinal cord lesion, etc.), metabolic / endocrine (diabetes mellitus,\\r\\n     hypercalcemia, hypothyroid, etc.), cardiorespiratory diseases\\r\\n\\r\\n  -  Health problems which may prevent standing from sitting, walking (orthopedic,\\r\\n     neurological, cardiorespiratory, etc.)\\r\\n\\r\\n  -  Malignancy, acute inflammation, intestinal tumor\\r\\n\\r\\n  -  History of gastrointestinal and pelvic surgery or spinal surgery other than\\r\\n     cholecystectomy, appendectomy, or hysterectomy\\r\\n\\r\\n  -  Visual, auditory or cognitive problems which may prevent participation to the study.\\r\\n\\r\\n  -  Tumor, presence of skin problems in the application area\\r\\n\\r\\n  -  Presence of laxative use for functional constipation in the last four weeks or\\r\\n     patients on laxative therapy.\\r\\n\\r\\n  -  Alarm symptoms (unexplained, more than 10% weight loss in 3 months, hemorrhoids and\\r\\n     anal fissures, rectal bleeding, family history of colon cancer)\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '20 Years',\n",
       "    'maximumAge': '40 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mennat Allah Ahmed',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01228423121',\n",
       "      'email': 'mennamohamed309@gmail.com'}],\n",
       "    'locations': [{'facility': 'Abo Khalefa emergency hospital',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Ismailia',\n",
       "      'country': 'Egypt',\n",
       "      'geoPoint': {'lat': 30.60427, 'lon': 32.27225}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003248',\n",
       "      'term': 'Constipation'}],\n",
       "    'ancestors': [{'id': 'D000012817',\n",
       "      'term': 'Signs and Symptoms, Digestive'}],\n",
       "    'browseLeaves': [{'id': 'M6472',\n",
       "      'name': 'Constipation',\n",
       "      'asFound': 'Constipation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15622',\n",
       "      'name': 'Signs and Symptoms, Digestive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T6034', 'name': 'Quality of Life', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05140525',\n",
       "    'orgStudyIdInfo': {'id': 'Pro00105903'},\n",
       "    'organization': {'fullName': 'Duke University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH',\n",
       "    'officialTitle': 'Effects of Combination Medical Therapy Followed by Balloon Pulmonary Angioplasty on Right Ventricular-PA Coupling and Hemodynamics in Chronic Thromboembolic Pulmonary Hypertension',\n",
       "    'acronym': 'EPIPHANY'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2021-10-28',\n",
       "    'studyFirstSubmitQcDate': '2021-11-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2021-12-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr Sudarshan Rajagopal',\n",
       "     'investigatorTitle': 'Associate Professor of Medicine',\n",
       "     'investigatorAffiliation': 'Duke University'},\n",
       "    'leadSponsor': {'name': 'Dr Sudarshan Rajagopal', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Actelion', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The main goal of this study is to determine the effects of combination medical therapy\\r\\n(Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and\\r\\nright ventricular (RV) function (including advanced assessments of RV-pulmonary artery\\r\\n(PA) coupling from invasive hemodynamics) in participants with inoperable or post-PTE\\r\\nresidual CTEPH.',\n",
       "    'detailedDescription': 'Recent presented but unpublished results from trials of BPA vs riociguat for inoperable\\r\\nCTEPH (NCT02634203) have demonstrated that BPA provides a more significant hemodynamic\\r\\nbenefit than medical therapy. The investigators hypothesize that participants who are\\r\\ntreated with upfront combination medical therapy followed by BPA will have significant\\r\\nimprovements in their hemodynamics and RV-PA coupling that can be monitored over time.'},\n",
       "   'conditionsModule': {'conditions': ['CTEPH'],\n",
       "    'keywords': ['Inoperable', 'Post-PTE']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 15, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'participants with inoperable CTEPH',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'subject with inoperable Chronic thromboembolic Pulmonary Hypertension',\n",
       "      'interventionNames': ['Drug: Macitentan Tablets',\n",
       "       'Drug: Riociguat',\n",
       "       'Device: balloon pulmonary angioplasty']},\n",
       "     {'label': 'post PTE residual CTEPH',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Subject with post pulmonary endarterectomy (PTE) residual Chronic Thromboembolic\\r\\nPulmonary Hypertension',\n",
       "      'interventionNames': ['Drug: Macitentan Tablets',\n",
       "       'Drug: Riociguat',\n",
       "       'Device: balloon pulmonary angioplasty']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Macitentan Tablets',\n",
       "      'description': '10 mg oral once daily',\n",
       "      'armGroupLabels': ['participants with inoperable CTEPH',\n",
       "       'post PTE residual CTEPH'],\n",
       "      'otherNames': ['OPSUMIT']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Riociguat',\n",
       "      'description': '1 mg to 2.5mg oral three times daily',\n",
       "      'armGroupLabels': ['participants with inoperable CTEPH',\n",
       "       'post PTE residual CTEPH'],\n",
       "      'otherNames': ['Adempas']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'balloon pulmonary angioplasty',\n",
       "      'description': 'on hemodynamics and RV function (including advanced assessments of RV-PA coupling',\n",
       "      'armGroupLabels': ['participants with inoperable CTEPH',\n",
       "       'post PTE residual CTEPH']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in end-systolic elastance (Ees) divided by arterial elastance (Ea) (Ees/Ea) at three time points: Baseline, Timepoint 1 and Timepoint 2.',\n",
       "      'description': 'Ees is a measure of right ventricular (RV) - pulmonary arterial (PA) coupling, with a\\r\\nnormal value of Ees/Ea > 0.8 (dimensionless - no units). For subjects with Ees/Ea > 0.8\\r\\nat the start of the study, we will evaluate the absolute change in Ees/Ea between\\r\\ntimepoints. For those with an Ees/Ea < 0.8, we will also determine whether participants\\r\\nhave an improvement to > 0.8.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change in six-minute walk distance (6MWD) in meters.',\n",
       "      'description': '6MWD will be determined at baseline, timepoint 1 and timepoint 2. Absolute change between\\r\\nthese timepoints will be determined.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'},\n",
       "     {'measure': 'Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) in picogram/milliliters.',\n",
       "      'description': 'NT-proBNP will be determined at baseline, timepoint 1 and timepoint 2. Absolute change\\r\\nbetween these timepoints will be determined.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'},\n",
       "     {'measure': 'Change in Cardiac index as measured by liters per minute per meters squared at right heart catheterization.',\n",
       "      'description': 'Right heart catheterization will be performed at baseline, timepoint 1 and timepoint 2\\r\\nand parameters determined. Absolute change between these timepoints will be determined.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'},\n",
       "     {'measure': 'Change in pulmonary vascular resistance as measured by Wood units at right heart catheterization.',\n",
       "      'description': 'Right heart catheterization will be performed at baseline, timepoint 1 and timepoint 2\\r\\nand parameters determined. Absolute change between these timepoints will be determined.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'},\n",
       "     {'measure': 'Change in right atrial pressure as measured by millimeters of mercury at right heart catheterization.',\n",
       "      'description': 'Right heart catheterization will be performed at baseline, timepoint 1 and timepoint 2\\r\\nand parameters determined. Absolute change between these timepoints will be determined.',\n",
       "      'timeFrame': 'Baseline (before starting all treatments); Timepoint 1 (after starting medical therapy; up to 6 months after baseline); Timepoint 2 (after balloon pulmonary angioplasty (BPA); up to 12 months after baseline)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\nSubjects must meet all of the following inclusion criteria to be eligible for enrollment\\r\\ninto the trial:\\r\\n\\r\\n  1. Age ≥ 18 years' old\\r\\n\\r\\n  2. Diagnosis of CTEPH\\r\\n\\r\\n  3. Not a candidate for PTE\\r\\n\\r\\n  4. Candidate for BPA based on suitable anatomy and disease burden\\r\\n\\r\\n  5. Treatment-naïve (no CTEPH or pulmonary arterial hypertension (PAH)-specific medical\\r\\n     therapies) with plans for initiation of CTEPH/PAH-specific medical therapy and\\r\\n     treatment with BPA.\\r\\n\\r\\n  6. Willing and able to give informed consent and adhere to visit/protocol schedules\\r\\n     (Consent must be given before any study procedures are performed).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Subjects presenting with any of the following will not be included in the trials:\\r\\n\\r\\n       1. Moderate to severe heart disease (LVEF < 45% or severe LV Hypertrophy)\\r\\n\\r\\n       2. Sarcoidosis\\r\\n\\r\\n       3. Active cancer\\r\\n\\r\\n       4. Sickle cell anemia\\r\\n\\r\\n       5. Liver disease (Childs-Pugh class C)\\r\\n\\r\\n       6. Prisoners\\r\\n\\r\\n       7. Pregnant, planning pregnancy or lactating\\r\\n\\r\\n       8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia,\\r\\n          inability to lie supine)\\r\\n\\r\\n       9. Contraindication to riociguat or macitentan\\r\\n\\r\\n      10. Medical or psychological conditions which, in the opinion of the investigator,\\r\\n          might create undue risk to the subject or interfere with the subject's ability\\r\\n          to comply with the protocol requirements\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'David Ptashnik, MS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '9196682642',\n",
       "      'email': 'david.ptashnik@duke.edu'}],\n",
       "    'overallOfficials': [{'name': 'Sudarshan Rajagopal, MD, PhD',\n",
       "      'affiliation': 'Duke Health System',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Duke University Medical Center',\n",
       "      'city': 'Durham',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27710',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'David Ptashnik, MS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '919-668-2642',\n",
       "        'email': 'david.patshnik@duke.edu'},\n",
       "       {'name': 'Sudarshan Rajagopal, MD, PhD',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M10024',\n",
       "      'name': 'Hypertension',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10027', 'name': 'Hypertension, Pulmonary', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T1316',\n",
       "      'name': 'Chronic Thromboembolic Pulmonary Hypertension',\n",
       "      'asFound': 'CTEPH',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000533860',\n",
       "      'term': 'Macitentan'},\n",
       "     {'id': 'C000542595', 'term': 'Riociguat'}],\n",
       "    'ancestors': [{'id': 'D000065130',\n",
       "      'term': 'Endothelin A Receptor Antagonists'},\n",
       "     {'id': 'D000065128', 'term': 'Endothelin Receptor Antagonists'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000065131', 'term': 'Endothelin B Receptor Antagonists'},\n",
       "     {'id': 'D000020536', 'term': 'Enzyme Activators'}],\n",
       "    'browseLeaves': [{'id': 'M256040',\n",
       "      'name': 'Riociguat',\n",
       "      'asFound': 'Approved by',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M258148',\n",
       "      'name': 'Macitentan',\n",
       "      'asFound': 'End-expiratory pressure',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M30468',\n",
       "      'name': 'Endothelin A Receptor Antagonists',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M30466',\n",
       "      'name': 'Endothelin Receptor Antagonists',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05384522',\n",
       "    'orgStudyIdInfo': {'id': 'INRCA_002_2022'},\n",
       "    'organization': {'fullName': 'Istituto Nazionale di Ricovero e Cura per Anziani',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': \"Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease\",\n",
       "    'officialTitle': \"Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease\",\n",
       "    'acronym': 'BioGenPark'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-10',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-01-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-01-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-05-17',\n",
       "    'studyFirstSubmitQcDate': '2022-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-04',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-05', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Istituto Nazionale di Ricovero e Cura per Anziani',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"BioGenParkinson is an observational, prospective cohort study evaluating biomarkers of\\r\\nParkinson's Disease (PD) progression in community-dwelling subjects aged 65 years or\\r\\nmore, consecutively referring to INRCA outpatient clinic of the Neurology Unit. Selected\\r\\npatients will undergo clinical and laboratory evaluations at the baseline, and will be\\r\\nfollowed up after 6 and 12 months. The biological evaluation will include the\\r\\ndetermination of i) routine biological parameters ii) advanced biomarkers such as\\r\\nepigenetic analysis of DNA methylation, genetic analysis on multiple loci associated with\\r\\nPD progression and specific proteins associated with motor and non-motor decline. After\\r\\nobtaining all data, multiple statistical analysis will be performed to evaluate the most\\r\\naccurate prognostic biomarkers of PD progression at this stage of disease.\",\n",
       "    'detailedDescription': \"The objective of the BioGenParkinson study is the evaluation of the prognostic accuracy\\r\\nof epigenetic, genetic and protein biomarkers in relation to Parkinson's Disease (PD)\\r\\nmotor symptoms progression (assessed by changes in Unified Parkinson's Disease Rating\\r\\nScale Part III (UPDRS III)) in biological samples of 103 PD patients aged 65 or more.\\r\\nChanges of quality of life (assessed by Parkinson's Disease Questionnaire 39 item\\r\\n(PDQ-39)) and cognitive performance (assessed by the Mini-Mental State Examination\\r\\n(MMSE)) will be also investigated. The characterization of the PD patients' phenotypes\\r\\nand genotypes will allow the investigation on the predisposition to a severe progression\\r\\nof the disease, in order to early predict the progression of the disease and improving\\r\\nthe accuracy of personalized interventions. The evidence collected will inform\\r\\nmultidisciplinary and personalized interventions in the future.\\r\\n\\r\\nAmong the advanced biomarkers that will be evaluated in the Study, epigenetic analysis of\\r\\nCpG loci such as cg17445913 in KCNB1 gene, cg02920897 in DLEU2 gene and cg01754178 in\\r\\nPTPRN2 gene are expected to improve the prognostic accuracy of motor and cognitive\\r\\ndecline of PD patients at Hoehn and Yahr stage II/III after 12 months of follow up.\\r\\nGenetic analysis in purified genomic DNA samples will be performed on multiple loci\\r\\nassociated with PD progression such as rs2230288 and rs75548401 in order to confirm their\\r\\nassociation with motor decline over time, and to assess their association with non-motor\\r\\ndecline.\\r\\n\\r\\nProtein analysis on bone sialoprotein (BSP), osteomodulin (OMD), aminoacylase-1 (ACY1),\\r\\nand growth hormone receptor (GHR) will be also evaluated with respect to motor and\\r\\nnon-motor decline in PD patients in order to be compared with the other biomarkers.\\r\\nScores on UPDRS Parts III, obtained by using using the published cut-offs classification\\r\\nof MDS-UPDRS severity, will be drawn at the baseline, at 6-month and at 12-month\\r\\nfollow-up visits, in order to assess PD motor progression. Additional assessments include\\r\\ndemographic and clinical data, Parkinson Disease Questionnaire 39 item (PDQ-39) Hoehn and\\r\\nYahr stage, MMSE, Frontal Assessment Battery (FAB), list of disease and medication,\\r\\nfalls, functional status, quality of life and socio-economic characteristics.\"},\n",
       "   'conditionsModule': {'conditions': ['Parkinson Disease'],\n",
       "    'keywords': ['Parkinson disease',\n",
       "     'aging',\n",
       "     'biomarkers',\n",
       "     'DNA methylation',\n",
       "     'precision medicine',\n",
       "     'epigenomics',\n",
       "     'genetics',\n",
       "     'disease progression']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "     'description': 'A volume of approximately 35 mL (5ml EDTA tubes, 5ml LiHep tubes, 10 ml serum tubes, 10\\r\\nml whole blood tubes and 5 ml citrate tubes) of peripheral blood will be collected at\\r\\nbaseline and after 6 and 12 months. The buffy coat for DNA extraction will be stored from\\r\\nthe same tubes. Five mL of urine will be collected from all study participants at\\r\\nbaseline and at 6 and 12 months.'},\n",
       "    'enrollmentInfo': {'count': 103, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': \"Parkinson's Disease subjects\",\n",
       "      'description': 'Subjects with Parkinson Disease aged 65 years or more at Hoehn and Yahr stage ≤3',\n",
       "      'interventionNames': ['Other: blood samples collection']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'blood samples collection',\n",
       "      'description': 'Blood samples will be drawn at baseline and at 6 and 12 months from baseline',\n",
       "      'armGroupLabels': [\"Parkinson's Disease subjects\"]}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Prognostic role of epigenetic biomarkers with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the baseline\\r\\nmethylation status of the following epigenetic biomarkers: CpG loci cg17445913,\\r\\ncg02920897 and cg01754178. PD motor decline will be defined by an increase of UPDRS III\\r\\nat least of 2.4 points/year.\",\n",
       "      'timeFrame': 'Baseline and 12 months later'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Prognostic role of genetic biomarkers with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the presence\\r\\nof mutations of the GBA coding variants rs2230288 and rs75548401. PD motor decline will\\r\\nbe defined by an increase of UPDRS III at least of 2.4 points/year.\",\n",
       "      'timeFrame': 'Baseline and 12 months later'},\n",
       "     {'measure': 'Prognostic role of bone sialoprotein (BSP) with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the levels\\r\\nof baseline bone sialoprotein (BSP). PD motor decline will be defined by an increase of\\r\\nUPDRS III at least of 2.4 points/year.\",\n",
       "      'timeFrame': 'Baseline and 12 months later'},\n",
       "     {'measure': 'Prognostic role of osteomodulin (OMD) with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the levels\\r\\nof baseline osteomodulin (OMD).\",\n",
       "      'timeFrame': 'Baseline and 12 months later'},\n",
       "     {'measure': 'Prognostic role of aminoacylase-1 (ACY1) with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the levels\\r\\nof baseline aminoacylase-1 (ACY1).PD motor decline will be defined by an increase of\\r\\nUPDRS III at least of 2.4 points/year.\",\n",
       "      'timeFrame': 'Baseline and 12 months later'},\n",
       "     {'measure': 'Prognostic role of growth hormone receptor (GHR) with respect to the advancing of PD motor decline',\n",
       "      'description': \"Change of Unified Parkinson's Disease Rating Scale (UPDRSIII) in relation to the levels\\r\\nof baseline growth hormone receptor (GHR).PD motor decline will be defined by an increase\\r\\nof UPDRS III at least of 2.4 points/year.\",\n",
       "      'timeFrame': 'Baseline and 12 months later'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  PD at Hoehn and Yahr stage ≤3\\r\\n\\r\\n  -  MMSE test ≥24 score\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  MMSE score < 24\\r\\n\\r\\n  -  Severe cardiovascular diseases (including congestive heart failure NYHA=4, acute\\r\\n     coronary syndrome, stroke)\\r\\n\\r\\n  -  History of traumatic brain injury, previous deep brain surgery\\r\\n\\r\\n  -  Current substance or alcohol abuse\\r\\n\\r\\n  -  Reduced life expectancy less than six months',\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '65 Years',\n",
       "    'stdAges': ['OLDER_ADULT'],\n",
       "    'studyPopulation': 'Community-dwelling subjects aged 65 years or more with Parkinson Disease at Hoehn and\\r\\nYahr stage ≤3',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Anna Rita Bonfigli',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+390718003719',\n",
       "      'email': 'a.bonfigli@inrca.it'}],\n",
       "    'overallOfficials': [{'name': 'Giuseppe Pelliccioni, MD',\n",
       "      'affiliation': 'IRCCS INRCA, Ancona, Italy',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010300',\n",
       "      'term': 'Parkinson Disease'}],\n",
       "    'ancestors': [{'id': 'D000020734', 'term': 'Parkinsonian Disorders'},\n",
       "     {'id': 'D000001480', 'term': 'Basal Ganglia Diseases'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000009069', 'term': 'Movement Disorders'},\n",
       "     {'id': 'D000080874', 'term': 'Synucleinopathies'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M13213',\n",
       "      'name': 'Parkinson Disease',\n",
       "      'asFound': \"Parkinson's Disease\",\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20559', 'name': 'Disease Progression', 'relevance': 'LOW'},\n",
       "     {'id': 'M22494', 'name': 'Parkinsonian Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M25603', 'name': 'Ganglion Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M16358', 'name': 'Synovial Cyst', 'relevance': 'LOW'},\n",
       "     {'id': 'M4774', 'name': 'Basal Ganglia Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12029', 'name': 'Movement Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M2217', 'name': 'Synucleinopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06421025',\n",
       "    'orgStudyIdInfo': {'id': '69HCL23_0915'},\n",
       "    'secondaryIdInfos': [{'id': '2023-A02208-37',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'ID-RCB'}],\n",
       "    'organization': {'fullName': 'Hospices Civils de Lyon', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Blood Viscosity in Polycythemia Patients',\n",
       "    'officialTitle': 'Evaluation of Blood Viscosity and Hyperviscosity-related Complications Relationship in Patients With Patients With Polycythemia',\n",
       "    'acronym': 'POLYVISCO'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2031-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2031-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-15',\n",
       "    'studyFirstSubmitQcDate': '2024-05-15',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Hospices Civils de Lyon', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Polycythemia (PG) corresponds to an increase in erythrocyte parameters on a blood test. A\\r\\ndistinction is usually made between primary and secondary PG. The most common primary PG\\r\\nis Vaquez's disease, a hematological cancer. In Vaquez disease, an increase in hematocrit\\r\\nhas been reported to be associated with a logarithmic increase in blood viscosity.\\r\\n\\r\\nThe main complications of primary PGs (especially in Vaquez disease) are thromboembolic\\r\\ncomplications. In contrast, thromboembolic complications are rarer in secondary PG. In\\r\\nVaquez disease, a hematocrit ≤ 45% has been defined as the therapeutic goal for\\r\\nsignificantly reducing thromboembolic risk. However, this has not been established for\\r\\nsecondary PGs. All in all, the definition of the 45% threshold is based solely on\\r\\nclinical studies with no obvious biological argument. What's more, simply lowering blood\\r\\nmass through cytoreduction alone does not appear to be sufficient to significantly reduce\\r\\nthromboembolic risk.\\r\\n\\r\\nTo investigator knowledge, there are no studies prospectively evaluating blood viscosity,\\r\\nits determinants and coagulation in different types of polycythemia. Nor are there any\\r\\ndata on the direct effect on blood viscosity of the various treatments usually offered.\"},\n",
       "   'conditionsModule': {'conditions': ['Polycythemia Secondary',\n",
       "     'Polycythemia, Primary'],\n",
       "    'keywords': ['Polycythemia',\n",
       "     'viscosity',\n",
       "     'thromboelastometry',\n",
       "     'thrombosis']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Patients with polycythemia',\n",
       "      'description': 'Patients with polycythemia defined as hematocrit level greater than or equal to 49% in\\r\\nmen and 48% in women, whatever the suspected etiology. Primitive and secondary\\r\\npolycythemia are eligible in this observational study. Patients should not have start any\\r\\ncytoreductive therapy prior inclusion.'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Whole blood viscosity levels in patients with polycythemia',\n",
       "      'description': 'The investigators expect higher blood viscosity values in polyglobulic patients with\\r\\nsymptoms of clinical hyperviscosity than in polyglobulic patients without symptoms of\\r\\nclinical hyperviscosity, but no differences in hematocrit between the two polycythemia\\r\\ngroups',\n",
       "      'timeFrame': 'Baseline'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  18 years of age or older\\r\\n\\r\\n  -  Followed for a diagnosis or suspicion of polycythemia (hematocrit greater than or\\r\\n     equal to 49% in men and 48% in women), whatever the suspected etiology.\\r\\n\\r\\n  -  Patient affiliated to a social security scheme or similar\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patient having undergone therapeutic bloodletting within 3 months prior to\\r\\n     inclusion, or having initiated cytoreductive therapy prior to inclusion.\\r\\n\\r\\n  -  Any disease or condition other than polycythemia, chronic or not, likely to induce a\\r\\n     change in blood viscosity (at the investigator's discretion)\\r\\n\\r\\n  -  Patient participating in another interventional research protocol that may interfere\\r\\n     with the present protocol (at the investigator's discretion).\\r\\n\\r\\n  -  Patient under guardianship, curatorship or safeguard of justice\\r\\n\\r\\n  -  Person under psychiatric care\\r\\n\\r\\n  -  Patient under legal protection.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patients with polycythemia defined as hematocrit level greater than or equal to 49% in\\r\\nmen and 48% in women, whatever the suspected etiology. Primitive and secondary\\r\\npolycythemia are eligible in this observational study. Patients should not have start any\\r\\ncytoreductive therapy prior inclusion.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mael HEIBLIG, MD,PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '478862240',\n",
       "      'phoneExt': '+33',\n",
       "      'email': 'mael.heiblig@chu-lyon.fr'}],\n",
       "    'locations': [{'facility': \"Service d'hématologie, Hôpital Lyon Sud\",\n",
       "      'city': 'Pierre-Bénite',\n",
       "      'state': 'Lyon',\n",
       "      'zip': '69495',\n",
       "      'country': 'France',\n",
       "      'geoPoint': {'lat': 45.7009, 'lon': 4.82511}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '23216616',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.'},\n",
       "     {'pmid': '12750170',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Vogel J, Kiessling I, Heinicke K, Stallmach T, Ossent P, Vogel O, Aulmann M, Frietsch T, Schmid-Schonbein H, Kuschinsky W, Gassmann M. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood. 2003 Sep 15;102(6):2278-84. doi: 10.1182/blood-2003-01-0283. Epub 2003 May 15.'},\n",
       "     {'pmid': '7376820',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wade JP, du Boulay GH, Marshall J, Pearson TC, Russell RW, Shirley JA, Symon L, Wetherley-Mein G, Zilkha E. Cerebral blood flow, haematocrit and viscosity in subjects with a high oxygen affinity haemoglobin variant. Acta Neurol Scand. 1980 Apr;61(4):210-5. doi: 10.1111/j.1600-0404.1980.tb01485.x.'},\n",
       "     {'pmid': '30478311',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9. No abstract available.'},\n",
       "     {'pmid': '11373690',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Pearson TC. Hemorheology in the erythrocytoses. Mt Sinai J Med. 2001 May;68(3):182-91.'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011087',\n",
       "      'term': 'Polycythemia Vera'},\n",
       "     {'id': 'D000011086', 'term': 'Polycythemia'}],\n",
       "    'ancestors': [{'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000019046', 'term': 'Bone Marrow Neoplasms'},\n",
       "     {'id': 'D000019337', 'term': 'Hematologic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001855', 'term': 'Bone Marrow Diseases'},\n",
       "     {'id': 'D000009196', 'term': 'Myeloproliferative Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M12307',\n",
       "      'name': 'Neoplasm Metastasis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16686', 'name': 'Thrombosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M13971',\n",
       "      'name': 'Polycythemia',\n",
       "      'asFound': 'Polycythemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13972',\n",
       "      'name': 'Polycythemia Vera',\n",
       "      'asFound': 'Polycythemia, Primary',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M21070', 'name': 'Bone Marrow Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M21314', 'name': 'Hematologic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12149',\n",
       "      'name': 'Myeloproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4614',\n",
       "      'name': 'Polycythemia Vera',\n",
       "      'asFound': 'Polycythemia, Primary',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1311',\n",
       "      'name': 'Chronic Myeloproliferative Disorders',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06116422',\n",
       "    'orgStudyIdInfo': {'id': 'Pro00114248'},\n",
       "    'organization': {'fullName': 'Duke University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Nutrition and Obesity in Under-Represented Populations: Food Insecurity Research to Advance Science and Improve Health',\n",
       "    'officialTitle': 'Nutrition and Obesity in Under-Represented Populations: Food Insecurity Research to Advance Science and Improve Health: A Multi-disciplinary Approach for Study and Mitigation of Food Insecurity and Obesity',\n",
       "    'acronym': 'NOURISH'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-24',\n",
       "    'studyFirstSubmitQcDate': '2023-10-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Duke University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Food insecurity is associated with obesity in children, and childhood obesity leads to\\r\\nlong term health consequences. While existing research shows that food benefit programs\\r\\nreduce food insecurity, little is known about the mediating factors between food benefit\\r\\nprograms and child health. The purpose of this study is to understand if the resolution\\r\\nof food insecurity in young children with early onset obesity can improve body mass index\\r\\n(BMI) over one year, and if so, by what mechanisms. The investigators will conduct a\\r\\nrandomized comparative effectiveness study among infants (n=228) aged 12 months at risk\\r\\nfor food insecurity and deliver two different food security interventions. Both will\\r\\nprovide families with $50/week for one year of study enrollment. The first group will\\r\\nreceive this as an unrestricted cash benefit (\"cash benefit group\") and the second group\\r\\nwill receive this as a benefit in the form of weekly grocery purchases with the support\\r\\nof a trained nutrition expert to guide healthy grocery purchasing (\"grocery benefit\\r\\ngroup\"). The investigators will also construct a contemporary comparison cohort of\\r\\ninfants meeting the inclusion/exclusion criteria from the electronic health record, using\\r\\npropensity score matching to allow comparisons between both intervention groups and usual\\r\\ncare. The primary endpoint is difference in BMI at 12 months post-enrollment (24 months\\r\\nof age). Secondary outcomes include measures of nutrition, food security, electronic\\r\\nhealth record data related to general child health, and other factors related to parental\\r\\nstress and unmet social needs. Patients will have the opportunity to participate in\\r\\npost-study interviews to report on intervention satisfaction, and facilitators and\\r\\nbarriers of infant feeding. Data analysis will be conducted by a trained statistician\\r\\n(Duke Biostatistics, Epidemiology, and Research Design; BERD) and will employ a two-means\\r\\ntest for a repeated-measures design. The benefits to participants outweigh the minimal\\r\\nrisks of loss of privacy, and confidential information will be managed carefully to\\r\\nminimize this risk.'},\n",
       "   'conditionsModule': {'conditions': ['Pediatric Obesity',\n",
       "     'Food Insecurity',\n",
       "     'Nutrition, Healthy',\n",
       "     'Nutrition Poor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Comparative effectiveness study.',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 228, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cash Benefit Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"Provides financial support weekly, in the form of an unrestricted cash benefit. The\\r\\ninvestigators will partner with Held to provide the card to participants, load the card\\r\\nwith $50/week for the 12 months of enrollment, and view the purchases at the vendor level\\r\\nusing an existing dashboard Held maintains. Participants will also receive a monthly\\r\\nnutrition guidance brochure tailored to the infant's developmental stage.\",\n",
       "      'interventionNames': ['Behavioral: Grocery intervention - unrestricted']},\n",
       "     {'label': 'Grocery Benefit Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Provides financial support weekly in the form of a grocery benefit. The investigators\\r\\nwill enroll participants in the Food Lion MVP program, linking the account to a Duke\\r\\nemail address. The study team will work with the participants to order $50 worth of\\r\\ngroceries from Food Lion, for the participants to pick up from the store. Groceries will\\r\\nbe ordered weekly for the 12 months of enrollment and coordinators will have access to\\r\\nview items purchased at Food Lion by each participant.',\n",
       "      'interventionNames': ['Behavioral: Grocery intervention - restricted']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Grocery intervention - unrestricted',\n",
       "      'description': 'Receives financial support in an unrestricted fashion (i.e., can use the money for\\r\\nwhatever they need).',\n",
       "      'armGroupLabels': ['Cash Benefit Group']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Grocery intervention - restricted',\n",
       "      'description': 'Receives financial support restricted to the purchase of items at a grocery store, and\\r\\nwith monthly grocery shopping coaching from a trained nutrition expert.',\n",
       "      'armGroupLabels': ['Grocery Benefit Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in BMI (Body Mass Index)',\n",
       "      'description': 'At 12 months post-enrollment (24 months of age).',\n",
       "      'timeFrame': '1 year'}],\n",
       "    'otherOutcomes': [{'measure': 'Change in Food Security',\n",
       "      'description': 'As measured by an 18 item food insecurity screen to assess food insecurity levels.',\n",
       "      'timeFrame': 'baseline, 3, 6, 9 and 12 months'},\n",
       "     {'measure': 'Change in Infant Dietary Quality',\n",
       "      'description': 'As measured by the USDA multipass food recall tool (ASA24).',\n",
       "      'timeFrame': 'baseline, 6 months, and 12 months'},\n",
       "     {'measure': 'Change in Unmet social needs',\n",
       "      'description': 'Changes in social determinants of health affecting the family as measured by the\\r\\nHealthLeads questionnaire.',\n",
       "      'timeFrame': 'baseline, 6 months, and 12 months'},\n",
       "     {'measure': 'Perceived stress scale',\n",
       "      'description': 'As measured by a 10 item perceived stress scale for parents.',\n",
       "      'timeFrame': 'baseline, 6 months, and 12 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion:\\r\\n\\r\\n  -  Aged 9-12 months and their primary caregiver \"parent\".\\r\\n\\r\\n  -  Medicaid and WIC-eligible (proxy for \"at risk for food insecurity\")\\r\\n\\r\\n  -  World Health Organization BMI ≥ 95%ile at current or most recent encounter\\r\\n     (early-onset obesity)\\r\\n\\r\\n  -  Caregiver speaks either English or Spanish as their primary language.\\r\\n\\r\\n  -  Infant was born as a singleton infant at ≥ 35 weeks gestational age with birth\\r\\n     weight ≥ 3% per the sex-specific WHO growth standard (also could use our criteria\\r\\n     for SGA, which is <10% for Olsen reference)\\r\\n\\r\\nExclusion:\\r\\n\\r\\n  -  Diagnosed with monogenic obesity.\\r\\n\\r\\n  -  Diagnosis affecting growth or feeding (e.g., congenital heart disease, cleft\\r\\n     lip/palate, inborn errors of metabolism, malabsorption, Prader-Willi disease, etc.)\\r\\n\\r\\n  -  Current enrollment of a household member in Healthy Lifestyles, adult obesity\\r\\n     treatment program, or active enrollment in a nutrition or obesity-related\\r\\n     intervention\\r\\n\\r\\n  -  Plans to move from the area in the next 12 months.\\r\\n\\r\\n  -  Parent is currently pregnant.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '12 Months',\n",
       "    'maximumAge': '24 Months',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Steph Bryant, MPH, RD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '919-620-5305',\n",
       "      'email': 'stephanie.l.bryant@duke.edu'},\n",
       "     {'name': 'Janna Howard, MPH',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '919-620-4793',\n",
       "      'email': 'janna.howard@duke.edu'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009765',\n",
       "      'term': 'Obesity'},\n",
       "     {'id': 'D000063766', 'term': 'Pediatric Obesity'},\n",
       "     {'id': 'D000044342', 'term': 'Malnutrition'}],\n",
       "    'ancestors': [{'id': 'D000050177', 'term': 'Overweight'},\n",
       "     {'id': 'D000044343', 'term': 'Overnutrition'},\n",
       "     {'id': 'D000009748', 'term': 'Nutrition Disorders'},\n",
       "     {'id': 'D000001835', 'term': 'Body Weight'}],\n",
       "    'browseLeaves': [{'id': 'M12701',\n",
       "      'name': 'Obesity',\n",
       "      'asFound': 'Obesity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M30155',\n",
       "      'name': 'Pediatric Obesity',\n",
       "      'asFound': 'Pediatric Obesity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M25306',\n",
       "      'name': 'Malnutrition',\n",
       "      'asFound': 'Nutrition Poor',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26186', 'name': 'Overweight', 'relevance': 'LOW'},\n",
       "     {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'},\n",
       "     {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5114', 'name': 'Body Weight', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06332430',\n",
       "    'orgStudyIdInfo': {'id': 'CW-202'},\n",
       "    'organization': {'fullName': 'Canwell Biotech Limited',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas',\n",
       "    'officialTitle': 'A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN2109 in Subjects With Unresectable or Metastatic Advanced Solid Tumors or Lymphomas.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-20',\n",
       "    'studyFirstSubmitQcDate': '2024-03-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Canwell Biotech Limited', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with\\r\\nunstable or metastatic advanced solid tumors or lymphomas.',\n",
       "    'detailedDescription': 'The scope of the study is to evaluate the safety of CAN2109 in humans, explore its\\r\\nsafety, efficacy and collect data on the pharmacokinetics, as well as on the\\r\\npharmacodynamic effect of the drug on the immune system locally and systemically, and on\\r\\ntumor markers.'},\n",
       "   'conditionsModule': {'conditions': ['Solid Tumor', 'Lymphoma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 27, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'CAN2109',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'CAN2109 IT injection every three weeks (Q3W)',\n",
       "      'interventionNames': ['Drug: CAN2109']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'CAN2109',\n",
       "      'description': 'CAN2109 IT injection (once every 3 weeks)',\n",
       "      'armGroupLabels': ['CAN2109']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety and tolerability',\n",
       "      'description': 'Safety and tolerability as determined by assessment of dose limiting toxicities and the\\r\\nmaximum tolerated dose or maximal assessed dose per protocol of CAN2109 with cancers.',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'Recommended Phase 2 Dose (RP2D)',\n",
       "      'description': 'To determine a recommended phase 2 dose of CAN21909 for further development by evaluating\\r\\nnumber of patients with treatment-related adverse events as assessed by the Common\\r\\nTerminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).',\n",
       "      'timeFrame': '12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'To determine the efficacy of CAN2109',\n",
       "      'description': 'Proportion of patients experiencing a tumor response or a stable disease according to\\r\\nRECIST 1.1 or iRECIST 1.1 as appropriate.',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'To evaluate the pharmacodynamics of CAN2109',\n",
       "      'description': 'Maximum observed plasma and tumor concentration of CAN2109 after IT administration.',\n",
       "      'timeFrame': '12 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Able and willing to provide written informed consent and willing to comply with the\\r\\n     study's requirements.\\r\\n\\r\\n  2. Male or female age ≥ 18 years at screening.\\r\\n\\r\\n  3. Metastatic or locally advanced solid tumor that has progressed on, is refractory to,\\r\\n     or for which there is no efficacious standard of care therapy. Preferred tumor types\\r\\n     include the following:\\r\\n\\r\\n     a. Carcinoma of skin, melanoma, Merkel cell carcinoma (MCC), breast cancer, head and\\r\\n     neck squamous cell carcinoma (HNSCC), sarcoma, cervical carcinoma, and colorectal\\r\\n     cancer\\r\\n\\r\\n  4. Performance status of 0-1 on the ECOG Performance Scale.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Unresolved toxicities from prior therapy, defined as having not resolved to Common\\r\\n     Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1,\\r\\n     with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.\\r\\n\\r\\n  2. Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or\\r\\n     equivalent.\\r\\n\\r\\n  3. Has an active infection requiring systemic therapy.\\r\\n\\r\\n  4. Unstable/inadequate cardiac function defined as follows:\\r\\n\\r\\n       1. New York Heart Association Class 3 or 4 congestive heart failure\\r\\n\\r\\n       2. uncontrolled hypertension\\r\\n\\r\\n       3. acute coronary syndrome within 6 months\\r\\n\\r\\n       4. clinical important cardiac arrhythmia\\r\\n\\r\\n       5. mean corrected QT (QTc) interval corrected for heart rate > 480 ms.\\r\\n\\r\\n  5. A history of interstitial lung disease.\\r\\n\\r\\n  6. A history of coagulopathy resulting in uncontrolled bleeding or other bleeding\\r\\n     disorders.\\r\\n\\r\\n  7. Participated in a clinical study of an investigational agent within 30 days of\\r\\n     screening.\\r\\n\\r\\n  8. Has known psychiatric, substance abuse, or other disorders that would interfere with\\r\\n     cooperation with the requirements of the study in the opinion of the investigator.\\r\\n\\r\\n  9. Is pregnant or breastfeeding.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Herui Yao, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 020-34070412',\n",
       "      'email': 'yaoherui@mail.sysu.edu.cn'},\n",
       "     {'name': 'Erwei Song, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 020 81332507',\n",
       "      'email': 'songew@mail.sysu.edu.cn'}],\n",
       "    'locations': [{'facility': 'Sun Yat-Sen University Sun Yat-Sen Memorial Hospital',\n",
       "      'city': 'Guangzhou',\n",
       "      'state': 'Guangdong',\n",
       "      'zip': '510535',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008223',\n",
       "      'term': 'Lymphoma'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008232', 'term': 'Lymphoproliferative Disorders'},\n",
       "     {'id': 'D000008206', 'term': 'Lymphatic Diseases'},\n",
       "     {'id': 'D000007160', 'term': 'Immunoproliferative Disorders'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11220',\n",
       "      'name': 'Lymphoma',\n",
       "      'asFound': 'Lymphoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11225',\n",
       "      'name': 'Lymphoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10206',\n",
       "      'name': 'Immunoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3543',\n",
       "      'name': 'Lymphosarcoma',\n",
       "      'asFound': 'Lymphoma',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06314425',\n",
       "    'orgStudyIdInfo': {'id': 'IRB_20240714'},\n",
       "    'organization': {'fullName': 'Swiss Dental Solutions',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Zirconia Implants: Practice-based Evidence',\n",
       "    'officialTitle': 'Prospective Clinical Series With Zirconia Implants',\n",
       "    'acronym': 'SDS'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'ENROLLING_BY_INVITATION',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-07',\n",
       "    'studyFirstSubmitQcDate': '2024-03-15',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Swiss Dental Solutions', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'VISTA Institute for Therapeutic Innovations',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is a prospective case series clinical study to examine the effectiveness of\\r\\nCeramic dental implants manufactured by Swiss Dental Solutions (SDS). Participants with\\r\\nan indication from the dentist for teeth extraction and replacement are invited to\\r\\nparticipate in this study. Participating in this study will involve the use of dental\\r\\nimplants manufactured by Swiss Dental Solutions (SDS zirconia dental implants),\\r\\nsubmission of the case data, including pre-operative information, intra-operative\\r\\ndetails, and post-operative follow-up data, to the study site and its collaborating\\r\\npartners.\\r\\n\\r\\nThe SDS zirconia dental implants used in this research are FDA cleared devices that are\\r\\navailable for dental treatments.',\n",
       "    'detailedDescription': 'To evaluate the effectiveness of one-piece ceramic implants placed into fresh extraction\\r\\nsockets and provide practical clinical evidence, the investigators will assess their\\r\\nperformance in defined clinical settings, encompassing a variety of clinical situations,\\r\\npatients, and practitioners. This evaluation, conducted according to a precise surgical\\r\\nand treatment protocol, considers factors such as patient and clinician variability and\\r\\nlong-term outcomes in routine clinical practice.\\r\\n\\r\\nStudy Question:\\r\\n\\r\\nThe cumulative survival rate (CSR), Marginal Bone Level (MBL) and Pink Esthetic Score\\r\\n(PES) of one-piece ceramic implants supporting crowns during a 12-month follow-up period\\r\\nwill be determined.'},\n",
       "   'conditionsModule': {'conditions': ['Dental Implants', 'Ceramic Implant'],\n",
       "    'keywords': ['ceramic implants',\n",
       "     'titanium implants',\n",
       "     'peri-implantitis',\n",
       "     'marginal bone loss',\n",
       "     'soft tissue',\n",
       "     'bone augmentation',\n",
       "     'immediate implantation',\n",
       "     'dental implants',\n",
       "     'immediate loading']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Immediate loading of ceramic implants',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Tooth/teeth are extracted with minimally invasive approach using piezo surgery and when\\r\\nnecessary sectioning after local anesthesia (Articaine 40 mg/mL with epinephrine 10\\r\\nμg/mL; or Lidocaine 20mg/ml with 10 ug/ml). Extraction sockets are thoroughly\\r\\ndegranulated to remove all remnants of soft tissue and residual restorations or material\\r\\nwhich may have extended beyond the tooth apex. After copious irrigation, the socket\\r\\ncondition is recorded, which includes, thickness and location of buccal/facial crestal\\r\\nalveolar bone.',\n",
       "      'interventionNames': ['Procedure: Immediate dental implants placements on fresh sockets after tooth extraction']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Immediate dental implants placements on fresh sockets after tooth extraction',\n",
       "      'description': 'Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to\\r\\nbe placed within the fresh extraction sockets. The immediate implants are placed using a\\r\\nminimally invasive technique without vertical releasing incisions. Implant placements are\\r\\nperformed following the SDS osteotomy protocol after sulcus marginal and crestal incision\\r\\nor flapless surgery. The same surgeon places implants for all patients. Infected sites\\r\\nare debrided using piezo surgery touch.',\n",
       "      'armGroupLabels': ['Immediate loading of ceramic implants']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Cumulative Survival Rate (CSR)',\n",
       "      'description': 'The cumulative survival rate is determined as the percentage of implants that remained in\\r\\nplace over the observation period for each patient. 100% of survival is defined as\\r\\nabsence of implant loss.',\n",
       "      'timeFrame': '12-month follow-up'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Marginal Bone Loss (MBL)',\n",
       "      'description': 'The vertical bone height is measured mesially and distally on intraoral periapical\\r\\nradiographs. The values are assessed at specific time points as follows: T(0) immediately\\r\\nafter implant placement, T(1) 6 months after implant placement, T(2) 12 months after\\r\\nimplant placement.\\r\\n\\r\\nThe clinical success of the implants is defined in four groups as follows:\\r\\n\\r\\n  -  Group I < 2 mm of radiographic bone loss without tenderness, mobility, or exudate.\\r\\n\\r\\n  -  Group II radiographic bone loss of 2-4 mm without mobility or tenderness.\\r\\n\\r\\n  -  Group III radiographic bone loss > 4 mm but less than half the implant length with\\r\\n     no mobility or exudation.\\r\\n\\r\\n  -  Group IV implant loss.',\n",
       "      'timeFrame': '12-month follow-up'}],\n",
       "    'otherOutcomes': [{'measure': 'Pink Esthetic Score (PES)',\n",
       "      'description': 'The PES parameters are the presence of papilla (mesial and distal), soft tissue, height\\r\\nof marginal gingiva, alveolar processes, and soft tissue color and texture. The values\\r\\nare assessed at specific time points as follows: T(0) immediately after implant\\r\\nplacement, T(1) 6 months after implant placement, T(2) 12 months after implant placement.\\r\\nThe seven variables are scored on a scale ranging from 0 to 2 points, with a maximum\\r\\nscore of 14 and a minimum score of zero in relation to esthetic parameters.',\n",
       "      'timeFrame': '12-month follow-up'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  The need for implant placement in position of single or multiple teeth to be\\r\\n     extracted and to replace up to 3 teeth\\r\\n\\r\\n  -  Availability of patient for a minimum follow-up of one year following implantation\\r\\n\\r\\n  -  Availability of complete follow-up data in medical records\\r\\n\\r\\n  -  Availability of post-operative and follow-up periapical radiographs\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  History of head and neck irradiation\\r\\n\\r\\n  -  History of bisphosphonate or medications that induce osteonecrosis of the jaw\\r\\n\\r\\n  -  Untreated systemic diseases that are known to affect wound healing, such as\\r\\n     uncontrolled diabetes mellitus\\r\\n\\r\\n  -  Immunocompromised or immunoproliferative diseases\\r\\n\\r\\n  -  Heavy Smoking of &gt;10 cigarettes per day',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '85 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Homayoun Zadeh, DDS PhD',\n",
       "      'affiliation': 'VISTA Institute for Therapeutic Innovations',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Brighton Periodontal & Implant Dental Group',\n",
       "      'city': 'Woodland Hills',\n",
       "      'state': 'California',\n",
       "      'zip': '91367',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 34.16834, 'lon': -118.60592}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M28893',\n",
       "      'name': 'Peri-Implantitis',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11014', 'name': 'Lidocaine', 'relevance': 'LOW'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M7992', 'name': 'Epinephrine', 'relevance': 'LOW'},\n",
       "     {'id': 'M5609', 'name': 'Carticaine', 'relevance': 'LOW'},\n",
       "     {'id': 'M30371', 'name': 'Racepinephrine', 'relevance': 'LOW'},\n",
       "     {'id': 'M211043', 'name': 'Epinephryl borate', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'},\n",
       "     {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'},\n",
       "     {'abbrev': 'Resp', 'name': 'Respiratory System Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05969457',\n",
       "    'orgStudyIdInfo': {'id': 'CHU de Rouen'},\n",
       "    'organization': {'fullName': 'University Hospital, Rouen',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effect of Preventive Analgesia by Injection of a Local Anesthetic Before Vaginal Incision for Hysterectomy by vNOTES Approach',\n",
       "    'officialTitle': 'Effect of Preventive Analgesia by Injection of a Local Anesthetic Before Vaginal Incision for Hysterectomy by vNOTES Approach: Randomized, Double-blind Study',\n",
       "    'acronym': 'ANOTES'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-10-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-10-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-17',\n",
       "    'studyFirstSubmitQcDate': '2023-07-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University Hospital, Rouen', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Groupe Hospitalier du Havre',\n",
       "      'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The research procedure is the injection of 20 mL of Ropivacaine solution (vs. saline) to\\r\\ncreate a paracervical block at the beginning of surgery, while the patient is already\\r\\nunder general anesthesia.\\r\\n\\r\\nThis injection will take place 3 minutes before the vaginal incision, via 4 injection\\r\\npoints. Injections are made 3 mm deep into the vaginal cul de sac.\\r\\n\\r\\nRandomization takes place before surgery by vNOTES:\\r\\n\\r\\n  -  Experienced group: Local anesthesia with injection of Ropivacaine (20mL of\\r\\n     ropivacaine 7.5 mg/mL, i.e. 150mg) and general anesthesia\\r\\n\\r\\n  -  Control group: Injection of 20mL of placebo (saline) and general anesthesia\\r\\n\\r\\nIn both groups, systematic intraoperative and postoperative analgesia will be identical.'},\n",
       "   'conditionsModule': {'conditions': ['Hysterotomy; Affecting Fetus']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 108, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Experienced group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Administration of Naropeine',\n",
       "      'interventionNames': ['Drug: Naropeine', 'Other: questionnaires']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Administration of a saline solution',\n",
       "      'interventionNames': ['Other: questionnaires', 'Other: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Naropeine',\n",
       "      'description': 'Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e.\\r\\n150mg)',\n",
       "      'armGroupLabels': ['Experienced group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'questionnaires',\n",
       "      'description': 'Numerical Rating scale Questionnaire FSFI Qustionnaire SF12 Questionnaire DN4',\n",
       "      'armGroupLabels': ['Control group', 'Experienced group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Injection of 20 mL of NaCl',\n",
       "      'armGroupLabels': ['Control group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'pain after surgery',\n",
       "      'description': 'Pain will be assessed by the post-operative hospital nurse using a numerical rating scale\\r\\n(NRS) NRS score from 1 to 10 -> 10 correspoding to the worst pain',\n",
       "      'timeFrame': '4hours after surgery'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adult patients aged 18 to 70 inclusive\\r\\n\\r\\n  -  Patient scheduled for vNOTES surgery for total hysterectomy for benign pathology,\\r\\n     whether or not associated with an adnexal procedure (unilateral or bilateral\\r\\n     salpingectomy or adnexectomy (for cysts smaller than 6 cm)).\\r\\n\\r\\n  -  Person having read and understood the information letter and signed the consent form\\r\\n\\r\\n  -  Person affiliated to a social security scheme\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Suspicion of malignant pathology\\r\\n\\r\\n  -  History of rectal surgery\\r\\n\\r\\n  -  History of pelvic inflammatory disease\\r\\n\\r\\n  -  Suspicion of recto-vaginal endometriosis\\r\\n\\r\\n  -  Virginity\\r\\n\\r\\n  -  Contraindication to NAROPEINE 7.5 mg/mL, solution for injection in ampoule\\r\\n\\r\\n  -  Contraindication to PROAMP SODIUM CHLORIDE 0.9%, solution for injection\\r\\n\\r\\n  -  Patients on a low-salt diet\\r\\n\\r\\n  -  History of more than 2 caesarean sections\\r\\n\\r\\n  -  Estimated uterine size > 700 g according to the following formula y = 0.35x + 107 (x\\r\\n     = a × b × c), based on measurements taken on preoperative imaging (MRI or\\r\\n     ultrasound). a=longitudinal diameter, b=sagital diameter, c=transverse diameter.3\\r\\n\\r\\n  -  BMI > 35\\r\\n\\r\\n  -  Contraindication to analgesic molecules in intraoperative and postoperative\\r\\n     protocols.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'genderDescription': 'Women',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'David Mallet',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '02 32 88 82 65',\n",
       "      'phoneExt': '+33',\n",
       "      'email': 'secretariat.DRC@chu-rouen.fr'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M1112',\n",
       "      'name': 'Surgical Wound',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC26', 'name': 'Wounds and Injuries'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000077212',\n",
       "      'term': 'Ropivacaine'}],\n",
       "    'ancestors': [{'id': 'D000000779', 'term': 'Anesthetics, Local'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'}],\n",
       "    'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M1700',\n",
       "      'name': 'Ropivacaine',\n",
       "      'asFound': 'MBT',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M4109', 'name': 'Anesthetics, Local', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06436924',\n",
       "    'orgStudyIdInfo': {'id': 'SAFE HV'},\n",
       "    'organization': {'fullName': 'Heart Rhythm Clinical and Research Solutions, LLC',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day',\n",
       "    'officialTitle': 'Safety and Efficacy of Workflows of High Volume Single Operators in a Left Atrial Appendage Occlusion Device Implant Procedural Day: SAFE HV'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-22',\n",
       "    'studyFirstSubmitQcDate': '2024-05-28',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Heart Rhythm Clinical and Research Solutions, LLC',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Boston Scientific Corporation',\n",
       "      'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'SAFE HV is an observational, prospective, multi-center, non-randomized study evaluating\\r\\nreal-world clinical experience of centers where a single procedural physician schedules\\r\\neight or more left atrial appendage occlusion (LAAO) device implant procedures in a\\r\\nsingle calendar day.',\n",
       "    'detailedDescription': 'Since 2009, Watchman FLX™ and its predecessor, Watchman™ have provided a safe and\\r\\neffective alternative to oral anticoagulation for over 200,000 patients in the United\\r\\nStates and Europe. Advancements in the design of the Watchman FLX™ have made the device\\r\\navailable to a wider range of patients. As more patients qualify for the device, more\\r\\nimplant procedures are necessary to provide them with this life-changing treatment\\r\\noption.\\r\\n\\r\\nSome Watchman FLX™ implanters perform high volumes of implant procedures on certain days.\\r\\nWhile performing a high-volume of implant procedures is desirable for many reasons, it\\r\\nmust be determined that cases performed under such circumstances are comparable in safety\\r\\nand efficacy to implant procedures performed at lower volumes. While there has been no\\r\\ndifferentiation between high and low volume cases in previous studies, data obtained in\\r\\nthis study will be compared to overall safety and efficacy data available from the\\r\\nPINNACLE FLX clinical trial and the SURPASS analysis to ensure that safety and efficacy\\r\\noutcomes are comparable.\\r\\n\\r\\nAdditionally, this study will collect data on the workflows of these high-volume\\r\\nimplanters that will help determine which factors contribute to the successful\\r\\nperformance of high volumes of Watchman FLX™ implants in a single day. In the future this\\r\\ninformation may be used to help other implanters optimize workflows to increase their\\r\\nvolume of daily implants and hence, provide more opportunities for patients to access\\r\\nthis transformative device.'},\n",
       "   'conditionsModule': {'conditions': ['Atrial Fibrillation']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 678, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Subjects undergoing LAAO device implant',\n",
       "      'description': 'Watchman LAAO device implant',\n",
       "      'interventionNames': ['Device: Left Atrial Appendage Device Implant']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Left Atrial Appendage Device Implant',\n",
       "      'description': 'The Watchman Device is implanted into the left atrial appendage and is designed to close\\r\\nit off and keep blood clots from escaping that area.',\n",
       "      'armGroupLabels': ['Subjects undergoing LAAO device implant']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Peri-procedural complications',\n",
       "      'description': 'Incidence of peri-procedural complications summarized descriptively and compared to\\r\\nhistorical data',\n",
       "      'timeFrame': 'Procedure through discharge, an average of 1-3 days'},\n",
       "     {'measure': 'Peri-device leakage',\n",
       "      'description': 'Assessed by successful closure of the left atrial appendage defined by peri-device\\r\\nleakage of <5mm. This will be identified at the post implant imaging.',\n",
       "      'timeFrame': 'Date of implant up to 90 days'},\n",
       "     {'measure': 'Late onset complications',\n",
       "      'description': 'Incidence of post procedure complications summarized descriptively and compared to\\r\\nhistorical data.',\n",
       "      'timeFrame': 'Discharge to 30 days.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. 18 years of age or older\\r\\n\\r\\n  2. Able and willing to participate in baseline and follow up evaluations for the full\\r\\n     length of the study\\r\\n\\r\\n  3. Clinically qualified, in the opinion of the Investigator, to receive a LAAO device\\r\\n\\r\\n  4. Receiving a Watchman FLX™ or Watchman FLX Pro™ LAAO device as part of their plan of\\r\\n     care\\r\\n\\r\\n  5. Having their LAAO device implant procedure scheduled on a qualifying high-volume*\\r\\n     procedure day as assessed within 2 days (≤ 2 calendar days) prior to the planned\\r\\n     procedure date\\r\\n\\r\\n     *high-volume - a calendar day in which the single implanting physician schedules ≥ 8\\r\\n     LAAO device implant procedures, regardless of the device manufacturer\\r\\n\\r\\n  6. Willing and able to provide informed consent\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Enrolled in an investigational drug or device clinical trial, or any trial that\\r\\n     dictates the treatment plan\\r\\n\\r\\n  2. In the opinion of the Investigator, any known contraindication to a LAAO device or\\r\\n     implant procedure\\r\\n\\r\\n  3. Having their LAAO device implant procedure scheduled on a day in which the single\\r\\n     implanting physician scheduled < 8 LAAO device implant procedures as assessed within\\r\\n     2 days (≤ 2 calendar days) prior to the planned procedure date',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'The study population will include subjects who are clinically qualified for a Watchman\\r\\nFLX™ or Watchman FLX Pro™ LAAO device implant and would receive one regardless of\\r\\nparticipation in the study, who meet all eligibility criteria for the study, and present\\r\\nat participating institutions for a LAAO device implant procedure on a day in which a\\r\\nsingle implanting physician scheduled at least eight LAAO device implant procedures,\\r\\nregardless of the device manufacturer (i.e., high-volume).',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Lynn Landborg',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '763-381-9135',\n",
       "      'email': 'safe@hrcrs.com'},\n",
       "     {'name': 'Carolyn Mills',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '205-807-0864',\n",
       "      'email': 'cmills@hrcrs.com'}],\n",
       "    'overallOfficials': [{'name': 'Saumil Oza, MD',\n",
       "      'affiliation': \"St. Vincent's\",\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Memorial Health University Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Savannah',\n",
       "      'state': 'Georgia',\n",
       "      'zip': '31404',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Lindsey Lamb, MHSA',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '912-350-9032',\n",
       "        'email': 'lindsey.lamb@hcahealthcare.com'},\n",
       "       {'name': 'Ritzie A Trinidad, MBA',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '912-350-3110',\n",
       "        'email': 'RitzieAnne.trinidad@hcahealthcare.com'},\n",
       "       {'name': 'Todd Senn, MD', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'David Newton, MD', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001281',\n",
       "      'term': 'Atrial Fibrillation'}],\n",
       "    'ancestors': [{'id': 'D000001145', 'term': 'Arrhythmias, Cardiac'},\n",
       "     {'id': 'D000006331', 'term': 'Heart Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M4586',\n",
       "      'name': 'Atrial Fibrillation',\n",
       "      'asFound': 'Atrial Fibrillation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4453', 'name': 'Arrhythmias, Cardiac', 'relevance': 'LOW'},\n",
       "     {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06392386',\n",
       "    'orgStudyIdInfo': {'id': 'ARGX-113-2207'},\n",
       "    'secondaryIdInfos': [{'id': '2023-506159-12-00', 'type': 'CTIS'}],\n",
       "    'organization': {'fullName': 'argenx', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis',\n",
       "    'officialTitle': 'An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-26',\n",
       "    'studyFirstSubmitQcDate': '2024-04-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-26',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'argenx', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD),\\r\\nsafety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric\\r\\nparticipants with gMG aged 2 to <18 years. The primary goal is to confirm an appropriate\\r\\ndose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this\\r\\nstudy. Participants will receive injections of efgartigimod PH20 SC and will be monitored\\r\\nfor safety until the end of the study. At the end of the follow-up period, eligible\\r\\nparticipants may roll over to an open-label extension (OLE) study.'},\n",
       "   'conditionsModule': {'conditions': ['Generalized Myasthenia Gravis']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Efgartigimod PH20 SC',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants aged 12 to <18 years receiving efgartigimod PH20 SC treatment',\n",
       "      'interventionNames': ['Biological: Efgartigimod PH20 SC']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'Efgartigimod PH20 SC',\n",
       "      'description': 'Subcutaneous injections',\n",
       "      'armGroupLabels': ['Efgartigimod PH20 SC']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysis',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysis',\n",
       "      'timeFrame': 'Up to 12 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of adverse events (AEs)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Severity of adverse events (AEs)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Incidence of serious adverse events (SAEs)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Severity of serious adverse events (SAEs)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Incidence of adverse events of special interest (AESI)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Severity of adverse events of special interest (AESI)',\n",
       "      'timeFrame': 'Up to 14 weeks'},\n",
       "     {'measure': 'Efgartigimod serum concentrations',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Absolute values of total Immunoglobulin G (IgG) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline values of total Immunoglobulin G (IgG) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Percentage change from baseline values of total Immunoglobulin G (IgG) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Percentage change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Incidence of antibodies against rHuPH20 in serum samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Prevalence of antibodies against rHuPH20 in serum samples',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Absolute value of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score, appropriate for pediatric use',\n",
       "      'description': 'Minimum value: 0 (no impairment); Maximum value: 24 (highest impairment)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score, appropriate for pediatric use',\n",
       "      'description': 'Minimum value: 0 (no impairment); Maximum value: 24 (highest impairment)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Absolute value of Quantitative Myasthenia Gravis (QMG) score',\n",
       "      'description': 'Minimum value: 0 (no impairment); Maximum value: 39 (most severe impairment)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline of Quantitative Myasthenia Gravis (QMG) score',\n",
       "      'description': 'Minimum value: 0 (no impairment); Maximum value: 39 (most severe impairment)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Absolute value of EuroQoL 5 Dimensions Youth (EQ-5D-Y) score',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline value of EuroQoL 5 Dimensions Youth (EQ-5D-Y) score',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline value of Neuro-QoL Pediatric Fatigue Score',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Change from baseline value of Clinical Global Impression of Improvement (CGI-I)',\n",
       "      'timeFrame': 'Up to 12 weeks'},\n",
       "     {'measure': 'Changes in protective antibody titers to vaccines',\n",
       "      'timeFrame': 'Up to 12 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  The participant (and/or their legally authorized representative) understands the\\r\\n     requirements of the study and is capable of providing written informed\\r\\n     consent/assent and complying with protocol requirements\\r\\n\\r\\n  -  The participant is aged 2 to <18 years at the time of informed consent/assent\\r\\n\\r\\n  -  The participant has been diagnosed with generalised Myasthenia Gravis that is\\r\\n     supported by a physical examination and confirmed seropositivity for\\r\\n     anti-acetylcholine receptor antibodies\\r\\n\\r\\n  -  The participant has had an unsatisfactory response to immunosuppressants,\\r\\n     corticosteroids, or acetylcholinesterase inhibitors but is on stable concomitant MG\\r\\n     therapy. If receiving corticosteroids and/or immunosuppressants, must be on a stable\\r\\n     dose for ≥1 month before screening\\r\\n\\r\\n  -  The participant agrees to use birth control consistent with local regulations and\\r\\n     people of child-bearing potential must have a negative blood pregnancy test at\\r\\n     screening and a negative urine pregnancy test before receiving the study drug\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Is a female adolescent of child-bearing potential who is pregnant and/or lactating\\r\\n     or intends to become pregnant during their participation in the study\\r\\n\\r\\n  -  Has worsening muscle weakness secondary to a concurrent infection or as a result of\\r\\n     a medication\\r\\n\\r\\n  -  Has a documented lack of clinical response to plasma exchange (PLEX)\\r\\n\\r\\n  -  Received a live or live-attenuated vaccine within <4 weeks before screening\\r\\n\\r\\n  -  Received a thymectomy within 3 months before screening or is planning to get a\\r\\n     thymectomy during their participation in the study\\r\\n\\r\\n  -  Has a known autoimmune disease or any medical condition that would interfere with an\\r\\n     accurate assessment of clinical symptoms of generalised Myasthenia Gravis or puts\\r\\n     the participant at undue risk\\r\\n\\r\\n  -  History of malignancy, cancer, unless considered cured by adequate treatment with no\\r\\n     evidence of recurrence for ≥3 years. Adequately treated participants with the\\r\\n     following cancers can be included at any time: Basal cell or squamous cell skin\\r\\n     cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental\\r\\n     histological findings of prostate cancer\\r\\n\\r\\n  -  Clinically significant active infection that is not sufficiently resolved in the\\r\\n     investigator's opinion or positive serum test at screening for active infection with\\r\\n     any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV\\r\\n\\r\\n  -  Has a positive PCR test for SARS-CoV-2 at screening\\r\\n\\r\\n  -  Has/had a clinically significant disease, had recent major surgery (within 3 months\\r\\n     of screening) or intends to have major surgery during the study, or has/had any\\r\\n     other medical condition that, in the investigator's opinion, would confound the\\r\\n     results of the study or put the participant at undue risk\\r\\n\\r\\n  -  Has received a different study drug in another clinical study within <12 before\\r\\n     screening\\r\\n\\r\\n  -  Is currently participating in another interventional clinical study\\r\\n\\r\\n  -  Has previously participated in an efgartigimod clinical study and received at least\\r\\n     one dose of study drug\\r\\n\\r\\n  -  Has a known hypersensitivity to study drug or any of its excipients\\r\\n\\r\\n  -  Has a history of or current episode of alcohol, drug, or medication abuse as\\r\\n     assessed by the investigator\\r\\n\\r\\n  -  Use of some medications before screening (more information is found in the protocol)\\r\\n\\r\\nThe complete list of exclusion criteria can be found in the protocol.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '2 Years',\n",
       "    'maximumAge': '17 Years',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Sabine Coppieters, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '857-350-4834',\n",
       "      'email': 'clinicaltrials@argenx.com'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009157',\n",
       "      'term': 'Myasthenia Gravis'},\n",
       "     {'id': 'D000018908', 'term': 'Muscle Weakness'}],\n",
       "    'ancestors': [{'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000020361', 'term': 'Paraneoplastic Syndromes, Nervous System'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000010257', 'term': 'Paraneoplastic Syndromes'},\n",
       "     {'id': 'D000020274', 'term': 'Autoimmune Diseases of the Nervous System'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "     {'id': 'D000020511', 'term': 'Neuromuscular Junction Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12112',\n",
       "      'name': 'Myasthenia Gravis',\n",
       "      'asFound': 'Myasthenia Gravis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20944',\n",
       "      'name': 'Muscle Weakness',\n",
       "      'asFound': 'Myasthenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13204', 'name': 'Paresis', 'relevance': 'LOW'},\n",
       "     {'id': 'M4554', 'name': 'Asthenia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22619',\n",
       "      'name': 'Neuromuscular Manifestations',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M13170', 'name': 'Paraneoplastic Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'M22160',\n",
       "      'name': 'Paraneoplastic Syndromes, Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22094',\n",
       "      'name': 'Autoimmune Diseases of the Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22297',\n",
       "      'name': 'Neuromuscular Junction Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3973',\n",
       "      'name': 'Myasthenia Gravis',\n",
       "      'asFound': 'Myasthenia Gravis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06193863',\n",
       "    'orgStudyIdInfo': {'id': '22468'},\n",
       "    'organization': {'fullName': 'Bayer', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure',\n",
       "    'officialTitle': 'Special Drug Use Investigation of Rivaroxaban in Pediatric Patients With Congenital Heart Disease (CHD) Who Had Undergone the Fontan Procedure'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-21',\n",
       "    'studyFirstSubmitQcDate': '2023-12-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-05', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Bayer', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'Janssen Research & Development, LLC',\n",
       "      'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This is an observational study in which the data from children with congenital heart\\r\\ndisease will be collected and studied. These children will include those who are\\r\\nprescribed rivaroxaban by their doctors after a heart surgery called the Fontan\\r\\nprocedure.\\r\\n\\r\\nCongenital heart disease (CHD) is a heart problem that some children are born with. It\\r\\nsometimes requires a surgery called the Fontan procedure to improve the blood flow in the\\r\\nbody. The Fontan procedure can increase the risk of the formation of blood clots in the\\r\\nblood vessels (called thrombosis), which might lead to death.\\r\\n\\r\\nThe study drug, rivaroxaban, is an approved treatment for preventing the formation of\\r\\nblood clots. It is a type of anticoagulant that prevents the blood from clotting by\\r\\nblocking a protein responsible for it. Rivaroxaban can increase the risk of bleeding.\\r\\n\\r\\nA previous study suggested that the number of major bleeding episodes did not differ much\\r\\nwhile taking rivaroxaban compared to aspirin in children with CHD who had undergone the\\r\\nFontan procedure. However, there is limited information available for Japanese patients.\\r\\n\\r\\nTo better understand the safety and potential risks of this drug in children, more\\r\\nknowledge is needed about the use of rivaroxaban in the real world.\\r\\n\\r\\nThe main purpose of this study is to learn more about the occurrence of major bleeding or\\r\\nnon-major bleeding in children who were treated with rivaroxaban. Major bleeding is\\r\\ndefined as a serious or life-threatening bleeding episode that can have an impact on a\\r\\nperson's health and requires medical attention. Non-major bleeding is defined as a type\\r\\nof bleeding that may negatively impact a person's health if not treated.\\r\\n\\r\\nThe data will be collected from December 2023 to June 2026. Researchers will observe each\\r\\nparticipant for up to 30 days after stopping the treatment or for a maximum of 2 years.\\r\\n\\r\\nIn this study, only available data from regular health visits will be collected. No\\r\\nvisits or tests are required as part of this study. Researchers will use the medical\\r\\nrecords or interview the children and/or their guardians during regular visits.\"},\n",
       "   'conditionsModule': {'conditions': ['Prevention of Venous Thromboembolism',\n",
       "     'Congenital Heart Disease',\n",
       "     'Fontan Procedure',\n",
       "     'Children'],\n",
       "    'keywords': ['Prevention of thrombi/emboli formation']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Rivaroxaban',\n",
       "      'description': 'Pediatric patients with CHD who had undergone the Fontan procedure were prescribed with\\r\\nXarelto before enrollment.',\n",
       "      'interventionNames': ['Drug: Rivaroxaban (Xarelto, BAY59-7939)']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Rivaroxaban (Xarelto, BAY59-7939)',\n",
       "      'description': 'At the discretion of the treating physician, based on the recommendations written in the\\r\\nlocal product information.',\n",
       "      'armGroupLabels': ['Rivaroxaban']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Occurrence of major bleeding or clinically relevant non-major bleeding',\n",
       "      'timeFrame': 'Up to 2 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Occurrence of any bleeding',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Occurrence of all adverse events (AEs)',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Occurrence of thrombotic events',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Descriptive summary of patient demographics/characteristics',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Dosing patterns of rivaroxaban',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients under the age of 18 years\\r\\n\\r\\n  -  Patients diagnosed with CHD who had undergone the Fontan procedure by the\\r\\n     investigator under routine clinical practice, and must be judged appropriate\\r\\n     for/decided to be treated with rivaroxaban by the investigator under routine\\r\\n     clinical practice\\r\\n\\r\\n  -  Informed consent form obtained from a legal representative\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Participation in an investigational program with interventions outside of routine\\r\\n     clinical practice\\r\\n\\r\\n  -  Contraindications according to the local marketing authorization\\r\\n\\r\\n  -  Previous treatment with rivaroxaban',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'maximumAge': '18 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT'],\n",
       "    'studyPopulation': 'Patients under the age of 18 years with a diagnosis of CHD who had undergone the Fontan\\r\\nprocedure treated with rivaroxaban has been made by the treating physician before study\\r\\nenrollment.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Bayer Clinical Trials Contact',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(+)1-888-84 22937',\n",
       "      'email': 'clinical-trials-contact@bayer.com'}],\n",
       "    'locations': [{'facility': 'Many Locations',\n",
       "      'city': 'Multiple Locations',\n",
       "      'country': 'Japan'}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': \"Click here for access to information about Bayer's transparency standards and Bayer\\r\\nstudies.\",\n",
       "      'url': 'https://clinicaltrials.bayer.com/'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'Availability of this study\\'s data will later be determined according to Bayer\\'s\\r\\ncommitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\".\\r\\nThis pertains to scope, timepoint and process of data access. As such, Bayer commits to\\r\\nsharing upon request from qualified researchers patient-level clinical trial data,\\r\\nstudy-level clinical trial data, and protocols from clinical trials in patients for\\r\\nmedicines and indications approved in the US and EU as necessary for conducting\\r\\nlegitimate research. This applies to data on new medicines and indications that have been\\r\\napproved by the EU and US regulatory agencies on or after January 01, 2014. Interested\\r\\nresearchers can use www.vivli.org to request access to anonymized patient-level data and\\r\\nsupporting documents from clinical studies to conduct research. Information on the Bayer\\r\\ncriteria for listing studies and other relevant information is provided in the member\\r\\nsection of the portal.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006331',\n",
       "      'term': 'Heart Diseases'},\n",
       "     {'id': 'D000013923', 'term': 'Thromboembolism'},\n",
       "     {'id': 'D000006330', 'term': 'Heart Defects, Congenital'},\n",
       "     {'id': 'D000054556', 'term': 'Venous Thromboembolism'}],\n",
       "    'ancestors': [{'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000016769', 'term': 'Embolism and Thrombosis'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000018376', 'term': 'Cardiovascular Abnormalities'},\n",
       "     {'id': 'D000000013', 'term': 'Congenital Abnormalities'}],\n",
       "    'browseLeaves': [{'id': 'M9419',\n",
       "      'name': 'Heart Diseases',\n",
       "      'asFound': 'Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16686', 'name': 'Thrombosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M9418',\n",
       "      'name': 'Heart Defects, Congenital',\n",
       "      'asFound': 'Congenital Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7784', 'name': 'Embolism', 'relevance': 'LOW'},\n",
       "     {'id': 'M16682',\n",
       "      'name': 'Thromboembolism',\n",
       "      'asFound': 'Thromboembolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M27780',\n",
       "      'name': 'Venous Thromboembolism',\n",
       "      'asFound': 'Venous Thromboembolism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19128', 'name': 'Embolism and Thrombosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12', 'name': 'Congenital Abnormalities', 'relevance': 'LOW'},\n",
       "     {'id': 'M20503',\n",
       "      'name': 'Cardiovascular Abnormalities',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000069552',\n",
       "      'term': 'Rivaroxaban'}],\n",
       "    'ancestors': [{'id': 'D000065427', 'term': 'Factor Xa Inhibitors'},\n",
       "     {'id': 'D000000991', 'term': 'Antithrombins'},\n",
       "     {'id': 'D000015842', 'term': 'Serine Proteinase Inhibitors'},\n",
       "     {'id': 'D000011480', 'term': 'Protease Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000925', 'term': 'Anticoagulants'}],\n",
       "    'browseLeaves': [{'id': 'M463',\n",
       "      'name': 'Rivaroxaban',\n",
       "      'asFound': 'Benefit',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M30513', 'name': 'Factor Xa Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4307', 'name': 'Antithrombins', 'relevance': 'LOW'},\n",
       "     {'id': 'M4306', 'name': 'Antithrombin III', 'relevance': 'LOW'},\n",
       "     {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M18391',\n",
       "      'name': 'Serine Proteinase Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4244', 'name': 'Anticoagulants', 'relevance': 'LOW'},\n",
       "     {'id': 'T18', 'name': 'Serine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'AnCoag', 'name': 'Anticoagulants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05973422',\n",
       "    'orgStudyIdInfo': {'id': 'CIP-0001 Sigi FIH Study CIP'},\n",
       "    'organization': {'fullName': 'Tandem Diabetes Care, Inc.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes',\n",
       "    'officialTitle': 'Sigi Insulin Management System - First-in-Human Study',\n",
       "    'acronym': 'SigiFIH'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-25',\n",
       "    'studyFirstSubmitQcDate': '2023-07-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-01-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-01-11', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Tandem Diabetes Care, Inc.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This early feasibility first-in-human study is a prospective single-arm single-center\\r\\nstudy of Sigi insulin patch pump. After a 1st day and night under medical surveillance\\r\\nduring a hotel stay, Sigi system will be evaluated during 15 days at home in adults with\\r\\ntype 1 diabetes.',\n",
       "    'detailedDescription': 'Sigi Insulin Management System (Sigi) is a novel insulin patch pump intended for\\r\\nsubcutaneous delivery if insulin at set and variable rates for the management of diabetes\\r\\nmellitus in persons requiring insulin. Sigi is offering superior delivery accuracy and\\r\\nprecision, accelerated occlusion detection, wearable patch pump, pre-filled insulin\\r\\ncartridges and smartphone control.\\r\\n\\r\\nGlycemia is CGM controlled and for safety purposes, CGM data are shared with study\\r\\nmedical team during the whole study.\\r\\n\\r\\nSigi FIH Study is conducted in a single clinical site in Lausanne University Hospital\\r\\n(CHUV) in Switzerland.'},\n",
       "   'conditionsModule': {'conditions': ['Type 1 Diabetes'],\n",
       "    'keywords': ['Insulin patch pump',\n",
       "     'CGM control',\n",
       "     'Smartphone control',\n",
       "     'Pre-filled insulin cartridges',\n",
       "     'Occlusion detection']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'DEVICE_FEASIBILITY',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'SIGI Insulin Management System Observed and At-Home Use',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Current insulin pump users with type 1 diabetes, age 18+, will use the SIGI insulin\\r\\nmanagement system for 1 day observed in the hospital setting, then for 2 more weeks of\\r\\noutpatient use.',\n",
       "      'interventionNames': ['Device: SIGI Insulin Management System']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'SIGI Insulin Management System',\n",
       "      'description': 'Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor\\r\\nusing the Dexcom App.',\n",
       "      'armGroupLabels': ['SIGI Insulin Management System Observed and At-Home Use']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Serious Adverse Events',\n",
       "      'description': 'Number of serious adverse events',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Adverse Events',\n",
       "      'description': 'Number of adverse events',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Adverse Device Effects',\n",
       "      'description': 'Number of adverse device effects (ADE)',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Serious adverse device effects (SADE)',\n",
       "      'description': 'Number of serious adverse device effects (ADE)',\n",
       "      'timeFrame': '15 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Severe hypoglycemia events, as a indicator of successful CSII self-management with Sigi',\n",
       "      'description': 'Number of severe hypoglycemia events (with cognitive impairment such that assistance of\\r\\nanother individual is needed for treatment) during study',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Diabetic ketoacidosis events, as a indicator of successful CSII self-management with Sigi',\n",
       "      'description': 'Number of diabetic ketoacidosis events',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Acceptance and confidence of PI to proceed to outpatient use',\n",
       "      'description': 'Number of participants who pass the observed use setting as evaluated by PI and proceed\\r\\nto outpatient use.',\n",
       "      'timeFrame': '1 day'},\n",
       "     {'measure': 'Acceptance and confidence of participant to proceed to outpatient use',\n",
       "      'description': 'Number of participants who pass the observed use setting as evaluated by participants and\\r\\nproceed to outpatient use.',\n",
       "      'timeFrame': '1 day'},\n",
       "     {'measure': 'Device deficiencies',\n",
       "      'description': 'Number of device deficiencies (device issues) recorded during study use',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Evaluation of pad duration (days)',\n",
       "      'description': 'Collect pad replacement dates to calculate the pad survival rate at 3 days',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Occlusion detection rate',\n",
       "      'description': 'Rate of occlusions detected by the system over the total wear period (number of\\r\\nocclusions/total wear time in days)',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Evaluation of skin tolerance',\n",
       "      'description': 'Number of recorded skin reactions, including skin related adverse events, during the 15\\r\\nday wear time.',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'Evaluation of overall device tolerance',\n",
       "      'description': 'Number of reports related to discomfort at the infusion site, including discomfort\\r\\nrelated adverse events, during the 15 day wear time.',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'System Usability Scale (SUS) at baseline and 15 days for the PAD',\n",
       "      'description': 'System Usability Scores (SUS)-composite score from 0 to 100 with higher scores indicating\\r\\nbetter perceived usability, collected at baseline and 15 days for evaluation of the PAD.',\n",
       "      'timeFrame': '15 days'},\n",
       "     {'measure': 'System Usability Scale (SUS) at baseline and 15 days for the Pump Assembly',\n",
       "      'description': 'System Usability Scores (SUS)-composite score from 0 to 100 with higher scores indicating\\r\\nbetter perceived usability, collected at baseline and 15 days for evaluation of the pump\\r\\nassembly.',\n",
       "      'timeFrame': '15 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Informed consent signed\\r\\n\\r\\n  -  Patients with T1D since more than 1 year\\r\\n\\r\\n  -  Adults 18+years\\r\\n\\r\\n  -  Patients under sensor augmented pump for at least 6 months\\r\\n\\r\\n  -  Hybrid closed-loop users willing to switch to manual mode 15 days before study\\r\\n\\r\\n  -  Patients with calculated insulin-to-carb ratio and correction factor\\r\\n\\r\\n  -  Patients with total daily insulin above 30 insulin units\\r\\n\\r\\n  -  Patients with correction factor below 3.5 mmol/L\\r\\n\\r\\n  -  No severe hypoglycemic or ketoacidosis episode requiring third-party intervention\\r\\n     within the past 12 months\\r\\n\\r\\n  -  Active users of Teflon infusion sets\\r\\n\\r\\n  -  Patients willing to use a smartphone interface to use their pump and to answer study\\r\\n     questionnaires\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with T2D\\r\\n\\r\\n  -  Patients with T1D under multiple daily injections\\r\\n\\r\\n  -  Patients using Apidra and not willing to switch to NovoRapid / Fiasp / Humalog\\r\\n\\r\\n  -  Patients with history of skin diseases (e.g. generalized eczema, plan lichen,\\r\\n     psoriasis)\\r\\n\\r\\n  -  Patients with known allergy to some insulins\\r\\n\\r\\n  -  Clarke's score ≥ 4 (hypoglycemia unawareness)\\r\\n\\r\\n  -  Severe late complications of diabetes, like severe neuropathy, non-stabilized\\r\\n     proliferative retinopathy, EGF < 30 mL/min, myocardial infarction or stroke within\\r\\n     the last 3 months\\r\\n\\r\\n  -  Glycated hemoglobin HbA1c > 8.5 % at screening visit\\r\\n\\r\\n  -  Medications interacting with glucose homeostasis (e.g. steroids)\\r\\n\\r\\n  -  Pregnant of breastfeeding women\\r\\n\\r\\n  -  Planned operation / MRI / CT requiring removal of infusion pad over the 15 days of\\r\\n     the study\\r\\n\\r\\n  -  Planned travel over the 15 days of the study\\r\\n\\r\\n  -  Persons under guardianship or incapable of judgement\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Alain Woodtli',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+41786032519',\n",
       "      'email': 'awoodtli@tandemdiabetes.com'},\n",
       "     {'name': 'Laetitia Galea',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+41215523676',\n",
       "      'email': 'lgalea@tandemdiabetes.com'}],\n",
       "    'overallOfficials': [{'name': 'Anne Wojtusciszyn, MD',\n",
       "      'affiliation': 'CHUV Centre Hospitalier Universitaire Vaudois',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003922',\n",
       "      'term': 'Diabetes Mellitus, Type 1'}],\n",
       "    'ancestors': [{'id': 'D000003920', 'term': 'Diabetes Mellitus'},\n",
       "     {'id': 'D000044882', 'term': 'Glucose Metabolism Disorders'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7115',\n",
       "      'name': 'Diabetes Mellitus',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7117',\n",
       "      'name': 'Diabetes Mellitus, Type 1',\n",
       "      'asFound': 'Type 1 Diabetes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M25403',\n",
       "      'name': 'Glucose Metabolism Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000007328',\n",
       "      'term': 'Insulin'}],\n",
       "    'ancestors': [{'id': 'D000007004', 'term': 'Hypoglycemic Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M10365',\n",
       "      'name': 'Insulin',\n",
       "      'asFound': 'Day 1',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'},\n",
       "     {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06426758',\n",
       "    'orgStudyIdInfo': {'id': 'NanjingMU2'},\n",
       "    'organization': {'fullName': 'Nanjing Medical University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': \"Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation\",\n",
       "    'officialTitle': \"The Morbidity of Graves' Disease and Recurrence Rate of Hyperthyroidism Due to Epstein-Barr Virus Lytic Reactivation\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-09-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-09-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-19',\n",
       "    'studyFirstSubmitQcDate': '2024-05-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Xiao-Ming Mao',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'Nanjing Medical University'},\n",
       "    'leadSponsor': {'name': 'Xiao-Ming Mao', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Natural Science Foundation of China',\n",
       "      'class': 'OTHER_GOV'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus\\r\\n(EBV) was significantly associated with the onset of Graves'disease (GD), however, the\\r\\nmorbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment\\r\\ndue to lytic reactivation of EBV is not understood. We will recruit patients with newly\\r\\ndiagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In\\r\\norder to confirm lytic reactivation of EBV, the number of EBV DNA copies，mRNA and protein\\r\\nexpression of immediate-early, early and late lytic EBV genes，EBV +TRAb+cells will be\\r\\ntested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence\\r\\nof hyperthyroidism was evaluated.\",\n",
       "    'detailedDescription': 'The lytic reactivation of latent EBV play importment roles in development of GD and\\r\\nrecurrence rate of hyperthyroidism. The aim of this study is to evaluate the proportion\\r\\nof lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism.\\r\\n\\r\\nAll patients satisfied the diagnostic criteria for GD. The diagnotic remission of\\r\\nhyperthyroidism was included of clinical symptoms and elevated FT3 and FT4, the patients\\r\\nwho have been received antithyroid drugs (methimazole or propylthiouracil) titration\\r\\ntreatment for 18 or more months and of antithyroid drugs titration treatment and\\r\\nwithdrawal antithyroid drugs at least 3 months.\\r\\n\\r\\nThe evaluation of lytic reactivation of latent EBV including EBV DNA copies，mRNA and\\r\\nprotein expression of immediate-early, early and late lytic genes，and EBV +TRAb+cells.\\r\\nThe EBV DNA copies was tested with PCR, mRNA and protein expression of immediate-early,\\r\\nearly and late lytic EBV genes were analysed with RT-qPCR or Western blot and EBV\\r\\n+TRAb+cells were evaluated with flow cytometry.\\r\\n\\r\\nAll statistical tests were performed using GraphPad Prism V8.0.'},\n",
       "   'conditionsModule': {'conditions': ['Graves Disease',\n",
       "     \"Graves' Disease in Remission\",\n",
       "     'Epstein-Barr Virus'],\n",
       "    'keywords': ['Graves Disease',\n",
       "     'Relapse of hyperthyroidism',\n",
       "     'Epstein-Barr virus',\n",
       "     'Lytic reactivation',\n",
       "     'Morbidity']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "     'description': 'Following DNA isolation with a QIAamp DNA Blood Mini Kit, the number of EBV copies in\\r\\nPBMCs was detected using real-time PCR assay by means of the ISEX variant of the EBV PCR\\r\\nkit. The results are expressed in units of EBV DNA copies/µg of DNA, EBV DNA copies/mL of\\r\\nPBMCs suspension, and EBV DNAcopies/100,000 cells.\\r\\n\\r\\nPeripheral blood samples were collected from patients with GD and recurrence of\\r\\nhyperthyroidism.Total RNA was extracted from blood using the conventional TRIzol method.\\r\\nReverse transcription was performed using PrimeScript RT Reagent Kit with cDNA Eraser for\\r\\ntwo-step reverse transcription polymerase chain reaction.'},\n",
       "    'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'The incidence rate of GD and and recurrence of hyperthyroidism due to lytic reactivation of EBV',\n",
       "      'description': 'The GD patients with high number of EBV DNA copies, EBV +TRAb+cells and overexpression\\r\\nlytic genes are considered as lytic reactivation of EBV',\n",
       "      'timeFrame': '3 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  The clinical evaluation included patient history, physical examination, and thyroid\\r\\n     ultrasonography. Laboratory and diagnostic testing included determination of serum\\r\\n     levels of free thyroxine (FT4), T3 ( FT3), thyrotropin (TSH), TPOAb, TGAb, and serum\\r\\n     levels of thyrotropin receptor antibody (TRAb).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with subacute thyroiditis, hyperfunctioning thyroid nodules, iodine\\r\\n     hyperthyroidism, drug-induced hyperthyroidism, or other causes of hyperthyroidism\\r\\n     were also excluded. The exclusion criteria for both patients with GD included\\r\\n     diabetes, infectious diseases, other chronic diseases, and cancer.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Xiao-Ming Mao, MD.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86-18951670295',\n",
       "      'email': 'maoxming@163.com'},\n",
       "     {'name': 'Guo-Qing Li, PhD.',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'liguqi941001@163.com'}],\n",
       "    'locations': [{'facility': 'Nanjing First Hospital, Nanjing Medical University',\n",
       "      'city': 'Nanjing',\n",
       "      'state': 'Jiangsu',\n",
       "      'zip': '210006',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Xiao-Ming Mao, MD.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+86-18951670295',\n",
       "        'email': 'maoxming@163.com'},\n",
       "       {'name': 'Guo-Qing Li, PhD.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+86-15895915500',\n",
       "        'email': 'liguqi941001@163.com'}],\n",
       "      'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000020031',\n",
       "      'term': 'Epstein-Barr Virus Infections'},\n",
       "     {'id': 'D000006111', 'term': 'Graves Disease'},\n",
       "     {'id': 'D000006980', 'term': 'Hyperthyroidism'}],\n",
       "    'ancestors': [{'id': 'D000014777', 'term': 'Virus Diseases'},\n",
       "     {'id': 'D000007239', 'term': 'Infections'},\n",
       "     {'id': 'D000006566', 'term': 'Herpesviridae Infections'},\n",
       "     {'id': 'D000004266', 'term': 'DNA Virus Infections'},\n",
       "     {'id': 'D000014412', 'term': 'Tumor Virus Infections'},\n",
       "     {'id': 'D000005094', 'term': 'Exophthalmos'},\n",
       "     {'id': 'D000009916', 'term': 'Orbital Diseases'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'},\n",
       "     {'id': 'D000006042', 'term': 'Goiter'},\n",
       "     {'id': 'D000013959', 'term': 'Thyroid Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14850',\n",
       "      'name': 'Recurrence',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21881',\n",
       "      'name': 'Epstein-Barr Virus Infections',\n",
       "      'asFound': 'Epstein-Barr Virus',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9214',\n",
       "      'name': 'Graves Disease',\n",
       "      'asFound': \"Graves' Disease\",\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10031',\n",
       "      'name': 'Hyperthyroidism',\n",
       "      'asFound': 'Hyperthyroidism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9643', 'name': 'Herpesviridae Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M7442', 'name': 'DNA Virus Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M17162', 'name': 'Tumor Virus Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M8237', 'name': 'Exophthalmos', 'relevance': 'LOW'},\n",
       "     {'id': 'M12845', 'name': 'Orbital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9147', 'name': 'Goiter', 'relevance': 'LOW'},\n",
       "     {'id': 'M16718', 'name': 'Thyroid Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06270316',\n",
       "    'orgStudyIdInfo': {'id': 'CT-AMT-191-01'},\n",
       "    'organization': {'fullName': 'UniQure Biopharma B.V.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease',\n",
       "    'officialTitle': 'A Phase 1/2, Single Dose, Dose Escalation Study of Intravenous AAV5-GLA (AMT-191) in Adult Males With Classic Fabry Disease'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-04-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-04-29', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-19',\n",
       "    'studyFirstSubmitQcDate': '2024-02-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'UniQure Biopharma B.V.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is an open-label multi-center study to evaluate safety and biomarkers of efficacy of\\r\\na single dose of intravenously-administered AMT-191. The study will also include\\r\\nexploratory functional efficacy assessments. The plan is to investigate 2 sequential dose\\r\\ncohorts in 3-6 Participants per cohort. Participants will be monitored for 24 hours\\r\\nfollowing AMT-191 administration then follow-up study visits will continue for 24 months,\\r\\nduring which safety, pharmacokinetics/pharmacodynamics, biomarkers, and efficacy\\r\\nassessments will be performed. Participants will continue receiving their regularly\\r\\nscheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal.',\n",
       "    'detailedDescription': 'Fabry disease (FD) is a lysosomal storage disorder resulting from the absent or deficient\\r\\nactivity of the lysosomal enzyme, α-galactosidase A (GLA). Despite availability of an\\r\\nenzyme replacement therapy (ERT) to prevent the progression of the renal, cardiac, and\\r\\ncerebrovascular symptoms, ERT is not curative and has variable impact on the disease\\r\\nprogression for patients.\\r\\n\\r\\nA recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time\\r\\nintravenous (IV) administration will be investigated in this study. This recombinant\\r\\nAAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human\\r\\nα-galactosidase A.\\r\\n\\r\\nDelivery of AMT-191 to the systemic circulation is expected to result in a therapeutic\\r\\neffect by promoting the liver expression of the lysosomal enzyme GLA in plasma and\\r\\nleukocytes levels in patients with FD.'},\n",
       "   'conditionsModule': {'conditions': ['Fabry Disease'],\n",
       "    'keywords': ['GLA', 'gene therapy', 'ERT', 'FD']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Cohort 1 - Dose level 1: 6.0 x 10e13 gc/kg - 3 Participants (plus additional 3 if needed\\r\\nto assess dose-limiting toxicity)',\n",
       "      'interventionNames': ['Drug: AMT-191']},\n",
       "     {'label': 'Cohort 2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Cohort 2 - Dose level 2: 3.0 x 10e14 gc/kg - 3 Participants (plus additional 3 if needed\\r\\nto assess dose-limiting toxicity)',\n",
       "      'interventionNames': ['Drug: AMT-191']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'AMT-191',\n",
       "      'description': 'A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time\\r\\nintravenous (IV) administration will be investigated in this study. This recombinant\\r\\nAAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human\\r\\nα-galactosidase A.\\r\\n\\r\\nDelivery of AMT-191 to the systemic circulation is expected to result in a therapeutic\\r\\neffect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in\\r\\npatients with FD.',\n",
       "      'armGroupLabels': ['Cohort 1', 'Cohort 2']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]',\n",
       "      'description': '• Number of Participants with Treatment-Emergent Adverse Events TEAE(n,%) by CTCAE v4.0.',\n",
       "      'timeFrame': '26 Months'},\n",
       "     {'measure': 'Duration of Vector deoxyribonucleic acid (DNA) shedding presented in blood, saliva, feces, semen, and urine',\n",
       "      'description': 'The duration of vector shedding DNA presented in bodily fluids such as blood, saliva,\\r\\nfeces, semen, and urine will be followed in participants from baseline value to BLOQ.',\n",
       "      'timeFrame': '26 Months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Male of age ≥ 18 years and < 50 years\\r\\n\\r\\n  2. Confirmed clinical diagnosis of classic Fabry disease (FD) defined as:\\r\\n\\r\\n       1. Absent or minimal GLA enzyme activity < 1% of the testing laboratory's normal\\r\\n          reference level measured in isolated peripheral leukocytes regardless of\\r\\n          variant status; OR\\r\\n\\r\\n       2. Galactosidase A gene (GLA) pathogenic or likely pathogenic variant associated\\r\\n          with classic FD phenotype identified on molecular genetic testing\\r\\n\\r\\n  3. eGFR ≥ 45 mL/min/1.73 m2 and ≤ 75 mL/min/1.73m2\\r\\n\\r\\n  4. Participant agrees that for a period of at least 18 months following dosing, will\\r\\n     only have sexual intercourse with a condom.\\r\\n\\r\\n  5. Suboptimal response after at least 12 months of enzyme replacement therapy (ERT)\\r\\n     treatment. Suboptimal response is defined as plasma lyso-Gb3 ≥ 2.3 nanograms per\\r\\n     milliliter (ng/mL) at Screening and one or both of the following:\\r\\n\\r\\n       -  Persistent neuropathic pain (intermittent or continuous) over a period of at\\r\\n          least 3 months defined as average pain intensity > 3 on a scale of 0-10\\r\\n          assessed by the Numeric Pain Rating Scale\\r\\n\\r\\n       -  Presence of gastrointestinal symptoms (abdominal cramping, constipation, or\\r\\n          diarrhea), reported by the participant as moderate or severe and that are\\r\\n          either persistent or occurring two or more times over the 12 weeks prior to\\r\\n          consent\\r\\n\\r\\n  6. Weight ≤ 80 kilograms (kg)\\r\\n\\r\\n  7. Able and willing to provide informed consent\\r\\n\\r\\n  8. Has received or agrees to receive a meningococcal vaccine at least 6 weeks prior to\\r\\n     planned date of dosing with AMT-191\\r\\n\\r\\n  9. Agrees to have no vaccinations within 6 weeks prior to and 6 weeks after dosing with\\r\\n     AMT-191\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Any hypersensitivity reaction to ERT or infusion reaction in the 12 months prior to\\r\\n     consent that either required medical intervention or was of severity grade 3 or\\r\\n     above based on Common Terminology Criteria for Adverse Events (CTCAE v5.0)\\r\\n\\r\\n  2. Proteinuria, with urine creatinine ratio > 1 at Screening\\r\\n\\r\\n  3. Any previous treatment with investigational drug within 3 months prior to first\\r\\n     Screening assessment\\r\\n\\r\\n  4. Any previous treatment with gene therapy\\r\\n\\r\\n  5. Any anticipated participation in interventional studies for the treatment of FD\\r\\n\\r\\n  6. Current use of chaperone therapy such as miglastat (Galafold®)\\r\\n\\r\\n  7. Malignancy within 5 years of Screening, except for basal or squamous cell carcinoma\\r\\n     of the skin\\r\\n\\r\\n  8. Positive serology test at Screening for hepatitis B surface antigen (HbsAg),\\r\\n     hepatitis C antibody (HCAb), or human immunodeficiency virus (HIV), or active or\\r\\n     latent infection with tuberculosis (TB) measured by QuantiFERON test\\r\\n\\r\\n  9. Active or ongoing infection or any other significant concurrent, uncontrolled\\r\\n     medical condition including, but not limited to, renal, hepatic, cardiovascular,\\r\\n     hematological, GI, endocrine (such as diabetes mellitus with poor glycemic control),\\r\\n     pulmonary, neurological, cerebral, or psychiatric disease, alcoholism, drug\\r\\n     dependency, or any other psychological disorder that could, in the opinion of the\\r\\n     Investigator, risk the safety of the Participant, or interfere with adherence to the\\r\\n     protocol procedures or interpretation of results\\r\\n\\r\\n 10. Evidence of any liver disease, including hepatitis, fibrosis, cirrhosis of the\\r\\n     liver, neoplastic lesion, or any known medical condition that could impact the\\r\\n     intended transduction of the vector and or expression and activity of the protein\\r\\n\\r\\n 11. History of kidney transplantation or currently on hemodialysis or peritoneal\\r\\n     dialysis\\r\\n\\r\\n 12. Moderately severe to severe cardiovascular disease in the opinion of the\\r\\n     Investigator, including left ventricular ejection fraction (LVEF) < 45% on Screening\\r\\n     CMR; history of stroke or transient ischemic attacks within the 12 months prior to\\r\\n     Screening; history of ventricular tachycardia, history of or detection of other\\r\\n     significant arrhythmia during screening; significant thromboembolic disease history\\r\\n     (e.g., pulmonary embolism); or history of thrombotic risk resulting in current use\\r\\n     of anticoagulant/antiplatelet agents (not including prophylactic use of low-dose\\r\\n     aspirin)\\r\\n\\r\\n 13. Systolic blood pressure >140 millimeters of mercury (mmHg) (inclusive) and/or\\r\\n     diastolic blood pressure outside the range of 60 to 85 mmHg (inclusive) at\\r\\n     Screening.\\r\\n\\r\\n       -  Patients with a known history of hypertension above these thresholds are only\\r\\n          allowed in the study if they are taking inhibitors of renin angiotensin system\\r\\n          (such as angiotensin-converting enzyme [ACE] inhibitors and angiotensin II\\r\\n          receptor blockers [ARBs]), and/or beta blockers per current applicable standard\\r\\n          of care guidelines at a dose which results in blood pressure within the\\r\\n          allowable range as measured at Screening.\\r\\n\\r\\n 14. Glycated hemoglobin (HbA1c) at Screening outside the range of 4% to 7% (inclusive)\\r\\n\\r\\n 15. Contraindication to systemic corticosteroid therapy or immunosuppressive therapy\\r\\n\\r\\n 16. Chronic steroid use, defined as ≥ 3 months of oral corticosteroid use within the 12\\r\\n     months prior to Screening\\r\\n\\r\\n 17. Known uncontrolled allergic conditions or allergy/hypersensitivity to any component\\r\\n     of the AMT-191 excipients\\r\\n\\r\\n 18. Screening laboratory values for renal and liver function that meet or exceed any of\\r\\n     the following:\\r\\n\\r\\n       1. ALT > 2 x upper limit of normal for the testing laboratory (ULN)\\r\\n\\r\\n       2. AST > 2 x ULN\\r\\n\\r\\n       3. Total Bilirubin > 2 x ULN (except if this is caused by Gilbert disease)\\r\\n\\r\\n       4. Alkaline phosphatase (ALP) > 2 x ULN\\r\\n\\r\\n       5. Creatinine > 2 x ULN\\r\\n\\r\\n 19. Screening laboratory values for hematologic and coagulation function that meet any\\r\\n     of the following:\\r\\n\\r\\n       1. Red blood cell count < 4.5 x10e6/μl\\r\\n\\r\\n       2. Platelet count < 150 x10e3/μl\\r\\n\\r\\n       3. International normalized ratio (INR) >1.1\\r\\n\\r\\n 20. Significant anatomical abnormalities on renal ultrasound such as the presence of\\r\\n     only 1 kidney, significant differences in kidney sizes between the right and left\\r\\n     kidneys (>1.5 centimeters [cm]), or presence of kidney cysts\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'MALE',\n",
       "    'genderBased': True,\n",
       "    'genderDescription': 'Male of age ≥ 18 years and < 50 years',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '50 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Christy Quintana',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+1 781-879-6442',\n",
       "      'email': 'amt191_clinical_trials@uniqure.com'},\n",
       "     {'name': 'Katarzyna Nowek',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31 6 27 29 79 31',\n",
       "      'email': 'amt191_clinical_trials@uniqure.com'}],\n",
       "    'locations': [{'facility': 'Lysosomal & Rare Disorders Research and Treatment Center, Inc',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Fairfax',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '22030',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Lauren Noll',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '571-732-4655',\n",
       "        'email': 'LNoll@ldrtc.org'},\n",
       "       {'name': 'Ozlem Goker-Alpan', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000795',\n",
       "      'term': 'Fabry Disease'}],\n",
       "    'ancestors': [{'id': 'D000013106', 'term': 'Sphingolipidoses'},\n",
       "     {'id': 'D000020140',\n",
       "      'term': 'Lysosomal Storage Diseases, Nervous System'},\n",
       "     {'id': 'D000020739', 'term': 'Brain Diseases, Metabolic, Inborn'},\n",
       "     {'id': 'D000001928', 'term': 'Brain Diseases, Metabolic'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000059345', 'term': 'Cerebral Small Vessel Diseases'},\n",
       "     {'id': 'D000002561', 'term': 'Cerebrovascular Disorders'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000040181', 'term': 'Genetic Diseases, X-Linked'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000008661', 'term': 'Metabolism, Inborn Errors'},\n",
       "     {'id': 'D000008064', 'term': 'Lipidoses'},\n",
       "     {'id': 'D000008052', 'term': 'Lipid Metabolism, Inborn Errors'},\n",
       "     {'id': 'D000016464', 'term': 'Lysosomal Storage Diseases'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'},\n",
       "     {'id': 'D000052439', 'term': 'Lipid Metabolism Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M4124',\n",
       "      'name': 'Fabry Disease',\n",
       "      'asFound': 'Fabry Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15904', 'name': 'Sphingolipidoses', 'relevance': 'LOW'},\n",
       "     {'id': 'M18871',\n",
       "      'name': 'Lysosomal Storage Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5205', 'name': 'Brain Diseases, Metabolic', 'relevance': 'LOW'},\n",
       "     {'id': 'M22498',\n",
       "      'name': 'Brain Diseases, Metabolic, Inborn',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M29437',\n",
       "      'name': 'Cerebral Small Vessel Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5810', 'name': 'Cerebrovascular Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M24877',\n",
       "      'name': 'Genetic Diseases, X-Linked',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M11641', 'name': 'Metabolism, Inborn Errors', 'relevance': 'LOW'},\n",
       "     {'id': 'M11064', 'name': 'Lipidoses', 'relevance': 'LOW'},\n",
       "     {'id': 'M11054',\n",
       "      'name': 'Lipid Metabolism, Inborn Errors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27029',\n",
       "      'name': 'Lipid Metabolism Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T2169',\n",
       "      'name': 'Fabry Disease',\n",
       "      'asFound': 'Fabry Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T5335', 'name': 'Sphingolipidosis', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M11110',\n",
       "      'name': 'Liver Extracts',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06438016',\n",
       "    'orgStudyIdInfo': {'id': '205/2024'},\n",
       "    'organization': {'fullName': 'Dhulikhel Hospital', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Stress Management Training for Nursing Professionals in a Tertiary Care Center in Nepal',\n",
       "    'officialTitle': 'Exploring the Efficiency of Stress Management Training Programs in Reducing Stress Levels Within Nursing Professionals in a Tertiary Care Center in Nepal'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-27',\n",
       "    'studyFirstSubmitQcDate': '2024-05-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Rebecca Makaju Shrestha',\n",
       "     'investigatorTitle': 'Psychologist',\n",
       "     'investigatorAffiliation': 'Dhulikhel Hospital'},\n",
       "    'leadSponsor': {'name': 'Dhulikhel Hospital', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to learn if stress management programs can help\\r\\nalleviate existing and prevent future symptoms of stress in nursing professionals working\\r\\nin a tertiary care center in Nepal.\\r\\n\\r\\nResearchers will compare the treatment group (exposed to stress management training) to\\r\\nthe control group (not exposed to stress management training) to see if\\r\\n\\r\\n  1. Stress management sessions lead to reduction of levels of stress among nurses at\\r\\n     tertiary level hospital in Nepal.\\r\\n\\r\\n  2. To compare the pre and post training stress levels among participants of\\r\\n     intervention and control group\\r\\n\\r\\nParticipants will Fill out the Depression, Anxiety and Stress Scale 21 and the Perceived\\r\\nStress Scale before either being exposed to a 4-session stress management training\\r\\n(treatment group) or not being exposed to such training (control). All participants (both\\r\\ngroups) will fill out the Depression, Anxiety and Stress Scale 21 and the Perceived\\r\\nStress Scale for pre-post comparative measure.',\n",
       "    'detailedDescription': 'This study will aim to explore the effectiveness of a stress management program in\\r\\nnursing professionals in a community teaching hospital in Nepal. A 4-day stress\\r\\nmanagement training program will be conducted and pre and post-training stress levels\\r\\nwill be measured using the Perceived Stress Scale (PSS) and the Stress-Subscale of the\\r\\nDepression, Anxiety and Stress Scale-21 (DASS-21) one week prior to and after the\\r\\ntraining program. This experimental pre-post double arm study will involve 86\\r\\nparticipants - all nursing staff from the Dhulikhel Hospital. Participants will be\\r\\ndivided into 2 groups - treatment and control. The treatment group will be further\\r\\ndivided into 2 groups of 20-25. The stress management training program will be held\\r\\nacross 4 weeks with both groups receiving one training course each week (eg. Week 1 -\\r\\nsession 1; Week 2 - session 2). Both questionnaires will be distributed again to both\\r\\ngroups, 1 month after the last stress management session (1 - month follow up) .The\\r\\ncontrol group whilst not being subjected to the Stress management training during the\\r\\nstudy period, will obtain the training upon study completion.'},\n",
       "   'conditionsModule': {'conditions': ['Mental Health'],\n",
       "    'keywords': ['Stress; Stress Management; Nursing; Nepal']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Treatment group will obtain stress management whilst the control will not. The control\\r\\ngroup will obtain stress management one month upon study completion',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 86, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Stress Management Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants in this group will be provided with a demographic questionnaire, the DASS-21\\r\\nand the PSS one week prior to and after the stress management training. The treatment\\r\\ngroup will be sub-divided into 2 groups of 20-25 participants and subjected to a\\r\\n4-session stress management training program over the course of 4-weeks (one 40 minute\\r\\nsession each week). The DASS and the PSS will be administered to this group one week and\\r\\none month post completion of the final stress management training session.',\n",
       "      'interventionNames': ['Other: Stress Management Training']},\n",
       "     {'label': 'Control Group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': \"This control group will fill out the DASS-21 and PSS with the treatment group prior to\\r\\nthe treatment group commencing stress management and will also fill out the DASS-21 and\\r\\nPSS upon completion of the treatment group's stress management training. This group will\\r\\nhowever not obtain stress management training during the study. Training will be provided\\r\\nupon study completion.\"}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Stress Management Training',\n",
       "      'description': 'The intervention will comprise of 4 sessions delivered over 4 weeks. The training session\\r\\nwill be structured as follows: Session 1 - Psychoeducation relating to stress and its\\r\\neffects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive\\r\\ntechniques to cope with stress and Session 4- Behavioral techniques to cope with stress.\\r\\nBoth verbal and written means will be used to provide this training.',\n",
       "      'armGroupLabels': ['Stress Management Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Depression Anxiety Stress Scale - 21',\n",
       "      'description': \"The DASS-21 is a 21-item tool measuring signs and symptoms of depression, anxiety and\\r\\nstress. The DASS-21 displays good to excellent internal consistency. Previous studies\\r\\nhave reported a Cronbach's α ranging from 0.82 - 0.90 for Depression, .74 - .83 for\\r\\nAnxiety, and 82 - .87 for Stress. The DASS-21 has also been validated in Nepal with good\\r\\nreliability for each subscale, with Cronbach's alphas 0.79 for Anxiety, 0.91 for Stress,\\r\\nand 0.93 for Depression.\",\n",
       "      'timeFrame': 'One week prior to 4-week intervention, one week and one month post-intervention.'},\n",
       "     {'measure': 'Perceived Stress Scale',\n",
       "      'description': \"The PSS displays good internal consistency with a Cronbach's α ranging from 0.74 - 0.91.\\r\\nA Nepali version of the PSS has also been evaluated yielding validity, strong overall\\r\\ninternal consistency (Cronbach's α = 0.95) and inter-rater reliability (ICC = 0.96).\",\n",
       "      'timeFrame': 'One week prior to 4-week intervention, one week and one month post-intervention.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Nurses employed at the Dhulikhel Hospital\\r\\n\\r\\n  -  Minimum one year work experience\\r\\n\\r\\n  -  Minimum qualification certificate level of nursing\\r\\n\\r\\n  -  Fluent in spoken and written English\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Nurses with the post of nurse manager and above\\r\\n\\r\\n  -  Nursing Students\\r\\n\\r\\n  -  History having undergone stress management training in the past\\r\\n\\r\\n  -  Absent for one or more sessions\\r\\n\\r\\n  -  Incidence of a major stressful/critical life event during the study (e.g., divorce,\\r\\n     death, and other critical events)',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '8 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Rebecca Makaju Shrestha, Psychology',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '9820114531',\n",
       "      'email': 'rebecca.m.shrestha@gmail.com'},\n",
       "     {'name': 'Subasna Shrestha, MN',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '9849294785',\n",
       "      'email': 'subasnashrestha@gmail.com'}],\n",
       "    'locations': [{'facility': 'Dhulikhel Hospital',\n",
       "      'city': 'Dhulikhel',\n",
       "      'state': 'Kavrepalanchowk',\n",
       "      'zip': '45200',\n",
       "      'country': 'Nepal',\n",
       "      'contacts': [{'name': 'Rebecca Shrestha, MClinPsych',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '9820114531',\n",
       "        'email': 'rebecca.m.shrestha@gmail.com'},\n",
       "       {'name': 'Subasna Shrestha, MN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '9849294785',\n",
       "        'email': 'subasnashrestha@gmail.com'},\n",
       "       {'name': 'Rebecca Shrestha, MClinPsych',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Subasna Shrestha, MN', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 27.6221, 'lon': 85.54281}}]},\n",
       "   'referencesModule': {'references': [{'type': 'BACKGROUND',\n",
       "      'citation': 'Behzadi S, Alizadeh Z, Samani NK, Ghasemi A, Fereidouni Z, Rostami K. Effect of stress management on job stress of intensive care unit nurses in hospitals affiliated to the University of Medical Sciences. Archivos Venezolanos de Farmacología y Terapéutica. 2021;40(8):824-7.'},\n",
       "     {'type': 'BACKGROUND',\n",
       "      'citation': 'Hakim RM, Walton LM, Schwartz JJ, Futrell SM, Zaaeed N, Raigangar VL. Nepali Version of the Ten-Item Perceived Stress Scale: Translation and Validation Study for Bhutanese Refugees. In2023 Combined Sections Meeting (CSM) 2023 Feb 25. APTA.'},\n",
       "     {'pmid': '25031113',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lee EH. Review of the psychometric evidence of the perceived stress scale. Asian Nurs Res (Korean Soc Nurs Sci). 2012 Dec;6(4):121-7. doi: 10.1016/j.anr.2012.08.004. Epub 2012 Sep 18.'},\n",
       "     {'pmid': '34161668',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Thapa DK, Visentin D, Kornhaber R, Cleary M. Psychometric properties of the Nepali language version of the Depression Anxiety Stress Scales (DASS-21). Nurs Open. 2022 Nov;9(6):2608-2617. doi: 10.1002/nop2.959. Epub 2021 Jun 23.'},\n",
       "     {'pmid': '31916468',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Zanon C, Brenner RE, Baptista MN, Vogel DL, Rubin M, Al-Darmaki FR, Goncalves M, Heath PJ, Liao HY, Mackenzie CS, Topkaya N, Wade NG, Zlati A. Examining the Dimensionality, Reliability, and Invariance of the Depression, Anxiety, and Stress Scale-21 (DASS-21) Across Eight Countries. Assessment. 2021 Sep;28(6):1531-1544. doi: 10.1177/1073191119887449. Epub 2020 Jan 9.'},\n",
       "     {'pmid': '27186196',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Pahlavanzadeh S, Asgari Z, Alimohammadi N. Effects of stress management program on the quality of nursing care and intensive care unit nurses. Iran J Nurs Midwifery Res. 2016 May-Jun;21(3):213-8. doi: 10.4103/1735-9066.180376.'},\n",
       "     {'pmid': '33952346',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Chaabane S, Chaabna K, Bhagat S, Abraham A, Doraiswamy S, Mamtani R, Cheema S. Perceived stress, stressors, and coping strategies among nursing students in the Middle East and North Africa: an overview of systematic reviews. Syst Rev. 2021 May 5;10(1):136. doi: 10.1186/s13643-021-01691-9.'},\n",
       "     {'pmid': '31912984',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Dutton S, Kozachik SL. Evaluating the Outcomes of a Web-Based Stress Management Program for Nurses and Nursing Assistants. Worldviews Evid Based Nurs. 2020 Feb;17(1):32-38. doi: 10.1111/wvn.12417. Epub 2020 Jan 8.'},\n",
       "     {'pmid': '12499451',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Mimura C, Griffiths P. The effectiveness of current approaches to workplace stress management in the nursing profession: an evidence based literature review. Occup Environ Med. 2003 Jan;60(1):10-5. doi: 10.1136/oem.60.1.10.'},\n",
       "     {'type': 'BACKGROUND',\n",
       "      'citation': 'Ducharme F, Dubé V, Lévesque L, Saulnier D, Giroux F. An online stress management training program as a supportive nursing intervention for family caregivers of an elderly person. Canadian Journal of Nursing Informatics. 2011 Jun;6(2):1-9.'},\n",
       "     {'pmid': '12670386',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Edwards D, Burnard P. A systematic review of stress and stress management interventions for mental health nurses. J Adv Nurs. 2003 Apr;42(2):169-200. doi: 10.1046/j.1365-2648.2003.02600.x.'},\n",
       "     {'pmid': '25703040',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Sailaxmi G, Lalitha K. Impact of a stress management program on stress perception of nurses working with psychiatric patients. Asian J Psychiatr. 2015 Apr;14:42-5. doi: 10.1016/j.ajp.2015.01.002. Epub 2015 Feb 7.'},\n",
       "     {'pmid': '31021944',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lary A, Borimnejad L, Mardani-Hamooleh M. The Impact of a Stress Management Program on the Stress Response of Nurses in Neonatal Intensive Care Units: A Quasi-Experimental Study. J Perinat Neonatal Nurs. 2019 Apr/Jun;33(2):189-195. doi: 10.1097/JPN.0000000000000396.'},\n",
       "     {'pmid': '31840391',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Alkhawaldeh JMA, Soh KL, Mukhtar FBM, Peng OC, Anshasi HA. Stress management interventions for intensive and critical care nurses: A systematic review. Nurs Crit Care. 2020 Mar;25(2):84-92. doi: 10.1111/nicc.12489. Epub 2019 Dec 15.'},\n",
       "     {'pmid': '36767797',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Izdebski Z, Kozakiewicz A, Bialorudzki M, Dec-Pietrowska J, Mazur J. Occupational Burnout in Healthcare Workers, Stress and Other Symptoms of Work Overload during the COVID-19 Pandemic in Poland. Int J Environ Res Public Health. 2023 Jan 30;20(3):2428. doi: 10.3390/ijerph20032428.'},\n",
       "     {'pmid': '7726811',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u.'},\n",
       "     {'pmid': '6668417',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983 Dec;24(4):385-96. No abstract available.'},\n",
       "     {'pmid': '22049282',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Yazdani M, Rezaei S, Pahlavanzadeh S. The effectiveness of stress management training program on depression, anxiety and stress of the nursing students. Iran J Nurs Midwifery Res. 2010 Fall;15(4):208-15.'},\n",
       "     {'pmid': '28316750',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Pahlevani M, Ebrahimi M, Radmehr S, Amini F, Bahraminasab M, Yazdani M. Effectiveness of stress management training on the psychological well-being of the nurses. J Med Life. 2015;8(Spec Iss 4):313-318.'},\n",
       "     {'pmid': '36181253',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Kumar N, Jin Y. Impact of nurses' emotional labour on job stress and emotional exhaustion amid COVID-19: The role of instrumental support and coaching leadership as moderators. J Nurs Manag. 2022 Oct;30(7):2620-2632. doi: 10.1111/jonm.13818. Epub 2022 Oct 11.\"},\n",
       "     {'pmid': '32007680',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Woo T, Ho R, Tang A, Tam W. Global prevalence of burnout symptoms among nurses: A systematic review and meta-analysis. J Psychiatr Res. 2020 Apr;123:9-20. doi: 10.1016/j.jpsychires.2019.12.015. Epub 2020 Jan 22.'},\n",
       "     {'pmid': '27969025',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Hersch RK, Cook RF, Deitz DK, Kaplan S, Hughes D, Friesen MA, Vezina M. Reducing nurses' stress: A randomized controlled trial of a web-based stress management program for nurses. Appl Nurs Res. 2016 Nov;32:18-25. doi: 10.1016/j.apnr.2016.04.003. Epub 2016 Apr 9.\"}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06396026',\n",
       "    'orgStudyIdInfo': {'id': 'TLL-018-303'},\n",
       "    'organization': {'fullName': 'Hangzhou Highlightll Pharmaceutical Co., Ltd',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of Efficacy and Safety of TLL-018 in CSU Participants',\n",
       "    'officialTitle': 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria With Inadequate Controll to Second Generation H1-antihistamines'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-03-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-29',\n",
       "    'studyFirstSubmitQcDate': '2024-04-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Hangzhou Highlightll Pharmaceutical Co., Ltd',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate\\r\\nthe Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic\\r\\nSpontaneous Urticaria (CSU) With Inadequate Controll to Second Generation\\r\\nH1-antihistamines.',\n",
       "    'detailedDescription': 'This is a randomized, double-blind, single-dummy, placebo-parallel-group, phase 3 study\\r\\nto assess the safety and efficacy of TLL-018 in Moderate-to-Severe Chronic Spontaneous\\r\\nUrticaria (CSU) participants who had an Inadequate Controll to Second Generation\\r\\nH1-antihistamines.'},\n",
       "   'conditionsModule': {'conditions': ['Chronic Spontaneous Urticaria']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Drug: TLL-018 Drug: Placebo',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 436, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Arm 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'TLL018 tablets,1piece,BID',\n",
       "      'interventionNames': ['Drug: TLL-018 tablets']},\n",
       "     {'label': 'Arm 2',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo tablets,1piece,BID',\n",
       "      'interventionNames': ['Drug: Placebo tablets']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'TLL-018 tablets',\n",
       "      'description': 'Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks',\n",
       "      'armGroupLabels': ['Arm 1']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo tablets',\n",
       "      'description': 'Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets\\r\\ntaken orally 1 pieces BlD for 40 weeks.',\n",
       "      'armGroupLabels': ['Arm 2']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in UAS7 at Week 12',\n",
       "      'description': 'To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from\\r\\nbaseline in UAS7 at Week 12 by assessing absolute change from baseline in weekly\\r\\nUrticaria Activity Score (UAS7) at week 12.\\r\\n\\r\\nThe UAS7 is a scoring system to evaluate urticaria signs and symptoms. It is based on\\r\\nscoring wheals (hive severity score) and itch (itch severity score) separately on a scale\\r\\nof 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is\\r\\ncalculated by adding together the daily scores, which can range from 0 to 6, for 7 days.\\r\\nThis results in a maximum total score of 42, and a minimum possible score of 0.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Change from baseline in ISS7 at Week 12',\n",
       "      'description': 'To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from\\r\\nbaseline in ISS7 at Week 12 by assessing absolute change from baseline in weekly Itch\\r\\nSeverity Score (ISS7) at week 12.\\r\\n\\r\\nThe ISS7 is the itch severity score for 7 days, and it ranges from 0 to 21.',\n",
       "      'timeFrame': '12 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change from baseline in HSS7 at Week 12',\n",
       "      'description': 'To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from\\r\\nbaseline in HSS7 at Week 12 by assessing absolute change from baseline in hive severity\\r\\nscore (HSS7) at week 12.\\r\\n\\r\\nThe HSS7 is the hive severity score for 7 days, and it ranges from 0 to 21.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Proportion of Participants With UAS7≤6 Response at Week 12',\n",
       "      'description': 'To demonstrate that a greater proportion of participants achieve disease activity control\\r\\nUAS7≤6 at Week 12 who are treated with TLL-018 compared to placebo-treated participants\\r\\nby assessing achievement of UAS7≤6 at week 12.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Proportion of Participants With UAS7=0 Response at Week 12',\n",
       "      'description': 'To demonstrate that a greater proportion of participants achieve complete absence of\\r\\nhives and itch (UAS7 = 0) at Week 12 who are treated with TLL-018 compared to\\r\\nplacebo-treated participants by achievement of UAS7 = 0 at week 12.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Proportion of Participants With DLQI=0/1 Response at Week 12',\n",
       "      'description': 'To demonstrate that a greater proportion of participants who are treated with TLL-018\\r\\nachieve DLQI = 0/1 at Week 12 compared to placebo-treated participants by assessing\\r\\nachievement of DLQI = 0/1 at week 12.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Change from baseline in DLQI at Week 12',\n",
       "      'description': 'To demonstrate that TLL-018 is superior to placebo in CSU with respect to change from\\r\\nbaseline in DLQI at Week 12 by assessing absolute change from baseline in DLQI at week\\r\\n12.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events',\n",
       "      'description': 'To demonstrate the safety and tolerability of TLL-018 by assessing occurrence of\\r\\ntreatment emergent adverse events and serious adverse events during the study.',\n",
       "      'timeFrame': '52 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Aged between 18 and 75.\\r\\n\\r\\n  -  Diagnosis of CSU refractory to secomd-generation H1-AH.\\r\\n\\r\\n  -  CSU diagnosis for ≥ 6 months.\\r\\n\\r\\n  -  The presence of itch and hivese despite current use of an approved dose of H1-AH\\r\\n     prior to screening visit.\\r\\n\\r\\n  -  UAS7 score (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7\\r\\n     days prior to randomization (Day 1).\\r\\n\\r\\n  -  Participants were required to take a stable standard dose of a second generation\\r\\n     H1-AH concomitantly according to local guidelines.\\r\\n\\r\\n  -  Willing and able to complete UPDD for the duration of the study.\\r\\n\\r\\n  -  Evidence of urticaria confirmed by the investigator prior to randomization.\\r\\n\\r\\n  -  Women of Child Bearing Potential (WOCBP) should not be pregnant or breastfeeding and\\r\\n     the pregnancy test should be negative before randomization.\\r\\n\\r\\n  -  Participants (whether male or female) should have adequate barrier contraception\\r\\n     during the whole treatment period and at least 90 days after treatment; subjects\\r\\n     should avoid the sperm or ovum donation for at least six months after treatment.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Participants meeting Chinese Guidelines for Urticaria Diagnosis and Treatment with\\r\\n     the following concomitant diseases cannot be enrolled:\\r\\n\\r\\n       1. Clearly defined underlying etiology for chronic urticarias other than CSU. E.g.\\r\\n          induced urticaria, including but not limited to artificial urticaria.\\r\\n\\r\\n       2. Any disease, which may have symptoms of urticaria and/or angioedema, including\\r\\n          but not limited to urticaria and vasculitis.\\r\\n\\r\\n       3. Suffering from other chronic pruritic diseases that may affect the judgment of\\r\\n          efficacy results, such as psoriasis, atopic dermatitis, etc.\\r\\n\\r\\n       4. Previous malignancy, herpes zoster, active tuberculosis.\\r\\n\\r\\n       5. Other symptoms of progressive or uncontrolled renal, hepatic, hematological,\\r\\n          gastrointestinal, endocrine, pulmonary, cardiovascular, neurological,\\r\\n          psychiatric, or cerebral disease.\\r\\n\\r\\n       6. Taking part in this study, in the opinion of the investigator, places the\\r\\n          patient at unacceptable risk.\\r\\n\\r\\n  -  Participants with any of the following prior therapies or concomitant medications\\r\\n     cannot be enrolled:\\r\\n\\r\\n       1. Have received any study drug within 4 weeks or less than 5 elimination of\\r\\n          half-life period before randomization (whichever is longer).\\r\\n\\r\\n       2. Have received biological agent within 3 months or 5 elimination of half-life\\r\\n          period prior to randomization (whichever is longer).\\r\\n\\r\\n       3. Have received immunosuppressive/modulatory drug within 4 weeks before\\r\\n          randomization.\\r\\n\\r\\n       4. Have received any live vaccine within 2 months before randomization or plan to\\r\\n          receive a live vaccine during the study.\\r\\n\\r\\n  -  Have experienced major surgery within 4 weeks before randomization, or expected to\\r\\n     receive major surgical treatment after enrollment;\\r\\n\\r\\n  -  Have donated blood more than 400 ml or received blood transfusion within 3 months\\r\\n     prior to the study.\\r\\n\\r\\n  -  History of drug or alcohol abuse within 6 months prior to screening.\\r\\n\\r\\n  -  Allergy to ingredients or excipients of H1-AH or TLL-018.\\r\\n\\r\\n  -  Laboratory test results are abnormal and may interfere the study judged by\\r\\n     investigators.\\r\\n\\r\\n  -  Participants are not appropriate for participation in any other situation or\\r\\n     condition in this study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000014581',\n",
       "      'term': 'Urticaria'},\n",
       "     {'id': 'D000080223', 'term': 'Chronic Urticaria'}],\n",
       "    'ancestors': [{'id': 'D000017445', 'term': 'Skin Diseases, Vascular'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000006969', 'term': 'Hypersensitivity, Immediate'},\n",
       "     {'id': 'D000006967', 'term': 'Hypersensitivity'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M17330',\n",
       "      'name': 'Urticaria',\n",
       "      'asFound': 'Urticaria',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2129',\n",
       "      'name': 'Chronic Urticaria',\n",
       "      'asFound': 'Chronic Spontaneous Urticaria',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M19714', 'name': 'Skin Diseases, Vascular', 'relevance': 'LOW'},\n",
       "     {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'},\n",
       "     {'id': 'M10020',\n",
       "      'name': 'Hypersensitivity, Immediate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M9709',\n",
       "      'name': 'Histamine Antagonists',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9710', 'name': 'Histamine H1 Antagonists', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05949580',\n",
       "    'orgStudyIdInfo': {'id': 'MN44358'},\n",
       "    'organization': {'fullName': 'Hoffmann-La Roche', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis',\n",
       "    'officialTitle': 'Study to Evaluate the Usability of Introducing Integrated Digital Solutions Into Clinical Practice and the Value of Their Use in the Medical Care of Patients With Multiple Sclerosis (MS)',\n",
       "    'acronym': 'ILLUMINATE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-11-07', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-11-07', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-10',\n",
       "    'studyFirstSubmitQcDate': '2023-07-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'icometrix', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'The main purpose of this study is to assess the usability and value of the multiple\\r\\nsclerosis (MS) care management platform in terms of improved monitoring of people with MS\\r\\n(pwMS) in clinical practice.\\r\\n\\r\\nThis is a two-year prospective data collection study with additional data collection at\\r\\nbaseline evaluating medical practice over a period of at least one year before the\\r\\nintroduction of the MS care management platform.',\n",
       "    'detailedDescription': \"The MS care management platform consists of:\\r\\n\\r\\nA) icobrain ms, a cloud-based artificial intelligence (AI) solution to quantify brain\\r\\nvolume and brain abnormalities and changes thereof on magnetic resonance imaging (MRI)\\r\\nscans and thereby providing insights into subclinical changes during disease progression\\r\\nin MS.\\r\\n\\r\\nB) icompanion ms, which consists of i) A free participant mobile application (app) and\\r\\nwebsite to keep track of participant reported health and medications and prepare\\r\\nparticipants for the next consultation.\\r\\n\\r\\nii) A web portal for healthcare professionals (HCPs), which is accessible via web\\r\\nbrowser. The MS care team will be able to access the participants' data entered via the\\r\\nparticipant app (active linking of systems by the participant required), as well as their\\r\\nparticipants' MRI images and icobrain ms volumetric brain reports automatically imported\\r\\nby the hospital picture archiving and communications system (PACS).\"},\n",
       "   'conditionsModule': {'conditions': ['Relapsing Remitting Multiple Sclerosis'],\n",
       "    'keywords': ['icobrain',\n",
       "     'icompanion',\n",
       "     'Multiple Sclerosis',\n",
       "     'Medical device',\n",
       "     'Patient app',\n",
       "     'Digital',\n",
       "     'Care management',\n",
       "     'Magnetic resonance imaging (MRI)',\n",
       "     'Deep learning',\n",
       "     'Artificial Intelligence (AI)',\n",
       "     'Patient Reported Outcomes (PRO)']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'People with RRMS',\n",
       "      'description': 'Participants with relapsing-remitting multiple sclerosis (RRMS) will have to complete\\r\\nvarious questionnaire from which data will be collected for patient-reported outcomes\\r\\n(PROs) using the icompanion patient app and the HCPs will complete various questionnaires\\r\\nusing the icompanion HCP portal.',\n",
       "      'interventionNames': ['Device: MS Care Platform (icobrain ms and icompanion ms)']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'MS Care Platform (icobrain ms and icompanion ms)',\n",
       "      'description': 'The MS care management platform consists of the following components:\\r\\n\\r\\n  1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain\\r\\n     abnormalities and changes thereof on MRI scans;\\r\\n\\r\\n  2. icompanion ms which consists of free participant mobile application (app) and a web\\r\\n     portal for HCPs.\\r\\n\\r\\nThe information collected in the icompanion ms patient app and icobrain ms is then\\r\\nbrought together in the icompanion ms HCP web portal which allows a comprehensive\\r\\noverview of disease data for every single participant.',\n",
       "      'armGroupLabels': ['People with RRMS']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'HCPs: Median of the System Usability Scale (SUS) Score Reported by Radiologists and Neurologists at Month 6',\n",
       "      'description': 'SUS is a validated scale that assesses subjective usability of a system, or, in this\\r\\ncase, the MS care management platform. The SUS consists of a 10-item questionnaire with\\r\\nfive response options ranging from Strongly agree (5) to Strongly disagree (1). The items\\r\\nscores are converted into a score from 0 (negative) to 100 (positive). A score of ≥50\\r\\nindicates that the MS care management platform is acceptable, and a score above 68 is\\r\\nconsidered above average. The final SUS score is not a percentile or a percentage and the\\r\\nSUS acceptability guidelines on how to interpret the score are: <51=awful; 51-68=poor;\\r\\n68=okay; 68-80.3=good; > 80.3=excellent; 100=best imaginable score.',\n",
       "      'timeFrame': 'Month 6'},\n",
       "     {'measure': 'HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 12',\n",
       "      'description': 'SUS is a validated scale that assesses subjective usability of a system, or, in this\\r\\ncase, the MS care management platform. The SUS consists of a 10-item questionnaire with\\r\\nfive response options ranging from Strongly agree (5) to Strongly disagree (1). The items\\r\\nscores are converted into a score from 0 (negative) to 100 (positive). A score of ≥50\\r\\nindicates that the MS care management platform is acceptable, and a score above 68 is\\r\\nconsidered above average. The final SUS score is not a percentile or a percentage and the\\r\\nSUS acceptability guidelines on how to interpret the score are: <51=awful; 51-68=poor;\\r\\n68=okay; 68-80.3=good; > 80.3=excellent; 100=best imaginable score.',\n",
       "      'timeFrame': 'Month 12'},\n",
       "     {'measure': 'HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 24',\n",
       "      'description': 'SUS is a validated scale that assesses subjective usability of a system, or, in this\\r\\ncase, the MS care management platform. The SUS consists of a 10-item questionnaire with\\r\\nfive response options ranging from Strongly agree (5) to Strongly disagree (1). The items\\r\\nscores are converted into a score from 0 (negative) to 100 (positive). A score of ≥50\\r\\nindicates that the MS care management platform is acceptable, and a score above 68 is\\r\\nconsidered above average. The final SUS score is not a percentile or a percentage and the\\r\\nSUS acceptability guidelines on how to interpret the score are: <51=awful; 51-68=poor;\\r\\n68=okay; 68-80.3=good; > 80.3=excellent; 100=best imaginable score.',\n",
       "      'timeFrame': 'Month 24'},\n",
       "     {'measure': 'Participants: Median Score of the mHealth App Usability Questionnaire (MAUQ) [MAUQ_E (Ease of Use) MAUQ_I (Interface and Satisfaction)] at Baseline',\n",
       "      'description': 'MAUQ_E and MAUQ_I are subscales of a validated self-report survey (MAUQ) in which\\r\\nparticipants report how easy the app (icompanion MS patient app) was to use and rate\\r\\ntheir satisfaction with the user interface of the app. MAUQ_E consists of a 5-item\\r\\nquestionnaire with seven response options ranging from Strongly agree to Strongly\\r\\ndisagree. Ease of use scores range from 5 to 35 with higher scores indicating greater\\r\\nease of use. MAUQ_I consists of a 7-item questionnaire with seven response options; from\\r\\nStrongly agree to Strongly disagree. Interface and satisfaction scores range from 7 to 49\\r\\nwith higher scores indicating greater satisfaction.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 12',\n",
       "      'description': 'MAUQ_E and MAUQ_I are subscales of a validated self-report survey (MAUQ) in which\\r\\nparticipants report how easy the app (icompanion MS patient app) was to use and rate\\r\\ntheir satisfaction with the user interface of the app. MAUQ_E consists of a 5-item\\r\\nquestionnaire with seven response options ranging from Strongly agree to Strongly\\r\\ndisagree. Ease of use scores range from 5 to 35 with higher scores indicating greater\\r\\nease of use. MAUQ_I consists of a 7-item questionnaire with seven response options; from\\r\\nStrongly agree to Strongly disagree. Interface and satisfaction scores range from 7 to 49\\r\\nwith higher scores indicating greater satisfaction.',\n",
       "      'timeFrame': 'Month 12'},\n",
       "     {'measure': 'Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 24',\n",
       "      'description': 'MAUQ_E and MAUQ_I are subscales of a validated self-report survey (MAUQ) in which\\r\\nparticipants report how easy the app (icompanion MS patient app) was to use and rate\\r\\ntheir satisfaction with the user interface of the app. MAUQ_E consists of a 5-item\\r\\nquestionnaire with seven response options ranging from Strongly agree to Strongly\\r\\ndisagree. Ease of use scores range from 5 to 35 with higher scores indicating greater\\r\\nease of use. MAUQ_I consists of a 7-item questionnaire with seven response options; from\\r\\nStrongly agree to Strongly disagree. Interface and satisfaction scores range from 7 to 49\\r\\nwith higher scores indicating greater satisfaction.',\n",
       "      'timeFrame': 'Month 24'},\n",
       "     {'measure': 'Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by Semi-structured Interviews (SSIs) at Month 6',\n",
       "      'description': 'To assess the change in perception of disease worsening by the HCPs, two versions of the\\r\\nSSIs are available, one version is for radiology and the other for neurology. The HCPs\\r\\nare required to answer a set of 3 questions with 6 response options ranging from strongly\\r\\ndisagree to strongly agree and also select the reasons for agreeing/disagreeing from the\\r\\noptions listed. If HCPs agree, they can select between aspects of the disease\\r\\nactivity/progression for which the system provides an increased ability to detect\\r\\nchanges. The questionnaire also includes an item with a yes/no response. A scale ranging\\r\\nfrom 1 to 6 will be attributed to these responses (with 1 being strongly disagree and 6\\r\\nbeing strongly agree). The higher the score, the higher the impact of the tools in the\\r\\nperception of disease worsening.',\n",
       "      'timeFrame': 'Baseline to Month 6'},\n",
       "     {'measure': 'Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 12',\n",
       "      'description': 'To assess the change in perception of disease worsening by the HCPs, two versions of the\\r\\nSSIs are available, one version is for radiology and the other for neurology. The HCPs\\r\\nare required to answer a set of 3 questions with 6 response options ranging from strongly\\r\\ndisagree to strongly agree and also select the reasons for agreeing/disagreeing from the\\r\\noptions listed. If HCPs agree, they can select between aspects of the disease\\r\\nactivity/progression for which the system provides an increased ability to detect\\r\\nchanges. The questionnaire also includes an item with a yes/no response. A scale ranging\\r\\nfrom 1 to 6 will be attributed to these responses (with 1 being strongly disagree and 6\\r\\nbeing strongly agree). The higher the score, the higher the impact of the tools in the\\r\\nperception of disease worsening.',\n",
       "      'timeFrame': 'Baseline to Month 12'},\n",
       "     {'measure': 'Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 24',\n",
       "      'description': 'To assess the change in perception of disease worsening by the HCPs, two versions of the\\r\\nSSIs are available, one version is for radiology and the other for neurology. The HCPs\\r\\nare required to answer a set of 3 questions with 6 response options ranging from strongly\\r\\ndisagree to strongly agree and also select the reasons for agreeing/disagreeing from the\\r\\noptions listed. If HCPs agree, they can select between aspects of the disease\\r\\nactivity/progression for which the system provides an increased ability to detect\\r\\nchanges. The questionnaire also includes an item with a yes/no response. A scale ranging\\r\\nfrom 1 to 6 will be attributed to these responses (with 1 being strongly disagree and 6\\r\\nbeing strongly agree). The higher the score, the higher the impact of the tools in the\\r\\nperception of disease worsening.',\n",
       "      'timeFrame': 'Baseline to Month 24'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change From Baseline in Time Needed for MRI Review, Assessed by SSIs of Radiologists',\n",
       "      'description': 'To assess the change in time required for MRI review, the radiologists are required to\\r\\nanswer a set of 2 questions; one question with a yes/no response (whether icobrain ms\\r\\nsave time when reading an MRI) and another question where in the HCPs will express the\\r\\ntime saved in minutes (absolute) and in percentage (relative) while reading an MRI while\\r\\nusing icobrain ms.',\n",
       "      'timeFrame': 'Baseline, 6, 12 and 24 months'},\n",
       "     {'measure': 'Change From Baseline in Time Needed for Visit Preparation, Assessed by SSIs of Neurologists',\n",
       "      'description': 'To assess the change in time required for visit preparation, the neurologist is required\\r\\nto answer a set of 3 questions with 6 response options ranging from strongly disagree to\\r\\nstrongly agree and if the response selected is \"agree\" a free text field is available to\\r\\nexplain the reason for agreeing.',\n",
       "      'timeFrame': 'Baseline, 6, 12 and 24 months'},\n",
       "     {'measure': 'Change From Baseline in Health Literacy Assessed by the Health Literacy Questionnaire (HLQ)',\n",
       "      'description': 'The HLQ explores dimensions of health literacy such as social support relationship with\\r\\ncaregivers, health information evaluation or ability to engage with caregivers.\\r\\nParticipants will be asked to rate \"How strongly do you disagree or agree with the\\r\\nfollowing statements?\". The options provided are: strongly disagree, disagree, agree and\\r\\nstrongly agree, which are scored from 1 to 4, respectively. In 2nd part of the HLQ,\\r\\nparticipants will be asked \"How easy or difficult are the following tasks for you to do\\r\\nnow?\" The options for these scales are: cannot do, usually difficult, sometimes\\r\\ndifficult, usually easy and always easy, which were scored from 1 to 5, respectively. For\\r\\nboth the parts higher the score higher is the health literacy of a participant.',\n",
       "      'timeFrame': 'Baseline, 12 and 24 months'},\n",
       "     {'measure': 'Change From Baseline in Participant Autonomy Assessed by the Patient Activation Measure® 13 (PAM13)',\n",
       "      'description': 'PAM 13 is a measure used to assess the participant knowledge, skill, and confidence for\\r\\nself-management of health, consisting of 13 questions. Each of the 13 items can be\\r\\nanswered with one of four possible response options, which are \"disagree strongly\" (1),\\r\\n\"disagree\" (2), \"agree\" (3), \"agree strongly\" (4). Scores will be summed to calculate the\\r\\noverall raw score, then transformed to a scale with a theoretical range 0 to 100, based\\r\\non calibration tables, with higher PAM scores indicating higher participant activation.',\n",
       "      'timeFrame': 'Baseline, 12 and 24 months'},\n",
       "     {'measure': 'Change From Baseline in Medication Adherence, Assessed by the Morisky Medication Adherence Scale (MMAS)',\n",
       "      'description': 'The MMAS 8-item questionnaire is a recognized indicator of medication adherence,\\r\\nconsisting of 8 questions with a sum score ranging between 0 and 8 points. The higher\\r\\nscore indicates higher adherence to the prescribed therapy recommendation. It has been\\r\\nagreed that the score of 8 could be categorized as having high adherence, score between 6\\r\\nand 7 as medium adherence and scores of 5 and less as low adherence. A positive change\\r\\nscore will reflect an improvement in the adherence.',\n",
       "      'timeFrame': 'Baseline, 12 and 24 months'},\n",
       "     {'measure': 'Time in Days Needed for the Successful Installation and Integration of all Components in the MS Care Management Platform',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Number of HCPs at Each Study Center Registered on the MS Care Management Platform',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Factors Influencing HCPs Adoption to MS Care Management Platform Measured by SSIs',\n",
       "      'description': 'Factors influencing HCPs adoption to the MS care platform will be measured using the\\r\\nSSIs. The questionnaire includes three items with a yes/no response along with a free\\r\\ntext field to provide an elaboration based on the responses selected.',\n",
       "      'timeFrame': 'Baseline, 6, 12 and 24 months'},\n",
       "     {'measure': 'Number of MRI Scans per Study Center Analyzed With icobrain ms',\n",
       "      'timeFrame': 'Baseline, 6, 12, 18 and 24 months'},\n",
       "     {'measure': 'Level of Engagement on Platform Assessed Monthly by the Number of Logins and Time Spent on Individual Portal Pages in the HCP Portal',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Factors Influencing HCPs Adherence Measured by SSIs',\n",
       "      'description': \"Factors influencing HCPs adherence to the MS care platform will be measured using the\\r\\nSSIs. The questionnaire includes three item with a yes/no response along with a free text\\r\\nfield to provide an elaboration if 'yes' is selected.\",\n",
       "      'timeFrame': 'Baseline, 6, 12 and 24 months'},\n",
       "     {'measure': 'Number of Participants at Each Study Center That Register for the icompanion ms Patient app',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Reasons for not Registering for icompanion ms Patient app as Described by the HCP Through the icompanion ms HCP Portal',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Average Number of Activities in the icompanion ms Patient app per Patient per Month',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Number of Participants Using the icompanion ms Patient app With at Least 2 Activities Within 2 Months, Assessed per Month',\n",
       "      'timeFrame': 'Baseline up to 2 months of enrollement (Up to approximately 12 months)'},\n",
       "     {'measure': 'Number of Participants That Stop Using the icompanion ms Patient app (no Activity for More Than 4 Months), Assessed per Month',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'Reasons for not Using the icompanion ms Patient app Regularly as Described by HCP Through the icompanion ms HCP Portal',\n",
       "      'timeFrame': 'Up to 24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Able to comply with the study protocol, including having a smartphone and being able\\r\\n     and willing to access the icompanion ms patient app on a regular basis. To use all\\r\\n     functionalities of the icompanion ms patient app, the user's smartphone must comply\\r\\n     with the minimum system requirements (Android version 5.0 or above, iOS version 11\\r\\n     or above)\\r\\n\\r\\n  -  Have a valid email address (for registration of icompanion ms)\\r\\n\\r\\n  -  Have a definite diagnosis of RRMS\\r\\n\\r\\n  -  Time since MS diagnosis ≥1 year\\r\\n\\r\\n  -  Medical history recorded for at least 1 year before enrollment\\r\\n\\r\\n  -  Expanded Disability Status Scale (EDSS) <5.5\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any contra-indications to using icompanion ms patient app or website, as per the\\r\\n     investigator's discretion\\r\\n\\r\\n  -  Inability to complete an MRI\\r\\n\\r\\n  -  Currently involved in an interventional trial\\r\\n\\r\\n  -  Diagnosis of progressive MS (primary progressive multiple sclerosis [PPMS] or\\r\\n     secondary progressive multiple sclerosis [SPMS])\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Participants with MS are enrolled in this study. Participants with RRMS were chosen\\r\\nbecause most available disease modifying therapies (DMTs) are approved for this subgroup,\\r\\nand hence guiding care in this population is most relevant.',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'MN44358 https://forpatients.roche.com/',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '888-662-6728 (U.S. Only)',\n",
       "      'email': 'global-roche-genentech-trials@gene.com'}],\n",
       "    'overallOfficials': [{'name': 'Clinical Trials',\n",
       "      'affiliation': 'icometrix',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'At this stage of our research, we do not intend to share externally individual\\r\\npatient-level data generated by this study. Nonetheless, it remains our objective to\\r\\nensure the dissemination of our collective insights and findings from the study to the\\r\\nscientific and medical community. All external publications will be appropriately agreed\\r\\nupon by the study collaborators and coordinated as per our publication plan.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009103',\n",
       "      'term': 'Multiple Sclerosis'},\n",
       "     {'id': 'D000020529', 'term': 'Multiple Sclerosis, Relapsing-Remitting'},\n",
       "     {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000020278', 'term': 'Demyelinating Autoimmune Diseases, CNS'},\n",
       "     {'id': 'D000020274', 'term': 'Autoimmune Diseases of the Nervous System'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000003711', 'term': 'Demyelinating Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M15415',\n",
       "      'name': 'Sclerosis',\n",
       "      'asFound': 'Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12060',\n",
       "      'name': 'Multiple Sclerosis',\n",
       "      'asFound': 'Multiple Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22314',\n",
       "      'name': 'Multiple Sclerosis, Relapsing-Remitting',\n",
       "      'asFound': 'Relapsing Remitting Multiple Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22098',\n",
       "      'name': 'Demyelinating Autoimmune Diseases, CNS',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22094',\n",
       "      'name': 'Autoimmune Diseases of the Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6909', 'name': 'Demyelinating Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06269289',\n",
       "    'orgStudyIdInfo': {'id': 'SBU-KOMSERN-001'},\n",
       "    'organization': {'fullName': 'Saglik Bilimleri Universitesi',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effects of Web-Based Education on Patient Empowerment and Asthma Control in Asthma Patients',\n",
       "    'officialTitle': 'Effects of Web-Based Education on Patient Empowerment and Asthma Control in Asthma Patients'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-02',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-12',\n",
       "    'studyFirstSubmitQcDate': '2024-02-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Saglik Bilimleri Universitesi',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Asthma is defined as a chronic inflammatory disorder of the airways associated with an\\r\\nextreme increase in airway hyperresponsiveness leading to recurrent wheezing, shortness\\r\\nof breath, chest tightness, and coughing attacks. The World Health Organization states\\r\\nthat approximately 339 million individuals worldwide have asthma and more than 400\\r\\nthousand deaths occur due to asthma every year.\\r\\n\\r\\nWith effective and sustainable asthma management, it is possible to reduce\\r\\ndisease-related complaints, admissions to emergency units and hospitalizations, limit the\\r\\nphysiological and psychological effects of the disease, prevent dependence on healthcare\\r\\nprofessionals and caregivers, increase the quality of life and reduce the mortality of\\r\\nthe disease. Patient education, which is within the educational role of professional\\r\\nnurses, is very important in asthma management. The research was planned in a\\r\\nsingle-center, randomized control group pretest-posttest design. The sample will consist\\r\\nof individuals who applied to the Allergy and Immunology clinic of Sureyyapasa Chest\\r\\nDiseases and Surgery Training and Research Hospital between May 2024 and January 2024,\\r\\nwho have been diagnosed with asthma for at least one year and who accept the study [25\\r\\nintervention group - 25 control group]. Groups will be determined using the random\\r\\nnumbers table from the simple random sampling method. A web-based asthma education module\\r\\nwill be created in line with the literature, and participants in the intervention group\\r\\nwill be given synchronous training in 5 modules. After meeting the individuals in the\\r\\nintervention and control groups and obtaining verbal and written consent, they will be\\r\\nasked to fill out the Patient Information Form, Patient Empowerment Scale and Asthma\\r\\nControl Test prepared via Google Forms. A 30-minute training session will be given to the\\r\\nintervention group every week and there will be short evaluations after each training.\\r\\nWhen the 5th Module is completed, the intervention group will be asked to fill out the\\r\\nPatient Empowerment Scale and Asthma Control Test Scale. No intervention will be applied\\r\\nto the control group. 5. At the end of the module, the Patient Empowerment Scale and\\r\\nAsthma Control Test will be completed by individuals in the control group. It is thought\\r\\nthat web-based asthma education that individuals will receive will positively affect\\r\\ntheir empowerment levels and increase their disease control.',\n",
       "    'detailedDescription': \"The episodic nature of asthma symptoms and exacerbations makes effective self-management\\r\\nof the condition a necessity. Less than 40% of individuals with asthma monitor their\\r\\nsymptoms regularly, and the proportion who initiate a prescribed course of action at the\\r\\nfirst sign of an exacerbation is even lower. Many patients have difficulty recognizing\\r\\nearly signs of worsening and often fail to implement asthma action plans.\\r\\n\\r\\nMany factors such as air pollution, genetic factors, cigarette smoke, allergens,\\r\\nrespiratory infections and stress contribute to the development of asthma and triggering\\r\\nattacks. For this reason, a multifaceted approach is required in the treatment and\\r\\ncontrol of asthma.\\r\\n\\r\\nPeople with severe asthma may have debilitating symptoms that persist despite high-dose\\r\\ntreatment. Clinical guidelines for severe asthma recommend concepts such as\\r\\npatient-centeredness, shared decision-making, and self-management, with autonomy at its\\r\\ncore. To improve outcomes in individuals with mild or severe asthma, guidelines emphasize\\r\\nthe importance of patient-centeredness, shared decision-making, and self-management.\\r\\nCentral to these concepts is autonomy, a term widely used and valued in the healthcare\\r\\nliterature for which there is no gold standard definition.\\r\\n\\r\\nIn parallel with the developments and changes in the field of information technology in\\r\\nrecent years, the internet has replaced classical communication and teaching applications\\r\\nand has become used in many different areas such as keeping up with current information,\\r\\nsocial sharing, communicating professionally, shopping, banking transactions and\\r\\neducation. Internet use has also become increasingly widespread in the field of health.\\r\\nInternet users can obtain ideas about their own health and the health of the individuals\\r\\naround them through the information they obtain from health websites.\\r\\n\\r\\nToday, meeting the increasing demand for health services and supporting nursing care\\r\\nrequires greater use of technology. Nurses who care for a healthy/sick individual and are\\r\\nclosest to them should have all the information about the individuals' health as soon as\\r\\npossible in order to provide quality care, ensure their safety and interact quickly.\\r\\nEffectively used technology prevents waste of medical equipment, ensures proper use of\\r\\nresources, evidence-based practice, and improves standards and quality of care by\\r\\nproviding clinical decision-making support. Nurses use technology as a tool of change by\\r\\ndirecting this process and policies in order to provide quality, qualified and low-cost\\r\\ncare to individuals and society.\\r\\n\\r\\nWeb-based education (WTE), which is a distance education method, is defined as an\\r\\neducation program created by taking advantage of the features of the internet and\\r\\ncomputer technologies.\\r\\n\\r\\nWeb-based training is classified as synchronous or asynchronous according to the\\r\\ncommunication method. Synchronous education is a method in which two-way communication is\\r\\nprovided and mutual interaction occurs simultaneously, although the teacher and the\\r\\nstudent are physically in different environments.\\r\\n\\r\\nWTE systems allow individuals to receive education independently of time, place and\\r\\ndistance. WTE systems are widely used in the healthcare field, especially in the\\r\\nmanagement of chronic diseases. This burden placed on the healthcare system by\\r\\nindividuals with chronic diseases puts a strain on all countries of the world, including\\r\\ncountries with strong social security systems; Many countries are turning to home care,\\r\\nwhich is a more economical system, instead of costly institutional care, the role of\\r\\nhospitals is limited to acute health care, and family members are expected to take a\\r\\ngreater role in care.\\r\\n\\r\\nEducational programs aimed at individuals, families and society aim to prevent diseases\\r\\nand improve health; There are many studies showing that it is effective in providing\\r\\ndisease management for those who are sick. WTE programs are cost-effective because they\\r\\ncan reach large audiences in a short time and save time.\\r\\n\\r\\nWeb-based self-care interventions have the potential to reduce health disparities by\\r\\nremoving barriers to accessing health care. However, there is a lack of evidence on the\\r\\neffects of these interventions on chronic conditions.\\r\\n\\r\\nThe cornerstones of asthma treatment are guideline-based medication adherence and asthma\\r\\neducation programs that aim to equip the individual for effective self-management of the\\r\\ndisease.\"},\n",
       "   'conditionsModule': {'conditions': ['Asthma', 'Patient Empowerment'],\n",
       "    'keywords': ['asthma',\n",
       "     'web based intervention',\n",
       "     'education',\n",
       "     'nursing',\n",
       "     'patient empowerment']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'The research was designed as a randomized controlled experimental study with a\\r\\npretest-posttest design.',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'intervention group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'It will be determined using a table of random numbers. The group has been diagnosed for\\r\\nat least 1 year, It will consist of people (25) between the ages of 18-65, who can read\\r\\nand write in Turkish, who volunteer to participate in the study and who have not received\\r\\nany training before. After meeting the individuals and obtaining their verbal and written\\r\\nconsent, they will be asked to fill out the Patient Information Form, Patient Empowerment\\r\\nScale and Asthma Control Test obtained through Google Forms. Post-tests will be applied\\r\\nto individuals who complete all 5 modules of training.',\n",
       "      'interventionNames': ['Other: web based education']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"The participants will be individuals who apply to the Allergy and Immunology Clinic of\\r\\nIstanbul Sureyyapasa Chest Diseases and Surgery Training and Research Hospital, have been\\r\\ndiagnosed with asthma for at least one year and agree to participate in the study. It\\r\\nwill consist of people who are between the ages of 18-65, understand Turkish, know how to\\r\\nread and write. Twenty five people selected by the randomization table method will be in\\r\\nthe control group. They will be given the Ministry of Health's asthma education brochure.\\r\\nAs in the intervention group, pre-test and post-test will be conducted.\",\n",
       "      'interventionNames': ['Other: Standard education brochure']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'web based education',\n",
       "      'description': 'Training presentations will be prepared in 5 modules by taking expert opinions in line\\r\\nwith the literature. Training will be aimed at empowering patients to control asthma. It\\r\\nwill include topics such as medication use, device use, exercise and disease management.\\r\\nEach week, an intervention group will be invited online to a module and the training will\\r\\nbe given by the researcher.',\n",
       "      'armGroupLabels': ['intervention group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Standard education brochure',\n",
       "      'description': 'The control group will not be given web-based training, but will be given the standard\\r\\nasthma education brochure of the Ministry of Health.',\n",
       "      'armGroupLabels': ['Control group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'patient empowerment scale (PES)',\n",
       "      'description': 'The scale consists of 37 items and five factors. Scale rating: 5-point Likert (1 =\\r\\nstrongly disagree - 5 = strongly agree) The score that can be obtained from the scale\\r\\nvaries between 37 and 185. As the score from the scale increases towards 5, patient\\r\\nempowerment is considered high, and as it decreases towards 1, patient empowerment is\\r\\nconsidered low.',\n",
       "      'timeFrame': 'five weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Asthma Control Test (ACT)',\n",
       "      'description': 'A self-administered questionnaire containing five items assessing frequency of shortness\\r\\nof breath, general asthma symptoms, use of rescue medications, impact of asthma on daily\\r\\nfunctioning, and overall self-assessment of asthma control. Each item contains five\\r\\nresponse options with values ranging from 1 to 5. An ACT score of <20 indicates\\r\\nuncontrolled asthma.',\n",
       "      'timeFrame': 'five weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Receiving treatment with a diagnosis of asthma for at least 1 year\\r\\n\\r\\n  -  Having severe asthma\\r\\n\\r\\n  -  Not having had any previous training\\r\\n\\r\\n  -  Being between the ages of 18-65,\\r\\n\\r\\n  -  Knowing how to read, write,\\r\\n\\r\\n  -  Volunteering to participate in research\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Having received treatment for less than 1 year\\r\\n\\r\\n  -  Being educated,\\r\\n\\r\\n  -  Not being at the level of severe asthma,\\r\\n\\r\\n  -  Not meeting the age criterion,\\r\\n\\r\\n  -  Not having the ability to understand, read and write Turkish',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Neslihan Komser',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+905514032996',\n",
       "      'email': '191002101@ogrenci.sbu.edu.tr'}],\n",
       "    'overallOfficials': [{'name': 'Neslihan Komser',\n",
       "      'affiliation': 'SUREYYAPASA CHEST DISEASES AND THORACIC SURGERY TRAINING AND RESEARCH HOSPITAL',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital',\n",
       "      'city': 'Istanbul',\n",
       "      'zip': '34854',\n",
       "      'country': 'Turkey',\n",
       "      'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001249',\n",
       "      'term': 'Asthma'}],\n",
       "    'ancestors': [{'id': 'D000001982', 'term': 'Bronchial Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000008173', 'term': 'Lung Diseases, Obstructive'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012130', 'term': 'Respiratory Hypersensitivity'},\n",
       "     {'id': 'D000006969', 'term': 'Hypersensitivity, Immediate'},\n",
       "     {'id': 'D000006967', 'term': 'Hypersensitivity'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M4556',\n",
       "      'name': 'Asthma',\n",
       "      'asFound': 'Asthma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5258', 'name': 'Bronchial Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M11170',\n",
       "      'name': 'Lung Diseases, Obstructive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'},\n",
       "     {'id': 'M14967',\n",
       "      'name': 'Respiratory Hypersensitivity',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10020',\n",
       "      'name': 'Hypersensitivity, Immediate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06409962',\n",
       "    'orgStudyIdInfo': {'id': '5345'},\n",
       "    'organization': {'fullName': 'Universidad de Córdoba', 'class': 'OTHER'},\n",
       "    'briefTitle': 'A New Technological Intervention to Address Childhood Obesity:',\n",
       "    'officialTitle': 'A New Technological Intervention to Address Childhood Obesity: Approach to Multidimensional Intervention',\n",
       "    'acronym': 'NURSPEDIAOBE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-12-12', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-17',\n",
       "    'studyFirstSubmitQcDate': '2024-05-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Pilar Aparicio Martinez',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'Universidad de Córdoba'},\n",
       "    'leadSponsor': {'name': 'Universidad de Córdoba', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Childhood obesity is a global public health issue, with rising prevalence rates. In\\r\\nSpain, the problem is significant, particularly in the southern regions. Factors\\r\\ncontributing to childhood obesity include dietary habits, lack of physical activity, and\\r\\nsocioeconomic influences.\\r\\n\\r\\nEfforts to address childhood obesity in Spain include various programs focusing on\\r\\ndietary modification, increased physical activity, and family involvement. Despite these\\r\\ninitiatives, there is a need for continued intervention, as changing dietary and\\r\\nlifestyle patterns have led to reduced fruit and vegetable consumption and increased\\r\\nsedentary behavior among children.\\r\\n\\r\\nChildhood obesity has concerning health implications, including heart-related issues.\\r\\nEchocardiography plays a vital role in early detection.\\r\\n\\r\\nGiven the limited research on the impact of childhood obesity on musculoskeletal\\r\\ndevelopment and mobility, a comprehensive study is needed to analyze its prevalence and\\r\\nassociated factors. The study aims to assess the effectiveness of nutritional\\r\\ninterventions administered by school nurses.\\r\\n\\r\\nIn summary, childhood obesity in Spain is a growing concern, with multifaceted causes and\\r\\nhealth implications. Ongoing efforts are required to combat this issue and promote\\r\\nhealthier lifestyles among children.',\n",
       "    'detailedDescription': 'An elevated Body Mass Index (BMI) in the child population represents a significant global\\r\\npublic health concern. According to the World Health Organization (WHO), overweight\\r\\noccurs in children aged 6-19 when the BMI exceeds one or more standard deviations from\\r\\nthe median established in WHO child growth patterns.\\r\\n\\r\\nEpidemiological data reflects that since the late 20th century, childhood obesity has\\r\\nincreased from 4.9% (31.5 million) to 6% (40.6 million) worldwide. According to data from\\r\\nthe Childhood Obesity Surveillance Initiative (COSI) within the European Union (EU),\\r\\nchildren in Spain aged 6-9 have a 42% overweight rate and a 19% obesity rate. In\\r\\ncomparison, girls have a 41% overweight rate and a 17% obesity rate, positioning Spain as\\r\\nthe fourth EU country with the highest prevalence of overweight and obesity in children.\\r\\n\\r\\nWithin the national territory, 4 out of 10 schoolchildren have excess weight, with the\\r\\nhighest prevalence in the southern regions. The autonomous community with the lowest\\r\\nincidence of childhood overweight is Navarra, with 15%, and the highest is the Region of\\r\\nMurcia, with 40%. Andalusians present a high prevalence rate of 33.4%. In general, the\\r\\ncountry\\'s northern regions have lower figures, while the southern region has the highest\\r\\nrates of childhood overweight. It has also been observed that there is a higher\\r\\nlikelihood of being overweight in rural areas than in urban areas.\\r\\n\\r\\nThis could be due to regional differences in habits during the three critical periods for\\r\\nthe development of childhood obesity: the preconception period involving maternal\\r\\nfactors, the first 1000 days of life (9 months of pregnancy + 2 years of life), and the\\r\\nadiposity rebound between 5-7 years. Childhood overweight is also highly influenced by\\r\\nfactors such as maternal overweight, early introduction of complementary feeding before 6\\r\\nmonths of age, smoking during pregnancy, low parental educational levels, and the\\r\\nexcessive use of screens such as mobile phones or tablets at an early age.\\r\\n\\r\\nThe most relevant factors in overweight are diet, physical inactivity, physical activity,\\r\\nand lifestyle habits. However, when it comes to minors, all these factors are strongly\\r\\ninfluenced by the cultural, social, and institutional environment, as well as the\\r\\nfamily\\'s socioeconomic level.\\r\\n\\r\\nIn Spain, Andalusia is one of the autonomous communities with a lower income index (0.67)\\r\\nand a lower average expenditure on public health at 0.33%. However, the community puts in\\r\\nthe most effort to implement policies against obesity, with a score of 5.19.\\r\\n\\r\\nNumerous campaigns have been launched to prevent childhood obesity, developed by the\\r\\nSpanish Agency for Consumer Affairs, Food Safety, and Nutrition (AECOSAN) as part of the\\r\\nnutrition, physical activity, and obesity prevention (NAOS) strategy. Additionally, the\\r\\nAndalusian Ministry of Health and Families has implemented plans such as \"Growing in\\r\\nHealth,\" \"Evaluation of Food Offer in Andalusian Schools 2019-2020,\" and the \"Health\\r\\nthroughout Life\" campaign.\\r\\n\\r\\nAll these programs coincide on three fundamental aspects when addressing childhood\\r\\nobesity: interventions to modify dietary habits promoting balanced and healthy eating,\\r\\nincreasing fruit and vegetable consumption while minimizing sugar intake; interventions\\r\\nto promote physical activity, encouraging at least one hour of exercise daily; and,\\r\\nlastly, family involvement interventions to achieve proper adherence to these changes.\\r\\n\\r\\nThese interventions are necessary today because, over the past decades, there have been\\r\\nchanges in eating patterns and diets, resulting in a decrease in the consumption of\\r\\nfruits, vegetables, legumes, and fresh products, as well as an increase in the\\r\\nconsumption of processed foods with higher sugar, fat, salt content, and poorer\\r\\nnutritional quality. According to COSI initiative data, Spain is where children consume\\r\\nthe least fruits and vegetables daily. There have also been changes in physical activity,\\r\\nwith studies showing that 25% of Spanish children are sedentary.\\r\\n\\r\\nOne of the direct consequences of childhood overweight is morphological heart\\r\\nalterations, reflected in left ventricular hypertrophy and cardiac diastolic alterations.\\r\\nNumerous scientific studies have established a close relationship between obesity in\\r\\nchildren and adolescents and an increase in epicardial fat, which can lead to cardiac and\\r\\nvascular abnormalities. In fact, having a high BMI at a young age has become a\\r\\nsignificant risk factor for the premature development of cardiovascular diseases that\\r\\nwere previously considered exclusive to adults. These changes are visible through\\r\\nechocardiography, especially in epicardial fat.\\r\\n\\r\\nAs a non-invasive diagnostic tool, Echocardiography has gained a fundamental role in\\r\\nearly detection of these alterations in the pediatric population affected by an increase\\r\\nin epicardial fat. Its early implementation allows for precise cardiac and vascular\\r\\nfunction assessment, improving these young patients\\' quality of life and prognosis. These\\r\\nmeasurements and modifications have been analyzed recently, although more data on younger\\r\\npopulations and post-pandemic needs to be collected. Furthermore, to address this growing\\r\\nchallenge, it is crucial to raise awareness about the importance of maintaining a healthy\\r\\nweight early and promote research and the application of preventive and intervention\\r\\nstrategies to reduce epicardial fat in the pediatric population.\\r\\n\\r\\nDue to all the aforementioned reasons, coupled with the limited number of current\\r\\npublications that deeply analyze the consequences of childhood obesity on the development\\r\\nof the musculoskeletal system and children\\'s mobility, it is essential to conduct a study\\r\\nof the population and subsequently intervene to promote healthy growth and development in\\r\\nchildren.\\r\\n\\r\\nTherefore, the objective is to establish the impact of a nutritional intervention by a\\r\\nschool nurse on a group of schoolchildren.'},\n",
       "   'conditionsModule': {'conditions': ['Body Weight',\n",
       "     'Dyslipidemias',\n",
       "     'Musculoskeletal Diseases'],\n",
       "    'keywords': ['pediatric',\n",
       "     'body mass index',\n",
       "     'intervention',\n",
       "     'anthopometric',\n",
       "     'blood pressure']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': \"Our proposed intervention, which integrates nutritional intervention with the use of\\r\\ninnovative technologies, holds significant potential for yielding tangible outcomes in\\r\\nthe prevention and management of this condition within the region. By doing so, it\\r\\nmitigates the risk of overweight and obesity-related pathologies in adulthood.\\r\\n\\r\\nThe inclusion of both experimental and control groups in the sample distribution will\\r\\nfacilitate an effective evaluation of the nutritional intervention, offering concrete\\r\\ndata on the efficacy of the implemented strategies. Furthermore, the comprehensive\\r\\nassessment encompassing anthropometric measurements, biometric data, and physical\\r\\nactivity records will provide a detailed understanding of the intervention's effects on\\r\\nthe school population.\",\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'The randomisation will be conducted based on an artificial model, utilising a coding\\r\\nsystem that assigns numerical identifiers to names, postal codes, and grade levels. This\\r\\napproach ensures a systematic and unbiased selection process, allowing for a fair\\r\\nrepresentation of participants across various demographic factors.\\r\\n\\r\\nThe sampling has been estimaited by Epidat program. The experimental group, receiving\\r\\nnutritional intervention, will consist of approximately 50% of the total sample,\\r\\nequivalent to 215 participants. Meanwhile, the control group, not receiving the\\r\\nintervention, will comprise the remaining 50% of the sample, also around 215\\r\\nparticipants. This distribution will enable an effective comparison of results between\\r\\nthe two groups and assess the effectiveness of the nutritional intervention.',\n",
       "      'whoMasked': ['INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 215, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Technological intervention',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The experimental arm integrates technology-based interventions-podcasts, gamification,\\r\\nand virtual reality-to promote nutritional education and healthy behaviors. Tailored\\r\\npodcasts cover topics like healthy eating habits and balanced nutrition, while\\r\\ngamification enhances motivation. Virtual reality offers immersive environments for\\r\\nexploring healthy choices. Both experimental and control groups enable a comprehensive\\r\\nevaluation, collecting data through measurements, biometrics, and activity records.',\n",
       "      'interventionNames': ['Other: Technological combination']},\n",
       "     {'label': 'No-technological intervention: traditional brochure',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'The control arm will focus on a non-technological intervention, specifically utilizing\\r\\ntraditional brochures. Participants in this arm will receive printed materials containing\\r\\ninformation on basic nutritional guidelines, healthy eating habits, and the importance of\\r\\nbalanced nutrition. The brochure-based intervention aims to provide essential information\\r\\nin a straightforward format, emphasizing key messages related to healthy eating\\r\\npractices. Participants will have access to pamphlets outlining dietary recommendations,\\r\\nportion control, and tips for making nutritious food choices.'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Technological combination',\n",
       "      'description': 'The intervention comprises workshops, individualized counseling, cooking classes, and\\r\\nphysical activity promotion. It emphasizes nutritional education, hands-on cooking, and\\r\\nbehavioral modification techniques. Participants receive personalized guidance and\\r\\nresources to make sustainable dietary and lifestyle changes. Social support networks\\r\\nfoster motivation and accountability. By combining these components, the intervention\\r\\naims to empower participants with the knowledge, skills, and support needed for long-term\\r\\nhealth improvements.',\n",
       "      'armGroupLabels': ['Technological intervention'],\n",
       "      'otherNames': ['Impact of technology on healthy lifestyle']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Weight (kg)',\n",
       "      'description': \"Weight, as a pivotal anthropometric measure, will be quantified using a validated weight\\r\\nmachine, alongside a body composition monitor such as the BF511. The validated weight\\r\\nmachine adheres to established calibration standards, ensuring precision and consistency\\r\\nin measurements. It employs advanced technology to accurately assess an individual's\\r\\nweight in kilograms (kg), providing reliable data for scientific analyses.\",\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Height (m2)',\n",
       "      'description': 'Height will be registered in meters squared (m^2) for its precise evaluation. Employing a\\r\\nvalidated tachymeter, a specialized instrument designed for accurate measurements,\\r\\nensures meticulous assessment of height.',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Percentage Lean Mass (LM) (%)',\n",
       "      'description': 'The lean fat, calculated in percentage, will be obtained using a validated weight\\r\\nmachine, alongside a body composition monitor such as the BF511.',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Percentage Fat Mass (FM) (%)',\n",
       "      'description': 'The lean fat, calculated in percentage, will be obtained using a validated weight\\r\\nmachine, alongside a body composition monitor such as the BF511.',\n",
       "      'timeFrame': '1st month, 3 month, 6 month, 9 month, 12th and 15th month'},\n",
       "     {'measure': 'Body Mass Index (kg/m2)',\n",
       "      'description': 'The Body Mass Index will be calculated using the percentiles according to age group and\\r\\nsex.',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Waist circumference (cm)',\n",
       "      'description': 'The waist circumference (cm) of the children will be measured via an inextensible\\r\\nmeasuring tape at the initial visit (1st month or V0) and at the last visit (15th month\\r\\nor V6).The measurement follows the recommendations of the International Standards for\\r\\nAnthropometric Assessment',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Hip circumference(cm)',\n",
       "      'description': 'The Hip circumference(cm) of the children will be measured via an inextensible measuring\\r\\ntape at the initial visit (1st month or V0) and at the last visit (15th month or V6).The\\r\\nmeasurement follows the recommendations of the International Standards for Anthropometric\\r\\nAssessment',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Arm circumference (cm)',\n",
       "      'description': 'The arm circumference (cm) of the children will be measured via an inextensible measuring\\r\\ntape at the initial visit (1st month or V0) and at the last visit (15th month or V6).The\\r\\nmeasurement follows the recommendations of the International Standards for Anthropometric\\r\\nAssessment',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Calf circumference (cm)',\n",
       "      'description': 'The arm circumference (cm) of the children will be measured via an inextensible measuring\\r\\ntape at the initial visit (1st month or V0) and at the last visit (15th month or V6).The\\r\\nmeasurement follows the recommendations of the International Standards for Anthropometric\\r\\nAssessment',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Validated nutritional assessment questionnaire: adherence to the Mediterranean diet (KIDMED)',\n",
       "      'description': 'he KIDMED will be used to determine adherence to the change in diet from the initial\\r\\nvisit (V0) and the final visit (V6). This questionnaire is formed by 16 questions related\\r\\nto adherence to the Mediterranean diet, in addition to 7 items complementary to the test.\\r\\nAll questions were answered positively or negatively. Of the 16 main questions, questions\\r\\nnumber 6, 11, 14, and 16, in their affirmative answers had a negative meaning, so they\\r\\nwere worth (-1), on the other hand, the remaining questions whose affirmative answers\\r\\nrepresented a positive value concerning the Mediterranean diet were scored with (+1).\\r\\nNegative responses do not score (0). According to the test, the results are grouped into\\r\\ndifferent levels of adherence to the Mediterranean diet, low (score 0 to 3), medium\\r\\n(score 4-7), and high (8 to 12).',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Food Consumption Frequency',\n",
       "      'description': 'Food Frequency Questionnaire (FFQ) will be used to determine the consumption of food and\\r\\nthe change in diet from the initial visit (V0) and the final visit (V6). Energy and\\r\\nnutrient intakes were calculated using Spanish food composition tables\\r\\n\\r\\nFood consumption frequency refers to the rate at which individuals consume different\\r\\ntypes of food within a specific time frame, typically measured over a day, week, or\\r\\nmonth. This variable captures the frequency with which individuals consume various food\\r\\ngroups, such as fruits, vegetables, grains, proteins, and processed foods. It provides\\r\\ninsight into dietary patterns and habits, indicating how often individuals incorporate\\r\\ndifferent foods into their regular eating routines.',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'},\n",
       "     {'measure': 'Blood pressure',\n",
       "      'description': 'The systolic and diastolic blood pressure will be taken using an Omron-validated\\r\\ntensiometer with two measurements between 15 minutes each measurement from the 1st visit\\r\\n(v0) to the last (v6).',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'}],\n",
       "    'secondaryOutcomes': [{'measure': '3D avatar system for anthropometric measures',\n",
       "      'description': 'The validation of avatar systems based on artificial vision involves assessing the\\r\\naccuracy, reliability, and effectiveness of virtual representations controlled by\\r\\nartificial intelligence algorithms. These avatars, generated using artificial vision\\r\\ntechnology, mimic human-like behavior and interactions within virtual environments.\\r\\nValidation encompasses rigorous testing to ensure that avatars accurately interpret and\\r\\nrespond to visual inputs, such as facial expressions or gestures, in a manner consistent\\r\\nwith human perception.\\r\\n\\r\\nThe validation of avatar systems based on artificial vision involves assessing the\\r\\naccuracy, reliability, and effectiveness of virtual representations controlled by\\r\\nartificial intelligence algorithms. The results of the model will provide, using the\\r\\nheight and weight previously measured with the Body Composition validated weight scale,\\r\\nwill be obtained the arm, waist, calf and arm circumferences.',\n",
       "      'timeFrame': 'From 12 weeks (1st measurement) up 15th months (6th measurement)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Students from the school\\r\\n\\r\\n  -  Pediatric from age 6 to 16\\r\\n\\r\\n  -  Students from the school that confirmed approval\\r\\n\\r\\n  -  Signed informed consent by the minor\\r\\n\\r\\n  -  Signed informed consent by the minor's parents or guardians.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Presence of HbA1c levels below 5.7%\\r\\n\\r\\n  -  Presence of HbA1c levels above 6.4%\\r\\n\\r\\n  -  Presence of pathological metabolic diseases, such as diabetes or metabolic syndrome\\r\\n\\r\\n  -  Presence of other diseases related to intestinal integrity or skin issues.\\r\\n\\r\\n  -  Lack of the signed informed consent by the minor and legal guardian\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '6 Years',\n",
       "    'maximumAge': '16 Years',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Manuel J Guzmán Roldán, Msc',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0034 957482125',\n",
       "      'email': 'jefaturadeprimaria@colegiovirgendelcarmen.com'}],\n",
       "    'overallOfficials': [{'name': 'Manuel Vaquero Abellan, MD, Msc, PhD',\n",
       "      'affiliation': 'Universidad de Córdoba',\n",
       "      'role': 'STUDY_DIRECTOR'},\n",
       "     {'name': 'Manuel Vaquero Alvárez, MD, Msc, PhD',\n",
       "      'affiliation': 'Maimónides Biomedical Research Institute of Córdoba',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Isabel Blancas Sanchez, MD, Msc, PhD',\n",
       "      'affiliation': 'Primary Care, Jaen',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '36079871',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Blancas-Sanchez IM, Del Rosal Jurado M, Aparicio-Martinez P, Quintana Navarro G, Vaquero-Abellan M, Castro Jimenez RA, Fonseca Pozo FJ. A Mediterranean-Diet-Based Nutritional Intervention for Children with Prediabetes in a Rural Town: A Pilot Randomized Controlled Trial. Nutrients. 2022 Sep 1;14(17):3614. doi: 10.3390/nu14173614.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'The data of the participants will be made available to other researchers under\\r\\nconsideration and analysis of the research committee.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009140',\n",
       "      'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000050171', 'term': 'Dyslipidemias'},\n",
       "     {'id': 'D000063766', 'term': 'Pediatric Obesity'},\n",
       "     {'id': 'D000001835', 'term': 'Body Weight'}],\n",
       "    'ancestors': [{'id': 'D000009765', 'term': 'Obesity'},\n",
       "     {'id': 'D000050177', 'term': 'Overweight'},\n",
       "     {'id': 'D000044343', 'term': 'Overnutrition'},\n",
       "     {'id': 'D000009748', 'term': 'Nutrition Disorders'},\n",
       "     {'id': 'D000052439', 'term': 'Lipid Metabolism Disorders'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'},\n",
       "     {'id': 'M30155',\n",
       "      'name': 'Pediatric Obesity',\n",
       "      'asFound': 'Childhood Obesity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5114',\n",
       "      'name': 'Body Weight',\n",
       "      'asFound': 'Body Weight',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26181',\n",
       "      'name': 'Dyslipidemias',\n",
       "      'asFound': 'Dyslipidemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12097',\n",
       "      'name': 'Musculoskeletal Diseases',\n",
       "      'asFound': 'Musculoskeletal Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26186', 'name': 'Overweight', 'relevance': 'LOW'},\n",
       "     {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'},\n",
       "     {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27029',\n",
       "      'name': 'Lipid Metabolism Disorders',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06436391',\n",
       "    'orgStudyIdInfo': {'id': 'He1'},\n",
       "    'organization': {'fullName': 'Nigde Omer Halisdemir University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effectiveness of Two Different Methods in Heel Blood Collection',\n",
       "    'officialTitle': 'Effect of Kinesio Tape and ShotBlocker on Pain, Comfort and Crying Duration in Heel Blood Collection in Infants: Randomized Controlled Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-10-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Nigde Omer Halisdemir University',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Selcuk University', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study aims to evaluate the effectiveness of 2 non-pharmacological methods that will\\r\\nreduce the traumatizing effect of routine heel pricking in infant babies within the scope\\r\\nof the metabolic endocrine screening program. One of the interventions to be used in the\\r\\nstudy is kinesio taping, a type of taping that does not contain any medication. Another\\r\\nintervention is Shotblocker, which does not belong to any drug or device group.',\n",
       "    'detailedDescription': \"Studies on pain indicate that severe pain experienced in the early period of life causes\\r\\na weakening of the cognitive functions of the infant, especially by shrinking the\\r\\nthalamic volume. Pain management in the neonatal period aims to help the infant cope with\\r\\npain by relieving it. For effective pain management, it is very important to diagnose and\\r\\nevaluate the baby's response to pain early and accurately within a multidisciplinary team\\r\\napproach, and to select appropriate interventions to alleviate the pain experience. It is\\r\\nstated that nonpharmacological methods in relieving procedural pain strengthen the baby's\\r\\nnatural regulation and coping mechanisms when faced with painful intervention and reduce\\r\\npain and stress. For this reason, this study aimed to determine the effect of kinesiology\\r\\ntaping and ShotBlocker applied to the heel during heel blood collection in infant babies\\r\\non pain, comfort and crying time.\"},\n",
       "   'conditionsModule': {'conditions': ['Infant Behavior', 'Pain'],\n",
       "    'keywords': ['Pain Management', 'Kinesiotape', 'Nursing', 'Therapy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'The study will be conducted with infants of mothers who meet the inclusion criteria and\\r\\nagree to participate in the study. After explaining the study to the parents, the study\\r\\nwill start after obtaining their verbal and written consent. Randomization will be random\\r\\nassignment to a control group or two intervention groups (1:1:1) with sequentially\\r\\nnumbered, sealed, opaque envelopes containing randomly generated numbers after mothers\\r\\nhave obtained informed consent. Randomization will be carried out via www.random.org\\r\\nusing a table of random numbers. This will be done by an independent statistician and\\r\\nenvelopes will be given to the researchers',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Single Blinded for mothers',\n",
       "      'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 72, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Kinesio tape group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'To the infants in the experimental group; Kinesio tape application will be performed by\\r\\nan experienced physiotherapist whom has a M.Sc. degree and kinesio tape certificate.',\n",
       "      'interventionNames': ['Other: Kinesio taping']},\n",
       "     {'label': 'ShotBlocker group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'To the infants in the second experimental group; Shotblocker application will be\\r\\nperformed by another researcher.',\n",
       "      'interventionNames': ['Other: ShotBlocker']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'These infants will not receive any intervention in the heel prick procedure. Routine heel\\r\\nblood collection will be performed.'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Kinesio taping',\n",
       "      'description': \"Kinesio taping will be applied to the lateral part of the baby's heel to increase blood\\r\\nflow. Blood collection will always be performed by the same nurse\",\n",
       "      'armGroupLabels': ['Kinesio tape group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'ShotBlocker',\n",
       "      'description': \"Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal\\r\\npressure.\",\n",
       "      'armGroupLabels': ['ShotBlocker group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Determining the descriptive characteristics of infants',\n",
       "      'description': '1-Infant Introduction Form The questionnaire created by the researchers consisted of a\\r\\ntotal of 10 questions including infant gender, gestational age, postnatal age, birth\\r\\nweight and some demographic characteristics.',\n",
       "      'timeFrame': 'Average 5 minutes'},\n",
       "     {'measure': 'Follow-up of infants',\n",
       "      'description': '2- Infant Follow-up Form: This form is the form to record the duration of the procedure\\r\\nand the duration of crying.',\n",
       "      'timeFrame': 'Average 5 minutes'},\n",
       "     {'measure': 'The effect of Kinesio tape and ShotBlocker on pain',\n",
       "      'description': '3- Neonatal Infant Pain Scale (NIPS):This scale, which was developed in 1993 to evaluate\\r\\nbehavioral and physiological pain responses of preterm and term infants, was adapted into\\r\\nTurkish in 1999. A high score indicates that the severity of pain.',\n",
       "      'timeFrame': 'Average 5 minutes'}],\n",
       "    'secondaryOutcomes': [{'measure': \"The effect of Kinesio tape and ShotBlocker application in infants in the experimental groups' comfort .\",\n",
       "      'description': '1-COMFORTneo scale: The scale was revised under the name COMFORTneo scale and its\\r\\nvalidity and reliability were established. COMFORTneo measures only behavioral parameters\\r\\nin the newborn without physiological parameters. It is Likert-type and evaluates the\\r\\ncomfort needs, pain and distress of newborns followed up in intensive care. The lowest\\r\\nscore that can be obtained from the scale is 6 and the highest score is 30. As the score\\r\\nincreases, it is understood that the baby is not comfortable and needs interventions to\\r\\nprovide comfort.',\n",
       "      'timeFrame': 'Average 5 minutes'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Term birth infants,\\r\\n\\r\\n  -  Infants with a birth weight of 2500 g and above\\r\\n\\r\\n  -  Infants with stable clinical condition\\r\\n\\r\\n  -  Infants who can perform vital functions without support,\\r\\n\\r\\n  -  Infants who were fed, calm and not crying within one hour before the procedure will\\r\\n     be included.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  With a genetic or congenital anomaly,\\r\\n\\r\\n  -  Neurological, cardiological and metabolic diseases,\\r\\n\\r\\n  -  In need of respiratory support,\\r\\n\\r\\n  -  Infants receiving analgesics, antiepileptics before the procedure will be excluded.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '38 Weeks',\n",
       "    'maximumAge': '41 Months',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Hilal KURT SEZER, Ph.D.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+903882112815',\n",
       "      'email': 'hilalkurt26@hotmail.com'},\n",
       "     {'name': 'Saltuk Gazi SESIGUZEL, M.Sc.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+903882112815',\n",
       "      'email': 'saltuksesiguzel@ohu.edu.tr'}],\n",
       "    'overallOfficials': [{'name': 'Sibel KUCUKOGLU, Ph.D.',\n",
       "      'affiliation': 'Selcuk University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '27964912',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Chik YM, Ip WY, Choi KC. The Effect of Upper Limb Massage on Infants' Venipuncture Pain. Pain Manag Nurs. 2017 Feb;18(1):50-57. doi: 10.1016/j.pmn.2016.10.001. Epub 2016 Dec 10.\"},\n",
       "     {'pmid': '3317037',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 1987 Nov 19;317(21):1321-9. doi: 10.1056/NEJM198711193172105. No abstract available.'},\n",
       "     {'pmid': '28779961',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Erkut Z, Yildiz S. The Effect of Swaddling on Pain, Vital Signs, and Crying Duration during Heel Lance in Newborns. Pain Manag Nurs. 2017 Oct;18(5):328-336. doi: 10.1016/j.pmn.2017.05.007. Epub 2017 Aug 2.'},\n",
       "     {'pmid': '28160271',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Foster JP, Taylor C, Spence K. Topical anaesthesia for needle-related pain in newborn infants. Cochrane Database Syst Rev. 2017 Feb 4;2(2):CD010331. doi: 10.1002/14651858.CD010331.pub2.'},\n",
       "     {'pmid': '35572360',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Harvey EG. Kinesio taping to address post-sternotomy scars in pediatric patients: A case report. Scars Burn Heal. 2022 May 11;8:20595131221095355. doi: 10.1177/20595131221095355. eCollection 2022 Jan-Dec.'},\n",
       "     {'pmid': '27883227',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Kurdahi Badr L, Demerjian T, Daaboul T, Abbas H, Hasan Zeineddine M, Charafeddine L. Preterm infants exhibited less pain during a heel stick when they were played the same music their mothers listened to during pregnancy. Acta Paediatr. 2017 Mar;106(3):438-445. doi: 10.1111/apa.13666. Epub 2016 Dec 13.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'It will be shared after the article is published'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M13066',\n",
       "      'name': 'Pain',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419569',\n",
       "    'orgStudyIdInfo': {'id': 'P.T.REC/012/003450'},\n",
       "    'organization': {'fullName': 'Cairo University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Efficacy of High Power Laser Versus Low Level Laser in Ultrasonographic and Functional Outcomes in Patients With Knee Osteoarthritis',\n",
       "    'officialTitle': 'Efficacy of High Power Laser Versus Low Level Laser in Ultrasonographic and Functional Outcomes in Patients With Knee Osteoarthritis',\n",
       "    'acronym': 'OA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-15', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-15', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-14',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Nabil Mahmoud Ismail Abdel-Aal',\n",
       "     'investigatorTitle': 'principle investigator nabil mahmoud ismail abdel-aal',\n",
       "     'investigatorAffiliation': 'Cairo University'},\n",
       "    'leadSponsor': {'name': 'Cairo University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'this study will be conducted to compare between high power laser and low-intensity laser\\r\\non ultrasonographic and functional outcomes in patients with knee osteoarthritis',\n",
       "    'detailedDescription': 'Osteoarthritis (OA) is a major source of pain, disability, and socioeconomic cost\\r\\nworldwide. The epidemiology of the disorder is complex and multifactorial, with genetic,\\r\\nbiological, and biomechanical components. It is estimated that 63 to 85 percent of\\r\\nAmericans over age 65 have radiographic signs of OA and that 35 to 50 percent have\\r\\nsymptoms of pain, stiffness or limitation of motion. Between 9 and 12 percent of elderly\\r\\nAmericans (approximately 3 million people) have enough impairment from OA that they\\r\\ncannot perform their major activities, and half of these individuals are totally disabled\\r\\n(confined to bed or a wheelchair). High power laser therapy (HPL) that involves\\r\\nhigher-intensity laser radiation is a new, painless, and powerful modality that showed\\r\\nsignificant results in pain reduction. One of the modalities commonly used by clinicians\\r\\nwas Low Level Laser Therapy introduced as an alternative, safe and non-invasive treatment\\r\\nfor OA about 30 years ago.A more recent systemic review investigated the effects of\\r\\nlow-level and high-intensity laser therapy as adjunctive to rehabilitation exercise on\\r\\npain, stiffness and function in knee osteoarthritis and concluded that Both LLLT and HPL\\r\\nare beneficial as adjuncts to rehabilitation exercise in the management of knee OA. Based\\r\\non an indirect comparison, the HPL and exercise seems to have higher efficacy in reducing\\r\\nknee pain and stiffness, and in increasing function. To confirm this finding, a direct\\r\\ncomparative investigation of the two types of laser therapy may be necessary. ninety\\r\\npatients with knee osteoarthritis will be assigned randomly to three groups; the first\\r\\nexperimental will receive high power laser plus conventional physical therapy, second one\\r\\nwill receive low-intensity laser and traditional physical therapy, finally, the third\\r\\ngroup will receive traditionally therapy only'},\n",
       "   'conditionsModule': {'conditions': ['Knee Osteoarthritis'],\n",
       "    'keywords': ['High Power Laser',\n",
       "     'Low Level Laser',\n",
       "     'Ultrasonographic changes',\n",
       "     'Knee Osteoarthritis']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'high power laser and low level laser',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'maskingDescription': 'opaque sealed envelop',\n",
       "      'whoMasked': ['INVESTIGATOR', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'high power laser',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'thirty patients will receive high-power laser and conventional physical therapy three\\r\\ntimes a week for eight weeks',\n",
       "      'interventionNames': ['Other: high power laser',\n",
       "       'Other: conventional physical therapy']},\n",
       "     {'label': 'low level laser',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'thirty patients will receive low level laser and conventional physical therapy three\\r\\ntimes a week for eight weeks',\n",
       "      'interventionNames': ['Other: low level laser',\n",
       "       'Other: conventional physical therapy']},\n",
       "     {'label': 'conventional physical therapy',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'thirty patients will receive conventional physical therapy three times a week for eight\\r\\nweeks',\n",
       "      'interventionNames': ['Other: conventional physical therapy']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'high power laser',\n",
       "      'description': 'Sessions will performed with scanning in longitudinal and perpendicular direction on the\\r\\nmedial and lateral sides of the knee with Laser scanner machine. handpiece was positioned\\r\\nin contact and perpendicularly while the patient in a supine lying position with the knee\\r\\nflexed at 30° to open the joint surfaces to the laser beam (optical windows). The\\r\\nscanning was performed transversely and longitudinally in the anterior, medial, and\\r\\nlateral aspects of the knee joint with emphasis on the application on the joint line\\r\\nbetween the tibial and femoral epicondyles. The total energy delivered to the patient\\r\\nduring one session was 1,250 J through three phases of treatment. The initial phase is\\r\\nperformed with fast manual scanning with a total of 500 J. In the initial phase, the\\r\\nlaser fluency is set to two successive subphases of 710 and 810 mJ/cm2 for a total of 500\\r\\nJ.',\n",
       "      'armGroupLabels': ['high power laser']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'low level laser',\n",
       "      'description': 'patients will receive laser with 0.5 W to gain energy density of 6 J/cm2, and total\\r\\nenergy of 240 J during one session. LASER apparatus that will be used is Chattanoga\\r\\nIntelect Laser with 850nm wavelength and 200mW power Lasers. Same three phases like HPL\\r\\nwith different energy dose. First phase: Fast manual scan 100 J. Second 10 point joint\\r\\nline phase with evey point 14 seconds and 4J to deliver a total of 40 J in this phase.\\r\\nThird phase: Slow manual scan 100 J.',\n",
       "      'armGroupLabels': ['low level laser']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'conventional physical therapy',\n",
       "      'description': 'the patients will receive conventiobal physical therapy in the form of Exercise therapy\\r\\nprogram (1) Warm-up exercises: Walking at the usual speed on a flat surface for 10 min\\r\\nwith hamstring and calf gentle stretches.(2) Major exercises for knee OA: Straight leg\\r\\nraise, quadriceps setting, heel raise, one leg balance, step ups, and quadriceps\\r\\nstrengthening exercises. The US protocol consists of continuous ultrasonic waves of 1 MHz\\r\\nfrequency and 1 W/cm2 intensity applied with a 5-cm diameter applicator. The patients\\r\\nwill be placed in a supine position, and the US applied to the medial and lateral parts\\r\\n(5 min on each side) of the knee in circular movements with the probe at right angles to\\r\\nensure maximum absorption of the energy.',\n",
       "      'armGroupLabels': ['conventional physical therapy',\n",
       "       'high power laser',\n",
       "       'low level laser']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'osteophyte diameter',\n",
       "      'description': 'ultrasonographe device will be used to assess the osteophyte diameter',\n",
       "      'timeFrame': 'up to eight weeks'},\n",
       "     {'measure': 'hyaline cartilage thickness assessment',\n",
       "      'description': 'utrasonographe device will be used to assess hyaline cartilage thickness',\n",
       "      'timeFrame': 'up to eight weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'knee function',\n",
       "      'description': 'Knee Injury and Osteoarthritis Outcome Score questionnaire will be used to assess knee\\r\\nfunction.five patient-relevant subscales of KOOS are scored separately: Pain (nine\\r\\nitems); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function\\r\\n(five items); Quality of Life (four items). A Likert scale is used and all items have\\r\\nfive possible answer options scored from 0 (No Problems) to 4 (Extreme Problems) and each\\r\\nof the five scores is calculated as the sum of the items included. Scores are transformed\\r\\nto a 0-100 scale, with zero representing extreme knee problems and 100 representing no\\r\\nknee problems as common in orthopaedic assessment scales and generic measures. Scores\\r\\nbetween 0 and 100 represent the percentage of total possible score achieved.',\n",
       "      'timeFrame': 'up to eight weeks'},\n",
       "     {'measure': 'pain intensity',\n",
       "      'description': 'Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line\\r\\nbetween the \"no pain\" anchor and the patient\\'s mark, providing a range of scores from\\r\\n0-100. A higher score indicates greater pain intensity. The following cut points on the\\r\\npain VAS have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain\\r\\n(45-74 mm), and severe pain (75-100 mm)',\n",
       "      'timeFrame': 'up to eight weeks'},\n",
       "     {'measure': 'knee range of motion',\n",
       "      'description': 'digital goniometer will be used to assess knee range of motion',\n",
       "      'timeFrame': 'up to eight weeks'},\n",
       "     {'measure': 'pressure pain threshold',\n",
       "      'description': 'algometer will be used to assess pressure pain threshold',\n",
       "      'timeFrame': 'up to eight weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  X-ray stages II and III osteoarthritis\\r\\n\\r\\n  -  Age between 45 and 75 years.\\r\\n\\r\\n  -  BMI equal to or less than 35.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Unwillingness to participate in the study.\\r\\n\\r\\n  -  Uncompleted evaluation/treatment programs.\\r\\n\\r\\n  -  Any damage to the knee joint during the study.\\r\\n\\r\\n  -  Using any treatment other than prescribed therapeutic protocols.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '45 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'mohamed H abdo, doctoral',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01007433819',\n",
       "      'email': 'theorymtc@gmail.com'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010003',\n",
       "      'term': 'Osteoarthritis'},\n",
       "     {'id': 'D000020370', 'term': 'Osteoarthritis, Knee'}],\n",
       "    'ancestors': [{'id': 'D000001168', 'term': 'Arthritis'},\n",
       "     {'id': 'D000007592', 'term': 'Joint Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000012216', 'term': 'Rheumatic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12926',\n",
       "      'name': 'Osteoarthritis',\n",
       "      'asFound': 'Osteoarthritis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22168',\n",
       "      'name': 'Osteoarthritis, Knee',\n",
       "      'asFound': 'Knee Osteoarthritis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4476', 'name': 'Arthritis', 'relevance': 'LOW'},\n",
       "     {'id': 'M10621', 'name': 'Joint Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15045', 'name': 'Rheumatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6323', 'name': 'Collagen Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419972',\n",
       "    'orgStudyIdInfo': {'id': 'UV_Menopause'},\n",
       "    'organization': {'fullName': 'University of Valencia', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Multimodal Program for Climacteric Women',\n",
       "    'officialTitle': 'Effectiveness of a Combined Education and Exercise Program on the Physical, Functional and Psychological Status of Climacteric Women.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-25', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-02-28', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Laura Fuentes Aparicio',\n",
       "     'investigatorTitle': 'Assistant Professor of Physiotherapy',\n",
       "     'investigatorAffiliation': 'University of Valencia'},\n",
       "    'leadSponsor': {'name': 'University of Valencia', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Your study seems to aim at emphasizing the significance of non-pharmacological and\\r\\nnon-hormonal approaches in managing menopausal symptoms, particularly focusing on muscle\\r\\ntraining and education. This holistic approach acknowledges the importance of physical\\r\\nwell-being, psychological support, and education to enhance women's quality of life\\r\\nduring the menopausal transition.\",\n",
       "    'detailedDescription': \"Climacteric is a time of great transition for all women physically, mentally, and\\r\\nemotionally . This transition involves a host of physical, endocrine, and psychological\\r\\nchanges that are influenced by ethnic, psychological, and sociocultural factors . Each\\r\\nwoman's experience of the menopausal transition is unique; therefore, a one-size-fits-all\\r\\napproach to symptom management is not sufficient .\\r\\n\\r\\nMenopause is a retrospective diagnosis and is said to occur when menstrual activity has\\r\\nceased for at least 12 consecutive months with no other physiologic or pathologic\\r\\nexplanation for it . It marks the end of reproductive life and ovarian follicular\\r\\nactivity by the onset of an estrogen deficiency that triggers various symptoms .\\r\\n\\r\\nThe main symptoms aggregated according to the Menopause Rating Score MRS include somatic\\r\\nsymptoms [vasomotor symptoms (hot flashes and night sweats), sleeping difficulties,\\r\\nfatigue, palpitations, joint pain, worsening muscle ability and function, skin/eye\\r\\ndryness, and skin and hair changes], psychological [mental confusion, mood swings,\\r\\nincreased anxiety, irritability], and urogenital [genitourinary syndrome symptoms\\r\\n(vaginal dryness, dyspareunia, irritation, itching, sexual dysfunction), bladder symptoms\\r\\n(altered frequency, level of urgency and incontinence).\\r\\n\\r\\nFocusing on the musculature and ligaments, we must also think about the tissues of the\\r\\npelvic floor muscle (PFM), which are affected by the drop in estrogen levels, due to the\\r\\nexistence of estrogen receptors in ligaments, musculature and pelvic support structures.\\r\\nThe pelvic floor as a whole has an important role in supporting the organs of the pelvic\\r\\ncavity and is involved in the closing and opening mechanisms of the urethral, vaginal and\\r\\nanal tract . Taking this into account, what can be worked on voluntarily is the\\r\\nmusculature.\\r\\n\\r\\nThis estrogenic variation is also responsible for the onset of cardiovascular disease\\r\\nduring the menopausal period, which is characterized by variations in the lipid profile\\r\\nand the predominant accumulation of abdominal fat.\\r\\n\\r\\nTreatments to treat menopausal symptoms include hormonal preparations, non-hormonal\\r\\nmedications and non-pharmacological therapies. The latter two, non-pharmacological and\\r\\nnon-hormonal therapies are generally the least studied.\\r\\n\\r\\nOn genitourinary and urinary syndrome symptoms, the musculature has a fundamental role,\\r\\nand working on it will produce improvements in these factors. By training the pelvic\\r\\nfloor muscle (PFM) there is a greater blood supply, which this will lead to a relaxation\\r\\nof the tissues and an increase in elasticity that will help in the genitourinary\\r\\nsyndrome; and on the other hand, its training, increasing strength, will improve the\\r\\ncontrol and efficacy of the closing and opening of the urethral, vaginal and anal tracts\\r\\n.\\r\\n\\r\\nOn the other hand, physical activity will help in weight loss and improve body\\r\\ncomposition parameters .\\r\\n\\r\\nIt should be noted that the information provided to women influences the understanding\\r\\nand how menopause and its symptoms are faced, being relevant to provide knowledge and\\r\\neducation by the general practitioner or a qualified health personnel.\\r\\n\\r\\nTherefore, this study seeks to expand the information on non-pharmacological and\\r\\nnon-hormonal therapies, such as active training of the pelvic floor muscle, generic\\r\\nmuscle training and education, due to their potential efficacy.\"},\n",
       "   'conditionsModule': {'conditions': ['Climacteric Syndrome',\n",
       "     'Postmenopausal Symptoms',\n",
       "     'Menopause',\n",
       "     'Perimenopausal Disorder'],\n",
       "    'keywords': ['perimenopause',\n",
       "     'climacteric',\n",
       "     'Postmenopause',\n",
       "     \"women's health\"]},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 115, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Experimental',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'They will receive multimodal physiotherapy programme, which will combine therapeutic\\r\\nexercise based in general strength exercise combined with a pelvic floor education\\r\\nprogram.',\n",
       "      'interventionNames': ['Other: multimodal physiotherapy programme']},\n",
       "     {'label': 'Control',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'They will not receive any type of intervention'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'multimodal physiotherapy programme',\n",
       "      'description': 'The intervention to which the climacteric women will be subjected will consist of a\\r\\ncombined program of education and general strength and pelvic floor muscles exercises of\\r\\n8 weeks duration, at a rate of 2 sessions/week. Each of the sessions will last 60 min,\\r\\nexcept for the first one, which will be 90 min.',\n",
       "      'armGroupLabels': ['Experimental']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Upper limb muscle strength',\n",
       "      'description': 'For performed the upper limb muscle strength (kg) evaluation will use different\\r\\ndynamometry test\\r\\n\\r\\nDynamometry of Upper limb muscle: using the Hand grip strength (stable position - elbow\\r\\n90º and arm in contact with the trunk , hold dynamometer with the hand and perform\\r\\nmaximum grip force for 5seconds.',\n",
       "      'timeFrame': '8 weeks (2 assessment times: T1(pre-intervention), T2 (Immediately post-intervention)and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Lower limb muscle strength',\n",
       "      'description': 'The quadriceps dynamometry test (Lafayette Instrument) will be used to evaluate the\\r\\nmuscular strength of the lower extremities, the unit of measure will be. The Lafayette\\r\\nmeasuring range is 0-300 lbs (136.1 kg/1335 N).',\n",
       "      'timeFrame': '8 weeks (2 assessment times: T1(pre-intervention), T2 (Immediately post-intervention)and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Trunk flexor isometric strength',\n",
       "      'description': 'For the isometric strength of the trunk flexors, the central dynamometry test (Lafayette\\r\\nInstrument) will be used: the patient will be in the supine position with the knees\\r\\nstraight, the hips flexed at 30° and the trunk at 30°; placing the dynamometer on the\\r\\nsternum, below the suprasternal notch, the participants should place their hands on the\\r\\nopposite acromion processes.The Lafayette measuring range is 0-300 lbs (136.1 kg/1335 N).',\n",
       "      'timeFrame': '8 weeks (2 assessment times: T1(pre-intervention), T2 (Immediately post-intervention)and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Abdominopelvic muscle function',\n",
       "      'description': 'The Supine Bridge Test involves lying on a mat with knees and hips flexed, lifting the\\r\\npelvis off the floor for alignment. The Prone Bridge requires lying face down on elbows,\\r\\nlifting the pelvis so only forearms and toes touch the floor. In the Side Bridge, one\\r\\nlies on their side, supporting the body with elbow, forearm, and feet while lifting the\\r\\nhips. Participants hold each position as long as possible to assess core strength and\\r\\nstability.',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention)and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Abdominal ultrasound image',\n",
       "      'description': 'Will be measure abdominal wall thickness at rest and during a draw-in maneuver for\\r\\nTransversus abdominis (TrA), obliquus internus (IO), and obliquus externus (EO) on the\\r\\ndominant side. Subjects will lie supine with hips and knees flexed. Using a 5.3-10\\r\\nMegaHertz (MHz) linear probe, the transducer will be centered transversely just above the\\r\\niliac crest at the umbilical level and aligned with the axillary midline. Three\\r\\nmeasurements will be taken at each point, averaged for analysis, with the M-line set to\\r\\nthe midline for precise measurements. Changes in muscle thickness (cm) reflecting muscle\\r\\nactivation will be observed.',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Pelvic floor muscle ultrasound image',\n",
       "      'description': 'Transabdominal ultrasound will be used, for this purpose convex probe will be place at\\r\\nsuprapubic level in B-mode will be used (3.5-5MegaHertz (Mhz). Three measurements at each\\r\\npoint and use the mean of the 3 for subsequent analyses. Changes in muscle thickness\\r\\nrefected by muscle activation will be calculated as the thickness during contraction\\r\\nminus the resting thickness (cm) .',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'},\n",
       "     {'measure': '30s chair-stand test',\n",
       "      'description': 'Women will start from a seated position with feet flat on the floor and arms crossed,\\r\\nrise completely with hips and knees extended, then sit back down touching the seat,\\r\\nrepeat for 30 seconds. Chair leaning against a wall, usual footwear. If unable to stand,\\r\\nhands can be placed on legs or mobility aids can be used, scored as adapted test. It is\\r\\nrecommended to practice 2-3 slow repetitions for comprehension. Scoring: Count the total\\r\\nnumber of complete bipedestation (up and down) in a test. If at least one bipedestation\\r\\nis completed in 30 seconds, it is counted. If unable to stand, the score is zero. Record\\r\\nthe adapted score if applicable.',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Inmediately post-intervention) and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Pelvic floor muscles strength',\n",
       "      'description': 'Vaginal palpation will be done using the Modified Oxford Scale, which comprises 6 levels.\\r\\nIt demonstrates good interobserver reliability and serves as a subjective scale for\\r\\nclinical rather than research purposes. To gauge sensitivity to change, each point was\\r\\nsupplemented with a +/-, expanding the scale to include 15 degrees.',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention)'},\n",
       "     {'measure': 'Pelvic floor muscles Dynamometry',\n",
       "      'description': \"A commercially available instrumented plastic dynamometric speculum (Pelvimeter, Phenix,\\r\\nMontpellier, France) was utilized to measure pelvic floor muscle (PFM) tone and maximum\\r\\nintravaginal pelvic floor muscle (PFM) strength generated through maximal voluntary\\r\\ncontraction the measure will be reported in grams. All numerical values of pelvic floor\\r\\nmuscle (PFM) dynamometry tone are presented as raw values, including the ambient pressure\\r\\nvalue (170 g). Latex or polyethylene protective covers were used, and the dynamometer was\\r\\ncomfortably aligned in the participant's vaginal canal throughout the experiment. Pelvic\\r\\nfloor muscle strength was calculated as the mean of three maximum voluntary contractions.\",\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Menopause symptoms',\n",
       "      'description': 'The Menopause Rating Scale (MRS) is a widely used tool for assessing symptoms related to\\r\\nmenopause.\\r\\n\\r\\nThe scoring scheme increases point by point with increasing subjectively perceived\\r\\nsymptom severity for each of the 11 items (severity 0 [no complaint] to 4 score points\\r\\n[very severe symptoms]). The composite score for each of the dimensions (subscales) is\\r\\nbased on the sum of the scores for each item of the respective dimensions. The composite\\r\\nscore (total score) is the sum of the dimension scores.',\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Psychologic condition',\n",
       "      'description': 'The Beck Depression Inventory (BDI) is a widely used self-report inventory for measuring\\r\\nthe severity of depression symptoms. It consists of 21 multiple-choice questions, each\\r\\nassessing a different symptom of depression such as sadness, pessimism, guilt, and\\r\\nsuicidal thoughts. Respondents rate the severity of each symptom over the past two weeks.\\r\\nScores are summed to yield a total score, with higher scores indicating more severe\\r\\ndepressive symptoms. The BDI is frequently used in clinical and research settings to\\r\\nassess depression severity and monitor treatment progress.',\n",
       "      'timeFrame': '8 weeks (2 assessent times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'},\n",
       "     {'measure': 'Urinary symptoms',\n",
       "      'description': \"The Pelvic Floor Distress Inventory-20 (PFDI-20) is a recommended questionnaire for\\r\\nevaluating pelvic floor disorder (PFD) symptoms and measuring their impact on women's\\r\\nquality of life. This questionnaire is validated in Spanish. The PFDI-20 reflects\\r\\ndifferent perspectives, thus including 20 questions divided into three symptom scales:\\r\\npelvic organ prolapse symptoms (POP-DI) (questions 1 to 6); colorectal-anal symptoms\\r\\n(CRADI) (questions 7-14); and urinary symptoms (UDI) (questions 15-20). The questions in\\r\\nthe CRADI scale are about fecal incontinence (FI), except for question 11, which\\r\\naddresses flatulence incontinence; whereas the UDI scale addresses urinary symptoms\\r\\nspecifically. Question 16 pertains to urgency urinary incontinence (UUI), and question 17\\r\\npertains to stress urinary incontinence (SUI). Each question can be answered on four\\r\\nlevels of dysfunction: none, mild, moderate, and severe.\",\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention)'},\n",
       "     {'measure': 'Pelvic floor health knowledge',\n",
       "      'description': \"Pelvic Floor Impact Questionnaire (PIKQ)It is a tool used to assess the impact of pelvic\\r\\nfloor disorders, such as urinary incontinence, colorectal-anal symptoms, and genital\\r\\nprolapse, on various aspects of a person's life, including activities, relationships, and\\r\\nemotions. The questionnaire consists of seven questions for each symptom category (urine,\\r\\ncolorectal-anal, and genital prolapse), with responses rated on a scale of none, mild,\\r\\nmoderate, or severe. The total score is calculated by summing the scores from each\\r\\ncategory, with a maximum possible score of 300.\",\n",
       "      'timeFrame': '8 weeks (2 assesment times: T1(pre-intervention), T2 (Immediately post-intervention) and T3 (3-months follow-up)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Women aged ≥45 years\\r\\n\\r\\n  -  Women in climacteric period\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Musculoskeletal, cognitive, infectious, neurological, or cardiorespiratory pathology\\r\\n     impairing assessment or program completion.\\r\\n\\r\\n  -  Surgical intervention in lumbopelvic or gynecological region within the last 6\\r\\n     months.\\r\\n\\r\\nUndergoing oncological treatment.\\r\\n\\r\\n* Also included women with stable hormone replacement therapy for at least the last 6\\r\\nmonths.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'minimumAge': '45 Years',\n",
       "    'maximumAge': '85 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Laura Fuentes-Aparicio, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '669682391',\n",
       "      'phoneExt': '51227',\n",
       "      'email': 'laura.fuentes@uv.es'}],\n",
       "    'locations': [{'facility': 'Laura Fuentes Aparicio',\n",
       "      'city': 'Valencia',\n",
       "      'zip': '46010',\n",
       "      'country': 'Spain',\n",
       "      'contacts': [{'name': 'Laura Fuentes-Aparicio, PT PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '669682391',\n",
       "        'email': 'laura.fuentes@uv.es'}],\n",
       "      'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T6036',\n",
       "      'name': 'Menopause',\n",
       "      'asFound': 'Climacteric',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06382168',\n",
       "    'orgStudyIdInfo': {'id': 'D19-11186'},\n",
       "    'organization': {'fullName': 'Delta-Fly Pharma, Inc.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia',\n",
       "    'officialTitle': 'Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': True},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-03-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-19',\n",
       "    'studyFirstSubmitQcDate': '2024-04-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Delta-Fly Pharma, Inc.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined\\r\\nwith venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a\\r\\n14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax\\r\\nfollowing an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day\\r\\nof DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews\\r\\ntoxicity after one treatment cycle. If DLTs are minimal, more patients are added to\\r\\nconfirm safety. If the lower dose level shows tolerability, it proceeds to the Phase II\\r\\nexpansion to assess the treatment's effectiveness against leukemia using a Simon's\\r\\ntwo-stage design, targeting up to 17 participants.\",\n",
       "    'detailedDescription': \"This study is a Phase I/II, open-label trial exploring dosage and expansion cohorts to\\r\\nassess the safety and preliminary efficacy of DFP-10917 in combination with venetoclax\\r\\nfor patients with relapsed or refractory acute myeloid leukemia (AML). DFP-10917 will be\\r\\nadministered as a 14-day continuous intravenous infusion starting on Day 1, followed by a\\r\\n14-day rest period, during each 28-day cycle. This will occur concurrently with\\r\\nvenetoclax, administered orally at a dose of 400 mg daily for 14 days following a dose\\r\\nramp-up phase (100 mg and 200 mg on Day 1 and 2, respectively).\\r\\n\\r\\nIn Phase I, the starting dose for DFP-10917 is 4 mg/m²/day, administered concurrently\\r\\nwith 400 mg of venetoclax once daily for 14 days (Dose Level 1). The Data Monitoring\\r\\nCommittee (DMC) will assess dose-limiting toxicities (DLTs) after three patients are\\r\\nenrolled at this dose level and the last patient has completed the 4-week safety\\r\\nassessment period (i.e., one cycle of the combination regimen). At Dose Level 1 (4\\r\\nmg/m²/day of DFP-10917 with venetoclax 400 mg daily for 14 days), if none of the three\\r\\npatients experience a DLT, the study will enroll an additional three patients at this\\r\\ndose level to confirm the combination's safety and tolerability. If one out of three\\r\\npatients experiences a DLT, up to three additional patients may be enrolled. If one or\\r\\nfewer out of six treated patients experience a DLT at Dose Level 1, this dose will be\\r\\ndeclared the recommended Phase II dose (RP2D) and used in the Phase II expansion cohort.\\r\\nIf two or more patients out of the total three to six patients at Dose Level 1 experience\\r\\na DLT, the study will continue enrollment at Dose Level 1 (4 mg/m²/day of DFP-10917 for\\r\\n14 days concurrently with venetoclax 400 mg daily for 10 days of each 28-day cycle) to\\r\\ndetermine the safety and tolerability of Dose Level -1. A patient who discontinues\\r\\ntherapy during Cycle 1 without experiencing DLTs is considered evaluable for safety\\r\\npurposes only if all scheduled doses of DFP-10917 and at least 80% of the venetoclax\\r\\ndoses were administered in the first cycle. Once the RP2D of DFP-10917 in combination\\r\\nwith venetoclax is determined, the expansion cohort will begin enrollment to evaluate the\\r\\nanti-leukemia efficacy of this combination. A Simon's two-stage min-max design will be\\r\\nemployed, with up to 17 patients expected to participate.\"},\n",
       "   'conditionsModule': {'conditions': ['Leukemia, Myeloid, Acute']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 39, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Dose Level 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'DFP-10917 4 mg/m^2/day with venetoclax 400 mg once daily for 14 days',\n",
       "      'interventionNames': ['Drug: DFP-10917', 'Drug: Venetoclax']},\n",
       "     {'label': 'Dose Level -1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'DFP-10917 4 mg/m^2/day with venetoclax 400 mg once daily for 10 days',\n",
       "      'interventionNames': ['Drug: DFP-10917', 'Drug: Venetoclax']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'DFP-10917',\n",
       "      'description': 'DFP-10917 4 mg/m^2/day is given as a continuous 14-day intravenous infusion, followed by\\r\\na 14-day rest in each 28-day cycle.',\n",
       "      'armGroupLabels': ['Dose Level -1', 'Dose Level 1']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': 'Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day\\r\\ncycle.',\n",
       "      'armGroupLabels': ['Dose Level -1', 'Dose Level 1']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with dose-limiting toxicities assessed by CTCAE v5.0.',\n",
       "      'timeFrame': 'From the first day of treatment start until 30 days after treatment completion.'},\n",
       "     {'measure': 'Number of patients with treatment-related adverse events assessed by CTCAE v5.0.',\n",
       "      'timeFrame': 'The first 28 days of study treatment (Cycle 1).'},\n",
       "     {'measure': 'Recommended Phase 2 dose of DFP-10917 in combination with venetoclax (the dose at which <2 out of 6 patients experience a dose-limiting toxicity during the safety assessment period).',\n",
       "      'timeFrame': 'The first 28 days of study treatment (Cycle 1).'}],\n",
       "    'secondaryOutcomes': [{'measure': 'The proportion of patients who achieve complete remission.',\n",
       "      'timeFrame': 'From the start of the study treatment to the first documented progression or death from any cause, whichever occurs first, assessed for up to 100 months.'},\n",
       "     {'measure': 'The proportion of patients who achieve complete remission or complete remission with incomplete hematologic recovery.',\n",
       "      'timeFrame': 'From the start of the study treatment to the first documented progression or death from any cause, whichever occurs first, assessed for up to 100 months.'},\n",
       "     {'measure': 'The proportion of patients achieving complete remission or complete remission with incomplete hematologic recovery, and morphologic leukemia-free state.',\n",
       "      'timeFrame': 'From the start of the study treatment to the first documented progression or death from any cause, whichever occurs first, assessed for up to 100 months.'},\n",
       "     {'measure': 'Overall survival.',\n",
       "      'timeFrame': 'From the start of the study treatment to death from any cause, whichever occurs first, assessed for up to 100 months.'},\n",
       "     {'measure': 'Progression-free survival.',\n",
       "      'timeFrame': 'From the start of the study treatment to the first documented progression or death from any cause, whichever occurs first, assessed for up to 100 months.'},\n",
       "     {'measure': 'Maximum concentration of DFP-10917.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Area under the curve of DFP-10917.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'}],\n",
       "    'otherOutcomes': [{'measure': 'Volume of distribution of DFP-10917.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Clearance of DFP-10917.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Time to maximum concentration of venetoclax.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Maximum concentration of venetoclax.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Elimination half-life of venetoclax.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'},\n",
       "     {'measure': 'Area under the curve of venetoclax.',\n",
       "      'timeFrame': 'The first 15 days of study treatment.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Signed informed consent and ability to comply with protocol requirements.\\r\\n\\r\\n  -  Histologically or pathologically confirmed diagnosis of acute myeloid leukemia based\\r\\n     on World Health Organization classification that has relapsed after, or is\\r\\n     refractory to, up to 2 prior induction regimens that may have included intensive\\r\\n     chemotherapy (e.g., \"7+3\" cytarabine and daunorubicin), epigenetic therapy (i.e.,\\r\\n     azacitidine or decitabine with/without venetoclax), or targeted therapy (e.g.,\\r\\n     FLT-3, IDH 1/2, BCL-2, monoclonal antibody).\\r\\n\\r\\n(Relapse is defined as reemergence of ≥5% leukemia blasts in bone marrow or ≥1% blasts in\\r\\nperipheral blood 90 days to 24 months after first complete remission or complete\\r\\nremission with incomplete hematologic recovery. Refractory acute myeloid leukemia is\\r\\ndefined as persistent disease ≥28 days after initiation of intensive induction therapy\\r\\n(up to 2 induction cycles) or relapse <90 days after first complete remission or complete\\r\\nremission with incomplete hematologic recover. Refractory disease for patients undergoing\\r\\nhypomethylating agent induction is defined as lack of remission following at least 2\\r\\ncycles of epigenetic therapy without reduction in bone marrow blast status).\\r\\n\\r\\n  -  Adequate organ function as defined by the following laboratory values:\\r\\n\\r\\n       -  Creatinine clearance >30 mL/min (by Cockcroft-Gault method),\\r\\n\\r\\n       -  Total serum bilirubin <1.5 × upper limit of normal unless due to Gilbert\\'s\\r\\n          syndrome, leukemic organ involvement, hemolysis or considered an effect of\\r\\n          regular blood transfusions,\\r\\n\\r\\n       -  Alanine aminotransferase and aspartate aminotransferase <3 × upper limit of\\r\\n          normal, unless due to leukemic organ involvement.\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2).\\r\\n\\r\\n  -  Projected life expectancy of ≥12 weeks.\\r\\n\\r\\n  -  Female patients of childbearing potential must:\\r\\n\\r\\n       -  Have a negative serum or urine pregnancy test prior to study treatment\\r\\n          initiation.\\r\\n\\r\\n       -  Agree to use at least 1 highly effective form of contraception during study\\r\\n          treatment and for 3 months after the last dose.\\r\\n\\r\\n  -  Male patients with female partners of childbearing potential must -- Agree to use at\\r\\n     least 1 highly effective form of contraception during study treatment and for at\\r\\n     least 3 months after the last dose.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any >Grade 1 persistent clinically significant toxicities from prior chemotherapy.\\r\\n\\r\\n  -  Leukemic blast count >25 × 109/L. Hydroxyurea permitted to control leukocytosis.\\r\\n\\r\\n  -  Known history of human immunodeficiency virus or active hepatitis B or active\\r\\n     hepatitis C infection.\\r\\n\\r\\n  -  Concomitant malignancies for which patients are receiving active therapy at the time\\r\\n     of signing consent. Patients with adequately treated basal or squamous cell\\r\\n     carcinoma of the skin, adequately treated carcinoma in situ (e.g., cervix), breast\\r\\n     cancer receiving adjuvant endocrine therapy or prostate cancer not under active\\r\\n     systemic treatment other than hormonal therapy may enroll irrespective of the time\\r\\n     of diagnosis, with Medical Monitor approval.\\r\\n\\r\\n  -  Known active central nervous system involvement by leukemia. Patients with\\r\\n     previously diagnosed central nervous system leukemia are eligible if the central\\r\\n     nervous system leukemia is under control and intrathecal treatment may continue\\r\\n     throughout the study.\\r\\n\\r\\n  -  Diagnosis of acute promyelocytic leukemia.\\r\\n\\r\\n  -  Prior exposure to anticancer therapies including chemotherapy, radiotherapy or other\\r\\n     investigational therapy, including targeted small molecule agents within 14 days of\\r\\n     the first day of study treatment or within 5 half-lives prior to first dose of study\\r\\n     treatment. Note that hydroxyurea up to 5 g daily × 3 days is permitted to reduce\\r\\n     elevated white blood cell (WBC) count.\\r\\n\\r\\n  -  Venetoclax exposure in more than 1 prior regimen.\\r\\n\\r\\n  -  Prior exposure to biologic agents (e.g., monoclonal antibodies) for anti-neoplastic\\r\\n     intent within 14 days prior to first dose of study drug.\\r\\n\\r\\n  -  Prior hematopoietic stem cell transplantation.\\r\\n\\r\\n  -  Malabsorption syndrome or other condition that precludes enteral route of\\r\\n     administration.\\r\\n\\r\\n  -  Pregnancy or lactation.\\r\\n\\r\\n  -  Active uncontrolled systemic infection (viral, bacterial, or fungal).\\r\\n\\r\\n  -  Ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers, P-gp\\r\\n     inhibitors, or narrow therapeutic index P-gp substrates that cannot be discontinued\\r\\n     at least 1 week prior to start of venetoclax dosing excluding antifungal\\r\\n     prophylaxis.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Scott Frank',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+81 362311278',\n",
       "      'email': 'sfrank1206@delta-flypharma.co.jp'}],\n",
       "    'locations': [{'facility': 'UCI Chao Family Comprehensive Cancer Center',\n",
       "      'city': 'Orange',\n",
       "      'state': 'California',\n",
       "      'zip': '92868',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kiran Naqvi', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.78779, 'lon': -117.85311}},\n",
       "     {'facility': 'Atrium Health Wake Forest Baptist Comprehensive Cancer Center',\n",
       "      'city': 'Winston-Salem',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27157',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Timothy Pardee',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 36.09986, 'lon': -80.24422}},\n",
       "     {'facility': 'Simmons Cancer Center: UT Southwestern',\n",
       "      'city': 'Dallas',\n",
       "      'state': 'Texas',\n",
       "      'zip': '75235',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 32.78306, 'lon': -96.80667}},\n",
       "     {'facility': 'University of Vermont Cancer Center',\n",
       "      'city': 'Burlington',\n",
       "      'state': 'Vermont',\n",
       "      'zip': '05401',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Diego Adrianzen Herrer',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 44.47588, 'lon': -73.21207}},\n",
       "     {'facility': 'University of Virginia Cancer Center',\n",
       "      'city': 'Charlottesville',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '22911',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Michael Keng', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Leukemia, Myeloid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Leukemia, Myeloid, Acute',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Leukemia, Myeloid, Acute',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000579720',\n",
       "      'term': 'Venetoclax'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Extended',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06394492',\n",
       "    'orgStudyIdInfo': {'id': 'SHR-A1921-303'},\n",
       "    'organization': {'fullName': 'Suzhou Suncadia Biopharmaceuticals Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer',\n",
       "    'officialTitle': \"A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-27',\n",
       "    'studyFirstSubmitQcDate': '2024-04-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Suzhou Suncadia Biopharmaceuticals Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This study is a randomized, open-label, controlled, phase III study to evaluate the\\r\\nefficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients\\r\\nwith platinum-resistant recurrent epithelial ovarian cancer.\"},\n",
       "   'conditionsModule': {'conditions': ['Ovarian Cancer']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'To evaluate the efficacy and safety of SHR-A1921 compared with investigator-chosen\\r\\nchemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 440, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Treatment group 1: SHR-A1921',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: SHR-A1921']},\n",
       "     {'label': \"Treatment group 2: Investigator's choice of chemotherapy\",\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'interventionNames': ['Drug: Doxorubicin',\n",
       "       'Drug: Paclitaxel',\n",
       "       'Drug: Topotecan']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'SHR-A1921',\n",
       "      'description': 'SHR-A1921 dose 1',\n",
       "      'armGroupLabels': ['Treatment group 1: SHR-A1921']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Doxorubicin',\n",
       "      'description': 'Doxorubicin dose 2',\n",
       "      'armGroupLabels': [\"Treatment group 2: Investigator's choice of chemotherapy\"]},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Paclitaxel',\n",
       "      'description': 'Paclitaxel dose 3',\n",
       "      'armGroupLabels': [\"Treatment group 2: Investigator's choice of chemotherapy\"]},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Topotecan',\n",
       "      'description': 'Topotecan dose 4',\n",
       "      'armGroupLabels': [\"Treatment group 2: Investigator's choice of chemotherapy\"]}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-free Survival (PFS) assessed by site investigator as per RECIST 1.1',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall Survival (OS)',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'Objective Response Rate (ORR), assessed by site investigator as per RECIST 1.1',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'Duration of Response (DoR), assessed by site investigator as per RECIST 1.1',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'Disease Control Rate (DCR), assessed by site investigator as per RECIST 1.1',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'Response Rate (RR) assessed by RECIST 1.1 and Gynaecologic Cancer Intergroup (GCIG) criteria',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'CA-125 Response Rate assessed by the Gynaecologic Cancer Intergroup (GCIG) criteria',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'},\n",
       "     {'measure': 'Adverse Events',\n",
       "      'timeFrame': 'Screening up to study completion, an average of 1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Voluntary participation and written informed consent.\\r\\n\\r\\n  2. 18 years and older, female.\\r\\n\\r\\n  3. Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or\\r\\n     fallopian tube cancer.\\r\\n\\r\\n  4. Patients must have platinum-resistant disease\\r\\n\\r\\n  5. Be able to provide fresh or archived tumour tissue.\\r\\n\\r\\n  6. At least one measurable lesion according to RECIST v1.1.\\r\\n\\r\\n  7. Eastern Cooperative Oncology Group (ECOG) score: 0-1.\\r\\n\\r\\n  8. With a life expectancy ≥ 12 weeks.\\r\\n\\r\\n  9. Adequate bone marrow reserve and organ function.\\r\\n\\r\\n 10. Contraception is required during the trial.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with\\r\\n     clinical symptoms.\\r\\n\\r\\n  2. Previous or co-existing malignancies.\\r\\n\\r\\n  3. Current or History of ILD.\\r\\n\\r\\n  4. Clinical symptoms or diseases of the heart that are not well controlled.\\r\\n\\r\\n  5. Arterial/venous thrombosis events occurred before the first dose.\\r\\n\\r\\n  6. Grade ≥2 bleeding events of CTCAE occurred before the first dose.\\r\\n\\r\\n  7. Gastrointestinal perforation or fistula, urethral fistula, abdominal abscess\\r\\n     occurred before the first dose.\\r\\n\\r\\n  8. Patients with intestinal obstruction or parenteral nutrition before the first dose.\\r\\n\\r\\n  9. Serious infection before the first dose.\\r\\n\\r\\n 10. Active hepatitis B or active hepatitis C.\\r\\n\\r\\n 11. Received systemic anticancer treatments 4 weeks prior to the initiation of the study\\r\\n     treatment.\\r\\n\\r\\n 12. Treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.\\r\\n\\r\\n 13. Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.\\r\\n\\r\\n 14. History of severe hypersensitivity reactions to either the drug substances or\\r\\n     inactive ingredients of SHR-A1921.\\r\\n\\r\\n 15. Other inappropriate situation considered by the investigator.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Shuni Wang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 021-61053363',\n",
       "      'email': 'shuni.wang@hengrui.com'},\n",
       "     {'name': 'Di Zong',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 021-61053363',\n",
       "      'email': 'di.zong@hengrui.com'}],\n",
       "    'locations': [{'facility': 'National Cancer Center/Tumor Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College',\n",
       "      'city': 'Beijing',\n",
       "      'state': 'Beijing',\n",
       "      'zip': '100021',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Lingyin Wu, Doctor', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}},\n",
       "     {'facility': 'Zhejiang Cancer Hospital',\n",
       "      'city': 'Hangzhou',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '310022',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Tao Zhu, Doctor', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010051',\n",
       "      'term': 'Ovarian Neoplasms'},\n",
       "     {'id': 'D000077216', 'term': 'Carcinoma, Ovarian Epithelial'}],\n",
       "    'ancestors': [{'id': 'D000004701', 'term': 'Endocrine Gland Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000010049', 'term': 'Ovarian Diseases'},\n",
       "     {'id': 'D000000291', 'term': 'Adnexal Diseases'},\n",
       "     {'id': 'D000005831', 'term': 'Genital Diseases, Female'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000005833', 'term': 'Genital Neoplasms, Female'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000006058', 'term': 'Gonadal Disorders'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'}],\n",
       "    'browseLeaves': [{'id': 'M12974',\n",
       "      'name': 'Ovarian Neoplasms',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1704',\n",
       "      'name': 'Carcinoma, Ovarian Epithelial',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14850', 'name': 'Recurrence', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M7863', 'name': 'Endocrine Gland Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M12972', 'name': 'Ovarian Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M3643', 'name': 'Adnexal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8945', 'name': 'Genital Neoplasms, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9163', 'name': 'Gonadal Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4352',\n",
       "      'name': 'Ovarian Cancer',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4354',\n",
       "      'name': 'Ovarian Epithelial Cancer',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000017239',\n",
       "      'term': 'Paclitaxel'},\n",
       "     {'id': 'D000004317', 'term': 'Doxorubicin'},\n",
       "     {'id': 'D000019772', 'term': 'Topotecan'}],\n",
       "    'ancestors': [{'id': 'D000000972',\n",
       "      'term': 'Antineoplastic Agents, Phytogenic'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000050257', 'term': 'Tubulin Modulators'},\n",
       "     {'id': 'D000050256', 'term': 'Antimitotic Agents'},\n",
       "     {'id': 'D000050258', 'term': 'Mitosis Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000903', 'term': 'Antibiotics, Antineoplastic'},\n",
       "     {'id': 'D000059005', 'term': 'Topoisomerase II Inhibitors'},\n",
       "     {'id': 'D000059003', 'term': 'Topoisomerase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000059004', 'term': 'Topoisomerase I Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M19537',\n",
       "      'name': 'Paclitaxel',\n",
       "      'asFound': 'Surgery',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7492',\n",
       "      'name': 'Doxorubicin',\n",
       "      'asFound': 'Women',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M227339', 'name': 'Liposomal doxorubicin', 'relevance': 'LOW'},\n",
       "     {'id': 'M231', 'name': 'Albumin-Bound Paclitaxel', 'relevance': 'LOW'},\n",
       "     {'id': 'M21674',\n",
       "      'name': 'Topotecan',\n",
       "      'asFound': 'PD-1',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26197', 'name': 'Tubulin Modulators', 'relevance': 'LOW'},\n",
       "     {'id': 'M26196', 'name': 'Antimitotic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4224',\n",
       "      'name': 'Antibiotics, Antitubercular',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M29349',\n",
       "      'name': 'Topoisomerase I Inhibitors',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05947760',\n",
       "    'orgStudyIdInfo': {'id': 'STUDY20230720'},\n",
       "    'organization': {'fullName': 'University Hospitals Cleveland Medical Center',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Magnesium as an Adjuvant Agent for Postoperative Pain',\n",
       "    'officialTitle': 'Magnesium as an Adjuvant Agent for Postoperative Pain Control Following Periacetabular Osteotomy'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-04-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-04-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-05',\n",
       "    'studyFirstSubmitQcDate': '2023-07-05',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Robert Wetzel, MD',\n",
       "     'investigatorTitle': 'Orthopedic Trauma Surgeon',\n",
       "     'investigatorAffiliation': 'University Hospitals Cleveland Medical Center'},\n",
       "    'leadSponsor': {'name': 'University Hospitals Cleveland Medical Center',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Participants are being asked to participate in this research study because they have\\r\\nelected to undergo periacetabular osteotomy (PAO). This research study is looking at if\\r\\nusing IV magnesium during surgery can help to reduce pain after surgery.'},\n",
       "   'conditionsModule': {'conditions': ['Pain, Postoperative'],\n",
       "    'keywords': ['periacetabular osteotomy',\n",
       "     'IV magnesium sulfate',\n",
       "     'Decreased opioid usage']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 64, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'IV Magnesium Sulfate adjuvant group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants in this group will receive standard-of-care procedures intraoperatively and\\r\\npostoperatively along with IV magnesium sulfate for pain control.',\n",
       "      'interventionNames': ['Drug: IV Magnesium Sulfate']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Participants in this group will receive standard-of-care procedures intraoperatively and\\r\\npost-operatively for pain control.'}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'IV Magnesium Sulfate',\n",
       "      'description': 'Participants will receive IV Magnesium Sulfate intraoperatively.',\n",
       "      'armGroupLabels': ['IV Magnesium Sulfate adjuvant group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in pain as measured by the Visual Analog Scale (VAS)',\n",
       "      'description': 'The VAS is a scale from 0-10 with 0 being no pain and 10 being the worst pain ever',\n",
       "      'timeFrame': 'Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year'},\n",
       "     {'measure': 'Change in number of narcotic medications consumed as measured by the medical record review',\n",
       "      'timeFrame': 'Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change in PROMIS scores',\n",
       "      'description': 'The PROMIS is a 14 item questionnaire is a set of person-centered measures that evaluates\\r\\nand monitors physical, mental, and social health in adults and children. It can be used\\r\\nwith the general population and with individuals living with chronic conditions. Scores\\r\\nare typically between 20-80, but may be 0-100.',\n",
       "      'timeFrame': '2 weeks, 6 weeks, 3 months, 6 months, 1 year'},\n",
       "     {'measure': 'Change in modified Harris Hip Scores (mHHS)',\n",
       "      'description': 'The mHHS is a scoring system for functional outcomes post periactabular osteotomies that\\r\\nhas a scale of 0-100, 0 being the lowest functional outcome and 100 being the highest',\n",
       "      'timeFrame': '2 weeks, 6 weeks, 3 months, 6 months, 1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients undergoing periacetabular osteotomy with or without adjuvant hip\\r\\n     arthroscopy\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  illiterate or non-English speaking patients\\r\\n\\r\\n  -  patients with 2nd or 3rd degree AV block\\r\\n\\r\\n  -  patients with severe renal insufficiency\\r\\n\\r\\n  -  patients with heart failure\\r\\n\\r\\n  -  patients with bradycardia',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '14 Years',\n",
       "    'maximumAge': '89 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Elika Fanaeian, MS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '7608846031',\n",
       "      'email': 'elika.fanaeian@uhhospitals.org'}],\n",
       "    'overallOfficials': [{'name': 'Robert Wetzel, MD',\n",
       "      'affiliation': 'University Hospitals',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University Hospitals',\n",
       "      'city': 'Cleveland',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '44106',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Elika Fanaeian, MS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '760-884-6031',\n",
       "        'email': 'elika.fanaeian@uhhospitals.org'}],\n",
       "      'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010149',\n",
       "      'term': 'Pain, Postoperative'}],\n",
       "    'ancestors': [{'id': 'D000011183', 'term': 'Postoperative Complications'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M13069',\n",
       "      'name': 'Pain, Postoperative',\n",
       "      'asFound': 'Pain, Postoperative',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M14065',\n",
       "      'name': 'Postoperative Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000008278',\n",
       "      'term': 'Magnesium Sulfate'}],\n",
       "    'ancestors': [{'id': 'D000000700', 'term': 'Analgesics'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000000889', 'term': 'Anti-Arrhythmia Agents'},\n",
       "     {'id': 'D000000927', 'term': 'Anticonvulsants'},\n",
       "     {'id': 'D000002121', 'term': 'Calcium Channel Blockers'},\n",
       "     {'id': 'D000049990', 'term': 'Membrane Transport Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'},\n",
       "     {'id': 'D000015149', 'term': 'Tocolytic Agents'},\n",
       "     {'id': 'D000012102', 'term': 'Reproductive Control Agents'}],\n",
       "    'browseLeaves': [{'id': 'M11270',\n",
       "      'name': 'Magnesium Sulfate',\n",
       "      'asFound': 'Aerobic exercise',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4033', 'name': 'Analgesics, Opioid', 'relevance': 'LOW'},\n",
       "     {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4213', 'name': 'Anti-Arrhythmia Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4246', 'name': 'Anticonvulsants', 'relevance': 'LOW'},\n",
       "     {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'},\n",
       "     {'id': 'M5384', 'name': 'Calcium Channel Blockers', 'relevance': 'LOW'},\n",
       "     {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'},\n",
       "     {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "     {'id': 'M17869', 'name': 'Tocolytic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'},\n",
       "     {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'AntiConv', 'name': 'Anticonvulsants'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06417489',\n",
       "    'orgStudyIdInfo': {'id': '2024-165-002'},\n",
       "    'organization': {'fullName': 'Peking University First Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients',\n",
       "    'officialTitle': 'Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin Compared to Sequential Metformin Therapy in Newly Diagnosed Type 2 Diabetes Patients'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-11',\n",
       "    'studyFirstSubmitQcDate': '2024-05-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-11',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Peking University First Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study evaluated the efficacy and safety of initial combined treatment of\\r\\nHenggliptin, Retagliptin and Metformin by including new type 2 diabetes patients. This\\r\\nstudy is a multicenter, randomized, open label, positive control study. It is planned to\\r\\ninclude 160 new type 2 diabetes patients who meet the inclusion criteria of the study.\\r\\nThe study is divided into three stages: screening period (V0, -14d-0), treatment period\\r\\n(V1-V8, D1-24w) and safe follow-up period (V9, 28w), with a total of 10 planned visits.\\r\\nThis study was divided into an experimental group and a control group. The experimental\\r\\ngroup received a one-time addition of 10 mg qd of Henggliptin, 100 mg qd of Regagliptin,\\r\\nand 500mg of Metformin. The control group was first treated with metformin. If the blood\\r\\nsugar level did not meet the standard (fasting blood glucose (FPG)&gt;7mmol/L,\\r\\npostprandial blood glucose (PPG)&gt;10mmol/L), Henggeliflozin 10 mg qd was sequentially\\r\\nadded. If the blood sugar level did not meet the standard after 4 weeks, Regagliptin 100\\r\\nmg qd was added. During the follow-up period, evaluate blood glucose control, pancreatic\\r\\nislet function, and safety in both groups of patients.'},\n",
       "   'conditionsModule': {'conditions': ['Type 2 Diabetes']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Combination therapy',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of\\r\\nmetformin from the first to second week is 500mg bid, and the dose from the third to\\r\\nfourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the\\r\\nresearcher shall increase the dosage according to the patient's tolerance situation. The\\r\\nminimum dose is 1000mg/day.\",\n",
       "      'interventionNames': ['Drug: Combination therapy']},\n",
       "     {'label': 'Sequential treatment group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"Metformin, the dose from the first to second week is 500mg bid, and the dose from the\\r\\nthird to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated,\\r\\nthe researcher shall increase the dosage according to the patient's tolerance situation.\\r\\nThe minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels\\r\\nwere measured. For those whose blood glucose levels did not meet the standard (fasting\\r\\nblood glucose (FPG)>7mmol/L, postprandial blood glucose (PPG)>10mmol/L), 10 mg qd of\\r\\nHenagliflozin Proline was sequentially added. If the blood glucose levels did not meet\\r\\nthe standard after 4 weeks of treatment (FPG>7mmol/L, PPG>10mmol/L), 100 mg qd of\\r\\nRuigeliflozin was added\",\n",
       "      'interventionNames': ['Drug: Sequential treatment group']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Combination therapy',\n",
       "      'description': 'Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of\\r\\nmetformin from the first to second week is 500mg bid, and the dose from the third to\\r\\nfourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the\\r\\nresearcher shall increase the dosage according to the patient&#39;s tolerance situation.\\r\\nThe minimum dose is 1000mg/day.',\n",
       "      'armGroupLabels': ['Combination therapy']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Sequential treatment group',\n",
       "      'description': 'Metformin, the dose from the first to second week is 500mg bid, and the dose from the\\r\\nthird to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated,\\r\\nthe researcher shall increase the dosage according to the patient&#39;s tolerance\\r\\nsituation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood\\r\\nglucose levels were measured. For those whose blood glucose levels did not meet the\\r\\nstandard (fasting blood glucose (FPG)&gt;7mmol/L, postprandial blood glucose\\r\\n(PPG)&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood\\r\\nglucose levels did not meet the standard after 4 weeks of treatment (FPG&gt;7mmol/L,\\r\\nPPG&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added',\n",
       "      'armGroupLabels': ['Sequential treatment group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of subjects with HbA1c<7% at 12w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 12 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'The proportion of subjects with HbA1c<7% at week 24',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 24 weeks'},\n",
       "     {'measure': 'The proportion of subjects with HbA1c<6.5% at 12 week',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 12 weeks'},\n",
       "     {'measure': 'The proportion of subjects with HbA1c<6.5% at 24 week',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 24 weeks'},\n",
       "     {'measure': 'Changes in HbA1c compared to baseline at 12 weeks',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 12 weeks'},\n",
       "     {'measure': 'Changes in HbA1c compared to baseline at 24 weeks',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 24 weeks'},\n",
       "     {'measure': 'Changes in fingertip blood glucose (seven point blood glucose spectrum) compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in 2hPPG compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in FBG compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in systolic pressure compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in diastolic pressure compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in body weight compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in waist circumference compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in eGFR compared to baseline at 4w, 8w, 12w, and 24w',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 4/8/12/24 weeks'},\n",
       "     {'measure': 'Changes in C-peptide levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 12 and 24 weeks'},\n",
       "     {'measure': 'Changes in insulin levels during the 12 and 24 weeks compared to baseline during abdominal and 2-hour postprandial periods',\n",
       "      'timeFrame': 'From enrollment to the end of treatment at 12 and 24 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Untreated newly diagnosed T2DM patients;\\r\\n\\r\\n  2. Age ≥ 18 years old;\\r\\n\\r\\n  3. 8.0% ≤ HbA1c&lt;11.0%;\\r\\n\\r\\n  4. 19 kg/m2 ≤ BMI&lt;35 kg/m2;\\r\\n\\r\\n  5. eGFR ≥ 60 ml/min1.73m2;\\r\\n\\r\\n  6. Voluntarily participate and sign an informed consent form\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Pregnant and lactating women, as well as women of childbearing age who are unwilling\\r\\n     to take reliable contraceptive measures;\\r\\n\\r\\n  2. Individuals who are known to be allergic to Henggliflozin, Regagliptin, or\\r\\n     Metformin;\\r\\n\\r\\n  3. Other types of diabetes except type 2 diabetes;\\r\\n\\r\\n  4. Type 2 diabetes with a history of ketoacidosis (DKA) in the last 6 months;\\r\\n\\r\\n  5. NYHA cardiac grade IV patients;\\r\\n\\r\\n  6. Within 30 days prior to the screening visit, admission due to acute coronary\\r\\n     syndrome (ST segment elevation myocardial infarction, non ST segment elevation\\r\\n     myocardial infarction, or unstable angina), percutaneous coronary intervention, or\\r\\n     cardiac surgery; Or plan to undergo percutaneous coronary intervention or cardiac\\r\\n     surgery within 3 months.\\r\\n\\r\\n  7. Confirmed respiratory system diseases (such as chronic obstructive pulmonary\\r\\n     disease, pulmonary arterial hypertension, etc.);\\r\\n\\r\\n  8. History of acute or chronic pancreatitis;\\r\\n\\r\\n  9. Uncontrolled hypertension, defined as systolic blood pressure ≥ 160 mmHg and/or\\r\\n     diastolic blood pressure ≥ 100 mmHg (average of three supine blood pressure\\r\\n     measurements) during screening visits;\\r\\n\\r\\n 10. Patients with orthostatic hypotension and/or systolic blood pressure&lt;90 mmHg at\\r\\n     visit 0 or visit 1, or clinically diagnosed as having low blood volume;\\r\\n\\r\\n 11. Diagnosed malignant tumor patients with an expected life expectancy of less than 1\\r\\n     year;\\r\\n\\r\\n 12. Patients with a history of recurrent urinary and reproductive tract infections\\r\\n     (judged by clinical doctors);\\r\\n\\r\\n 13. Patients who participate in other clinical trials within 3 months;\\r\\n\\r\\n 14. Alcohol or drug addiction.\\r\\n\\r\\n 15. In addition to the above, the researchers determined that patients who are not\\r\\n     suitable to participate in this clinical trial.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Junqing Zhang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '8613611167278',\n",
       "      'email': 'nan.gu@pkufh.cn'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003920',\n",
       "      'term': 'Diabetes Mellitus'},\n",
       "     {'id': 'D000003924', 'term': 'Diabetes Mellitus, Type 2'}],\n",
       "    'ancestors': [{'id': 'D000044882', 'term': 'Glucose Metabolism Disorders'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7115',\n",
       "      'name': 'Diabetes Mellitus',\n",
       "      'asFound': 'Diabetes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7119',\n",
       "      'name': 'Diabetes Mellitus, Type 2',\n",
       "      'asFound': 'Type 2 Diabetes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M25403',\n",
       "      'name': 'Glucose Metabolism Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M11667',\n",
       "      'name': 'Metformin',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T15', 'name': 'Proline', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06420362',\n",
       "    'orgStudyIdInfo': {'id': '80-23-05'},\n",
       "    'organization': {'fullName': 'Biruni University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Blood Flow Restriction Training in Basketball Players',\n",
       "    'officialTitle': 'Examination of the Effect of Exercise Training With Upper Extremity Blood Flow Restriction on Upper Extremity Muscle Strength and Performance in Basketball Players'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-15', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-09',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Buket AKINCI',\n",
       "     'investigatorTitle': 'Assoc.Prof.',\n",
       "     'investigatorAffiliation': 'Biruni University'},\n",
       "    'leadSponsor': {'name': 'Biruni University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Blood Flow Restrictive Exercises (BFR) provide strength increase with less load than\\r\\nrequired for traditional muscle strengthening and power. As an alternative for\\r\\npopulations that have difficulty training with high loads and speeds, low-intensity BFR\\r\\ntraining has been shown to improve muscle strength and aerobic parameters and to be safe,\\r\\neven in professional athletes and individuals with chronic diseases in various\\r\\npopulations. The aim of our study is to examine the effects of BFR applied to the upper\\r\\nextremity on upper extremity muscle strength and performance in basketball players.',\n",
       "    'detailedDescription': 'Basketball is a demanding sport that requires participants to display a high level of\\r\\nphysical fitness and special sporting skills. Basketball requires a high level of\\r\\nanaerobic and aerobic conditioning and is not only a team sport, but also a sport that\\r\\nrequires players to demonstrate their individual characteristics. In this regard, it is\\r\\nthought that the determination of performance components based on field tests is a more\\r\\nsuitable method for determining the athletic levels of athletes with special needs.\\r\\n\\r\\nBFR, which aims to restrict blood flow to the muscle during exercise, is traditionally\\r\\nknown as \\'kaatsu\\'. Blood flow is restricted with a pressure-controlled and monitorable\\r\\nexercise belt produced for BFR. In order for the method to be successful, the tourniquet\\r\\nmethod must be applied to the proximal region of the extremity, and in this way, less\\r\\nblood flow to the muscle can actually be achieved.\\r\\n\\r\\nWith BFR, it is recommended that the external pressure be made sufficient to restrict the\\r\\narterial oxygen pressure between 40% and 80%, and it is thought that the effects of\\r\\nexercise increase in this hypoxic environment. In this way, it is sufficient to perform\\r\\nthe exercises at 20% to 40% of the 1 maximum repetition, not 60-85%, which is normally\\r\\nrequired for muscle hypertrophy. An ischemic and hypoxic muscle environment during BFR;\\r\\nIt has been hypothesized that it is produced to cause high levels of metabolic stress and\\r\\nmechanical tension. Both metabolic stress and mechanical tension have been described as\\r\\n\"primary hypertrophy factors\" and are theorized to activate other mechanisms for muscle\\r\\ngrowth.\\r\\n\\r\\nStrength training performed by restricting blood flow plays an important role in muscle\\r\\nhypertrophy by activating the endocrine system. It has been proven that low-intensity\\r\\nblood flow restriction training increases the plasma concentration of growth hormone more\\r\\nthan normal exercises. BFR involves low-intensity resistance training and is placed on\\r\\nthe proximal portion of the lower or upper extremity muscles to be worked with a bandage\\r\\nor cuff that restricts blood flow, providing appropriate superficial pressure.\\r\\n\\r\\nThe aim of this study is to examine the effects of BFR applied to the upper extremity on\\r\\nupper extremity muscle strength and performance in basketball players.'},\n",
       "   'conditionsModule': {'conditions': ['Basketball Players'],\n",
       "    'keywords': ['bloodflowrestriction',\n",
       "     'basketball',\n",
       "     'basketball performance',\n",
       "     'kaatsu training']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Blood Flow Restriction Training Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'While the basketball players continue their current basketball training; The 90-minute\\r\\nBFR program will be applied 3 sessions a week for 3 weeks. In the BFR program, biceps\\r\\ncurls, triceps curls, shoulder presses, shoulder abduction exercises and sport-specific\\r\\nroutine training will be applied. Exercises: 30% of 1 maximum repetition with resistance\\r\\nand 60% of arterial occlusion pressure restricted; Based on previous studies in the\\r\\nliterature, the first set will be performed with 30 repetitions and the other three sets\\r\\nwith 15 repetitions, a total of 4 sets and a 30-second rest between sets. There will be a\\r\\n10-minute warm-up exercise before each BFR training and a 10-minute cool-down exercise at\\r\\nthe end of the training.',\n",
       "      'interventionNames': ['Other: Blood Flow Restriction']},\n",
       "     {'label': 'Routine Training',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Initial evaluations will be made for all participants. Then, they will continue their\\r\\nroutine basketball training programs for 3 weeks.'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Blood Flow Restriction',\n",
       "      'description': 'Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a\\r\\nweight with which athletes can perform a maximum of 10 repetitions. The number of\\r\\nrepetitions obtained here and the weight lifted will be written into the Brzycki formula,\\r\\nwhose validity and reliability has been proven, and 1-TM will be calculated.\\r\\n\\r\\nBrzycki formula; 1-TM = [100 x (Weight Lifted) / [(102.78 - 2.78 x (Number of Reps)] The\\r\\narterial occlusion pressure of the participants will be measured with a Doppler\\r\\nUltrasound device by increasing the cuff to the point where the auscultatory pulse of the\\r\\nbrachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this\\r\\nvalue will be calculated and BFR will be performed during the exercises.',\n",
       "      'armGroupLabels': ['Blood Flow Restriction Training Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Bench press test',\n",
       "      'description': \"Bench Press 1RM test will be applied for upper extremity muscle strength. the athlete's\\r\\n1RM weight will be determined.\",\n",
       "      'timeFrame': 'Change from Baseline Bench press test at 3 weeks and 6 weeks'},\n",
       "     {'measure': 'Hand Grip Strength',\n",
       "      'description': '\"Jamar (NY 10533)\" brand dynamometer, one of the hydraulic measuring instruments, will be\\r\\nused to measure grip force.',\n",
       "      'timeFrame': 'Change from Baseline Hand Grip Strength at 3 weeks and 6 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': '20 m Sprint Test',\n",
       "      'description': 'A 20 m speed test will be applied to evaluate the speed of the participants. Running\\r\\nbasketball players will be asked to run the 20-meter track at maximum level after\\r\\nstarting.',\n",
       "      'timeFrame': 'Change from Baseline Bench press test at 3 weeks and 6 weeks'},\n",
       "     {'measure': 'T Agility Test',\n",
       "      'description': 'T test will be applied to evaluate the agility of the participants.The best time of the\\r\\nparticipants will be recorded.',\n",
       "      'timeFrame': 'Change from Baseline T Agility Test at 3 weeks and 6 weeks'},\n",
       "     {'measure': 'Free Throw Test',\n",
       "      'description': 'A shooting test will be applied to evaluate the shooting skills of the athletes. Athletes\\r\\nwill be asked to make 2 sets of free throws with 8 repetitions after the \"Start\" command\\r\\nfrom the starting position behind the foul (free throw) line. Total scores will be\\r\\nrecorded at the end of the test.',\n",
       "      'timeFrame': 'Change from Baseline Free Throw Test at 3 weeks and 6 weeks'},\n",
       "     {'measure': 'Fatigue Assessment',\n",
       "      'description': 'The modified Borg CR10 scale will be used to evaluate perceived fatigue.',\n",
       "      'timeFrame': 'immediately after each BFR session'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Being between the ages of 18-25,\\r\\n\\r\\n  -  Having been attending training regularly for at least one year,\\r\\n\\r\\n  -  Having been playing basketball as a licensed player for at least 3 months,\\r\\n\\r\\n  -  Male athletes,\\r\\n\\r\\n  -  Volunteering to participate in the study\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Individuals with orthopedic or neurological disabilities that may prevent the\\r\\n     exercise test,\\r\\n\\r\\n  -  Individuals who have had a sports injury in the last 6 months,\\r\\n\\r\\n  -  Not actively participating in training,\\r\\n\\r\\n  -  Taking a break from sports\\r\\n\\r\\n  -  Individuals with inadequate cooperation',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '25 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Buket AKINCI, Assoc.Prof.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+90 212 409 12 12',\n",
       "      'phoneExt': '1208',\n",
       "      'email': 'bakinci@biruni.edu.tr'},\n",
       "     {'name': 'Busra ERDEM, PT',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+90 530 084 18 51',\n",
       "      'email': 'berdemerdemb@gmail.com'}],\n",
       "    'overallOfficials': [{'name': 'Buket AKINCI, Assoc.Prof.',\n",
       "      'affiliation': 'Biruni University',\n",
       "      'role': 'STUDY_CHAIR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "    'description': 'The data will be shared during the publication process if the journal will ask.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT04955210',\n",
       "    'orgStudyIdInfo': {'id': 'fdpicu-18'},\n",
       "    'organization': {'fullName': \"Children's Hospital of Fudan University\",\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children',\n",
       "    'officialTitle': 'Establishment of a Multi-Center Big Data System for Severe Infection and a Collaborative Network on Sepsis in Chinese Children'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-02',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2021-03-26',\n",
       "    'studyFirstSubmitQcDate': '2021-07-04',\n",
       "    'studyFirstPostDateStruct': {'date': '2021-07-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-06',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': \"Children's Hospital of Fudan University\",\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': '  1. To research the current situation of severe infection in children in China, and to\\r\\n     investigate the incidence, prognosis and disease burden of severe infection in\\r\\n     children in different regions of China. 2. Establish the risk prediction model and\\r\\n     diagnosi model of severe infection in children, and verify the accuracy of the model\\r\\n     in multi-center; 3. To study the effectiveness and safety of different treatments in\\r\\n     real diagnosis and treatment, and to evaluate the efficacy of subgroups under\\r\\n     different ages and high risk factors.',\n",
       "    'detailedDescription': \"1.Children between 0 and 18 years old. 2.Severe pneumonia and/or sepsis.Patients were\\r\\nincluded who meet the guidline for diagnosis and treatment of community-acquired\\r\\npneumonia in Children (2019) issued by the National Health Commission of the people's\\r\\nRepublic of China and/or who meet the International Guide to the 2020 campaign to Save\\r\\nsepsis: management of septic shock and sepsis-related organ dysfunction in children.\\r\\n3.notifiable infectious diseases.4.The researcher believes that he is not suitable to\\r\\nparticipate in other situations in this study.5.Participants in other clinical trials in\\r\\nthe same period.\"},\n",
       "   'conditionsModule': {'conditions': ['Critical Illness', 'Severe Sepsis'],\n",
       "    'keywords': ['Sepsis', 'Critical Illness', 'severe infection']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'OTHER',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 5000, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Severe infection',\n",
       "      'description': 'Children with severe infection in PICU',\n",
       "      'interventionNames': ['Other: Not applicable（Cohort study）']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Not applicable（Cohort study）',\n",
       "      'description': 'This is a prospective observational study and does not include interventions.',\n",
       "      'armGroupLabels': ['Severe infection']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'survival rate',\n",
       "      'description': 'The survival rate of children in 28 days after their discharged from PICU',\n",
       "      'timeFrame': 'within 28 days after they discharged from PICU'}],\n",
       "    'secondaryOutcomes': [{'measure': 'length of stay in PICU',\n",
       "      'description': 'Time from PICU admission to discharge',\n",
       "      'timeFrame': 'within 28 days after they discharged from PICU'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Children between 0 and 18 years old.\\r\\n\\r\\n  2. Severe pneumonia and/or sepsis.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. notifiable infectious diseases.\\r\\n\\r\\n  2. The researcher believes that he is not suitable to participate in other situations\\r\\n     in this study.\\r\\n\\r\\n  3. Participants in other clinical trials in the same period.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '29 Days',\n",
       "    'maximumAge': '18 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT'],\n",
       "    'studyPopulation': \"All children hospitalized in PICU of Children's Hospital of Fudan University from April\\r\\n2021 to April 2025\",\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Guoping Lu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '13788904150',\n",
       "      'email': '13788904150@163.com'}],\n",
       "    'overallOfficials': [{'name': 'Guoping Lu',\n",
       "      'affiliation': \"The Children's Hospital of Fudan University\",\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007239',\n",
       "      'term': 'Infections'},\n",
       "     {'id': 'D000018805', 'term': 'Sepsis'},\n",
       "     {'id': 'D000014115', 'term': 'Toxemia'},\n",
       "     {'id': 'D000016638', 'term': 'Critical Illness'}],\n",
       "    'ancestors': [{'id': 'D000018746',\n",
       "      'term': 'Systemic Inflammatory Response Syndrome'},\n",
       "     {'id': 'D000007249', 'term': 'Inflammation'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'}],\n",
       "    'browseLeaves': [{'id': 'M19010',\n",
       "      'name': 'Critical Illness',\n",
       "      'asFound': 'Critical Illness',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M20864',\n",
       "      'name': 'Sepsis',\n",
       "      'asFound': 'Sepsis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16869',\n",
       "      'name': 'Toxemia',\n",
       "      'asFound': 'Sepsis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M20818',\n",
       "      'name': 'Systemic Inflammatory Response Syndrome',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10293', 'name': 'Inflammation', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC01', 'name': 'Infections'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06314646',\n",
       "    'orgStudyIdInfo': {'id': '3747'},\n",
       "    'organization': {'fullName': 'Istituto Clinico Humanitas',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Transanal Transection and Single-stapled Anastomosis (TTSS) in Rectal Cancer Patients',\n",
       "    'officialTitle': 'Postoperative and Long-term Outcomes of Transanal Tran-section and Single-stapled Anastomosis (TTSS) in Rectal Can-cer Patients: a Multicentric International IDEAL Stage 2b Prospective Parallel Cohort Study',\n",
       "    'acronym': 'TTSS-REC'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-11',\n",
       "    'studyFirstSubmitQcDate': '2024-03-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-18',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Istituto Clinico Humanitas', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The Transanal Transection and Single-Stapled anastomosis (TTSS) technique may be a valid\\r\\nalternative to traditional double-stapled anastomosis for low rectal cancer surgery. This\\r\\nstudy aims to compare the postoperative and functional outcomes of patients receiving\\r\\nTTSS and traditional double-stapled anastomosis.',\n",
       "    'detailedDescription': 'The Transanal Transection and Single-Stapled anastomosis (TTSS) technique has become a\\r\\nvalid alternative to the standard double-stapled anastomosis approach in the surgical\\r\\ntreatment of low rectal cancer. Recent evidence showed a significantly reduced number of\\r\\nanastomotic leaks in patients undergoing TTSS compared with patients receiving\\r\\ndouble-stapled anastomosis, suggesting that TTSS may be technically feasible and may\\r\\nprovide a surgical advantage over the traditional double-stapled technique. However,\\r\\nthese studies were severely limited by their single-center and retrospective nature. This\\r\\nstudy aims to confirm the retrospective findings by extending the data collection to\\r\\nadditional countries and provide prospective data collection.'},\n",
       "   'conditionsModule': {'conditions': ['Rectal Cancer', 'Surgery'],\n",
       "    'keywords': ['Rectal Cancer',\n",
       "     'Transanal Transection and Single-Stapled anastomosis',\n",
       "     'Total Mesorectal Excision']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 472, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Transanal Transection and Single-Stapled anastomosis (TTSS)',\n",
       "      'description': 'Patients will undergo rectal cancer surgery through low rectal resection with Transanal\\r\\nTransection and Single-Stapled anastomosis (TTSS)',\n",
       "      'interventionNames': ['Procedure: Transanal Transection and Single-Stapled anastomosis (TTSS)']},\n",
       "     {'label': 'Double-stapled Total Mesorectal Excision (TME)',\n",
       "      'description': 'Patients will undergo rectal cancer surgery through low rectal resection with\\r\\ndouble-stapled anastomosis Total Mesorectal Excision (TME)',\n",
       "      'interventionNames': ['Procedure: Double-stapled Total Mesorectal Excision (TME)']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Transanal Transection and Single-Stapled anastomosis (TTSS)',\n",
       "      'description': 'Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis\\r\\n(TTSS)',\n",
       "      'armGroupLabels': ['Transanal Transection and Single-Stapled anastomosis (TTSS)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Double-stapled Total Mesorectal Excision (TME)',\n",
       "      'description': 'Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)',\n",
       "      'armGroupLabels': ['Double-stapled Total Mesorectal Excision (TME)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of anastomotic leak',\n",
       "      'description': 'Rate difference of clinical and/or radiological anastomotic leaks in the study cohorts.',\n",
       "      'timeFrame': '90 days after surgery'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Rate of postoperative complications',\n",
       "      'description': 'Rate difference of overall postoperative complications- classified according to the\\r\\nClavien-Dindo scale [ranging from 0 (no complications) to 5 (complications leading to\\r\\ndeath)]- in the study cohorts.',\n",
       "      'timeFrame': '90 days after surgery'},\n",
       "     {'measure': 'Postoperative Recovery Profile (PRP) score',\n",
       "      'description': 'Median difference of Postoperative Recovery Profile (PRP) [ranging from 0 (completely\\r\\nrecovered) to 68 (not recovered)] in the study cohorts.',\n",
       "      'timeFrame': '90 days after surgery'},\n",
       "     {'measure': 'Proportion of patients fit for stoma closure',\n",
       "      'description': 'Proportion difference of patients fit for stoma closure in the study cohorts. Patients\\r\\nfit for stoma closure have already closed the stoma or have an intact anastomosis as\\r\\ndemonstrated by a water contrast enema, Computed Tomography (CT) scan, endoscopic, or\\r\\nsurgical revision.',\n",
       "      'timeFrame': '12 months after surgery'},\n",
       "     {'measure': 'Healthcare costs',\n",
       "      'description': 'Median difference of healthcare costs (direct and indirect) in the study cohorts.',\n",
       "      'timeFrame': '12 months after surgery'},\n",
       "     {'measure': 'Low Anterior Resection Syndrome (LARS) score',\n",
       "      'description': 'Median difference of Low Anterior Resection Syndrome (LARS) score [ranging from 0 (no\\r\\nLARS symptoms) to 42 (severe LARS symptoms)] in the study cohorts.',\n",
       "      'timeFrame': '6 months after surgery or stoma closure'},\n",
       "     {'measure': 'Low Anterior Resection Syndrome (LARS) score',\n",
       "      'description': 'Median difference of Low Anterior Resection Syndrome (LARS) score [ranging from 0 (no\\r\\nLARS symptoms) to 42 (severe LARS symptoms)] in the study cohorts.',\n",
       "      'timeFrame': '12 months after surgery or stoma closure'},\n",
       "     {'measure': 'Low Anterior Resection Syndrome (LARS) score',\n",
       "      'description': 'Median difference of Low Anterior Resection Syndrome (LARS) score [ranging from 0 (no\\r\\nLARS symptoms) to 42 (severe LARS symptoms)] in the study cohorts.',\n",
       "      'timeFrame': '24 months after surgery or stoma closure'},\n",
       "     {'measure': 'Cancer recurrence',\n",
       "      'description': 'Incidence rate difference of cancer recurrence- defined as any local or distal recurrence\\r\\nor metastasis- in the study cohorts.',\n",
       "      'timeFrame': '24 months after surgery'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adult (≥ 18 years old) patients, men and women, diagnosed with rectal cancer\\r\\n     scheduled for elective rectal resection with Total Mesorectal Excision (TME) with\\r\\n     double-stapled or Transanal Transection and Single-Stapled anastomosis (TTSS)\\r\\n     approaches.\\r\\n\\r\\n  -  Patients scheduled for open, laparoscopic, or robotic surgery.\\r\\n\\r\\n  -  Patients preoperatively indicated for sphincter-saving procedures with or without\\r\\n     protective-stoma.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Immediate or delayed hand-sewn coloanal anastomosis.\\r\\n\\r\\n  -  Patients requiring abdominoperineal resection (APR). Patients undergoing unplanned\\r\\n     non-reconstructive surgery will be withdrawn from the study.\\r\\n\\r\\n  -  Patients with concurrent or previous invasive pelvic malignant tumors. Patients with\\r\\n     an intraoperative evidence of invasive pelvic malignant tumors will be withdrawn\\r\\n     from the study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'The study population will include adult patients diagnosed with rectal cancer scheduled\\r\\nfor elective rectal resection with double-stapled or Transanal Transection and\\r\\nSingle-Stapled anastomosis (TTSS).',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Annalisa Maroli, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '02 8224 7776',\n",
       "      'phoneExt': '0039',\n",
       "      'email': 'colorapp@humanitas.it'},\n",
       "     {'name': 'Stefano De Zanet, MS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '02 8224 4623',\n",
       "      'phoneExt': '0039',\n",
       "      'email': 'colorapp@humanitas.it'}],\n",
       "    'overallOfficials': [{'name': 'Antonino Spinelli, MD, PhD',\n",
       "      'affiliation': 'IRCCS Huamanitas Research Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000012004',\n",
       "      'term': 'Rectal Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000015179', 'term': 'Colorectal Neoplasms'},\n",
       "     {'id': 'D000007414', 'term': 'Intestinal Neoplasms'},\n",
       "     {'id': 'D000005770', 'term': 'Gastrointestinal Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000012002', 'term': 'Rectal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14846',\n",
       "      'name': 'Rectal Neoplasms',\n",
       "      'asFound': 'Rectal Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17890', 'name': 'Colorectal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M10448', 'name': 'Intestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14844', 'name': 'Rectal Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06254495',\n",
       "    'orgStudyIdInfo': {'id': 'SGN35C-001'},\n",
       "    'organization': {'fullName': 'Seagen Inc.', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Safety Study of SGN-35C in Adults With Advanced Cancers',\n",
       "    'officialTitle': 'A Phase 1, Open-label Study to Evaluate SGN-35C in Adults With Advanced Malignancies'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-02-28', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-08-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-02',\n",
       "    'studyFirstSubmitQcDate': '2024-02-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-12', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Seagen Inc.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood\\r\\ncells that fight infection. There are several types of lymphoma. This study will enroll\\r\\npeople who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or\\r\\ndiffuse large B cell lymphoma (DLBCL).\\r\\n\\r\\nThis clinical trial uses a drug called SGN-35C . The study drug is in testing and has not\\r\\nbeen approved for sale. This is the first time SGN -35C will be used in people.\\r\\n\\r\\nThis study will test the safety of SGN-35C in participants with lymphoma. It will also\\r\\nstudy the side effects of this drug. A side effect is anything a drug does to the body\\r\\nbesides treating the disease.\\r\\n\\r\\nThis study will have three parts. Parts A and B of the study will find out the best dose\\r\\nand dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find\\r\\nout how safe SGN-35C is and if it works to treat select lymphomas.'},\n",
       "   'conditionsModule': {'conditions': ['Hodgkin Disease',\n",
       "     'Lymphoma, T-Cell, Peripheral',\n",
       "     'Lymphoma, Large B-Cell, Diffuse',\n",
       "     'Lymphoma, Large-Cell, Anaplastic'],\n",
       "    'keywords': ['cHL', 'PTCL', 'sALCL', 'DLBCL', 'Seattle Genetics']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 170, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'SGN-35C',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SGN-35C Monotherapy',\n",
       "      'interventionNames': ['Drug: SGN-35C']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'SGN-35C',\n",
       "      'description': 'Given into the vein (IV; intravenously)',\n",
       "      'armGroupLabels': ['SGN-35C']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with adverse events (AEs)',\n",
       "      'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally\\r\\nassociated with the use of study intervention , whether or not considered related to the\\r\\nstudy intervention',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Number of participants with laboratory abnormalities',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Number of participants with dose modifications due to AEs',\n",
       "      'timeFrame': 'Up to approximately 1 year'},\n",
       "     {'measure': 'Number of participants with dose-limiting toxicities (DLTs)',\n",
       "      'timeFrame': 'Up to 21 days'},\n",
       "     {'measure': 'Number of participants with DLTs by dose level',\n",
       "      'timeFrame': 'Up to 21 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Number of participants with antidrug antibodies (ADA)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Area under the concentration time curve (AUC)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Maximum concentration (Cmax)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Time at which the maximum concentration occurs (Tmax)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Apparent terminal half-life (t1/2)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Trough concentration (Ctrough)',\n",
       "      'description': 'To be summarized using descriptive statistics',\n",
       "      'timeFrame': 'Through 30-37 days after last study treatment, approximately 1 year'},\n",
       "     {'measure': 'Objective response rate (ORR) as assessed by the investigator',\n",
       "      'description': 'A participant is determined to have an objective response if, based on Lugano criteria\\r\\n(Cheson 2014), they achieve a complete response (CR) or partial response (PR) as assessed\\r\\nby the investigator. The ORR is defined as the percentage of participants with an\\r\\nobjective response.',\n",
       "      'timeFrame': 'Up to approximately 1 year'},\n",
       "     {'measure': 'CR rate as assessed by the investigator',\n",
       "      'description': 'CR rate is defined as the proportion of participants with CR.',\n",
       "      'timeFrame': 'Up to approximately 1 year'},\n",
       "     {'measure': 'Duration of response (DOR)',\n",
       "      'description': 'DOR is defined as the time from the start of the first documentation of objective tumor\\r\\nresponse (CR or PR) to the first documentation of tumor progression per Lugano criteria\\r\\n(Cheson 2014) as assessed by the investigator or to death due to any cause, whichever\\r\\ncomes first.',\n",
       "      'timeFrame': 'Up to approximately 1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Tumor type\\r\\n\\r\\n  -  For dose escalation and dose optimization (Parts A and B):\\r\\n\\r\\n       -  Participants with a histologically confirmed lymphoid neoplasm who in the\\r\\n          judgement of the investigator have no appropriate standard therapy available at\\r\\n          the time of enrollment and are a candidate for SGN- 35C treatment. Eligible\\r\\n          subtypes and treatment status are as follows:\\r\\n\\r\\n            -  Participants with relapsed/refractory (R/R) cHL: should have received at\\r\\n               least 3 prior systemic therapies including autologous stem cell transplant\\r\\n               [ASCT] (ASCT and the associated high-dose chemotherapy prior to ASCT are\\r\\n               considered to be 1 prior line) or an anti-PD-1 agent (or refused/were\\r\\n               ineligible); or 2 prior systemic therapies if, according to the\\r\\n               investigator, no other appropriate standard treatment is available.\\r\\n\\r\\n            -  Participants with R/R PTCL (excluding systematic anaplastic large cell\\r\\n               lymphoma [sALCL]): should have received at least 2 prior systemic\\r\\n               therapies, or 1 prior systemic therapy if, according to the investigator,\\r\\n               no other appropriate standard treatment is available.\\r\\n\\r\\n            -  Participants with R/R sALCL: should have received at least 2 prior\\r\\n               systemic therapies, including 1 brentuximab vedotin-containing regimen, or\\r\\n               1 prior line of systemic therapy including brentuximab vedotin,\\r\\n               cyclophosphamide, doxorubicin, and prednisone.\\r\\n\\r\\n            -  Participants with R/R DLBCL: should have received at least 2 prior\\r\\n               systemic therapies, including ASCT and chimeric antigen receptor (CAR)\\r\\n               T-cell therapy, or were ineligible, or refused.\\r\\n\\r\\n       -  Participants with PTCL and DLBCL must have a detectable cluster of\\r\\n          differentiation 30 (CD30) expression level (≥1%) in tumor tissue from the most\\r\\n          recent biopsy obtained at or after relapse by local testing.\\r\\n\\r\\n  -  For dose expansion (Part C):\\r\\n\\r\\n       -  Participants are eligible irrespective of CD30 expression on tumor tissue;\\r\\n          however, participants must provide tumor tissue for evaluation of CD30\\r\\n          expression from the most recent biopsy obtained at or after relapse.\\r\\n\\r\\n       -  Participants with cHL, PTCL, sALCL, and DLBCL: Eligible subtypes are the same\\r\\n          as defined in Parts A and B\\r\\n\\r\\n       -  If activated, the biology cohort may enroll the populations included in Parts\\r\\n          A, B, and C.\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1\\r\\n\\r\\n  -  Fluorodeoxyglucose positron emission tomography (FDG-PET) avid and bidimensional\\r\\n     measurable disease as documented by radiographic technique (spiral computed\\r\\n     tomography [CT] preferred)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Previous exposure to any antibody-drug conjugates (ADCs) with camptothecin-based\\r\\n     payload.\\r\\n\\r\\n  -  History of another malignancy within 3 years before the first dose of study drug, or\\r\\n     any evidence of residual disease from a previously diagnosed malignancy. Exceptions\\r\\n     are malignancies with a negligible risk of metastasis or death\\r\\n\\r\\n  -  Active cerebral/meningeal disease related to the underlying malignancy\\r\\n\\r\\n  -  Received previous ASCT infusion <12 weeks prior to the first dose of SGN-35C.\\r\\n\\r\\n  -  Previous allogeneic stem cell transplant (SCT) if they meet any of the following\\r\\n     criteria:\\r\\n\\r\\n       -  <100 days from allogeneic SCT. Participants ≥100 days from allogeneic SCT who\\r\\n          are stable without immunosuppressive therapy for at least 12 weeks are\\r\\n          permitted.\\r\\n\\r\\n       -  Active acute or chronic graft-versus-host disease (GVHD) or receiving\\r\\n          immunosuppressive therapy as treatment for or prophylaxis against GVHD.\\r\\n\\r\\n  -  History of clinically significant GI bleeding, intestinal obstruction, or GI\\r\\n     perforation within 6 months of initiation of trial treatment.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Seagen Trial Information Support',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '866-333-7436',\n",
       "      'email': 'clinicaltrials@seagen.com'}],\n",
       "    'overallOfficials': [{'name': 'Medical Monitor',\n",
       "      'affiliation': 'Seagen Inc.',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'City of Hope',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Duarte',\n",
       "      'state': 'California',\n",
       "      'zip': '91010',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Alex F Herrera',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '626-256-4673',\n",
       "        'email': 'aherrera@coh.org'},\n",
       "       {'name': 'Alex F Herrera', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008223',\n",
       "      'term': 'Lymphoma'},\n",
       "     {'id': 'D000006689', 'term': 'Hodgkin Disease'},\n",
       "     {'id': 'D000016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'},\n",
       "     {'id': 'D000016399', 'term': 'Lymphoma, T-Cell'},\n",
       "     {'id': 'D000016411', 'term': 'Lymphoma, T-Cell, Peripheral'},\n",
       "     {'id': 'D000017728', 'term': 'Lymphoma, Large-Cell, Anaplastic'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008232', 'term': 'Lymphoproliferative Disorders'},\n",
       "     {'id': 'D000008206', 'term': 'Lymphatic Diseases'},\n",
       "     {'id': 'D000007160', 'term': 'Immunoproliferative Disorders'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000016393', 'term': 'Lymphoma, B-Cell'},\n",
       "     {'id': 'D000008228', 'term': 'Lymphoma, Non-Hodgkin'}],\n",
       "    'browseLeaves': [{'id': 'M11220',\n",
       "      'name': 'Lymphoma',\n",
       "      'asFound': 'Lymphoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18829',\n",
       "      'name': 'Lymphoma, T-Cell',\n",
       "      'asFound': 'Lymphoma, T-Cell',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18833',\n",
       "      'name': 'Lymphoma, T-Cell, Peripheral',\n",
       "      'asFound': 'Lymphoma, T-Cell, Peripheral',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18831',\n",
       "      'name': 'Lymphoma, Large B-Cell, Diffuse',\n",
       "      'asFound': 'Lymphoma, Large B-Cell, Diffuse',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9751',\n",
       "      'name': 'Hodgkin Disease',\n",
       "      'asFound': \"Hodgkin's Disease\",\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19941',\n",
       "      'name': 'Lymphoma, Large-Cell, Anaplastic',\n",
       "      'asFound': 'Lymphoma, Large-Cell, Anaplastic',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11225',\n",
       "      'name': 'Lymphoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10206',\n",
       "      'name': 'Immunoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M18828', 'name': 'Lymphoma, B-Cell', 'relevance': 'LOW'},\n",
       "     {'id': 'M11222', 'name': 'Lymphoma, Non-Hodgkin', 'relevance': 'LOW'},\n",
       "     {'id': 'T3543',\n",
       "      'name': 'Lymphosarcoma',\n",
       "      'asFound': 'Lymphoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T2817', 'name': 'Hodgkin Lymphoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T640', 'name': 'B-cell Lymphoma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000079963',\n",
       "      'term': 'Brentuximab Vedotin'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000000922', 'term': 'Immunotoxins'},\n",
       "     {'id': 'D000018796', 'term': 'Immunoconjugates'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M2088',\n",
       "      'name': 'Brentuximab Vedotin',\n",
       "      'asFound': 'Sustained',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4241', 'name': 'Immunotoxins', 'relevance': 'LOW'},\n",
       "     {'id': 'M20855', 'name': 'Immunoconjugates', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06413355',\n",
       "    'orgStudyIdInfo': {'id': '19923'},\n",
       "    'organization': {'fullName': 'Abramson Cancer Center at Penn Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'FAPI-74 PET/CT in Adults With Fibrosis',\n",
       "    'officialTitle': 'Fibroblast Activating Protein (FAP) PET/CT in Adults With Fibrotic Conditions'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-09',\n",
       "    'studyFirstSubmitQcDate': '2024-05-09',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Abramson Cancer Center at Penn Medicine',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This protocol is intended as a basket protocol designed to evaluate the use of Fibroblast\\r\\nActivating Protein (FAP) PET/CT in imaging the presence of fibrosis caused by a variety\\r\\nof medical conditions where fibrosis is believed to lead to pathological effects and poor\\r\\nprognosis.',\n",
       "    'detailedDescription': 'A study to evaluate subjects with fibrosis-inducing medical conditions that are known or\\r\\nsuspected to cause tissue fibrosis (e.g. cancer-associated, post-infection,\\r\\npost-radiation, pre or post-transplant, cardiac, liver, kidney or pulmonary fibrosis).\\r\\nThis protocol is intended to expand as needed with imaging arms designed to evaluate the\\r\\nuse of Fibroblast Activating Protein (FAP) PET/ CT in imaging the presence fibrosis\\r\\ncaused by medical conditions where fibrosis is believed to lead to pathological effects\\r\\nand poor prognosis.\\r\\n\\r\\n[18F]-FAPI-74 is a positron emitting radiolabeled FAP inhibitor that will be used with a\\r\\npositron emission tomography/computed tomography (PET/CT) scan that will be completed in\\r\\neach subject who has a clinical suspicion of fibrotic disease.\\r\\n\\r\\nPET/CT imaging will be used to evaluate the distribution of fibroblast activating protein\\r\\n(FAP) in major organs and other tissues affected with fibrotic diseases or conditions.\\r\\nThis is an observational study in that [F-18]-FAPI-74 PET/CT will not be used to direct\\r\\ntreatment decisions. While patients and referring physicians will not be blinded to the\\r\\n[F-18]-FAPI-74 PET/CT results, any medical or treatment decisions related to their\\r\\nunderlying clinical diagnosis will be made by the treating physicians based upon clinical\\r\\ncriteria.\\r\\n\\r\\nAfter injection of [F-18]-FAPI-74, patients will undergo a vertex to mid-thigh scan,\\r\\nstarting at approximately 60 minutes post injection. PET/CT imaging sessions will include\\r\\nan injection of approximately 8.0 mCi (expected range of doses is expected to be 6.0-8.0\\r\\nmCi) of [F-18]-FAPI-74 intravenously. Data will be collected to evaluate uptake of\\r\\n[F-18]-FAPI-74 in sites of suspected fibrosis and in major organs.\\r\\n\\r\\nAn optional second PET/CT using [F-18]-FAPI-74 can be considered at the request of the\\r\\ninvestigators at any clinically relevant time point. This second scan may be used to\\r\\nquantify the changes in fibrosis over time as part of the natural progression of the\\r\\nfibrotic condition, or to observe changes in [F-18]- FAPI-74 uptake in response to\\r\\ntherapeutic interventions.'},\n",
       "   'conditionsModule': {'conditions': ['Fibrosis (Morphologic Abnormality)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'DIAGNOSTIC',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 25, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'FAPI-74 PET/CT Scan',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Head and neck cancer (up to 5 subjects), post tubercular lung disease (PTLD, up to 10\\r\\nsubjects) and exploratory (up to 10 subjects) with fibrosis-inducing medical conditions\\r\\nthat are known or suspected to cause tissue fibrosis (e.g. cancer-associated,\\r\\npostinfection, post-radiation, pre/post-transplant, cardiac, liver, kidney or pulmonary\\r\\nfibrosis).',\n",
       "      'interventionNames': ['Drug: [F-18]-FAPI-74']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': '[F-18]-FAPI-74',\n",
       "      'description': 'A positron-emitting radiopharmaceutical that has been studied in animals for selective\\r\\nmeasurement of the in vivo expression of FAP with positron emission tomography (PET/CT).',\n",
       "      'armGroupLabels': ['FAPI-74 PET/CT Scan'],\n",
       "      'otherNames': [\"[18F] aluminium fluorine ((S)-2,2'(7- (2-(4-(3-(4-(2-(2- cyanopyrrolidin-1-yl)-2 oxoethylcarbamoyl)quinolin-6-yloxy) propyl)piperazin-1-yl)-2-oxoethyl)-1,4,7- triazonane-1,4-diyl)diacetic acid\"]}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall FAPI-74 PET/CT Image Analysis',\n",
       "      'description': 'The overall quality of the generated images will be evaluated. Initial imaging of the\\r\\nvertex to mid-thigh will be used to investigate regional tracer uptake in suspected sites\\r\\nof fibrosis and normal tissues for this novel radiotracer. Uptake and retention of\\r\\n[F-18]-FAPI-74 in known or suspected sites of fibrotic disease will be evaluated visually\\r\\nby trained radiology readers, the principal investigator, or designee. A number of\\r\\nanalysis methods may be tested to identify the optimal method for analyses for future\\r\\nstudies with this radiotracer. [F-18]-FAPI-74 PET/CT scans will be interpreted both\\r\\nqualitatively and quantitatively.',\n",
       "      'timeFrame': '3 years'},\n",
       "     {'measure': 'Head and Neck Cancer FAPI-74 PET/CT Image Analysis',\n",
       "      'description': '[18F]-FAPi74 PET/CT data: Areas of uptake in tumors and healthy tissue will be measured\\r\\nby SUVmax and semiquantitative analysis will be conducted. In each case, lesion uptake\\r\\nwill be marked as low, medium, and high avidity. Each lesion and lymph node will be\\r\\nseparately measured and quantified. Measurements will be made by Dr. Sellmyer and\\r\\nco-Investigators (n=3).',\n",
       "      'timeFrame': '3 years'},\n",
       "     {'measure': 'PTLD FAPI-74 PET/CT Image Analysis',\n",
       "      'description': 'Quantitative interpretation of FAP expression, will be recorded as a Standardized Uptake\\r\\nValue (SUV). Max, mean, and peak SUV values will be recorded for a region-of-interest\\r\\nencompassing a single primary lesion.',\n",
       "      'timeFrame': '3 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nHead and Neck Cancer Cohort:\\r\\n\\r\\n  1. Participants will be ≥ 21 years of age\\r\\n\\r\\n  2. Diagnosis of oropharyngeal squamous cell carcinoma (OPSCC)\\r\\n\\r\\n  3. Determined to be surgical candidates\\r\\n\\r\\nPTLD Cohort:\\r\\n\\r\\n  1. Participants will be ≥ 21 years of age\\r\\n\\r\\n  2. Diagnosed with microbiologically confirmed DS-pTB (culture positive)\\r\\n\\r\\n  3. Completed DS-pTB treatment according to IDSA guidelines in the past 3 months to 2\\r\\n     years\\r\\n\\r\\n  4. Negative test for sputum Mtb culture at least two consecutive times during TB\\r\\n     treatment without a subsequent positive Mtb culture (indicating cure as per CDC\\r\\n     guidelines)\\r\\n\\r\\nAll Cohorts:\\r\\n\\r\\n  1. History of known or suspected fibrosis-inducing medical condition\\r\\n\\r\\n  2. Participants must be informed of the investigational nature of this study and be\\r\\n     willing to provide written informed consent and participate in this study in\\r\\n     accordance with institutional and federal guidelines prior to study-specific\\r\\n     procedures.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nHead and Neck Cancer Cohort:\\r\\n\\r\\n  1. Participant is not eligible for tissue resection\\r\\n\\r\\nPTLD Cohort:\\r\\n\\r\\n  1. Diagnosed with TB that is resistant to rifampin\\r\\n\\r\\n  2. History of alternative pulmonary disease\\r\\n\\r\\n  3. Have been administered corticosteroids or any other systemic investigational agents\\r\\n     within 3 months of screening\\r\\n\\r\\n  4. Have symptoms or signs suggestive of active TB at the time of screening\\r\\n\\r\\nAll Cohorts:\\r\\n\\r\\n  1. Women of childbearing potential may not be pregnant or breastfeeding. A negative\\r\\n     pregnancy test will be required before [F-18]- FAPI-74injection.\\r\\n\\r\\n  2. Inability to tolerate imaging procedures in the opinion of an investigator or\\r\\n     treating physician\\r\\n\\r\\n  3. Any current medical condition, illness, or disorder as assessed by medical record\\r\\n     review and/or self-reported that is considered by a physician investigator to be a\\r\\n     condition that could compromise participant safety or successful participation in\\r\\n     the study\\r\\n\\r\\n  4. Treatment with a therapeutic agent targeting fibroblast activation protein (FAP)\\r\\n     within 1 month prior to study enrollment.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '21 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Erin Schubert',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '215-573-6569',\n",
       "      'email': 'erinschu@pennmedicine.upenn.edu'},\n",
       "     {'name': 'Mary Hansbury',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '215-746-8192',\n",
       "      'email': 'mary.hansbury@pennmedicine.upenn.edu'}],\n",
       "    'overallOfficials': [{'name': 'Mark A Sellmyer, MD, PhD',\n",
       "      'affiliation': 'University of Pennsylvania',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Pennsylvania',\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19104',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Erin Schubert',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '215-573-6569',\n",
       "        'email': 'erinshu@pennmedicine.upenn.edu'},\n",
       "       {'name': 'Mark A Sellymer, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'mark.sellymer@pennmedicine.upenn.edu'},\n",
       "       {'name': 'Mark A Sellmyer, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005355',\n",
       "      'term': 'Fibrosis'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M12',\n",
       "      'name': 'Congenital Abnormalities',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8485',\n",
       "      'name': 'Fibrosis',\n",
       "      'asFound': 'Fibrosis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000077489',\n",
       "      'term': 'Piperazine'},\n",
       "     {'id': 'D000008463', 'term': 'Mebendazole'},\n",
       "     {'id': 'C000006589', 'term': 'Piperazine citrate'},\n",
       "     {'id': 'C000105999', 'term': 'DMP 777'}],\n",
       "    'ancestors': [{'id': 'D000000969', 'term': 'Antinematodal Agents'},\n",
       "     {'id': 'D000000871', 'term': 'Anthelmintics'},\n",
       "     {'id': 'D000000977', 'term': 'Antiparasitic Agents'},\n",
       "     {'id': 'D000000890', 'term': 'Anti-Infective Agents'},\n",
       "     {'id': 'D000050257', 'term': 'Tubulin Modulators'},\n",
       "     {'id': 'D000050256', 'term': 'Antimitotic Agents'},\n",
       "     {'id': 'D000050258', 'term': 'Mitosis Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M8587', 'name': 'Fluorides', 'relevance': 'LOW'},\n",
       "     {'id': 'M1815',\n",
       "      'name': 'Piperazine',\n",
       "      'asFound': 'Prevnar 13™',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11446',\n",
       "      'name': 'Mebendazole',\n",
       "      'asFound': 'Prevnar 13™',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M234880',\n",
       "      'name': 'Piperazine citrate',\n",
       "      'asFound': 'Prevnar 13™',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M256301',\n",
       "      'name': 'DMP 777',\n",
       "      'asFound': 'Prevnar 13™',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11110', 'name': 'Liver Extracts', 'relevance': 'LOW'},\n",
       "     {'id': 'M21258', 'name': 'Radiopharmaceuticals', 'relevance': 'LOW'},\n",
       "     {'id': 'M21320', 'name': 'Citric Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'M1837', 'name': 'Sodium Citrate', 'relevance': 'LOW'},\n",
       "     {'id': 'M4196', 'name': 'Anthelmintics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4294', 'name': 'Antiparasitic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M26197', 'name': 'Tubulin Modulators', 'relevance': 'LOW'},\n",
       "     {'id': 'M26196', 'name': 'Antimitotic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T382', 'name': 'Citrate', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'AnCoag', 'name': 'Anticoagulants'},\n",
       "     {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05837455',\n",
       "    'orgStudyIdInfo': {'id': '202305007'},\n",
       "    'organization': {'fullName': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer',\n",
       "    'officialTitle': 'NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-11-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-11-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-18',\n",
       "    'studyFirstSubmitQcDate': '2023-04-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-06',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Swim Across America', 'class': 'UNKNOWN'},\n",
       "     {'name': 'The Foundation for Barnes-Jewish Hospital', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant\\r\\ntreatment selection. It is the hypothesis that this will improve clinical response for\\r\\npostmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer\\r\\nand identify those who may not require neoadjuvant chemotherapy, with a primary focus on\\r\\noutcomes in Black patients.',\n",
       "    'detailedDescription': 'Risk category is defined as follows:\\r\\n\\r\\n  -  Low risk:\\r\\n\\r\\n       -  Baseline Ki67 ≤ 10% (OR)\\r\\n\\r\\n       -  Luminal A molecular intrinsic subtype by PAM50\\r\\n\\r\\n  -  High risk:\\r\\n\\r\\n       -  Non-Luminal A molecular intrinsic subtype by PAM50 (OR)\\r\\n\\r\\n       -  In cases of non-diagnostic PAM50 molecular intrinsic subtype, patients will\\r\\n          enroll in the high-risk group and undergo Week 4 tumor biopsy.'},\n",
       "   'conditionsModule': {'conditions': ['Breast Cancer',\n",
       "     'Cancer of the Breast'],\n",
       "    'keywords': ['breast cancer',\n",
       "     'postmenopausal women',\n",
       "     'Ki67',\n",
       "     'PAM50 subtype',\n",
       "     'breast cancer disparities']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 81, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Low-risk group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Baseline breast MRI and research specimen collection prior to the start of treatment\\r\\n     with standard of care anastrozole. All patients will have one 28-day cycle of\\r\\n     anastrozole, followed by determination of breast cancer risk category by\\r\\n     incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic\\r\\n     subtype by PAM50.\\r\\n\\r\\n  -  An additional blood draw for research purposes at Week 4 (no breast tumor biopsy at\\r\\n     this time point) and continue to receive 5 additional 28-day cycles of anastrozole.\\r\\n\\r\\n  -  After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment\\r\\n     breast MRI followed by standard of care surgery.',\n",
       "      'interventionNames': ['Device: VENTANA MIB-1 Ki67 assay',\n",
       "       'Device: Oncotype DX® Recurrence Score',\n",
       "       'Device: PAM50-based Prosigna breast cancer gene signature assay',\n",
       "       'Drug: Anastrozole']},\n",
       "     {'label': 'High-risk endocrine-sensitive group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Baseline breast MRI and research specimen collection prior to the start of treatment\\r\\n     with standard of care anastrozole. All patients will have one 28-day cycle of\\r\\n     anastrozole, followed by determination of breast cancer risk category by\\r\\n     incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic\\r\\n     subtype by PAM50.\\r\\n\\r\\n  -  An additional blood draw and breast tumor tissue collection at Week 4 to assess\\r\\n     Ki67. Patients with Week 4 Ki67 ≤10% (the high-risk endocrine-sensitive group) will\\r\\n     continue to receive 5 additional 28-day cycles of anastrozole.\\r\\n\\r\\n  -  After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment\\r\\n     breast MRI followed by standard of care surgery.',\n",
       "      'interventionNames': ['Device: VENTANA MIB-1 Ki67 assay',\n",
       "       'Device: Oncotype DX® Recurrence Score',\n",
       "       'Device: PAM50-based Prosigna breast cancer gene signature assay',\n",
       "       'Drug: Anastrozole']},\n",
       "     {'label': 'High-risk endocrine-resistant group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Baseline breast MRI and research specimen collection prior to the start of treatment\\r\\n     with standard of care anastrozole. All patients will have one 28-day cycle of\\r\\n     anastrozole, followed by determination of breast cancer risk category by\\r\\n     incorporating results from baseline Ki67, Oncotype DX RS, and molecular intrinsic\\r\\n     subtype by PAM50.\\r\\n\\r\\n  -  An additional blood draw and breast tumor tissue collection at Week 4 to assess\\r\\n     Ki67. Patients with Week 4 Ki67 >10% (the high-risk endocrine-resistant group) will\\r\\n     receive escalated therapy with ~5-6 additional months of standard of care\\r\\n     chemotherapy (combination anthracycline- and/or taxane-based at the discretion of\\r\\n     their physician).\\r\\n\\r\\n  -  After completion of ~6 months of neoadjuvant treatment, will undergo post-treatment\\r\\n     breast MRI followed by standard of care surgery.',\n",
       "      'interventionNames': ['Device: VENTANA MIB-1 Ki67 assay',\n",
       "       'Device: Oncotype DX® Recurrence Score',\n",
       "       'Device: PAM50-based Prosigna breast cancer gene signature assay',\n",
       "       'Drug: Combination anthracycline and/or taxane based treatment']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'VENTANA MIB-1 Ki67 assay',\n",
       "      'description': 'Ki67 scoring determination (standard of care) utilizing the Ki67 MIB-1 assay (clone 30-9)\\r\\n(VENTANA) will be performed at baseline, Week 4 (+/- 14 days - high-risk group only), and\\r\\nat time of surgery in accordance with the International Ki67 in Breast Cancer Working\\r\\nGroup guidelines.',\n",
       "      'armGroupLabels': ['High-risk endocrine-resistant group',\n",
       "       'High-risk endocrine-sensitive group',\n",
       "       'Low-risk group']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Oncotype DX® Recurrence Score',\n",
       "      'description': 'Oncotype DX® Recurrence Score (RS) testing - assessing expression of 21 genes including\\r\\n16 cancer-related genes and 5 reference genes - will be performed as standard of care in\\r\\na central laboratory (Exact Sciences) on RNA extracted from formalin-fixed\\r\\nparaffin-embedded core-biopsy samples.',\n",
       "      'armGroupLabels': ['High-risk endocrine-resistant group',\n",
       "       'High-risk endocrine-sensitive group',\n",
       "       'Low-risk group']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'PAM50-based Prosigna breast cancer gene signature assay',\n",
       "      'description': 'This PAM50-based Prosigna breast cancer gene signature assay for intrinsic molecular\\r\\nsubtype determination will be performed on formalin-fixed, paraffin-embedded (FFPE)\\r\\ncore-biopsy samples.',\n",
       "      'armGroupLabels': ['High-risk endocrine-resistant group',\n",
       "       'High-risk endocrine-sensitive group',\n",
       "       'Low-risk group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Anastrozole',\n",
       "      'description': 'Standard of care',\n",
       "      'armGroupLabels': ['High-risk endocrine-sensitive group',\n",
       "       'Low-risk group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Combination anthracycline and/or taxane based treatment',\n",
       "      'description': 'Standard of care',\n",
       "      'armGroupLabels': ['High-risk endocrine-resistant group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective response rate (ORR) by breast MRI in the combined low-risk plus high-risk endocrine-sensitive groups (pooled endocrine therapy-responders)',\n",
       "      'description': '  -  ORR is defined as patients achieving clinical complete response (CR) or partial\\r\\n     response (PR) according to RECIST v1.1.\\r\\n\\r\\n  -  Complete Response (CR): disappearance of all target and non-target lesions. Residual\\r\\n     lesions thought to be non-malignant should be further investigated before CR can be\\r\\n     accepted.\\r\\n\\r\\n  -  Partial Response (PR): ≥30% decrease in the sum of measures of target lesions,\\r\\n     taking as reference the baseline sum of diameters. Non-target lesions must be\\r\\n     non-PD.',\n",
       "      'timeFrame': 'Through completion of treatment (estimated to be 6 months)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Breast conservation surgery (BCS) conversion rate by cohort and treatment assignment',\n",
       "      'timeFrame': 'Through completion of surgery (estimated to be 6 months)'},\n",
       "     {'measure': 'Proportion of patients who will require oncoplastic breast reduction surgery before and after neoadjuvant treatment',\n",
       "      'timeFrame': 'Through completion of surgery (estimated to be 6 months)'},\n",
       "     {'measure': 'Objective response rate (ORR) by breast MRI in the high-risk endocrine-sensitive group',\n",
       "      'description': '  -  ORR is defined as patients achieving clinical complete response (CR) or partial\\r\\n     response (PR) according to modified RECIST v1.1.\\r\\n\\r\\n  -  Complete Response (CR): disappearance of all target and non-target lesions. Residual\\r\\n     lesions thought to be non-malignant should be further investigated before CR can be\\r\\n     accepted.\\r\\n\\r\\n  -  Partial Response (PR): ≥30% decrease in the sum of measures of target lesions,\\r\\n     taking as reference the baseline sum of diameters. Non-target lesions must be\\r\\n     non-PD.',\n",
       "      'timeFrame': 'Through completion of treatment (estimated to be 6 months)'},\n",
       "     {'measure': 'Objective response rate (ORR) by breast MRI in the high-risk endocrine-resistant group (high risk patients with week 4 Ki67 > 10% post anastrozole)',\n",
       "      'description': '  -  ORR is defined as patients achieving clinical complete response (CR) or partial\\r\\n     response (PR) according to modified RECIST v1.1.\\r\\n\\r\\n  -  Complete Response (CR): disappearance of all target and non-target lesions. Residual\\r\\n     lesions thought to be non-malignant should be further investigated before CR can be\\r\\n     accepted.\\r\\n\\r\\n  -  Partial Response (PR): ≥30% decrease in the sum of measures of target lesions,\\r\\n     taking as reference the baseline sum of diameters. Non-target lesions must be\\r\\n     non-PD.',\n",
       "      'timeFrame': 'Through completion of treatment (estimated to be 6 months)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Histologically or cytologically confirmed newly diagnosed clinical stage II or III\\r\\n     (by AJCC 8th edition - at least T2, any N, M0 or if N1+ then any T) ER-positive (ER\\r\\n     > 10%), any PR, and HER2-negative breast cancer with complete surgical excision of\\r\\n     the breast cancer after neoadjuvant therapy as the treatment goal.\\r\\n\\r\\n       -  HER2 negative must be assessed by FISH or IHC staining 0 or 1+ according to\\r\\n          ASCO/CAP guidelines.\\r\\n\\r\\n  -  Tumor size ≥2 cm in one dimension by clinical or radiographic examination (WHO\\r\\n     criteria), if clinically axillary lymph node negative. Patients with histologically\\r\\n     confirmed resectable locoregional nodal involvement may enroll regardless of tumor\\r\\n     size. A palpable mass is not required as long as the mass is at least 2 cm in one\\r\\n     dimension by radiographic exam.\\r\\n\\r\\n  -  ECOG performance status 0 or 1.\\r\\n\\r\\n  -  Eligible to receive neoadjuvant aromatase inhibitor, as per treating physician.\\r\\n\\r\\n  -  Eligible to receive neoadjuvant standard of care anthracycline- and/or taxane-based\\r\\n     chemotherapy regimen, as per treating physician.\\r\\n\\r\\n  -  Able to tolerate breast MRI with intravenous contrast administration. Must be able\\r\\n     to complete the applicable MRI screening evaluation form.\\r\\n\\r\\n  -  Adequate bone marrow and organ function, as determined by the treating physician.\\r\\n\\r\\n  -  Known history of hepatitis C virus (HCV) infection is permissible provided the\\r\\n     patient has been treated and cured.\\r\\n\\r\\n  -  At least 18 years of age.\\r\\n\\r\\n  -  Postmenopausal status, defined as one of the following:\\r\\n\\r\\n       -  Age ≥ 60 years\\r\\n\\r\\n       -  Age < 60 with intact uterus and amenorrhea for 12 consecutive months or more\\r\\n\\r\\n       -  Status post bilateral oophorectomy, total hysterectomy\\r\\n\\r\\n  -  Ability to understand and willingness to sign an IRB approved written informed\\r\\n     consent document (or that of legally authorized representative, if applicable), and\\r\\n     willing and able to comply with scheduled visits and treatment schedule.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Inflammatory breast cancer (cT4d disease as per AJCC 8th edition).\\r\\n\\r\\n  -  Locally recurrent or metastatic disease (cM1 disease as per AJCC 8th edition).\\r\\n\\r\\n  -  Bilateral breast cancer.\\r\\n\\r\\n  -  Prior systemic therapy for the indexed breast cancer.\\r\\n\\r\\n  -  Pre-existing Grade ≥2 neuropathy.\\r\\n\\r\\n  -  Uncontrolled intercurrent illness that would limit compliance with study\\r\\n     requirements.\\r\\n\\r\\n  -  A history of other malignancy ≤5 years prior to the indexed breast cancer diagnosis\\r\\n     with the exception of basal cell or squamous cell carcinoma of the skin which were\\r\\n     treated with local resection only or adequately treated carcinoma in situ of the\\r\\n     cervix.\\r\\n\\r\\n  -  Concurrent participation in any investigational therapeutic trial for treatment of\\r\\n     breast cancer.\\r\\n\\r\\n  -  Contraindication to breast MRI, such as:\\r\\n\\r\\n       -  Prior allergic reaction to gadolinium-based MR contrast agents.\\r\\n\\r\\n       -  Renal insufficiency (glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2)\\r\\n          measured within the past 60 days which precludes safe administration of the\\r\\n          contrast agent.\\r\\n\\r\\n  -  Known HIV positivity that in the judgement of the treating physician would impact\\r\\n     safety of chemotherapy receipt.\\r\\n\\r\\n  -  A history of allergic reactions attributed to compounds of similar chemical or\\r\\n     biologic composition to anastrozole, taxanes (paclitaxel or nab-paclitaxel),\\r\\n     anthracyclines (doxorubicin or epirubicin) or cyclophosphamide.\\r\\n\\r\\n  -  Evidence of uncontrolled ongoing or active infection, requiring parenteral\\r\\n     anti-bacterial, anti-viral, or anti-fungal therapy ≤ 7 days prior to administration\\r\\n     of study treatment. Patients receiving prophylactic antibiotics (e.g., for\\r\\n     prevention of a urinary tract infection or chronic obstructive pulmonary disease)\\r\\n     are eligible.\\r\\n\\r\\n  -  Any uncontrolled medical condition that in the opinion of the Investigator would\\r\\n     pose a risk to participant safety or interfere with study participation or\\r\\n     interpretation of individual participant results.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Nusayba A Bagegni, M.D.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '314-273-3022',\n",
       "      'email': 'nbagegni@wustl.edu'}],\n",
       "    'overallOfficials': [{'name': 'Nusayba Bagegni, M.D.',\n",
       "      'affiliation': 'Washington University School of Medicine',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Washington University School of Medicine',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Saint Louis',\n",
       "      'state': 'Missouri',\n",
       "      'zip': '63110',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Nusayba A Bagegni, M.D.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '314-273-3022',\n",
       "        'email': 'nbagegni@wustl.edu'},\n",
       "       {'name': 'Nusayba A Bagegni, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Cynthia X Ma, M.D., Ph.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Emily L Podany, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Katherine Weilbaecher, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Debbie L Bennett, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'John Olson, M.D., Ph.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Katherine Glover-Collins, M.D., Ph.D.',\n",
       "        'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Fouad Boulos, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Ian Hagemann, M.D., Ph.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Jingqin (Rosy) Luo, Ph.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Carolina Salvador, M.D.', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School\\r\\nof Medicine',\n",
       "      'url': 'http://www.siteman.wustl.edu'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001943',\n",
       "      'term': 'Breast Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001941', 'term': 'Breast Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5220',\n",
       "      'name': 'Breast Neoplasms',\n",
       "      'asFound': 'Breast Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5218', 'name': 'Breast Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000077384',\n",
       "      'term': 'Anastrozole'},\n",
       "     {'id': 'C000080625', 'term': 'Taxane'}],\n",
       "    'ancestors': [{'id': 'D000018931',\n",
       "      'term': 'Antineoplastic Agents, Hormonal'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000047072', 'term': 'Aromatase Inhibitors'},\n",
       "     {'id': 'D000065088', 'term': 'Steroid Synthesis Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000004965', 'term': 'Estrogen Antagonists'},\n",
       "     {'id': 'D000006727', 'term': 'Hormone Antagonists'},\n",
       "     {'id': 'D000006730',\n",
       "      'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M1781',\n",
       "      'name': 'Anastrozole',\n",
       "      'asFound': 'Migraine',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M147959',\n",
       "      'name': 'Taxane',\n",
       "      'asFound': 'Vertebra',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8681', 'name': 'Formaldehyde', 'relevance': 'LOW'},\n",
       "     {'id': 'M20966',\n",
       "      'name': 'Antineoplastic Agents, Hormonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M25769', 'name': 'Aromatase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M8116', 'name': 'Estrogens', 'relevance': 'LOW'},\n",
       "     {'id': 'M8114', 'name': 'Estrogen Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M30483',\n",
       "      'name': 'Estrogen Receptor Antagonists',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "     {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06346912',\n",
       "    'orgStudyIdInfo': {'id': 'TXB2023022'},\n",
       "    'organization': {'fullName': 'Zhejiang University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL',\n",
       "    'officialTitle': 'A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-12',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-29',\n",
       "    'studyFirstSubmitQcDate': '2024-04-03',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-04', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'He Huang',\n",
       "     'investigatorTitle': 'Clinical Professor',\n",
       "     'investigatorAffiliation': 'Zhejiang University'},\n",
       "    'leadSponsor': {'name': 'Zhejiang University', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Shanghai YaKe Biotechnology Ltd.',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for\\r\\nrefractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.',\n",
       "    'detailedDescription': 'In this study, 20 patients with relapsed refractory B-cell ALL and B-cell NHL were\\r\\nproposed to undergo CD19-BAFF CAR-T cell therapy. Under the premise that its safety has\\r\\nbeen clarified in previous studies, further observation and evaluation of the\\r\\neffectiveness of CD19-BAFF CAR-T cell therapy for relapsed refractory B-cell ALL and\\r\\nB-cell NHL; At the same time, on the basis of expanding the sample size, more safety data\\r\\non CD19-BAFF CAR-T cell treatment for relapsed refractory B-cell ALL and B-cell NHL were\\r\\naccumulated, including rare and delayed complications.'},\n",
       "   'conditionsModule': {'conditions': ['Acute Lymphoblastic Leukemia,B-Cell',\n",
       "     'Non-hodgkin Lymphoma,B Cell'],\n",
       "    'keywords': ['CD19-BAFF CAR-T']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['EARLY_PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Administration of CD19-BAFF Targeted CAR T-cells',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose escalation follows the standard 3+3 dose escalation design. A total of 3 dose levels\\r\\nare set for subjects.',\n",
       "      'interventionNames': ['Biological: CD19-BAFF Targeted CAR T-cells']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'CD19-BAFF Targeted CAR T-cells',\n",
       "      'description': 'Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion',\n",
       "      'armGroupLabels': ['Administration of CD19-BAFF Targeted CAR T-cells'],\n",
       "      'otherNames': ['CD19-BAFF Targeted CAR T-cells injection']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Dose-limiting toxicity (DLT)',\n",
       "      'description': 'Adverse events assessed according to NCI-CTCAE v5.0 criteria',\n",
       "      'timeFrame': 'Up to 28 years after Treatment'},\n",
       "     {'measure': 'Incidence of treatment-emergent adverse events (TEAEs)',\n",
       "      'description': 'Incidence of treatment-emergent adverse events [Safety and Tolerability]',\n",
       "      'timeFrame': 'Up to 2 years after Treatment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall response rate ,ORR',\n",
       "      'description': 'The proportion of patients with CR (complete response) /CRi (complete response with\\r\\nincomplete blood cell recovery) and PR (partial response).',\n",
       "      'timeFrame': 'Up to 12 weeks after CAR-T infusion'},\n",
       "     {'measure': 'Duration of remission ,DOR',\n",
       "      'description': 'The time from CR/CRi and PR to disease relapsed or death due to disease progression after\\r\\nCAR-T infusion',\n",
       "      'timeFrame': 'Up to 1 years after CAR-T infusion'},\n",
       "     {'measure': 'Event-free survival, EFS',\n",
       "      'description': 'The time from first achieving CR/CRi to relapse or death',\n",
       "      'timeFrame': 'Up to 1 years after CAR-T infusion'},\n",
       "     {'measure': 'Overall survival, OS',\n",
       "      'description': 'The time from CAR-T infusion to death due to any cause',\n",
       "      'timeFrame': 'Up to 1 years after CAR-T infusion'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  \\r\\n\\r\\n       1. Gender unlimited，18< Age;\\r\\n\\r\\n  -  \\r\\n\\r\\n       2. Patients diagnosed with B-cell acute lymphoblastic leukemia through\\r\\n          histological or immunophenotyping tests; The clear diagnosis of B-cell non\\r\\n          Hodgkin's lymphoma by cellular or histopathological examination mainly includes\\r\\n          diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma\\r\\n\\r\\n  -  \\r\\n\\r\\n       3. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):\\r\\n\\r\\n       1. CR not achieved after standardized chemotherapy;\\r\\n\\r\\n       2. CR achieved following the first induction, but CR duration is less than 12\\r\\n          months;\\r\\n\\r\\n       3. Ineffectively after first or multiple remedial treatments;\\r\\n\\r\\n       4. 2 or more relapses;\\r\\n\\r\\n  -  \\r\\n\\r\\n       4. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow\\r\\n          is >5% (by morphology), and/or >1% (by flow cytometry);\\r\\n\\r\\n  -  \\r\\n\\r\\n       5. Philadelphia-chromosome-negative (Ph-) patients; or\\r\\n          Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI\\r\\n          treatments or do not respond to 2 TKI treatments;\\r\\n\\r\\n  -  \\r\\n\\r\\n       6. Relapsed or refractory B-NHL (meeting one of the following conditions):\\r\\n\\r\\n       1. No response or relapse after second-line or above chemotherapy regimens;\\r\\n\\r\\n       2. Primary drug resistance;\\r\\n\\r\\n       3. Relapse after auto-HSCT;\\r\\n\\r\\n  -  \\r\\n\\r\\n       7. At least one assessable tumor lesion per Lugano 2014 criteria;\\r\\n\\r\\n  -  \\r\\n\\r\\n       8. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal,\\r\\n          creatinine ≤ 176.8 umol/L;\\r\\n\\r\\n  -  \\r\\n\\r\\n       9. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;\\r\\n\\r\\n  -  \\r\\n\\r\\n      10. No active infection in the lungs, blood oxygen saturation in indoor air is ≥\\r\\n          92%;\\r\\n\\r\\n  -  \\r\\n\\r\\n      11. Estimated survival time ≥ 3 months;\\r\\n\\r\\n  -  \\r\\n\\r\\n      12. ECOG performance status 0 to 2;\\r\\n\\r\\n  -  \\r\\n\\r\\n      13. Patients or their legal guardians volunteer to participate in the study and\\r\\n          sign the informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  \\r\\n\\r\\n       1. History of craniocerebral trauma, conscious disturbance, epilepsy,\\r\\n          cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;\\r\\n\\r\\n  -  \\r\\n\\r\\n       2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as\\r\\n          severe arrhythmia in the past;\\r\\n\\r\\n  -  \\r\\n\\r\\n       3. Pregnant/lactating women, or male or female patients with fertility who are\\r\\n          unwilling to take effective contraceptive measures during the study period or\\r\\n          at least 6 months after the last cell infusion\\r\\n\\r\\n  -  \\r\\n\\r\\n       4. Patients with HIV infection;\\r\\n\\r\\n  -  \\r\\n\\r\\n       5. Active infection of hepatitis B virus or hepatitis C virus;\\r\\n\\r\\n  -  \\r\\n\\r\\n       6. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation\\r\\n          signal;\\r\\n\\r\\n  -  \\r\\n\\r\\n       7. Other uncontrolled diseases that were not suitable for this trial;\\r\\n\\r\\n  -  \\r\\n\\r\\n       8. Individuals who have received CAR-T therapy, CAR-NK therapy, or any other gene\\r\\n          modified cell therapy product within 6 months;\\r\\n\\r\\n  -  \\r\\n\\r\\n       9. Any situations that the investigator believes may increase the risk of patients\\r\\n          or interfere with the results of study.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'He Huang, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '86-13605714822',\n",
       "      'email': 'hehuangyu@126.com'},\n",
       "     {'name': 'Yongxian Hu, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '86-15957162012',\n",
       "      'email': 'huyongxian2000@aliyun.com'}],\n",
       "    'overallOfficials': [{'name': 'He Huang, MD',\n",
       "      'affiliation': 'Zhejiang University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'The first affiliated hospital of medical college of zhejiang university',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Hangzhou',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '310000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'He Huang, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86-13605714822',\n",
       "        'email': 'hehuangyu@126.com'},\n",
       "       {'name': 'Yongxian Hu, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+8615957162012',\n",
       "        'email': 'huyongxian2000@aliyun.com'}],\n",
       "      'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000054198',\n",
       "      'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'},\n",
       "     {'id': 'D000016393', 'term': 'Lymphoma, B-Cell'},\n",
       "     {'id': 'D000015448', 'term': 'Leukemia, B-Cell'}],\n",
       "    'ancestors': [{'id': 'D000008228', 'term': 'Lymphoma, Non-Hodgkin'},\n",
       "     {'id': 'D000008223', 'term': 'Lymphoma'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008232', 'term': 'Lymphoproliferative Disorders'},\n",
       "     {'id': 'D000008206', 'term': 'Lymphatic Diseases'},\n",
       "     {'id': 'D000007160', 'term': 'Immunoproliferative Disorders'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000007945', 'term': 'Leukemia, Lymphoid'},\n",
       "     {'id': 'D000007938', 'term': 'Leukemia'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11220', 'name': 'Lymphoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M10945', 'name': 'Leukemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M27585',\n",
       "      'name': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma',\n",
       "      'asFound': 'Acute Lymphoblastic Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10951', 'name': 'Leukemia, Lymphoid', 'relevance': 'LOW'},\n",
       "     {'id': 'M18828',\n",
       "      'name': 'Lymphoma, B-Cell',\n",
       "      'asFound': 'Lymphoma, B-Cell',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18115',\n",
       "      'name': 'Leukemia, B-Cell',\n",
       "      'asFound': 'Leukemia, B-Cell',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11222', 'name': 'Lymphoma, Non-Hodgkin', 'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11225',\n",
       "      'name': 'Lymphoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11203', 'name': 'Lymphatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10206',\n",
       "      'name': 'Immunoproliferative Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3543', 'name': 'Lymphosarcoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T175',\n",
       "      'name': 'Acute Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Lymphoblastic Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3533', 'name': 'Lymphoblastic Lymphoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T640',\n",
       "      'name': 'B-cell Lymphoma',\n",
       "      'asFound': 'Lymphoma, B-Cell',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05972681',\n",
       "    'orgStudyIdInfo': {'id': '2023-14825'},\n",
       "    'organization': {'fullName': 'Montefiore Medical Center',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'The PAIN (Pelvic Area Injection for Numbness) Study',\n",
       "    'officialTitle': 'A Randomized Controlled Trial of Bupivacaine for Local Pain Control Following Perineal Laceration Repair in Patients With Pre-existing Epidural Analgesia'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-08', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-17',\n",
       "    'studyFirstSubmitQcDate': '2023-07-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-03',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Montefiore Medical Center', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The prevalence of perineal lacerations is more than 75% of all vaginal deliveries. The\\r\\nrepair of such lacerations in the institution is usually done using lidocaine for\\r\\nnon-epiduralized patients versus no local injection in patients with a pre-existing\\r\\nepidural analgesia. The prevalence of epidural analgesia use among women who underwent\\r\\nvaginal delivery in cross-sectional study of over 2 million deliveries in the United\\r\\nStates was 71.1%. Once the analgesic effect of the epidural analgesia fades, the\\r\\nlaceration may cause uncontrolled postpartum pain which can affect both the physical and\\r\\nmental recovery period, extend hospital stays, and increase the potential for serious\\r\\nadverse reactions with pain medications.\\r\\n\\r\\nThe research hypothesis of this study is that adding a locally injected analgesic, which\\r\\nwill take effect once the epidural analgesia fades, may alleviate perineal pain and\\r\\nimprove women's overall well-being and satisfaction.\\r\\n\\r\\nThis is a superiority two-arm, quadruple-blinded, prospective randomized controlled trial\\r\\nwith the objective to determine if prolonged analgesia and higher rate of maternal\\r\\nsatisfaction are found when bupivacaine with epinephrine infiltration is used for\\r\\nperineal repair as compared to sham injection in patients with pre-existing effective\\r\\nepidural analgesia at time of perineal laceration repair. Women with a working epidural\\r\\nanalgesia, and status post a vaginal delivery involving a second-degree laceration will\\r\\nbe invited to participate. Women in the local anesthesia (LA) arm will get a LA injected\\r\\nto the laceration and women in the sham arm will get an injection with saline. The\\r\\ndifferences in perineal pain between the groups will be evaluated at time of the first\\r\\nanalgesic (TFA) demand, maternal satisfaction at 24 hours, and visual analog scale (VAS)\\r\\npain score.\"},\n",
       "   'conditionsModule': {'conditions': ['Vaginal Laceration During Delivery']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Local Anesthesia arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Bupivicaine and Epinephrine',\n",
       "      'interventionNames': ['Drug: Bupivacaine', 'Drug: Epinephrine']},\n",
       "     {'label': 'Normal saline sham arm',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'interventionNames': ['Other: Sham normal saline arm']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Bupivacaine',\n",
       "      'description': '10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.',\n",
       "      'armGroupLabels': ['Local Anesthesia arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Epinephrine',\n",
       "      'description': 'Epinephrine (1:200,000) injected to the vaginal laceration site.',\n",
       "      'armGroupLabels': ['Local Anesthesia arm']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Sham normal saline arm',\n",
       "      'description': '10 milliliter (ml) of normal saline injected to the vaginal laceration site.',\n",
       "      'armGroupLabels': ['Normal saline sham arm']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to first analgesic',\n",
       "      'description': 'Average time to first analgesic (TFA) will be evaluated per patient as the duration\\r\\ninterval following injection to administration of the first analgesic, as applicable.',\n",
       "      'timeFrame': 'Up to 24 hours after perineal laceration'},\n",
       "     {'measure': 'Maternal Satisfaction',\n",
       "      'description': \"Maternal satisfaction will be assessed by participants' rating their ability to carry out\\r\\ntheir daily living activities at 24hrs using a 4-point scale (very poor; poor; good; or\\r\\nvery good)\",\n",
       "      'timeFrame': '24 hours after perineal laceration'},\n",
       "     {'measure': 'Maternal Satisfaction',\n",
       "      'description': \"Maternal satisfaction will be assessed by participants' rating their ability to carry out\\r\\ntheir daily living activities at 24hrs using a 4-point scale (very poor; poor; good; or\\r\\nvery good)\",\n",
       "      'timeFrame': '48 hours after perineal laceration'},\n",
       "     {'measure': 'Maternal Satisfaction',\n",
       "      'description': \"Maternal satisfaction will be assessed by participants' rating their ability to carry out\\r\\ntheir daily living activities at 24hrs using a 4-point scale (very poor; poor; good; or\\r\\nvery good)\",\n",
       "      'timeFrame': '7 days after perineal laceration'},\n",
       "     {'measure': 'Pain score after injection at perineal laceration',\n",
       "      'description': 'Participants will self-report measures of symptoms using the Visual Analog Scale (VAS) to\\r\\ndetermine acute and chronic pain. Participants record a single handwritten mark at one\\r\\npoint along the length of a 10-cm line that represents a continuum between the two ends\\r\\nof a scale where \"no pain\" is on the left end (0 cm) of the scale and the \"worst pain\" is\\r\\non the right end of the scale (10 cm). Measurements from the starting point (left end) of\\r\\nthe scale to the patients\\' marks are recorded in centimeters and are interpreted as the\\r\\nintensity of pain. The values will be used to track pain progression for a patient and to\\r\\ncompare pain between patients with similar conditions',\n",
       "      'timeFrame': 'Immediately and 24 hours after perineal laceration'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  >= 18 years old\\r\\n\\r\\n  -  Healthy with a singleton pregnancy\\r\\n\\r\\n  -  English or Spanish speaking\\r\\n\\r\\n  -  Ongoing functioning epidural throughout the laceration repair\\r\\n\\r\\n  -  Ability to consent for themselves\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Women who underwent an operative vaginal delivery and whose vaginal delivery was\\r\\n     complicated by a postpartum hemorrhage\\r\\n\\r\\n  -  Multiple gestation\\r\\n\\r\\n  -  Complaints of non-functional epidural\\r\\n\\r\\n  -  Allergic to bupivacaine and/or epinephrine\\r\\n\\r\\n  -  Epidural was a combined spinal-epidural (CSE)\\r\\n\\r\\n  -  Received an epidural top-off < 3 hours from the perineal repair\\r\\n\\r\\n  -  Experienced extreme pain at time of study consent (pain scale score > 3 on 0-10\\r\\n     scale)',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Clarissa P Diniz, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '718-904-2767',\n",
       "      'email': 'cdiniz@montefiore.org'},\n",
       "     {'name': 'Fatima Estrada, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '718-904-2767',\n",
       "      'email': 'festrada@montefiore.org'}],\n",
       "    'overallOfficials': [{'name': 'Fatima Estrada, MD',\n",
       "      'affiliation': 'Montefiore Medical Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Montefiore Medical Center',\n",
       "      'city': 'Bronx',\n",
       "      'state': 'New York',\n",
       "      'zip': '10467',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Clarissa P Diniz, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '718-904-2767',\n",
       "        'email': 'cdiniz@montefiore.org'}],\n",
       "      'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000022125',\n",
       "      'term': 'Lacerations'}],\n",
       "    'ancestors': [{'id': 'D000014947', 'term': 'Wounds and Injuries'}],\n",
       "    'browseLeaves': [{'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M22785',\n",
       "      'name': 'Lacerations',\n",
       "      'asFound': 'Laceration',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10038', 'name': 'Hypesthesia', 'relevance': 'LOW'},\n",
       "     {'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC26', 'name': 'Wounds and Injuries'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000004837',\n",
       "      'term': 'Epinephrine'},\n",
       "     {'id': 'D000002045', 'term': 'Bupivacaine'}],\n",
       "    'ancestors': [{'id': 'D000000779', 'term': 'Anesthetics, Local'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000000316', 'term': 'Adrenergic alpha-Agonists'},\n",
       "     {'id': 'D000000322', 'term': 'Adrenergic Agonists'},\n",
       "     {'id': 'D000018663', 'term': 'Adrenergic Agents'},\n",
       "     {'id': 'D000018377', 'term': 'Neurotransmitter Agents'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000318', 'term': 'Adrenergic beta-Agonists'},\n",
       "     {'id': 'D000001993', 'term': 'Bronchodilator Agents'},\n",
       "     {'id': 'D000001337', 'term': 'Autonomic Agents'},\n",
       "     {'id': 'D000018927', 'term': 'Anti-Asthmatic Agents'},\n",
       "     {'id': 'D000019141', 'term': 'Respiratory System Agents'},\n",
       "     {'id': 'D000009184', 'term': 'Mydriatics'},\n",
       "     {'id': 'D000013566', 'term': 'Sympathomimetics'},\n",
       "     {'id': 'D000014662', 'term': 'Vasoconstrictor Agents'}],\n",
       "    'browseLeaves': [{'id': 'M5315',\n",
       "      'name': 'Bupivacaine',\n",
       "      'asFound': 'Following',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M7992',\n",
       "      'name': 'Epinephrine',\n",
       "      'asFound': 'Growth',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M30371', 'name': 'Racepinephrine', 'relevance': 'LOW'},\n",
       "     {'id': 'M211043', 'name': 'Epinephryl borate', 'relevance': 'LOW'},\n",
       "     {'id': 'M4109', 'name': 'Anesthetics, Local', 'relevance': 'LOW'},\n",
       "     {'id': 'M20746', 'name': 'Adrenergic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M3668', 'name': 'Adrenergic alpha-Agonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M3673', 'name': 'Adrenergic Agonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M3670', 'name': 'Adrenergic beta-Agonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M5269', 'name': 'Bronchodilator Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M20963', 'name': 'Anti-Asthmatic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M21137', 'name': 'Respiratory System Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M12139', 'name': 'Mydriatics', 'relevance': 'LOW'},\n",
       "     {'id': 'M16345', 'name': 'Sympathomimetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M17409', 'name': 'Vasoconstrictor Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'},\n",
       "     {'abbrev': 'Resp', 'name': 'Respiratory System Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06349408',\n",
       "    'orgStudyIdInfo': {'id': 'CIBI3001A101'},\n",
       "    'organization': {'fullName': 'Innovent Biologics (Suzhou) Co. Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors',\n",
       "    'officialTitle': 'A Phase 1/2 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-01',\n",
       "    'studyFirstSubmitQcDate': '2024-04-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-05', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-05', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Innovent Biologics (Suzhou) Co. Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a Phase 1/2 multicenter, multi-regional, open-label, first-in-human study of\\r\\nIBI3001 in participants with unresectable, locally advanced or metastatic solid tumors.\\r\\nIt includes a Phase 1 section to identify Maximum Tolerated Dose (MTD)/Recommended Phase\\r\\n2 Dose (RP2D) of IBI3001, and a Phase 2 section to explore and confirm the efficacy,\\r\\nsafety and tolerability of IBI3001 at its RP2D.'},\n",
       "   'conditionsModule': {'conditions': ['Locally Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 180, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Open-label: IBI3001 monotherapy',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: IBI3001']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'IBI3001',\n",
       "      'description': 'The provisional dose levels are planned to be evaluated, but it is possible for\\r\\nadditional and/or intermediate dose levels to be added during the study.\\r\\n\\r\\nIBI3001 is proposed to be administered by intravenous infusion (IV)',\n",
       "      'armGroupLabels': ['Open-label: IBI3001 monotherapy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of subjects with adverse events',\n",
       "      'description': 'Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE\\r\\nv5.0 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Number of subjects with clinically significant changes in physical examination results',\n",
       "      'description': 'Clinically significant abnormal physical examination findings reported by the\\r\\ninvestigator.',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Number of subjects with clinically significant changes in vital signs',\n",
       "      'description': 'Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)',\n",
       "      'description': 'Dose limiting toxicity (DLT) to establish MTD or RP2D',\n",
       "      'timeFrame': '24 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Plasma concentration (Cmax) of IBI3001',\n",
       "      'description': 'Plasma concentration of IBI3001 for single and multiple doses.',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Area under the curve (AUC) of IBI3001',\n",
       "      'description': 'AUC of IBI3001 for single and multiple doses',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Time to maximum concentration (Tmax) of IBI3001',\n",
       "      'description': 'Tmax of IBI3001 for single and multiple doses.',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Clearance (CL) of IBI3001',\n",
       "      'description': 'Clearance of IBI3001 from the plasma',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Volume of distribution (V) of IBI3001',\n",
       "      'description': 'Apparent volume of distribution of IBI3001',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Half-life (T1/2) of IBI3001',\n",
       "      'description': 'T1/2 of IBI3001 for single and multiple doses',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Immunogenicity of IBI3001',\n",
       "      'description': 'Incidence of anti-drug (IBI3001) antibody',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Objective response rate (ORR)',\n",
       "      'description': 'ORR as evaluated per the RECIST v1.1 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Duration of response (DoR)',\n",
       "      'description': 'DoR as evaluated per the RECIST v1.1 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Disease control rate (DCR)',\n",
       "      'description': 'DCR as evaluated per the RECIST v1.1 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Time to response (TTR)',\n",
       "      'description': 'TTR as evaluated per the RECIST v1.1 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Progression free survival (PFS)',\n",
       "      'description': 'PFS as evaluated per the RECIST v1.1 criteria',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'Overall survival.',\n",
       "      'timeFrame': '24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\r\\n\\r\\n  1. Male or female participants ≥ 18 years old;\\r\\n\\r\\n  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;\\r\\n\\r\\n  3. Has an anticipated life expectancy of ≥ 12 weeks;\\r\\n\\r\\n  4. Adequate bone marrow and organ function:\\r\\n\\r\\nCriteria for Phase 1 only:\\r\\n\\r\\n  1. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid\\r\\n     Tumors (RECIST) Version 1.1.\\r\\n\\r\\n  2. Has a documented (histologically- or cytologically-proven), unresectable, locally\\r\\n     advanced or metastatic solid tumor that is refractory to or intolerable with\\r\\n     standard treatment.\\r\\n\\r\\nKey Exclusion Criteria:\\r\\n\\r\\n  1. Progressed or refractory to an antibody drug conjugate that consists of a\\r\\n     topoisomerase I inhibitor;\\r\\n\\r\\n  2. Plan to receive other antitumor therapy during the study excluding palliative\\r\\n     radiotherapy for the purpose of symptom (like pain) relief that must also not have\\r\\n     an impact on tumor assessment throughout the study;\\r\\n\\r\\n  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);\\r\\n\\r\\n  4. Gastrointestinal perforation and/or fistula within 6 months prior to first\\r\\n     administration of the study drug, and not recovered after surgical treatment;\\r\\n\\r\\n  5. Known symptomatic central nervous system (CNS) metastases.\\r\\n\\r\\n  6. History of pneumonia requiring corticosteroids therapy, or history of clinically\\r\\n     significant lung diseases; Uncontrolled diseases;\\r\\n\\r\\n  7. History of endotracheal or gastrointestinal stent implantation;\\r\\n\\r\\n  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring\\r\\n     intervention;\\r\\n\\r\\n  9. Esophageal or gastric varices requiring immediate intervention;\\r\\n\\r\\n 10. Not eligible to participate in this study at the discretion of the investigator;\\r\\n\\r\\n 11. Do not have adequate treatment washout period before study drug administration. -',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Yue Qu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 18664524992',\n",
       "      'email': 'yue.qu@innoventbio.com'}],\n",
       "    'locations': [{'facility': 'Wollongong Public',\n",
       "      'city': 'Wollongong',\n",
       "      'state': 'New South Wales',\n",
       "      'zip': '2500',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'Daniel Brungs',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Daniel.brungs@health.nsw.gov.au'}],\n",
       "      'geoPoint': {'lat': -34.424, 'lon': 150.89345}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06420908',\n",
       "    'orgStudyIdInfo': {'id': 'ARL-ESCC-001'},\n",
       "    'organization': {'fullName': 'Hebei Medical University Fourth Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)',\n",
       "    'officialTitle': 'Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC): A Prospective, Single-arm, Phase II Clinical Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-15',\n",
       "    'studyFirstSubmitQcDate': '2024-05-15',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Jun wang',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Hebei Medical University Fourth Hospital'},\n",
       "    'leadSponsor': {'name': 'Hebei Medical University Fourth Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1\\r\\nantibody) combined with chemotherapy, then guided by PET-CT assessment to change the\\r\\nfollowing chemoradiotherapy regiment for locally advanced unresectable ESCC.'},\n",
       "   'conditionsModule': {'conditions': ['Esophageal Squamous Cell Carcinoma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'PET-CT responders',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SUV (PETr) reduction >35%',\n",
       "      'interventionNames': ['Drug: Adebrelimab+TP/FP+ radiation therapy']},\n",
       "     {'label': 'PET-CT non-responders',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SUV (PETr) reduction ≤35%',\n",
       "      'interventionNames': ['Drug: Adebrelimab+FP/TP+ radiation therapy']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Adebrelimab+TP/FP+ radiation therapy',\n",
       "      'description': 'Induction stage：\\r\\n\\r\\nAdebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel\\r\\n135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400\\r\\nmg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;\\r\\n\\r\\nTreatment stage:\\r\\n\\r\\nTP : nab-paclitaxel paclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin\\r\\nAUC=5, d1, iv, q3w FP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w\\r\\nRadiation therapy (50.4Gy-60Gy/28-33f);\\r\\n\\r\\nConsolidation stage:\\r\\n\\r\\nAdebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity\\r\\noccurs.',\n",
       "      'armGroupLabels': ['PET-CT responders']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Adebrelimab+FP/TP+ radiation therapy',\n",
       "      'description': 'Induction stage：\\r\\n\\r\\nAdebrelimab : 1200mg d1, iv, q3w TP : nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel\\r\\n135-175mg/m2, d1, iv; carboplatin AUC=5-6, d1, iv, q3w FP : fluorouracil 400mg/m2, 2400\\r\\nmg/m2 (48 hours), d1; cisplatin 75mg/m2, d1, iv, q3w 2 cycles;\\r\\n\\r\\nTreatment stage: (switch to a different chemotherapy drug which not used during the\\r\\nearlier induction phase)\\r\\n\\r\\nFP : fluorouracil 300mg/m2/d, iv; cisplatin 75mg/m2, d1, iv, q3w TP : nab-paclitaxel\\r\\npaclitaxel 60-70mg/m2, or paclitaxel 75mg/m2, d1, iv; carboplatin AUC=5, d1, iv, q3w\\r\\nRadiation therapy (50.4Gy-60Gy/28-33f);\\r\\n\\r\\nConsolidation stage:\\r\\n\\r\\nAdebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity\\r\\noccurs.',\n",
       "      'armGroupLabels': ['PET-CT non-responders']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression free survival (PFS)',\n",
       "      'description': 'Baseline to measured date of progression or death from any cause',\n",
       "      'timeFrame': 'evaluated in 24 months since the treatment began'}],\n",
       "    'secondaryOutcomes': [{'measure': '1. Objective response rate (ORR)',\n",
       "      'description': 'Baseline to measured stable disease',\n",
       "      'timeFrame': 'tumor assessment every 6 weeks since the treatment began，up to 24 monthss'},\n",
       "     {'measure': '2. Duration of Overall Response（DoR）',\n",
       "      'description': 'The duration of overall response is measured from the time that measurement criteria are\\r\\nmet for complete response or partial response until the first date that recurrent or\\r\\nprogressive disease is objectively documented.',\n",
       "      'timeFrame': 'tumor assessment every 6 weeks since the treatment began，up to 24 months'},\n",
       "     {'measure': '3. Overall survival (OS)',\n",
       "      'description': 'Baseline to measured date of death from any cause',\n",
       "      'timeFrame': 'the first day of treatment to death or last survival confirm date,up to 24 months'},\n",
       "     {'measure': '4. Adverse events',\n",
       "      'description': 'Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version\\r\\n4.03. The number of Participants with adverse events will be recorded at each treatment\\r\\nvisit.',\n",
       "      'timeFrame': 'up to 24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n1.Age 18-75 years old, both men and women; 2.Histopathology confirmed as esophageal\\r\\nsquamous cell carcinoma，stage II-IVa：T1N2-3M0，T2-4bN+M0； 3.If technically feasible, all\\r\\npatients are recommended to have local staging determined by endoscopic ultrasound (EUS);\\r\\nThe endoscopic examination report or gastrointestinal (GI) clinical records should\\r\\nclearly indicate the T and N stages; Perform PET-CT examination; 4.Except for basal or\\r\\nsquamous cell skin cancer, bladder cancer in situ or cervical cancer, there is no history\\r\\nof malignant tumor within 5 years; Patients with malignant tumors who have undergone\\r\\nsurgical treatment in the past and those who have survived disease-free for more than 5\\r\\nyears meet the inclusion criteria; 5.Have not received any systemic anti-tumor treatment\\r\\nin the past (systemic chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.)\\r\\n6.According to RECIST 1.1, at least one measurable lesion; 7.ECOG: 0~1; 8.Expected\\r\\nsurvival period ≥ 12 weeks; 9.Major organ function has to meet the following certeria:\\r\\n\\r\\n  1. Blood routine examination:\\r\\n\\r\\n       1. HB≥90g/L;\\r\\n\\r\\n       2. ANC ≥ 1.5 × 109 / L;\\r\\n\\r\\n       3. PLT ≥ 100 × 109 / L;\\r\\n\\r\\n  2. Biochemical examination:\\r\\n\\r\\n       1. ALT and AST < 2.5×ULN;\\r\\n\\r\\n       2. TBIL ≤ 1.5×ULN;\\r\\n\\r\\n       3. Cr ≤ 1.5×ULN; 9. Left ventricular ejection fraction (LVEF) ≥50%; 11. Women of\\r\\n          childbearing age should agree to use contraceptives (such as intrauterine\\r\\n          devices, contraceptives or condoms) during the study period and within 6 months\\r\\n          after the end of the study; negative serum or urine pregnancy test within 7\\r\\n          days prior to study enrollment And must be non-lactating patients; males should\\r\\n          agree to patients who must use contraception during the study period and within\\r\\n          6 months after the end of the study period; 12. Participants were willing to\\r\\n          join in this study, and written informed consent, good adherence, cooperate\\r\\n          with the follow-up.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Previous history of esophageal cancer surgery；\\r\\n\\r\\n  2. Higher risk of esophageal perforation or fistula；\\r\\n\\r\\n  3. Received systemic immunosuppressive therapy within 14 days prior to the first study\\r\\n     medication；\\r\\n\\r\\n  4. Known or suspected to have interstitial pneumonia; Other moderate to severe lung\\r\\n     diseases that may seriously affect respiratory function;\\r\\n\\r\\n  5. The patient has any active autoimmune disease or history of autoimmune disease (such\\r\\n     as the following, but not limited to: autoimmune hepatitis, enteritis, systemic\\r\\n     lupus erythematosus, rheumatoid arthritis; patients with vitiligo, Asthma has been\\r\\n     completely relieved in childhood, and patients who do not need any intervention\\r\\n     after adulthood can be included; asthma patients who require bronchodilators for\\r\\n     medical intervention cannot be included);\\r\\n\\r\\n  6. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome\\r\\n     (AIDS), active hepatitis B (HBV DNA ≥ 1000 copies/ml or 500IU/ml), hepatitis C\\r\\n     (positive hepatitis C antibody, and HCV-RNA is higher than the lower limit of\\r\\n     detection of the analytical method)；\\r\\n\\r\\n  7. Within 6 months, cerebral vascular accidents (including transient ischemic attacks\\r\\n     or symptomatic pulmonary embolism) occur;\\r\\n\\r\\n  8. History of cardiovascular disease with significant clinical significance, including\\r\\n     but not limited to: (1) congestive heart failure (NYHA grade>2); (2) Unstable angina\\r\\n     pectoris; (3) Have experienced myocardial infarction within 3 months; (4) Any\\r\\n     supraventricular arrhythmias or ventricular arrhythmias that require treatment or\\r\\n     intervention;\\r\\n\\r\\n  9. Severe infections within 4 weeks before study drug administration, or active\\r\\n     infection with CTCAE ≥ 2 grade treated with antibiotics within 2 weeks before study\\r\\n     drug administration;\\r\\n\\r\\n 10. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell\\r\\n     transplantation;\\r\\n\\r\\n 11. History of psychiatric drugs abuse and can't quit or patients with mental disorders;\\r\\n\\r\\n 12. The researchers think inappropriate.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jun Wang, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '13931182128',\n",
       "      'email': 'wangjunzr@163.com'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002277',\n",
       "      'term': 'Carcinoma'},\n",
       "     {'id': 'D000002294', 'term': 'Carcinoma, Squamous Cell'},\n",
       "     {'id': 'D000077277', 'term': 'Esophageal Squamous Cell Carcinoma'}],\n",
       "    'ancestors': [{'id': 'D000009375',\n",
       "      'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000018307', 'term': 'Neoplasms, Squamous Cell'},\n",
       "     {'id': 'D000004938', 'term': 'Esophageal Neoplasms'},\n",
       "     {'id': 'D000005770', 'term': 'Gastrointestinal Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000006258', 'term': 'Head and Neck Neoplasms'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000004935', 'term': 'Esophageal Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5534',\n",
       "      'name': 'Carcinoma',\n",
       "      'asFound': 'Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5550',\n",
       "      'name': 'Carcinoma, Squamous Cell',\n",
       "      'asFound': 'Squamous Cell Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1733',\n",
       "      'name': 'Esophageal Squamous Cell Carcinoma',\n",
       "      'asFound': 'Esophageal Squamous Cell Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20451', 'name': 'Neoplasms, Squamous Cell', 'relevance': 'LOW'},\n",
       "     {'id': 'M8088', 'name': 'Esophageal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M9348', 'name': 'Head and Neck Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8085', 'name': 'Esophageal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T2141', 'name': 'Esophageal Cancer', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M19537',\n",
       "      'name': 'Paclitaxel',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M18650', 'name': 'Carboplatin', 'relevance': 'LOW'},\n",
       "     {'id': 'M8600', 'name': 'Fluorouracil', 'relevance': 'LOW'},\n",
       "     {'id': 'M231', 'name': 'Albumin-Bound Paclitaxel', 'relevance': 'LOW'},\n",
       "     {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06396091',\n",
       "    'orgStudyIdInfo': {'id': '8951-CL-5203'},\n",
       "    'organization': {'fullName': 'Astellas Pharma Inc', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer',\n",
       "    'officialTitle': 'A Phase 1 Open-label Study to Assess the Safety and Tolerability of Zolbetuximab (IMAB362) in Combination With Chemotherapy (mFOLFIRINOX) in Participants With CLDN18.2 Positive Metastatic Pancreatic Adenocarcinoma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': True,\n",
       "     'nctId': 'NCT06048081',\n",
       "     'statusForNctId': 'AVAILABLE'},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-07-03', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-07-03', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-30',\n",
       "    'studyFirstSubmitQcDate': '2024-04-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Astellas Pharma Global Development, Inc.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed,\\r\\nthe cancer has usually spread to other parts of the body (metastatic). The standard\\r\\ntreatment is chemotherapy, but other treatments are needed to improve outcomes in people\\r\\nwith pancreatic cancer.\\r\\n\\r\\nIn this study, zolbetuximab will be given together with chemotherapy to people with\\r\\npancreatic cancer. Zolbetuximab attaches to a protein called CLDN18.2 found at high\\r\\nlevels on the surface of the cancer tumor. This switches on the immune system to attack\\r\\nthe tumor.\\r\\n\\r\\nAdults 18 years or older with metastatic pancreatic cancer who have not previously had\\r\\nchemotherapy can take part in the study.\\r\\n\\r\\nThere are 2 main aims of this study:\\r\\n\\r\\n  -  To check the safety of zolbetuximab, when given with chemotherapy in people with\\r\\n     metastatic pancreatic cancer\\r\\n\\r\\n  -  To check if people could cope with (tolerate) any medical problems during the study\\r\\n     This is an open-label study. This means people in the study and the study doctors\\r\\n     will know that people will receive zolbetuximab with chemotherapy. Different small\\r\\n     groups will receive lower to higher doses of zolbetuximab with chemotherapy.\\r\\n\\r\\nZolbetuximab and chemotherapy will be given through a vein. This is called an infusion.\\r\\nPeople will receive zolbetuximab on the first day they receive chemotherapy. This will\\r\\nhappen every 14 days in a 28-day cycle.\\r\\n\\r\\nPeople will receive zolbetuximab and chemotherapy in the study clinic and at home. Also,\\r\\ndoctors will check for any medical problems. People will also have a health check\\r\\nincluding blood tests. On some visits they will also have scans to check for any changes\\r\\nin their cancer.\\r\\n\\r\\nPeople will visit the study clinic about 7 days after they stop treatment. They will be\\r\\nasked about any medical problems and will have a health check including blood tests.\\r\\n\\r\\nAfter this, people will have several more visits to the study clinic for health checks.\\r\\nThe number of visits and checks done at each visit will depend on the health of each\\r\\nperson and whether they complete their treatment or not.'},\n",
       "   'conditionsModule': {'conditions': ['Claudin 18.2 (CLDN18.2) Positive Metastatic Pancreatic Adenocarcinoma'],\n",
       "    'keywords': ['CLDN18.2 positive metastatic pancreatic adenocarcinoma',\n",
       "     'mFOLFIRINOX',\n",
       "     'Claudin 18.2']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 12, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'zolbetuximab and mFOLFIRINOX',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive 1 of 2 dose levels of zolbetuximab in combination with\\r\\nmFOLFIRINOX.',\n",
       "      'interventionNames': ['Drug: zolbetuximab', 'Drug: mFOLFIRINOX']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'zolbetuximab',\n",
       "      'description': 'Zolbetuximab will be administered intravenously on day 1 then every two weeks.',\n",
       "      'armGroupLabels': ['zolbetuximab and mFOLFIRINOX'],\n",
       "      'otherNames': ['IMAB362']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'mFOLFIRINOX',\n",
       "      'description': 'Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be\\r\\nadministered intravenously within 2 days after administration of zolbetuximab.',\n",
       "      'armGroupLabels': ['zolbetuximab and mFOLFIRINOX']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of Dose Limiting Toxicities (DLT)',\n",
       "      'description': 'A DLT will be defined as any event meeting the DLT criteria occurring during the DLT\\r\\nassessment period that is related to zolbetuximab.',\n",
       "      'timeFrame': 'Up to 28 days'},\n",
       "     {'measure': 'Safety assessed by Adverse Events (AEs)',\n",
       "      'description': 'An AE is any untoward medical occurrence in a patient or clinical study participant\\r\\ntemporally associated with the use of a study intervention, whether or not considered\\r\\nrelated to the study intervention. An AE can therefore be any unfavorable and unintended\\r\\nsign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated)\\r\\ntemporally associated with the use of study intervention. This includes events related to\\r\\nthe comparator, if applicable, and events related to the (study) procedures.',\n",
       "      'timeFrame': 'Up to 16 months'},\n",
       "     {'measure': 'Number of participants with laboratory value abnormalities and/or adverse events (AEs)',\n",
       "      'description': 'Number of participants with potentially clinically significant laboratory values.',\n",
       "      'timeFrame': 'Up to 16 months'},\n",
       "     {'measure': 'Number of participants with vital sign abnormalities and/or adverse events (AEs)',\n",
       "      'description': 'Number of participants with potentially clinically significant vital sign values.',\n",
       "      'timeFrame': 'Up to 16 months'},\n",
       "     {'measure': 'Number of participants with electrocardiograms (ECG) abnormalities and or adverse events',\n",
       "      'description': 'Number of participants with potentially clinically significant ECG values.',\n",
       "      'timeFrame': 'Up to 16 months'},\n",
       "     {'measure': 'Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scores',\n",
       "      'description': 'The ECOG scale will be used to assess performance status. Grades range from 0 (fully\\r\\nactive) to 5 (dead). Negative change scores indicate an improvement. Positive scores\\r\\nindicate a decline in performance.',\n",
       "      'timeFrame': 'Up to 15 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Pharmacokinetics (PK) of zolbetuximab in serum: End of infusion concentrations',\n",
       "      'description': 'End of infusion concentrations will be derived from the PK serum samples collected.',\n",
       "      'timeFrame': 'Up to 1 month'},\n",
       "     {'measure': 'PK of zolbetuximab in serum: Concentration Immediately Prior to Dosing at multiple dosing (Ctrough)',\n",
       "      'description': 'Ctrough will be derived from the PK serum samples collected.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Number of participants with positive antidrug antibodies (ADA) to zolbetuximab',\n",
       "      'timeFrame': 'Up to 15 months'},\n",
       "     {'measure': 'Change from baseline in Cancer Antigen 19-9 (CA 19-9)',\n",
       "      'description': 'Serum CA19-9 will be assessed.',\n",
       "      'timeFrame': 'Baseline up to 13 months'},\n",
       "     {'measure': 'Best Overall Response (BOR) Rate',\n",
       "      'description': 'The BOR is determined once all tumor response data for the participant is available.\\r\\nParticipants will be classified by BOR on study as outlined in Response Evaluation\\r\\nCriteria in Solid Tumors (RECIST) v1.1.',\n",
       "      'timeFrame': 'Up to 15 months'},\n",
       "     {'measure': 'Overall Response Rate (ORR)',\n",
       "      'description': 'ORR is defined as the proportion of participants with best overall response as confirmed\\r\\ncomplete response (CR) or partial response based on RECIST v1.1 as assessed by\\r\\ninvestigator.',\n",
       "      'timeFrame': 'Up to 15 months'},\n",
       "     {'measure': 'Disease Control Rate (DCR)',\n",
       "      'description': 'DCR is defined as the proportion of participants with a complete or partial response as\\r\\nassessed by investigator based on RECIST v1.1.',\n",
       "      'timeFrame': 'Up to 15 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Participant has histologically or cytologically confirmed adenocarcinoma of\\r\\n     pancreas.\\r\\n\\r\\n  -  Participant must have metastatic pancreatic adenocarcinoma that has not been\\r\\n     previously treated with chemotherapy:\\r\\n\\r\\n       -  Prior treatment with 5-fluorouracil or gemcitabine administered as a radiation\\r\\n          sensitizer during and up to 4 weeks after radiation therapy is allowed (if\\r\\n          there is lingering toxicity, then the sponsor should be consulted).\\r\\n\\r\\n       -  If a participant received neoadjuvant/adjuvant therapy, tumor recurrence or\\r\\n          disease progression must have occurred at least 6 months after completing the\\r\\n          last dose of the neoadjuvant/adjuvant therapy.\\r\\n\\r\\n       -  Participant whose disease progressed on prior treatment with mFOLFIRINOX are\\r\\n          not eligible.\\r\\n\\r\\n  -  Participant has a measurable lesion(s) on at least 1 metastatic site based on RECIST\\r\\n     v1.1 within 28 days prior to enrollment. For participants with only 1 measurable\\r\\n     lesion and prior radiotherapy, the lesion must be outside the field of prior\\r\\n     radiotherapy or must have documented progression following radiation therapy.\\r\\n\\r\\n  -  Participant's tumor is CLDN18.2 positive, defined as ≥ 75% of tumor cells\\r\\n     demonstrating moderate to strong membranous CLDN18 staining as determined by central\\r\\n     immunohistochemistry testing.\\r\\n\\r\\n  -  Female subject is not pregnant and at least 1 of the following conditions apply:\\r\\n\\r\\n       -  Not a woman of childbearing potential (WOCBP)\\r\\n\\r\\n       -  WOCBP who has a negative urine or serum pregnancy test at screening or within\\r\\n          48 hours prior to day 1; and agrees to follow the contraceptive guidance from\\r\\n          the time of informed consent through at least 6 months after final study\\r\\n          intervention administration.\\r\\n\\r\\n  -  Female participant must not be breastfeeding or lactating starting at screening and\\r\\n     throughout the treatment period and for 6 months after the final study intervention\\r\\n     administration.\\r\\n\\r\\n  -  Female participant must not donate ova starting at first administration of study\\r\\n     intervention and throughout the treatment period and for 6 months after the final\\r\\n     study intervention administration.\\r\\n\\r\\n  -  A male participant must agree to use contraception with female partner(s) of\\r\\n     childbearing potential (including breastfeeding partner) throughout the treatment\\r\\n     period and for 6 months after final study intervention administration.\\r\\n\\r\\n  -  A male participant must agree to remain abstinent or use a condom with pregnant\\r\\n     partner(s) for the duration of the pregnancy throughout the treatment period and for\\r\\n     6 months after final study intervention administration.\\r\\n\\r\\n  -  A male participant must not donate sperm during the treatment period and for 6\\r\\n     months after final study intervention administration.\\r\\n\\r\\n  -  Participant agrees not to participate in another interventional study while\\r\\n     receiving study intervention in the present study/participating in the present\\r\\n     study.\\r\\n\\r\\n  -  Participant has ECOG performance status 0 or 1.\\r\\n\\r\\n  -  Participant has predicted life expectancy ≥ 12 weeks.\\r\\n\\r\\n  -  Participant must meet all of the following criteria based on the laboratory tests\\r\\n     collected within 14 days prior to enrollment. In case of multiple laboratory data\\r\\n     within this period, the most recent data should be used.\\r\\n\\r\\n  -  Participant must meet all of criteria based on laboratory tests during screening\\r\\n     period.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Participant has prior severe allergic reaction; suspected, known immediate or\\r\\n     delayed hypersensitivity; or intolerance or contraindication to known ingredients of\\r\\n     zolbetuximab or other monoclonal antibody, including humanized or chimeric\\r\\n     antibodies.\\r\\n\\r\\n  -  Participant has prior severe allergic reaction; suspected, known immediate or\\r\\n     delayed hypersensitivity; or intolerance or contraindication to any component of\\r\\n     mFOLFIRINOX.\\r\\n\\r\\n  -  Participant has known dihydropyrimidine dehydrogenase (DPD) deficiency.\\r\\n\\r\\n  -  Participant has a known history of a positive test for human immunodeficiency virus\\r\\n     infection or known active hepatitis B (positive HBs Ag) or hepatitis C infection.\\r\\n\\r\\n       -  For participants who are negative for hepatitis B surface antigen, but\\r\\n          hepatitis B core antibody positive, a hepatitis B virus deoxyribonucleic acid\\r\\n          test will be performed and if positive, the participant will be excluded.\\r\\n\\r\\n       -  Participants with positive hepatitis C serology but negative hepatitis C virus\\r\\n          ribonucleic acid test results are eligible.\\r\\n\\r\\n       -  Participants treated for hepatitis C with undetectable viral load results are\\r\\n          eligible.\\r\\n\\r\\n  -  Participant has a history of interstitial pneumonia or pulmonary fibrosis.\\r\\n\\r\\n  -  Participant has pleural effusion or ascites ≥ Grade 3 per Common Terminology\\r\\n     Criteria for Adverse Events (CTCAE) v4.03.\\r\\n\\r\\n  -  Participant has an active autoimmune disease that has required systemic treatment in\\r\\n     the past 3 months prior to enrollment.\\r\\n\\r\\n  -  Participant has active infection requiring systemic therapy that has not completely\\r\\n     resolved within 7 days prior to enrollment.\\r\\n\\r\\n  -  Participant has significant cardiovascular disease, including:\\r\\n\\r\\n       -  Congestive heart failure (defined as New York Heart Association Class III or\\r\\n          IV), myocardial infarction, unstable angina, coronary angioplasty, coronary\\r\\n          stenting,coronary artery bypass graft, cerebrovascular accident or hypertensive\\r\\n          crisis within 6 months prior to enrollment;\\r\\n\\r\\n       -  History of clinically significant ventricular arrhythmias (i.e., sustained\\r\\n          ventricular tachycardia, ventricular fibrillation or torsades de pointes);\\r\\n\\r\\n       -  QT interval corrected for heart rate (QTc) > 450 msec for male participants;\\r\\n          QTc interval > 470 msec for female participants;\\r\\n\\r\\n       -  Cardiac arrhythmias requiring anti-arrhythmic medications (Participants with\\r\\n          rate-controlled atrial fibrillation for > 1 month prior to enrollment are\\r\\n          eligible).\\r\\n\\r\\n  -  Participant has a history of central nervous system metastases and/or carcinomatous\\r\\n     meningitis from pancreatic adenocarcinoma.\\r\\n\\r\\n  -  Participant has known peripheral sensory neuropathy ≥ Grade 2 per CTCAE v4.03 unless\\r\\n     the absence of deep tendon reflexes is the sole neurological abnormality.\\r\\n\\r\\n  -  Participant has had diarrhea within 24 hours prior to enrollment.\\r\\n\\r\\n  -  Participant has had a major surgical procedure ≤ 28 days prior to enrollment.\\r\\n\\r\\n  -  Participant without complete recovery from a major surgical procedure ≤ 14 days\\r\\n     prior to enrollment.\\r\\n\\r\\n  -  Participant has a psychiatric illness or social situations that would preclude study\\r\\n     compliance.\\r\\n\\r\\n  -  Participant has another malignancy for which treatment is required.\\r\\n\\r\\n  -  Participant has any concurrent disease, infection or co-morbid condition that\\r\\n     interferes with the ability of the participant to participate in the study, which\\r\\n     places the participant at undue risk or complicates the interpretation of data.\\r\\n\\r\\n  -  Participant has received radiotherapy for metastatic pancreatic adenocarcinoma\\r\\n     unless the radiotherapy was completed > 14 days prior to enrollment and has\\r\\n     recovered from any related toxicity.\\r\\n\\r\\n  -  Participant has received systemic immunosuppressive therapy, including systemic\\r\\n     corticosteroids within 14 days prior to enrollment.\\r\\n\\r\\n  -  Participant using a physiologic replacement dose of hydrocortisone or its equivalent\\r\\n     (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of\\r\\n     prednisone), receiving a single dose of systemic corticosteroids or receiving\\r\\n     systemic corticosteroids as premedication for radiologic imaging contrast use is\\r\\n     allowed.\\r\\n\\r\\n  -  Participant has a present or previous history of participation in a study of the\\r\\n     study intervention.\\r\\n\\r\\n  -  Participant has a previous history of investigational study intervention\\r\\n     administration.\\r\\n\\r\\n  -  Participant uses strong inhibitors or inducers of CYP3A or UGT1A1 when using\\r\\n     irinotecan.\\r\\n\\r\\n  -  Participant has received any investigational therapy within 28 days prior to\\r\\n     screening.\\r\\n\\r\\n  -  Participant has any condition which makes the participant unsuitable for study\\r\\n     participation.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Astellas Pharma Global Development, Inc.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '800-888-7704',\n",
       "      'email': 'Astellas.registration@astellas.com'}],\n",
       "    'overallOfficials': [{'name': 'Medical Director',\n",
       "      'affiliation': 'Astellas Pharma Global Development, Inc.',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': 'Access to anonymized individual participant level data will not be provided for this\\r\\ntrial as it meets one or more of the exceptions described on\\r\\nwww.clinicalstudydatarequest.com under \"Sponsor Specific Details for Astellas.\"'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000230',\n",
       "      'term': 'Adenocarcinoma'}],\n",
       "    'ancestors': [{'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M13110',\n",
       "      'name': 'Pancreatic Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3585',\n",
       "      'name': 'Adenocarcinoma',\n",
       "      'asFound': 'Adenocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4387', 'name': 'Pancreatic Cancer', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M1671',\n",
       "      'name': 'Irinotecan',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6191', 'name': 'Leucovorin', 'relevance': 'LOW'},\n",
       "     {'id': 'M8600', 'name': 'Fluorouracil', 'relevance': 'LOW'},\n",
       "     {'id': 'M1674', 'name': 'Oxaliplatin', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Micro', 'name': 'Micronutrients'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06211491',\n",
       "    'orgStudyIdInfo': {'id': 'UDS filling speed'},\n",
       "    'organization': {'fullName': 'Pusan National University Yangsan Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Autonomic Dysreflexia in Spinal Cord Injuries: UDS Filling Speed Impact',\n",
       "    'officialTitle': 'Autonomic Dysreflexia Clinical Characteristics According to the Filling Speed in Urodynamics in Individuals With Spinal Cord Injuries'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-21',\n",
       "    'studyFirstSubmitQcDate': '2024-01-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Sungchul Huh',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'Pusan National University Yangsan Hospital'},\n",
       "    'leadSponsor': {'name': 'Pusan National University Yangsan Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'In patients with spinal cord injury, the investigators want to understand and understand\\r\\nthe differences in AD prevalence and characteristics according to bladder injection rate,\\r\\nand to determine which factors have a greater influence between bladder expansion or\\r\\ninjection rate.',\n",
       "    'detailedDescription': \"It has been reported that there is a difference in the degree of AD between the bladder\\r\\nand urinary tract motility tests, suggesting a potential difference according to the\\r\\ninjection rate. According to Liu et al., the authors noted that stimulation of the\\r\\nurethra, prostate, and internal sphincter appears to induce AD more strongly than the\\r\\ninjection rate. In addition, the two main factors contributing to AD among urinary\\r\\nkinetics tests are the patient's age and bladder maximum urination pressure. Considering\\r\\nthese factors is important in preventing AD during urinary kinetics tests. Despite these\\r\\nprevious studies, the prevalence and severity of AD according to the injection rate of\\r\\nurinary kinetics tests in SCI have not been quantitatively evaluated.\"},\n",
       "   'conditionsModule': {'conditions': ['Spinal Cord Injuries',\n",
       "     'Autonomic Dysreflexia',\n",
       "     'UDS Filling Speed']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Urodynamic test',\n",
       "      'description': 'Urodynamic testing is performed using saline solution at the same temperature as body\\r\\ntemperature (37 degrees) at two injection speeds of 10 mL/min and 100 mL/min,\\r\\nrespectively.'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Bladder volume (ml)',\n",
       "      'description': '(1) at first AD at an infusion rate of 10 mL/min (2) at first AD at an infusion rate of\\r\\n100 mL/min',\n",
       "      'timeFrame': 'Immediately after the test'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Bladder compliance (mL/cmH2O)',\n",
       "      'timeFrame': 'Immediately after the test'},\n",
       "     {'measure': 'Symptoms (Y/N)', 'timeFrame': 'Immediately after the test'},\n",
       "     {'measure': 'Blood pressure (mmHg)',\n",
       "      'timeFrame': 'Immediately after the test'},\n",
       "     {'measure': 'Heart rate (bpm)',\n",
       "      'timeFrame': 'Immediately after the test'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Patients with chronic spinal cord injury 6 months after receiving the award\\r\\n\\r\\n  2. Patients with confirmed AD due to bladder fullness in previous urodynamic test\\r\\n\\r\\n  3. Patients confirmed to have neurological damage level C1-T6, AIS A or B\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patients who cannot perform the test because their systolic blood pressure remains\\r\\n     at 150 mmHg during the urodynamic test\\r\\n\\r\\n  2. Patients who cannot undergo testing due to hemodynamic instability\\r\\n\\r\\n  3. Patients who cannot undergo testing due to overt urinary tract infection',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Chronic spinal cord injuries',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000013119',\n",
       "      'term': 'Spinal Cord Injuries'},\n",
       "     {'id': 'D000020211', 'term': 'Autonomic Dysreflexia'},\n",
       "     {'id': 'D000014947', 'term': 'Wounds and Injuries'}],\n",
       "    'ancestors': [{'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000020196', 'term': 'Trauma, Nervous System'},\n",
       "     {'id': 'D000001342', 'term': 'Autonomic Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M15916',\n",
       "      'name': 'Spinal Cord Injuries',\n",
       "      'asFound': 'Spinal Cord Injury',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22038',\n",
       "      'name': 'Autonomic Dysreflexia',\n",
       "      'asFound': 'Autonomic Dysreflexia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17685',\n",
       "      'name': 'Wounds and Injuries',\n",
       "      'asFound': 'Injury',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22023', 'name': 'Trauma, Nervous System', 'relevance': 'LOW'},\n",
       "     {'id': 'M4643',\n",
       "      'name': 'Autonomic Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M27979', 'name': 'Primary Dysautonomias', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC26', 'name': 'Wounds and Injuries'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06313294',\n",
       "    'orgStudyIdInfo': {'id': '230929002'},\n",
       "    'organization': {'fullName': 'Pontificia Universidad Catolica de Chile',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Postoperative Follow-up Via Text Messages Automated Versus Telephone in Patients With Continuous Regional Anesthesia',\n",
       "    'officialTitle': 'Postoperative Follow-up Via Text Messages Automated Versus Telephone in Patients With Continuous Regional Anesthesia',\n",
       "    'acronym': 'txt-RA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-23',\n",
       "    'studyFirstSubmitQcDate': '2024-03-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-15', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Pontificia Universidad Catolica de Chile',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Monitoring performed by a trained operator has proven to be useful and valued by patients\\r\\nafter the use of continuous regional anesthesia. A health professional calls each patient\\r\\nto gather information about their recovery. However, this direct communication strategy\\r\\nrequires time and resources, especially if many patients are involved.\\r\\n\\r\\nA modern and convenient approach involves the use of immediate communication technology\\r\\nfor follow-up after a procedure. They may contain specific questions that patients can\\r\\neasily answer from their mobile devices.\\r\\n\\r\\nAutomated text messages could be associated with greater convenience and ease for\\r\\npatients with response rates at least like the traditional method. Phone calls, on the\\r\\nother hand, may be less scalable and require more human resources.\\r\\n\\r\\nThe objective of the project is to evaluate the feasibility of monitoring through\\r\\nautomated electronic messaging by evaluating its usability using a validated scale in\\r\\nSpanish. response rate on the first day and adherence rate compared to that of the\\r\\ntraditional method. Secondarily, adherence and differences in satisfaction will be\\r\\ncompared.',\n",
       "    'detailedDescription': 'Communication with patients after performing any procedure under regional anesthesia is\\r\\nessential to evaluate pain control, measure patient satisfaction, and detect\\r\\npost-surgical and post-anesthetic complications.\\r\\n\\r\\nHowever, for outpatients, achieving follow-up through phone calls can be a real\\r\\nchallenge. Gessner et al report that successful daily telephone contact for patients\\r\\ndischarged with a continuous perineural blocking catheter varies between 49 and 65%.\\r\\nWhile their results with the use of an automated messaging system, delivered results as\\r\\npromising as a response rate of 91%, considering a range of 18 to 90 years.\\r\\n\\r\\nIt is known that the mobile application market is expanding with great diversity on\\r\\ndifferent devices. For this reason, there is great competition among application\\r\\ndevelopers to create those that best fulfill the tasks proposed each day.\\r\\n\\r\\nFor this, the usability of mobile applications is a crucial tool to obtain a competitive\\r\\nadvantage in these circumstances.\\r\\n\\r\\nThe significance of the expected results described above will open a door to the\\r\\nsequential or gradual implementation of a system that allows us to reduce the time and/or\\r\\nnumber of people required per day to achieve adequate follow-up of the patients. In\\r\\naddition, it would leave room for new projects that seek to devise an ordered work plan\\r\\nto identify the subgroup of patients who objectively require a live call to evaluate\\r\\ncomplications of the procedure.\\r\\n\\r\\nThe hypothesis is that the use of a mobile monitoring application in patients using\\r\\npostoperative continuous ambulatory regional analgesia is associated with usability\\r\\nlevels equal to or higher than the 64th percentile measured on the SUS usability scale in\\r\\nits Spanish version.\\r\\n\\r\\nTo determine the degree of satisfaction that exists between the use of an automated\\r\\nsystem for the monitoring of patients undergoing continuous regional anesthesia at the\\r\\nUC-Christus Clinical Hospital. How much it impacts adherence to follow-up will also be\\r\\nreviewed, comparing it with the traditional method (telephone interview).\\r\\n\\r\\nA convenience sample of 100 consecutive patients will be selected with continuous\\r\\noutpatient regional analgesia performed in the wards of the UC-Christus Clinical\\r\\nHospital, San Carlos de Apoquindo Clinic and Santa Lucía Medical Center. For this, for a\\r\\nmaximum period of 6 months, 100 patients will be randomly distributed into 2 groups, one\\r\\nfor conventional telephone follow-up and the other for use of the app.'},\n",
       "   'conditionsModule': {'conditions': ['Anesthesia',\n",
       "     'Regional Anesthesia',\n",
       "     'Nerve Pain'],\n",
       "    'keywords': ['Anesthesia, Regional',\n",
       "     'Regional Anesthesia',\n",
       "     'Continuous Nerve Block',\n",
       "     'Ambulatory',\n",
       "     'Outpatient follow-up']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Participants will are assigned to one of two groups in parallel for the duration of the\\r\\nstudy',\n",
       "     'primaryPurpose': 'DIAGNOSTIC',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'The research patients will be blind to the proposed intervention.',\n",
       "      'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'App Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'In this group the patients will use the app for asking about related to pain, patient\\r\\nsatisfaction and another complications.',\n",
       "      'interventionNames': ['Other: Tracking application app']},\n",
       "     {'label': 'Telephone interview group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'In this group the patients will receive the calling by one member of the healthcare team\\r\\nasking items related to pain, patient satisfaction and another complications.',\n",
       "      'interventionNames': ['Other: Telephone interview']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Tracking application app',\n",
       "      'description': 'An app will be implemented for mobile monitoring in patients who use continuous\\r\\npostoperative ambulatory regional analgesia.',\n",
       "      'armGroupLabels': ['App Group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Telephone interview',\n",
       "      'description': 'Patients who use continuous postoperative outpatient regional analgesia will be followed\\r\\nup using the current traditional method of post-discharge telephone call.',\n",
       "      'armGroupLabels': ['Telephone interview group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Usability level of the tracking application',\n",
       "      'description': 'To determine the level of usability of the application using the SUS scale developed by\\r\\nJohn Brooke in 1986. This scale consists of 10 Likert-type statements. To calculate the\\r\\nresult, the statements have an answer that will be equivalent to 1, 2, 3, 4 or 5,\\r\\ndepending on said answer. The answers to the odd and even statements are added and then\\r\\nsubtracted 5 and 25, respectively. The sum of both results is subsequently multiplied by\\r\\n2.5 to obtain a result that ranges from 0 to 100, with 64 being our cut-off point to\\r\\nconsider it acceptable.',\n",
       "      'timeFrame': '1, 2 and 3 days after discharge.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Patient satisfaction with Perception of Quality in Anesthesia',\n",
       "      'description': \"Measure and compare the level of patient satisfaction using the Perception of Quality in\\r\\nAnesthesia (PQA) scale validated in Spanish. In this instrument, the patient was asked to\\r\\nrespond using a five-point Likert scale.\\r\\n\\r\\nThe extremes of the scale were labelled 'very poor' to 'very good' or 'definitely not' to\\r\\n'definitely yes' depending upon the question. Unsatisfactory patient responses were\\r\\ndefined as a score of ≤3, any response 'yes' to the awareness question, or any\\r\\ndescription of nausea or vomiting in the PONV question.\\r\\n\\r\\nA quality index was calculated for each PQA question by multiplying the importance score\\r\\nagainst the performance score.\",\n",
       "      'timeFrame': '1, 2 and 3 days after discharge.'},\n",
       "     {'measure': 'Patient adherence',\n",
       "      'description': 'Measure and compare patient adherence using the app versus the telephone follow-up\\r\\nmethod, defined as rate of response during the three days of follow-up.',\n",
       "      'timeFrame': '1, 2 and 3 days after discharge.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Elective surgery with continuous ambulatory regional analgesia\\r\\n\\r\\n  -  Able to understand, use and operate a smartphone to view the mobile application\\r\\n\\r\\n  -  ASA I - II\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Ages under 17 or over 76 years\\r\\n\\r\\n  -  Emergency surgery',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Erick Strange, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(+56) 95504 3270',\n",
       "      'email': 'strange.erick@gmail.com'},\n",
       "     {'name': 'Fernando Altermatt, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(+56) 95504 3270',\n",
       "      'email': 'falterma@uc.cl'}],\n",
       "    'overallOfficials': [{'name': 'Fernando Altermatt, MD',\n",
       "      'affiliation': 'Pontificia Universidad Catolica de Chile',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'Pontificia Universidad Catolica de Chile',\n",
       "      'city': 'Santiago',\n",
       "      'state': 'Metropolitana',\n",
       "      'zip': '450881',\n",
       "      'country': 'Chile',\n",
       "      'contacts': [{'name': 'Victor Contreras, MSN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '223549217',\n",
       "        'email': 'vecontre@uc.cl'},\n",
       "       {'name': 'Erick Strange, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009437',\n",
       "      'term': 'Neuralgia'}],\n",
       "    'ancestors': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M12381',\n",
       "      'name': 'Neuralgia',\n",
       "      'asFound': 'Nerve Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06428760',\n",
       "    'orgStudyIdInfo': {'id': 'ashmehmetonut'},\n",
       "    'organization': {'fullName': 'Ankara City Hospital Bilkent',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Relationship Between Preoperative Subcutaneous Trochanteric Fat Thickness and Postoperative Infection Risk',\n",
       "    'officialTitle': 'The Effect of Preoperative Subcutaneous Trochanteric Fat Thickness and Trochanteric Soft Tissue Thickness on Postoperative Infection Risk in Patients Undergoing Hemiarthroplasty for Femoral Neck Fracture'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-10-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-04-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-15',\n",
       "    'studyFirstSubmitQcDate': '2024-05-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Ankara City Hospital Bilkent', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The effect of preoperative subcutaneous trochanteric fat thickness and trochanteric soft\\r\\ntissue thickness on postoperative infection risk in patients undergoing hemiarthroplasty\\r\\nfor femoral neck fracture',\n",
       "    'detailedDescription': 'Obesity is a growing problem for healthcare systems and orthopaedic surgeons, with 29% of\\r\\nthe adult population in the UK and 40% in the US affected by obesity. The most commonly\\r\\nused measure of obesity in healthcare is body mass index (BMI), and the World Health\\r\\nOrganisation defines obesity as a BMI ≥ 30 kg/m2. Much of the arthroplasty literature has\\r\\nalso focused on the use of BMI as a measure of obesity.\\r\\n\\r\\nBMI-defined obesity is associated with an increased risk of perioperative complications\\r\\n(including infection and dislocation) in total hip arthroplasty. It has also been shown\\r\\nthat there is a gradual increase in anaesthetic time, operative time and length of\\r\\nhospital stay as BMI increases in obese patients.\\r\\n\\r\\nBMI is an imperfect measure because it does not take into account age, sex, race, fat\\r\\ndistribution or muscle mass. Previous studies have shown that subcutaneous fat depth (FD)\\r\\nis an independent risk factor for wound infection in cervical and lumbar spine surgery\\r\\nand after laparotomy. It is not known whether increased subcutaneous fat and soft tissue\\r\\nmass are associated with an increased risk of complications after arthroplasty for\\r\\nfemoral neck fractures.\\r\\n\\r\\nThe aim of this study was to investigate whether preoperative measurement of subcutaneous\\r\\nadipose tissue by radiography and computed tomography (CT) and muscle thickness in the\\r\\ngluteus medius/minus, gluteus maximus, anterior and medial compartments by computed\\r\\ntomography (CT) in femoral neck fractures correlate with infection rates at postoperative\\r\\nfollow-up.\\r\\n\\r\\nHypothesis: In patients with high body mass index (BMI) with femoral neck fractures, the\\r\\ninvestigators believe that the relationship between increased subcutaneous adipose tissue\\r\\non radiographs and CT sections and wound infection is as effective as the relationship\\r\\nbetween increased muscle thickness in the gluteus medius/minimus, gluteus maximus,\\r\\nanterior and medial compartments measured on CT sections and wound infection.'},\n",
       "   'conditionsModule': {'conditions': ['Hip Infection'],\n",
       "    'keywords': ['subcutaneous trochanteric fat thickness',\n",
       "     'infection',\n",
       "     'femoral neck fracture',\n",
       "     'soft tissue thickness',\n",
       "     'obesity',\n",
       "     'hemiarthroplasty']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '6 Months',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Effect of trochanteric fat and soft tissue',\n",
       "      'description': 'The aim of this study was to evaluate the effect of peritrochanteric fat thickness and\\r\\nhip soft tissue parameters on postoperative wound infection in patients with femoral neck\\r\\nfracture.\\r\\n\\r\\nPeritrochanteric fat thickness will be measured on preoperative radiographs along with\\r\\nsourcil to skin surface, greater trochanter tip to skin surface, and lateral greater\\r\\ntrochanter to skin surface values.\\r\\n\\r\\nHip soft tissue assessment will be measured with the parameters of gluteus medius/minus,\\r\\ngluteus maximus, muscle thickness in the anterior and medial compartments on preoperative\\r\\nCT sections.',\n",
       "      'timeFrame': 'Pre-operative'},\n",
       "     {'measure': 'Wound infection',\n",
       "      'description': 'Wound infection is assessed using investigator dressings. In assessing surgical wound\\r\\ninfection, an ASEPSIS score will be calculated for each patient to standardise for serous\\r\\nexudate, erythema, purulent exudate, deep tissue separation at the wound site.',\n",
       "      'timeFrame': 'First 3 months after surgery'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Hospital Length of Stay (LOS)',\n",
       "      'description': 'Hospital Length of Stay (LOS): Evaluate the duration of hospitalization following\\r\\nsurgery, as prolonged LOS may be associated with increased risk of nosocomial infections\\r\\nincluding SSIs.',\n",
       "      'timeFrame': '1 months'},\n",
       "     {'measure': 'Mortality Rate',\n",
       "      'description': 'Mortality Rate: Assess mortality rates within a defined follow-up period following\\r\\nsurgery, as postoperative infections, especially in vulnerable populations such as\\r\\nelderly patients with femoral neck fractures, may contribute to increased mortality.\\r\\n\\r\\nMortality risk is measured by the Charlson comorbidity index.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Body Mass Index',\n",
       "      'description': \"It has been suggested that there is a relationship between body mass index and\\r\\npost-operative wound infection. This index is measured in kg/m2 using the patient's\\r\\nheight and weight.\",\n",
       "      'timeFrame': 'Measured once preoperatively'},\n",
       "     {'measure': 'Biochemistry Scans',\n",
       "      'description': 'WBC, leukocyte, neutrophil, lymphocyte, albumin, CRP parameters will be evaluated in\\r\\nroutine biochemistry scans',\n",
       "      'timeFrame': '1 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients over 65 years of age\\r\\n\\r\\n  -  Femoral neck fractures\\r\\n\\r\\n  -  Female patients\\r\\n\\r\\n  -  Patients undergoing hemiarthroplasty\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients younger than 65 years\\r\\n\\r\\n  -  Male patients\\r\\n\\r\\n  -  Patients with immunosuppressive conditions\\r\\n\\r\\n  -  Intertrochanteric fractures\\r\\n\\r\\n  -  Patients with revision surgery\\r\\n\\r\\n  -  Pathological femoral neck fractures',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '65 Years',\n",
       "    'stdAges': ['OLDER_ADULT'],\n",
       "    'studyPopulation': 'Female patients over 65 years of age who were admitted to our hospital with a history of\\r\\na femoral neck fracture and who underwent hemiarthroplasty.',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Ankara Bilkent City Hospital',\n",
       "      'city': 'Ankara',\n",
       "      'state': 'Cankaya',\n",
       "      'zip': '06800',\n",
       "      'country': 'Turkey',\n",
       "      'geoPoint': {'lat': 39.91987, 'lon': 32.85427}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007239',\n",
       "      'term': 'Infections'},\n",
       "     {'id': 'D000003141', 'term': 'Communicable Diseases'},\n",
       "     {'id': 'D000005265', 'term': 'Femoral Neck Fractures'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000006620', 'term': 'Hip Fractures'},\n",
       "     {'id': 'D000005264', 'term': 'Femoral Fractures'},\n",
       "     {'id': 'D000050723', 'term': 'Fractures, Bone'},\n",
       "     {'id': 'D000014947', 'term': 'Wounds and Injuries'},\n",
       "     {'id': 'D000025981', 'term': 'Hip Injuries'},\n",
       "     {'id': 'D000007869', 'term': 'Leg Injuries'}],\n",
       "    'browseLeaves': [{'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'},\n",
       "     {'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26370', 'name': 'Fractures, Bone', 'relevance': 'LOW'},\n",
       "     {'id': 'M8403',\n",
       "      'name': 'Femoral Neck Fractures',\n",
       "      'asFound': 'Femoral Neck Fractures',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6368',\n",
       "      'name': 'Communicable Diseases',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'M9696', 'name': 'Hip Fractures', 'relevance': 'LOW'},\n",
       "     {'id': 'M8402', 'name': 'Femoral Fractures', 'relevance': 'LOW'},\n",
       "     {'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'},\n",
       "     {'id': 'M23105', 'name': 'Hip Injuries', 'relevance': 'LOW'},\n",
       "     {'id': 'M10881', 'name': 'Leg Injuries', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06292780',\n",
       "    'orgStudyIdInfo': {'id': 'R5458-ONC-2274'},\n",
       "    'secondaryIdInfos': [{'id': '2023-507809-34-00',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'EUCT Number'}],\n",
       "    'organization': {'fullName': 'Regeneron Pharmaceuticals',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)',\n",
       "    'officialTitle': 'A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis',\n",
       "    'acronym': 'LINKER-AL2'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-08-20', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2035-02-20', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-27',\n",
       "    'studyFirstSubmitQcDate': '2024-02-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-05', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Regeneron Pharmaceuticals', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is researching an experimental drug called linvoseltamab (\"study drug\").\\r\\n\\r\\nThis study is focused on patients who have AL amyloidosis that has returned or have\\r\\nfailed other therapies and need to be treated again.\\r\\n\\r\\nThe study consists of 2 phases (Phase 1 and Phase 2):\\r\\n\\r\\n  -  In Phase 1, linvoseltamab will be given to a small number of participants to study\\r\\n     the side effects of the study drug and to determine the recommended doses of the\\r\\n     study drug to be given to participants in Phase 2.\\r\\n\\r\\n  -  In Phase 2, linvoseltamab will be given to more participants to continue to assess\\r\\n     the side effects of the study drug and to evaluate the ability of linvoseltamab to\\r\\n     treat AL amyloidosis.\\r\\n\\r\\nThe study is looking at several other research questions, including:\\r\\n\\r\\n  -  How many participants treated with linvoseltamab have improvement in the abnormal\\r\\n     proteins that cause organ problems and for how long\\r\\n\\r\\n  -  How many participants treated with linvoseltamab have improvement in the heart or\\r\\n     kidney and for how long\\r\\n\\r\\n  -  What the right dosing regimen is for linvoseltamab\\r\\n\\r\\n  -  What side effects may happen from taking linvoseltamab\\r\\n\\r\\n  -  How much linvoseltamab is in your blood at different times\\r\\n\\r\\n  -  Whether the body makes antibodies against linvoseltamab (which could make the drug\\r\\n     less effective or could lead to side effects)'},\n",
       "   'conditionsModule': {'conditions': ['Relapsed/Refractory Systemic Light Chain Amyloidosis'],\n",
       "    'keywords': ['Amyloid light-chain (AL)',\n",
       "     'Multiple Myeloma (MM)',\n",
       "     'Pathogenic light chains']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'interventionModelDescription': 'Note: Participants enrolled in Phase 2 will be randomized 1:1',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 220, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Phase 1: Cohort 1: Low Dose',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose Escalation: Non-Randomized',\n",
       "      'interventionNames': ['Drug: Linvoseltamab']},\n",
       "     {'label': 'Phase 1: Cohort 2: High Dose',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose Escalation: Non-Randomized',\n",
       "      'interventionNames': ['Drug: Linvoseltamab']},\n",
       "     {'label': 'Phase 2: Low Dose',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose Expansion: Participants will be randomized in a 1:1 ratio',\n",
       "      'interventionNames': ['Drug: Linvoseltamab']},\n",
       "     {'label': 'Phase 2: High Dose',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose Expansion: Participants will be randomized in a 1:1 ratio',\n",
       "      'interventionNames': ['Drug: Linvoseltamab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Linvoseltamab',\n",
       "      'description': 'anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody',\n",
       "      'armGroupLabels': ['Phase 1: Cohort 1: Low Dose',\n",
       "       'Phase 1: Cohort 2: High Dose',\n",
       "       'Phase 2: High Dose',\n",
       "       'Phase 2: Low Dose'],\n",
       "      'otherNames': ['REGN5458']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of dose-limiting toxicity (DLTs)',\n",
       "      'description': 'Phase 1',\n",
       "      'timeFrame': 'Up to 28 Days'},\n",
       "     {'measure': 'Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 3 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Achievement of hematologic CR, as determined by the IRC',\n",
       "      'description': 'Phase 1',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Achievement of hematologic very good partial response (VGPR) or better response (CR + VGPR), as determined by the IRC',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Achievement of overall hematologic response (PR or better), as determined by the IRC',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Time to initial hematologic response',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Time to best hematologic response',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Duration of hematologic response (ie, best response, VGPR or better, overall response), as determined by the IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Hematologic progression-free survival (PFS)',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Incidence of death', 'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Incidence of treatment-emergent adverse events (TEAEs)',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of TEAEs', 'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of serious adverse events (SAEs)',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of SAEs', 'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of adverse events of special interest (AESIs)',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of AESIs', 'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Achievement of overall hematologic response (PR or better), as determined by the IRC in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of TEAEs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of TEAEs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of SAEs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of SAEs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of AESIs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Severity of AESIs in dose regimen 1 vs 2',\n",
       "      'description': 'Phase 2',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Time from treatment initiation to hematologic disease progression as determined by the IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time from treatment initiation to cardiac deterioration, as determined by the IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time from treatment initiation to kidney deterioration as determined by the IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time from treatment initiation to death as determined by the IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time from initiation of treatment to date of death from any cause',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Achievement of renal response in participants with renal involvement at baseline, as determined by IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Achievement of cardiac response in participants with cardiac involvement at baseline, as determined by IRC',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time to first renal response in participants with renal involvement at baseline',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Time to first cardiac response in participants with cardiac involvement at baseline',\n",
       "      'timeFrame': 'Up to 7 years'},\n",
       "     {'measure': 'Linvoseltamab concentration in serum over time',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Incidence of anti-drug antibodies (ADAs) to linvoseltamab over time',\n",
       "      'timeFrame': 'Up to 39 months'},\n",
       "     {'measure': 'Titers of ADAs to linvoseltamab over time',\n",
       "      'timeFrame': 'Up to 39 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\\r\\n\\r\\n  1. Confirmed diagnosis of AL amyloidosis, as described in the protocol\\r\\n\\r\\n  2. Measurable disease as defined by serum difference between involved and uninvolved\\r\\n     free light chains (dFLC) concentration, as described in the protocol\\r\\n\\r\\n  3. Previously treated after at least 1 prior therapy and no more than 4 lines of\\r\\n     therapy (including autologous stem cell transplant) and requiring further treatment\\r\\n     as assessed by the Investigator\\r\\n\\r\\n  4. N-terminal pro b-type natriuretic peptide (NT-proBNP) ≤8500 ng/L during screening\\r\\n\\r\\n  5. Adequate hepatic, hematologic, renal, and cardiac function, as described in the\\r\\n     protocol\\r\\n\\r\\n  6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2 at screening\\r\\n\\r\\nKey Exclusion Criteria:\\r\\n\\r\\n  1. History of other non-AL amyloidosis\\r\\n\\r\\n  2. Greater than 60% plasmacytosis on a bone marrow biopsy and/or aspirate during\\r\\n     screening\\r\\n\\r\\n  3. Presence of lytic bone lesion(s) or extramedullary plasmacytoma on imaging during\\r\\n     screening\\r\\n\\r\\n  4. Myocardial infarction within the past 6 months prior to the first screening visit\\r\\n\\r\\n  5. Known active infection requiring hospitalization or treatment with IV\\r\\n     anti-infectives within 28 days of first administration of study drug\\r\\n\\r\\nNOTE: Other protocol defined inclusion/exclusion criteria apply',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Clinical Trials Administrator',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '844-734-6643',\n",
       "      'email': 'clinicaltrials@regeneron.com'}],\n",
       "    'overallOfficials': [{'name': 'Clinical Trial Management',\n",
       "      'affiliation': 'Regeneron Pharmaceuticals',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'All Individual Patient Data (IPD) that underlie publicly available results will be\\r\\nconsidered for sharing.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'],\n",
       "    'timeFrame': 'When Regeneron has received marketing authorization from major health authorities (e.g.,\\r\\nFDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA),\\r\\netc.) for the product and indication, has made results publicly available (e.g.,\\r\\nscientific publication, scientific conference, clinical trial registry), has the legal\\r\\nauthority to share the data, and has ensured the ability to protect participant privacy.',\n",
       "    'accessCriteria': \"Qualified researchers can submit a proposal for access to individual patient or aggregate\\r\\nlevel data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's\\r\\nIndependent Research Request Evaluation Criteria can be found at:\\r\\nhttps://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-\\r\\nIndependent-Research-Request-Evaluation-Criteria.pdf\",\n",
       "    'url': 'https://vivli.org/'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000686',\n",
       "      'term': 'Amyloidosis'}],\n",
       "    'ancestors': [{'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12058',\n",
       "      'name': 'Multiple Myeloma',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M27588', 'name': 'Neoplasms, Plasma Cell', 'relevance': 'LOW'},\n",
       "     {'id': 'M4021',\n",
       "      'name': 'Amyloidosis',\n",
       "      'asFound': 'Amyloidosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1483',\n",
       "      'name': 'Immunoglobulin Light-chain Amyloidosis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3947', 'name': 'Multiple Myeloma', 'relevance': 'LOW'},\n",
       "     {'id': 'T254',\n",
       "      'name': 'AL Amyloidosis',\n",
       "      'asFound': 'Light Chain Amyloidosis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4225',\n",
       "      'name': 'Antibodies',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20194', 'name': 'Antibodies, Bispecific', 'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06431880',\n",
       "    'orgStudyIdInfo': {'id': '36246PR638/4/24'},\n",
       "    'organization': {'fullName': 'Tanta University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'External Oblique Intercostal Plane Block Versus Thoracic Paravertebral Block for Post Thoracotomy Pain',\n",
       "    'officialTitle': 'External Oblique Intercostal Plane Block Versus Thoracic Paravertebral Block for Post Thoracotomy Pain: A Randomized Non-inferiority Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-16',\n",
       "    'studyFirstSubmitQcDate': '2024-05-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Mohammed Said ElSharkawy',\n",
       "     'investigatorTitle': 'Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.',\n",
       "     'investigatorAffiliation': 'Tanta University'},\n",
       "    'leadSponsor': {'name': 'Tanta University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this study is to compare the effectiveness of analgesia achieved by external\\r\\noblique intercostal plane block (EOIPB)and thoracic paravertebral block (TPVB) for\\r\\npostoperative pain management in patients undergoing open thoracotomy.',\n",
       "    'detailedDescription': 'Acute thoracotomy pain is multifactorial in nature. It involves nociceptive and\\r\\nneuropathic mechanisms originating from somatic and visceral afferents. The main sources\\r\\nof pain are intercostal nerves, the vagus nerve and phrenic nerve in the pleura, the\\r\\nsuperficial cervical plexus, and the brachial plexus in the ipsilateral shoulder.'},\n",
       "   'conditionsModule': {'conditions': ['External Oblique Intercostal Plane Block',\n",
       "     'Thoracic Paravertebral Block',\n",
       "     'Post Thoracotomy Pain']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'External oblique intercostal plane block',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients will receive external oblique intercostal plane block.',\n",
       "      'interventionNames': ['Other: External oblique intercostal plane block']},\n",
       "     {'label': 'Thoracic paravertebral block',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients will receive thoracic paravertebral block.',\n",
       "      'interventionNames': ['Other: Thoracic paravertebral block']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'External oblique intercostal plane block',\n",
       "      'description': 'Patients will receive external oblique intercostal plane block',\n",
       "      'armGroupLabels': ['External oblique intercostal plane block']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Thoracic paravertebral block',\n",
       "      'description': 'Patients will receive thoracic paravertebral block',\n",
       "      'armGroupLabels': ['Thoracic paravertebral block']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Total morphine consumption',\n",
       "      'description': 'Rescue analgesia of morphine will be given as 2 mg bolus if the numeric rating scale\\r\\n(NRS) > 3 to be repeated after 30 min if pain persists until the numeric rating scale <\\r\\n4. numeric rating scale will be assessed at 0, 4, 8, 12, 18 and 24h postoperatively.',\n",
       "      'timeFrame': '24 hours postoperatively'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Intraoperative fentanyl consumption',\n",
       "      'description': 'Additional fentanyl bolus dosages of 1 µg/kg IV will be administered if heart rate or\\r\\nmean arterial blood pressure elevated more than 20% of the baseline (after exclusion of\\r\\nother causes than pain).',\n",
       "      'timeFrame': 'Intraoperative'},\n",
       "     {'measure': 'Mean arterial pressure',\n",
       "      'description': 'Mean arterial pressure will be recorded preoperative, before performing of block, and\\r\\nevery 15 min till the end of surgery.',\n",
       "      'timeFrame': 'Till the end of surgery'},\n",
       "     {'measure': 'Heart rate',\n",
       "      'description': 'Heart rate will be recorded preoperative, before performing of block, and every 15 min\\r\\ntill the end of surgery.',\n",
       "      'timeFrame': 'Till the end of surgery'},\n",
       "     {'measure': 'Time to the 1st rescue analgesia',\n",
       "      'description': 'All patients will receive paracetamol 1 gm every 6 h as routine analgesia. Rescue\\r\\nanalgesia of morphine will be given as 2 mg bolus if the numeric rating scale > 3 to be\\r\\nrepeated after 30 min if pain persists until the numeric rating scale < 4. NRS will be\\r\\nassessed at 0, 4, 8, 12, 18 and 24h postoperatively',\n",
       "      'timeFrame': '24 hours postoperatively'},\n",
       "     {'measure': 'Degree of pain',\n",
       "      'description': 'Degree of pain will be measured using numeric rating scale (NRS) (0 represents \"no pain\"\\r\\nwhile 10 represents \"the worst pain imaginable\").NRS will be assessed at 0, 4, 8, 12, 18\\r\\nand 24h postoperatively.',\n",
       "      'timeFrame': '24 hours postoperatively'},\n",
       "     {'measure': 'Complications',\n",
       "      'description': 'Complications such as bradycardia, hypotension, nausea, vomiting, respiratory depression,\\r\\nlocal anesthetic systemic toxicity (LAST) or any other complication will be recorded.',\n",
       "      'timeFrame': '24 hour postoperatively'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age ≥ 18 years.\\r\\n\\r\\n  -  Both sexes.\\r\\n\\r\\n  -  American Society of Anesthesiology (ASA) physical status I-III.\\r\\n\\r\\n  -  Scheduled for open thoracotomy\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with neurological or intellectual disability.\\r\\n\\r\\n  -  Infection at the injection site.\\r\\n\\r\\n  -  Opioid addiction.\\r\\n\\r\\n  -  Allergic reaction to local anesthetics.\\r\\n\\r\\n  -  Coagulation abnormalities.\\r\\n\\r\\n  -  Drug abuse.\\r\\n\\r\\n  -  Pregnancy.\\r\\n\\r\\n  -  Severe liver and/or renal failure.\\r\\n\\r\\n  -  Uncontrolled hypertension.\\r\\n\\r\\n  -  Severe cardiovascular problems.\\r\\n\\r\\n  -  Diabetes mellitus.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mohammed S Elsharkawy, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '00201148207870',\n",
       "      'email': 'mselsharkawy@med.tanta.edu.eg'}],\n",
       "    'locations': [{'facility': 'Tanta University Hospitals',\n",
       "      'city': 'Tanta',\n",
       "      'state': 'El-Gharbia Governorate, Egypt',\n",
       "      'zip': '31527',\n",
       "      'country': 'Egypt',\n",
       "      'contacts': [{'name': 'Mohammed S Elsharkawy, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '00201148207870',\n",
       "        'email': 'mselsharkawy@med.tanta.edu.eg'},\n",
       "       {'name': 'Saad A Moharam, MD', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Ahmed E Abo ElKheir, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 30.78847, 'lon': 31.00192}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'The data will be available upon a reasonable request from the corresponding author after\\r\\nthe end of study for one year.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL'],\n",
       "    'timeFrame': 'After the end of study for one year.',\n",
       "    'accessCriteria': 'The data will be available upon a reasonable request from the corresponding author.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000784',\n",
       "      'term': 'Aortic Dissection'}],\n",
       "    'ancestors': [{'id': 'D000094665', 'term': 'Dissection, Blood Vessel'},\n",
       "     {'id': 'D000000783', 'term': 'Aneurysm'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000094683', 'term': 'Acute Aortic Syndrome'},\n",
       "     {'id': 'D000001018', 'term': 'Aortic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M4114',\n",
       "      'name': 'Aortic Dissection',\n",
       "      'asFound': 'Thoracic',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3081', 'name': 'Dissection, Blood Vessel', 'relevance': 'LOW'},\n",
       "     {'id': 'M4113', 'name': 'Aneurysm', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M3085', 'name': 'Acute Aortic Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M4334', 'name': 'Aortic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06425120',\n",
       "    'orgStudyIdInfo': {'id': '2023-ZX074'},\n",
       "    'organization': {'fullName': 'China National Center for Cardiovascular Diseases',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'briefTitle': 'Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease',\n",
       "    'officialTitle': 'Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-17',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Jing Li',\n",
       "     'investigatorTitle': 'JingLi, MD, PhD, professor',\n",
       "     'investigatorAffiliation': 'China National Center for Cardiovascular Diseases'},\n",
       "    'leadSponsor': {'name': 'China National Center for Cardiovascular Diseases',\n",
       "     'class': 'OTHER_GOV'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This trials aims to assess, in 240 eligible patients with coronary heart disease, the\\r\\neffects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to\\r\\n12 weeks of Xuesaitong Soft Capsules.',\n",
       "    'detailedDescription': 'In this multicenter, randomized, double-blind, placebo-controlled trial in patients with\\r\\ncoronary heart disease,240 eligible patients aged ≥18 years will be randomized to receive\\r\\nplacebo or Xuesaitong Soft Capsules(1.32g/d) and be followed up for 3 months. The primary\\r\\nendpoint of this study is hsCRP change from baseline to 3 months. The secondary endpoint\\r\\nis the changes of following indicators or scores from baseline to 3 months:(Ⅰ)other\\r\\ninflammation indicators except for hsCRP. (Ⅱ) inhibition of platelet aggregation;\\r\\n(Ⅲ)endothelial function indicators; (Ⅳ)blood lipid levels; (Ⅴ) seattle angina\\r\\nquestionnaire score; (Ⅵ)36-item short form health survey score. The safety of using\\r\\nXuesaitong soft capsules in patients with coronary heart disease will also be evaluated.\\r\\nThe generalized linear mixed effects model will be used to evaluate the efficacy endpoint\\r\\nfor the \"full analysis set\". For the safety analysis set, Chi-square test will be used to\\r\\nevaluate the safety endpoint.'},\n",
       "   'conditionsModule': {'conditions': ['Coronary Heart Disease']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 240, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Xuesaitong Soft Capsule',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Each participant in the Xuesaitong Soft Capsule treatment group will take a daily dose of\\r\\n1.32g.',\n",
       "      'interventionNames': ['Drug: Xuesaitong Soft Capsule']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Each participant in the placebo group will take matching placebo.',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Xuesaitong Soft Capsule',\n",
       "      'description': 'Each participant in the xuesaitong soft capsule treatment group will take a daily dose of\\r\\n1.32g.',\n",
       "      'armGroupLabels': ['Xuesaitong Soft Capsule'],\n",
       "      'otherNames': ['LixuwangⓇ']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Each participant in the placebo group will take matching placebo.',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'hsCRP',\n",
       "      'description': 'Changes in high-sensitivity C-reactive protein level from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Other inflammation indicators',\n",
       "      'description': 'Changes in levels of interleukin-6, interleukin-10, interleukin-1β, tumor necrosis\\r\\nfactor-α from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'IPA',\n",
       "      'description': 'Changes in level of inhibition of platelet aggregation from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Vascular endothelial function',\n",
       "      'description': 'Changes in intercellular adhesion molecule-1, von Willebrand factor, and endothelin-1\\r\\nlevels from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Blood lipid profiles',\n",
       "      'description': 'Changes in total cholesterol, low-density lipoprotein cholesterol, high-density\\r\\nlipoprotein cholesterol, small low-density lipoprotein cholesterol, and triglyceride\\r\\nlevels from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Seattle Angina Questionnaire',\n",
       "      'description': 'Changes in Seattle angina scores from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'SF-36',\n",
       "      'description': 'Changes in Health Survey Scale (SF-36 Scale) scores from baseline at 12 weeks',\n",
       "      'timeFrame': '12 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Age ≥18 years old\\r\\n\\r\\n  2. Chronic coronary artery disease: meet any of the following conditions, and the\\r\\n     condition is stable for at least 6 months:\\r\\n\\r\\n       1. History of myocardial infarction\\r\\n\\r\\n       2. Have received coronary interventional therapy\\r\\n\\r\\n       3. There are symptoms of myocardial ischemia (such as chest pain) and objective\\r\\n          evidence (stress electrocardiogram or stress myocardial perfusion imaging\\r\\n          indicated myocardial ischemia or coronary artery stenosis ≥50% )\\r\\n\\r\\n  3. High-sensitivity C-reactive protein ≥2mg/L\\r\\n\\r\\n  4. Currently taking moderate or above intensity statins lipid-lowering drugs\\r\\n\\r\\n  5. Currently taking antiplatelet drugs\\r\\n\\r\\n  6. Sign informed consent\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients fulfilling any of the following criteria are not eligible for inclusion in\\r\\n     this trial:\\r\\n\\r\\n       1. Acute coronary syndrome occurred or received percutaneous coronary intervention\\r\\n          therapy within the past 6 months\\r\\n\\r\\n       2. Previously received coronary artery bypass grafting\\r\\n\\r\\n       3. Stroke occurred within the previous 6 months\\r\\n\\r\\n       4. Symptomatic heart failure (HF) in the past, or documented left ventricular\\r\\n          ejection fraction < 35%\\r\\n\\r\\n       5. Revascularization or surgical procedures are planned within the next 3 months\\r\\n\\r\\n       6. Progressive neuromuscular disease, or creatine kinase (CK) levels > 3 times the\\r\\n          normal upper limit (ULN)\\r\\n\\r\\n       7. Lupus, inflammatory bowel disease, severe arthritis and other inflammatory\\r\\n          diseases\\r\\n\\r\\n       8. Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic\\r\\n          steroids are currently being taken or planned during the study\\r\\n\\r\\n       9. History of hereditary dyslipidemia such as familial hypercholesterolemia\\r\\n\\r\\n      10. There has been a change in lipid regulation treatment within the past 1 month,\\r\\n          or there is a current adjustment plan\\r\\n\\r\\n      11. History of symptomatic non-traumatic cerebral hemorrhage at any time in the\\r\\n          past\\r\\n\\r\\n      12. History of gastrointestinal bleeding or major surgery within the past 6 months\\r\\n\\r\\n      13. Use of Xuesaitong soft capsules or preparations containing the main ingredients\\r\\n          of Xuesaitong in the past 1 month\\r\\n\\r\\n      14. There were clear adverse reactions to the main components of Xuesaitong in the\\r\\n          past\\r\\n\\r\\n      15. Active liver disease, or alanine aminotransferase (ALT) levels > 3 times the\\r\\n          upper limit of normal (ULN)\\r\\n\\r\\n      16. Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/\\r\\n          (min×1.73m2)\\r\\n\\r\\n      17. Pregnancy or planned pregnancy, or breastfeeding\\r\\n\\r\\n      18. Malignant tumors, or other serious diseases with an estimated survival of less\\r\\n          than 1 year\\r\\n\\r\\n      19. Mental disorders or communication disorders, cognitive impairment, or other\\r\\n          serious medical conditions that may affect study participation\\r\\n\\r\\n      20. Have participated in or are participating in other clinical trials within the\\r\\n          last 1 month\\r\\n\\r\\n      21. Poor adherence to follow-up or medication is known',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jing Li, MD, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 (010) 6086 6077',\n",
       "      'email': 'jing.li@fwoxford.org'},\n",
       "     {'name': 'Yan Li, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 (010) 6086 6795',\n",
       "      'email': 'liyan@fuwai.com'}],\n",
       "    'overallOfficials': [{'name': 'Jing Li, MD, PhD',\n",
       "      'affiliation': 'National Center for Cardiovascular Diseases',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Jiamin Liu, MD',\n",
       "      'affiliation': 'National Center for Cardiovascular Diseases',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Fuwai Hospital, Chinese Academy of Medical Sciences',\n",
       "      'city': 'Beijing',\n",
       "      'state': 'Beijing',\n",
       "      'zip': '100087',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Ying Sun, BA',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '18310888612',\n",
       "        'email': 'ying.sun@fwoxford.org'}],\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006331',\n",
       "      'term': 'Heart Diseases'},\n",
       "     {'id': 'D000003327', 'term': 'Coronary Disease'},\n",
       "     {'id': 'D000003324', 'term': 'Coronary Artery Disease'},\n",
       "     {'id': 'D000017202', 'term': 'Myocardial Ischemia'}],\n",
       "    'ancestors': [{'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000001161', 'term': 'Arteriosclerosis'},\n",
       "     {'id': 'D000001157', 'term': 'Arterial Occlusive Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M6546',\n",
       "      'name': 'Coronary Artery Disease',\n",
       "      'asFound': 'Coronary Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19506',\n",
       "      'name': 'Myocardial Ischemia',\n",
       "      'asFound': 'Coronary Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6549',\n",
       "      'name': 'Coronary Disease',\n",
       "      'asFound': 'Coronary Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9419',\n",
       "      'name': 'Heart Diseases',\n",
       "      'asFound': 'Heart Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M4465',\n",
       "      'name': 'Arterial Occlusive Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06393673',\n",
       "    'orgStudyIdInfo': {'id': 'HS-10384-201'},\n",
       "    'organization': {'fullName': 'Hansoh BioMedical R&D Company',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women',\n",
       "    'officialTitle': 'A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-27',\n",
       "    'studyFirstSubmitQcDate': '2024-04-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Hansoh BioMedical R&D Company',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the\\r\\nefficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor\\r\\nsymptoms.',\n",
       "    'detailedDescription': 'The phase 2 study is consisted with 2 doses. The aim is to detect the efficacy, safety,\\r\\npharmacokinetics and pharmacodynamics characteristics of HS-10384 in participants with\\r\\nvasomotor symptoms.'},\n",
       "   'conditionsModule': {'conditions': ['Vasomotor Symptoms'],\n",
       "    'keywords': ['HS-10384', 'Vasomotor symptoms', 'postmenopausal women']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 195, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'HS-10384 Dose 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose level 1 of HS-10384',\n",
       "      'interventionNames': ['Drug: HS-10384 tablet Dose 1',\n",
       "       'Drug: HS-10384-matched placebo tablets']},\n",
       "     {'label': 'HS-10384 Dose 2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Dose level 2 of HS-10384',\n",
       "      'interventionNames': ['Drug: HS-10384 tablet Dose 2',\n",
       "       'Drug: HS-10384-matched placebo tablets']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'interventionNames': ['Drug: HS-10384-matched placebo tablets']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HS-10384 tablet Dose 1',\n",
       "      'description': 'Administered orally QD',\n",
       "      'armGroupLabels': ['HS-10384 Dose 1']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'HS-10384 tablet Dose 2',\n",
       "      'description': 'Administered orally QD',\n",
       "      'armGroupLabels': ['HS-10384 Dose 2']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'HS-10384-matched placebo tablets',\n",
       "      'description': 'Administered orally QD',\n",
       "      'armGroupLabels': ['HS-10384 Dose 1', 'HS-10384 Dose 2', 'Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 4;',\n",
       "      'timeFrame': 'Baseline to Week 4'},\n",
       "     {'measure': 'Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 12;',\n",
       "      'timeFrame': 'Baseline to Week 12'},\n",
       "     {'measure': 'Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4;',\n",
       "      'timeFrame': 'Baseline to Week 4'},\n",
       "     {'measure': 'Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 12.',\n",
       "      'timeFrame': 'Baseline to Week 12'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Mean change in the frequency of moderate and severe vasomotor symptoms from baseline to each study week;',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Mean change in the severity of moderate and severe vasomotor symptoms from baseline to each study week;',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Mean change in the hot flash score of moderate and severe vasomotor symptoms from baseline to each study week;',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Mean percent reduction of 50% and 100% of moderate and severe vasomotor symptoms from baseline to each study week.',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Incidence and severity of treatment-emergent adverse events;',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Number of participants with clinical laboratory abnormalities;',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Number of participants with abnormalities of vital signs',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Number of participants with abnormalities of physical examinations',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Change from baseline in ECG parameters',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Change from baseline in plasma bone density marker concentrations',\n",
       "      'timeFrame': 'Baseline to Week 15'},\n",
       "     {'measure': 'Change from baseline in Endometrial health assessment.',\n",
       "      'timeFrame': 'Baseline to Week 15'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Women between 40 and 65 years old (including extremes);\\r\\n\\r\\n  2. The body mass index at screening is between 18.5~30 kg/m2 (including extremes)；\\r\\n\\r\\n  3. Subjects are postmenopausal women at screening as qualified by any of the following\\r\\n     criteria: spontaneous amenorrhea ≥ 12 months, or spontaneous amenorrhea ≥ 6 months\\r\\n     and FSH>40 IU/L (without other obvious pathological or physiological reasonsbefore\\r\\n     screening), or documented surgical sterilization (such as hysterectomy, bilateral\\r\\n     salpingectomy or bilateral oophorectomy, etc.);\\r\\n\\r\\n  4. At least 50 moderate to severe vasomotor symptoms per week (ie, 7 consecutive days),\\r\\n     or 7 moderate to severe vasomotor symptoms per day (ie, 7 consecutive days) recorded\\r\\n     in the daily diary during the screening period;\\r\\n\\r\\n  5. The blood pregnancy test of female subjects at baseline period is negative.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Participants with disease history of unexplained uterine bleeding, endometrial\\r\\n     hyperplasia, ovarian tumor, pituitary tumor, or other diseases evaluated by the\\r\\n     principal investigator as not suitable for this study;\\r\\n\\r\\n  2. Have a history of migraine within 3 months before screening;\\r\\n\\r\\n  3. Uncontrolled hypertension and a systolic blood pressure ≥140 mmHg and/or a diastolic\\r\\n     blood pressure ≥90 mmHg;\\r\\n\\r\\n  4. Previous or current history of a malignant tumor, except for basal cell carcinoma;\\r\\n\\r\\n  5. Participants with clinically significant diseases (such as neuropsychiatric system,\\r\\n     cardiovascular system, urinary system, digestive system, respiratory system,\\r\\n     skeletal muscle system, endocrine and metabolic system, blood system, skin disease,\\r\\n     immune system, tumor, etc.) were evaluated by the researcher as not suitable for\\r\\n     this study;\\r\\n\\r\\n  6. Within 4 weeks or 5 half-lives (whichever is longer) before taking drug,\\r\\n     participants have taken hormonal treatment, hormonal contraceptive or other therapy\\r\\n     due to VMS;\\r\\n\\r\\n  7. Within 4 weeks or 5 half-lives (whichever is longer) before screening, and during\\r\\n     the whole study period, it is expected to take any medicine and health care\\r\\n     products, including prescription drugs, immunomodulator or Chinese herbal medicine,\\r\\n     etc.;\\r\\n\\r\\n  8. Participants have participated in any interventional study or taken study drugs\\r\\n     within 3 months before screening;\\r\\n\\r\\n  9. Judged by the Investigator to be unsuited to participate in the study based on\\r\\n     findings observed during physical examination, vital sign assessment, or 12-lead\\r\\n     electrocardiogram (ECG), et al.;\\r\\n\\r\\n 10. Active liver disease or jaundice, or values of alanine aminotransferase (ALT) or\\r\\n     aspartate aminotransferase (AST) >2.5 x the upper limit of normal (ULN); or total\\r\\n     bilirubin or direct bilirubin >1.5 x ULN;\\r\\n\\r\\n 11. Creatinine >1.5 x ULN; or estimated glomerular filtration rate (eGFR) using the\\r\\n     CKD-EPI formula ≤59 mL/min/1.73 sqm at the screening visit;',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '40 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Qi Yu, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(+86)13701227034',\n",
       "      'email': 'yuqimd@163.com'}],\n",
       "    'locations': [{'facility': 'Chinese Academy of Medical Sciences (CAMS)Peking Union Medical College (PUMC)',\n",
       "      'city': 'Shanghai',\n",
       "      'state': 'Shanghai',\n",
       "      'zip': '100032',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Qi Yu, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '(+86)13701227034',\n",
       "        'email': 'yuqimd@163.com'}],\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M21519',\n",
       "      'name': 'Hot Flashes',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06411873',\n",
       "    'orgStudyIdInfo': {'id': '24779'},\n",
       "    'organization': {'fullName': 'Indonesia University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of High Protein Enteral Nutrition on Critically Ill Postoperative Children',\n",
       "    'officialTitle': 'The Effect of High Protein Enteral Nutrition on Critically Ill Postoperative Children: A Study of Nitrogen Balance and Intestinal Fatty Acid Binding Protein'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr. dr. Irene Yuniar, Sp.A(K)',\n",
       "     'investigatorTitle': 'Lecturer of Indonesia University',\n",
       "     'investigatorAffiliation': 'Indonesia University'},\n",
       "    'leadSponsor': {'name': 'Indonesia University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is o determine the feasibility and efficacy of high\\r\\nenteral protein in critically ill postoperative children. It will also learn about the\\r\\nsafety of high enteral protein for critically ill postoperative children. The main\\r\\nquestions it aims to answer are:\\r\\n\\r\\nDoes high enteral protein improve nitrogen balance in critically ill postoperative\\r\\nchildren? Does high enteral protein reduce levels of Intestinal Fatty Acid Binding\\r\\nProtein (I-FABP) in critically ill postoperative children?\\r\\n\\r\\nResearchers will compare high enteral protein to a standard enteral protein to see if\\r\\nhigh enteral protein works to improve nitrogen balance and reduces levels of Intestinal\\r\\nFatty Acid Binding Protein (I-FABP) in critically ill postoperative children.\\r\\n\\r\\nParticipants will:\\r\\n\\r\\nTake high enteral protein or standard enteral protein for 72 hours The nitrogen balance\\r\\nand I-FABP levels will be assessed both before and after enteral feeding.\\r\\n\\r\\nMonitoring and reporting of adverse events and serious adverse events will be conducted\\r\\nin accordance with good clinical practice guidelines.',\n",
       "    'detailedDescription': 'Postoperative care in critically ill children often involves careful attention to\\r\\nnutritional support to optimize recovery and outcomes. Among the various nutritional\\r\\ninterventions, high protein enteral nutrition has gained significant attention for its\\r\\npotential benefits in this population. Adequate protein intake is essential for wound\\r\\nhealing, immune function, and muscle preservation, all of which are crucial aspects of\\r\\nrecovery following surgery in critically ill children.\\r\\n\\r\\nHigh protein enteral nutrition offers a targeted approach to meet the increased protein\\r\\nrequirements during the postoperative period. By providing a concentrated source of\\r\\nprotein directly into the gastrointestinal tract, it bypasses potential barriers\\r\\nassociated with oral intake and facilitates nutrient absorption in a controlled manner.\\r\\nAdditionally, enteral nutrition is preferred over parenteral nutrition due to its lower\\r\\nrisk of complications and potential to maintain gut integrity and function.\\r\\n\\r\\nDespite its theoretical advantages, the clinical efficacy of high protein enteral\\r\\nnutrition in critically ill postoperative children remains an area of ongoing research.\\r\\nStudies investigating its impact on nitrogen balance, muscle protein synthesis, immune\\r\\nfunction, and clinical outcomes are essential for guiding nutritional practices in this\\r\\nvulnerable population.\\r\\n\\r\\nThis study aim to evaluate the effect of high protein enteral nutrition on critically ill\\r\\npostoperative children, with a focus on assessing nitrogen balance and intestinal fatty\\r\\nacid binding protein levels. Through comprehensive analysis, potential benefits and\\r\\nchallenges associated with this nutritional intervention will be identified, ultimately\\r\\ninforming evidence-based nutritional strategies for optimizing postoperative care in\\r\\ncritically ill pediatric patients.'},\n",
       "   'conditionsModule': {'conditions': ['Enteral Nutrition',\n",
       "     'Postoperative',\n",
       "     'Critically Ill Children'],\n",
       "    'keywords': ['Proteins',\n",
       "     'Enteral',\n",
       "     'Critically ill children',\n",
       "     'Postoperative']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This trial is an interventional study with two arms. Participants will be randomised to\\r\\nhigh enteral protein or standard enteral protein. For both trial arms, participants will\\r\\nbe provided with enteral nutrition (EN) as per standard of care.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'maskingDescription': 'Subjects were recruited through consecutive sampling until the required number of\\r\\nparticipants was reached. They were then randomly assigned into study groups using block\\r\\nrandomization. The randomization process was conducted online via\\r\\nhttps://www.sealedenvelope.com/, overseen by the methodology team. Results were stored\\r\\nsecurely, inaccessible to researchers. Allocation concealment was ensured with\\r\\nsequentially numbered sealed opaque envelopes, indicating standard or high-protein\\r\\nenteral nutrition. These were handed to a designated nutritionist coordinator,\\r\\nindependent of the research team, responsible for storage, preparation, and distribution.\\r\\nResearch assistants informed the coordinator of subjects, who then prepared the assigned\\r\\nnutrition accordingly. High-protein enteral nutrition resembled standard nutrition to\\r\\nmaintain blindness. Researchers, patients, families, nurses, and physicians remained\\r\\nunaware of the nutrition type.',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 76, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Control Group',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'The patients included in the control group received the customary protein amount and were\\r\\nfed a standard formula (Pediacomplete, Abbot, Indonesia)',\n",
       "      'interventionNames': ['Dietary Supplement: Control Group']},\n",
       "     {'label': 'Intervention Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The patients included in the intervention group received the same formula like control\\r\\ngroup with the addition of modular protein supplement PURO ISOPRO WPI Whey Isolate PLAIN,\\r\\nPuro Pure Nutrition, Sukoharjo, Indonesia (BPOM : MD 862312050010)',\n",
       "      'interventionNames': ['Dietary Supplement: Intervention Group']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Control Group',\n",
       "      'description': 'Composition of formula per 100 mL : energy (100 kcal), protein (3 g), carbohydrate (13.54\\r\\ng), lipids (3.93 g), protein energy ratio/PER 12%, osmolarity (310 mOsm/L), renal solute\\r\\nload/RSL (27.5 mOsm/100 kcal)',\n",
       "      'armGroupLabels': ['Control Group']},\n",
       "     {'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Intervention Group',\n",
       "      'description': 'Composition of formula per 100 mL : energy (105.5 kcal), protein (4.35 g), carbohydrate\\r\\n(13.54 g), lipids (3.93 g), protein energy ratio/PER 16.5%, osmolarity (333.5 mOsm/L),\\r\\nrenal solute load/RSL (27.7 mOsm/100 kcal)',\n",
       "      'armGroupLabels': ['Intervention Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Nitrogen Balance',\n",
       "      'description': 'The Nitrogen Balance was calculated by subtracting nitrogen losses from the nitrogen\\r\\nintake, including urinary, faecal and miscellaneous losses (dermal, sweat, integumentary)\\r\\nwith the following formula:\\r\\n\\r\\nNitrogen Balance (mg/kg) = nitrogen intake (mg/kg) -(total urine nitrogen (mg/kg) + 75\\r\\nmg/kg) where 75 mg/kg represents faecal and miscellaneous nitrogen losses. The total\\r\\nurinary nitrogen (TUN) excretion was estimated as the urinary urea nitrogen (UUN)\\r\\nconcentration (mg/kg) × 1.25 to include nitrogen losses in the form of ammonia,\\r\\ncreatinine, uric acid and amino acids. The UUN check from 24 hours urine sample.',\n",
       "      'timeFrame': 'Nitrogen balance will be assessed both before and after 72 hours enteral feeding'},\n",
       "     {'measure': 'I-FABP Levels',\n",
       "      'description': 'The blood samples for measuring I-FABP levels (pg/mL) will be securely transported to and\\r\\nprocessed at Prodia Laboratory.',\n",
       "      'timeFrame': 'I-FABP levels will be assessed both before and after 72 hours enteral feeding'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Critically ill postoperative children (age 1 to 5 years of age)\\r\\n\\r\\n  2. Hemodynamically stable within 48 hours postoperative\\r\\n\\r\\n  3. The patient receives enteral nutrition within 48 hours postoperative\\r\\n\\r\\n  4. The patient can undergo observation and examination for up to 72 hours after enteral\\r\\n     nutrition therapy\\r\\n\\r\\n  5. The parents/guardians are willing to participate in the study by signing the\\r\\n     informed consent\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patients with absolute contraindications (paralytic/mechanical ileus,\\r\\n     gastrointestinal obstruction, gastrointestinal perforation) or relative\\r\\n     contraindications (gastrointestinal dysmotility, necrotizing enterocolitis, toxic\\r\\n     megacolon, extensive peritonitis, gastrointestinal bleeding, gastrointestinal\\r\\n     fistula) to enteral nutrition administration.\\r\\n\\r\\n  2. Patients with a history of cow's milk allergy or using special formula milk.\\r\\n\\r\\n  3. Patients still receiving breast milk (breastfeeding).\\r\\n\\r\\n  4. Patients at high risk of refeeding syndrome according to ASPEN consensus\\r\\n\\r\\n  5. Patients with acute or chronic kidney disorders.\\r\\n\\r\\n  6. Patients with liver disorders.\\r\\n\\r\\n  7. Patients with diabetes mellitus.\\r\\n\\r\\n  8. Patients with inborn errors of metabolism.\\r\\n\\r\\n  9. Patients receiving total parenteral nutrition.\\r\\n\\r\\n 10. Patients requiring continuous life support devices such as continuous renal\\r\\n     replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO).\\r\\n\\r\\n 11. Nitrogen balance cannot be measured (patients with drainage production >1 ml/kg/hour\\r\\n     or bleeding >10% of total blood volume at the time of enteral nutrition initiation).\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '1 Year',\n",
       "    'maximumAge': '5 Years',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Irene Yuniar',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+6281380327808',\n",
       "      'email': 'irene.tambunan@yahoo.co.id'}],\n",
       "    'locations': [{'facility': 'RSUPN Dr. Cipto Mangunkusumo',\n",
       "      'city': 'Jakarta Pusat',\n",
       "      'state': 'DKI Jakarta',\n",
       "      'zip': '10430',\n",
       "      'country': 'Indonesia',\n",
       "      'geoPoint': {'lat': -6.1818, 'lon': 106.8223}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000016638',\n",
       "      'term': 'Critical Illness'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M19010',\n",
       "      'name': 'Critical Illness',\n",
       "      'asFound': 'Critically Ill',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'T435',\n",
       "      'name': 'Whey Protein',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06113965',\n",
       "    'orgStudyIdInfo': {'id': 'StudyID00000301'},\n",
       "    'organization': {'fullName': 'MetroHealth Medical Center',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Neural Operant Conditioning',\n",
       "    'officialTitle': 'Neural Operant Conditioning to Improve Walking After Stroke'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-10',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-05-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-23',\n",
       "    'studyFirstSubmitQcDate': '2023-10-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-10-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-11-02', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'James Sulzer',\n",
       "     'investigatorTitle': 'James Sulzer, PhD',\n",
       "     'investigatorAffiliation': 'MetroHealth Medical Center'},\n",
       "    'leadSponsor': {'name': 'MetroHealth Medical Center', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to learn if operant conditioning can reduce spasticity\\r\\nin order to improve walking in stroke patient. The main questions it aims to answer are:\\r\\n\\r\\n  -  Can participants self-regulate reflex excitability\\r\\n\\r\\n  -  Can participants self-regulate reflex, reduce spasticity and improve walking\\r\\n     Participants will undergo surface stimulation to evoke spinal reflexes and will be\\r\\n     asked to control these reflexes therefore reducing spasticity.\\r\\n\\r\\nResearchers will compare result to able bodied participants to see if [insert effects]',\n",
       "    'detailedDescription': 'The study purpose is to investigate the possibility and later effect of spinal reflex\\r\\nself-regulation in post-stroke stiff-knee gait. The intervention will consist of direct\\r\\ncurrent surface stimulation of the peripheral nerves using electrical stimulation.\\r\\nStimulation will evoke a motor response that will be collected through surface EMG\\r\\nelectrodes and processed to depict a measure of the response as feedback to the\\r\\nparticipant to complete the loop of operant conditioning. The participant will attempt to\\r\\nmodulate their responses over multiple sessions to cause this depiction to either\\r\\nincrease or decrease its value depending on an established target.\\r\\n\\r\\n.'},\n",
       "   'conditionsModule': {'conditions': ['Stroke',\n",
       "     'Chronic Stroke',\n",
       "     'Gait, Hemiplegic',\n",
       "     'Gait, Spastic',\n",
       "     'Walking, Difficulty']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Experimental: Post-stroke Stiff-Knee Gait Participants',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Individuals with post-stroke Stiff-Knee gait',\n",
       "      'interventionNames': ['Other: Peripheral Nerve Stimulation']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Peripheral Nerve Stimulation',\n",
       "      'description': 'Electrical stimulation of peripheral nerves to measure resulting gait kinematics and\\r\\nsurface muscle activity',\n",
       "      'armGroupLabels': ['Experimental: Post-stroke Stiff-Knee Gait Participants']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Surface electromyographic recording of leg muscles',\n",
       "      'description': 'Recording electrical activity of leg muscles during walking in response to peripheral\\r\\nnerve stimulation',\n",
       "      'timeFrame': 'baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment'}],\n",
       "    'secondaryOutcomes': [{'measure': '10 meter walk test',\n",
       "      'description': '10 meter walk test with collection of gait kinematics captured using an inertial motion\\r\\ncapture camera system',\n",
       "      'timeFrame': 'baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment'},\n",
       "     {'measure': 'quadriceps pendulum test',\n",
       "      'description': 'This is a method of evaluating spasticity using gravity to provoke the muscular stretch\\r\\nreflex allowing for the collection of joint angle data. This data will aid in assessing\\r\\nchanges in joint angles as a result of training.',\n",
       "      'timeFrame': 'baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment'},\n",
       "     {'measure': 'Five Times Sit to Stand Test',\n",
       "      'description': 'measures lower extremity functional strength. This test will measure your leg strength by\\r\\nasking you to sit down and stand up from a chair 5 times as fast as possible.',\n",
       "      'timeFrame': 'baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment'},\n",
       "     {'measure': 'TMS',\n",
       "      'description': \"non-invasive brain stimulation device, will be used to elicit a motor evoked response in\\r\\nparticipants via low frequency stimulation to the cortical regions associated with the\\r\\nmuscles being investigated. This approach will test the integrity of the participant's\\r\\nCST in relation to the intervention and assessments being conducted\",\n",
       "      'timeFrame': 'Baseline, Week 12 - end of treatment'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Sign and date consent form\\r\\n\\r\\n  2. At least 3 months since stroke event\\r\\n\\r\\n  3. Over 18 years of age at time of eligibility\\r\\n\\r\\n  4. Ability to stand upright and walk for at least 5 minutes\\r\\n\\r\\n  5. Premorbidly independent\\r\\n\\r\\n  6. Mild to moderate gait impairment\\r\\n\\r\\n  7. Reduced knee flexion during walking relative to the unimpaired side\\r\\n\\r\\n  8. Unilateral hemiparesis of the lower limbs\\r\\n\\r\\n  9. Ability to evoke muscle responses through peripheral nerve stimulation, spinal cord\\r\\n     stimulation, and transcranial magnetic stimulation\\r\\n\\r\\n 10. Medically stable\\r\\n\\r\\n 11. Skin intact on hemiparetic leg, abdomen, and scalp\\r\\n\\r\\n 12. Ability to evoke muscle responses and/or reflex responses through peripheral nerve\\r\\n     stimulation, spinal cord stimulation, and/or transcranial magnetic stimulation\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Co-existing neurological condition other than prior stroke involving the hemiparetic\\r\\n     lower limb (e.g., peripheral nerve injury, PD, SCI, TBI, MS).\\r\\n\\r\\n  2. History of lower limb musculoskeletal injury\\r\\n\\r\\n  3. Functionally relevant osteoarthritis and weight bearing restriction\\r\\n\\r\\n  4. Functionally relevant polyneuropathy resulting in lack of sensation in the lower leg\\r\\n\\r\\n  5. Functionally relevant cognitive impairment\\r\\n\\r\\n  6. Functionally relevant vision impairment\\r\\n\\r\\n  7. Pregnant\\r\\n\\r\\n  8. Botox injection to the ipsilateral leg in the last 12 weeks or taking oral\\r\\n     anti-spasticity medications\\r\\n\\r\\n  9. Taking part in physical therapy for any walking-related impairment\\r\\n\\r\\n 10. Cardiac pacemaker or other implanted electronic systems\\r\\n\\r\\n 11. Uncontrolled seizure disorder\\r\\n\\r\\n 12. Use of seizure lowering threshold medications and the discretion of the study\\r\\n     physician\\r\\n\\r\\n 13. Deficits in communication that interfere with reasonable study participation\\r\\n\\r\\n 14. Severely impaired cognition and communication\\r\\n\\r\\n 15. Severe lower limb pain',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Kristine Hansen, PT',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '216-957-3584',\n",
       "      'email': 'khansen1@metrohealth.org'}],\n",
       "    'overallOfficials': [{'name': 'James Sulzer, PhD',\n",
       "      'affiliation': 'MetroHealth Medical Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'MetroHealth Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Cleveland',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '44109',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kristine Hansen, PT',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '216-957-3584',\n",
       "        'email': 'khansen1@metrohealth.org'},\n",
       "       {'name': 'James Sulzer, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '26371855',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Burpee JL, Lewek MD. Biomechanical gait characteristics of naturally occurring unsuccessful foot clearance during swing in individuals with chronic stroke. Clin Biomech (Bristol, Avon). 2015 Dec;30(10):1102-7. doi: 10.1016/j.clinbiomech.2015.08.018. Epub 2015 Sep 2.'},\n",
       "     {'pmid': '32843057',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Akbas T, Kim K, Doyle K, Manella K, Lee R, Spicer P, Knikou M, Sulzer J. Rectus femoris hyperreflexia contributes to Stiff-Knee gait after stroke. J Neuroeng Rehabil. 2020 Aug 26;17(1):117. doi: 10.1186/s12984-020-00724-z.'},\n",
       "     {'pmid': '25914638',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Li S, Francisco GE. New insights into the pathophysiology of post-stroke spasticity. Front Hum Neurosci. 2015 Apr 10;9:192. doi: 10.3389/fnhum.2015.00192. eCollection 2015.'},\n",
       "     {'pmid': '30127749',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Li S, Francisco GE, Zhou P. Post-stroke Hemiplegic Gait: New Perspective and Insights. Front Physiol. 2018 Aug 2;9:1021. doi: 10.3389/fphys.2018.01021. eCollection 2018.'},\n",
       "     {'pmid': '18164331',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil. 2008 Jan;89(1):56-61. doi: 10.1016/j.apmr.2007.08.131.'},\n",
       "     {'pmid': '34692437',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Dehnadi Moghadam A, Hasanzadeh H, Dehnadi Moghadam F. Evaluation of the Effect of Intranasal Lidocaine in the Treatment of Spasticity in Patients with Traumatic Brain Injury. Anesth Pain Med. 2021 Aug 15;11(4):e115849. doi: 10.5812/aapm.115849. eCollection 2021 Aug.'},\n",
       "     {'pmid': '26321489',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Navarrete-Opazo AA, Gonzalez W, Nahuelhual P. Effectiveness of Oral Baclofen in the Treatment of Spasticity in Children and Adolescents With Cerebral Palsy. Arch Phys Med Rehabil. 2016 Apr;97(4):604-618. doi: 10.1016/j.apmr.2015.08.417. Epub 2015 Aug 28.'},\n",
       "     {'pmid': '6663327',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wolpaw JR, Braitman DJ, Seegal RF. Adaptive plasticity in primate spinal stretch reflex: initial development. J Neurophysiol. 1983 Dec;50(6):1296-311. doi: 10.1152/jn.1983.50.6.1296.'},\n",
       "     {'pmid': '3480233',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wolpaw JR, Lee CL. Motoneuron response to dorsal root stimulation in anesthetized monkeys after spinal cord transection. Exp Brain Res. 1987;68(2):428-33. doi: 10.1007/BF00248809.'},\n",
       "     {'pmid': '7714584',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Chen XY, Wolpaw JR. Operant conditioning of H-reflex in freely moving rats. J Neurophysiol. 1995 Jan;73(1):411-5. doi: 10.1152/jn.1995.73.1.411.'},\n",
       "     {'pmid': '19420246',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Thompson AK, Chen XY, Wolpaw JR. Acquisition of a simple motor skill: task-dependent adaptation plus long-term change in the human soleus H-reflex. J Neurosci. 2009 May 6;29(18):5784-92. doi: 10.1523/JNEUROSCI.4326-08.2009.'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000020521', 'term': 'Stroke'},\n",
       "     {'id': 'D000020233', 'term': 'Gait Disorders, Neurologic'},\n",
       "     {'id': 'D000051346', 'term': 'Mobility Limitation'}],\n",
       "    'ancestors': [{'id': 'D000002561', 'term': 'Cerebrovascular Disorders'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M22306',\n",
       "      'name': 'Stroke',\n",
       "      'asFound': 'Stroke',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12085', 'name': 'Muscle Spasticity', 'relevance': 'LOW'},\n",
       "     {'id': 'M22058',\n",
       "      'name': 'Gait Disorders, Neurologic',\n",
       "      'asFound': 'Gait, Hemiplegic',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26689',\n",
       "      'name': 'Mobility Limitation',\n",
       "      'asFound': 'Walking, Difficulty',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5810', 'name': 'Cerebrovascular Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06397807',\n",
       "    'orgStudyIdInfo': {'id': 'CMUH-112-01'},\n",
       "    'organization': {'fullName': 'China Medical University Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Postoperative Pain Management on Patients Undergoing Lung Tumor Resection',\n",
       "    'officialTitle': 'Postoperative Pain Management on Patients Undergoing Video-assisted Thoracoscopic (VATS) Lung Tumor Resection: a Prospective Cohort Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-03-02', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-30',\n",
       "    'studyFirstSubmitQcDate': '2024-04-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Hsin-Yuan Fang',\n",
       "     'investigatorTitle': 'Associate Director of China Medical University Hospital',\n",
       "     'investigatorAffiliation': 'China Medical University Hospital'},\n",
       "    'leadSponsor': {'name': 'China Medical University Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Multimodal analgesia (MMA) is an essential part of Enhanced Recovery After Surgery (ERAS)\\r\\nprotocol. The principle of MMA is to manage pain with analgesics of multiple classes\\r\\nacting on distinct target sites through different strategies. MMA can reduce the adverse\\r\\nreaction caused by opioids and improve the quality of recovery from surgery. Inadequate\\r\\npostoperative pain management will increase the risk of complications, including\\r\\npneumonia, deep vein thrombosis, infection, delayed surgical healing, and chronic\\r\\npostoperative pain.',\n",
       "    'detailedDescription': 'This prospective, observational study is planned to investigate the efficacy of different\\r\\nMMA regimens conducting in our hospital. Patients undergoing video-assisted thoracoscopic\\r\\n(VATS) lung tumor resection will be invited to participate in the study and grouped based\\r\\non the MMA regimens. Anxiety, quality of recovery, pain intensity will be evaluated pre-\\r\\nand post-operatively. Demographic data, surgery record, medicine record and postoperative\\r\\ncomplications will be gained from medical history system and analyzed.'},\n",
       "   'conditionsModule': {'conditions': ['Postoperative Pain',\n",
       "     'Lung Cancer',\n",
       "     'Lung Tumor'],\n",
       "    'keywords': ['Video-assisted thoracoscopic (VATS) lung tumor resection',\n",
       "     'Naldebain',\n",
       "     'Dinalbuphine sebacate',\n",
       "     'Multimodal analgesia',\n",
       "     'Enhanced Recovery After Surgery',\n",
       "     'ERAS',\n",
       "     'MMA']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'NALDEBAIN',\n",
       "      'description': 'Patients injected with dinalbuphine sebacate intramuscularly will be allocated to\\r\\nNALDEBAIN group.',\n",
       "      'interventionNames': ['Drug: Dinalbuphine sebacate',\n",
       "       'Drug: Analgesic injectables',\n",
       "       'Drug: Enteral analgesics']},\n",
       "     {'label': 'CONTROL',\n",
       "      'description': 'Patients receiving postoperative pain management without dinalbuphine sebacate will be\\r\\nallocated to CONTROL group.',\n",
       "      'interventionNames': ['Drug: Analgesic injectables',\n",
       "       'Drug: Enteral analgesics']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Dinalbuphine sebacate',\n",
       "      'description': 'Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS\\r\\nwill slowly releases to blood vessel and be hydrolyzed to nalbuphine after\\r\\nintramuscularly injection. The analgesic effect lasts around 5 to 7 days.',\n",
       "      'armGroupLabels': ['NALDEBAIN'],\n",
       "      'otherNames': ['Naldebain']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Analgesic injectables',\n",
       "      'description': 'Opioids, NSAIDs or acetamol will be administrated as need.',\n",
       "      'armGroupLabels': ['CONTROL', 'NALDEBAIN'],\n",
       "      'otherNames': ['A.I.']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Enteral analgesics',\n",
       "      'description': 'Opioids, NSAIDs or acetaminophen will be prescribed if necessary.',\n",
       "      'armGroupLabels': ['CONTROL', 'NALDEBAIN'],\n",
       "      'otherNames': ['E.A.']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Postoperative pain intensity',\n",
       "      'description': 'Pain intensity is assessed by numerical rating scale (NRS) daily during hospital stay\\r\\nafter delivery. NRS is a 11-point scale which labeled from zero (no pain) to ten (worst\\r\\npain). The area under the curve of NRS are calculated.',\n",
       "      'timeFrame': 'Within 3 days after surgery'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Consumption of analgesics',\n",
       "      'description': 'The mean total consumption of analgesics during the hospital stay after delivery.',\n",
       "      'timeFrame': 'Within 7 days after surgery'},\n",
       "     {'measure': 'GAD-7',\n",
       "      'description': 'This self-administered patient questionnaire is used as a screening tool and severity\\r\\nmeasure for generalised anxiety disorder (GAD). Respondents are asked to rate each item\\r\\nfor frequency of occurrence using a 4-point Likert scale (Not at all = 0, Several days =\\r\\n1, More than half the days = 2, and Nearly every day = 3). All responses are summed to\\r\\ncalculate the total GAD-7 score.',\n",
       "      'timeFrame': 'At baseline, 7 days and 3 months after surgery'},\n",
       "     {'measure': 'QoR-15',\n",
       "      'description': 'The quality of recovery-15 (QoR-15) is a patient-reported outcome measurement measuring\\r\\nQoR after surgery and anesthesia. The scale is arbitrary and ranges from 0 (extremely\\r\\npoor QoR) to 150 (excellent QoR).',\n",
       "      'timeFrame': 'At baseline, 7 days and 3 months after surgery'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. aged above 18.\\r\\n\\r\\n  2. diagnosed as lung cancer.\\r\\n\\r\\n  3. planning to undergo primary, video-assisted thoracoscopic lung tumor resection.\\r\\n\\r\\n  4. American Society of Anesthesiology Physical Class 1~3.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. unable to take assessments of the endpoints.\\r\\n\\r\\n  2. having this surgery in an emergency.\\r\\n\\r\\n  3. surgery involving other orangs, such as esophagus and stomach.\\r\\n\\r\\n  4. severe abnormality of cardiac, hepatic, or renal function.\\r\\n\\r\\n  5. allergic to opioids.\\r\\n\\r\\n  6. allergic to NSAIDs.\\r\\n\\r\\n  7. diagnosed as chronic pain or chronic use of analgesics.\\r\\n\\r\\n  8. unsuitable for participation judged by investigator.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patient scheduled to have video-assisted thoracoscopic lung tumor resection in China\\r\\nMedical University Hospital.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Po-Han Li',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+886-4-22052121',\n",
       "      'phoneExt': '12939',\n",
       "      'email': 'bryan21825114@gmail.com'}],\n",
       "    'overallOfficials': [{'name': 'Hsin-Yuan Fang',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Po-Han Li',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Kin-Shing Poon',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Hsiurong Liao',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Tzu-Min Huang',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Yu-Cheng Shen',\n",
       "      'affiliation': 'China Medical University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008175',\n",
       "      'term': 'Lung Neoplasms'},\n",
       "     {'id': 'D000010149', 'term': 'Pain, Postoperative'}],\n",
       "    'ancestors': [{'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000011183', 'term': 'Postoperative Complications'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M13069',\n",
       "      'name': 'Pain, Postoperative',\n",
       "      'asFound': 'Postoperative Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11172',\n",
       "      'name': 'Lung Neoplasms',\n",
       "      'asFound': 'Lung Tumors',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M14065',\n",
       "      'name': 'Postoperative Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000000700',\n",
       "      'term': 'Analgesics'}],\n",
       "    'ancestors': [{'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M2340',\n",
       "      'name': 'Acetaminophen',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4032',\n",
       "      'name': 'Analgesics',\n",
       "      'asFound': 'Auditory',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4033', 'name': 'Analgesics, Opioid', 'relevance': 'LOW'},\n",
       "     {'id': 'M12217', 'name': 'Nalbuphine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Antipy', 'name': 'Antipyretics'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06386302',\n",
       "    'orgStudyIdInfo': {'id': 'CSIIT-A36'},\n",
       "    'organization': {'fullName': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia',\n",
       "    'officialTitle': 'A Multicenter, Randomized, Controlled Clinical Trial of Chidamide Combined With Venetoclax and Azacitidine in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Not Suitable for Intensive Chemotherapy'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-23',\n",
       "    'studyFirstSubmitQcDate': '2024-04-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Wei Hui, MD',\n",
       "     'investigatorTitle': 'Director',\n",
       "     'investigatorAffiliation': 'Institute of Hematology & Blood Diseases Hospital, China'},\n",
       "    'leadSponsor': {'name': 'Institute of Hematology & Blood Diseases Hospital, China',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'To evaluate the feasibility, effectiveness and safety of chidamide combined with\\r\\nvenetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia\\r\\n(AML) who are not suitable for intensive chemotherapy.'},\n",
       "   'conditionsModule': {'conditions': ['AML', 'Acute Myeloid Leukemia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 184, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Chidamide combined with venetoclax, azacitidine group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"Chidamide (C): 30 mg/d orally on d1, 4, 8, 11 or 10 mg QD, d1-d14, adjusted according to\\r\\npatient tolerance Azacitidine (A): 75 mg/m 2 /d subcutaneous injection d1-d7 Venetoclax\\r\\n(V): 100 mg d1 200 mg d 2 400 mg d3-d28 Orally\\r\\n\\r\\nA treatment cycle is 28 days , and subjects will continue to receive treatment allocation\\r\\naccording to the investigator's assessment until documented disease progression,\\r\\nintolerable toxicity, withdrawal of consent, or the subject meets other conditions for\\r\\nterminating treatment. Program Standards (whichever occurs first).\",\n",
       "      'interventionNames': ['Drug: Chidamide',\n",
       "       'Drug: Venetoclax',\n",
       "       'Drug: azacitidine']},\n",
       "     {'label': 'venetoclax, azacitidine group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"azacitidine: 75 mg/m 2 /d subcutaneous injection d1-d7 Venetoclax: 100 mg day 1, 200 mg\\r\\nday 2, 400 mg day 3-d28 orally A treatment cycle is 28 days , and subjects will continue\\r\\nto receive treatment allocation according to the investigator's assessment until\\r\\ndocumented disease progression, intolerable toxicity, withdrawal of consent, or the\\r\\nsubject meets other conditions for terminating treatment. Program Standards (whichever\\r\\noccurs first).\",\n",
       "      'interventionNames': ['Drug: Venetoclax', 'Drug: azacitidine']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Chidamide',\n",
       "      'description': '30 mg/d orally twice-weekly',\n",
       "      'armGroupLabels': ['Chidamide combined with venetoclax, azacitidine group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': '100 mg d1 200 mg d 2 400 mg d3-d28 Orally',\n",
       "      'armGroupLabels': ['Chidamide combined with venetoclax, azacitidine group',\n",
       "       'venetoclax, azacitidine group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'azacitidine',\n",
       "      'description': '75 mg/m 2 /d subcutaneous injection or IV d1-d7',\n",
       "      'armGroupLabels': ['Chidamide combined with venetoclax, azacitidine group',\n",
       "       'venetoclax, azacitidine group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Composite complete remission rate',\n",
       "      'description': 'Composite complete remission rate after 2 cycles of treatment [Complete remission, CR) +\\r\\ncomplete remission with incomplete blood count (CR with incomplete blood count recovery,\\r\\nCRi); CR + CRi ]',\n",
       "      'timeFrame': '2 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall response rate (ORR)',\n",
       "      'description': 'Overall response rate (ORR), including complete remission (Complete remission (CR),\\r\\ncomplete remission with incomplete blood count (CR with incomplete blood count recovery\\r\\n(CRi), morphological leukemia free state (MLFS), and partial remission (PR) as a\\r\\npercentage of the total number of patients participating in the efficacy analysis.',\n",
       "      'timeFrame': '24months'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'Overall survival (OS): defined as the number of days from the date of randomization to\\r\\nthe date of death. Subjects who have not died will be censored on the last date they are\\r\\nknown to be alive .',\n",
       "      'timeFrame': '24months'},\n",
       "     {'measure': 'MRD response rate',\n",
       "      'description': 'Minimal residual disease (MRD)rate: defined as less than 0.1% remaining blasts per white\\r\\nblood cell, as measured by bone marrow examination. Other thresholds can also be explored\\r\\nand correlated with efficacy results. Subjects who are randomized but not assessed for\\r\\nMRD will be considered MRD response rate non-responders. The proportion of subjects\\r\\nachieving an MRD response (CR + CRi) was calculated.',\n",
       "      'timeFrame': '24months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  （1）Age ≥18 years old, no gender limit ;\\r\\n\\r\\n  -  （2）be diagnosed with AML (non-M3) according to WHO 2016 standards;\\r\\n\\r\\n  -  （3）No previous treatment;\\r\\n\\r\\n  -  （4）Ineligible for intensive chemotherapy based on the following definitions: ≥75\\r\\n     years of age or 18 to 74 years of age with at least one of the following\\r\\n     comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status of 2 or\\r\\n     3 A history of cardiac disease such as congestive heart failure Treatment is\\r\\n     required, or ejection fraction ≤ 50%, or chronic stable angina, diffusing capacity\\r\\n     of lung for carbon monoxide (DLCO) ≤ 65%, or forced expiratory volume in first\\r\\n     second (FEV1) ≤ 65%, creatinine clearance ≥ 30 mL/min to < 45 mL/min, moderate\\r\\n     hepatic impairment, total bilirubin > 1.5 to ≤ 3.0 × ULN, other comorbidities that\\r\\n     are not suitable for intensive chemotherapy in the physician's judgment.\\r\\n\\r\\n  -  （5）Subjects must have an ECOG performance status score of: 0 to 2 for subjects aged\\r\\n     ≥ 75 years or 0 to 3 for subjects aged ≥ 18 to 74 years.\\r\\n\\r\\n  -  （6）Other comorbidities that are not suitable for intensive chemotherapy in the\\r\\n     doctor's judgment;\\r\\n\\r\\n  -  （7）Expected survival time ≥3 months;\\r\\n\\r\\n  -  （8）Have the ability to understand and be willing to sign the informed consent form\\r\\n     for this study.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  (1) Combined with other malignant tumors\\r\\n\\r\\n  -  (2) Have ever received treatment with chidamide and / or venetoclax or azacitidine;\\r\\n\\r\\n  -  (3) The risk is assessed as low risk according to the NCCN 2022 guidelines\\r\\n     [t(8;21)(q22;q22.1);RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16\\r\\n     )(p13.1;q22);CBFB-MYH11 ] ;\\r\\n\\r\\n  -  (4) The subject is known to have AML central nervous system (CNS) infiltration;\\r\\n\\r\\n  -  (5) Have undergone cardiac angioplasty or stent placement within 12 months before\\r\\n     signing the informed consent form , or have a history of myocardial infarction,\\r\\n     unstable angina, or other clinically significant heart disease;\\r\\n\\r\\n  -  (6 ) Active infections (including bacterial, fungal or viral infections) and organ\\r\\n     bleeding that cannot be controlled clinically;\\r\\n\\r\\n  -  (7) Pregnant or lactating women;\\r\\n\\r\\n  -  (8) Participated in any other clinical research within 3 months before signing the\\r\\n     informed consent form ;\\r\\n\\r\\n  -  (9 ) The researcher believes that it is not suitable to participate in this study;\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jianxiang Wang, Medical PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '022-23909273',\n",
       "      'email': 'wangjx@ihcams.ac.cn'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000001374',\n",
       "      'term': 'Azacitidine'},\n",
       "     {'id': 'C000579720', 'term': 'Venetoclax'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Extended',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4673',\n",
       "      'name': 'Azacitidine',\n",
       "      'asFound': 'Frequency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06393179',\n",
       "    'orgStudyIdInfo': {'id': 'OPEN-RESPIRATORY'},\n",
       "    'organization': {'fullName': 'Southeast University, China',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Epidemiology and Treatment Strategy of Open Respiratory Phenotype in Critically Ill Patients',\n",
       "    'officialTitle': 'Epidemiology and Treatment Strategy of Open Respiratory Phenotype in Critically Ill Patients'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-27',\n",
       "    'studyFirstSubmitQcDate': '2024-04-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Ling Liu',\n",
       "     'investigatorTitle': 'Director of Intensive Care Unit, Principal Investigator, Clinical Professor',\n",
       "     'investigatorAffiliation': 'Southeast University, China'},\n",
       "    'leadSponsor': {'name': 'Southeast University, China', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Monitoring airway pressure is essential for patients with mechanical ventilation.\\r\\nHowever, static airway pressure does not reflect alveolar pressure at all. Airway\\r\\npressure is supposed to completely interrupt the communication between proximal airway\\r\\nopening and the distal alveolar and/or small airway structures. In this condition, some\\r\\nalveoli may still be inflated but do not communicate with proximal airways and auto-PEEP\\r\\nwill give a biased estimated of mean alveolar pressure. To be note, distinguishing the\\r\\nairway closure and alveolar collapse can be challenging at times. The quasi-static PV\\r\\ncurve is a useful bedside tool to set mechanical ventilation, which may help us to\\r\\nidentify the airway closure and alveolar collapse. Meanwhile, the quasi-static PV curve\\r\\ncan only reflects a global behaviour of the lung, while EIT may be a useful tool to\\r\\nassess the regional information on airway closure and alveolar collapse.'},\n",
       "   'conditionsModule': {'conditions': ['Mechanical Ventilation Pressure High',\n",
       "     'Critical Illness'],\n",
       "    'keywords': ['mechanical ventilation',\n",
       "     'airway closure',\n",
       "     'alveolar collapse']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'DIAGNOSTIC',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'P-V curve group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Enrolled patients will receive a PV curve with a low-flow insufflation of 5 L/min\\r\\nstarting from 0 cmH2O to a maximal airway pressure corresponding to the plateau pressure.',\n",
       "      'interventionNames': ['Other: pressure-volume curve with a low-flow insufflation of 5 L/min']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'pressure-volume curve with a low-flow insufflation of 5 L/min',\n",
       "      'description': 'The patient undergoes a pressure-volume curve with a low-flow insufflation of 5 L/min\\r\\nwhile in a state of analgesia, sedation, and absence of spontaneous breathing.',\n",
       "      'armGroupLabels': ['P-V curve group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'the rate of airway closure and alveolar collapse',\n",
       "      'description': 'airway closure and alveolar collapse are monitored by PV curve with a low-flow\\r\\ninsufflation of 5 L/min',\n",
       "      'timeFrame': 'up to 24 hours'},\n",
       "     {'measure': 'Phenotype of respiratory open pressure',\n",
       "      'description': 'According to the characteristics of the low inflation point of PV curve, the respiratory\\r\\nopen pressure phenotype was constructed',\n",
       "      'timeFrame': 'up to 24 hours'}],\n",
       "    'secondaryOutcomes': [{'measure': 'respiratory system compliance',\n",
       "      'description': 'Respiratory system compliance is calculated as the ratio of tidal volume to the\\r\\ndifference between plateau pressure and positive end-expiratory pressure.',\n",
       "      'timeFrame': 'up to 24 hours'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adult patients undergoing controlled mechanical ventilation\\r\\n\\r\\n  -  The duration of endotracheal intubation < 48 hrs\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Severe hemodynamic instability\\r\\n\\r\\n  -  Severe chronic lung disease requiring long-term home oxygen therapy\\r\\n\\r\\n  -  Patients without analgesic sedation\\r\\n\\r\\n  -  Decline to participate in the study\\r\\n\\r\\n  -  Refusal to sign informed consent',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'ling liu, phD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '15901599659',\n",
       "      'email': 'liulingdoctor@126.com'},\n",
       "     {'name': 'xueyan yuan, phD',\n",
       "      'role': 'CONTACT',\n",
       "      'email': '18826401594@163.com'}],\n",
       "    'overallOfficials': [{'name': 'ling liu',\n",
       "      'affiliation': 'Zhongda Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University',\n",
       "      'city': 'Nanjing',\n",
       "      'state': 'Jiangsu',\n",
       "      'zip': '210000',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000016638',\n",
       "      'term': 'Critical Illness'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M19010',\n",
       "      'name': 'Critical Illness',\n",
       "      'asFound': 'Critical Illness',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15577', 'name': 'Shock', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05564390',\n",
       "    'orgStudyIdInfo': {'id': 'NCI-2022-07006'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2022-07006',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MYELOMATCH', 'type': 'OTHER', 'domain': 'SWOG'},\n",
       "     {'id': 'MYELOMATCH', 'type': 'OTHER', 'domain': 'CTEP'},\n",
       "     {'id': 'U10CA180888',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/U10CA180888'}],\n",
       "    'organization': {'fullName': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'},\n",
       "    'briefTitle': 'MyeloMATCH MSRP: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study',\n",
       "    'officialTitle': 'Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-05-15', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-05-15', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-09-27',\n",
       "    'studyFirstSubmitQcDate': '2022-09-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-10-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': \"This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a\\r\\nscreening tool and specific laboratory tests to help improve participants' ability to\\r\\nregister to clinical trials throughout the course of their myeloid cancer (acute myeloid\\r\\nleukemia or myelodysplastic syndrome) treatment. This study involves testing patients'\\r\\nbone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is\\r\\nany molecule in the body that can be measured. Doctors look at markers to learn what is\\r\\nhappening in the body. Knowing about certain markers can give doctors more information\\r\\nabout what is driving the cancer and how to treat it. Testing patients' bone marrow and\\r\\nblood will show doctors if patients have markers that specific drugs can target. The\\r\\nmarker testing in this study will let doctors know if they can match patients with a\\r\\ntreatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer\\r\\nthey have.\",\n",
       "    'detailedDescription': \"PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To evaluate the feasibility of MATCHBox generating all data needed for assignment to a\\r\\nmyeloMATCH clinical trial or determination that no assignment is available, within 72\\r\\nhours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent\\r\\ntherapy.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. To describe the time to generation of all treatment assignment data, time to treatment\\r\\nassignment, percent assigned to a myeloMATCH clinical trial, and the percent of screened\\r\\nparticipants who register to a myeloMATCH clinical trial:\\r\\n\\r\\nIa. For the first Tier 1 myeloMATCH clinical trial assignment; Ib. For Tiers 2, 3, and 4\\r\\nmyeloMATCH clinical trial assignment; Ic. Within each tier of myeloMATCH clinical trials;\\r\\nId. Within each clinical basket of myeloMATCH clinical trials; Ie. Over time, across and\\r\\nwithin the categories above.\\r\\n\\r\\nOUTLINE:\\r\\n\\r\\nREGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study.\\r\\nPatients' bone marrow and blood specimens undergo rapid genetic testing. Patients are\\r\\nthen assigned to a specific protocol containing a therapy targeted to the patient's\\r\\nmutational profile. If there is no targetable mutation, the patient is placed on a\\r\\nprotocol testing novel combinations that do not contain a target-specific drug.\\r\\n\\r\\nTREATMENT: Patients are assigned to a specific treatment protocol.\\r\\n\\r\\nMM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid\\r\\nleukemia (AML) are randomized to 1 of 3 arms.\\r\\n\\r\\nARM I: Patients receive daunorubicin intravenously (IV), cytarabine IV, and venetoclax\\r\\norally (PO) on study and undergo bone marrow aspiration and collection of blood samples\\r\\non study and as clinically indicated.\\r\\n\\r\\nARM II: Patients receive azacitidine IV or subcutaneously (SC) and venetoclax PO on study\\r\\nand undergo bone marrow aspiration and collection of blood samples on study and as\\r\\nclinically indicated.\\r\\n\\r\\nARM III: Patients receive daunorubicin IV and cytarabine IV on study and undergo bone\\r\\nmarrow aspiration and collection of blood samples on study and as clinically indicated.\\r\\n\\r\\nMM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 4\\r\\narms.\\r\\n\\r\\nARM I: Patients receive cytarabine IV and daunorubicin IV per standard approach on study.\\r\\nPatients also undergo a bone marrow aspiration and collection of blood throughout the\\r\\ntrial.\\r\\n\\r\\nARM II: Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study.\\r\\nPatients also undergo a bone marrow aspiration and collection of blood throughout the\\r\\ntrial.\\r\\n\\r\\nARM III: Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also\\r\\nundergo a bone marrow aspiration and collection of blood throughout the trial.\\r\\n\\r\\nARM IV: Patients receive daunorubicin and cytarabine liposome (Vyxeos) IV on study.\\r\\nPatients also undergo a bone marrow aspiration and collection of blood throughout the\\r\\ntrial.\\r\\n\\r\\nMM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have\\r\\ncompleted a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with\\r\\npartial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (>\\r\\n0.1%) are randomized to 1 of 4 arms.\\r\\n\\r\\nARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration\\r\\nand biopsy on study. Patients may also undergo echocardiogram (ECHO) and/or multigated\\r\\nacquisition scan (MUGA) as clinically indicated.\\r\\n\\r\\nARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone\\r\\nmarrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as\\r\\nclinically indicated.\\r\\n\\r\\nARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone\\r\\nmarrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as\\r\\nclinically indicated.\\r\\n\\r\\nARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo\\r\\nbone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as\\r\\nclinically indicated.\\r\\n\\r\\nMM1OA-EA02: Patients are randomized to 1 of 3 regimens.\\r\\n\\r\\nREGIMEN 1:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine intravenously (IV) or subcutaneously (SC) on days\\r\\n1-7 and venetoclax orally (PO) on days 1-28 of each cycle. Treatment repeats every 28\\r\\ndays for up to 2 cycles or until patient achieves remission, whichever comes first, in\\r\\nthe absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on\\r\\ndays 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nREGIMEN 2:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and\\r\\ngilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2\\r\\ncycles or until patient achieves remission, whichever comes first, in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nREGIMEN 3:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days\\r\\n1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for\\r\\nup to 2 cycles or until patient achieves remission, whichever comes first, in the absence\\r\\nof disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAll patients undergo bone marrow biopsy and aspiration as well as blood sample collection\\r\\non the trial.\"},\n",
       "   'conditionsModule': {'conditions': ['Acute Myeloid Leukemia',\n",
       "     'Myelodysplastic Syndrome']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 750, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax\\r\\nPO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or\\r\\nuntil patient achieves remission, whichever comes first, in the absence of disease\\r\\nprogression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on\\r\\ndays 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and\\r\\ngilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2\\r\\ncycles or until patient achieves remission, whichever comes first, in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Drug: Gilteritinib',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days\\r\\n1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for\\r\\nup to 2 cycles or until patient achieves remission, whichever comes first, in the absence\\r\\nof disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Drug: Gilteritinib',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo\\r\\nbone marrow aspiration and collection of blood samples on study and as clinically\\r\\nindicated.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1YA-CTG01 Arm II (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow\\r\\naspiration and collection of blood samples on study and as clinically indicated.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow\\r\\naspiration and collection of blood samples on study and as clinically indicated.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride']},\n",
       "     {'label': 'MM1YA-S01 Arm I (cytarabine, daunorubicin)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive cytarabine IV and daunorubicin IV per standard approach on study.\\r\\nPatients also undergo a bone marrow aspiration and collection of blood throughout the\\r\\ntrial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride']},\n",
       "     {'label': 'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study. Patients\\r\\nalso undergo a bone marrow aspiration and collection of blood throughout the trial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1YA-S01 Arm III (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also undergo a\\r\\nbone marrow aspiration and collection of blood throughout the trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM1YA-S01 Arm IV (Vyxeos)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive Vyxeos IV on study. Patients also undergo a bone marrow aspiration and\\r\\ncollection of blood throughout the trial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Liposome-encapsulated Daunorubicin-Cytarabine']},\n",
       "     {'label': 'MM2YA-EA01 Arm A (cytarabine)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and\\r\\nbiopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.',\n",
       "      'interventionNames': ['Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Drug: Cytarabine',\n",
       "       'Procedure: Echocardiography',\n",
       "       'Procedure: Multigated Acquisition Scan']},\n",
       "     {'label': 'MM2YA-EA01 Arm B (cytarabine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow\\r\\naspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically\\r\\nindicated.',\n",
       "      'interventionNames': ['Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Drug: Cytarabine',\n",
       "       'Procedure: Echocardiography',\n",
       "       'Procedure: Multigated Acquisition Scan',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM2YA-EA01 Arm C (Vyxeos, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow\\r\\naspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically\\r\\nindicated.',\n",
       "      'interventionNames': ['Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Procedure: Echocardiography',\n",
       "       'Drug: Liposome-encapsulated Daunorubicin-Cytarabine',\n",
       "       'Procedure: Multigated Acquisition Scan',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'MM2YA-EA01 Arm D (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone\\r\\nmarrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as\\r\\nclinically indicated.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Bone Marrow Aspiration and Biopsy',\n",
       "       'Procedure: Echocardiography',\n",
       "       'Procedure: Multigated Acquisition Scan',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'Screening (mutation carrier screening)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone\\r\\nmarrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a\\r\\nspecific protocol containing a therapy targeted to the patient's mutational profile. If\\r\\nthere is no targetable mutation, the patient is placed on a protocol testing novel\\r\\ncombinations that do not contain a target-specific drug.\",\n",
       "      'interventionNames': ['Procedure: Mutation Carrier Screening']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Azacitidine',\n",
       "      'description': 'Given IV or SC',\n",
       "      'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)',\n",
       "       'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1YA-CTG01 Arm II (azacitidine, venetoclax)',\n",
       "       'MM1YA-S01 Arm III (azacitidine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm D (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['5 AZC',\n",
       "       '5-AC',\n",
       "       '5-Azacitidine',\n",
       "       '5-Azacytidine',\n",
       "       '5-AZC',\n",
       "       'Azacytidine',\n",
       "       'Azacytidine, 5-',\n",
       "       'Ladakamycin',\n",
       "       'Mylosar',\n",
       "       'U-18496',\n",
       "       'Vidaza']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo collection of blood samples',\n",
       "      'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)',\n",
       "       'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm II (azacitidine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)',\n",
       "       'MM1YA-S01 Arm I (cytarabine, daunorubicin)',\n",
       "       'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'MM1YA-S01 Arm III (azacitidine, venetoclax)',\n",
       "       'MM1YA-S01 Arm IV (Vyxeos)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Aspiration',\n",
       "      'description': 'Undergo bone marrow aspiration',\n",
       "      'armGroupLabels': ['MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm II (azacitidine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)',\n",
       "       'MM1YA-S01 Arm I (cytarabine, daunorubicin)',\n",
       "       'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'MM1YA-S01 Arm III (azacitidine, venetoclax)',\n",
       "       'MM1YA-S01 Arm IV (Vyxeos)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Aspiration and Biopsy',\n",
       "      'description': 'Undergo bone marrow aspiration and biopsy',\n",
       "      'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)',\n",
       "       'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM2YA-EA01 Arm A (cytarabine)',\n",
       "       'MM2YA-EA01 Arm B (cytarabine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm C (Vyxeos, venetoclax)',\n",
       "       'MM2YA-EA01 Arm D (azacitidine, venetoclax)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cytarabine',\n",
       "      'description': 'Given',\n",
       "      'armGroupLabels': ['MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)',\n",
       "       'MM1YA-S01 Arm I (cytarabine, daunorubicin)',\n",
       "       'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'MM2YA-EA01 Arm A (cytarabine)',\n",
       "       'MM2YA-EA01 Arm B (cytarabine, venetoclax)'],\n",
       "      'otherNames': ['.beta.-Cytosine arabinoside',\n",
       "       '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-.beta.-D-Arabinofuranosylcytosine',\n",
       "       '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-Beta-D-arabinofuranosylcytosine',\n",
       "       '1.beta.-D-Arabinofuranosylcytosine',\n",
       "       '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-',\n",
       "       '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-',\n",
       "       'Alexan',\n",
       "       'Ara-C',\n",
       "       'ARA-cell',\n",
       "       'Arabine',\n",
       "       'Arabinofuranosylcytosine',\n",
       "       'Arabinosylcytosine',\n",
       "       'Aracytidine',\n",
       "       'Aracytin',\n",
       "       'Aracytine',\n",
       "       'Beta-Cytosine Arabinoside',\n",
       "       'CHX-3311',\n",
       "       'Cytarabinum',\n",
       "       'Cytarbel',\n",
       "       'Cytosar',\n",
       "       'Cytosine Arabinoside',\n",
       "       'Cytosine-.beta.-arabinoside',\n",
       "       'Cytosine-beta-arabinoside',\n",
       "       'Erpalfa',\n",
       "       'Starasid',\n",
       "       'Tarabine PFS',\n",
       "       'U 19920',\n",
       "       'U-19920',\n",
       "       'Udicil',\n",
       "       'WR-28453']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Daunorubicin Hydrochloride',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm III (daunorubicin, cytarabine)',\n",
       "       'MM1YA-S01 Arm I (cytarabine, daunorubicin)',\n",
       "       'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)'],\n",
       "      'otherNames': ['Cerubidin',\n",
       "       'Cerubidine',\n",
       "       'Cloridrato de Daunorubicina',\n",
       "       'Daunoblastin',\n",
       "       'Daunoblastina',\n",
       "       'Daunoblastine',\n",
       "       'Daunomycin Hydrochloride',\n",
       "       'Daunomycin, hydrochloride',\n",
       "       'Daunorubicin.HCl',\n",
       "       'Daunorubicini Hydrochloridum',\n",
       "       'FI-6339',\n",
       "       'Ondena',\n",
       "       'RP-13057',\n",
       "       'Rubidomycin Hydrochloride',\n",
       "       'Rubilem']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Echocardiography',\n",
       "      'description': 'Undergo ECHO',\n",
       "      'armGroupLabels': ['MM2YA-EA01 Arm A (cytarabine)',\n",
       "       'MM2YA-EA01 Arm B (cytarabine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm C (Vyxeos, venetoclax)',\n",
       "       'MM2YA-EA01 Arm D (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['EC']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Gilteritinib',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['ASP-2215', 'ASP2215']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Liposome-encapsulated Daunorubicin-Cytarabine',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['MM1YA-S01 Arm IV (Vyxeos)',\n",
       "       'MM2YA-EA01 Arm C (Vyxeos, venetoclax)'],\n",
       "      'otherNames': ['CPX-351',\n",
       "       'Cytarabine and Daunorubicin Liposomal',\n",
       "       'Cytarabine-Daunorubicin Liposome for Injection',\n",
       "       'Daunorubicin and Cytarabine (Liposomal)',\n",
       "       'Liposomal AraC-Daunorubicin CPX-351',\n",
       "       'Liposomal Cytarabine-Daunorubicin',\n",
       "       'Liposome-encapsulated Combination of Daunorubicin and Cytarabine',\n",
       "       'Vyxeos']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Multigated Acquisition Scan',\n",
       "      'description': 'Undergo MUGA',\n",
       "      'armGroupLabels': ['MM2YA-EA01 Arm A (cytarabine)',\n",
       "       'MM2YA-EA01 Arm B (cytarabine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm C (Vyxeos, venetoclax)',\n",
       "       'MM2YA-EA01 Arm D (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['Blood Pool Scan',\n",
       "       'Equilibrium Radionuclide Angiography',\n",
       "       'Gated Blood Pool Imaging',\n",
       "       'Gated Heart Pool Scan',\n",
       "       'MUGA',\n",
       "       'MUGA Scan',\n",
       "       'Multi-Gated Acquisition Scan',\n",
       "       'Radionuclide Ventriculogram Scan',\n",
       "       'Radionuclide Ventriculography',\n",
       "       'RNVG',\n",
       "       'SYMA Scanning',\n",
       "       'Synchronized Multigated Acquisition Scanning']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Mutation Carrier Screening',\n",
       "      'description': 'Undergo rapid genetic testing',\n",
       "      'armGroupLabels': ['Screening (mutation carrier screening)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)',\n",
       "       'MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'MM1YA-CTG01 Arm II (azacitidine, venetoclax)',\n",
       "       'MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'MM1YA-S01 Arm III (azacitidine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm B (cytarabine, venetoclax)',\n",
       "       'MM2YA-EA01 Arm C (Vyxeos, venetoclax)',\n",
       "       'MM2YA-EA01 Arm D (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['ABT-0199',\n",
       "       'ABT-199',\n",
       "       'ABT199',\n",
       "       'GDC-0199',\n",
       "       'RG7601',\n",
       "       'Venclexta',\n",
       "       'Venclyxto']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Timing of treatment assignment',\n",
       "      'description': 'Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a\\r\\nmyeloMATCH clinical trial or determination that no assignment is available, within 72\\r\\nhours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent\\r\\ntherapy. For first treatment assignment and separately for each subsequent treatment\\r\\nassignments: every 50 participants for the first 250 participants and then every 100\\r\\nparticipants thereafter, the proportion of participants (cumulative and new participants\\r\\nsince prior analysis) with all MDNet data need to determine a treatment assignment within\\r\\n72 hours for first assignment and 10 days for subsequent assignments after the MDNet\\r\\nreceives specimens will be tallied.',\n",
       "      'timeFrame': 'Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Time to MDNet generating all data required for treatment assignment',\n",
       "      'description': 'Will be assessed for the first (induction) treatment assignment, for post-induction\\r\\ntreatment assignment, within each tier of clinical trials, within each clinical basket of\\r\\nclinical trials, and over time (since last report and in 6 months intervals).',\n",
       "      'timeFrame': 'Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy'},\n",
       "     {'measure': 'Time to treatment assignment',\n",
       "      'description': 'Will be assessed for the first (induction) treatment assignment, for post-induction\\r\\ntreatment assignment, within each tier of clinical trials, within each clinical basket of\\r\\nclinical trials, and over time (since last report and in 6 months intervals).',\n",
       "      'timeFrame': 'Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy'},\n",
       "     {'measure': 'Percent assigned to a myeloMATCH clinical trial',\n",
       "      'description': 'Will be assessed for the first (induction) treatment assignment, for post-induction\\r\\ntreatment assignment, within each tier of clinical trials, within each clinical basket of\\r\\nclinical trials, and over time (since last report and in 6 months intervals).',\n",
       "      'timeFrame': 'Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy'},\n",
       "     {'measure': 'Percent of screened participants who register to a protocol',\n",
       "      'description': 'Will be assessed for the first (induction) treatment assignment, for post-induction\\r\\ntreatment assignment, within each tier of clinical trials, within each clinical basket of\\r\\nclinical trials, and over time (since last report and in 6 months intervals).',\n",
       "      'timeFrame': 'Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Participants must be suspected to have previously untreated acute myeloid leukemia\\r\\n     (AML) or myelodysplastic syndrome (MDS). For participants assigned an AML basket\\r\\n     protocol, there cannot be a history of previous myeloproliferative neoplasm (MPN) or\\r\\n     MDS.\\r\\n\\r\\n  -  Participants must be >= 18 years of age.\\r\\n\\r\\n  -  Participants must agree to have specimens submitted. Note: Email notification of\\r\\n     treatment protocol assignment must be received prior to treatment protocol\\r\\n     registration.\\r\\n\\r\\n  -  Participants must be offered the opportunity to participate in specimen banking.\\r\\n     Note: With participant consent, specimens must be collected and submitted via the\\r\\n     Clinical/Correlative Sample Management System (CSMS).\\r\\n\\r\\n  -  Participants must be informed of the investigational nature of this study and must\\r\\n     sign and give informed consent in accordance with institutional and federal\\r\\n     guidelines.\\r\\n\\r\\n       -  Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration\\r\\n          process the treating institution's identity is provided in order to ensure that\\r\\n          the current (within 365 days) date of institutional review board approval for\\r\\n          this study has been entered in the system.\\r\\n\\r\\n  -  The Master Screening and Reassessment Protocol (MSRP) is only used in sites where\\r\\n     the relevant AML clinical trials are open. For example, if a site does not have a\\r\\n     myeloMATCH tier 1 study for older AML open for enrollment, such older AML patients\\r\\n     should not be consented for the MSRP\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Participants must not have received prior anti-cancer therapy for AML or MDS.\\r\\n\\r\\n       -  Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.\\r\\n\\r\\n  -  Participants must not have a prior or concurrent malignancy that requires concurrent\\r\\n     anti-cancer therapy\\r\\n\\r\\n       -  Note: active hormonal therapy is allowed\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Jerald P Radich',\n",
       "      'affiliation': 'SWOG Cancer Research Network',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how\\r\\nclinical trial data is shared, access the link to the NIH data sharing policy page',\n",
       "    'url': 'https://grants.nih.gov/policy/sharing.htm'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009190',\n",
       "      'term': 'Myelodysplastic Syndromes'}],\n",
       "    'ancestors': [{'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000001855', 'term': 'Bone Marrow Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M10945', 'name': 'Leukemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M10955', 'name': 'Leukemia, Myeloid', 'relevance': 'LOW'},\n",
       "     {'id': 'M18127', 'name': 'Leukemia, Myeloid, Acute', 'relevance': 'LOW'},\n",
       "     {'id': 'M14164', 'name': 'Preleukemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12145',\n",
       "      'name': 'Myelodysplastic Syndromes',\n",
       "      'asFound': 'Myelodysplastic Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T3993',\n",
       "      'name': 'Myelodysplastic Syndromes',\n",
       "      'asFound': 'Myelodysplastic Syndrome',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000003561',\n",
       "      'term': 'Cytarabine'},\n",
       "     {'id': 'D000001374', 'term': 'Azacitidine'},\n",
       "     {'id': 'C000579720', 'term': 'Venetoclax'},\n",
       "     {'id': 'D000003630', 'term': 'Daunorubicin'},\n",
       "     {'id': 'C000609080', 'term': 'Gilteritinib'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000000998', 'term': 'Antiviral Agents'},\n",
       "     {'id': 'D000000890', 'term': 'Anti-Infective Agents'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000000903', 'term': 'Antibiotics, Antineoplastic'},\n",
       "     {'id': 'D000059005', 'term': 'Topoisomerase II Inhibitors'},\n",
       "     {'id': 'D000059003', 'term': 'Topoisomerase Inhibitors'},\n",
       "     {'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M6766',\n",
       "      'name': 'Cytarabine',\n",
       "      'asFound': 'Multi-',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4673',\n",
       "      'name': 'Azacitidine',\n",
       "      'asFound': 'Frequency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6832',\n",
       "      'name': 'Daunorubicin',\n",
       "      'asFound': 'Size',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M58265',\n",
       "      'name': 'Gilteritinib',\n",
       "      'asFound': 'Probable',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M4314', 'name': 'Antiviral Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4224',\n",
       "      'name': 'Antibiotics, Antitubercular',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05906602',\n",
       "    'orgStudyIdInfo': {'id': '2022-1620'},\n",
       "    'organization': {'fullName': 'University of Illinois at Chicago',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke',\n",
       "    'officialTitle': 'Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-02-17',\n",
       "    'studyFirstSubmitQcDate': '2023-06-06',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-06-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Sangeetha Madhavan',\n",
       "     'investigatorTitle': 'Professor, Physical Therapy',\n",
       "     'investigatorAffiliation': 'University of Illinois at Chicago'},\n",
       "    'leadSponsor': {'name': 'University of Illinois at Chicago',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to test ischemic conditioning (blood flow restriction)\\r\\nas a neuromodulatory technique to improve gait function in stroke. Neuromodulation is\\r\\nemerging as a promising adjunct strategy to facilitate changes in brain activity and\\r\\nimprove motor behavior following a neurological injury such as stroke.\\r\\n\\r\\nThe main questions this trial aims to answer are:\\r\\n\\r\\n  -  Can ischemic conditioning produce neuromodulatory changes in the lower limb primary\\r\\n     motor cortex?\\r\\n\\r\\n  -  Can ischemic conditioning be used as a neuromodulatory technique to improve\\r\\n     strength, motor control, and gait speed in individuals with stroke when compared to\\r\\n     sham ischemic conditioning?\\r\\n\\r\\nParticipants will take part in two sessions of ischemic conditioning where a cuff\\r\\n(similar to ones that measure blood pressure) will be placed around the thigh and\\r\\ninflated to one of two blood flow restriction pressures (real or sham). Each participant\\r\\nwill experience measures of brain activity and motor behavior testing before and after\\r\\nboth sessions (ischemic conditioning and sham ischemic conditioning).\\r\\n\\r\\nResearchers will investigate ischemic conditioning as neuromodulation modality in stroke\\r\\nto see if ischemic conditioning can produce beneficial changes in brain activity and\\r\\nimprovements on subsequent motor behavior tasks.'},\n",
       "   'conditionsModule': {'conditions': ['Stroke']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Participants will be masked to the type of ischemic conditioning they receive (real or\\r\\nsham). Treatment arms/ session order (ischemic conditioning and sham ischemic\\r\\nconditioning) will be randomized.',\n",
       "      'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Ischemic Conditioning',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'While seated, a rapid inflation cuff, similar to those used to measure blood pressure,\\r\\nwill be placed around the paretic thigh to perform real ischemic conditioning. The\\r\\npressure of the cuff will be increased for 5 minutes followed by no pressure for 5\\r\\nminutes, repeated 5 times for a total of 50 minutes.',\n",
       "      'interventionNames': ['Device: Real Ischemic Conditioning']},\n",
       "     {'label': 'Sham Ischemic Conditioning',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': 'While seated, a rapid inflation cuff, similar to those used to measure blood pressure,\\r\\nwill be placed around the paretic thigh to perform sham or fake ischemic conditioning.\\r\\nThe pressure of the cuff will be increased for 5 minutes followed by no pressure for 5\\r\\nminutes, repeated 5 times for a total of 50 minutes.',\n",
       "      'interventionNames': ['Device: Sham Ischemic Conditioning']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Real Ischemic Conditioning',\n",
       "      'description': '10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5\\r\\nminutes), repeated 5 times for a total of 50 minutes.',\n",
       "      'armGroupLabels': ['Ischemic Conditioning']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Sham Ischemic Conditioning',\n",
       "      'description': 'Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely\\r\\nin cuff pressure during blood flow restriction to replicate to replicate perceived\\r\\ntightness without arterial blood flow restriction.',\n",
       "      'armGroupLabels': ['Sham Ischemic Conditioning']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in corticomotor excitability',\n",
       "      'description': 'Excitability of the primary lower limb motor cortex will be assessed using single pulse\\r\\ntranscranial magnetic stimulation (TMS) and motor evoked potentials (MEPs) will be\\r\\nrecorded from the tibialis anterior muscle of the paretic leg.',\n",
       "      'timeFrame': 'Changes in corticomotor excitability will be calculated within and between sessions at baseline, immediate-post, and 30-minutes-post one session of sham IC, real IC, and aerobic exercise.'},\n",
       "     {'measure': 'Change in transcallosal inhibition',\n",
       "      'description': 'Inhibition from the stimulated hemisphere to the non-stimulated hemisphere will be\\r\\nquantified as a measure of the ipsilateral silent period (iSP) using single pulse\\r\\ntranscranial magnetic stimulation (TMS) and motor evoked potentials (MEPs) will be\\r\\nrecorded from the tibialis anterior muscle of the leg ipsilateral to TMS stimulation.',\n",
       "      'timeFrame': 'Changes in transcallosal inhibition will be calculated within and between sessions at baseline, immediate-post, and 30-minutes-post one session of sham IC, real IC, and aerobic exercise.'},\n",
       "     {'measure': 'Change in ankle motor control',\n",
       "      'description': 'Reaction time will be measured using a choice reaction time task involving rapid ankle\\r\\ndorsiflexion and plantarflexion movements in a custom built ankle-tracking device.',\n",
       "      'timeFrame': 'Changes in ankle motor control will be calculated within and between sessions at baseline, immediate-post, and 30-minutes-post one session of sham IC, real IC, and aerobic exercise.'},\n",
       "     {'measure': 'Change in lower limb strength',\n",
       "      'description': 'Participants will perform 3 trials each of maximum ankle dorsiflexion and plantarflexion\\r\\nstrength.',\n",
       "      'timeFrame': 'Changes in strength will be calculated within and between sessions at baseline, immediate-post, and 30-minutes-post one session of sham IC, real IC, and aerobic exercise.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Numerical Rating Scale (NRS) for Pain',\n",
       "      'description': 'Subjective measures of pain will be reported during ischemic conditioning and sham\\r\\nischemic conditioning using a Numerical Rating Scale (NRS) from 0 (no pain) to 10 (worst\\r\\npain).',\n",
       "      'timeFrame': 'During each real and sham ischemic conditioning session, pain scores will be reported for each participant during intervals of blow flow restriction and reperfusion through study completion, an average of 1 year.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Single, stroke > 6 months since onset\\r\\n\\r\\n  -  Residual hemiparetic gait deficits (e.g., abnormal gait pattern)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Lesions affecting the brainstem or cerebellum\\r\\n\\r\\n  -  Other neurological disorders that may interfere with motor function\\r\\n\\r\\n  -  Unhealed decubiti, persistent infections that may interfere with ability to perform\\r\\n     test procedures\\r\\n\\r\\n  -  Significant cognitive or communication impairment (Mini-Mental State Examination\\r\\n     (MMSE<21)), which could impede the understanding of the purpose of procedures of the\\r\\n     study\\r\\n\\r\\n  -  Botulinum toxin (Botox) treatments to the lower limb within the past 6 months\\r\\n\\r\\n  -  Pregnant women\\r\\n\\r\\n  -  Contraindications to transcranial magnetic stimulation (TMS) or ischemic\\r\\n     conditioning (IC) (Listed below)\\r\\n\\r\\nTMS General Exclusion Criteria:\\r\\n\\r\\n  -  Previous adverse reaction to TMS\\r\\n\\r\\n  -  Skull abnormalities or fractures\\r\\n\\r\\n  -  Concussion within the last 6 months\\r\\n\\r\\n  -  Unexplained, recurring headaches\\r\\n\\r\\n  -  Implanted cardiac pacemaker\\r\\n\\r\\n  -  Metal implants in the head or face\\r\\n\\r\\n  -  History of seizures or epilepsy\\r\\n\\r\\n  -  Use of medications that could alter cortical excitability or increase risk of\\r\\n     seizure (e.g., antidepressants, antipsychotics, anxiolytics, anticonvulsants)\\r\\n\\r\\n  -  Current pregnancy\\r\\n\\r\\nIC General Exclusion Criteria:\\r\\n\\r\\n  -  History of thrombosis (i.e., blood clots) including venous thrombosis or deep vein\\r\\n     thrombosis (DVT).\\r\\n\\r\\n  -  Blood clots in the leg, or any condition in which compression of the thigh or\\r\\n     transient ischemia is contraindicated (i.e., open wounds in the leg, bruising, nerve\\r\\n     damage, etc.)\\r\\n\\r\\n  -  Peripheral arterial grafts in the lower extremity\\r\\n\\r\\n  -  History of uncontrolled hypertension\\r\\n\\r\\n  -  History of peripheral vascular disease or hematological disease',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '21 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mark Q Cummings, BS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '3123550084',\n",
       "      'email': 'mcummi8@uic.edu'}],\n",
       "    'overallOfficials': [{'name': 'Sangeetha Madhavan, PT, PhD',\n",
       "      'affiliation': 'University of Illinois at Chicago',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Illinois Chicago',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60612',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Mark Cummings',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '312-355-0084',\n",
       "        'email': 'mcummi8@uic.edu'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000020521',\n",
       "      'term': 'Stroke'}],\n",
       "    'ancestors': [{'id': 'D000002561', 'term': 'Cerebrovascular Disorders'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M22306',\n",
       "      'name': 'Stroke',\n",
       "      'asFound': 'Stroke',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M5810', 'name': 'Cerebrovascular Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06383884',\n",
       "    'orgStudyIdInfo': {'id': '2024-02-134'},\n",
       "    'organization': {'fullName': 'Samsung Medical Center', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion',\n",
       "    'officialTitle': 'An Open Label, Phase 2 Basket Study of Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-04-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-04-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-16',\n",
       "    'studyFirstSubmitQcDate': '2024-04-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Se-Hoon Lee',\n",
       "     'investigatorTitle': 'M.D. Professor',\n",
       "     'investigatorAffiliation': 'Samsung Medical Center'},\n",
       "    'leadSponsor': {'name': 'Samsung Medical Center', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The NRG1 gene is located on chromosome 8 (8p12 region) and encode NRG1. NRG1 gene is\\r\\ntranslated to generate six different proteins (I-VI) and at least 31 isoforms. NRG1\\r\\nproteins are structurally related to EGF and contain an EGF-like motif that binds and\\r\\nactivates ErbB3 and ErbB4. Upon ligand binding, these receptors form homodimers or\\r\\nheterodimers, which results in phosphorylation of the intrinsic kinase domain, and\\r\\nactivation of the PI3K-AKT, MAPK, and other pathways.\\r\\n\\r\\nThe overall incidence of NRG1 fusions is very rare. In many tumor types, only limited\\r\\nnumbers of NRG1 fusion variant have been identified. By percentage, there is no organ\\r\\ndominance of the presence of NRG1 fusions. In an analysis of 21, 858 tumor specimens that\\r\\nunderwent anchored multiplex PCR for targeted RNA sequencing, the prevalence of NRG1\\r\\nfusions was 0.2%. Of these, CD74 was the most common partner (29%), followed by ATP1B1\\r\\n(10%), SDC4 (7%), and RBPMS (5%), and most CD74-NRG1 fusions have been reported in\\r\\npatients with lung IMA. NRG1 fusions result in aberrant expression of the epidermal\\r\\ngrowth factor (EGF)-like domain of neuregulin-1 (NRG1) on the cell surface binds\\r\\nprimarily to ErbB3 and ErbB4, leading to heterodimerization or oligomerization with other\\r\\nERBB family members. NRG1-mediated activation of ErbB3 promotes dimerization with EGFR,\\r\\nErbB2, and ErbB4. These partners phosphorylate ErbB3, forming docking sites for\\r\\nSH2-domain proteins, leading to pathologic activation of multiple signal transduction\\r\\npathways, including the phosphoinositide 3-kinase (PI3K) pathway. Subsequently, ErbB3\\r\\nexpression was noted at high levels, and the proteins were phosphorylated, in\\r\\nfusion-positive cases. Targeting ErbB3 signaling therefore represents a promising\\r\\ntherapeutic approach for patients with NRG1 fusion-positive malignancies.',\n",
       "    'detailedDescription': \"This is a global, multicenter, open-label, Phase 2 study exploring the efficacy and\\r\\nsafety of patritumab deruxtecan in patients with NRG1 fusion solid tumor. Patients with\\r\\ntumor harboring NRG1 fusion will be identified through previously documented mutation\\r\\ntesting performed prior to screening. The presence of NRG1 fusion will be retrospectively\\r\\nconfirmed by central testing via next generation sequencing (NGS) or FISH or Anchored\\r\\nmultiplex PCR for targeted RNA sequencing (AMP). The study has a basket design and\\r\\nincludes several cohorts, either defined by an actionable somatic mutation and tumor\\r\\nhistology.\\r\\n\\r\\nPatritumab deruxtecan will be dosed at 5.6mg/kg as an itravenous (IV) infusion\\r\\nadministered on Day 1 of each 21-day cycle. Dose reductions or interruptions, and\\r\\ninitiation of supportive care, are allowed as deemed appropriate by the investigator.\\r\\n\\r\\nThe study start date is the date when the first subject has signed the main informed\\r\\nconsent. A subject is eligible to be enrolled into the interventional phase of the study\\r\\nwhen the Investigator or designee has obtained written consent, has confirmed all\\r\\neligibility criteria have been met by the subject, and all Screening procedures have been\\r\\ncompleted.\\r\\n\\r\\nA Simon's optimal 2-stage design (with significance level 5%, power of 80%) will be used\\r\\nto determine whether patritumab deruxtecan has sufficient activity to warrant further\\r\\ndevelopment. The null hypothesis is carried through into the second stage before it is\\r\\nrejected or not. Early study termination will be permitted if data at the first stage\\r\\nindicate that the treatment is ineffective.\\r\\n\\r\\nAs the range of ORR in NRG1 fusion patients treated with chemotherapy or\\r\\nchemoimmunotherapy was found to be 0% to 13%, the investigators considered the average 6%\\r\\nwill be considered unacceptable, whereas the ORR of patients who treated with afatinib\\r\\nwas 25%, the investigators hypothesized the average of ORR 25% will merit further study\\r\\n(alternative hypothesis).\\r\\n\\r\\nIn the first stage, enrollment will continue until 7 patients received at least one dose\\r\\nof study treatment and completed the first tumor assessment by the investigator (response\\r\\nevaluable). If no responses are observed, the second stage for the cohort must be\\r\\ndiscontinued. Otherwise, 23 additional response evaluable patients will be accrued for a\\r\\ntotal of 30 patients in the cohort, considering 15% of dropout rate. The null hypothesis\\r\\nwill be rejected if at least 4 responses are observed in Stage 2.\\r\\n\\r\\nThe study will be divided into 3 periods: a Screening Period, Treatment Period, and\\r\\nFollow-up Period.\\r\\n\\r\\nThe primary analysis of ORR will be conducted after all enrolled subjects have either a\\r\\nminimum of 9 months of follow-up or have discontinued from the study earlier. The final\\r\\nanalysis will occur after all subjects have discontinued from the study.\"},\n",
       "   'conditionsModule': {'conditions': ['Solid Tumor, Adult'],\n",
       "    'keywords': ['Patritumab deruxtecan', 'NRG1 fusion']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Patritumab deruxtecan treatment arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day\\r\\ncycle as a fixed dose regimen of 5.6 mg/kg Q3W.',\n",
       "      'interventionNames': ['Drug: Patritumab Deruxtecan']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Patritumab Deruxtecan',\n",
       "      'description': 'Patritumab deruxtecan will be administered as an IV infusion Q3W on Day 1 of each 21-day\\r\\ncycle as a fixed dose regimen of 5.6 mg/kg Q3W.',\n",
       "      'armGroupLabels': ['Patritumab deruxtecan treatment arm'],\n",
       "      'otherNames': ['U3-1402']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective response rate(ORR)',\n",
       "      'description': 'assessed by investigator per RECIST v1.1',\n",
       "      'timeFrame': '12 month after completion of enrollment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Duration of response (DoR)',\n",
       "      'description': 'DoR as assessed by investigator per RECIST v1.1',\n",
       "      'timeFrame': 'up to 30 month'},\n",
       "     {'measure': 'Progression-free survival(PFS)',\n",
       "      'description': 'PFS as assessed by investigator per RECIST v1.1',\n",
       "      'timeFrame': 'up to 30 month'},\n",
       "     {'measure': 'Disease-control rate(DCR)',\n",
       "      'description': 'DCR as assessed by investigator and Investigator per RECIST v1.1',\n",
       "      'timeFrame': 'up to 30 month'},\n",
       "     {'measure': 'Best percentage change in the SoD of measurable tumors',\n",
       "      'description': 'SoD as assessed by investigator per RECIST V1.1',\n",
       "      'timeFrame': 'up to 30 month'},\n",
       "     {'measure': 'Overall survival(OS)',\n",
       "      'description': 'Death date is collected until the subject discontinues the study.',\n",
       "      'timeFrame': 'up to 30 month'}],\n",
       "    'otherOutcomes': [{'measure': 'Incidence of Adverse events (CTCAE v5.0)',\n",
       "      'description': 'Safety during the study',\n",
       "      'timeFrame': \"From the start to the end of the subject's study, an average of 6 month\"}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Sign and date the tissue informed consent form (ICF) and the main ICF, prior to the\\r\\n     start of any study-specific qualification procedures.\\r\\n\\r\\n  -  Male or female participants aged ≥18 years (follow local regulatory requirements if\\r\\n     the legal age of consent for study participation is >18 years old).\\r\\n\\r\\n  -  Histologically or cytologically documented locally advanced or metastatic solid\\r\\n     tumor not amenable to curative surgery or radiation.\\r\\n\\r\\n  -  Documentation of NRG1 fusion detected from tumor tissue or blood sample, including\\r\\n     but not limited to TruSightOncology-500, Guardant-360 or FoundationOne®CDx (F1CDx).\\r\\n\\r\\n  -  At least 1 measurable lesion confirmed by investigator as per RECIST v1.1\\r\\n\\r\\n  -  At least 1 measurable lesion confirmed per RECIST v1.1\\r\\n\\r\\n  -  Consented and willing to provide required tumor tissue of sufficient quantity (as\\r\\n     defined in the Laboratory Manual) and of adequate tumor tissue content (as confirmed\\r\\n     by hematoxylin and eosin [H&E] staining). Required tumor tissue can be provided as\\r\\n     either:\\r\\n\\r\\n       1. Pretreatment tumor biopsy from at least 1 lesion not previously irradiated and\\r\\n          amenable to core biopsy OR\\r\\n\\r\\n       2. Archival tumor tissue collected from a biopsy performed within 3 months prior\\r\\n          to signing of the tissue consent and since progression while on or after\\r\\n          treatment with the most recent cancer therapy regimen.\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at\\r\\n     Screening.\\r\\n\\r\\n  -  Has adequate bone marrow reserve and organ function based on local laboratory data\\r\\n     within 14 days prior to Cycle 1 Day\\r\\n\\r\\n       1. Platelet count: ≥100,000/mm^3 or ≥100 × 10^9/L (platelet transfusions are not\\r\\n          allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)\\r\\n\\r\\n       2. Hemoglobin: ≥9.0 g/dL (transfusion and/or growth factor support is allowed)\\r\\n\\r\\n       3. Absolute neutrophil count: ≥1500/mm^3 or ≥1.5 × 10^9/L\\r\\n\\r\\n       4. Serum creatinine (SCr) or creatinine clearance (CrCl): SCr ≤1.5 × upper limit\\r\\n          of normal (ULN), OR CrCl ≥30 mL/min as calculated using the Cockcroft-Gault\\r\\n          equation or measured CrCl\\r\\n\\r\\n       5. Aspartate aminotransferase/alanine aminotransferase: ≤3 × ULN (if liver\\r\\n          metastases are present, ≤5 × ULN)\\r\\n\\r\\n       6. Total bilirubin: ≤1.5 × ULN if no liver metastases (<3 × ULN in the presence of\\r\\n          documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver\\r\\n          metastases)\\r\\n\\r\\n       7. Serum albumin: ≥2.5 g/dL\\r\\n\\r\\n       8. Prothrombin time (PT) or PT-International normalized ratio (INR) and activated\\r\\n          partial thromboplastin time (aPTT)/PTT: ≤1.5 × ULN, except for subjects on\\r\\n          coumarin-derivative anticoagulants or other similar anticoagulant therapy, who\\r\\n          must have PT-INR within therapeutic range as deemed appropriate by the\\r\\n          Investigator\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any history of interstitial lung disease (including pulmonary fibrosis or radiation\\r\\n     pneumonitis) has current interstitial lung disease (ILD) or is suspected to have\\r\\n     such disease by imaging during screening.\\r\\n\\r\\n  -  Clinically severe respiratory compromise (based on Investigator's assessment)\\r\\n     resulting from intercurrent pulmonary illnesses including, but not limited to:\\r\\n\\r\\n       1. Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months prior\\r\\n          to the study enrollment, severe asthma, severe chronic obstructive pulmonary\\r\\n          disease [COPD]), restrictive lung disease, pleural effusion);\\r\\n\\r\\n       2. Any autoimmune, connective tissue or inflammatory disorders with pulmonary\\r\\n          involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis); OR\\r\\n          prior complete pneumonectomy.\\r\\n\\r\\n  -  Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or\\r\\n     equivalent anti-inflammatory or any form of immunosuppressive therapy prior to\\r\\n     enrollment. Participants who require use of bronchodilators, inhaled or topical\\r\\n     steroids, or local steroid injections may be included in the study.\\r\\n\\r\\n  -  Evidence of any leptomeningeal disease.\\r\\n\\r\\n  -  Evidence of clinically active spinal cord compression or brain metastases.\\r\\n\\r\\n  -  Inadequate washout period prior to Cycle 1 Day 1, defined as:\\r\\n\\r\\n       1. Whole brain radiation therapy <14 days or stereotactic brain radiation therapy\\r\\n          <7 days;\\r\\n\\r\\n       2. Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s)\\r\\n          from a previous cancer treatment regimen or clinical study (other than EGFR\\r\\n          TKI), <14 days or 5 half-lives, whichever is longer;\\r\\n\\r\\n       3. Monoclonal antibodies, other than immune checkpoint inhibitors, such as\\r\\n          bevacizumab (anti-VEGF) and cetuximab (anti-EGFR) <28 days;\\r\\n\\r\\n       4. Immune checkpoint inhibitor therapy <21 days;\\r\\n\\r\\n       5. Major surgery (excluding placement of vascular access) <28 days;\\r\\n\\r\\n       6. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field\\r\\n          of radiation <28 days or palliative radiation therapy <14 days; or\\r\\n\\r\\n       7. Chloroquine or hydroxychloroquine <14 days.\\r\\n\\r\\n  -  Prior treatment with an anti-human epidermal growth factor receptor 3 (HER3)\\r\\n     antibody or single-agent topoisomerase I inhibitor.\\r\\n\\r\\n  -  Prior treatment with an antibody drug conjugate (ADC) that consists of any\\r\\n     topoisomerase I inhibitor\\r\\n\\r\\n  -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities\\r\\n     (other than alopecia) not yet resolved to National Cancer Institute Common\\r\\n     Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, Grade ≤1 or baseline.\\r\\n     Participants with chronic Grade 2 toxicities may be eligible at the discretion of\\r\\n     the Investigator.\\r\\n\\r\\n  -  Has history of other active malignancy within 3 years prior to enrollment, except:\\r\\n\\r\\n       1. Adequately treated non-melanoma skin cancer;\\r\\n\\r\\n       2. Superficial bladder tumors (Ta, Tis, T1);\\r\\n\\r\\n       3. Well-differentiated thyroid cancer\\r\\n\\r\\n       4. Adequately treated intraepithelial carcinoma of the cervix uteri;\\r\\n\\r\\n       5. Low risk non-metastatic prostate cancer (with Gleason score <7, and following\\r\\n          local treatment or ongoing active surveillance);\\r\\n\\r\\n       6. Any other curatively treated in situ disease.\\r\\n\\r\\n  -  Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1\\r\\n\\r\\n  -  Active hepatitis B and/or hepatitis C infection, such as those with serologic\\r\\n     evidence of viral infection within 28 days of Cycle 1 Day 1.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Se-Hoon Lee, MD, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+82-10-4579-7640',\n",
       "      'email': 'sehoon.lee@samsung.com'}],\n",
       "    'overallOfficials': [{'name': 'Se-Hoon Lee, MD, PhD',\n",
       "      'affiliation': 'Samsung Medical Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Samsung Medical Center',\n",
       "      'city': 'Seoul',\n",
       "      'zip': '06351',\n",
       "      'country': 'Korea, Republic of',\n",
       "      'contacts': [{'name': 'Se-Hoon Lee, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+82-10-4579-7640',\n",
       "        'email': 'sehoon.lee@samsung.com'}],\n",
       "      'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000710748',\n",
       "      'term': 'Patritumab deruxtecan'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M347672',\n",
       "      'name': 'Patritumab deruxtecan',\n",
       "      'asFound': 'Thalassemia Major',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06096779',\n",
       "    'orgStudyIdInfo': {'id': 'ML44719'},\n",
       "    'organization': {'fullName': 'Genentech, Inc.', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis',\n",
       "    'officialTitle': 'A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis',\n",
       "    'acronym': 'Kirros'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-02', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-11-16', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-18',\n",
       "    'studyFirstSubmitQcDate': '2023-10-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Genentech, Inc.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the safety and efficacy of atezolizumab and\\r\\nbevacizumab, or atezolizumab alone, as first-line treatment in participants with\\r\\nunresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with\\r\\nChild-Pugh B7 or B8 cirrhosis.',\n",
       "    'detailedDescription': 'This is a Phase II, open-label, multicohort, multicenter study in participants with\\r\\nunresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) who have\\r\\nChild-Pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this\\r\\ntreatment setting. The study is designed to non-comparatively evaluate the safety and\\r\\nefficacy of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort\\r\\nB) in this population.'},\n",
       "   'conditionsModule': {'conditions': ['Hepatocellular Carcinoma'],\n",
       "    'keywords': ['Cirrhosis',\n",
       "     'liver cancer',\n",
       "     'liver tumor',\n",
       "     'Child-Pugh B',\n",
       "     'hepatocellular carcinoma',\n",
       "     'atezolizumab',\n",
       "     'bevacizumab',\n",
       "     'Immune Checkpoint Inhibitor',\n",
       "     'Digestive System Neoplasms']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cohort A: Atezolizumab+Bevacizumab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive Atezolizumab plus Bevacizumab until unacceptable toxicity or\\r\\nloss of clinical benefit as determined by the investigator.',\n",
       "      'interventionNames': ['Drug: Atezolizumab', 'Drug: Bevacizumab']},\n",
       "     {'label': 'Cohort B: Atezolizumab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive Atezolizumab until unacceptable toxicity or loss of clinical\\r\\nbenefit as determined by the investigator.',\n",
       "      'interventionNames': ['Drug: Atezolizumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Atezolizumab',\n",
       "      'description': 'Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each\\r\\n21-day cycle.',\n",
       "      'armGroupLabels': ['Cohort A: Atezolizumab+Bevacizumab',\n",
       "       'Cohort B: Atezolizumab'],\n",
       "      'otherNames': ['Tecentriq']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Bevacizumab',\n",
       "      'description': 'Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each\\r\\n21-day cycle.',\n",
       "      'armGroupLabels': ['Cohort A: Atezolizumab+Bevacizumab'],\n",
       "      'otherNames': ['Avastin']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants with Adverse Events',\n",
       "      'timeFrame': 'Baseline through the end of the study (up to approximately 36 months)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR)',\n",
       "      'description': 'Investigator-assessed confirmed ORR is defined as proportion of participants with a CR/PR\\r\\non two consecutive occasions ≥ 4 weeks apart with the use of RECIST v1.1 and HCC mRECIST\\r\\nin Cohorts A and B.',\n",
       "      'timeFrame': 'Randomization up to approximately 36 months'},\n",
       "     {'measure': 'Duration of Response (DOR)',\n",
       "      'description': 'Investigator-assessed DOR is defined as the time from the first occurrence of a confirmed\\r\\nobjective response to the time of disease progression, or death from any cause, whichever\\r\\noccurs first, with the use of RECIST v1.1 and HCC mRECIST in Cohorts A and B',\n",
       "      'timeFrame': 'Randomization up to approximately 36 months'},\n",
       "     {'measure': 'Progression Free Survival (PFS)',\n",
       "      'description': 'Investigator-assessed PFS is defined as the time from treatment initiation to the first\\r\\noccurrence of disease progression with the use of RECIST v1.1 and HCC mRECIST, or death\\r\\nfrom any cause, whichever occurs first, in Cohorts A and B.',\n",
       "      'timeFrame': 'Randomization up to approximately 36 months'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'OS is defined as the time from treatment initiation to the date of death due to any cause\\r\\nin Cohorts A and B.',\n",
       "      'timeFrame': 'Randomization up to approximately 36 months'},\n",
       "     {'measure': 'Change From Baseline in EORTC QLQ-C30 Scores',\n",
       "      'description': 'The QLQ-C30 is a validated, reliable self-reported measure. It consists of 30 questions\\r\\nthat assess five aspects of participant functioning, three symptom scales, global health\\r\\nstatus and quality of life (QoL), and six single items with a recall period of the\\r\\nprevious week. Scale scores can be obtained for the multi-item scales. The functioning\\r\\nand symptoms items are scored on a 4-point scale that ranges from \"not at all\" to \"very\\r\\nmuch,\" and the global health status and QoL items are scored on a 7-point scale that\\r\\nranges from \"very poor\" to \"excellent.\"',\n",
       "      'timeFrame': 'Baseline up to approximately 36 months'},\n",
       "     {'measure': 'Change From Baseline in QLQ-HCC18 Scores',\n",
       "      'description': 'The EORTC QLQ-HCC18 is a disease-specific measure designed for use along with the EORTC\\r\\nQLQ-C30 in patients with HCC. It contains six multi-item symptom scales, and two\\r\\nsingle-item scales for a total of 18 questions with a recall period the past week.',\n",
       "      'timeFrame': 'Baseline up to approximately 36 months'},\n",
       "     {'measure': 'Change from baseline in PRO-CTCAE Scores',\n",
       "      'description': 'The PRO-CTCAE is a validated item bank that is used to characterize the presence,\\r\\nfrequency of occurrence, severity, and/or degree of interference with daily function of\\r\\n78 patient-reportable symptomatic treatment toxicities.',\n",
       "      'timeFrame': 'Baseline up to approximately 36 months'},\n",
       "     {'measure': 'Change From Baseline in IL46 Scores',\n",
       "      'description': 'The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is\\r\\nrated on a scale from 1 to 4, ranging from \"not at all\" to \"very much\".',\n",
       "      'timeFrame': 'Baseline up to approximately 36 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'General Inclusion Criteria:\\r\\n\\r\\n  -  Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by\\r\\n     histology/cytology or clinically by American Association for the Study of Liver\\r\\n     Diseases (AASLD) criteria in cirrhotic patients\\r\\n\\r\\n  -  Disease that is not amenable to curative surgical and/or locoregional therapies\\r\\n\\r\\n  -  No prior systemic treatment (including systemic investigational agents) for locally\\r\\n     advanced or metastatic and/or unresectable HCC\\r\\n\\r\\n  -  Measurable disease (at least one untreated target lesion) according to RECIST v1.1\\r\\n\\r\\n  -  ECOG Performance Status of 0-2 within 7 days prior to initiation of study treatment\\r\\n\\r\\n  -  Child-Pugh B7 or B8 cirrhosis at screening and within 7 days prior to study\\r\\n     treatment\\r\\n\\r\\n  -  Adequate hematologic and end-organ function\\r\\n\\r\\n  -  Life expectancy of at least 12 weeks\\r\\n\\r\\n  -  Female participants of childbearing potential must be willing to avoid pregnancy and\\r\\n     egg donation\\r\\n\\r\\nGeneral Exclusion Criteria:\\r\\n\\r\\n  -  Pregnancy or breastfeeding\\r\\n\\r\\n  -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies\\r\\n\\r\\n  -  Treatment with investigational therapy within 28 days prior to initiation of study\\r\\n     treatment\\r\\n\\r\\n  -  Treatment with locoregional therapy to liver within 28 days prior to initiation of\\r\\n     study treatment, or non-recovery from side effects of any such procedure\\r\\n\\r\\n  -  Treatment with systemic immunostimulatory agents\\r\\n\\r\\n  -  Treatment with systemic immunosuppressive medication\\r\\n\\r\\n  -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of\\r\\n     study treatment\\r\\n\\r\\n  -  Inadequately controlled hypertension\\r\\n\\r\\n  -  Active or history of autoimmune disease or immune deficiency\\r\\n\\r\\n  -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced\\r\\n     pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on\\r\\n     screening chest computed tomography (CT) scan\\r\\n\\r\\n  -  History of malignancy other than HCC within 3 years prior to screening, with the\\r\\n     exception of malignancies with a negligible risk of metastasis or death\\r\\n\\r\\n  -  Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed\\r\\n     cholangiocarcinoma and HCC\\r\\n\\r\\n  -  Symptomatic, untreated, or actively progressing central nervous system (CNS)\\r\\n     metastases\\r\\n\\r\\n  -  Prior allogeneic stem cell or solid organ transplantation\\r\\n\\r\\n  -  Listed for liver transplantation\\r\\n\\r\\n  -  Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)\\r\\n\\r\\n  -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or\\r\\n     that are at high risk for bleeding\\r\\n\\r\\n  -  A prior bleeding event due to esophageal and/or gastric varices within 6 months\\r\\n     prior to initiation of study treatment\\r\\n\\r\\n  -  Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study\\r\\n     treatment\\r\\n\\r\\n  -  History of hepatic encephalopathy requiring hospitalization or treatment escalation\\r\\n     within 6 months prior to study treatment, or any continued symptoms of\\r\\n     encephalopathy despite medical management\\r\\n\\r\\n  -  History, planned, or recommended placement of transjugular intrahepatic\\r\\n     portosystemic shunt (TIPS)\\r\\n\\r\\n  -  History of ascites requiring therapeutic paracentesis over the last 3 months\\r\\n\\r\\n  -  History of spontaneous bacterial peritonitis within last 12 months',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Reference Study ID Number: ML44719 https://forpatients.roche.com/',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '888-662-6728 (U.S. and Canada)',\n",
       "      'email': 'global-roche-genentech-trials@gene.com'}],\n",
       "    'overallOfficials': [{'name': 'Clinical Trials',\n",
       "      'affiliation': 'Hoffmann-La Roche',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'University of Southern California-Keck School of Medicine -1975 Zonal Ave',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Los Angeles',\n",
       "      'state': 'California',\n",
       "      'zip': '90089-5601',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 34.05223, 'lon': -118.24368}},\n",
       "     {'facility': 'University of Southern California; Oncology/Hematology',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Newport Beach',\n",
       "      'state': 'California',\n",
       "      'zip': '92663',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 33.61891, 'lon': -117.92895}},\n",
       "     {'facility': 'University of California Irvine Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Orange',\n",
       "      'state': 'California',\n",
       "      'zip': '92868',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 33.78779, 'lon': -117.85311}},\n",
       "     {'facility': 'University of California Davis Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Sacramento',\n",
       "      'state': 'California',\n",
       "      'zip': '95817',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 38.58157, 'lon': -121.4944}},\n",
       "     {'facility': 'Hartford Healthcare Cancer Institute at Hartford Hospital',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Hartford',\n",
       "      'state': 'Connecticut',\n",
       "      'zip': '06106',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 41.76371, 'lon': -72.68509}},\n",
       "     {'facility': 'LSU Health Baton Rouge; North Clinic',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Baton Rouge',\n",
       "      'state': 'Louisiana',\n",
       "      'zip': '70805',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 30.45075, 'lon': -91.15455}},\n",
       "     {'facility': 'Our Lady of the Lake Physician Group',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Baton Rouge',\n",
       "      'state': 'Louisiana',\n",
       "      'zip': '70808-4375',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 30.45075, 'lon': -91.15455}},\n",
       "     {'facility': 'Barbara Ann Karmanos Cancer Institute',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Detroit',\n",
       "      'state': 'Maine',\n",
       "      'zip': '48201-2013',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 44.79257, 'lon': -69.29671}},\n",
       "     {'facility': 'Rutgers Cancer Institute of New Jersey',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'New Brunswick',\n",
       "      'state': 'New Jersey',\n",
       "      'zip': '08901',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.48622, 'lon': -74.45182}},\n",
       "     {'facility': 'Rutgers Cancer Institute of New Jersey at University Hospital',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Newark',\n",
       "      'state': 'New Jersey',\n",
       "      'zip': '07103',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.73566, 'lon': -74.17237}},\n",
       "     {'facility': 'Montefiore Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Bronx',\n",
       "      'state': 'New York',\n",
       "      'zip': '10467',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.84985, 'lon': -73.86641}},\n",
       "     {'facility': 'Long Island Heart Associates',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Mineola',\n",
       "      'state': 'New York',\n",
       "      'zip': '11501-4298',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.74927, 'lon': -73.64068}},\n",
       "     {'facility': 'NYU Langone Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'New York',\n",
       "      'state': 'New York',\n",
       "      'zip': '10016-9451',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.71427, 'lon': -74.00597}},\n",
       "     {'facility': 'Levine Cancer Institute',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Charlotte',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '28204',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 35.22709, 'lon': -80.84313}},\n",
       "     {'facility': 'Kaiser Permanente Westside Medical Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Hillsboro',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97124-5806',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 45.52289, 'lon': -122.98983}},\n",
       "     {'facility': 'Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Pittsburgh',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '15240',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.44062, 'lon': -79.99589}},\n",
       "     {'facility': 'The West Clinic (East Campus)',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Germantown',\n",
       "      'state': 'Tennessee',\n",
       "      'zip': '38138-1762',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 35.08676, 'lon': -89.81009}},\n",
       "     {'facility': 'Liver Institute at Methodist Dallas',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Dallas',\n",
       "      'state': 'Texas',\n",
       "      'zip': '75203-1260',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 32.78306, 'lon': -96.80667}},\n",
       "     {'facility': 'Kelsey Research Foundation',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77025-1669',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': 'Maryview Hospital, Inc.',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Newport News',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '23602',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 37.08339, 'lon': -76.46965}},\n",
       "     {'facility': \"Bon Secours St. Mary's Hospital\",\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Richmond',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '23226-1925',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 37.55376, 'lon': -77.46026}},\n",
       "     {'facility': 'Benaroya Research Institute at Virginia Mason',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Seattle',\n",
       "      'state': 'Washington',\n",
       "      'zip': '98101-2756',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 47.60621, 'lon': -122.33207}},\n",
       "     {'facility': 'Pan American Center for Oncology Trials, LLC',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Rio Piedras',\n",
       "      'zip': '00935',\n",
       "      'country': 'Puerto Rico',\n",
       "      'geoPoint': {'lat': 18.39745, 'lon': -66.04989}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Qualified researchers may request access to individual patient level data through the\\r\\nclinical study data request platform (www.vivli.org). Further details on Roche's criteria\\r\\nfor eligible studies are available here ( https://vivli.org/ourmember/roche/). For\\r\\nfurther details on Roche's Global Policy on the Sharing of Clinical Information and how\\r\\nto request access to related clinical study documents, see here\\r\\n(https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/ou\\r\\nr_commitment_to_data_sharing.htm).\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002277',\n",
       "      'term': 'Carcinoma'},\n",
       "     {'id': 'D000006528', 'term': 'Carcinoma, Hepatocellular'},\n",
       "     {'id': 'D000005355', 'term': 'Fibrosis'}],\n",
       "    'ancestors': [{'id': 'D000009375',\n",
       "      'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000008113', 'term': 'Liver Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000008107', 'term': 'Liver Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M11103',\n",
       "      'name': 'Liver Cirrhosis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5534',\n",
       "      'name': 'Carcinoma',\n",
       "      'asFound': 'Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9613',\n",
       "      'name': 'Carcinoma, Hepatocellular',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11113', 'name': 'Liver Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8485',\n",
       "      'name': 'Fibrosis',\n",
       "      'asFound': 'Cirrhosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M11107', 'name': 'Liver Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000068258',\n",
       "      'term': 'Bevacizumab'},\n",
       "     {'id': 'C000594389', 'term': 'Atezolizumab'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000020533', 'term': 'Angiogenesis Inhibitors'},\n",
       "     {'id': 'D000043924', 'term': 'Angiogenesis Modulating Agents'},\n",
       "     {'id': 'D000006133', 'term': 'Growth Substances'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000006131', 'term': 'Growth Inhibitors'},\n",
       "     {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M246',\n",
       "      'name': 'Bevacizumab',\n",
       "      'asFound': 'Non-',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2342',\n",
       "      'name': 'Immune Checkpoint Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M349417',\n",
       "      'name': 'Atezolizumab',\n",
       "      'asFound': 'Relapsed',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11110', 'name': 'Liver Extracts', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22318', 'name': 'Angiogenesis Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M9231', 'name': 'Growth Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Hemat', 'name': 'Hematinics'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06383364',\n",
       "    'orgStudyIdInfo': {'id': 'SHS-Pharm - 1 - 2024'},\n",
       "    'organization': {'fullName': 'University of Southern Denmark',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of a Medication Coordinator on the Quality of Patients Medication Treatment',\n",
       "    'officialTitle': 'The Effect of a Medication Coordinator on the Quality of Patients Medication Treatment (MEDCOOR) - Randomized Controlled Trial',\n",
       "    'acronym': 'MEDCOOR'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'ENROLLING_BY_INVITATION',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-06-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-18',\n",
       "    'studyFirstSubmitQcDate': '2024-04-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University of Southern Denmark',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'To examine the effect of a Medication Coordinator, who facilitates medication reviews in\\r\\nclose collaboration with patients using My Medication Plan to reduce the risk of\\r\\npost-hospital inappropriate medication usage.',\n",
       "    'detailedDescription': \"Patients' safety can be compromised in the transition of care between healthcare sectors.\\r\\nOptimal information flow across healthcare sectors and individualized medication\\r\\ntreatment tailored to each patient is key to prevent adverse events and optimize patient\\r\\ntreatment. Particularly, the inclusion of the general practitioner is important in this\\r\\nprocess; it could become a challenge to keep medication changes if this communication\\r\\nlink is missing. The framework for complex intervention allows flexibility and adaption\\r\\nin meeting patients' needs by implementing tailored, possibly complex interventions in\\r\\ndifferent healthcare settings. To examine the effect of a Medication Coordinator, who\\r\\nfacilitates medication reviews in close collaboration with patients using My Medication\\r\\nPlan. The primary outcome is the proportion of potentially inappropriate medications.\\r\\nSecondary outcomes include patient-reported outcomes i.e., quality of life and medication\\r\\nburden. Additional outcomes include the patient's individual Medication Risk Score, if\\r\\nthe patients are readmitted, and if the patients have contacted the staff at the hospital\\r\\nunit after the hospital discharge.\"},\n",
       "   'conditionsModule': {'conditions': ['Medication Review',\n",
       "     'Polypharmacy',\n",
       "     'Potentially Inappropriate Medication',\n",
       "     'Quality of Life',\n",
       "     'Medication Therapy Management'],\n",
       "    'keywords': ['Polypharmacy',\n",
       "     'Medication review',\n",
       "     'Patient care management',\n",
       "     'Empowerment',\n",
       "     'Potentially inappropriate medication list',\n",
       "     'Hospital to home transition',\n",
       "     'Medication quality',\n",
       "     'medication optimization',\n",
       "     'Treatment burden']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['CARE_PROVIDER']}},\n",
       "    'enrollmentInfo': {'count': 140, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Interventions group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The Medication Coordinator facilitates the medication reviews in close collaboration with\\r\\nthe patients by applying concepts of motivational interview in combination with My\\r\\nMedication Plan',\n",
       "      'interventionNames': ['Behavioral: Medication Coordinator']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': \"Usual treatment from a team consisting of hospital physicians, nurses, nurse assistants,\\r\\nand as needed occupational therapists, physiotherapist, and clinical dieticians.\\r\\nMedication reconciliation might be a part of the patients' usual care performed by\\r\\nphysicians or pharmacologist present at the acute ward. Hospital physicians and/or nurses\\r\\nmight perform patient counselling about medication treatment during hospitalization\"}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Medication Coordinator',\n",
       "      'description': 'The Medication Coordinator calls the patient app seven days after discharge in the\\r\\ntransition of care from hospital to home',\n",
       "      'armGroupLabels': ['Interventions group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in potentially inappropriate medication according to Potentially Inappropriate Medication List',\n",
       "      'description': 'Evaluating the patients drug treatment to assess if a drug is a potentially inappropriate\\r\\nmedication',\n",
       "      'timeFrame': 'Baseline and 6 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Evaluation of patients experiences quality of life with the EQ-5D and EQ-VAS.',\n",
       "      'description': 'EQ-5D contains five questions regarding five domains: mobility, self-care, usual\\r\\nactivities, pain/discomfort, and anxiety/depression each with five answer categories: no\\r\\nproblems, slight problems, moderate problems, severe problems, and extreme problems.\\r\\nPermission for using the Danish EQ-5D version have been granted by EuroQol.\\r\\n\\r\\nThe EQ-VAS is a vertical VAS with the patient reporting their perceived quality of life\\r\\nfrom 0-100 (60). The endpoints are labelled with \"The worst health you can imagine\" (0)\\r\\nand \"The best health you can imagine\" (100). This VAS is used to quantify the measure of\\r\\nhealth that reflects the patient\\'s own perception.',\n",
       "      'timeFrame': 'Baseline and 3 months'},\n",
       "     {'measure': 'Evaluation of patients experienced quality of life with visual analogue scale (VAS).',\n",
       "      'description': 'The patients are to score their experienced VAS regarding quality of life with VAS.\\r\\n\\r\\nThe VAS is a vertical VAS and ranges from zero (low quality of life) to 100 (the highest\\r\\nquality of life) by numbers. The endpoints are label with \"The worst quality of life you\\r\\ncan image\" (0) and \"The highest quality of life you can image\" (100).',\n",
       "      'timeFrame': 'Baseline and 3 months'},\n",
       "     {'measure': 'Evaluation of patients experienced treatment burden with the questionnaire Multimorbidity treatment burden questionnaire (MTBQ).',\n",
       "      'description': 'The MTBQ is a validated tool to assess patients perceived treatment burden. Treatment\\r\\nburden is described as patients perception of the effort required to look after their\\r\\nhealth and the effect of this on their everyday life. A Danish version of the MTBQ has\\r\\nbeen validated and is applied upon permission.\\r\\n\\r\\nThe MTBQ is a ten-item questionnaire with good content validity, high internal\\r\\nreliability, and good construct validity. The questions covers aspects of medication\\r\\nmanagement self-monitoring, contact with healthcare professionals, obtaining information,\\r\\nimplementing life-style changes, and relying on help. The answers are a five point Likert\\r\\nscale with the possibilities: \"Not difficult\" (0), \"A little difficult\" (1), \"Quite\\r\\ndifficult\" (2), \"Very difficult\" (3), \"Extremely difficult\" (4), and \"Does not apply\"\\r\\n(0). The MTBQ scores are categorized into no burden (score 0), low burden (score < 10),\\r\\nmedium burden (score 10-22), and high burden (score ≥ 22).',\n",
       "      'timeFrame': 'Baseline and 3 months'},\n",
       "     {'measure': 'Evaluation of patients experienced medication burden with visual analogue scale (VAS).',\n",
       "      'description': 'An additional VAS regarding treatment burden is added. The VAS is a vertical VAS and\\r\\nranges from zero (no burden at all) to 100 (the highest burden imagined) by numbers. The\\r\\nendpoints are labelled with \"The worst burden you can imagine\" (0) and \"The highest\\r\\nburden you can imagine\" (100).',\n",
       "      'timeFrame': 'Baseline and 3 months'},\n",
       "     {'measure': 'Patient readmission 30 days after hospital discharge',\n",
       "      'description': 'Patient readmissions are evaluated 30 days after hospital discharge. As a \"did\" or \"did\\r\\nnot\" and a time-to-event, with a restriction of 30 days. The readmissions are assessed\\r\\nthrough the electronic patient journal.',\n",
       "      'timeFrame': '30 days after the patient has been discharged from the hospital.'},\n",
       "     {'measure': 'Patient contact to the ward 30 days after hospital discharge',\n",
       "      'description': 'Patient contact to the ward are evaluated 30 days after hospital discharge. As a \"did\" or\\r\\n\"did not\" and a time-to-event, with the restriction of 30 days. And if possible to assess\\r\\nwhich question the patient had to the ward, if it was drug-related or more disease\\r\\nspecific. The readmission are assessed through the electronic patient journal.',\n",
       "      'timeFrame': '30 days after the patient has been discharged from the hospital.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  all hospitalized patients, who are prescribed at least five medications specified in\\r\\n     the Electronic Patient Journal (EPJ) used at ward\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  unable to communicate in Danish, cognitively impaired e.g. suffering from dementia\\r\\n     or Alzheimer's, or cannot cooperate due to e.g. hallucination or aggressive behavior\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Sygehus Sønderjylland',\n",
       "      'city': 'Aabenraa',\n",
       "      'state': 'Southern Denmark',\n",
       "      'zip': '6200',\n",
       "      'country': 'Denmark',\n",
       "      'geoPoint': {'lat': 55.04434, 'lon': 9.41741}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'T6034',\n",
       "      'name': 'Quality of Life',\n",
       "      'asFound': 'Quality of Life',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06238323',\n",
       "    'orgStudyIdInfo': {'id': 'STUDY00008385'},\n",
       "    'secondaryIdInfos': [{'id': 'R01TW012671',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/R01TW012671'}],\n",
       "    'organization': {'fullName': 'University of Rochester', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Lafiya HIV Self-testing Study Protocol',\n",
       "    'officialTitle': 'Adaptation and Feasibility of Many Men Many Voices (3MV), an HIV Prevention Intervention to Reduce Intersectional Stigma and Increase HIVST Among YSMM Residing in Ghanaian Slums - A Clustered Pre-post Pilot Trial Protocol'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-04-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-04-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-01-25',\n",
       "    'studyFirstSubmitQcDate': '2024-01-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-06',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': \"Gamji Rabiu Abu-Ba'are\",\n",
       "     'investigatorTitle': 'Assistant professor',\n",
       "     'investigatorAffiliation': 'University of Rochester'},\n",
       "    'leadSponsor': {'name': 'University of Rochester', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University of Ghana', 'class': 'OTHER'},\n",
       "     {'name': 'George Washington University', 'class': 'OTHER'},\n",
       "     {'name': 'Yale University', 'class': 'OTHER'},\n",
       "     {'name': 'Fogarty International Center of the National Institute of Health',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The study aims to address low testing and related issues such as stigma, low-risk\\r\\nperception, and concerns about confidentiality affecting testing. To overcome these\\r\\nchallenges, the study proposes to adapt the Many Men Many Voices (3MV) into a modified\\r\\nversion called LAFIYA to tackle intersectional stigma and improve HIVST among young\\r\\nsexual minority men in Ghana.'},\n",
       "   'conditionsModule': {'conditions': ['HIV Prevention and Care']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'All participants',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will be young sexual minority men (YSMM) and providers from healthcare\\r\\ninstitutions working with YSMM.',\n",
       "      'interventionNames': ['Behavioral: LAFIYA']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'LAFIYA',\n",
       "      'description': 'LAFIYA will be a modified version of the Many Men Many Voices (3MV) targeted at\\r\\naddressing reducing stigma and increasing HIV self-testing uptake among young sexual\\r\\nminority men. LAFIYA will be developed into a comprehensive intervention manual for a\\r\\nlarge-scale trial using the ADAPTT-IT framework.',\n",
       "      'armGroupLabels': ['All participants']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in percentage of participants that reported the intervention as acceptable',\n",
       "      'description': 'Participants will be provided with a survey that inquires if HIVST meets their approval,\\r\\nmeets their needs, and if they welcome the use of HIVST. Participants will answer yes or\\r\\nno, and reported is the change in the percentage of participants that answered yes to\\r\\neach question.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Change in percentage of participants that reported the intervention as appropriate',\n",
       "      'description': 'Participants will be provided with a survey that inquires if HIVST seems reasonable, if\\r\\nHIVST seems like a good match, and if HIVST seems applicable. Participants will answer\\r\\nyes or no, and reported is the change in the percentage of participants that answered yes\\r\\nto each question.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Change in percentage of participants that reported the intervention as feasible.',\n",
       "      'description': 'Participants will be provided with a survey that inquires if HIVST seems easy to use, if\\r\\nHIVST seems challenging, and if HIVST seems practical. Participants will answer yes or\\r\\nno, and reported is the change in the percentage of participants that answered yes to\\r\\neach question.',\n",
       "      'timeFrame': 'Baseline to 3 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change in the number of HIV tests',\n",
       "      'description': 'We are going to collect the total number of HIV tests performed by all participants and\\r\\nreport the mean change in number.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Mean change in the Basic Needs Satisfaction Scale.',\n",
       "      'description': 'The Basic Needs Satisfaction scale is a 9 question scale that asks participants general\\r\\nquestions about experiences of feeling free within their community while identifying as\\r\\nYSMM. The outcome measure will analyze changes in average scores over time. The Basic\\r\\nNeeds Satisfaction Scale is scored on a scale ranging from 1 to 10, where 1 represents\\r\\nthe lowest possible level of basic needs satisfaction, and 10 represents the highest',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants to report resilience/bouncing back after hard times.',\n",
       "      'description': 'Participants will be provided with a 6 question survey that inquires into a percentage\\r\\nchange in their level of resilience. Each question inquires into their ability to bounce\\r\\nback or cope with challenges, with responses categorized as \"yes\" or \"no.\" The survey\\r\\nresults are then analyzed by calculating the percentage of participants who responded\\r\\naffirmatively (yes) to each question. The average percentage across all questions is\\r\\ncalculated to arrive at an overall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants that reported enacted stigma.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the rate at\\r\\nwhich they experienced unfair treatment by others. Each question will inquire into\\r\\nexperiences of unfair treatment, with responses categorized as \"yes\" or \"no.\" The survey\\r\\nresults are then analyzed by calculating the percentage of participants who responded\\r\\naffirmatively (yes) to each question. The average percentage across all questions is\\r\\ncalculated for an overall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants that reported vicarious stigma.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the percentage\\r\\nrate at which they have heard stories about other YSMM stigma experiences. Each question\\r\\ninquires whether they have heard stories of other YSMM experiencing stigma, with\\r\\nresponses categorized as \"yes\" or \"no.\" The survey results are then analyzed by\\r\\ncalculating the percentage of participants who responded affirmatively (yes) to each\\r\\nquestion. The average percentage across all questions is calculated to arrive at an\\r\\noverall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants that reported perceived stigma.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the level of\\r\\nagreement or disagreement on perceived stigma. Each question inquires whether they agree\\r\\nor disagree with perceived stigma, with responses categorized as \"yes\" or \"no.\" The\\r\\nsurvey results are then analyzed by calculating the percentage of participants who\\r\\nresponded affirmatively (yes) to each question. The average percentage across all\\r\\nquestions is calculated to arrive at an overall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage in participants that reported internalized stigma.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the percentage\\r\\nchange in internalized stigma. Each question inquires into their experience of\\r\\ninternalized stigma, with responses categorized as \"yes\" or \"no.\" The survey results are\\r\\nthen analyzed by calculating the percentage of participants who responded affirmatively\\r\\n(yes) to each question. The average percentage across all questions is calculated to\\r\\narrive at an overall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants that reported stigma for involving in same sex relations.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the frequency\\r\\nat which they encounter stigma from engaging in same-sex relations. Each question\\r\\ninquires into their experiences of stigma from engaging in same-sex relationships, with\\r\\nresponses categorized as \"yes\" or \"no.\" The survey results are then analyzed by\\r\\ncalculating the percentage of participants who responded affirmatively (yes) to each\\r\\nquestion. The average percentage across all questions is calculated to arrive at an\\r\\noverall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Percentage of participants that reported stigma from being gender non-conforming.',\n",
       "      'description': 'Participants will be provided with a 10 question survey that inquires into the frequency\\r\\nat which they encounter stigma due to their feminine mannerisms. Each question inquires\\r\\ninto their experiences of stigma from being gender non-conforming, with responses\\r\\ncategorized as \"yes\" or \"no.\" The survey results are then analyzed by calculating the\\r\\npercentage of participants who responded affirmatively (yes) to each question. The\\r\\naverage percentage across all questions is calculated to arrive at an overall percent\\r\\nscore.',\n",
       "      'timeFrame': 'Baseline to 3 months'},\n",
       "     {'measure': 'Healthcare climate',\n",
       "      'description': 'Participants will be provided with a 6 question survey that inquires into the frequency\\r\\nat which they encounter negative health provider attitudes. Each question inquires into\\r\\ntheir experiences when dealing with health providers, with responses categorized as \"yes\"\\r\\nor \"no.\" The survey results are then analyzed by calculating the percentage of\\r\\nparticipants who responded affirmatively (yes) to each question. The average percentage\\r\\nacross all questions is calculated to arrive at an overall percent score.',\n",
       "      'timeFrame': 'Baseline to 3 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  YSMM: To be eligible to participate in the interview, the person must be between 18\\r\\n     to 25 years old, have no experience using unassisted HIVST kits, do not know their\\r\\n     HIV status or tested negative, currently identifies as cis-gender man, and have had\\r\\n     sex with another man within six months before engaging with the recruitment team and\\r\\n     must reside within a slum community in the Greater Accra Metropolitan area.\\r\\n\\r\\n  -  Providers: To be eligible to participate in the interview, the person must have\\r\\n     experience providing sexual health services such as HIV testing, counseling, and\\r\\n     linkage to prevention and care services for at least one year. Must reside within\\r\\n     the Greater Accra Metropolitan area and have worked with YSMM on HIV prevention and\\r\\n     care.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  YSMM: Those who fall under 18 years or above 25 years will be excluded from the\\r\\n     study. YSMM who have experience with unassisted HIVST kits, know their HIV status,\\r\\n     or tested positive for HIV will be excluded from the study. YSMM who do not identify\\r\\n     as cis-gender man and have not had sex with another man within six months before\\r\\n     engaging with the recruitment team will be excluded from the study. YSMM who do not\\r\\n     reside within a slum community in the Greater Accra Metropolitan area will be\\r\\n     excluded from the study.\\r\\n\\r\\n  -  Providers: Persons who do not have experience providing services such as HIV\\r\\n     testing, counseling, and linkage to prevention and care services for at least one\\r\\n     year will be excluded from the study. Providers not residing within the Greater\\r\\n     Accra Metropolitan area and have not worked with YSMM on HIV prevention and care\\r\\n     will be excluded.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '25 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': \"Gamji R Abu-Ba'are, PhD\",\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '16077595760',\n",
       "      'email': 'GamjiRabiu_Abubaare@URMC.Rochester.edu'},\n",
       "     {'name': 'Kwasi Torpey, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+233302213820',\n",
       "      'email': 'Ktorpey@ug.edu.gh'}],\n",
       "    'locations': [{'facility': 'University of Ghana',\n",
       "      'city': 'Accra',\n",
       "      'country': 'Ghana',\n",
       "      'contacts': [{'name': 'Kwasi Torpey, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Ktorpey@ug.edu.gh'}],\n",
       "      'geoPoint': {'lat': 5.55602, 'lon': -0.1969}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M3522',\n",
       "      'name': 'Acquired Immunodeficiency Syndrome',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M18250', 'name': 'HIV Infections', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06404879',\n",
       "    'orgStudyIdInfo': {'id': '25.09.2023/07'},\n",
       "    'organization': {'fullName': 'Giresun University', 'class': 'OTHER'},\n",
       "    'briefTitle': \"The Effect of Parental Anxiety Level on the Child's Anxiety Level and Postoperative Pain in Children Undergoing Surgery.\",\n",
       "    'officialTitle': \"The Relationship Between Pre-operative Parental Anxiety Level and the Child's Anxiety Level and Its Effect on Postoperative Pain in Children Aged 2-6 Years Who Will Undergo Inguinal Area Surgery.\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-29',\n",
       "    'studyFirstSubmitQcDate': '2024-05-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dilek Yeniay',\n",
       "     'investigatorTitle': 'Anesthesiology and Reanimation physician',\n",
       "     'investigatorAffiliation': 'Giresun University'},\n",
       "    'leadSponsor': {'name': 'Giresun University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this prospective study is to investigate whether the anxiety levels of parents\\r\\nof children aged 2-6 years who will undergo inguinal area surgery have an effect on the\\r\\nchild&#39;s preoperative anxiety level and postoperative pain level.',\n",
       "    'detailedDescription': 'Hospitalization of children for any health problem or treatment is a complex and\\r\\ndifficult process that negatively affects the child and his family and creates stress.\\r\\nSurgical treatment in children can be planned or unplanned, minor or major, invasive or\\r\\nnon-invasive, but every type of surgery is considered a stressful experience. Studies\\r\\nhave shown that by controlling the anxiety and fear experienced in the preoperative\\r\\nperiod, children can achieve faster recovery in the postoperative period, better pain\\r\\ntolerance and earlier discharge. For this reason, we aim to contribute to the literature\\r\\nby investigating whether the anxiety levels of the parents of children aged 2-6 who will\\r\\nundergo inguinal area surgery affect the child&#39;s preoperative anxiety level and\\r\\npostoperative pain level.'},\n",
       "   'conditionsModule': {'conditions': ['Anxiety', 'Children'],\n",
       "    'keywords': ['children',\n",
       "     'anxiety',\n",
       "     'analgesia',\n",
       "     'pediatric',\n",
       "     'anaesthesia']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '1 Day',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'children group',\n",
       "      'description': 'Are between the ages of 2-6, are planned to undergo surgery under general anesthesia due\\r\\nto inguinal area pathology, No mental or neurological disorders in both mother and child\\r\\nNo vision, hearing or speech problems in both mother and child Parents and children who\\r\\nvolunteer to participate in the research will be included in the study.\\r\\n\\r\\nThose who did not volunteer to participate in the study, Undergoing surgery with a\\r\\npathology other than the inguinal area, Having emergency surgery Children with\\r\\npathologies (mental retardation, neurological problems, etc.) that may cause difficulty\\r\\nin communicating with both the family and the child will not be included in the study.',\n",
       "      'interventionNames': ['Other: determining scores with tests']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'determining scores with tests',\n",
       "      'description': 'Parents of children preparing for the operation will be given a child and family\\r\\ninformation form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will\\r\\nbe asked to fill them out themselves.\\r\\n\\r\\nAn anesthesia technician blind to the content of the study will calculate and take notes\\r\\non the children&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative\\r\\nAnxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation\\r\\nmask is shown (T4).\\r\\n\\r\\nFLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and\\r\\ncomplications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th\\r\\nminutes of all children taken to the recovery unit in the postoperative period will be\\r\\nrecorded by the recovery unit nurse. . Children who are thought to have pain according to\\r\\nthe FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be\\r\\ntaken.',\n",
       "      'armGroupLabels': ['children group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Anxiety level of parents',\n",
       "      'description': 'It will be measured with STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms.',\n",
       "      'timeFrame': 'preoperative period'},\n",
       "     {'measure': 'Anxiety level of the child undergoing surgery',\n",
       "      'description': \"According to the m-YPAS (modified Yale Preoperative Anxiety) scale, children's anxiety\\r\\nlevels will be calculated in the preoperative waiting room (T1) and when the anesthesia\\r\\nventilation mask is shown (T4).\",\n",
       "      'timeFrame': 'preoperative and intraoperative period'},\n",
       "     {'measure': 'Pain levels of children undergoing surgery',\n",
       "      'description': 'Pain levels of all children taken to the recovery unit will be measured with the FLACC\\r\\n(Face, Legs, Activity, Cry, Consolabilityscale) score at the 5th, 10th, 20th and 30th\\r\\nminutes.',\n",
       "      'timeFrame': 'postoperative period'}],\n",
       "    'secondaryOutcomes': [{'measure': 'heart rate',\n",
       "      'description': 'beats/min',\n",
       "      'timeFrame': 'intraoperative period'},\n",
       "     {'measure': 'heart rate',\n",
       "      'description': 'beats/min',\n",
       "      'timeFrame': 'up to 8 hour postoperative'},\n",
       "     {'measure': 'complication',\n",
       "      'description': 'such as nausea, vomiting and desaturation',\n",
       "      'timeFrame': 'up to 24 hour postoperative'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  The child is between the ages of 2-6\\r\\n\\r\\n  -  Patients scheduled for surgery under general anesthesia due to inguinal area\\r\\n     pathology\\r\\n\\r\\n  -  Surgery performed as planned\\r\\n\\r\\n  -  There is no mental or neurological disorder in both the mother and the child.\\r\\n\\r\\n  -  There are no vision, hearing or speech problems in both the mother and the child.\\r\\n\\r\\n  -  Parents and children who volunteer to participate in the research\\r\\n\\r\\n  -  Children with ASA I\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Not volunteering to participate in the study (those for whom parental consent cannot\\r\\n     be obtained)\\r\\n\\r\\n  -  Those who underwent surgery with a pathology other than the inguinal area\\r\\n\\r\\n  -  Having emergency surgery\\r\\n\\r\\n  -  Children at risk with ASA 2 and above\\r\\n\\r\\n  -  Having a pathology that may cause difficulty in communicating with both the family\\r\\n     and the child (such as mental retardation, neurological problem).',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '2 Years',\n",
       "    'maximumAge': '6 Years',\n",
       "    'stdAges': ['CHILD'],\n",
       "    'studyPopulation': 'Children who are planned to undergo surgery under general anesthesia due to inguinal area\\r\\npathology',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'DİLEK YENİAY',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+905375521553',\n",
       "      'email': 'dgyeniay@gmail.com'}],\n",
       "    'locations': [{'facility': 'Giresun Gynecology and Pediatrics Training Research Hospital',\n",
       "      'city': 'Giresun',\n",
       "      'state': 'Centre',\n",
       "      'zip': '28000',\n",
       "      'country': 'Turkey',\n",
       "      'contacts': [{'name': 'Dilek Giresun Gynecology and Pediatrics Training Research Hospital',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+90 454 2163600',\n",
       "        'email': 'dgyeniay@gmail.com'},\n",
       "       {'name': 'Dilek Yeniay', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.91698, 'lon': 38.38741}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010149',\n",
       "      'term': 'Pain, Postoperative'},\n",
       "     {'id': 'D000001008', 'term': 'Anxiety Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001523', 'term': 'Mental Disorders'},\n",
       "     {'id': 'D000011183', 'term': 'Postoperative Complications'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M13069',\n",
       "      'name': 'Pain, Postoperative',\n",
       "      'asFound': 'Postoperative Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4324',\n",
       "      'name': 'Anxiety Disorders',\n",
       "      'asFound': 'Anxiety',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14065',\n",
       "      'name': 'Postoperative Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11595', 'name': 'Meperidine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AdjAn', 'name': 'Adjuvants, Anesthesia'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05839379',\n",
       "    'orgStudyIdInfo': {'id': 'TarGeT-SCR'},\n",
       "    'organization': {'fullName': \"Nationwide Children's Hospital\",\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Targeted Pediatric High-Grade Glioma Therapy',\n",
       "    'officialTitle': 'Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2034-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-20',\n",
       "    'studyFirstSubmitQcDate': '2023-05-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': \"Nationwide Children's Hospital\",\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this study is to perform genetic sequencing on brain tumors from children,\\r\\nadolescents, and young adult patients who have been newly diagnosed with a high-grade\\r\\nglioma. This molecular profiling will decide if patients are eligible to participate in a\\r\\nsubsequent treatment-based clinical trial based on the genetic alterations identified in\\r\\ntheir tumor.',\n",
       "    'detailedDescription': 'A novel, molecularly-guided, multi-arm phase umbrella II trial is proposed in children,\\r\\nadolescents, and young adults with newly diagnosed HGG, including DIPG, in which we will\\r\\n(1) conduct comprehensive molecular screening of tumor tissue using a multi-omic approach\\r\\n(WES/WGS, gene fusion panels/RNASeq, DNA methylation microarray) across international\\r\\nCONNECT genomics cores with rapid return of clinical results, (2) stratify patients to\\r\\nbiologically-targeted treatment arms, based on the tumor molecular profile and\\r\\nhistopathology, and (3) perform longitudinal evaluation of peripheral blood,\\r\\ncerebrospinal fluid (CSF), and/or tumor tissue as well as advanced neuro-imaging to\\r\\ndetermine genomic, immune, and radiologic biomarkers predictive of response, recurrence,\\r\\nresistance, and toxicity.\\r\\n\\r\\nBased on results of the above tumor molecular profiling and pathology-based confirmation\\r\\nof HGG diagnosis, eligible patients will be assigned to one of several biologically\\r\\nguided treatment arms on a phase II trial.\\r\\n\\r\\nApproximately 400-450 patients will be enrolled on the screening protocol through which\\r\\nbiospecimens (paired tumor DNA/RNA and normal comparator samples) will undergo extensive\\r\\nmolecular profiling to assess eligibility to any of the therapeutic subprotocols of the\\r\\nphase II study.'},\n",
       "   'conditionsModule': {'conditions': ['High Grade Glioma',\n",
       "     'Diffuse Intrinsic Pontine Glioma',\n",
       "     'Anaplastic Astrocytoma',\n",
       "     'Glioblastoma',\n",
       "     'Glioblastoma Multiforme',\n",
       "     'Diffuse Midline Glioma, H3 K27M-Mutant',\n",
       "     'Metastatic Brain Tumor',\n",
       "     'WHO Grade III Glioma',\n",
       "     'WHO Grade IV Glioma']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'OTHER',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "     'description': 'Brain tumor samples with matched normal comparator (blood preferred alternatively, saliva\\r\\nor buccal swab)'},\n",
       "    'enrollmentInfo': {'count': 450, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Molecular profiling',\n",
       "      'description': 'Utilize molecular, clinical, and histopathologic data to assess eligibility for specific\\r\\nbiologically-guided treatment subprotocols among pediatric, adolescent and young adult\\r\\npatients with newly diagnosed HGG, including DIPG.',\n",
       "      'timeFrame': '4 years'},\n",
       "     {'measure': 'Feasibility of molecular profiling and enrollment to a TarGeT treatment protocol',\n",
       "      'description': 'Determine the percent of pediatric, adolescent, and young adult patients newly diagnosed\\r\\nwith HGG, including DIPG, who undergo comprehensive molecular characterization across\\r\\nclinical molecular testing laboratories at CONNECT sites and begin treatment on a TarGeT\\r\\ntreatment subprotocol within 10 calendar days of starting radiation therapy (RT) (if\\r\\ntreatment involves an agent given concurrently with RT) or within 35 days of completion\\r\\nof RT (if treatment involves adjuvant maintenance therapy).',\n",
       "      'timeFrame': '4 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Genomic Research',\n",
       "      'description': 'Increase knowledge of the genomic and immunologic landscape of newly-diagnosed pediatric\\r\\nand young adult HGGs, including DIPG, through comprehensive molecular characterization.',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Germline susceptibility testing',\n",
       "      'description': 'Determine the frequency and spectrum of germline cancer susceptibility mutations in\\r\\nchildren and young adults with HGG and DIPG and assess the feasibility of return of those\\r\\nresults.',\n",
       "      'timeFrame': '4 years'},\n",
       "     {'measure': 'Biobanking',\n",
       "      'description': 'Prospectively collect tumor tissue from diagnostic biopsy/resection as well as baseline\\r\\nperipheral blood and cerebrospinal fluid (CSF) samples for the CONNECT biorepository to\\r\\nbe used in correlative research for the present trial as well as future studies.',\n",
       "      'timeFrame': '4 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Age: Patients must be ≥12 months and ≤30 years of age at the time of enrollment onto\\r\\n     this screening protocol.\\r\\n\\r\\n  2. Diagnosis: Patients with newly diagnosed HGG, including DIPG are eligible. The\\r\\n     diagnosis of HGG must have been confirmed by local pathology review. for the\\r\\n     diagnosis of DIPG, patients must have a tumor with pontine epicenter and diffuse\\r\\n     involvement of at least 2/3 of the pons, with histopathology consistent with diffuse\\r\\n     WHO grade 2-4 glioma (eg, diffuse astrocytoma, anaplastic astrocytoma, glioblastoma,\\r\\n     H3K27-altered diffuse midline glioma). For all other tumors, histologic grade must\\r\\n     be WHO grade 3-4.\\r\\n\\r\\n  3. Disease Status: There are no disease status requirements for enrollment.\\r\\n\\r\\n       -  Measurable disease is not required. Patients without measurable disease are\\r\\n          eligible.\\r\\n\\r\\n       -  Patients with metastatic/disseminated or multifocal disease or gliomatosis\\r\\n          cerebri are eligible.\\r\\n\\r\\n       -  Patients with a primary spinal tumor are eligible.\\r\\n\\r\\n       -  Patients with secondary, radiation related HGG are eligible.\\r\\n\\r\\n  4. Prior Therapy for HGG: Surgery, radiation, and/or dexamethasone are permissible.\\r\\n     Temozolomide concurrent with radiation is permissible, but not recommended. No other\\r\\n     prior anticancer therapy for HGG will be allowed.\\r\\n\\r\\n     Timing from surgery to start of RT: For patients who have started RT, radiation must\\r\\n     have started within 31 days of definitive surgery or biopsy (if patient had two\\r\\n     surgeries, radiation must have started within 31 days from second surgery).\\r\\n\\r\\n  5. Tumor Sample Availability OR results from previous molecular profiling/targeted\\r\\n     sequencing\\r\\n\\r\\n       -  If a patient screens through OPTION #1, tumor sample in addition to normal\\r\\n          comparator tissue (peripheral blood or saliva) must be submitted for\\r\\n          comprehensive molecular screening at the time of screening enrollment.\\r\\n\\r\\n       -  If a patient screens through OPTIONS #2 or #3, results from previously\\r\\n          performed molecular profiling must be submitted following enrollment. It is\\r\\n          highly recommended that results be uploaded within 7 days of enrollment (if\\r\\n          results are available at time of enrollment) or within 7 days of results\\r\\n          becoming available (if pending at time of enrollment) to allow adequate time\\r\\n          for central review.\\r\\n\\r\\n  6. Informed Consent: All patients and/or their parents or legally authorized\\r\\n     representatives must sign a written informed consent. Assent, when appropriate, will\\r\\n     be obtained according to institutional guidelines.\\r\\n\\r\\n  7. Enrollment timeline: Patients are eligible to enroll on the TarGeT-SCR anytime\\r\\n     between diagnosis and the following specific timepoints post completion of RT\\r\\n\\r\\n       -  Patients screening through OPTION #1 are eligible to enroll anytime between\\r\\n          diagnosis and 10 days post RT.\\r\\n\\r\\n       -  Patients screening through OPTIONS #2 or #3 are eligible to enroll anytime\\r\\n          between diagnosis and 21 days post RT.\\r\\n\\r\\nHowever, it is important to note the following:\\r\\n\\r\\n  -  For treatment protocols that include targeted therapy administered concurrently with\\r\\n     RT, patients must start treatment within 10 calendar days of starting RT.\\r\\n\\r\\n  -  For treatment protocols that only include maintenance/adjuvant therapy (no systemic\\r\\n     therapy given concurrently with radiation), patients must start treatment by 35 days\\r\\n     post RT\\r\\n\\r\\n     #SCREENING OPTIONS\\r\\n\\r\\n  -  OPTION1: Molecular screening through CONNECT TarGeT Clinical Testing Laboratories\\r\\n\\r\\n  -  OPTION2: Molecular screening through a national comprehensive tumor profiling\\r\\n     program\\r\\n\\r\\n  -  OPTION3: Clinically validated targeted sequencing or focused profiling\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n-Tumors that do not meet HGG and DIPG diagnoses specified above',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '12 Months',\n",
       "    'maximumAge': '39 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT'],\n",
       "    'studyPopulation': 'Pediatric and young adult patients new diagnosed with High Grade Glioma including Diffuse\\r\\nIntrinsic Pontine Glioma (per 2021 WHO CNS tumor classification)',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Leonie Mikael, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '16147223284',\n",
       "      'email': 'leonie.mikael@nationwidechildrens.org'}],\n",
       "    'overallOfficials': [{'name': 'Maryam Fouladi, MD',\n",
       "      'affiliation': \"Nationwide Children's Hospital\",\n",
       "      'role': 'STUDY_CHAIR'},\n",
       "     {'name': 'Margot Lazow, MD',\n",
       "      'affiliation': \"Nationwide Children's Hospital\",\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': \"Children's Hospital Colorado\",\n",
       "      'city': 'Aurora',\n",
       "      'state': 'Colorado',\n",
       "      'zip': '80045',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kathleen H Dorris, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '720-777-8314',\n",
       "        'email': 'kathleen.dorris@childrenscolorado.org'}],\n",
       "      'geoPoint': {'lat': 39.72943, 'lon': -104.83192}},\n",
       "     {'facility': \"Children's National Medical Center\",\n",
       "      'city': 'Washington',\n",
       "      'state': 'District of Columbia',\n",
       "      'zip': '20010',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Eugene M Hwang, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '202-476-5046',\n",
       "        'email': 'ehwang@childrensnational.org'}],\n",
       "      'geoPoint': {'lat': 38.89511, 'lon': -77.03637}},\n",
       "     {'facility': \"Ann & Robert H. Lurie Children's Hospital of Chicago\",\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60611',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Ashley O Plant, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '312-227-4090',\n",
       "        'email': 'Aplant@luriechildrens.org'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "     {'facility': 'Dana-Farber Cancer Institute',\n",
       "      'city': 'Boston',\n",
       "      'state': 'Massachusetts',\n",
       "      'zip': '02215',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Susan C Chi, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '617-632-4386',\n",
       "        'email': 'Susan_chi@dfci.harvard.edu'}],\n",
       "      'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "     {'facility': 'Duke University Health System',\n",
       "      'city': 'Durham',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27708',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'David H Ashley, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '919-681-3824',\n",
       "        'email': 'david.ashley@duke.edu'}],\n",
       "      'geoPoint': {'lat': 35.99403, 'lon': -78.89862}},\n",
       "     {'facility': \"Cincinnati Children's Hospital Medical Center\",\n",
       "      'city': 'Cincinnati',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45229',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 39.12713, 'lon': -84.51435}},\n",
       "     {'facility': \"Nationwide Children's Hospital\",\n",
       "      'city': 'Columbus',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '43205',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Maryam Fouladi',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '614-722-5758',\n",
       "        'email': 'Maryam.fouladi@nationwidechildrens.org'}],\n",
       "      'geoPoint': {'lat': 39.96118, 'lon': -82.99879}},\n",
       "     {'facility': \"Children's Hospital of Philadelphia\",\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19104',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Michael J Fisher, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '215-590-5188',\n",
       "        'email': 'fisherm@email.chop.edu'}],\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}},\n",
       "     {'facility': \"Texas Children's Hospital\",\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77030',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Patricia Baxter, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '832-824-4681',\n",
       "        'email': 'pabaxter@txch.org'}],\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': \"Seattle Children's Hospital\",\n",
       "      'city': 'Seattle',\n",
       "      'state': 'Washington',\n",
       "      'zip': '98105',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Sarah Leary, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '206-987-2106',\n",
       "        'email': 'sarah.leary@seattlechildrens.org'}],\n",
       "      'geoPoint': {'lat': 47.60621, 'lon': -122.33207}},\n",
       "     {'facility': \"Sydney Children's Hospital\",\n",
       "      'city': 'Randwick',\n",
       "      'state': 'New South Wales',\n",
       "      'zip': '2031',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'David Ziegler, MBBS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61293821730',\n",
       "        'email': 'd.ziegler@unsw.edu.au'}],\n",
       "      'geoPoint': {'lat': -33.91439, 'lon': 151.24895}},\n",
       "     {'facility': \"Queensland Children's Hospital\",\n",
       "      'city': 'South Brisbane',\n",
       "      'state': 'Queensland',\n",
       "      'zip': '4101',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'Tim Hassall, MBBS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61730683593',\n",
       "        'email': 'tim.hassall@health.qld.gov.au'}],\n",
       "      'geoPoint': {'lat': -27.48034, 'lon': 153.02049}},\n",
       "     {'facility': \"Perth Children's Hospital\",\n",
       "      'city': 'Perth',\n",
       "      'state': 'Western Australia',\n",
       "      'zip': '6000',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'Nick Gottardo, MBChB',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61864560241',\n",
       "        'email': 'nick.gottardo@health.wa.gov.au'}],\n",
       "      'geoPoint': {'lat': -31.95224, 'lon': 115.8614}},\n",
       "     {'facility': 'The Hospital for Sick Children (SickKids)',\n",
       "      'city': 'Toronto',\n",
       "      'state': 'Ontario',\n",
       "      'zip': 'M5G1X8',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Eric Bouffet, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '4168137457',\n",
       "        'email': 'eric.bouffet@sickkids.ca'}],\n",
       "      'geoPoint': {'lat': 43.70011, 'lon': -79.4163}},\n",
       "     {'facility': \"Montreal Children's Hospital\",\n",
       "      'city': 'Montréal',\n",
       "      'state': 'Quebec',\n",
       "      'zip': 'H4A3J1',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Genevieve Legault, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '5144124400',\n",
       "        'phoneExt': '60497',\n",
       "        'email': 'Genevieve.legault4@mcgill.ca'}],\n",
       "      'geoPoint': {'lat': 45.50884, 'lon': -73.58781}},\n",
       "     {'facility': \"Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)\",\n",
       "      'city': 'Heidelberg',\n",
       "      'state': 'Baden-Württemberg',\n",
       "      'zip': '69120',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Olaf Witt, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0496221423570',\n",
       "        'email': 'o.witt@kitz-heidelberg.de'}],\n",
       "      'geoPoint': {'lat': 49.40768, 'lon': 8.69079}},\n",
       "     {'facility': 'Princess Máxima Center',\n",
       "      'city': 'Utrecht',\n",
       "      'zip': '3720',\n",
       "      'country': 'Netherlands',\n",
       "      'contacts': [{'name': 'Jasper van der Lugt, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '31 6 18559694',\n",
       "        'email': 'J.vanderLugt@prinsesmaximacentrum.nl'}],\n",
       "      'geoPoint': {'lat': 52.09083, 'lon': 5.12222}},\n",
       "     {'facility': 'Great Ormond Street Hospital',\n",
       "      'city': 'London',\n",
       "      'zip': 'WC1N 3JH',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Darren Hargrave, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '02078138525',\n",
       "        'email': 'darren.hargrave@nhs.net'}],\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005909',\n",
       "      'term': 'Glioblastoma'},\n",
       "     {'id': 'D000005910', 'term': 'Glioma'},\n",
       "     {'id': 'D000001254', 'term': 'Astrocytoma'},\n",
       "     {'id': 'D000080443', 'term': 'Diffuse Intrinsic Pontine Glioma'}],\n",
       "    'ancestors': [{'id': 'D000018302', 'term': 'Neoplasms, Neuroepithelial'},\n",
       "     {'id': 'D000017599', 'term': 'Neuroectodermal Tumors'},\n",
       "     {'id': 'D000009373', 'term': 'Neoplasms, Germ Cell and Embryonal'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009380', 'term': 'Neoplasms, Nerve Tissue'},\n",
       "     {'id': 'D000001932', 'term': 'Brain Neoplasms'},\n",
       "     {'id': 'D000016543', 'term': 'Central Nervous System Neoplasms'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000020295', 'term': 'Brain Stem Neoplasms'},\n",
       "     {'id': 'D000015192', 'term': 'Infratentorial Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M9019',\n",
       "      'name': 'Glioblastoma',\n",
       "      'asFound': 'Glioblastoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9020',\n",
       "      'name': 'Glioma',\n",
       "      'asFound': 'Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5209', 'name': 'Brain Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2159',\n",
       "      'name': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'asFound': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4561',\n",
       "      'name': 'Astrocytoma',\n",
       "      'asFound': 'Anaplastic Astrocytoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20446',\n",
       "      'name': 'Neoplasms, Neuroepithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20388',\n",
       "      'name': 'Neuroectodermal Tumors, Primitive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12318',\n",
       "      'name': 'Neoplasms, Germ Cell and Embryonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'},\n",
       "     {'id': 'M18937',\n",
       "      'name': 'Central Nervous System Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22108', 'name': 'Brain Stem Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17898', 'name': 'Infratentorial Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'T2518',\n",
       "      'name': 'Glioblastoma',\n",
       "      'asFound': 'Glioblastoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T2519',\n",
       "      'name': 'Glioma',\n",
       "      'asFound': 'Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1865',\n",
       "      'name': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'asFound': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T364',\n",
       "      'name': 'Anaplastic Astrocytoma',\n",
       "      'asFound': 'Anaplastic Astrocytoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06093503',\n",
       "    'orgStudyIdInfo': {'id': 'M22-142'},\n",
       "    'secondaryIdInfos': [{'id': '2022-502283-20-00',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'EU CT'}],\n",
       "    'organization': {'fullName': 'AbbVie', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein',\n",
       "    'officialTitle': 'Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-10',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-04-11', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-04-11', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-17',\n",
       "    'studyFirstSubmitQcDate': '2023-10-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-10-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-10-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Cancer is a condition where cells in a specific part of body grow and reproduce\\r\\nuncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which\\r\\ncancer cells form in the tissues of the lung. The purpose of this study is to assess how\\r\\ntelisotuzumab vedotin in combination with osimertinib affects the disease state compared\\r\\nto standard of care in adult participants with locally advanced/metastatic non-squamous\\r\\nNSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene and that\\r\\noverexpresses the c-Met protein. Change in disease activity will be assessed.\\r\\n\\r\\nTelisotuzumab vedotin is an investigational drug being developed for the treatment of\\r\\nNSCLC that overexpresses the c-Met protein. Participants are randomly placed in one of\\r\\nthe two groups to receive telisotuzumab vedotin and osimertinib or standard of care\\r\\nchemotherapy. Approximately 250 adult participants with locally advanced/metastatic\\r\\nnon-squamous NSCLC that has a mutation in the EGFR gene and that overexpresses the c-Met\\r\\nprotein will be enrolled in the study in approximately 180 sites worldwide.\\r\\n\\r\\nParticipants will receive intravenous telisotuzumab vedotin every 2 weeks in combination\\r\\nwith oral osimertinib tablets daily or standard of care chemotherapy\\r\\n(carboplatin/pemetrexed or cisplatin/pemetrexed as prescribed by the physician). Overall\\r\\nduration of the study is estimated to be approximately 47 months.\\r\\n\\r\\nThere may be higher treatment burden for participants in this trial compared to their\\r\\nstandard of care. Participants will attend regular visits during the study at a hospital\\r\\nor clinic. The effect of the treatment will be checked by medical assessments, blood\\r\\ntests, checking for side effects and completing questionnaires.'},\n",
       "   'conditionsModule': {'conditions': ['Non-Small Cell Lung Cancer'],\n",
       "    'keywords': ['Non-Small Cell Lung Cancer',\n",
       "     'Telisotuzumab Vedotin',\n",
       "     'ABBV-399',\n",
       "     'Osimertinib',\n",
       "     'Cisplatin',\n",
       "     'Carboplatin',\n",
       "     'Pemetrexed',\n",
       "     'c-Met',\n",
       "     'NSCLC',\n",
       "     'Teliso-V',\n",
       "     'TeliMET NSCLC-03']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Telisotuzumab Vedotin and Osimertinib',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive telisotuzumab vedotin every 2 weeks in combination with\\r\\nosimertinib, until disease progression or unacceptable toxicity.',\n",
       "      'interventionNames': ['Drug: Telisotuzumab Vedotin',\n",
       "       'Drug: Osimertinib']},\n",
       "     {'label': 'Standard of Care',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive standard of care chemotherapy (carboplatin/pemetrexed or\\r\\ncisplatin/pemetrexed as prescribed by the physician), until disease progression or\\r\\nunacceptable toxicity.',\n",
       "      'interventionNames': ['Drug: Cisplatin',\n",
       "       'Drug: Carboplatin',\n",
       "       'Drug: Pemetrexed']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Telisotuzumab Vedotin',\n",
       "      'description': 'Intravenous (IV) Infusion',\n",
       "      'armGroupLabels': ['Telisotuzumab Vedotin and Osimertinib'],\n",
       "      'otherNames': ['ABBV-399']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Osimertinib',\n",
       "      'description': 'Oral: Tablet',\n",
       "      'armGroupLabels': ['Telisotuzumab Vedotin and Osimertinib']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cisplatin',\n",
       "      'description': 'IV Infusion',\n",
       "      'armGroupLabels': ['Standard of Care']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Carboplatin',\n",
       "      'description': 'IV Infusion',\n",
       "      'armGroupLabels': ['Standard of Care']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Pemetrexed',\n",
       "      'description': 'IV Infusion',\n",
       "      'armGroupLabels': ['Standard of Care']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'PFS in the Population of Participants with no Central Nervous System (CNS) Metastases at Baseline',\n",
       "      'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic\\r\\nprogression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\\r\\nper ICR or death from any cause, whichever occurs earlier. Participants with no PFS event\\r\\nwill be censored at the last evaluable radiographic assessment per ICR. Participants with\\r\\nno event and no evaluable post-baseline assessment will be censored at randomization.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'PFS in the Overall Population',\n",
       "      'description': 'PFS is defined as the time from randomization to the first occurrence of radiographic\\r\\nprogression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\\r\\nper ICR or death from any cause, whichever occurs earlier.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'Overall Response (OR) in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': 'OR (per ICR) is defined as participants achieving a best overall response of confirmed\\r\\ncomplete response (CR) or confirmed partial response (PR) per ICR based on RECIST v1.1.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'OR in the Overall Population',\n",
       "      'description': 'OR (per ICR) is defined as participants achieving a best overall response of confirmed CR\\r\\nor confirmed PR per ICR based on RECIST v1.1.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'Duration of Response (DoR) in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': 'DoR is defined for confirmed responders as the time from the initial response (CR or PR)\\r\\nper ICR to the first occurrence of radiographic progression per RECIST v1.1 or death from\\r\\nany cause, whichever occurs first.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'DoR in the Overall Population',\n",
       "      'description': 'DoR is defined for confirmed responders as the time from the initial response (CR or PR)\\r\\nper ICR to the first occurrence of radiographic progression per RECIST v1.1 or death from\\r\\nany cause, whichever occurs first.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'Overall Survival (OS) in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': 'OS is defined as the time from randomization to the event of death from any cause.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'OS in the Overall Population',\n",
       "      'description': 'OS is defined as the time from randomization to the event of death from any cause.',\n",
       "      'timeFrame': 'Up to Approximately 41 Months'},\n",
       "     {'measure': 'Change in Physical Functioning using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': \"The EORTC QLQ-LC13 is the lung cancer specific module of the core EORTC QLQ-C30.2 The\\r\\nQLQ-LC13 includes 13 questions that include both multi-item and single-item scales of\\r\\nlung cancer-associated symptoms (e.g., pain, coughing, hemoptysis, and dyspnea) and\\r\\nside-effects from chemo- and radiotherapy (e.g., hair loss, neuropathy, sore mouth and\\r\\ndysphagia). With the exception of 2 pain questions, which have dichotomous response\\r\\ncategories (no or yes) and a free response if 'yes' is selected, all items on the\\r\\nQLQ-LC13 are scored on a 4-point Likert scale ranging from 1 (not at all) to (very much).\\r\\nThe items have a 1-week recall period. All scale and item scores are linearly transformed\\r\\nto a 0 to 100 scale, with higher scores representing increasing symptom levels or\\r\\nimpacts.\",\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Change in Physical Functioning using EORTC QLQ-LC13 in the Overall Population',\n",
       "      'description': \"The EORTC QLQ-LC13 is the lung cancer specific module of the core EORTC QLQ-C30.2 The\\r\\nQLQ-LC13 includes 13 questions that include both multi-item and single-item scales of\\r\\nlung cancer-associated symptoms (e.g., pain, coughing, hemoptysis, and dyspnea) and\\r\\nside-effects from chemo- and radiotherapy (e.g., hair loss, neuropathy, sore mouth and\\r\\ndysphagia). With the exception of 2 pain questions, which have dichotomous response\\r\\ncategories (no or yes) and a free response if 'yes' is selected, all items on the\\r\\nQLQ-LC13 are scored on a 4-point Likert scale ranging from 1 (not at all) to (very much).\\r\\nThe items have a 1-week recall period. All scale and item scores are linearly transformed\\r\\nto a 0 to 100 scale, with higher scores representing increasing symptom levels or\\r\\nimpacts.\",\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Change in Physical Functioning as Measured by the Physical Functioning Domain of the EORTC QLQ-C30 in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients\\r\\nparticipating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales\\r\\n(physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue,\\r\\npain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as\\r\\nwell as subscales assessing global health/quality of life and financial impact. Raw\\r\\nscores are transformed to a scale of 0 to 100, with higher scores representing better\\r\\nfunctioning/quality of life and greater symptom burden.',\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Change in Physical Functioning as Measured by the Physical Functioning Domain of the EORTC QLQ-C30 in the Overall Population',\n",
       "      'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients\\r\\nparticipating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales\\r\\n(physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue,\\r\\npain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as\\r\\nwell as subscales assessing global health/quality of life and financial impact. Raw\\r\\nscores are transformed to a scale of 0 to 100, with higher scores representing better\\r\\nfunctioning/quality of life and greater symptom burden.',\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Change in Quality of Life as Measured by the Global Health Status/Quality of Life Domain of the EORTC QLQ-C30 in the Population of Participants with no CNS Metastases at Baseline',\n",
       "      'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients\\r\\nparticipating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales\\r\\n(physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue,\\r\\npain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as\\r\\nwell as subscales assessing global health/quality of life and financial impact. Raw\\r\\nscores are transformed to a scale of 0 to 100, with higher scores representing better\\r\\nfunctioning/quality of life and greater symptom burden.',\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Change in Quality of Life as Measured by the Global Health Status/Quality of Life Domain of the EORTC QLQ-C30 in the Overall Population',\n",
       "      'description': 'The EORTC QLQ-C30 assesses health-related quality of life in cancer patients\\r\\nparticipating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales\\r\\n(physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue,\\r\\npain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as\\r\\nwell as subscales assessing global health/quality of life and financial impact. Raw\\r\\nscores are transformed to a scale of 0 to 100, with higher scores representing better\\r\\nfunctioning/quality of life and greater symptom burden.',\n",
       "      'timeFrame': 'Up to 41 Months'},\n",
       "     {'measure': 'Percentage of Participants With Adverse Events (AEs)',\n",
       "      'description': 'An AE is defined as any untoward medical occurrence in a participant or clinical\\r\\ninvestigation participant administered a pharmaceutical product which does not\\r\\nnecessarily have a causal relationship with the treatment. The investigator assesses the\\r\\nrelationship of each event to the use of study drug.',\n",
       "      'timeFrame': 'Up to 41 Months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Must have metastatic/locally advanced non-squamous NSCLC with documented epidermal\\r\\n     growth factor receptor (EGFR) mutation del19 or L858R, with or without T790M\\r\\n     mutation, and no identified EGFR mutations known to confer resistance to osimertinib\\r\\n     (for instance C797S).\\r\\n\\r\\n  -  Must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an\\r\\n     AbbVie designated immunohistochemistry (IHC) laboratory.\\r\\n\\r\\n  -  Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\\r\\n\\r\\n  -  Must have measurable disease per response evaluation criteria in solid tumors\\r\\n     (RECIST) version 1.1.\\r\\n\\r\\n  -  Must have received one prior regimen in the metastatic setting, consisting of a\\r\\n     third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor\\r\\n     (TKi) (for instance, osimertinib). Participant must have had one disease progression\\r\\n     while on this third generation EGFR TKi. Prior-rechallenge with a third generation\\r\\n     EGFR TKi is not allowed. Treatment with a first or second generation EGFR TKi\\r\\n     immediately prior to the third generation EGFR TKi will not count as one prior\\r\\n     regimen. Those who have received a third generation EGFR TKi as adjuvant therapy,\\r\\n     and have progressed within 6 months of the last dose of treatment will be eligible\\r\\n     (i.e., considered as having received a third generation EGFR TKi in the metastatic\\r\\n     setting).\\r\\n\\r\\n  -  Must be considered appropriate for platinum therapy based on the assessment of the\\r\\n     treating physician.\\r\\n\\r\\n  -  Participants with metastases to the central nervous system (CNS) are eligible only\\r\\n     after definitive therapy (such as surgery or radiotherapy) is provided and:\\r\\n\\r\\n       -  There is no evidence of progression of CNS metastases at least 4 weeks after\\r\\n          definitive therapy.\\r\\n\\r\\n       -  Participant is asymptomatic and off or on a stable or reducing dose of systemic\\r\\n          steroids and/or anticonvulsants for at least 4 weeks prior to first dose of\\r\\n          telisotuzumab vedotin.\\r\\n\\r\\n       -  There is no leptomeningeal seeding of the disease.\\r\\n\\r\\n  -  History of prior radiation pneumonitis in the radiation field (fibrosis) is\\r\\n     permitted.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Have adenosquamous histology, nor sarcomatoid features.\\r\\n\\r\\n  -  Alterations in ALK, ROS1, or BRAF that predict sensitivity to targeted therapies.\\r\\n\\r\\n  -  Have small-cell histology.\\r\\n\\r\\n  -  Have received prior chemotherapy in the metastatic setting. For the enrollment\\r\\n     criterion, if a subject has received one to two cycles of platinum-based\\r\\n     chemotherapy prior to starting a third generation EGFR TKi, without progression and\\r\\n     while awaiting EGFR status results, it will not be counted as \"prior platinum\\r\\n     therapy.\" Those who have received platinum-based chemotherapy as adjuvant therapy,\\r\\n     and have progressed within 6 months of the last dose will be counted as having\\r\\n     received a prior platinum therapy in the metastatic setting.\\r\\n\\r\\n  -  Have a history of other malignancies except those listed in the protocol.\\r\\n\\r\\n  -  Have a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,\\r\\n     bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or\\r\\n     evidence of active pneumonitis on screening chest computed tomography (CT) scan.\\r\\n\\r\\n  -  Have unresolved adverse events (AEs) >= Grade 2 from prior anticancer therapy,\\r\\n     except for alopecia or anemia.\\r\\n\\r\\n  -  Have had major surgery within 21 days prior to the first dose of telisotuzumab\\r\\n     vedotin.\\r\\n\\r\\n  -  Have clinically significant condition(s) including but not limited to those listed\\r\\n     in the protocol.\\r\\n\\r\\n  -  Clinically significant liver disease, including hepatitis, current alcohol abuse, or\\r\\n     cirrhosis.\\r\\n\\r\\n  -  Grade >= 2 edema or lymphedema.\\r\\n\\r\\n  -  Grade >= 2 ascites or pleural effusion.\\r\\n\\r\\n  -  Grade >= 2 neuropathy.\\r\\n\\r\\n  -  Active uncontrolled bacterial or viral infection.\\r\\n\\r\\n  -  Active corneal disorder.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'ABBVIE CALL CENTER',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '844-663-3742',\n",
       "      'email': 'abbvieclinicaltrials@abbvie.com'}],\n",
       "    'overallOfficials': [{'name': 'ABBVIE INC.',\n",
       "      'affiliation': 'AbbVie',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Related Info',\n",
       "      'url': 'https://www.abbvieclinicaltrials.com/study/?id=M22-142'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor.\\r\\nThis includes access to anonymized, individual and trial-level data (analysis data sets),\\r\\nas well as other information (e.g., protocols, analyses plans, clinical study reports),\\r\\nas long as the trials are not part of an ongoing or planned regulatory submission. This\\r\\nincludes requests for clinical trial data for unlicensed products and indications.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'],\n",
       "    'timeFrame': 'For details on when studies are available for sharing visit\\r\\nhttps://vivli.org/ourmember/abbvie/',\n",
       "    'accessCriteria': 'Access to this clinical trial data can be requested by any qualified researchers who\\r\\nengage in rigorous independent scientific research, and will be provided following review\\r\\nand approval of a research proposal and statistical analysis plan and execution of a data\\r\\nsharing statement. Data requests can be submitted at any time after approval in the US\\r\\nand/or EU and a primary manuscript is accepted for publication. For more information on\\r\\nthe process, or to submit a request, visit the following link\\r\\nhttps://www.abbvieclinicaltrials.com/hcp/data-sharing/',\n",
       "    'url': 'https://vivli.org/ourmember/abbvie/'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008175',\n",
       "      'term': 'Lung Neoplasms'},\n",
       "     {'id': 'D000002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}],\n",
       "    'ancestors': [{'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000002283', 'term': 'Carcinoma, Bronchogenic'},\n",
       "     {'id': 'D000001984', 'term': 'Bronchial Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M5546',\n",
       "      'name': 'Carcinoma, Non-Small-Cell Lung',\n",
       "      'asFound': 'Non-Small Cell Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11172',\n",
       "      'name': 'Lung Neoplasms',\n",
       "      'asFound': 'Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20559', 'name': 'Disease Progression', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'},\n",
       "     {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000016190',\n",
       "      'term': 'Carboplatin'},\n",
       "     {'id': 'D000068437', 'term': 'Pemetrexed'},\n",
       "     {'id': 'C000596361', 'term': 'Osimertinib'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000005493', 'term': 'Folic Acid Antagonists'},\n",
       "     {'id': 'D000019384', 'term': 'Nucleic Acid Synthesis Inhibitors'},\n",
       "     {'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M18650',\n",
       "      'name': 'Carboplatin',\n",
       "      'asFound': 'System',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M145673',\n",
       "      'name': 'Osimertinib',\n",
       "      'asFound': 'Angioplasty',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M264',\n",
       "      'name': 'Pemetrexed',\n",
       "      'asFound': 'Strategies',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'},\n",
       "     {'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'},\n",
       "     {'id': 'M8619', 'name': 'Folic Acid Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T447', 'name': 'Folinic Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'},\n",
       "     {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'},\n",
       "     {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Micro', 'name': 'Micronutrients'},\n",
       "     {'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'Vi', 'name': 'Vitamins'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06431243',\n",
       "    'orgStudyIdInfo': {'id': 'ZLPM-003-1.0'},\n",
       "    'organization': {'fullName': 'Chengdu Zenitar Biomedical Technology Co., Ltd',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors',\n",
       "    'officialTitle': 'An Open, Multicenter Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Combination of Puesta Mesylate for Injection in the Treatment of Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-11-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-20',\n",
       "    'studyFirstSubmitQcDate': '2024-05-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Chengdu Zenitar Biomedical Technology Co., Ltd',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Primary Purpose Phase Ib Evaluate the safety and tolerability of the combination of\\r\\npuesta mesylate in the treatment of advanced solid tumors; and explore the dose-limiting\\r\\ntoxicity (DLT) and maximum tolerated dose (MTD) of the combination of puesta mesylate in\\r\\npatients with advanced solid tumors; Determine the recommended phase II dose (RP2D) for\\r\\nthe combination of puesta mesylate in the treatment of advanced solid tumors.\\r\\n\\r\\nPhase IIa. To further evaluate the preliminary efficacy of the combination of puesta\\r\\nmesylate in patients with advanced solid tumors.\\r\\n\\r\\nSecondary objective Phase Ib Evaluate the safety and tolerability of poystat mesylate\\r\\nmonotherapy in advanced solid tumors; To evaluate the preliminary efficacy of the\\r\\ncombination of poystat mesylate in patients with advanced solid tumors; To evaluate the\\r\\npharmacokinetic profile of the combination of puesta mesylate in the treatment of\\r\\nadvanced solid tumors.\\r\\n\\r\\nPhase IIa To further evaluate the safety and tolerability of the combination of puesta\\r\\nmesylate in the treatment of advanced solid tumors; To evaluate the pharmacokinetic\\r\\nprofile of the combination of puesta mesylate in the treatment of advanced solid tumors.\\r\\n\\r\\nExploratory Objective. To evaluate the pharmacodynamic significance of biomarkers in the\\r\\ncombination of puesta mesylate for the treatment of advanced solid tumors.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'A group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'In Cohort A, subjects in the ascending-dose group received PM IV, administered at a\\r\\nfrequency of BiW (2 times per week) for 2 weeks, i.e., on days 1, 4, 8, and 11 of each\\r\\ncycle, with a 1-week discontinuation to allow for a 21-day cycle (with a minimum interval\\r\\nof ≥48 h between each of the 2 doses within the same dosing cycle), and exemestane was\\r\\nadministered orally once a day within 30 min after the end of breakfast as one tablet (\\r\\n25 mg). Based on the results obtained in the dose-escalation phase, the necessity of the\\r\\nphase IIa expansion cohort and the dose of PM to be administered will be decided after\\r\\ndiscussion by the SMC, and the phase IIa cohort expansion is expected to select 1-2 dose\\r\\ngroups of 10-15 cases each, with a total of 19-54 cases in this cohort',\n",
       "      'interventionNames': ['Drug: A group Purinostat Mesylate 6mg/m2',\n",
       "       'Drug: A group Purinostat Mesylate 8.4mg/m2',\n",
       "       'Drug: A group Purinostat Mesylate 11.2mg/m2',\n",
       "       'Drug: A group Purinostat Mesylate 15.0mg/m2']},\n",
       "     {'label': 'B group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'In Cohort B, subjects in the ascending dose group all received PM IV drip administered at\\r\\na frequency of BiW (2 times per week) for 2 consecutive weeks, i.e., on days 1, 4, 8, and\\r\\n11 of each cycle, with a 1-week discontinuation for a 21-day cycle (with a minimum\\r\\ninterval of ≥48 h between each of the 2 doses in the same dosing cycle). Tirelizumab was\\r\\nadministered as 200 mg IV every 3 weeks, administered on the first day of each cycle.\\r\\nBased on the results obtained during the dose-escalation phase, the need for and the dose\\r\\nof the Phase IIa expansion cohort will be determined after discussion by the Safety\\r\\nManagement Committee (SMC), and the Phase IIa cohort expansion is expected to select 1-2\\r\\ndosage groups of 10-15 cases each.',\n",
       "      'interventionNames': ['Drug: B group Purinostat Mesylate 6.0mg/m2',\n",
       "       'Drug: B group Purinostat Mesylate 8.4 mg/m2',\n",
       "       'Drug: B group Purinostat Mesylate 11.2 mg/m2',\n",
       "       'Drug: B group Purinostat Mesylate 15.0 mg/m2']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'A group Purinostat Mesylate 6mg/m2',\n",
       "      'description': 'Purinostat Mesylate 6mg/m2 + EM 25mg',\n",
       "      'armGroupLabels': ['A group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'A group Purinostat Mesylate 8.4mg/m2',\n",
       "      'description': 'Purinostat Mesylate 8.4mg/m2 + EM 25mg',\n",
       "      'armGroupLabels': ['A group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'A group Purinostat Mesylate 11.2mg/m2',\n",
       "      'description': 'Purinostat Mesylate 11.2mg/m2 + EM 25mg',\n",
       "      'armGroupLabels': ['A group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'A group Purinostat Mesylate 15.0mg/m2',\n",
       "      'description': 'Purinostat Mesylate 15.0mg/m2 + EM 25mg',\n",
       "      'armGroupLabels': ['A group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'B group Purinostat Mesylate 6.0mg/m2',\n",
       "      'description': 'Purinostat Mesylate 6.0mg/m2 + Tislelizumab 200mg',\n",
       "      'armGroupLabels': ['B group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'B group Purinostat Mesylate 8.4 mg/m2',\n",
       "      'description': 'Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg',\n",
       "      'armGroupLabels': ['B group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'B group Purinostat Mesylate 11.2 mg/m2',\n",
       "      'description': 'Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg',\n",
       "      'armGroupLabels': ['B group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'B group Purinostat Mesylate 15.0 mg/m2',\n",
       "      'description': 'Purinostat Mesylate 15.0mg/m2 + Tislelizumab 200mg',\n",
       "      'armGroupLabels': ['B group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective remission rate (ORR)',\n",
       "      'description': 'defined as the proportion of subjects with an overall efficacy response of complete\\r\\nremission (CR) or partial remission (PR) after at least one baseline evaluation during\\r\\nthe trial.',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Complete Remission Rate (CRR)',\n",
       "      'description': 'defined as the proportion of subjects with an overall efficacy response of CR after at\\r\\nleast one baseline evaluation during the trial;',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'},\n",
       "     {'measure': 'Disease Control Rate (DCR)',\n",
       "      'description': 'defined as the proportion of subjects with an overall efficacy response of CR, PR and\\r\\nstable disease (SD) after at least one baseline evaluation during the trial;',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'},\n",
       "     {'measure': 'Duration of remission (DOR)',\n",
       "      'description': 'defined as the duration from first remission (PR and above) to disease progression or\\r\\ndeath;',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'},\n",
       "     {'measure': 'Time to Tumor Remission (TTR)',\n",
       "      'description': 'defined as the time from first dose to the appearance of PR and beyond;',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'},\n",
       "     {'measure': 'Progression-free survival (PFS)',\n",
       "      'description': 'defined as the time from first dose to disease progression or death',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'defined as the time from first dose to death.',\n",
       "      'timeFrame': 'Second cycle Day 30 / Fourth cycle Day 60 / Sixth cycle Day 90 (each cycle is 21 days)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. age: ≥18 years and ≤75 years, regardless of gender;\\r\\n\\r\\n  2. at least one measurable lesion as defined by RECIST 1.1 in the Screening Phase\\r\\n     (non-measurable lesions with simple bone metastases only are acceptable in the Dose\\r\\n     Escalation Phase of the Breast Cancer Cohort);\\r\\n\\r\\n  3. single-agent dose-escalation phase in Phase Ib: Locally advanced or metastatic solid\\r\\n     tumors, including but not limited to triple-negative breast cancer, colorectal\\r\\n     cancer, and uroepithelial carcinoma, that have been diagnosed by histologic or\\r\\n     cytologic confirmation of pathology and have failed standard therapy, or for which\\r\\n     there is no standard treatment regimen available or for which standard therapy is\\r\\n     not appropriate at this stage;\\r\\n\\r\\nPhase Ib Combination Dose Escalation Phase:\\r\\n\\r\\n  1. Combination exemestane for Cohort A (breast cancer):\\r\\n\\r\\n     Perimenopausal, premenopausal, and postmenopausal women with breast cancer confirmed\\r\\n     by histopathology or cytologic pathology to be estrogen receptor (ER)-positive,\\r\\n     progesterone receptor (PgR)-negative or -positive, and non-HER2-positive (including\\r\\n     HER2-negative and low-expressing populations); Progression or recurrence after at\\r\\n     least 1 line of prior endocrine therapy (whether at advanced stage, in the setting\\r\\n     of metastasis, or with neoadjuvant chemotherapy), and prior availability of no more\\r\\n     than 1 line of chemotherapy (note: if prior endocrine therapy was adjuvant to\\r\\n     exemestane, the disease-free interval after discontinuation of exemestane needs to\\r\\n     be >12 months); Not suitable for surgical resection therapy; Definition of menopause\\r\\n     is subject to one of the following conditions: a) prior bilateral oophorectomy; b)\\r\\n     60 years of age and older; c) younger than 60 years of age, not on chemotherapy,\\r\\n     tamoxifen, toremifene, or ovarian suppression therapy within one year prior to\\r\\n     enrollment, who has been naturally menopausal for more than 12 months, and whose\\r\\n     serum follicle-stimulating hormone and oestradiol are at postmenopausal levels; d)\\r\\n     younger than 60 years of age, who is undergoing tamoxifen moxifene or toremifene\\r\\n     therapy, and serum follicle-stimulating hormone and estradiol levels are in the\\r\\n     postmenopausal range for two consecutive periods; e). Failure to meet the above\\r\\n     criteria is considered to be in the premenopausal or perimenopausal period, and\\r\\n     female subjects will be required to meet the following criteria: initiation of a\\r\\n     luteinizing hormone-releasing hormone (LHRH) agonist, such as goserelin, leuprolide,\\r\\n     etc., at least 28 ± 2 prior to the first administration of study drug (hormone level\\r\\n     eligibility will be required for those who have been on an LHRH agonist for ≥ 21\\r\\n     days and < 26 days prior to the first administration of the study drug), and the\\r\\n     subject requires continued use of this class of medication for the duration of study\\r\\n     treatment;\\r\\n\\r\\n  2. Combination tirilizumab for treatment of Cohort B (solid tumors):\\r\\n\\r\\nPatients with locally advanced or metastatic solid tumors who have a cytologically or\\r\\nhistologically confirmed diagnosis and have failed standard therapy, or for whom there is\\r\\nno standard therapeutic regimen, or for whom standard therapy is not appropriate at this\\r\\nstage, as defined by standard therapy failure for each tumor type below:\\r\\n\\r\\nNon-small cell lung cancer: (1) patients with metastatic no driver mutation: disease\\r\\nprogression or recurrence after at least second-line treatment (including\\r\\nplatinum-containing chemotherapy); (2) patients whose tumors have driver mutations such\\r\\nas EGFR, ROS1, ALK, etc., should have received a failed targeted therapy against these\\r\\nmutations, and then after at least second-line treatment (including platinum-containing\\r\\nchemotherapy) disease progression or recurrence; Small cell lung cancer: disease\\r\\nprogression or recurrence after at least two lines of prior therapy; Colorectal cancer:\\r\\ndisease progression or recurrence after at least two lines of prior therapy (standard\\r\\nchemotherapy regimens received include fluorouracil or its derivatives, oxaliplatin, and\\r\\nirinotecan, BRAF inhibitors for patients with BRAF V600E mutation, and PD-1/PD-L1 therapy\\r\\nfor those who meet the MSI-H/dMMR criteria). (treatment); Squamous cell carcinoma of the\\r\\nhead and neck: disease progression or recurrence after at least two lines of prior\\r\\ntherapy, including platinum-containing chemotherapy; Uroepithelial carcinoma: disease\\r\\nprogression or recurrence after at least two lines of prior therapy\\r\\n(guideline-recommended regimens include PD-1/PD-L1 therapy, platinum-containing\\r\\nchemotherapy regimens, paclitaxel-based chemotherapy regimens, vediclizumab, and\\r\\nvincristine, and erdatinib has been used in patients with FGFR2/3 mutations); Esophageal\\r\\ncancer: disease progression or recurrence after at least two lines of prior therapy,\\r\\nincluding platinum-containing chemotherapy; cervical cancer: disease progression or\\r\\nrecurrence after at least two lines of prior therapy (including platinum-containing\\r\\nchemotherapy; patients meeting the criteria for PD-L1 positivity or TMB-H or MSI-H/dMMR\\r\\nneed to have been treated with PD-1/PD-L1) Hepatocellular carcinoma: Disease progression\\r\\nor recurrence after at least two lines of prior therapy; Renal cell carcinoma: disease\\r\\nprogression or recurrence after at least two lines of prior therapy;\\r\\n\\r\\nPhase IIa Dose Expansion Phase:\\r\\n\\r\\nThe tumor type and tumor tissue biomarker requirements for each expansion cohort enrolled\\r\\nin Phase IIa will be based on Phase Ib data and SMC discussion for further decision\\r\\nmaking; 4. ECOG ≤ 1 point; 5. expected survival ≥ 12 weeks; 6. organ function levels must\\r\\nmeet the following requirements:\\r\\n\\r\\n  1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L;\\r\\n\\r\\n  2. Hemoglobin (HGB) ≥ 90 g/L;\\r\\n\\r\\n  3. Platelet count (PLT) ≥100×109/L;\\r\\n\\r\\n  4. serum creatinine ≤1.5 × ULN or estimated creatinine clearance ≥60 mL/min (according\\r\\n     to the Cockcroft and Gault formula);\\r\\n\\r\\n  5. serum total bilirubin (TBil) ≤ 1.5 x ULN, allowing TBil > 1.5 x ULN but direct\\r\\n     bilirubin (DBil) < ULN for subjects with hepatic metastases or GILBERT syndrome; and\\r\\n     AST and ALT ≤ 2.5 x ULN, allowing AST/ALT ≤ 5 x ULN for subjects with hepatic\\r\\n     metastases or GILBERT syndrome; 7. those who agree to participate in this study and\\r\\n     sign the informed consent form; 8. remission of all acute toxicities from prior\\r\\n     anticancer therapy or surgery to baseline severity or NCI-CTCAE version 5.0 ≤ Grade\\r\\n     1 (with the exception of alopecia or other toxicities deemed by the investigator to\\r\\n     pose no safety risk to the patient).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. a known severe allergy to the study drug, combination drug, or any of its excipients\\r\\n     (hydroxypropyl betacyclodextrin, arginine, glucosamine, mannitol);\\r\\n\\r\\n  2. current or prior other malignancy (except adequately treated basal cell or squamous\\r\\n     cell carcinoma of the skin, or carcinoma in situ of the uterine cervix) unless\\r\\n     treated radically and with evidence of recurrence-free metastasis within the last 5\\r\\n     years;\\r\\n\\r\\n  3. symptomatic central nervous system (CNS) metastases or asymptomatic CNS metastases\\r\\n     requiring steroid therapy within 2 weeks prior to the first dose of study drug.\\r\\n     Subjects with carcinomatous meningitis or molluscum contagiosum spread;\\r\\n\\r\\n  4. last systemic antineoplastic therapy (chemotherapy, targeted therapy, immunotherapy,\\r\\n     biologic agent therapy, etc.) within 4 weeks prior to the first PM administration,\\r\\n     with the following stipulations: nitrosoureas (e.g., carmustine, lomustine, etc.) or\\r\\n     mitomycin C within 6 weeks prior to the first administration of the study drug; oral\\r\\n     fluorouracil, small molecule targeted drugs within 2 weeks prior to the first\\r\\n     administration of the study drug, or within 2 weeks prior to the first\\r\\n     administration of a known drug within 5 half-lives (whichever is longer); local\\r\\n     palliative radiotherapy within 2 weeks prior to the first administration of study\\r\\n     drug; final administration of endocrine therapy within 4 weeks prior to the first\\r\\n     administration of study drug; and receipt of herbal or proprietary Chinese medicine\\r\\n     with an antitumor indication within 2 weeks prior to the first administration of\\r\\n     study drug;\\r\\n\\r\\n  5. patients who have received a prior HDAC inhibitor;\\r\\n\\r\\n  6. patients with prior exemestane therapy are not eligible for enrollment in the\\r\\n     combination exemestane treatment cohort, but are permitted to be included if the\\r\\n     patient has a disease-free interval DFI of >12 months after exemestane adjuvant\\r\\n     therapy;\\r\\n\\r\\n  7. patients previously treated with anti-PD-1/PD-L1 antibodies are not eligible for\\r\\n     enrollment in the combination tirilizumab treatment cohort, unless the patient has\\r\\n     had a prior benefit after treatment in the advanced/metastatic phase* then inclusion\\r\\n     is permitted;\\r\\n\\r\\n       -  Benefit following anti-PD-1/PD-L1 antibody therapy is defined as meeting any of\\r\\n          the following:\\r\\n\\r\\n            1. Best efficacy of CR or PR as assessed by imaging after receiving\\r\\n               anti-PD-1/PD-L1 antibody therapy alone or in combination with\\r\\n               targeted/other immunologic agents;\\r\\n\\r\\n            2. Treatment with anti-PD-1/PD-L1 antibody in combination with chemotherapy\\r\\n               with no imaging evidence of disease progression within ≤ 6 months of\\r\\n               treatment.\\r\\n\\r\\n  8. those who have had a serious infection within 4 weeks prior to the first\\r\\n     administration of PM, or who have had an active infection requiring oral or\\r\\n     intravenous antibiotic therapy within the previous 2 weeks;\\r\\n\\r\\n  9. receiving blood transfusions, recombinant human thrombopoietin, recombinant human\\r\\n     interleukin-11, erythropoietin, and granulocyte colony-stimulating factor within 2\\r\\n     weeks prior to the first dose of study drug;\\r\\n\\r\\n 10. breast cancer: symptomatic, advanced patients who have disseminated to viscera and\\r\\n     are at short-term risk of life-threatening complications (patients with visceral\\r\\n     crises), patients with inflammatory breast cancer;\\r\\n\\r\\n 11. prior immune-related adverse events of grade ≥3 on immunotherapy are not eligible\\r\\n     for enrollment in the combination tirilizumab treatment cohort;\\r\\n\\r\\n 12. patients with active or pre-existing autoimmune disease with potential for relapse\\r\\n     (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.) are not\\r\\n     eligible for enrollment in the cohort of co-tirilizumab; the following patients are\\r\\n     allowed: patients with type I diabetes mellitus, and patients with autoimmune\\r\\n     thyroiditis who may be eligible for alternative therapy;\\r\\n\\r\\n 13. Patients who have received systemically administered corticosteroids (prednisone >\\r\\n     10 mg/day or equivalent) or other immunosuppressive agents within 14 days prior to\\r\\n     the first dose of PM are not eligible for enrollment in the cohort of co-tirilizumab\\r\\n     therapy; except for the following: treatment with topical, ophthalmic,\\r\\n     intra-articular, intranasal, and inhaled corticosteroids, and short-term\\r\\n     prophylactic use of corticosteroids, eg. use of contrast media.\\r\\n\\r\\n 14. have uncontrolled or significant cardiovascular disease, including: (1) New York\\r\\n     Heart Association (NYHA) Class II or greater congestive heart failure, unstable\\r\\n     angina, myocardial infarction within 6 months prior to the first dose of PM, or the\\r\\n     presence of an arrhythmia requiring treatment, left ventricular ejection fraction\\r\\n     (LVEF) <50% at screening; (2) Primary cardiomyopathy (e.g., dilated cardiomyopathy,\\r\\n     hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy,\\r\\n     restrictive cardiomyopathy, undetermined cardiomyopathy); (3) Screening-phase\\r\\n     symptomatic coronary heart disease requiring pharmacologic treatment; (4) A history\\r\\n     of clinically significant QTcF interval prolongation or a mean corrected QT interval\\r\\n     (QTc) >450 msec (men) or >470 msec (women) on 3 electrocardiograms (ECGs) of the\\r\\n     QTcF interval during the screening period (retesting is required and 3 average\\r\\n     corrected values are taken only if the first ECG suggests that the QTc is >450 msec\\r\\n     (men) or >470 msec (women)). (only the first ECG suggesting a QTc >450 msec (men) or\\r\\n     >470 msec (women) needs to be retested and averaged over 3 corrections); a history\\r\\n     of long QT syndrome or a confirmed family history of long QT syndrome; a history of\\r\\n     clinically significant ventricular arrhythmia or current use of antiarrhythmic\\r\\n     medications or implantation of defibrillation devices for the treatment of\\r\\n     ventricular arrhythmias; (5) Cerebrovascular accident (including cerebral\\r\\n     hemorrhage, cerebral infarction, transient ischemic attack, etc.) within 6 months\\r\\n     prior to the first dose of PM; (6) Inadequate blood pressure control during the\\r\\n     screening period (whether or not on antihypertensive medication): systolic blood\\r\\n     pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; (7) Other cardiovascular\\r\\n     diseases judged by the investigator to be inappropriate for enrollment.\\r\\n\\r\\n 15. Uncontrolled electrolyte disturbances that may interfere with the action of QTc\\r\\n     prolonging medications (e.g., hypocalcemia <1.0 mmol/L, hypokalemia <lower limit of\\r\\n     normal, hypomagnesemia <0.5 mmol/L), but retesting after interventional therapy is\\r\\n     permitted;\\r\\n\\r\\n 16. current or past history of interstitial lung disease of any severity and/or severely\\r\\n     impaired lung function;\\r\\n\\r\\n 17. the presence of third interstitial fluid (e.g., pleural fluid and ascites) that\\r\\n     cannot be controlled by drainage or other means;\\r\\n\\r\\n 18. major surgical procedures requiring general anesthesia or not withdrawn from other\\r\\n     clinical trials within 4 weeks prior to the first dose of PM; surgical procedures\\r\\n     requiring local/epidural anesthesia from which the patient has not recovered (except\\r\\n     for tissue biopsy) within 2 weeks prior to enrollment;\\r\\n\\r\\n 19. clinically significant active infection of the following, including hepatitis B\\r\\n     (HBV) and hepatitis C (HCV). Active hepatitis B was defined as subjects who were\\r\\n     HBsAg-positive or HBcAb-positive with HBV-DNA above the lower limit of detection\\r\\n     (i.e., the upper limit of normal values in the testing department of each study\\r\\n     center), who achieved HBV-DNA negativity after antiviral treatment, who received\\r\\n     antiviral medications for at least 2 weeks prior to the first dose of medication,\\r\\n     and who were willing to continue to be treated with anti-hepatitis B virus for the\\r\\n     duration of the study were allowed to enroll in the study, and active Hepatitis C\\r\\n     was defined as HCV antibody positivity and HCV-RNA above the lower limit of\\r\\n     detection (upper limit of normal). Positive syphilis spirochete antibody (TP-Ab) and\\r\\n     positive syphilis non-specific antibody titer (RPR);\\r\\n\\r\\n 20. a history of immunodeficiency, including a positive test for antibodies to human\\r\\n     immunodeficiency virus (HIV), or other acquired, congenital immunodeficiency\\r\\n     disease, or a history of organ transplantation;\\r\\n\\r\\n 21. participation in another interventional clinical trial within 4 weeks prior to\\r\\n     enrollment;\\r\\n\\r\\n 22. female patients who are pregnant or breastfeeding or who are unable to ensure the\\r\\n     use of contraception during the study period and for at least 6 months after the\\r\\n     last treatment with poystat\\r\\n\\r\\n 23. other serious acute or chronic medical or psychiatric conditions or abnormal\\r\\n     laboratory tests that may increase the risk of participation in the study or\\r\\n     increase the risk associated with administration of the study drug or interfere with\\r\\n     the results of the study, and other conditions that, in the opinion of the\\r\\n     investigator, make the patient unsuitable for participation in this study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Liangkun Sun, bachelor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '15885742617',\n",
       "      'email': 'bailing_stt@126.com'},\n",
       "     {'name': 'Zheng Jiang, bachelor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '19048075294',\n",
       "      'email': 'zhengjiang@zenitar.cn'}],\n",
       "    'overallOfficials': [{'name': 'Herui Yao, Doctor',\n",
       "      'affiliation': 'Sun Yat-sen Memorial Hospital,Sun Yat-sen University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Yongsheng Wang, Doctor',\n",
       "      'affiliation': 'West China Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University',\n",
       "      'city': 'Guanzhou',\n",
       "      'state': 'Guangzhou',\n",
       "      'zip': '510000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Liushan Qu',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '020-81332587',\n",
       "        'email': 'sysyxllwyh@163.com'}]},\n",
       "     {'facility': 'Chengdu Xinhua Hospital',\n",
       "      'city': 'Chengdu',\n",
       "      'state': 'Sichuan',\n",
       "      'zip': '610000',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M137899',\n",
       "      'name': 'Tislelizumab',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M247237', 'name': 'Exemestane', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06271538',\n",
       "    'orgStudyIdInfo': {'id': 'EP-USM-122023-001'},\n",
       "    'organization': {'fullName': 'EP Plus Group Sdn Bhd', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome',\n",
       "    'officialTitle': 'A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-03-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-14',\n",
       "    'studyFirstSubmitQcDate': '2024-02-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'EP Plus Group Sdn Bhd', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'The objective of this randomized, double-blind, placebo-controlled study is to evaluate\\r\\nthe effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency,\\r\\nimproving quality of life, and addressing psychological distress in individuals diagnosed\\r\\nwith irritable bowel syndrome (IBS), as compared to those who receive no intervention.',\n",
       "    'detailedDescription': 'Irritable bowel syndrome (IBS) is a condition linked to disturbances in the gut-brain\\r\\naxis and dysbiosis. Although probiotic modulation of dysbiosis appears promising for IBS\\r\\ntreatment, identifying the specific beneficial strains remains uncertain. Furthermore,\\r\\neven with an effective probiotic strain, variations in efficacy among populations are\\r\\nobserved due to environmental heterogeneity, particularly dietary influences.\\r\\n\\r\\nThis study seeks to provide efficacy insights into Skal Pro powder 2g (containing\\r\\nLactobacillus plantarum 299v 1x10^10 colony forming unit (CFU) and GOS), shedding light\\r\\non the unique mechanisms of LP299V within the Malaysian population through a randomized\\r\\ncontrolled trial (RCT).'},\n",
       "   'conditionsModule': {'conditions': ['Irritable Bowel Syndrome',\n",
       "     'Gastrointestinal Diseases',\n",
       "     'Colonic Diseases, Functional',\n",
       "     'Intestinal Disease',\n",
       "     'Digestive System Disease',\n",
       "     'Pathologic Processes',\n",
       "     'Colonic Disease',\n",
       "     'Disease'],\n",
       "    'keywords': ['probiotic',\n",
       "     'Lactobacillus plantarum 299v',\n",
       "     'randomized controlled study']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Skal Pro',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Skal Pro in the form of 2g sachet powder contains 10 billion CFU of freeze-dried\\r\\nLactobacillus plantarum 299v (LP299V) and galactooligosaccharides (GOS).',\n",
       "      'interventionNames': ['Combination Product: Skal Pro']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo is an oral formulation of inert powder. Placebo and Skal Pro are identical in\\r\\nshape, size, colour, packaging and taste.',\n",
       "      'interventionNames': ['Other: Placebo']}],\n",
       "    'interventions': [{'type': 'COMBINATION_PRODUCT',\n",
       "      'name': 'Skal Pro',\n",
       "      'description': 'One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10^10 CFU and GOS',\n",
       "      'armGroupLabels': ['Skal Pro']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro\\r\\nsachet',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Improving the severity of symptoms in individuals with IBS, assessed by IBS Symptom Severity Scale (IBSSSS)',\n",
       "      'description': 'IBSSS questionnaire contains five questions that measures, on a 100-point visual analogue\\r\\nscale (VAS), the severity of abdominal pain, the frequency of abdominal pain, the\\r\\nseverity of abdominal distension, dissatisfaction with bowel habits, and interference\\r\\nwith quality of life (QOL). All five components contribute to the scores equally,\\r\\nyielding a theoretically range of 0 - 500, with a higher score indicating worse\\r\\ncondition. The Malay version questionnaire will be used.',\n",
       "      'timeFrame': 'Assessed at baseline, Week 1, Week 2, and Week 4.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change in stool consistency (Bristol Stool Scale), assessed by daily stool diary',\n",
       "      'description': 'Daily diary of stool consistency of each bowel movement based on Bristol Stool Scale\\r\\n(Type 1-7), from type 1-2 = separate hard lump stool, type 3-4= ideal stool, type 5-7\\r\\n=loose stool',\n",
       "      'timeFrame': 'Assessed daily from baseline to Week 4.'},\n",
       "     {'measure': 'Change in stool frequency and satisfaction after passing stool, assessed by daily stool diary',\n",
       "      'description': 'Daily diary of number of bowel movements.',\n",
       "      'timeFrame': 'Assessed daily from baseline to Week 4.'},\n",
       "     {'measure': 'Change in abdominal bloating, assessed by Bloating Severity Questionnaire (BSQ)',\n",
       "      'description': 'Originally developed by Thiwan et al., this research group then translated and validated\\r\\nthe BSQ in the Malay language (BSQ-M) [13]. There are 2 sub-scales, the 6-item Sev-Gen\\r\\n(Severity-General) and 5-item Sev-24 (Severity-24 hour) with responses in seven-point\\r\\nLikert scale on different degree of severity (from 1 = never to 7=always). For this\\r\\nstudy, only the Sev-Gen will be used.',\n",
       "      'timeFrame': 'Assessed at baseline, Week 1, Week 2, and Week 4.'},\n",
       "     {'measure': 'Improvement in Quality of Life, assessed by EQ-5D-5L Questionnaire',\n",
       "      'description': \"The 5-level EQ-5D version (EQ-5D-5L) was introduced by the EuroQol Group in 2009, and\\r\\nconsist of 2 sections, 1) the EQ-5D descriptive system and 2) the EQ visual analogue\\r\\nscale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care,\\r\\nusual activities, pain or discomfort and anxiety/depression. Each dimension has 5 levels:\\r\\nno problems, slight problems, moderate problems, severe problems, and extreme problems.\\r\\nThe EQ VAS records the patient's self-rated health on a vertical visual analogue scale,\\r\\nwhere the endpoints are labelled 'The best health the participant can imagine' and 'The\\r\\nworst health the participant can imagine'. The VAS can be used as a quantitative measure\\r\\nof health outcome that reflect the patient's own judgement. The Malay version\\r\\nquestionnaire will be used.\",\n",
       "      'timeFrame': 'Assessed at baseline, Week 1, Week 2, and Week 4.'},\n",
       "     {'measure': 'Change in Visceral Sensitivity Index',\n",
       "      'description': 'The Visceral Sensitivity Index (VSI) is a 15-item questionnaire which measures\\r\\ngastrointestinal symptom-specific anxiety. Replies to each item are provided on a 6-point\\r\\nscale from \"strongly disagree\" (scored as 0) to \"strongly agree\" (scored as 5). A Malay\\r\\nversion of the questionnaire was developed using standard forward-back translation\\r\\nprocedures. The Malay version questionnaire will be used.',\n",
       "      'timeFrame': 'Assessed at baseline, Week 1, Week 2, and Week 4.'},\n",
       "     {'measure': 'Assessment of psychological dysfunction suing Catastrophizing Questionnaire',\n",
       "      'description': 'The Coping Strategies Questionnaire (CSQ) - Catastrophizing (CAT) subscale consists of\\r\\nsix questions on a 6-point Likert scale, with response options ranging from 0 (never) to\\r\\n5 (very frequently). The Malay version questionnaire will be used.',\n",
       "      'timeFrame': 'Assessed at baseline, Week 1, Week 2, and Week 4.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  IBS diagnosed using the Rome IV criteria\\r\\n\\r\\n  -  Age above 18 years old and any gender\\r\\n\\r\\n  -  Any subtypes of IBS (diarrhea, constipation or mixed)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass,\\r\\n     strong family history of cancer)\\r\\n\\r\\n  -  Was prescribed antibiotic (s) within the past one month\\r\\n\\r\\n  -  Medical conditions that contraindicate probiotic use including severe sepsis and\\r\\n     pregnancy\\r\\n\\r\\n  -  Presence of bowel malignancy\\r\\n\\r\\n  -  Diagnosis of bowel infection within the past one month\\r\\n\\r\\n  -  Previous abdominal surgeries\\r\\n\\r\\n  -  Patients with overt psychiatric illnesses including schizophrenia and manic\\r\\n     disorders\\r\\n\\r\\n  -  A history of allergy to probiotic\\r\\n\\r\\n  -  Was prescribed probiotic (s) within the past one month\\r\\n\\r\\n  -  Was previously prescribed probiotic Skal Pro™ (LP299V™)',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jonathan Khor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+60122888024',\n",
       "      'email': 'jonathankhor@epplusgroup.com'}],\n",
       "    'overallOfficials': [{'name': 'Yeong Yeh Lee, MD, PhD',\n",
       "      'affiliation': 'Hospital Universiti Sains Malaysia',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Hospital Universiti Sains Malaysia',\n",
       "      'city': 'Kubang Kerian',\n",
       "      'state': 'Kelantan',\n",
       "      'zip': '16150',\n",
       "      'country': 'Malaysia',\n",
       "      'contacts': [{'name': 'Yeong Yeh Lee, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+6097676846',\n",
       "        'phoneExt': '6845',\n",
       "        'email': 'yylee@usm.my'},\n",
       "       {'name': 'Yeong Yeh Lee, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Thai Hau Koo, MD', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 6.09123, 'lon': 102.27938}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000043183',\n",
       "      'term': 'Irritable Bowel Syndrome'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000003108', 'term': 'Colonic Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000003109', 'term': 'Colonic Diseases, Functional'},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'}],\n",
       "    'browseLeaves': [{'id': 'M6336',\n",
       "      'name': 'Colonic Diseases',\n",
       "      'asFound': 'Colonic Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6337',\n",
       "      'name': 'Colonic Diseases, Functional',\n",
       "      'asFound': 'Colonic Diseases, Functional',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M25118',\n",
       "      'name': 'Irritable Bowel Syndrome',\n",
       "      'asFound': 'Irritable Bowel Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8883',\n",
       "      'name': 'Gastrointestinal Diseases',\n",
       "      'asFound': 'Gastrointestinal Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7255',\n",
       "      'name': 'Digestive System Diseases',\n",
       "      'asFound': 'Digestive System Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10444',\n",
       "      'name': 'Intestinal Diseases',\n",
       "      'asFound': 'Intestinal Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T6034', 'name': 'Quality of Life', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'T355',\n",
       "      'name': 'Acidophilus',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06148038',\n",
       "    'orgStudyIdInfo': {'id': '103565'},\n",
       "    'organization': {'fullName': 'Medical University of South Carolina',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'CBD for Breast Cancer Primary Tumors',\n",
       "    'officialTitle': 'A Phase 1a \"Window Trial\" of Cannabidiol (CBD) For Breast Cancer Primary Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-17',\n",
       "    'studyFirstSubmitQcDate': '2023-11-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-05',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Nancy Demore',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Medical University of South Carolina'},\n",
       "    'leadSponsor': {'name': 'Medical University of South Carolina',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a randomized placebo controlled double blind window of opportunity trial. A\\r\\nmaximum of 120 patients will be enrolled. Up to 60 patients with invasive breast cancer\\r\\nwill be enrolled into cohort 1, and up to 60 patients with DCIS will be enrolled into\\r\\ncohort 2. Patients in each cohort will be randomized 1:1 to either CBD or placebo control\\r\\nusing permuted block randomization with random block sizes of 2 or 4. The time window\\r\\nbetween CBD or placebo initiation and surgery will be between 5 days and 56 days.'},\n",
       "   'conditionsModule': {'conditions': ['Breast Cancer']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This is a randomized placebo controlled double blind window of opportunity trial. A\\r\\nmaximum of 120 patients will be enrolled. Up to 60 patients with invasive breast cancer\\r\\nwill be enrolled into cohort 1, and up to 60 patients with DCIS will be enrolled into\\r\\ncohort 2. Patients in each cohort will be randomized 1:1 to either CBD or placebo control\\r\\nusing permuted block randomization with random block sizes of 2 or 4. The time window\\r\\nbetween CBD or placebo initiation and surgery will be between 5 days and 56 days.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'CBD Oral',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'CBD Oral 350mg twice daily for 28 days',\n",
       "      'interventionNames': ['Drug: CBD Oral']},\n",
       "     {'label': 'Placebo control',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo control Oral twice daily for 28 days',\n",
       "      'interventionNames': ['Other: Control']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'CBD Oral',\n",
       "      'description': 'CBD Oral 350mg twice daily for 28 days',\n",
       "      'armGroupLabels': ['CBD Oral']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Control',\n",
       "      'description': 'Placebo Control',\n",
       "      'armGroupLabels': ['Placebo control']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'CBD and cell proliferation',\n",
       "      'description': 'To determine whether oral administration of cannabidiol (CBD) causes biological changes\\r\\nrelated to cell proliferation (using Ki67 expression as a marker) in primary tumors of\\r\\nbreast cancer patients.',\n",
       "      'timeFrame': '2 months'},\n",
       "     {'measure': 'CBD and apoptosis',\n",
       "      'description': 'To determine whether oral administration of cannabidiol (CBD) causes biological changes\\r\\nrelated to apoptosis (using Ki67 expression as a marker) in primary tumors of breast\\r\\ncancer patients.',\n",
       "      'timeFrame': '2 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE 5.0',\n",
       "      'description': 'To determine adverse event relationship to oral CBD extract in patients with breast\\r\\ncancer.',\n",
       "      'timeFrame': '2 months'},\n",
       "     {'measure': 'GAD-7 anxiety level scoring at Pre and post CBD administration',\n",
       "      'description': 'To determine whether CBD administered in the period waiting for surgery reduces\\r\\nself-reported anxiety from baseline to time of surgery as measured by the GAD-7 patient\\r\\nreported outcomes scale.',\n",
       "      'timeFrame': '2 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Histologically confirmed invasive breast cancer (stages I, II, or III) or DCIS with\\r\\n     primary tumor(s) ≥ 0.8 cm on mammogram, ultrasound, MRI, or physical exam 2.18 years\\r\\n     of age or older 3.Subject must understand risks and benefits of the protocol and be\\r\\n     able to give informed consent 4.Women of child-bearing potential (WOCBP) must agree\\r\\n     to use an approved form of birth control and to have a negative pregnancy test\\r\\n     result before registration. WOCBP is defined as any female who has experienced\\r\\n     menarche and who has not undergone surgical sterilization (hysterectomy or bilateral\\r\\n     oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12\\r\\n     consecutive months of amenorrhea in a woman over 45 in the absence of other\\r\\n     biological or physiological causes.\\r\\n\\r\\n  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 6.Adequate\\r\\n     hematologic and end organ function, defined by the following laboratory results\\r\\n     obtained within 14 days prior to registration:\\r\\n\\r\\n  -  ANC ≥ 1.5 × 109/L\\r\\n\\r\\n  -  Platelet count ≥ 100 × 109/L\\r\\n\\r\\n  -  Hemoglobin ≥ 9 g/dL\\r\\n\\r\\n  -  Albumin ≥ 2.5 g/dL\\r\\n\\r\\n  -  Bilirubin ≤ 1.5 × the upper limit of normal (ULN)\\r\\n\\r\\n  -  AST, ALT, and alkaline phosphatase ≤ 3 × ULN\\r\\n\\r\\n  -  Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min on the basis\\r\\n     of measured CrCl from a 24-hour urine collection or Cockcroft-Gault* glomerular\\r\\n     filtration rate estimation:\\r\\n\\r\\n     (140-age) × (weight in kg) × (0.85 if female) 72 × (serum creatinine in mg/dL)\\r\\n\\r\\n     * The Modification of Diet in Renal Disease (Levey et al. 2006) and the Chronic\\r\\n     Kidney Disease Epidemiology Collaboration (Levey et al. 2009) formulas for\\r\\n     estimation of glomerular filtration rate are also acceptable.\\r\\n\\r\\n       7. Ability and capacity to comply with the study and follow-up procedures 8.\\r\\n          Subjects must be scheduled for surgery no less than 5 days from the planned\\r\\n          start of day 1 and no more than 56 days from the planned start of day 1.\\r\\n\\r\\n       9. If patients are taking home regimens of CBD or marijuana, they must consent to\\r\\n          abstain for the length of the trial.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy\\r\\n\\r\\n  2. Subjects who are pregnant or are lactating.\\r\\n\\r\\n  3. Patients taking drugs metabolized by cytochrome p450 (warfarin, amiodarone,\\r\\n     levothyroxine, clobazam, lamotrigine, valproate, prednisolone, hydrocortisone,\\r\\n     clarithromycin, itraconazole, erythromycin, fluconazole, clopidogrel, rifampin,\\r\\n     sulfamethoxazole, any opioids, antiepileptic medications (including carbamazapine,\\r\\n     phenytoin, valproic acid, but excepting of gabapentin, clonazepam, or diazepam).\\r\\n\\r\\n  4. Routine use of recreational or medicinal marijuana products (defined as > 4 times\\r\\n     per month) or illicit drug use including opioids, cocaine, amphetamines, PCP, LSD\\r\\n\\r\\n  5. Concurrent use of over-the-counter CBD oil, Marinol®, Delta-8 THC, or cannabis\\r\\n\\r\\n  6. History of allergic reactions attributed to compounds of similar chemical or\\r\\n     biologic composition to CBD or placebo\\r\\n\\r\\n  7. Underlying history of epilepsy/ recurrent seizure disorder or unexplained seizure\\r\\n     within past 6 months\\r\\n\\r\\n  8. Patients with uncontrolled cardiovascular disease defined by myocardial infarction,\\r\\n     stroke, or transient ischemic attack, or need for coronary stent placement within\\r\\n     past six months.\\r\\n\\r\\n  9. Patients with a psychiatric illness or psychiatric symptoms that would prevent them\\r\\n     from completing study procedures or would disqualify them from surgical intervention\\r\\n     (e.g., untreated schizophrenia, bipolar disorder, or suicide ideation/attempt\\r\\n     resulting in psychiatric hospitalization within the last 30 days).\\r\\n\\r\\n 10. Women who are pregnant or breastfeeding or who refuse to practice an effective form\\r\\n     of birth control (condoms, diaphragm, birth control pill, IUD)',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Alan Brisendine',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '843-792-9007',\n",
       "      'email': 'brisend@musc.edu'},\n",
       "     {'name': 'Jasmin M Brooks',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'brooksjm@musc.edu'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001943',\n",
       "      'term': 'Breast Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001941', 'term': 'Breast Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5220',\n",
       "      'name': 'Breast Neoplasms',\n",
       "      'asFound': 'Breast Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5218', 'name': 'Breast Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M5445',\n",
       "      'name': 'Cannabidiol',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'AntiConv', 'name': 'Anticonvulsants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06357195',\n",
       "    'orgStudyIdInfo': {'id': '2024H0075'},\n",
       "    'organization': {'fullName': 'Ohio State University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients',\n",
       "    'officialTitle': 'Implementation of DIAMOND-Lewy Guidelines for Emergency Department Antipsychotic Use in Older Patients With Cognitive and Movement Disorders'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-10-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-10-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-04',\n",
       "    'studyFirstSubmitQcDate': '2024-04-04',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-10',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Douglas Scharre',\n",
       "     'investigatorTitle': 'Professor of Clinical Neurology and Psychiatry, Division Director of Cognitive Neurology',\n",
       "     'investigatorAffiliation': 'Ohio State University'},\n",
       "    'leadSponsor': {'name': 'Ohio State University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this observational study is to learn about current practices for the acute\\r\\nneuropsychiatric management of older adults during emergency department (ED) visits.\\r\\nResearchers will compare current standard of care practices with implemented guideline\\r\\npractice to see if standardized medication guidelines help reduce the usage of\\r\\nantipsychotics and/or benzodiazepines during acute presentations. The main questions this\\r\\nstudy aims to answer are:\\r\\n\\r\\n  -  How many older adults are receiving antipsychotics or benzodiazepines during\\r\\n     emergency department visits?\\r\\n\\r\\n  -  Why are older adults receiving antipsychotics or benzodiazepines during emergency\\r\\n     department visits?\\r\\n\\r\\n  -  How many older adults who receive antipsychotics or benzodiazepines during emergency\\r\\n     department visits have an underlying cognitive or movement disorder?\\r\\n\\r\\n  -  What effects does administration of antipsychotics or benzodiazepines during\\r\\n     emergency department visits have on patient outcomes in older adults and adults with\\r\\n     neurocognitive disorders?\\r\\n\\r\\n  -  Does implementation of standardized medication guidelines help reduce the usage of\\r\\n     antipsychotics and/or benzodiazepines during acute presentations?',\n",
       "    'detailedDescription': \"Lewy Body Dementia (LBD) is the second most common type of dementia next to Alzheimer's\\r\\nDementia, but many patients with this disease go undiagnosed or misdiagnosed. A clinical\\r\\nfeature of this disease is sensitivity to certain medications such as antipsychotics and\\r\\nbenzodiazepines, which can potentially worsen their symptoms and/or increase the risk of\\r\\ndeath. With neuropsychiatric symptoms being the leading cause for acute hospital visits\\r\\nin patients with LBD, over a third of patients receive antipsychotics in the hospital, a\\r\\nthird end up needing a higher level of care after discharge, and a third of patients with\\r\\ndementia end up dying within the first year after an ED visit. Currently, there is not\\r\\nenough data for the best pharmacologic management of acute behavioral disturbances in\\r\\nolder patients, but we do have international LBD guidelines that we can start to\\r\\nimplement.\\r\\n\\r\\nSince the ED is a place with high usage of antipsychotics/benzodiazepines, the purpose of\\r\\nthis study is to measure the proportion of older patients who are receiving these\\r\\nmedications during an ED visit. Of the older patients who received these medications,\\r\\nthis study will measure which fraction of the patients might have an underlying diagnosis\\r\\nof dementia or movement disorder. The goal is to implement new hospital guidelines to\\r\\nhelp reduce the usage of these medications in older patients, thus the study will measure\\r\\nthe proportion of older patients receiving these medications before and after the new\\r\\nhospital guidelines are implemented. The study will also directly measure the treatment\\r\\nknowledge of providers working in the ED by having them answer a clinical\\r\\nscenario/patient case question before and after the guidelines are presented to them. The\\r\\nultimate goal of this study is to help improve patient outcomes in older people who visit\\r\\nthe hospital by avoiding medications that could be potentially harmful to their health.\"},\n",
       "   'conditionsModule': {'conditions': ['Emergency Psychiatric',\n",
       "     'Cognition Disorder',\n",
       "     'Movement Disorders',\n",
       "     'Antipsychotics and Neuroleptics Toxicity',\n",
       "     'Dementia With Lewy Bodies',\n",
       "     'Alteration in Mental Status',\n",
       "     'Behavior',\n",
       "     'Aging']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'OTHER',\n",
       "     'timePerspective': 'CROSS_SECTIONAL'},\n",
       "    'enrollmentInfo': {'count': 1000, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Antipsychotic/Benzodiazepine',\n",
       "      'description': 'Name of medication used',\n",
       "      'timeFrame': 'From admission to discharge, up to 30 days'},\n",
       "     {'measure': 'Clinical Indication',\n",
       "      'description': 'Reason for antipsychotic or benzodiazepine administration',\n",
       "      'timeFrame': 'From admission to discharge, up to 30 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Length of Stay',\n",
       "      'description': 'Number of hours spent in the ED, number of days spent during hospital admission',\n",
       "      'timeFrame': 'From admission to discharge, up to 30 days'},\n",
       "     {'measure': 'Disposition',\n",
       "      'description': 'Discharge location order',\n",
       "      'timeFrame': 'From admission to discharge, up to 30 days'},\n",
       "     {'measure': 'Code Status',\n",
       "      'description': 'Resuscitation orders at the time of admission and discharge',\n",
       "      'timeFrame': 'From admission to discharge, up to 30 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients over the age of 54\\r\\n\\r\\n  -  Received antipsychotic/benzodiazepine in the ED\\r\\n\\r\\n  -  Have clinical signs or symptoms of underlying cognitive or movement disorders\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  None',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '54 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Older adults >54 years old who receive antipsychotics or benzodiazepines in the ED and\\r\\nolder adults >54 years old who have underlying neurocognitive disorders and receive\\r\\nantipsychotics or benzodiazepines in the ED.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Shari M Duarte, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '6142938000',\n",
       "      'email': 'shari.duarte@osumc.edu'},\n",
       "     {'name': 'Nicole E Vrettos, MS, CCRP',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '6142938000',\n",
       "      'email': 'nicole.vrettos@osumc.edu'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '31519472',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, Allan LM, Thomas AJ, O'Brien JT. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020 Feb;19(2):157-169. doi: 10.1016/S1474-4422(19)30153-X. Epub 2019 Sep 10.\"},\n",
       "     {'pmid': '21747029',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol. 2011 Jul;68(7):899-904. doi: 10.1001/archneurol.2011.139.'},\n",
       "     {'pmid': '30930058',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Spears CC, Besharat A, Monari EH, Martinez-Ramirez D, Almeida L, Armstrong MJ. Causes and outcomes of hospitalization in Lewy body dementia: A retrospective cohort study. Parkinsonism Relat Disord. 2019 Jul;64:106-111. doi: 10.1016/j.parkreldis.2019.03.014. Epub 2019 Mar 23.'},\n",
       "     {'pmid': '35612546',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Hill JD, Schmucker AM, Siman N, Goldfeld KS, Cuthel AM, Chodosh J, Bouillon-Minois JB, Grudzen CR. Emergency and post-emergency care of older adults with Alzheimer's disease/Alzheimer's disease related dementias. J Am Geriatr Soc. 2022 Sep;70(9):2582-2591. doi: 10.1111/jgs.17833. Epub 2022 May 25.\"},\n",
       "     {'pmid': '37662063',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Russek NS, Skappak C, Scheuermeyer F, Brousseau AA, McLeod SL, Melady D, Spencer M. Pharmacological Management of Agitation and Delirium in Older Adults: a Survey of Practices in Canadian Emergency Departments. Can Geriatr J. 2023 Sep 1;26(3):405-409. doi: 10.5770/cgj.26.666. eCollection 2023 Sep.'},\n",
       "     {'pmid': '28592453',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7.\"}],\n",
       "    'seeAlsoLinks': [{'label': 'DIAMOND-Lewy Management Toolkit',\n",
       "      'url': 'https://research.ncl.ac.uk/diamondlewy/managementtoolkit/'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009069',\n",
       "      'term': 'Movement Disorders'},\n",
       "     {'id': 'D000020961', 'term': 'Lewy Body Disease'},\n",
       "     {'id': 'D000004630', 'term': 'Emergencies'},\n",
       "     {'id': 'D000003072', 'term': 'Cognition Disorders'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000003704', 'term': 'Dementia'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000019965', 'term': 'Neurocognitive Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'},\n",
       "     {'id': 'D000020734', 'term': 'Parkinsonian Disorders'},\n",
       "     {'id': 'D000001480', 'term': 'Basal Ganglia Diseases'},\n",
       "     {'id': 'D000080874', 'term': 'Synucleinopathies'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M6301',\n",
       "      'name': 'Cognition Disorders',\n",
       "      'asFound': 'Cognition Disorders',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7796',\n",
       "      'name': 'Emergencies',\n",
       "      'asFound': 'Emergency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6904', 'name': 'Dementia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12029',\n",
       "      'name': 'Movement Disorders',\n",
       "      'asFound': 'Movement Disorders',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22693',\n",
       "      'name': 'Lewy Body Disease',\n",
       "      'asFound': 'Dementia With Lewy Bodies',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21836', 'name': 'Neurocognitive Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M22494', 'name': 'Parkinsonian Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M25603', 'name': 'Ganglion Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M16358', 'name': 'Synovial Cyst', 'relevance': 'LOW'},\n",
       "     {'id': 'M4774', 'name': 'Basal Ganglia Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2217', 'name': 'Synucleinopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M16904',\n",
       "      'name': 'Antipsychotic Agents',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06427304',\n",
       "    'orgStudyIdInfo': {'id': '2023-A01313-42'},\n",
       "    'organization': {'fullName': \"Gérond'if\", 'class': 'OTHER'},\n",
       "    'briefTitle': 'Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure',\n",
       "    'officialTitle': 'Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure',\n",
       "    'acronym': 'ARNOLD'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-02', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-02', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-24',\n",
       "    'studyFirstSubmitQcDate': '2024-05-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': \"Gérond'if\", 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Tne aim purpose of this observational, multicentre and propective study is to determine\\r\\nthe prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older\\r\\nhospitalized within the last 12 months for heart failure with left ventricular\\r\\nhypertrophy (septum ≥ 12 mm) on echocardiography',\n",
       "    'detailedDescription': 'Patients recruitment will be curry out in 31 geriatric or cardiologic centres.\\r\\n\\r\\nPatients will be recruited for 24 months. Each patient will participate in the study for\\r\\n12 months (baseline visit, follow-up phone calls every 3 months up to 12 months i.e., at\\r\\n3, 6, 9 and 12 months).\\r\\n\\r\\nThe following data will be collected at teh baseline visit: Medical history, demography,\\r\\nclinical data, frailty status assessed by Fried, Triage Risk Screening Tool (TRST),\\r\\ntriggers for cardiac decompensation, biological examination, genetic testing,\\r\\nechocardiographic data and other data.\\r\\n\\r\\nBone scanning with 99mTc-DPD or 99mTc-HMDP (early or late time with SPECT will be done\\r\\nduring hospitalization or after discharge depending on availability at the imaging\\r\\ncentre.\\r\\n\\r\\nThe results of each examination will be evaluated to establish the existence and degree\\r\\nof fixation in the myocardium and to determine its distribution.\\r\\n\\r\\nFollow-up phone s will be conducted every 3 months up to 12 months to collect\\r\\nhospitalizations for heart failure, hospitalizations for other cardio-vascular events,\\r\\nhospitalizations for non-cardiac events, admission to nursing homes or long-term care\\r\\n(LTC) facilities and death'},\n",
       "   'conditionsModule': {'conditions': ['Cardiac Amyloidosis'],\n",
       "    'keywords': ['Cardiac amyloidosis',\n",
       "     'Heart failure with left ventricular hypertrophy',\n",
       "     'Positive bone scintigraphy']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 637, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Assessment of the number of patients with cardiac amyloidosis according bon scintigraphy',\n",
       "      'timeFrame': 'At inclusion'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Assessment of commorbidity risk according Charlson Comorbidity Index (CCI)',\n",
       "      'description': 'The Charlson Comorbidity Index (CCI) assesses the level of comorbidity by considering the\\r\\nlevel of severity of 19 predefined comorbid disorders and the number of disorders present\\r\\namong them.',\n",
       "      'timeFrame': 'At inclusion'},\n",
       "     {'measure': 'Assessment of the degree of patient dependence according Katz Index of Independence in Activities of Daily Living (ADL)',\n",
       "      'description': 'Katz Index of Independence in Activities of Daily Living is an unabbreviated scale title.\\r\\n\\r\\nThis Index ranks adequacy of performance in the six functions of bathing, dressing,\\r\\ntoileting, transferring, continence, and feeding. Patients are scored yes/no for\\r\\nindependence in each of the six functions. A score of 6 indicates full function, 4\\r\\nindicates moderate impairment, and 2 or less indicates severe functional impairment.',\n",
       "      'timeFrame': 'At inclusion'},\n",
       "     {'measure': 'Measuring cognitive impairment according Mini-Mental State Examination (MMSE) score',\n",
       "      'description': 'The Mini-Mental State Examination is an unabbreviated scale title. This scale was\\r\\ndeveloped as a brief screening tool to provide a quantitative evaluation of cognitive\\r\\nimpairment and to record cognitive changes over time.\\r\\n\\r\\nThe measure yields a total score of 30. A score of 23 or less is the generally accepted\\r\\ncutoff point indicating the presence of cognitive impairment. Levels of impairment have\\r\\nalso been classified as none (24-30); mild (18-23) and severe (0-17)',\n",
       "      'timeFrame': 'At inclusion'},\n",
       "     {'measure': 'Estimating the probability of neuropathic pain according \"DN4 Questionnaire\"',\n",
       "      'description': 'This questionnaire is an unabbreviated score title, it was originally developed and\\r\\nvalidated in French (4 items of neuropathic pain). It was identified as one of the most\\r\\nsuitable neuropathic pain screening tools for clinical use:\\r\\n\\r\\n  -  Sensitivity: Ranges from 75-98%. Proven high sensitivity for central neuropathic\\r\\n     pain and polyneuropathies. Sensitivity is low for tigeminal neuralgia. Moderate\\r\\n     sensitivity for detecting a neuropathic component of pain in people with chronic\\r\\n     pain.\\r\\n\\r\\n  -  Specificity: Ranges from 37-96%.',\n",
       "      'timeFrame': 'At inclusion'},\n",
       "     {'measure': 'Assessment of physical frailty according Fried scale',\n",
       "      'description': 'This is an unabbreviated scale title.\\r\\n\\r\\nAssessment of 5 dimensions:\\r\\n\\r\\n  -  0, 1 or 2 pathological dimensions = lack of frailty\\r\\n\\r\\n  -  3, 4 or 5 pathological dimensions = presence of frailty',\n",
       "      'timeFrame': 'At inclusion'},\n",
       "     {'measure': 'Assessment of Failty status using the Short Emergency Geriatric Assessment (SEGA)',\n",
       "      'description': 'This is an unabbreviated scale title.\\r\\n\\r\\n  -  if SEGA score < ou = 8 : Not very frail\\r\\n\\r\\n  -  if it contained in the interval [9;11] : Rather frail\\r\\n\\r\\n  -  if it > ou = 12 : Very frail',\n",
       "      'timeFrame': 'At inclusion'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Aged ≥ 80 years\\r\\n\\r\\n  -  Hospitalised for decompensation of heart failure in the last 12 months\\r\\n\\r\\n  -  Subjects with hypertrophy of the septum or left ventricle at cardiac echography\\r\\n     (defined as ≥ 12 mm)\\r\\n\\r\\n  -  Subjects able to undergo a bone scintigraphy scan\\r\\n\\r\\n  -  Subjects willing to participate\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Subjects refusing to participate\\r\\n\\r\\n  -  Subjects admitted to palliative care unit.\\r\\n\\r\\n  -  Subjects under guardianship\\r\\n\\r\\n  -  Subjects with a definite diagnosis of cardiac amyloidosis',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '80 Years',\n",
       "    'stdAges': ['OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patients with cardiac amyloidosis expressed by a positive bone scintigraphy.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Isabelle Dufour',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+33 (0) 185781011',\n",
       "      'email': 'isabelle.dufour@gerondif.org'},\n",
       "     {'name': 'Prisca Lucas, MPH PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+33 (0)185737323',\n",
       "      'email': 'prisca.lucas@gerondif.org'}],\n",
       "    'overallOfficials': [{'name': 'Olivier Hanon, MD PhD',\n",
       "      'affiliation': 'Geriatric Department, Broca hospital',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'Geriatric Department, Broca Hospital',\n",
       "      'city': 'Paris',\n",
       "      'state': 'IIe-de-France',\n",
       "      'zip': '75013',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Olivier Hanon, MD PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+33 (0)144083503',\n",
       "        'email': 'olivier.hanon@aphp.fr'}],\n",
       "      'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006333',\n",
       "      'term': 'Heart Failure'},\n",
       "     {'id': 'D000000686', 'term': 'Amyloidosis'}],\n",
       "    'ancestors': [{'id': 'D000006331', 'term': 'Heart Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10035',\n",
       "      'name': 'Hypertrophy',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9421',\n",
       "      'name': 'Heart Failure',\n",
       "      'asFound': 'Heart Failure',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4021',\n",
       "      'name': 'Amyloidosis',\n",
       "      'asFound': 'Amyloidosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19658',\n",
       "      'name': 'Hypertrophy, Left Ventricular',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05669846',\n",
       "    'orgStudyIdInfo': {'id': 'HCC 22-078'},\n",
       "    'organization': {'fullName': 'University of Pittsburgh', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC',\n",
       "    'officialTitle': 'Phase II Feasibility Study of Responder-derived FMT (R-FMT) and Pembrolizumab in Relapsed/Refractory PD-L1 Positive NSCLC'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-12-20',\n",
       "    'studyFirstSubmitQcDate': '2022-12-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-01-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-15', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Diwakar Davar',\n",
       "     'investigatorTitle': 'Assistant Professor of Medicine - Hematology, Oncology',\n",
       "     'investigatorAffiliation': 'University of Pittsburgh'},\n",
       "    'leadSponsor': {'name': 'Diwakar Davar', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Gateway for Cancer Research',\n",
       "      'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This study is to determine if a fecal microbiota transplant (FMT) improves the body's\\r\\nability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.\",\n",
       "    'detailedDescription': 'The study evaluating the addition of R-FMT to pembrolizumab in PD-1 R/R NSCLC will be\\r\\nconducted over a 104-week period. Patients with anti-PD-1 R/R NSCLC are eligible to\\r\\nenroll. Prior exposure to microbiome modulating therapy is exclusionary. Suitable\\r\\npatients will be identified at the time of progression upon PD-1 monotherapy or PD-1\\r\\ncontaining regimens. Patients will undergo a 35-day screening evaluation consisting of\\r\\nsystemic staging scans, tumor biopsy, stool/blood serologic studies to confirm\\r\\nsuitability.\\r\\n\\r\\nOnce enrolled, patients will be seromatched with a suitable donor. Suitable donors are\\r\\nadvanced cancer patients who have undergone PD-1 monotherapy and are currently in durable\\r\\nremission (median PFS >24 months from initiation of PD-1 therapy) with no ongoing irAE as\\r\\ndelineated below. Patients will receive R-FMT (induction) via colonoscopy on C1D1 and\\r\\nC3D1. R-FMT (maintenance) via sigmoidoscopy on C4D1 and will be repeated every 9 weeks.\\r\\nAll patients will additionally receive pembrolizumab at 200mg every three weeks. Patients\\r\\nwill be treated until disease progression or intolerable toxicity or completion of 2\\r\\nyears of therapy, whichever comes first.'},\n",
       "   'conditionsModule': {'conditions': ['Non Small Cell Lung Cancer'],\n",
       "    'keywords': ['Relapsed', 'Refractory']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 26, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Fecal Microbiota Transplant (FMT) with Pembrolizumab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The FMT along with an intestinal biopsy will be performed as outpatient by a\\r\\ngastroenterologist. The FMT is infused into the colon by performing a colonoscopy\\r\\n(Treatment Phase 1) and by a sigmoidoscopy (Treatment Phase 2). FMT will be performed on\\r\\nCycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with\\r\\nCycle 4 Day 1 during Treatment Phase 2.\\r\\n\\r\\nPembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks\\r\\nstarting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.',\n",
       "      'interventionNames': ['Drug: Fecal Microbiota Transplant (FMT)',\n",
       "       'Drug: Pembrolizumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Fecal Microbiota Transplant (FMT)',\n",
       "      'description': 'FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed\\r\\nwith a saline or other solution, strained and infused into the colon by performing a\\r\\ncolonoscopy and sigmoidoscopy. The FMT consists of introducing normal bacterial flora\\r\\ncontained in the stool collected from a donor into the small intestine. In this case, the\\r\\ndonors are patients with advanced metastatic non-small cell lung cancer (NSCLC) who have\\r\\nundergone PD-1 therapy (nivolumab or pembrolizumab) and are currently in a durable\\r\\nremission that is ongoing. The FMT will be performed on Cycle 1 Day 1 and Cycle 3 Day 1\\r\\nduring Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment\\r\\nPhase 2.',\n",
       "      'armGroupLabels': ['Fecal Microbiota Transplant (FMT) with Pembrolizumab']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'description': 'Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks\\r\\nstarting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.',\n",
       "      'armGroupLabels': ['Fecal Microbiota Transplant (FMT) with Pembrolizumab'],\n",
       "      'otherNames': ['Keytruda']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR) per RECIST v1.1',\n",
       "      'description': 'The proportion of patients with objective response (Complete Response (CR) or Partial\\r\\nResponse (PR)) to R-FMT and pembrolizumab treatment in PD-1 primary refractory NSCLC as\\r\\nassessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph\\r\\nnodes (whether target or non-target) must have reduction in short axis to <10 mm. For\\r\\nnon-target lesions: Disappearance of all non-target lesions and normalization of tumor\\r\\nmarker level. All lymph nodes must be non-pathological in size (<10mm short axis); PR: At\\r\\nleast a 30% decrease in the sum of diameters of target lesions, taking as reference the\\r\\nbaseline sum diameters.',\n",
       "      'timeFrame': 'Up to 5 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of Adverse Events Related to Treatment',\n",
       "      'description': 'Frequency of Adverse Events and specifically ≥grade 2 irAEs per CTCAE v5.0 in PD-1\\r\\nprimary refractory NSCLC in patients treated with R-FMT and pembrolizumab, to assess\\r\\noverall safety, feasibility and tolerability of treatment.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'Objective Response Rate (ORR) per iRECIST',\n",
       "      'description': 'The proportion of patients Complete Response (irCR) or Partial Response (irPR) to\\r\\ntreatment as assessed per iRECIST. irCR:Disappearance of non-nodal lesions.All pathologic\\r\\nlymph nodes <10 mm (short axis) (2 consecutive measurements ≥4 weeks apart); irPR :≥30%\\r\\ndecrease from baseline (2 consecutive measurements ≥4 weeks apart). Disappearance of all\\r\\nnon-nodal lesions.All pathologic lymph nodes <10 mm (Non-Target Lesions:Any other than\\r\\ndisappearance of all non-nodal lesions and reduction of pathologic lymph nodes <10 mm).\\r\\nBaseline tumor burden: sum of single diameters (short axis for nodal lesions, longest\\r\\ndiameter for other lesions) for target lesions. In subsequent scans, the diameters of new\\r\\nmeasurable lesions are added to the tumor burden. Re-treatment: ≤5 target lesions (=/≠\\r\\noriginal lesions) are selected and a new baseline tumor burden will be established. (no\\r\\ndistinct iRECIST assessment until radiographic progression per RECIST 1.1 is observed).',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'CD8+ TIL and intra-tumoral myeloid cell density',\n",
       "      'description': 'Percentage of CD8+ T cells in intra-tumoral myeloid cells in pre-treatment biopsy samples\\r\\nassess using multiplex IHC.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'Progression-free Survival (PFS)',\n",
       "      'description': 'The median length of time from initiation of study drug(s) disease progression as defined\\r\\nby RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters\\r\\nof target lesions, taking as reference the smallest sum on study (this includes the\\r\\nbaseline sum if that is the smallest on study). The sum must also demonstrate an absolute\\r\\nincrease of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'The median length of time that patients remain alive after treatment.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': '6-month Progression-free Survival',\n",
       "      'description': 'Percentage of patients without disease progression at 6 months after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 6 months'},\n",
       "     {'measure': '1-year Progression-free Survival (PFS)',\n",
       "      'description': 'Percentage of patients without disease progression at 1 year after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': '2-year Progression-free Survival (PFS)',\n",
       "      'description': 'Percentage of patients without disease progression at 2 years after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': '1-year Overall Survival (OS)',\n",
       "      'description': 'Percentage of patients that are alive at 1 year after start of treatment.',\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': '2-year Overall Survival (OS)',\n",
       "      'description': 'Percentage of patients that are alive at 2 years after start of treatment.',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  The participant (or legally acceptable representative if applicable) provides\\r\\n     written informed consent for the trial.\\r\\n\\r\\n  -  Male/female participants who are at least 18 years of age on the day of signing\\r\\n     informed consent.\\r\\n\\r\\n  -  Male participants: A male participant must agree to use a contraception as detailed\\r\\n     in Appendix 3 of this protocol during the treatment period and for at least 120 days\\r\\n     after the last dose of study treatment and refrain from donating sperm during this\\r\\n     period.\\r\\n\\r\\n  -  Female participants: A female participant is eligible to participate if she is not\\r\\n     pregnant, not breastfeeding, and at least one of the following conditions applies:\\r\\n     Not a woman of childbearing potential (WOCBP) or A WOCBP who agrees to follow the\\r\\n     contraceptive guidance during the treatment period and for at least 120 days after\\r\\n     the last dose of study treatment.\\r\\n\\r\\n  -  Histologically or cytologically confirmed diagnosis of stage IV PD-L1+ NSCLC.\\r\\n     Patients with either squamous or non-squamous NSCLC may enroll. Documented PD-L1\\r\\n     status (defined as 1% or greater) as determined by immunohistochemistry with\\r\\n     anti-PD-L1 antibody (IHC 22C3 pharmDx or other FDA approved diagnostic method) from\\r\\n     a core or excisional biopsy (fine needle aspirate is not sufficient). Patients with\\r\\n     small cell, large cell, neuroendocrine and/or sarcomatoid NSCLC are excluded.\\r\\n\\r\\n  -  Participants must have progressed on treatment with an anti-PD(L)1 ICI administered\\r\\n     either as monotherapy or in combination with other checkpoint inhibitors or other\\r\\n     standard/investigational therapies. PD-1 treatment progression is defined by meeting\\r\\n     all the following criteria:\\r\\n\\r\\n       -  Has received at least 2 doses of an approved anti-PD(L)1 ICI administered as a\\r\\n          single agent, in combination with chemotherapy, and/or in combination with\\r\\n          other investigational therapy.\\r\\n\\r\\n       -  Participants who progressed on/within 3 months of adjuvant therapy with\\r\\n          anti-PD(L)1 ICI will eligible.\\r\\n\\r\\n       -  Demonstrated disease progression after anti-PD-1/L1 as defined by RECIST v1.1.\\r\\n          The initial evidence of PD is to be confirmed by a second assessment no sooner\\r\\n          than 4 weeks from the date of the first documented PD.\\r\\n\\r\\n       -  Progressive disease has been documented within 12 weeks from the last dose of\\r\\n          anti-PD-1/anti-PD-L1 mAb.\\r\\n\\r\\n       -  NOTE: Progressive disease must be determined as above.\\r\\n\\r\\n       -  NOTE: Only patients with primary progressive disease wherein best response to\\r\\n          anti-PD(L)1 therapy is PD or SD less than/equal to 6 months are eligible. If\\r\\n          multiple anti-PD(L)1 lines were received, the patient is eligible if the\\r\\n          response is similar (PD or SD less than/equal to 6 months) for all anti-PD(L)1\\r\\n          lines of therapy.\\r\\n\\r\\n       -  NOTE: This determination is made by the treating investigator. Once PD is\\r\\n          confirmed, the initial date of PD documentation will be considered the date of\\r\\n          PD.\\r\\n\\r\\n       -  NOTE: Anti-PD(L)1 ICI need not be the most recent line of therapy administered.\\r\\n\\r\\n  -  Patients with CNS disease are eligible if CNS metastases are treated and deemed\\r\\n     stable prior to date of enrollment.\\r\\n\\r\\n       -  NOTE: All patients will undergo CNS imaging at the time of Screening. Patients\\r\\n          with treated brain metastases will need repeat CNS imaging to document\\r\\n          stability.\\r\\n\\r\\n       -  NOTE: Stability is defined based on appearance of treated lesions on a\\r\\n          contrast-enhanced CT or MRI brain study performed as part of screening by\\r\\n          radiologist, radiation oncologist or neurosurgeon (whichever is most\\r\\n          appropriate); absence of new or enlarging brain metastases; and no longer\\r\\n          requiring systemic steroids (≤ 10 mg/day prednisone or equivalent) for at least\\r\\n          one week prior to enrollment.\\r\\n\\r\\n       -  NOTE: The contrast-enhanced CT or MRI brain imaging study should be performed\\r\\n          no sooner than 2 weeks after most recent surgical and/or radiological\\r\\n          intervention.\\r\\n\\r\\n       -  NOTE: If lesions were discovered during Screening, the patient may be eligible\\r\\n          if the lesions are treated and stable based on the above criteria.\\r\\n\\r\\n       -  NOTE: Patients with leptomeningeal involvement (leptomeningeal enhancement on\\r\\n          MRI/CT imaging and/or positive CSF cytology) are excluded regardless of\\r\\n          stability.\\r\\n\\r\\n  -  Prior treatment(s)\\r\\n\\r\\n       -  NOTE: Prior anti-CTLA-4 ICI is allowed but not required.\\r\\n\\r\\n       -  NOTE: Patients with known oncogenic driver (including but not limited to EGFR,\\r\\n          ALK, ROS, MET alterations) must have received and progressed past\\r\\n          driver-specific therapy.\\r\\n\\r\\n  -  Willingness to repeatedly receive FMT administered endoscopically (colonoscopy or\\r\\n     sigmoidoscopy) following necessary bowel preparation pre-procedure.\\r\\n\\r\\n       -  NOTE: Understands infectious risks associated with FMT administration. Although\\r\\n          FMT infusate has been screened for bacteria, viruses, fungi and parasites there\\r\\n          is a risk of transmission of known and unknown infectious organisms contained\\r\\n          in the donor stool. Post-FMT bacteremia (e.g., E. coli), sepsis and fatal\\r\\n          events may rarely occur.\\r\\n\\r\\n       -  NOTE: Understands non-infectious risks associated with FMT administration.\\r\\n          Possible allergy and/or anaphylaxis to antigens in donor stool. Theoretical\\r\\n          risk of developing disease possibly related to donor gut microbiota including\\r\\n          but not limited to: obesity, metabolic syndrome, cardiovascular disease,\\r\\n          autoimmune conditions, allergic/atopic disorders, neurologic disorders,\\r\\n          psychiatric conditions and malignancy.\\r\\n\\r\\n       -  NOTE: Understand risks associated with endoscopy (colonoscopy or sigmoidoscopy)\\r\\n          including risk of infection transmission, colonic perforation, aspiration\\r\\n          pneumonia, and death.\\r\\n\\r\\n       -  NOTE: Understand that data regarding the long-term safety risk of FMT are\\r\\n          lacking.\\r\\n\\r\\n  -  Presence of measurable disease based on RECIST 1.1. Patients need to have at least\\r\\n     one measurable lesion and a separate lesion for biopsy. Patients with only 1 lesion\\r\\n     may be enrolled after discussion with Sponsor-Investigator. Lesions situated in a\\r\\n     previously irradiated area are considered measurable if progression has been\\r\\n     demonstrated in such lesions.\\r\\n\\r\\n  -  Able to provide newly obtained core or excisional biopsy of a tumor lesion not\\r\\n     previously irradiated to undergo tumor biopsy (core, punch, incisional or\\r\\n     excisional). Biopsy must meet minimal sampling criteria.\\r\\n\\r\\n  -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n  -  Life expectancy of at least 12 weeks, as estimated using the Gustave Roussy Immune\\r\\n     Score (GRIm-Score); i.e., must meet no more than 1 of the following criteria:\\r\\n\\r\\n       -  Albumin < 3.5 g/dL\\r\\n\\r\\n       -  Lactate dehydrogenase (LDH) > ULN\\r\\n\\r\\n       -  Neutrophils-to-lymphocyte ratio (NLR) > 6\\r\\n\\r\\n  -  Have adequate organ function as defined below. Specimens must be collected within 28\\r\\n     days prior to the start of study intervention.\\r\\n\\r\\n       -  Absolute neutrophil count (ANC) ≥1500/µL\\r\\n\\r\\n       -  Platelets ≥100 000/µL\\r\\n\\r\\n       -  Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L (Criteria must be met without\\r\\n          erythropoietin dependency and without packed red blood cell (pRBC) transfusion\\r\\n          within last 2 weeks)\\r\\n\\r\\n       -  Creatinine OR measured or calculated creatinine clearance (GFR can also be used\\r\\n          in place of creatinine or CrCl) (Creatinine clearance (CrC) should be\\r\\n          calculated per institutional standard) ≤1.5 x ULN OR ≥30 mL/min for participant\\r\\n          with creatinine levels >1.5 x institutional ULN\\r\\n\\r\\n       -  Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total\\r\\n          bilirubin levels >1.5 × ULN\\r\\n\\r\\n       -  AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver\\r\\n          metastases)\\r\\n\\r\\n       -  International normalized ratio (INR) OR prothrombin time (PT); Activated\\r\\n          partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving\\r\\n          anticoagulant therapy as long as PT or aPTT is within therapeutic range of\\r\\n          intended use of anticoagulants\\r\\n\\r\\n  -  Criteria for patients with hepatitis B and C:\\r\\n\\r\\n       -  Screening for hepatitis B and C are required.\\r\\n\\r\\n       -  For hepatitis B positive patients: Patients who are hepatitis B positive (i.e.,\\r\\n          HBsAg positive) or have a history of history of hepatitis B (i.e., HBcAb\\r\\n          positive, or history of documented hepatitis B infection) are eligible if they\\r\\n          have received hepatitis B directed antiviral therapy for at least 4 weeks and\\r\\n          have undetectable HBV viral load (HBV DNA) prior to enrollment. Participants\\r\\n          should remain on antiviral therapy throughout study intervention and follow\\r\\n          local guidelines for HBV antiviral therapy post completion of study\\r\\n          intervention.\\r\\n\\r\\n       -  For hepatitis C positive patients: Patients who are hepatitis C positive (i.e.,\\r\\n          HCV antibody reactive) or have a history of history of hepatitis C (i.e.,\\r\\n          history of documented hepatitis C infection) are eligible if they have received\\r\\n          and completed hepatitis C directed antiviral therapy at least 4 weeks and have\\r\\n          undetectable HCV viral load (HCV RNA) prior to enrollment.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Diagnosis of non-squamous/adenocarcinoma NSCLC histologies including small cell,\\r\\n     large cell, neuroendocrine and/or sarcomatoid histologies.\\r\\n\\r\\n  -  Prior therapies:\\r\\n\\r\\n       -  Receipt of prior agent(s) targeting the intestinal microbiome including but not\\r\\n          limited to: FMT, defined bacterial consortia, single bacterial species and/or\\r\\n          microbiota derived peptides.\\r\\n\\r\\n       -  Prior chemotherapy, targeted therapy, and/or small molecule therapy within 2\\r\\n          weeks (or 4 half-lives) prior to study Day 1.\\r\\n\\r\\n       -  Prior radiotherapy within 2 weeks of start of study intervention. Participants\\r\\n          must have recovered from all radiation-related toxicities, not require\\r\\n          corticosteroids, and not have had radiation pneumonitis. A 2-week washout is\\r\\n          permitted for palliative radiation (≤2 weeks of radiotherapy) to disease\\r\\n          including CNS disease.\\r\\n\\r\\n  -  Presence of an absolute contraindication(s) to FMT administration:\\r\\n\\r\\n       -  Toxic megacoon\\r\\n\\r\\n       -  Severe dietary allergies (e.g., shellfish, nuts, seafood)\\r\\n\\r\\n       -  Inflammatory bowel disease\\r\\n\\r\\n  -  Patients who have not adequately recovered (i.e., ≤Grade 1 or at baseline or ≤Grade\\r\\n     2 endocrinopathy) from adverse events (AEs) due to a previously administered agent.\\r\\n\\r\\n  -  A WOCBP who has a positive urine pregnancy test at Screening. If the urine test is\\r\\n     positive or cannot be confirmed as negative, a serum pregnancy test will be\\r\\n     required.\\r\\n\\r\\n  -  Has received a live vaccine within 30 days prior to the first dose of study drug.\\r\\n\\r\\n       -  Examples of live vaccines include, but are not limited to, the following:\\r\\n          measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,\\r\\n          Bacillus Calmette-Guérin (BCG), SARS-CoV-2 and typhoid vaccine.\\r\\n\\r\\n       -  Seasonal influenza vaccines for injection are generally killed virus vaccines\\r\\n          and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are\\r\\n          live attenuated vaccines and are not allowed.\\r\\n\\r\\n  -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\\r\\n     (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of\\r\\n     immunosuppressive therapy within 14 days prior to the first dose of study drug.\\r\\n\\r\\n  -  Has active autoimmune disease that has required systemic treatment in the past 2\\r\\n     years (i.e., with use of disease modifying agents, corticosteroids or\\r\\n     immunosuppressive drugs).\\r\\n\\r\\n     --- NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic\\r\\n     corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is\\r\\n     not considered a form of systemic treatment and is allowed.\\r\\n\\r\\n  -  Concurrent non-hematologic malignancy within 3 years of data of first planned dose\\r\\n     of therapy except for tumors with a negligible risk of metastasis and/or death as\\r\\n     defined below:\\r\\n\\r\\n       -  Adequately treated non-invasive malignancies including but not limited to\\r\\n          melanoma in situ (MIS), cutaneous squamous cell carcinoma (cSCC), in situ cSCC,\\r\\n          basal cell carcinoma (BCC), CIS of cervix, or DCIS/LCIS of breast.\\r\\n\\r\\n       -  Low-risk early-stage prostate adenocarcinoma (T1-T2a N0 M0 and Gleason score ≤6\\r\\n          and PSA ≤10 ng/mL) for which the management plan is active surveillance, or\\r\\n          prostate adenocarcinoma with biochemical-only recurrence with documented PSA\\r\\n          doubling time of > 12 months for which the management plan is active\\r\\n          surveillance.\\r\\n\\r\\n       -  Indolent hematologic malignancies for which the management plan is active\\r\\n          surveillance including but not limited to CLL/indolent lymphoma. Patients with\\r\\n          high-risk hematologic malignancies (CML, ALL, AML, Hodgkin's or non-Hodgkin's\\r\\n          lymphoma) are excluded even if the management plan is active surveillance.\\r\\n\\r\\n  -  Active (i.e., symptomatic or growing) central nervous system (CNS) metastases.\\r\\n\\r\\n       -  NOTE: Participants with previously treated brain metastases may participate\\r\\n          provided they are radiologically stable, i.e., without evidence of progression\\r\\n          for at least 2 weeks by repeat imaging (note that the repeat imaging should be\\r\\n          performed during Screening), clinically stable and without requirement of\\r\\n          steroid treatment for at least 14 days prior to first dose of study\\r\\n          intervention.\\r\\n\\r\\n       -  NOTE: Patients with leptomeningeal disease are excluded.\\r\\n\\r\\n  -  Has severe hypersensitivity (≥Grade 3) to anti-PD(L)1 inhibitor.\\r\\n\\r\\n  -  Has a systemic disease that requires systemic pharmacologic doses of corticosteroids\\r\\n     greater than 10 mg daily prednisone (or equivalent).\\r\\n\\r\\n       -  NOTE: Participants who are currently receiving steroids at a dose of ≤10 mg\\r\\n          daily do not need to discontinue steroids prior to enrollment.\\r\\n\\r\\n       -  NOTE: Participants that require topical, ophthalmologic, injected and/or\\r\\n          inhalational steroids are not excluded from the study.\\r\\n\\r\\n       -  NOTE: Participants with hypothyroidism stable on hormone replacement or\\r\\n          Sjogren's syndrome are not excluded from the study.\\r\\n\\r\\n       -  NOTE: Participants who require active immunosuppression (greater than steroid\\r\\n          dose discussed above) for any reason are excluded from the study.\\r\\n\\r\\n  -  Has a history of interstitial lung disease or active, non-infectious pneumonitis\\r\\n     that required steroids or has current pneumonitis.\\r\\n\\r\\n  -  Has a history of non-infectious myocarditis or symptomatic cardiac co-morbidities\\r\\n     requiring active management.\\r\\n\\r\\n       -  NOTE: Patients with a history of symptomatic congestive heart failure (New York\\r\\n          Heart Association Functional Classification III or IV) are excluded.\\r\\n\\r\\n       -  NOTE: Patients with a history of unstable angina, serious uncontrolled cardiac\\r\\n          arrhythmia, or myocardial infarction 6 months prior to study entry are\\r\\n          excluded.\\r\\n\\r\\n  -  Active infections:\\r\\n\\r\\n       -  Any active infection requiring systemic therapy.\\r\\n\\r\\n       -  Active TB (Bacillus Tuberculosis).\\r\\n\\r\\n       -  Active COVID-19 infection and/or exposure to SARS-CoV-2: Positive SARS-CoV-2\\r\\n          result on nasopharyngeal and/or stool specimens (by RT-PCR test); Active\\r\\n          COVID-19 infection (per CDC guidelines); Exposure to active COVID-19 infected\\r\\n          patient (as confirmed using SARS-CoV-2 RT-PCR test or other approved test) as\\r\\n          defined per CDC guidelines.\\r\\n\\r\\n       -  Active human immunodeficiency virus (HIV) infection. Patients will be evaluated\\r\\n          for HIV during screening.\\r\\n\\r\\n       -  Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV\\r\\n          DNA) and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV\\r\\n          RNA) infection.\\r\\n\\r\\n  -  Has a history or current evidence of any condition, therapy, or laboratory\\r\\n     abnormality that might confound the results of the study, interfere with the\\r\\n     participant's participation for the full duration of the study, or is not in the\\r\\n     best interest of the participant to participate, in the opinion of the treating\\r\\n     investigator.\\r\\n\\r\\n  -  Has known psychiatric or substance abuse disorders that would interfere with\\r\\n     cooperation with the requirements of the trial.\\r\\n\\r\\n  -  Is pregnant or breastfeeding or expecting to conceive or father children within the\\r\\n     projected duration of the study, starting with the Screening visit through 120 days\\r\\n     after the last dose of trial treatment.\\r\\n\\r\\n  -  Has had an allogenic tissue/solid organ transplant.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Amy Rose, RN, BSN',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '412-647-8587',\n",
       "      'email': 'kennaj@upmc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Diwakar Davar, MD',\n",
       "      'affiliation': 'University of Pittsburgh',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'UPMC Hillman Cancer Center',\n",
       "      'city': 'Pittsburgh',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '15232',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Amy Rose, RN, BSN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '412-647-8587',\n",
       "        'email': 'kennaj@upmc.edu'},\n",
       "       {'name': 'Diwakar Davar, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002289',\n",
       "      'term': 'Carcinoma, Non-Small-Cell Lung'}],\n",
       "    'ancestors': [{'id': 'D000002283', 'term': 'Carcinoma, Bronchogenic'},\n",
       "     {'id': 'D000001984', 'term': 'Bronchial Neoplasms'},\n",
       "     {'id': 'D000008175', 'term': 'Lung Neoplasms'},\n",
       "     {'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5546',\n",
       "      'name': 'Carcinoma, Non-Small-Cell Lung',\n",
       "      'asFound': 'Non-Small Cell Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'},\n",
       "     {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000582435',\n",
       "      'term': 'Pembrolizumab'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M349416',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'asFound': 'Blind',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M1854', 'name': 'Nivolumab', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2342',\n",
       "      'name': 'Immune Checkpoint Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T120', 'name': 'Cola', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05876546',\n",
       "    'orgStudyIdInfo': {'id': 'EF184A'},\n",
       "    'organization': {'fullName': 'Eurofarma Laboratorios S.A.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Evaluation of Skin Irritancy and Sensitization of a Liquid Bandage',\n",
       "    'officialTitle': 'Assessment of the Primary, Accumulated Irritability and Skin Sensitization Potential of an Elastic Collodion-based Liquid Bandage Under Controlled and Maximized Conditions (RIPT)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-27',\n",
       "    'studyFirstSubmitQcDate': '2023-05-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Eurofarma Laboratorios S.A.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The investigational product constitutes a medical device that is freely accessible to\\r\\nconsumers and, as such, must be safe under real or reasonably foreseeable conditions of\\r\\nuse and its safety must be tested before being placed on the market.\\r\\n\\r\\nTherefore, this study was designed to evaluate the biocompatibility of the experimental\\r\\nproduct, as provided for in legislation.'},\n",
       "   'conditionsModule': {'conditions': ['Skin Care'],\n",
       "    'keywords': ['Contact test', 'HRIPT']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': \"Induction period (3 weeks): the experimental and control product will be applied through\\r\\na patch test on the participants' back for 3 consecutive weeks, with 3 weekly\\r\\napplications, with the first week being the primary irritation phase and the two\\r\\nconsecutive weeks being the irritation phase. accumulated irritation. Rest period (10 to\\r\\n15 days): corresponds to the rest period, when participants will remain without any\\r\\ncontact test applied to their back, which will follow the induction period, where there\\r\\nwill be no application of the experimental and control product. Challenge period (3\\r\\ndays): the experimental and control product will be applied to the participants' back, in\\r\\na naïve area. Products will be removed after 48 hours, with readings taking place after\\r\\nremoval and approximately 24 hours after removal. This period corresponds to the\\r\\nsensitization phase.\",\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Liquid bandage',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'liquid bandage - The liquid bandage will be distributed on a contact test filter paper\\r\\ndisc, appropriately identified, in the letter of the alphabet corresponding to the\\r\\nexperimental product.',\n",
       "      'interventionNames': ['Device: Liquid bandage']},\n",
       "     {'label': 'Saline Solution',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': 'saline solution - The sterile saline solution (NaCl 0.9%) will be used as control in\\r\\nanother contact test filter paper disc, appropriately identified, in the letter of the\\r\\nalphabet corresponding to the control.',\n",
       "      'interventionNames': ['Device: Saline Solution']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Liquid bandage',\n",
       "      'description': \"The liquid bandage will be applied through a patch test to the participants' backs for 3\\r\\nconsecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of\\r\\nbetween 10 and 15 days. The liquid bandage will be applied again to the participants'\\r\\nback, in a naive area and removed after 48 hours.\",\n",
       "      'armGroupLabels': ['Liquid bandage']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Saline Solution',\n",
       "      'description': \"The saline solution will be applied via patch test to the participants' backs for 3\\r\\nconsecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of\\r\\nbetween 10 and 15 days. The saline solution will be applied again to the participants'\\r\\nback, in a naive area and removed after 48 hours.\",\n",
       "      'armGroupLabels': ['Saline Solution']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Prove the absence of primary irritability potential of the experimental product under maximized conditions.',\n",
       "      'description': '  -  Occurrence of primary irritation;\\r\\n\\r\\n  -  Occurrence of accumulated irritation;\\r\\n\\r\\n  -  Occurrence of sensitization;\\r\\n\\r\\n  -  Occurrence of AEs ;\\r\\n\\r\\n  -  Treatment discontinuations due to AEs . It is expected that after the study period,\\r\\n     the product will be considered safe because it does not promote a positive\\r\\n     irritability response and skin sensitization in the study group. No statistical\\r\\n     inference analysis will be performed. The results will be presented in the form of\\r\\n     tables demonstrating whether or not there was a positive response of irritability or\\r\\n     skin sensitization in the study group. During the study, the regions of the product\\r\\n     and control application will be evaluated and if any clinical sign is found, it will\\r\\n     be classified according to the scale recommended by the International Contact\\r\\n     Dermatitis Research Group - ICDRG - (FISHER, 1995).',\n",
       "      'timeFrame': '6 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age between 18 and 70 years old.\\r\\n\\r\\n  -  Fitzpatrick phototype I to IV.\\r\\n\\r\\n  -  Presence of intact skin in the test region.\\r\\n\\r\\n  -  Agreement to comply with the study procedures and requirements and attend the\\r\\n     institute on the days and times determined for the assessments.\\r\\n\\r\\n  -  Signature of the Informed Consent Form (ICF) before carrying out any study\\r\\n     procedure.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Presence of skin marks in the test region that interfere with the assessment of\\r\\n     possible skin reactions (for example, pigmentation disorders, vascular\\r\\n     malformations, scars, increased hairiness, large quantities of ephelides and nevus,\\r\\n     sunburn).\\r\\n\\r\\n  -  Presence of active dermatosis (local or disseminated) that could interfere with the\\r\\n     study results.\\r\\n\\r\\nistory of atopy (atopic dermatitis, allergic rhinitis, allergic bronchitis, allergic\\r\\nconjunctivitis, etc.).\\r\\n\\r\\n  -  History of allergic reactions, irritation or intense sensations of discomfort to\\r\\n     topical products such as, for example, cosmetics, health products or medicines.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Gleyce Lima',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 5090 8411',\n",
       "      'phoneExt': '8411',\n",
       "      'email': 'gleyce.lima@eurofarma.com'},\n",
       "     {'name': 'Luiza Terranova',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 5090 8421',\n",
       "      'email': 'luiza.terranova@eurofarma.com'}],\n",
       "    'locations': [{'facility': 'Eurofarma Laboratorios S.A',\n",
       "      'city': 'São Paulo',\n",
       "      'zip': '06696-000',\n",
       "      'country': 'Brazil',\n",
       "      'contacts': [{'name': 'Gleyce Lima',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '55 11 5090 8411',\n",
       "        'phoneExt': '8411',\n",
       "        'email': 'gleyce.lima@eurofarma.com'},\n",
       "       {'name': 'Luiza Terranova',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '55 1 15090 8421',\n",
       "        'email': 'luiza.terranova@eurofarma.com'}],\n",
       "      'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06353568',\n",
       "    'orgStudyIdInfo': {'id': '5.888.210'},\n",
       "    'organization': {'fullName': 'University of Nove de Julho',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effect of Photobiomodulation as a Preventive Treatment for Diabetic Foot',\n",
       "    'officialTitle': 'Effect of Photobiomodulation as a Preventive Treatment for Diabetic Foot: Randomized Controlled Blinded Clinical Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-10-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-27',\n",
       "    'studyFirstSubmitQcDate': '2024-04-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-09', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-09', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Kristianne Porta Santos Fernandes',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'University of Nove de Julho'},\n",
       "    'leadSponsor': {'name': 'University of Nove de Julho', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study seeks to evaluate the effect of photobiomodulation (PBM) in the prevention of\\r\\nDiabetic foot (DF), in patients at moderate and high risk for its development, through a\\r\\ncontrolled, randomized, double-blind clinical trial. Individuals between 18 and 75 years\\r\\nold of both sexes, with type 2 diabetes mellitus (DM), and moderate and high risk for DF\\r\\nwill be randomized and allocated into 2 groups of 32 participants each. The PBM Group\\r\\nwill use a boot with 1344 LEDs, 504 of which are 660 nm located on the sides of the boot\\r\\n(28.5 milliwatt, 10 J per LED); 504 850 nm also located on the sides of the boot (23\\r\\nmilliwatt, 8 J per LED); 168 of 660 nm located at the base of the boot (28.5 milliwatt,\\r\\n10 J per LED); 168 of 850 nm also located at the base of the boot (23 milliwatt, 8 J per\\r\\nLED) once a day for 6 minutes, for 60 days and will receive therapeutic education.\\r\\nParticipants will be evaluated at baseline, after 30 days (clinical examination) and\\r\\nafter 60 days (clinical examination, Peripheral Neuropathy (PN) assessment, Peripheral\\r\\nArtery Disease (PAD) assessment, blood and urine tests, and quality of life).',\n",
       "    'detailedDescription': 'Diabetic foot (DF) prevention involves risk classification, systemic care, assessment of\\r\\nPeripheral Artery Disease (PAD) and Peripheral Neuropathy (PN), regular foot examination,\\r\\ntherapeutic education, and routine use of appropriate footwear. Photobiomodulation (PBM)\\r\\nhas been successfully applied in the healing of DF. In addition to the therapeutic\\r\\neffects of PBM, its preventive effects have attracted the attention of researchers. This\\r\\nstudy seeks to evaluate the effect of PBM in the prevention of DF, in patients at\\r\\nmoderate and high risk for its development, through a controlled, randomized,\\r\\ndouble-blind clinical trial. Individuals between 18 and 75 years old of both sexes, with\\r\\ntype 2 DM, and moderate and high risk for DF will be randomized and allocated into 2\\r\\ngroups of 32 participants each. The PBM Group will use a boot with 1344 LEDs, 504 of\\r\\nwhich are 660 nm located on the sides of the boot (28.5 milliwatt, 10 J per LED); 504 850\\r\\nnm also located on the sides of the boot (23 milliwatt, 8 J per LED); 168 of 660 nm\\r\\nlocated at the base of the boot (28.5 milliwatt, 10 J per LED); 168 of 850 nm also\\r\\nlocated at the base of the boot (23 milliwatt, 8 J per LED) once a day for 6 minutes, for\\r\\n60 days and will receive therapeutic education. Participants will be evaluated at\\r\\nbaseline and after 30 days (clinical examination) and 60 days (clinical examination, PN\\r\\nassessment, PAD assessment, blood and urine tests, and quality of life). The collected\\r\\ndata will be stored, and organized in a repository and the appropriate statistical tests\\r\\nwill be applied for each specific analysis. In all tests, a significance level of 5% will\\r\\nbe adopted.'},\n",
       "   'conditionsModule': {'conditions': ['Diabetic Foot'],\n",
       "    'keywords': ['photobiomodulation',\n",
       "     'diabetes mellitus',\n",
       "     'therapeutic education',\n",
       "     'LED light']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'The PBM Group will use a boot with 1344 LEDs once daily for 6 minutes, over 60 days, and\\r\\nwill receive therapeutic education.\\r\\n\\r\\nThe Control Group will use a non-therapeutic LED boot (placebo) for 6 minutes once daily\\r\\nfor 60 days and will also receive therapeutic education.\\r\\n\\r\\nParticipants will be assessed at the beginning of the study (baseline) and after 30 days\\r\\n(clinical examination) and 60 days (clinical examination, assessment of Peripheral\\r\\nneuropathy, assessment of peripheral artery disease, blood and urine tests, and quality\\r\\nof life evaluation).',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'maskingDescription': \"  -  1 physician-researcher who will conduct all initial evaluations and follow-up\\r\\n     examinations (excluding Doppler ultrasound, Ankle-Brachial Index - ABI, and\\r\\n     Toe-Brachial Index - TBI), without knowledge of the subjects' allocation, and will\\r\\n     administer the Informed Consent Form (ICF).\\r\\n\\r\\n  -  1 Vascular surgeon researcher who will perform Doppler ultrasound, Ankle-Brachial\\r\\n     Index (ABI), and Toe-Brachial Index (TBI) measurements during the initial assessment\\r\\n     and follow-up examinations, without knowledge of the subjects' allocation.\\r\\n\\r\\n  -  1 Nurse researcher who will retrieve the allocation envelope and provide the\\r\\n     appropriate PBM equipment (active or placebo), as well as provide recommendations\\r\\n     for its use at home.\\r\\n\\r\\n  -  1 Researcher, who will not participate in any assessments, will prepare\\r\\n     randomization and envelopes to ensure allocation confidentiality.\\r\\n\\r\\n  -  2 physician residents who will provide daily contact for device usage control,\\r\\n     guidance, addressing inquiries, etc.\",\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 64, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Photobiomodulation Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The PBM Group will use a boot with 1344 LEDs once daily for 6 minutes, over a period of\\r\\n60 days, and will receive therapeutic education.',\n",
       "      'interventionNames': ['Device: Photobiomodulation',\n",
       "       'Behavioral: Therapeutic education']},\n",
       "     {'label': 'Control Group',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': 'The Control Group will use a non-therapeutic LED boot (placebo) for 6 minutes once daily\\r\\nfor 60 days and will also receive therapeutic education.',\n",
       "      'interventionNames': ['Device: Simulation of Photobiomodulation',\n",
       "       'Behavioral: Therapeutic education']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Photobiomodulation',\n",
       "      'description': 'The PBM Group will use a boot with 1344 LEDs, including 504 LEDs of 660 nm located on the\\r\\nsides of the boot (28.5 mW, 10 J per LED); 504 LEDs of 850 nm also located on the sides\\r\\nof the boot (23 mW, 8 J per LED); 168 LEDs of 660 nm located at the base of the boot\\r\\n(28.5 mW, 10 J per LED); and 168 LEDs of 850 nm also located at the base of the boot (23\\r\\nmW, 8 J per LED) once daily for 6 minutes, over 60 days.',\n",
       "      'armGroupLabels': ['Photobiomodulation Group']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Simulation of Photobiomodulation',\n",
       "      'description': 'The Control Group will use a non-therapeutic LED boot (sham procedure) for 6 minutes once\\r\\ndaily for 60 days. The boot used is identical to the active boot, but there is no light\\r\\nemission.',\n",
       "      'armGroupLabels': ['Control Group']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Therapeutic education',\n",
       "      'description': 'Participants will receive therapeutic education regarding nutrition, foot examination,\\r\\nself-care, and guidance on physical activity.',\n",
       "      'armGroupLabels': ['Control Group', 'Photobiomodulation Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Ulcer Incidence',\n",
       "      'description': 'The incidence of foot ulcers will be assessed through clinical examination. In addition\\r\\nto these in-person assessments, participants will be monitored daily via telephone\\r\\ncontact, during which the researchers (resident physicians) will inquire about any\\r\\nchanges in the skin, discomfort, and the use of PBM equipment.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Ulcer Incidence',\n",
       "      'description': 'The incidence of foot ulcers will be assessed through clinical examination. In addition\\r\\nto these in-person assessments, participants will be monitored daily via telephone\\r\\ncontact, during which the researchers (resident physicians) will inquire about any\\r\\nchanges in the skin, discomfort, and the use of PBM equipment.',\n",
       "      'timeFrame': 'at 30 days'},\n",
       "     {'measure': 'Ulcer Incidence',\n",
       "      'description': 'The incidence of foot ulcers will be assessed through clinical examination. In addition\\r\\nto these in-person assessments, participants will be monitored daily via telephone\\r\\ncontact, during which the researchers (resident physicians) will inquire about any\\r\\nchanges in the skin, discomfort, and the use of PBM equipment.',\n",
       "      'timeFrame': 'at 60 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Tactile sensitivity with Semmes-Weinstein monofilament',\n",
       "      'description': 'This assessment will be conducted using the Semmes-Weinstein esthesiometer 5.07 with a 10\\r\\ng filament, following the standard technique outlined in the IWGDF 2019 guidelines, as\\r\\ndescribed in Annex 1. The test will be performed at three different locations on both\\r\\nfeet. Protective sensation will be considered present if the patient responds correctly\\r\\nin two out of three applications at each location, and absent if they respond incorrectly\\r\\nin two out of three applications. Each esthesiometer will be used to evaluate a maximum\\r\\nof 10 participants on the same day and discarded after 70 evaluations to maintain\\r\\naccuracy.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Tactile sensitivity with Semmes-Weinstein monofilament',\n",
       "      'description': 'This assessment will be conducted using the Semmes-Weinstein esthesiometer 5.07 with a 10\\r\\ng filament, following the standard technique outlined in the IWGDF 2019 guidelines, as\\r\\ndescribed in Annex 1. The test will be performed at three different locations on both\\r\\nfeet. Protective sensation will be considered present if the patient responds correctly\\r\\nin two out of three applications at each location, and absent if they respond incorrectly\\r\\nin two out of three applications. Each esthesiometer will be used to evaluate a maximum\\r\\nof 10 participants on the same day and discarded after 70 evaluations to maintain\\r\\naccuracy.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Vibratory sensitivity',\n",
       "      'description': 'Participants will be tested with a 128 Hz tuning fork applied to the dorsal aspect of the\\r\\ndistal phalanx of the first toe (hallux) or another toe if the hallux is absent. The test\\r\\nwill be considered positive if the participant responds correctly to at least two out of\\r\\nthree applications and negative if two out of three responses are incorrect',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Vibratory sensitivity',\n",
       "      'description': 'Participants will be tested with a 128 Hz tuning fork applied to the dorsal aspect of the\\r\\ndistal phalanx of the first toe (hallux) or another toe if the hallux is absent. The test\\r\\nwill be considered positive if the participant responds correctly to at least two out of\\r\\nthree applications and negative if two out of three responses are incorrect',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Assessment of Achilles reflex',\n",
       "      'description': 'The assessment of the Achilles reflex will be conducted with the participant seated, with\\r\\nthe foot relaxed and suspended in slight dorsiflexion. A gentle tap will be applied with\\r\\na reflex hammer to the Achilles tendon. The result will be considered abnormal if plantar\\r\\nflexion reflex of the foot is not observed. The loss of the Achilles tendon reflex is\\r\\nassociated with diabetic neuropathy',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Assessment of Achilles reflex',\n",
       "      'description': 'The assessment of the Achilles reflex will be conducted with the participant seated, with\\r\\nthe foot relaxed and suspended in slight dorsiflexion. A gentle tap will be applied with\\r\\na reflex hammer to the Achilles tendon. The result will be considered abnormal if plantar\\r\\nflexion reflex of the foot is not observed. The loss of the Achilles tendon reflex is\\r\\nassociated with diabetic neuropathy',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Neuropathy Symptom Score (NSS)',\n",
       "      'description': 'For the calculation of ESN, patients will be asked about: the sensation of pain or\\r\\ndiscomfort in the legs and the occurrence, location, timing, and relief of symptoms such\\r\\nas fatigue, cramps, itching, burning, numbness, and tingling in the lower limb. PN will\\r\\nbe considered mild when ESN scores between 3 and 4, moderate when between 5 and 6, or\\r\\nsevere when reaching 7 to 9 points.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Neuropathy Symptom Score (NSS)',\n",
       "      'description': 'For the calculation of ESN, patients will be asked about: the sensation of pain or\\r\\ndiscomfort in the legs and the occurrence, location, timing, and relief of symptoms such\\r\\nas fatigue, cramps, itching, burning, numbness, and tingling in the lower limbs. PN will\\r\\nbe considered mild when ESN scores between 3 and 4, moderate when between 5 and 6, or\\r\\nsevere when reaching 7 to 9 points.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Neuropathic Impairment Score (NIS)',\n",
       "      'description': 'Painful sensitivity will be assessed by applying pressure for 1 second with a\\r\\nblunt-tipped pin on the dorsal surface of the skin near the hallux nail, and thermal\\r\\nsensitivity will be assessed using a metal rod cooled to 32 and 36°C applied at the same\\r\\nlocation.\\r\\n\\r\\nBefore the tests, procedures will be demonstrated on the hands. Sensitivities will be\\r\\nscored on each foot as present (0 points) or reduced/absent (1 point). The reflex will be\\r\\nscored as normal (0 points), present with effort (1 point), or absent (2 points). ECN\\r\\nranges from 0 to 10, obtained by summing the scores of both feet. Values between 3 and 5\\r\\nindicate mild neuropathy signs, between 6-8 indicate moderate neuropathy signs, and\\r\\nbetween 9 and 10 indicate severe neuropathy signs',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Neuropathic Impairment Score (NIS)',\n",
       "      'description': 'Painful sensitivity will be assessed by applying pressure for 1 second with a\\r\\nblunt-tipped pin on the dorsal surface of the skin near the hallux nail, and thermal\\r\\nsensitivity will be assessed using a metal rod cooled to 32 and 36°C applied at the same\\r\\nlocation.\\r\\n\\r\\nBefore the tests, procedures will be demonstrated on the hands. Sensitivities will be\\r\\nscored on each foot as present (0 points) or reduced/absent (1 point). The reflex will be\\r\\nscored as normal (0 points), present with effort (1 point), or absent (2 points). ECN\\r\\nranges from 0 to 10, obtained by summing the scores of both feet. Values between 3 and 5\\r\\nindicate mild neuropathy signs, between 6-8 indicate moderate neuropathy signs, and\\r\\nbetween 9 and 10 indicate severe neuropathy signs',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Evaluation of the degree of ischemia',\n",
       "      'description': 'The ankle-brachial index (ABI) will be measured by placing the sphygmomanometer cuff in\\r\\nthe usual manner on the UL (above the elbow crease) and just above the ankle bones\\r\\n(ankle) on the LL with the patient in a supine position; inflating the cuff until the\\r\\nsound of blood flow becomes inaudible and then deflating it until the first sound of\\r\\nblood flow is heard, which corresponds to the maximum systolic pressure. Measurements\\r\\nwill be repeated three times.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Evaluation of the degree of ischemia',\n",
       "      'description': 'The ankle-brachial index (ABI) will be measured by placing the sphygmomanometer cuff in\\r\\nthe usual manner on the UL (above the elbow crease) and just above the ankle bones\\r\\n(ankle) on the LL with the patient in a supine position; inflating the cuff until the\\r\\nsound of blood flow becomes inaudible and then deflating it until the first sound of\\r\\nblood flow is heard, which corresponds to the maximum systolic pressure. Measurements\\r\\nwill be repeated three times.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Systolic peak velocity',\n",
       "      'description': 'In the distal segments of the anterior and posterior tibial arteries and fibular artery\\r\\nin cm²/s measured by Doppler ultrasound.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Systolic peak velocity',\n",
       "      'description': 'In the distal segments of the anterior and posterior tibial arteries and fibular artery\\r\\nin cm²/s measured by Doppler ultrasound.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Resistance Index',\n",
       "      'description': 'In the distal segments of the anterior and posterior tibial arteries and fibular artery -\\r\\ncalculated by the formula (systolic peak velocity - diastolic peak velocity) / systolic\\r\\npeak velocity.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Resistance Index',\n",
       "      'description': 'In the distal segments of the anterior and posterior tibial arteries and fibular artery -\\r\\ncalculated by the formula (systolic peak velocity - diastolic peak velocity) / systolic\\r\\npeak velocity.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Waveform pattern',\n",
       "      'description': 'The waveform pattern of the distal segments of the anterior and posterior tibial arteries\\r\\nand fibular artery in Doppler ultrasound examination will be classified as triphasic,\\r\\nbiphasic, or monophasic.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Waveform pattern',\n",
       "      'description': 'The waveform pattern of the distal segments of the anterior and posterior tibial arteries\\r\\nand fibular artery in Doppler ultrasound examination will be classified as triphasic,\\r\\nbiphasic, or monophasic.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Evaluation of claudication',\n",
       "      'description': 'The accuracy of using the Edinburgh Claudication Questionnaire alone is debatable, but\\r\\nthis instrument can be used as a complement to clinical evaluation data for PAD. The\\r\\nquestionnaire consists of 6 questions and has been validated for Portuguese. The\\r\\ndefinition of positive claudication requires the following set of responses: 1 = \"yes\", 2\\r\\n= \"no\", 3 = \"yes\", 5 = \"usually disappears in 10 minutes or less\", and 6 = \"calf\" and/or\\r\\n\"thigh\" and/or \"buttock\" (regardless of whether other locations are marked) or NEGATIVE\\r\\nif any different combination is marked. Question 4 is not used to define the presence but\\r\\nrather the severity of claudication: \"No\" = Grade 1 (mild severity); and \"Yes\" = Grade 2.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Evaluation of claudication',\n",
       "      'description': 'The accuracy of using the Edinburgh Claudication Questionnaire alone is debatable, but\\r\\nthis instrument can be used as a complement to clinical evaluation data for PAD. The\\r\\nquestionnaire consists of 6 questions and has been validated for Portuguese. The\\r\\ndefinition of positive claudication requires the following set of responses: 1 = \"yes\", 2\\r\\n= \"no\", 3 = \"yes\", 5 = \"usually disappears in 10 minutes or less\", and 6 = \"calf\" and/or\\r\\n\"thigh\" and/or \"buttock\" (regardless of whether other locations are marked) or NEGATIVE\\r\\nif any different combination is marked. Question 4 is not used to define the presence but\\r\\nrather the severity of claudication: \"No\" = Grade 1 (mild severity); and \"Yes\" = Grade 2.',\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Thermography',\n",
       "      'description': \". To utilize this technique, the imaging room should be climate-controlled with a\\r\\nstabilized temperature between 21 and 23°C. After removing shoes and socks, participants\\r\\nwill lie in a supine position with a pillow under their legs without ankle support,\\r\\nkeeping their legs slightly apart for at least 15 minutes to allow temperature\\r\\nequilibrium and circulation stabilization of the limbs. Participants will be instructed\\r\\nto clean their lower limbs or take a bath at least 2 hours before the examination, avoid\\r\\nphysical activity on the day of the examination, and refrain from applying creams or any\\r\\nsubstances to the lower limbs. Infrared images (thermograms) will be captured by a highly\\r\\nsensitive infrared sensor (18mm, resolution 320x240 pixels), Flir T420®, supported on a\\r\\ntripod maintained at 150 cm from the participants' foot soles, and a 15 cm ruler will be\\r\\nincluded in each image.\",\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Thermography',\n",
       "      'description': \". To utilize this technique, the imaging room should be climate-controlled with a\\r\\nstabilized temperature between 21 and 23°C. After removing shoes and socks, participants\\r\\nwill lie in a supine position with a pillow under their legs without ankle support,\\r\\nkeeping their legs slightly apart for at least 15 minutes to allow temperature\\r\\nequilibrium and circulation stabilization of the limbs. Participants will be instructed\\r\\nto clean their lower limbs or take a bath at least 2 hours before the examination, avoid\\r\\nphysical activity on the day of the examination, and refrain from applying creams or any\\r\\nsubstances to the lower limbs. Infrared images (thermograms) will be captured by a highly\\r\\nsensitive infrared sensor (18mm, resolution 320x240 pixels), Flir T420®, supported on a\\r\\ntripod maintained at 150 cm from the participants' foot soles, and a 15 cm ruler will be\\r\\nincluded in each image..\",\n",
       "      'timeFrame': 'at 60 days'},\n",
       "     {'measure': 'Quality of Life Assessment',\n",
       "      'description': 'The quality of life of individuals will be assessed using the Diabetes-21 instrument,\\r\\nwhich is a multidimensional scale adapted from the Diabetes-39, validated for Brazilian\\r\\nPortuguese.',\n",
       "      'timeFrame': 'Baseline (Before the intervention)'},\n",
       "     {'measure': 'Quality of Life Assessment',\n",
       "      'description': 'The quality of life of individuals will be assessed using the Diabetes-21 instrument,\\r\\nwhich is a multidimensional scale adapted from the Diabetes-39, validated for Brazilian\\r\\nPortuguese.',\n",
       "      'timeFrame': 'at 60 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Individuals diagnosed with type 2 Diabetes Mellitus (according to American Diabetes\\r\\n     Association 2021 criteria),\\r\\n\\r\\n  -  both sexes,\\r\\n\\r\\n  -  between 18 and 75 years,\\r\\n\\r\\n  -  Individuals classified, according to the International Working Group on the Diabetic\\r\\n     Foot (IWGDF- 2019) scale, as moderate to high risk for developing diabetic foot,\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Pregnant women\\r\\n\\r\\n  -  Individuals diagnosed with type 1 diabetics,\\r\\n\\r\\n  -  Individuals with neuropathy secondary to uncontrolled conditions (hypothyroidism,\\r\\n     vitamin B12 deficiency, alcoholism),\\r\\n\\r\\n  -  Individuals diagnosed with active infectious condition at the time of inclusion,\\r\\n\\r\\n  -  Individuals diagnosed with active ulcer or infectious skin lesion on the legs/feet,\\r\\n\\r\\n  -  Individuals with historic of osteomyelitis,\\r\\n\\r\\n  -  Individuals with Parkinson's disease,\\r\\n\\r\\n  -  Individuals with contracture condition,\\r\\n\\r\\n  -  Individuals with severe lower limb ischemia (Fontaine III and IV - Rutherford 4 to\\r\\n     6),\\r\\n\\r\\n  -  Individuals with a suspicious skin lesion for neoplasms or cutaneous dysplasias on\\r\\n     the legs/feet\\r\\n\\r\\n  -  Individuals diagnosed with oncologic disease or undergoing treatment within the last\\r\\n     3 (three) months,\\r\\n\\r\\n  -  Individuals presenting unstable angina, recent acute myocardial infarction, history\\r\\n     of severe arrhythmia within the last six months,\\r\\n\\r\\n  -  Individuals diagnosed with decompensated Chronic Obstructive Pulmonary Disease\\r\\n     (COPD),\\r\\n\\r\\n  -  Inability to understand the ICF,\\r\\n\\r\\n  -  Inability to attend appointments regularly.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Kristianne KS Fernandes, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+55 011 33859287',\n",
       "      'email': 'kristianneporta@gmail.com'},\n",
       "     {'name': 'Roselene Lourenço, PhD', 'role': 'CONTACT'}],\n",
       "    'overallOfficials': [{'name': 'Kristianne KS Fernandes, PhD',\n",
       "      'affiliation': 'University of Nove de Julho',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000017719',\n",
       "      'term': 'Diabetic Foot'}],\n",
       "    'ancestors': [{'id': 'D000003925', 'term': 'Diabetic Angiopathies'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000016523', 'term': 'Foot Ulcer'},\n",
       "     {'id': 'D000007871', 'term': 'Leg Ulcer'},\n",
       "     {'id': 'D000012883', 'term': 'Skin Ulcer'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000048909', 'term': 'Diabetes Complications'},\n",
       "     {'id': 'D000003920', 'term': 'Diabetes Mellitus'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000003929', 'term': 'Diabetic Neuropathies'}],\n",
       "    'browseLeaves': [{'id': 'M7115',\n",
       "      'name': 'Diabetes Mellitus',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M19933',\n",
       "      'name': 'Diabetic Foot',\n",
       "      'asFound': 'Diabetic Foot',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7120', 'name': 'Diabetic Angiopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17206', 'name': 'Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M18919', 'name': 'Foot Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M10883', 'name': 'Leg Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M15686', 'name': 'Skin Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7124', 'name': 'Diabetic Neuropathies', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06410703',\n",
       "    'orgStudyIdInfo': {'id': 'CW-103'},\n",
       "    'organization': {'fullName': 'Canwell Biotech Limited',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'CAN1012 Combined With PD-1 in Patients With Solid Tumors',\n",
       "    'officialTitle': 'A Phase Ib/IIa, Dose Escalation, Open-Label Study of Intratumoral CAN1012 Combined With PD-1 in Patients With Unresectable or Metastatic Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-05',\n",
       "    'studyFirstSubmitQcDate': '2024-05-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-10',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Canwell Biotech Limited', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose\\r\\nescalation study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable\\r\\nor Metastatic Advanced Solid Tumors who have exhausted options for standard of care\\r\\ntherapy.',\n",
       "    'detailedDescription': 'The scope of the study is to evaluate the safety of the combination therapy of CAN1012\\r\\nand PD-1 in human, study its efficacy and pharmacokinetics profiles, as well as explore\\r\\nits pharmacodynamic effects and biomarkers.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 71, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'CAN1012(0.01mg)+Toripalimab(240mg)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'CAN1012(0.01mg)+Toripalimab(240mg)',\n",
       "      'interventionNames': ['Drug: CAN1012']},\n",
       "     {'label': 'CAN1012(0.017mg)+Toripalimab(240mg)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'CAN1012(0.017mg)+Toripalimab(240mg)',\n",
       "      'interventionNames': ['Drug: CAN1012']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'CAN1012',\n",
       "      'description': 'CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the\\r\\napproved dose of 240mg IV Q3W',\n",
       "      'armGroupLabels': ['CAN1012(0.017mg)+Toripalimab(240mg)',\n",
       "       'CAN1012(0.01mg)+Toripalimab(240mg)'],\n",
       "      'otherNames': ['Toripalimab']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety and tolerability',\n",
       "      'description': 'Safety and tolerability as determined by assessing dose limiting toxicities, the maximum\\r\\ntolerated dose or maximal assessed dose per protocol in combination with toripalimab\\r\\n(anti-PD-1) with patients.',\n",
       "      'timeFrame': '1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'To determine the MTD and or RP2D of CAN1012 Combined with PD-1',\n",
       "      'description': 'Monitor a tumor response to the combination therapy according to RECIST 1.1 or iRECIST\\r\\n1.1 as appropriate.',\n",
       "      'timeFrame': 'Monitor a tumor response to the combination therapy according to RECIST 1.1 or iRECIST 1.1 as appropriate.'},\n",
       "     {'measure': 'To determine the Pharmacokinetics of CAN1012 Combined with PD-1',\n",
       "      'description': 'Determine CAN1012 concentrations in plasma after IT administration.',\n",
       "      'timeFrame': '1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Able and willing to provide written informed consent and willing to comply with the\\r\\n     study's requirements.\\r\\n\\r\\n  2. Male or female age ≥ 18 years at screening.\\r\\n\\r\\n  3. Patients with histologically and cytologically confirmed locally advanced or\\r\\n     metastatic solid tumors who have been refractory or intolerant to standard therapies\\r\\n     or for whom no standard therapy exists.\\r\\n\\r\\n  4. Metastatic or locally advanced solid tumor that has progressed on, is refractory to,\\r\\n     or for which there is no efficacious standard of care therapy. Preferred tumor types\\r\\n     include the following:\\r\\n\\r\\n     Carcinoma of skin, melanoma, Merkel cell carcinoma (MCC), breast cancer, head and\\r\\n     neck squamous cell carcinoma (HNSCC), sarcoma, cervical carcinoma, and colorectal\\r\\n     cancer\\r\\n\\r\\n  5. Performance status of 0-1 on the ECOG Performance Scale.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Unresolved toxicities from prior therapy, defined as having not resolved to Common\\r\\n     Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5.0) Grade 0 or 1,\\r\\n     with exception of endocrinopathies from prior therapy, alopecia, and vitiligo.\\r\\n\\r\\n  2. Treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or\\r\\n     equivalent.\\r\\n\\r\\n  3. Has an active infection requiring systemic therapy.\\r\\n\\r\\n  4. Unstable/inadequate cardiac function defined as follows:\\r\\n\\r\\n       1. New York Heart Association Class 3 or 4 congestive heart failure\\r\\n\\r\\n       2. uncontrolled hypertension\\r\\n\\r\\n       3. acute coronary syndrome within 6 months\\r\\n\\r\\n       4. clinical important cardiac arrhythmia\\r\\n\\r\\n       5. mean corrected QT (QTc) interval corrected for heart rate\\r\\n          >450msec（male），>470msec（female）.\\r\\n\\r\\n  5. A history of interstitial lung disease.\\r\\n\\r\\n  6. A history of coagulopathy resulting in uncontrolled bleeding or other bleeding\\r\\n     disorders.\\r\\n\\r\\n  7. Participated in a clinical study of an investigational agent within 30 days of\\r\\n     screening.\\r\\n\\r\\n  8. Has known psychiatric, substance abuse, or other disorders that would interfere with\\r\\n     cooperation with the requirements of the study in the opinion of the investigator.\\r\\n\\r\\n  9. Is pregnant or breastfeeding.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Herui Yao, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 020-34070412',\n",
       "      'email': 'yaoherui@mail.sysu.edu.cn'}],\n",
       "    'locations': [{'facility': 'Sun Yat-Sen University Sun Yat-Sen Memorial Hospital',\n",
       "      'city': 'Guangzhou',\n",
       "      'state': 'Guangdong',\n",
       "      'zip': '510535',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06300203',\n",
       "    'orgStudyIdInfo': {'id': 'CM310_IIS_SAR07'},\n",
       "    'organization': {'fullName': 'Beijing Tongren Hospital', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis',\n",
       "    'officialTitle': 'The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study',\n",
       "    'acronym': 'MEGREZ'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-02',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-02',\n",
       "    'studyFirstSubmitQcDate': '2024-03-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-02',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Beijing Tongren Hospital', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal\\r\\nmucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic\\r\\nindividuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea,\\r\\nitching, and nasal congestion, which may be accompanied by ocular symptoms, including eye\\r\\nitching, tearing, redness, and burning sensation, which are more common in patients with\\r\\nhay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of\\r\\npatients with AR, suggesting a comorbid feature of allergic disease.',\n",
       "    'detailedDescription': \"AR is a common clinical chronic nasal disease, affecting 10% to 20% of the world's\\r\\npopulation, and has become a global health problem. AR not only seriously affects the\\r\\nquality of life of patients, resulting in patient fatigue, impaired learning, attention,\\r\\nand decision-making ability, but also causes a heavy social burden.\\r\\n\\r\\nAR has a variety of classification methods. According to the type of allergen, it can be\\r\\ndivided into seasonal (SAR, common allergens are seasonal allergens such as pollen) and\\r\\nperennial (PAR, common allergens are indoor allergens such as dust mites or occupational\\r\\nallergies), which is a classification method often used in clinical studies. According to\\r\\nthe course of the disease, it can be divided into intermittent (symptom onset < 4\\r\\ndays/week, or < 4 consecutive weeks) and persistent (symptom onset ≥ 4 days/week, and ≥ 4\\r\\nconsecutive weeks). According to the severity of the disease, it can be divided into\\r\\nminor AR (mild symptoms, with no significant impact on quality of life) and\\r\\nmoderate-severe AR (more severe or severe symptoms, with significant impact on quality of\\r\\nlife). The results of the cooperative survey showed that persistent moderate-to-severe\\r\\ndisease was the most common in the overall population, accounting for 52.2%, indicating\\r\\nthat the treatment and control of AR has become an urgent problem to be solved.\"},\n",
       "   'conditionsModule': {'conditions': ['Seasonal Allergic Rhinitis']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Interleukin-4 receptor responders',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Interleukin-4 receptor was injected subcutaneously.',\n",
       "      'interventionNames': ['Biological: Interleukin-4 receptor responders']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo was injected subcutaneously.',\n",
       "      'interventionNames': ['Other: Placebo']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'Interleukin-4 receptor responders',\n",
       "      'description': 'Interleukin-4 receptor was injected subcutaneously.',\n",
       "      'armGroupLabels': ['Interleukin-4 receptor responders']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Placebo was injected subcutaneously.',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Average change from baseline in daily retrospective total nasal symptom score (rTNSS) at week 2.',\n",
       "      'description': 'Average change from baseline in daily retrospective total nasal symptom score (rTNSS)\\r\\nduring treatment period. The Total Nasal Symptom Score (TNSS) is the sum of the four\\r\\nsymptom scores of runny nose, nasal congestion, nasal itching, and sneezing, with each\\r\\nsymptom scoring from 0 to 3.',\n",
       "      'timeFrame': 'up to Week 2'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Voluntarily sign the informed consent form.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Have any condition that are not suitable for participating in this study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Luo Zhang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86-13910830399',\n",
       "      'email': 'dr.luozhang@139.com'}],\n",
       "    'overallOfficials': [{'name': 'Luo Zhang',\n",
       "      'affiliation': 'Beijing Tong-Ren hospital',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'Beijing Tongren Hospital, Capital Medical University',\n",
       "      'city': 'Beijing',\n",
       "      'state': 'Beijing',\n",
       "      'zip': '100000',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000012220',\n",
       "      'term': 'Rhinitis'},\n",
       "     {'id': 'D000065631', 'term': 'Rhinitis, Allergic'},\n",
       "     {'id': 'D000006255', 'term': 'Rhinitis, Allergic, Seasonal'}],\n",
       "    'ancestors': [{'id': 'D000012141', 'term': 'Respiratory Tract Infections'},\n",
       "     {'id': 'D000007239', 'term': 'Infections'},\n",
       "     {'id': 'D000009668', 'term': 'Nose Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000010038', 'term': 'Otorhinolaryngologic Diseases'},\n",
       "     {'id': 'D000012130', 'term': 'Respiratory Hypersensitivity'},\n",
       "     {'id': 'D000006969', 'term': 'Hypersensitivity, Immediate'},\n",
       "     {'id': 'D000006967', 'term': 'Hypersensitivity'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M15049',\n",
       "      'name': 'Rhinitis',\n",
       "      'asFound': 'Rhinitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M30545',\n",
       "      'name': 'Rhinitis, Allergic',\n",
       "      'asFound': 'Allergic Rhinitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9345',\n",
       "      'name': 'Rhinitis, Allergic, Seasonal',\n",
       "      'asFound': 'Seasonal Allergic Rhinitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14978',\n",
       "      'name': 'Respiratory Tract Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12604', 'name': 'Nose Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12961',\n",
       "      'name': 'Otorhinolaryngologic Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'},\n",
       "     {'id': 'M14967',\n",
       "      'name': 'Respiratory Hypersensitivity',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10020',\n",
       "      'name': 'Hypersensitivity, Immediate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'BC09', 'name': 'Ear, Nose, and Throat Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000015847',\n",
       "      'term': 'Interleukin-4'}],\n",
       "    'ancestors': [{'id': 'D000000276', 'term': 'Adjuvants, Immunologic'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000018501', 'term': 'Antirheumatic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M18396',\n",
       "      'name': 'Interleukin-4',\n",
       "      'asFound': 'Eicosapentaenoic acid (EPA)',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3628', 'name': 'Adjuvants, Immunologic', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06426290',\n",
       "    'orgStudyIdInfo': {'id': 'CHMY-2021-06'},\n",
       "    'organization': {'fullName': 'Centre Hospitalier de Moulins Yzeure',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Prediction of Response to Bariatric Surgery in Patients With Severe Obesity',\n",
       "    'officialTitle': 'Prediction of Response to Bariatric Surgery Treatment in Patients Suffering From Severe Obesity, Based on the Scales of the MMPI-2-RF Questionnaire Carried Out Preoperatively',\n",
       "    'acronym': 'PREDI-CHIRBA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-03', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-16',\n",
       "    'studyFirstSubmitQcDate': '2024-05-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Centre Hospitalier de Moulins Yzeure',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is an retrospective and prospective (ambispective) study with data collection from\\r\\nvolunteer patients who passed an MMPI-2-RF (Minnesota Multiphasic Personality\\r\\nInventory-2-Restructured form) questionnaire in the preoperative phase of a bariatric\\r\\nsurgery project.\\r\\n\\r\\nThe evolution of their BMI will be correlated to psychological dimensions collected in\\r\\npatient questionnaires, before and after bariatric surgery.\\r\\n\\r\\nThe presence of possible risk factors such as depression, anxiety, eating disorders,\\r\\nquality of life, satisfaction and the perception of body, could make it possible to\\r\\nestablish adapted therapies before surgery, in order to attenuate or eliminate the\\r\\npresence of these factors, and improve BMI evolution and bariatric surgery success.',\n",
       "    'detailedDescription': 'A first phase of data collection will concern data from the MMPI-2-RF questionnaire as\\r\\nwell as clinical data, collected during preoperative consultations.\\r\\n\\r\\nFor the second phase, post-operative data will be collected, during a routine follow-up\\r\\nconsultation in the nutrition Department, where specific psychological questionnaires are\\r\\ntaken by patients.'},\n",
       "   'conditionsModule': {'conditions': ['Body Weight Changes']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'OTHER'},\n",
       "    'enrollmentInfo': {'count': 360, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'post-surgery psychological evaluation',\n",
       "      'description': 'Following questionnaires will be done :\\r\\n\\r\\nPatient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) Three Factor\\r\\nEating Questionnaire (TFEQ-R21) Quality of life for obesity and dietetic questionnaire\\r\\n(EQVOD) Body Esteem Scale (BES) Figure Rating Scale (auto-questionnaire)'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Determine the predictive value of depressive symptomatology dimension on the evolution of BMI.',\n",
       "      'description': 'Depressive dimension assessed by the preoperative MMPI-2-RF questionnaire and compared to\\r\\nthe same dimension from post-surgery psychological questionnaires.',\n",
       "      'timeFrame': 'At inclusion psychological consultation'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Determine the predictive value of anxiety symptomatology dimension on the evolution of BMI',\n",
       "      'description': 'Anxiety dimension assessed by the preoperative MMPI-2-RF questionnaire and compared to\\r\\nthe same dimension from post-surgery psychological questionnaires.',\n",
       "      'timeFrame': 'At inclusion psychological consultation'},\n",
       "     {'measure': 'Determine the predictive value of eating behavior dimension on the evolution of BMI',\n",
       "      'description': 'Eating behaviour dimension assessed by the preoperative MMPI-2-RF questionnaire and\\r\\ncompared to the same dimension from post-surgery psychological questionnaires.',\n",
       "      'timeFrame': 'At inclusion psychological consultation'},\n",
       "     {'measure': 'Determine the predictive value of quality of life dimension on the evolution of BMI',\n",
       "      'description': 'Quality of life dimension assessed by the preoperative MMPI-2-RF questionnaire and\\r\\ncompared to the same dimension from post-surgery psychological questionnaires.',\n",
       "      'timeFrame': 'At inclusion psychological consultation'},\n",
       "     {'measure': 'Determine the predictive value of satisfaction and body perception dimensions on the evolution of BMI',\n",
       "      'description': 'satisfaction and body perception dimensions assessed by the preoperative MMPI-2-RF\\r\\nquestionnaire and compared to the same dimension from post-surgery psychological\\r\\nquestionnaires.',\n",
       "      'timeFrame': 'At inclusion psychological consultation'},\n",
       "     {'measure': 'Determine typical profiles of patients who have finally denied surgery apart from medical contraindications',\n",
       "      'description': 'Using the MMPI-2-RF preoperative questionnaire',\n",
       "      'timeFrame': 'At inclusion psychological consultation'},\n",
       "     {'measure': 'Identify the risk factors for abandonment or difficulties after the intervention, in order to establish appropriate preoperative treatments before surgery',\n",
       "      'description': 'Using the MMPI-2-RF preoperative questionnaire',\n",
       "      'timeFrame': 'At inclusion psychological consultation'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Having been treated in the Nutrition department for severe obesity and considered\\r\\n     for bariatric surgery because having met the criteria validating bariatric surgery:\\r\\n\\r\\n  -  Having passed the MMPI-2-RF questionnaire between January 1, 2014 and December 31,\\r\\n     2023 in the preoperative phase, as part of psychological follow-up\\r\\n\\r\\n  -  Having benefited from bariatric surgery or patients who have abandoned the surgery\\r\\n     plan for a reason other than a medical contraindication.\\r\\n\\r\\n  -  Informed of the study, having agreed to participate and not having opposed the use\\r\\n     of their data\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Subjects who generated an invalid MMPI-2-RF questionnaire, according to the test\\r\\n     validity criteria (verified by the principal investigator)\\r\\n\\r\\n  -  Subjects who expressly objected to the use of their data for this study\\r\\n\\r\\n  -  Subjects who have not undergone bariatric surgery due to a medical contraindication.\\r\\n\\r\\n  -  Patient unable to understand the study or complete the post-operative phase visit\\r\\n\\r\\n  -  Persons under guardianship or curators or under legal protection',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patients with severe obesity : BMI > 40 kg/m2 or > 35 kg/m2 associated with at least one\\r\\ncomorbidity likely to be improved after surgery.\\r\\n\\r\\n  -  Failure of well-conducted medical, nutritional, dietetic and psychotherapeutic\\r\\n     monitoring for 6-12 months\\r\\n\\r\\n  -  Lack of sufficient weight loss or failure to maintain weight loss',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Virginie ALLASSEUR, psychologist',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '33478357884',\n",
       "      'email': 'v.allasseur@ch-moulins-yzeure.fr'},\n",
       "     {'name': 'Sophie PAGNON, CRA',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '33470357822',\n",
       "      'email': 's.pagnon@ch-moulins-yzeure.fr'}],\n",
       "    'overallOfficials': [{'name': 'Virginie ALLASSEUR, psychologist',\n",
       "      'affiliation': 'Centre Hospitalier de Moulins Yzeure',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Centre hospitalier Moulins-Yzeure',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Moulins',\n",
       "      'zip': '03000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'psychologist',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '33478357884',\n",
       "        'email': 'v.allasseur@ch-moulins-yzeure.fr'},\n",
       "       {'name': 'Sophie PAGNON, CRA',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '33470357822',\n",
       "        'email': 's.pagnon@ch-moulins-yzeure.fr'},\n",
       "       {'name': 'Virginie ALLASSEUR', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 46.56667, 'lon': 3.33333}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009767',\n",
       "      'term': 'Obesity, Morbid'},\n",
       "     {'id': 'D000001835', 'term': 'Body Weight'},\n",
       "     {'id': 'D000001836', 'term': 'Body Weight Changes'}],\n",
       "    'ancestors': [{'id': 'D000009765', 'term': 'Obesity'},\n",
       "     {'id': 'D000050177', 'term': 'Overweight'},\n",
       "     {'id': 'D000044343', 'term': 'Overnutrition'},\n",
       "     {'id': 'D000009748', 'term': 'Nutrition Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M12701', 'name': 'Obesity', 'relevance': 'LOW'},\n",
       "     {'id': 'M5114',\n",
       "      'name': 'Body Weight',\n",
       "      'asFound': 'Body Weight',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12702',\n",
       "      'name': 'Obesity, Morbid',\n",
       "      'asFound': 'Severe Obesity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5115',\n",
       "      'name': 'Body Weight Changes',\n",
       "      'asFound': 'Body Weight Changes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26186', 'name': 'Overweight', 'relevance': 'LOW'},\n",
       "     {'id': 'M25307', 'name': 'Overnutrition', 'relevance': 'LOW'},\n",
       "     {'id': 'M12684', 'name': 'Nutrition Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06106672',\n",
       "    'orgStudyIdInfo': {'id': 'CNP-106-5.001'},\n",
       "    'organization': {'fullName': 'COUR Pharmaceutical Development Company, Inc.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis',\n",
       "    'officialTitle': 'A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-106 in Subjects Ages 18-75 With Generalized Myasthenia Gravis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-08', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-24',\n",
       "    'studyFirstSubmitQcDate': '2023-10-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-30', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'COUR Pharmaceutical Development Company, Inc.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability,\\r\\npharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.',\n",
       "    'detailedDescription': 'This is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety,\\r\\ntolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.\\r\\nThe clinical study lasts 222-days (up to 42 days for Screening, 180 Study Days). Subjects\\r\\nages 18-75 with generalized myasthenia gravis (MG) will be screened up to 42 days prior\\r\\nto enrollment into the clinical study.'},\n",
       "   'conditionsModule': {'conditions': ['Myasthenia Gravis',\n",
       "     'Generalized Myasthenia',\n",
       "     'AChR Myasthenia Gravis',\n",
       "     'MuSK MG']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 54, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'CNP-106',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '200 mL intravenous infusion on Day 1 and Day 8: CNP-106',\n",
       "      'interventionNames': ['Drug: CNP-106']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'CNP-106 Placebo',\n",
       "      'interventionNames': ['Other: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'CNP-106',\n",
       "      'description': 'CNP-106 is comprised of an antigenic AChR Peptide Pool (~1 μg of each AChRα and AChRε\\r\\npeptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a\\r\\nnegatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide,\\r\\n50:50 acid-end group)) particles (400-800 nm in size).',\n",
       "      'armGroupLabels': ['CNP-106']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'CNP-106 Placebo',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs),',\n",
       "      'description': 'Frequency tables will be presented by treatment group for all AEs and SAEs by System\\r\\nOrgan Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by\\r\\ntreatment group for AEs leading to COUR Pharmaceuticals Development Company, Inc.\\r\\nConfidential CNP-106-5.001 Protocol; IND 28774 Page 53 of 65 discontinuation from IP and\\r\\nstudy, by severity, and by causality. No formal statistical testing will be done.',\n",
       "      'timeFrame': 'Through study day 180'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change from baseline in antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180.',\n",
       "      'description': 'The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups\\r\\nwill be analyzed using ANOVA.',\n",
       "      'timeFrame': 'Through study day 180'},\n",
       "     {'measure': 'Change from baseline in activated antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180.',\n",
       "      'description': 'The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups\\r\\nwill be analyzed using ANOVA.',\n",
       "      'timeFrame': 'Through study day 180'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Subjects who are willing and able to provide Institutional Review Board (IRB)\\r\\n     approved written informed consent and privacy language as per national regulations.\\r\\n\\r\\n  2. Men and non-pregnant women, ages 18-75 years inclusive.\\r\\n\\r\\n  3. Female subjects of childbearing potential must agree not to become pregnant during\\r\\n     the clinical study, have a negative pregnancy test at the Screening Visit, and agree\\r\\n     to one of the following:\\r\\n\\r\\n       -  Use two highly effective forms of birth control starting at initial screening\\r\\n          and continuing throughout the study duration.\\r\\n\\r\\n       -  Practice abstinence starting at initial screening and continuing throughout the\\r\\n          study duration.\\r\\n\\r\\n  4. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification\\r\\n     Class III-IV (Cohort 1). Upon successful DMC review and approval of preliminary\\r\\n     safety data obtained from Cohort 1 through Day 15, Cohort 2 will enroll subjects\\r\\n     with MGFA Clinical Classification Class II-IV.\\r\\n\\r\\n  5. Subjects positive for anti-AChR antibodies by radioimmunoassay (RIA) (Mayo Clinic).\\r\\n\\r\\n6, Subjects with MG-ADL Score ≥ 6 at Screening and Baseline Visit with ≥ 50% of the score\\r\\nderived from non-ocular symptoms.\\r\\n\\r\\n  7. Subjects with QMG Score ≥ 11 at Screening and Baseline Visit. 8. For subjects on any\\r\\n     medication used to treat the symptoms of MG (ex. Corticosteroids, pyridostigmine),\\r\\n     subjects must be on a stable dose for a minimum of 90 days prior to enrollment and\\r\\n     must agree not to increase their dose through clinical study duration unless\\r\\n     reviewed and approved by the medical monitor and the site investigator.\\r\\n\\r\\n  9. Female subjects who agree to not breastfeed starting at initial screening and\\r\\n     throughout the study duration.\\r\\n\\r\\n 10. Female subjects who agree to not donate ova starting at initial screening and\\r\\n     throughout the study duration.\\r\\n\\r\\n 11. Male subjects with a spouse or partner of childbearing potential, who themselves and\\r\\n     their spouse or partner agree to practice an effective form of birth control as\\r\\n     discussed with the study doctor or study staff starting at Screening and throughout\\r\\n     the study duration.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification\\r\\n     Class I or V.\\r\\n\\r\\n  2. Subjects with a history of cerebrovascular accident in the past 12 months.\\r\\n\\r\\n  3. Subjects with MG-ADL Score < 6 at Screen or Subjects with MG-ADL Score ≥ 6 at Screen\\r\\n     with ˂ 50% of the score derived from non-ocular symptoms.\\r\\n\\r\\n  4. Subjects with QMG Score < 11 at Screen.\\r\\n\\r\\n  5. Subjects who have used the following medications:\\r\\n\\r\\n       -  Tacrolimus within 6 months prior to the first dosing;\\r\\n\\r\\n       -  Methotrexate within 5 half-lives or 90 days after last dose (whichever is\\r\\n          longer);\\r\\n\\r\\n       -  Anti-FcRn inhibitors (ex. Efgartigimod) within 5 half-lives or 90 days after\\r\\n          last dose (whichever is longer);\\r\\n\\r\\n       -  C5 complement inhibitor (ex. Eculizumab) within 5 half-lives or 90 days after\\r\\n          last dose (whichever is longer);\\r\\n\\r\\n       -  Anti-CD20 (ex. Rituximab) within 5 half-lives for 90 days after last dose\\r\\n          (whichever is longer);\\r\\n\\r\\n       -  Inclusion of subjects on other immunomodulatory drugs will be at the discretion\\r\\n          of the medical monitor and study site investigator.\\r\\n\\r\\n  6. Subjects who have used immunoglobulins given SC or IV (SCIg or IVIg) or\\r\\n     plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.\\r\\n\\r\\n  7. Subjects who have had thymectomy or any other thymic surgery performed within 12\\r\\n     months prior to Screening.\\r\\n\\r\\n  8. Subjects with untreated thymic malignancy, carcinoma, or thymoma.\\r\\n\\r\\n  9. Subjects with a history of tuberculosis or positive PPD skin test.\\r\\n\\r\\n 10. Subjects who have received administration of any live vaccine (other than intranasal\\r\\n     Influenza) within 28 days or subunit vaccine within 14 days prior to Screening or\\r\\n     are planning to receive any vaccination throughout the study duration.\\r\\n\\r\\n 11. Subjects who have received any COVID-19 vaccine within 14 days prior to Screening.\\r\\n     Subjects who have received the first dose of any COVID-19 vaccine may not screen for\\r\\n     the study until 14 days following their last dose of the vaccine if applicable.\\r\\n\\r\\n 12. Subjects with laboratory test results at Screening or prior to study dosing that are\\r\\n     outside the normal limits and considered by the investigator to be clinically\\r\\n     significant. Note: Clinically significant laboratory test results at screening that\\r\\n     are related to the condition (MG) are acceptable as long as all inclusion and no\\r\\n     other exclusion criteria are met.\\r\\n\\r\\n 13. Subjects with positive test results for hepatitis B surface antigen (HbsAg),\\r\\n     hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV)\\r\\n     antigen/antibody as determined at Screening.\\r\\n\\r\\n 14. Subjects with a history of or currently active immune disorders other than MG\\r\\n     (including autoimmune disease) unless the condition, after discussion with the\\r\\n     medical monitor and study site investigator, has been deemed to be acceptable for\\r\\n     the subject's participation in this clinical study.\\r\\n\\r\\n 15. Subjects with a history of or current active diseases other than myasthenia gravis\\r\\n     requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone,\\r\\n     budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless\\r\\n     the condition, after discussion with the medical monitor and site investigator, has\\r\\n     been deemed to be acceptable for the subject's participation in this clinical study.\\r\\n\\r\\n 16. Subjects with a clinical history of significant cardiovascular disease as determined\\r\\n     by the Investigator.\\r\\n\\r\\n 17. Subjects with a complication or medical history of malignancy within the past 5\\r\\n     years which, in the investigator's opinion, makes the subject unsuitable for study\\r\\n     participation.\\r\\n\\r\\n 18. Subjects with a history of mast cell activation disease.\\r\\n\\r\\n 19. Subjects who, in the investigator's opinion, will be unable to adhere to study\\r\\n     procedures.\\r\\n\\r\\n 20. Subjects who have received an investigational therapy other than CNP-106 within 28\\r\\n     days or 5 half-lives, whichever is longer, prior to Screening.\\r\\n\\r\\n 21. Subjects with any known active condition which, in the investigator's opinion, makes\\r\\n     the subject unsuitable for study participation.\\r\\n\\r\\n 22. Known sensitivity to any components of CNP-106 (PLGA, sucrose, mannitol or sodium\\r\\n     citrate).\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jason Penix',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '773-339-5745',\n",
       "      'email': 'jpenix@courpharma.com'},\n",
       "     {'name': 'Lynlee Muehring',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '773-322-0646',\n",
       "      'email': 'lmuehring@courpharma.com'}],\n",
       "    'overallOfficials': [{'name': 'Roy First, MD',\n",
       "      'affiliation': 'COUR Pharmaceutical',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'Barrow Neurological Institute',\n",
       "      'city': 'Phoenix',\n",
       "      'state': 'Arizona',\n",
       "      'zip': '85013',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Nicole Turcotte',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '602-406-4775',\n",
       "        'email': 'nicole.turcotte@dignityhealth.org'},\n",
       "       {'name': 'Shafeeq Ladha, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "     {'facility': 'Neuromuscular Clinic and Research Center',\n",
       "      'city': 'Phoenix',\n",
       "      'state': 'Arizona',\n",
       "      'zip': '85028',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Lucia Rodriguez',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '480-314-1007',\n",
       "        'phoneExt': '6',\n",
       "        'email': 'lrodriguez@nrcaz.com'},\n",
       "       {'name': 'Kumaraswamy Sivakumar, MD',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.44838, 'lon': -112.07404}},\n",
       "     {'facility': 'Infusion for Health',\n",
       "      'city': 'Brea',\n",
       "      'state': 'California',\n",
       "      'zip': '92835',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Danielle Mendoza',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '626-536-8974',\n",
       "        'email': 'damendoza@infusionforhealth.com'},\n",
       "       {'name': 'Derrick Florin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.91668, 'lon': -117.90006}},\n",
       "     {'facility': 'University of California, Irvine',\n",
       "      'city': 'Orange',\n",
       "      'state': 'California',\n",
       "      'zip': '92868',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Archita Patel',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '714-456-2275',\n",
       "        'email': 'chuny@hs.uci.edu'},\n",
       "       {'name': 'Ali A Habib, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.78779, 'lon': -117.85311}},\n",
       "     {'facility': 'Yale University',\n",
       "      'city': 'New Haven',\n",
       "      'state': 'Connecticut',\n",
       "      'zip': '06516',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Erika Renkl',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '860-304-5626',\n",
       "        'email': 'erika.renkl@yale.edu'},\n",
       "       {'name': 'Bhaskar Roy, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 41.30815, 'lon': -72.92816}},\n",
       "     {'facility': 'Quantix Research, LLC',\n",
       "      'city': 'Miami',\n",
       "      'state': 'Florida',\n",
       "      'zip': '33173',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Hector Fernandez',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '305-230-7371',\n",
       "        'email': 'hector.fernandez@quantixresearch.com'},\n",
       "       {'name': 'Sergio Jaramillo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 25.77427, 'lon': -80.19366}},\n",
       "     {'facility': 'University of South Florida',\n",
       "      'city': 'Tampa',\n",
       "      'state': 'Florida',\n",
       "      'zip': '33612',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Naraly Requena',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '813-974-0575',\n",
       "        'email': 'naraly@usf.edu'},\n",
       "       {'name': 'Tuan Vu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 27.94752, 'lon': -82.45843}},\n",
       "     {'facility': 'University of Kansas Medical Center',\n",
       "      'city': 'Kansas City',\n",
       "      'state': 'Kansas',\n",
       "      'zip': '66160',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Abby Davis',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '913-945-9934',\n",
       "        'email': 'adavis54@kumc.edu'},\n",
       "       {'name': 'Mazen DiMachkie', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.11417, 'lon': -94.62746}},\n",
       "     {'facility': 'University of Minnesota',\n",
       "      'city': 'Minneapolis',\n",
       "      'state': 'Minnesota',\n",
       "      'zip': '55455',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Sarah Hilbert',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '612-624-5978',\n",
       "        'email': 'hilbe010@umn.edu'},\n",
       "       {'name': 'Jeffrey Allen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 44.97997, 'lon': -93.26384}},\n",
       "     {'facility': 'Ohio State University Wexner Medical Center',\n",
       "      'city': 'Columbus',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '43221',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Julie Agriesti',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '614-293-4098',\n",
       "        'email': 'Julie.Agriesti@osumc.edu'},\n",
       "       {'name': 'Miriam Freimer, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.96118, 'lon': -82.99879}},\n",
       "     {'facility': 'Medical University of South Carolina',\n",
       "      'city': 'Charleston',\n",
       "      'state': 'South Carolina',\n",
       "      'zip': '29425',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Alison Line',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '843-792-2845',\n",
       "        'email': 'line@musc.edu'},\n",
       "       {'name': 'Katherine Ruzhansky, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 32.77657, 'lon': -79.93092}},\n",
       "     {'facility': 'Nerve and Muscle Center of Texas',\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77030',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Amy Megerle',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '713-654-4900',\n",
       "        'email': 'houneuamy@msn.com'},\n",
       "       {'name': 'Aziz Shaibani, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': 'Virginia Commonwealth University',\n",
       "      'city': 'Richmond',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '23298',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Taylor Parkinson',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '804-482-1833',\n",
       "        'email': 'taylor.parkinson@vcuhealth.org'},\n",
       "       {'name': 'Gordon Smith, MD, FAAN', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009157',\n",
       "      'term': 'Myasthenia Gravis'},\n",
       "     {'id': 'D000018908', 'term': 'Muscle Weakness'}],\n",
       "    'ancestors': [{'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000020361', 'term': 'Paraneoplastic Syndromes, Nervous System'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000010257', 'term': 'Paraneoplastic Syndromes'},\n",
       "     {'id': 'D000020274', 'term': 'Autoimmune Diseases of the Nervous System'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "     {'id': 'D000020511', 'term': 'Neuromuscular Junction Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12112',\n",
       "      'name': 'Myasthenia Gravis',\n",
       "      'asFound': 'Myasthenia Gravis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20944',\n",
       "      'name': 'Muscle Weakness',\n",
       "      'asFound': 'Myasthenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13204', 'name': 'Paresis', 'relevance': 'LOW'},\n",
       "     {'id': 'M4554', 'name': 'Asthenia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22619',\n",
       "      'name': 'Neuromuscular Manifestations',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M13170', 'name': 'Paraneoplastic Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'M22160',\n",
       "      'name': 'Paraneoplastic Syndromes, Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22094',\n",
       "      'name': 'Autoimmune Diseases of the Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22297',\n",
       "      'name': 'Neuromuscular Junction Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3973',\n",
       "      'name': 'Myasthenia Gravis',\n",
       "      'asFound': 'Myasthenia Gravis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05994872',\n",
       "    'orgStudyIdInfo': {'id': '2023-0562'},\n",
       "    'organization': {'fullName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction',\n",
       "    'officialTitle': 'A Randomized Controlled Trial of Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction: a Prospective, Multicenter, Single-blind, Randomized Controlled Surgical Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-08',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-08-09',\n",
       "    'studyFirstSubmitQcDate': '2023-08-09',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-08-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-08-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Second Affiliated Hospital, School of Medicine, Zhejiang University',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Ningbo Medical Center Lihuili Hospital',\n",
       "      'class': 'OTHER_GOV'},\n",
       "     {'name': 'Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Shaoxing Traditional Chinese Medicine Hospital',\n",
       "      'class': 'UNKNOWN'},\n",
       "     {'name': 'Lishui Municipal Central Hospital', 'class': 'OTHER_GOV'},\n",
       "     {'name': \"The First People's Hospital of Huzhou\", 'class': 'OTHER'},\n",
       "     {'name': \"Jiande First People's Hospital\", 'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Anterior cruciate ligament (ACL) injuries and bone tunnel enlargement (BTE) after ACL\\r\\nreconstruction (ACLR) remain frequent issues. Bone dust (BD) produced by tunnel\\r\\npreparation with osteogenic ability and reverse drilling (RD), an easy compaction\\r\\ntechnique, make it accessible to enhance tendon-bone healing in ACLR. We hyposize that RD\\r\\nand BD synergistically improve outcomes after arthroscopic ACLR by improving peritunnel\\r\\nbone and preventing BTE.',\n",
       "    'detailedDescription': 'Compaction technique can create a denser bone tunnel wall with more cancellous bone\\r\\nautografting in situ by sequentially compressing cancellous bone trabeculae to bone\\r\\ntunnel walls, in contrast to conventional extraction reaming by which an enlarged gap is\\r\\ncreated and initial direct integration is limited between implants and bone, as chunks of\\r\\ncancellous bone are torn out, thereby being removed outside the tunnel. Biologically, a\\r\\ncompaction technique was reported to increase the bone volume around grafts and provide a\\r\\nlarger area of bone-to-graft contact for bone integration because of the spring-back\\r\\neffect. Mechanically, compaction of the bone graft into the femoral tunnel was reported\\r\\nto significantly increase stiffness of the grafts. Reverse drilling (RD) can compress\\r\\nperitunnel bone at the time of bone tunnel preparation to make the tunnel wall denser and\\r\\nsmoother in comparison with extraction drilling (ED), reverse drilling yields the same\\r\\ncompaction effect as the compaction technique. Bone dust (BD) is commonly defined as\\r\\npieces of bone produced by a power-driven tool. It is universally accepted that bone\\r\\ndebris more than 200 mm in particle size is classified as particulate bone and that bone\\r\\ndebris no more than 200 mm is classified as BD. When applied for ACLR, BD could fully\\r\\nutilize the advantages of an autologous bone graft while avoiding invasive and traumatic\\r\\nbone harvesting procedures, as bone tunnel preparation is accompanied by the production\\r\\nof a considerable amount of BD. Therefore, BD grafting is promising for improving\\r\\ntendon-bone healing with safety and simplification. We refer to the technique of\\r\\nretaining BD in the bone tunnel after RD as the reverse drilling technique. We hyposize\\r\\nthat reverse drilling technique can improve outcomes after arthroscopic anterior cruciate\\r\\nligament reconstruction by improving peritunnel bone and preventing bone tunnel\\r\\nenlargement.'},\n",
       "   'conditionsModule': {'conditions': ['Anterior Cruciate Ligament Injuries'],\n",
       "    'keywords': ['Reverse drilling technique',\n",
       "     'Anterior cruciate ligament reconstruction',\n",
       "     'Tendon-to-bone healing']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'maskingDescription': 'Surgical doctor team, patient, outcome assessor, data analyst and image reviewer are\\r\\nmasked.',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 216, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Traditional extraction drilling',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': 'A standard hamstring autograft procedure was performed using traditional extraction\\r\\ndrilling to prepare bone tunnel (n = 108).',\n",
       "      'interventionNames': ['Procedure: Traditional extraction drilling']},\n",
       "     {'label': 'Reverse drilling technique',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A standard hamstring autograft procedure was performed using reverse drilling technique\\r\\nto prepare bone tunnel (n = 108).',\n",
       "      'interventionNames': ['Procedure: Reverse drilling technique']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Reverse drilling technique',\n",
       "      'description': 'A standard hamstring autograft procedure was performed using reverse drilling technique\\r\\nto prepare bone tunnel.',\n",
       "      'armGroupLabels': ['Reverse drilling technique']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Traditional extraction drilling',\n",
       "      'description': 'A standard hamstring autograft procedure was performed using traditional extraction\\r\\ndrilling to prepare bone tunnel.',\n",
       "      'armGroupLabels': ['Traditional extraction drilling']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'IKDC Subjective Score',\n",
       "      'description': 'This table consists of knee joint assessment (10 items) and knee ligament examination (8\\r\\nitems), which includes joint pain, exercise level, and daily activity ability, with a\\r\\ntotal score of 0-100 points.',\n",
       "      'timeFrame': 'Patients will be followed up regularly at 3, 6, 9, 12, and 24 months after surgery.'},\n",
       "     {'measure': 'Bone tunnel enlargement',\n",
       "      'description': 'Measurement of bone tunnel enlargement through postoperative image',\n",
       "      'timeFrame': 'Patients will be followed up regularly at 3, 6, 9, 12, and 24 months after surgery.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Instrumented AP Knee Laxity',\n",
       "      'description': 'Arthrometer testing (KT-1000; MEDMetric) was used to measure the anterior displacement of\\r\\nthe tibia with respect to the femur under 130 N of applied anterior force and performed\\r\\nin duplicate on each leg.',\n",
       "      'timeFrame': 'Patients will be followed up regularly at 3, 6, 9, 12, and 24 months after surgery.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nPatients with definite anterior cruciate ligament injuries on imaging or intraoperative\\r\\narthroscopy (Sherman grading II and III), plan surgery within 45 days from injury; have\\r\\nbasic literacy skills and unimpeded communication; have a smartphone and are able to use\\r\\nWeChat; and have been given informed consent and have signed to obtain an informed\\r\\nconsent form, and the process must be in accordance with GCP requirements.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1) Combined with other knee injuries (posterior cruciate ligament injury, patellar\\r\\n     dislocation, osteoarthritis, etc.); 2) Suffering from systemic immune diseases; 3)\\r\\n     Presence of other diseases or inflammatory diseases of the knee, including\\r\\n     osteoarthritis, cervical spondylosis, rheumatoid arthritis, fibromyalgia, and\\r\\n     rheumatic polymyalgia, etc.; 4) Patients who have had localized hormone injection\\r\\n     therapy within 3 months; 5) Those who have participated in a clinical trials or are\\r\\n     undergoing other clinical trials; 6) Those with severe primary cardiovascular\\r\\n     lesions, pulmonary diseases, endocrine and metabolic diseases or serious diseases\\r\\n     affecting their survival, such as tumors or AIDS, which in the opinion of the\\r\\n     investigator are not suitable for enrollment; 7) Those with severe hepatic lesions,\\r\\n     renal lesions, and hematologic lesions, such as renal function exceeding the upper\\r\\n     limit of normal values and hepatic function exceeding two times the upper limit of\\r\\n     normal values; and 8) Those with viral hepatitis, infectious diseases, severe\\r\\n     abnormalities of coagulation mechanism and other diseases that the investigator\\r\\n     considers inappropriate for surgery; 9) Pregnant or lactating women, or those who\\r\\n     plan to conceive during the follow-up period, with a positive result of urinary\\r\\n     human chorionic gonadotropin test prior to sampling; menstruating women should wait\\r\\n     until the end of their menstruation period to undergo the surgery; 10) Patients with\\r\\n     severe neurological or psychiatric disorders; 11) Those with a suspected or\\r\\n     confirmed alcoholic substance abuse history; 12) Vulnerable groups: mentally ill,\\r\\n     critically ill patients, pregnant women, illiterate, minors, cognitively impaired.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '55 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Haobo Wu, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 13958122387',\n",
       "      'email': '2505014@zju.edu.cn'},\n",
       "     {'name': 'An Liu, MD', 'role': 'CONTACT', 'email': 'la@zju.edu.cn'}],\n",
       "    'overallOfficials': [{'name': 'Haobo Wu, MD',\n",
       "      'affiliation': '2nd Affiliated Hospital, School of Medicine, Zhejiang University, China',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': \"The First People's Hospital of Huzhou\",\n",
       "      'city': 'Huzhou',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '313000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Zhanfeng Zhang, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 30.8703, 'lon': 120.0933}},\n",
       "     {'facility': \"Jiande First People's Hospital\",\n",
       "      'city': 'Jiande',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '311600',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Jie Xiao, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 35.23931, 'lon': 102.33897}},\n",
       "     {'facility': 'Lishui Municipal Central Hospital',\n",
       "      'city': 'Lishui',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '323000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Weidong Wu, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 28.46042, 'lon': 119.91029}},\n",
       "     {'facility': 'Ningbo Medical Center Lihuili Hospital',\n",
       "      'city': 'Ningbo',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '315000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Jin Li, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 29.87819, 'lon': 121.54945}},\n",
       "     {'facility': 'Shaoxing Traditional Chinese Medicine Hospital',\n",
       "      'city': 'Shaoxing',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '312000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Jianzeng Shen, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 30.00237, 'lon': 120.57864}},\n",
       "     {'facility': 'Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University',\n",
       "      'city': 'Taizhou',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '318000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Xiaobo Zhou, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 32.49069, 'lon': 119.90812}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '35486517',\n",
       "      'type': 'RESULT',\n",
       "      'citation': \"Hoogeslag RAG, Huis In 't Veld R, Brouwer RW, de Graaff F, Verdonschot N. Acute Anterior Cruciate Ligament Rupture: Repair or Reconstruction? Five-Year Results of a Randomized Controlled Clinical Trial. Am J Sports Med. 2022 Jun;50(7):1779-1787. doi: 10.1177/03635465221090527. Epub 2022 Apr 29.\"},\n",
       "     {'pmid': '32298131',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Murray MM, Fleming BC, Badger GJ; BEAR Trial Team; Freiberger C, Henderson R, Barnett S, Kiapour A, Ecklund K, Proffen B, Sant N, Kramer DE, Micheli LJ, Yen YM. Bridge-Enhanced Anterior Cruciate Ligament Repair Is Not Inferior to Autograft Anterior Cruciate Ligament Reconstruction at 2 Years: Results of a Prospective Randomized Clinical Trial. Am J Sports Med. 2020 May;48(6):1305-1315. doi: 10.1177/0363546520913532. Epub 2020 Apr 16.'},\n",
       "     {'pmid': '35988569',\n",
       "      'type': 'RESULT',\n",
       "      'citation': \"Beard DJ, Davies L, Cook JA, Stokes J, Leal J, Fletcher H, Abram S, Chegwin K, Greshon A, Jackson W, Bottomley N, Dodd M, Bourke H, Shirkey BA, Paez A, Lamb SE, Barker K, Phillips M, Brown M, Lythe V, Mirza B, Carr A, Monk P, Morgado Areia C, O'Leary S, Haddad F, Wilson C, Price A; ACL SNNAP Study Group. Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial. Lancet. 2022 Aug 20;400(10352):605-615. doi: 10.1016/S0140-6736(22)01424-6.\"},\n",
       "     {'pmid': '16325084',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Fauno P, Kaalund S. Tunnel widening after hamstring anterior cruciate ligament reconstruction is influenced by the type of graft fixation used: a prospective randomized study. Arthroscopy. 2005 Nov;21(11):1337-41. doi: 10.1016/j.arthro.2005.08.023.'},\n",
       "     {'pmid': '25681503',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Weber AE, Delos D, Oltean HN, Vadasdi K, Cavanaugh J, Potter HG, Rodeo SA. Tibial and Femoral Tunnel Changes After ACL Reconstruction: A Prospective 2-Year Longitudinal MRI Study. Am J Sports Med. 2015 May;43(5):1147-56. doi: 10.1177/0363546515570461. Epub 2015 Feb 13.'},\n",
       "     {'pmid': '36326437',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Yang W, Li C, Ji X, Yao M, Hong J, Qu Z, Liu A, Wu H. Synergistic Effect of Reverse Drilling and Bone Dust on Femoral Tendon-Bone Healing After Anterior Cruciate Ligament Reconstruction in a Rabbit Model. Am J Sports Med. 2022 Dec;50(14):3844-3855. doi: 10.1177/03635465221129267. Epub 2022 Nov 3.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000070598',\n",
       "      'term': 'Anterior Cruciate Ligament Injuries'}],\n",
       "    'ancestors': [{'id': 'D000007718', 'term': 'Knee Injuries'},\n",
       "     {'id': 'D000007869', 'term': 'Leg Injuries'},\n",
       "     {'id': 'D000014947', 'term': 'Wounds and Injuries'}],\n",
       "    'browseLeaves': [{'id': 'M601',\n",
       "      'name': 'Anterior Cruciate Ligament Injuries',\n",
       "      'asFound': 'Anterior Cruciate Ligament Injuries',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10738', 'name': 'Knee Injuries', 'relevance': 'LOW'},\n",
       "     {'id': 'M10881', 'name': 'Leg Injuries', 'relevance': 'LOW'},\n",
       "     {'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC26', 'name': 'Wounds and Injuries'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419101',\n",
       "    'orgStudyIdInfo': {'id': 'KS2024051'},\n",
       "    'organization': {'fullName': 'Xuanwu Hospital, Beijing', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Exploring the Diagnostic Biomarkers of Cognitive Disorders in China',\n",
       "    'officialTitle': 'Cohort Study on Biomarkers of Cognitive Disorders in China'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2034-05-10', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2035-05-10', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-13',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Cuibai Wei，Clinical Professor',\n",
       "     'investigatorTitle': 'Xuanwu Hospital, Capital Medical University',\n",
       "     'investigatorAffiliation': 'Xuanwu Hospital, Beijing'},\n",
       "    'leadSponsor': {'name': 'Cuibai Wei，Clinical Professor', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'First Hospital of Shijiazhuang City',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Chongqing Medical University', 'class': 'OTHER'},\n",
       "     {'name': 'Tianjin Huanhu Hospital', 'class': 'OTHER'},\n",
       "     {'name': 'Central hospital Affiliated to Shandong First Medical University',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Dementia is a syndrome characterized by progressive global cognitive impairment that\\r\\nimpairs occupational, family, or social functioning. It detrimentally affects personal\\r\\nhealth and quality of life, imposing significant medical economy, social and\\r\\npsychological burden on the countries and the patients' family. The internationally\\r\\nrenowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI\\r\\ncohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc.\\r\\nEstablishing standardized and shared longitudinal follow-up dementia cohorts and clinical\\r\\ndatabase is an essential challenge for constructing dementia cohort in China. Moreover,\\r\\nthere is a lack of large-scale prospective longitudinal follow-up cohorts within the\\r\\nChinese population that cover subjective cognitive decline (SCD) to explore biomarkers\\r\\nwith diagnostic and early warning value for different kinds of dementia and pre-dementia\\r\\nstages. The study will rely on the dementia cohort based on Chinese population to explore\\r\\nthe biological phenotype characteristics of the pre-dementia stage and different dementia\\r\\nsubtypes, and observe the dynamic change rules of the dementia cohort vertically, so as\\r\\nto foster early intervention and improve prognosis for individuals with dementia.\",\n",
       "    'detailedDescription': 'The 3000 patients with pre-dementia stage and different dementia subtypes will be\\r\\nenrolled in this study, and data will be collected in the baseline including\\r\\ndemographics, clinical symptoms, assessment of neuropsychology, neuroimaging,\\r\\nneuroelectrophysiology, blood samples, cerebrospinal fluid, etc. The changes of these\\r\\ndata were dynamically observed through an annual follow-up. According to the\\r\\nneuropsychological evaluation results of follow-up, the subjects were divided into\\r\\ndementia progression (dementia-P) and dementia stabilization (dementia-S). Difference in\\r\\nclinical phenotype, neuropsychology, electrophysiology, neuroimaging, and body fluid\\r\\nmulti-omics indicators between the two subtypes were compared and analyzed. The\\r\\nneuropsychological testes in patients with dementia included some neuropsychological\\r\\nscales such as, Clinical Dementia Rating (CDR), Mini-Mental State Examination (MMSE),\\r\\nMontreal Cognitive Assessment (MoCA), etc. Multi-model neuroimaging evaluation screen the\\r\\ncandidate neuroimaging markers, including structure and functional brain magnetic\\r\\nresonance imaging (MRI), Diffusion tensor image (DTI), 18\\r\\nF-2-fluro-D-deoxy-glucose-positron emission tomography (18F-FDG-PET)，Amyloid-PET and\\r\\ntau-PET. To exploring neuroelectrophysiology biomarkers collect the data on\\r\\npolysomnography, resting state electroencephalogram, and evoked potentials (P1, N1, P2,\\r\\nN2, etc.). ELISA, SIMOA and other analytical methods were used to detect the contents\\r\\nrelated to dementia progression in the blood, cerebrospinal fluid, urine, saliva and\\r\\nfeces. Multi-dimensional screening and identifying biomarkers of disease diagnosis and\\r\\nprogression in all stages, from subjective cognitive impairment to mild cognitive\\r\\nimpairment to dementia, in line with the characteristics of the Chinese population.'},\n",
       "   'conditionsModule': {'conditions': ['Biomarkers', 'Dementia'],\n",
       "    'keywords': ['dementia', 'diagnostic biomarkers']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITH_DNA',\n",
       "     'description': 'blood samples, CSF, urine, faeces, saliva'},\n",
       "    'enrollmentInfo': {'count': 3000, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'dementia progression',\n",
       "      'description': 'dementia-P (Compared with the baseline, MMSE score declined ≥ 4 points per year)'},\n",
       "     {'label': 'dementia stabilization',\n",
       "      'description': 'dementia-S (Compared with the baseline, MMSE score decreased < 4 points per year）'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of change in global cognition as measured by Clinical Dementia Rating (CDR).',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales CDR. CDR, a multidimensional scale for dementia\\r\\nseverity, which scored 0-3, with higher scores indicating worse functioning.',\n",
       "      'timeFrame': '10 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Rate of change in global cognition as measured by Mini-Mental State Examination (MMSE)',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales MMSE. MMSE scores range from 0-30, with higher scores\\r\\nrepresenting better cognitive function.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': 'Rate of change in global cognition as measured by Montreal Cognitive Assessment (MoCA)',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales MoCA. MoCA scores range from 0-30, with higher scores\\r\\nrepresenting better cognitive function.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': \"Rate of change in the severity of cognitive impairment as assessed by Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-cog).\",\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales ADAS-cog. ADAS-cog scores range from 0-70, with\\r\\nhigher scores indicating better global cognitive function.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': 'Rate of change in memory function as assessed by World Health Organization-University of California, Los Angeles, auditory verbal learning test (WHO-UCLA AVLT).',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales like WHO-UCLA AVLT. WHO-UCLA AVLT scores depend on\\r\\nthe number of correct words, which ranges from 0-15, with higher scores representing\\r\\nbetter memory function.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': 'Rate of change in language function as assessed by Boston Naming Test (BNT).',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales like BNT. BNT scores range from 0-30, with higher\\r\\nscores representing better language function.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': 'Rate of change in psychobehavioral symptoms as assessed by Neuropsychiatric Inventory (NPI).',\n",
       "      'description': 'Assess statistically significant difference in score between dementia-P and dementia-S\\r\\nusing the neuropsychological scales like NPI. Patient assessment grading scores range\\r\\nfrom 0-144 in NPI, and caregivers distress grading scores range from 0-60, with 0\\r\\nrepresenting the best.',\n",
       "      'timeFrame': '10 years'},\n",
       "     {'measure': \"Rate of change in activities of daily living as assessed by Alzheimer's Disease Cooperative Study-Activity of Daily Living (ADCS-ADL).\",\n",
       "      'description': 'Assess statistically significant difference between in score dementia-P and dementia-S\\r\\nusing the neuropsychological scales like ADCS-ADL. ADCS-ADL scores range from 0-54, with\\r\\nhigher scores indicating better completion ability.',\n",
       "      'timeFrame': '10 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Male or female patients aged ≥40 and ≤90years;\\r\\n\\r\\n  -  Chief complaint or others describe a cognitive decline;\\r\\n\\r\\n  -  Ability to communicate in Chinese;\\r\\n\\r\\n  -  The patients and their families were informed and signed the informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  MMSE<10;\\r\\n\\r\\n  -  There are other neurological diseases that can cause brain dysfunction (such as\\r\\n     depression, brain tumors, Parkinson's disease, metabolic encephalopathy,\\r\\n     encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal\\r\\n     intracranial pressure hydrocephalus, etc.);\\r\\n\\r\\n  -  There are other systemic diseases that can cause cognitive impairment (such as\\r\\n     hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia,\\r\\n     folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug\\r\\n     abuse, etc.);\\r\\n\\r\\n  -  Suffering from a disease that cannot cooperate with the completion of cognitive\\r\\n     examination;\\r\\n\\r\\n  -  There are contraindications to nuclear magnetic resonance;\\r\\n\\r\\n  -  There is mental and neurodevelopmental delay;\\r\\n\\r\\n  -  Refuse to draw blood;\\r\\n\\r\\n  -  Refuse to sign the informed consent.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '40 Years',\n",
       "    'maximumAge': '90 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'This project will enroll about 3000 patients with dementia, who meet the inclusion and\\r\\nexclusion criteria, including subjective cognitive decline (SCD), MCI, AD, frontotemporal\\r\\ndementia (FTD), dementia with Lewy bodies (DLB), etc.',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Cuibai Wei',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '83198319',\n",
       "      'email': 'weicb@xwhosp.org'}],\n",
       "    'overallOfficials': [{'name': 'Cuibai Wei',\n",
       "      'affiliation': 'Xuan Wu Hospital of Capital Medical University, Beijing, China, 100053',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003704',\n",
       "      'term': 'Dementia'},\n",
       "     {'id': 'D000060825', 'term': 'Cognitive Dysfunction'},\n",
       "     {'id': 'D000003072', 'term': 'Cognition Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000019965', 'term': 'Neurocognitive Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M6301',\n",
       "      'name': 'Cognition Disorders',\n",
       "      'asFound': 'Cognitive Disorders',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6904',\n",
       "      'name': 'Dementia',\n",
       "      'asFound': 'Dementia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29705',\n",
       "      'name': 'Cognitive Dysfunction',\n",
       "      'asFound': 'Cognitive Disorders',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21836', 'name': 'Neurocognitive Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05952401',\n",
       "    'orgStudyIdInfo': {'id': '202307051'},\n",
       "    'secondaryIdInfos': [{'id': 'P50CA244431',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/P50CA244431'}],\n",
       "    'organization': {'fullName': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Implementation Science to Reduce the Disparity in Tobacco Treatment Among Individuals With Serious Mental Illness',\n",
       "    'officialTitle': 'Implementation Science to Reduce the Disparity in Tobacco Treatment Among Individuals With Serious Mental Illness (ISRAISE)',\n",
       "    'acronym': 'ISRAISE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'ENROLLING_BY_INVITATION',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-11',\n",
       "    'studyFirstSubmitQcDate': '2023-07-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-19', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Cancer Institute (NCI)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a pilot trial to examine the feasibility and preliminary effect of a multilevel\\r\\nintervention \\'Nudges to Quit\\' on smoking cessation in patients with serious mental\\r\\nillness who smoke in a community mental health center (CMHC). \"Nudges to Quit\" is a\\r\\nmultilevel intervention to increate engagement of patient, case worker, and pharmacist\\r\\nwith tobacco treatment. The pilot trial is to generate the needed evidence for designing\\r\\na future large trial to evaluate the effect of \\'Nudges to Quit\\' as a multilevel\\r\\nintervention to increase tobacco treatment and reduce tobacco use among patients with\\r\\nserious mental illness.',\n",
       "    'detailedDescription': 'The overarching goal of this pilot project is to reduce the disparity in the treatment of\\r\\ntobacco use among individuals with serious mental illness (SMI) with low burden,\\r\\nmulti-level implementation strategies, an important need reflected in existing evidence\\r\\nand a recent survey of community needs. Individuals with SMI have a much higher smoking\\r\\nprevalence (60% vs. 15%) and die 25 years earlier compared to the general population.\\r\\nDespite the fact that SMI patients express interest in and have success with\\r\\nevidence-based smoking cessation treatment, inadequate provision of treatment in\\r\\ncommunity mental health centers (CMHCs) contributes to the high smoking prevalence and\\r\\nrelated health consequences among the mentally ill. The pilot trial aims to understand\\r\\nthe feasibility and preliminary effects of a multilevel intervention \"Nudges to Quit,\"\\r\\ndesigned to increase patient, case worker, and pharmacist engagement with tobacco\\r\\ntreatment in a community mental health clinic setting. Therefore, the investigators\\r\\npropose a pilot randomized trial of 60 patients. Patients will be randomized with 1:1\\r\\nallocation to usual care vs. intervention \"Nudges to Quit\". All patients will receive\\r\\npre-appointment tobacco treatment needs assessment (t1) with patient input as decision\\r\\nsupport for their care team. For patients in the intervention arm, their care team (case\\r\\nworker and pharmacist) will receive nudge reminders based on patient-reported tobacco\\r\\ntreatment need assessment to offer tobacco treatment. For patients in the usual care arm,\\r\\nthe team will proceed with usual care and receive the intervention at 3 months\\r\\npost-enrollment (t2) to ensure all participants will receive benefit from the\\r\\nintervention with variation in timing. All patients will receive a baseline (t1), 3 month\\r\\n(t2), and 6 month follow-up survey (t3). In Aim 1, the investigators will test the effect\\r\\nof nudges on patient receipt of tobacco treatment. The investigators hypothesize patient\\r\\nreceipt of tobacco cessation treatment such as medication and counseling will be higher\\r\\nafter delivery of nudges over usual care. In Aim 2, the investigators will test the\\r\\neffect of nudges on smoking behaviors. The investigators hypothesize smoking behaviors\\r\\nwill be positively effected in the nudges to quit group compared to usual care. In Aim 3,\\r\\nthe investigators will evaluate the feasibility and preliminary effect of this pilot\\r\\nproject for a future R01 proposal to systematically evaluate this multilevel intervention\\r\\nadapted for CMHCs.'},\n",
       "   'conditionsModule': {'conditions': ['Smoking',\n",
       "     'Smoking Cessation',\n",
       "     'Tobacco Use Cessation'],\n",
       "    'keywords': ['Patient Reported Outcomes',\n",
       "     'Smoking Cessation',\n",
       "     'Smoking Behaviors',\n",
       "     'Nicotine Addiction',\n",
       "     'Tobacco treatment']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': \"Patients will be randomized on a 1:1 basis to usual care or intervention 'nudges to\\r\\nquit'.\",\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Usual Care',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients will receive general brief advice about smoking cessation at patient tobacco\\r\\ntreatment needs assessment then receive the intervention at 3 months.',\n",
       "      'interventionNames': ['Behavioral: Usual Care']},\n",
       "     {'label': '\"Nudges to Quit\"',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients will receive a multilevel intervention that includes reminders to care team to\\r\\nincrease tobacco treatment engagement.',\n",
       "      'interventionNames': ['Behavioral: \"Nudges\"']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Usual Care',\n",
       "      'description': 'Usual care will be informed by practice guidelines (patient smoking cessation handout and\\r\\nbrief advice).',\n",
       "      'armGroupLabels': ['Usual Care']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': '\"Nudges\"',\n",
       "      'description': 'Patients in the experimental arm will receive practice guidelines (patient smoking\\r\\ncessation handout and brief advice) and \"Nudges to Quit\", guideline-informed messages\\r\\nimmediately following patient tobacco treatment needs assessment.',\n",
       "      'armGroupLabels': ['\"Nudges to Quit\"']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients receiving any tobacco treatment',\n",
       "      'description': 'This will be quantified by the proportion of patients who receive any tobacco treatment\\r\\n(medication and/or counseling).',\n",
       "      'timeFrame': 'At 3 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Proportion of patients receiving any tobacco treatment',\n",
       "      'description': 'This will be quantified by the proportion of patients who receive any tobacco treatment\\r\\n(medication and/or counseling).',\n",
       "      'timeFrame': 'At 6 months'},\n",
       "     {'measure': 'Readiness to quit smoking',\n",
       "      'description': 'This will be quantified by the proportion of current smokers in the stage of change\\r\\nclassifications of Precontemplation, Contemplation, Preparation, or Action.',\n",
       "      'timeFrame': 'At 3 months, 6 months'},\n",
       "     {'measure': 'Smoking abstinence',\n",
       "      'description': 'This will be quantified by the proportion of smokers with bioverified point prevalence\\r\\nabstinence smoking abstinence at 3 months.',\n",
       "      'timeFrame': '3 months post intervention'},\n",
       "     {'measure': 'Abstinence outcomes across multiple time points',\n",
       "      'description': 'The outcome measure is abstinence (self-reported no smoking (not even a puff of a\\r\\ncigarette) for at least seven days prior to the assessment) over these time points.',\n",
       "      'timeFrame': 'At 3 months, 6 months'},\n",
       "     {'measure': 'Smoking quantity across multiple time points',\n",
       "      'description': 'The outcome measure is smoking quantity (self-reported average cigarettes smoked per day\\r\\nfor the past 30 days prior to the assessment) over these time points.',\n",
       "      'timeFrame': 'At 3 months, 6 months'},\n",
       "     {'measure': 'Quit attempts',\n",
       "      'description': 'This outcome measure is the number of quit attempts over these time points.',\n",
       "      'timeFrame': 'At 3 months, 6 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patient of participating clinic\\r\\n\\r\\n  -  Current smoker, >5 cigarettes per day\\r\\n\\r\\n  -  Age 18 years or older\\r\\n\\r\\n  -  Can speak and understand English\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Active use or receipt of tobacco treatment (medication or counseling) within the\\r\\n     past 30 days',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Li-Shiun Chen, M.D., MPH, ScD',\n",
       "      'affiliation': 'Washington University School of Medicine',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Washington University School of Medicine',\n",
       "      'city': 'Saint Louis',\n",
       "      'state': 'Missouri',\n",
       "      'zip': '63110',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School\\r\\nof Medicine',\n",
       "      'url': 'http://www.siteman.wustl.edu'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001523',\n",
       "      'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M4815',\n",
       "      'name': 'Mental Disorders',\n",
       "      'asFound': 'Mental Illness',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19100', 'name': 'Behavior, Addictive', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M12478',\n",
       "      'name': 'Nicotine',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06415487',\n",
       "    'orgStudyIdInfo': {'id': 'ACE2016-001'},\n",
       "    'organization': {'fullName': 'Acepodia Biotech, Inc.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)',\n",
       "    'officialTitle': 'A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-12-18', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-03-25', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-30',\n",
       "    'studyFirstSubmitQcDate': '2024-05-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-10',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Acepodia Biotech, Inc.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from\\r\\nhealthy donors, that is under investigation for the treatment of Locally Advanced or\\r\\nMetastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).\\r\\n\\r\\nThe ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to\\r\\nevaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of\\r\\nACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal\\r\\nGrowth Factor Receptor (EGFR).'},\n",
       "   'conditionsModule': {'conditions': ['Locally Advanced Solid Tumor',\n",
       "     'Metastatic Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'ACE2016 ONLY: 1 DOSE',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'ACE2016 dose escalation, monotherapy. Lymphodepleting regimen followed by escalating\\r\\ndoses of ACE2016.',\n",
       "      'interventionNames': ['Drug: Cyclophosphamide',\n",
       "       'Drug: Fludarabine',\n",
       "       'Drug: ACE2016']},\n",
       "     {'label': 'ACE2016 ONLY: 3 DOSES',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'ACE2016 recommended dose, monotherapy. Lymphodepleting regimen followed by recommended\\r\\ndose of ACE2016.',\n",
       "      'interventionNames': ['Drug: Cyclophosphamide',\n",
       "       'Drug: Fludarabine',\n",
       "       'Drug: ACE2016']},\n",
       "     {'label': 'ACE2016 AND PEMBROLIZUMAB: 3 DOSES',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'ACE2016 recommended dose, in combination with pembrolizumab. Lymphodepleting regimen\\r\\nfollowed by recommended dose of ACE2016, giving in combination with pembrolizumab.',\n",
       "      'interventionNames': ['Drug: Cyclophosphamide',\n",
       "       'Drug: Fludarabine',\n",
       "       'Drug: ACE2016',\n",
       "       'Drug: Pembrolizumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Cyclophosphamide',\n",
       "      'description': 'Lymphodepleting agent',\n",
       "      'armGroupLabels': ['ACE2016 AND PEMBROLIZUMAB: 3 DOSES',\n",
       "       'ACE2016 ONLY: 1 DOSE',\n",
       "       'ACE2016 ONLY: 3 DOSES']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Fludarabine',\n",
       "      'description': 'Lymphodepleting agent',\n",
       "      'armGroupLabels': ['ACE2016 AND PEMBROLIZUMAB: 3 DOSES',\n",
       "       'ACE2016 ONLY: 1 DOSE',\n",
       "       'ACE2016 ONLY: 3 DOSES']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'ACE2016',\n",
       "      'description': 'Allogeneic gamma delta T (gdT) cell therapy',\n",
       "      'armGroupLabels': ['ACE2016 AND PEMBROLIZUMAB: 3 DOSES',\n",
       "       'ACE2016 ONLY: 1 DOSE',\n",
       "       'ACE2016 ONLY: 3 DOSES']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'description': 'Immune checkpoint anti-PD-1 antibody',\n",
       "      'armGroupLabels': ['ACE2016 AND PEMBROLIZUMAB: 3 DOSES']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of DLTs, AESIs, Grade 3 or higher TEAEs, TEAEs considered related to ACE2016, TEAEs resulting in death, SAEs, related SAEs, and TEAEs leading to treatment discontinuation will be summarized by cohort',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Change from baseline in clinical laboratory tests results',\n",
       "      'description': 'Number of subject with change from baseline clinical significant lab findings by cohort\\r\\n(descriptive)',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Change from baseline in vital signs results',\n",
       "      'description': 'Number of subjects with change from baseline clinical significant vital signs findings by\\r\\ncohort (descriptive)',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Recommended Dose (RD)', 'timeFrame': '1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Persistence of ACE2016 before and after administration',\n",
       "      'description': 'Half-life of ACE2016',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Measure of anti-ACE2016 antibodies after administration',\n",
       "      'description': 'Titration of anti-ACE2016 antibodies after administration',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Objective Response Rate (ORR)',\n",
       "      'description': 'Proportion of subjects assessed as having a complete response (CR) or partial response\\r\\n(PR) according to RECIST v1.1',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Disease Control Rate (DCR)',\n",
       "      'description': 'Number of subjects with a complete response (CR), partial response (PR) or stable disease\\r\\n(SD) as defined by RECIST v1.1',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Duration Of Response (DOR)',\n",
       "      'description': 'Duration (time) from the first tumor assessment showing response per RECIST v1.1 to the\\r\\ntime of disease progression or death.',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Progression Free Survival (PFS)',\n",
       "      'description': 'Duration (time) from first ACE2016 cell infusion to first documentation of disease\\r\\nprogression per RECIST v1.1 or death',\n",
       "      'timeFrame': '1 year'}],\n",
       "    'otherOutcomes': [{'measure': 'Pharmacodynamics of ACE2016',\n",
       "      'description': 'Change from baseline IL2,6,8,10 IFN TNF, and change in TBNK cell subsets.',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'gdT infiltration in tumor mass',\n",
       "      'description': 'Optional biopsy to examine gdT cell infiltration',\n",
       "      'timeFrame': '1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Locally advanced unresectable or metastatic solid tumors that have failed at least\\r\\n     two lines of therapy (one of which must be targeted therapy)\\r\\n\\r\\n  -  At least one measurable lesion as defined by RECIST v1.1 criteria\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\\r\\n\\r\\n  -  Adequate hematologic and renal, hepatic and cardiac function\\r\\n\\r\\n  -  Oxygen saturation via pulse oximeter ≥92% at rest on room air\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Prior treatment with a genetically modified cell therapy product targeting EGFR\\r\\n\\r\\n  -  History of allogeneic transplantation\\r\\n\\r\\n  -  Subjects with active CNS metastases\\r\\n\\r\\n  -  History or presence of clinically relevant Central Nervous System (CNS) disorder\\r\\n     (e.g. epilepsy)\\r\\n\\r\\n  -  Clinically significant active infection\\r\\n\\r\\n  -  Human Immunodeficiency Virus (HIV) infection, active hepatitis B infection, or\\r\\n     hepatitis C infection.\\r\\n\\r\\n  -  History of malignancies with the exception of certain treated malignancies with no\\r\\n     evidence of disease.\\r\\n\\r\\n  -  Primary immunodeficiency disorder\\r\\n\\r\\n  -  Pregnant or lactating female\\r\\n\\r\\n  -  Any medical, psychological, familial, or sociological conditions that, in the\\r\\n     opinion of the Investigator or Sponsor Medical Monitor, would impair the ability of\\r\\n     the subject to receive study treatment or comply with study requirements, including\\r\\n     understanding and rendering of informed consent',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Stephanie Chien',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+1 415 366 7822',\n",
       "      'email': 'clinical@acepodiabio.com'}],\n",
       "    'locations': [{'facility': 'SCRI Denver Drug Development Unit',\n",
       "      'city': 'Denver',\n",
       "      'state': 'Colorado',\n",
       "      'zip': '80218',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'James Vick', 'role': 'CONTACT'},\n",
       "       {'name': 'Jason Henry, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.73915, 'lon': -104.9847}},\n",
       "     {'facility': 'Sarah Cannon Research Institute (SCRI) Oncology Partners',\n",
       "      'city': 'Nashville',\n",
       "      'state': 'Tennessee',\n",
       "      'zip': '37203',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Emily Lay Petcu', 'role': 'CONTACT'},\n",
       "       {'name': 'Meredith Pelster, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000003520',\n",
       "      'term': 'Cyclophosphamide'},\n",
       "     {'id': 'C000582435', 'term': 'Pembrolizumab'},\n",
       "     {'id': 'C000024352', 'term': 'Fludarabine'}],\n",
       "    'ancestors': [{'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018501', 'term': 'Antirheumatic Agents'},\n",
       "     {'id': 'D000018906', 'term': 'Antineoplastic Agents, Alkylating'},\n",
       "     {'id': 'D000000477', 'term': 'Alkylating Agents'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000019653', 'term': 'Myeloablative Agonists'},\n",
       "     {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M6727',\n",
       "      'name': 'Cyclophosphamide',\n",
       "      'asFound': 'Cycle',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M283230',\n",
       "      'name': 'Fludarabine',\n",
       "      'asFound': 'Combined',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M225513', 'name': 'Fludarabine phosphate', 'relevance': 'LOW'},\n",
       "     {'id': 'M349416',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'asFound': 'Blind',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M11900', 'name': 'Mitogens', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M20942',\n",
       "      'name': 'Antineoplastic Agents, Alkylating',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3820', 'name': 'Alkylating Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2342',\n",
       "      'name': 'Immune Checkpoint Inhibitors',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06317649',\n",
       "    'orgStudyIdInfo': {'id': 'NCI-2024-01987'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-01987',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MM1OA-EA02',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'ECOG-ACRIN Cancer Research Group'},\n",
       "     {'id': 'MM1OA-EA02', 'type': 'OTHER', 'domain': 'CTEP'},\n",
       "     {'id': 'U10CA180820',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/U10CA180820'}],\n",
       "    'organization': {'fullName': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'},\n",
       "    'briefTitle': 'Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)',\n",
       "    'officialTitle': 'A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-10-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-10-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-16',\n",
       "    'studyFirstSubmitQcDate': '2024-03-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-19', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-19', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and\\r\\nvenetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in\\r\\ntreating older and unfit patients with acute myeloid leukemia and FLT3 mutations.\\r\\nAzacitidine is a drug that is absorbed into DNA and leads to the activation of cancer\\r\\nsuppressor genes, which are genes that help control cell growth. Venetoclax is in a class\\r\\nof medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of\\r\\ncancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib\\r\\nis in a class of medications called kinase inhibitors. It works by blocking the action of\\r\\na certain naturally occurring substance that may be needed to help cancer cells multiply.\\r\\nThis study may help doctors find out if these different approaches are better than the\\r\\nusual approaches. To decide if they are better, the study doctors are looking to see if\\r\\nthe study drugs lead to a higher percentage of patients achieving a deeper remission\\r\\ncompared to the usual approach.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To compare the achievement rate of measured residual disease negative (MRDneg)\\r\\ncomplete remission (CR) of either triplet regimen to azacitidine and venetoclax alone\\r\\nwithin 4 cycles of therapy.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. To compare the achievement rate of MRDneg CR/complete remission with incomplete count\\r\\nrecovery (CRi)/complete remission with partial hematologic recovery (CRh) of either\\r\\ntriplet regimen to azacitidine and venetoclax alone within 4 cycles of therapy.\\r\\n\\r\\nII. To determine the safety and tolerability of the combination of gilteritinib,\\r\\nazacitidine, and venetoclax, if both of the triplet regimens show superiority to the\\r\\nazacitidine plus venetoclax regimen.\\r\\n\\r\\nIII. To determine the optimal sequence and duration of gilteritinib, when added to\\r\\nazacitidine and venetoclax if both of the triplet regimens show superiority to the\\r\\nazacitidine plus venetoclax regimen.\\r\\n\\r\\nIV. To estimate the rates of complete remission (CR), complete remission with incomplete\\r\\ncount recovery (CRi), and complete remission with partial hematologic recovery (CRh),\\r\\nmorphologic leukemia-free state (MLFS), event-free survival (EFS), and overall survival\\r\\n(OS) of the combination of gilteritinib, azacitidine, and venetoclax versus azacitidine\\r\\nand venetoclax alone.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\n\\r\\nI. To establish the degree reduction in FLT3- internal tandem duplication (ITD) mutation\\r\\nburden after 2 and 4 cycles of therapy using a highly sensitive next-generation\\r\\nsequencing (NGS) MRD assay and compare the median reduction in the investigational\\r\\nregimens among patients with CR/CRi/CRh to that of control regimen.\\r\\n\\r\\nII. To determine if the degree of FLT3 ITD reduction is associated with the duration of\\r\\nremission.\\r\\n\\r\\nIII. To monitor which mutations are present at the time of relapse. IV. To monitor which\\r\\nco-mutations at presentation are associated with lack of response to these regimens.\\r\\n\\r\\nV. To determine if the FLT3 AR /variant allele frequency (VAF) is associated with\\r\\nresponse to the regimens.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 3 regimens.\\r\\n\\r\\nREGIMEN 1:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine intravenously (IV) or subcutaneously (SC) on days\\r\\n1-7 of each cycle and venetoclax orally (PO) on days 1-28 of each cycle. Treatment\\r\\nrepeats every 28 days for up to 2 cycles or until patient achieves remission, whichever\\r\\ncomes first, in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on\\r\\ndays 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nREGIMEN 2:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and\\r\\ngilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2\\r\\ncycles or until patient achieves remission, whichever comes first, in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nREGIMEN 3:\\r\\n\\r\\nINDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days\\r\\n1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for\\r\\nup to 2 cycles or until patient achieves remission, whichever comes first, in the absence\\r\\nof disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nAll patients undergo bone marrow biopsy and aspiration as well as blood sample collection\\r\\non the trial.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up every 3 months if patient\\r\\nis < 2 years from first registration, and every 6 months if patient is 2-5 years from\\r\\nfirst registration. All patients, including those who discontinue protocol therapy early,\\r\\nare followed for response until progression, even if non-protocol therapy is initiated,\\r\\nand for survival for 10 years from the date of randomization.'},\n",
       "   'conditionsModule': {'conditions': ['Acute Myeloid Leukemia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 147, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Regimen 1 (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax\\r\\nPO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or\\r\\nuntil patient achieves remission, whichever comes first, in the absence of disease\\r\\nprogression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on\\r\\ndays 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Procedure: Bone Marrow Biopsy',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and\\r\\ngilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2\\r\\ncycles or until patient achieves remission, whichever comes first, in the absence of\\r\\ndisease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Procedure: Bone Marrow Biopsy',\n",
       "       'Drug: Gilteritinib',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'Regimen 3 (azacitidine, venetoclax, gilteritinib)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days\\r\\n1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for\\r\\nup to 2 cycles or until patient achieves remission, whichever comes first, in the absence\\r\\nof disease progression or unacceptable toxicity.\\r\\n\\r\\nCONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days\\r\\n1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2\\r\\nyears in the absence of disease progression or unacceptable toxicity.\\r\\n\\r\\nPatients undergo bone marrow biopsy and aspiration as well as blood sample collection on\\r\\nthe trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Procedure: Bone Marrow Biopsy',\n",
       "       'Drug: Gilteritinib',\n",
       "       'Drug: Venetoclax']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Azacitidine',\n",
       "      'description': 'Given IV or SC',\n",
       "      'armGroupLabels': ['Regimen 1 (azacitidine, venetoclax)',\n",
       "       'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['5 AZC',\n",
       "       '5-AC',\n",
       "       '5-Azacitidine',\n",
       "       '5-Azacytidine',\n",
       "       '5-AZC',\n",
       "       'Azacytidine',\n",
       "       'Azacytidine, 5-',\n",
       "       'Ladakamycin',\n",
       "       'Mylosar',\n",
       "       'U-18496',\n",
       "       'Vidaza']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo blood sample collection',\n",
       "      'armGroupLabels': ['Regimen 1 (azacitidine, venetoclax)',\n",
       "       'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Aspiration',\n",
       "      'description': 'Undergo bone marrow biopsy and aspiration',\n",
       "      'armGroupLabels': ['Regimen 1 (azacitidine, venetoclax)',\n",
       "       'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Biopsy',\n",
       "      'description': 'Undergo bone marrow biopsy and aspiration',\n",
       "      'armGroupLabels': ['Regimen 1 (azacitidine, venetoclax)',\n",
       "       'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['Biopsy of Bone Marrow', 'Biopsy, Bone Marrow']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Gilteritinib',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['ASP-2215', 'ASP2215']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['Regimen 1 (azacitidine, venetoclax)',\n",
       "       'Regimen 2 (azacitidine, venetoclax, gilteritinib)',\n",
       "       'Regimen 3 (azacitidine, venetoclax, gilteritinib)'],\n",
       "      'otherNames': ['ABT-0199',\n",
       "       'ABT-199',\n",
       "       'ABT199',\n",
       "       'GDC-0199',\n",
       "       'RG7601',\n",
       "       'Venclexta',\n",
       "       'Venclyxto']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of measured residual disease (MRD) negative complete remission (CR)',\n",
       "      'description': 'Will be assessed by multiparameter flow cytometry at a level of ≤ 1 residual blast /\\r\\n1,000 leukocytes (≤ 10^-3).',\n",
       "      'timeFrame': 'Up to 4 cycles of treatment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall survival',\n",
       "      'description': 'Will be calculated using the Kaplan-Meier method.',\n",
       "      'timeFrame': 'Time between randomization and death from any cause, assessed up to 10 years'},\n",
       "     {'measure': 'Event-free survival',\n",
       "      'description': 'Will be calculated using the Kaplan-Meier method.',\n",
       "      'timeFrame': 'Time from randomization to failure to achieve complete remission (CR), CR with incomplete count recovery, and CR with partial hematologic recovery, or to relapse after CR/CRi/CRh or to death in remission, assessed up to 10 years'},\n",
       "     {'measure': 'Incidence of adverse events',\n",
       "      'description': 'Will be determined using the Common Terminology Criteria for Adverse Events version 5\\r\\ncriteria.',\n",
       "      'timeFrame': 'Up to 10 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patient must be ≥ 60 years of age or adults ˂ 60 who in the opinion of the treating\\r\\n     physician are better served by azanucleoside-based therapy rather than intensive,\\r\\n     cytarabine-based induction based on clinical status (i.e., performance status, age >\\r\\n     75 years), organ dysfunction, or disease biology\\r\\n\\r\\n  -  Patient must have a morphologically confirmed diagnosis of AML according to the\\r\\n     World Health Organization (WHO) 2016 classification excluding acute promyelocytic\\r\\n     leukemia (APL) with PML-RARA, AML with RUNX1-RUNX1T1, or AML with CBFB-MYH11\\r\\n\\r\\n  -  Patient must have no prior therapy for AML with the exception of hydroxyurea and\\r\\n     all-trans retinoic acid (ATRA), or leukapheresis. Patients with cytarabine-based\\r\\n     emergency therapy prior to the start of therapy on this trial are eligible\\r\\n\\r\\n  -  Patient must have no prior therapy with hypomethylating agents or FLT3 inhibitors\\r\\n\\r\\n  -  Patient must have the FLT3-ITD or D835 mutation based on MyeloMATCH Master Screening\\r\\n     and Reassessment Protocol (MSRP)\\r\\n\\r\\n  -  Patient must be assigned to this protocol by the myeloMATCH MSRP\\r\\n\\r\\n  -  Patient must not be pregnant or breast-feeding due to the potential harm to an\\r\\n     unborn fetus and possible risk for adverse events in nursing infants with the\\r\\n     treatment regimens being used.\\r\\n\\r\\n       -  All patients of childbearing potential must have a blood test or urine study\\r\\n          within 14 days prior to registration to rule out pregnancy.\\r\\n\\r\\n       -  A patient of childbearing potential is defined as anyone, regardless of sexual\\r\\n          orientation or whether they have undergone tubal ligation, who meets the\\r\\n          following criteria: 1) has achieved menarche at some point, 2) has not\\r\\n          undergone a hysterectomy or bilateral oophorectomy; or 3) has not been\\r\\n          naturally postmenopausal (amenorrhea following cancer therapy does not rule out\\r\\n          childbearing potential) for at least 24 consecutive months (i.e., has had\\r\\n          menses at any time in the preceding 24 consecutive months)\\r\\n\\r\\n  -  Patient of childbearing potential and/or sexually active patients must not expect to\\r\\n     conceive or father children by using an accepted and effective method(s) of\\r\\n     contraception or by abstaining from sexual intercourse for the duration of their\\r\\n     participation in the study. Contraception measures must continue for 30 days after\\r\\n     the last dose of venetoclax for all patients and for 6 months after the last dose of\\r\\n     gilteritinib for patients of childbearing potential and for 4 months after the last\\r\\n     dose of gilteritinib for male patients with partners of childbearing potential.\\r\\n     Patient must not breastfeed during treatment and for 2 months after treatment ends\\r\\n\\r\\n  -  Patient must have the ability to understand and the willingness to sign a written\\r\\n     informed consent document. Patients with impaired decision-making capacity (IDMC)\\r\\n     who have a legally authorized representative (LAR) or caregiver and/or family member\\r\\n     available will also be considered eligible\\r\\n\\r\\n  -  Total bilirubin 2X ≤ institutional upper limit of normal (ULN) (unless thought to be\\r\\n     elevated due to disease involvement or Gilbert's syndrome)\\r\\n\\r\\n  -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase\\r\\n     [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase\\r\\n     [SGPT]) =< 3.0 x institutional ULN\\r\\n\\r\\n       -  Either measured or estimated by Cockcroft-Gault equation\\r\\n\\r\\n  -  Creatinine clearance of ≥ 30 mL/min/1.73m^2\\r\\n\\r\\n  -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral\\r\\n     therapy with undetectable viral load within 6 months of registration/randomization\\r\\n     are eligible for this trial\\r\\n\\r\\n  -  For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV\\r\\n     viral load must be undetectable on suppressive therapy, if indicated\\r\\n\\r\\n  -  Patients with a history of hepatitis C virus (HCV) infection must have been treated\\r\\n     and cured. For patients with HCV infection who are currently on treatment, they are\\r\\n     eligible if they have an undetectable HCV viral load\\r\\n\\r\\n  -  Patient must not have a baseline corrected QT interval ≥ 480 msec using Fredericia\\r\\n     correction (QTcF)\\r\\n\\r\\n  -  Patient must not have the medical necessity for ongoing treatment with a strong\\r\\n     CYP3A4 inducing drug\\r\\n\\r\\n  -  Patients with a prior or concurrent malignancy whose natural history or treatment\\r\\n     does not have the potential to interfere with the safety or efficacy assessment of\\r\\n     the investigational regimen are eligible for this trial\\r\\n\\r\\n  -  Patients with known history or current symptoms of cardiac disease, or history of\\r\\n     treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac\\r\\n     function using the New York Heart Association Functional Classification. To be\\r\\n     eligible for this trial, patients should be class 2B or better\\r\\n\\r\\n  -  Patients must not have an active or uncontrolled infection\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Jessica K Altman',\n",
       "      'affiliation': 'ECOG-ACRIN Cancer Research Group',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how\\r\\nclinical trial data is shared, access the link to the NIH data sharing policy page.',\n",
       "    'url': 'https://grants.nih.gov/policy/sharing.htm'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000001374',\n",
       "      'term': 'Azacitidine'},\n",
       "     {'id': 'C000579720', 'term': 'Venetoclax'},\n",
       "     {'id': 'C000609080', 'term': 'Gilteritinib'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000092004', 'term': 'Tyrosine Kinase Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4673',\n",
       "      'name': 'Azacitidine',\n",
       "      'asFound': 'Frequency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M58265',\n",
       "      'name': 'Gilteritinib',\n",
       "      'asFound': 'Probable',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M2889', 'name': 'Tyrosine Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05554406',\n",
       "    'orgStudyIdInfo': {'id': 'NCI-2022-07535'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2022-07535',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MM1YA-S01', 'type': 'OTHER', 'domain': 'SWOG'},\n",
       "     {'id': 'MM1YA-S01', 'type': 'OTHER', 'domain': 'CTEP'},\n",
       "     {'id': 'U10CA180888',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/U10CA180888'}],\n",
       "    'organization': {'fullName': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'},\n",
       "    'briefTitle': 'Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)',\n",
       "    'officialTitle': 'A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-03-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-03-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-09-22',\n",
       "    'studyFirstSubmitQcDate': '2022-09-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-09-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase II MyeloMATCH treatment trial tests whether the standard approach of\\r\\ncytarabine and daunorubicin in comparison to the following experimental regimens works to\\r\\nshrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin\\r\\nand cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3)\\r\\nazacitidine and venetoclax. \"High-risk\" refers to traits that have been known to make the\\r\\nAML harder to treat. Cytarabine is in a class of medications called antimetabolites. It\\r\\nworks by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a\\r\\nclass of medications called anthracyclines. It also works by slowing or stopping the\\r\\ngrowth of cancer cells in the body. Azacitidine is in a class of medications called\\r\\ndemethylation agents. It works by helping the bone marrow to produce normal blood cells\\r\\nand by killing abnormal cells. Venetoclax is in a class of medications called B-cell\\r\\nlymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2,\\r\\na protein needed for cancer cell survival. There is evidence that these newer\\r\\nexperimental treatment regimens may work better in getting rid of more AML compared to\\r\\nthe standard approach of cytarabine and daunorubicin.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To compare measurable residual disease (MRD) negative complete remission (CR) rates\\r\\nbetween each of the experimental regimens and cytarabine + daunorubicin (7+3).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. To estimate the frequency and severity of toxicities with each of the regimens.\\r\\n\\r\\nII. To estimate complete remission (CR) rates, complete remission with incomplete count\\r\\nrecovery (CRi, with and without MRD) rates, event-free survival (EFS), time to relapse,\\r\\nrelapse-free survival (RFS), and overall survival (OS) with each of the regimens.\\r\\n\\r\\nIII. To describe and compare MRD negative CR rates by genomic subgroups within and across\\r\\nrandomized arms.\\r\\n\\r\\nBAKING OBJECTIVE:\\r\\n\\r\\nI. To bank specimens for future correlative studies.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 4 arms.\\r\\n\\r\\nARM I: Patients receive cytarabine intravenously (IV) and daunorubicin IV per standard\\r\\napproach on study. Patients also undergo a bone marrow aspiration and collection of blood\\r\\nthroughout the trial.\\r\\n\\r\\nARM II: Patients receive cytarabine IV and daunorubicin IV with venetoclax orally (PO) on\\r\\nstudy. Patients also undergo a bone marrow aspiration and collection of blood throughout\\r\\nthe trial.\\r\\n\\r\\nARM III: Patients receive azacitidine subcutaneously (SC) or IV and venetoclax PO on\\r\\nstudy. Patients also undergo a bone marrow aspiration and collection of blood throughout\\r\\nthe trial.\\r\\n\\r\\nARM IV: Patients receive daunorubicin and cytarabine liposome IV on study. Patients also\\r\\nundergo a bone marrow aspiration and collection of blood throughout the trial.'},\n",
       "   'conditionsModule': {'conditions': ['Acute Myeloid Leukemia',\n",
       "     'Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm',\n",
       "     'Acute Myeloid Leukemia Post Cytotoxic Therapy',\n",
       "     'Acute Myeloid Leukemia, Myelodysplasia-Related']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 268, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Arm I (cytarabine, daunorubicin)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive cytarabine IV and daunorubicin IV per standard approach on study.\\r\\nPatients also undergo a bone marrow aspiration and collection of blood throughout the\\r\\ntrial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride']},\n",
       "     {'label': 'Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive cytarabine IV and daunorubicin IV with venetoclax PO on study. Patients\\r\\nalso undergo a bone marrow aspiration and collection of blood throughout the trial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'Arm III (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive azacitidine SC or IV and venetoclax PO on study. Patients also undergo a\\r\\nbone marrow aspiration and collection of blood throughout the trial.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'Arm IV (daunorubicin and cytarabine liposome)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive daunorubicin and cytarabine liposome IV on study. Patients also undergo\\r\\na bone marrow aspiration and collection of blood throughout the trial.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspiration',\n",
       "       'Drug: Liposome-encapsulated Daunorubicin-Cytarabine']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Azacitidine',\n",
       "      'description': 'Given SC or IV',\n",
       "      'armGroupLabels': ['Arm III (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['5 AZC',\n",
       "       '5-AC',\n",
       "       '5-Azacitidine',\n",
       "       '5-Azacytidine',\n",
       "       '5-AZC',\n",
       "       'Azacytidine',\n",
       "       'Azacytidine, 5-',\n",
       "       'Ladakamycin',\n",
       "       'Mylosar',\n",
       "       'U-18496',\n",
       "       'Vidaza']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo collection of blood',\n",
       "      'armGroupLabels': ['Arm I (cytarabine, daunorubicin)',\n",
       "       'Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'Arm III (azacitidine, venetoclax)',\n",
       "       'Arm IV (daunorubicin and cytarabine liposome)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Aspiration',\n",
       "      'description': 'Undergo bone marrow aspiration',\n",
       "      'armGroupLabels': ['Arm I (cytarabine, daunorubicin)',\n",
       "       'Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'Arm IV (daunorubicin and cytarabine liposome)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cytarabine',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Arm I (cytarabine, daunorubicin)',\n",
       "       'Arm II (cytarabine, daunorubicin, venetoclax)'],\n",
       "      'otherNames': ['.beta.-Cytosine arabinoside',\n",
       "       '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-.beta.-D-Arabinofuranosylcytosine',\n",
       "       '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-Beta-D-arabinofuranosylcytosine',\n",
       "       '1.beta.-D-Arabinofuranosylcytosine',\n",
       "       '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-',\n",
       "       '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-',\n",
       "       'Alexan',\n",
       "       'Ara-C',\n",
       "       'ARA-cell',\n",
       "       'Arabine',\n",
       "       'Arabinofuranosylcytosine',\n",
       "       'Arabinosylcytosine',\n",
       "       'Aracytidine',\n",
       "       'Aracytin',\n",
       "       'Aracytine',\n",
       "       'Beta-Cytosine Arabinoside',\n",
       "       'CHX-3311',\n",
       "       'Cytarabinum',\n",
       "       'Cytarbel',\n",
       "       'Cytosar',\n",
       "       'Cytosine Arabinoside',\n",
       "       'Cytosine-.beta.-arabinoside',\n",
       "       'Cytosine-beta-arabinoside',\n",
       "       'Erpalfa',\n",
       "       'Starasid',\n",
       "       'Tarabine PFS',\n",
       "       'U 19920',\n",
       "       'U-19920',\n",
       "       'Udicil',\n",
       "       'WR-28453']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Daunorubicin Hydrochloride',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Arm I (cytarabine, daunorubicin)',\n",
       "       'Arm II (cytarabine, daunorubicin, venetoclax)'],\n",
       "      'otherNames': ['Cerubidin',\n",
       "       'Cerubidine',\n",
       "       'Cloridrato de Daunorubicina',\n",
       "       'Daunoblastin',\n",
       "       'Daunoblastina',\n",
       "       'Daunoblastine',\n",
       "       'Daunomycin Hydrochloride',\n",
       "       'Daunomycin, hydrochloride',\n",
       "       'Daunorubicin.HCl',\n",
       "       'Daunorubicini Hydrochloridum',\n",
       "       'FI-6339',\n",
       "       'Ondena',\n",
       "       'RP-13057',\n",
       "       'Rubidomycin Hydrochloride',\n",
       "       'Rubilem']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Liposome-encapsulated Daunorubicin-Cytarabine',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Arm IV (daunorubicin and cytarabine liposome)'],\n",
       "      'otherNames': ['CPX-351',\n",
       "       'Cytarabine and Daunorubicin Liposomal',\n",
       "       'Cytarabine-Daunorubicin Liposome for Injection',\n",
       "       'Daunorubicin and Cytarabine (Liposomal)',\n",
       "       'Liposomal AraC-Daunorubicin CPX-351',\n",
       "       'Liposomal Cytarabine-Daunorubicin',\n",
       "       'Liposome-encapsulated Combination of Daunorubicin and Cytarabine',\n",
       "       'Vyxeos']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['Arm II (cytarabine, daunorubicin, venetoclax)',\n",
       "       'Arm III (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['ABT-0199',\n",
       "       'ABT-199',\n",
       "       'ABT199',\n",
       "       'GDC-0199',\n",
       "       'RG7601',\n",
       "       'Venclexta',\n",
       "       'Venclyxto']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Minimal residual disease (MRD) response (Arm 1, 2 and 4)',\n",
       "      'description': 'Will be analyzed using intent-to-treat (ITT) principles.',\n",
       "      'timeFrame': 'After induction (28 days) or re-induction (56 days)'},\n",
       "     {'measure': 'Minimal residual disease (MRD) response (Arm 3)',\n",
       "      'description': 'Will be analyzed using intent-to-treat (ITT) principles.',\n",
       "      'timeFrame': 'After two cycles of therapy (56 days)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Event-free survival (EFS)',\n",
       "      'description': 'Will be estimated using the Kaplan-Meier method.',\n",
       "      'timeFrame': 'From randomization to the first of: primary refractory disease; progressive disease; off protocol therapy without complete remission (CR) or CR with incomplete count recovery (CRi); relapse from CR or CRi, or death from any cause, assessed up to 5 years'},\n",
       "     {'measure': 'Relapse-free survival (RFS)',\n",
       "      'description': 'Defined for only patients achieving complete remission (CR), or CR with incomplete\\r\\nhematologic recovery (CRi). Will be estimated using the Kaplan-Meier method.',\n",
       "      'timeFrame': 'From the date of achievement of a remission until the date of relapse or death from any cause, assessed up to 5 years'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'Will be estimated using the Kaplan-Meier method.',\n",
       "      'timeFrame': 'From day of randomization on study until death from any cause, assessed up to 5 years'},\n",
       "     {'measure': 'Time to relapse',\n",
       "      'description': 'Will be estimated with cumulative incidence curves with death without relapse analyzed a\\r\\ncompeting event. Response per 2017 European LeukemiaNet (ELN) guidelines will be\\r\\ntabulated and exact 95% confidence intervals will be calculated.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'MRD negative complete remission (MRDneg CR)',\n",
       "      'description': \"MRDneg CR rates will be tabulated by genomic subgroups within randomized arms and pooling\\r\\narms. Rates across arms will be compared using Fisher's exact test. All p-values reported\\r\\nwill be nominal.\",\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'Incidence of adverse events',\n",
       "      'description': 'Will be analyzed using National Cancer Institute Common Terminology Criteria for Adverse\\r\\nEvents version (v) 5.0',\n",
       "      'timeFrame': 'Up to 5 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  STEP 1 REGISTRATION:\\r\\n\\r\\n  -  Participants must have been registered to Master Screening and Re-Assessment\\r\\n     Protocol, myeloMATCH MSRP, prior to consenting to this study. Participants must have\\r\\n     been assigned to this clinical trial, via MATCHBox, prior to registration to this\\r\\n     study.\\r\\n\\r\\n       -  Note: Pre-enrollment/diagnosis labs must have already been performed under the\\r\\n          MSRP\\r\\n\\r\\n  -  Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per\\r\\n     World Health Organization (WHO) criteria\\r\\n\\r\\n  -  Participants must have high-risk (adverse) AML per European LeukemiaNet (ELN) 2017\\r\\n     criteria\\r\\n\\r\\n  -  Participants with therapy-related AML (t-AML), or with AML evolving from an\\r\\n     antecedent hematologic disorder (such as myeloproliferative neoplasm), or AML with\\r\\n     myelodysplasia-related changes (AML-MRC) are eligible\\r\\n\\r\\n  -  Participants must not have received or be currently receiving any prior therapy for\\r\\n     acute myeloid leukemia. Hydroxyurea to control the white blood cells (WBC) is\\r\\n     allowed prior to registration and initiation of protocol-defined therapy. All trans\\r\\n     retinoic acid (ATRA) given until a diagnosis of acute promyelocytic leukemia is\\r\\n     ruled out is also allowed.\\r\\n\\r\\n  -  A single dose of intrathecal chemotherapy is allowed prior to study entry\\r\\n\\r\\n  -  Prior anthracycline therapy is allowed but must not exceed a cumulative lifetime\\r\\n     dose of 200 mg/m^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA)\\r\\n     exposure is allowed, as long as not for AML diagnosis\\r\\n\\r\\n  -  Participants must be between 18 and 59 years of age\\r\\n\\r\\n  -  Participants must have Zubrod Performance Status =< 3 as determined by a history and\\r\\n     physical (H&P) completed within 14 days prior to registration\\r\\n\\r\\n  -  Participants must have a complete medical history and physical exam within 7 days\\r\\n     prior to registration\\r\\n\\r\\n  -  Participants must be able to swallow and retain oral medications and have no known\\r\\n     gastrointestinal disorders likely to interfere with absorption of oral medications\\r\\n\\r\\n  -  Participants with known human immunodeficiency virus (HIV)-infection must be on\\r\\n     effective anti-retroviral therapy at time of registration and have undetectable HIV\\r\\n     viral load within 6 months prior to registration\\r\\n\\r\\n  -  Participants with evidence of chronic hepatitis B virus (HBV) infection must have\\r\\n     undetectable HBV viral load within 28 days prior to registration and be on\\r\\n     suppressive therapy, if indicated\\r\\n\\r\\n  -  Participants with a history of hepatitis C virus (HCV) infection must have been\\r\\n     treated and cured. Participants with active HCV infection who are currently on\\r\\n     treatment must have an undetectable HCV viral load within 28 days prior to\\r\\n     registration\\r\\n\\r\\n  -  The following tests must be performed within 14 days prior to registration to\\r\\n     establish baseline values:\\r\\n\\r\\n       -  Complete blood count (CBC)/Differential/Platelets\\r\\n\\r\\n       -  Total Bilirubin\\r\\n\\r\\n       -  Lactate Dehydrogenase (LDH)\\r\\n\\r\\n       -  Albumin\\r\\n\\r\\n       -  Glucose\\r\\n\\r\\n       -  Fibrinogen\\r\\n\\r\\n  -  Participants must have adequate kidney function as evidenced by creatinine clearance\\r\\n     >= 30mL/min (by Cockcroft Gault) within 28 days prior to registration\\r\\n\\r\\n  -  Participants must have adequate liver function as evidenced by aspartate\\r\\n     aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of\\r\\n     normal (ULN), and total bilirubin =< 2.0 x ULN (or 5.0 x ULN if the participant has\\r\\n     a history of Gilbert\\'s disease) within 28 days prior to registration\\r\\n\\r\\n  -  Total bilirubin =< 2.0 x ULN (or 5.0 x ULN if the participant has a history of\\r\\n     Gilbert\\'s disease) within 28 days prior to registration\\r\\n\\r\\n  -  Participants must have adequate cardiac function as determined by echocardiography\\r\\n     or multi-gated acquisition (MUGA) scan with an ejection fraction >= 50% within 28\\r\\n     days prior to registration\\r\\n\\r\\n  -  Participants with a prior or concurrent malignancy whose natural history (in the\\r\\n     opinion of the treating physician) does not have the potential to interfere with the\\r\\n     safety or efficacy assessment of the investigational regimen are eligible for this\\r\\n     trial. No concurrent therapies for such malignancy are allowed with the exception of\\r\\n     hormonal therapy\\r\\n\\r\\n  -  Participants must have agreed to have specimens submitted for translational medicine\\r\\n     (MRD) under the myeloMATCH MSRP and specimens must be submitted\\r\\n\\r\\n  -  Participants must be offered participation in banking for future research. With\\r\\n     participant\\'s consent, specimens must be submitted\\r\\n\\r\\n  -  Participants must be informed of the investigational nature of this study and must\\r\\n     sign and give informed consent in accordance with institutional and federal\\r\\n     guidelines\\r\\n\\r\\n  -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the\\r\\n     treating institution\\'s identity is provided in order to ensure that the current\\r\\n     (within 365 days) date of institutional review board approval for this study has\\r\\n     been entered in the system\\r\\n\\r\\n  -  STEP 2 REGISTRATION - POST-REMISSION THERAPY\\r\\n\\r\\n  -  Participants must have achieved a CR or CRi on Step 1 induction/reinduction\\r\\n     treatment and be in CR or CRi at the time of Step 2 registration\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  STAGE 1 REGISTRATION:\\r\\n\\r\\n  -  Acute promyelocytic leukemia is excluded\\r\\n\\r\\n  -  Participants with favorable or intermediate risk disease are excluded\\r\\n\\r\\n  -  Participants with FLT3 mutations (ITD or TKD) are excluded\\r\\n\\r\\n  -  Participants with t(9;22) translocation are also excluded\\r\\n\\r\\n  -  Participants must not be receiving or planning to receive any other investigational\\r\\n     agents before completing protocol therapy\\r\\n\\r\\n  -  Participants with known history of Wilson\\'s disease or other known copper-metabolism\\r\\n     disorder are excluded\\r\\n\\r\\n  -  Participants must not be pregnant or nursing. Women/men of reproductive potential\\r\\n     must have agreed to use 2 contraception methods. A woman is considered to be of\\r\\n     \"reproductive potential\" if she has had menses at any time in the preceding 12\\r\\n     consecutive months. In addition to routine contraceptive methods (e.g., hormonal\\r\\n     contraceptives [examples include birth control pills, vaginal rings, or patches]\\r\\n     associated with inhibition of ovulation for at least 1 month prior to taking study\\r\\n     drug), \"effective contraception\" also includes heterosexual celibacy and surgery\\r\\n     intended to prevent pregnancy (or with a side-effect of pregnancy prevention)\\r\\n     defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation.\\r\\n     However, if at any point a previously celibate participant chooses to become\\r\\n     heterosexually active during the time period for use of contraceptive measures\\r\\n     outlined in the protocol, he/she is responsible for beginning contraceptive\\r\\n     measures. A barrier method should be used during this study along with hormonal\\r\\n     contraceptives from initial study drug administration to 30 days after the last dose\\r\\n     of study drug as drug-drug interaction with venetoclax is unknown',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '59 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Paul J Shami',\n",
       "      'affiliation': 'SWOG Cancer Research Network',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how\\r\\nclinical trial data is shared, access the link to the NIH data sharing policy page.',\n",
       "    'url': 'https://grants.nih.gov/policy/sharing.htm'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'},\n",
       "     {'id': 'D000009196', 'term': 'Myeloproliferative Disorders'},\n",
       "     {'id': 'D000054437',\n",
       "      'term': 'Myelodysplastic-Myeloproliferative Diseases'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000001855', 'term': 'Bone Marrow Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12149',\n",
       "      'name': 'Myeloproliferative Disorders',\n",
       "      'asFound': 'Myeloproliferative Neoplasms',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14164', 'name': 'Preleukemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12145', 'name': 'Myelodysplastic Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'M27707',\n",
       "      'name': 'Myelodysplastic-Myeloproliferative Diseases',\n",
       "      'asFound': 'Myelodysplastic/Myeloproliferative Neoplasms',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T1311',\n",
       "      'name': 'Chronic Myeloproliferative Disorders',\n",
       "      'asFound': 'Myeloproliferative Neoplasms',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3993', 'name': 'Myelodysplastic Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'T3994',\n",
       "      'name': 'Myelodysplastic/myeloproliferative Disease',\n",
       "      'asFound': 'Myelodysplastic/Myeloproliferative Neoplasms',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000003561',\n",
       "      'term': 'Cytarabine'},\n",
       "     {'id': 'D000001374', 'term': 'Azacitidine'},\n",
       "     {'id': 'C000579720', 'term': 'Venetoclax'},\n",
       "     {'id': 'D000003630', 'term': 'Daunorubicin'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000000998', 'term': 'Antiviral Agents'},\n",
       "     {'id': 'D000000890', 'term': 'Anti-Infective Agents'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000000903', 'term': 'Antibiotics, Antineoplastic'},\n",
       "     {'id': 'D000059005', 'term': 'Topoisomerase II Inhibitors'},\n",
       "     {'id': 'D000059003', 'term': 'Topoisomerase Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M6766',\n",
       "      'name': 'Cytarabine',\n",
       "      'asFound': 'Multi-',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4673',\n",
       "      'name': 'Azacitidine',\n",
       "      'asFound': 'Frequency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6832',\n",
       "      'name': 'Daunorubicin',\n",
       "      'asFound': 'Size',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6263', 'name': 'Coal Tar', 'relevance': 'LOW'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M4314', 'name': 'Antiviral Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4224',\n",
       "      'name': 'Antibiotics, Antitubercular',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Derm', 'name': 'Dermatologic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06343870',\n",
       "    'orgStudyIdInfo': {'id': 'ESTIME'},\n",
       "    'organization': {'fullName': 'University of Sao Paulo General Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)',\n",
       "    'officialTitle': 'Pharmacokinetic, Clinical, Hormonal and Therapeutic Effects of the Use of Estradiol and Testosterone Hormonal Subdermal Implants in Women With Natural Menopause, Premature Ovarian Failure or Surgical Menopause Due to Cervical Cancer.',\n",
       "    'acronym': 'ESTIME'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-01-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-04-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-18',\n",
       "    'studyFirstSubmitQcDate': '2024-03-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-26',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Edmund Baracat',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'University of Sao Paulo General Hospital'},\n",
       "    'leadSponsor': {'name': 'University of Sao Paulo General Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Estrogen and androgen deficiencies negatively impact the quality of life of women at\\r\\ndifferent stages of life, especially after menopause. New modalities and new therapeutic\\r\\nalternatives have been researched. Parenteral administration of estradiol and\\r\\ntestosterone could be effective to treat symptoms secondary to estrogen and androgen\\r\\ndeficiencies and minimize these adverse events. This study evaluates the efficiency of\\r\\nsubdermal implant-bioabsorbable use in women with menopausal symptoms associated with\\r\\nsecondary estrogen and androgen deficiencies in women with natural menopause, premature\\r\\novarian failure or surgical menopause due to cervical cancer. Pharmacokinetic,\\r\\nbiochemical, metabolic, thromboembolic and hormonal data will be evaluated, as well as\\r\\nthe effects on quality of life, menopausal symptoms and sexual function after treatment.',\n",
       "    'detailedDescription': 'The clinical study will be carried out on 140 women, who will be divided into three\\r\\ngroups: (1) postmenopausal women with menopausal and sexual symptoms (n=60); (2) women\\r\\nwith premature ovarian failure (n=40); (3) women with cervical cancer undergoing\\r\\nabdominal hysterectomy with bilateral adnexectomy, with menopausal and sexual symptoms\\r\\n(n=40).\\r\\n\\r\\nAll participants will answer questionnaires to assess quality of life, menopausal\\r\\nsymptoms and sexual function. All participants will undergo general physical and\\r\\ngynecological examinations, as well as hormonal, biochemical, thromboembolic and imaging\\r\\ntests.\\r\\n\\r\\nThe study will last six months. The included participants will undergo the following\\r\\nvisits: inclusion (post-selection) and 1, 3 and 6 months after implant insertion. For the\\r\\npharmacokinetic study, blood samples will be collected at the following periods:\\r\\ninclusion (before implant placement) and after 1h, 2h, 3h, 6h and 12h; one week, two\\r\\nweeks and one month after placement, and then monthly until six months after implant\\r\\ninsertion, to evaluate serum levels of Luteinizing hormone, Follicle stimulating hormone,\\r\\nestradiol, estrone, total testosterone and sex hormone-binding globulin.\\r\\n\\r\\nClinical, biochemical, hormonal and therapeutic parameters will be evaluated before\\r\\nplacement (inclusion) and after 3 and 6 months. The Mann Whitney test will be applied to\\r\\nevaluate differences between measurements and the chi-square test will be applied to\\r\\nanalyze the proportions of improvement between groups before and after treatment.'},\n",
       "   'conditionsModule': {'conditions': ['Menopause',\n",
       "     'Testosterone Deficiency',\n",
       "     'Estrogen Deficiency'],\n",
       "    'keywords': ['menopause', 'estrogen', 'testosterone']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel Assignment',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 140, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Testosterone',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)',\n",
       "      'interventionNames': ['Drug: testosterone pellet (100 mg)']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Subdermal implant-bioabsorbable placebo pellet (cholesterol)',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'testosterone pellet (100 mg)',\n",
       "      'description': 'Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of\\r\\ntestosterone)',\n",
       "      'armGroupLabels': ['Testosterone'],\n",
       "      'otherNames': ['testosterone subdermal implant']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pellet of cholesterol (placebo)',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluate hormonal, metabolic thromboembolic and clinical effects on climacteric symptoms',\n",
       "      'description': 'evaluate concentration in serum of luteinizing hormone, follicle stimulating hormone,\\r\\nestradiol, estrone, total testosterone and sex hormone-binding globulin.',\n",
       "      'timeFrame': '6 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Evaluate response in quality of life and sexual function',\n",
       "      'description': 'Evaluate response on vulvovaginal atrophy and genitourinary syndrome of menopause,\\r\\nhormonal and metabolic effects on climacteric symptoms, using the Kupperman Menopausal\\r\\nIndex; response in quality of life and sexual function; hormonal and metabolic effects;',\n",
       "      'timeFrame': '6 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  menopause time of 2 to 6 years;\\r\\n\\r\\n  -  Body Mass Index between 25 and 30 kg/m2;\\r\\n\\r\\n  -  women hysterectomized and ovariectomized due to cervical cancer;\\r\\n\\r\\n  -  women with premature ovarian failure and under 40 years of age;\\r\\n\\r\\n  -  active sex life;\\r\\n\\r\\n  -  absence of severe depression and anxiety, confirmed by evaluation using the Beck\\r\\n     (specific for depression) and Beck (specific for anxiety) questionnaires.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  disabling illnesses;\\r\\n\\r\\n  -  use of medications that inhibit sexual desire;\\r\\n\\r\\n  -  inability to answer the questionnaires;\\r\\n\\r\\n  -  altered routine exams and comorbidities:\\r\\n\\r\\n       -  Severe hypertension with Blood Pressure measurement > 160 x 90 mmHg in two\\r\\n          measurements\\r\\n\\r\\n       -  clinical or subclinical thyroid dysfunction with Thyroid-stimulating hormone >\\r\\n          4 mIU/L\\r\\n\\r\\n       -  dyslipidemia - fasting triglyceride level > 400 mg/dL\\r\\n\\r\\n       -  presence of occult blood in feces\\r\\n\\r\\n       -  hyperprolactinemia (>29ng/mL)\\r\\n\\r\\n       -  fasting blood glucose > 100 mg/dL\\r\\n\\r\\n       -  presence of osteopenia or osteoporosis\\r\\n\\r\\n       -  BIRADS classification greater than or equal to 3 on mammography\\r\\n\\r\\n       -  presence of endometrial echo > 4mm on transvaginal ultrasound\\r\\n\\r\\n       -  presence of changes in oncotic colpocytology\\r\\n\\r\\n  -  diagnosis after psychological screening of moderate to severe anxiety/depression.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '60 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'André Malavasi, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 981348231',\n",
       "      'email': 'drandreluiz@usp.br'},\n",
       "     {'name': 'Edmund Baracat, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 981348231',\n",
       "      'email': 'drandreluiz@usp.br'}],\n",
       "    'overallOfficials': [{'name': 'Edmund Baracat, PhD',\n",
       "      'affiliation': 'Instituto do Coracao',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '26125962',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lev-Sagie A. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations. Clin Obstet Gynecol. 2015 Sep;58(3):476-91. doi: 10.1097/GRF.0000000000000126.'},\n",
       "     {'pmid': '18313505',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Nelson HD. Menopause. Lancet. 2008 Mar 1;371(9614):760-70. doi: 10.1016/S0140-6736(08)60346-3.'},\n",
       "     {'pmid': '26366796',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Calleja-Agius J, Brincat MP. The urogenital system and the menopause. Climacteric. 2015;18 Suppl 1:18-22. doi: 10.3109/13697137.2015.1078206.'},\n",
       "     {'pmid': '32852449',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976-992. doi: 10.1097/GME.0000000000001609.'},\n",
       "     {'pmid': '7856686',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):562-7. doi: 10.1016/0002-9378(95)90573-1.'},\n",
       "     {'pmid': '19440781',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Kingsberg S, Althof SE. Evaluation and treatment of female sexual disorders. Int Urogynecol J Pelvic Floor Dysfunct. 2009 May;20 Suppl 1:S33-43. doi: 10.1007/s00192-009-0833-x.'},\n",
       "     {'pmid': '6140343',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Brincat M, Magos A, Studd JW, Cardozo LD, O'Dowd T, Wardle PJ, Cooper D. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Lancet. 1984 Jan 7;1(8367):16-8. doi: 10.1016/s0140-6736(84)90183-1.\"}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M25869',\n",
       "      'name': 'Premature Birth',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5830', 'name': 'Uterine Cervical Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M19020',\n",
       "      'name': 'Primary Ovarian Insufficiency',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11577', 'name': 'Menopause, Premature', 'relevance': 'LOW'},\n",
       "     {'id': 'T6036',\n",
       "      'name': 'Menopause',\n",
       "      'asFound': 'Menopause',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000008777',\n",
       "      'term': 'Methyltestosterone'},\n",
       "     {'id': 'D000013739', 'term': 'Testosterone'},\n",
       "     {'id': 'C000010792', 'term': 'Testosterone undecanoate'},\n",
       "     {'id': 'C000004648', 'term': 'Testosterone enanthate'},\n",
       "     {'id': 'C000016131', 'term': 'Testosterone 17 beta-cypionate'}],\n",
       "    'ancestors': [{'id': 'D000000728', 'term': 'Androgens'},\n",
       "     {'id': 'D000006728', 'term': 'Hormones'},\n",
       "     {'id': 'D000006730',\n",
       "      'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018931', 'term': 'Antineoplastic Agents, Hormonal'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000045930', 'term': 'Anabolic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M8116', 'name': 'Estrogens', 'relevance': 'LOW'},\n",
       "     {'id': 'M266279',\n",
       "      'name': 'Estradiol 17 beta-cypionate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M266280', 'name': 'Estradiol 3-benzoate', 'relevance': 'LOW'},\n",
       "     {'id': 'M8108', 'name': 'Estradiol', 'relevance': 'LOW'},\n",
       "     {'id': 'M234941', 'name': 'Polyestradiol phosphate', 'relevance': 'LOW'},\n",
       "     {'id': 'M16509',\n",
       "      'name': 'Testosterone',\n",
       "      'asFound': 'Absence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11751',\n",
       "      'name': 'Methyltestosterone',\n",
       "      'asFound': 'Absence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M223475',\n",
       "      'name': 'Testosterone undecanoate',\n",
       "      'asFound': 'Absence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M223485',\n",
       "      'name': 'Testosterone enanthate',\n",
       "      'asFound': 'Absence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M235012',\n",
       "      'name': 'Testosterone 17 beta-cypionate',\n",
       "      'asFound': 'Absence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4059', 'name': 'Androgens', 'relevance': 'LOW'},\n",
       "     {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "     {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M20966',\n",
       "      'name': 'Antineoplastic Agents, Hormonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3032',\n",
       "      'name': 'Anabolic Androgenic Steroids',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M25605', 'name': 'Anabolic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06420349',\n",
       "    'orgStudyIdInfo': {'id': 'MC230406'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-03613',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MC230406', 'type': 'OTHER', 'domain': 'Mayo Clinic in Arizona'},\n",
       "     {'id': '23-012778',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Mayo Clinic Institutional Review Board'}],\n",
       "    'organization': {'fullName': 'Mayo Clinic', 'class': 'OTHER'},\n",
       "    'briefTitle': 'NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma',\n",
       "    'officialTitle': 'Phase 1b Study of the Novel GCN2 Kinase Activator NXP800 in Patients With Advanced Cholangiocarcionoma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase I trial tests the safety, best dose, and effectiveness of NXP800 in treating\\r\\npatients with cholangiocarcinoma that may have spread from where it first started to\\r\\nnearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread\\r\\nfrom where it first started (primary site) to other places in the body (metastatic).\\r\\nNXP800 inhibits a pathway called the heat shock factor 1 (HSF1) pathway. The inhibition\\r\\nof this pathway inhibits proliferation, migration, survival, and metastasis in\\r\\nsusceptible tumor cells. Overexpressed, amplified and/or overactivated in many cancer\\r\\ncells, HSF1 activates a set of genes that play a key role in tumor initiation,\\r\\nprogression and metastasis. Inhibiting this pathway may in turn inhibit tumor initiation,\\r\\nprogression, and/or metastasis. Giving NXP800 may be safe, tolerable and/or effective in\\r\\ntreating patients with advanced or metastatic cholangiocarcinoma.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To determine the maximum tolerated dose (MTD)/recommended phase 2 dose for heat shock\\r\\nfactor 1 pathway inhibitor NXP800 (NXP800).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. To determine the toxicity profile of NXP800. II. To determine the best response for\\r\\nNXP800 using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.\\r\\n\\r\\nIII. To estimate the overall survival (OS) for NXP800. IV. To estimate the\\r\\nprogression-free survival (PFS) for NXP800.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\n\\r\\nI. To evaluate transcriptomic features associated with sensitivity, resistance and\\r\\npharmacodynamic effect of NXP800 using serial ribonucleic acid-sequencing (RNA-Seq).\\r\\n\\r\\nII. To assess tumor evolution with NXP800 using serial whole genome-sequencing (Seq).\\r\\n\\r\\nIII. To assess tumor evolution with NXP800 using serial circulating tumor\\r\\ndeoxyribonucleic acid (DNA) (ct-DNA).\\r\\n\\r\\nIV. To estimate tumor marker response using serial CA19-9/carcinoembryonic antigen (CEA).\\r\\n\\r\\nOUTLINE: This is a dose de-escalation study of NXP800 followed by a dose-expansion study.\\r\\n\\r\\nPatients receive NXP800 orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles\\r\\nrepeat every 28 days in the absence of disease progression or unacceptable toxicity.\\r\\nPatients also undergo computed tomography (CT), magnetic resonance imaging (MRI), and/or\\r\\npositron emission tomography (PET) at baseline and on study. Patients may optionally\\r\\nundergo ultrasound-guided liver biopsy and/or collection of blood samples on study and\\r\\nduring follow up.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up every 6 months until\\r\\nprogressive disease or death for up to 3 years.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Cholangiocarcinoma',\n",
       "     'Metastatic Cholangiocarcinoma',\n",
       "     'Refractory Cholangiocarcinoma',\n",
       "     'Stage III Hilar Cholangiocarcinoma AJCC v8',\n",
       "     'Stage III Intrahepatic Cholangiocarcinoma AJCC v8',\n",
       "     'Stage IV Hilar Cholangiocarcinoma AJCC v8',\n",
       "     'Stage IV Intrahepatic Cholangiocarcinoma AJCC v8']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Treatment (NXP800)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive NXP800 PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in\\r\\nthe absence of disease progression or unacceptable toxicity. Patients also undergo CT,\\r\\nMRI, and/or PET at baseline and on study. Patients may optionally undergo\\r\\nultrasound-guided liver biopsy and/or collection of blood samples on study and during\\r\\nfollow up.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Biological: Heat Shock Factor 1 Pathway Inhibitor NXP800',\n",
       "       'Procedure: Magnetic Resonance Imaging',\n",
       "       'Procedure: Positron Emission Tomography',\n",
       "       'Procedure: Ultrasound-Guided Biopsy']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo collection of blood samples',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Computed Tomography',\n",
       "      'description': 'Undergo CT',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['CAT',\n",
       "       'CAT Scan',\n",
       "       'Computed Axial Tomography',\n",
       "       'Computerized Axial Tomography',\n",
       "       'Computerized axial tomography (procedure)',\n",
       "       'Computerized Tomography',\n",
       "       'Computerized Tomography (CT) scan',\n",
       "       'CT',\n",
       "       'CT Scan',\n",
       "       'tomography']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'Heat Shock Factor 1 Pathway Inhibitor NXP800',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['CCT 361814',\n",
       "       'CCT-361814',\n",
       "       'CCT361814',\n",
       "       'HSF1 Pathway Inhibitor NXP800',\n",
       "       'NXP-800',\n",
       "       'NXP800',\n",
       "       'VK2019']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Magnetic Resonance Imaging',\n",
       "      'description': 'Undergo MRI',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['Magnetic Resonance',\n",
       "       'Magnetic Resonance Imaging (MRI)',\n",
       "       'Magnetic resonance imaging (procedure)',\n",
       "       'Magnetic Resonance Imaging Scan',\n",
       "       'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance',\n",
       "       'MR',\n",
       "       'MR Imaging',\n",
       "       'MRI',\n",
       "       'MRI Scan',\n",
       "       'MRIs',\n",
       "       'NMR Imaging',\n",
       "       'NMRI',\n",
       "       'Nuclear Magnetic Resonance Imaging',\n",
       "       'sMRI',\n",
       "       'Structural MRI']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Positron Emission Tomography',\n",
       "      'description': 'Undergo PET',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['Medical Imaging, Positron Emission Tomography',\n",
       "       'PET',\n",
       "       'PET Scan',\n",
       "       'Positron emission tomography (procedure)',\n",
       "       'Positron Emission Tomography Scan',\n",
       "       'Positron-Emission Tomography',\n",
       "       'proton magnetic resonance spectroscopic imaging',\n",
       "       'PT']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Ultrasound-Guided Biopsy',\n",
       "      'description': 'Undergo ultrasound-guided liver biopsy',\n",
       "      'armGroupLabels': ['Treatment (NXP800)'],\n",
       "      'otherNames': ['Ultrasound Biopsy', 'Ultrasound Guided Biopsy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD)',\n",
       "      'description': 'MTD is defined as the dose level below the lowest dose that induces dose-limiting\\r\\ntoxicity in at least one-third of patients.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Recommended phase 2 dose',\n",
       "      'description': 'Recommended phase 2 dose is based on MTD (Outcome 1).',\n",
       "      'timeFrame': 'Up to 12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of adverse events',\n",
       "      'description': 'Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor\\r\\nsite will be explored and summarized. Frequency distributions, graphical techniques and\\r\\nother descriptive measures will form the basis of these analyses. The grade 3+ adverse\\r\\nevents will also be described and summarized in a similar fashion.',\n",
       "      'timeFrame': 'Up to 30 days after the administration of the last dose of study drug'},\n",
       "     {'measure': 'Best response',\n",
       "      'description': \"Best response is defined to be the best objective status recorded. The patient's best\\r\\nresponse assignment will depend on the achievement of both measurement and confirmation\\r\\ncriteria. The Response Evaluation Criteria in Solid Tumors 1.1 criteria will be used for\\r\\ntumor evaluation and patients will be re-evaluated every 8 weeks. Responses will be\\r\\nsummarized by simple descriptive summary statistics delineating complete and partial\\r\\nresponses as well as stable and progressive disease in this patient population (overall\\r\\nand by dose level). The number of responses may indicate further evaluation for specific\\r\\ntumor types in a phase II setting.\",\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'OS will be estimated using the Kaplan-Meier method. The median OS and corresponding 95%\\r\\nconfidence interval (by Brookmeyer and Crowley) will be reported.',\n",
       "      'timeFrame': 'Up to 3 years'},\n",
       "     {'measure': 'Progression-free survival (PFS)',\n",
       "      'description': 'PFS will be estimated using the Kaplan-Meier method. The median PFS and corresponding 95%\\r\\nconfidence interval (by Brookmeyer and Crowley) will be reported.',\n",
       "      'timeFrame': 'Up to 3 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Age ≥ 18 years\\r\\n\\r\\n  -  Histologically/cytologically confirmed biliary tract cancer\\r\\n\\r\\n  -  Advanced or metastatic disease that is refractory to gemcitabine or fluoropyrimidine\\r\\n     based therapy, or if there is intolerance to these regimens\\r\\n\\r\\n  -  Measurable disease by RECIST 1.1\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\\r\\n\\r\\n  -  Anticipated life expectancy of > 12 weeks\\r\\n\\r\\n  -  Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration)\\r\\n\\r\\n  -  Absolute neutrophil count (ANC) ≥ 1500/mm^3 (obtained ≤ 14 days prior to\\r\\n     registration)\\r\\n\\r\\n  -  Platelet count ≥ 100,000/mm^3 (obtained ≤ 14 days prior to registration)\\r\\n\\r\\n  -  Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (obtained ≤ 14\\r\\n     days prior to registration)\\r\\n\\r\\n  -  Alanine aminotransferase (ALT) ≤ 2.5 x ULN (obtained ≤ 14 days prior to\\r\\n     registration)\\r\\n\\r\\n  -  Total bilirubin ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)\\r\\n\\r\\n  -  Serum creatinine ≤ 1.5 x ULN (obtained ≤ 14 days prior to registration)\\r\\n\\r\\n  -  Provide written informed consent\\r\\n\\r\\n  -  Negative pregnancy test done ≤ 7 days prior to registration, for persons of\\r\\n     childbearing potential only\\r\\n\\r\\n       -  NOTE: If the urine test is positive or cannot be confirmed as negative, a serum\\r\\n          pregnancy test will be required\\r\\n\\r\\n  -  Willing to use a highly effective method of contraception from the first dose of\\r\\n     study medication through 180 days after the last dose of study medication, for\\r\\n     persons of childbearing potential or persons able to father a child only\\r\\n\\r\\n  -  Willing to return to enrolling institution for follow-up (during the active\\r\\n     monitoring phase of the study)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any of the following because this study involves an investigational agent whose\\r\\n     genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn\\r\\n     are unknown:\\r\\n\\r\\n       -  Pregnant persons.\\r\\n\\r\\n       -  Nursing persons.\\r\\n\\r\\n       -  Persons of childbearing potential who are unwilling to employ adequate\\r\\n          contraception\\r\\n\\r\\n  -  Systemic anti-neoplastic therapy or radiation therapy ≤ 14 days prior to\\r\\n     registration\\r\\n\\r\\n  -  Major surgical procedure ≤ 28 days prior to registration\\r\\n\\r\\n  -  Ongoing therapy related events > grade 2\\r\\n\\r\\n  -  Presence of another primary malignancy not in remission\\r\\n\\r\\n  -  New York Heart Classification 3 or greater heart failure\\r\\n\\r\\n  -  QT/corrected QT (QTc) interval > 470 ms using Fredericia's QT correction formula\\r\\n\\r\\n  -  Uncontrolled brain metastatic disease\\r\\n\\r\\n  -  Uncontrolled infection\\r\\n\\r\\n  -  Any other comorbidities within the opinion of the investigator interfere with the\\r\\n     investigation of the protocol\\r\\n\\r\\n  -  Usage of drugs that strongly inhibit or induce CYP3A4 ≤ 7 days prior to registration\\r\\n     and for the duration of NXP800 dosing. Drugs that are low, medium, or other\\r\\n     inhibitors of CYP3A4 are not prohibited and should be used with caution. Drugs that\\r\\n     inhibit BCRP are not prohibited but should be used with caution, since NXP800 was\\r\\n     found to be a BCRP substrate\\r\\n\\r\\n  -  Usage of seville oranges, grapefruit or grapefruit juice or products ≤ 7 days prior\\r\\n     to registration and for the duration of NXP800 dosing\\r\\n\\r\\n  -  Unwillingness to follow study related procedures\\r\\n\\r\\n  -  Inability to provide informed consent\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Clinical Trials Referral Office',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '855-776-0015',\n",
       "      'email': 'mayocliniccancerstudies@mayo.edu'}],\n",
       "    'overallOfficials': [{'name': 'Mitesh J. Borad, M.D.',\n",
       "      'affiliation': 'Mayo Clinic',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Mayo Clinic in Arizona',\n",
       "      'city': 'Scottsdale',\n",
       "      'state': 'Arizona',\n",
       "      'zip': '85259',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Clinical Trials Referral Office',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '855-776-0015',\n",
       "        'email': 'mayocliniccancerstudies@mayo.edu'},\n",
       "       {'name': 'Mitesh J. Borad, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Mayo Clinic Clinical Trials',\n",
       "      'url': 'https://www.mayo.edu/research/clinical-trials'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000018281',\n",
       "      'term': 'Cholangiocarcinoma'},\n",
       "     {'id': 'D000018285', 'term': 'Klatskin Tumor'}],\n",
       "    'ancestors': [{'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M20426',\n",
       "      'name': 'Cholangiocarcinoma',\n",
       "      'asFound': 'Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20430',\n",
       "      'name': 'Klatskin Tumor',\n",
       "      'asFound': 'Hilar Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T755',\n",
       "      'name': 'Bile Duct Cancer',\n",
       "      'asFound': 'Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3241',\n",
       "      'name': 'Klatskin Tumor',\n",
       "      'asFound': 'Hilar Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3096',\n",
       "      'name': 'Intrahepatic Cholangiocarcinoma',\n",
       "      'asFound': 'Intrahepatic Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M11110',\n",
       "      'name': 'Liver Extracts',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06381349',\n",
       "    'orgStudyIdInfo': {'id': 'GPOEM-GEMS'},\n",
       "    'organization': {'fullName': 'University of Auckland, New Zealand',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Predicting Outcomes of GPOEM Using Gastric Electrical Mapping',\n",
       "    'officialTitle': 'Predicting Outcomes of Gastric Peroral Endoscopic Myotomy Using a Gastric Electrical Mapping System: GPOEM-GEMS',\n",
       "    'acronym': 'GPOEM-GEMS'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-15',\n",
       "    'studyFirstSubmitQcDate': '2024-04-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Chris Varghese',\n",
       "     'investigatorTitle': 'Lead Clinical Investigator',\n",
       "     'investigatorAffiliation': 'University of Auckland, New Zealand'},\n",
       "    'leadSponsor': {'name': 'Chris Varghese', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Gastric peroral endoscopic myotomy (GPOEM) is a minimally-invasive procedure that\\r\\ninvolves dividing the pylorus, to enhance gastric emptying in gastroparesis patients.\\r\\nThis is a single-arm, multi-centre, prospective observational study to determine the\\r\\nclinical utility of Gastric Alimetry in predicting GPOEM treatment outcomes. The\\r\\ninvestigators further aim to develop a clinical decision rule to inform patient\\r\\nselection. Gastric Alimetry will be conducted <1 month prior to GPOEM. All subjects will\\r\\nthen be followed up for 12 months.',\n",
       "    'detailedDescription': \"This protocol proposes no change to the clinical management of patients which is left to\\r\\nthe discretion of the patients' primary clinical team.\\r\\n\\r\\nPatients as part of this study will undergo a baseline assessment via Gastric Alimetry,\\r\\nand concurrent symptom, quality of life, and health psychology questions.\\r\\n\\r\\nGPOEM will be performed as per standard site protocol, with data captured in RDCap.\\r\\n\\r\\nPatients will be followed up at 1-month, 3-month, 6-months, and 12-months using the myCap\\r\\n(REDCap) app.\\r\\n\\r\\nParticipants and clinicians can opt-in for a repeat Gastric Alimetry test at 6 or 12\\r\\nmonths following their GPOEM procedure.\"},\n",
       "   'conditionsModule': {'conditions': ['Gastroparesis'],\n",
       "    'keywords': ['endoscopy', 'electrophysiology', 'phenotyping']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Adult patients with gastroparesis',\n",
       "      'description': '  1. Provision of signed and dated informed consent form understand the risks and\\r\\n     benefits of the study\\r\\n\\r\\n  2. Aged ≥18 years old\\r\\n\\r\\n  3. Patients must be clinically selected for GPOEM at their respective study site.\\r\\n\\r\\n  4. Patients are undergoing their index GPOEM procedure',\n",
       "      'interventionNames': ['Diagnostic Test: Gastric Alimetry test']}],\n",
       "    'interventions': [{'type': 'DIAGNOSTIC_TEST',\n",
       "      'name': 'Gastric Alimetry test',\n",
       "      'description': \"Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's\\r\\nresults will not inform clinical management in this observational study.\",\n",
       "      'armGroupLabels': ['Adult patients with gastroparesis']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Gastroparesis Cardinal Symptom Index (GCSI)',\n",
       "      'description': '≥ 1 decrease in total GCSI score [higher score = worse symptoms]',\n",
       "      'timeFrame': '6 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Patient Assessment of Upper GastroIntestinal Disorders-Quality of Life (PAGI-QoL)',\n",
       "      'description': '0 - 5; higher score = better quality of life',\n",
       "      'timeFrame': '1, 3, 6, and 12 months'},\n",
       "     {'measure': 'EQ-5D scores',\n",
       "      'description': '0 - 1; higher score being better quality of life',\n",
       "      'timeFrame': '1, 3, 6, and 12 months'},\n",
       "     {'measure': 'Patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM)',\n",
       "      'description': '0 - 1; higher score being increased symptom burden',\n",
       "      'timeFrame': '1, 3, 6, and 12 months'},\n",
       "     {'measure': 'Patient Health Questionnaire - 8 (PHQ-8)',\n",
       "      'description': '0 - 12; higher score being increased depression severity',\n",
       "      'timeFrame': '6, and 12 months'},\n",
       "     {'measure': 'Generalized Anxiety Disorder 7-item (GAD-7)',\n",
       "      'description': '0 - 21; higher score indicates increased anxiety',\n",
       "      'timeFrame': '6, and 12 months'},\n",
       "     {'measure': 'Perceived Stress Scale 4 (PSS-4)',\n",
       "      'description': '0 - 16; higher scores indicate higher stress',\n",
       "      'timeFrame': '6, and 12 months'},\n",
       "     {'measure': 'Brief Illness Perception Questionnaire-Revised',\n",
       "      'description': '0 - 80; higher scores indicate worse illness perception',\n",
       "      'timeFrame': '6, and 12 months'},\n",
       "     {'measure': 'Alimetry® Gut-Brain Wellbeing (AGBW)',\n",
       "      'description': '0 - 40; higher scores indicate higher mental health burden',\n",
       "      'timeFrame': '1, 3, 6, and 12 months'},\n",
       "     {'measure': 'Work Productivity and Activity Impairment (WPAI)',\n",
       "      'description': '0-100%; higher scores indicating increased loss of work productivity and activity\\r\\nimpairment',\n",
       "      'timeFrame': '12 months'}],\n",
       "    'otherOutcomes': [{'measure': 'Change in Gastric Alimetry Phenotype',\n",
       "      'description': 'Change in phenotype classification on repeat Gastric Alimetry testing before and after\\r\\nG-POEM',\n",
       "      'timeFrame': '6'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Aged 18 years or older\\r\\n\\r\\n  -  Indicated for GPOEM\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Pregnant or breast-feeding\\r\\n\\r\\n  -  Inability to perform Gastric Alimetry test: history of severe skin allergies or\\r\\n     sensitivity to cosmetics or lotions; chronically damaged or vulnerable epigastric\\r\\n     skin (fragile skin, wounds, inflammation); patients unable to remain in a relaxed\\r\\n     reclined position for the test duration.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Adult patients aged 18-years or older with gastroparesis awaiting a G-POEM procedure that\\r\\nare able to undergo Gastric Alimetry testing.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Chris Varghese, MBChB',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+64 (0) 9 923 9820',\n",
       "      'email': 'cvar706@aucklanduni.ac.nz'}],\n",
       "    'locations': [{'facility': 'University of Auckland',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Auckland',\n",
       "      'zip': '1010',\n",
       "      'country': 'New Zealand',\n",
       "      'contacts': [{'name': 'Chris Varghese, MBChB',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+64 (0) 9 923 9820',\n",
       "        'email': 'cvar706@aucklanduni.ac.nz'}],\n",
       "      'geoPoint': {'lat': -36.84853, 'lon': 174.76349}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000018589',\n",
       "      'term': 'Gastroparesis'}],\n",
       "    'ancestors': [{'id': 'D000013272', 'term': 'Stomach Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000010243', 'term': 'Paralysis'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M20685',\n",
       "      'name': 'Gastroparesis',\n",
       "      'asFound': 'Gastroparesis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16062', 'name': 'Stomach Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M13157', 'name': 'Paralysis', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'T2445',\n",
       "      'name': 'Gastroparesis',\n",
       "      'asFound': 'Gastroparesis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06395506',\n",
       "    'orgStudyIdInfo': {'id': '23-0215'},\n",
       "    'organization': {'fullName': 'The University of Texas Medical Branch, Galveston',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation',\n",
       "    'officialTitle': 'An Open-label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Cancer Survivors',\n",
       "    'acronym': 'THRIVE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-05-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-19',\n",
       "    'studyFirstSubmitQcDate': '2024-04-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'The University of Texas Medical Branch, Galveston',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'ThriveWell Cancer Foundation',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The study's purpose is to evaluate whether creatine supplementation can help breast\\r\\ncancer survivors respond quicker to exercise by improving strength, endurance, and body\\r\\ncomposition. We are seeking to compare information collected from healthy woman of the\\r\\nsame age who have never had breast cancer to those participants who have had breast\\r\\ncancer and undergone chemotherapy treatment.\",\n",
       "    'detailedDescription': 'The primary objective of this study is to determine the effects of creatine\\r\\nsupplementation in modulating strength and physical function in breast cancer survivors\\r\\nthat have recently completed chemotherapy. The primary objective is to determine the\\r\\neffects of creatine in modulating strength and physical function in cancer survivors.'},\n",
       "   'conditionsModule': {'conditions': ['Breast Cancer',\n",
       "     'Breast Cancer Female',\n",
       "     'Muscle Weakness'],\n",
       "    'keywords': ['Breast Cancer',\n",
       "     'Breast Cancer Female',\n",
       "     'Exercise',\n",
       "     'Creatine Supplement']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This study plans to enroll 30 breast cancer patients who have completed chemotherapy\\r\\nwithin 6 months prior to consenting for this study. Each arm will have 15 participants.\\r\\nOne arm will receive creatine and the other will serve as the control group with no\\r\\ncreatine.',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Age-Matched Control Group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Women who have never been diagnosed with cancer.'},\n",
       "     {'label': 'Creatine Supplement Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Those randomized to receive creatine (experimental group) will be initially dosed at 20\\r\\ng/day for 7 days to boost availability of creatine systemically. Thereafter, the dose\\r\\nwill be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.\\r\\nParticipants will engage in three center-based exercise sessions each week for 12 weeks;\\r\\neach session lasting roughly 1-hour. Participants will be given a fitbit (electronic\\r\\nwatch that measures steps or heart rate) as well to track heart rate and monitor activity\\r\\nthroughout the study.',\n",
       "      'interventionNames': ['Dietary Supplement: Creatine']},\n",
       "     {'label': 'Non-Creatine Supplement Group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Participants will engage in three center-based exercise sessions each week for 12 weeks;\\r\\neach session lasting roughly 1-hour. Participants will be given a Fitbit (electronic\\r\\nwatch that measures steps or heart rate) as well to track heart rate and monitor activity\\r\\nthroughout the study.'}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Creatine',\n",
       "      'description': 'Those randomized to receive creatine (experimental group) will be initially dosed at 20\\r\\ng/day for 7 days to boost availability of creatine systemically. Thereafter, the dose\\r\\nwill be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.',\n",
       "      'armGroupLabels': ['Creatine Supplement Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in strength in breast cancer survivors',\n",
       "      'description': 'Determine the change in strength in breast cancer survivors by comparing pre and post\\r\\nmeasurements of strength measurement tools including 1RM/10RM/Biodex evaluations.',\n",
       "      'timeFrame': 'baseline and 12 weeks'},\n",
       "     {'measure': 'Change in physical functional capacity in breast cancer survivors',\n",
       "      'description': 'Determine the change in strength in breast cancer survivors by comparing pre and post\\r\\nmeasurements of the six minute walk test.',\n",
       "      'timeFrame': 'baseline and 12 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change intramuscular storage of creatine',\n",
       "      'description': 'Determine the change in intramuscular storage of creatine by comparing pre and post\\r\\nvastus lateralis muscle using MRI.',\n",
       "      'timeFrame': 'baseline and 12 weeks'},\n",
       "     {'measure': 'Change in body composition in cancer survivors',\n",
       "      'description': 'Determine the change in body composition in breast cancer survivors by pre and post\\r\\nmeasurements of bone mass as well as lean vs fat mass via a DEXA scan.',\n",
       "      'timeFrame': 'baseline and 12 weeks'},\n",
       "     {'measure': 'Change in the return of strength for breast cancer survivors with creatine + exercise',\n",
       "      'description': 'Breast cancer survivors who complete 12-weeks of exercise with creatine supplementation\\r\\ngroup who regained strength and physical function to that of women of similar age who\\r\\nnever had cancer.',\n",
       "      'timeFrame': '12 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria (Breast Cancer Group)\\r\\n\\r\\n  -  Age 18-75 years of age\\r\\n\\r\\n  -  Diagnosis of breast cancer requiring chemotherapy\\r\\n\\r\\n  -  Recent (within 6 months) completion of chemotherapy\\r\\n\\r\\n  -  Willing to attend 3 virtual-based exercise sessions per week\\r\\n\\r\\n  -  Able to take oral medications\\r\\n\\r\\n  -  Participant is willing and able to provide consent to participating in the study\\r\\n\\r\\n  -  Serum creatinine ≤ 1.5 x ULN or Estimated glomerular filtration rate (eGFR) ≥30\\r\\n     mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation.\\r\\n\\r\\nExclusion criteria (Breast Cancer Group)\\r\\n\\r\\n  -  Physical indications where performing exercise may be limited and/or contraindicated\\r\\n\\r\\n  -  Poorly controlled hypertension (blood pressure > 160/95mmHg)\\r\\n\\r\\n  -  Current tobacco use (within 6 months)\\r\\n\\r\\n  -  Anabolic steroids use\\r\\n\\r\\n  -  Pitting edema greater than 2+\\r\\n\\r\\n  -  Currently undergoing chemotherapy treatment for cancer\\r\\n\\r\\n  -  History of moderate-severe heart disease (New York Heart Classification greater than\\r\\n     grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of\\r\\n     stairs or less; abnormal breath sounds on auscultation)\\r\\n\\r\\n  -  Pregnant or plan to become pregnant during the study\\r\\n\\r\\n  -  Recent (within one month) or anticipated treatment with corticosteroids (except for\\r\\n     short term use during the time of chemotherapy), or other appetite stimulants\\r\\n\\r\\n  -  Serum creatinine > 1.5 x ULN or Estimated glomerular filtration rate (eGFR) < 30\\r\\n     mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\\r\\n\\r\\n  -  Currently taking creatine supplements\\r\\n\\r\\n  -  Lack of availability to a smartphone and/or internet\\r\\n\\r\\nInclusion Criteria (Healthy Age-matched Control Group)\\r\\n\\r\\n  -  Age 18-75 years of age\\r\\n\\r\\n  -  Have never been diagnosed with cancer\\r\\n\\r\\n  -  Willing to provide consent to participate in this study\\r\\n\\r\\nExclusion Criteria (Healthy Age-matched Control Group)\\r\\n\\r\\n  -  Physical indications where performing exercise may be limited and/or contraindicated\\r\\n\\r\\n  -  Poorly controlled hypertension (blood pressure > 160/95mmHg)\\r\\n\\r\\n  -  Current tobacco use (within 6 months)\\r\\n\\r\\n  -  Anabolic steroids use\\r\\n\\r\\n  -  Pitting edema greater than 2+\\r\\n\\r\\n  -  History of cancer diagnosis\\r\\n\\r\\n  -  History of moderate-severe heart disease (New York Heart Classification greater than\\r\\n     grade II) or pulmonary disease (dyspnea on exertion upon climbing one flight of\\r\\n     stairs or less; abnormal breath sounds on auscultation)\\r\\n\\r\\n  -  Pregnant or currently taking prescribed medication to prepare for pregnancy (i.e.\\r\\n\\r\\nhormonal therapy for IVF)\\r\\n\\r\\n  -  Recent (within one month) treatment with corticosteroids\\r\\n\\r\\n  -  Recent (within one month) use of appetite stimulants or appetite suppressants\\r\\n\\r\\n  -  Serum creatinine > 1.5 x ULN or Estimated glomerular filtration rate (eGFR) < 30\\r\\n     mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation\\r\\n\\r\\n  -  Diagnosed Bipolar Disorder or MDQ score indicative of bipolar disorder or\\r\\n     Neurological disorders\\r\\n\\r\\n  -  Uncontrolled diabetes (A1c of 6.5% or higher)\\r\\n\\r\\n  -  Currently taking creatine supplements\\r\\n\\r\\n  -  Lack of availability to a smartphone and/or internet',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Lisa Thibodeaux, RN,BSN',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '4094741756',\n",
       "      'email': 'lbthibod@utmb.edu'},\n",
       "     {'name': 'Rebecca Geck, MPH,APRN,CPT',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '4092660496',\n",
       "      'email': 'raschaef@utmb.edu'}],\n",
       "    'overallOfficials': [{'name': 'Darpan Patel, PhD',\n",
       "      'affiliation': 'University of Texas',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'The University of Texas Medical Branch, Galveston',\n",
       "      'city': 'Galveston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77555',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Lisa Thibodeaux, RN,BSN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '409-474-1756',\n",
       "        'email': 'lbthibod@utmb.edu'},\n",
       "       {'name': 'Rebecca Geck, MPH,APRN,CPT',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '4092660496',\n",
       "        'email': 'raschaef@utmb.edu'}],\n",
       "      'geoPoint': {'lat': 29.30135, 'lon': -94.7977}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001943',\n",
       "      'term': 'Breast Neoplasms'},\n",
       "     {'id': 'D000018908', 'term': 'Muscle Weakness'}],\n",
       "    'ancestors': [{'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001941', 'term': 'Breast Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M5220',\n",
       "      'name': 'Breast Neoplasms',\n",
       "      'asFound': 'Breast Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20944',\n",
       "      'name': 'Muscle Weakness',\n",
       "      'asFound': 'Muscle Weakness',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13204', 'name': 'Paresis', 'relevance': 'LOW'},\n",
       "     {'id': 'M4554', 'name': 'Asthenia', 'relevance': 'LOW'},\n",
       "     {'id': 'M5218', 'name': 'Breast Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22619',\n",
       "      'name': 'Neuromuscular Manifestations',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M12478',\n",
       "      'name': 'Nicotine',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T385',\n",
       "      'name': 'Creatine',\n",
       "      'asFound': 'Elbow',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06417606',\n",
       "    'orgStudyIdInfo': {'id': 'IEC-ZN-01-AF 09'},\n",
       "    'organization': {'fullName': 'Tongji Hospital', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma',\n",
       "    'officialTitle': 'A Single-arm, Prospective Clinical Study of Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-04-20', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-21',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Zhiyong Huang',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'Tongji Hospital'},\n",
       "    'leadSponsor': {'name': 'Zhiyong Huang', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A single-arm, prospective clinical study was conducted to enroll 20 subjects. Each\\r\\nsubject was treated with oral Lenvatinib + Adebrelimab + GEMOX (gemcitabine +\\r\\noxaliplatin). The treatment phase before surgery was 3 cycles, and the evaluation was\\r\\nperformed every 2 cycles. The evaluation was repeated before surgery, and the decision of\\r\\nsurgery was made according to the evaluation results.\\r\\n\\r\\nTo evaluate the efficacy and safety of Lenvatinib and Adebrelimab combined with GEMOX in\\r\\nthe perioperative treatment of potentially resectable intrahepatic cholangiocarcinoma.'},\n",
       "   'conditionsModule': {'conditions': ['Intrahepatic Cholangiocarcinoma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Lenvatinib and Adebrelimab Combined With GEMOX（Gemcitabine and oxaliplatin）',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight < 60Kg, 8mg/ day）；\\r\\nAdebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous\\r\\ndrip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin,\\r\\n100mg/m2, was given every 3 weeks）',\n",
       "      'interventionNames': ['Drug: Lenvatinib']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Lenvatinib',\n",
       "      'description': 'Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight < 60Kg, 8mg/ day）；\\r\\nAdebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous\\r\\ndrip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin,\\r\\n100mg/m2, was given every 3 weeks）',\n",
       "      'armGroupLabels': ['Lenvatinib and Adebrelimab Combined With GEMOX（Gemcitabine and oxaliplatin）'],\n",
       "      'otherNames': ['Adebrelimab', 'GEMOX（Gemcitabine and oxaliplatin）']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'ORR',\n",
       "      'description': 'Objective Response Rate',\n",
       "      'timeFrame': 'through study completion, an average of 1 year'},\n",
       "     {'measure': 'DFS',\n",
       "      'description': 'Disease Free Survival',\n",
       "      'timeFrame': 'through study completion, an average of 1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'R0 resection rate',\n",
       "      'description': 'The tumor was completely removed with negative margins, meaning no residual tumor',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'OS',\n",
       "      'description': 'Overall Survival',\n",
       "      'timeFrame': 'Up to 24 months'},\n",
       "     {'measure': 'DCR',\n",
       "      'description': 'Disease Control Rate',\n",
       "      'timeFrame': 'DCR will be calculated as the percentage of patients who achieved Stable Disease(SD) or better for more than 8 weeks (RECIST v1.1)'},\n",
       "     {'measure': 'EFS',\n",
       "      'description': 'Event Free Survival',\n",
       "      'timeFrame': 'Up to 12/24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Voluntarily participated in this study, signed informed consent, aged 18-80 years\\r\\n\\r\\n  -  Patients with locally advanced intrahepatic cholangiocarcinoma: (meet at least one\\r\\n     of the following) A, the number of intrahepatic tumors was 2-3 B, the intrahepatic\\r\\n     tumor is single but >5cm in diameter C, the tumor was close to the 1/2 grade branch\\r\\n     of the hepatic pedicle, making RO resection difficult D. Lymph node metastasis: MRI\\r\\n     or PET/CT suggested regional lymph node metastasis\\r\\n\\r\\n  -  The WHO/ECOG PS score was 0-1\\r\\n\\r\\n  -  Imaging examination (CT/MRI/PET-CT) showed no distant metastasis\\r\\n\\r\\n  -  Child-Pugh grade: A (≤6 points)\\r\\n\\r\\n  -  Expected survival time ≥6 months\\r\\n\\r\\n  -  No previous systemic treatment for hepatocellular carcinoma, including chemotherapy,\\r\\n     targeted therapy, immunotherapy, etc. Patients who had undergone previous curative\\r\\n     surgery or curative ablation were allowed, except those who had a recurrence within\\r\\n     2 years after curative surgery and those who had received other previous local\\r\\n     treatment\\r\\n\\r\\n  -  If you have hepatitis B virus (HBV) infection, such as HBsAg positive, you need to\\r\\n     test HBV-DNA, and HBV-DNA should be less than 500IU/mL (; Patients with HBV-DNA of\\r\\n     more than 500 IU per milliliter received antiviral therapy (only nucleoside agents\\r\\n     such as entecavir, tenofovir dipivoxil fumarate, and tenofovir propofol fumarate\\r\\n     tablets) for at least 1 week before randomization and had a decrease in viral copy\\r\\n     number by a factor of more than 10. For patients with HBV infection, antiviral\\r\\n     therapy should be received throughout the study period. Patients who are positive\\r\\n     for hepatitis C virus (HCV) -RNA must receive antiviral therapy according to\\r\\n     treatment guidelines\\r\\n\\r\\n  -  Organs and bone marrow are sufficiently functional, defined as follows:\\r\\n\\r\\n       1. hemoglobin ≥9g/dL\\r\\n\\r\\n       2. absolute neutrophil count ≥1.5 × 109/L\\r\\n\\r\\n       3. platelet count ≥ 100 × 109/L\\r\\n\\r\\n       4. serum bilirubin ≤2.0× upper limit of normal (ULN); This condition does not\\r\\n          apply to patients with proven Gilbert's syndrome. Any clinically significant\\r\\n          biliary obstruction had to be relieved prior to enrollment in the study.\\r\\n\\r\\n       5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be\\r\\n          ≤2.5×ULN. For patients with liver metastases, ALT and AST should be ≤5 × ULN.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  The investigator deemed the subject unfit to participate in the study\\r\\n\\r\\n  -  Have active autoimmune disease or a history of autoimmune disease with possible\\r\\n     recurrence (including but not limited to autoimmune hepatitis, interstitial\\r\\n     pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism,\\r\\n     hypothyroidism)\\r\\n\\r\\n  -  Use of immunosuppressant or systemic hormone therapy to achieve immunosuppression\\r\\n     within 2 weeks before treatment (dose >10mg/ day of prednisone or other effective\\r\\n     hormones)\\r\\n\\r\\n  -  patients with active infection, unexplained fever ≥38.5℃ within 1 week before\\r\\n     randomization, or white blood cell count >15×109/L during screening; Therapeutic\\r\\n     antibiotics, administered orally or intravenously, were given within 2 weeks before\\r\\n     randomization\\r\\n\\r\\n  -  Patients with innate or acquired immune deficiency (e.g., HIV infection)\\r\\n\\r\\n  -  History of other primary malignancies, with the exception of malignancies treated\\r\\n     with curative treatment, known absence of active disease ≥5 years before the first\\r\\n     study intervention, and low potential risk of recurrence; Basal cell carcinoma of\\r\\n     the skin, squamous cell carcinoma of the skin, or lentigo maligna that has received\\r\\n     potentially curative treatment; Or carcinoma in situ that has been adequately\\r\\n     treated without evidence of disease\\r\\n\\r\\n  -  Patients with clinically significant bleeding symptoms or a clear bleeding tendency\\r\\n     within 6 months before treatment, such as gastrointestinal bleeding, severe\\r\\n     esophagogastric varices, hemorrhagic gastric ulcer, or angiitis, can be reexamined\\r\\n     if fecal occult blood is positive at baseline, and if it is still positive after\\r\\n     reexamination, gastroscopy is required\\r\\n\\r\\n  -  Known inherited or acquired bleeding (e.g. coagulopathy) or thrombophilia, such as\\r\\n     in patients with hemophilia, coagulation disorders, thrombocytopenia, etc.;\\r\\n     Currently receiving full-dose oral or injectable anticoagulants or thrombolytic\\r\\n     agents for therapeutic purposes (prophylactic use such as low-dose aspirin is\\r\\n     allowed)\\r\\n\\r\\n  -  Known allergies to any study drug or excipients\\r\\n\\r\\n  -  Participate in other drug clinical trials within 4 weeks before randomization\\r\\n\\r\\n  -  Pregnant or lactating women\\r\\n\\r\\n  -  Other factors considered by the investigator to be unsuitable for participation in\\r\\n     the study\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Zunyi Zhang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '86-15827413728',\n",
       "      'email': 'zunyizhangtjmu@163.com'},\n",
       "     {'name': 'Guan Tan',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '86-15971812255',\n",
       "      'email': 'd202382316@hust.edu.cn'}],\n",
       "    'overallOfficials': [{'name': 'Zhiyong Huang',\n",
       "      'affiliation': 'Tongji Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Tongji Hospital',\n",
       "      'city': 'Wuhan',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Zunyi Zhang',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86-15827413728',\n",
       "        'email': 'zunyizhangtjmu@163.com'},\n",
       "       {'name': 'Guan Tan',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86-15971812255',\n",
       "        'email': 'd202382316@hust.edu.cn'}],\n",
       "      'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000018281',\n",
       "      'term': 'Cholangiocarcinoma'}],\n",
       "    'ancestors': [{'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M20426',\n",
       "      'name': 'Cholangiocarcinoma',\n",
       "      'asFound': 'Intrahepatic Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T755',\n",
       "      'name': 'Bile Duct Cancer',\n",
       "      'asFound': 'Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3096',\n",
       "      'name': 'Intrahepatic Cholangiocarcinoma',\n",
       "      'asFound': 'Intrahepatic Cholangiocarcinoma',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000093542',\n",
       "      'term': 'Gemcitabine'},\n",
       "     {'id': 'D000077150', 'term': 'Oxaliplatin'},\n",
       "     {'id': 'C000531958', 'term': 'Lenvatinib'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M2985',\n",
       "      'name': 'Gemcitabine',\n",
       "      'asFound': 'Activity',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M353738',\n",
       "      'name': 'Lenvatinib',\n",
       "      'asFound': 'Primary care',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1674',\n",
       "      'name': 'Oxaliplatin',\n",
       "      'asFound': 'Outcomes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05935306',\n",
       "    'orgStudyIdInfo': {'id': 'Pain after endodontic surgery'},\n",
       "    'organization': {'fullName': 'University of Nove de Julho',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery',\n",
       "    'officialTitle': 'Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery: a Randomized Controlled Clinical Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-11-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-06-18',\n",
       "    'studyFirstSubmitQcDate': '2023-07-06',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-05',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-06', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Anna Carolina Ratto Tempestini Horliana',\n",
       "     'investigatorTitle': 'Clinical Investigator',\n",
       "     'investigatorAffiliation': 'University of Nove de Julho'},\n",
       "    'leadSponsor': {'name': 'University of Nove de Julho', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The objective of this study will be to evaluate if photobiomodulation (FBM) can reduce\\r\\npostoperative pain in patients who will undergo endodontic surgery. For this randomized,\\r\\ncontrolled and double-blind clinical study, 34 patients without comorbidities who need\\r\\nendodontic surgery in the upper jaw (15 to 25 teeth) will be recruited. They will be\\r\\nrandomly divided into an experimental group (n = 17) photobiomodulation (808nm, 100 mW,\\r\\nand 4J/cm2 with 5 points per vestibular). Applications will be made in the immediate\\r\\npostoperative period and 24 hours after surgery. Control group (n = 17) a FBM simulation\\r\\nwill be performed in the same way as in the experimental group. In this group, the\\r\\nrequired analgesia will be administered within the standard with ibuprofen. Both groups\\r\\nwill perform the necessary conventional procedures considered the gold standard in the\\r\\nliterature. Both the patient and the evaluator will be blinded to the intervention\\r\\nperformed. The primary outcome variable of the study will be postoperative pain, which\\r\\nwill be assessed using the visual analog scale at all postoperative control visits\\r\\n(baseline, 24 hours and 7 days). As for the secondary outcome variables, the amount of\\r\\nsystemic medication received according to the patient's need (will be provided by the\\r\\ninvestigator).. Radiographic images will be obtained after 1 and 2 months for evaluation\\r\\nof the repair (dimensions of the lesion, radiopacity). These radiographs will be taken\\r\\ndigitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft\\r\\ntissues in the anterior portion of the intra and extra-oral maxilla will also be\\r\\nevaluated. In addition, a digital thermometer. These parameters will be evaluated 24\\r\\nhours and 7 days after the intervention. The X-rays will be taken in the 1st and 3rd\\r\\nmonth respectively.\",\n",
       "    'detailedDescription': \"Photobiomodulation (FBM) has shown favorable results in the postoperative period of\\r\\nendodontic surgery, however, up to now, the level of evidence in this procedure is low.\\r\\nThe objective of this study will be to evaluate if photobiomodulation (FBM) can reduce\\r\\npostoperative pain in patients who will undergo endodontic surgery. For this randomized,\\r\\ncontrolled, and double-blind clinical study, 34 Uruguayan participants of both sexes who\\r\\npreviously consulted at the Clínica Universitaria de la Salud, with a diagnosis of\\r\\nperiodontitis with an apical lesion less than 10mm with or without a fistula, diagnosed\\r\\nclinically and radiographically, in the upper maxillary region (from 15 to 25) will be\\r\\nrecruited. Participants included in the study must have periapical lesions who have\\r\\nalready undergone endodontic treatment (lesions smaller than 10mm in their greatest\\r\\ndiameter - Metin et al., 2018, single and chronic lesions), no comorbidities, age from 18\\r\\nto 70 years, both genders, healthy permanent teeth with good hygiene. Participants will\\r\\nbe excluded if they are taking drugs that affect bone metabolism and the inflammatory\\r\\nprocess (for example corticosteroids, bisphosphonates), Smokers, pregnant or lactating\\r\\nwomen, if used anti-inflammatory drugs in the last 3 months before surgery, who do not\\r\\nfollow the guidelines or have an injury in the acute phase (pain, edema, exudate). They\\r\\nwill be randomly divided into an experimental group (n = 17) photobiomodulation (808nm,\\r\\n100 mW, and 4J/cm2 with 5 points per vestibular). Applications will be made in the\\r\\nimmediate postoperative period and 24 hours after surgery. Control group (n = 17) FBM\\r\\nsimulation will be performed in the same way as in the experimental group. In this group,\\r\\nthe required analgesia will be administered within the standard with ibuprofen. Both\\r\\ngroups will perform the necessary conventional procedures considered the gold standard in\\r\\nthe literature. Both the patient and the evaluator will be blinded to the intervention\\r\\nperformed. The primary outcome variable of the study will be postoperative pain, which\\r\\nwill be assessed using the visual analog scale at all postoperative control visits\\r\\n(baseline, 24 hours, and 7 days). As for the secondary outcome variables, the amount of\\r\\nsystemic medication received according to the patient's need (will be provided by the\\r\\ninvestigator). Radiographic images will be obtained after 1 and 3 months for evaluation\\r\\nof the repair (dimensions of the lesion, radiopacity). These radiographs will be taken\\r\\ndigitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft\\r\\ntissues in the anterior portion of the intra and extra-oral maxilla will also be\\r\\nevaluated. In addition, the temperature with a digital thermometer. These parameters will\\r\\nbe evaluated 24 hours and 7 days after the intervention. The X-rays will be taken in the\\r\\n1st and 3rd months, respectively. Once all the data have been collected, their normality\\r\\nwill be tested, and the one-way ANOVA test and the complementary Tukey test will be\\r\\ncarried out. Data will be presented as mean ± standard deviation (SD) and the accepted\\r\\np-value will be <0.0\"},\n",
       "   'conditionsModule': {'conditions': ['Photobiomodulation',\n",
       "     'Endodontic Disease',\n",
       "     'Pain',\n",
       "     'Inflammation',\n",
       "     'Surgery']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This randomized, controlled, double-blind superiority clinical trial meets the criteria\\r\\nfor designing a clinical trial in accordance with the SPIRIT Statement. It was accepted\\r\\nby Research Ethics Committee (CEP) of the Catholic University of Uruguay',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'maskingDescription': 'Thus for the participant does not identify the group to which he belongs, the device\\r\\nactivation sound (beep) will be recorded and it will turn on at the time of application..\\r\\nImmediately after finishing the suture, the investigator in charge of applying the FBM\\r\\nwill remove and open 1 envelope (without changing the numerical sequence of the other\\r\\nenvelopes) and perform the indicated procedure or its simulation. Only this researcher\\r\\nwill know the nature of the treatments.',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 34, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'G1- Control group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Conventional treatment + FBM simulation (n = 17 patients): All participants will undergo\\r\\nthe same conventional surgical procedure. Patients will receive the FBM simulation and\\r\\nwill be treated identically to the G2 group. The person responsible for applying the FBM\\r\\nwill simulate the radiation by placing the devices in the same places described for the\\r\\nFBM group, however, the equipment will remain turned off. Thus for the participant does\\r\\nnot identify the group to which he belongs, the device activation sound (beep) will be\\r\\nrecorded and it will turn on at the time of application.',\n",
       "      'interventionNames': ['Drug: Ibuprofen',\n",
       "       'Other: Photobiomodulation simulation']},\n",
       "     {'label': 'G2- Intervention group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Conventional treatment with placebo ibuprofen + FBM (n = 17) All participants will\\r\\nundergo the same surgical procedure. Patients will receive FBM (Table 1) and will be\\r\\ntreated identically to the G2 group.\\r\\n\\r\\nThe irradiated region will be on the lesion at 4 equidistant points on the vertex of a\\r\\nflat square 1 cm away. A dot will be irradiated in the middle of the square (Figure 1).\\r\\nPlacebo ibuprofen will be manipulated.',\n",
       "      'interventionNames': ['Device: Photobiomodulation',\n",
       "       'Other: Ibuprofen simulation']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Ibuprofen',\n",
       "      'description': 'All participants will undergo the same conventional surgical procedure. Patients will\\r\\nreceive the FBM simulation and will be treated identically to the G2 group.',\n",
       "      'armGroupLabels': ['G1- Control group'],\n",
       "      'otherNames': ['antinflamatory']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Photobiomodulation simulation',\n",
       "      'description': 'The person responsible for applying the FBM will simulate the radiation by placing the\\r\\ndevices in the same places described for the FBM group, however, the equipment will\\r\\nremain turned off.',\n",
       "      'armGroupLabels': ['G1- Control group']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Photobiomodulation',\n",
       "      'description': '. Patients will receive FBM and will be treated identically to the G2 group. The\\r\\nirradiated region will be on the lesion at 4 equidistant points on the vertex of a flat\\r\\nsquare 1 cm away.',\n",
       "      'armGroupLabels': ['G2- Intervention group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Ibuprofen simulation',\n",
       "      'description': 'Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)',\n",
       "      'armGroupLabels': ['G2- Intervention group'],\n",
       "      'otherNames': ['antinflamatory placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain in postoperative period - baseline',\n",
       "      'description': 'Pain will be measured during the immediate postoperative period of endodontic surgery\\r\\nusing the Visual Analogue Scale (VAS) measured in millimeters, where \"0\" is no pain and\\r\\n\"10\" is the worst pain in life (Metin et al. ., 2018, Sampaio-Filho et al., 2018).',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Pain in postoperative period - 24 hours after treatment',\n",
       "      'description': 'Pain will be measured at 24hours of postoperative period of endodontic surgery using the\\r\\nVisual Analogue Scale (VAS) measured in millimeters, where \"0\" is no pain and \"10\" is the\\r\\nworst pain in life (Metin et al. ., 2018, Sampaio-Filho et al., 2018).',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Pain in postoperative period -7 days after treatment',\n",
       "      'description': 'Pain will be measured at 7d of postoperative period of endodontic surgery using the\\r\\nVisual Analogue Scale (VAS) measured in millimeters, where \"0\" is no pain and \"10\" is the\\r\\nworst pain in life (Metin et al., 2018, Sampaio-Filho et al., 2018).',\n",
       "      'timeFrame': '7 days after treatment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Quantity of painkillers ingested in the period - baseline',\n",
       "      'description': 'the number of painkillers ingested will be counted. The analgesic used will be only\\r\\nparacetamol that will be administered to the patient, but it is advisable to take it only\\r\\nin case of pain (Sampaio-Filho et al., 2018). A procedure will be carried out to monitor\\r\\nthe adherence of the participants (for example, each patient will be asked to bring the\\r\\npain reliever pack to the appointment to see how it is used).',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Quantity of painkillers ingested in the period - 24 hours after treatment',\n",
       "      'description': 'the quantity of painkillers ingested in the 24-hours will be counted. The analgesic used\\r\\nwill be only paracetamol that will be administered to the patient, but it is advisable to\\r\\ntake it only in case of pain (Sampaio-Filho et al., 2018). A procedure will be carried\\r\\nout to monitor the adherence of the participants (for example, each patient will be asked\\r\\nto bring the pain reliever pack to the appointment to see how it is used).',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Quantity of painkillers ingested in the period - 7 days after treatment',\n",
       "      'description': 'the number of painkillers ingested in the 7-day period will be counted. The analgesic\\r\\nused will be only paracetamol that will be administered to the patient, but it is\\r\\nadvisable to take it only in case of pain (Sampaio-Filho et al., 2018). A procedure will\\r\\nbe carried out to monitor the adherence of the participants (for example, each patient\\r\\nwill be asked to bring the pain reliever pack to the appointment to see how it is used).',\n",
       "      'timeFrame': '7 days after treatment'},\n",
       "     {'measure': 'Edema - baseline',\n",
       "      'description': 'A scale will be used to quantify the amount of edema as recommended by some authors\\r\\n(Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1\\r\\n= intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Edema - 24 hours after treatment',\n",
       "      'description': 'A scale will be used to quantify the amount of edema as recommended by some authors\\r\\n(Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1\\r\\n= intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Edema - 7 days after treatment',\n",
       "      'description': 'A scale will be used to quantify the amount of edema as recommended by some authors\\r\\n(Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1\\r\\n= intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).',\n",
       "      'timeFrame': '7 days after treatment'},\n",
       "     {'measure': 'Ecchymosis - baseline',\n",
       "      'description': 'is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is\\r\\ncaused by the rupture of one or more blood capillaries and one of the causes is surgical\\r\\ntrauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot\\r\\n4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Ecchymosis - 24 hours after treatment',\n",
       "      'description': 'is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is\\r\\ncaused by the rupture of one or more blood capillaries and one of the causes is surgical\\r\\ntrauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot\\r\\n4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Ecchymosis -7 days after treatment',\n",
       "      'description': 'is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is\\r\\ncaused by the rupture of one or more blood capillaries and one of the causes is surgical\\r\\ntrauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot\\r\\n4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).',\n",
       "      'timeFrame': '7 days after treatment'},\n",
       "     {'measure': 'Soft tissue healing - baseline',\n",
       "      'description': 'Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation,\\r\\nno pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain.\\r\\nScore 3: no opening at the incision line, active drainage, advanced inflammation,\\r\\nmoderate to advanced pain. Score 4: opening at the incision line, active drainage,\\r\\nadvanced inflammation, ongoing pain.',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Soft tissue healing - 24 hours after treatment',\n",
       "      'description': 'Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation,\\r\\nno pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain.\\r\\nScore 3: no opening at the incision line, active drainage, advanced inflammation,\\r\\nmoderate to advanced pain. Score 4: opening at the incision line, active drainage,\\r\\nadvanced inflammation, ongoing pain.',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Soft tissue healing -7 days after treatment',\n",
       "      'description': 'Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation,\\r\\nno pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain.\\r\\nScore 3: no opening at the incision line, active drainage, advanced inflammation,\\r\\nmoderate to advanced pain. Score 4: opening at the incision line, active drainage,\\r\\nadvanced inflammation, ongoing pain.',\n",
       "      'timeFrame': '7 days after treatment'},\n",
       "     {'measure': 'Bone consolidation - baseline',\n",
       "      'description': 'Periapical radiography will evaluate the changes in the area of the defect (bone\\r\\ndensity). Periapical radiographs will always be performed with the same equipment using\\r\\nthe parallelism technique. The area of the defect will be measured by multiplying the\\r\\nlongest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs,\\r\\nthe longest diameter of the lesion was measured and the periapical index was evaluated.\\r\\nThe periapical index was recorded according to the following parameters: 0 = no lesion, 1\\r\\n= periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a\\r\\ndiameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 =\\r\\nperiapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency\\r\\ngreater than 8.1 mm in diameter.',\n",
       "      'timeFrame': 'at baseline'},\n",
       "     {'measure': 'Bone consolidation - 24 hours after treatment',\n",
       "      'description': 'Periapical radiography will evaluate the changes in the area of the defect (bone\\r\\ndensity). Periapical radiographs will always be performed with the same equipment using\\r\\nthe parallelism technique. The area of the defect will be measured by multiplying the\\r\\nlongest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs,\\r\\nthe longest diameter of the lesion was measured and the periapical index was evaluated.\\r\\nThe periapical index was recorded according to the following parameters: 0 = no lesion, 1\\r\\n= periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a\\r\\ndiameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 =\\r\\nperiapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency\\r\\ngreater than 8.1 mm in diameter.',\n",
       "      'timeFrame': '24 hours after treatment'},\n",
       "     {'measure': 'Bone consolidation - 7 days after treatment',\n",
       "      'description': 'Periapical radiography will evaluate the changes in the area of the defect (bone\\r\\ndensity). Periapical radiographs will always be performed with the same equipment using\\r\\nthe parallelism technique. The area of the defect will be measured by multiplying the\\r\\nlongest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs,\\r\\nthe longest diameter of the lesion was measured and the periapical index was evaluated.\\r\\nThe periapical index was recorded according to the following parameters: 0 = no lesion, 1\\r\\n= periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a\\r\\ndiameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 =\\r\\nperiapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency\\r\\ngreater than 8.1 mm in diameter.',\n",
       "      'timeFrame': '7 days after treatment'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria\\r\\n\\r\\n:• Patients with periapical lesions who have already undergone endodontic treatment\\r\\n(lesions smaller than 10mm in their greatest diameter - Metin et al., 2018, single and\\r\\nchronic lesions)\\r\\n\\r\\n  -  Patients with not comorbidities,\\r\\n\\r\\n  -  Age from 18 to 70 years,\\r\\n\\r\\n  -  Both genders,\\r\\n\\r\\n  -  Healthy permanent teeth with good hygiene.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Who are taking drugs that affect bone metabolism and the inflammatory process (for\\r\\n     example: corticosteroids, bisphosphonates),\\r\\n\\r\\n  -  Smokers, pregnant or lactating women,\\r\\n\\r\\n  -  Who used anti-inflammatory drugs in the last 3 months before surgery.\\r\\n\\r\\n  -  Who for any reason interrupted the evolution of the treatment for not attending\\r\\n     joint appointments.\\r\\n\\r\\n  -  Patients who do not follow the guidelines or have an injury in the acute phase\\r\\n     (pain, edema, exudate)',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003788',\n",
       "      'term': 'Dental Pulp Diseases'},\n",
       "     {'id': 'D000007249', 'term': 'Inflammation'},\n",
       "     {'id': 'D000010149', 'term': 'Pain, Postoperative'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000011183', 'term': 'Postoperative Complications'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000014076', 'term': 'Tooth Diseases'},\n",
       "     {'id': 'D000009057', 'term': 'Stomatognathic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M13069',\n",
       "      'name': 'Pain, Postoperative',\n",
       "      'asFound': 'Post Operative Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10293',\n",
       "      'name': 'Inflammation',\n",
       "      'asFound': 'Inflammation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M6984',\n",
       "      'name': 'Dental Pulp Diseases',\n",
       "      'asFound': 'Endodontic Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14065',\n",
       "      'name': 'Postoperative Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M16831', 'name': 'Tooth Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000007052',\n",
       "      'term': 'Ibuprofen'}],\n",
       "    'ancestors': [{'id': 'D000000894',\n",
       "      'term': 'Anti-Inflammatory Agents, Non-Steroidal'},\n",
       "     {'id': 'D000018712', 'term': 'Analgesics, Non-Narcotic'},\n",
       "     {'id': 'D000000700', 'term': 'Analgesics'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000893', 'term': 'Anti-Inflammatory Agents'},\n",
       "     {'id': 'D000018501', 'term': 'Antirheumatic Agents'},\n",
       "     {'id': 'D000016861', 'term': 'Cyclooxygenase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M10102',\n",
       "      'name': 'Ibuprofen',\n",
       "      'asFound': 'Wound',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4218',\n",
       "      'name': 'Anti-Inflammatory Agents, Non-Steroidal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'},\n",
       "     {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'},\n",
       "     {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M19209', 'name': 'Cyclooxygenase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'},\n",
       "     {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06344949',\n",
       "    'orgStudyIdInfo': {'id': 'B2024-074'},\n",
       "    'organization': {'fullName': 'Shanghai Zhongshan Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Ciprofol Versus Propofol for Tracheal Intubation in ICU',\n",
       "    'officialTitle': 'Ciprofol Versus Propofol for Tracheal Intubation in ICU Patients: a Randomized Controlled Pilot Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-01',\n",
       "    'studyFirstSubmitQcDate': '2024-03-31',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Shanghai Zhongshan Hospital', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The physiological reserves of critically ill patients are relatively low, and the risk of\\r\\ncomplications related to tracheal intubation in the ICU is higher than in the operating\\r\\nroom. ICU tracheal intubation complications account for approximately 40% -45% of\\r\\npatients, including severe hypotension (10% -43%), severe hypoxemia (9% -25%), and\\r\\ncardiac arrest (2% -3%).Ciprofol is a novel 2,6-disubstituted phenol derivative that\\r\\ntargeting γ-aminobutyric acid type A (GABAA)-receptor. There are four indications of\\r\\nciprofol that have been approved by NMPA in recent two years: sedation and anesthesia in\\r\\nnon-tracheal intubation procedure/operation, induction and maintenance of general\\r\\nanesthesia, sedation during intensive care, sedation and maintenance in gynecological\\r\\noutpatient surgery. The aim of this study is to compare the effects of propofol and\\r\\npropofol on the circulatory system during tracheal intubation in ICU patients, in order\\r\\nto provide a safer induction sedation regimen for emergency tracheal intubation in\\r\\ncritically ill patients.'},\n",
       "   'conditionsModule': {'conditions': ['Emergency Tracheal Intubation in Critically Ill Patients']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Ciprofol Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: Ciprofol']},\n",
       "     {'label': 'Propofol Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'interventionNames': ['Drug: Propofol']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Ciprofol',\n",
       "      'description': 'The sedation before tracheal intubation with Ciprofol',\n",
       "      'armGroupLabels': ['Ciprofol Group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Propofol',\n",
       "      'description': 'The sedation before tracheal intubation with Propofol',\n",
       "      'armGroupLabels': ['Propofol Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'cardiovascular collapse within 30minutes from the start of the intubation procedure',\n",
       "      'description': 'defined as occurrence of at least one of the following events: systolic blood pressure<65\\r\\nmm Hg recorded at least once; systolic blood pressure<90 mm Hg for>30 minutes; SBP\\r\\ndecreased more than 20% from baseline;new requirement for, or increase of vasopressors.',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Success rate of sedation',\n",
       "      'description': 'Success rate of sedation',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'Successful intubation on the first attempt',\n",
       "      'description': 'Successful intubation on the first attempt',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'Time from initiation of study drug administration to successful tracheal intubation (within 30 minutes)',\n",
       "      'description': 'Time from initiation of study drug administration to successful tracheal intubation\\r\\n(within 30 minutes)',\n",
       "      'timeFrame': 'Time from initiation of study drug administration to successful tracheal intubation (within 30 minutes)'},\n",
       "     {'measure': 'The incidence of cardiac arrest within 30 minutes after tracheal intubation',\n",
       "      'description': 'The incidence of cardiac arrest within 30 minutes after tracheal intubation',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'The incidence of bradycardia within 30 minutes after tracheal intubation',\n",
       "      'description': 'The incidence of bradycardia within 30 minutes after tracheal intubation',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'The incidence of hypoxemia within 30 minutes after tracheal intubation',\n",
       "      'description': 'The incidence of hypoxemia within 30 minutes after tracheal intubation',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'new requirement or increase of vasopressors',\n",
       "      'description': 'new requirement or increase of vasopressors',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'new requirement or increase of antiarrhythmic drugs',\n",
       "      'description': 'new requirement or increase of antiarrhythmic drugs',\n",
       "      'timeFrame': '30 minutes from the the intubation procedure'},\n",
       "     {'measure': 'Length of ICU stay and treatment outcome',\n",
       "      'description': 'Length of ICU stay and treatment outcome',\n",
       "      'timeFrame': 'From the start of randomization until patients were transferred out of the ICU or discharged'},\n",
       "     {'measure': '28 days without mechanical ventilation',\n",
       "      'description': '28 days without mechanical ventilation',\n",
       "      'timeFrame': 'From the beginning of patients enrolled to 28 days after enrollment'},\n",
       "     {'measure': '28-day mortality rate',\n",
       "      'description': '28-day mortality rate',\n",
       "      'timeFrame': 'within 28 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients who need to undergo tracheal intubation under sedation after entering the\\r\\n     ICU;\\r\\n\\r\\n  -  Age range from 18 to 85 years old;\\r\\n\\r\\n  -  Patients or their families have a full understanding of the purpose and significance\\r\\n     of this trial, voluntarily participate in this clinical trial, and sign an informed\\r\\n     consent form.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients who are allergic to the study drugs, or patients with contraindications to\\r\\n     the study drugs;\\r\\n\\r\\n  -  Patients with difficult airways (MACOCHA ≥ 3 points);\\r\\n\\r\\n  -  Patients who require emergency intubation due to sudden cardiac arrest;\\r\\n\\r\\n  -  Patients who require conscious intubation;\\r\\n\\r\\n  -  Patients who can maintain mean arterial pressure (MAP) above 65mmHg using of one or\\r\\n     more vasoactive drugs (equivalent (-)-noradrenaline > 0.3 μg kg min);\\r\\n\\r\\n  -  In a state of imminent death;\\r\\n\\r\\n  -  Pregnant and/or lactating women; Subject judged by the investigator to have any\\r\\n     other factors unsuitable for participation in the study',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '85 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'referencesModule': {'references': [{'pmid': '36045781',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Admass BA, Endalew NS, Tawye HY, Melesse DY, Workie MM, Filatie TD. Evidence-based airway management protocol for a critical ill patient in medical intensive care unit: Systematic review. Ann Med Surg (Lond). 2022 Aug 4;80:104284. doi: 10.1016/j.amsu.2022.104284. eCollection 2022 Aug.'},\n",
       "     {'pmid': '35433310',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Tarwade P, Smischney NJ. Endotracheal intubation sedation in the intensive care unit. World J Crit Care Med. 2022 Jan 9;11(1):33-39. doi: 10.5492/wjccm.v11.i1.33. eCollection 2022 Jan 9.'},\n",
       "     {'pmid': '26084896',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Perbet S, De Jong A, Delmas J, Futier E, Pereira B, Jaber S, Constantin JM. Incidence of and risk factors for severe cardiovascular collapse after endotracheal intubation in the ICU: a multicenter observational study. Crit Care. 2015 Jun 18;19(1):257. doi: 10.1186/s13054-015-0975-9.'},\n",
       "     {'pmid': '30706173',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Honore PM, De Bels D, Barreto Gutierrez L, Spapen HD. Hemoadsorption therapy in the critically ill: solid base but clinical haze. Ann Intensive Care. 2019 Jan 31;9(1):22. doi: 10.1186/s13613-019-0491-1. No abstract available.'},\n",
       "     {'pmid': '24536033',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Koenig SJ, Lakticova V, Narasimhan M, Doelken P, Mayo PH. Safety of Propofol as an Induction Agent for Urgent Endotracheal Intubation in the Medical Intensive Care Unit. J Intensive Care Med. 2015 Dec;30(8):499-504. doi: 10.1177/0885066614523100. Epub 2014 Feb 17.'},\n",
       "     {'pmid': '35157236',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Luo Z, Tu H, Zhang X, Wang X, Ouyang W, Wei X, Zou X, Zhu Z, Li Y, Shangguan W, Wu H, Wang Y, Guo Q. Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study. CNS Drugs. 2022 Mar;36(3):301-313. doi: 10.1007/s40263-021-00890-1. Epub 2022 Feb 14.'},\n",
       "     {'pmid': '36618929',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wu B, Zhu W, Wang Q, Ren C, Wang L, Xie G. Efficacy and safety of ciprofol-remifentanil versus propofol-remifentanil during fiberoptic bronchoscopy: A prospective, randomized, double-blind, non-inferiority trial. Front Pharmacol. 2022 Dec 21;13:1091579. doi: 10.3389/fphar.2022.1091579. eCollection 2022.'},\n",
       "     {'pmid': '35922771',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Chen BZ, Yin XY, Jiang LH, Liu JH, Shi YY, Yuan BY. The efficacy and safety of ciprofol use for the induction of general anesthesia in patients undergoing gynecological surgery: a prospective randomized controlled study. BMC Anesthesiol. 2022 Aug 3;22(1):245. doi: 10.1186/s12871-022-01782-7.'},\n",
       "     {'pmid': '36647565',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Liang P, Dai M, Wang X, Wang D, Yang M, Lin X, Zou X, Jiang K, Li Y, Wang L, Shangguan W, Ren J, He H. Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. Eur J Anaesthesiol. 2023 Jun 1;40(6):399-406. doi: 10.1097/EJA.0000000000001799. Epub 2023 Jan 19.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000004630',\n",
       "      'term': 'Emergencies'},\n",
       "     {'id': 'D000016638', 'term': 'Critical Illness'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M19010',\n",
       "      'name': 'Critical Illness',\n",
       "      'asFound': 'Critically Ill',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7796',\n",
       "      'name': 'Emergencies',\n",
       "      'asFound': 'Emergency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000015742',\n",
       "      'term': 'Propofol'}],\n",
       "    'ancestors': [{'id': 'D000006993', 'term': 'Hypnotics and Sedatives'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018686', 'term': 'Anesthetics, Intravenous'},\n",
       "     {'id': 'D000018681', 'term': 'Anesthetics, General'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'}],\n",
       "    'browseLeaves': [{'id': 'M18307',\n",
       "      'name': 'Propofol',\n",
       "      'asFound': 'Symptoms',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10043', 'name': 'Hypnotics and Sedatives', 'relevance': 'LOW'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M20766', 'name': 'Anesthetics, Intravenous', 'relevance': 'LOW'},\n",
       "     {'id': 'M20761', 'name': 'Anesthetics, General', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06382636',\n",
       "    'orgStudyIdInfo': {'id': '23-101'},\n",
       "    'organization': {'fullName': 'The Cleveland Clinic', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes',\n",
       "    'officialTitle': 'Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes',\n",
       "    'acronym': 'OPUS'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-02-28', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-02-28', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-01-08',\n",
       "    'studyFirstSubmitQcDate': '2024-04-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'The Cleveland Clinic', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The goal of this study is to ensure that pregnant patients have the resources and support\\r\\nneeded to access Prenatal Screening & Diagnostic Testing (PS&D) in an informed and\\r\\nevidence-based fashion by developing an innovative digital tool to support patients'\\r\\ndecision-making and contributing fundamental knowledge to advance science in a way that\\r\\npromotes patients' access to new prenatal applications of genomic science and technology.\\r\\nOur central hypothesis is that, by focusing on patient engagement as a key driver to\\r\\nimprove patient outcomes, the use of an evidence-based artificial-intelligence (AI)\\r\\npowered patient engagement tool will increase patients' ability to seek information and\\r\\nstructure a decision-making process that, in turn, increases informed decisions about\\r\\nPS&D and decreases decisional conflict associated with those decisions.\\r\\n\\r\\nUsing data from NEST (Ensuring Patients Informed Access to NIPT [non-invasive prenatal\\r\\ntesting]), the investigators designed the next iteration of NEST, a point-of care shared\\r\\ndecision-making tool powered by artificial intelligence (AI) to provide a personalized\\r\\nand dynamic decision support tool: Obstetric Prenatal Genetic Testing Engagement Solution\\r\\n(OPUS). OPUS is an AI-enabled healthcare chatbot (a computer program capable of\\r\\nprocessing and simulating human conversation) that provides patients with personalized\\r\\ninformation and decision-making support at different stages of the PS&D pathway. It\\r\\nfunctions using a series of questions contained in the NEST with a branching logic\\r\\nsequence of questions and answers based on the responses to and from the patient, using a\\r\\nconversational and adaptable interaction. It also contains nested tiers of information,\\r\\nranging from introductory to detailed information about patient engagement, health\\r\\nliteracy, the different PS&D options, and resources to learn about insurance coverage for\\r\\nPS&D. OPUS was designed to be accessed by patients with different technological resources\\r\\nand preferences, using a cell phone, a mobile device, or a computer.\",\n",
       "    'detailedDescription': \"Study overview:\\r\\n\\r\\nThe investigators will conduct a randomized cluster trial to examine the impact of the\\r\\nObstetric Prenatal Genetic Testing Engagement Solution (OPUS) on the decision-making\\r\\nprocess about Prenatal Screening & Diagnostic Testing (PS&D) from the perspectives of\\r\\npatients, partners, and providers. In doing so, the investigators will examine important\\r\\nchanges that have taken place in genetic technology and healthcare. In-depth,\\r\\nsemi-structured interviews will be conducted to gain greater insight into the\\r\\ndecision-making process and strategies throughout pregnancy to gain a longitudinal\\r\\nunderstanding of how decision-making unfolds with the utilization of tests and\\r\\ngestational age. The investigators will employ a method that allows for the study of\\r\\ndecision-making across diverse patient and provider populations, including urban and\\r\\nrural communities and academic and community practices, to understand how these factors\\r\\nin addition to social determinants of health influence patients' informed access to PS&D.\\r\\nThe team will collaborate the Advisory Group and in consultation with the Data Safety\\r\\nmonitoring Board (DSMB) assembled for this study, to ensure scientific rigor in the\\r\\nexperimental design and conduct of the study, analysis and interpretation of the data,\\r\\nand dissemination of the final results and version of the tool.\\r\\n\\r\\nMethods:\\r\\n\\r\\nStudy population and recruitment: Participants will include three groups: (1) Obstetric\\r\\n(OB) providers, (2) patients, and (3) patient partners. Subject recruitment will take\\r\\nplace at the three study sites: (1) the Cleveland Clinic Health System, (2) the\\r\\nMetroHealth Medical System, and (3) the Neighborhood Family Practice Community Health\\r\\nCenters.\\r\\n\\r\\nRandomization:\\r\\n\\r\\nProviders will be randomized by practice into: (1) the intervention arm utilizing OPUS or\\r\\n(2) the control arm utilizing standard practice patterns with respect to education and\\r\\ncounseling (usual care). The rationale for randomization by practice is to prevent\\r\\ncontamination between study arms, as a patient may see more than one provider within a\\r\\npractice over the course of her prenatal care.\\r\\n\\r\\nComparators:\\r\\n\\r\\nIntervention: OPUS is a chatbot that will provide an artificial intelligence (AI) powered\\r\\nconversational and personalized interaction to assist patients in seeking information\\r\\nabout their PS&D options. It was designed by Cleveland Clinic Information Technology (IT)\\r\\nand Power Objects/Microsoft with the goal of meeting patients where they are in their\\r\\ndecision-making regarding the nature and detail of information and decision-support\\r\\nneeded to navigate PS&D decisions. OPUS can be accessed from a cell phone, mobile device,\\r\\nor computer using a web-based or text-based approach. It was also developed based on\\r\\nexisting studies demonstrating the benefits of healthcare chatbots. The investigators\\r\\nwill implement mechanisms that minimize barriers to access OPUS: making tablets available\\r\\non-site for patients with limited technology and providing broadband Intent as needed to\\r\\naccess OPUS (intervention) or other educational resources (intervention and control\\r\\ngroups). OPUS will utilize the Microsoft Azure Health Bot and Dynamics 365 technology and\\r\\nbuild on the existing Cleveland Clinic health IT solutions to support patient engagement\\r\\nin other clinical contexts that meet requirements of Health Information Portability and\\r\\nAccountability Act (HIPAA) and encryption for protected health information (PHI)\\r\\nmanagement.\\r\\n\\r\\nParticipants will be exposed to OPUS at three key time points as determined by our NEST\\r\\nR01. Time Point 1 (T1) - Prior to the initial prenatal visit: This represents the time\\r\\nperiod before patients initiate discussions with their providers about genetic risk and\\r\\nPS&D. It may include patients at 7-21 weeks estimated gestational age (EGA). Time Point 2\\r\\n(T2) - Prior to the initial PS&D decision: This time point represents the patients'\\r\\ninitial step in the PS&D decision-making pathway. It may include patients at 9-23 weeks\\r\\nEGA. Time Point 3 (T3) - Prior to the 2nd trimester anatomical ultrasound (US): This is a\\r\\ntime point with different significance for patients based on initial PS&D choices. This\\r\\nincludes patients who present for (a) an initial assessment after declining all PS&D\\r\\nprior to the 2nd trimester ultrasound, (b) follow-up assessment after receiving an\\r\\nabnormal result on a prior screening, or (c) subsequent routine assessment after\\r\\nreceiving a normal result on a prior screen or diagnostic test. It may include patients\\r\\nat 18-23 weeks EGA. Participants may opt-out of engaging with OPUS at any time point in\\r\\nthe study.\\r\\n\\r\\nControl: The control group will receive standard counseling per usual care. They will\\r\\nproceed with the appointment with the scheduled provider, who will discuss genetic risk\\r\\nand assessment per his or her usual counseling and practice patterns.\\r\\n\\r\\nAim 1. Determine the ability of OPUS to structure a decision-making process about PS&D\\r\\nthat aligns with patient needs and preferences compared to usual care.\\r\\n\\r\\nThe investigators hypothesize that patients exposed to OPUS will have higher levels of\\r\\nengagement that will enable them to structure a shared or informed decision-making\\r\\nprocess that aligns with their needs and preferences.\\r\\n\\r\\nPatient Measures:\\r\\n\\r\\nInformation about participants' demographics, reproductive, and medical history will be\\r\\ncollected from the electronic medical records (EMR). The investigators will then collect\\r\\ndata using administration of a series of surveys, and semi-structured interviews to\\r\\nassess the impact of OPUS at the key time points in the decision-making pathway. All\\r\\ninstruments will be distributed and completed via Research Electronic Data Capture\\r\\n(REDCap) Survey, with a paper version available at participant request. The investigators\\r\\nwill also make tablets available at the clinical visit for participants to complete the\\r\\nsurvey.\\r\\n\\r\\nPatient Activation:\\r\\n\\r\\nThe investigators will utilize a modified version of the Patient Activation Measure\\r\\n(PAM)-13 to measure patient activation regarding PS&D decisions. The PAM-13 is a widely\\r\\nused, standardized measure of patient activation in healthcare decisions. It is an\\r\\ninterval-level scale developed to assess respondents' understanding of their role in the\\r\\ncare process and having the knowledge, skill, and confidence to manage healthcare\\r\\ndecisions.\\r\\n\\r\\nDecision preferences status/preferences:\\r\\n\\r\\nThe investigators will measure participants' preferences regarding decision-making,\\r\\nexperiences with shared decision making (SDM). The investigators will measure\\r\\ndecision-making decisions/preferences at the following timepoints: T1 Pre-visit, and T1\\r\\nPost-visit. This will include questions about printed or online materials accessed for\\r\\nself-education.\\r\\n\\r\\nDecision-making:\\r\\n\\r\\nThe research assistant will place a small audio-recording device in the exam room to\\r\\nrecord the content, interaction, and duration of dialogue about genetic risk and risk\\r\\nassessment and remove it immediately after the visit. This approach will allow for\\r\\nevaluation of patient and patient/partner dyads in healthcare discussions with the\\r\\nprovider. The investigators have elected to audio record instead of video record to\\r\\nminimize the Hawthorne effect and because of the sensitive nature of the physical exam\\r\\nduring this visit. Our prior work has demonstrated that this approach can be successfully\\r\\nused.\\r\\n\\r\\nInterviews:\\r\\n\\r\\nThe investigators will conduct semi-structured interviews with a subset of patients at T1\\r\\nPost-visit, T2 Post-test, (n = 40) to gain additional information about OPUS's usability,\\r\\nfeasibility, and acceptability of the intervention. The interviews will be guided by an\\r\\ninterview guide developed in conjunction with the Advisory Group and audio recorded for\\r\\ndata analysis purposes.\\r\\n\\r\\nProvider measures:\\r\\n\\r\\nProviders will complete a baseline questionnaire (OB1) at the time of enrollment to\\r\\ncollect information about demographics, medical education, and training (including any\\r\\ntraining specific to healthcare communication), and clinical practice. It will also\\r\\ncontain a self-assessment of the providers' ability to facilitate a SDM process.\\r\\n\\r\\nAim 2. Determine the ability of OPUS to improve a patient's ability to make an informed\\r\\nchoice about PS&D compared to usual care.\\r\\n\\r\\nThe investigators hypothesize that patients exposed to OPUS will have higher rates of\\r\\ninformed choice regarding the utilization or decline of prenatal genetic testing.\\r\\n\\r\\nData collection:\\r\\n\\r\\nPatients will complete the Informed Choice for Screens and Diagnostic Tests survey\\r\\n(ICSD), an instrument developed and validated as part of NEST at the following intervals:\\r\\nT1-Pre-visit, T1 Post-visit, T2 Post-test, and T3 Pre-ultrasound (US). The investigators\\r\\nwill also assess health literacy using the validated self-administered medical term\\r\\nrecognition test (METER), an instrument successfully used during NEST.\\r\\n\\r\\nData analysis:\\r\\n\\r\\nAnalysis will be conducted to determine the impact of OPUS on the variables of knowledge,\\r\\nattitudes, and deliberation; the variables will be analyzed together as components of the\\r\\ninformed choice and then separately to understand the effect of exposure to OPUS on each\\r\\nvariable. The investigators will also examine the change of these variables together and\\r\\nseparately from T1 to T2 and T3. Based on the methods described by the author Marteau and\\r\\nadapted for the ICSD, the variables of knowledge and attitudes, and choice will be\\r\\ncategorized. These data will be summed to determine whether responses at different time\\r\\npoints represented an informed choice (good knowledge, positive attitude, and intention\\r\\nor decision to utilize consistent with behavior) or an uninformed choice (poor knowledge,\\r\\nnegative attitude and attitude was inconsistent with behavior) for the utilized screen or\\r\\ndiagnostic test. Logistic regression methods will be used to assess differences in\\r\\nexposure to OPUS and reproductive, demographic (e.g., race/ethnicity, technology access,\\r\\nsocial economic status [SES]), and clinical practice variables.\\r\\n\\r\\nAim 3. Determine the extent to which OPUS reduces patients' uncertainty and decisional\\r\\nconflict associated with PS&D decisions.\\r\\n\\r\\nThe investigators hypothesize that patients exposed to OPUS will have lower levels of\\r\\ndecisional uncertainty and conflict throughout the PS&D pathway compared to patients\\r\\nexposed to usual care.\\r\\n\\r\\nData collection:\\r\\n\\r\\nThe investigators will use the validated Decisional Conflict Scale (DCS) to examine the\\r\\npresence of decisional conflict, understand its impact on patient experience, and\\r\\nidentify modifiable factors to reduce it at T2, T3 and T4. This validated instrument was\\r\\nused successfully as part of NEST that uses Likert scale items to measure personal\\r\\nperceptions of uncertainty in the decision-making process and modifiable factors\\r\\ncontributing to uncertainty. Our goal in selecting this measure is to assess the process\\r\\nof obtaining information and making a choice, not the outcome of the decision to utilize\\r\\n(or not utilize) PS&D.\\r\\n\\r\\nData analysis:\\r\\n\\r\\nAnalysis will be conducted to determine the impact of OPUS on decisional conflict\\r\\nindependently and as a function of informed choice (including variables of knowledge,\\r\\nattitudes, and deliberation separately and together), patient activation, and SDM/IDM.\\r\\nAnalysis will be conducted in a fashion described by the author O'Connor to determine the\\r\\nlevel of decisional conflict. Logistic regression will be used to assess correlations\\r\\nbetween informed choice measures, patient demographic measures, and measures of\\r\\ndecisional conflict. The data for each time point will be combined, and the analysis\\r\\nre-run using repeated measures logistic regression methods and including test time as an\\r\\nadditional independent variable. Analyses will be conducted to examine differences in\\r\\nreduction of decisional conflict in addition to baseline uncertainty and anxiety across\\r\\nsubgroups, including by race/ethnicity, knowledge/health literacy, insurance status,\\r\\nreproductive history.\"},\n",
       "   'conditionsModule': {'conditions': ['Prenatal Disorder'],\n",
       "    'keywords': ['Prenatal Genetic Screening',\n",
       "     'Prenatal Diagnostic Testing',\n",
       "     'Shared Decision Making',\n",
       "     'Informed Choice',\n",
       "     'Decisional Regret']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 600, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Standard of care',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'This group will utilize standard care with respect to healthcare provider practices for\\r\\neducation and counseling surrounding prenatal screening and diagnostic testing options.',\n",
       "      'interventionNames': ['Behavioral: Standard Care']},\n",
       "     {'label': 'Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'This arm will utilize an artificial intelligence AI enabled healthcare chatbot that\\r\\nprovides patients with personalized information and decision-making support at different\\r\\nstages of the prenatal screen and diagnostic testing pathways.',\n",
       "      'interventionNames': ['Behavioral: Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Standard Care',\n",
       "      'description': 'This group will utilize standard care with respect to healthcare provider practices.',\n",
       "      'armGroupLabels': ['Standard of care']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot',\n",
       "      'description': 'This group will be exposed to the AI enabled healthcare chatbot.',\n",
       "      'armGroupLabels': ['Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient activation',\n",
       "      'description': 'Time spent in chatbot',\n",
       "      'timeFrame': '1-day'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Able to read and speak English\\r\\n\\r\\n  -  Able to provide consent to participate in the study\\r\\n\\r\\n  -  Offered routine aneuploidy screening and diagnostic testing\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Less than 18 years of age\\r\\n\\r\\n  -  Not currently pregnant or an intrauterine pregnancy has not yet been established\\r\\n\\r\\n  -  Unable to provide informed consent for research participation\\r\\n\\r\\n  -  Unable to read and speak English',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'genderDescription': 'Pregnant females',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '50 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Ruth Farrell, MD, MA',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '216-445-7085',\n",
       "      'email': 'farrelr@ccf.org'},\n",
       "     {'name': 'Christina Collart, MEd',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '216-470-9796',\n",
       "      'email': 'collarc@ccf.org'}],\n",
       "    'overallOfficials': [{'name': 'Ruth Farrell, MD, MA',\n",
       "      'affiliation': 'The Cleveland Clinic',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Neighborhood Family Practice',\n",
       "      'city': 'Cleveland',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '44102',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Heidi Gullett, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '216-368-0776',\n",
       "        'email': 'hlg31@case.edu'}],\n",
       "      'geoPoint': {'lat': 41.4995, 'lon': -81.69541}},\n",
       "     {'facility': 'MetroHealth Medical Center',\n",
       "      'city': 'Cleveland',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '44109',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Angela Ranzini, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '216-778-3513',\n",
       "        'email': 'aranzini@metrohealth.org'}],\n",
       "      'geoPoint': {'lat': 41.4995, 'lon': -81.69541}},\n",
       "     {'facility': 'Cleveland Clinic',\n",
       "      'city': 'Cleveland',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '44195',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Ruth Farrell, MD, MA',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '216-445-7085',\n",
       "        'email': 'farrelr@ccf.org'},\n",
       "       {'name': 'Christina Collart, MEd',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '216-470-9796',\n",
       "        'email': 'collarc@ccf.org'}],\n",
       "      'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06037317',\n",
       "    'orgStudyIdInfo': {'id': 'CT-3505-I-03'},\n",
       "    'organization': {'fullName': 'Shouyao Holdings (Beijing) Co. LTD',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors',\n",
       "    'officialTitle': 'A Phase Ib, Multi-center, Open-Lable, Dose-Escalation and Dose-Expansion Study of Efficacy and Safety of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-06',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-09-07',\n",
       "    'studyFirstSubmitQcDate': '2023-09-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-09-14', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-02', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Shouyao Holdings (Beijing) Co. LTD',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is an open-label, single-arm, multicenter, phase Ib study to evaluate the efficacy\\r\\nand safety of SY-3505 capsule in patients with locally advanced or metastatic, LTK\\r\\nfusion-positive solid tumor who have progressed on or are intolerant to prior standard\\r\\ntherapy.',\n",
       "    'detailedDescription': 'The study will be conducted in 2 parts:\\r\\n\\r\\nDose-escalation phase: Participants will be allocated to one of the three dose groups of\\r\\n500mg, 600mg, or 800mg and receive a single dose of SY-3505 capsules, followed by a 7-day\\r\\nsafety observation period and pharmacokinetic (PK) assessment. Subsequently, SY-3505 will\\r\\nbe administered once daily in 28-day treatment cycles. This phase is designed to\\r\\ndetermine the DLTs (Dose-limiting toxicity) and recommended phase II dose (RP2D) and\\r\\ncharacterize the safety, tolerability and PK of SY-3505 in patients with LTK\\r\\nfusion-positive solid tumors.\\r\\n\\r\\nDose-expansion phase: Participants will be assigned to one of the 1-2 dose groups\\r\\ndetermined during the dose-escalation phase, and receive SY-3505 capsules once daily in\\r\\n28-day treatment cycles. This phase is designed to evaluate the anti-tumor activity (ORR,\\r\\nDCR and DOR) of SY-3505 in patients with LTK fusion-positive solid tumors.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor'],\n",
       "    'keywords': ['SY-3505',\n",
       "     'Leukocyte receptor tyrosine kinase fusion-positive']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 38, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Dose-escalation and Dose-expansion',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'In dose-escalation phase, SY-3505 will be given orally in ascending doses (escalation\\r\\ncohort) until the DLT or RP2D is reached.\\r\\n\\r\\nIn dose-expansion phase, SY-3505 will be given at RP2D in 28-day cycle continuously.',\n",
       "      'interventionNames': ['Drug: SY-3505']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'SY-3505',\n",
       "      'description': 'LTK tyrosine kinase inhibitor',\n",
       "      'armGroupLabels': ['Dose-escalation and Dose-expansion'],\n",
       "      'otherNames': ['CT-3505', 'Ficonalkib']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of adverse events (AEs)',\n",
       "      'description': 'Characterization of the safety and tolerability',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Incidence of dose limiting toxicities (DLTs)',\n",
       "      'description': 'Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) in Cycle 1',\n",
       "      'timeFrame': 'Escalation Cycle 1 (28 days)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Pharmacokinetics (Cmax) for SY-3505',\n",
       "      'description': 'Defined as maximum observed plasma concentration',\n",
       "      'timeFrame': 'Protocol-defined time points during Cycle 1 and 2 of treatment (each cycle is 28 days)'},\n",
       "     {'measure': 'Pharmacokinetics (Tmax) for SY-3505',\n",
       "      'description': 'Defined as time to maximum plasma concentration',\n",
       "      'timeFrame': 'Protocol-defined time points during Cycle 1 and 2 of treatment (each cycle is 28 days)'},\n",
       "     {'measure': 'Pharmacokinetics (AUC0-t) for SY-3505',\n",
       "      'description': 'Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the\\r\\nlast quantifiable measurable plasma concentration',\n",
       "      'timeFrame': 'Protocol-defined time points during Cycle 1 and 2 of treatment (each cycle is 28 days)'},\n",
       "     {'measure': 'Pharmacokinetics (t½) for SY-3505',\n",
       "      'description': 'Defined as the apparent plasma terminal phase disposition half-life',\n",
       "      'timeFrame': 'Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)'},\n",
       "     {'measure': 'Overall Response Rate (ORR) as assessed by RECIST v1.1',\n",
       "      'description': 'Preliminary anti-tumor activity of SY-3505 in patients with LTK-fusion advanced solid\\r\\ntumor',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Disease control rate (DCR) as assessed by RECIST v1.1',\n",
       "      'description': 'Preliminary anti-tumor activity of SY-3505 in patients with LTK-fusion advanced solid\\r\\ntumor',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Duration of response (DOR) as assessed by RECIST v1.1',\n",
       "      'description': 'Preliminary anti-tumor activity of SY-3505 in patients with LTK-fusion advanced solid\\r\\ntumor',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patients must meet all of the following criteria to be eligible for this study:\\r\\n\\r\\n       1. Age ≥ 18 years at the time of signing the Informed Consent Form (ICF).\\r\\n\\r\\n       2. Histologically or cytologically confirmed locally advanced (as assessed by the\\r\\n          investigator, unresectable tumor or tumor recurrence following standard therapy\\r\\n          with evidence of progression [PD] or intolerance to prior therapy) or\\r\\n          metastatic solid tumor and failure of standard treatment with evidence of\\r\\n          disease progression on imaging.\\r\\n\\r\\n       3. Agreement to provide a required tumor tissue sample (preferably fresh biopsy\\r\\n          tissue or archived tumor tissue within 2 years prior to first dosing) that has\\r\\n          been tested by the central laboratory and determined to be positive for LTK\\r\\n          gene fusion.\\r\\n\\r\\n       4. At least one measurable extracranial lesion as defined by Response Evaluation\\r\\n          Criteria in Solid Tumors (RECIST) v 1.1 criteria.\\r\\n\\r\\n       5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\\r\\n\\r\\n       6. Expected survival of ≥ 3 months.\\r\\n\\r\\n       7. Resolution of any treatment-related AEs related to prior anticancer therapy to\\r\\n          NCI-CTCAE v 5.0 grade ≤ 1 (excluding toxicities judged by the investigator to\\r\\n          be of no safety concern, e.g., hair loss, prior platinum-related grade 2\\r\\n          peripheral neuropathy) before the first dosing.\\r\\n\\r\\n       8. Organ function levels must meet the following requirements:\\r\\n\\r\\n            1. No blood products, hematopoietic growth factors (e.g., G-CSF,\\r\\n               erythropoietin), or other drugs that correct abnormal blood counts for at\\r\\n               least 2 weeks before first dosing and the following blood counts: ANC ≥\\r\\n               1.5 × 10^9/L, PLT count ≥ 100 × 10^9/L, Hb ≥ 90 g/L.\\r\\n\\r\\n            2. Liver function: TBIL ≤ 1.5 × upper limit of normal (ULN) in the absence of\\r\\n               liver metastases, and AST and ALT ≤ 2.5 × ULN; in the presence of liver\\r\\n               metastases, AST and ALT ≤ 5.0 × ULN, and TBIL ≤ 3 × ULN.\\r\\n\\r\\n            3. Pancreatic function: Serum total amylase ≤ 1.5 × ULN and serum lipase ≤\\r\\n               1.5 × ULN (subjects with serum total amylase > 1.5 × ULN but with serum\\r\\n               lipase within the ULN range may be eligible).\\r\\n\\r\\n            4. Renal function: Creatinine clearance (Ccr) ≥ 50 mL/min (calculated using\\r\\n               the Cockcroft and Gault formula).\\r\\n\\r\\n            5. Coagulation function: International normalized ratio (INR) and prothrombin\\r\\n               time (PT) ≤ 2 × ULN (except for patients receiving anticoagulant therapy).\\r\\n\\r\\n       9. Able to take oral medications and comply with scheduled visits and related\\r\\n          procedures per protocol.\\r\\n\\r\\n      10. Female subjects of childbearing potential must agree to use highly effective\\r\\n          contraception during the entire study period and for at least 3 months after\\r\\n          the last dose\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients who meet any of the following criteria are not eligible for this study:\\r\\n\\r\\n       1. Carrying known major driver gene mutations other than LTK gene, such as EGFR,\\r\\n          MET, ALK, ROS1, NTRK, etc. (Patients with co-mutations may be discussed with\\r\\n          the investigator for eligibility).\\r\\n\\r\\n       2. History of hypersensitivity reactions to any component or excipient of SY-3505\\r\\n          capsules.\\r\\n\\r\\n       3. Concurrent primary malignancy, with the following exceptions: adequately\\r\\n          treated in situ carcinoma, non-melanoma skin cancer, in situ cervical cancer,\\r\\n          or in situ breast cancer, and cured malignancies without recurrence for at\\r\\n          least 2 years prior to study entry.\\r\\n\\r\\n       4. Symptomatic primary central nervous system (CNS) tumors, symptomatic CNS\\r\\n          metastases, leptomeningeal carcinomatosis, or untreated spinal cord\\r\\n          compression. Patients with stable CNS disease (defined as no evidence of\\r\\n          progression on imaging for at least 4 weeks prior to first dosing, with all\\r\\n          neurological symptoms returned to baseline, and without evidence of new or\\r\\n          enlarging brain metastases, and no CNS surgery or radiation treatment within 4\\r\\n          weeks prior to first dosing, and no stereotactic radiosurgery [SRS] within 2\\r\\n          weeks prior to first dosing, and no steroids for at least 2 weeks) are\\r\\n          eligible. (Note: Carcinomatous meningitis is not allowed, regardless of\\r\\n          clinical stability).\\r\\n\\r\\n       5. Presence of any of the following conditions or diseases at screening that are\\r\\n          inadequately controlled with the best possible medical management:\\r\\n\\r\\n            1. Active systemic bacterial, viral, or fungal infections.\\r\\n\\r\\n            2. Pleural effusion, peritoneal effusion, or pericardial effusion that is not\\r\\n               controlled after intervention (defined as significant if reaccumulation of\\r\\n               fluid requiring drainage occurs within 2 weeks of the prior intervention\\r\\n               with associated symptoms).\\r\\n\\r\\n            3. Poorly controlled diabetes mellitus (defined as fasting blood glucose ≥\\r\\n               11.1 mmol/L and/or HbA1c ≥ 8%).\\r\\n\\r\\n            4. Symptomatic hyperthyroidism or hypothyroidism not well controlled by\\r\\n               medical management as assessed by the investigator.\\r\\n\\r\\n            5. Clinically significant electrolyte disturbances (e.g., severe\\r\\n               hypocalcemia, hypomagnesemia, hypokalemia) as assessed by the\\r\\n               investigator.\\r\\n\\r\\n            6. Clinically significant gastrointestinal diseases that may interfere with\\r\\n               the absorption of study drug (e.g., active ulcerative colitis, Crohn's\\r\\n               disease, gastrointestinal ulcers, or major gastrointestinal surgery that\\r\\n               might affect drug absorption).\\r\\n\\r\\n       6. Severe cardiovascular diseases/abnormalities meeting any of the following\\r\\n          criteria:\\r\\n\\r\\n            1. QT interval corrected for heart rate (QTcF) > 470 msec for females or >\\r\\n               450 msec for males as calculated by the Fridericia formula during\\r\\n               screening (subjects with suspected drug-induced QTcF prolongation that is\\r\\n               assessed by the investigator as safely controllable may be eligible after\\r\\n               correction with medication).\\r\\n\\r\\n            2. Left ventricular ejection fraction (LVEF) < 50%.\\r\\n\\r\\n            3. Myocardial infarction, unstable angina, or clinically significant\\r\\n               arrhythmias (e.g., grade 2 second-degree heart block or third-degree heart\\r\\n               block) within 6 months prior to the first dosing.\\r\\n\\r\\n            4. Class III or IV congestive heart failure as classified by the New York\\r\\n               Heart Association (NYHA).\\r\\n\\r\\n            5. Poorly controlled hypertension, a history of unstable hypertension, or a\\r\\n               history of poor compliance with antihypertensive treatment as assessed by\\r\\n               the investigator.\\r\\n\\r\\n       7. Active viral infections or a history of the following:\\r\\n\\r\\n            1. Active hepatitis B (HBV) infection (defined as HBsAg positive and HBV DNA\\r\\n               ≥ 2 × 10^3 IU/mL at screening, unless HBV DNA levels have decreased to < 2\\r\\n               × 10^3 IU/mL after regular antiviral therapy, in which case the patient\\r\\n               may be eligible), or active hepatitis C (HCV) infection (HCV RNA > central\\r\\n               laboratory ULN) at screening.\\r\\n\\r\\n            2. HIV positivity at screening or known other immunodeficiency disease.\\r\\n\\r\\n            3. Previous organ transplantation, hematopoietic stem cell transplantation,\\r\\n               or bone marrow transplantation.\\r\\n\\r\\n       8. Other significant systemic diseases, including but not limited to active\\r\\n          pulmonary disease (e.g., active tuberculosis, interstitial lung disease), that,\\r\\n          in the investigator's judgment, may affect the interpretation of study results\\r\\n          or pose high risks to the patient.\\r\\n\\r\\n       9. Use of strong CYP3A4 inhibitors or inducers within 2 weeks before the first\\r\\n          dosing or during the study period, as follows:\\r\\n\\r\\n            1. CYP3A4 Inhibitors: Azanavir, Clarithromycin, Erdafitinib, Itraconazole,\\r\\n               Ketoconazole, Nafitamone, Letermovir, Saquinavir, Telithromycin,\\r\\n               Vinorelbine, Grapefruit (juice).\\r\\n\\r\\n            2. CYP3A4 Inducers: Carbamazepine, Phenobarbital, Phenytoin, Rifabutin,\\r\\n               Rifampicin, St. John's Wort, Rifapentine.\\r\\n\\r\\n      10. Receipt of any of the following anticancer treatments:\\r\\n\\r\\n            1. Bone marrow radiation or extensive radiotherapy involving more than 30% of\\r\\n               the bone marrow: within 4 weeks before first dosing.\\r\\n\\r\\n            2. Palliative radiotherapy: within 7 days before first dosing.\\r\\n\\r\\n            3. Other anticancer treatments such as chemotherapy, targeted therapy\\r\\n               (immunotherapy or other antibody therapy), antitumor Chinese medicine, or\\r\\n               others: within 2 weeks before first dosing or within 5 half-lives of the\\r\\n               treatment (whichever is longer).\\r\\n\\r\\n      11. Major surgery within 4 weeks before first dosing (major surgery defined as a\\r\\n          surgery grade ≥ 3, excluding placement of a central venous catheter, tumor\\r\\n          puncture biopsy, and gastrostomy tube placement) or significant traumatic\\r\\n          injury that has not fully recovered.\\r\\n\\r\\n      12. Participation in other clinical studies within 4 weeks before first dosing\\r\\n          (except for those that do not use investigational drugs or investigational\\r\\n          medical devices; subjects who have discontinued treatment from other clinical\\r\\n          studies and are only undergoing follow-up are excluded).\\r\\n\\r\\n      13. Severe thromboembolic events within 1 year before the first dosing (e.g.,\\r\\n          cerebrovascular accidents [including transient ischemic attacks], deep vein\\r\\n          thrombosis, pulmonary embolism) or a bleeding tendency/risks within 30 days\\r\\n          before the first dosing (e.g., significant gastrointestinal bleeding).\\r\\n\\r\\n      14. Pregnant or lactating women.\\r\\n\\r\\n      15. Other circumstances, as determined by the investigator, which make the patient\\r\\n          unsuitable for participation in this clinical trial, such as other serious\\r\\n          acute or chronic diseases that may increase the patient's related risks in the\\r\\n          study or laboratory abnormalities that may interfere with the interpretation of\\r\\n          study results.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Yinghui Sun, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '86-10-88858616',\n",
       "      'email': 'yhsun@centaurusbio.com'}],\n",
       "    'overallOfficials': [{'name': 'Yinghui Sun, PhD',\n",
       "      'affiliation': 'Shouyao Holdings (Beijing) Co. LTD',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Cancer Hospital, Chinese Academy of Medical Sciences',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Beijing',\n",
       "      'zip': '100021',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Yuankai Shi, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '86-10-87788293',\n",
       "        'email': 'syuankai@cicams.ac.cn'}],\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M2889',\n",
       "      'name': 'Tyrosine Kinase Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T22', 'name': 'Tyrosine', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'AA', 'name': 'Amino Acids'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06371417',\n",
       "    'orgStudyIdInfo': {'id': 'RAY902CT'},\n",
       "    'organization': {'fullName': 'Chugai Pharmaceutical', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)',\n",
       "    'officialTitle': 'Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-04',\n",
       "    'studyFirstSubmitQcDate': '2024-04-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Chugai Pharmaceutical', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics,\\r\\npharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of\\r\\nclassical complement pathway, after multiple dose administration in patients with\\r\\nimmunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP),\\r\\nBehçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM)\\r\\nand immune thrombocytopenia (ITP).\"},\n",
       "   'conditionsModule': {'conditions': ['Antiphospholipid Syndrome (APS)',\n",
       "     'Bullous Pemphigoid (BP)',\n",
       "     \"Behçet's Syndrome (BS)\",\n",
       "     'Dermatomyositis (DM)',\n",
       "     'Immune-mediated Necrotizing Myopathy (IMNM)',\n",
       "     'Immune Thrombocytopenia (ITP)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 144, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'RAY121',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'All enrolled patients will receive RAY121 multiple dose',\n",
       "      'interventionNames': ['Drug: RAY121']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'RAY121',\n",
       "      'description': 'Injection',\n",
       "      'armGroupLabels': ['RAY121']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Adverse events (AEs)',\n",
       "      'description': 'Incidence, severity, and causal relationship of AEs',\n",
       "      'timeFrame': 'Baseline to Week 32'}],\n",
       "    'secondaryOutcomes': [{'measure': 'RAY121 concentration',\n",
       "      'description': 'Serum RAY121 concentration',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'AUCτ',\n",
       "      'description': 'Area under the concentration-time curve over a dosing interval (AUCτ)',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Cmax',\n",
       "      'description': 'Maximum observed serum concentration (Cmax)',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Cmin',\n",
       "      'description': 'Minimum observed serum concentration (Cmin)',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Active C1s',\n",
       "      'description': 'Active C1s',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Total C1s',\n",
       "      'description': 'Total C1s',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Complement activity (classical pathway)',\n",
       "      'description': 'Complement activity (classical pathway)',\n",
       "      'timeFrame': 'Baseline to Week 32'},\n",
       "     {'measure': 'Anti-RAY121 antibodies',\n",
       "      'description': 'Titer of anti-RAY121 antibodies',\n",
       "      'timeFrame': 'Baseline to Week 32'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Signed informed consent form\\r\\n\\r\\n  2. Age >= 18 and <=75 at the time of signing informed consent form (except for BP; Age\\r\\n     >=18 and <= 85 with Karnofsky score >= 60% at screening)\\r\\n\\r\\n  3. Ability to comply with the study protocol\\r\\n\\r\\n  4. For women of childbearing potential: agreement to remain abstinent (refrain from\\r\\n     heterosexual intercourse) or use highly effective contraceptive methods\\r\\n\\r\\n  5. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or\\r\\n     use contraceptive measures, and agreement to refrain from donating sperm\\r\\n\\r\\n  6. APS cohort: Established primary APS defined by the following criteria (at least one\\r\\n     of the laboratory criteria and one of the clinical criteria must be met):\\r\\n\\r\\n       -  Laboratory criteria (aPL profile)\\r\\n\\r\\n            -  Persistently positive lupus anticoagulant (LA) test\\r\\n\\r\\n            -  Persistently positive anticardiolipin (aCL) immunoglobulin G (IgG) isotype\\r\\n\\r\\n            -  Persistently positive anti-beta-2 glycoprotein-1 (aβ2GPI) IgG isotype\\r\\n\\r\\n       -  Clinical criteria\\r\\n\\r\\n            -  Livedoid vasculopathy and presence of skin ulcer\\r\\n\\r\\n            -  Acute/chronic aPL nephropathy\\r\\n\\r\\n  7. BP cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Age >= 18 and <= 85 with Karnofsky score >= 60 %\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Predominant cutaneous lesions\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Diagnosis with BP with following assessments positive:\\r\\n\\r\\n       -  a Positive direct immunofluorescence, and either\\r\\n\\r\\n       -  b Positive indirect immunofluorescence, or\\r\\n\\r\\n       -  c Positive serology on ELISA for BP180 autoantibody\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Bullous Pemphigoid Disease Area Index (BPDAI) score >= 20\\r\\n\\r\\n       -  \\r\\n\\r\\n            5) Weekly average of daily Peak Pruritus Numerical Rating Score (PP-NRS) >=4\\r\\n\\r\\n       -  \\r\\n\\r\\n            6) Accept to take photograph of bullous lesions\\r\\n\\r\\n  8. BS cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Diagnosed with BS\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Oral ulcers that occurred at least 3 times in the previous 12 month period\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Have at least 2 oral ulcers over the 4 weeks prior to screening\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Have at least 2 oral ulcers at Week 0\\r\\n\\r\\n       -  \\r\\n\\r\\n            5) Have prior treatment with at least 1 non-biologic BS therapy\\r\\n\\r\\n       -  \\r\\n\\r\\n            6) Patients who need systemic therapy as whose oral or mucocutaneous ulcers\\r\\n               cannot be adequately controlled by topical therapy\\r\\n\\r\\n  9. DM cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Diagnosed with definite or probable inflammatory myopathies and\\r\\n               categorized as DM\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Patients with inadequate response to corticosteroids and/or\\r\\n               immune-suppressants or intolerance to DM therapies\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Manual Muscle Test-8 (MMT-8) score < 142, with at least one abnormality in\\r\\n               the following Core Set Measures:\\r\\n\\r\\n            -  Patient Global Activity Visual Analogue Scale (PtGA-VAS) >= 2 cm\\r\\n\\r\\n            -  Physician Global Activity Visual Analogue Scale (PhGA-VAS) >= 2 cm\\r\\n\\r\\n            -  Global extra-muscular activity >= 2 cm\\r\\n\\r\\n            -  At least one muscle enzyme > 1.5 times upper limit of normal (ULN)\\r\\n\\r\\n            -  Health Assessment Questionnaire (HAQ) >= 0.25\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Moderate to severe DM defined as CDASI activity score > 14\\r\\n\\r\\n 10. IMNM cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Clinically Diagnosed with IMNM as anti-HMGCR myopathy or anti-SRP myopathy\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Creatine kinase (CK) > 1,000 U/L\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Patients who have an inadequate response to corticosteroids and/or\\r\\n               immunosuppressants or intolerance to IMNM therapies\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) MMT-8 score < 142\\r\\n\\r\\n 11. ITP cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Confirmed diagnosis of persistent/chronic ITP based on the following\\r\\n               criteria:\\r\\n\\r\\n            -  ITP defined per the current guidelines\\r\\n\\r\\n            -  Platelet count <= 30 × 10^9/L on 2 consecutive occasions\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Lack of an sustained adequate platelet count response to a thrombopoietin\\r\\n               receptor agonist and at least one other ITP treatment or a second\\r\\n               thrombopoietin receptor agonist (TPO-RA)\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) A history of response with an platelet counts increase more than 20 ×\\r\\n               10^9/L from baseline by at least one prior line of therapy\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. History of anaphylaxis or hypersensitivity to a biologic agent\\r\\n\\r\\n  2. Active infection requiring systemic antiviral, antibiotics or antifungal\\r\\n\\r\\n  3. Planned surgery during the study\\r\\n\\r\\n  4. Pregnant or breastfeeding, or intending to become pregnant\\r\\n\\r\\n  5. Any serious medical condition or abnormality in clinical laboratory tests that\\r\\n     precludes the patient's safe participation in and completion of the study\\r\\n\\r\\n  6. Clinically significant ECG abnormalities\\r\\n\\r\\n  7. Illicit drug or alcohol abuse\\r\\n\\r\\n  8. Clinical diagnosis of autoimmune diseases other than the target disease (except for\\r\\n     Sjögren's syndrome in DM and IMNM)\\r\\n\\r\\n  9. Positive for hepatitis B surface antigen\\r\\n\\r\\n 10. Positive for hepatitis C virus antibody\\r\\n\\r\\n 11. Positive for human immunodeficiency virus antibody\\r\\n\\r\\n 12. Evidence of current infection with tuberculosis\\r\\n\\r\\n 13. History of cancer within 5 years\\r\\n\\r\\n 14. Treatment with investigational therapy within 28 days or 5 half-lives\\r\\n\\r\\n 15. Previous and current treatment with anti-C1s antibody at any time\\r\\n\\r\\n 16. Other complement inhibitors within 3 months\\r\\n\\r\\n 17. Patients who receive any treatments which fall into the Prohibited Therapy Criteria\\r\\n\\r\\n 18. Patients with an elevated alanine aminotransferase or aspartate aminotransferase >\\r\\n     1.5 × ULN in combination with an elevated total bilirubin > 1.5 × ULN\\r\\n\\r\\n 19. APS cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) APS associated with other systemic autoimmune disease\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Acute thrombosis (arterial or venous acute thrombosis diagnosis) within 30\\r\\n               days before screening\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Patients with thrombotic APS without any anticoagulation treatment\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Treatment with prohibited medications\\r\\n\\r\\n 20. BP cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Initiation of treatment with or increase in the dose of systemic or\\r\\n               topical corticosteroid within 2 weeks\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Current treatment with a drug that may cause or exacerbate BP unless the\\r\\n               dose has been stable\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Initiation of treatment with topical calcineurin inhibitor, or topical\\r\\n               phosphodiesterase (PDE) 4 inhibitor within 7 days\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Treatment with prohibited medications\\r\\n\\r\\n 21. BS cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) BS-related active major organ involvement-ocular lesions requiring\\r\\n               immunosuppressive therapy, pulmonary (e.g., pulmonary artery aneurysm),\\r\\n               vascular (e.g., thrombophlebitis), gastrointestinal (e.g., ulcers along\\r\\n               the gastrointestinal tract), and central nervous systems (e.g.,\\r\\n               meningoencephalitis) manifestations\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) History of venous or arterial thrombosis within 1 year\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Treatment with prohibited medications\\r\\n\\r\\n 22. DM cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) PhGA-VAS improvement >= 3, or clinically relevant improvement between\\r\\n               screening and baseline\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Overlap myositis (except for overlap with Sjögren's syndrome), connective\\r\\n               tissue disease associated DM, inclusion body myositis, polymyositis, IMNM,\\r\\n               juvenile DM or drug-induced myopathy\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Cancer-associated myositis\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Significant muscle damage\\r\\n\\r\\n       -  \\r\\n\\r\\n            5) Past history of severe Interstitial lung disease flare, severe\\r\\n               non-infectious lung inflammation which required active intervention, or\\r\\n               multiple episodes of lung disease\\r\\n\\r\\n       -  \\r\\n\\r\\n            6) Severe respiratory muscle weakness\\r\\n\\r\\n       -  \\r\\n\\r\\n            7) Severe bulbar palsy\\r\\n\\r\\n       -  \\r\\n\\r\\n            8) Treatment with prohibited medications\\r\\n\\r\\n 23. IMNM cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) PhGA-VAS improvement >= 3, or clinically relevant improvement between\\r\\n               screening and baseline\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Overlap myositis (except for overlap with Sjögren's syndrome), connective\\r\\n               tissue disease associated DM, inclusion body myositis, polymyositis,\\r\\n               juvenile DM or druginduced myopathy\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) Cancer-associated myositis\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Significant muscle damage\\r\\n\\r\\n       -  \\r\\n\\r\\n            5) Past history of severe Interstitial lung disease (ILD) flare, severe\\r\\n               non-infectious lung inflammation which required active intervention, or\\r\\n               multiple episodes of lung disease\\r\\n\\r\\n       -  \\r\\n\\r\\n            6) Severe respiratory muscle weakness\\r\\n\\r\\n       -  \\r\\n\\r\\n            7) Severe bulbar palsy\\r\\n\\r\\n       -  \\r\\n\\r\\n            8) Treatment with prohibited medications\\r\\n\\r\\n 24. ITP cohort:\\r\\n\\r\\n       -  \\r\\n\\r\\n            1) Secondary ITP\\r\\n\\r\\n       -  \\r\\n\\r\\n            2) Clinical diagnosis or history of Myelodysplastic Syndrome or autoimmune\\r\\n               hemolytic anemia\\r\\n\\r\\n       -  \\r\\n\\r\\n            3) History of venous or arterial thrombosis within 12 months\\r\\n\\r\\n       -  \\r\\n\\r\\n            4) Patients who experienced major bleeding within 4 weeks\\r\\n\\r\\n       -  \\r\\n\\r\\n            5) Treatment with prohibited medications\\r\\n\\r\\n       -  \\r\\n\\r\\n            6) Any laboratory test results meet either of the following criteria at\\r\\n               screening:\\r\\n\\r\\n            -  Hemoglobin <10 g/dL\\r\\n\\r\\n            -  Thyroid-stimulating hormone >= 10 μIU/mL\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '85 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Clinical trials information',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': 'only use Email',\n",
       "      'email': 'clinical-trials@chugai-pharm.co.jp'}],\n",
       "    'overallOfficials': [{'name': 'Sponsor Chugai Pharmaceutical Co.Ltd',\n",
       "      'affiliation': 'clinical-trials@chugai-pharm.co.jp',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Oregon Health & Science University',\n",
       "      'city': 'Portland',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97239',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 45.52345, 'lon': -122.67621}},\n",
       "     {'facility': 'Hokkaido University Hospital',\n",
       "      'city': 'Sapporo',\n",
       "      'state': 'Hokkaido',\n",
       "      'zip': '060-0808',\n",
       "      'country': 'Japan',\n",
       "      'geoPoint': {'lat': 43.06667, 'lon': 141.35}},\n",
       "     {'facility': 'Tohoku University Hospital',\n",
       "      'city': 'Sendai',\n",
       "      'state': 'Miyagi',\n",
       "      'zip': '980-8574',\n",
       "      'country': 'Japan',\n",
       "      'geoPoint': {'lat': 38.26667, 'lon': 140.86667}},\n",
       "     {'facility': 'Osaka University Hospital',\n",
       "      'city': 'Suita',\n",
       "      'state': 'Osaka',\n",
       "      'zip': '565-0871',\n",
       "      'country': 'Japan',\n",
       "      'geoPoint': {'lat': 34.76143, 'lon': 135.51567}},\n",
       "     {'facility': 'Hamamatsu University Hospital',\n",
       "      'city': 'Hamamatsu',\n",
       "      'state': 'Shizuoka',\n",
       "      'zip': '431-3192',\n",
       "      'country': 'Japan',\n",
       "      'geoPoint': {'lat': 34.7, 'lon': 137.73333}},\n",
       "     {'facility': 'Toho University Omori Medical Center',\n",
       "      'city': 'Ota-ku',\n",
       "      'state': 'Tokyo',\n",
       "      'zip': '143-8540',\n",
       "      'country': 'Japan',\n",
       "      'geoPoint': {'lat': 36.3, 'lon': 139.36667}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Qualified researchers may request access to individual patient level data through the\\r\\nclinical study data request platform. For further details on Chugai's Data Sharing Policy\\r\\nand how to request access to related clinical study documents, see here\\r\\n(www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003882',\n",
       "      'term': 'Dermatomyositis'},\n",
       "     {'id': 'D000001528', 'term': 'Behcet Syndrome'},\n",
       "     {'id': 'D000013921', 'term': 'Thrombocytopenia'},\n",
       "     {'id': 'D000016553', 'term': 'Purpura, Thrombocytopenic, Idiopathic'},\n",
       "     {'id': 'D000010391', 'term': 'Pemphigoid, Bullous'},\n",
       "     {'id': 'D000016736', 'term': 'Antiphospholipid Syndrome'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000001791', 'term': 'Blood Platelet Disorders'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000095542', 'term': 'Cytopenia'},\n",
       "     {'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000011696', 'term': 'Purpura, Thrombocytopenic'},\n",
       "     {'id': 'D000011693', 'term': 'Purpura'},\n",
       "     {'id': 'D000001778', 'term': 'Blood Coagulation Disorders'},\n",
       "     {'id': 'D000057049', 'term': 'Thrombotic Microangiopathies'},\n",
       "     {'id': 'D000006474', 'term': 'Hemorrhagic Disorders'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000006470', 'term': 'Hemorrhage'},\n",
       "     {'id': 'D000012877', 'term': 'Skin Manifestations'},\n",
       "     {'id': 'D000017285', 'term': 'Polymyositis'},\n",
       "     {'id': 'D000009220', 'term': 'Myositis'},\n",
       "     {'id': 'D000003240', 'term': 'Connective Tissue Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000012872', 'term': 'Skin Diseases, Vesiculobullous'},\n",
       "     {'id': 'D000009059', 'term': 'Mouth Diseases'},\n",
       "     {'id': 'D000009057', 'term': 'Stomatognathic Diseases'},\n",
       "     {'id': 'D000014606', 'term': 'Uveitis, Anterior'},\n",
       "     {'id': 'D000015864', 'term': 'Panuveitis'},\n",
       "     {'id': 'D000014605', 'term': 'Uveitis'},\n",
       "     {'id': 'D000014603', 'term': 'Uveal Diseases'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'},\n",
       "     {'id': 'D000014657', 'term': 'Vasculitis'},\n",
       "     {'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000056660', 'term': 'Hereditary Autoinflammatory Diseases'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000012873', 'term': 'Skin Diseases, Genetic'},\n",
       "     {'id': 'D000017445', 'term': 'Skin Diseases, Vascular'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16680',\n",
       "      'name': 'Thrombocytopenia',\n",
       "      'asFound': 'Thrombocytopenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7077',\n",
       "      'name': 'Dermatomyositis',\n",
       "      'asFound': 'Dermatomyositis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19097',\n",
       "      'name': 'Antiphospholipid Syndrome',\n",
       "      'asFound': 'Antiphospholipid Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10200',\n",
       "      'name': 'Immune System Diseases',\n",
       "      'asFound': 'Immunological Diseases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18945',\n",
       "      'name': 'Purpura, Thrombocytopenic, Idiopathic',\n",
       "      'asFound': 'Immune Thrombocytopenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13302',\n",
       "      'name': 'Pemphigoid, Bullous',\n",
       "      'asFound': 'Bullous Pemphigoid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4820',\n",
       "      'name': 'Behcet Syndrome',\n",
       "      'asFound': 'Behcet Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14547', 'name': 'Purpura', 'relevance': 'LOW'},\n",
       "     {'id': 'M14550', 'name': 'Purpura, Thrombocytopenic', 'relevance': 'LOW'},\n",
       "     {'id': 'M5072', 'name': 'Blood Platelet Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M3170', 'name': 'Cytopenia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M21977', 'name': 'Hemostatic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M5059',\n",
       "      'name': 'Blood Coagulation Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M28682',\n",
       "      'name': 'Thrombotic Microangiopathies',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9560', 'name': 'Hemorrhagic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9556', 'name': 'Hemorrhage', 'relevance': 'LOW'},\n",
       "     {'id': 'M15680', 'name': 'Skin Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M19579', 'name': 'Polymyositis', 'relevance': 'LOW'},\n",
       "     {'id': 'M12172', 'name': 'Myositis', 'relevance': 'LOW'},\n",
       "     {'id': 'M6464', 'name': 'Connective Tissue Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15675',\n",
       "      'name': 'Skin Diseases, Vesiculobullous',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12019', 'name': 'Mouth Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17353', 'name': 'Uveitis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17354', 'name': 'Uveitis, Anterior', 'relevance': 'LOW'},\n",
       "     {'id': 'M18408', 'name': 'Panuveitis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17351', 'name': 'Uveal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17405', 'name': 'Vasculitis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M13414',\n",
       "      'name': 'Familial Mediterranean Fever',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M28536',\n",
       "      'name': 'Hereditary Autoinflammatory Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M15676', 'name': 'Skin Diseases, Genetic', 'relevance': 'LOW'},\n",
       "     {'id': 'M19714', 'name': 'Skin Diseases, Vascular', 'relevance': 'LOW'},\n",
       "     {'id': 'T1814',\n",
       "      'name': 'Dermatomyositis',\n",
       "      'asFound': 'Dermatomyositis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T438',\n",
       "      'name': 'Antiphospholipid Syndrome',\n",
       "      'asFound': 'Antiphospholipid Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3021',\n",
       "      'name': 'Immune Thrombocytopenia',\n",
       "      'asFound': 'Immune Thrombocytopenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T3007',\n",
       "      'name': 'Idiopathic Thrombocytopenic Purpura',\n",
       "      'asFound': 'Immune Thrombocytopenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T891',\n",
       "      'name': 'Bullous Pemphigoid',\n",
       "      'asFound': 'Bullous Pemphigoid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T706',\n",
       "      'name': 'BehÃ§et Disease',\n",
       "      'asFound': 'Behcet Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4054',\n",
       "      'name': 'Necrotizing Autoimmune Myopathy',\n",
       "      'asFound': 'Immune-Mediated Necrotizing Myopathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4623', 'name': 'Polymyositis', 'relevance': 'LOW'},\n",
       "     {'id': 'T3001',\n",
       "      'name': 'Idiopathic Inflammatory Myopathy',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4396', 'name': 'Panuveitis', 'relevance': 'LOW'},\n",
       "     {'id': 'T5824', 'name': 'Uveal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T2237',\n",
       "      'name': 'Familial Mediterranean Fever',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M6392',\n",
       "      'name': 'Complement System Proteins',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06411041',\n",
       "    'orgStudyIdInfo': {'id': '24MMHIS120e'},\n",
       "    'organization': {'fullName': 'National Yang Ming Chiao Tung University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effects of a Combined Program of Pelvic Floor Muscle Training and Yoga',\n",
       "    'officialTitle': 'Effects of a Combined Program of Pelvic Floor Muscle Training and Yoga on Relieving Genitourinary Symptoms, and Improving Sexual Function and Quality of Life in Asian Women With Breast Cancer'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-08',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Yuan-Mei Liao, RN, PhD',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'National Yang Ming Chiao Tung University'},\n",
       "    'leadSponsor': {'name': 'Yuan-Mei Liao, RN, PhD', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study aims to examine the effects of Pelvic Floor Muscle Training (PFMT) combined\\r\\nwith yoga on relieving genitourinary symptoms, symptom-related quality of life, and\\r\\nimproving sexual function in women with breast cancer. This study is a parallel\\r\\nrandomized study with two groups. Women will be assigned to the experimental or control\\r\\ngroup by using the block randomization method. The experimental group will receive\\r\\nregular care and a 12-week program of PFMT and yoga. The control group will receive\\r\\nregular care. We collect relevant data from both groups at baseline and 4, 8, 12, and 24\\r\\nweeks after baseline during the study period.',\n",
       "    'detailedDescription': 'This study will be conducted with the approval obtained from the Institutional Review\\r\\nBoard (IRB) of MacKay Memorial Hospital. This parallel-two-group randomized experimental\\r\\nstudy including an experimental group and a control group examines the effects of pelvic\\r\\nfloor muscle training (PFMT) combined with yoga on genitourinary symptoms,\\r\\nsymptom-related quality of life, and sexual function. A sample of women with breast\\r\\ncancer experiencing ≥1 genitourinary symptom(s) will be recruited and assigned to an\\r\\nexperimental group or a control group by using the block randomization method. The\\r\\nexperimental group will receive regular care and a 12-week program of PFMT and yoga. We\\r\\nwill provide the experimental group with 12 days of online group practice sections of\\r\\nPFMT and yoga (weekly 60-minute practice incudes yoga 40 minutes, PFMT 15 minutes, and\\r\\nreflection 5 minutes). We expect them to perform 36 days of home-based practice of PFMT\\r\\nand yoga with 3 days/week of yoga for 40 minutes and PFMT for 15 minutes. The control\\r\\ngroup will receive regular care and relevant educational materials after data collection.\\r\\nInformation will be collected at five time points: baseline and 4, 8, 12, and 24 weeks\\r\\nafter baseline. Generalized estimating equation procedures will be used to examine the\\r\\neffects of the intervention. We hypothesized that the experimental group will display\\r\\nmore significant improvements in genitourinary symptoms, symptom-related influences, and\\r\\nsexual function than those shown in the control group.'},\n",
       "   'conditionsModule': {'conditions': ['Genitourinary Symptoms',\n",
       "     'Sexual Function',\n",
       "     'Quality of Life']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'The experimental group will receive regular care and a 12-week program of pelvic floor\\r\\nmuscle training (PFMT) and yoga. The control group will receive regular care.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'The outcome assessor will not be informed about the group of the participants',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Intervention group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The experimental group will receive regular care and a 12-week program of pelvic floor\\r\\nmuscle training (PFMT) and yoga',\n",
       "      'interventionNames': ['Behavioral: Pelvic Floor Muscle Training (PFMT) and yoga']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'The control group will receive regular care'}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Pelvic Floor Muscle Training (PFMT) and yoga',\n",
       "      'description': 'The experimental group participants will be instructed to perform the practice session\\r\\nfour days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40\\r\\nminutes/day.) will result in weekly practice times for pelvic floor muscle training\\r\\n(PFMT) of 60 minutes and for yoga of ≥150 minutes.',\n",
       "      'armGroupLabels': ['Intervention group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Vulvovaginal Symptoms',\n",
       "      'description': 'The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises\\r\\nfour subscales to assess vulvovaginal symptoms experienced during the past week (Items\\r\\n1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and\\r\\nSexual-impact Items 16, 18-21). The response options for all items are \"Yes\" (1 point)\\r\\nand \"No\" (0 point). Subscale scores are the sum of the scores for the items included in\\r\\nthat subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or\\r\\nfour subscale scores (0-20 points for sexually active women). A higher C-VSQ total score\\r\\nindicates experiencing greater severity of vulvovaginal symptoms and symptom-related\\r\\ninfluences.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Vulvovaginal Symptoms',\n",
       "      'description': 'The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises\\r\\nfour subscales to assess vulvovaginal symptoms experienced during the past week (Items\\r\\n1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and\\r\\nSexual-impact Items 16, 18-21). The response options for all items are \"Yes\" (1 point)\\r\\nand \"No\" (0 point). Subscale scores are the sum of the scores for the items included in\\r\\nthat subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or\\r\\nfour subscale scores (0-20 points for sexually active women). A higher C-VSQ total score\\r\\nindicates experiencing greater severity of vulvovaginal symptoms and symptom-related\\r\\ninfluences.',\n",
       "      'timeFrame': '4 weeks after baseline'},\n",
       "     {'measure': 'Vulvovaginal Symptoms',\n",
       "      'description': 'The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises\\r\\nfour subscales to assess vulvovaginal symptoms experienced during the past week (Items\\r\\n1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and\\r\\nSexual-impact Items 16, 18-21). The response options for all items are \"Yes\" (1 point)\\r\\nand \"No\" (0 point). Subscale scores are the sum of the scores for the items included in\\r\\nthat subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or\\r\\nfour subscale scores (0-20 points for sexually active women). A higher C-VSQ total score\\r\\nindicates experiencing greater severity of vulvovaginal symptoms and symptom-related\\r\\ninfluences.',\n",
       "      'timeFrame': '8 weeks after baseline'},\n",
       "     {'measure': 'Vulvovaginal Symptoms',\n",
       "      'description': 'The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises\\r\\nfour subscales to assess vulvovaginal symptoms experienced during the past week (Items\\r\\n1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and\\r\\nSexual-impact Items 16, 18-21). The response options for all items are \"Yes\" (1 point)\\r\\nand \"No\" (0 point). Subscale scores are the sum of the scores for the items included in\\r\\nthat subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or\\r\\nfour subscale scores (0-20 points for sexually active women). A higher C-VSQ total score\\r\\nindicates experiencing greater severity of vulvovaginal symptoms and symptom-related\\r\\ninfluences.',\n",
       "      'timeFrame': '12 weeks after baseline'},\n",
       "     {'measure': 'Vulvovaginal Symptoms',\n",
       "      'description': 'The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises\\r\\nfour subscales to assess vulvovaginal symptoms experienced during the past week (Items\\r\\n1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and\\r\\nSexual-impact Items 16, 18-21). The response options for all items are \"Yes\" (1 point)\\r\\nand \"No\" (0 point). Subscale scores are the sum of the scores for the items included in\\r\\nthat subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or\\r\\nfour subscale scores (0-20 points for sexually active women). A higher C-VSQ total score\\r\\nindicates experiencing greater severity of vulvovaginal symptoms and symptom-related\\r\\ninfluences.',\n",
       "      'timeFrame': '24 weeks after baseline'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Urinary symptoms',\n",
       "      'description': 'We investigated eight common urinary symptoms using the lower urinary tract symptoms\\r\\n(LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased\\r\\ndaytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent\\r\\nstream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete\\r\\nemptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a\\r\\ngreater number of different types of urinary symptoms.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Urinary symptoms',\n",
       "      'description': 'We investigated eight common urinary symptoms using the lower urinary tract symptoms\\r\\n(LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased\\r\\ndaytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent\\r\\nstream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete\\r\\nemptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a\\r\\ngreater number of different types of urinary symptoms.',\n",
       "      'timeFrame': '4 weeks after baseline'},\n",
       "     {'measure': 'Urinary symptoms',\n",
       "      'description': 'We investigated eight common urinary symptoms using the lower urinary tract symptoms\\r\\n(LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased\\r\\ndaytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent\\r\\nstream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete\\r\\nemptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a\\r\\ngreater number of different types of urinary symptoms.',\n",
       "      'timeFrame': '8 weeks after baseline'},\n",
       "     {'measure': 'Urinary symptoms',\n",
       "      'description': 'We investigated eight common urinary symptoms using the lower urinary tract symptoms\\r\\n(LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased\\r\\ndaytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent\\r\\nstream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete\\r\\nemptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a\\r\\ngreater number of different types of urinary symptoms.',\n",
       "      'timeFrame': '12 weeks after baseline'},\n",
       "     {'measure': 'Urinary symptoms',\n",
       "      'description': 'We investigated eight common urinary symptoms using the lower urinary tract symptoms\\r\\n(LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased\\r\\ndaytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent\\r\\nstream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete\\r\\nemptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a\\r\\ngreater number of different types of urinary symptoms.',\n",
       "      'timeFrame': '24 weeks after baseline'}],\n",
       "    'otherOutcomes': [{'measure': 'Sexual function',\n",
       "      'description': 'The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire\\r\\n(Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items\\r\\n11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of\\r\\nall the item scores. A higher FSFI total score indicates better overall sexual\\r\\nfunctioning.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Sexual function',\n",
       "      'description': 'The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire\\r\\n(Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items\\r\\n11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of\\r\\nall the item scores. A higher FSFI total score indicates better overall sexual\\r\\nfunctioning.',\n",
       "      'timeFrame': '4 weeks after baseline'},\n",
       "     {'measure': 'Sexual function',\n",
       "      'description': 'The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire\\r\\n(Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items\\r\\n11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of\\r\\nall the item scores. A higher FSFI total score indicates better overall sexual\\r\\nfunctioning.',\n",
       "      'timeFrame': '8 weeks after baseline'},\n",
       "     {'measure': 'Sexual function',\n",
       "      'description': 'The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire\\r\\n(Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items\\r\\n11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of\\r\\nall the item scores. A higher FSFI total score indicates better overall sexual\\r\\nfunctioning.',\n",
       "      'timeFrame': '12 weeks after baseline'},\n",
       "     {'measure': 'Sexual function',\n",
       "      'description': 'The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire\\r\\n(Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items\\r\\n11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of\\r\\nall the item scores. A higher FSFI total score indicates better overall sexual\\r\\nfunctioning.',\n",
       "      'timeFrame': '24 weeks after baseline'},\n",
       "     {'measure': 'Quality of life and distress associated with pelvic floor symptoms',\n",
       "      'description': 'The 20-item Pelvic Floor Distress Invebtory-20 (PFDI-20) consists of three sections:\\r\\nPelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress\\r\\nInventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20).\\r\\nThe total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe\\r\\ninfluences associated with pelvic floor symptoms.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Quality of life and distress associated with pelvic floor symptoms',\n",
       "      'description': 'The 20-item Pelvic Floor Distress Invebtory-20 (PFDI-20) consists of three sections:\\r\\nPelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress\\r\\nInventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20).\\r\\nThe total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe\\r\\ninfluences associated with pelvic floor symptoms.',\n",
       "      'timeFrame': '4 weeks after baseline'},\n",
       "     {'measure': 'Quality of life and distress associated with pelvic floor symptoms',\n",
       "      'description': 'The 20-item Pelvic Floor Distress Invebtory-20 (PFDI-20) consists of three sections:\\r\\nPelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress\\r\\nInventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20).\\r\\nThe total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe\\r\\ninfluences associated with pelvic floor symptoms.',\n",
       "      'timeFrame': '8 weeks after baseline'},\n",
       "     {'measure': 'Quality of life and distress associated with pelvic floor symptoms',\n",
       "      'description': 'The 20-item Pelvic Floor Distress Invebtory-20 (PFDI-20) consists of three sections:\\r\\nPelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress\\r\\nInventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20).\\r\\nThe total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe\\r\\ninfluences associated with pelvic floor symptoms.',\n",
       "      'timeFrame': '12 weeks after baseline'},\n",
       "     {'measure': 'Quality of life and distress associated with pelvic floor symptoms',\n",
       "      'description': 'The 20-item Pelvic Floor Distress Invebtory-20 (PFDI-20) consists of three sections:\\r\\nPelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress\\r\\nInventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20).\\r\\nThe total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe\\r\\ninfluences associated with pelvic floor symptoms.',\n",
       "      'timeFrame': '24 weeks after baseline'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Women aged 20-60 years\\r\\n\\r\\n  -  Women with a confirmed diagnosis of breast cancer (Stages I-III) for ≥3 months\\r\\n\\r\\n  -  Women who experience ≥1 genitourinary symptom(s)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Women with other types of cancer diagnoses (e.g., endometrial cancer and ovarian\\r\\n     cancer)\\r\\n\\r\\n  -  Women with inadequately managed chronic conditions (e.g., an individual with\\r\\n     diabetes having HbA1c level >7%)',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'genderDescription': 'Women who aged 20-60 years, with a confirmed diagnosis of breast cancer (Stages I-III)\\r\\nfor ≥3 months, and experience ≥1 genitourinary symptom(s)',\n",
       "    'minimumAge': '20 Years',\n",
       "    'maximumAge': '60 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Yuan-Mei Liao, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '886-2-28267347',\n",
       "      'email': 'ymliao@nycu.edu.tw'},\n",
       "     {'name': 'Yueh-Ching Lee, MSN',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 's063@mail.mkc.edu.tw'}],\n",
       "    'overallOfficials': [{'name': 'Yuan-Mei Liao, PhD',\n",
       "      'affiliation': 'National Yang Ming Chiao Tung University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Data are available on request due to privacy and ethical restrictions.',\n",
       "    'infoTypes': ['SAP'],\n",
       "    'timeFrame': 'Baseline and 4, 8, 12 weeks after baseline',\n",
       "    'accessCriteria': 'Data are available on request due to privacy and ethical restrictions.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M5220',\n",
       "      'name': 'Breast Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T6034',\n",
       "      'name': 'Quality of Life',\n",
       "      'asFound': 'Quality of Life',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06427434',\n",
       "    'orgStudyIdInfo': {'id': 'P.T.REC/012/004494'},\n",
       "    'organization': {'fullName': 'Cairo University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Effect of Modified Lumbar Sustained Natural Apophyseal Glide on Postnatal Low Back Pain',\n",
       "    'officialTitle': 'Effect of Modified Lumbar Sustained Natural Apophyseal Glide on Low Back Pain in Postnatal Women'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-19',\n",
       "    'studyFirstSubmitQcDate': '2024-05-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Mina Nageib Soliman',\n",
       "     'investigatorTitle': 'Principal investigator',\n",
       "     'investigatorAffiliation': 'Cairo University'},\n",
       "    'leadSponsor': {'name': 'Cairo University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study will be carried out to evaluate the effect of modified lumbar Sustained\\r\\nNatural Apophyseal Glide on low back pain in postnatal women.',\n",
       "    'detailedDescription': 'In fact, up to 75% of women who suffer from pregnancy-related back pain may continue to\\r\\nhave pain after giving birth. Women who experience LBP or pelvic girdle pain (PGP) at 3\\r\\nmonths postpartum were found to be at higher risk for persistent or chronic LBP. Of these\\r\\nwomen, only 6% recover within 6-18 months after giving birth.\\r\\n\\r\\nA modified lumbar Sustained Natural Apophyseal Glide (SNAG) is an existing Mulligan\\r\\nmobilization technique performed with a combination of joint glide and physiological\\r\\nspinal movement. The glide can be applied to the spinous processes, facets, or\\r\\nunilaterally over the transverse processes while the patient performs the active\\r\\nexercise.\\r\\n\\r\\nFew studies have been concerned with the effects of modified \"SNAGS\" on the lumbar spine\\r\\n. So, this study will be done to investigate its effect on low back pain in postnatal\\r\\nwomen aiming to improve their function to accomplish their daily living activities and\\r\\nreduce the side effects of medical treatment.'},\n",
       "   'conditionsModule': {'conditions': ['Low Back Pain']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Strengthening and stretching exercises',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The participants will be asked to perform strengthening and stretching exercises to the\\r\\nback and abdominal muscles for 30 min, three times per week for 4 weeks.',\n",
       "      'interventionNames': ['Other: Strengthening and stretching exercises to the back and abdominal muscles']},\n",
       "     {'label': 'Modified Lumbar Sustained Natural Apophyseal Glide',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The participants will receive Modified Sustained Natural Apophyseal Glide on the affected\\r\\nlumbar level for 30 sec three times per week for 4 weeks. In addition to strengthening\\r\\nand stretching exercises to the back and abdominal muscles for 30 min, three times per\\r\\nweek for 4 weeks',\n",
       "      'interventionNames': ['Other: Strengthening and stretching exercises to the back and abdominal muscles',\n",
       "       'Other: Modified Lumbar Sustained Natural Apophyseal Glide']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Strengthening and stretching exercises to the back and abdominal muscles',\n",
       "      'description': 'Strengthening and stretching exercises to the back and abdominal muscles will be\\r\\nperformed for 30 min, three times per week for 4 weeks.',\n",
       "      'armGroupLabels': ['Modified Lumbar Sustained Natural Apophyseal Glide',\n",
       "       'Strengthening and stretching exercises']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Modified Lumbar Sustained Natural Apophyseal Glide',\n",
       "      'description': 'Modified Sustained Natural Apophyseal Glide will be applied on the affected lumbar level\\r\\nfor 30 sec three times per week for 4 weeks.',\n",
       "      'armGroupLabels': ['Modified Lumbar Sustained Natural Apophyseal Glide']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain intenesity',\n",
       "      'description': 'The visual analogue scale is a 10 cm calibrated line with 0 representing no pain and 10\\r\\nrepresenting the worst pain; will be used to assess the severity of pain before and after\\r\\ntreatment for all participants in both groups.',\n",
       "      'timeFrame': 'within 4 weeks'},\n",
       "     {'measure': 'Lumbar flexion range of motion',\n",
       "      'description': \"The modified Schober test will be used to measure the lumbar flexion range of motion\\r\\n(ROM) by using the tape measurement. Each participant will be asked to stand erect with\\r\\nher feet about shoulder-width apart to stabilize the pelvis. Then, the posterior superior\\r\\niliac spines(PSIS) will be determined by the therapist's both thumbs, and then an ink\\r\\nline will be drawn along the midline of the lumbar spines horizontal to the PSIS to mark\\r\\nthe midpoint between the two PSIS. Then tape will be used to identify and mark two\\r\\npoints: one is 10 cm superior to the midpoint (A), and another is 5 cm inferior to the\\r\\nmidpoint (B). The participant will be instructed to bend forward as much as she can while\\r\\nkeeping both knees straight, the new distance between superior and inferior skin marking\\r\\nwill be measured in centimeters. The increased distance along the tape due to lumbar\\r\\nflexion is normally about 6-7 cm (less than 5 cm should be considered abnormal).\",\n",
       "      'timeFrame': 'within 4 weeks'},\n",
       "     {'measure': 'Lumbar extension range of motion',\n",
       "      'description': 'The modified Schober test will be used to measure the lumbar extension range of motion\\r\\n(ROM) by using the tape measurement while the patient is in a standing position.\\r\\n\\r\\nThe participant will be instructed to put her hands on her buttocks and bend backward\\r\\ninto full lumbar extension and the new distance between the superior and inferior skin\\r\\nmarkings will be measured in centimeters by the tape measurement. The change in the\\r\\ndifference between the marks is used to indicate the amount of lumbar extension.\\r\\n\\r\\nThe increased distance along the tape due to the extension of the lumbar spine is\\r\\nnormally about 2-3 cm (less than 1 cm should be considered abnormal).',\n",
       "      'timeFrame': 'within 4 weeks'},\n",
       "     {'measure': 'Lumbar lateral flexion range of motion',\n",
       "      'description': 'The participant will be asked to stand erect with her feet about shoulder-width apart.\\r\\nBoth right and left lateral flexion will be measured by the tape as the distance from the\\r\\ntip of the index finger to the floor at maximal comfortable lateral flexion. The\\r\\nparticipant will be instructed to bend her trunk laterally as much as she can. The normal\\r\\nvalue of lateral spinal flexion is 16.2-28.0 cm.',\n",
       "      'timeFrame': 'within 4 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Functional disability',\n",
       "      'description': 'Functional disability will be assessed by the Oswestry Disability Index, it was developed\\r\\nas a clinical valid and reliable assessment tool that would provide an estimate of\\r\\ndisability expressed as a percentage score. It is composed of 10 questions and it takes\\r\\naround 5min for a patient to complete. Each of the 10 questions is scored from 0 to 5,\\r\\ngiving a maximum score of 50. The total score is then converted into a percentage by\\r\\nmultiplying it by 2. Scores are stratified into severity: 0-20, minimal disability;\\r\\n21-40, moderate disability; 41-60, severe disability; 61-80, crippling back pain; 81-100,\\r\\nbed-bound. A low score = low degree of disability, a high score = high degree of\\r\\ndisability.',\n",
       "      'timeFrame': 'within 4 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. All participants will be diagnosed as chronic postnatal low back pain.\\r\\n\\r\\n  2. Their ages will be ranged from 20 to 35 years old.\\r\\n\\r\\n  3. Their body mass index (BMI) will not exceed 30 kg/m2.\\r\\n\\r\\n  4. All participants have the same social level.\\r\\n\\r\\n  5. All participants have the same lifestyle.\\r\\n\\r\\n  6. Their number of parity will be ranged from 2-4 children.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Spinal fracture or any other neurological disorders.\\r\\n\\r\\n  2. Lumbar spinal stenosis from lumbar disc herniation, degenerative joint diseases, or\\r\\n     spondylolisthesis.\\r\\n\\r\\n  3. Women with BMI > 30 kg/m2.\\r\\n\\r\\n  4. Participants who had pelvic pathology.\\r\\n\\r\\n  5. Skin disease interferes with mobilization application.\\r\\n\\r\\n  6. Gynecological diseases (chronic pelvic pain, uterine prolapse and retroversion\\r\\n     flexion of the uterus).',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '20 Years',\n",
       "    'maximumAge': '35 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mina soliman, PHD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01283605551',\n",
       "      'email': 'karmamedicalcenter@gmail.com'},\n",
       "     {'name': 'Afaf Botla, Assistant professor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01283126608',\n",
       "      'email': 'drafafmohamed@cu.edu.eg'}],\n",
       "    'overallOfficials': [{'name': 'Azza Kassab, professor',\n",
       "      'affiliation': 'Cairo University',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'infoTypes': ['STUDY_PROTOCOL']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001416',\n",
       "      'term': 'Back Pain'},\n",
       "     {'id': 'D000017116', 'term': 'Low Back Pain'}],\n",
       "    'ancestors': [{'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M4714',\n",
       "      'name': 'Back Pain',\n",
       "      'asFound': 'Back Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19433',\n",
       "      'name': 'Low Back Pain',\n",
       "      'asFound': 'Low Back Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06361719',\n",
       "    'orgStudyIdInfo': {'id': '2312INF'},\n",
       "    'organization': {'fullName': 'Société des Produits Nestlé (SPN)',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Efficacy of Two HMOs in Chinese Infants',\n",
       "    'officialTitle': \"Efficacy of a Ready to Feed (RTF) Starter Liquid Infant Formula Containing 2'FL and LNnT in Chinese Infants: A Double-blind, Randomized Controlled Trial Including a Breastfed Reference Group\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-11', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-06', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-08',\n",
       "    'studyFirstSubmitQcDate': '2024-04-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-08',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Société des Produits Nestlé (SPN)',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a randomized, controlled, double-blind, intervention trial of healthy male and\\r\\nfemale term infants to evaluate the efficacy of the 2 HMOs on beneficially modulating the\\r\\ngut microbiota, gut maturation, gut barrier integrity, immune response, and other\\r\\ndevelopmental outcomes in healthy Chinese infants. The trial consists of 2 randomized\\r\\nformula-fed groups, and a non-randomized breastfed reference group.'},\n",
       "   'conditionsModule': {'conditions': ['Healthy Infants'],\n",
       "    'keywords': ['Human Milk Oligosaccharides',\n",
       "     'Infant gut microbiota',\n",
       "     'Infant gut health',\n",
       "     'Immune response',\n",
       "     'Growth',\n",
       "     'Tolerance']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 262, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Experimental Group (EG)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Starter infant formula supplemented with two HMOs. Following the intervention period, the\\r\\ninfants will consume a standard infant follow-up formula (non-trial formula).',\n",
       "      'interventionNames': ['Other: Experimental Group (EG)']},\n",
       "     {'label': 'Control Group (CG)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Starter infant formula not supplemented with two HMOs. Following the intervention period,\\r\\nthe infants will consume a standard infant follow-up formula (non-trial formula).',\n",
       "      'interventionNames': ['Other: Control Group (CG)']},\n",
       "     {'label': 'Breastfed Group (BG)',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Breast Milk'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Experimental Group (EG)',\n",
       "      'description': 'Starter infant formula will be administered to the participants orally, ad libtium to 6\\r\\nmonths, after which they will transfer to a classical follow-up formula (non-trial\\r\\nformula) until the end of the trial (12 months of age).',\n",
       "      'armGroupLabels': ['Experimental Group (EG)']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Control Group (CG)',\n",
       "      'description': 'Starter infant formula will be administered to the participants orally, ad libtium to 6\\r\\nmonths, after which they will transfer to a classical follow-up formula (non-trial\\r\\nformula) until the end of the trial (12 months of age).',\n",
       "      'armGroupLabels': ['Control Group (CG)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Bifidobacteria abundance in fecal samples',\n",
       "      'description': 'Bifidobacteria abundance using qPCR technology',\n",
       "      'timeFrame': 'just prior to 3 months of age'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Gut microbiota composition',\n",
       "      'description': 'Relative abundance of beneficial and potentially pathogenic species using next generation\\r\\nsequencing (NGS) technology',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Fecal metabolism',\n",
       "      'description': 'Fecal pH analyzed using HPLC as well as targeted or untargeted metabolomics profiling',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Fecal metabolism',\n",
       "      'description': 'Short chain fatty acids analyzed using HPLC as well as targeted or untargeted\\r\\nmetabolomics profiling',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Fecal markers of intestinal immune health',\n",
       "      'description': 'Fecal secretory IgA measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of gut barrier function',\n",
       "      'description': 'Calprotectin measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of gut barrier function',\n",
       "      'description': 'α-1-antitrypsin measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of gut barrier function',\n",
       "      'description': 'Lipocalin-2 measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of inflammation',\n",
       "      'description': 'Levels of cytokines such as IL-1β measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of inflammation',\n",
       "      'description': 'Levels of cytokines such as IFN-γ measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Fecal markers of inflammation',\n",
       "      'description': 'Levels of cytokines such as TNF-α measured by ELISA',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Stool patterns',\n",
       "      'description': 'Stool frequency, consistency, and difficulty in passing stools assessed using a 1-day\\r\\nretrospective stool consistency diary (24-hr recall)',\n",
       "      'timeFrame': 'From enrollment until 14 days'},\n",
       "     {'measure': 'Stool patterns',\n",
       "      'description': 'Stool frequency, consistency, and difficulty in passing stools assessed using a 3-day\\r\\nprospective collection recorded in the stool consistency diary.',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'GI symptoms and behaviors',\n",
       "      'description': 'IGSQ-13 Questionnaire',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Immune competence',\n",
       "      'description': 'Pediatric Immune System Index score',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Infant sleep duration and night-time wakings per 24 hours',\n",
       "      'description': 'Brief infant sleep questionnaire (BISQ)',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Infant Health Related Quality of Life',\n",
       "      'description': 'Infant Toddler Quality of Life Questionnaire (ITQoL -SF47)',\n",
       "      'timeFrame': 'From enrollment until 6 months of age'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Weight (g) and corresponding Z-scores',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Length (cm) and corresponding Z-scores',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Head circumference (cm) and corresponding Z-scores',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Weight gain and corresponding Z-scores',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Length gain, corresponding Z-scores',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Physical Examination',\n",
       "      'timeFrame': 'At enrollment and at 12 months of age'},\n",
       "     {'measure': 'Infant Illness',\n",
       "      'description': 'Infant Illness Diary',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Infant illness, infections and medication usage',\n",
       "      'description': 'AEs and Serious Adverse Events (SAEs)',\n",
       "      'timeFrame': 'From the time the informed consent form has been signed at enrollment infant age less than 3 days until 12 months of age'},\n",
       "     {'measure': 'Medication use (type and duration)',\n",
       "      'description': 'Concomitant medication form and Infant Illness Diary',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'}],\n",
       "    'otherOutcomes': [{'measure': 'Formula feeding',\n",
       "      'description': 'Total quantity of milk consumed for formula-feeding',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Breastfeeding',\n",
       "      'description': 'The frequency of breastfeeding, duration and type of breastfeeding (exclusive,\\r\\npredominant, partial)',\n",
       "      'timeFrame': 'From enrollment until 12 months of age'},\n",
       "     {'measure': 'Infant dietary pattern',\n",
       "      'description': '3-day food diary',\n",
       "      'timeFrame': 'From 6 months of age until 12 months of age'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Healthy male and female infants of post-natal age of 3-14 days (date of birth = day\\r\\n     0), inclusive, at enrolment\\r\\n\\r\\n  -  Evidence of personally signed and dated informed consent document indicating that\\r\\n     the infant's parent(s)/ legally accepted representatives LAR have been informed of\\r\\n     all pertinent aspects of the trial.\\r\\n\\r\\n  -  Infants whose parent(s) have reached the legal age of majority in China.\\r\\n\\r\\n  -  Infants whose parent(s)/LAR are willing and able to comply with scheduled visits,\\r\\n     and the requirements of the trial protocol.\\r\\n\\r\\n  -  Infants whose parent(s)/LAR can be contacted directly by telephone throughout the\\r\\n     trial.\\r\\n\\r\\n  -  Infants whose parent(s)/LAR have a working freezer.\\r\\n\\r\\n  -  Singleton, healthy, full-term gestational birth (≥ 37 completed weeks of gestation),\\r\\n     with a birth weight of ≥ 2.5 kg and ≤ 4.5 kg.\\r\\n\\r\\n  -  For the formula-fed groups: infant is exclusively consuming and tolerating a cow' s\\r\\n     milk infant formula for at least 3 days prior to enrolment. The infant's mother has\\r\\n     independently elected not to breastfeed.\\r\\n\\r\\n  -  For the breastfed reference group: infant has been exclusively consuming breastmilk\\r\\n     since birth and the infant's mother has made the decision to continue exclusively\\r\\n     breastfeeding until at least 3 months of age.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Infants with conditions requiring infant feedings other than those specified in the\\r\\n     protocol.\\r\\n\\r\\n  -  Infants receiving complementary foods or liquids defined as 4 or more teaspoons per\\r\\n     day or approximately 20 g per day of complementary foods or liquids at or prior to\\r\\n     enrolment.\\r\\n\\r\\n  -  Infants who have a medical condition or history that could increase the risk\\r\\n     associated with trial participation or interfere with the interpretation of trial\\r\\n     results, including: Evidence of major congenital malformations (e.g., cleft palate,\\r\\n     extremity malformation). Documented or suspected systemic or congenital infections\\r\\n     (e.g., human immunodeficiency virus, cytomegalovirus, syphilis). Previous or ongoing\\r\\n     severe medical or laboratory abnormality (acute or chronic) which, in the judgment\\r\\n     of the investigator, would make the infant inappropriate for entry into the trial.\\r\\n\\r\\n  -  Infants who are presently receiving or have received prior to enrolment probiotic\\r\\n     supplements or any of the following: medication(s) or supplement(s) which are known\\r\\n     or suspected to affect the following: fat digestion, absorption, and/or metabolism\\r\\n     (e.g., pancreatic enzymes); stool characteristics and microbiota (e.g., oral and\\r\\n     systemic antibiotics, glycerine suppositories, bismuth-containing medications,\\r\\n     docusate, Maltsupex, or lactulose); growth (e.g. insulin or growth hormone); gastric\\r\\n     acid secretion.\\r\\n\\r\\n  -  Currently participating or having participated in another clinical trial since\\r\\n     birth.\\r\\n\\r\\n  -  Infant who has known or suspected cows' milk protein intolerance / allergy, lactose\\r\\n     intolerance, soy intolerance / allergy.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '3 Days',\n",
       "    'maximumAge': '14 Days',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Qiaoji Li',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '008613910051543',\n",
       "      'email': 'qiaoji.li@rd.nestle.com'},\n",
       "     {'name': 'Joyce Li',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '008615810125435',\n",
       "      'email': 'Joyce.Li@rd.nestle.com'}],\n",
       "    'overallOfficials': [{'name': 'Wei Cai, MD',\n",
       "      'affiliation': 'Shanghai Institute for Pediatric Research, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06048718',\n",
       "    'orgStudyIdInfo': {'id': 'MEDOPP596'},\n",
       "    'secondaryIdInfos': [{'id': '2023-506702-39-00',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'EU CT'}],\n",
       "    'organization': {'fullName': 'MedSIR', 'class': 'OTHER'},\n",
       "    'briefTitle': 'T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases',\n",
       "    'officialTitle': 'Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting With Newly Diagnosed or Progressing Brain Metastases',\n",
       "    'acronym': 'TUXEDO-4'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-09',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-09', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-09-06',\n",
       "    'studyFirstSubmitQcDate': '2023-09-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-09-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'MedSIR', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Daiichi Sankyo', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'TUXEDO-4 is an international, multicentric, single arm, phase II study aiming to gather\\r\\nadditional solid evidence of Trastuzumab-Deruxtecan (T-DXd) activity in patients with\\r\\nHuman Epidermal Growth Factor Receptor 2 (HER2)-low breast cancer with active brain\\r\\nmetastases.\\r\\n\\r\\nThis study will analyze the efficacy of T-DXd as determined by overall response rate\\r\\n(ORR) at any timepoint as judged by best CNS response according to RANO-BM criteria.',\n",
       "    'detailedDescription': 'This is an international, multicentric, single arm, phase II study to evaluate the safety\\r\\nand efficacy of T-DXd in HER2-low breast cancer with newly diagnosed or progressing brain\\r\\nmetastases with or without untreated type II leptomeningeal disease (LMD).\\r\\n\\r\\nUpon meeting all selection criteria, a total of 27 patients will be enrolled as follows:\\r\\n13 patients will be accrued in stage 1 to receive T-DXd and additional 14 patients will\\r\\nbe accrued in stage 2 according to the number of responses seen in stage 1.\\r\\n\\r\\nThe main objective is to analyze the efficacy of T-DXd as determined by ORR at any\\r\\ntimepoint as judged by best CNS response according to RANO-BM criteria.\\r\\n\\r\\nEnd of study is estimated to occur approximately 11 months after the last patient\\r\\nincluded in the study starts treatment, unless premature termination of the study.'},\n",
       "   'conditionsModule': {'conditions': ['Breast Cancer',\n",
       "     'Metastatic Breast Cancer'],\n",
       "    'keywords': ['breast cancer', 'HER2-low', 'brain metastases', 'T-DXd']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'interventionModelDescription': \"Single-arm, two-stage optimal Simon's design, phase II clinical trial.\",\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 27, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'T-DXd',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients will receive T-DXd at 5.4 mg/kg administered as an intravenous (IV) infusion\\r\\nevery three-weeks (Q3W) until disease progression, unacceptable toxicity, death, or\\r\\ndiscontinuation from the study.',\n",
       "      'interventionNames': ['Drug: Trastuzumab-Deruxtecan (T-DXd)']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Trastuzumab-Deruxtecan (T-DXd)',\n",
       "      'description': 'Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of\\r\\nhumanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same\\r\\namino acid sequence as trastuzumab, covalently linked to the membrane-permeable\\r\\ntopoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable\\r\\ntetrapeptide-based linker, selectively cleaved within tumor cells.',\n",
       "      'armGroupLabels': ['T-DXd'],\n",
       "      'otherNames': ['DS-8021a, ENHERTU']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'ORR at any time point as judged by best central nervous system (CNS) response in all patients.',\n",
       "      'description': 'To assess efficacy, defined as overall response rate (ORR) at any timepoint as judged by\\r\\nbest CNS response according to RANO-BM criteria.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'ORR as judged by best response for extracranial (EC) and overall lesions in all patients.',\n",
       "      'description': 'ORR for EC and overall lesions, defined as the rate of patients with complete response\\r\\n(CR) or partial response (PR), determined locally by the investigator per RECIST criteria\\r\\nv.1.1.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Bicompartmental clinical benefit rate (Bi-CBR) in all patients.',\n",
       "      'description': 'Bi-CBR defined as the sum of CR rate, PR rate and more than 24 weeks stable disease (SD)\\r\\nrate, and determined locally by the investigator through the use of RANO-BM criteria for\\r\\nintracranial (IC) lesions and RECIST v.1.1 for EC and overall lesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Bicompartmental disease control rate (Bi-DCR) in all patients.',\n",
       "      'description': 'Bi-DCR, defined as CR+PR+SD, determined locally by the investigator per RANO-BM criteria\\r\\nfor IC lesions and RECIST criteria v.1.1 for both EC and overall lesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Time to response (TTR) in all patients.',\n",
       "      'description': 'TTR, defined as the period from the treatment initiation to time of the first objective\\r\\ntumor response (tumor shrinkage of ≥ 30%) observed for patients who achieved a CR or PR,\\r\\nas per RANO-BM for intracranial lesions and RECIST v.1.1 for extracranial and overall\\r\\nlesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Duration of response (DoR) in all patients.',\n",
       "      'description': 'DoR, defined as the period from the first occurrence of a documented objective response\\r\\nto disease progression or death from any cause, observed for patients who achieved a CR\\r\\nor PR, as per RANO-BM for intracranial lesions and RECIST v.1.1 for extracranial and\\r\\noverall lesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Best percentage of change in tumor burden in all patients.',\n",
       "      'description': 'Best percentage of change in tumor burden as per RANO-BM for intracranial lesions and\\r\\nRECIST v.1.1 for extracranial and overall measurable lesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Progression-free survival (PFS) in all patients.',\n",
       "      'description': 'PFS, defined as the period from treatment initiation to the first occurrence of disease\\r\\nprogression or death from any cause, whichever occurs first. Progression will be\\r\\ndetermined locally per RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for both\\r\\nEC and overall lesions.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Overall survival (OS) in all patients.',\n",
       "      'description': 'OS, defined as the period from treatment initiation to death from any cause, determined\\r\\nlocally by the investigator.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Incidence of Adverse Events [Safety and Tolerability]',\n",
       "      'description': 'To evaluate incidence and severity of adverse events, with severity determined in\\r\\naccordance to NCI-CTCAE v.5.0',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Evaluation of the quality of life (QoL) in all patients (QLQ-c30 questionnaire).',\n",
       "      'description': 'Assessment of QoL with the European Organization for Research and Treatment of Cancer\\r\\n(EORTC) quality of life questionnaire (QLQ-c30).\\r\\n\\r\\nChanges from baseline is fitted to a repeated measures model including subjects as a\\r\\nrandom effect, baseline, and post-baseline evaluations. Time to Improvement and\\r\\nDeterioration Analysis Using a threshold value for improvement and deterioration specific\\r\\nto the measures of interest, time to improvement and time to deterioration could be\\r\\nestimated. Distributions of time-to-event variables will be estimated using the\\r\\nKaplan-Meier method. Median times to event with 2-sided 95% confidence intervals will be\\r\\nestimated.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Evaluation of the quality of life (QoL) in all patients (QLQ-BN20 questionnaire).',\n",
       "      'description': 'Assessment of QoL with the brain cancer specific questionnaire (QLQ-BN20 ). Changes from\\r\\nbaseline is fitted to a repeated measures model including subjects as a random effect,\\r\\nbaseline, and post-baseline evaluations. Time to Improvement and Deterioration Analysis\\r\\nUsing a threshold value for improvement and deterioration specific to the measures of\\r\\ninterest, time to improvement and time to deterioration could be estimated. Distributions\\r\\nof time-to-event variables will be estimated using the Kaplan-Meier method. Median times\\r\\nto event with 2-sided 95% confidence intervals will be estimated.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Evaluation of the quality of life (QoL) in all patients (QLQ-BR45 questionnaire).',\n",
       "      'description': 'Assessment of QoL with the BC specific questionnaire (QLQ-BR45). Changes from baseline is\\r\\nfitted to a repeated measures model including subjects as a random effect, baseline, and\\r\\npost-baseline evaluations. Time to Improvement and Deterioration Analysis Using a\\r\\nthreshold value for improvement and deterioration specific to the measures of interest,\\r\\ntime to improvement and time to deterioration could be estimated. Distributions of\\r\\ntime-to-event variables will be estimated using the Kaplan-Meier method. Median times to\\r\\nevent with 2-sided 95% confidence intervals will be estimated.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'},\n",
       "     {'measure': 'Evaluation of neurologic function in all patients.',\n",
       "      'description': 'To evaluate the neurologic function with clinician-reported outcome Neurologic Assessment\\r\\nin Neuro-Oncology (NANO) scale.\\r\\n\\r\\nThe NANO is an objective clinician-reported outcome of neurologic function that consists\\r\\nof 9 neurologic domains: gait, strength, ataxia (upper extremity), sensation, visual\\r\\nfields, facial strength, language, level of consciousness, and behavior.\\r\\n\\r\\nEach domain is subdivided into 3 or 4 levels of function with scores based on discrete\\r\\nquantifiable measures. Levels of function for each domain range from 0 to 2 or 0 to 3. A\\r\\nscore of 0 indicates normal function, while the highest score indicates the most severe\\r\\nlevel of deficit for that domain.',\n",
       "      'timeFrame': 'From baseline until approximately 11 months after the last patient included in the study starts treatment.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Patient must be capable to understand the purpose of the study and have signed\\r\\n     written informed consent form (ICF) prior to beginning specific protocol procedures.\\r\\n\\r\\n  2. Female or male patients ≥ 18 years of age at the time of signing ICF.\\r\\n\\r\\n  3. Radiologically documented metastatic breast cancer with locally documented HER2-low\\r\\n     status according to the 2018 ASCO/CAP guidelines.\\r\\n\\r\\n  4. Life expectancy ≥ 12 weeks.\\r\\n\\r\\n  5. Karnofsky Performance Status (KPS) ≥70%, Eastern Cooperative Oncology Group (ECOG)\\r\\n     performance status (PS) 0-2.\\r\\n\\r\\n  6. Participants with contraindications to T-DXd therapy cannot be enrolled to the\\r\\n     study.\\r\\n\\r\\n  7. Newly diagnosed or progressive BM without indication for immediate local therapy.\\r\\n\\r\\n  8. Measurable disease by Response Assessment in Neuro-Oncology Brain Metastases\\r\\n     (RANO-BM) criteria.\\r\\n\\r\\n  9. Presenting with one of the following:\\r\\n\\r\\n       -  ≥1 brain lesion, measurable (≥10 mm per local radiological assessment) or;\\r\\n\\r\\n       -  Patients may or may not have untreated type II LMD per European Association of\\r\\n          Neuro-Oncology (EANO)- European Society for Molecular Oncology (ESMO) criteria.\\r\\n\\r\\n 10. Patients must have undergone ≥1 line of systemic treatment in the advanced setting.\\r\\n\\r\\n 11. Patients have adequate treatment washout period before enrolment, defined as:\\r\\n\\r\\n       -  local therapy (major surgery and radiotherapy) or antibody treatment ≥4 weeks;\\r\\n\\r\\n       -  targeted agents, chemotherapy, small molecule, or anti-cancer hormonal therapy\\r\\n          ≥3 weeks.\\r\\n\\r\\n 12. Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by either an\\r\\n     echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before\\r\\n     enrolment.\\r\\n\\r\\n 13. Patient has adequate bone marrow, liver, renal and coagulation function:\\r\\n\\r\\n       -  Hematological: without platelet, red blood cell transfusion, and/or granulocyte\\r\\n          colony-stimulating factor support within 7 days before first study treatment\\r\\n          dose.\\r\\n\\r\\n       -  Hepatic: Serum albumin ≥ 2.5 g/dL; total bilirubin ≤ 1.5 times upper limit of\\r\\n          normal (ULN) (≤ 3 in patients with liver metastases or know history of\\r\\n          Gilbert's disease); alkaline phosphatase (ALP) ≤ 2.5 times ULN; aspartate\\r\\n          transaminase (AST) and alanine transaminase (ALT) ≤ 3 times ULN (≤ 5 in\\r\\n          patients with liver metastases); international normalized ratio (INR) < 1.5.\\r\\n\\r\\n       -  Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min/1.73 m2\\r\\n          based on Cockcroft-Gault glomerular filtration rate estimation for patients\\r\\n          with creatinine levels above institutional normal.\\r\\n\\r\\n 14. Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as\\r\\n     determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for\\r\\n     Adverse Events (CTCAE) version 5.0 (v.5.0). Participants with chronic Grade 2\\r\\n     toxicities may be eligible per the discretion of the investigator.\\r\\n\\r\\n     Note: Except for alopecia or other toxicities not considered a safety risk for the\\r\\n     patient at investigator's discretion.\\r\\n\\r\\n 15. For women of childbearing potential: agreement to remain abstinent (must refrain\\r\\n     from heterosexual intercourse) or use highly effective contraceptive methods, or two\\r\\n     effective contraceptive methods, as defined in the CSP, during the treatment period\\r\\n     and for at least 7 months after the last dose of study treatment, whichever is\\r\\n     longer. Women of childbearing potential must have a negative serum pregnancy test\\r\\n     within 14 days before study treatment initiation and must agree to refrain from\\r\\n     donating eggs during the entire study treatment period and for 7 months after the\\r\\n     last administration of the study drug.\\r\\n\\r\\n 16. Being male subjects, surgically sterile or having agreed with true abstinence (must\\r\\n     refrain from heterosexual intercourse), or whose female partners are willing to\\r\\n     agree with true abstinence or use barrier contraceptive measures mentioned above\\r\\n     during the entire study treatment period and for 4 months after the last\\r\\n     administration of the study drug. Males must agree to refrain from donating sperm\\r\\n     during the entire study treatment period and for 4 months after the last\\r\\n     administration of the study drug.\\r\\n\\r\\n 17. Patients must be able to tolerate therapy.\\r\\n\\r\\n 18. Patients must be accessible for treatment and follow-up.\\r\\n\\r\\nExclusion criteria:\\r\\n\\r\\n  1. Current participation in another therapeutic clinical trial.\\r\\n\\r\\n  2. Treatment with approved or investigational cancer therapy such as antibody treatment\\r\\n     within 4 weeks prior to initiation of study drug; or targeted agents, chemotherapy,\\r\\n     small molecule, or anti-cancer hormonal therapy within 3 weeks prior to initiation\\r\\n     of study drug.\\r\\n\\r\\n  3. Patients have a concurrent malignancy or malignancy within five years of study\\r\\n     enrolment with the exception of carcinoma in situ of the cervix, non-melanoma skin\\r\\n     carcinoma, stage I uterine cancer or contralateral breast cancer within the last 3\\r\\n     years. For other cancers considered to have a low risk of recurrence, discussion\\r\\n     with the Medical Monitor is required.\\r\\n\\r\\n  4. Prior treatment with T-DXd.\\r\\n\\r\\n  5. Known allergy or hypersensitivity to T-DXd or any of the drug components.\\r\\n\\r\\n  6. Medical history of myocardial infarction (MI) within 6 months before enrolment,\\r\\n     symptomatic congestive heart failure (New York Heart Association Class II to IV).\\r\\n\\r\\n  7. LVEF < 50% as determined by echocardiogram (ECHO) or multi-gated acquisition (MUGA)\\r\\n     scan within 28 days prior to treatment.\\r\\n\\r\\n  8. Long corrected QTcF interval prolongation to > 470 ms based on average of screening\\r\\n     triplicate 12-lead electrocardiogram (ECG).\\r\\n\\r\\n  9. History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that\\r\\n     required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis\\r\\n     cannot be ruled out by imaging at screening.\\r\\n\\r\\n 10. Lung criteria:\\r\\n\\r\\n       1. Lung-specific intercurrent clinically significant illnesses including, but not\\r\\n          limited to, any underlying pulmonary disorder (eg, pulmonary emboli within 3\\r\\n          months of study enrolment, severe asthma, severe COPD, restrictive lung\\r\\n          disease, pleural effusion etc).\\r\\n\\r\\n       2. Any autoimmune, connective tissue or inflammatory disorders (ie, rheumatoid\\r\\n          arthritis, Sjogren's, sarcoidosis, etc.) where there is documented, or a\\r\\n          suspicion of pulmonary involvement at the time of screening. Full details of\\r\\n          the disorder should be recorded in the eCRF for participants who are included\\r\\n          in the study.\\r\\n\\r\\n       3. Prior pneumonectomy.\\r\\n\\r\\n 11. Any autoimmune, connective tissue or inflammatory disorders (e.g., Rheumatoid\\r\\n     arthritis, Sjögren's, sarcoidosis etc.) where there is documented, or a suspicion of\\r\\n     pulmonary involvement at the time of screening.\\r\\n\\r\\n 12. Pregnant or lactating women.\\r\\n\\r\\n 13. Any serious medical condition or abnormality in clinical laboratory tests that, in\\r\\n     the investigator's judgment, precludes the patient's safe participation in and\\r\\n     completion of the study.\\r\\n\\r\\n 14. Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV).\\r\\n     Patients with past HBV infection or resolved HBV infection (defined as having a\\r\\n     negative hepatitis B surface antibody [HBsAg] test and a positive hepatitis B core\\r\\n     antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible.\\r\\n     Patients positive for HCV antibody are eligible only if polymerase chain reaction\\r\\n     (PCR) is negative for HCV RNA.\\r\\n\\r\\n 15. Known human immunodeficiency virus (HIV) infection that is not well controlled. All\\r\\n     of the following criteria are required to define an HIV infection that is well\\r\\n     controlled: undetectable viral RNA, CD4+ count ≥ 350, no history of AIDS-defining\\r\\n     opportunistic infection within the past 12 months, and stable for at least 4 weeks\\r\\n     on the same anti-HIV medications (meaning there are no expected further changes in\\r\\n     that time to the number or type of antiretroviral drugs in the regimen). If an HIV\\r\\n     infection meets the above criteria, monitoring of viral RNA load and CD4+ count is\\r\\n     recommended.\\r\\n\\r\\n 16. History of a major surgical procedure (defined as requiring general anesthesia) or\\r\\n     significant traumatic injury within 21 days prior to enrolment, or patients who have\\r\\n     not recovered from the side effects of any major surgery.\\r\\n\\r\\n 17. A history of uncontrolled seizures, central nervous system (CNS) disorders or\\r\\n     serious and/or unstable pre-existing psychiatric disability judged by the\\r\\n     investigator to be clinically significant and adversely affecting compliance to\\r\\n     study drugs or interfering with subject safety.\\r\\n\\r\\n 18. Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral)\\r\\n     corticosteroids or other immunosuppressive medications except for managing adverse\\r\\n     events (inhaled steroids or intra articular steroid injections are permitted in this\\r\\n     study). Corticosteroids (dexamethasone at 4 mg or equivalent doses) are allowed only\\r\\n     for the treatment of bone metastases and for the treatment of specific adverse drug\\r\\n     reactions. The use of stable corticosteroid therapy in patients with BM can be\\r\\n     discussed with the Medical Monitor.\\r\\n\\r\\n     Note: Hematopoietic growth factors may be used for prophylaxis or treatment based on\\r\\n     the clinical judgment of the investigator. Concomitant use of dietary supplements,\\r\\n     medications not prescribed by the Investigator, and alternative/complementary\\r\\n     treatments is discouraged, but not prohibited. Prophylactic or supportive treatment\\r\\n     of study-drug induced adverse events will be otherwise as per investigator's\\r\\n     discretion and institutional guidelines.\\r\\n\\r\\n 19. Patients with known substance abuse or any other medical conditions such as\\r\\n     clinically significant cardiac or psychological conditions, that may, in the opinion\\r\\n     of the investigator, interfere with the subject's participation in the clinical\\r\\n     study or evaluation of the clinical study results.\\r\\n\\r\\n 20. Use of concurrent investigational agents, endocrine treatments, or other concomitant\\r\\n     anti-cancer therapies.\\r\\n\\r\\n 21. Participants who are unable or unwilling to comply with the requirements of the\\r\\n     protocol in the opinion of the investigator.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Marta Campolier',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+ 34 623 333 647',\n",
       "      'email': 'marta.campolier@medsir.org'},\n",
       "     {'name': 'Susana Vitorino',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+ 34 932 214 135',\n",
       "      'email': 'trialsregister.medsir@medsir.org'}],\n",
       "    'overallOfficials': [{'name': 'Maximilian Marhold, MD, PhD, PD',\n",
       "      'affiliation': 'Medical University of Vienna, Vienna General Hospital, Vienna, Austria',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Matthias Preusser, MD, Prof',\n",
       "      'affiliation': 'Medical University of Vienna, Vienna General Hospital, Vienna, Austria',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001943',\n",
       "      'term': 'Breast Neoplasms'},\n",
       "     {'id': 'D000009362', 'term': 'Neoplasm Metastasis'},\n",
       "     {'id': 'D000001932', 'term': 'Brain Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001941', 'term': 'Breast Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000009385', 'term': 'Neoplastic Processes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000016543', 'term': 'Central Nervous System Neoplasms'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5220',\n",
       "      'name': 'Breast Neoplasms',\n",
       "      'asFound': 'Breast Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12307',\n",
       "      'name': 'Neoplasm Metastasis',\n",
       "      'asFound': 'Metastases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5209',\n",
       "      'name': 'Brain Neoplasms',\n",
       "      'asFound': 'Brain Metastases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5218', 'name': 'Breast Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'},\n",
       "     {'id': 'M18937',\n",
       "      'name': 'Central Nervous System Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000068878',\n",
       "      'term': 'Trastuzumab'},\n",
       "     {'id': 'C000614160', 'term': 'Trastuzumab deruxtecan'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000018796', 'term': 'Immunoconjugates'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'relevance': 'LOW'},\n",
       "     {'id': 'M325',\n",
       "      'name': 'Trastuzumab',\n",
       "      'asFound': 'Medication',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M233243',\n",
       "      'name': 'Trastuzumab deruxtecan',\n",
       "      'asFound': 'Aspirate',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M10122', 'name': 'Immunoglobulin G', 'relevance': 'LOW'},\n",
       "     {'id': 'M19117',\n",
       "      'name': 'Immunoglobulins, Intravenous',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M29349',\n",
       "      'name': 'Topoisomerase I Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M259982', 'name': 'Exatecan', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20855', 'name': 'Immunoconjugates', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06429618',\n",
       "    'orgStudyIdInfo': {'id': '01/07 22.01.2024'},\n",
       "    'organization': {'fullName': \"Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital\",\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Adolescent Polycystic Ovary Syndrome on a Low-carbohydrate Diet',\n",
       "    'officialTitle': 'Effect of a Low-carbohydrate Diet on Outcomes According to Phenotype in Juvenile Polycystic Ovary Syndrome',\n",
       "    'acronym': 'PCOS'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-18',\n",
       "    'studyFirstSubmitQcDate': '2024-05-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Mujde Can Ibanoglu',\n",
       "     'investigatorTitle': 'Assoc. Prof',\n",
       "     'investigatorAffiliation': \"Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital\"},\n",
       "    'leadSponsor': {'name': \"Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital\",\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of the study was to investigate the changes in the clinical and biochemical\\r\\nparameters of adolescents on a low-carbohydrate diet in relation to their PCOS phenotype\\r\\nin the 3rd trimester.',\n",
       "    'detailedDescription': 'Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by\\r\\nmenstrual irregularities, anovulation, clinical and/or biochemical symptoms of\\r\\nhyperandrogenism (hirsutism and/or acne), micropolycystic ovaries, and metabolic\\r\\nabnormalities. In addition, some clinical and laboratory phenotypic features have been\\r\\ndefined that were not previously included in the PCOS definition criteria, but which\\r\\ncomplement the clinical picture and influence the severity and morbidity of the clinical\\r\\npicture. Phenotype A: HA + OD + PCOM; phenotype B: HA + OD; phenotype C: HA + PCOM and\\r\\nphenotype D: OD + PCOM.For adult patients, internationally recognized diagnostic criteria\\r\\nhave been developed based on combinations of otherwise unexplained hyperandrogenism,\\r\\nanovulation and polycystic ovary and are covered by the Rotterdam Consensus Criteria.\\r\\nHowever, in the adolescent age group, the frequency of anovulatory cycles and associated\\r\\nmenstrual irregularities, the frequent symptoms of hyperandrogenism and acne vulgaris in\\r\\nthe developmental phase, the problems with testosterone measurement and the prevalence of\\r\\npolycystic ovarian morphology in normal adolescents complicate the diagnosis.\\r\\n\\r\\nPCOS is a serious clinical and psychological problem for adolescent girls. Key\\r\\ninterventions include lifestyle modification, including diet, physical activity and\\r\\nweight loss. These measures have been shown to alter the course of the disease in\\r\\noverweight and obese girls. In particular, it is known that high glycemic index\\r\\ncarbohydrate intake and glycemic load lead to a rapid rise in blood glucose levels and\\r\\nincreased insulin production.\\r\\n\\r\\nIt is therefore thought that reducing the amount of insulin could have a more positive\\r\\neffect on PCOS than the usual carbohydrates. A low-carbohydrate diet is an effective,\\r\\nweight-independent approach in the treatment of metabolic disorders in PCOS patients.\\r\\nWith this in mind, this study aimed to evaluate the clinical and biochemical outcomes at\\r\\nmonth 3 after application of the low-carbohydrate diet in adolescents according to their\\r\\nPCOS phenotype.'},\n",
       "   'conditionsModule': {'conditions': ['Polycystic Ovary Syndrome',\n",
       "     'Adolescent Behavior',\n",
       "     'Diet Habit'],\n",
       "    'keywords': ['phenotype',\n",
       "     'polycystic ovary syndrome',\n",
       "     'adolescents',\n",
       "     'low carbonhydrate diet']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '3 Months',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Phenotype A',\n",
       "      'description': 'PHENOTYPE A: Hyperandrogenism + Ovulatory Dysfunction + PCOM',\n",
       "      'interventionNames': ['Dietary Supplement: Low carbonhydrate diet']},\n",
       "     {'label': 'Phenotype B',\n",
       "      'description': 'PHENOTYPE B: HA+OD',\n",
       "      'interventionNames': ['Dietary Supplement: Low carbonhydrate diet']},\n",
       "     {'label': 'Phenotype C',\n",
       "      'description': 'PHENOTYPE C: HA+PCOM',\n",
       "      'interventionNames': ['Dietary Supplement: Low carbonhydrate diet']},\n",
       "     {'label': 'Phenotype D',\n",
       "      'description': 'PHENOTYPE D: OD+PCOM',\n",
       "      'interventionNames': ['Dietary Supplement: Low carbonhydrate diet']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Low carbonhydrate diet',\n",
       "      'description': 'Each patient will receive a 3-month low-carbohydrate (40% CHO) diet from the same\\r\\ndietitian. Whether the patients adhere to the diet and which components the prescribed\\r\\ndiet consists of is recorded in detail. After 3 months of standard application, the\\r\\npatient is examined again by the gynecologist and obstetrician at the PCOS clinic.',\n",
       "      'armGroupLabels': ['Phenotype A',\n",
       "       'Phenotype B',\n",
       "       'Phenotype C',\n",
       "       'Phenotype D'],\n",
       "      'otherNames': ['0.', '3.month']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Evaluation of clinical outcomes at month 3 after application of a low-carbohydrate diet according to PCOS phenotypes in adolescents.',\n",
       "      'description': 'Age, smoking, physical activity status, weight, height, body mass index (weight\\r\\n(kilogram)/height*2 (meter2)), waist circumference(centimeters), degree of hirsutism\\r\\n(Ferriman-Gallwey Hirsutism Scoring Scale; lowest 8 highest: 24) were obtained from\\r\\nhospital records. Calculation of BMI: Height and body weight of the patients were\\r\\nmeasured using professionally calibrated devices. BMI was calculated using the formula\\r\\nBMI = weight (kg)/height (m)2.',\n",
       "      'timeFrame': '3 months'},\n",
       "     {'measure': 'Evaluation of biochemical outcomes at month 3 after application of a low-carbohydrate diet according to PCOS phenotypes in adolescents.',\n",
       "      'description': 'Collection of serum samples: C-reactive protein (CRP) (mg/dL), complete blood analysis,\\r\\nsex hormone-binding globulin (SHBG), free and total testosterone (ng/mL), 17-OH\\r\\nprogesterone (mIU/mL), prolactin (ng/mL), thyroid stimulating hormone (TSH) (mIU/mL),\\r\\nandrostenedione (mosm/kg), dehydroepiandrosterone sulfate (DHEA-S) (μg/dL), Total\\r\\ncholesterol (mg/dL), high-density lipoprotein (HDL) cholesterol (mg/dL), low-density\\r\\nlipoprotein (LDL) cholesterol (mg/dL), triglycerides (mg/dL), fasting blood glucose, 50 g\\r\\nscreening test values were analyzed in the biochemistry laboratory. Serum levels of\\r\\nDHEA-S, 17-OH-progesterone and testosterone were measured using the radiometric method.\\r\\nThe blood count was measured using the Sysmex/XN-1000 (2016) blood analyzer. Serum levels\\r\\nof DHEA-S, 17-OH-progesterone and free testosterone were measured using a radiomonassay.\\r\\nSerum lipid and glucose levels were analyzed using the AU680 Chemistry System (Beckman\\r\\nCoulter, Fullerton, CA, USA).',\n",
       "      'timeFrame': '3 months'},\n",
       "     {'measure': 'Evaluation of insulin resistance at month 3 after application of a low-carbohydrate diet according to PCOS phenotypes in adolescents.',\n",
       "      'description': \"Calculation of insulin resistance: A fasting blood glucose level between 100-125 mg/dl\\r\\nwas considered as 'impaired fasting glucose'. A Homeostatic Model Assessment Insulin\\r\\nResistance (HOMA-IR) value of ≥2.5 was defined as insulin resistance. Insulin resistance\\r\\nwas calculated using the formula of the homeostatic model. [HOMA-IR= fasting glucose\\r\\n(mg/dl)xfasting insulin (mIU/mL)/405].\",\n",
       "      'timeFrame': '3 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  at least 1 year has passed since menarche\\r\\n\\r\\n  -  under 24 years old\\r\\n\\r\\n  -  patients who have not received an oral contraceptive method and have given verbal\\r\\n     and written informed consent will be included.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  over 24 years old\\r\\n\\r\\n  -  hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, thyroid\\r\\n     diseases\\r\\n\\r\\n  -  neuromuscular, liver, pancreatic or gastrointestinal diseases\\r\\n\\r\\n  -  hormonal medication such as antiandrogens, antidiabetics, glucocorticoids, insulin\\r\\n     sensitizers or lipid regulators\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '12 Years',\n",
       "    'maximumAge': '24 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT'],\n",
       "    'studyPopulation': 'The study will be conducted based on the 2018 ESHRE/ASRM guideline:\\r\\n\\r\\n  1. Oligo and/or anovulation*\\r\\n\\r\\n  2. Clinical and/or biochemical hyperandrogenism *Oligo and/or anovulation are defined\\r\\n     as follows:\\r\\n\\r\\n       -  It is considered normal in the first year after menarche as part of the\\r\\n          pubertal transition\\r\\n\\r\\n       -  Between 1-3 years after menarche: < 21 or > 45 days\\r\\n\\r\\n       -  3 years after menarche - perimenopause: < 21 or > 35 days or < 8 cycles per\\r\\n          year\\r\\n\\r\\n       -  1 year after menarche: >90 days for each menstrual cycle\\r\\n\\r\\n       -  Absence of menstruation at the age of 15 years or 3 years after menarche.\\r\\n\\r\\nIdentification of phenotype groups:\\r\\n\\r\\nPHENOTYPE A: HA+ OD + PCOM PHENOTYPE B: HA+OD PHENOTYPE C: HA+PCOM PHENOTYPE D: OD+PCOM.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mujde Can Ibanoglu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '05323089488',\n",
       "      'email': 'Drmujdecan@gmail.com'},\n",
       "     {'name': 'Yaprak Engin-Ustun',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'ustunyaprak@yahoo.com'}],\n",
       "    'overallOfficials': [{'name': 'Mujde Can Ibanoglu',\n",
       "      'affiliation': \"Ankara Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, Turkey.\",\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '36096151',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Joham AE, Pena AS. Polycystic Ovary Syndrome in Adolescence. Semin Reprod Med. 2022 Mar;40(1-02):e1-e8. doi: 10.1055/s-0042-1757138. Epub 2022 Sep 12.'},\n",
       "     {'pmid': '27664216',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016 Dec;31(12):2841-2855. doi: 10.1093/humrep/dew218. Epub 2016 Sep 22.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011085',\n",
       "      'term': 'Polycystic Ovary Syndrome'},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000010048', 'term': 'Ovarian Cysts'},\n",
       "     {'id': 'D000003560', 'term': 'Cysts'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000010049', 'term': 'Ovarian Diseases'},\n",
       "     {'id': 'D000000291', 'term': 'Adnexal Diseases'},\n",
       "     {'id': 'D000005831', 'term': 'Genital Diseases, Female'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "     {'id': 'D000006058', 'term': 'Gonadal Disorders'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13970',\n",
       "      'name': 'Polycystic Ovary Syndrome',\n",
       "      'asFound': 'Polycystic Ovary Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6765', 'name': 'Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M12971', 'name': 'Ovarian Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M12972', 'name': 'Ovarian Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M3643', 'name': 'Adnexal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9163', 'name': 'Gonadal Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06391099',\n",
       "    'orgStudyIdInfo': {'id': 'OSU-21335'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-01894',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'}],\n",
       "    'organization': {'fullName': 'Ohio State University Comprehensive Cancer Center',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer',\n",
       "    'officialTitle': 'Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to Immunotherapy'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-25',\n",
       "    'studyFirstSubmitQcDate': '2024-04-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-25',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Marium Husain',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Ohio State University Comprehensive Cancer Center'},\n",
       "    'leadSponsor': {'name': 'Ohio State University Comprehensive Cancer Center',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase I trial studies how well a ketogenic dietary intervention works to improve\\r\\nresponse to immunotherapy in patients with melanoma and kidney cancer that has spread\\r\\nfrom where it first started (primary site) to other places in the body (metastatic). A\\r\\nketogenic diet (KD) means eating fewer carbohydrates and more fats. The purpose is to use\\r\\nketones (normal breakdown from fat) instead of glucose (sugar) as an energy source.\\r\\nResearchers want to see whether a ketogenic diet can improve tumor response in patients\\r\\nreceiving immune checkpoint inhibitors (ICI). ICI are newer treatment options that help\\r\\nthe immune system better fight some cancers. Following a KD may improve tumor response in\\r\\npatients with metastatic melanoma and metastatic kidney cancer treated with ICI.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To evaluate the safety and feasibility of establishing a ketogenic dietary\\r\\nintervention trial with longitudinal biospecimen collection in the Ohio State University\\r\\nComprehensive Cancer Center (OSUCCC) cutaneous and genitourinary oncology clinics.\\r\\n\\r\\nEXPLORATORY OBJECTIVE:\\r\\n\\r\\nI. To assess whether the microbiome (binary, high versus [vs] low diversity) mediates the\\r\\nrelationship between time in ketosis (days with peripheral blood beta-hydroxybutyric acid\\r\\n[BHB] > 0.5 mM) and tumor size over the course of treatment.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM I: Patients undergo a ketogenic dietary intervention with personalized coaching from\\r\\na dietician about the KD, which includes extensive educational and ongoing support on the\\r\\nKD and continuous ketone monitoring by talking to a dietician directly, with the ability\\r\\nto text a dietician at any time and expect a response within 12 hours over 24weeks.\\r\\nPatients also undergo daily blood glucose and ketone monitoring, undergo computed\\r\\ntomography (CT), undergo blood sample collection and may undergo stool sample collection\\r\\non the study.\\r\\n\\r\\nARM II: Patients follow a standard of care diet on the study.'},\n",
       "   'conditionsModule': {'conditions': ['Clinical Stage IV Cutaneous Melanoma AJCC v8',\n",
       "     'Metastatic Cutaneous Melanoma',\n",
       "     'Metastatic Renal Cell Carcinoma',\n",
       "     'Stage IV Renal Cell Cancer AJCC v8']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Arm I (Ketogenic diet)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients undergo a ketogenic dietary intervention with personalized coaching from a\\r\\ndietician about the KD, which includes extensive educational and ongoing support on the\\r\\nKD and continuous ketone monitoring by talking to a dietician directly, with the ability\\r\\nto text a dietician at any time and expect a response within 12 hours over 24weeks.\\r\\nPatients also undergo daily blood glucose and ketone monitoring, undergo CT, undergo\\r\\nblood sample collection and may undergo stool sample collection on the study.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Other: Dietary Intervention',\n",
       "       'Other: Educational Activity',\n",
       "       'Other: Glucose Measurement',\n",
       "       'Other: Ketone Measurement',\n",
       "       'Other: Questionnaire Administration']},\n",
       "     {'label': 'Arm II (usual caare)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients follow a standard of care diet on the study.',\n",
       "      'interventionNames': ['Other: Best Practice']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Best Practice',\n",
       "      'description': 'Undergo standard of care diet',\n",
       "      'armGroupLabels': ['Arm II (usual caare)'],\n",
       "      'otherNames': ['standard of care', 'standard therapy']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo blood and stool sample collection',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Computed Tomography',\n",
       "      'description': 'Under CT',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)'],\n",
       "      'otherNames': ['CAT',\n",
       "       'CAT Scan',\n",
       "       'Computed Axial Tomography',\n",
       "       'Computerized Axial Tomography',\n",
       "       'Computerized axial tomography (procedure)',\n",
       "       'Computerized Tomography',\n",
       "       'Computerized Tomography (CT) scan',\n",
       "       'CT',\n",
       "       'CT Scan',\n",
       "       'tomography']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Dietary Intervention',\n",
       "      'description': 'Undergo ketogenic diet',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)'],\n",
       "      'otherNames': ['Dietary Modification',\n",
       "       'intervention, dietary',\n",
       "       'Nutrition Intervention',\n",
       "       'Nutrition Interventions',\n",
       "       'Nutritional Interventions']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Educational Activity',\n",
       "      'description': 'Receive coaching support',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Glucose Measurement',\n",
       "      'description': 'Undergo blood glucose testing',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)'],\n",
       "      'otherNames': ['GLUC', 'Glucose']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Ketone Measurement',\n",
       "      'description': 'Undergo ketone measurement',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)'],\n",
       "      'otherNames': ['Ketones']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Questionnaire Administration',\n",
       "      'description': 'Ancillary studies',\n",
       "      'armGroupLabels': ['Arm I (Ketogenic diet)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of adverse events',\n",
       "      'description': 'Will be assessed by immune-related adverse events (irAEs), serious adverse events (SAEs),\\r\\nTreatment Emergent Adverse Events (TEAEs), clinical laboratory, vital signs, physical\\r\\nexaminations. Will be monitored during study visits and telephone calls using the\\r\\nNational Cancer Institute Common Terminology Criteria for Adverse Events version 5.0,\\r\\nwhich also includes irAEs. Grade 3, 4 and 5 toxicities will be reported as adverse\\r\\nevents.',\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': 'Adherence (feasibility measure)',\n",
       "      'description': 'Adherence will be defined as > 80% of days in ketosis and compliant as collecting all gut\\r\\nmicrobiome specimens. Diet adherence and progress will be assessed daily using at-home\\r\\nwhole capillary blood glucose and continuous ketone monitoring devices',\n",
       "      'timeFrame': 'Up to 1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Males and females, age >= 18 years\\r\\n\\r\\n  -  Clinical site A will include patients with confirmed diagnosis of metastatic\\r\\n     melanoma (including those with brain metastases) receiving first line treatment with\\r\\n     combination nivolumab and ipilimumab or single agent ipilimumab, nivolumab,\\r\\n     pembrolizumab\\r\\n\\r\\n  -  Clinical site B will include patients with confirmed diagnosis of metastatic renal\\r\\n     cell carcinoma (RCC) (including those with brain metastases) receiving first line\\r\\n     treatment with combination nivolumab and ipilimumab or single agent PD-1 inhibitor\\r\\n     (e.g., nivolumab, pembrolizumab)\\r\\n\\r\\n  -  Scheduled for imaging every 6 to 12 weeks for metastatic melanoma (MM) and mRCC as\\r\\n     is standard of care per National Comprehensive Cancer Network (NCCN) guidelines\\r\\n\\r\\n  -  Able to read, understand, and provide written informed consent\\r\\n\\r\\n  -  Willing to provide stool specimen for research studies as outlined in the timeline\\r\\n\\r\\n  -  Willing to participate in a ketogenic diet (KD)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Individuals < 18 years of age\\r\\n\\r\\n  -  Unable or unwilling to provide consent\\r\\n\\r\\n  -  Patients with type 1 diabetes mellitus or type 2 diabetes using insulin\\r\\n\\r\\n  -  Patients who are clinically underweight (body mass index [BMI] < 18.5) at the start\\r\\n     of treatment\\r\\n\\r\\n  -  Other active malignancy (other than adequately treated and cured basal or squamous\\r\\n     cell skin cancer, curatively treated in situ disease, or any other cancer from which\\r\\n     the patient has been disease free >=5 years)\\r\\n\\r\\n  -  Currently consuming a low-carbohydrate (< 130 g/day) or ketogenic diet or done so in\\r\\n     the last 6-months\\r\\n\\r\\n  -  Women who are known to be pregnant are excluded. However no additional pregnancy\\r\\n     testing out of what would be recommended prior to initiating anti-cancer therapy\\r\\n     will be performed solely for this study\\r\\n\\r\\n  -  Patients currently participating in an interventional or therapeutic clinical trial\\r\\n     involving the use of active anti-cancer therapy',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'The Ohio State Comprehensive Cancer Center',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '800-293-5066',\n",
       "      'email': 'OSUCCCClinicaltrials@osumc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Marium Husain, MD, MPH',\n",
       "      'affiliation': 'Ohio State University Comprehensive Cancer Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Ohio State University Comprehensive Cancer Center',\n",
       "      'city': 'Columbus',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '43210',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Marium Husain, MD, MPH',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '614-366-6567',\n",
       "        'email': 'Marium.Husain@osumc.edu'},\n",
       "       {'name': 'Marium Husain, MD, MPH', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'The Jamesline',\n",
       "      'url': 'http://cancer.osu.edu'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008545',\n",
       "      'term': 'Melanoma'},\n",
       "     {'id': 'D000002292', 'term': 'Carcinoma, Renal Cell'},\n",
       "     {'id': 'D000096142', 'term': 'Melanoma, Cutaneous Malignant'},\n",
       "     {'id': 'D000012878', 'term': 'Skin Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000018358', 'term': 'Neuroendocrine Tumors'},\n",
       "     {'id': 'D000017599', 'term': 'Neuroectodermal Tumors'},\n",
       "     {'id': 'D000009373', 'term': 'Neoplasms, Germ Cell and Embryonal'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000009380', 'term': 'Neoplasms, Nerve Tissue'},\n",
       "     {'id': 'D000018326', 'term': 'Nevi and Melanomas'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000007680', 'term': 'Kidney Neoplasms'},\n",
       "     {'id': 'D000014571', 'term': 'Urologic Neoplasms'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000007674', 'term': 'Kidney Diseases'},\n",
       "     {'id': 'D000014570', 'term': 'Urologic Diseases'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M11528',\n",
       "      'name': 'Melanoma',\n",
       "      'asFound': 'Melanoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5548',\n",
       "      'name': 'Carcinoma, Renal Cell',\n",
       "      'asFound': 'Renal Cell Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3212',\n",
       "      'name': 'Melanoma, Cutaneous Malignant',\n",
       "      'asFound': 'Cutaneous Melanoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10703', 'name': 'Kidney Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M15681',\n",
       "      'name': 'Skin Neoplasms',\n",
       "      'asFound': 'Cutaneous Melanoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20495', 'name': 'Neuroendocrine Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20388',\n",
       "      'name': 'Neuroectodermal Tumors, Primitive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12318',\n",
       "      'name': 'Neoplasms, Germ Cell and Embryonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'},\n",
       "     {'id': 'M12448', 'name': 'Nevus, Pigmented', 'relevance': 'LOW'},\n",
       "     {'id': 'M12446', 'name': 'Nevus', 'relevance': 'LOW'},\n",
       "     {'id': 'M20470', 'name': 'Nevi and Melanomas', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M17320', 'name': 'Urologic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10698', 'name': 'Kidney Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T4906',\n",
       "      'name': 'Renal Cell Carcinoma',\n",
       "      'asFound': 'Renal Cell Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1341',\n",
       "      'name': 'Clear Cell Renal Cell Carcinoma',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4091', 'name': 'Neuroendocrine Tumor', 'relevance': 'LOW'},\n",
       "     {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M2853',\n",
       "      'name': 'Immunomodulating Agents',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06352541',\n",
       "    'orgStudyIdInfo': {'id': 'SOPH232-1122/I'},\n",
       "    'organization': {'fullName': 'Laboratorios Sophia S.A de C.V.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.',\n",
       "    'officialTitle': 'Phase I Clinical Study, Evaluating Safety and Tolerability of PRO-232 an Ophthalmic Solution, Versus Placebo, When Applied to the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers.',\n",
       "    'acronym': 'PRO-232'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-02',\n",
       "    'studyFirstSubmitQcDate': '2024-04-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-11', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Laboratorios Sophia S.A de C.V.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a phase I study evaluating safety and tolerability through the incidence of\\r\\nunexpected adverse events and IOP measurement, as well as through the incidence of\\r\\nstinging after its administration, compared to placebo.',\n",
       "    'detailedDescription': 'The variables to be evaluated include:\\r\\n\\r\\nPrimary (safety):\\r\\n\\r\\n  -  Unexpected adverse events\\r\\n\\r\\n  -  IOP\\r\\n\\r\\nPrimary (tolerability):\\r\\n\\r\\n  -  Stinging\\r\\n\\r\\nSecondary (safety):\\r\\n\\r\\n  -  Expected and related adverse events\\r\\n\\r\\n  -  BCVA\\r\\n\\r\\n  -  Ocular surface stining\\r\\n\\r\\nSecondary (tolerability):\\r\\n\\r\\n  -  Other ocular symptoms (foreign body sensation and tearing)\\r\\n\\r\\nThe operational definition states a difference under 15% in order to consider non\\r\\ninferior the safety and tolerability profile of PRO-232 compared to placebo.'},\n",
       "   'conditionsModule': {'conditions': ['Healthy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Phase I, controlled, comparative, parallel groups, double blind, one center.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'maskingDescription': 'Double blind.',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 34, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'PRO-232',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  PRO-232. Moxifloxacin 0.5% y Dexamethasone Phosphate 0.1% Ophthalmic solution.\\r\\n\\r\\n  -  Dosage: 1 drop QID [4] (four times per day) for 7 days on right eye.',\n",
       "      'interventionNames': ['Drug: PRO-232']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': '  -  Placebo. Sodium Chloride.\\r\\n\\r\\n  -  Dosage: 1 drop QID [4] (four times per day) for 7 days on right eye.',\n",
       "      'interventionNames': ['Other: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'PRO-232',\n",
       "      'description': 'Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%',\n",
       "      'armGroupLabels': ['PRO-232']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Sodium Chloride 0.9%',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence Unexpected Related Adverse Reactions',\n",
       "      'description': 'Any unfavorable medical condition affecting the subject after the administration of the\\r\\ninvestigation product, related to such intervention.',\n",
       "      'timeFrame': 'Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)'},\n",
       "     {'measure': 'Changes in intraocular pressure (IOP)',\n",
       "      'description': 'Previous instillation of topical anesthetic, the IOP (right eye) will be measured through\\r\\na Goldmann tonometer during visits',\n",
       "      'timeFrame': 'Days 0 (Basal Visit) 3 (Visit 1), 8 (Final Visit)'},\n",
       "     {'measure': 'Incidence of Stinging',\n",
       "      'description': \"The subjects will be questioned regarding this symptom's incidence (right eye),\\r\\nfrecuency, duration and severity will not be considered, only its incidence will.\",\n",
       "      'timeFrame': 'Days 0 (Basal Visit, 3 (Visit 1) and 8 (Final Visit)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of Expected Related Adverse Events',\n",
       "      'description': 'Incidence of expexted related adverse events according to those previously described in\\r\\nbibliography: itching, blurry vision, eyelid pain, conjunctival hyperemia, ocular\\r\\nhypertension.',\n",
       "      'timeFrame': 'Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call)'},\n",
       "     {'measure': 'Changes in Best Corrected Visual Acuity (BCVA)',\n",
       "      'description': 'BCVA will be evaluated through Snellen chart',\n",
       "      'timeFrame': 'Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)'},\n",
       "     {'measure': 'Changes in the integrity of the ocular surface (fluorescein staining)',\n",
       "      'description': 'Changes in the integrity of the ocular surface using fluorescein staining and evaluated\\r\\nthrough the Oxford scale. The standard Oxford scale for fluorescein staining has the\\r\\nfollowing criteria: Grade 0- Equal to or less than panel A; Grade I- Equal to or less\\r\\nthan panel B, greater than panel A; Grade II- Equal to or less than panel C, greater than\\r\\npanel B; Grade III- Equal or less than panel D, greater than panel C; Grade IV- Equal or\\r\\nless than panel E, greater than panel D; Grade V- Greater than panel E.',\n",
       "      'timeFrame': 'Days 0 (Basal Visit), Days 3 (Visit 1) and 8 (Final Visit)'},\n",
       "     {'measure': 'Incidence of ocular symptoms (foreign body sensation and tearing)',\n",
       "      'description': \"The subjects will be questioned regarding this symptoms' incidence.\",\n",
       "      'timeFrame': 'Days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Having the ability to voluntarily give their signed informed consent.\\r\\n\\r\\n  -  Ophthalmologically and clinically healthy subjects.\\r\\n\\r\\n  -  Being able to and willing to comply with scheduled visits, treatment plan, and other\\r\\n     study procedures.\\r\\n\\r\\n  -  Age between 18 to 45 years.\\r\\n\\r\\n  -  Male or female gender.\\r\\n\\r\\n  -  Women of childbearing potential who have not undergone Bilateral Tubal Occlusion\\r\\n     (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure\\r\\n     continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF])\\r\\n     of the use of a hormonal contraceptive method or intrauterine device (IUD) during\\r\\n     the study period.\\r\\n\\r\\n  -  Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.\\r\\n\\r\\n  -  Corneal staining ≤ grade I on the Oxford Scale.\\r\\n\\r\\n  -  Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  History of hypersensitivity to fluoroquinolones, steroid anti-inflammatories, or any\\r\\n     of the components of the drugs under investigation.\\r\\n\\r\\n  -  Use of ophthalmic medications from any pharmacological group.\\r\\n\\r\\n  -  Use of medications by any other route of administration.\\r\\n\\r\\n  -  Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or\\r\\n     antibiotics by any route of administration in the last 30 days.\\r\\n\\r\\n  -  History of eye surgery in the last 6 months.\\r\\n\\r\\n  -  Use of contact lenses for a period less than two weeks prior to the start of the\\r\\n     study, and during the intervention period of this study.\\r\\n\\r\\n  -  In the case of women: being pregnant, breastfeeding, or planning to become pregnant\\r\\n     within the study period.\\r\\n\\r\\n  -  Having participated in any clinical research study 30 days prior to inclusion in\\r\\n     this study.\\r\\n\\r\\n  -  Having previously participated in this same study.\\r\\n\\r\\n  -  History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic\\r\\n     Arterial Hypertension.\\r\\n\\r\\n  -  Diagnosis of glaucoma or ocular hypertension.\\r\\n\\r\\n  -  Known diagnosis of liver or heart disease.\\r\\n\\r\\n  -  Presenting active inflammatory or infectious disease at the time of entry into the\\r\\n     study.\\r\\n\\r\\n  -  Presenting unresolved lesions or traumas at the time of entry into the study.\\r\\n\\r\\n  -  Having been subjected to non-ophthalmological surgical procedures in the last 3\\r\\n     months.\\r\\n\\r\\n  -  Being or having an immediate family member (e.g., spouse, parent/legal guardian,\\r\\n     sibling, or child) who is an employee of the research site or the sponsor, and who\\r\\n     directly participates in this study.\\r\\n\\r\\n  -  Active smoking (specified as the consumption of cigarettes regardless of the amount\\r\\n     and frequency, 4 weeks prior to study inclusion and during the intervention period\\r\\n     of this study).\\r\\n\\r\\n  -  Active alcoholism (specified as the consumption of alcoholic beverages, regardless\\r\\n     of the amount and frequency, 72 hours prior to study inclusion and during the\\r\\n     intervention period of this study).\\r\\n\\r\\nElimination Criteria\\r\\n\\r\\n  -  Withdrawal of their consent to participate in the study (informed consent form).\\r\\n\\r\\n  -  Occurrence of a serious adverse event, whether related or not to the interventions,\\r\\n     that in the opinion of the principal investigator (PI) and/or the sponsor, could\\r\\n     affect the patient's fitness to safely continue with the study procedures.\\r\\n\\r\\n  -  Non-tolerability or hypersensitivity to any of the compounds used during the tests\\r\\n     -(fluorescein, tetracaine).\\r\\n\\r\\n  -  Non-tolerability or hypersensitivity to any of the drugs under investigation.\\r\\n\\r\\n  -  Adherence < 80% determined by the subject's diary and corroborated by the final\\r\\n     weight of the research products (RP) compared to the initial weight.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Alejandra Sanchez, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '33 3001 4200',\n",
       "      'phoneExt': '1190',\n",
       "      'email': 'alejandra.sanchez@sophia.com.mx'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M7102',\n",
       "      'name': 'Dexamethasone',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M12814', 'name': 'Ophthalmic Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M1722', 'name': 'Moxifloxacin', 'relevance': 'LOW'},\n",
       "     {'id': 'M235549', 'name': 'Dexamethasone acetate', 'relevance': 'LOW'},\n",
       "     {'id': 'M342056',\n",
       "      'name': 'Dexamethasone 21-phosphate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M266292',\n",
       "      'name': 'Norgestimate, ethinyl estradiol drug combination',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'AnEm', 'name': 'Antiemetics'},\n",
       "     {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05933941',\n",
       "    'orgStudyIdInfo': {'id': 'CamiloJcURVFM'},\n",
       "    'organization': {'fullName': 'Camilo Jose Cela University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Virtual Reality as a Treatment Tool for Chronic Neck Pain in Patients With Fibromyalgia',\n",
       "    'officialTitle': 'Virtual Reality as a Treatment Tool for Chronic Neck Pain in Patients With Fibromyalgia',\n",
       "    'acronym': 'VRTCNPPFM'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-06-19',\n",
       "    'studyFirstSubmitQcDate': '2023-06-28',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-06', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': \"Edurne Úbeda D'Ocasar\",\n",
       "     'investigatorTitle': \"Doctor Edurne Úbeda D'Ocasar\",\n",
       "     'investigatorAffiliation': 'Camilo Jose Cela University'},\n",
       "    'leadSponsor': {'name': 'Camilo Jose Cela University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Fibromyalgia (FM) is a disease characterized by widespread pain, fatigue and cognitive\\r\\nalterations, among other symptoms, neck pain being the most frequent and debilitating.\\r\\nVirtual reality (VR) has emerged as a breakthrough for the treatment of such chronic\\r\\nconditions. The objective of this study is to evaluate the efficacy of VR in the\\r\\ntreatment of chronic neck pain in patients with FM. Material and methods: Single-blind\\r\\nrandomized clinical trial study. Patients with FM who meet the inclusion criteria will be\\r\\nrecruited and will be distributed into three groups (GC, G1, G2). G1 (VR + cervical\\r\\nmobility exercises), G2 (cervical mobility exercises), control group (CG). The treatment\\r\\nwill be administered twice a week for 4 weeks. Measurements of variables such as FIQ,\\r\\nEQ-5D, kinesiophobia, pain (VAS and algometer), range of motion (ROM), fatigue and\\r\\nadherence to treatment will be performed.\\r\\n\\r\\nA follow-up is intended to be carried out 15 days and a month after the end of the study.',\n",
       "    'detailedDescription': 'RESEARCH QUESTIONS: Can virtual reality combined with exercise improve the quality of\\r\\nlife and impact of fibromyalgia? Can exercise performed with VR improve kinesiophobia,\\r\\ncervical range of motion, and pain? Will VR lead to improvements in patients\\' exercise\\r\\nfunctional capacity?\\r\\n\\r\\nThe aim is to collect a sample of more than 50 patients with fibromyalgia and cervical\\r\\npain lasting more than three months. Variables to be collected include cervical range of\\r\\nmotion (measured with goniometry), pain (measured with a visual analog scale and pressure\\r\\nalgometry at two cervical points), kinesiophobia (TSK questionnaire), impact of\\r\\nfibromyalgia (FIQ), quality of life (EQ-5D), fatigue (BORG visual scale), disability\\r\\ncaused by cervical pain (questionnaire), central sensitization (questionnaire), and\\r\\nfunctional capacity (measured with the \"timed-up and go\" physical test).\\r\\n\\r\\nRecruitment was conducted through the Fibromyalgia and Chronic Pain Association of\\r\\nMostoles. A one-month treatment will be administered with two sessions per week (with at\\r\\nleast one day in between), totaling 8 sessions lasting approximately 30 to 40 minutes\\r\\neach. Measurements will be taken before starting the treatment, at the end of the\\r\\ntreatment, 15 days after completion, and 30 days after completing the entire treatment.\\r\\n\\r\\nSubjects will be randomized into three groups: a control group (CG) that will not receive\\r\\ntreatment, Group 1 (G1) that will receive cervical mobility exercise combined with\\r\\nexercise using virtual reality (VR), and Group 2 (G2) that will receive cervical mobility\\r\\nexercise alone.'},\n",
       "   'conditionsModule': {'conditions': ['Fibromyalgia'],\n",
       "    'keywords': ['virtual reality',\n",
       "     'chronic pain',\n",
       "     'exercises',\n",
       "     'fibromyalgia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Group 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'This group will perform cervical mobility exercises and exercises with virtual reality\\r\\nglasses. 2 sessions will be held per week with a total of 8 sessions',\n",
       "      'interventionNames': ['Other: Virtual reality']},\n",
       "     {'label': 'Group 2',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'This group will only perform cervical mobility exercises at two sessions per week with a\\r\\ntotal of 8 sessions.',\n",
       "      'interventionNames': ['Other: Exercises']},\n",
       "     {'label': 'Control group',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'This group will not receive any treatment or perform any type of exercise during the\\r\\nduration of this study.'}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Virtual reality',\n",
       "      'description': 'This is a game set in space in which you pilot a spaceship and have to go through rings\\r\\nwhile dodging meteorites, all controlled by neck movements. Before starting the game, the\\r\\nassigned therapist is in charge of establishing the necessary movement parameters. In\\r\\naddition, the software allows you to modify the difficulty of the game. We will start the\\r\\nfirst 3 sessions in \"easy\" mode, where cervical mobility does not exceed 30º. The\\r\\nfollowing 3 sessions will be configured in \"medium\" mode, reaching 60º of mobility. In\\r\\nthe last 2 sessions, we will select the \"hard\" mode, which not only increases the speed\\r\\nof the spacecraft but also covers the entire range of cervical mobility.',\n",
       "      'armGroupLabels': ['Group 1']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Exercises',\n",
       "      'description': 'The patients perform mobility and strengthening exercises for the cervical region, in\\r\\nwhich they are required to complete 1 set of 10 repetitions for each exercise. The\\r\\npatient should rest for at least 30 seconds between exercises.',\n",
       "      'armGroupLabels': ['Group 2']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Pain (VAS)',\n",
       "      'description': 'visual analogic scale. the maximum value will be 10 and the minimum value will be 0. The\\r\\nhigher the score, the more pain the patient will have.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Pain (algometry)',\n",
       "      'description': 'Algometer. the maximum value will be 5 and the minimum value will be 0. The higher the\\r\\nscore, the less pain the patient will have.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one moth), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Pain (NDI)',\n",
       "      'description': 'Neck Disability Index. Score from 0 to 50. The higher the score, the greater the\\r\\ndisability.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one moth), 15 days after finishing the treatment and 30 days after finishing the treatment.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Fatigue (BORG)',\n",
       "      'description': 'Visual Scale BORG. Score from 0 to 10. The higher the score, the greater the perception\\r\\nof fatigue.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Range Of Movement (goniometry)',\n",
       "      'description': 'Goniometry of the upper trapezius and suboccipital muscles. Score from 0 to 360º. The\\r\\nhigher the degree, the greater the mobility of the patient',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one moth), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Fibromyalgia Impact (FIQ)',\n",
       "      'description': 'Fibromyalgia Impact Questionnaire. The higher the score obtained, the greater the impact\\r\\nof fibromyalgia on the patient.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Quality of life (EQ-5D)',\n",
       "      'description': 'EQ-5D Questionnaire. Score from 0 to 15. The higher the score, the worse the quality of\\r\\nlife',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'Central Sensibilization (CSI)',\n",
       "      'description': 'Central Sensibiliztion Questionnaire. the result obtained ranges from 0 to 100 and the\\r\\nhigher the value obtained from the questionnaire the greater the degree of awareness',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'kinesiophobia (TSK)',\n",
       "      'description': 'TSK Questionnaire. Each item is scored on a 4-point Likert scale (1 to 4). The response\\r\\nformat and numerical values are as follows: (1) strongly agree, (2) disagree, (3) agree,\\r\\nand (4) strongly agree.\\r\\n\\r\\n(2) disagree, (3) agree, and (4) strongly agree. The scoring of items 4, 8, 12 and 16\\r\\nmust be inverted to calculate the final score, which can range from 17 to 68.\\r\\n\\r\\n17 and 68 and which is obtained by adding the values of the different items.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'},\n",
       "     {'measure': 'functional capacity (timed-up and go)',\n",
       "      'description': 'exercise test (timed-up and go).If the patient takes less than 10 seconds to perform the\\r\\ntest, the patient is considered to be at low risk of falling.\\r\\n\\r\\nconsidered low risk of falling. Between 10 and 20 seconds: indicates fragility (risk of\\r\\nfalling).\\r\\n\\r\\nrisk of falling). More than 20 seconds: High risk of falling.',\n",
       "      'timeFrame': 'base line; after finishing the treatment (one month), 15 days after finishing the treatment and 30 days after finishing the treatment.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Fibromyalgia condition\\r\\n\\r\\n  -  present neck pain during the last 3 months\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  present any pathology that contraindicates the use of virtual reality\\r\\n\\r\\n  -  being pregnant at the moment of the study.\\r\\n\\r\\n  -  not accepting the informed consent.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '20 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Edurne Ú Docasar',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+34918153131',\n",
       "      'phoneExt': '19217',\n",
       "      'email': 'eubeda@ucjc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Edurne Ú Docasar',\n",
       "      'affiliation': 'Associate Professor',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005356',\n",
       "      'term': 'Fibromyalgia'},\n",
       "     {'id': 'D000009209', 'term': 'Myofascial Pain Syndromes'},\n",
       "     {'id': 'D000019547', 'term': 'Neck Pain'}],\n",
       "    'ancestors': [{'id': 'D000009135', 'term': 'Muscular Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000012216', 'term': 'Rheumatic Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M21485',\n",
       "      'name': 'Neck Pain',\n",
       "      'asFound': 'Neck Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29442', 'name': 'Chronic Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M8486',\n",
       "      'name': 'Fibromyalgia',\n",
       "      'asFound': 'Fibromyalgia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12161',\n",
       "      'name': 'Myofascial Pain Syndromes',\n",
       "      'asFound': 'Fibromyalgia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M12092', 'name': 'Muscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15045', 'name': 'Rheumatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6323', 'name': 'Collagen Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06408766',\n",
       "    'orgStudyIdInfo': {'id': '2024-26'},\n",
       "    'organization': {'fullName': 'Bandırma Onyedi Eylül University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Investigating the Effects of Smartphone Use on the Masseter Muscle',\n",
       "    'officialTitle': 'Investigating the Short and Long-term Effects of Smartphone Use on the Masseter Muscle'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-10-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-10', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Hazel Çelik Güzel',\n",
       "     'investigatorTitle': 'PhD',\n",
       "     'investigatorAffiliation': 'Bandırma Onyedi Eylül University'},\n",
       "    'leadSponsor': {'name': 'Bandırma Onyedi Eylül University',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this study was to determine the short- and long-term effects of smartphone use\\r\\non the masseter muscle. In the short term, to investigate whether repetitive thumb\\r\\nmovements during phone use will cause a spontaneous muscle activation and/or tenderness\\r\\nin the masseter muscle; in the long term, to investigate the relationship between\\r\\nstrength change and tenderness of the tenar and masseter muscles depending on the\\r\\nintensity and duration of phone use.',\n",
       "    'detailedDescription': 'A total of 120 healthy university students aged 18-30 years at Bandırma Onyedi Eylül\\r\\nUniversity will be included in our study. Descriptive data form, Smartphone Addiction\\r\\nScale - Short Form, Edinburg Hand Preference Inventory, pressure pain threshold, muscle\\r\\nactivity, lateral grip strength, hand grip strength will be evaluated in the participant\\r\\nstudents.'},\n",
       "   'conditionsModule': {'conditions': ['Smartphone Addiction',\n",
       "     'Masseter Muscle Hypertrophy',\n",
       "     'Masseter Muscle Spasm'],\n",
       "    'keywords': ['Smartphone Addiction', 'masseter', 'thenar']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'CROSS_SECTIONAL'},\n",
       "    'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Smartphone Addiction Scale-Short Form',\n",
       "      'description': 'In our study, the Smartphone Addiction Scale-Short Form will be filled out to evaluate\\r\\nthe intensity of smartphone use of students, and the daily duration of smartphone use\\r\\nwill be recorded. This scale consists of 10 6-point Likert-type items used to measure the\\r\\nrisk of smartphone addiction. Scores on the scale range from 10-60, with an increase in\\r\\nscore indicating an increased risk for smartphone addiction. The cut-off score of the\\r\\nscale was determined as 31 for men and 33 for women in the Korean sample.',\n",
       "      'timeFrame': '4 months'},\n",
       "     {'measure': 'Edinburg Hand Preference Inventory',\n",
       "      'description': 'Edinburg Hand Preference Inventory will be used to determine the dominant hand in our\\r\\nstudy. This scale asks which hand is used while performing 10 activities such as\\r\\n\"writing\", \"drawing\", \"brushing teeth\", \"holding a fork (while eating)\". For each\\r\\nactivity; left hand preference is -10 points, right hand preference is +10 points and\\r\\nboth hand preference is 0 points. After hand preference for all activities, the highest\\r\\nscore that individuals can get is +100 and the lowest score is -100. A \"negative\" score\\r\\nis in favor of \"left-handedness\" and a \"positive\" score is in favor of\\r\\n\"right-handedness\". According to this scoring, individuals with a score between \"+40 and\\r\\n+100\" are recorded as \"right-handed\", individuals with a score between \"-30 and +30\" as\\r\\n\"two-handed\", and individuals with a score between \"-100 and -40\" as \"left-handed\".',\n",
       "      'timeFrame': '4 months'},\n",
       "     {'measure': 'Pressure Pain Threshold Assessment',\n",
       "      'description': 'In our study, pressure pain threshold measurement of the dominant and non-dominant side\\r\\nmasseter and tenar muscles before and after the activity will be evaluated with Baseline\\r\\nmanual algometer (2.5 kg-11 lb).',\n",
       "      'timeFrame': '4 months'},\n",
       "     {'measure': 'Muscle Activation Measurement',\n",
       "      'description': 'In our study, a four-channel Neurotrac Myoplus Pro 4 EMG Biofeedback device will be used\\r\\nfor superficial electromyographic (EMG) measurements of the masseter muscle. The results\\r\\nof electromyographic activity will be presented as both mean data (microvolts) and\\r\\nnormalized mean data (%MVC- Maximum Voluntary Contraction). The mean, minimum and peak\\r\\ncontraction values of the activation will be recorded, the variability of the activation\\r\\nproduced will be evaluated with the Inter Quantile Range (IQR). The average muscle\\r\\nactivations that will occur in the muscle will be used as %MVC.',\n",
       "      'timeFrame': '4 months'},\n",
       "     {'measure': 'Hand Grip Strength Assessment',\n",
       "      'description': \"Hand grip strength will be measured with 'Saehan Hydraulic Hand Dynamometer'. A total of\\r\\nthree measurements will be made for each hand with a 15 s break between each measurement\\r\\nof the extremity and the average of the three measurements will be taken. Test results\\r\\nwill be recorded in kilograms.\",\n",
       "      'timeFrame': '4 months'},\n",
       "     {'measure': 'Finger Lateral Grip Strength Assessment',\n",
       "      'description': \"Hand grip strength will be measured with 'Saehan Hydraulic pinch gauge'. Three\\r\\nmeasurements will be made for each hand in total with a 30-second break between each\\r\\nmeasurement and the average of the three measurements will be recorded in kilograms.\",\n",
       "      'timeFrame': '4 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Smartphone users students between the ages of 18-30 years\\r\\n\\r\\n  -  Students whose voluntary informed consent was obtained\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Individuals undergoing masseter botox application\\r\\n\\r\\n  -  Individuals diagnosed with TMJ disorder and/or bruxism\\r\\n\\r\\n  -  Individuals with musculoskeletal problems with evidence of a systemic, specific\\r\\n     pathologic condition such as fracture of the hand, finger, upper extremity and/or\\r\\n     TMJ, rheumatoid disease\\r\\n\\r\\n  -  Individuals who have undergone any surgical operation related to hand, finger, upper\\r\\n     extremity and/or TMJ problem\\r\\n\\r\\n  -  Individuals with less than 6 months of physiotherapy and rehabilitation services\\r\\n     related to hand, finger, upper extremity and/or TMJ\\r\\n\\r\\n  -  Individuals with facial paralysis\\r\\n\\r\\n  -  Individuals with diagnosed psychiatric illness.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '30 Years',\n",
       "    'stdAges': ['ADULT'],\n",
       "    'studyPopulation': 'University students',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000013035', 'term': 'Spasm'},\n",
       "     {'id': 'D000014313', 'term': 'Trismus'},\n",
       "     {'id': 'D000006984', 'term': 'Hypertrophy'},\n",
       "     {'id': 'D000016739', 'term': 'Behavior, Addictive'},\n",
       "     {'id': 'D000082424', 'term': 'Internet Addiction Disorder'}],\n",
       "    'ancestors': [{'id': 'D000003192', 'term': 'Compulsive Behavior'},\n",
       "     {'id': 'D000007175', 'term': 'Impulsive Behavior'},\n",
       "     {'id': 'D000020763', 'term': 'Pathological Conditions, Anatomical'},\n",
       "     {'id': 'D000088942', 'term': 'Technology Addiction'},\n",
       "     {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M9999',\n",
       "      'name': 'Hyperkinesis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10035',\n",
       "      'name': 'Hypertrophy',\n",
       "      'asFound': 'Hypertrophy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12077', 'name': 'Muscle Cramp', 'relevance': 'LOW'},\n",
       "     {'id': 'M15837',\n",
       "      'name': 'Spasm',\n",
       "      'asFound': 'Muscle Spasm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19100',\n",
       "      'name': 'Behavior, Addictive',\n",
       "      'asFound': 'Addiction',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17065',\n",
       "      'name': 'Trismus',\n",
       "      'asFound': 'Masseter Muscle Spasm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2355',\n",
       "      'name': 'Internet Addiction Disorder',\n",
       "      'asFound': 'Smartphone Addiction',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6418', 'name': 'Compulsive Behavior', 'relevance': 'LOW'},\n",
       "     {'id': 'M10220', 'name': 'Impulsive Behavior', 'relevance': 'LOW'},\n",
       "     {'id': 'M22519',\n",
       "      'name': 'Pathological Conditions, Anatomical',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2684', 'name': 'Technology Addiction', 'relevance': 'LOW'},\n",
       "     {'id': 'M22619',\n",
       "      'name': 'Neuromuscular Manifestations',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06424665',\n",
       "    'orgStudyIdInfo': {'id': 'F0041-101'},\n",
       "    'organization': {'fullName': 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of FZ-AD005 in Patients With Advanced Solid Tumors',\n",
       "    'officialTitle': 'A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FZ-AD005 in Patients With Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-12',\n",
       "    'studyFirstSubmitQcDate': '2024-05-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability,\\r\\nPharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with\\r\\nAdvanced Solid Tumors.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 162, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'FZ-AD005',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: FZ-AD005']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'FZ-AD005',\n",
       "      'description': 'Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005\\r\\nuntil confirmed progression, unaccepted toxicity, or any criterion for withdrawal from\\r\\nthe study.',\n",
       "      'armGroupLabels': ['FZ-AD005']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'The dose limiting toxicity ( DLT)',\n",
       "      'description': 'To determine the dose limiting toxicities (DLTs) of FZ-AD005',\n",
       "      'timeFrame': '21 Days (first cycle)'},\n",
       "     {'measure': 'Maximum Tolerable Dose (MTD)',\n",
       "      'description': 'To determine the maximum tolerated dose (MTD) and/or recommended doses for expansion\\r\\n(RDEs). RDEs will not exceed MTD.',\n",
       "      'timeFrame': '21 Days (first cycle)'},\n",
       "     {'measure': 'Adverse Events (AEs）',\n",
       "      'description': 'To check the numbers of AEs happened during the course of trial.',\n",
       "      'timeFrame': 'Screening up to study completion, assessed up to 60 months'},\n",
       "     {'measure': 'Objective Response Rate (ORR)',\n",
       "      'description': 'To evaluate the objective response rate (ORR) [Complete Response (CR) + Partial Response\\r\\n(PR)] of FZ-AD005 according to RECIST 1.1',\n",
       "      'timeFrame': 'Up to 60 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Progression free survival(PFS)',\n",
       "      'description': 'Progression-free survival (PFS) was defined as the interval from the first dose start\\r\\ndate to the date of disease progression defined as documented progressive disease (PD) or\\r\\ndeath from any cause, whichever occurs first.',\n",
       "      'timeFrame': 'Up to 60 months'},\n",
       "     {'measure': 'Duration of Response(DOR)',\n",
       "      'description': 'Duration of Response was defined as the duration of overall response measured from the\\r\\ntime measurement criteria are met for CR or PR (whichever is first recorded) until the\\r\\nfirst date that recurrent or progressive disease is objectively documented (taking as\\r\\nreference for progressive disease the smallest measurements recorded since the treatment\\r\\nstarted).',\n",
       "      'timeFrame': 'Up to 60 months'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'overall survival was defined as the time from the date of the first dose start date to\\r\\nthe date of death due to any cause.',\n",
       "      'timeFrame': 'Up to 60 months'},\n",
       "     {'measure': 'Anti Drug Antibody (ADA)',\n",
       "      'description': 'To check the\" Anti Drug Antibody\" develops in participants against the FZ-AD005 through\\r\\nblood sample',\n",
       "      'timeFrame': 'Up to 36 months'},\n",
       "     {'measure': 'Time to peak (Tmax)',\n",
       "      'description': 'To measure the time to reach the maximum contraction of Total Antibody, Free DXd and\\r\\nFZ-AD005 in study participants',\n",
       "      'timeFrame': 'Up to 18 weeks'},\n",
       "     {'measure': 'Terminal elimination half-life (t1/2)',\n",
       "      'description': \"To measure the time of Total Antibody, Free DXd and FZ-AD005 will take to eliminate half\\r\\nof it's concentration from participants.\",\n",
       "      'timeFrame': 'Up to 18 weeks'},\n",
       "     {'measure': 'Maximum observed plasma concentration (Cmax)',\n",
       "      'description': 'To measure the maximum concentration participants obtained of Total Antibody, Free DXd\\r\\nand FZ-AD004 in their blood plasma.',\n",
       "      'timeFrame': 'Up to 18 weeks'},\n",
       "     {'measure': 'Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity',\n",
       "      'description': 'To measure the drug profile for absorption, distribution, metabolism and excretion for\\r\\nTotal Antibody, Free DXd and FZ-AD005 in participants blood plasma',\n",
       "      'timeFrame': 'Up to 18 weeks'},\n",
       "     {'measure': 'Time to Cmax (Tmax)',\n",
       "      'description': 'To measure the time to reach the maximum contraction of Total Antibody, Free DXd and\\r\\nFZ-AD005 in study participants',\n",
       "      'timeFrame': 'Up to 18 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Patients able to give written informed consent;\\r\\n\\r\\n  2. Age ≥ 18 and ≤ 75 years old, male or female;\\r\\n\\r\\n  3. Patients have histological or cytological diagnosis with advanced solid tumors (\\r\\n     especially SCLC or LCNEC);\\r\\n\\r\\n  4. Willingness to provide tumor tissue for testing ;\\r\\n\\r\\n  5. Have measurable lesions defined in RECIST v. 1.1;\\r\\n\\r\\n  6. Expected survival ≥ 3 months;\\r\\n\\r\\n  7. Eastern Cancer Cooperative Group (ECOG) performance status 0-1;\\r\\n\\r\\n  8. Patients of child bearing potential must agree to take contraception during the\\r\\n     study and for 6 months after the last day of treatment.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patients who have had previous treatment with any anti-DLL3 antibody；\\r\\n\\r\\n  2. Have had other malignant tumors in the past 5 years;\\r\\n\\r\\n  3. Patients who are receiving other anti-tumor treatments within 4 weeks prior to the\\r\\n     first dose;\\r\\n\\r\\n  4. Have active CNS (central nervous system) metastasis；\\r\\n\\r\\n  5. Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;\\r\\n\\r\\n  6. Had undergone systemic high-dose steroids within 2 weeks of initiation of study\\r\\n     treatment;\\r\\n\\r\\n  7. Patients have psychiatric history;\\r\\n\\r\\n  8. Female patients who are breastfeeding or pregnant;\\r\\n\\r\\n  9. Other reasons that researchers believe are inappropriate to participate in this\\r\\n     study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mengli Zhou',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '00-86-021-58953355',\n",
       "      'email': 'mlzhou@fd-zj.com'}],\n",
       "    'locations': [{'facility': 'Hunan Cancer Hospital',\n",
       "      'city': 'Changsha',\n",
       "      'state': 'Hunan',\n",
       "      'zip': '410013',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Lin Wu', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 28.19874, 'lon': 112.97087}},\n",
       "     {'facility': 'Shanghai East Hospital',\n",
       "      'city': 'Shanghai',\n",
       "      'state': 'Shanghai',\n",
       "      'zip': '200120',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Caicun Zhou', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}},\n",
       "     {'facility': 'Shanghai Pulmonary Hospital',\n",
       "      'city': 'Shanghai',\n",
       "      'state': 'Shanghai',\n",
       "      'zip': '200120',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Shengxiang Ren', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}},\n",
       "     {'facility': 'Zhejiang Cancer Hospital',\n",
       "      'city': 'Hangzhou',\n",
       "      'state': 'Zhejiang',\n",
       "      'zip': '310022',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Zhengbo Song', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000055752',\n",
       "      'term': 'Small Cell Lung Carcinoma'},\n",
       "     {'id': 'D000018278', 'term': 'Carcinoma, Neuroendocrine'}],\n",
       "    'ancestors': [{'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000002283', 'term': 'Carcinoma, Bronchogenic'},\n",
       "     {'id': 'D000001984', 'term': 'Bronchial Neoplasms'},\n",
       "     {'id': 'D000008175', 'term': 'Lung Neoplasms'},\n",
       "     {'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000018358', 'term': 'Neuroendocrine Tumors'},\n",
       "     {'id': 'D000017599', 'term': 'Neuroectodermal Tumors'},\n",
       "     {'id': 'D000009373', 'term': 'Neoplasms, Germ Cell and Embryonal'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009380', 'term': 'Neoplasms, Nerve Tissue'}],\n",
       "    'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M11172', 'name': 'Lung Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M28323',\n",
       "      'name': 'Small Cell Lung Carcinoma',\n",
       "      'asFound': 'Small Cell Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20423',\n",
       "      'name': 'Carcinoma, Neuroendocrine',\n",
       "      'asFound': 'Neuroendocrine Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5540', 'name': 'Carcinoma, Bronchogenic', 'relevance': 'LOW'},\n",
       "     {'id': 'M5260', 'name': 'Bronchial Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20495', 'name': 'Neuroendocrine Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20388',\n",
       "      'name': 'Neuroectodermal Tumors, Primitive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12318',\n",
       "      'name': 'Neoplasms, Germ Cell and Embryonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'},\n",
       "     {'id': 'T5271',\n",
       "      'name': 'Small Cell Lung Cancer',\n",
       "      'asFound': 'Small Cell Lung Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4091', 'name': 'Neuroendocrine Tumor', 'relevance': 'LOW'},\n",
       "     {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06328686',\n",
       "    'orgStudyIdInfo': {'id': 'STUDY00005787'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2023-10895',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'STUDY00005787',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Emory University Hospital/Winship Cancer Institute'},\n",
       "     {'id': 'WINSHIP5883-23',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Emory University Hospital/Winship Cancer Institute'},\n",
       "     {'id': 'P30CA138292',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/P30CA138292'}],\n",
       "    'organization': {'fullName': 'Emory University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases',\n",
       "    'officialTitle': 'Arginine With Whole Brain Radiation Therapy for the Treatment of Brain Metastases'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-19',\n",
       "    'studyFirstSubmitQcDate': '2024-03-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-19', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Lisa Sudmeier',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Emory University'},\n",
       "    'leadSponsor': {'name': 'Emory University', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Cancer Institute (NCI)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This early phase I trial evaluates different administration techniques (oral or\\r\\nintravenous) for arginine and tests the safety of giving arginine with whole brain\\r\\nradiation therapy in patients who have cancer that has spread from where it first started\\r\\n(primary site) to the brain (brain metastases). Arginine is an essential amino acid.\\r\\nAmino acids are the molecules that join together to form proteins in the body. Arginine\\r\\nsupplementation has been shown to improve how brain metastases respond to radiation\\r\\ntherapy. The optimal dosing of arginine for this purpose has not been determined. This\\r\\nstudy measures the level of arginine in the blood with oral and intravenous dosing at\\r\\nspecific time intervals before and after drug administration to determine the best dosing\\r\\nstrategy.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. Determine the bioavailability of orally-administered arginine (L-arginine).\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. Test the safety of daily arginine administration with standard-fractionation whole\\r\\nbrain radiation therapy (WBRT).\\r\\n\\r\\nII. Determine the side effect profile of oral and intravenous (IV) L-arginine. III.\\r\\nQuantify frontal cortex blood volume/flow changes following L-arginine (L-arg)\\r\\nadministration.\\r\\n\\r\\nIV. Describe immunological effects of oral versus (vs.) IV arginine. V. Describe the\\r\\nmetabolic effects of oral vs. IV arginine.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 arms.\\r\\n\\r\\nARM A: Patients receive L-arginine IV over 10-20 minutes followed by WBRT approximately 1\\r\\nhour later for up to 10 days of treatment over 2 weeks in the absence of disease\\r\\nprogression or unacceptable toxicity. Patients also undergo computed tomography (CT) at\\r\\nscreening, undergo collection of blood samples and spectroscopy on study, and undergo\\r\\nmagnetic resonance imaging (MRI) at screening and follow up.\\r\\n\\r\\nARM B: Patients receive L-arginine orally (PO) followed by WBRT approximately 1 hour\\r\\nlater for up to 10 days of treatment over 2 weeks in the absence of disease progression\\r\\nor unacceptable toxicity. Patients also undergo CT at screening, undergo collection of\\r\\nblood samples and spectroscopy on study, and undergo MRI at screening and follow up.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 1 month and then\\r\\nquarterly for 1 year.'},\n",
       "   'conditionsModule': {'conditions': ['Metastatic Malignant Neoplasm in the Brain',\n",
       "     'Metastatic Malignant Solid Neoplasm']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['EARLY_PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Arm A (IV L-arginine, WBRT)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive L-arginine IV over 10-20 minutes followed by WBRT approximately 1 hour\\r\\nlater for up to 10 days of treatment over 2 weeks in the absence of disease progression\\r\\nor unacceptable toxicity. Patients also undergo CT at screening, undergo collection of\\r\\nblood samples and spectroscopy on study, and undergo MRI at screening and follow up.',\n",
       "      'interventionNames': ['Dietary Supplement: Arginine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Procedure: Magnetic Resonance Imaging',\n",
       "       'Procedure: Spectroscopy',\n",
       "       'Radiation: Whole-Brain Radiotherapy']},\n",
       "     {'label': 'Arm B (oral L-arginine, WBRT)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive L-arginine PO followed by WBRT approximately 1 hour later for up to 10\\r\\ndays of treatment over 2 weeks in the absence of disease progression or unacceptable\\r\\ntoxicity. Patients also undergo CT at screening, undergo collection of blood samples and\\r\\nspectroscopy on study, and undergo MRI at screening and follow up.',\n",
       "      'interventionNames': ['Dietary Supplement: Arginine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Procedure: Magnetic Resonance Imaging',\n",
       "       'Procedure: Spectroscopy',\n",
       "       'Radiation: Whole-Brain Radiotherapy']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Arginine',\n",
       "      'description': 'Given IV or PO',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)'],\n",
       "      'otherNames': ['Amino-5-guanidino-pentanoic acid', 'Arg', 'L-Arginine']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo collection of blood samples',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Computed Tomography',\n",
       "      'description': 'Undergo CT',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)'],\n",
       "      'otherNames': ['CAT',\n",
       "       'CAT Scan',\n",
       "       'Computed Axial Tomography',\n",
       "       'Computerized Axial Tomography',\n",
       "       'Computerized axial tomography (procedure)',\n",
       "       'Computerized Tomography',\n",
       "       'CT',\n",
       "       'CT Scan',\n",
       "       'tomography']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Magnetic Resonance Imaging',\n",
       "      'description': 'Undergo MRI',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)'],\n",
       "      'otherNames': ['Magnetic Resonance',\n",
       "       'Magnetic resonance imaging (procedure)',\n",
       "       'Magnetic Resonance Imaging Scan',\n",
       "       'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance',\n",
       "       'MR',\n",
       "       'MR Imaging',\n",
       "       'MRI',\n",
       "       'MRI Scan',\n",
       "       'MRIs',\n",
       "       'NMR Imaging',\n",
       "       'NMRI',\n",
       "       'Nuclear Magnetic Resonance Imaging',\n",
       "       'sMRI',\n",
       "       'Structural MRI']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Spectroscopy',\n",
       "      'description': 'Undergo spectroscopy',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)']},\n",
       "     {'type': 'RADIATION',\n",
       "      'name': 'Whole-Brain Radiotherapy',\n",
       "      'description': 'Undergo WBRT',\n",
       "      'armGroupLabels': ['Arm A (IV L-arginine, WBRT)',\n",
       "       'Arm B (oral L-arginine, WBRT)'],\n",
       "      'otherNames': ['WBRT', 'whole-brain radiation therapy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Peak plasma L-arginine (arginine) and arginine metabolite concentration',\n",
       "      'description': 'By compartmental pharmacokinetic analysis, the plasma arginine levels at before\\r\\nadministration, 10 min, 30 min, 1 hour, 2 hours, and 4 hours post administration will be\\r\\nused to estimate the median time to reach the peak plasma arginine and the mean value of\\r\\npeak. This will be done separately by two arms.',\n",
       "      'timeFrame': 'Within 4 hours of oral and intravenous (IV) dosing of L-arginine'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of adverse events associated with delivering L-arginine with standard fractionation whole brain radiation therapy',\n",
       "      'description': \"Will be evaluated using complete metabolic panel and symptom assessment. The descriptive\\r\\nstatistics (e.g., summary statistics for numerical measurements and frequency/percentage\\r\\nfor categorical measurements) along with data visualization (e.g., box plot repeated by\\r\\ntime points) will mainly be considered for all 10 patients or separated by arms. As\\r\\nneeded, the comparison between the two arms will be carried out mainly by non-parametric\\r\\ntests (e.g., Wilcoxon sum-rank test, Fisher's exact test). The change before and after\\r\\ntreatment can be tested using a paired-test (e.g., Wilcoxon signed rank test). All\\r\\nanalyses will be explored for all 10 patients or separated by arms as appropriate.\",\n",
       "      'timeFrame': 'At 1 week into radiation and at completion of 2 week course'},\n",
       "     {'measure': 'Side effect profile of oral and IV arginine',\n",
       "      'description': \"Will be evaluated using symptom assessment at time of lab draw. The descriptive\\r\\nstatistics (e.g., summary statistics for numerical measurements and frequency/percentage\\r\\nfor categorical measurements) along with data visualization (e.g., box plot repeated by\\r\\ntime points) will mainly be considered for all 10 patients or separated by arms. As\\r\\nneeded, the comparison between the two arms will be carried out mainly by non-parametric\\r\\ntests (e.g., Wilcoxon sum-rank test, Fisher's exact test). The change before and after\\r\\ntreatment can be tested using a paired-test (e.g., Wilcoxon signed rank test). All\\r\\nanalyses will be explored for all 10 patients or separated by arms as appropriate.\",\n",
       "      'timeFrame': 'On days 1, 5, and 10'},\n",
       "     {'measure': 'Frontal cortex blood volume/flow changes with L-arginine administration',\n",
       "      'description': \"Cerebral blood flow (CBF) and oxygen utilization will be measured using diffuse optical\\r\\nspectroscopy and diffuse correlation spectroscopy after arginine administration.\\r\\n\\r\\nThe descriptive statistics (e.g., summary statistics for numerical measurements and\\r\\nfrequency/percentage for categorical measurements) along with data visualization (e.g.,\\r\\nbox plot repeated by time points) will mainly be considered for all 10 patients or\\r\\nseparated by arms. As needed, the comparison between the two arms will be carried out\\r\\nmainly by non-parametric tests (e.g., Wilcoxon sum-rank test, Fisher's exact test). The\\r\\nchange before and after treatment can be tested using a paired-test (e.g., Wilcoxon\\r\\nsigned rank test). All analyses will be explored for all 10 patients or separated by arms\\r\\nas appropriate.\",\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': 'Describe The Immunological Effects of Oral versus IV Arginine',\n",
       "      'description': 'Administration of both oral and IV formulations of L-arginine will stimulate T-cell\\r\\nproliferation and expression of effector molecules. A phenotypic analysis of circulating\\r\\nimmune cells will be conducted by spectral flow cytometry during treatment.',\n",
       "      'timeFrame': 'Up to 10 days'},\n",
       "     {'measure': 'Describe The Metabolic Effects of Oral versus IV Arginine',\n",
       "      'description': 'Administration of both oral and IV formulations of L-arginine will stimulate T-cell\\r\\nproliferation and expression of effector molecules. Arginine metabolites, including\\r\\nornithine, citrulline, will have a delayed increase following arginine administration. A\\r\\nphenotypic analysis of circulating immune cells will be conducted by spectral flow\\r\\ncytometry during treatment.',\n",
       "      'timeFrame': 'Up to 10 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Diagnosis of brain metastases from any primary cancer\\r\\n\\r\\n  -  Planned to undergo whole-brain radiation therapy (Hippocampal avoidant is ok)\\r\\n\\r\\n  -  No systemic anti-neoplastic agent concurrent with WBRT (memantine is ok)\\r\\n\\r\\n  -  Not inpatient at the time of treatment start\\r\\n\\r\\n  -  Age 18 or older\\r\\n\\r\\n  -  Able to consent for self\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patient unwilling/unable to receive daily arginine treatment (IV or oral) for the 10\\r\\n     days of WBRT\\r\\n\\r\\n  -  Systemic therapy continuing during WBRT\\r\\n\\r\\n  -  Creatinine > 1.5 x the upper limit of normal\\r\\n\\r\\n  -  Alanine aminotransferase (ALT) > 6x the upper limit of normal\\r\\n\\r\\n  -  Patient planned to be treated as an inpatient\\r\\n\\r\\n  -  Age < 18 years\\r\\n\\r\\n  -  Adult not able to consent for self\\r\\n\\r\\n  -  Pregnant\\r\\n\\r\\n  -  Prisoners\\r\\n\\r\\n  -  Cognitively impaired/impaired decision-making capacity',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Lisa Sudmeier, MD, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '404-778-3473',\n",
       "      'email': 'lisa.jane.sudmeier@emory.edu'}],\n",
       "    'overallOfficials': [{'name': 'Lisa Sudmeier, MD, PhD',\n",
       "      'affiliation': 'Emory University Hospital/Winship Cancer Institute',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Emory University Hospital/Winship Cancer Institute',\n",
       "      'city': 'Atlanta',\n",
       "      'state': 'Georgia',\n",
       "      'zip': '30322',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Lisa Sudmeier, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '404-712-9625',\n",
       "        'email': 'lsudmei@emory.edu'},\n",
       "       {'name': 'Agnes Harutyunyan',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'aharuty@emory.edu'},\n",
       "       {'name': 'Lisa Sudmeier, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.749, 'lon': -84.38798}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'},\n",
       "     {'id': 'D000001932', 'term': 'Brain Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000016543',\n",
       "      'term': 'Central Nervous System Neoplasms'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12307',\n",
       "      'name': 'Neoplasm Metastasis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M5209',\n",
       "      'name': 'Brain Neoplasms',\n",
       "      'asFound': 'Brain Metastases',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18937',\n",
       "      'name': 'Central Nervous System Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'T1',\n",
       "      'name': 'Arginine',\n",
       "      'asFound': '6 hours',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'AA', 'name': 'Amino Acids'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05660863',\n",
       "    'orgStudyIdInfo': {'id': '21607'},\n",
       "    'organization': {'fullName': 'Guangzhou Magpie Pharmaceuticals Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets',\n",
       "    'officialTitle': 'A Bridged Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Dose of MN-08 in Healthy Subjects'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-09',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-12-01',\n",
       "    'studyFirstSubmitQcDate': '2022-12-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-12-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-09-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-09-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Guangzhou Magpie Pharmaceuticals Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose\\r\\nstudy in two ascending dose cohorts of healthy subjects. The primary objective of the\\r\\ntrial is to assess the safety and tolerability of multiple doses of MN-08 tablet\\r\\nadministered for 6.5 consecutive days in healthy subjects.'},\n",
       "   'conditionsModule': {'conditions': ['Pulmonary Arterial Hypertension']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 16, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'cohort 1：MN-08 24 mg/day',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '2 x 6 mg MN-08 tablets for a total dose of 12 mg or 2 matching placebo tablets (given\\r\\napproximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.',\n",
       "      'interventionNames': ['Drug: MN-08 24 mg/day']},\n",
       "     {'label': 'cohort 2：MN-08 60 mg/day',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '5 x 6 mg MN-08 tablets for a total dose of 30 mg or 5 matching placebo tablets (given\\r\\napproximately every 12 hours) for 6.5 consecutive days, until the morning dose of Day 7.',\n",
       "      'interventionNames': ['Drug: MN-08 60 mg/day']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'MN-08 24 mg/day',\n",
       "      'description': 'Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of\\r\\n24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the\\r\\nmorning of Day 7.',\n",
       "      'armGroupLabels': ['cohort 1：MN-08 24 mg/day']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'MN-08 60 mg/day',\n",
       "      'description': 'Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of\\r\\n60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on\\r\\nthe morning of Day 7.',\n",
       "      'armGroupLabels': ['cohort 2：MN-08 60 mg/day']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and severity of TEAEs and SAEs',\n",
       "      'description': 'Incidence and severity of treatment emergent adverse events (TEAEs) and Serious Adverse\\r\\nEvents (SAEs) after multiple doses of MN-08 administered for 6.5 consecutive days in\\r\\nhealthy subjects.',\n",
       "      'timeFrame': 'Through study completion, an average of 12 days'},\n",
       "     {'measure': 'Incidence and severity of treatment-related adverse events',\n",
       "      'description': 'Incidence and severity of treatment-related adverse events determined by changes from\\r\\nscreening (baseline) of findings from vital signs, ECG, and clinical laboratory\\r\\nparameters per the National Cancer Institute (NCI) Common Terminology Criteria for\\r\\nAdverse Events (CTCAE) version 5.',\n",
       "      'timeFrame': 'Through study completion, an average of 12 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Single dose peak plasma concentration (Cmax) for MN-08',\n",
       "      'description': 'Peak plasma concentration (Cmax) for MN-08 after single oral doses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 12 hours post dose after the morning dosing of Day 1.'},\n",
       "     {'measure': 'Single dose area under the plasma concentration versus time curve (AUC) for MN-08',\n",
       "      'description': 'Area under the plasma concentration versus time curve (AUC) for MN-08 after single oral\\r\\ndoses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 12 hours post dose after the morning dosing of Day 1.'},\n",
       "     {'measure': 'Single dose time to peak plasma concentration (Tmax) for MN-08',\n",
       "      'description': 'Time to peak plasma concentration (Tmax) for MN-08 after single oral doses of MN-08\\r\\ntablets.',\n",
       "      'timeFrame': 'Pre dose and up to 12 hours post dose after the morning dosing of Day 1.'},\n",
       "     {'measure': 'Repeated dose peak plasma concentration (Cmax) for MN-08',\n",
       "      'description': 'Peak plasma concentration (Cmax) for MN-08 after multiple oral doses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'},\n",
       "     {'measure': 'Repeated dose steady-state plasma concentration (Css) for MN-08',\n",
       "      'description': 'Steady-state concentration (Css) for MN-08 after multiple oral doses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'},\n",
       "     {'measure': 'Repeated dose area under the plasma concentration versus time curve (AUC) for MN-08',\n",
       "      'description': 'Area under the plasma concentration versus time curve (AUC) for MN-08 after multiple oral\\r\\ndoses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'},\n",
       "     {'measure': 'Repeated dose time to peak plasma concentration (Tmax) for MN-08',\n",
       "      'description': 'Time to peak plasma concentration (Tmax) for MN-08 after multiple oral doses of MN-08\\r\\ntablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'},\n",
       "     {'measure': 'Repeated dose terminal elimination half-life (t1/2) for MN-08 in plasma',\n",
       "      'description': 'Terminal elimination half-life (t1/2) for MN-08 after multiple oral doses of MN-08\\r\\ntablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'},\n",
       "     {'measure': 'Repeated dose ratio of accumulation (RA) for MN-08',\n",
       "      'description': 'Ratio of accumulation (RA) for MN-08 after multiple oral doses of MN-08 tablets.',\n",
       "      'timeFrame': 'Pre dose and up to 120 hours post dose after the morning dosing of Day 7.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\nSubjects must meet all the following criteria to be included in the study:\\r\\n\\r\\n  1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months\\r\\n     prior to screening), ≥ 18 and ≤ 45 years of age, with body mass index (BMI) > 18.0\\r\\n     and < 30.0 kg/m2 , and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.\\r\\n\\r\\n  2. Healthy as defined by:\\r\\n\\r\\n       1. the absence of clinically significant illness and surgery within 4 weeks prior\\r\\n          to the first dosing. Subjects vomiting within 24 hours pre-dose will be\\r\\n          carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at\\r\\n          the discretion of the Investigator.\\r\\n\\r\\n       2. the absence of a clinically significant history of neurological, endocrine,\\r\\n          cardiovascular, respiratory, hematological, immunological, psychiatric,\\r\\n          gastrointestinal, renal, hepatic, and metabolic disease.\\r\\n\\r\\n  3. Female subjects must not be pregnant, breastfeeding, or at risk to become pregnant\\r\\n     during study participation. Female subjects must have a negative serum pregnancy\\r\\n     test at screening (within 72 hours of the first dose of study medication) if of\\r\\n     childbearing potential, or be of non-childbearing potential. Non-childbearing\\r\\n     potential is defined as:\\r\\n\\r\\n       1. post-menopausal female (absence of menses for 12 months prior to the first\\r\\n          study drug administration, or having had a bilateral oophorectomy, or\\r\\n          hysterectomy with bilateral oophorectomy at least 6 months prior to the first\\r\\n          study drug administration); or\\r\\n\\r\\n       2. surgically sterile female (hysterectomy or tubal ligation at least 6 months\\r\\n          prior to drug administration).\\r\\n\\r\\n  4. Female subjects of childbearing potential (childbearing potential defined as not\\r\\n     post menopausal nor surgically sterile) must agree to use a reliable method of birth\\r\\n     control (see below for details) or remain abstinent during the study, starting with\\r\\n     the screening visit until at least 90 days after the last study drug administration.\\r\\n\\r\\n  5. Male subjects who have not been vasectomized for at least 6 months, and who are\\r\\n     sexually active with a female partner of childbearing potential must be willing to\\r\\n     use one of the following acceptable contraceptive methods from the first study drug\\r\\n     administration until at least 90 days after the last study drug administration:\\r\\n\\r\\n       1. simultaneous use of a male condom and, for the female partner, hormonal\\r\\n          contraceptives used since at least 4 weeks prior or intra-uterine contraceptive\\r\\n          device placed since at least 4 weeks prior to study.\\r\\n\\r\\n       2. simultaneous use of a male condom and, for the female partner, a diaphragm or\\r\\n          cervical cap with intravaginally applied spermicide.\\r\\n\\r\\n  6. Male subjects (including men who have had a vasectomy) with a pregnant partner must\\r\\n     agree to use a condom from the first study drug administration until at least 90\\r\\n     days after the last study drug administration.\\r\\n\\r\\n  7. Male subjects must be willing not to donate sperm until 90 days following the last\\r\\n     study drug administration\\r\\n\\r\\n  8. Capable of signing the informed consent form.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nSubjects to whom any of the following applies will be excluded from the study:\\r\\n\\r\\n  1. Any clinically significant abnormality at physical examination, clinically\\r\\n     significant abnormal laboratory test results or positive test for hepatitis B,\\r\\n     hepatitis C, or HIV found during medical screening.\\r\\n\\r\\n  2. Subjects with any following clinical illness at screening, including but not limited\\r\\n     to respiratory, circulatory, digestive, hematological, endocrine, immunological,\\r\\n     dermatological, and ENT abnormalities.\\r\\n\\r\\n  3. Subjects with digestive, liver, or kidney diseases which could affect the\\r\\n     pharmacokinetics of drugs.\\r\\n\\r\\n  4. Positive urine drug screen, alcohol breath test, or urine cotinine test at\\r\\n     screening.\\r\\n\\r\\n  5. History of allergic reactions to MN-08 or other related drugs, or to any excipient\\r\\n     in the formulation.\\r\\n\\r\\n  6. Positive pregnancy test at screening.\\r\\n\\r\\n  7. Clinically significant ECG abnormalities or vital sign abnormalities, including:\\r\\n     systolic BP lower than 90 or over 139 mmHg, diastolic BP lower than 60 or over 89\\r\\n     mmHg, or HR less than 55 or over 100 bpm; orthostatic BP: decrease in systolic blood\\r\\n     pressure of 20 mmHg or higher, decrease in diastolic blood pressure of 10 mmHg or\\r\\n     higher, or increase in heart rate of 30 bpm or higher within 2 to 3 minutes after\\r\\n     passing from a supine to a standing position at screening.\\r\\n\\r\\n  8. History of significant alcohol abuse within 1 year prior to screening or regular use\\r\\n     of alcohol within 6 months prior to the screening visit (more than 14 units of\\r\\n     alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40%\\r\\n     alcohol]).\\r\\n\\r\\n  9. History of significant drug abuse within 1 year prior to screening, or use of soft\\r\\n     drugs (such as marijuana) within 3 months prior to the screening visit, or hard\\r\\n     drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including\\r\\n     heroin, and amphetamine derivatives) within 1 year prior to screening.\\r\\n\\r\\n 10. Subjects drinking excessive amounts of tea, coffee, or caffeinated beverages (more\\r\\n     than 8 cups,1 cup = 250 mL) every day before the screening, or those who cannot\\r\\n     agree to prohibit drinking tea, coffee, and/or products containing caffeine,\\r\\n     grapefruit, or poppy 24 hours before dosing and during the study period.\\r\\n\\r\\n 11. Smoking history of 5 cigarettes per day within 3 months before the study, or those\\r\\n     who cannot stop smoking 24 h before dosing and during the study period.\\r\\n\\r\\n 12. Have undergone major surgery 6 months before the study, or plan to have surgery\\r\\n     during the study.\\r\\n\\r\\n 13. Have been vaccinated within 3 months prior to the study.\\r\\n\\r\\n 14. Participation in a clinical research study involving the administration of an\\r\\n     investigational or marketed drug or device within 30 days prior to the first dosing,\\r\\n     administration of a biological product in the context of a clinical research study\\r\\n     within 90 days prior to the first dosing, or concomitant participation in an\\r\\n     investigational study involving no drug or device administration.\\r\\n\\r\\n 15. Use of medications for the time frames specified below, except for medications\\r\\n     prescribed by the Investigator on a case-by-case basis because they have been judged\\r\\n     unlikely to affect the pharmacokinetic profile of the study drug or subject safety\\r\\n     (e.g., topical drug products without significant systemic absorption):\\r\\n\\r\\n       1. Prescription medications within 14 days prior to the first dosing.\\r\\n\\r\\n       2. Over-the-counter products and natural health products (including herbal\\r\\n          remedies, homeopathic and traditional medicines, probiotics, food supplements\\r\\n          such as vitamins, minerals, amino acids, essential fatty acids, and protein\\r\\n          supplements used in sports) within 7 days prior to the first dosing, except for\\r\\n          the occasional use of acetaminophen (up to 2 g daily).\\r\\n\\r\\n       3. Depot injection or implantation of any drug within 3 months prior to the first\\r\\n          dosing.\\r\\n\\r\\n       4. Any drugs known to induce or inhibit hepatic drug metabolism (including St.\\r\\n          John's Wort) within 30 days prior to the first dosing.\\r\\n\\r\\n 16. Donation of plasma within 7 days prior to dosing. Donation or blood loss (excluding\\r\\n     volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than\\r\\n     499 mL within 56 days prior to the first dosing.\\r\\n\\r\\n 17. Any reason which, in the opinion of the Investigator, would prevent the subject from\\r\\n     participating in the study.\\r\\n\\r\\n 18. Breastfeeding subject.\\r\\n\\r\\n 19. Any history of suicidal ideation or suicidal behavior (within 2 years prior to\\r\\n     screening), as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS;\\r\\n     baseline version).\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000081029',\n",
       "      'term': 'Pulmonary Arterial Hypertension'}],\n",
       "    'ancestors': [{'id': 'D000006976', 'term': 'Hypertension, Pulmonary'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10024',\n",
       "      'name': 'Hypertension',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2261',\n",
       "      'name': 'Pulmonary Arterial Hypertension',\n",
       "      'asFound': 'Pulmonary Arterial Hypertension',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10027', 'name': 'Hypertension, Pulmonary', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4807',\n",
       "      'name': 'Pulmonary Arterial Hypertension',\n",
       "      'asFound': 'Pulmonary Arterial Hypertension',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06249386',\n",
       "    'orgStudyIdInfo': {'id': '0219135'},\n",
       "    'secondaryIdInfos': [{'id': 'R34AA030820',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/R34AA030820'},\n",
       "     {'id': 'Pro00113641',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Duke University School of Medicine'},\n",
       "     {'id': 'STUDY00022679', 'type': 'OTHER', 'domain': 'RTI International'}],\n",
       "    'organization': {'fullName': 'RTI International', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder',\n",
       "    'officialTitle': 'Adapting and Piloting Behavioral Activation for Veterans With Co-Occurring AUD and Posttraumatic Stress Disorder'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-11', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-11', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-01-30',\n",
       "    'studyFirstSubmitQcDate': '2024-02-07',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-02-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'RTI International', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Institute on Alcohol Abuse and Alcoholism (NIAAA)',\n",
       "      'class': 'NIH'},\n",
       "     {'name': 'Duke University', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to compare an adaptation of Behavioral Activation, a\\r\\nbehavioral intervention, to Relapse Prevention treatment, another behavioral\\r\\nintervention, in a sample of U.S. military veterans with co-occurring alcohol use\\r\\ndisorder (AUD) and posttraumatic stress disorder (PTSD).\\r\\n\\r\\nThe primary aims of this study are to:\\r\\n\\r\\n  1. Adapt Behavioral Activation to treat veterans with AUD/PTSD,\\r\\n\\r\\n  2. Evaluate the feasibility, acceptability, and preliminary effects of Behavioral\\r\\n     Activation for AUD/PTSD, and\\r\\n\\r\\n  3. Explore geospatial analysis as a new method for measuring AUD/PTSD recovery.\\r\\n\\r\\nParticipants will complete self-report and interview measures immediately before and\\r\\nimmediately after treatment. Participants will also be asked to participate in passive\\r\\ngeospatial assessment for 14-day periods immediately before and immediately after\\r\\ntreatment. Participants will be randomized to treatment condition, which involves 8\\r\\nsessions of either Behavioral Activation or Relapse Prevention, delivered individually by\\r\\na trained study therapist.',\n",
       "    'detailedDescription': 'Alcohol use disorder (AUD) frequently co-occurs with posttraumatic stress disorder (PTSD)\\r\\namong U.S. military veterans. Compared to veterans with AUD only, veterans with AUD/PTSD\\r\\nhave greater symptom severity, more psychosocial functioning difficulties, and higher\\r\\nrisk of suicide. Many people with AUD/PTSD perform behaviors aimed at avoiding unpleasant\\r\\nemotions (e.g., drinking to avoid trauma-related nightmares, skipping social events to\\r\\navoid anxiety-provoking crowds). These \"avoidance behaviors\" provide temporary relief\\r\\nfrom unpleasant emotions, but they maintain AUD/PTSD and interfere with long-term\\r\\nfunctioning. Although treatments for AUD/PTSD exist, they emphasize symptom reduction\\r\\n(not functional improvement) and have dropout rates as high as 50%. Originally developed\\r\\nto treat depression, Behavioral Activation (BA) is an intervention that increases daily\\r\\nparticipation in rewarding, alcohol-free activities relevant to patients\\' social,\\r\\nvocational, and health-related values. Randomized controlled trials (RCTs) adapting BA\\r\\nfor other disorders have shown that BA is efficacious for adults with alcohol/drug use\\r\\ndisorders and acceptable to veterans with PTSD, but BA has not been used to treat\\r\\nco-occurring AUD/PTSD. Additionally, because RCTs of AUD/PTSD treatments typically\\r\\nemphasize significant mean group differences in AUD/PTSD outcomes, less is known about\\r\\nthe degree to which these treatments yield clinically significant improvements at the\\r\\nindividual level. Individual-level improvements in AUD/PTSD should be evident not only in\\r\\nsubjective clinical assessments, but also in objective measures of geospatial activity.\\r\\nSpecifically, patients\\' daily geospatial activity is likely to change as they decrease\\r\\ntheir avoidance behaviors and increase their engagement in various social, vocational,\\r\\nand health-promoting activities. Advances in geospatial methods, coupled with discreet\\r\\nand portable global positioning system (GPS) trackers, have made it possible to\\r\\nobjectively measure people\\'s spatial movement within their communities. Yet although\\r\\ngeospatial methods have been used to identify social determinants of alcohol use, they\\r\\nhave not been used to measure response to AUD or AUD/PTSD treatment. As the long-term\\r\\nobjectives of this work are to identify a more acceptable AUD/PTSD treatment option and\\r\\nimprove the measurement of AUD/PTSD recovery, this R34 project will address the following\\r\\nspecific aims: (1) adapt BA for use with veterans with AUD/PTSD; (2) evaluate the\\r\\nfeasibility, acceptability, and preliminary effects of BA, relative to Relapse\\r\\nPrevention, for veterans with AUD/PTSD in a pilot RCT; and (3) explore geospatial\\r\\nanalysis of GPS-collected data as a new approach to measuring AUD/PTSD treatment\\r\\nresponse. This study will advance research and practice by piloting a novel application\\r\\nof BA and a novel measure of AUD/PTSD recovery. This project aligns with the National\\r\\nInstitute on Alcohol Abuse and Alcoholism\\'s special interest in investigating treatments\\r\\nfor patients with AUD and co-occurring disorders, dimensions of functioning and\\r\\nwell-being associated with recovery, and innovative methods for evaluating AUD treatment\\r\\nand recovery.'},\n",
       "   'conditionsModule': {'conditions': ['Alcohol Use Disorder',\n",
       "     'Posttraumatic Stress Disorder']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Participants will be block randomized to either Behavioral Activation treatment (n=23) or\\r\\nRelapse Prevention treatment (n=23).',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': \"Outcomes assessors will be blind to treatment condition. The participant, study\\r\\ntherapist, and PI (providing clinical consultation and evaluating therapist fidelity to\\r\\ntreatment protocol) will not be blinded to participants' assigned treatment condition.\",\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 46, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Behavioral Activation (BA)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Individual psychotherapy',\n",
       "      'interventionNames': ['Behavioral: Behavioral Activation (BA)']},\n",
       "     {'label': 'Relapse Prevention (RP)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Individual psychotherapy',\n",
       "      'interventionNames': ['Behavioral: Relapse Prevention (RP)']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Behavioral Activation (BA)',\n",
       "      'description': 'BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial\\r\\nfunctioning via psychoeducation, activity monitoring, values clarification, and activity\\r\\nscheduling.',\n",
       "      'armGroupLabels': ['Behavioral Activation (BA)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Relapse Prevention (RP)',\n",
       "      'description': 'RP reduces alcohol use via increasing awareness and avoidance of high-risk situations,\\r\\nenhancing drink refusal skills, improving assertiveness, and other strategies.',\n",
       "      'armGroupLabels': ['Relapse Prevention (RP)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Timeline Follow-Back (alcohol use)',\n",
       "      'description': 'Changes in past-30-day alcohol consumption from baseline to immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'Clinician-Administered PTSD Scale for DSM-5 (PTSD severity)',\n",
       "      'description': 'Changes in past-month PTSD severity from baseline to immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Brief Inventory of Psychosocial Functioning (psychosocial functioning)',\n",
       "      'description': 'Changes in past-30-day psychosocial functioning from baseline to immediately\\r\\npost-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'Geospatial activity',\n",
       "      'description': 'Changes in past-14-day geospatial activity metrics (e.g., activity space) from baseline\\r\\nto immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'PTSD Checklist for DSM-5 (PCL-5)',\n",
       "      'description': 'Changes in past-month PTSD severity from baseline to immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'Generalized Anxiety Disorder-7 (GAD-7)',\n",
       "      'description': 'Changes in past-2-week anxiety severity from baseline to immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'Patient Health Questionnaire-9 (PHQ-9)',\n",
       "      'description': 'Changes in past-2-week depressive symptom severity from baseline to immediately\\r\\nposttreatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'},\n",
       "     {'measure': 'Insomnia Severity Index',\n",
       "      'description': 'Changes in past-2-week sleep disturbance from baseline to immediately post-treatment',\n",
       "      'timeFrame': 'Through study completion, an average of 3 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Be a U.S. veteran,\\r\\n\\r\\n  2. Be 18 to 65 years old,\\r\\n\\r\\n  3. Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for\\r\\n     current AUD,\\r\\n\\r\\n  4. Report 3+ heavy drinking days (5+ drinks for men/4+ drinks for women) and 1+ heavy\\r\\n     drinking week (15+ drinks men/8+ drinks women) in the past 30 days,\\r\\n\\r\\n  5. Meet DSM-5 criteria for current PTSD,\\r\\n\\r\\n  6. Endorse at least moderate difficulties with psychosocial functioning, defined as a\\r\\n     score of 31+ on the Brief Inventory of Psychosocial Functioning (BIPF),\\r\\n\\r\\n  7. Be fluent and literate in English, and\\r\\n\\r\\n  8. Be able to provide voluntary, informed consent to participate.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Lifetime mania/hypomania or current psychosis,\\r\\n\\r\\n  2. Lifetime history of seizures,\\r\\n\\r\\n  3. Lifetime alcohol withdrawal-related delirium or hallucinations,\\r\\n\\r\\n  4. Prior inpatient alcohol withdrawal management,\\r\\n\\r\\n  5. A score of 10+ on the Clinical Institute Withdrawal Assessment of Alcohol Scale,\\r\\n     Revised (CIWA-Ar),\\r\\n\\r\\n  6. Current DSM-5 severe drug use disorder (DUD) except for severe tobacco use disorder\\r\\n     (which is not exclusionary) or past-30-day heroin or non-prescription opioid use,\\r\\n\\r\\n  7. Psychotropic (including alcohol abstinence) medication changes within 90 days of\\r\\n     study enrollment or plans to change medications during the study,\\r\\n\\r\\n  8. Current/planned non-study BA for any disorder during the study, or\\r\\n\\r\\n  9. Current/planned evidence-based psychotherapy for AUD, PTSD, or DUD during the study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Shannon M Blakey, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '919-485-5427',\n",
       "      'email': 'sblakey@rti.org'}],\n",
       "    'overallOfficials': [{'name': 'Shannon M Blakey, PhD',\n",
       "      'affiliation': 'RTI International',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Eric B Elbogen, PhD',\n",
       "      'affiliation': 'Duke University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Duke University School of Medicine',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Durham',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27710',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Eric B Elbogen, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'eric.elbogen@duke.edu'}],\n",
       "      'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'De-identified data from consenting participants will be submitted to the National\\r\\nInstitute on Alcohol Abuse and Alcoholism Data Archive.',\n",
       "    'timeFrame': 'All collection data are shared automatically two years after the grant end date specified\\r\\non the first Notice of Award. PI requests for exceptions will be considered for only\\r\\nextreme and unusual circumstances (e.g., unanticipated life event [death of family\\r\\nmember] or other force majeure).',\n",
       "    'accessCriteria': 'Data access requires sponsorship by an Institution on behalf of Recipient(s) and\\r\\nsatisfaction of any other criteria required by the National Institute on Alcohol Abuse\\r\\nand Alcoholism Data Archive.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000437',\n",
       "      'term': 'Alcoholism'},\n",
       "     {'id': 'D000040921', 'term': 'Stress Disorders, Traumatic'},\n",
       "     {'id': 'D000000428', 'term': 'Alcohol Drinking'},\n",
       "     {'id': 'D000013313', 'term': 'Stress Disorders, Post-Traumatic'}],\n",
       "    'ancestors': [{'id': 'D000068099',\n",
       "      'term': 'Trauma and Stressor Related Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'},\n",
       "     {'id': 'D000004327', 'term': 'Drinking Behavior'},\n",
       "     {'id': 'D000019973', 'term': 'Alcohol-Related Disorders'},\n",
       "     {'id': 'D000019966', 'term': 'Substance-Related Disorders'},\n",
       "     {'id': 'D000064419', 'term': 'Chemically-Induced Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M24916',\n",
       "      'name': 'Stress Disorders, Traumatic',\n",
       "      'asFound': 'Stress Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16103',\n",
       "      'name': 'Stress Disorders, Post-Traumatic',\n",
       "      'asFound': 'Posttraumatic Stress Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3774',\n",
       "      'name': 'Alcohol Drinking',\n",
       "      'asFound': 'Alcohol Use',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3783',\n",
       "      'name': 'Alcoholism',\n",
       "      'asFound': 'Alcohol Use Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'},\n",
       "     {'id': 'M222',\n",
       "      'name': 'Trauma and Stressor Related Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M7502', 'name': 'Drinking Behavior', 'relevance': 'LOW'},\n",
       "     {'id': 'M21842', 'name': 'Alcohol-Related Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M21837',\n",
       "      'name': 'Substance-Related Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M30302',\n",
       "      'name': 'Chemically-Induced Disorders',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC25', 'name': 'Substance Related Disorders'},\n",
       "     {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M3777',\n",
       "      'name': 'Ethanol',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05922124',\n",
       "    'orgStudyIdInfo': {'id': 'V0.1 May 2023'},\n",
       "    'organization': {'fullName': 'Rambam Health Care Campus',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii',\n",
       "    'officialTitle': 'Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)',\n",
       "    'acronym': 'CASCADE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-09', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-05-31',\n",
       "    'studyFirstSubmitQcDate': '2023-06-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-06-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Rambam Health Care Campus', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Monaldi Hospital', 'class': 'OTHER'},\n",
       "     {'name': 'Rutgers Robert Wood Johnson Medical School', 'class': 'OTHER'},\n",
       "     {'name': 'Pisa University Hospital', 'class': 'UNKNOWN'},\n",
       "     {'name': 'Assaf-Harofeh Medical Center', 'class': 'OTHER_GOV'},\n",
       "     {'name': 'Sheba Medical Center', 'class': 'OTHER_GOV'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'Patients with bloodstream infections, hospital acquired pneumonia or\\r\\nventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii\\r\\n(CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to\\r\\npatients treated treated with colistin alone or colistin combined with meropenem.',\n",
       "    'detailedDescription': 'This will be a prospective controlled clinical study with historical controls.\\r\\n\\r\\nIn the prospective CASCADE study consecutive consenting patients with bloodstream\\r\\ninfections, hospital acquired pneumonia or ventilator-associated pneumonia will be\\r\\ntreated with cefiderocol combined with ampicillin sulbactam in 3 hospitals in Israel and\\r\\n2 hospitals in Italy, all endemic for CRAB. We plan to recruit 150 patients into this\\r\\nprospective studies.\\r\\n\\r\\nThe CASCADE cohort will be compared to patients treated for the same types of infection\\r\\nin two recently completed randomized controlled trials (AIDA and OVERCOME). These trials\\r\\ncompared between treatment with colistin vs. treatment with colistin-meropenem\\r\\ncombination therapy, both finding no difference between treatment groups among patients\\r\\nwith carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia. Thus, patients in\\r\\nCASCADE will be compared to all patients with CRAB bloodstream infections, hospital\\r\\nacquired pneumonia or ventilator-associated pneumonia in these randomized controlled\\r\\ntrials.'},\n",
       "   'conditionsModule': {'conditions': ['Carbapenem Resistant Bacterial Infection',\n",
       "     'Acinetobacter Bacteremia',\n",
       "     'Acinetobacter Pneumonia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Controlled clinical study with historical controls',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 734, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cefiderocol + ampicillin-sulbactam',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Cefiderocol 2 gram intravenous (IV) q8 hours and ampicillin-sulbactam 3 gram IV q6 hours\\r\\nfor patients with normal creatinine clearance, both administered as extended infusion of\\r\\n3 hours. Dosing adjusted according to reduced and augmented renal clearance and to renal\\r\\nreplacement therapies.',\n",
       "      'interventionNames': ['Drug: Cefiderocol',\n",
       "       'Drug: Ampicillin-sulbactam']},\n",
       "     {'label': 'Colistin or colistin + meropenem',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Colistin 9 million units (MIU) intravenous (IV) loading dose followed by 4.5 MIU for\\r\\npatients with normal creatinine clearance +/- meropenem 2 gram IV administered as\\r\\nextended infusion of 3 hours. Dosing adjusted according to reduced and augmented renal\\r\\nclearance and to renal replacement therapies.',\n",
       "      'interventionNames': ['Drug: Colistin', 'Drug: Meropenem']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Cefiderocol',\n",
       "      'description': 'Test drug regimen',\n",
       "      'armGroupLabels': ['Cefiderocol + ampicillin-sulbactam'],\n",
       "      'otherNames': ['Fetroja']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Ampicillin-sulbactam',\n",
       "      'description': 'Synergistic combination',\n",
       "      'armGroupLabels': ['Cefiderocol + ampicillin-sulbactam'],\n",
       "      'otherNames': ['Unasyn']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Colistin',\n",
       "      'description': 'Historical comparator',\n",
       "      'armGroupLabels': ['Colistin or colistin + meropenem']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Meropenem',\n",
       "      'description': 'Historical comparator synergistic combination',\n",
       "      'armGroupLabels': ['Colistin or colistin + meropenem']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'All cause mortality',\n",
       "      'description': 'Death from any cause',\n",
       "      'timeFrame': '28 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'All cause mortality',\n",
       "      'description': 'Death from any cause',\n",
       "      'timeFrame': '14 days'},\n",
       "     {'measure': 'Clinical failure',\n",
       "      'description': 'Composite of:\\r\\n\\r\\n  -  Death\\r\\n\\r\\n  -  Systolic blood pressure ≤90 mmHg or need for vasopressor support\\r\\n\\r\\n  -  Worsening sequential organ failure assessment score (SOFA) score, define as:\\r\\n\\r\\n       -  for baseline SOFA ≥ 3: stable or increased\\r\\n\\r\\n       -  for baseline SOFA <3: any increase\\r\\n\\r\\n  -  For patients with hospital-acquired pneumonia (HAP)/ ventilator-associated pneumonia\\r\\n     (VAP), partial pressure of oxygen in arterial blood (PaO2)/ fraction of inspired\\r\\n     oxygen (FiO2) ratio worsened\\r\\n\\r\\n  -  For patients with bacteremia, growth of the initial isolate in blood cultures after\\r\\n     ≥ 5 days since study treatment start',\n",
       "      'timeFrame': 'Day 10-14'},\n",
       "     {'measure': 'Microbiological failure',\n",
       "      'description': 'Isolation of the initial isolate (phenotypically identical) in blood cultures 5 days or\\r\\nmore after start of treatment or in respiratory samples 7 days or more.',\n",
       "      'timeFrame': 'Day 5-7'},\n",
       "     {'measure': 'Resistance development to cefiderocol',\n",
       "      'description': \"Development of carbapenemase-producing Enterobacterales (CPE), non-CPE\\r\\ncarbapenem-resistant Enterobacterales (CRE), carbapenem-resistant A. baumannii (CRAB) and\\r\\ncarbapenem-resistant Pseudomonas aeruginosa (CRPA) resistance to cefiderocol in clinical\\r\\nand surveillance cultures collected as defined in the study's protocol\",\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Hospital stay',\n",
       "      'description': 'Among 28-day survivors',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Decline in functional capacity',\n",
       "      'description': 'Functional capacity will be assessed in four categories: independent; requires some\\r\\nassistance; requires assistance for activities of daily living (ADL); and bedridden.\\r\\nDecline in functional capacity will be defined as any 1-category worsening.',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Adverse event - Clostridiodes difficile infection',\n",
       "      'description': 'Diarrhea with a positive C. difficile toxin test',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Adverse event - renal failure',\n",
       "      'description': 'Renal failure due to any reason using the RIFLE ( risk, injury, failure, loss, End stage\\r\\nkidney disease) criteria (classifying patients to None, Risk, Injury, Failure, Loss and\\r\\nESRD) at day 14 and day 28 and defined as worsening by two RIFLE categories (e.g. from\\r\\nRisk to Failure, etc.)',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Adverse event - Acute liver injury',\n",
       "      'description': 'Increase in aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3-fold or\\r\\nincreased bilirubin >2 above upper limits of normal (ULN) or baseline value if higher\\r\\nthan ULN.',\n",
       "      'timeFrame': '28 days'}],\n",
       "    'otherOutcomes': [{'measure': 'Desirability of Outcome Ranking (DOOR)',\n",
       "      'description': 'Defined DOOR outcome analysis: Alive no event; Alive 1 event; Alive 2 events; Alive 3\\r\\nevents; Dead. The DOOR events will be: (1) Clinical failure as defined above (2) Hospital\\r\\nstay >14 days from enrolment (3) Adverse events: renal failure, Clostridiodes difficile\\r\\ninfection or acute liver injury',\n",
       "      'timeFrame': '28 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nAdults >18 years with bacteremia or hospital-acquired pneumonia (HAP)/\\r\\nventilator-associated pneumonia (VAP) (Table 3) caused by carbapenem-resistant A.\\r\\nbaumannii (CRAB) (meropenem and/ or imipenem minimal inhibitory concentration (MIC) >8\\r\\nμg/mL) susceptible to cefiderocol (disc zone diameter >=17 mm, corresponding to an MIC <2\\r\\nμg/mL). We will include CRAB regardless of colistin, ampicillin-sulbactam, minocycline,\\r\\ntigecycline, trimethoprim/sulfamethoxazole and/or aminoglycoside susceptibility of the\\r\\nisolate. Attribution of the HAP/ VAP to CRAB will be allowed with isolation of CRAB from\\r\\nany respiratory sample within 7 days prior to the clinical diagnosis of pneumonia.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  More than 72 hours of therapy with in-vitro coverage against the CRAB within 96\\r\\n     hours of enrolment\\r\\n\\r\\n  -  Polymicrobial carbapenem-susceptible infections: growth of other pathogens\\r\\n     susceptible to carbapenems, or another beta-lactam, deemed clinically-significant by\\r\\n     the treating physicians in blood or sputum (with HAP/ VAP). We will allow\\r\\n     recruitment of patients with other carbapenem-resistant Gram-negative bacteria\\r\\n\\r\\n  -  CRAB susceptible any beta-lactam other than cefiderocol\\r\\n\\r\\n  -  Coronavirus 2019 (COVID-19) co-infection\\r\\n\\r\\n  -  Immediate-type hypersensitivity to penicillin\\r\\n\\r\\n  -  Pregnant women\\r\\n\\r\\n  -  Previous participation in the trial\\r\\n\\r\\n  -  Lack of informed consent, considering the procedures acceptable to ethics committees\\r\\n     per locale, including deferred consent\\r\\n\\r\\n  -  Infection requiring treatment for over 14 days, at the discretion of the\\r\\n     investigators\\r\\n\\r\\n  -  Life expectancy less than 24 hours or expected futility of antibiotic treatment',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '16 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mical Paul',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0502062140',\n",
       "      'email': 'paulm@technion.ac.il'},\n",
       "     {'name': 'Marco Falcone',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'marco.falcone@unipi.it'}],\n",
       "    'overallOfficials': [{'name': 'Marco Falcone',\n",
       "      'affiliation': 'Pisa University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Dafna Yahav',\n",
       "      'affiliation': 'Sheba Medical Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Mical Paul',\n",
       "      'affiliation': 'Rambam Health Care Campus',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '37538951',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Kaye KS, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu CH, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, Paul M, Roilides E, Rybak M, Samarkos M, Sims M, Tancheva D, Tsiodras S, Kett D, Patel G, Calfee D, Leibovici L, Power L, Munoz-Price S, Stevenson K, Susick L, Latack K, Daniel J, Chiou C, Divine GW, Ghazyaran V, Pogue JM. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evid. 2023 Jan;2(1):10.1056/evidoa2200131. doi: 10.1056/evidoa2200131. Epub 2022 Dec 6.'},\n",
       "     {'pmid': '29456043',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Protocol will be published. At the end of the study the database will be made available\\r\\nfrom the lead author.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "    'timeFrame': 'As soon as published',\n",
       "    'accessCriteria': 'Justification to lead author'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011014',\n",
       "      'term': 'Pneumonia'},\n",
       "     {'id': 'D000001424', 'term': 'Bacterial Infections'},\n",
       "     {'id': 'D000016470', 'term': 'Bacteremia'}],\n",
       "    'ancestors': [{'id': 'D000012141', 'term': 'Respiratory Tract Infections'},\n",
       "     {'id': 'D000007239', 'term': 'Infections'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000001423', 'term': 'Bacterial Infections and Mycoses'},\n",
       "     {'id': 'D000018805', 'term': 'Sepsis'},\n",
       "     {'id': 'D000018746', 'term': 'Systemic Inflammatory Response Syndrome'},\n",
       "     {'id': 'D000007249', 'term': 'Inflammation'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M18877',\n",
       "      'name': 'Bacteremia',\n",
       "      'asFound': 'Bacteremia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13904',\n",
       "      'name': 'Pneumonia',\n",
       "      'asFound': 'Pneumonia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4722',\n",
       "      'name': 'Bacterial Infections',\n",
       "      'asFound': 'Bacterial Infections',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14978',\n",
       "      'name': 'Respiratory Tract Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12136', 'name': 'Mycoses', 'relevance': 'LOW'},\n",
       "     {'id': 'M4721',\n",
       "      'name': 'Bacterial Infections and Mycoses',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20864', 'name': 'Sepsis', 'relevance': 'LOW'},\n",
       "     {'id': 'M16869', 'name': 'Toxemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M20818',\n",
       "      'name': 'Systemic Inflammatory Response Syndrome',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10293', 'name': 'Inflammation', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000077731',\n",
       "      'term': 'Meropenem'},\n",
       "     {'id': 'D000003091', 'term': 'Colistin'},\n",
       "     {'id': 'D000000667', 'term': 'Ampicillin'},\n",
       "     {'id': 'D000013407', 'term': 'Sulbactam'},\n",
       "     {'id': 'D000097602', 'term': 'Cefiderocol'},\n",
       "     {'id': 'C000035444', 'term': 'Sultamicillin'}],\n",
       "    'ancestors': [{'id': 'D000000900', 'term': 'Anti-Bacterial Agents'},\n",
       "     {'id': 'D000000890', 'term': 'Anti-Infective Agents'},\n",
       "     {'id': 'D000065093', 'term': 'beta-Lactamase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000017262', 'term': 'Siderophores'},\n",
       "     {'id': 'D000007502', 'term': 'Iron Chelating Agents'},\n",
       "     {'id': 'D000002614', 'term': 'Chelating Agents'},\n",
       "     {'id': 'D000064449', 'term': 'Sequestering Agents'},\n",
       "     {'id': 'D000097902', 'term': 'Beta Lactam Antibiotics'}],\n",
       "    'browseLeaves': [{'id': 'M1889',\n",
       "      'name': 'Meropenem',\n",
       "      'asFound': 'Expiratory',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4003',\n",
       "      'name': 'Ampicillin',\n",
       "      'asFound': 'Passed',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16193',\n",
       "      'name': 'Sulbactam',\n",
       "      'asFound': 'Physical education',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M207969',\n",
       "      'name': 'Sultamicillin',\n",
       "      'asFound': 'Trichloroacetic acid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6319',\n",
       "      'name': 'Colistin',\n",
       "      'asFound': 'Urea',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3356',\n",
       "      'name': 'Cefiderocol',\n",
       "      'asFound': 'DMF',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M30450', 'name': 'beta-Lactamase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M10533', 'name': 'Iron', 'relevance': 'LOW'},\n",
       "     {'id': 'M5860', 'name': 'Chelating Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10534', 'name': 'Iron Chelating Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10789', 'name': 'Lactams', 'relevance': 'LOW'},\n",
       "     {'id': 'M25772', 'name': 'beta-Lactams', 'relevance': 'LOW'},\n",
       "     {'id': 'M4224',\n",
       "      'name': 'Antibiotics, Antitubercular',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3444', 'name': 'Beta Lactam Antibiotics', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Micro', 'name': 'Micronutrients'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06436235',\n",
       "    'orgStudyIdInfo': {'id': 'IRB24-0024'},\n",
       "    'organization': {'fullName': 'University of Chicago', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Kidney Stone Inflammation',\n",
       "    'officialTitle': 'Inflammation and Insulin Resistance in Kidney Stone Patients'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-08-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-03',\n",
       "    'studyFirstSubmitQcDate': '2024-05-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University of Chicago', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This observational study aims to look at the connections between kidney stones, insulin\\r\\nresistance, and inflammation. The researchers hypothesize that people who form calcium\\r\\nkidney stones and have insulin resistance may have higher levels of inflammation because\\r\\nthey have more visceral fat (fat around the abdominal organs).\\r\\n\\r\\nThe study will recruit 20 people who have had calcium kidney stones but don't have\\r\\ndiabetes, and 20 healthy people who haven't had kidney stones. All the participants will\\r\\ncome to the research center at the University of Chicago Medicine. Participants will have\\r\\na dual-energy X-ray absorptiometry (DEXA) scan to measure their visceral fat, and give\\r\\nblood and urine samples. The blood will be tested for insulin resistance, inflammatory\\r\\nmarkers, and other metabolic factors. The urine will be analyzed for substances that\\r\\nincrease kidney stone risk.\\r\\n\\r\\nThe main goal is to see if the kidney stone formers with insulin resistance have more\\r\\nvisceral fat compared to those without insulin resistance and the healthy participants.\\r\\nThe researchers will also compare inflammatory marker levels between groups, and look at\\r\\nhow visceral fat, inflammatory markers, insulin resistance, and urine stone risk factors\\r\\nare related.\\r\\n\\r\\nThe findings may help explain how kidney stones are connected to metabolic conditions\\r\\nlike diabetes and cardiovascular disease. Researchers hope this information will help\\r\\nidentify stone formers at risk early and develop preventive treatments in the future.\",\n",
       "    'detailedDescription': \"Participants will be recruited from the University of Chicago Medicine Kidney Stone\\r\\nClinic (stone formers) and research participant registries (controls). After providing\\r\\ninformed consent, participants will complete the following procedures:\\r\\n\\r\\nPre-Study:\\r\\n\\r\\n  1. One week prior, participants will discontinue vitamin C, multivitamins, calcium\\r\\n     supplements, and diuretics.\\r\\n\\r\\n  2. One day prior, participants will complete a 24-hour urine collection and food\\r\\n     frequency questionnaire at home.\\r\\n\\r\\nStudy Visit:\\r\\n\\r\\n  2. Participants will be admitted to the University of Chicago's Clinical Research\\r\\n     Center (CRC) in a fasted state.\\r\\n\\r\\n  3. Three timed (45 minute) urine and blood specimen collections will occur.\\r\\n\\r\\n  4. Three seated blood pressure measurements will be taken.\\r\\n\\r\\n  5. Anthropometric measurements including height, weight, waist and neck circumference\\r\\n     will be obtained.\\r\\n\\r\\n  6. A dual-energy X-ray absorptiometry (DEXA) scan will be performed to measure visceral\\r\\n     fat content and bone density.\\r\\n\\r\\n  7. A brief clinical history will be obtained, including data on kidney stone episodes,\\r\\n     procedures, and current stone burden.\\r\\n\\r\\n  8. Participants will remain fasted until all biological samples have been collected.\\r\\n     Water intake will be allowed ad libitum.\\r\\n\\r\\nSample Analysis:\\r\\n\\r\\nUrine:\\r\\n\\r\\n1.24-hour and timed urine samples will be analyzed for kidney stone risk chemistries\\r\\nincluding volume, pH, solutes (calcium, oxalate, uric acid, citrate, etc).\\r\\n\\r\\n  2. Urine supersaturations for calcium oxalate, calcium phosphate, and uric acid will be\\r\\n     calculated using EQUIL2 software.\\r\\n\\r\\n  3. Urine albumin and creatinine will be measured.\\r\\n\\r\\n  4. Remaining urine will be stored at -80°C for potential future assays.\\r\\n\\r\\nBlood:\\r\\n\\r\\n  1. Serum glucose will be measured at the CRC laboratory.\\r\\n\\r\\n  2. Serum insulin, C-peptide, glucagon, GLP-1, and inflammatory markers\\r\\n     (high-sensitivity CRP [C-reactive protein], IL-6, MMPs [matrix metalloproteinases],\\r\\n     TNF-alpha, endotrophin) will be measured at the Diabetes Research and Training\\r\\n     Center at the University of Chicago.\\r\\n\\r\\n  3. Other serum chemistries (electrolytes, calcium, creatinine, HbA1c, lipids) will be\\r\\n     measured at the clinical laboratory.\\r\\n\\r\\n  4. Remaining serum will be stored at -80°C.\"},\n",
       "   'conditionsModule': {'conditions': ['Kidney Stone', 'Stone, Kidney']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_CONTROL',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA',\n",
       "     'description': 'Any urine or serum/plasma that is not utilized for the specified measurements in this\\r\\nstudy will be frozen at -80°C and retained as biospecimens.'},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Kidney stone formers',\n",
       "      'description': 'The study team plans to enroll 20 non-diabetic participants with a history of at least\\r\\none calcium-based kidney stone. Activities are the same for both cohorts, as follows:\\r\\n\\r\\n  -  Before clinic visit, participants will halt specific supplements and diuretics for a\\r\\n     week.\\r\\n\\r\\n  -  At home, they complete a dietary questionnaire and collect 24-hour urine.\\r\\n\\r\\n  -  On the 7th day, they visit University of Chicago CRC. There, we will take\\r\\n     measurements (height, weight) and DEXA scan, alongside kidney stone history review.\\r\\n\\r\\n  -  Throughout the day, participants provide urine and blood samples, undergo blood\\r\\n     pressure checks, and fast until sample collection.\\r\\n\\r\\n  -  Samples undergo testing for kidney stone, inflammation, and diabetes risk factors\\r\\n     and are stored for future research.'},\n",
       "     {'label': 'Control cohort',\n",
       "      'description': 'The study team plans to enroll 20 healthy control participants with no history of kidney\\r\\nstones or family history of kidney stones. Activities are the same for both cohorts, as\\r\\nfollows:\\r\\n\\r\\n  -  Before clinic visit, participants will halt specific supplements and diuretics for a\\r\\n     week.\\r\\n\\r\\n  -  At home, they complete a dietary questionnaire and collect 24-hour urine.\\r\\n\\r\\n  -  On the 7th day, they visit University of Chicago CRC. There, we will take\\r\\n     measurements (height, weight) and DEXA scan, alongside kidney stone history review.\\r\\n\\r\\n  -  Throughout the day, participants provide urine and blood samples, undergo blood\\r\\n     pressure checks, and fast until sample collection.\\r\\n\\r\\n  -  Samples undergo testing for kidney stone, inflammation, and diabetes risk factors\\r\\n     and are stored for future research.'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Difference in visceral fat content in participants who form kidney stones with insulin resistance compared to participants who form kidney stones without insulin resistance and controls',\n",
       "      'description': 'Levels of visceral fat as measured by dual x-ray absorptiometry (DEXA).',\n",
       "      'timeFrame': '1 week total, one half day in the CRC'},\n",
       "     {'measure': 'Difference in inflammatory markers between participants who form kidney stones and controls',\n",
       "      'description': 'Markers of systemic inflammation, including high-sensitivity CRP, interleukin-6, MMP-7,\\r\\nMMP-9, TNF-alpha, and endotrophin.',\n",
       "      'timeFrame': '1 week total, one half day in the CRC'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Correlation between visceral fat and inflammatory markers',\n",
       "      'description': 'Correlation between visceral fat levels (measured by dual x-ray absorptiometry [DEXA])\\r\\nand the following markers of systemic inflammation:\\r\\n\\r\\n  -  High-sensitivity C-reactive protein (CRP)\\r\\n\\r\\n  -  Interleukin-6 (IL-6)\\r\\n\\r\\n  -  Matrix metalloproteinase-7 (MMP-7)\\r\\n\\r\\n  -  Matrix metalloproteinase-9 (MMP-9)\\r\\n\\r\\n  -  Tumor necrosis factor-alpha (TNF-alpha)\\r\\n\\r\\n  -  Endotrophin',\n",
       "      'timeFrame': '1 week total, one half day in the CRC'},\n",
       "     {'measure': 'Differences in urine composition',\n",
       "      'description': 'Differences in urine composition based on:\\r\\n\\r\\n  -  Levels of insulin resistance\\r\\n\\r\\n  -  Visceral fat content (measured by DEXA)\\r\\n\\r\\n  -  Levels of inflammatory markers (CRP, IL-6, MMP-7, MMP-9, TNF-alpha, endotrophin)',\n",
       "      'timeFrame': '1 week total, one half day in the CRC'},\n",
       "     {'measure': 'Differences in visceral fat levels',\n",
       "      'description': 'Differences in visceral fat levels (measured by DEXA) between kidney stone patients and\\r\\ncontrols',\n",
       "      'timeFrame': '1 week total, one half day in the CRC'},\n",
       "     {'measure': 'Differences in insulin resistance between kidney stone patients and controls',\n",
       "      'description': 'Differences in insulin resistance between kidney stone patients and controls, measured\\r\\nby:\\r\\n\\r\\n  -  Fasting blood glucose\\r\\n\\r\\n  -  Fasting insulin\\r\\n\\r\\n  -  Homeostatic model assessment of insulin resistance (HOMA-IR)',\n",
       "      'timeFrame': 'Time Frame: 1 week total, one half day in the CRC'},\n",
       "     {'measure': 'Differences in markers of systemic inflammation between kidney stone patients and controls',\n",
       "      'description': 'Differences in markers of systemic inflammation between kidney stone patients and\\r\\ncontrols, including:\\r\\n\\r\\n  -  High-sensitivity C-reactive protein (CRP)\\r\\n\\r\\n  -  Interleukin-6 (IL-6)\\r\\n\\r\\n  -  Matrix metalloproteinase-7 (MMP-7)\\r\\n\\r\\n  -  Matrix metalloproteinase-9 (MMP-9)\\r\\n\\r\\n  -  Tumor necrosis factor-alpha (TNF-alpha)\\r\\n\\r\\n  -  Endotrophin',\n",
       "      'timeFrame': 'Time Frame: 1 week total, one half day in the CRC'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Stone formers:\\r\\n\\r\\n  -  Age 18-70\\r\\n\\r\\n  -  History of at least one calcium-based kidney stone\\r\\n\\r\\n  -  Healthy Controls:\\r\\n\\r\\n  -  Age 18-70\\r\\n\\r\\n  -  No history of kidney stone or family history of kidney stones\\r\\n\\r\\nExclusion Criteria (for both groups):\\r\\n\\r\\n  -  History of primarily uric acid\\r\\n\\r\\n  -  Cysteine, or struvite stones\\r\\n\\r\\n  -  History of diabetes or impaired glucose tolerance\\r\\n\\r\\n  -  Previous thiazide use\\r\\n\\r\\n  -  Anyone on a medication that cannot be stopped that may affect urine composition\\r\\n\\r\\n  -  Previous bariatric surgery or ileostomy\\r\\n\\r\\n  -  Primary hyperparathyroidism and elevated serum calcium.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Kidney Stone Former Group:\\r\\n\\r\\nAge 18-70 years old History of at least one calcium-based kidney stone\\r\\n\\r\\nControl Group:\\r\\n\\r\\nAge 18-70 years old No personal history of kidney stones No family history of kidney\\r\\nstones\\r\\n\\r\\nExclusion Criteria for Both Groups:\\r\\n\\r\\nHistory of primarily uric acid, cysteine, or struvite stones History of diabetes or\\r\\nimpaired glucose tolerance Previous thiazide diuretic use Medications that cannot be\\r\\nstopped that may affect urine composition Previous bariatric surgery or ileostomy Primary\\r\\nhyperparathyroidism and elevated serum calcium',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Megan Prochaska, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '773-702-1000',\n",
       "      'phoneExt': '45488',\n",
       "      'email': 'mprocha2@medicine.bsd.uchicago.edu'},\n",
       "     {'name': 'Elaine Worcester, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '773-702-3630',\n",
       "      'email': 'eworcest@medicine.bsd.uchicago.edu'}],\n",
       "    'overallOfficials': [{'name': 'Megan Prochaska, MD',\n",
       "      'affiliation': 'University of Chicago',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Chicago Medical Center',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60637',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007669',\n",
       "      'term': 'Kidney Calculi'},\n",
       "     {'id': 'D000053040', 'term': 'Nephrolithiasis'},\n",
       "     {'id': 'D000007249', 'term': 'Inflammation'},\n",
       "     {'id': 'D000002137', 'term': 'Calculi'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000020763', 'term': 'Pathological Conditions, Anatomical'},\n",
       "     {'id': 'D000007674', 'term': 'Kidney Diseases'},\n",
       "     {'id': 'D000014570', 'term': 'Urologic Diseases'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000052878', 'term': 'Urolithiasis'},\n",
       "     {'id': 'D000014545', 'term': 'Urinary Calculi'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10693',\n",
       "      'name': 'Kidney Calculi',\n",
       "      'asFound': 'Kidney Stone',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10293',\n",
       "      'name': 'Inflammation',\n",
       "      'asFound': 'Inflammation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M27126',\n",
       "      'name': 'Nephrolithiasis',\n",
       "      'asFound': 'Kidney Stone',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5399',\n",
       "      'name': 'Calculi',\n",
       "      'asFound': 'Stone',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10370', 'name': 'Insulin Resistance', 'relevance': 'LOW'},\n",
       "     {'id': 'M22519',\n",
       "      'name': 'Pathological Conditions, Anatomical',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10698', 'name': 'Kidney Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M27103', 'name': 'Urolithiasis', 'relevance': 'LOW'},\n",
       "     {'id': 'M17295', 'name': 'Urinary Calculi', 'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365',\n",
       "      'name': 'Insulin',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'},\n",
       "     {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'},\n",
       "     {'id': 'M7411', 'name': 'Diuretics', 'relevance': 'LOW'},\n",
       "     {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06030986',\n",
       "    'orgStudyIdInfo': {'id': 'PREDOHCA'},\n",
       "    'organization': {'fullName': 'Kepler University Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Prediction of Outcome in Out-of-Hospital Cardiac Arrest',\n",
       "    'officialTitle': 'Prediction of Outcome in Out-of-Hospital Cardiac Arrest',\n",
       "    'acronym': 'PREDOHCA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-09-03',\n",
       "    'studyFirstSubmitQcDate': '2023-09-03',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-09-11', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-04',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-05', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Kepler University Hospital', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"In the course of prehospital respiratory and circulatory arrest, approximately 1000\\r\\npersons are resuscitated by cardiopulmonary resuscitation in Upper Austria every year.\\r\\nDespite constant further development of methods, equipment and continuous training of the\\r\\nrescue and emergency medical teams working on site, the majority of patients who have to\\r\\nbe resuscitated prehospital still die. However, even patients whose circulatory function\\r\\ncan be restored during prehospital resuscitation (Return of Spontaneous Circulation,\\r\\nROSC) require intensive medical care for days to weeks and often find it very difficult\\r\\nto return to a normal, independent life.\\r\\n\\r\\nThe success of resuscitation measures depends on the quality of the resuscitation\\r\\nperformed as well as on patient-specific factors. Evaluation scales such as the Cerebral\\r\\nPerformance Category score (CPC) allow a posteriori assessment of resuscitation success.\\r\\nNowadays, it is very difficult to estimate the outcome of resuscitation a priori. In many\\r\\ncases, it is not at all clear at the beginning of the treatment pathway whether the\\r\\nindividual patient is expected to have an unfavorable prognosis in the context of\\r\\nrespiratory arrest or whether a restitutio ad integrum is possible.\\r\\n\\r\\nThus, the decision to continue or discontinue resuscitation can only be made on the basis\\r\\nof an individual physician's assessment. In addition to the primary concern of stopping\\r\\nresuscitation too early, there is also the risk that medical resources are used beyond\\r\\nthe normal level after resuscitation without expecting a successful outcome. Estimating\\r\\nand categorizing the subsequent outcome is difficult and emotionally stressful for the\\r\\ntreating team in the acute situation. Some factors that influence outcome are now known:\\r\\nAs cerebral hypoperfusion increases, the probability of survival decreases sharply with\\r\\neach passing minute. In this context, potentially reversible causes have been identified\\r\\nin different works, allowing causal therapy to improve neurological outcome. In addition\\r\\nto the most important therapy bridging hypoperfusion, chest compression, with the aim of\\r\\nensuring minimal perfusion of the brain, immediate defibrillation should be mentioned in\\r\\nparticular, which now allows medical laypersons to use defibrillators as part of the\\r\\nPublic Access Defibrillation Network.\\r\\n\\r\\nDespite all efforts, however, it is not yet possible to make reliable statements about\\r\\nthe probable outcome of persons with respiratory and circulatory arrest with a high\\r\\ndegree of certainty in a large number of cases at an early stage.\\r\\n\\r\\nArtificial intelligence refers to the ability of machines to perform cognitive tasks,\\r\\nsuch as recognizing objects in images and classifying them. For a long time, many\\r\\nprocesses were too complex to explore through sufficient computing power, storage\\r\\ncapacity, and understanding. More recently, however, technological advances have brought\\r\\nmachine learning (ML) and the constructs behind it, including those based on so-called\\r\\nneural networks (known since about 1950), back to the fore. Not only the development of\\r\\ntheoretical models, but after extensive testing also devices applicable in daily routine\\r\\noperation are available.\\r\\n\\r\\nModern machine learning methods are enabling a variety of new approaches to assessing\\r\\noperations, including modeling complex systems and finding relationships between models.\"},\n",
       "   'conditionsModule': {'conditions': ['Cardiac Arrest']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'RETROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 10000, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'ILCOR Utstein OHCA Core Outcome Positive',\n",
       "      'description': 'Respectively for all core outcomes defined.',\n",
       "      'interventionNames': ['Diagnostic Test: ILCOR Utstein OHCA Core Outcome']},\n",
       "     {'label': 'ILCOR Utstein OHCA Core Outcome Negative',\n",
       "      'description': 'Respectively for all core outcomes defined.',\n",
       "      'interventionNames': ['Diagnostic Test: ILCOR Utstein OHCA Core Outcome']}],\n",
       "    'interventions': [{'type': 'DIAGNOSTIC_TEST',\n",
       "      'name': 'ILCOR Utstein OHCA Core Outcome',\n",
       "      'description': 'ILCOR Utstein OHCA Core Outcome',\n",
       "      'armGroupLabels': ['ILCOR Utstein OHCA Core Outcome Negative',\n",
       "       'ILCOR Utstein OHCA Core Outcome Positive']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'AUC-ROC for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'description': 'AUC-ROC for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'AUC-PRC for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'description': 'AUC-PRC for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'F1-Score for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'description': 'F1-Score for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'Confusion Matrix for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'description': 'Confusion Matrix for Prediction of ILCOR Utstein OHCA Core Outcome',\n",
       "      'timeFrame': '2015-01-01 to 2023-10-31'}],\n",
       "    'secondaryOutcomes': [{'measure': 'AUC-ROC for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'description': 'AUC-ROC for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'AUC-PRC for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'description': 'AUC-PRC for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'F1-Score for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'description': 'F1-Score for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'},\n",
       "     {'measure': 'Confusion Matrix for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'description': 'Confusion Matrix for Prediction of Diagnosis at Hospital Discharge',\n",
       "      'timeFrame': '2015-01-01 - 2023-10-31'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients 18 years or older AND\\r\\n\\r\\n  -  between 2015-01-01 and 2023-10-31 AND\\r\\n\\r\\n  -  have been treated by emergency medical teams of the Austrian Red Cross, District\\r\\n     Branch of Upper Austria AND\\r\\n\\r\\n  -  have suffered out-of-hospital cardiac arrest AND\\r\\n\\r\\n  -  have been treated by emergency physicians while out of hospital AND\\r\\n\\r\\n  -  have been transported to the Kepler University Hospital, Linz, Austria\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  none',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'As described in the inclusion criteria.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Thomas Tschoellitsch, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+435768083',\n",
       "      'phoneExt': '78132',\n",
       "      'email': 'thomas.tschoellitsch@jku.at'},\n",
       "     {'name': 'Jens Meier, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+435768083',\n",
       "      'phoneExt': '2158',\n",
       "      'email': 'jens.meier@kepleruniklinikum.at'}],\n",
       "    'locations': [{'facility': 'Kepler University Hospital',\n",
       "      'city': 'Linz',\n",
       "      'state': 'Upper Austria',\n",
       "      'zip': '4020',\n",
       "      'country': 'Austria',\n",
       "      'contacts': [{'name': 'Jens Meier, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+435768083',\n",
       "        'phoneExt': '2158',\n",
       "        'email': 'jens.meier@kepleruniklinikum.at'},\n",
       "       {'name': 'Thomas Tschoellitsch, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+435768083',\n",
       "        'phoneExt': '78132',\n",
       "        'email': 'thomas.tschoellitsch@jku.at'}],\n",
       "      'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006323',\n",
       "      'term': 'Heart Arrest'},\n",
       "     {'id': 'D000058687', 'term': 'Out-of-Hospital Cardiac Arrest'}],\n",
       "    'ancestors': [{'id': 'D000006331', 'term': 'Heart Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M9411',\n",
       "      'name': 'Heart Arrest',\n",
       "      'asFound': 'Cardiac Arrest',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29208',\n",
       "      'name': 'Out-of-Hospital Cardiac Arrest',\n",
       "      'asFound': 'Out-of-hospital Cardiac Arrest',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06389786',\n",
       "    'orgStudyIdInfo': {'id': 'MC230504'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-03306',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': '23-009377',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Mayo Clinic Institutional Review Board'},\n",
       "     {'id': 'MC230504', 'type': 'OTHER', 'domain': 'Mayo Clinic'}],\n",
       "    'organization': {'fullName': 'Mayo Clinic', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer',\n",
       "    'officialTitle': 'Safe Omission of Pelvic Lymph Node Dissection (SOuND) During Radical Prostatectomy: Diagnostic Accuracy of rhPSMA-7.3(18F) PET/CT, mpMRI and Patient Clinical Factors to Predict Lymph Node Metastasis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-25',\n",
       "    'studyFirstSubmitQcDate': '2024-04-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-25',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron\\r\\nemission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who\\r\\nare at risk of having their disease spread to the lymph nodes in those undergoing radical\\r\\nprostatectomy for prostate cancer that has not spread to other parts of the body\\r\\n(localized). Prostate specific membrane antigen (PSMA) PET/computed tomography (CT) has\\r\\nemerged as an option to stage newly diagnosed high risk prostate cancer patients. PSMA\\r\\nPET/CT has demonstrated improved diagnostic accuracy for identifying metastasis. PET is\\r\\nprocedure in which a small amount of radioactive glucose (sugar) is injected into a vein,\\r\\nand a scanner is used to make detailed, computerized pictures of areas inside the body\\r\\nwhere the glucose is used. Because cancer cells often use more glucose than normal cells,\\r\\nthe pictures can be used to find cancer cells in the body. MRI is procedure in which\\r\\nradio waves and a powerful magnet linked to a computer are used to create detailed\\r\\npictures of areas inside the body. These pictures can show the difference between normal\\r\\nand diseased tissue. This study may help researchers learn whether 18F-rhPSMA-7.3 PET/\\r\\nMRI may improve predicting which patients are at risk of lymph node metastases and who\\r\\nare suitable candidates for pelvic lymph node dissection in patients with localized\\r\\nhigh-risk prostate cancer undergoing radical prostatectomy.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To investigate the diagnostic ability of flotufolastat F-18 gallium (18F-rhPSMA-7.3)\\r\\nPSMA PET/MRI prior to radical prostatectomy in newly diagnosed, high-risk prostate cancer\\r\\npatients.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. Calculating the specificity, positive-predictive value, and negative-predictive value\\r\\nfor the detection of lymph node positivity.\\r\\n\\r\\nII. Investigating the rates of biochemical recurrence (BCR) as measured by post-operative\\r\\nprostate specific antigen (PSA) (PSA > 0.20) at pre-defined timepoints in patients.\\r\\n\\r\\nOUTLINE:\\r\\n\\r\\nPatients receive 18F-rhPSMA-7.3 intravenously (IV) and undergo PET/MRI up to 30 days\\r\\nprior to standard of care (SOC) robotic radical prostatectomy with bilateral pelvic lymph\\r\\nnode dissection. Patients also undergo CT or MRI, bone scan and tissue collection during\\r\\nscreening.\\r\\n\\r\\nUpon completion of study treatment, patients are followed up at 6 weeks, 3 months, 9\\r\\nmonths, and 12 months post-surgery.'},\n",
       "   'conditionsModule': {'conditions': ['Localized Prostate Carcinoma',\n",
       "     'Oligometastatic Prostate Carcinoma',\n",
       "     'Stage I Prostate Cancer AJCC v8',\n",
       "     'Stage II Prostate Cancer AJCC v8',\n",
       "     'Stage III Prostate Cancer AJCC v8',\n",
       "     'Stage IVA Prostate Cancer AJCC v8']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Screening (18F-rhPSMA-7.3 PET/MRI)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive 18F-rhPSMA-7.3 IV and undergo PET/MRI up to 30 days prior to SOC robotic\\r\\nradical prostatectomy with bilateral pelvic lymph node dissection. Patients also undergo\\r\\nCT or MRI, bone scan and tissue collection during screening.',\n",
       "      'interventionNames': ['Procedure: Bilateral Pelvic Lymph Node Dissection',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Scan',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Other: Electronic Health Record Review',\n",
       "       'Other: Flotufolastat F-18 Gallium',\n",
       "       'Procedure: Laparoscopic Radical Prostatectomy with Robotics',\n",
       "       'Procedure: Magnetic Resonance Imaging',\n",
       "       'Procedure: Positron Emission Tomography']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Bilateral Pelvic Lymph Node Dissection',\n",
       "      'description': 'Undergo bilateral pelvic lymph node dissection',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo tissue sample collection',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Scan',\n",
       "      'description': 'Undergo bone scan',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['Bone Scintigraphy']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Computed Tomography',\n",
       "      'description': 'Undergo CT',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['CAT',\n",
       "       'CAT Scan',\n",
       "       'Computed Axial Tomography',\n",
       "       'Computerized Axial Tomography',\n",
       "       'Computerized axial tomography (procedure)',\n",
       "       'Computerized Tomography',\n",
       "       'Computerized Tomography (CT) scan',\n",
       "       'CT',\n",
       "       'CT Scan',\n",
       "       'tomography']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Electronic Health Record Review',\n",
       "      'description': 'Ancillary studies',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Flotufolastat F-18 Gallium',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['(18F)-rhPSMA-7.3',\n",
       "       '18F-rhPSMA-7.3',\n",
       "       '18FrhPSMA-7.3',\n",
       "       'F-18-rhPSMA-7.3',\n",
       "       'Fluorine F 18 Radiohybrid PSMA-7.3',\n",
       "       'Fluorine F 18 rhPSMA-7.3',\n",
       "       'Fluorine-18 rhPSMA-7.3',\n",
       "       'Posluma',\n",
       "       'rhPSMA-7.3 (18F)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Laparoscopic Radical Prostatectomy with Robotics',\n",
       "      'description': 'Undergo robotic radical prostatectomy',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['RARP', 'Robot-assisted Radical Prostatectomy']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Magnetic Resonance Imaging',\n",
       "      'description': 'Undergo MRI or PET/MRI',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['Magnetic Resonance',\n",
       "       'Magnetic Resonance Imaging (MRI)',\n",
       "       'Magnetic resonance imaging (procedure)',\n",
       "       'Magnetic Resonance Imaging Scan',\n",
       "       'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance',\n",
       "       'MR',\n",
       "       'MR Imaging',\n",
       "       'MRI',\n",
       "       'MRI Scan',\n",
       "       'MRIs',\n",
       "       'NMR Imaging',\n",
       "       'NMRI',\n",
       "       'Nuclear Magnetic Resonance Imaging',\n",
       "       'sMRI',\n",
       "       'Structural MRI']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Positron Emission Tomography',\n",
       "      'description': 'Undergo PET/MRI',\n",
       "      'armGroupLabels': ['Screening (18F-rhPSMA-7.3 PET/MRI)'],\n",
       "      'otherNames': ['Medical Imaging, Positron Emission Tomography',\n",
       "       'PET',\n",
       "       'PET Scan',\n",
       "       'Positron emission tomography (procedure)',\n",
       "       'Positron Emission Tomography Scan',\n",
       "       'Positron-Emission Tomography',\n",
       "       'proton magnetic resonance spectroscopic imaging',\n",
       "       'PT']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Sensitivity of flotufolastat F-18 gallium (18F-rhPSMA-7.3) positron emission tomography (PET)/magnetic resonance (MRI) for the detection of lymph node metastasis',\n",
       "      'description': \"Defined as the presence of lymph node positivity determined on final pathologic analysis\\r\\ncompared to findings on preoperative 18F-rhPSMA-7.3 PSMA PET/MRI. Continuous variables\\r\\nwill be summarized as mean (standard deviation) or median (range) while categorical\\r\\nvariables will be reported as frequency (percentage). Chi-squared test or Fisher's exact\\r\\ntest will be used to compare the proportion of correct results will be compared between\\r\\nrhPSMA-7.3(18F) PET/MRI and the standard care. Will be two-sided with p value < 0.05\\r\\nconsidered statistically significant.\",\n",
       "      'timeFrame': 'Up to 12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Specificity',\n",
       "      'description': \"Defined as absence of lymph node metastasis on final pathologic analysis compared to\\r\\nfindings on preoperative 18F-rhPSMA-7.3 PSMA PET/MRI.\\r\\n\\r\\nWill be calculated as specificity with 95% confidence intervals. Chi-squared test or\\r\\nFisher's exact test will be used to compare the proportion of correct results between\\r\\nrhPSMA-7.3(18F) PET/MRI and the standard care.\",\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Positive/negative predictive value',\n",
       "      'description': 'Defined as findings on 18F-rhPSMA-7.3 prostate specific membrane antigen (PSMA) PET/MRI\\r\\ncompared to the presence or absence of lymph node metastasis on final pathologic\\r\\nanalysis. Proportion of correct results will be compared between rhPSMA-7.3(18F) PET/MRI\\r\\nand the standard care.',\n",
       "      'timeFrame': 'Up to 120 months'},\n",
       "     {'measure': 'Prostate specific antigen (PSA): < 5, 5-10, 10-20, > 20',\n",
       "      'description': 'Will investigate the impact of PSA as a clinicopathologic variable on lymph node\\r\\nmetastasis when used alone and in combination with PSMA PET/MRI using 18F-rhPSMA-7.3.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Gleason score',\n",
       "      'description': 'Will investigate the impact of Gleason score as a clinicopathologic variable on lymph\\r\\nnode metastasis when used alone and in combination with PSMA PET/MRI using\\r\\n18F-rhPSMA-7.3. Gleason score is a grading system for prostate cancer ranging from 6\\r\\n(low-grade cancer) to 10 (high-grade cancer).',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Digital rectal examination',\n",
       "      'description': 'Will investigate the impact of digital rectal examination as clinicopathologic variable\\r\\non lymph node metastasis when used alone and in combination with PSMA PET/MRI using\\r\\n18F-rhPSMA-7.3.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Number of patients where management has changed',\n",
       "      'description': 'Defined by the number of patients where PSMA PET/MRI depicts metastatic lesions (e.g.\\r\\nvisceral/skeletal) or suspicious lymph nodes outside the true pelvis where standard of\\r\\ncare imaging was negative. Proportion of correct results will be compared between\\r\\nrhPSMA-7.3(18F) PET/MRI and the standard care.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Rates of biochemical recurrent disease (BCR)',\n",
       "      'description': 'BCR rates will be defined as PSA > 0.20 between patients with either negative or positive\\r\\nevidence of PSMA avid disease as indicated on the 18F-rhPSMA-7.3 PSMA PET /MRI and\\r\\ncorrelated to historical controls. Patients with positive and negative preop imaging\\r\\nresults will be compared.',\n",
       "      'timeFrame': 'Up to 12 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Male subjects with at least age 30 to 85\\r\\n\\r\\n  -  Primary diagnosis of prostate cancer selected for surgical intervention (radical\\r\\n     prostatectomy with extended lymph node dissection)\\r\\n\\r\\n  -  Primary diagnosis of untreated American Urological Association (AUA) guidelines\\r\\n     high-risk localized prostate cancer, hormone-naïve prostate cancer via contrast\\r\\n     enhanced prostate MRI + tissue sampling\\r\\n\\r\\n  -  Planned elective radical prostatectomy with extended pelvic lymph node dissection\\r\\n\\r\\n  -  Clinical oligometastatic disease with < 3 nodes positive on 18F-rhPSMA-7.3 PSMA\\r\\n\\r\\n  -  Patient has the willingness to comply with instruction of the investigator\\r\\n\\r\\n  -  Patient has the willingness to comply with follow-up surveillance\\r\\n\\r\\n  -  Have ability to provide full written consent\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  High-risk cancer planned for neoadjuvant therapy\\r\\n\\r\\n  -  Patients with a history of more than two weeks treatment with immunosuppressants\\r\\n     (including systemic corticosteroids), cytotoxic chemotherapy within one month prior\\r\\n     to initial screening, or who receive such medications during the screening period,\\r\\n     or who are anticipated to require such medications during the course of the study\\r\\n\\r\\n  -  Patients that have had prior hormonal therapy such as Lupron or oral antiandrogens\\r\\n\\r\\n  -  Clinical oligometastatic disease with > 3 nodes positive on 18F-rhPSMA-7.3 PSMA\\r\\n\\r\\n  -  Previous history of pelvic radiation\\r\\n\\r\\n  -  Patients with obesity defined as body mass index (BMI) > 40 kg/m^2\\r\\n\\r\\n  -  History of prior mesh for inguinal hernia repair\\r\\n\\r\\n  -  Scheduled at the time of screening to undergo chemotherapy, radiation, hormone\\r\\n     therapy, or open surgery during the study period\\r\\n\\r\\n  -  Inability to lie still for 75 minutes during 18F-rhPSMA-7.3 PSMA PET-MRI imaging\\r\\n\\r\\n  -  Any neurologic disorder or psychiatric disorder that might confound postsurgical\\r\\n     assessments\\r\\n\\r\\n  -  Has any condition(s), which seriously compromises the subject's ability to\\r\\n     participate in this study, sign consent, or has a known history of poor adherence\\r\\n     with medical treatment\\r\\n\\r\\n  -  Received administration of an investigational drug within 30 days prior to study,\\r\\n     and/or has planned administration of another investigational product or procedure\\r\\n     during participation in this study\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '30 Years',\n",
       "    'maximumAge': '85 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Ram A. Pathak, M.D.',\n",
       "      'affiliation': 'Mayo Clinic',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Mayo Clinic in Florida',\n",
       "      'city': 'Jacksonville',\n",
       "      'state': 'Florida',\n",
       "      'zip': '32224-9980',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Clinical Trials Referral Office',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '855-776-0015',\n",
       "        'email': 'mayocliniccancerstudies@mayo.edu'},\n",
       "       {'name': 'Ram A. Pathak, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Mayo Clinic Clinical Trials',\n",
       "      'url': 'https://www.mayo.edu/research/clinical-trials'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002277',\n",
       "      'term': 'Carcinoma'},\n",
       "     {'id': 'D000011471', 'term': 'Prostatic Neoplasms'},\n",
       "     {'id': 'D000008207', 'term': 'Lymphatic Metastasis'}],\n",
       "    'ancestors': [{'id': 'D000009375',\n",
       "      'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000005834', 'term': 'Genital Neoplasms, Male'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000005832', 'term': 'Genital Diseases, Male'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000011469', 'term': 'Prostatic Diseases'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'},\n",
       "     {'id': 'D000009362', 'term': 'Neoplasm Metastasis'},\n",
       "     {'id': 'D000009385', 'term': 'Neoplastic Processes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M12307',\n",
       "      'name': 'Neoplasm Metastasis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14335',\n",
       "      'name': 'Prostatic Neoplasms',\n",
       "      'asFound': 'Prostate Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5534',\n",
       "      'name': 'Carcinoma',\n",
       "      'asFound': 'Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11204',\n",
       "      'name': 'Lymphatic Metastasis',\n",
       "      'asFound': 'Lymph Node Metastasis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8946', 'name': 'Genital Neoplasms, Male', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8944', 'name': 'Genital Diseases, Male', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14333', 'name': 'Prostatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12330', 'name': 'Neoplastic Processes', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000005459',\n",
       "      'term': 'Fluorides'}],\n",
       "    'ancestors': [{'id': 'D000002327', 'term': 'Cariostatic Agents'},\n",
       "     {'id': 'D000020011', 'term': 'Protective Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M8587',\n",
       "      'name': 'Fluorides',\n",
       "      'asFound': 'Insufficiency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05973786',\n",
       "    'orgStudyIdInfo': {'id': '2023-506605-19-00 (EU CT#)'},\n",
       "    'organization': {'fullName': 'UMC Utrecht', 'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'officialTitle': 'A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'acronym': 'INTENSIFY BD'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-25',\n",
       "    'studyFirstSubmitQcDate': '2023-07-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr. Inge Winter',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'UMC Utrecht'},\n",
       "    'leadSponsor': {'name': 'Dr. Inge Winter', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Universität Münster', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Bipolar disorders affect approximately 4.5 million people across the European Union (EU)\\r\\nand are associated with high annual healthcare and societal costs. Bipolar disorder I and\\r\\nII represent disorders that cause extreme fluctuation in a person's mood, energy, and\\r\\nability to function, in which symptoms of (hypo)mania and depression alternate. The\\r\\ndepressive episodes of bipolar disorders are often referred to as bipolar depression\\r\\n(BD). In other words: it is a phase/state of the disorder. For many patients with BD, the\\r\\ndepressive polarity is often more pervasive and more debilitating than manic states, with\\r\\nestimates that depressed mood accounts for up to two-thirds of the time spent unwell,\\r\\neven with treatment. The burden of not received an effective treatment for BD is high:\\r\\nmore severe psychopathology, higher rates of unemployment, more hospitalisations, lower\\r\\nquality of life, lower cognitive functioning, risk of suicide, comorbidities and poorer\\r\\nsocial and occupational functioning and thus more carer burden. For BD, the treatment\\r\\nguidelines are very heterogeneous, amongst other reasons because the disease is\\r\\nheterogeneous and treatments should be tailored to the patients. There is no clear\\r\\ntreatment algorithm and it cannot yet be predicted which treatment will be effective.\\r\\nEspecially the place of adjunctive antidepressants is under debate. Usually, for\\r\\npsychiatric disorders (including bipolar disorder), a patient is considered to be\\r\\ntreatment-resistant is two medicinal treatments have been tried (in sufficient duration\\r\\nand dosage) without sufficient success. For BD, there is no consensus on when to consider\\r\\na patient as treatment-resistant, but the most common definition is after one prior\\r\\ntreatment failure. This raises the research question whether adjunctive antidepressants\\r\\nto treat BD should be introduced earlier in the treatment. Additionally, The INTENSIFY\\r\\ntrial is part of the larger Horizon 2021 project, with the central goal of paving the way\\r\\nfor a shift towards a treatment decision-making process tailored for the individual at\\r\\nrisk for treatment resistance. To that end, we aim to establish evidence-based criteria\\r\\nto make decisions of early intense treatment in individuals at risk for treatment\\r\\nresistance across the major psychiatric disorders of schizophrenia, bipolar disorder and\\r\\nmajor depression.\",\n",
       "    'detailedDescription': \"Rationale Bipolar disorders affect approximately 4.5 million people across the European\\r\\nUnion (EU) and are associated with high annual healthcare and societal costs. Bipolar\\r\\ndisorder I and II represent disorders that cause extreme fluctuation in a person's mood,\\r\\nenergy, and ability to function, in which symptoms of (hypo)mania and depression\\r\\nalternate. The depressive episodes of bipolar disorders are often referred to as bipolar\\r\\ndepression (BD). In other words: it is a phase/state of the disorder. For many patients\\r\\nwith BD, the depressive polarity is often more pervasive and more debilitating than manic\\r\\nstates, with estimates that depressed mood accounts for up to two-thirds of the time\\r\\nspent unwell, even with treatment. The burden of not received an effective treatment for\\r\\nBD is high: more severe psychopathology, higher rates of unemployment, more\\r\\nhospitalisations, lower quality of life, lower cognitive functioning, risk of suicide,\\r\\ncomorbidities and poorer social and occupational functioning and thus more carer burden.\\r\\nFor BD, the treatment guidelines are very heterogeneous, amongst other reasons because\\r\\nthe disease is heterogeneous and treatments should be tailored to the patients. There is\\r\\nno clear treatment algorithm and it cannot yet be predicted which treatment will be\\r\\neffective. Especially the place of adjunctive antidepressants is under debate. Usually,\\r\\nfor psychiatric disorders (including bipolar disorder), a patient is considered to be\\r\\ntreatment-resistant is two medicinal treatments have been tried (in sufficient duration\\r\\nand dosage) without sufficient success. For BD, there is no consensus on when to consider\\r\\na patient as treatment-resistant, but the most common definition is after one prior\\r\\ntreatment failure. This raises the research question whether adjunctive antidepressants\\r\\nto treat BD should be introduced earlier in the treatment. Additionally, The INTENSIFY\\r\\ntrial is part of the larger Horizon 2021 project, with the central goal of paving the way\\r\\nfor a shift towards a treatment decision-making process tailored for the individual at\\r\\nrisk for treatment resistance. To that end, we aim to establish evidence-based criteria\\r\\nto make decisions of early intense treatment in individuals at risk for treatment\\r\\nresistance across the major psychiatric disorders of schizophrenia, bipolar disorder and\\r\\nmajor depression.\\r\\n\\r\\nObjective The primary objective is to compare the treatment response (baseline; visit 2\\r\\nvs. end of treatment; visit 4), expressed as symptom severity at six weeks and changes in\\r\\nsymptom severity from baseline, as measured through the Montgomery-Åsberg Depression\\r\\nRating Scale (MADRS) under an early-intensified pharmacological treatment to that under\\r\\ntreatment as usual, in subjects who had a first-time treatment failure on their\\r\\nfirst-line treatment.\\r\\n\\r\\nMain trial endpoints Change in symptom severity total score from baseline (visit 2) to\\r\\nend of treatment (visit 4). This is measured using MADRS.\\r\\n\\r\\nSecondary trial endpoints\\r\\n\\r\\n  1. To compare changes in severity and improvement in global functioning assessed by the\\r\\n     Clinical Global Impression Scale (CGI) between the two treatment arms.\\r\\n\\r\\n  2. To compare changes in the levels of depression and anxiety between treatment arms.\\r\\n\\r\\n  3. To compare changes in quality of life and functioning measures between treatment\\r\\n     arms.\\r\\n\\r\\n  4. To compare changes in cognitive performance between treatment arms.\\r\\n\\r\\n  5. To compare the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\n     remission at visit 4.\\r\\n\\r\\n  6. To compare presence of side effects between treatment arms.\\r\\n\\r\\n  7. To compare use of concomitant medication between treatment arms.\\r\\n\\r\\n  8. To compare premature discontinuation (timing and reason) between treatment arms.\\r\\n\\r\\n  9. To compare changes in suicidal ideation between treatment arms.\\r\\n\\r\\n 10. To compare occurrence of (hypo)manic episode during the study between the treatment\\r\\n     arms.\\r\\n\\r\\nTrial design The clinical study is an international, multicenter controlled, randomised,\\r\\nopen label trial (with blinded raters), with a treatment duration of six weeks.\\r\\n\\r\\nTrial population The aim is to recruit 418 subjects with bipolar disorder type I or II,\\r\\ncurrently in a depressive episode. Male and female subjects, in- and out-patients, with\\r\\nthe age of at least 18 old are eligible for participation. The main exclusion criteria\\r\\nare defined to protect the wellbeing of subjects, e.g. being pregnant or breastfeeding,\\r\\nsubjects with previous failure on quetiapine, meeting any contraindications, or\\r\\nparticipants with a known intolerance to quetiapine.\\r\\n\\r\\nInterventions\\r\\n\\r\\nSubjects are randomised to treatment as usual (second-line treatment) or to the\\r\\nearly-intensified pharmacological treatment (third-line treatment). Treatment per can be\\r\\nfound in the table below:\\r\\n\\r\\nTable 1. Overview of treatment randomisation per study sample.\\r\\n\\r\\nTreatment as Usual (TAU) Switch to quetiapine plus lithium or valproate acid\\r\\nEarly-Intensified Pharmacological Treatment (EIPT) Switch to\\r\\n\\r\\n  1. one of the following: escitalopram, sertraline, duloxetine, bupropion or venlafaxine\\r\\n     plus\\r\\n\\r\\n  2. two of the following: lithium, valproate acid or quetiapine\\r\\n\\r\\nEthical considerations relating to the clinical trial including the expected benefit to\\r\\nthe individual subject or group of subjects represented by the trial subjects as well as\\r\\nthe nature and extent of burden and risks All medications studied in the current trial\\r\\nare widely used (alone or in combination) in clinical practice and the risks for side\\r\\neffects are well established. In the current study, clinical practice is mimicked as much\\r\\nas possible to maximize generalisability and for feasibility purposes. To this end,\\r\\nSummaries of Product Characteristics (SmPCs) are followed with regards to\\r\\ncontraindications (implemented as exclusion criterion), safety measures and allowed\\r\\ncombinations with other medications. Site visits and assessments are kept to a minimum to\\r\\nkeep subject burden at an acceptable level, while meeting the objectives of the study.\\r\\nBlood samples for biomarker analyses are only collected when subjects provide consent;\\r\\nsafety measures are performed as part of clinical routine.\\r\\n\\r\\nOverall, the risks are similar to daily clinical practice; the only difference relative\\r\\nto clinical practice is the application of three pharmacological treatments (EIPT) versus\\r\\ntwo (TAU) earlier in the illness. Still, these additional treatment options are also\\r\\ncommonly prescribed by clinicians. There are no indications in existing literature or\\r\\nclinical practice that the earlier introduction of these medications poses a safety risk\\r\\nwhen used in an earlier illness phase than indicated in the SmPC.\\r\\n\\r\\nA benefit of the study is that if it indeed turns out that the early-intensified\\r\\ntreatment is associated with more symptom improvement compared to treatment as usual,\\r\\nfuture patients have to go through less trial and error, which results in a reduced\\r\\nburden (higher quality of life, less unemployment, less hospitalisations) for patients\\r\\nand carers as well as lower societal and healthcare costs.\\r\\n\\r\\nIMPORTANT: the study was submitted to the European authorities before (see NCT05603104)\\r\\nand they requested to split this study into 3 studies (1 for each diagnostic category).\\r\\nWe have done this and created 3 new ClinicalTrials.gov studies as well, from which this\\r\\nis one for bipolar depression. The ClinicalTrials.gov numbers of the related trials are\\r\\nNCT05958875 for the INTENSIFY SZ trial and NCT05973851 for the INTENSIFY MDD trial. The\\r\\nsite in the UK (London) followed the advice and will submit 3 separate protocols and are\\r\\ntherefore included in the current record. However, Israel already submitted this as one\\r\\nprotocol. Therefore, we keep the old clinicaltrials.gov number for Israel (NCT05603104).\"},\n",
       "   'conditionsModule': {'conditions': ['Bipolar Depression']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified\\r\\npharmacological treatment (EIPT).',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Open label, except for the assessors of the primary outcome',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 418, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Bipolar Depression EIPT: Switch to one of the following combinations:',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Bipolar Depression randomized to EIPT: Switch to 1. one of the following: escitalopram,\\r\\nsertraline, or venlafaxine plus 2. two of the following: lithium, valproate acid or\\r\\nquetiapine',\n",
       "      'interventionNames': ['Drug: Escitalopram',\n",
       "       'Drug: Sertraline',\n",
       "       'Drug: Venlafaxine',\n",
       "       'Drug: Lithium',\n",
       "       'Drug: Valproate acid',\n",
       "       'Drug: Quetiapine']},\n",
       "     {'label': 'Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"Bipolar Depression randomized to TAU: Switch to quetiapine plus lithium or valproate acid\\r\\nCompound, brand, dosage, frequency and duration up to the investigator's discretion (in\\r\\naccordance with SmPC).\",\n",
       "      'interventionNames': ['Drug: Lithium',\n",
       "       'Drug: Valproate acid',\n",
       "       'Drug: Quetiapine']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Escitalopram',\n",
       "      'description': 'ATC code: N06AB10',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:'],\n",
       "      'otherNames': ['ATC code: N06AB10']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Sertraline',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:'],\n",
       "      'otherNames': ['ATC code: N06AB06']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venlafaxine',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:'],\n",
       "      'otherNames': ['ATC code: N06AX16']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Lithium',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:',\n",
       "       'Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine'],\n",
       "      'otherNames': ['ATC code: N05AN01']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Valproate acid',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:',\n",
       "       'Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine'],\n",
       "      'otherNames': ['ATC code: N03AG01']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Quetiapine',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Bipolar Depression EIPT: Switch to one of the following combinations:',\n",
       "       'Bipolar Depression TAU: Switch to quetiapine plus lithium or valproate acid or lamotrigine'],\n",
       "      'otherNames': ['ATC code: N05AH04']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Comparing the change in symptom severity on Montgomery Asberg Depression Rating Scale',\n",
       "      'description': 'Mean in symptom severity (EIPT vs. TAU) total score from baseline (visit 2) to end of\\r\\ntreatment (visit 4). This is measured using the Montgomery Asberg Depression Rating\\r\\nScale.Minimum score is 0, maximum score is 60. A bigger mean change means a better\\r\\noutcome',\n",
       "      'timeFrame': '6 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Compare proportion of participants that is in symptomatic remission',\n",
       "      'description': 'Comparison of the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\nremission at visit 4. Remission is defined as a Montgomery Asberg Depression Rating scale\\r\\nscore of ≤ 12.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the change in the severity and improvement CGI-S sub-scores',\n",
       "      'description': 'To compare changes in the severity sub-score of the Clinical Global Impression Scale (CGI\\r\\n2) between the two treatment arms (EIPT/TAU) over the six week treatment period (visit 2\\r\\nversus visit 4). Higher scores indicate higher illness severity. Minimum score: 1,\\r\\nmaximum score: 7',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the change in the severity and improvement CGI-I sub-scores',\n",
       "      'description': 'To compare mean changes in the total improvement sub-score of the Clinical Global\\r\\nImpression (CGI 2) between the two treatment arms (EIPT/TAU) over the six week treatment\\r\\nperiod (visit 2 versus visit 4). A higher score means lower treatment improvement.\\r\\nMinimum score: 1, maximum score: 7',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the changes in the levels of depression and anxiety',\n",
       "      'description': 'To compare changes in the levels of depression and anxiety as assessed with the Hospital\\r\\nAnxiety and Depression Scale between the two treatment arms (EIPT/TAU) over the four week\\r\\ntreatment period (visit 2 versus visit 4). Lower scores mean less depression and anxiety.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in cognitive performance as measured through the Trail Making Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Trail Making Test\\r\\nbetween the two treatment arms over the four weeks treatment period (visit 2 versus visit\\r\\n4). A lower time to complete the test means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Rey Auditory Verbal\\r\\nLearning Test between the two treatment arms over the six weeks treatment period (visit 2\\r\\nversus visit 4). A higher scores means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in subjective cognitive performance as measured through the Perceived Deficits Questionnaire',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Perceived Deficits\\r\\nQuestionnaire between the two treatment arms over the six weeks treatment period (visit 2\\r\\nversus visit 4). A higher scores means worse subjective cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in functioning on the Leuven Affective and Pleasure Scale',\n",
       "      'description': 'To compare changes in the functioning measure, Leuven Affective and Pleasure Scale,\\r\\nbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit\\r\\n4). A higher scores means worse functioning. Minimum score: 0, Maximum score: 160',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in functioning on the Sheehan Disability Scale',\n",
       "      'description': 'To compare changes in the functioning measure,Sheehan Disability Scale, between the two\\r\\ntreatment arms over the six weeks treatment period (visit 2 versus visit 4). A higher\\r\\nscores means worse functioning. Minimum score: 0, maximum score 30.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in quality of life measure, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form',\n",
       "      'description': 'To compare changes in quality of life measure, Quality of Life Enjoyment and Satisfaction\\r\\nQuestionnaire Short Form between the two treatment arms over the four weeks treatment\\r\\nperiod (visit 2 versus visit 4). A higher scores means better quality of life. Minimum\\r\\nscore: 16, maximum score: 80.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in quality of life measure, Quality of Life Scale -100, subscale inner tension',\n",
       "      'description': \"To compare changes in quality of life measure, Quality of Life Scale -100, subscale inner\\r\\ntension between the two treatment arms over the four weeks treatment period (visit 2\\r\\nversus visit 4). This is a dichotomous scale (unsatisfactory or satisfactory). More\\r\\n'satisfactory' answers means higher quality of life.\",\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the frequency of occurence of side effects between the two treatment arms.',\n",
       "      'description': 'To compare presence of side effects as measured through General Assessment of Side\\r\\nEffects Scale and reported spontaneously between the two treatment arms (EIPT/TAU) over\\r\\nthe six week treatment period (visit 2 versus visit 4). Higher scores means more side\\r\\neffects. Minimum score: 0 side effects, maximum score: 38 side effects.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the proportion of participants using concomitant medication between the two treatment arms.',\n",
       "      'description': 'To compare use of concomitant medication between the two treatment arms (EIPT/TAU) over\\r\\nthe six week treatment period (visit 2 versus visit 4) effects.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the proportion of participants who prematurely discontinue between the two treatment arms.',\n",
       "      'description': 'To compare premature discontinuation between the two treatment arms (EIPT/TAU) over the\\r\\nsix week treatment period (visit 2 versus visit 4).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the reason of participants that prematurely discontinue the study between the two treatment arms.',\n",
       "      'description': 'To compare the difference in reasons for premature discontinuation between the two\\r\\ntreatment arms (EIPT/TAU) over the six week treatment period (visit 2 versus visit 4).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in suicidal ideation between treatment arms.',\n",
       "      'description': \"Changes from baseline (visit 2) on Module B 'Suicidality' of the Mini International\\r\\nNeuropsychiatric Interview (v7.0.2) at V4 between the two treatment arms. A score of 1-8\\r\\npoints on this module means that the suicide risk is low, scores 9-16 means a moderate\\r\\nrisk and 17 points or higher means that there is a high risk. The minimum score is 0 and\\r\\nthe maximum score is 154.\",\n",
       "      'timeFrame': '6 weeks.'},\n",
       "     {'measure': 'To compare occurrence of (hypo)manic episode during the study between the treatment arms',\n",
       "      'description': 'Occurrence of (hypo)manic episodes throughout the study (including V5); EIPT vs TAU.\\r\\nScores of 12 or higher means that a participant is in a (hypo)manic episode of bipolar\\r\\ndisorder.',\n",
       "      'timeFrame': '6 weeks.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion criteria:\\r\\n\\r\\n  1. In- or out patients, at least 18 years of age.\\r\\n\\r\\n  2. Being willing and able to provide written informed consent. Having a legal guardian\\r\\n     to cosign is allowed. Informed consent will be signed at visit 1, before any study\\r\\n     procedure.\\r\\n\\r\\n  3. Female subjects of child bearing potential must use effective contraception during\\r\\n     the trial as per the requirements of the applicable SmPCs and should have a negative\\r\\n     pregnancy test at visit 1 (section 8.2.1).\\r\\n\\r\\n  4. Meeting diagnostic criteria for a primary diagnosis of bipolar depression (bipolar\\r\\n     disorder type I and II currently in a depressive episode), according to DSM-5. The\\r\\n     primary diagnosis will be confirmed by the Mini International Neuropsychiatric\\r\\n     Interview (MINI v7.0.2).\\r\\n\\r\\n  5. Subject currently experiences his/her first treatment failure due to lack of\\r\\n     efficacy; this treatment is a first-line pharmacotherapeutic agent for the primary\\r\\n     DSM-5 diagnosis, and was prescribed for at least 4 weeks within the dose range as\\r\\n     specified in the Summary of Product Characteristics (SmPCs).\\r\\n\\r\\n  6. Subject has failed on current psychopharmacological treatment of current episode BD\\r\\n     as confirmed by a CGI-I ≥3.\\r\\n\\r\\n  7. Subject and clinician intend to change pharmacotherapeutic treatment.\\r\\n\\r\\n  8. A minimum symptom severity threshold needs to be present (moderate level; see below)\\r\\n     and subject needs to experience functional impairment.\\r\\n\\r\\n       -  The minimum symptom severity threshold is a score of ≥20 on the Montgomery\\r\\n          Åsberg Depression Rating Scale (MADRS)\\r\\n\\r\\n       -  Functional impairment is defined as a score of 5 or higher on any of the three\\r\\n          scales of the Sheehan Disability Scale (SDS).\\r\\n\\r\\nExclusion criteria\\r\\n\\r\\n  1. Being pregnant or breastfeeding.\\r\\n\\r\\n  2. Subject has failed previously on quetiapine due to inefficacy (after treatment\\r\\n     duration of ≥ 4 weeks within an efficacious dose range according to the SmPC.\\r\\n\\r\\n  3. Subject has a known intolerance to quetiapine or to all EIPT medication or to all\\r\\n     TAU medication.\\r\\n\\r\\n  4. Meeting any of the contraindications for quetiapine, or to all EIPT medication or to\\r\\n     all TAU medication options, as specified within the applicable SmPC, supported by\\r\\n     clinically significant abnormal values on local laboratory tests, electrocardiogram\\r\\n     (ECG) or physical examinations. *\\r\\n\\r\\n  5. Subject has participated in another clinical trial in which the subject received an\\r\\n     experimental or investigational drug or agent within 30 days before visit 1.\\r\\n\\r\\n  6. Subject currently uses more than the allowed psychotropic concomitant medication and\\r\\n     needs to stay on this medication during the study.\\r\\n\\r\\n  7. Subject experiences any other significant disease or disorder which, in the opinion\\r\\n     of the investigator, may either put the subjects at risk because of participation in\\r\\n     the trial, or may influence the result of the trial, or the subject's ability to\\r\\n     participate in the trial.\\r\\n\\r\\n  8. Moderate or high suicidal ideation within the last 2 weeks, defined as a score of 9\\r\\n     or higher on Module B (Suicidality) of the Mini International Neuropsychiatric\\r\\n     Interview (MINI v7.0.2)\\r\\n\\r\\n  9. Subject meets criteria for current substance use disorder, as confirmed by the Mini\\r\\n     International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is\\r\\n     allowed, as well as mild alcohol and/or cannabis use disorder (as defined by MINI\\r\\n     v7.0.2). Moderate and severe alcohol and/or cannabis use disorder are not allowed.\\r\\n\\r\\n 10. Subjects have not been committed to an institution by virtue of an order issued\\r\\n     either by the judicial or the administrative authorities.\\r\\n\\r\\n 11. A score of 12 or higher on the Young Mania Rating Scale (YMRS) in order to exclude\\r\\n     subjects with predominant manic symptoms or mixed symptoms.\\r\\n\\r\\n 12. Subjects dependent on the sponsor, investigator or trial site must be excluded from\\r\\n     participation in advance.\\r\\n\\r\\n 13. Subjects with pre-existing severe liver damage (as tested within the local\\r\\n     laboratory test at visit 1).\\r\\n\\r\\n 14. Subjects with a history of antidepressant-induced mania or hypomania or recent rapid\\r\\n     cycling (based on the medical file of the potential participant or the clinical\\r\\n     judgment of the clinician).\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Inge Winter, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'i.winter@umcutrecht.nl'},\n",
       "     {'name': 'Cynthia Okhuijsen-Pfeifer, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'c.pfeifer@umcutrecht.nl'}],\n",
       "    'locations': [{'facility': 'Medical University Innsbruck',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Innsbruck',\n",
       "      'country': 'Austria',\n",
       "      'contacts': [{'name': 'Alex Hofer, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'a.hofer@i-med.ac.at'}],\n",
       "      'geoPoint': {'lat': 47.26266, 'lon': 11.39454}},\n",
       "     {'facility': 'Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Bielefeld',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Martin Driessen, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'martin.driessen@evkb.de'}],\n",
       "      'geoPoint': {'lat': 52.03333, 'lon': 8.53333}},\n",
       "     {'facility': 'University Hospital Frankfurt am Main - Goethe University',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Frankfurt am Main',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Andreas Reif, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'andreas.reif@kgu.de'}],\n",
       "      'geoPoint': {'lat': 50.11552, 'lon': 8.68417}},\n",
       "     {'facility': 'Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Mainz',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Klaus Lieb',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'klaus.lieb@lir-mainz.de'}],\n",
       "      'geoPoint': {'lat': 49.98419, 'lon': 8.2791}},\n",
       "     {'facility': 'Westfälische Wilhelms-Universität Münster',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Münster',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Bernhard Baune',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Bernhard.Baune@ukmuenster.de'}],\n",
       "      'geoPoint': {'lat': 51.96236, 'lon': 7.62571}},\n",
       "     {'facility': 'Universita degli Studi di Brescia',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Brescia',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Antonio Vita, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'antonio.vita@unibs.it'}],\n",
       "      'geoPoint': {'lat': 45.53558, 'lon': 10.21472}},\n",
       "     {'facility': 'University of Cagliari',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Cagliari',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Mirko Manchia, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'mirkomanchia@unica.it'}],\n",
       "      'geoPoint': {'lat': 39.23054, 'lon': 9.11917}},\n",
       "     {'facility': 'Università degli studi della Campania Luigi Vanvitelli',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Naples',\n",
       "      'zip': '80138',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Armida Mucci, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'armida.mucci@gmail.com'}],\n",
       "      'geoPoint': {'lat': 40.85216, 'lon': 14.26811}},\n",
       "     {'facility': 'Azienda Ospedaliero-Universitaria \"Città della Salute e della Scienza di Torino\"',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Turin',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Paola Rocca, MD,PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'paola.rocca@unito.it'}],\n",
       "      'geoPoint': {'lat': 45.07049, 'lon': 7.68682}},\n",
       "     {'facility': 'Fundació Clínic per a la Recerca Biomèdica',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Barcelona',\n",
       "      'country': 'Spain',\n",
       "      'contacts': [{'name': 'Eduard Vieta, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'EVIETA@clinic.cat'}],\n",
       "      'geoPoint': {'lat': 41.38879, 'lon': 2.15899}},\n",
       "     {'facility': \"King's College London, Psychiatry & Cognitive Neuroscience\",\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'London',\n",
       "      'zip': 'SE5 8AF',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Howes Oliver, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'oliver.howes@kcl.ac.uk'},\n",
       "       {'name': 'Allan Young, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'allan.young@kcl.ac.uk'}],\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'CSR']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003863',\n",
       "      'term': 'Depression'},\n",
       "     {'id': 'D000003866', 'term': 'Depressive Disorder'},\n",
       "     {'id': 'D000001714', 'term': 'Bipolar Disorder'}],\n",
       "    'ancestors': [{'id': 'D000001526', 'term': 'Behavioral Symptoms'},\n",
       "     {'id': 'D000019964', 'term': 'Mood Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'},\n",
       "     {'id': 'D000068105', 'term': 'Bipolar and Related Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M7058',\n",
       "      'name': 'Depression',\n",
       "      'asFound': 'Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7061',\n",
       "      'name': 'Depressive Disorder',\n",
       "      'asFound': 'Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4996',\n",
       "      'name': 'Bipolar Disorder',\n",
       "      'asFound': 'Bipolar Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'},\n",
       "     {'id': 'M21835', 'name': 'Mood Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M226',\n",
       "      'name': 'Bipolar and Related Disorders',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000014635',\n",
       "      'term': 'Valproic Acid'},\n",
       "     {'id': 'D000069348', 'term': 'Quetiapine Fumarate'},\n",
       "     {'id': 'D000069470', 'term': 'Venlafaxine Hydrochloride'},\n",
       "     {'id': 'D000020280', 'term': 'Sertraline'},\n",
       "     {'id': 'D000089983', 'term': 'Escitalopram'}],\n",
       "    'ancestors': [{'id': 'D000017367',\n",
       "      'term': 'Selective Serotonin Reuptake Inhibitors'},\n",
       "     {'id': 'D000014179', 'term': 'Neurotransmitter Uptake Inhibitors'},\n",
       "     {'id': 'D000049990', 'term': 'Membrane Transport Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000018377', 'term': 'Neurotransmitter Agents'},\n",
       "     {'id': 'D000018490', 'term': 'Serotonin Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000018687', 'term': 'Antidepressive Agents, Second-Generation'},\n",
       "     {'id': 'D000000928', 'term': 'Antidepressive Agents'},\n",
       "     {'id': 'D000011619', 'term': 'Psychotropic Drugs'},\n",
       "     {'id': 'D000014150', 'term': 'Antipsychotic Agents'},\n",
       "     {'id': 'D000014149', 'term': 'Tranquilizing Agents'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000018692', 'term': 'Antimanic Agents'},\n",
       "     {'id': 'D000068760',\n",
       "      'term': 'Serotonin and Noradrenaline Reuptake Inhibitors'},\n",
       "     {'id': 'D000000927', 'term': 'Anticonvulsants'},\n",
       "     {'id': 'D000018682', 'term': 'GABA Agents'}],\n",
       "    'browseLeaves': [{'id': 'M2732',\n",
       "      'name': 'Escitalopram',\n",
       "      'asFound': '2D',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19022', 'name': 'Lithium Carbonate', 'relevance': 'LOW'},\n",
       "     {'id': 'M17983', 'name': 'Citalopram', 'relevance': 'LOW'},\n",
       "     {'id': 'M22100',\n",
       "      'name': 'Sertraline',\n",
       "      'asFound': 'Transcranial Magnetic Stimulation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17383',\n",
       "      'name': 'Valproic Acid',\n",
       "      'asFound': 'Sleep Quality',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7104', 'name': 'Dexetimide', 'relevance': 'LOW'},\n",
       "     {'id': 'M439',\n",
       "      'name': 'Venlafaxine Hydrochloride',\n",
       "      'asFound': 'Premature',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1701', 'name': 'Lamotrigine', 'relevance': 'LOW'},\n",
       "     {'id': 'M399',\n",
       "      'name': 'Quetiapine Fumarate',\n",
       "      'asFound': 'Identified',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19649',\n",
       "      'name': 'Selective Serotonin Reuptake Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M15512', 'name': 'Serotonin', 'relevance': 'LOW'},\n",
       "     {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4247', 'name': 'Antidepressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M14474', 'name': 'Psychotropic Drugs', 'relevance': 'LOW'},\n",
       "     {'id': 'M16904', 'name': 'Antipsychotic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M12575', 'name': 'Norepinephrine', 'relevance': 'LOW'},\n",
       "     {'id': 'M305',\n",
       "      'name': 'Serotonin and Noradrenaline Reuptake Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4246', 'name': 'Anticonvulsants', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "     {'abbrev': 'AntiConv', 'name': 'Anticonvulsants'},\n",
       "     {'abbrev': 'AnDyAg', 'name': 'Anti-Dyskinesia Agents'},\n",
       "     {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "     {'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06361758',\n",
       "    'orgStudyIdInfo': {'id': 'B2023-326(2)'},\n",
       "    'organization': {'fullName': 'Shanghai Zhongshan Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC',\n",
       "    'officialTitle': 'Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC: A Single Arm, Multicenter, Phase II Trial. (SCALE)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-08',\n",
       "    'studyFirstSubmitQcDate': '2024-04-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Hui-Chuan Sun',\n",
       "     'investigatorTitle': 'Director',\n",
       "     'investigatorAffiliation': 'Shanghai Zhongshan Hospital'},\n",
       "    'leadSponsor': {'name': 'Shanghai Zhongshan Hospital', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Sun Yat-sen University', 'class': 'OTHER'},\n",
       "     {'name': 'Eastern Hepatobiliary Surgery Hospital', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy\\r\\nand safety of lenvatinib in combination with cadonilimab as second-line therapy in\\r\\nsubjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard\\r\\ntherapy of immunotheray and antiangiogenic therapy.'},\n",
       "   'conditionsModule': {'conditions': ['Hepatocellular Carcinoma'],\n",
       "    'keywords': ['cadonilimab (anti PD-1/CTLA-4 bispecific antibody)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cadonilimab+Lenvatinib',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: Cadonilimab+Lenvatinib']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Cadonilimab+Lenvatinib',\n",
       "      'description': 'Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight <60 kg) or 12mg\\r\\n(body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib\\r\\nuntil disease progression or withdrawn ICF or death, whichever comes first.',\n",
       "      'armGroupLabels': ['Cadonilimab+Lenvatinib']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR) per RECIST v1.1',\n",
       "      'description': 'Defined as the proportion of patients who achieved complete response (CR) and partial\\r\\nresponse (PR) according to RECIST v1.1.',\n",
       "      'timeFrame': 'Up to two years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Objective Response Rate (ORR) per mRECIST',\n",
       "      'description': 'Defined as the proportion of patients who achieved complete response (CR) and partial\\r\\nresponse (PR) according to mRECIST.',\n",
       "      'timeFrame': 'Up to two years'},\n",
       "     {'measure': 'Disease control Rate (DCR)',\n",
       "      'description': 'Defined as the proportion of patients who achieved complete response (CR), partial\\r\\nresponse (PR), and stable disease (SD) according to RECIST v1.1 and mRECIST respectively.',\n",
       "      'timeFrame': 'Up to two years'},\n",
       "     {'measure': 'Duration of response (DoR)',\n",
       "      'description': 'Defined as the time from the first dose to disease progression or death in patients who\\r\\nachieve complete or partial response.',\n",
       "      'timeFrame': 'Up to two years'},\n",
       "     {'measure': 'Progression-Free-Survival (PFS)',\n",
       "      'description': 'Defined as the time between signing the informed consent form to the disease progression\\r\\n(according to RECIST v1.1 criteria) or death due to any cause.',\n",
       "      'timeFrame': 'Up to two years'},\n",
       "     {'measure': 'Overall survival Overall survival (OS)',\n",
       "      'description': 'Defined as the time between the first dose to death due to any causes.',\n",
       "      'timeFrame': 'Up to three years'},\n",
       "     {'measure': 'Incidence of Adverse Events',\n",
       "      'description': 'Adverse events (AEs) ; serious adverse events (SAEs); Treatment related Adverse events\\r\\n(TRAEs); Use NCI-CTCAE version 5.0 for classification and grading.',\n",
       "      'timeFrame': 'Up to two years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Sign a written informed consent and be able to comply with the visit and related\\r\\n     procedures required by the study protocol\\r\\n\\r\\n  -  Age 18-75 years old, Male of Female\\r\\n\\r\\n  -  ECOG PS 0-1\\r\\n\\r\\n  -  histologically/cytologically or clinically (according to Chinese guidelines for\\r\\n     primary liver cancer diagnosis and treatment (2022) criteria) confirmed initial\\r\\n     diagnosis of HCC\\r\\n\\r\\n  -  Not suitable for radical surgery and/or local treatment, BCLC stage C or stage B who\\r\\n     failed local treatment\\r\\n\\r\\n  -  Patients who progressed on first-line standard system therapy (Atezolizumab plus\\r\\n     bevacizumab, sintilimab combined with bevacizumab, or Camrelizumab and Apatinib,\\r\\n     only these three regimenes) or with intolerable toxicity ( except for immunotherapy\\r\\n     intolerance)\\r\\n\\r\\n  -  Child Pugh A-B7\\r\\n\\r\\n  -  Expected survival time≥12 weeks\\r\\n\\r\\n  -  At least one measurable lesion (RECIST 1.1)\\r\\n\\r\\n  -  Enough organ and bone marrow function\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Fibrolamellar sarcomatoid or mixed cholangiocarcinoma-hepatocellular carcinoma.\\r\\n\\r\\n  -  Other anti-tumor therapies have been received after first-line systemic anti-tumor\\r\\n     therapy.\\r\\n\\r\\n  -  Have history of hepatic encephalopathy, or a history of liver transplantation.\\r\\n\\r\\n  -  There are clinical symptoms requiring drainage of pleural fluid, ascites,\\r\\n     pericardial effusion.\\r\\n\\r\\n  -  People with acute or chronic active hepatitis B or hepatitis C, hepatitis B virus\\r\\n     (HBV) DNA > 2000IU/ml or 10^4 copies /ml; Hepatitis C virus (HCV) RNA > 10^3 copies\\r\\n     /ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibodies were both positive.\\r\\n\\r\\n  -  Central nervous system metastasis.\\r\\n\\r\\n  -  Previous bleeding from esophageal or fundus varices due to portal hypertension\\r\\n     occurred within 6 months.\\r\\n\\r\\n  -  Autoimmune immune disease.\\r\\n\\r\\n  -  HIV infection.\\r\\n\\r\\n  -  Pregnant women.\\r\\n\\r\\n  -  The presence of any serious or uncontrolled systemic disease.\\r\\n\\r\\n  -  Other acute or chronic diseases, psychiatric disorders or abnormal laboratory test\\r\\n     values that may lead to the following results: increasing the risk associated with\\r\\n     research or drug administration, or interfering with the interpretation of research\\r\\n     results. The Investigator considers that there are other potential risks that are\\r\\n     not suitable for participation in the study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Huichuan Sun',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86-21-64041990',\n",
       "      'email': 'sun.huichuan@zs-hospital.sh.cn'},\n",
       "     {'name': 'Xiaodong Zhu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86-21-64041990',\n",
       "      'email': 'zhu.xiaodong@zs-hospital.sh.cn'}],\n",
       "    'overallOfficials': [{'name': 'Huichuan Sun',\n",
       "      'affiliation': 'Study Principal Investigator',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Zhongshan Hospital, Fudan University',\n",
       "      'city': 'Shanghai',\n",
       "      'state': 'Shanghai',\n",
       "      'zip': '200032',\n",
       "      'country': 'China',\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}},\n",
       "     {'facility': 'Sun Yat-sen University Cancer Center)',\n",
       "      'city': 'Guangzhou',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Li Xu', 'role': 'CONTACT'},\n",
       "       {'name': 'Li Xu', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 23.11667, 'lon': 113.25}},\n",
       "     {'facility': 'Eastern Hepatobiliary Surgery Hospital',\n",
       "      'city': 'Shanghai',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Kui Wang', 'role': 'CONTACT'},\n",
       "       {'name': 'Jun Xue', 'role': 'CONTACT'},\n",
       "       {'name': 'Kui Wang', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006528',\n",
       "      'term': 'Carcinoma, Hepatocellular'}],\n",
       "    'ancestors': [{'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008113', 'term': 'Liver Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000008107', 'term': 'Liver Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M9613',\n",
       "      'name': 'Carcinoma, Hepatocellular',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11113', 'name': 'Liver Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M11107', 'name': 'Liver Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000531958',\n",
       "      'term': 'Lenvatinib'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M353738',\n",
       "      'name': 'Lenvatinib',\n",
       "      'asFound': 'Primary care',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20194', 'name': 'Antibodies, Bispecific', 'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419634',\n",
       "    'orgStudyIdInfo': {'id': 'CA235-0001'},\n",
       "    'organization': {'fullName': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome',\n",
       "    'officialTitle': 'Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-02-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2030-09-16', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-14',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to assess the safety, tolerability, drug levels, drug\\r\\nefficacy and determine the recommended dose of BMS-986497 in participants with relapsed\\r\\nor refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).'},\n",
       "   'conditionsModule': {'conditions': ['Acute Myeloid Leukemia',\n",
       "     'Myelodysplastic Syndrome'],\n",
       "    'keywords': ['BMS-986497',\n",
       "     'First-in-Human',\n",
       "     'ORM-6151',\n",
       "     'Acute myeloid leukemia (AML)',\n",
       "     'Myelodysplastic syndrome (MDS)',\n",
       "     'Cluster of differentiation 33 (CD33)',\n",
       "     'G1 to S phase transition 1 (GSPT1)',\n",
       "     'Open label study']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 35, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Part 1: Dose Escalation BMS-986497',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: BMS-986497']},\n",
       "     {'label': 'Part 2: Dose Expansion BMS-986497',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: BMS-986497']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'BMS-986497',\n",
       "      'description': 'Specified dose on specified days',\n",
       "      'armGroupLabels': ['Part 1: Dose Escalation BMS-986497',\n",
       "       'Part 2: Dose Expansion BMS-986497']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of dose-limiting toxicities (DLTs)',\n",
       "      'timeFrame': 'Up to 21 days'},\n",
       "     {'measure': 'Incidence of treatment-emergent adverse events (TEAEs)',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Determine the Recommended Phase 2 Dose (RP2D)',\n",
       "      'timeFrame': 'Up to 2 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Maximum concentration (Cmax)',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Time to reach Cmax (Tmax)', 'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Area under the curve from time 0 to last quantifiable concentration (AUC0-last)',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Overall response rate (ORR)', 'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Duration of response (DoR)', 'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Best overall response (BOR)', 'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Complete remission (CR)', 'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Complete remission with incomplete hematologic recovery (Cri)',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Complete remission with partial hematologic recovery (CRh) rate',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Event-free survival (EFS)', 'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Transition rate to allogeneic hematopoietic stem cell transplantation (HSCT)',\n",
       "      'timeFrame': 'Up to 4 years'},\n",
       "     {'measure': 'Incidence of Anti-drug antibody (ADA) against BMS-986497',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia\\r\\n     (AML) or myelodysplastic syndrome (MDS).\\r\\n\\r\\n  -  Detectable levels of cluster of differentiation 33 (CD33) expression.\\r\\n\\r\\n  -  Failed alternative therapies with established benefit.\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ\\r\\n     function.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Acute Promyelocytic Leukemia.\\r\\n\\r\\n  -  Clinically active central nervous system leukemia.\\r\\n\\r\\n  -  Active malignant solid tumor.\\r\\n\\r\\n  -  Pregnant or breastfeeding.\\r\\n\\r\\n  -  Other protocol-defined inclusion/exclusion criteria apply.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'BMS Study Connect Contact Center www.BMSStudyConnect.com',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '855-907-3286',\n",
       "      'email': 'Clinical.Trials@bms.com'},\n",
       "     {'name': 'First line of the email MUST contain NCT # and Site #.',\n",
       "      'role': 'CONTACT'}],\n",
       "    'overallOfficials': [{'name': 'Bristol-Myers Squibb',\n",
       "      'affiliation': 'Bristol-Myers Squibb',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Local Institution - 0011',\n",
       "      'city': 'New Haven',\n",
       "      'state': 'Connecticut',\n",
       "      'zip': '06510',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0011', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 41.30815, 'lon': -72.92816}},\n",
       "     {'facility': 'Local Institution - 0010',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60611',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0010', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "     {'facility': 'Local Institution - 0007',\n",
       "      'city': 'Boston',\n",
       "      'state': 'Massachusetts',\n",
       "      'zip': '02114',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "     {'facility': 'Local Institution - 0014',\n",
       "      'city': 'Boston',\n",
       "      'state': 'Massachusetts',\n",
       "      'zip': '02114',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0014', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "     {'facility': 'Local Institution - 0013',\n",
       "      'city': 'Saint Louis',\n",
       "      'state': 'Missouri',\n",
       "      'zip': '63110',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 38.62727, 'lon': -90.19789}},\n",
       "     {'facility': 'Local Institution - 0008',\n",
       "      'city': 'Hackensack',\n",
       "      'state': 'New Jersey',\n",
       "      'zip': '07601',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0008', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 40.88593, 'lon': -74.04347}},\n",
       "     {'facility': 'Columbia University Irving Medical Center',\n",
       "      'city': 'New York',\n",
       "      'state': 'New York',\n",
       "      'zip': '10032',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.71427, 'lon': -74.00597}},\n",
       "     {'facility': 'Local Institution - 0006',\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77030',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0006', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': 'Local Institution - 0009',\n",
       "      'city': 'Fairfax',\n",
       "      'state': 'Virginia',\n",
       "      'zip': '22031',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 38.84622, 'lon': -77.30637}},\n",
       "     {'facility': 'Local Institution - 0002',\n",
       "      'city': 'Toronto',\n",
       "      'state': 'Ontario',\n",
       "      'zip': 'M5G 2M9',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Site 0002', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 43.70011, 'lon': -79.4163}},\n",
       "     {'facility': 'Local Institution - 0003',\n",
       "      'city': 'Montreal',\n",
       "      'state': 'Quebec',\n",
       "      'zip': 'H3T 1E2',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Site 0003', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'BMS Clinical Trial Information',\n",
       "      'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html'},\n",
       "     {'label': 'BMS Clinical Trial Patient Recruiting',\n",
       "      'url': 'https://www.bmsstudyconnect.com/s/US/English/USenHome'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': \"BMS will provide access to individual anonymized participant data upon request from\\r\\nqualified researchers, and subject to certain criteria.\\r\\n\\r\\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process\\r\\ncan be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and\\r\\nresearch/disclosurecommitment.html\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'},\n",
       "     {'id': 'D000011289', 'term': 'Preleukemia'},\n",
       "     {'id': 'D000009190', 'term': 'Myelodysplastic Syndromes'},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000001855', 'term': 'Bone Marrow Diseases'},\n",
       "     {'id': 'D000011230', 'term': 'Precancerous Conditions'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14164',\n",
       "      'name': 'Preleukemia',\n",
       "      'asFound': 'Myelodysplastic Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12145',\n",
       "      'name': 'Myelodysplastic Syndromes',\n",
       "      'asFound': 'Myelodysplastic Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5134', 'name': 'Bone Marrow Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14111', 'name': 'Precancerous Conditions', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T3993',\n",
       "      'name': 'Myelodysplastic Syndromes',\n",
       "      'asFound': 'Myelodysplastic Syndrome',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05926739',\n",
       "    'orgStudyIdInfo': {'id': '2023-A02460-45'},\n",
       "    'organization': {'fullName': 'Vivaltis', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Performance and Safety of the PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Musculoskeletal Disorders',\n",
       "    'officialTitle': 'Prospective Evaluation of the Performance and Safety of the PHENIX LIBERTY, a Medical Device for Electrostimulation and Biofeedback, in the Treatment of Locomotor Disorders'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-19', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-19', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-06-22',\n",
       "    'studyFirstSubmitQcDate': '2023-06-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Vivaltis', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'CEISO', 'class': 'INDUSTRY'},\n",
       "     {'name': 'Human Physio', 'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Evaluate the evolution of locomotor abilities in patients treated with functional\\r\\nelectrostimulation and biofeedback (PHENIX LIBERTY VIVALTIS device) for musculoskeletal\\r\\ndisorders of the knee and spine.\\r\\n\\r\\nDoes the use of the medical device in the treatment of musculoskeletal disorders lead to\\r\\nan improvement ?\\r\\n\\r\\nParticipants will use the medical device, which provides electrical stimulation,\\r\\nbiofeedback and pressure biofeedback to re-educate the muscles of the knee and spine area\\r\\nand',\n",
       "    'detailedDescription': \"Rational :\\r\\n\\r\\nToday, musculoskeletal disorders (MSDs) are considered to be one of the world's leading\\r\\npathologies. They are also the most widespread occupational pathology in Europe. MSDs\\r\\ninclude a variety of conditions affecting bones, joints, muscles and connective tissues.\\r\\nTo treat these disorders, the guidelines recommend non-drug therapies as first-line\\r\\ntreatments for chronic low-back pain and osteoarthritis pain, such as electrostimulation\\r\\nand biofeedback therapy.\\r\\n\\r\\nIn this context, the promoter wishes to carry out this study in order to reinforce the\\r\\ndata currently available on the medical device PHENIX LIBERTY.\\r\\n\\r\\nDesign:\\r\\n\\r\\nProspective, interventional with non invasive and non burdensome procedure,\\r\\nnon-comparative, multicenter, open-label study of a CE-marked medical device\\r\\n\\r\\nIntervention :\\r\\n\\r\\nAs part of this clinical investigation, the medical device under investigation is used in\\r\\naccordance with its usual use, and the patient's therapeutic procedure includes\\r\\nadditional, non-invasive procedures. These additional procedures relate to the addition\\r\\nof an end-of-life visit and validated questionnaires assessing functional deficiencies\\r\\nand impact on daily life.\\r\\n\\r\\nThe care will be conduct as follow:\\r\\n\\r\\n  -  1 inclusion visit (V0) (from 1 say to 15 days prior the the first functionnal\\r\\n     therapeutic re-education session)\\r\\n\\r\\n  -  12 sessions of functional therapeutic re-education, during which the PHENIX LIBERTY\\r\\n     device may be used. Sessions performed at regular intervals according to a schedule\\r\\n     drawn up by the physiotherapist (between 6 and 8 weeks);\\r\\n\\r\\n  -  1 end visit (V13), 1 week after the 12th session to complet questionnaires\\r\\n\\r\\nIn total, the patient will be followed 11 weeks maximum\"},\n",
       "   'conditionsModule': {'conditions': ['Musculoskeletal Disorder'],\n",
       "    'keywords': ['Electrical stimulation',\n",
       "     'Biofeedback',\n",
       "     'Knee',\n",
       "     'Low Back Pain']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 27, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Standard of care plus additional questionaire',\n",
       "      'type': 'OTHER',\n",
       "      'description': \"As part of this clinical investigation, the medical device under investigation is used in\\r\\naccordance with its usual use, and the patient's therapeutic procedure includes\\r\\nadditional, non-invasive procedures. These additional procedures relate to the addition\\r\\nof an endof- life visit and validated questionnaires assessing functional deficiencies\\r\\nand impact on daily life.\",\n",
       "      'interventionNames': ['Device: Electrical stimulation and biofeedback with Phenix Liberty medical device']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Electrical stimulation and biofeedback with Phenix Liberty medical device',\n",
       "      'description': '12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at\\r\\nregular intervals according to a schedule drawn up by the physiotherapist.\\r\\n\\r\\nThe patient will undergo 12 therapeutic functional reeducation sessions, at regular\\r\\nintervals according to a schedule drawn up by the physiotherapist, during which the\\r\\nPHENIX LIBERTY device may be used. The patients will complete questionnaires at the end\\r\\nof the care.\\r\\n\\r\\nOverall, the functional rehabilitation sessions will include muscle testing,\\r\\nelectrostimulation and biofeedback.\\r\\n\\r\\nThe follow up will be conduct as follow :\\r\\n\\r\\n  -  12 sessions between 6 and 8 weeks\\r\\n\\r\\n  -  1 end visit, within the week after the 12th session',\n",
       "      'armGroupLabels': ['Standard of care plus additional questionaire']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean change in Lower Extremity Functional Scale (LEFS) score on the impact of locomotor disorders of the knee',\n",
       "      'description': 'The Lower Extremity Functional Scale (LEFS) is used by physiotherapists and occupational\\r\\ntherapists in many clinical settings. It is an English-language measurement tool that\\r\\ncollects psychometric data and assesses the functional status of the lower limbs. It\\r\\nconsists of 20 questions on the level of difficulty experienced during everyday\\r\\nactivities.',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Mean change in the Oswestry Disability Index (ODI) score for the impact of locomotor disorders of the spine.',\n",
       "      'description': 'The ODI will be used to assess the disability caused by Lower Back Pain (LBP)\\r\\n\\r\\nThe Oswestry Disability Index (ODI), a patient-completed questionnaire that gives a\\r\\nsubjective percentage score of the level of function (disability) in activities of daily\\r\\nliving in people undergoing rehabilitation after low back pain. The questionnaire\\r\\nexamines the level of disability in 10 activities of daily living. Each item consists of\\r\\n6 statements rated from 0 to 5. With 0 indicating the lowest level of disability and 5\\r\\nthe highest, the total score is calculated as a percentage, with 0% indicating no\\r\\ndisability and 100% indicating the highest level of disability.',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'}],\n",
       "    'secondaryOutcomes': [{'measure': \"Change in patients' visual analog scale (VAS) pain scores for knee pain and/or spine pain at rest and on palpation\",\n",
       "      'description': 'The pain caused by the TMS of the knee and/or the spine will be assessed by the Visual\\r\\nAnalogue Scale (VAS).\\r\\n\\r\\nThe VAS is made up of a 10-centimeter line anchored by two ends of the pain. 10 is the\\r\\nfirst end being the \"maximum pain imaginable\" and 0 is the other end being \"no pain\"',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Trends in consumption of painkillers and anti-inflammatories',\n",
       "      'description': 'Rate of consuption of painkillers and anti-inflammatories',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes in the rate of improvement of hypertonia of the concerned area (knee or spine) through measurement of myoelectric activity',\n",
       "      'description': 'A surface Electromyography (EMG) will be used. Muscle electrical activity provides a\\r\\n\"map\" of muscle recruitment according to exercise conditions (position, relative load,\\r\\ntype of resistance, type of support, etc.).',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes in the rate of improvement of hypertonia of the concerned area (knee or spine) through Oxford Grading Scale',\n",
       "      'description': 'The Oxford scale is commonly used to manually assess muscle strength, and can help\\r\\ndiagnose problems in which weakness plays a role. According to the Oxford scale, muscle\\r\\nstrength is rated from 0 to 5 (0 being no muscle contraction > 5 being movement through a\\r\\nfull range against full resistance). Scoring is as follows: 0 → No visible or palpable\\r\\ncontraction, 1 → Visible/palpable muscle contraction but no movement, 2 → Movement across\\r\\nfull range with gravity eliminated (low strength), 3 → Movement across full range against\\r\\ngravity only (fair strength), 4 → Movement across full range against gravity with some\\r\\nresistance (good strength), 5 → Movement across full range against gravity with full\\r\\nresistance (normal strength).',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes in the rate of improvement in awakening and muscle strengthening through Oxford grading scale',\n",
       "      'description': 'The Oxford scale is commonly used to manually assess muscle strength, and can help\\r\\ndiagnose problems in which weakness plays a role. According to the Oxford scale, muscle\\r\\nstrength is rated from 0 to 5 (0 being no muscle contraction > 5 being movement through a\\r\\nfull range against full resistance). Scoring is as follows: 0 → No visible or palpable\\r\\ncontraction, 1 → Visible/palpable muscle contraction but no movement, 2 → Movement across\\r\\nfull range with gravity eliminated (low strength), 3 → Movement across full range against\\r\\ngravity only (fair strength), 4 → Movement across full range against gravity with some\\r\\nresistance (good strength), 5 → Movement across full range against gravity with full\\r\\nresistance (normal strength).',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes in the rate of improvement in awakening and muscle strengthening through measurement of myoelectric activity',\n",
       "      'description': 'A surface Electromyography (EMG) will be used. Muscle electrical activity provides a\\r\\n\"map\" of muscle recruitment according to exercise conditions (position, relative load,\\r\\ntype of resistance, type of support, etc.).',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes of microcirculation of the concerned spine area',\n",
       "      'description': 'Assessment on the basis of clinical palpation examination done by the practitioner',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes of the microcirculation of the concerned knee area',\n",
       "      'description': 'The measurement of the muscular perimeter around the concerned knee will be assessed by a\\r\\ntape measure',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Changes of the improvement of the motor control through the measurement of myoelectrical activity',\n",
       "      'description': 'A surface Electromyography (EMG) will be used. Muscle electrical activity provides a\\r\\n\"map\" of muscle recruitment according to exercise conditions (position, relative load,\\r\\ntype of resistance, type of support, etc.).',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': \"Change in patient's quality of life\",\n",
       "      'description': 'The SF-36 will be used to assess the quality of life score.\\r\\n\\r\\nThe SF-36, as described in the name, is a 36-item patient-reported questionnaire that\\r\\ncovers eight health domains: physical functioning (10 items), bodily pain (2 items), role\\r\\nlimitations due to physical health problems (4 items), role limitations due to personal\\r\\nor emotional problems (4 items), emotional well-being (5 items), social functioning (2\\r\\nitems), energy/fatigue (4 items), and general health perceptions (5 items). Scores for\\r\\neach domain range from 0 to 100, with a higher score defining a more favorable health\\r\\nstate.',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Pecentage of patients with an improvement in locomotor disorders',\n",
       "      'description': \"This outcome will be assessed according to the practitioner's opinion. Does the\\r\\npractitioner think that an improvement has been observed --> Yes / No ?\",\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Incidence of adverse events',\n",
       "      'description': 'Rate of the incidence of adverse events related to the medical device',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'},\n",
       "     {'measure': 'Evaluation of responses to the patient satisfaction questionnaire on the use of the PHENIX LIBERTY device after therapeutic management',\n",
       "      'description': 'The satisfaction questionnaire is constructed on the basis of the Likert Scale. The\\r\\nsponsor has written an questionnaire regarding the use of the Phenix Liberty for the\\r\\npatient. The Likert scale (or attitude scale) is a semantic rating system, generally\\r\\nconsisting of 5 or 7 items, used in surveys to measure and evaluate perceptions,\\r\\nattitudes and opinions. The evaluation will be based on the following responses: Strongly\\r\\nagree (=5) ; Agree (=4) ; Rather agree (=3) ; Rather disagree (=2) ; Disagree (=1= ;\\r\\nStrongly disagree (=0). The minimum score 0 means a worse outcome and the maximum score 5\\r\\nmeans a better outcome.',\n",
       "      'timeFrame': 'At Day 0 and Week 11 (at the end visit within the week after the 12th seance)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Adult patients (between 18 and 65 years of age);\\r\\n\\r\\n  -  Patient presenting at least one of the following symptoms related to a locomotor\\r\\n     disorder of the knee and/or spine: pain, hypertonia, amyotrophy, mobility\\r\\n     restriction, muscle weakness, reduction or loss of motor control, reduction in motor\\r\\n     pattern, trophic anomaly;\\r\\n\\r\\n  -  Patient able to make himself available to attend sessions regularly and is confident\\r\\n     of being able to complete all sessions; ;\\r\\n\\r\\n  -  Patient who has signed the study participation consent form;y;\\r\\n\\r\\n  -  Patient physically and mentally willing and able, according to the investigator's\\r\\n     judgment at the time of recruitment, to perform the procedures under study;\\r\\n\\r\\n  -  Patient with social security coverage.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with Stroke, Alzheimer's, multiple sclerosis, peripheral nervous system\\r\\n     disorders, spinal cord injury or with cognitive and/or behavioural disorders likely,\\r\\n     in the practitioner's judgement in the practitioner's judgement, interact with the\\r\\n     self-assessment or biofeedback;\\r\\n\\r\\n  -  Patients with hypersensitivity to electrostimulation;\\r\\n\\r\\n  -  Patients who, in the 1 month prior to inclusion, have had injections of\\r\\n     corticosteroids (e.g. hyaluronate) in the knee/spine concerned;\\r\\n\\r\\n  -  Patients with an implanted pacemaker or spinal cord pacemaker;\\r\\n\\r\\n  -  Pregnant at the time of the inclusion visit, or wishing to become pregnant during\\r\\n     the treatment period;\\r\\n\\r\\n  -  Patients who have renounced their liberty by administrative or judicial sentence, or\\r\\n     under guardianship or limited judicial protection;\\r\\n\\r\\n  -  Patient participating in another interventional clinical trial for the same\\r\\n     pathology or testing/having tested an investigational drug in the 30 days prior to\\r\\n     inclusion in the study;\\r\\n\\r\\n  -  Patient unable to read or write French;\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'George Billard',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0467274889',\n",
       "      'email': 'georges.billard@vivaltis.com'},\n",
       "     {'name': 'Camélia Bentaleb',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'camelia.bentaleb@ceiso.fr'}],\n",
       "    'overallOfficials': [{'name': 'Mathias Willame',\n",
       "      'affiliation': 'Human Physio',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Human Physio',\n",
       "      'city': 'Nîmes',\n",
       "      'zip': '30000',\n",
       "      'country': 'France',\n",
       "      'geoPoint': {'lat': 43.83333, 'lon': 4.35}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009140',\n",
       "      'term': 'Musculoskeletal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M4714', 'name': 'Back Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M19433', 'name': 'Low Back Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097',\n",
       "      'name': 'Musculoskeletal Diseases',\n",
       "      'asFound': 'Musculoskeletal Disorders',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06384339',\n",
       "    'orgStudyIdInfo': {'id': 'ID-ClimAct-1'},\n",
       "    'organization': {'fullName': 'University Psychiatric Clinics Basel',\n",
       "     'class': 'NETWORK'},\n",
       "    'briefTitle': 'ID-ClimAct. Influence of Social Motives of Clients and Staff on the Social Climate of Secure Settings',\n",
       "    'officialTitle': 'ID-ClimAct. Influence of Social Motives of Clients and Staff on the Social Climate of Secure Settings',\n",
       "    'acronym': 'ID-ClimAct'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-20', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-10-20', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-21',\n",
       "    'studyFirstSubmitQcDate': '2024-04-21',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-26',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Andrea Canel',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'University Psychiatric Clinics Basel'},\n",
       "    'leadSponsor': {'name': 'University Psychiatric Clinics Basel',\n",
       "     'class': 'NETWORK'},\n",
       "    'collaborators': [{'name': 'University of Basel', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The social climate in secure settings is an essential element to successful\\r\\nrehabilitation. Previous studies indicate that staff characteristics are a relevant\\r\\nfactor contributing to a beneficial social climate. Yet, secure settings form a specific\\r\\nand challenging work environment. Staff members are faced with clients who present a\\r\\nvariety of difficult emotional and behavioural problems. Social motives for caring and\\r\\ncooperation can be blocked in a threatening environment, favouring dysfunctional\\r\\ninterpersonal dynamics between individuals. This observational study explores the\\r\\nreciprocal influences of social motives between clients and staff on the social climate\\r\\nwithin secure settings.'},\n",
       "   'conditionsModule': {'conditions': ['Social Environment',\n",
       "     'Correctional Institutions',\n",
       "     'Rehabilitation of Criminals',\n",
       "     'Social Dominance',\n",
       "     'Interpersonal Relations']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_CONTROL',\n",
       "     'timePerspective': 'CROSS_SECTIONAL'},\n",
       "    'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Clients',\n",
       "      'description': 'Adult clients in a secure setting (i.e. prison or forensic mental health psychiatry',\n",
       "      'interventionNames': ['Diagnostic Test: CSIV, Social motive',\n",
       "       'Diagnostic Test: Interpersonal messages and behavior',\n",
       "       'Diagnostic Test: CCS, Social motive']},\n",
       "     {'label': 'Staff',\n",
       "      'description': 'Adult staff in a secure setting (including forensic healthcare staff, social workers,\\r\\nprobation officers, prison offers, education staff)',\n",
       "      'interventionNames': ['Diagnostic Test: CSIV, Social motive',\n",
       "       'Diagnostic Test: Interpersonal messages and behavior',\n",
       "       'Diagnostic Test: CCS, Social motive']}],\n",
       "    'interventions': [{'type': 'DIAGNOSTIC_TEST',\n",
       "      'name': 'CSIV, Social motive',\n",
       "      'description': 'The CSIV is a self-report measure and assesses interpersonal values using eight octant\\r\\nscales, which are aggregated into overall communion and agency scores, ranging from -4 to\\r\\n+4 .',\n",
       "      'armGroupLabels': ['Clients', 'Staff'],\n",
       "      'otherNames': ['Circumplex Scales of Interpersonal Values (CSIV; Locke, 2000)']},\n",
       "     {'type': 'DIAGNOSTIC_TEST',\n",
       "      'name': 'Interpersonal messages and behavior',\n",
       "      'description': 'The Impact Message Inventory - Circumplex (IMI-C) Brief Version is a self-report\\r\\ntransactional inventory designed to measure a target person\\'s interpersonal behavior on\\r\\nfour octant scales dominance, hostility, submissiveness, and friendliness by assessing\\r\\nthe covert responses or \"impact messages\" of another person. Each subscale consists of 7\\r\\nitems, with each item scored on a 4-point Likert scale from 1 (not at all) to 4 (very\\r\\nmuch so). The minimum score per scale is 7 and the maximum score is 28.',\n",
       "      'armGroupLabels': ['Clients', 'Staff'],\n",
       "      'otherNames': ['Impact Message Inventory - Circumplex (IMI-C; Kiesler, 2006)']},\n",
       "     {'type': 'DIAGNOSTIC_TEST',\n",
       "      'name': 'CCS, Social motive',\n",
       "      'description': 'The CCS is a elf-report inventory, that measures tendencies towards competitiveness\\r\\nversus caring in social interactions. The minimum score for the two subscales\\r\\ncompetitiveness and caring are 9 and the maximum score is 90.',\n",
       "      'armGroupLabels': ['Clients', 'Staff'],\n",
       "      'otherNames': ['Competitiveness and Caring Scale (CCS; McEwan, Gilbert, & Duarte, 2012)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Social Climate Perception',\n",
       "      'description': \"Measured through Essen Climate Evaluation Schema (EssenCES). The EssenCES uses a 5-point\\r\\nLikert scale for each item, ranging from 0 (never) to 4 (always). The three subscales\\r\\nTherapeutic Hold, Patients' Cohesion and Experienced Safety each comprises five items,\\r\\nthe minimum score for each subscale is 0 and the maximum is 20.\",\n",
       "      'timeFrame': 'Day 1'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Clients who are currently incarcerated within the specified secure settings.\\r\\n\\r\\n  -  Staff members currently employed in the specified secure settings.\\r\\n\\r\\n  -  Individuals (both clients and staff) who are capable of providing informed consent.\\r\\n\\r\\n  -  Clients who are deemed competent and not under any disciplinary restrictions that\\r\\n     would preclude participation.\\r\\n\\r\\n  -  Staff members who are directly involved with client care and management.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Clients who are not considered competent to provide informed consent.\\r\\n\\r\\n  -  Staff members who do not have direct interactions with clients (e.g., administrative\\r\\n     staff not involved in direct care).\\r\\n\\r\\n  -  Clients and staff from open prisons',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'The study will involve approximately 200 participants, consisting of both clients and\\r\\nstaff members from various secure settings such as prisons and forensic psychiatries in\\r\\nSwitzerland.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Andrea Canel, MSc',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+41 61 325 51 11',\n",
       "      'email': 'andrea.canel@upk.ch'}],\n",
       "    'overallOfficials': [{'name': 'Marc Graf, Prof. Dr.',\n",
       "      'affiliation': 'University Psychiatric Clinics Basel',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'University Psychiatric Clinics Basel, Clinic for Forensics',\n",
       "      'city': 'Basel',\n",
       "      'state': 'Basel-Stadt',\n",
       "      'zip': '4002',\n",
       "      'country': 'Switzerland',\n",
       "      'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06377696',\n",
       "    'orgStudyIdInfo': {'id': 'MC230713'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-02980',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MC230713', 'type': 'OTHER', 'domain': 'Mayo Clinic in Rochester'},\n",
       "     {'id': '23-005512',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Mayo Clinic Institutional Review Board'}],\n",
       "    'organization': {'fullName': 'Mayo Clinic', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy',\n",
       "    'officialTitle': \"Neuro-Oncology Anywhere: Deploying Mayo Clinic's Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin on Cognition and Quality of Life in Patients With History of Cranial Radiation\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-16',\n",
       "    'studyFirstSubmitQcDate': '2024-04-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-22', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Mayo Clinic', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase III trial evaluates whether patient care can be done remotely for patients\\r\\nhaving cranial (skull) radiation or who have previously had cranial radiation. In\\r\\naddition, this trial compares study outcomes between patients who get metformin and those\\r\\nwho do not. Cranial radiation, an essential component of brain tumor treatment, can\\r\\nresult in significant negative effects on cognitive (the ability to clearly think, learn,\\r\\nand remember) function. Wearable devices have been used in the field of neurology for\\r\\nseizure detection and assessment of patients with movement disorders. Wearable device\\r\\ntechnology has also been implemented for remote monitoring of cancer patients and for\\r\\ncancer clinical trials. Metformin is the active ingredient in a drug used to treat type 2\\r\\ndiabetes mellitus (a condition in which the body cannot control the level of sugar in the\\r\\nblood). It is also being studied in the treatment of cancer. Use of metformin may reduce\\r\\nrisk of cognitive decline following radiation therapy within the skull (intracranial).\\r\\nThese effects may be further strengthen by addition of device-based physical activity\\r\\npromotion. Mayo Test Drive is a web-based platform for remote self-administered cognitive\\r\\nassessment. Using Mayo Test Drive may help determine whether patient care can be done\\r\\nremotely, while simultaneously evaluating benefits of health promotion through use of a\\r\\nwearable watch device and metformin in preventing radiation-related cognitive decline.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. Determine the feasibility of completing serial remote cognitive, activity/sleep, and\\r\\nself-report assessments in clinical trial participants who have previously received\\r\\ncranial radiation.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. Assess the acceptance or satisfaction of patients with the remote monitoring in this\\r\\ntrial and how these may differ between those who receive metformin versus (vs.) not.\\r\\n\\r\\nII. Evaluate compliance and feasibility in terms of the adherence to study drug in those\\r\\nrandomized to receive metformin.\\r\\n\\r\\nIII. Assess and compare neurocognitive function scores and the impact of receiving\\r\\nmetformin + health promotion with wearable device vs. wearable device only.\\r\\n\\r\\nIV. Assess the safety and tolerability of metformin in patients who have previously\\r\\nreceived cranial radiation.\\r\\n\\r\\nEXPLORATORY OBJECTIVES:\\r\\n\\r\\nI. Investigate the relationship of metformin and other health outcomes such as activity\\r\\nand sleep data and how these compare to the results for patients who are randomized to\\r\\nthe control group, who do not receive metformin.\\r\\n\\r\\nII. Explore potential differences in these compliance and satisfaction measures and how\\r\\nthey may correspond to health disparities and social determinants of health.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 2 groups.\\r\\n\\r\\nGROUP A: Patients receive metformin orally (PO) twice day (BID) for 12 months. Treatment\\r\\nrepeats every 28 days for up to 12 months in the absence of disease progression or\\r\\nunacceptable toxicity. Patients also wear a wearable device to monitor health and undergo\\r\\nneurocognitive test throughout the study.\\r\\n\\r\\nGROUP B: Patients receive standard of care (SOC) treatment for 12 months. Patients also\\r\\nwear a wearable device to monitor health and undergo neurocognitive test throughout the\\r\\nstudy.\\r\\n\\r\\nUpon completion of study treatment, patients are followed up at 30 days then every 3\\r\\nmonths for up to 2 years.'},\n",
       "   'conditionsModule': {'conditions': ['Malignant Brain Neoplasm']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Group A (metformin)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive metformin PO BID for 12 months. Treatment repeats every 28 days for up\\r\\nto 12 months in the absence of disease progression or unacceptable toxicity. Patients\\r\\nalso wear a wearable device to monitor health and undergo neurocognitive test throughout\\r\\nthe study.',\n",
       "      'interventionNames': ['Other: Medical Device Usage and Evaluation',\n",
       "       'Drug: Metformin',\n",
       "       'Other: Neurocognitive Assessment',\n",
       "       'Other: Questionnaire Administration']},\n",
       "     {'label': 'Group B (usual care)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive SOC treatment for 12 months. Patients also wear a wearable device to\\r\\nmonitor health and undergo neurocognitive test throughout the study.',\n",
       "      'interventionNames': ['Other: Best Practice',\n",
       "       'Other: Medical Device Usage and Evaluation',\n",
       "       'Other: Neurocognitive Assessment',\n",
       "       'Other: Questionnaire Administration']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Best Practice',\n",
       "      'description': 'Receive SOC',\n",
       "      'armGroupLabels': ['Group B (usual care)'],\n",
       "      'otherNames': ['standard of care', 'standard therapy']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Medical Device Usage and Evaluation',\n",
       "      'description': 'Wear wearable device',\n",
       "      'armGroupLabels': ['Group A (metformin)', 'Group B (usual care)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Metformin',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['Group A (metformin)'],\n",
       "      'otherNames': ['N,N-dimethylbiguanide']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Neurocognitive Assessment',\n",
       "      'description': 'Undergo neurocognitive test',\n",
       "      'armGroupLabels': ['Group A (metformin)', 'Group B (usual care)']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Questionnaire Administration',\n",
       "      'description': 'Ancillary studies',\n",
       "      'armGroupLabels': ['Group A (metformin)', 'Group B (usual care)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Compliance of patients who complete the testing schedule for the cognitive assessments (Feasibility)',\n",
       "      'description': 'Feasibility will be assessed based on compliance of patients to the testing schedule for\\r\\nthe cognitive assessments using the Mayo Test Drive tool.',\n",
       "      'timeFrame': 'Baseline, 3 months, and 6 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall completion rates and compliance (Feasibility)',\n",
       "      'description': 'Will evaluate compliance of completing the patient-reported symptom assessments and the\\r\\nactivity and sleep assessments and will assess for any patterns within and between the\\r\\ntreatment arms.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Overall satisfaction',\n",
       "      'description': 'Satisfaction/acceptance rates will be evaluated using the European Organization for\\r\\nResearch and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C-30, which\\r\\nconsists of 30 questions, each answered on a 4-point (e.g., not at all, a little, quite a\\r\\nbit, very much) or a scale of 1-7 where 1=very poor and 7=excellent.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Adherence (Feasibility)',\n",
       "      'description': 'Adherence to study drug will be evaluated in those randomized to the metformin treatment\\r\\ngroup. Will consider sufficient adherence to be defined as taking at least 80% of the\\r\\nprescribed doses.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Neurocognitive scores',\n",
       "      'description': 'Neurocognitive scores will be assessed using the Mayo Test Drive, a web-based platform\\r\\nfor remote self-administered cognitive assessment that uses the Stricker Learning Span\\r\\n(SLS), which is a computer adaptive word-list memory test that matches test difficulty to\\r\\nuser performance, and the Symbols test, which is a measure of processing speed and\\r\\nexecutive functioning that requires timed visual matching. The primary outcome measure\\r\\nwill be the Mayo Test Drive raw composite (range 0 - 158). Higher scores indicate better\\r\\ncognitive test performance. Several secondary outcome measures will also be analyzed\\r\\nincluding but not limited to SLS sum of trials (0-108), an accuracy-weighted Symbols\\r\\nscore (0-50), and Symbols average response time for correct items (0+). Participants will\\r\\nhave opportunity to provide comments about the testing experience.',\n",
       "      'timeFrame': 'Up to 12 months'},\n",
       "     {'measure': 'Incidence of adverse events (AEs)',\n",
       "      'description': 'Safety and tolerability will be assessed on those randomized to receive metformin, as\\r\\ndefined using the Common Terminology Criteria for Adverse Events version 5. Any AEs will\\r\\nbe summarized with the maximum grade of each AE reported for each patient.',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age ≥ 18 years\\r\\n\\r\\n  -  Diagnosis of brain tumor requiring cranial radiation treatment NOTE: Patient may be\\r\\n     enrolled during or up to 3 years after completion of cranial radiation administered\\r\\n     for treatment of primary or metastatic intracranial tumor\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND\\r\\n     Karnofsky performance status (KPS) of ≥ 70\\r\\n\\r\\n  -  Expected survival ≥ 6 months in the opinion of treatment team\\r\\n\\r\\n  -  Willing and able to adhere with the protocol for the duration of the study including\\r\\n     undergoing treatment, and attending scheduled visits, and examinations\\r\\n\\r\\n  -  The following laboratory values obtained ≤ 30 days prior to registration:\\r\\n\\r\\n       -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN\\r\\n          [≤ 5 x upper limit normal (ULN) for patients with baseline liver disease]\\r\\n\\r\\n  -  Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing\\r\\n     potential only\\r\\n\\r\\n  -  Ability to complete cognitive assessments and questionnaires by themselves or with\\r\\n     assistance\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Uncontrolled and/or intercurrent illness or other condition which limits safety of\\r\\n     or compliance with study proceedings\\r\\n\\r\\n  -  Pregnant or nursing, imprisoned, or lacking capacity for understanding\\r\\n\\r\\n  -  Unable to swallow tablets or at risk for impaired absorption of oral medication\\r\\n\\r\\n  -  Currently taking the study agent (i.e., metformin), and cannot safely discontinue if\\r\\n     randomized to the control group (Group B)\\r\\n\\r\\n  -  Known hypersensitivity or allergy to metformin\\r\\n\\r\\n  -  Current use of resveratrol, CoQ10 (coenzyme Q10), coconut oil/other medium chain\\r\\n     triglyceride-containing (e.g., Axona) supplements, or curcumin and unwilling to\\r\\n     discontinue prior to registration and remain off these agents for study duration\\r\\n\\r\\n  -  Unable to read and speak English. Note: English doses not to need to be primary\\r\\n     language',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Ugur T. Sener, M.D.',\n",
       "      'affiliation': 'Mayo Clinic in Rochester',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Mayo Clinic in Rochester',\n",
       "      'city': 'Rochester',\n",
       "      'state': 'Minnesota',\n",
       "      'zip': '55905',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Clinical Trials Referral Office',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '855-776-0015',\n",
       "        'email': 'mayocliniccancerstudies@mayo.edu'},\n",
       "       {'name': 'Ugur T. Sener, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Mayo Clinic Clinical Trials',\n",
       "      'url': 'https://www.mayo.edu/research/clinical-trials'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001932',\n",
       "      'term': 'Brain Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000016543',\n",
       "      'term': 'Central Nervous System Neoplasms'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5209',\n",
       "      'name': 'Brain Neoplasms',\n",
       "      'asFound': 'Brain Neoplasms',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18937',\n",
       "      'name': 'Central Nervous System Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T6034', 'name': 'Quality of Life', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000008687',\n",
       "      'term': 'Metformin'}],\n",
       "    'ancestors': [{'id': 'D000007004', 'term': 'Hypoglycemic Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M11667',\n",
       "      'name': 'Metformin',\n",
       "      'asFound': 'Assessment',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06422117',\n",
       "    'orgStudyIdInfo': {'id': 'HSK16149-305'},\n",
       "    'organization': {'fullName': 'Haisco Pharmaceutical Group Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China',\n",
       "    'officialTitle': 'A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-07-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-08-07', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-16',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-20', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Haisco Pharmaceutical Group Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to\\r\\nsevere central neuropathic pain compared with placebo.'},\n",
       "   'conditionsModule': {'conditions': ['Central Neuropathic Pain']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 408, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'HSK16149 20mg-40mg bid',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Oral administration of 20mg twice daily for 12 weeks can be adjusted to 40mg twice daily\\r\\nbased on the efficacy and tolerability of the subject',\n",
       "      'interventionNames': ['Drug: HSK16149 20mg-40mg BID']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo,Oral,2 capsules, twice daily for 12 weeks',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HSK16149 20mg-40mg BID',\n",
       "      'description': 'Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;',\n",
       "      'armGroupLabels': ['HSK16149 20mg-40mg bid']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Placebo, oral, 2 capsules twice daily',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baseline',\n",
       "      'description': 'Changes in mean pain intensity (ADPS) at week 12 between HSK16149 and placebo were\\r\\ncompared from baseline;The pain NRS score divides a straight line into 10 segments, with\\r\\n0 to 10 indicating pain (a total of 11 points), 0 indicating no pain, and 10 indicating\\r\\nthe most intense pain. The pain NRS scores of the past 7 days were collected and the\\r\\naverage value was used as the ADPS score.',\n",
       "      'timeFrame': 'week12'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Voluntarily sign an informed consent form;\\r\\n\\r\\n  2. Able to read and complete survey questionnaires;\\r\\n\\r\\n  3. Male or female patients aged ≥ 18 years old;\\r\\n\\r\\n  4. The subject has a medical history and symptoms related to central neuropathic pain,\\r\\n     including spinal cord related neuropathic pain (subject enrollment ≥ 50%),\\r\\n     post-stroke central neuropathic pain, Parkinson's disease pain, and multiple\\r\\n     sclerosis pain, and must meet the following criteria: a) pain duration ≥ 3 months;\\r\\n     b) Characteristics that conform to neuropathic pain: DN4 scale score ≥ 4 points;\\r\\n\\r\\n  5. During screening visits, patients were assessed to have an average pain visual\\r\\n     analogue scale (VAS) score of ≥ 40 mm over the past 24 hours.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. The presence of other painful diseases that may affect the evaluation of neuropathic\\r\\n     pain;\\r\\n\\r\\n  2. Patients with spinal cord injury or stroke whose condition is unstable and is\\r\\n     expected to require surgical treatment;\\r\\n\\r\\n  3. There is a chronic systemic disease that the investigator has assessed may affect\\r\\n     the participant's participation in the study；\\r\\n\\r\\n  4. Meet any of the following laboratory test results: a) Hematology: WBC<3×109/L, N<\\r\\n     1.5 ×109/L, PLT< 75 ×109/L, or HB< 90 g/L; b) Liver function: ALT or AST> 2.5 × ULN;\\r\\n     Or TBIL> 1.5 × ULN; c) eGFR< 60 mL/min/1.73 m2; d) Creatine kinase > 2.0 × ULN;\\r\\n\\r\\n  5. Women who are pregnant, planning to become pregnant during the study period, or\\r\\n     breastfeeding; Women who do not wish to use reliable contraceptive methods\\r\\n     (including condoms, spermicides, or Iuds) for 28 days after signing up for the ICF\\r\\n     from the beginning to the last trial drug administration, or who plan to use\\r\\n     progesterone contraceptives during this period;\\r\\n\\r\\n  6. Mechanical operators engaged in high-altitude work, motor vehicle driving and other\\r\\n     dangerous activities during the study period;\\r\\n\\r\\n  7. Participated in any other clinical study within 30 days prior to screening;\\r\\n\\r\\n  8. The investigator determined that there were other conditions that were not suitable\\r\\n     for study participation.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009437',\n",
       "      'term': 'Neuralgia'}],\n",
       "    'ancestors': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'}],\n",
       "    'browseLeaves': [{'id': 'M12381',\n",
       "      'name': 'Neuralgia',\n",
       "      'asFound': 'Neuropathic Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404',\n",
       "      'name': 'Neurologic Manifestations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06367309',\n",
       "    'orgStudyIdInfo': {'id': '2023 - 02357'},\n",
       "    'organization': {'fullName': 'University Hospital, Basel, Switzerland',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'ExtrAperitoneaL Plasty vs Intraperitoneal oNlay mEsh in Ventral Hernia Repair',\n",
       "    'officialTitle': 'ExtrAperitoneaL Plasty vs Intraperitoneal oNlay mEsh in Ventral Hernia Repair - the Randomized Controlled ALPINE Trial',\n",
       "    'acronym': 'ALPINE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2030-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-27',\n",
       "    'studyFirstSubmitQcDate': '2024-04-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University Hospital, Basel, Switzerland',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'St. Clara Hospital, Basel, Switzerland',\n",
       "      'class': 'UNKNOWN'},\n",
       "     {'name': 'Innklinikum Altötting, Germany', 'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study investigates on the effect of two different operative techniques to treat\\r\\nabdominal wall hernias.\\r\\n\\r\\nThe goal of this clinical trial is to learn if the eTEP (Extended totally extraperitoneal\\r\\nrepair) technique leads to a better outcome than the IPOM (Intraperitoneal onlay mesh)\\r\\ntechnique.\\r\\n\\r\\nThe main questions it aims to answer are:\\r\\n\\r\\n  -  pain after the operation\\r\\n\\r\\n  -  rate of complications\\r\\n\\r\\n  -  rate of recurrence and reoperations\\r\\n\\r\\n  -  quality of life.\\r\\n\\r\\nParticipants will:\\r\\n\\r\\nEither be operated using the eTEP or the IPOM technique. Be followed up either in person\\r\\nor via email / phone call at day 1, day 7, day 14, 6 weeks, 6 months, 1, 3 and 5 years\\r\\nafter the surgery to asses the above-stated main and some more outcomes.'},\n",
       "   'conditionsModule': {'conditions': ['Ventral Hernia',\n",
       "     'Abdominal Wall Defect']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'maskingDescription': 'The trial participants and the assessors (trained investigators not involved in the\\r\\noperative procedures) of the primary outcome are blinded regarding the performed\\r\\nprocedure during the first seven days after the procedure to reduce bias. The blinding is\\r\\nguaranteed by not sharing the detailed operation report with anyone involved in the\\r\\naftercare of the patient or in the assessment of study outcomes.',\n",
       "      'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 138, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'eTEP (Extended totally extraperitoneal repair)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The anterior rectus sheath is incised and the retromuscular space is entered through the\\r\\nrectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the\\r\\nretromuscular space is performed. Two additional laparoscopic ports are established\\r\\n8-10cm lateral to the linea alba caudally to the initial port. The medial border of the\\r\\nrectus sheath is incised and the preperitoneal space below the linea alba is dissected.\\r\\nThe hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The\\r\\nmedial border of the right retromuscular space is then incised and blunt dissection is\\r\\nperformed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed\\r\\non the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh\\r\\nis fixed non-traumatically using glubran glue or no fixation at all.',\n",
       "      'interventionNames': ['Procedure: Extended totally extraperitoneal repair']},\n",
       "     {'label': 'IPOM (intraperitoneal onlay mesh)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three\\r\\nlaparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's\\r\\nleft side. The peritoneum is incised and detached from the umbilical and supraumbilical\\r\\nlinea alba. The peritoneum including the hernia sac and preperitoneal fat is resected.\\r\\nThe hernia orifice is then closed using a barbed suture. A coated mesh is than placed to\\r\\nthe ventral abdominal wall covering the closed hernia orifices (intended\\r\\nmesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and\\r\\nseveral absorbable tackers placed in double crown technique around the hernia orifice.\\r\\nThe capnoperitoneum is released, the trocars removed and the fascia closed with an\\r\\nabsorbable suture. The skin is sutured with absorbable sutures.\",\n",
       "      'interventionNames': ['Procedure: Intraperitoneal onlay mesh']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Extended totally extraperitoneal repair',\n",
       "      'description': 'The anterior rectus sheath is incised and the retromuscular space is entered through the\\r\\nrectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the\\r\\nretromuscular space is performed. Two additional laparoscopic ports are established\\r\\n8-10cm lateral to the linea alba caudally to the initial port. The medial border of the\\r\\nrectus sheath is incised and the preperitoneal space below the linea alba is dissected.\\r\\nThe hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The\\r\\nmedial border of the right retromuscular space is then incised and blunt dissection is\\r\\nperformed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed\\r\\non the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh\\r\\nis fixed non-traumatically using glubran glue or no fixation at all.',\n",
       "      'armGroupLabels': ['eTEP (Extended totally extraperitoneal repair)']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Intraperitoneal onlay mesh',\n",
       "      'description': \"Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three\\r\\nlaparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's\\r\\nleft side. The peritoneum is incised and detached from the umbilical and supraumbilical\\r\\nlinea alba. The peritoneum including the hernia sac and preperitoneal fat is resected.\\r\\nThe hernia orifice is then closed using a barbed suture. A coated mesh is than placed to\\r\\nthe ventral abdominal wall covering the closed hernia orifices (intended\\r\\nmesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and\\r\\nseveral absorbable tackers placed in double crown technique around the hernia orifice.\\r\\nThe capnoperitoneum is released, the trocars removed and the fascia closed with an\\r\\nabsorbable suture. The skin is sutured with absorbable sutures.\",\n",
       "      'armGroupLabels': ['IPOM (intraperitoneal onlay mesh)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'primary outcome: pain numeric rating scale (NRS)',\n",
       "      'description': 'pain, measured on the numeric rating scale (NRS) 0 - 10 24 hours after the surgical\\r\\nprocedure.',\n",
       "      'timeFrame': '24 hours'},\n",
       "     {'measure': 'pain outcome using the Patient-Reported Outcome Measurement Information System (PROMIS) Pain Intensity Short Form 3a',\n",
       "      'description': 'pain, measured using the Patient-Reported Outcome Measurement Information System (PROMIS)\\r\\nPain Intensity Short Form 3a 24 hours after the surgical procedure',\n",
       "      'timeFrame': '24 hours'}],\n",
       "    'secondaryOutcomes': [{'measure': 'pain mid-term',\n",
       "      'description': 'pain, measured on the visual analog scale (NRS) 0 - 10 and using the Patient-Reported\\r\\nOutcome Measurement Information System (PROMIS) Pain Intensity Short Form 3a after 7days,\\r\\n14 days, 6 weeks, 6 and 12 months (NRS 0-10)',\n",
       "      'timeFrame': '12 months'},\n",
       "     {'measure': 'recurrence and reoperation',\n",
       "      'description': 'Long-term outcome at 3 and 5 years with assessment of the number of patients with\\r\\nclinical and / or radiological recurrences and with assessment of the number of patients\\r\\nwho needed reoperations for either recurrences or other reasons such as mechanical bowel\\r\\nobstructions',\n",
       "      'timeFrame': '5 years'},\n",
       "     {'measure': 'LOS',\n",
       "      'description': 'Length of hospital stay',\n",
       "      'timeFrame': '30 days'},\n",
       "     {'measure': 'Functional recovery',\n",
       "      'description': 'Functional recovery measured using the European Quality of Life 5 Dimensions 5 Level\\r\\n(EQ-5D-5L) Questionnaire at 7 and 14 days, 6 weeks, 6 months, 1, 3 and 5 years.\\r\\n\\r\\nThe questionnaire uses 5 questions describing the patients health & abilities on that\\r\\nparticular day and a visual analogue scale question (0 = worst, 100 = best) on the\\r\\npatients health on that particular day.',\n",
       "      'timeFrame': '5 years'},\n",
       "     {'measure': 'Adverse events',\n",
       "      'description': 'Intraoperative adverse events (Bleeding, conversion rate, injury to bowel structures)\\r\\nPostoperative adverse events (ileus, seroma, hematoma, Surgical site infections (SSI),\\r\\npulmonary embolism) according to Clavien-Dindo Classification and scored according to the\\r\\nComprehensive Complication Index (CCI) up to 30 days after surgery.',\n",
       "      'timeFrame': '30 days'},\n",
       "     {'measure': 'Quality of life (SF 12)',\n",
       "      'description': 'Quality of life using the short form-12 (SF-12) questionnaire at 7 and 14 days, 6 weeks,\\r\\n6 months, 1, 3 and 5 years.\\r\\n\\r\\nThe 12-item Short Form Survey (SF-12) is a general health questionnaire that was first\\r\\npublished in 1995 as part of the Medical Outcomes Study (MOS). The SF-12 was constructed\\r\\nusing questions drawn from each of the 8 dimensions of the MOS 36 item Short Form Survey\\r\\n(SF-36).\\r\\n\\r\\nTwo summary scores are reported from the SF-12 - a mental component score (MCS-12) and a\\r\\nphysical component score (PCS-12).\\r\\n\\r\\nThe score ranges from 0 - 100, with a higher score indicating better physical and mental\\r\\nhealth functioning.',\n",
       "      'timeFrame': '5 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patient age >18 years\\r\\n\\r\\n  -  Informed consent obtained\\r\\n\\r\\n  -  Primary or incisional ventral hernia\\r\\n\\r\\n  -  Epigastric, umbilical or infraumbilical ventral hernias with transversal diameter\\r\\n     >1cm and </= 4cm, +/- rectus diastasis which doesn't demand specific treatment\\r\\n\\r\\n  -  If multiple hernias: cumulative transversal diameter </= 4cm\\r\\n\\r\\n  -  Considered eligible for minimally-invasive approach\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Subxyphoidal or suprapubic hernias\\r\\n\\r\\n  -  precedent hernia treatment with mesh placement in the retromuscular space\\r\\n\\r\\n  -  liver disease defined by the presence of ascites\\r\\n\\r\\n  -  end-stage renal disease requiring dialysis\\r\\n\\r\\n  -  need of an emergency surgery\\r\\n\\r\\n  -  pregnancy\\r\\n\\r\\n  -  need of rectus diastasis treatment intraoperatively\\r\\n\\r\\nCriteria for participating surgeons\\r\\n\\r\\n  -  Each participating surgeon has performed 20 or more laparoscopic IPOM procedures and\\r\\n     20 or more eTEP procedures.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Fiorenzo Angehrn, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0041 61 777 73 17',\n",
       "      'email': 'fiorenzo.angehrn@clarunis.ch'}],\n",
       "    'overallOfficials': [{'name': 'Julian Süsstrunk, MD',\n",
       "      'affiliation': 'Clarunis - Universitäres Bauchzentrum Basel',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Johannes Baur, MD',\n",
       "      'affiliation': 'Clarunis - Universitäres Bauchzentrum Basel',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'St. Clara Hospital',\n",
       "      'city': 'Basel',\n",
       "      'state': 'Basel-Stadt',\n",
       "      'zip': '4058',\n",
       "      'country': 'Switzerland',\n",
       "      'contacts': [{'name': 'Fiorenzo Angehrn, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'fiorenzo.angehrn@clarunis.ch'}],\n",
       "      'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "    'description': 'IPD may be shared upon reasonable request. Only anonymised data shall be shared.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006547', 'term': 'Hernia'},\n",
       "     {'id': 'D000006555', 'term': 'Hernia, Ventral'}],\n",
       "    'ancestors': [{'id': 'D000020763',\n",
       "      'term': 'Pathological Conditions, Anatomical'},\n",
       "     {'id': 'D000046449', 'term': 'Hernia, Abdominal'}],\n",
       "    'browseLeaves': [{'id': 'M9625',\n",
       "      'name': 'Hernia',\n",
       "      'asFound': 'Hernia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9633',\n",
       "      'name': 'Hernia, Ventral',\n",
       "      'asFound': 'Ventral Hernia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22519',\n",
       "      'name': 'Pathological Conditions, Anatomical',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M25675', 'name': 'Hernia, Abdominal', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05841056',\n",
       "    'orgStudyIdInfo': {'id': '2023.START-POAF'},\n",
       "    'organization': {'fullName': 'Population Health Research Institute',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial',\n",
       "    'officialTitle': 'Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients (START-POAF) Pilot Trial',\n",
       "    'acronym': 'START-POAF'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-11-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-01-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-04',\n",
       "    'studyFirstSubmitQcDate': '2023-04-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-15', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Population Health Research Institute',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The START-POAF pilot study is a prospective, open-label two-arm, randomized controlled\\r\\ntrial with blinded assessment of outcomes (PROBE). This pilot study will assess Atrial\\r\\nFibrillation (AF) recurrence and burden in patients with new-onset AF following cardiac\\r\\nsurgery.',\n",
       "    'detailedDescription': 'Atrial fibrillation (AF) is the most common abnormal heart rhythm in the world. In\\r\\npatients who have cardiac surgery, new AF is found as an early complication in more than\\r\\none out of every four surgeries. In the weeks and months after heart surgery, patients\\r\\nwho have new AF take a medication called amiodarone to keep their heart in rhythm as it\\r\\nheals. If the heart goes back into AF, patients can have symptoms of heart racing, heart\\r\\nfailure (fluid on the lungs) or stroke. Although amiodarone is effective, it can have\\r\\nside effects like dizziness, nausea and slow heart rate. It may also damage the lungs,\\r\\nliver and thyroid gland. Many patients are not able to complete their full prescribed\\r\\ncourse after surgery. Therefore, it is crucial that the investigators find the shortest\\r\\npossible length of treatment with amiodarone that will keep the heart in rhythm while\\r\\nminimizing the chance of side effects or organ damage. The START-POAF Pilot Randomized\\r\\nTrial will compare two different durations of amiodarone treatment: 1) in-hospital load\\r\\nonly and 2) in-hospital load plus 4 weeks after loading dose. All participants will wear\\r\\nan electrocardiogram (ECG) monitor for 4 weeks the day after they complete their loading\\r\\ndose. The investigators will compare the amount of AF seen on the ECG between the two\\r\\ngroups.'},\n",
       "   'conditionsModule': {'conditions': ['Atrial Fibrillation New Onset'],\n",
       "    'keywords': ['cardiac surgery', 'heart rhythm monitoring', 'amiodarone']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': '1:1 ratio to receive amiodarone 200 mg maintenance therapy daily for four weeks or no\\r\\nmaintenance therapy',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 400, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Amiodarone maintenance therapy',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Amiodarone 200 mg daily for four weeks',\n",
       "      'interventionNames': ['Drug: Amiodarone Hydrochloride 200 MG']},\n",
       "     {'label': 'No Amiodarone maintenance therapy',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'No ongoing Amiodarone maintenance therapy for four weeks'}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Amiodarone Hydrochloride 200 MG',\n",
       "      'description': '200 mg daily for 4 weeks',\n",
       "      'armGroupLabels': ['Amiodarone maintenance therapy'],\n",
       "      'otherNames': ['Pacerone', 'Cordarone']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': '3 patients per center per month',\n",
       "      'description': 'Ability to recruit an average of 3 participants per center per month',\n",
       "      'timeFrame': '2 years'},\n",
       "     {'measure': 'Less than 10% cross-over rate',\n",
       "      'description': 'Less than 10% cross-over rate',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': 'Intervention group taking at least 80% of their amiodarone 4 week maintenance therapy',\n",
       "      'description': 'Greater than and equal to 90% of the intervention group taking at least 80% of their\\r\\namiodarone 4 week maintenance therapy',\n",
       "      'timeFrame': '28 days'},\n",
       "     {'measure': '90% follow-up at 30 days',\n",
       "      'description': 'Greater than and equal to 90% follow-up at 30 days',\n",
       "      'timeFrame': 'At 30 days post randomization date'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Burden of atrial fibrillation',\n",
       "      'description': 'Defined as percent time in atrial fibrillation',\n",
       "      'timeFrame': 'In the 28 days measured by the continuous ECG monitor placed on the day after the participant finishes their 3-5g amiodarone loading dose'},\n",
       "     {'measure': 'Time to first AF > 6 minutes, >6 hours and >24 hours',\n",
       "      'description': 'Time to first AF > 6 minutes, >6 hours and >24 hours reported from the continuous ECG\\r\\nmonitor',\n",
       "      'timeFrame': 'In the 28 days measured by the continuous ECG monitor placed on the day after the participant finishes their 3-5g amiodarone loading dose'},\n",
       "     {'measure': 'Participants with at least one episode >6 minutes, >6 hours and >24 hours',\n",
       "      'description': 'Proportion of participants with at least one episode > 6 minutes, >6 hours and >24 hours\\r\\nreported from the continuous ECG',\n",
       "      'timeFrame': 'In the 28 days measured by the continuous ECG monitor placed on the day after the participant finishes their 3-5g amiodarone loading dose'}],\n",
       "    'otherOutcomes': [{'measure': 'Heart Failure',\n",
       "      'description': 'Number of participants who experience heart failure',\n",
       "      'timeFrame': '90 days after randomization'},\n",
       "     {'measure': 'Atrial Fibrillation',\n",
       "      'description': 'Number of participants who experience atrial fibrillation',\n",
       "      'timeFrame': '90 days after randomization'},\n",
       "     {'measure': 'A composite of stroke, myocardial infarction and cardiovascular death',\n",
       "      'description': 'Number of participants who have at least one of the following: stroke, myocardial\\r\\ninfarction or cardiovascular death',\n",
       "      'timeFrame': '90 days after randomization'},\n",
       "     {'measure': 'Major bleeding',\n",
       "      'description': 'Number of participants who experience a major bleed',\n",
       "      'timeFrame': '90 days after randomization'},\n",
       "     {'measure': 'Systemic arterial embolism',\n",
       "      'description': 'Number of participants who experience a systemic arterial embolism',\n",
       "      'timeFrame': '90 days after randomization'},\n",
       "     {'measure': 'Atrial Fibrillation Effect on QualiTy of life (AFEQT) Questionnaire',\n",
       "      'description': 'The Atrial Fibrillation Effect on Quality-of-life Questionnaire (AFEQT) evaluates\\r\\nsymptoms, daily activities, and treatment concerns participants have related to atrial\\r\\nfibrillation and will be completed on all participants',\n",
       "      'timeFrame': 'Collected at baseline, 30 day follow-up and 90 day follow-up'},\n",
       "     {'measure': 'SF-12 Questionnaire',\n",
       "      'description': 'The SF-12 questionnaire which assesses physical and mental health will be completed on\\r\\nall participants',\n",
       "      'timeFrame': 'Collected at baseline, 30 day follow-up and 90 day follow-up'},\n",
       "     {'measure': 'Electrical cardioversion',\n",
       "      'description': 'Proportion of participants who undergo electrical cardioversion',\n",
       "      'timeFrame': 'Randomization to 90 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Aged ≥18 years;\\r\\n\\r\\n  2. Have undergone cardiac surgery including CABG, valve surgery, ascending aorta\\r\\n     replacement, or combinations thereof within 14 days of randomization;\\r\\n\\r\\n  3. Had new-onset POAF (or flutter), documented by 12-lead ECG or lasting ≥ 1 hour on\\r\\n     telemetry. Patients can be in AF or sinus rhythm at the time of randomization;\\r\\n\\r\\n  4. Expected to receive 3 g - 5 g of amiodarone loading dose post-surgery.\\r\\n\\r\\n  5. Expected to be ready for hospital discharge within 48 h of randomization.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Documented preoperative history of paroxysmal, persistent or permanent AF;\\r\\n\\r\\n  2. Planned use of a class I or III anti-arrhythmic drug (other than study drug);\\r\\n\\r\\n  3. Patients who have undergone heart transplant, complex congenital heart surgery,\\r\\n     isolated ventricular assist device insertion, or AF ablation (surgical or catheter);\\r\\n\\r\\n  4. Known allergy to ECG adhesives;\\r\\n\\r\\n  5. Contraindication to amiodarone (i.e. hyperthyroidism, severe restrictive or\\r\\n     obstructive lung disease, Long QT syndrome, PR > 240 ms, high-grade AV block).\\r\\n\\r\\n  6. Individuals who are pregnant, breastfeeding, or of childbearing potential - female\\r\\n     subjects, premenopausal who are not surgically sterile, or, if sexually active not\\r\\n     practicing an effective method of birth control (e.g., prescription oral\\r\\n     contraceptives, contraceptive injections, intrauterine device, double-barrier\\r\\n     method, contraceptive patch, male partner sterilization) before entry and throughout\\r\\n     the study; and, for those of childbearing potential, who have a positive pregnancy\\r\\n     test at screening',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Ingrid Copland',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '905-512-4940',\n",
       "      'email': 'start-poaf@phri.ca'}],\n",
       "    'overallOfficials': [{'name': 'William McIntyre, MD',\n",
       "      'affiliation': 'Population Health Research Institute',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001281',\n",
       "      'term': 'Atrial Fibrillation'}],\n",
       "    'ancestors': [{'id': 'D000001145', 'term': 'Arrhythmias, Cardiac'},\n",
       "     {'id': 'D000006331', 'term': 'Heart Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M4586',\n",
       "      'name': 'Atrial Fibrillation',\n",
       "      'asFound': 'Atrial Fibrillation',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4453', 'name': 'Arrhythmias, Cardiac', 'relevance': 'LOW'},\n",
       "     {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000000638',\n",
       "      'term': 'Amiodarone'}],\n",
       "    'ancestors': [{'id': 'D000000889', 'term': 'Anti-Arrhythmia Agents'},\n",
       "     {'id': 'D000014665', 'term': 'Vasodilator Agents'},\n",
       "     {'id': 'D000026902', 'term': 'Potassium Channel Blockers'},\n",
       "     {'id': 'D000049990', 'term': 'Membrane Transport Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000026941', 'term': 'Sodium Channel Blockers'},\n",
       "     {'id': 'D000065609', 'term': 'Cytochrome P-450 CYP1A2 Inhibitors'},\n",
       "     {'id': 'D000065607', 'term': 'Cytochrome P-450 Enzyme Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000065688', 'term': 'Cytochrome P-450 CYP2C9 Inhibitors'},\n",
       "     {'id': 'D000065690', 'term': 'Cytochrome P-450 CYP2D6 Inhibitors'},\n",
       "     {'id': 'D000065692', 'term': 'Cytochrome P-450 CYP3A Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M4213',\n",
       "      'name': 'Anti-Arrhythmia Agents',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3976',\n",
       "      'name': 'Amiodarone',\n",
       "      'asFound': 'Carcinoma of the skin',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M23171',\n",
       "      'name': 'Potassium Channel Blockers',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M23177', 'name': 'Sodium Channel Blockers', 'relevance': 'LOW'},\n",
       "     {'id': 'M30025',\n",
       "      'name': 'Diuretics, Potassium Sparing',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M30537',\n",
       "      'name': 'Cytochrome P-450 Enzyme Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M30564',\n",
       "      'name': 'Cytochrome P-450 CYP3A Inhibitors',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "     {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06205485',\n",
       "    'orgStudyIdInfo': {'id': 'CCTG-CO32'},\n",
       "    'secondaryIdInfos': [{'id': 'CCTG-CO32',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'NCI/CTEP'},\n",
       "     {'id': 'NCI-2023-10515', 'type': 'OTHER', 'domain': 'NCI CTRP'}],\n",
       "    'organization': {'fullName': 'Canadian Cancer Trials Group',\n",
       "     'class': 'NETWORK'},\n",
       "    'briefTitle': 'Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer',\n",
       "    'officialTitle': 'A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer',\n",
       "    'acronym': 'NEO-RT'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2030-01-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2030-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-11',\n",
       "    'studyFirstSubmitQcDate': '2024-01-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Canadian Cancer Trials Group',\n",
       "     'class': 'NETWORK'},\n",
       "    'collaborators': [{'name': 'Alliance for Clinical Trials in Oncology',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'ECOG-ACRIN Cancer Research Group', 'class': 'NETWORK'},\n",
       "     {'name': 'NRG Oncology', 'class': 'OTHER'},\n",
       "     {'name': 'SWOG Cancer Research Network', 'class': 'NETWORK'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is being done to answer the following questions: Is the chance of rectal\\r\\ncancer responding the same if chemotherapy alone is given before limited surgery compared\\r\\nto chemotherapy and radiation therapy given together before limited surgery? If radiation\\r\\ntherapy is not given, is quality of life better?',\n",
       "    'detailedDescription': 'This study is being done to find out if this approach is better or worse than the usual\\r\\napproach for early rectal cancer. The usual approach is defined as care most people get\\r\\nfor early rectal cancer.\\r\\n\\r\\nThe usual approach for patients who are not in a study is surgery to remove the rectum or\\r\\ntreatment with chemotherapy and radiation therapy, followed by surgery. There are several\\r\\nchemotherapy drugs approved by Health Canada that are commonly used with radiation\\r\\ntherapy. For patients who get the usual approach for this cancer, about 90 out of 100 are\\r\\nfree of cancer after 5 years.\\r\\n\\r\\nIf a patient decides to take part in this study, they will either get a combination of\\r\\nchemotherapy drugs called FOLFOX or CAPOX for up to 12 weeks or will get chemotherapy\\r\\nwith radiation therapy for up to 6 weeks.\\r\\n\\r\\nAfter finishing treatment, and even if treatment is stopped early, the study doctor will\\r\\nwatch for side effects and determine which type of surgery would be best. After surgery,\\r\\npatients will be asked to come in every 4 months for 2 years, then every 6 months for an\\r\\nadditional year. Then will be checked every year for 2 years. This means seeing the study\\r\\ndoctor for up to 5 years after surgery. Patients may be seen more often if your study\\r\\ndoctor thinks it is necessary.'},\n",
       "   'conditionsModule': {'conditions': ['Rectal Cancer']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 250, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'FOLFOX OR CAPOX',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'FOLFOX= Six cycles of modified FOLFOX consisting of leucovorin, oxaliplatin and bolus\\r\\nfluoruracil (optional), infusional fluorouracil.\\r\\n\\r\\nCAPOX= Capecitabine twice daily for 14 days and Oxaliplatin on day 1',\n",
       "      'interventionNames': ['Drug: Leucovorin',\n",
       "       'Drug: Oxaliplatin',\n",
       "       'Drug: Fluoruracil',\n",
       "       'Drug: Capecitabine']},\n",
       "     {'label': 'ChemoRT',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Standard dose of infusional 5-Fluorouracil/capecitabine and radiation',\n",
       "      'interventionNames': ['Drug: Fluoruracil',\n",
       "       'Drug: Capecitabine',\n",
       "       'Radiation: Radiation']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Leucovorin',\n",
       "      'description': '400 mg/m2',\n",
       "      'armGroupLabels': ['FOLFOX OR CAPOX']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Oxaliplatin',\n",
       "      'description': '85 mg/m2 or 130 mg/m2 on day 1',\n",
       "      'armGroupLabels': ['FOLFOX OR CAPOX']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Fluoruracil',\n",
       "      'description': 'bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2',\n",
       "      'armGroupLabels': ['ChemoRT', 'FOLFOX OR CAPOX']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Capecitabine',\n",
       "      'description': '1,000 mg/m2 twice daily for 14 days',\n",
       "      'armGroupLabels': ['ChemoRT', 'FOLFOX OR CAPOX']},\n",
       "     {'type': 'RADIATION',\n",
       "      'name': 'Radiation',\n",
       "      'description': '54 Gy (27-30 fractions)',\n",
       "      'armGroupLabels': ['ChemoRT']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical response rate upon re-staging',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Quality of Life defined using the LARS score',\n",
       "      'timeFrame': '6 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Total Mesorectal Excision (TME) Free Survival',\n",
       "      'description': 'Defined as time from randomization to the time of TME attempt or performance, local\\r\\nrecurrence after complete clinical response (cCR), or death from any cause',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Disease Free Survival',\n",
       "      'description': 'Defined as time from randomization to local recurrence/regrowth after cCR that cannot be\\r\\nsalvaged with an R0 TM, M1 recurrence, or death',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Rate of downstaging to ypTO/1N0/X', 'timeFrame': '6 years'},\n",
       "     {'measure': 'Bowel function assessed by Low Anterior Resection Syndrome (LARS) Score',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Bladder function assessed by EORTC QLQ-CR29 urinary frequency and urinary incontinence subscales',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Sexual function assessed by EORTC QLQ-CR29 sexual interest (men), and sexual interest (women) subscales',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Other QoL functions assessed by subscales of FIQL',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Other QoL functions assessed by subscales of EORTC QLQ-C30',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Other QoL functions assessed by subscales of subscales of EORTC QLQ-CR29',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Number and severity of adverse events utilizing CTCAE v5.0',\n",
       "      'timeFrame': '6 years'},\n",
       "     {'measure': 'Validate the magnetic resonance tumour regression grade (MR-TRG) in patients with T1 and T2 rectal cancer',\n",
       "      'timeFrame': '6 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Histologically confirmed invasive, well-moderately differentiated rectal\\r\\n     adenocarcinoma, mismatch repair proficient.\\r\\n\\r\\n  -  MRI stage cT1 not eligible for transanal surgery or cT2.\\r\\n\\r\\n  -  cN0 stage based on pelvic MRI - including absence of radiographic evidence of\\r\\n     mesorectal nodal metastasis, tumour deposits or extramural venous invasion (EMVI).\\r\\n\\r\\n  -  M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen\\r\\n     and pelvis.\\r\\n\\r\\n  -  Mid to low-lying tumour eligible for transanal excision in the opinion of the\\r\\n     treating surgeon.\\r\\n\\r\\n  -  Medically fit to undergo radical TME surgery as per treating surgeon's decision.\\r\\n\\r\\n  -  Participant is able (i.e. sufficiently fluent) and willing to complete the quality\\r\\n     of life questionnaires in either English or French or Spanish.\\r\\n\\r\\n  -  Age of at least 18 years.\\r\\n\\r\\n  -  No contraindications to protocol chemotherapy.\\r\\n\\r\\n  -  Adequate normal organ and marrow function: ANC ≥ x 10^9/L; platelet count ≥ 100 x\\r\\n     10^9/L; bilirubin < 1.5 UNL, excluding Gilbert's syndrome; Estimated creatinine\\r\\n     clearance of ≥ 50ml/min\\r\\n\\r\\n  -  Patient must have an ECOG performance of <2 (or Karnofsty ≥ 60%).\\r\\n\\r\\n  -  Must be accessible for treatment and follow-up\\r\\n\\r\\n  -  Women/men of childbearing potential must have agreed to use a highly effective\\r\\n     contraceptive method during and for 6 months after completion of chemotherapy.\\r\\n\\r\\n  -  HIV-infected patients on effective anti-retroviral therapy with undetectable viral\\r\\n     load within 6 months are eligible for this trial.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Pathologic high-risk factors on diagnostic biopsy: high histologic grade (poorly\\r\\n     differentiated), mucinous or signet ring histology, lymphatic/vascular or perineural\\r\\n     invasion.\\r\\n\\r\\n  -  Patients with visible pelvic sidewall nodes on MRI.\\r\\n\\r\\n  -  Patients with unequivocal determination of nodal disease that, in the opinion of the\\r\\n     investigator, would prohibit protocol therapy administration.\\r\\n\\r\\n  -  Previous pelvic radiation for any reason, including brachytherapy alone.\\r\\n\\r\\n  -  Patients who have had primary lesion excised prior to enrollment.\\r\\n\\r\\n  -  Patients with a prior or concurrent malignancy whose natural history or treatment\\r\\n     does not have the potential to interfere with the safety or efficacy assessment of\\r\\n     the investigational regimen are eligible for this trial.\\r\\n\\r\\n  -  Prior treatment for rectal cancer.\\r\\n\\r\\n  -  Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD).\\r\\n\\r\\n  -  Potential trial participants should have recovered from clinically significant\\r\\n     adverse events of their most recent therapy/intervention prior to enrollment.\\r\\n\\r\\n  -  Patients with known history or current symptoms of cardiac disease, or history of\\r\\n     treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac\\r\\n     function using the New York Heart Association Functional Classification. To be\\r\\n     eligible for this trial, patients should be class 2B or better.\\r\\n\\r\\n  -  Any contra-indications to undergo MRI imaging.\\r\\n\\r\\n  -  Presence of anterior lesions above or near peritoneal reflection rendering the\\r\\n     patient ineligible for a transanal tumour excision.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': \"Chris O'Callaghan\",\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '613-533-6430',\n",
       "      'email': 'cocallaghan@ctg.queensu.ca'}],\n",
       "    'overallOfficials': [{'name': 'Hagen Kennecke',\n",
       "      'affiliation': 'Providence Portland Medical Centre, Portland, OR, USA',\n",
       "      'role': 'STUDY_CHAIR'},\n",
       "     {'name': 'Carl Brown',\n",
       "      'affiliation': \"St. Paul's Hospital, Vancouver, BC, Canada\",\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'UC Irvine Health/Chao Family Comprehensive Cancer Center',\n",
       "      'city': 'Orange',\n",
       "      'state': 'California',\n",
       "      'zip': '92868',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '877-827-8839',\n",
       "        'email': 'ucstudy@uci.edu'},\n",
       "       {'name': 'Jason A. Zell', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 33.78779, 'lon': -117.85311}},\n",
       "     {'facility': 'Northwestern University',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60611',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '312-695-1301',\n",
       "        'email': 'cancer@northwestern.edu'},\n",
       "       {'name': 'Aparna Kalyan', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "     {'facility': 'Carle Cancer Center',\n",
       "      'city': 'Urbana',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '61801',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '800-446-5532',\n",
       "        'email': 'Research@carle.com'},\n",
       "       {'name': 'Prem Sobti', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.11059, 'lon': -88.20727}},\n",
       "     {'facility': 'Miami Valley Hospital South',\n",
       "      'city': 'Centerville',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45459',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-528-2900',\n",
       "        'email': 'clinical.trials@daytonncorp.org'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.62839, 'lon': -84.15938}},\n",
       "     {'facility': 'Dayton Blood and Cancer Center',\n",
       "      'city': 'Dayton',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45409',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-276-8320'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.75895, 'lon': -84.19161}},\n",
       "     {'facility': 'Miami Valley Hospital',\n",
       "      'city': 'Dayton',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45409',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 39.75895, 'lon': -84.19161}},\n",
       "     {'facility': 'Miami Valley Hospital North',\n",
       "      'city': 'Dayton',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45415',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-528-2900',\n",
       "        'email': 'clinical.trials@daytonncorp.org'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.75895, 'lon': -84.19161}},\n",
       "     {'facility': 'Atrium Medical Center-Middletown Regional Hospital',\n",
       "      'city': 'Franklin',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45005-1066',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-528-2900',\n",
       "        'email': 'clinical.trials@daytonncorp.org'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.55895, 'lon': -84.30411}},\n",
       "     {'facility': 'Miami Valley Cancer Care and Infusion',\n",
       "      'city': 'Greenville',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45331',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-569-7515'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.10283, 'lon': -84.63301}},\n",
       "     {'facility': 'Upper Valley Medical Center',\n",
       "      'city': 'Troy',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45373',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '937-528-2900',\n",
       "        'email': 'clinical.trials@daytonncorp.org'},\n",
       "       {'name': 'Tarek M. Sabagh', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.0395, 'lon': -84.20328}},\n",
       "     {'facility': 'Legacy Good Samaritan Hospital and Medical Center',\n",
       "      'city': 'Portland',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97210',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Public Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '800-220-4937',\n",
       "        'email': 'cancer@lhs.org'},\n",
       "       {'name': 'Mei Dong', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000012004',\n",
       "      'term': 'Rectal Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000015179', 'term': 'Colorectal Neoplasms'},\n",
       "     {'id': 'D000007414', 'term': 'Intestinal Neoplasms'},\n",
       "     {'id': 'D000005770', 'term': 'Gastrointestinal Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000012002', 'term': 'Rectal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14846',\n",
       "      'name': 'Rectal Neoplasms',\n",
       "      'asFound': 'Rectal Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17890', 'name': 'Colorectal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M10448', 'name': 'Intestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14844', 'name': 'Rectal Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000002955',\n",
       "      'term': 'Leucovorin'},\n",
       "     {'id': 'D000069287', 'term': 'Capecitabine'},\n",
       "     {'id': 'D000005472', 'term': 'Fluorouracil'},\n",
       "     {'id': 'D000077150', 'term': 'Oxaliplatin'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000000931', 'term': 'Antidotes'},\n",
       "     {'id': 'D000020011', 'term': 'Protective Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000014803', 'term': 'Vitamin B Complex'},\n",
       "     {'id': 'D000014815', 'term': 'Vitamins'},\n",
       "     {'id': 'D000018977', 'term': 'Micronutrients'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'}],\n",
       "    'browseLeaves': [{'id': 'M377',\n",
       "      'name': 'Capecitabine',\n",
       "      'asFound': 'Function',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6191',\n",
       "      'name': 'Leucovorin',\n",
       "      'asFound': 'Video',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8600',\n",
       "      'name': 'Fluorouracil',\n",
       "      'asFound': 'PFA',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1674',\n",
       "      'name': 'Oxaliplatin',\n",
       "      'asFound': 'Outcomes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M4250', 'name': 'Antidotes', 'relevance': 'LOW'},\n",
       "     {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M8618', 'name': 'Folic Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'M17558', 'name': 'Vitamins', 'relevance': 'LOW'},\n",
       "     {'id': 'M17546', 'name': 'Vitamin B Complex', 'relevance': 'LOW'},\n",
       "     {'id': 'M21009', 'name': 'Micronutrients', 'relevance': 'LOW'},\n",
       "     {'id': 'M16885', 'name': 'Trace Elements', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'T446', 'name': 'Folic Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'T448', 'name': 'Folate', 'relevance': 'LOW'},\n",
       "     {'id': 'T475', 'name': 'Vitamin B9', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Micro', 'name': 'Micronutrients'},\n",
       "     {'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'Vi', 'name': 'Vitamins'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06370585',\n",
       "    'orgStudyIdInfo': {'id': 'SOPH229-0823/I'},\n",
       "    'organization': {'fullName': 'Laboratorios Sophia S.A de C.V.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF',\n",
       "    'officialTitle': 'Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF in Clinically Healthy Subjects'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-10',\n",
       "    'studyFirstSubmitQcDate': '2024-04-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Laboratorios Sophia S.A de C.V.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This is a phase I study evaluating safety and tolerability of PRO-229 ophthalmic solution\\r\\nthrough he incidence of unexpected adverse events, changes in Best Corrected Visual\\r\\nAcuity (BCVA), incidence of chemosis, and changes in ocular surface staining using the\\r\\nSjögren's International Collaborative Clinical Alliance (SICCA) Ocular Staining Score\\r\\n(OSS) scale compared to Lagricel® Ofteno PF in clinically healthy subjects.\",\n",
       "    'detailedDescription': \"The variables to be evaluated include:\\r\\n\\r\\nPrimary objective:\\r\\n\\r\\n  -  To evaluate the safety and tolerability of PRO-229 ophthalmic solution compared to\\r\\n     Lagricel® Ofteno PF in clinically healthy subjects.\\r\\n\\r\\nSpecific objective:\\r\\n\\r\\n  -  To compare the safety of PRO-229 formulation compared to Lagricel® Ofteno PF through\\r\\n     the incidence of adverse events related to both investigational products.\\r\\n\\r\\nSecondary Objectives:\\r\\n\\r\\n  -  To compare the safety of vs. PRO-229 formulation compared to Lagricel® Ofteno PF by\\r\\n     changes in Best Corrected Visual Acuity (BCVA).\\r\\n\\r\\n  -  To compare the safety of PRO-229 formulation compared to Lagricel® Ofteno PF by\\r\\n     changes in ocular surface staining assessed with the the Sjögren's International\\r\\n     Collaborative Clinical Alliance (SICCA) Ocular Staining Score (OSS) scale.\\r\\n\\r\\n  -  To compare the safety of PRO-229 formulation compared to Lagricel® Ofteno PF by the\\r\\n     incidence of chemosis.\\r\\n\\r\\n  -  To compare the tolerability of PRO-229 formulation compared to Lagricel® Ofteno PF\\r\\n     by changes in conjunctival hyperemia grades 3 or 4.\\r\\n\\r\\n  -  To ompare the tolerability of PRO-229 formulation compared to Lagricel® Ofteno\\r\\n     Ophthalmic PF by adherence to treatment.\"},\n",
       "   'conditionsModule': {'conditions': ['Dry Eye Disease',\n",
       "     'Ocular Surface Disease']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Phase I, controlled, comparative, double-masked, single-center, randomized, controlled\\r\\nclinical trial.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 36, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'PRO-229',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.\\r\\n\\r\\n  -  Dosage:1 drop QID [4] (four times per day) for 7 days on right both eyes.\\r\\n\\r\\n  -  Route of administration: Ophthalmic.\\r\\n\\r\\n  -  Presentation: Multidose dropper bottle.',\n",
       "      'interventionNames': ['Drug: PRO-229']},\n",
       "     {'label': 'Lagricel® Ofteno PF',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': '  -  Sodium hyaluronate 0.4%. Ophthalmic solution.\\r\\n\\r\\n  -  Dosage: 1 drop QID [4] (four times per day) for 7 days on right both eyes.\\r\\n\\r\\n  -  Route of administration: Ophthalmic.\\r\\n\\r\\n  -  Presentation: Multidose dropper bottle.',\n",
       "      'interventionNames': ['Drug: Lagricel® Ofteno PF']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'PRO-229',\n",
       "      'description': '  -  Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.',\n",
       "      'armGroupLabels': ['PRO-229']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Lagricel® Ofteno PF',\n",
       "      'description': '  -  Sodium hyaluronate 0.4%. Ophthalmic solution.',\n",
       "      'armGroupLabels': ['Lagricel® Ofteno PF']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence Unexpected Related Adverse Reactions',\n",
       "      'description': 'Any unfavorable medical condition affecting the subject after the administration of the\\r\\ninvestigation product, related to such intervention.',\n",
       "      'timeFrame': 'Through study completion, an average of 12 days. Evaluations will take place on days 0 (Basal Visit), 3 (Visit 1), 8 (Final Visit) and 12 (Safety Call) after the inclusion of each subject.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Changes in Best Corrected Visual Acuity (BCVA)',\n",
       "      'description': 'BCVA will be evaluated through Snellen chart',\n",
       "      'timeFrame': 'Through an average of 8 days. Evaluations will take place on days 0 (Basal Visit), 3 (Visit 1), and 8 (Final Visit) after the inclusion of each subject.'},\n",
       "     {'measure': 'Changes in ocular surface staining using SICCA ocular staining score scale',\n",
       "      'description': \"Changes in ocular surface staining will be evaluated using the Sjögren's International\\r\\nCollaborative Clinical Alliance (SICCA) Ocular Staining Score (OSS) scale compared to\\r\\nLagricel® Ofteno PF in clinically healthy subjects.\",\n",
       "      'timeFrame': 'Through an average of 8 days. Evaluations will take place on days 0 (Basal Visit), 3 (Visit 1), and 8 (Final Visit) after the inclusion of each subject.'},\n",
       "     {'measure': 'Incidence of chemosis',\n",
       "      'description': 'Incidence of chemosis will be evaluated through direct observation by principal\\r\\ninvestigator\\r\\n\\r\\n0 = Absent\\r\\n\\r\\n1 = Present',\n",
       "      'timeFrame': 'Through an average of 8 days. Evaluations will take place on days 0 (Basal Visit), 3 (Visit 1), and 8 (Final Visit) after the inclusion of each subject.'},\n",
       "     {'measure': 'Incidence of grade 3 or 4 conjunctival hyperemia.',\n",
       "      'description': 'Conjunctival hyperemia will be evaluated through Efron grading scale.',\n",
       "      'timeFrame': 'Through an average of 8 days. Evaluations will take place on days 0 (Basal Visit), 3 (Visit 1), and 8 (Final Visit) after the inclusion of each subject.'},\n",
       "     {'measure': 'Adherence to treatment (adherence)',\n",
       "      'description': \"Adherence will be evaluated through the treatment record in the subject's diary.\",\n",
       "      'timeFrame': 'Through an average of 8 days. This evaluations will take place on days 8 (Final Visit) after the inclusion of each subject.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Having the ability to voluntarily give their signed informed consent.\\r\\n\\r\\n  -  Ophthalmologically and clinically healthy subjects.\\r\\n\\r\\n  -  Being able to and willing to comply with scheduled visits, treatment plan, and other\\r\\n     study procedures.\\r\\n\\r\\n  -  Age between 18 to 45 years.\\r\\n\\r\\n  -  Male or female gender.\\r\\n\\r\\n  -  Women of childbearing potential who have not undergone Bilateral Tubal Occlusion\\r\\n     (BTO [Tubal Ligation]), hysterectomy, or bilateral oophorectomy must ensure\\r\\n     continuation (initiated ≥ 30 days prior to signing the informed consent form [ICF])\\r\\n     of the use of a hormonal contraceptive method or intrauterine device (IUD) during\\r\\n     the study period.\\r\\n\\r\\n  -  Best corrected visual acuity (BCVA) of 20/30 or better in both eyes.\\r\\n\\r\\n  -  Corneal staining ≤ grade I on the Oxford Scale.\\r\\n\\r\\n  -  Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  History of hypersensitivity to fluoroquinolones, steroid anti-inflammatories, or any\\r\\n     of the components of the drugs under investigation.\\r\\n\\r\\n  -  Use of ophthalmic medications from any pharmacological group.\\r\\n\\r\\n  -  Use of medications by any other route of administration.\\r\\n\\r\\n  -  Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or\\r\\n     antibiotics by any route of administration in the last 30 days.\\r\\n\\r\\n  -  History of eye surgery in the last 6 months.\\r\\n\\r\\n  -  Use of contact lenses for a period less than two weeks prior to the start of the\\r\\n     study, and during the intervention period of this study.\\r\\n\\r\\n  -  In the case of women: being pregnant, breastfeeding, or planning to become pregnant\\r\\n     within the study period.\\r\\n\\r\\n  -  Having participated in any clinical research study 30 days prior to inclusion in\\r\\n     this study.\\r\\n\\r\\n  -  Having previously participated in this same study.\\r\\n\\r\\n  -  History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic\\r\\n     Arterial Hypertension.\\r\\n\\r\\n  -  Diagnosis of glaucoma or ocular hypertension.\\r\\n\\r\\n  -  Known diagnosis of liver or heart disease.\\r\\n\\r\\n  -  Presenting active inflammatory or infectious disease at the time of entry into the\\r\\n     study.\\r\\n\\r\\n  -  Presenting unresolved lesions or traumas at the time of entry into the study.\\r\\n\\r\\n  -  Having been subjected to non-ophthalmological surgical procedures in the last 3\\r\\n     months.\\r\\n\\r\\n  -  Being or having an immediate family member (e.g., spouse, parent/legal guardian,\\r\\n     sibling, or child) who is an employee of the research site or the sponsor, and who\\r\\n     directly participates in this study.\\r\\n\\r\\n  -  Active smoking (specified as the consumption of cigarettes regardless of the amount\\r\\n     and frequency, 4 weeks prior to study inclusion and during the intervention period\\r\\n     of this study).\\r\\n\\r\\n  -  Active alcoholism (specified as the consumption of alcoholic beverages, regardless\\r\\n     of the amount and frequency, 72 hours prior to study inclusion and during the\\r\\n     intervention period of this study).\\r\\n\\r\\nElimination Criteria\\r\\n\\r\\n  -  Withdrawal of their consent to participate in the study (informed consent form).\\r\\n\\r\\n  -  Occurrence of a serious adverse event, whether related or not to the interventions,\\r\\n     that in the opinion of the principal investigator (PI) and/or the sponsor, could\\r\\n     affect the patient's fitness to safely continue with the study procedures.\\r\\n\\r\\n  -  Non-tolerability or hypersensitivity to any of the compounds used during the tests\\r\\n     -(fluorescein, tetracaine).\\r\\n\\r\\n  -  Non-tolerability or hypersensitivity to any of the drugs under investigation.\\r\\n\\r\\n  -  Adherence < 80% determined by the subject's diary and corroborated by the final\\r\\n     weight of the research products (RP) compared to the initial weight.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Alejandra Sanchez-Rios, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '33 3001 4200',\n",
       "      'email': 'alejandra.sanchez@sophia.com.mx'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000015352',\n",
       "      'term': 'Dry Eye Syndromes'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'}],\n",
       "    'ancestors': [{'id': 'D000007766', 'term': 'Lacrimal Apparatus Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M18040',\n",
       "      'name': 'Dry Eye Syndromes',\n",
       "      'asFound': 'Dry Eye Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10664',\n",
       "      'name': 'Keratoconjunctivitis Sicca',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8271',\n",
       "      'name': 'Eye Diseases',\n",
       "      'asFound': 'Eye Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M10786',\n",
       "      'name': 'Lacrimal Apparatus Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M9878',\n",
       "      'name': 'Hyaluronic Acid',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M12814', 'name': 'Ophthalmic Solutions', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06437288',\n",
       "    'orgStudyIdInfo': {'id': '2024-FXY-183'},\n",
       "    'organization': {'fullName': 'Sun Yat-sen University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Hematoporphyrin Photodynamic Therapy for Esophageal Cancer',\n",
       "    'officialTitle': 'Therapeutic Effectiveness of Hematoporphyrin Injection Based Photodynamic Therapy in Post-Treatment Recurrent or Residual Superficial Esophageal Cancer: A Prospective, Single-Arm, Multicentric Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-04-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-21',\n",
       "    'studyFirstSubmitQcDate': '2024-05-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-26',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Jian-jun Li',\n",
       "     'investigatorTitle': 'Prefessor, Endoscopy Department Administrative Director',\n",
       "     'investigatorAffiliation': 'Sun Yat-sen University'},\n",
       "    'leadSponsor': {'name': 'Sun Yat-sen University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to evaluate the effectiveness of photodynamic therapy\\r\\nusing hematoporphyrin injection in treating recurrent or residual superficial esophageal\\r\\ncancer. The primary purpose is to assess the ability of this intervention to achieve\\r\\ncomplete response in these patients.\\r\\n\\r\\nThe main question it aims to answer is:\\r\\n\\r\\n  -  What is the complete response rate at day 28 post-treatment with PDT using\\r\\n     hematoporphyrin injection in patients with recurrent or residual superficial\\r\\n     esophageal cancer? There is no comparison group in this single-arm study.\\r\\n\\r\\nParticipants will:\\r\\n\\r\\n  -  Be adults aged 18-80 with recurrent or residual superficial esophageal cancer after\\r\\n     prior treatment.\\r\\n\\r\\n  -  Receive an intravenous infusion of hematoporphyrin injection at a dose of 3mg/kg\\r\\n     over 60 minutes.\\r\\n\\r\\n  -  Undergo 630nm laser irradiation 48-72 hours after the infusion.\\r\\n\\r\\n  -  Be assessed for complete response at day 28 post-treatment, as well as\\r\\n     progression-free survival, overall survival, swallowing function, quality of life,\\r\\n     and adverse events throughout the study.'},\n",
       "   'conditionsModule': {'conditions': ['Esophageal Cancer',\n",
       "     'Photodynamic Therapy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'interventionModelDescription': 'Single-Stage Phase II Clinical Trials',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 198, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'photodynamic therapy',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Receive an intravenous infusion of hematoporphyrin injection at a dose of 3mg/kg over 60\\r\\nminutes.\\r\\n\\r\\nUndergo 630nm laser irradiation 48-72 hours after the infusion.',\n",
       "      'interventionNames': ['Drug: photodynamic therapy']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'photodynamic therapy',\n",
       "      'description': 'Receive an intravenous infusion of hematoporphyrin injection',\n",
       "      'armGroupLabels': ['photodynamic therapy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'The complete response rate evaluated by endoscopic ultrasound (EUS)',\n",
       "      'description': 'The proportion of patients showing a complete disappearance of the tumor following the\\r\\ntreatment, as assessed by EUS on day 28',\n",
       "      'timeFrame': '28 days after the treatment.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Progression free survival',\n",
       "      'description': 'Length of time during and after the treatment of a disease, in which a patient lives with\\r\\nthe disease but it does not get worse.',\n",
       "      'timeFrame': '3 years'},\n",
       "     {'measure': 'Overall survival',\n",
       "      'description': 'length of time from the start of the treatment until the death of the patient, regardless\\r\\nof the cause.',\n",
       "      'timeFrame': '3 years'},\n",
       "     {'measure': 'Adverse events',\n",
       "      'description': 'Adverse events of the treatment.',\n",
       "      'timeFrame': '1 month after the treatment'},\n",
       "     {'measure': 'Quality of life evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)',\n",
       "      'description': 'EORTC QLQ-C30 () is a 30-item questionnaire that assesses the quality of life of cancer\\r\\npatients.',\n",
       "      'timeFrame': '0.5 year; 1 year; 3 year'},\n",
       "     {'measure': \"Stooler's dysphagia grading\",\n",
       "      'description': \"Stooler's dysphagia grading is a clinical method used to categorize the severity of\\r\\nswallowing difficulties in patients with esophageal disorders, including esophageal\\r\\ncancer. It is based on the patient's ability to swallow liquids, semi-solids, and solids.\",\n",
       "      'timeFrame': '0.5 year; 1 year; 3 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adult patients aged 18-80 with recurrent or residual superficial esophageal cancer\\r\\n     after prior treatment.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Known hypersensitivity, severe comorbidities, pregnancy, etc.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jianjun Li, Doctor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '02087343009',\n",
       "      'phoneExt': '02087343009',\n",
       "      'email': 'lijj@sysucc.org.cn'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000004938',\n",
       "      'term': 'Esophageal Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000005770', 'term': 'Gastrointestinal Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006258', 'term': 'Head and Neck Neoplasms'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000004935', 'term': 'Esophageal Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M8088',\n",
       "      'name': 'Esophageal Neoplasms',\n",
       "      'asFound': 'Esophageal Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14850', 'name': 'Recurrence', 'relevance': 'LOW'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M9348', 'name': 'Head and Neck Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8085', 'name': 'Esophageal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T2141',\n",
       "      'name': 'Esophageal Cancer',\n",
       "      'asFound': 'Esophageal Cancer',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M9502',\n",
       "      'name': 'Hematoporphyrins',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Derm', 'name': 'Dermatologic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06417788',\n",
       "    'orgStudyIdInfo': {'id': 'CIR-ECL-2018-09'},\n",
       "    'organization': {'fullName': 'Universitat Internacional de Catalunya',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Dynamic Guided Implant Surgery VS Static Guided Surgery.',\n",
       "    'officialTitle': 'Dynamic Guided Implant Surgery VS Static Guided Surgery. A Pilot Randomized Clinical Trial.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-13',\n",
       "    'studyFirstSubmitQcDate': '2024-05-13',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Jordi Marquès Guasch',\n",
       "     'investigatorTitle': 'Jordi marques Guasch',\n",
       "     'investigatorAffiliation': 'Universitat Internacional de Catalunya'},\n",
       "    'leadSponsor': {'name': 'Universitat Internacional de Catalunya',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study aims to evaluate if dynamic-guided surgery is an accurate system for placing\\r\\ndental implants.\\r\\n\\r\\nResearchers will assess the dental implant accuracy of the dynamic guided system compared\\r\\nto the static pilot guide.\\r\\n\\r\\nParticipants will:\\r\\n\\r\\n  -  Receive implant treatment that will be placed by a dynamic or static pilot drill\\r\\n     guided system.\\r\\n\\r\\n  -  Receive post-operative radiological exam for comparative (on the same appointment).'},\n",
       "   'conditionsModule': {'conditions': ['Partially Edentulous Patients',\n",
       "     'Bone Crest of at Least 10 mm Length and 6 mm Width',\n",
       "     'Patients of at Least 18 Years Old']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Patients who need dental implants and fulfill the inclusion criteria will be randomly\\r\\nallocated to test group (dynamic guided system) or control group (static\\r\\nstereolithographic pilot drill guided system)',\n",
       "     'primaryPurpose': 'DEVICE_FEASIBILITY',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Due to the nature of the treatment, it is impossible to mask the treatment from the\\r\\nparticipant and the care provider. However, the data for analysis will be masked to the\\r\\ninvestigator responsible for assessing the accuracy of each implant placement system.',\n",
       "      'whoMasked': ['INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Test group or Dynamic guided group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"in this arm, the position and angulation of the implant in the patient's mouth will be\\r\\nguided by a dynamic guided system.\",\n",
       "      'interventionNames': ['Device: Dental implant placement']},\n",
       "     {'label': 'Control group or Static guided group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"In this arm, the position and angulation of the implant in the patient's mouth will be\\r\\nguided by a stereolitographic pilot drill guide.\",\n",
       "      'interventionNames': ['Procedure: Static guided implant placement']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Dental implant placement',\n",
       "      'description': 'Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)',\n",
       "      'armGroupLabels': ['Test group or Dynamic guided group'],\n",
       "      'otherNames': ['dynamic guided implant placement']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Static guided implant placement',\n",
       "      'description': 'Dental implant placement guided by a stereolithographic pilot drill guide.',\n",
       "      'armGroupLabels': ['Control group or Static guided group'],\n",
       "      'otherNames': ['control group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Implant placement accuracy at the implant platform level',\n",
       "      'description': 'Implant placement accuracy compared with the implant planning. Expressed in mm.',\n",
       "      'timeFrame': 'The data for the assessment is collected during the same appointment as the implant placement and requires an additional 20 minutes.'},\n",
       "     {'measure': 'Implant placement accuracy at the implant apex level',\n",
       "      'description': 'Implant placement accuracy compared with the implant planning. Expressed in mm.',\n",
       "      'timeFrame': 'The data for the assessment is collected during the same appointment as the implant placement and requires an additional 20 minutes.'},\n",
       "     {'measure': 'Implant placement accuracy at an angular evel',\n",
       "      'description': 'Implant placement accuracy compared with the implant planning. Expressed in degrees.',\n",
       "      'timeFrame': 'The data for the assessment is collected during the same appointment as the implant placement and requires an additional 20 minutes.'},\n",
       "     {'measure': 'Implant placement accuracy at the vertical plane.',\n",
       "      'description': 'Implant placement accuracy compared with the implant planning. Expressed in mm.',\n",
       "      'timeFrame': 'The data for the assessment is collected during the same appointment as the implant placement and requires an additional 20 minutes.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  18 years or older,\\r\\n\\r\\n  -  ASA type 1 or 2,\\r\\n\\r\\n  -  Full mouth plaque scores up to 25% (O'LEARY TJ. The plaque control record\\r\\n     1972;43:38), -Partially edentulous with at least one missing tooth\\r\\n\\r\\n  -  Having a bone crest of at least 10mm in length and 6mm in width.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  medical conditions contraindicating surgery,\\r\\n\\r\\n  -  untreated periodontal disease or caries\\r\\n\\r\\n  -  the need for bone augmentation\\r\\n\\r\\n  -  acute local infections\\r\\n\\r\\n  -  history of head/neck radiation.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '90 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Universitat Internacional de Catalunya',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Sant Cugat Del Vallès',\n",
       "      'state': 'Barcelona',\n",
       "      'zip': '08195',\n",
       "      'country': 'Spain',\n",
       "      'contacts': [{'name': 'Marques Guasch',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+447453802813',\n",
       "        'email': 'jmarques@uic.es'},\n",
       "       {'name': 'Gargallo Albiol',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+34637434270',\n",
       "        'email': 'jgargallo@uic.es'}],\n",
       "      'geoPoint': {'lat': 41.47063, 'lon': 2.08611}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '24837492',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Somogyi-Ganss E, Holmes HI, Jokstad A. Accuracy of a novel prototype dynamic computer-assisted surgery system. Clin Oral Implants Res. 2015 Aug;26(8):882-890. doi: 10.1111/clr.12414. Epub 2014 May 19.'},\n",
       "     {'pmid': '23062136',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Van Assche N, Vercruyssen M, Coucke W, Teughels W, Jacobs R, Quirynen M. Accuracy of computer-aided implant placement. Clin Oral Implants Res. 2012 Oct;23 Suppl 6:112-23. doi: 10.1111/j.1600-0501.2012.02552.x.'},\n",
       "     {'pmid': '23062137',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Hultin M, Svensson KG, Trulsson M. Clinical advantages of computer-guided implant placement: a systematic review. Clin Oral Implants Res. 2012 Oct;23 Suppl 6:124-35. doi: 10.1111/j.1600-0501.2012.02545.x.'},\n",
       "     {'pmid': '27643585',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Block MS, Emery RW, Lank K, Ryan J. Implant Placement Accuracy Using Dynamic Navigation. Int J Oral Maxillofac Implants. 2017 Jan/Feb;32(1):92-99. doi: 10.11607/jomi.5004. Epub 2016 Sep 19.'},\n",
       "     {'pmid': '28000275',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"D'haese J, Ackhurst J, Wismeijer D, De Bruyn H, Tahmaseb A. Current state of the art of computer-guided implant surgery. Periodontol 2000. 2017 Feb;73(1):121-133. doi: 10.1111/prd.12175.\"},\n",
       "     {'pmid': '29310817',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Sun TM, Lan TH, Pan CY, Lee HE. Dental implant navigation system guide the surgery future. Kaohsiung J Med Sci. 2018 Jan;34(1):56-64. doi: 10.1016/j.kjms.2017.08.011. Epub 2017 Dec 8.'},\n",
       "     {'pmid': '26452429',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Block MS, Emery RW. Static or Dynamic Navigation for Implant Placement-Choosing the Method of Guidance. J Oral Maxillofac Surg. 2016 Feb;74(2):269-77. doi: 10.1016/j.joms.2015.09.022. Epub 2015 Sep 30.'},\n",
       "     {'pmid': '4500182',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"O'Leary TJ, Drake RB, Naylor JE. The plaque control record. J Periodontol. 1972 Jan;43(1):38. doi: 10.1902/jop.1972.43.1.38. No abstract available.\"},\n",
       "     {'pmid': '28722969',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Doyle DJ, Hendrix JM, Garmon EH. American Society of Anesthesiologists Classification. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK441940/'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Plan to publish the IPD.',\n",
       "    'infoTypes': ['SAP', 'CSR'],\n",
       "    'timeFrame': 'when the data is available during the publication process'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009066',\n",
       "      'term': 'Mouth, Edentulous'}],\n",
       "    'ancestors': [{'id': 'D000009059', 'term': 'Mouth Diseases'},\n",
       "     {'id': 'D000009057', 'term': 'Stomatognathic Diseases'},\n",
       "     {'id': 'D000014076', 'term': 'Tooth Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12026',\n",
       "      'name': 'Mouth, Edentulous',\n",
       "      'asFound': 'Edentulous',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12019', 'name': 'Mouth Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M16831', 'name': 'Tooth Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05176288',\n",
       "    'orgStudyIdInfo': {'id': '21-575'},\n",
       "    'organization': {'fullName': 'Dana-Farber Cancer Institute',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Avelumab, Palbociclib and Axitinib in Advanced RCC',\n",
       "    'officialTitle': 'Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.',\n",
       "    'acronym': 'APART'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-09',\n",
       "    'overallStatus': 'WITHDRAWN',\n",
       "    'whyStopped': 'The overall protocol will be changed in a new amendment, which will be resubmitted under\\r\\nthe new IND.',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-08-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2021-12-06',\n",
       "    'studyFirstSubmitQcDate': '2021-12-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-01-04', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-09-04',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-09-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Bradley A. McGregor, MD',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Dana-Farber Cancer Institute'},\n",
       "    'leadSponsor': {'name': 'Bradley A. McGregor, MD', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Pfizer', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab\\r\\nand palbociclib) is safe and effective in slowing down the growth of advanced clear cell\\r\\nrenal cell carcinoma (ccRCC) in patients that have not received any prior systemic\\r\\ntreatment.\\r\\n\\r\\nThe names of the study drug involved in this study are/is:\\r\\n\\r\\n  -  Axitinib\\r\\n\\r\\n  -  Avelumab\\r\\n\\r\\n  -  Palbociclib',\n",
       "    'detailedDescription': 'This is a multi-center, single-arm, phase 2 study to evaluate the efficacy of the\\r\\ncombination of axitinib, avelumab, and palbociclib in patients with untreated, advanced\\r\\nclear cell renal cell carcinoma (ccRCC).\\r\\n\\r\\nThis research study involves an investigational drug combination (axitinib, avelumab and\\r\\npalbociclib) not approved by the FDA (USA Food and Drug Administration) for treatment of\\r\\nadvanced clear cell renal cell carcinoma (ccRCC), though the combination of axitinib and\\r\\navelumab has been approved for use in advanced clear cell renal cell carcinoma (ccRCC)\\r\\ntreatment. Palbociclib is a CDK inhibitor, which targets growing cancer cells by blocking\\r\\nhow a phosphate molecule is added to an important regulatory protein called\\r\\nretinoblastoma so preventing the formation of new cancer cells.\\r\\n\\r\\nStudy procedures include screening for eligibility, study treatment, participant\\r\\nevaluations and safety follow visits in addition to general health status follow-up after\\r\\nstudy treatment. Participants will receive study treatment for as long as they do not\\r\\nhave serious side effects and their disease does not get worse, and will be followed for\\r\\nas long as they remain on the study.\\r\\n\\r\\nIt is expected that about 25 people will take part in this research study.\\r\\n\\r\\nPfizer is supporting this research study by providing the study drugs (axitinib, avelumab\\r\\nand palbociclib).'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Clear Cell Renal Cell Carcinoma'],\n",
       "    'keywords': ['Advanced Clear Cell Renal Cell Carcinoma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Axitinib, Avelumab and Palbociclib',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'During each 28 day (+/- 3 days) study cycle, all participants will receive:\\r\\n\\r\\n  -  Axitinib: 2x Daily until it is determined participant must stop the drug\\r\\n\\r\\n  -  Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined\\r\\n     participant must stop the drug.\\r\\n\\r\\n  -  Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is\\r\\n     determined participant must stop the study drug',\n",
       "      'interventionNames': ['Drug: Axitinib',\n",
       "       'Drug: Palbociclib',\n",
       "       'Drug: Avelumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Axitinib',\n",
       "      'description': 'Taken Orally',\n",
       "      'armGroupLabels': ['Axitinib, Avelumab and Palbociclib'],\n",
       "      'otherNames': ['Inlyta']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Palbociclib',\n",
       "      'description': 'Taken Orally',\n",
       "      'armGroupLabels': ['Axitinib, Avelumab and Palbociclib'],\n",
       "      'otherNames': ['Ibrance']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Avelumab',\n",
       "      'description': 'Intravenous infusion',\n",
       "      'armGroupLabels': ['Axitinib, Avelumab and Palbociclib'],\n",
       "      'otherNames': ['Bavencio']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Best Overall Response Rate (ORR)',\n",
       "      'description': 'Objective response rate (ORR) is defined as the proportion of participants achieving\\r\\ncomplete response (CR) or partial response (PR) based on RECIST 1.1 criteria on\\r\\ntreatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target\\r\\nlesions and PR is at least a 30% decrease in the sum of the longest diameter (LD) of\\r\\ntarget lesions, taken as reference baseline sum LD. PR or better overall response assumes\\r\\nat a minimum incomplete response/stable disease (SD) for the evaluation of non-target\\r\\nlesions and absence of new lesions.',\n",
       "      'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, for duration of therapy assessed up to 100 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Median Progression-free survival (PFS)',\n",
       "      'description': 'Based on the Kaplan-Meier method, median progression-free survival (PFS) is defined as\\r\\nthe duration of time from study entry to documented disease progression (PD) or death.\\r\\nPer RECIST 1.1 criteria: progressive disease (PD) is at least a 20% increase in the sum\\r\\nof the longest diameter (LD) of target lesions taken as reference of the smallest sum LD\\r\\nrecorded since the treatment started or the appearance of one or more new lesions.\\r\\nDisease progression (PD) for the evaluation of non-target lesions is the appearance of\\r\\none or more new lesions and/or unequivocal progression of non-target lesions.',\n",
       "      'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months'},\n",
       "     {'measure': 'Median Overall Survival (OS)',\n",
       "      'description': 'Based on the Kaplan-Meier method overall survival (OS) is defined as the time from study\\r\\nentry to death or censored at date last known alive.',\n",
       "      'timeFrame': 'Participants followed for long-term for survival every 6 months from the end of treatment until death or lost to follow-up, up to 2 years after treatment discontinuation.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Histologically or cytologically confirmed unresectable advanced or metastatic renal\\r\\n     cell carcinoma with a clear cell component. Patient with sarcomatoid histology are\\r\\n     accepted.\\r\\n\\r\\n       -  A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a de novo\\r\\n          tumor biopsy obtained during screening will be required (biopsied tumor lesion\\r\\n          should not be a RECIST target lesion). Alternatively, a recently obtained\\r\\n          archival FFPE tumor tissue block (not cut slides from a primary or metastatic\\r\\n          tumor resection or biopsy) can be provided if the following criteria are met:\\r\\n\\r\\n            -  The biopsy or resection was performed within 1 year of registration AND\\r\\n\\r\\n            -  The patient has not received any intervening systemic anti-cancer\\r\\n               treatment from the time the tissue was obtained and registration onto the\\r\\n               current study. If an FFPE tissue block cannot be provided as per\\r\\n               documented regulations then 15 unstained slides (10 minimum) will be\\r\\n               acceptable\\r\\n\\r\\n       -  Availability of an archival FFPE tumor tissue block from primary diagnosis\\r\\n          specimen (if available and not provided per above). If an FFPE tissue block\\r\\n          cannot be provided as per documented regulations, then 15 unstained slides (10\\r\\n          minimum) will be acceptable\\r\\n\\r\\n       -  Additional tumor biopsies for research purposes prior to starting therapy,\\r\\n          after 2 months of therapy and at end of treatment are optional.\\r\\n\\r\\n  -  Measurable disease as per RECIST 1.1. See section 11 for the evaluation of\\r\\n     measurable disease.\\r\\n\\r\\n  -  Age ≥ 18 years.\\r\\n\\r\\n  -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\\r\\n\\r\\n  -  Normal organ and marrow function as defined below:\\r\\n\\r\\n       -  Absolute neutrophil count ≥1.5×109/L\\r\\n\\r\\n       -  Platelets ≥100×109/L\\r\\n\\r\\n       -  Hemoglobin ≥9g/dL (transfusions allowed)\\r\\n\\r\\n       -  Total bilirubin ≤2 × institutional upper limit of normal (ULN) with the\\r\\n          following exception: patients with known Gilbert disease should have a serum\\r\\n          bilirubin ≤ 3 x ULN\\r\\n\\r\\n       -  AST(SGOT)/ALT(SGPT) ≤3 × ULN with the following exception: patients with known\\r\\n          liver metastases should have AST and ALT ≤ 5 × ULN\\r\\n\\r\\n       -  Creatinine clearance ≥30 mL/min according to the Cockcroft-Gault equation.\\r\\n          (APPENDIX F)\\r\\n\\r\\n       -  Urine protein <2+ by dipstick; if dipstick ≥2+, then 24 hour urinary protein\\r\\n          <2g\\r\\n\\r\\n  -  Women of child-bearing potential and men must agree to use adequate contraception\\r\\n     (intrauterine device or barrier method of birth control; abstinence) prior to study\\r\\n     entry and for the duration of study participation. If condoms are used as a barrier\\r\\n     method, a spermicidal agent should be added as a double barrier protection. A\\r\\n     negative pregnancy serum test should be obtained within 7 days of therapy\\r\\n     initiation. Should a woman become pregnant or suspect she is pregnant while she or\\r\\n     her partner is participating in this study, she must discontinue treatment\\r\\n     immediately. Data on fetal outcome and breast-feeding are to be collected for\\r\\n     regulatory reporting and drug safety evaluation. Participants treated or enrolled on\\r\\n     this protocol must also agree to use adequate contraception prior to the study, for\\r\\n     the duration of study participation, and 30 days after completion of avelumab,\\r\\n     axitinib and palbociclib administration.\\r\\n\\r\\n  -  Ability to swallow oral medications.\\r\\n\\r\\n  -  Ability to understand and willingness to sign a written informed consent document.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Treatment with the following prior therapies:\\r\\n\\r\\n       -  Prior systemic therapy for advanced or metastatic RCC.\\r\\n\\r\\n       -  Prior adjuvant or neoadjuvant therapy for RCC if disease progression or relapse\\r\\n          has occurred within 12 months of last dose of such therapy. Treatment with an\\r\\n          immune checkpoint inhibitor in the adjuvant setting is allowed providing more\\r\\n          than 12 months have elapsed since completion of therapy.\\r\\n\\r\\n       -  Prior treatment with any immunotherapeutic agent (IL-2, IFN-∝, anti-PD(L)-1,\\r\\n          anti-CTLA-4, or any other antibody or drug targeting T-cell co-stimulation or\\r\\n          immune checkpoint pathways).\\r\\n\\r\\n       -  Prior therapy with axitinib or other therapies targeting VEGF pathway in the\\r\\n          metastatic setting (adjuvant therapy is allowed.\\r\\n\\r\\n       -  Prior therapy with any CDK4/6 inhibitor.\\r\\n\\r\\n  -  Participants with untreated brain metastases. Participants with metastatic CNS\\r\\n     tumors may participate in this trial, if the participant is ≥ 4 weeks from therapy\\r\\n     completion (incl. radiation and/or surgery), is clinically stable at the time of\\r\\n     study entry and is not receiving corticosteroid therapy >10 mg/day prednisone or\\r\\n     equivalent. A repeat MRI or CT brain to show stability is required.\\r\\n\\r\\n  -  Participants who have received wide field radiotherapy ≤ 4 weeks or limited field\\r\\n     radiation for palliation ≤ 2 weeks prior to starting study drug or who have not\\r\\n     recovered from side effects of such therapy to at least grade 1.\\r\\n\\r\\n  -  Untreated deep vein thrombosis or pulmonary embolism, or event of deep vein\\r\\n     thrombosis or pulmonary embolism within 2 weeks of treatment start. Patient should\\r\\n     be on at least 1 week of anticoagulation before C1D1.\\r\\n\\r\\n  -  Major surgery within the past 4 weeks or major radiation therapy within 2 weeks\\r\\n     prior to treatment start. Prior palliative radiotherapy to metastatic lesion(s) is\\r\\n     permitted, provided it has been completed at least 48 hours prior to patient\\r\\n     randomization.\\r\\n\\r\\n  -  The patient has serious and/or uncontrolled preexisting medical condition(s) that,\\r\\n     in the judgment of the investigator, would preclude participation in this study (for\\r\\n     example, interstitial lung disease - also see 3.2.22, severe dyspnea at rest or\\r\\n     requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine\\r\\n     clearance <30ml/min], history of major surgical resection involving the stomach or\\r\\n     small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting\\r\\n     chronic condition resulting in baseline Grade 2 or higher diarrhea).\\r\\n\\r\\n  -  Persisting toxicity related to prior therapy NCI CTCAE v5.0 Grade >1; however,\\r\\n     sensory neuropathy Grade ≤2 is acceptable.\\r\\n\\r\\n  -  Current or prior use of immunosuppressive medication within 7 days prior to\\r\\n     randomization, except the following:\\r\\n\\r\\n       -  Intranasal, inhaled, topical steroids, or local steroid injections (eg.\\r\\n          intra-articular injection).\\r\\n\\r\\n       -  Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or\\r\\n          equivalent.\\r\\n\\r\\n       -  Steroids as premedication for hypersensitivity reactions (eg. CT scan\\r\\n          premedication).\\r\\n\\r\\n  -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade≤3) or any\\r\\n     history of anaphylaxis.\\r\\n\\r\\n  -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory\\r\\n     agents. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid\\r\\n     disease not requiring immunosuppressive treatment are eligible.\\r\\n\\r\\n  -  Vaccination within 4 weeks of the first dose of avelumab and while on trial is\\r\\n     prohibited except for administration of inactivated vaccines (for example,\\r\\n     inactivated influenza vaccines).\\r\\n\\r\\n  -  Grade≥3 hemorrhage within 4 weeks of registration\\r\\n\\r\\n  -  Patient with active systemic bacterial infection (requiring IV antibiotics at the\\r\\n     time of initiating study treatment), fungal infection, or detectable viral\\r\\n     infection. Patients with known viral infection (such as HIV) are excluded given the\\r\\n     potential for interactions between antiretroviral agents and palbociclib and\\r\\n     axitinib, and the potential for increased risk of life-threatening infection with\\r\\n     therapy that is myelosuppressive. If patients are not known to have HIV, a HIV test\\r\\n     is required.\\r\\n\\r\\n  -  Patients with known Hepatitis B or Hepatitis C infection are excluded only if there\\r\\n     is evidence of active infection (detectable Hepatitis B surface antigen, detectable\\r\\n     Hepatitis C RNA).\\r\\n\\r\\n  -  Prior allogenic stem cell or solid organ transplant.\\r\\n\\r\\n  -  Impairment of gastrointestinal function or gastrointestinal disease that may\\r\\n     significantly alter the absorption of oral drugs (e.g., ulcerative diseases,\\r\\n     uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel\\r\\n     resection).\\r\\n\\r\\n  -  Participants who are currently taking therapeutic doses of warfarin sodium or any\\r\\n     other coumadin-derivative anticoagulant. Therapeutic use of low molecular weight\\r\\n     heparin and factor Xa inhibitors (eg. apixaban, rivaroxaban) is permitted.\\r\\n\\r\\n  -  Other malignancy diagnosed within 2 years of treatment start unless negligible risk\\r\\n     of metastases or death according to the investigator (included but not limited to\\r\\n     carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized\\r\\n     prostate cancer, ductal carcinoma in situ of the breast, non-muscle invasive\\r\\n     urothelial carcinoma, or other malignancy not deemed to impact patients 5-year life\\r\\n     expectancy).\\r\\n\\r\\n  -  Has a personal history of any of the following conditions: syncope of cardiovascular\\r\\n     etiology, ventricular arrhythmia of pathological origin (including, but not limited\\r\\n     to, ventricular tachycardia and ventricular fibrillation), sudden cardiac arrest.\\r\\n\\r\\n  -  Has had any major cardiovascular event within 6 months prior to treatment start,\\r\\n     including but not limited to: myocardial infarction, unstable angina,\\r\\n     cerebrovascular accident, transient ischemic event or New York Heart Association\\r\\n     Class III or IV heart failure.\\r\\n\\r\\n  -  Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2 or prolongation of the QTc\\r\\n     interval to >500 msec.\\r\\n\\r\\n  -  History of interstitial lung disease or other restrictive lung disease, as well as\\r\\n     history of symptomatic respiratory condition considered clinically significant by\\r\\n     the investigator. Individuals with a history of radiotherapy to the thorax will be\\r\\n     excluded.\\r\\n\\r\\n  -  Active or ex-smokers with a history of cigarette smoking greater than 30pack-yrs\\r\\n     (i.e., # of packs of cigarettes smoked per day x # of years patient has smoked >\\r\\n     30).\\r\\n\\r\\n  -  Participants with a known hypersensitivity to the study compounds or to its\\r\\n     excipients.\\r\\n\\r\\n  -  Current use or anticipated need for treatment with drugs or foods that are known\\r\\n     strong CYP3A4/5 inhibitors, including their administration within 10 days prior to\\r\\n     treatment start (eg. grapefruit juice or grapefruit/grapefruit-related citrus fruits\\r\\n     [eg. Seville oranges, pomelos], ketoconazole, miconazole, itraconazole,\\r\\n     voriconazole, posaconazole, clarithromycin, telithromycin, indinavir, saquinavir,\\r\\n     ritonavir, nelfinavir, amprenavir, fosamprenavir nefazodone, lopinavir,\\r\\n     troleandomycin, mibefradil, and conivaptan). The topical use of these medications\\r\\n     (if applicable), such as 2% ketoconazole cream, is allowed.\\r\\n\\r\\n  -  Current use or anticipated need for drugs that are known strong CYP3A4/5 inducers,\\r\\n     including their administration within 10 days prior to treatment start (eg.\\r\\n     phenobarbital, rifampin, phenytoin, carbamazepine, rifabutin, rifapentin,\\r\\n     clevidipine, St John's wort).\\r\\n\\r\\n  -  Participants who have taken herbal medications within 7 days prior to treatment\\r\\n     start. Herbal medications include, but are not limited to St. John's wort, Kava,\\r\\n     ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw\\r\\n     palmetto, and ginseng.\\r\\n\\r\\n  -  Females that are pregnant or lactating.\\r\\n\\r\\n  -  Judgement by the investigator that the patient is unsuitable to participate in the\\r\\n     study and the patient is unlikely to comply with study procedures, restrictions and\\r\\n     requirements.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Bradley McGregor, MD',\n",
       "      'affiliation': 'Dana-Farber Cancer Institute',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and\\r\\nethical sharing of data from clinical trials. De-identified participant data from the\\r\\nfinal research dataset used in the published manuscript may only be shared under the\\r\\nterms of a Data Use Agreement. Requests may be directed to: [contact information for\\r\\nSponsor Investigator or designee]. The protocol and statistical analysis plan will be\\r\\nmade available on Clinicaltrials.gov only as required by federal regulation or as a\\r\\ncondition of awards and agreements supporting the research.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF'],\n",
       "    'timeFrame': 'Data can be shared no earlier than 1 year following the date of publication',\n",
       "    'accessCriteria': 'Contact the Belfer Office for Dana-Farber Innovations (BODFI) at\\r\\ninnovation@dfci.harvard.edu'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31',\n",
       "    'removedCountries': ['United States']},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002277',\n",
       "      'term': 'Carcinoma'},\n",
       "     {'id': 'D000002292', 'term': 'Carcinoma, Renal Cell'}],\n",
       "    'ancestors': [{'id': 'D000009375',\n",
       "      'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000000230', 'term': 'Adenocarcinoma'},\n",
       "     {'id': 'D000007680', 'term': 'Kidney Neoplasms'},\n",
       "     {'id': 'D000014571', 'term': 'Urologic Neoplasms'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000007674', 'term': 'Kidney Diseases'},\n",
       "     {'id': 'D000014570', 'term': 'Urologic Diseases'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5534',\n",
       "      'name': 'Carcinoma',\n",
       "      'asFound': 'Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5548',\n",
       "      'name': 'Carcinoma, Renal Cell',\n",
       "      'asFound': 'Clear Cell Renal Cell Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M3585', 'name': 'Adenocarcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M10703', 'name': 'Kidney Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17320', 'name': 'Urologic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10698', 'name': 'Kidney Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T4906',\n",
       "      'name': 'Renal Cell Carcinoma',\n",
       "      'asFound': 'Renal Cell Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1341',\n",
       "      'name': 'Clear Cell Renal Cell Carcinoma',\n",
       "      'asFound': 'Clear Cell Renal Cell Carcinoma',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000500026',\n",
       "      'term': 'Palbociclib'},\n",
       "     {'id': 'C000609138', 'term': 'Avelumab'},\n",
       "     {'id': 'D000077784', 'term': 'Axitinib'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}],\n",
       "    'browseLeaves': [{'id': 'M344580',\n",
       "      'name': 'Avelumab',\n",
       "      'asFound': 'Reach',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1910',\n",
       "      'name': 'Axitinib',\n",
       "      'asFound': 'Chamber',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M223893',\n",
       "      'name': 'Palbociclib',\n",
       "      'asFound': 'Deficiency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06425588',\n",
       "    'orgStudyIdInfo': {'id': '24-0349'},\n",
       "    'secondaryIdInfos': [{'id': 'FACEFIT 2.0',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'EPA'}],\n",
       "    'organization': {'fullName': 'University of North Carolina, Chapel Hill',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Craniofacial Dimensions as Determinants of the Fitted Performance of Common Face Masks (FACEFIT 2.0)',\n",
       "    'officialTitle': 'Craniofacial Dimensions as Determinants of the Fitted Performance of Common Face Masks (FACEFIT 2.0)'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University of North Carolina, Chapel Hill',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Environmental Protection Agency (EPA)',\n",
       "      'class': 'FED'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study examines the role of craniofacial dimensions and self-evaluation thereof in\\r\\nthe protection afforded by masks commonly worn by the public as protection against\\r\\naerosol contaminants. The effectiveness of instructions for self-evaluation of\\r\\ncraniofacial dimensions will be tested against standard digital and manual craniometric\\r\\nmethods.\\r\\n\\r\\nApproximately 500 (18-70 year old) subjects of any gender.\\r\\n\\r\\nAfter consenting to participate in the study, subjects will use a short self-assessment\\r\\nquestionnaire to measure their craniofacial dimensions, and have their face measured\\r\\nusing standard anthropological techniques and a 3D camera. They will then enter a chamber\\r\\ncontaining an atmosphere of aerosolized salt particles where the fitted filtering\\r\\nefficiency of 2 types of face masks will be measured briefly. Participation time is\\r\\napproximately 60 minutes.',\n",
       "    'detailedDescription': \"Wearing a face mask is a primary protection strategy against airborne infectious agents\\r\\nas well as toxic aerosols such as wildfire smoke. Despite the ubiquitous presence of\\r\\nmasks in public life in recent years, the average person has a poor understanding of\\r\\nfactors that influence the fitted performance of the face coverings that they wear. This\\r\\nproblem is exacerbated by the lack of mask fit testing available to the public outside of\\r\\noccupational settings subject to regulation. As a result, the vast majority of the\\r\\npopulation currently wears masks with limited knowledge of their efficacy or the means to\\r\\nacquire it. A simple, validated method to quantitatively self-assess individual\\r\\ncraniofacial dimensions relative to that of the general population will permit members of\\r\\nthe public to make informed decisions about the types of mask that they wear in specific\\r\\nrisk situations, and whether to use fit enhancements to optimize their fitted\\r\\nperformance. In addition to limiting the morbidity associated with exposure to poor air\\r\\nquality, an individualized improvement in the efficacy of mask will have a multiplicative\\r\\neffect in the prevention of the transmission of infectious vectors.\\r\\n\\r\\nSubjects who are not excluded from the initial screening will be scheduled for consenting\\r\\nat the EPA Human Studies Facility (HSF). At the start of the visit, the study protocol\\r\\nwill be outlined, and informed consent obtained to initiate enrollment into the study.\\r\\nThere will be one session in this study. Consenting subjects will proceed immediately to\\r\\nthe participation phase.\\r\\n\\r\\nConsenting: There will be one (1) study consent form (form FF2.0 1). This consent form\\r\\nmust be signed by the participant and the study team member obtaining informed consent.\\r\\nThe subjects may ask any questions they have regarding their participation in the study\\r\\nat any time prior to or during their participation. Persons with child-bearing potential\\r\\nwill be required to self-administer a pregnancy test in a private bathroom. Those who\\r\\nself-administer a pregnancy test will have to confirm the results on the consent form in\\r\\norder to proceed to the study phase.\\r\\n\\r\\nBehavioral questionnaire: Subjects will complete a short questionnaire (Form FF2.0 2)\\r\\nthat asks about their predisposition to wear a face mask under a variety of scenarios.\\r\\nThis information will be used to guide public health communications during air quality\\r\\nemergencies.\\r\\n\\r\\nAssessment of self-evaluation instructions for craniofacial measurements: Subjects will\\r\\nuse instructions presented in a self-evaluation form (Form FF2.0 3) to measure their own\\r\\ncraniofacial dimensions using the rulers provided and a mirror. Subjects will receive no\\r\\nassistance with completing the self-assessment form. At intervals of approximately, 10-40\\r\\nsubjects, measurements obtained in the self-evaluation will be compared to the\\r\\ncraniofacial measurements obtained by a study team member. The results of the comparison\\r\\nwill be used to guide revisions of the instruction in the self-evaluation form in an\\r\\niterative manner. The protocol will be amended accordingly to update changes to the\\r\\nself-evaluation instructions.\\r\\n\\r\\nCraniofacial measurements: A 3 D scan of the subjects' face and head will be obtained by\\r\\naligning the head inside of an oval shown on a tablet screen. The image takes about 3\\r\\nseconds to generate and subjects will be asked to move their head slightly. In addition,\\r\\nmanual measurement of 4-8 craniofacial dimensions will be taken by a study team member\\r\\nusing calipers and a tape measure.\\r\\n\\r\\nLung Function Test. Participants will complete a breathing test (peak flow meter) before\\r\\nand after the facemask testing. Study personnel will coach the participant to take a full\\r\\nbreath in and then blow it out as hard and fast as they can. They may be asked to do this\\r\\nup to five times. This test measures the volume of air they can blow out (exhale) quickly\\r\\nafter taking a very deep breath. This is a method to measure lung function before and\\r\\nafter the testing procedure for safety purposes. The investigators will stop the study\\r\\nand not complete the mask fit testing if the participant's peak expiratory flow (as\\r\\nmeasured with the peak flow meter) is not ≥ 80.0% of their predicted value based on their\\r\\nage, height, and weight.\\r\\n\\r\\nAssessment of filtering face piece (FFP) use: The range of variability that exists in the\\r\\nsubject population while wearing two different types of face coverings will be assessed.\\r\\nMasks will consist of a KN95 mask and a surgical/procedure mask. The fitted filtration\\r\\nefficiency of each mask will be measured using aerosolized sodium chloride particles\\r\\n(mean aerodynamic diameter 0.040 microns) emitted by a particle generator. During the fit\\r\\ntesting, the concentration of aerosolized saline particles emitted by a TSI Particle\\r\\nGenerator will be approximately 5000-30000 particles/cc of air. The temperature in the\\r\\nchamber will vary between 20 and 30 oC, the relative humidity will be maintained at\\r\\napproximately 50 %.\\r\\n\\r\\nThe subject will remain seated in the chamber and complete a modified version the\\r\\nOccupational Safety and Health Administration Quantitative Fit Testing Protocol (Modified\\r\\nAmbient Aerosol CNC Quantitative Fit Testing Protocol for Filtering Facepiece\\r\\nTableA-2-RESPIRATORS). The subject will then move their head from left to right, taking\\r\\ntwo breaths at each extreme for 30 seconds. This will be followed by moving the head up\\r\\nand down, taking two beaths at each extreme for 30 seconds. The procedure will be\\r\\nrepeated after the addition of a clip to the ear-loops of the mask behind the neck of the\\r\\nsubject. In total, the testing time for the 2 masks with and without clip will be\\r\\napproximately 6 minutes.\"},\n",
       "   'conditionsModule': {'conditions': ['Healthy'],\n",
       "    'keywords': ['Healthy subjects',\n",
       "     'Mask',\n",
       "     'Mask fit',\n",
       "     'Fitted Filtration Efficiency',\n",
       "     'Self-Evaluation',\n",
       "     'Craniofacial Morphology',\n",
       "     '3D imaging']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'BASIC_SCIENCE',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Mask Testing',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'All participants will be fit tested while completing a modified version of the OSHA fit\\r\\ntest.',\n",
       "      'interventionNames': ['Other: Surgical/Procedure Mask Fit Testing',\n",
       "       'Other: KN95 Mask Fit testing']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Surgical/Procedure Mask Fit Testing',\n",
       "      'description': 'All participants will wear a surgical/procedure mask and be fit tested using a modified\\r\\nversion of the OSHA quantitative fit testing procedure.',\n",
       "      'armGroupLabels': ['Mask Testing']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'KN95 Mask Fit testing',\n",
       "      'description': 'All participants will wear a KN95 mask and be fit tested using a modified version of the\\r\\nOSHA quantitative fit testing procedure.',\n",
       "      'armGroupLabels': ['Mask Testing']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Fitted Filtration Efficiency',\n",
       "      'description': 'A mask fit procedure will be performed based on an OSHA (Occupational Safety and Health\\r\\nAdministration)- approved protocol during the baseline visit. The efficiency of masks\\r\\nwill be determined by a percentage of particle number measured behind the facemask over\\r\\nthe particle number in the ambient air. Mask fit efficiency values from different levels\\r\\nof mask fit instructions will be compared.',\n",
       "      'timeFrame': 'During fitting procedure (90 seconds for each condition)'},\n",
       "     {'measure': 'Cranial Morphology- Self Evaluation',\n",
       "      'description': 'Cranial morphology will be assessed using a self-evaluation that guides participants on\\r\\nhow to measure five dimensions of their head/face including: nose length, nose arc, face\\r\\nwidth, neck circumference, and ear breadth. Participants will record their measurement\\r\\nfor each cranial/facial features using the instructions provided on the self-evaluation\\r\\nform. Investigators will then use the five recorded values to cluster each participant\\r\\ninto one of four categories of overall face and head shape/size.',\n",
       "      'timeFrame': 'The self-evaluation will take approximately ten minutes and be filled out once during the study visit (Day 1).'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Cranial Morphology- Caliper Measurement',\n",
       "      'description': \"Calipers will be used to measure craniofacial features of each subject. Trained personnel\\r\\n(wearing gloves) will need to touch areas of the subject's face and scalp to ensure\\r\\nproper caliper measurements are collected. Measurements to be collected include: nose\\r\\nlength, face width, neck circumference, and ear breadth. All measurements have a common\\r\\nunit (cm).\",\n",
       "      'timeFrame': 'The craniometric assessment will take approximately 5 minutes and be completed before the fit testing procedure.'},\n",
       "     {'measure': 'Cranial Morphology- 3D Imaging',\n",
       "      'description': \"Subjects will self-administer a 3D scan of their face by aligning their head inside of an\\r\\noval shown on the camera screen, triggering the camera shutter. The image takes about 3\\r\\nseconds to generate and subjects will be asked to remain still during this time. The\\r\\nacquired facial images will be analyzed using digital image analysis software. The images\\r\\nwill be analyzed to measure the participant's nose gap area.\",\n",
       "      'timeFrame': 'The 3D imaging will take approximately 5 minutes and be completed before the fit testing procedure.'},\n",
       "     {'measure': 'FaceFit 2.0 Face Filtering PIece Usage Survey',\n",
       "      'description': 'Subjects will take a brief questionnaire regarding their masking behavior and perceptions\\r\\nof masks. The questionnaire will also ask participants to rate how big/small they think\\r\\ntheir head length, width, and size is compared to adults of the same age/gender. The\\r\\nsurvey is comprised of 34 questions that fall into the following sections:\\r\\nsociodemographic information, mask perception, experience with mask usage, knowledge of\\r\\nparticulate matter vs. volatile organic compounds, and perception of face shape and size.\\r\\nAll questions consist of four or five point likert scales corresponding to ordinal scores\\r\\n(No Impact to Significant Impact, 1-5)(Most Likely to Least Likely, 1-4). All questions\\r\\ncorrespond to the participant\\'s knowledge or perception and are recorded on an ordinal\\r\\nscale and thus the survey has no \"directionality\".',\n",
       "      'timeFrame': 'This survey will take about five minutes and be completed before the mask fit testing.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Age 18-70 years old healthy of any gender and ethnicity.\\r\\n\\r\\n  2. Subjects must be ambulatory and tolerate enclosed spaces.\\r\\n\\r\\n  3. Subjects must report being in good health\\r\\n\\r\\n  4. Subjects must pass COVID-19 screening questions and have had at least a primary\\r\\n     COVID-19 vaccination series.\\r\\n\\r\\n  5. Individuals with a BMI (kg/m2) that is greater than 16.0 and less than 50.0\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Persons who are pregnant, attempting to become pregnant or breastfeeding\\r\\n\\r\\n  2. Persons who are unable to read English well enough to follow written instructions or\\r\\n     a questionnaire.\\r\\n\\r\\n  3. Persons who have facial hair.\\r\\n\\r\\n  4. Individuals who have had an acute respiratory illness within 6 weeks.\\r\\n\\r\\n  5. Individuals who have active allergies.\\r\\n\\r\\n  6. Those who are not feeling well.\\r\\n\\r\\n  7. Anyone who is unable to walk unassisted, stand or sit still for 15 minutes at a\\r\\n     time.\\r\\n\\r\\n  8. Anyone who suffered a heart attack, cardiac arrest or stroke in the past 6 months.\\r\\n\\r\\n  9. Anyone who has been hospitalized overnight or sought urgent medical care in the last\\r\\n     30 days.\\r\\n\\r\\n 10. Anyone who has an unspecified illness, which in the judgment of the medical staff,\\r\\n     might increase the risk associated with this study will be a basis for exclusion.\\r\\n\\r\\n 11. Those who are pregnant, attempting to become pregnant or breastfeeding.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Robin Kaminski',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(919) 966-0604',\n",
       "      'email': 'Kaminski.Robin@epa.gov'},\n",
       "     {'name': 'Patrice Ratliffe',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(919)-966-0607',\n",
       "      'email': 'Ratliffe.Patrice@epa.gov'}],\n",
       "    'overallOfficials': [{'name': 'James Samet, PhD',\n",
       "      'affiliation': 'U.S. Environmental Protection Agency',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'U.S. Environmental Protection Agency Human Studies Facility',\n",
       "      'city': 'Chapel Hill',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27514',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Patrice Ratliffe',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '919-966-0607',\n",
       "        'email': 'ratliffe.patrice@epa.gov'},\n",
       "       {'name': 'James Samet, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '919-966-0665',\n",
       "        'email': 'samet.james@epa.gov'},\n",
       "       {'name': 'James Samet, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Deidentified individual data will be shared through the U.S. EPA's ScienceHub database.\\r\\nScienceHub is used to upload and store datasets associated with journal articles.\\r\\nNon-sensitive datasets are then made publicly accessible via the Environmental Dataset\\r\\nGateway in fulfillment of the EPA's requirement to adhere to the Office of Management and\\r\\nBudget's Open Data Policy.\",\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'ICF'],\n",
       "    'timeFrame': 'The data will be available to the public after the conclusion of the study and the\\r\\npublication of the manuscripts.',\n",
       "    'accessCriteria': 'Data will be available at the U.S. EPA Science Hub.',\n",
       "    'url': 'http://catalog.data.gov/dataset/epa-sciencehub'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M21089',\n",
       "      'name': 'Facies',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06381011',\n",
       "    'orgStudyIdInfo': {'id': 'BEUFTR-4'},\n",
       "    'organization': {'fullName': 'Bitlis Eren University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Local Vibration in Cervical Radiculopathy',\n",
       "    'officialTitle': 'Can Local Vibration be Used to Alleviate Symptoms of Cervical Radiculopathy?'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-17',\n",
       "    'studyFirstSubmitQcDate': '2024-04-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Omer Dursun',\n",
       "     'investigatorTitle': 'Asst. Prof.',\n",
       "     'investigatorAffiliation': 'Bitlis Eren University'},\n",
       "    'leadSponsor': {'name': 'Bitlis Eren University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this study is to evaluate the effect of local vibration application on the\\r\\nupper extremity pain, paresthesia, neck pain, and limitations in cervical joint range of\\r\\nmotion experienced by patients with cervical radiculopathy.',\n",
       "    'detailedDescription': 'At least 34 patients diagnosed with cervical radiculopathy who meet the inclusion and\\r\\nexclusion criteria will be included in the study. Subsequently, the patients will be\\r\\nrandomly divided into two groups. Patients in the first group will receive placebo local\\r\\nvibration application, while patients in the second group will undergo local vibration\\r\\napplication.'},\n",
       "   'conditionsModule': {'conditions': ['Cervical Radiculopathy'],\n",
       "    'keywords': ['neck pain', 'paresthesia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'maskingDescription': 'The evaluator and the researcher administering the local vibration application will be\\r\\ndifferent. Patients will be blinded to their group assignment.',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 34, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Sham Local Vibration Group',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': \"The placebo local vibration application will be applied bilaterally to the\\r\\ncervicothoracic region of the patients in the placebo group. For the application, the\\r\\npatient will be placed in an upright sitting position, and the local vibration device\\r\\nwill be moved without touching the patient's skin while it is operational.\",\n",
       "      'interventionNames': ['Other: Local Vibration']},\n",
       "     {'label': 'Local Vibration Intervention Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The patients in this group will receive bilateral local vibration application on the\\r\\ncervicothoracic region, utilizing two different frequency values, 50 Hz and 100 Hz.\\r\\nInitially, a flat attachment will be placed on the device, and application will be\\r\\nperformed on the neck and back regions for 5 minutes at a frequency of 50 Hz. Then, the\\r\\nother attachment of the device will be used, the frequency value will be increased to 100\\r\\nHz, and application will be performed on a total of 5 sensitive points specified by the\\r\\nmanufacturer in the neck and back regions, with one minute per point for a total of 5\\r\\nminutes. Local vibration will be applied to each side for ten minutes, totaling 20\\r\\nminutes, and this will be conducted for five consecutive days. To determine which side to\\r\\nstart the application from, a coin toss will be performed.',\n",
       "      'interventionNames': ['Other: Local Vibration']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Local Vibration',\n",
       "      'description': 'The patients in the study group will receive local vibration application including\\r\\ndifferent frequency values on the neck and back regions for five consecutive days.',\n",
       "      'armGroupLabels': ['Local Vibration Intervention Group',\n",
       "       'Sham Local Vibration Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Neck Pain',\n",
       "      'description': \"The effect of local vibration intervention on patients' neck pain will be evaluated using\\r\\nthe Patients' Global Impression of Improvement Scale. In this scale, patients will be\\r\\nasked to mark their perceived change in pain using the following options: 'very much\\r\\nbetter,' 'much better,' 'a little better,' 'no change,' 'a little worse,' 'much worse,'\\r\\nand 'very much worse.'\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'},\n",
       "     {'measure': 'Upper Limb Pain',\n",
       "      'description': \"The effect of local vibration intervention on patients' upper limb pain will be evaluated\\r\\nusing the Patients' Global Impression of Improvement Scale. In this scale, patients will\\r\\nbe asked to mark their perceived change in pain using the following options: 'very much\\r\\nbetter,' 'much better,' 'a little better,' 'no change,' 'a little worse,' 'much worse,'\\r\\nand 'very much worse.'\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'},\n",
       "     {'measure': 'Paresthesia',\n",
       "      'description': \"The effect of local vibration intervention on patients' paresthesia will be evaluated\\r\\nusing the Patients' Global Impression of Improvement Scale. In this scale, patients will\\r\\nbe asked to mark their perceived change in paresthesia using the following options: 'very\\r\\nmuch better,' 'much better,' 'a little better,' 'no change,' 'a little worse,' 'much\\r\\nworse,' and 'very much worse.'\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Cervical Range of Motion',\n",
       "      'description': \"The immediate and short-term effect of local vibration intervention on cervical range of\\r\\nmotion will be measured using a 10-inch standard manual goniometer. To measure cervical\\r\\nflexion and extension range of motion, the pivot point of the goniometer will be placed\\r\\nat the external auditory meatus. The fixed arm of the goniometer will be held vertically,\\r\\nand the moving arm will follow along the base of the nostrils. For measuring cervical\\r\\nrotation range of motion, measurements will be taken from behind the participants. The\\r\\npivot point of the goniometer will be placed at the vertex, while the fixed arm will be\\r\\nkept parallel to the acromion, and the moving arm will follow along with their nose.\\r\\nLateral flexion range of motion will be taken in front of the participants. The pivot\\r\\npoint of the goniometer will be placed over the sternal notch, with its fixed arm\\r\\nparallel to the acromion, and its moving arm will follow along the tip of the\\r\\nparticipants' nose.\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'},\n",
       "     {'measure': 'The Change in the Pressure Pain Threshold of the Upper Trapezius',\n",
       "      'description': \"The potential impact of local vibration intervention on patients' pain thresholds will be\\r\\nevaluated using an analog algometer. Pain threshold measurements will be taken at the\\r\\nupper trapezius muscle. The algometer will be positioned perpendicular to the measurement\\r\\nareas. Three measurements will be taken for each region, with a half-minute interval\\r\\nbetween measurements. The average of the three measurements will be calculated and\\r\\nrecorded. A change of 20-25% in the algometric measurement values will be considered\\r\\nsignificant.\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'},\n",
       "     {'measure': 'The Change in the Viscoelastic Properties of the Upper Trapezius',\n",
       "      'description': \"The effect of local vibration intervention on the viscoelastic properties of patients'\\r\\nupper trapezius will be measured using the myotonometer (MyotonPRO). The upper trapezius\\r\\nmyometric measurement will be taken with the patient lying face down on the treatment\\r\\ntable with their arms hanging loose, and measured from the midpoint between the C7\\r\\nspinous process and the acromion.\",\n",
       "      'timeFrame': 'Change from baseline neck pain immediately and five days after the intervention'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  \\r\\n\\r\\n       1. Between the ages of 18 and 70,\\r\\n\\r\\n  -  \\r\\n\\r\\n       2. Three of four tests of clinical prediction rule for cervical radiculopathy are\\r\\n          positive (spurling test, distraction test, upper limb tension test 1, and\\r\\n          ipsilateral cervical rotation less than 60 degrees)\\r\\n\\r\\n  -  \\r\\n\\r\\n       3. Unilateral paresthesia, upper extremity, and neck pain rated 3 or higher on the\\r\\n          numeric pain rating scale.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  \\r\\n\\r\\n       1. History of previous cervical or thoracic spinal surgery,\\r\\n\\r\\n  -  \\r\\n\\r\\n       2. Symptoms or signs of upper motor neuron disorder,\\r\\n\\r\\n  -  \\r\\n\\r\\n       3. Body mass index (BMI) of 30 kg/m2 or higher,\\r\\n\\r\\n  -  \\r\\n\\r\\n       4. Having received spinal injection in the last two weeks,\\r\\n\\r\\n  -  \\r\\n\\r\\n       5. Presence of local infection at the application site,\\r\\n\\r\\n  -  \\r\\n\\r\\n       6. Upper extremity nerve entrapment syndrome (such as carpal tunnel or cubital\\r\\n          tunnel syndrome),\\r\\n\\r\\n  -  \\r\\n\\r\\n       7. Diagnosis of systemic inflammatory arthritis (such as rheumatoid arthritis,\\r\\n          etc.),\\r\\n\\r\\n  -  \\r\\n\\r\\n       8. Having engaged in strenuous exercise in the last 24 hours',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Ömer Dursun, Asst. Prof.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '5426088687',\n",
       "      'phoneExt': '+90',\n",
       "      'email': 'fztomrdrsn@gmail.com'},\n",
       "     {'name': 'Erhan Dincer, M.Sc.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '5442543857',\n",
       "      'phoneExt': '+90',\n",
       "      'email': 'fzterhan@hotmail.com'}],\n",
       "    'overallOfficials': [{'name': 'Ömer Dursun, Asst. Prof.',\n",
       "      'affiliation': 'Bitlis Eren University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Gökmen Reyhanlı, M.D.',\n",
       "      'affiliation': 'Bitlis Tatvan State Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Erhan Dincer, M.Sc.',\n",
       "      'affiliation': 'Bitlis Eren University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Bitlis Eren University',\n",
       "      'city': 'Bitlis',\n",
       "      'state': 'Merkez',\n",
       "      'zip': '13000',\n",
       "      'country': 'Turkey',\n",
       "      'contacts': [{'name': 'Ömer Dursun, Asst. Prof.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '5426088687',\n",
       "        'phoneExt': '+90',\n",
       "        'email': 'fztomrdrsn@gmail.com'},\n",
       "       {'name': 'Erhan Dincer, M.Sc.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '5442543857',\n",
       "        'phoneExt': '+90',\n",
       "        'email': 'fzterhan@hotmail.com'}],\n",
       "      'geoPoint': {'lat': 38.40115, 'lon': 42.10784}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '12544957',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wainner RS, Fritz JM, Irrgang JJ, Boninger ML, Delitto A, Allison S. Reliability and diagnostic accuracy of the clinical examination and patient self-report measures for cervical radiculopathy. Spine (Phila Pa 1976). 2003 Jan 1;28(1):52-62. doi: 10.1097/00007632-200301010-00014.'},\n",
       "     {'pmid': '19465371',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Young IA, Michener LA, Cleland JA, Aguilera AJ, Snyder AR. Manual therapy, exercise, and traction for patients with cervical radiculopathy: a randomized clinical trial. Phys Ther. 2009 Jul;89(7):632-42. doi: 10.2522/ptj.20080283. Epub 2009 May 21. Erratum In: Phys Ther. 2009 Nov;89(11):1254-5. Phys Ther. 2010 May;90(5):825.'},\n",
       "     {'pmid': '28838857',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Thoomes EJ, van Geest S, van der Windt DA, Falla D, Verhagen AP, Koes BW, Thoomes-de Graaf M, Kuijper B, Scholten-Peeters WGM, Vleggeert-Lankamp CL. Value of physical tests in diagnosing cervical radiculopathy: a systematic review. Spine J. 2018 Jan;18(1):179-189. doi: 10.1016/j.spinee.2017.08.241. Epub 2017 Aug 31.'},\n",
       "     {'pmid': '24614255',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wong JJ, Cote P, Quesnele JJ, Stern PJ, Mior SA. The course and prognostic factors of symptomatic cervical disc herniation with radiculopathy: a systematic review of the literature. Spine J. 2014 Aug 1;14(8):1781-9. doi: 10.1016/j.spinee.2014.02.032. Epub 2014 Mar 12.'},\n",
       "     {'pmid': '31021691',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Young IA, Pozzi F, Dunning J, Linkonis R, Michener LA. Immediate and Short-term Effects of Thoracic Spine Manipulation in Patients With Cervical Radiculopathy: A Randomized Controlled Trial. J Orthop Sports Phys Ther. 2019 May;49(5):299-309. doi: 10.2519/jospt.2019.8150. Epub 2019 Apr 25.'},\n",
       "     {'pmid': '30664500',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Ayub A, Osama M, Ahmad S. Effects of active versus passive upper extremity neural mobilization combined with mechanical traction and joint mobilization in females with cervical radiculopathy: A randomized controlled trial. J Back Musculoskelet Rehabil. 2019;32(5):725-730. doi: 10.3233/BMR-170887.'},\n",
       "     {'pmid': '17013656',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Rubinstein SM, Pool JJ, van Tulder MW, Riphagen II, de Vet HC. A systematic review of the diagnostic accuracy of provocative tests of the neck for diagnosing cervical radiculopathy. Eur Spine J. 2007 Mar;16(3):307-19. doi: 10.1007/s00586-006-0225-6. Epub 2006 Sep 30.'},\n",
       "     {'pmid': '32178655',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Taso M, Sommernes JH, Kolstad F, Sundseth J, Bjorland S, Pripp AH, Zwart JA, Brox JI. A randomised controlled trial comparing the effectiveness of surgical and nonsurgical treatment for cervical radiculopathy. BMC Musculoskelet Disord. 2020 Mar 16;21(1):171. doi: 10.1186/s12891-020-3188-6.'},\n",
       "     {'pmid': '34663421',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Alshami AM, Bamhair DA. Effect of manual therapy with exercise in patients with chronic cervical radiculopathy: a randomized clinical trial. Trials. 2021 Oct 18;22(1):716. doi: 10.1186/s13063-021-05690-y.'},\n",
       "     {'pmid': '17204882',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Abbed KM, Coumans JV. Cervical radiculopathy: pathophysiology, presentation, and clinical evaluation. Neurosurgery. 2007 Jan;60(1 Supp1 1):S28-34. doi: 10.1227/01.NEU.0000249223.51871.C2.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011843',\n",
       "      'term': 'Radiculopathy'}],\n",
       "    'ancestors': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M21485', 'name': 'Neck Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M14689',\n",
       "      'name': 'Radiculopathy',\n",
       "      'asFound': 'Radiculopathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13205', 'name': 'Paresthesia', 'relevance': 'LOW'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06222528',\n",
       "    'orgStudyIdInfo': {'id': '8317'},\n",
       "    'organization': {'fullName': 'New York State Psychiatric Institute',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Reducing Stigma and Increasing Treatment Seeking Intentions Among Adolescents',\n",
       "    'officialTitle': 'Brief Personalized Videos to Reduce Stigma and Increase Treatment-seeking Behavior Among Adolescents With Depression'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-01-16',\n",
       "    'studyFirstSubmitQcDate': '2024-01-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Doron Amsalem',\n",
       "     'investigatorTitle': 'Assistant Professor of Clinical Psychiatry',\n",
       "     'investigatorAffiliation': 'New York State Psychiatric Institute'},\n",
       "    'leadSponsor': {'name': 'New York State Psychiatric Institute',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Depression is a leading cause of illness and disability in teenagers. Longer duration of\\r\\nuntreated depression (DUD) is associated with greater severity, poorer outcome, and\\r\\ncognitive impairment. Stigma toward people with depression has been identified as a\\r\\nbarrier to seeking help; therefore, reducing stigma toward young people at depressive\\r\\nrisk could enhance their receptivity to seeking treatment. Social contact is a form of\\r\\ninterpersonal contact with members of the stigmatized group and the most effective type\\r\\nof intervention for improvement in stigma-related knowledge and attitudes.\\r\\n\\r\\nIn a prior study, the investigators developed short video interventions to reduce stigma\\r\\nand increase treatment seeking among adolescents with depression. The videos feature\\r\\nadolescent protagonists varied by race/ethncitiy and gender (Black girl, Black boy, White\\r\\ngirl, White boy, Hispanic girl, Hispanic boy, nonbinary or transgender adolescent) who\\r\\nwill share their experiences with depression, challenges, and recovery process. The\\r\\ninvestigators would like to conduct a randomized controlled trial (RCT) to test the\\r\\nefficacy of these tailored videos as compared to a video control condition (which\\r\\nprovides information about depression and how to seek help but does not include a\\r\\npersonal story) on reducing self-stigma and increasing help-seeking intentions and\\r\\nbehavior at baseline, post, 2 week follow-up, and 4 week follow-up among adolescents ages\\r\\n14-18 recruited via Cloudresearch. The videos will be shown again at 2 week follow-up.',\n",
       "    'detailedDescription': 'In a randomized control trial (RCT) with pre-, post-intervention, and 2 and 4 week\\r\\nfollow-up assessments, the investigators aim to test the efficacy of brief social contact\\r\\nvideo interventions, varying protagonist race/ethnicity, as compared to video control in\\r\\nreducing depression related stigma and increasing treatment-seeking intentions and\\r\\nbehavior among adolescents ages 14-18 recruited via Cloudresearch, a crowdsourcing\\r\\nplatform. The control condition will include a video that will provide information about\\r\\ndepression and how to seek help but does not include a personal story. The tailored video\\r\\ninterventions will be assigned based on participant demographics and will include\\r\\nadolescent protagonists varied by race/ethnicity and gender (Black girl, Black boy, White\\r\\ngirl, White boy, Hispanic girl, Hispanic boy, nonbinary or transgender adolescent).\\r\\nVideos will be shown at baseline and 2 week follow-up. The investigators hypothesize that\\r\\n1) Brief social contact-based video interventions will reduce stigma towards depression\\r\\nand increase treatment-seeking intentions and behavior compared to video control which\\r\\nprovides information about depression and help seeking but does not include a personal\\r\\nstory.'},\n",
       "   'conditionsModule': {'conditions': ['Stigma, Social',\n",
       "     'Mental Health Disorder',\n",
       "     'Adolescent Behavior',\n",
       "     'Depression']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 1200, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Brief video intervention (Black Girl)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a Black girl protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (Black Girl)']},\n",
       "     {'label': 'Brief video intervention (Black Boy)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a Black boy protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (Black Boy)']},\n",
       "     {'label': 'Brief video intervention (Latinx Girl)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a Latinx girl protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (Latinx Girl)']},\n",
       "     {'label': 'Brief video intervention (Latinx Boy)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a Latinx boy protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (Latinx Boy)']},\n",
       "     {'label': 'Brief video intervention (White Girl)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a White girl protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (White Girl)']},\n",
       "     {'label': 'Brief video intervention (White Boy)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a White boy protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (White Boy)']},\n",
       "     {'label': 'Brief video intervention (Nonbinary or transgender)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'A brief social contact-based video with a nonbinary or transgender protagonist',\n",
       "      'interventionNames': ['Behavioral: Brief video intervention (Nonbinary or transgender)']},\n",
       "     {'label': 'Control',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'A brief video control condition with psychoeducation on depression and help seeking',\n",
       "      'interventionNames': ['Behavioral: Control Condition']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (Black Girl)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young Black girl, a\\r\\nprofessional actor, sharing her scripted personal story of struggles with depression and\\r\\nraising themes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (Black Girl)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (Black Boy)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young Black boy, a professional\\r\\nactor, sharing his scripted personal story of struggles with depression and raising\\r\\nthemes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (Black Boy)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (Latinx Girl)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young Latinx girl, a\\r\\nprofessional actor, sharing her scripted personal story of struggles with depression and\\r\\nraising themes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (Latinx Girl)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (Latinx Boy)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young Latinx boy, a\\r\\nprofessional actor, sharing his scripted personal story of struggles with depression and\\r\\nraising themes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (Latinx Boy)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (White Girl)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young White girl, a\\r\\nprofessional actor, sharing her scripted personal story of struggles with depression and\\r\\nraising themes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (White Girl)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (White Boy)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young White boy, a professional\\r\\nactor, sharing his scripted personal story of struggles with depression and raising\\r\\nthemes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (White Boy)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Brief video intervention (Nonbinary or transgender)',\n",
       "      'description': 'A brief social contact-based video. The video presented a young nonbinary or transgender\\r\\nadolescent, a professional actor, sharing their scripted personal story of struggles with\\r\\ndepression and raising themes of recovery and hope.',\n",
       "      'armGroupLabels': ['Brief video intervention (Nonbinary or transgender)']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Control Condition',\n",
       "      'description': 'A video that will provide information about depression and how to seek help but does not\\r\\ninclude a personal story.',\n",
       "      'armGroupLabels': ['Control']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Depression Stigma',\n",
       "      'description': \"The Depression Stigma Scale (DSS) is a self-report scale comprised of two 9-item\\r\\nsubscales measuring participants' personal beliefs about depression and participants'\\r\\nbeliefs about others' attitudes (Griffiths et al., 2004). The current study will only\\r\\nutilize the personal beliefs subscale. Each item is rated on a 5-point Likert scale\\r\\nranging from strongly disagree (1) to strongly agree (5). Scores range from 9 to 45.\\r\\nHigher scores indicate more stigma.\",\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Depression Stigma',\n",
       "      'description': \"The Depression Stigma Scale (DSS) is a self-report scale comprised of two 9-item\\r\\nsubscales measuring participants' personal beliefs about depression and participants'\\r\\nbeliefs about others' attitudes (Griffiths et al., 2004). The current study will only\\r\\nutilize the personal beliefs subscale. Each item is rated on a 5-point Likert scale\\r\\nranging from strongly disagree (1) to strongly agree (5). Scores range from 9 to 45.\\r\\nHigher scores indicate more stigma.\",\n",
       "      'timeFrame': 'Post (immediately after the videos are shown)'},\n",
       "     {'measure': 'Depression Stigma',\n",
       "      'description': \"The Depression Stigma Scale (DSS) is a self-report scale comprised of two 9-item\\r\\nsubscales measuring participants' personal beliefs about depression and participants'\\r\\nbeliefs about others' attitudes (Griffiths et al., 2004). The current study will only\\r\\nutilize the personal beliefs subscale. Each item is rated on a 5-point Likert scale\\r\\nranging from strongly disagree (1) to strongly agree (5). Scores range from 9 to 45.\\r\\nHigher scores indicate more stigma.\",\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Depression Stigma',\n",
       "      'description': \"The Depression Stigma Scale (DSS) is a self-report scale comprised of two 9-item\\r\\nsubscales measuring participants' personal beliefs about depression and participants'\\r\\nbeliefs about others' attitudes (Griffiths et al., 2004). The current study will only\\r\\nutilize the personal beliefs subscale. Each item is rated on a 5-point Likert scale\\r\\nranging from strongly disagree (1) to strongly agree (5). Scores range from 9 to 45.\\r\\nHigher scores indicate more stigma.\",\n",
       "      'timeFrame': '4 week follow-up'},\n",
       "     {'measure': 'Attitude Towards Seeking Professional Psychological Help',\n",
       "      'description': \"Treatment seeking intentions will be measured using three items from the Attitudes\\r\\nTowards Seeking Professional Psychological Help Scale (ATSPPHS) Scale (Elhai et al.,\\r\\n2008). Items include: 'I might want to have psychological counselling in the future', 'I\\r\\nwould want to get psychological help if I were worried or upset for a long period of\\r\\ntime' and 'A person with an emotional problem is not likely to solve it alone; he or she\\r\\nis more likely to solve it with professional help'. Responses range from 1 (disagree) to\\r\\n4 (agree). Total scores range from 3 to 12 with higher scores indicating higher treatment\\r\\nseeking intentions.\",\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Attitude Towards Seeking Professional Psychological Help',\n",
       "      'description': \"Treatment seeking intentions will be measured using three items from the Attitudes\\r\\nTowards Seeking Professional Psychological Help Scale (ATSPPHS) Scale (Elhai et al.,\\r\\n2008). Items include: 'I might want to have psychological counselling in the future', 'I\\r\\nwould want to get psychological help if I were worried or upset for a long period of\\r\\ntime' and 'A person with an emotional problem is not likely to solve it alone; he or she\\r\\nis more likely to solve it with professional help'. Responses range from 1 (disagree) to\\r\\n4 (agree). Total scores range from 3 to 12 with higher scores indicating higher treatment\\r\\nseeking intentions.\",\n",
       "      'timeFrame': 'Post (immediately after the videos are shown)'},\n",
       "     {'measure': 'Attitude Towards Seeking Professional Psychological Help',\n",
       "      'description': \"Treatment seeking intentions will be measured using three items from the Attitudes\\r\\nTowards Seeking Professional Psychological Help Scale (ATSPPHS) Scale (Elhai et al.,\\r\\n2008). Items include: 'I might want to have psychological counselling in the future', 'I\\r\\nwould want to get psychological help if I were worried or upset for a long period of\\r\\ntime' and 'A person with an emotional problem is not likely to solve it alone; he or she\\r\\nis more likely to solve it with professional help'. Responses range from 1 (disagree) to\\r\\n4 (agree). Total scores range from 3 to 12 with higher scores indicating higher treatment\\r\\nseeking intentions.\",\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Attitude Towards Seeking Professional Psychological Help',\n",
       "      'description': \"Treatment seeking intentions will be measured using three items from the Attitudes\\r\\nTowards Seeking Professional Psychological Help Scale (ATSPPHS) Scale (Elhai et al.,\\r\\n2008). Items include: 'I might want to have psychological counselling in the future', 'I\\r\\nwould want to get psychological help if I were worried or upset for a long period of\\r\\ntime' and 'A person with an emotional problem is not likely to solve it alone; he or she\\r\\nis more likely to solve it with professional help'. Responses range from 1 (disagree) to\\r\\n4 (agree). Total scores range from 3 to 12 with higher scores indicating higher treatment\\r\\nseeking intentions.\",\n",
       "      'timeFrame': '4 week follow-up'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Emotional engagement',\n",
       "      'description': 'Emotional engagement will be measured using the Emotional Engagement Scale (de Vreede et\\r\\nal., 2019). The scale includes three items asking about emotional engagement (e.g., \"I\\r\\ncare about the contents of this video\"), and response choices range from 1 (strongly\\r\\ndisagree) to 4 (strongly agree). Total scores range from 3 to 12, with higher scores\\r\\nindicating greater emotional engagement.',\n",
       "      'timeFrame': 'Post (immediately after the videos are shown'},\n",
       "     {'measure': 'Emotional engagement',\n",
       "      'description': 'Emotional engagement will be measured using the Emotional Engagement Scale (de Vreede et\\r\\nal., 2019). The scale includes three items asking about emotional engagement (e.g., \"I\\r\\ncare about the contents of this video\"), and response choices range from 1 (strongly\\r\\ndisagree) to 4 (strongly agree). Total scores range from 3 to 12, with higher scores\\r\\nindicating greater emotional engagement.',\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Treatment related stigma',\n",
       "      'description': 'Treatment-related stigma will be measured with the Self-Stigma of Seeking Help scale\\r\\n(SSOSH-3) (Brenner et al., 2021). Items include \"I would feel inadequate if I went to a\\r\\ntherapist for psychological help,\" \"It would make me feel inferior to ask a therapist for\\r\\nhelp,\" and \"If I went to a therapist, I would be less satisfied with myself.\" Response\\r\\nrange from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 3 to 15,\\r\\nwith higher scores indicating greater stigma.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Treatment related stigma',\n",
       "      'description': 'Treatment-related stigma will be measured with the Self-Stigma of Seeking Help scale\\r\\n(SSOSH-3) (Brenner et al., 2021). Items include \"I would feel inadequate if I went to a\\r\\ntherapist for psychological help,\" \"It would make me feel inferior to ask a therapist for\\r\\nhelp,\" and \"If I went to a therapist, I would be less satisfied with myself.\" Response\\r\\nrange from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 3 to 15,\\r\\nwith higher scores indicating greater stigma.',\n",
       "      'timeFrame': 'Post (immediately after the videos are shown)'},\n",
       "     {'measure': 'Treatment related stigma',\n",
       "      'description': 'Treatment-related stigma will be measured with the Self-Stigma of Seeking Help scale\\r\\n(SSOSH-3) (Brenner et al., 2021). Items include \"I would feel inadequate if I went to a\\r\\ntherapist for psychological help,\" \"It would make me feel inferior to ask a therapist for\\r\\nhelp,\" and \"If I went to a therapist, I would be less satisfied with myself.\" Response\\r\\nrange from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 3 to 15,\\r\\nwith higher scores indicating greater stigma.',\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Treatment related stigma',\n",
       "      'description': 'Treatment-related stigma will be measured with the Self-Stigma of Seeking Help scale\\r\\n(SSOSH-3) (Brenner et al., 2021). Items include \"I would feel inadequate if I went to a\\r\\ntherapist for psychological help,\" \"It would make me feel inferior to ask a therapist for\\r\\nhelp,\" and \"If I went to a therapist, I would be less satisfied with myself.\" Response\\r\\nrange from 1 (strongly disagree) to 5 (strongly agree). Total scores range from 3 to 15,\\r\\nwith higher scores indicating greater stigma.',\n",
       "      'timeFrame': '4 week follow-up'},\n",
       "     {'measure': 'Barriers to Access to Care Evaluation (BACE V3)',\n",
       "      'description': 'Barriers to care will be measured with items selected from the Barriers to Access to Care\\r\\nEvaluation (BACE v3) (Clement et al., 2012). Response range from 0 (not at all) to 3 (a\\r\\nlot). Total scores range from 0 to 24, with higher scores indicating greater barriers.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Barriers to Access to Care Evaluation (BACE V3)',\n",
       "      'description': 'Barriers to care will be measured with items selected from the Barriers to Access to Care\\r\\nEvaluation (BACE v3) (Clement et al., 2012). Response range from 0 (not at all) to 3 (a\\r\\nlot). Total scores range from 0 to 24, with higher scores indicating greater barriers.',\n",
       "      'timeFrame': 'Post (immediately after the videos are shown)'},\n",
       "     {'measure': 'Barriers to Access to Care Evaluation (BACE V3)',\n",
       "      'description': 'Barriers to care will be measured with items selected from the Barriers to Access to Care\\r\\nEvaluation (BACE v3) (Clement et al., 2012). Response range from 0 (not at all) to 3 (a\\r\\nlot). Total scores range from 0 to 24, with higher scores indicating greater barriers.',\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Barriers to Access to Care Evaluation (BACE V3)',\n",
       "      'description': 'Barriers to care will be measured with items selected from the Barriers to Access to Care\\r\\nEvaluation (BACE v3) (Clement et al., 2012). Response range from 0 (not at all) to 3 (a\\r\\nlot). Total scores range from 0 to 24, with higher scores indicating greater barriers.',\n",
       "      'timeFrame': '4 week follow-up'},\n",
       "     {'measure': 'Mental Health Treatment',\n",
       "      'description': 'One item will be utilized to measure prior mental health treatment: Have you ever\\r\\nreceived mental health treatment?',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Actual help seeking',\n",
       "      'description': 'Two items will be utilized to measure help seeking: Over the past 2 weeks, have you\\r\\nsought out mental health treatment? and Over the past 2 weeks, did you feel more\\r\\nable/willing to open up to others about how you are feeling?',\n",
       "      'timeFrame': '2 week follow-up'},\n",
       "     {'measure': 'Actual help seeking',\n",
       "      'description': 'Two items will be utilized to measure help seeking: Over the past 4 weeks, have you\\r\\nsought out mental health treatment? and Over the past 4 weeks, did you feel more\\r\\nable/willing to open up to others about how you are feeling?',\n",
       "      'timeFrame': '4 week follow-up'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Ages 14-18\\r\\n\\r\\n  -  English speaking\\r\\n\\r\\n  -  US Residents\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Age less than 14 or greater than 18\\r\\n\\r\\n  -  Non-English speaking\\r\\n\\r\\n  -  Non-US Resident',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '14 Years',\n",
       "    'maximumAge': '18 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'New York State Psychiatric Institute',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'New York',\n",
       "      'state': 'New York',\n",
       "      'zip': '10032',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Doron Amsalem, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '929-404-8802',\n",
       "        'email': 'Doron.Amsalem@nyspi.columbia.edu'}],\n",
       "      'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '15458995',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Griffiths KM, Christensen H, Jorm AF, Evans K, Groves C. Effect of web-based depression literacy and cognitive-behavioural therapy interventions on stigmatising attitudes to depression: randomised controlled trial. Br J Psychiatry. 2004 Oct;185:342-9. doi: 10.1192/bjp.185.4.342.'},\n",
       "     {'pmid': '18433879',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Elhai JD, Schweinle W, Anderson SM. Reliability and validity of the Attitudes Toward Seeking Professional Psychological Help Scale-Short Form. Psychiatry Res. 2008 Jun 30;159(3):320-9. doi: 10.1016/j.psychres.2007.04.020. Epub 2008 Apr 22.'},\n",
       "     {'type': 'BACKGROUND',\n",
       "      'citation': 'de Vreede T, Andel SA, de Vreede GJ, Spector P, Singh V, Padmanabhan B. What is engagement and how do we measure it? Toward a domain independent definition and scale. Proceedings of the 52nd Hawaii International Conference on System Sciences. 2019, Hawaii. p. 749-758.'},\n",
       "     {'pmid': '22546012',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Clement S, Brohan E, Jeffery D, Henderson C, Hatch SL, Thornicroft G. Development and psychometric properties the Barriers to Access to Care Evaluation scale (BACE) related to people with mental ill health. BMC Psychiatry. 2012 Jun 20;12:36. doi: 10.1186/1471-244X-12-36.'},\n",
       "     {'pmid': '32975438',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Brenner RE, Colvin KF, Hammer JH, Vogel DL. Using Item Response Theory to Develop Revised (SSOSH-7) and Ultra-Brief (SSOSH-3) Self-Stigma of Seeking Help Scales. Assessment. 2021 Jul;28(5):1488-1499. doi: 10.1177/1073191120958496. Epub 2020 Sep 25.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003863',\n",
       "      'term': 'Depression'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001526', 'term': 'Behavioral Symptoms'}],\n",
       "    'browseLeaves': [{'id': 'M7058',\n",
       "      'name': 'Depression',\n",
       "      'asFound': 'Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7061', 'name': 'Depressive Disorder', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815',\n",
       "      'name': 'Mental Disorders',\n",
       "      'asFound': 'Mental Health Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06333028',\n",
       "    'orgStudyIdInfo': {'id': '938'},\n",
       "    'organization': {'fullName': 'Bausch & Lomb Incorporated',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction',\n",
       "    'officialTitle': 'A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ACTUAL'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-20',\n",
       "    'studyFirstSubmitQcDate': '2024-03-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Bausch & Lomb Incorporated',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True},\n",
       "   'descriptionModule': {'briefSummary': 'A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing\\r\\nCataract Extraction',\n",
       "    'detailedDescription': 'A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study\\r\\nto Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract\\r\\nExtraction'},\n",
       "   'conditionsModule': {'conditions': ['Cataract']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'enVista Aspire intraocular lens (IOL)',\n",
       "      'description': 'Subjects bilaterally implanted with enVista Aspire EA IOLs.',\n",
       "      'interventionNames': ['Device: enVista Aspire EA IOLs']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'enVista Aspire EA IOLs',\n",
       "      'description': 'Subjects bilaterally implanted with enVista Aspire EA IOLs',\n",
       "      'armGroupLabels': ['enVista Aspire intraocular lens (IOL)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Mean binocular BCDVA (logMAR) at Visit 1',\n",
       "      'description': 'Mean binocular best-corrected distance visual acuity (BCDVA) (logMAR) at Visit 1.\\r\\nPhotopic BCDVA measured at 4 meters.',\n",
       "      'timeFrame': 'Day 90 to Day 180 after second eye implantation'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Subjects must be 22 years of age or older on the date the Informed Consent Form\\r\\n     (ICF) is signed.\\r\\n\\r\\n  2. Subjects with a post operative BCDVA of 20/40 or better.\\r\\n\\r\\n  3. Subjects must have the capability to understand and provide written informed consent\\r\\n     on the Institutional Review Board (IRB) approved ICF and authorization as\\r\\n     appropriate for local privacy regulations and willing and able to comply with the\\r\\n     follow-up study visit.\\r\\n\\r\\n  4. Subjects implanted bilaterally with enVista Aspire EA IOLs, powers ranging from + 6\\r\\n     to + 34.0 D, prior to enrollment into the study on or after 1 November 2023.\\r\\n\\r\\n  5. All subjects with a visually significant PCO (BCDVA worse than 20/40) who undergo a\\r\\n     YAG capsulotomy may be enrolled 30 days post YAG procedure and with a postoperative\\r\\n     BCDVA 20/40 or better.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Subjects with any serious ocular pathology or underlying systemic medical disease\\r\\n     (e.g., uncontrolled diabetes) or circumstance that, based on the Investigator's\\r\\n     judgment, could confound the results of the study.\\r\\n\\r\\n  2. Subjects with preoperative corneal astigmatism > 1.0 D in either eye, preoperative\\r\\n     irregular astigmatism, or preoperative skewed radial axis.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '22 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patient population at study site locations',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Rosangela Nolasco',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '949-259-1633',\n",
       "      'email': 'Rosangela.Nolasco2@bausch.com'},\n",
       "     {'name': 'Anya Loncaric',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '5102595284',\n",
       "      'email': 'aloncaric@bausch.com'}],\n",
       "    'locations': [{'facility': 'SITE 104',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Dover',\n",
       "      'state': 'New Jersey',\n",
       "      'zip': '07801',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.88399, 'lon': -74.5621}},\n",
       "     {'facility': 'Site 105',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Woodland Park',\n",
       "      'state': 'New Jersey',\n",
       "      'zip': '07424',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.88982, 'lon': -74.19487}},\n",
       "     {'facility': 'Site 103',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Garden City',\n",
       "      'state': 'New York',\n",
       "      'zip': '11530',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 40.72677, 'lon': -73.6343}},\n",
       "     {'facility': 'Site 106',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Charleston',\n",
       "      'state': 'South Carolina',\n",
       "      'zip': '29407',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 32.77657, 'lon': -79.93092}},\n",
       "     {'facility': 'Site 101',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Sugar Land',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77478',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 29.61968, 'lon': -95.63495}},\n",
       "     {'facility': 'Site 102',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Mount Pleasant',\n",
       "      'state': 'Wisconsin',\n",
       "      'zip': '53405',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 42.69743, 'lon': -87.85577}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002386',\n",
       "      'term': 'Cataract'}],\n",
       "    'ancestors': [{'id': 'D000007905', 'term': 'Lens Diseases'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5638',\n",
       "      'name': 'Cataract',\n",
       "      'asFound': 'Cataract',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10917', 'name': 'Lens Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06356961',\n",
       "    'orgStudyIdInfo': {'id': '2022Z4BB82'},\n",
       "    'secondaryIdInfos': [{'id': '2022Z4BB82',\n",
       "      'type': 'OTHER_GRANT',\n",
       "      'domain': 'Decreto Direttoriale n. 901 SH4(MUR-PRIN 2022)'}],\n",
       "    'organization': {'fullName': 'University of Bergamo', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Routine Outcome Monitoring and Feedback Informed Therapy in Italy',\n",
       "    'officialTitle': 'Routine Outcome Monitoring and Feedback Informed Therapy in Italy: 1st Italian RCT Large Population Study (PRIN - Italian Minister of Universities and Research Project)',\n",
       "    'acronym': 'FIT-ITALY'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-10-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-24',\n",
       "    'studyFirstSubmitQcDate': '2024-04-04',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-07',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-08', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Angelo Compare',\n",
       "     'investigatorTitle': 'Prof. Angelo Compare (PI)',\n",
       "     'investigatorAffiliation': 'University of Bergamo'},\n",
       "    'leadSponsor': {'name': 'University of Bergamo', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University of Palermo', 'class': 'OTHER'},\n",
       "     {'name': 'Politecnico di Milano', 'class': 'OTHER'},\n",
       "     {'name': 'Leiden University', 'class': 'OTHER'},\n",
       "     {'name': 'University of Ottawa', 'class': 'OTHER'},\n",
       "     {'name': 'University of Sheffield', 'class': 'OTHER'},\n",
       "     {'name': 'Brigham Young University', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The research project OutProFeed - Italy: Routine outcome monitoring and feedback informed\\r\\ntherapy in Italy: 1st Italian RCT large population study, represents the first Italian\\r\\nrandomised controlled trial (RCT) to evaluate the effectiveness of feedback-informed\\r\\npsychotherapy (FIT) to improve patients mental health outcomes and psychotherapy\\r\\nprocesses through the use of the digital platform Mindy.\\r\\n\\r\\nThe following project was awarded PRIN 2022 funding by the Ministry of University and\\r\\nResearch (MUR). This project has the University of Bergamo as lead partner, with the\\r\\nauxiliary participation of the University of Palermo and the Polytechnic University of\\r\\nMilan.\\r\\n\\r\\nGiven the innovative-experimental nature of the following research project, a digital\\r\\nplatform -Mindy- will be used, which allows the recruited professionals (once registered)\\r\\nan all-round management of all the professional activities inherent to the\\r\\npsychologist/psychotherapist profession (informed consent, online therapy, administration\\r\\nof psychometric instruments, etc.) and which also facilitates the administration of\\r\\npsychometric instruments. ) and which also facilitates data collection, subsequent\\r\\nanalysis and Routine Outcome Monitoring (ROM) and Feedback Informed Therapy (FIT)\\r\\nprocedures with ad hoc charts and digital tools, in accordance with the guidelines\\r\\ndictated by the GDPR regulations on health and clinical data. Each therapist involved in\\r\\nthe project, after having received guidance on the procedures and after having been\\r\\ninstructed to use the platform will involve 5 new patients in the following project. The\\r\\nonly inclusion criteria for patients are the following:\\r\\n\\r\\nI) Being of legal age II) Not having a diagnosis of psychosis and/or neurocognitive\\r\\ndisorders III) Consent to participate in the following research project IV) Being a new\\r\\npatient (new or less than three sessions carried out) We will randomly assign the\\r\\npreviously recruited psychotherapists and their patients to one of three conditions: (1)\\r\\ntreatment as usual (TAU) in which therapists and patients proceed with psychotherapy as\\r\\nthey normally would without receiving any initial training and using only Mindy as a\\r\\nsimplified digital folder (2) process and outcome monitoring (OPM) in which patients will\\r\\ncomplete process and outcome measures related to each psychotherapy session therapists\\r\\nwill receive basic feedback without Clinical Support Tools on these measures, they will\\r\\nuse the Mindy platform as a medical record and will not receive specific training on FIT\\r\\n(3) process and outcome monitoring with feedback (OPM-F) where patients will complete\\r\\nprocess and outcome measures related to each session and therapists will receive feedback\\r\\non the patient progress and experiences of the therapeutic alliance with specific\\r\\ntraining on feedback informed therapy (FIT) and will use the Mindy platform with all\\r\\nfeedback and Clinical Support Tools information, They will also receive monthly\\r\\nsupervision/coaching (for three months) to complete the FIT and ROM training on-going,\\r\\nwith practical discussion of the most difficult clinical cases and possible solutions to\\r\\nbe implemented in therapy.\\r\\n\\r\\nRecruitment of therapists will take place with the strategic participation of a pool of\\r\\nMIUR-recognised Schools of Specialisation in Psychotherapy\\r\\n(https://www.miur.it/ElencoSSPWeb/).\\r\\n\\r\\nProfessionals qualified to practise as psychologists who are in their third year of the\\r\\nSchools of Psychotherapy will be selected, as well as therapists who already have a\\r\\nregular diploma of specialisation in psychotherapy recognised by the MIUR\\r\\n(https://www.miur.it/ElencoSSPWeb/), and who are in active practice. There will be no\\r\\nrestrictions on the type of psychotherapy used by the professionals who will be recruited\\r\\n(the only criterion for inclusion is that it must be psychotherapy for a mental health\\r\\nissue). Therapists will not be aware of the randomisation procedure to reduce bias (Zelen\\r\\ndesign). Specifically, for the following research project we will use data from a maximum\\r\\nof 15 sessions (endpoints) carried out by all therapists of the 3 groups with the\\r\\nClinical Support System only for the therapists of the group (OPM-F) who, as previously\\r\\nmentioned, will receive ad hoc training; furthermore, various instruments (described in\\r\\nthe special section Instruments) will be compiled through the functional use of Mindy and\\r\\nin detail (cadence, purpose and research hypotheses) in the complete protocol in the next\\r\\nsection. Finally, through the administration of special questionnaires, factors\\r\\nindicative of therapists aptitude and competences for the use of digital tools in\\r\\nprofessional practice will be collected in order to obtain statistical clusters that can\\r\\nbe used as independent or control variables.',\n",
       "    'detailedDescription': '  -  Backgrounds:\\r\\n\\r\\nRoutine outcome monitoring (ROM), including feedback, has its roots in the practice-based\\r\\nevidence paradigm, particularly patient-centered research. The administration of outcome\\r\\nmeasures, either continuously or at regular intervals as a means of checking progress and\\r\\ninforming treatment decision making, can produce an ameliorative effect in addition to\\r\\nthe effects produced by standard psychological therapies. ROM has been referred to by\\r\\nvarious terms, but they all contain features that can be grouped into three sequential\\r\\nsteps: (i) collecting patient data in a regular and structured manner; (ii) providing the\\r\\ndata to the therapist and, on many occasions, to the patient as well; and (iii) when\\r\\nappropriate, adjusting the process or focus of therapy in light of the feedback that\\r\\nemerged. These three steps have been presented as a transtheoretical model of\\r\\nmeasurement-based care- Collect, Share, Act -while a definition of ROM that captures\\r\\nthese three steps describes it as the implementation of standardized measures, usually\\r\\nsession by session, to guide clinical decision making, monitor treatment progress, and\\r\\nindicate when functional modification of treatment is needed. ROM has been presented as a\\r\\nrelatively simple evidence-based practice that the clinician can add to any type of\\r\\npsychotherapy without requiring changes in that psychotherapy. The use of ROM and\\r\\nfeedback in routine care has long been recommended. A recent advisory committee advocated\\r\\nfor professional practice guidelines that focus on measurement-based care and feedback.\\r\\nThese guidelines include a statement that therapists should engage in regular evaluation\\r\\nof the treatment process and outcomes, incorporating this information into ongoing\\r\\ncollaboration with patients. International scientific organizations are called to\\r\\nincreasingly use Feedback Informed Therapy (FIT) and the use of ROM, to assess outcomes,\\r\\ninform goals, objectives,and to monitor individual progress and guide decisions about\\r\\nindividual care, treatment or service plans. The use of ROM is also supported by the\\r\\nRoadmap for Mental Health Research in Europe. In addition, national policymakers and\\r\\nregulatory bodies in some countries have made measurement of treatment outcomes\\r\\nmandatory.\\r\\n\\r\\nROM has been widely adopted in various therapeutic modalities for adults, for example, in\\r\\npsychodynamic therapy, couples therapy, and group therapy, as well as for specific\\r\\nproblems such as substance abuse and in youth settings. It is a pan-theoretical approach\\r\\nand, as a therapeutic method, combines elements of supervision, ongoing assessment, and\\r\\noverall quality assurance.\\r\\n\\r\\nIn addition to considerations of the effects and benefits of ROM, there is also a\\r\\nrelevant component of substantial change in the practice of professional activity in the\\r\\nproject due to the introduction of digital technology. While there is consensus in the\\r\\nscientific community that digital can be of benefit to professionals, similarly, evidence\\r\\nindicates that such benefits occur under various conditions, including the effective\\r\\nintegration of these technologies into daily practice. In this scenario, the possession\\r\\nand development of appropriate skills in the use of digital tools assumes a central role.\\r\\n\\r\\nEqually central to the implementation of digitally supported ROM is the usability of\\r\\ndigital technology, which will be tested through special experience and usability\\r\\nquestionnaires on both the patient and therapist sides. Usability will also be assessed\\r\\nthrough targeted interviews with a subsample of psychotherapists, following the track of\\r\\nvalidated technology usability questionnaires and analyzed through thematic analysis.\\r\\n\\r\\nFor the reasons expressed so far, the following research project \"OutProFeed - Italy:\\r\\nRoutine outcome monitoring and feedback informed therapy in Italy: 1st Italian RCT large\\r\\npopulation study\" is of fundamental scientific and clinical interest. It not only\\r\\nrepresents the first Italian randomized controlled trial (RCT) to evaluate the\\r\\neffectiveness of feedback-informed psychotherapy (FIT) in improving patients\\' mental\\r\\nhealth outcomes and psychotherapy processes, but also obtained PRIN 2022 funding from the\\r\\nMinistry of University and Research.\\r\\n\\r\\n-Aims and Objectives: The main objective of this study is to conduct the first Italian\\r\\nrandomized controlled trial to evaluate the effectiveness of feedback-informed\\r\\npsychotherapy in improving patient mental health outcomes and psychotherapy processes. To\\r\\nachieve this goal, after administering some batteries of questionnaires at baseline (T0)\\r\\nto therapists and patients, previously recruited psychotherapists and their patients will\\r\\nbe randomly assigned to one of three conditions: (i) treatment as usual (TAU) in which\\r\\ntherapists and patients proceed with psychotherapy as they normally would, (ii) process\\r\\nand outcome monitoring (OPM) in which patients will complete process and outcome measures\\r\\nrelated to each psychotherapy session but therapists will receive \"basic\" feedback\\r\\nwithout Clinical Support Tools on these measures, they will use the Mindy platform as a\\r\\nmedical record and will not receive specific training on FIT (iii) process and outcome\\r\\nmonitoring with feedback (OPM-F) in which patients will complete process and outcome\\r\\nmeasures related to each session and therapists will receive feedback on the patient\\'s\\r\\nprogress and the patient\\'s experiences of the therapeutic alliance. Therapists in\\r\\ncondition (iii) will receive specific training on the procedures and techniques inherent\\r\\nin feedback informed therapy (FIT), during the intervention phase (duration 15 sessions)\\r\\nthe Clinical Support System in FIT will guide them in the clinical application of the\\r\\nprocedures. In addition, they will receive monthly supervision (for three months) apt to\\r\\nprovide on-going clinical support on FIT and ROM, with practical discussion of the most\\r\\ndifficult clinical cases and possible solutions to be implemented in therapy. Therapists\\r\\nwill be blinded to the randomization procedure to reduce bias and prejudice. To assess\\r\\noutcomes, psychological distress will be measured before each session and symptom\\r\\nseverity at the beginning, at the end of treatment (set at session number 15, up to 6\\r\\nmonths) and three months later (follow-up). To evaluate the process in psychotherapy, the\\r\\nlevel of therapeutic alliance will be assessed after each session. To account for the\\r\\nimpact of individual propensity and skills toward digital tools, a clustering of\\r\\ntherapists performed on data collected at T0 aimed at creating \\'distinct profiles\\' and\\r\\nnon-overlapping respondents with respect to the measured variables will be considered.\\r\\nThe therapists involved in the study (in all conditions) after agreeing to the conditions\\r\\nof the study, will be introduced to the use of the digital platform Mindy (they will\\r\\nreceive a user manual) and its functionalities (a user manual with technical\\r\\nspecifications will be sent to participants and ad hoc training will be organized on its\\r\\nuse, declined according to the experimental conditions: TAU (use of the medical record in\\r\\nBASIC mode, without feedback and without routine outcome monitoring, thus only to\\r\\nfacilitate standard administration of questionnaires through MINDY and encourage \"simple\"\\r\\nuse of the medical record with the possibility of sitting also online); OPM (use of full\\r\\nMINDY but without the possibility of Clinical Support Tools on Feedback); OPM-F (full use\\r\\nof MINDY with attached Clinical Support Tools on feedback and supervision), as reflected\\r\\nin the research design.\\r\\n\\r\\nIn addition, therapists who are part of the OPM-F condition will receive, after the\\r\\nrandomization phase, specific training on feedback informed therapy (FIT) and will use\\r\\nthe platform with all the information pertaining to feedback, plus they will receive\\r\\nmonthly supervision with the trainer specializing in FIT. The other two conditions will\\r\\nbe placed on the \"waiting list\" and will receive training/supervision later after the\\r\\nexperimental phase. The Clinical Support Tools will offer digital alerts that will\\r\\nindicate in the dashboard those conditions defined as \"Not on track\", i.e., patients who\\r\\nare not responding well to therapy or who are deteriorating in some aspect (outcomes or\\r\\ntherapeutic alliance). Scores on the CORE-10 questionnaire that significantly worsen by\\r\\nat least 6 (Reliable Change Index) will be flagged, and a clinical support system will be\\r\\nprovided to help the therapist manage the clinical situation with purpose-built charts\\r\\nand questions. Working Alliance Inventory-C scores will be flagged with an alert with the\\r\\nfollowing rationale: (i) First five sessions, the method described will be used, in which\\r\\nthe patient\\'s averages (session-by-session) at WAI are used and the possibility of the\\r\\nrisk of breakdown is declined with level indications; if the difference between the\\r\\naverages (session-by-session) is between (-0. 25 and +n) there will be a stable WAI, if\\r\\nthe difference is between (-0.26 and -1) there will be a moderate rupture risk, while\\r\\nwith a drop of one point or more between the two averages (for one or more consecutive\\r\\nsessions) there will be a severe rupture risk alert. (ii) Instead, in the following\\r\\nsessions (sixth through fifteenth), the method described will be used, which involves the\\r\\nuse of an idiographic approach, based on the individual patient\\'s \"moving average,\" i.e.,\\r\\nan average updates after each assessment made and which also takes into account the\\r\\nprevious five assessments. In this case, the risk of breakdown is represented by changes\\r\\nin the total score at the individual patient\\'s WAI with the rationale of using standard\\r\\ndeviations from the mean, as a functional indicator: If the score is lower by at least\\r\\n1.5 (d.s) there will be a moderate alert, 2 d.s will be severe instead. A return within\\r\\n2-3 sessions to pre-risk levels of rupture (moderate or severe), i.e., increase in scores\\r\\nwith raising the mean by at least +1.5/+2 d.s will indicate resolution of rupture.\\r\\n\\r\\nManagement and administration of the tools will be available in the platform in all three\\r\\nconditions, with the differences between the three conditions being detailed. Therapy\\r\\nsessions will be either virtual, on a virtual platform managed and integrated by the\\r\\nplatform or live (as needed by the therapist). The decision between virtual vs. in-person\\r\\nsession will be investigated through interviews with therapists in the follow-up phase in\\r\\norder to gather drivers leading to the choice. In both cases, the platform will be used\\r\\nfor session and patient management and for administering the instruments in a\\r\\ncomputerized manner.\\r\\n\\r\\nPrimary Hypotheses.\\r\\n\\r\\nPatients whose therapists were in the OPM-F condition will have better outcomes in terms\\r\\nof reduction in symptom severity from before to six months after treatment than patients\\r\\nof therapists in the OPM condition and the TAU condition.\\r\\n\\r\\nPatients whose therapists were in the OPM-F condition will have better results in terms\\r\\nof decreasing discomfort from session to session than patients of therapists in the OPM\\r\\ncondition and the TAU condition.\\r\\n\\r\\nPatients of therapists in the OPM condition will have better results in terms of\\r\\nreduction of symptom severity from before to three months after treatment than patients\\r\\nand therapists in the TAU condition.\\r\\n\\r\\nPatients whose therapists were in the OPM condition will have better results regarding a\\r\\ndecrease in discomfort from session to session than therapists in the TAU condition.\\r\\n\\r\\nPatients of therapists in the OPM-F condition will report greater increases in\\r\\ntherapeutic alliance over the course of therapy sessions than patients in the OPM and TAU\\r\\nconditions.\\r\\n\\r\\nPatients of therapists in the OPM condition will show a greater increase in therapeutic\\r\\nalliance during therapy sessions than patients in the TAU condition.\\r\\n\\r\\n-Participants and instruments:\\r\\n\\r\\nPsychotherapy residents and/or Psychotherapists:\\r\\n\\r\\n180 to 350 will be recruited.\\r\\n\\r\\nCriteria for inclusion of therapists:\\r\\n\\r\\nTherapists with a regular MIUR-postgraduate degree in\\r\\npsychotherapy(https://www.miur.it/ElencoSSPWeb/), in active practice; and/or\\r\\npsychotherapists in at least their third year will be selected.\\r\\n\\r\\nThere will be no restrictions on the type of psychotherapy used by the professionals\\r\\nbeing recruited (the only criterion for inclusion is that it must be psychotherapy for a\\r\\nmental health issue).\\r\\n\\r\\nMeasures:\\r\\n\\r\\nDemographic questionnaires constructed for therapists and patients (i.e. age, gender,\\r\\nmarital status, educational qualification, contact details that are collected in MINDY\\r\\nplatform after the digital registration procedure of both therapist and related patients.\\r\\n\\r\\nThese data are recorded and stored upon agreement between the professionals and patients\\r\\nwith the MINDY platform and the University of Bergamo.\\r\\n\\r\\nQuestionnaire battery for Therapists*:\\r\\n\\r\\nAttachment:\\r\\n\\r\\nItalian version of the Experiences in Close Relationships Scale (ECR12). The Italian\\r\\nversion of the ECR-12 is a self-report measure of attachment to partners. The ECR-12\\r\\nmeasures two dimensions of attachment to partners, avoidant attachment (6 items) and\\r\\nanxious attachment (6 items). An example item is \"I am afraid of being left\" (1= Strongly\\r\\nDisagree; 7 = Strongly Agree).\\r\\n\\r\\nMentalization:\\r\\n\\r\\nItalian version of The Reflective Functioning Questionnaire-8 (RFQ-8) is a brief\\r\\nself-report measure of reflective functioning (i.e., the ability to understand the mental\\r\\nstates of self and others) that is supposed to capture individual differences in hypo-\\r\\nand hyper-mentalization. The RFQ-8 includes eight items that form the two subscales\\r\\n\"certainty about mental states\" (RFQ_C) and \"uncertainty about mental states\" (RFQ_U).\\r\\nRated on a 7-point Likert scale ranging from 1 (totally disagree) to 1 (totally\\r\\ndisagree).\\r\\n\\r\\nThe Italian version of the Multitheoretical List of Therapeutic Interventions-Therapists\\r\\nVersion (MULTI30) is a brief, valid and reliable instrument that is used to assess\\r\\npatients\\' and therapists\\' perceptions of the use of interventions and techniques of major\\r\\ntherapeutic approaches. Each item is rated on a 5-point Likert scale.\\r\\n\\r\\nEpistemic Trust:\\r\\n\\r\\nThe Italian version of the Epistemic Trust, Mistrust, and Credulity Questionnaire (ETMCQ)\\r\\nis a self-report questionnaire consisting of 15 items that assesses epistemic trust,\\r\\nmistrust, and credulity toward communication or communicated knowledge ; Epistemic trust\\r\\nrefers to an adaptive attitude in relatively benign social circumstances in which the\\r\\nindividual is selectively and appropriately open to social learning opportunities in the\\r\\ncontext of relationships. Epistemic distrust reflects the tendency to treat any source of\\r\\ninformation as unreliable or malicious, seeking to avoid being influenced by the\\r\\ncommunication of others. Epistemic gullibility refers to a marked lack of vigilance and\\r\\ndiscrimination, signaling a general lack of clarity about one\\'s position and resulting in\\r\\nvulnerability to misinformation and potential risk of exploitation. Higher scores\\r\\nindicate greater presence of the relative trait for each factor.\\r\\n\\r\\nTherapeutic Alliance:\\r\\n\\r\\nThe Working Alliance Inventory-Short Revised- Therapist Version (WAI-SR-T) The Working\\r\\nAlliance Inventory-SR-T (WAI-SR-T) is the 12-item short version of the therapist modules\\r\\nof the WAI. It measures the therapist\\'s emotional bonding and level of agreement with\\r\\ntherapy tasks and goals. Each item is rated on a 5-point Likert scale, from 1 never to 5\\r\\nalways. The reliability and validity of the WAI-SR-T have been repeatedly supported in a\\r\\nwide range of studies. The Italian version of the WAI-SR-T was used in the present study.\\r\\n\\r\\nBattery of questionnaires for Therapists related to the use of digital**:\\r\\n\\r\\n(with distinction between questionnaires to be delivered at t0 (*), t1 (**), t2 (***))\\r\\n\\r\\nIntensity of use of digital technologies in psychotherapeutic practice*\\r\\n\\r\\nThe \"Intensity of Digital Technology Use in Psychotherapeutic Practice\" questionnaire\\r\\nsurveys how frequently psychotherapists use digital technologies in their practice. This\\r\\nsurvey includes two key metrics: first, the frequency of online counseling sessions,\\r\\nmeasured on a 5-point Likert scale ranging from \"No sessions are conducted online\" to\\r\\n\"Almost all sessions were conducted online [rather than in-person].\" Secondly, the\\r\\nintensity of use of key digital technologies in professional practice (Digital\\r\\nPsychotherapy Clinical Record, Platforms dedicated to psychotherapist-patient\\r\\ncommunication, Telemedicine/Telepsychotherapy Platforms, Diary/Appointment Management\\r\\nPlatforms, E-mail for patient communication, WhatsApp or similar Apps for patient\\r\\ncommunication, Social media (e.g. dissemination of content related to his profession or\\r\\npromotion of his professional activity), Elearning platforms for continuing\\r\\neducation/updating, Software for administrative/accounting management) using a separate\\r\\n5-point Likert scale ranging from \"Never\" to \"Daily.\"\\r\\n\\r\\nPrescription or actual recommendation of mental health apps*. The questionnaire captures\\r\\nwhether in the past year the therapist has recommended mental health apps of various\\r\\ntypes (Apps for tracking symptoms or psychological states (diary for mood, anxiety\\r\\nstates, etc.), Apps for keeping track of a patient\\'s diary, Apps for supporting\\r\\ntherapeutic adherence, Apps for relaxation and mindfulness, Apps for supporting addiction\\r\\nmanagement, Serious Games, Apps for collecting PREMs/PROMs, Digital Therapies (clinically\\r\\nvalidated digital treatments).\\r\\n\\r\\nDigital-related technical competencies in professional practice*. The questionnaire on\\r\\n\"Digital-related technical competencies in professional practice\" is derived from the\\r\\nwork of Jarva, specifically at \"Factor 3: Information and communication technology (ICT)\\r\\ncompetence.\" It uses a 4-point Likert scale to measure respondents\\' level of agreement\\r\\nwith various statements related to their competence in using digital tools and\\r\\nInformation and Communication Technology (ICT) in their practice.\\r\\n\\r\\nEthical competencies related to digital in professional practice* The questionnaire on\\r\\n\"Ethical competence related to digital in professional practice\" is derived from Jarva,\\r\\nspecifically from their \"Factor 5: Ethical competence related to digital solutions\"\\r\\nsection. Like the previous questionnaire, a 4-point Likert scale is used to assess the\\r\\nlevel of agreement among respondents. The objective is to assess competence related to\\r\\nethical issues arising from the use of digital technologies in psychotherapeutic\\r\\npractice.\\r\\n\\r\\nPropensity to integrate digital technologies into one\\'s clinical practice* The\\r\\nquestionnaire on \"Propensity to Integrate Digital Technologies into One\\'s Clinical\\r\\nPractice\" investigates how willing and inclined psychotherapists are to incorporate\\r\\ndigital technologies into their practice. This is also adapted from Jarva, with reference\\r\\nto \" Factor 2: Digital solutions as part of work.\" Again, a 4-point Likert scale is used.\\r\\n\\r\\nNet Promoter Score (NPS)**, *** The Net Promoter Score, measures the likelihood that\\r\\ntherapists would recommend a specific digital platform to their colleagues. It uses a\\r\\nscale from 1 (low probability of recommendation) to 10 (high probability), thus assessing\\r\\nusers\\' satisfaction with and loyalty to the platform. It is a useful index for estimating\\r\\nthe degree of \"reception\" and impact of such tools in the professional context.\\r\\n\\r\\nPost-Study System Usability Questionnaire (PSSUQ)**, *** The Post-Study System Usability\\r\\nQuestionnaire, developed by Lewis, provides detailed feedback on the user experience with\\r\\nMINDY after use. Using a Likert scale of 1 to 7, therapists rate statements on overall\\r\\nsatisfaction, ease of use, efficiency, and clarity of information. The PSSUQ is useful in\\r\\nidentifying areas for improvement, ensuring that the system is functional and\\r\\nuser-friendly.\\r\\n\\r\\nBattery of questionnaires for Patients**:\\r\\n\\r\\n(Will be administered at T0,T2 and at follow up after 3 months). Notes: T0= Baseline, T1=\\r\\nAfter the tenth session, T2= End of treatment,Follow up: Six months after the end of\\r\\ntreatment.\\r\\n\\r\\nThe Italian version of the PhillyACES-Philadelphia Adverse Childhood Events Scale; is a\\r\\n10-item measure used to measure childhood trauma. The questionnaire assesses 10 types of\\r\\nchildhood trauma measured in the ACE study. Five are personal: physical abuse, verbal\\r\\nabuse, sexual abuse, physical neglect and emotional neglect. Five are related to other\\r\\nfamily members: an alcoholic parent, a mother victim of domestic violence, a family\\r\\nmember in prison, a family member diagnosed with mental illness, and the disappearance of\\r\\na parent due to divorce, death or abandonment .\\r\\n\\r\\nThe Italian version of the Experiences in Close Relationships Scale (described above);\\r\\nThe Italian version of the Generalized Anxiety Disorder scale (GAD-7) is a 7-item\\r\\nself-report screening instrument for the assessment of generalized anxiety disorder\\r\\n(GAD). Each item is rated on a 4-point Likert scale (0 = \"Not at all\" to 3 = \"Almost\\r\\nevery day\"), with higher scores reflecting greater severity of GAD. Specifically, scores\\r\\nfrom 0 to 4 indicate minimal anxiety, 5 to 9 indicate mild anxiety, 10 to 14 indicate\\r\\nmoderate anxiety, and 15 to 21 indicate severe anxiety\\r\\n\\r\\nThe Italian version of the Patient Health Questionnaire; (PHQ-9) is a 9-item self-report\\r\\ninstrument that assesses symptoms of depression. Each item is rated on a 4-point Likert\\r\\nscale (from 0 = \"Not at all\" to 3 = \"Almost every day\"), with higher scores indicating\\r\\ngreater severity of depression. Specifically, scores from 0 to 4 indicate no depressive\\r\\nsymptoms, 5 to 9 mild depression, 10 to 14 moderate depression, 15 to 19 moderately\\r\\nsevere depression, and 20 to 27 severe depression\\r\\n\\r\\nThe Italian version of the Clinical Outcomes in Routine Evaluation (CORE-10) is a short\\r\\n10-item measure for exploring psychological distress developed for monitoring outcomes in\\r\\nclinical settings. The CORE-10 is a shortened version of the 34-item CORE-OM. It features\\r\\nthree domains: i) problems: depression (2 items), anxiety (2 items), physical (1 item),\\r\\nand trauma (1 item); ii) functioning: general functioning (1 item), social functioning (1\\r\\nitem), and close relationships (1 item); and iii) risk: toward self (1 item). In\\r\\naddition, two items (i.e., item 2, \"I felt that I had someone to turn to for support when\\r\\nI needed it\" and item 3, \"I felt able to adapt in case of difficulty\") are positively\\r\\nworded and thus are reverse rated. The items are rated on a 5-point Likert-type scale\\r\\n(from 0 = not at all to 4 = most or all of the time), and higher total scores (i.e., the\\r\\nsum of all items, ranging from 0 to 40) indicate greater distress.\\r\\n\\r\\nThe Italian version of the Working Alliance Inventory-Short Revised- Client Version\\r\\n(WAI-SR-C). The Working Alliance Inventory-Short Revised (WAI-SR-C) is the 12-item short\\r\\nversion of the WAI\\'s patient modules. It measures patients\\' emotional bonding and their\\r\\nlevel of agreement with the tasks and goals of the therapy of therapy. Each item is rated\\r\\non a 5-point Likert scale, from 1 never to 5 always. The reliability and validity of the\\r\\nWAI-SR-C have been repeatedly supported in a wide range of studies.\\r\\n\\r\\nAfter the 10th session (T1;Therapist version and patient version). The Italian version of\\r\\nthe Multitheoretical List of Therapeutic Interventions (MULTI30; Solomonov et al., 2019)\\r\\nis a brief, valid and reliable instrument that is used to assess patients\\' and\\r\\ntherapists\\' perceptions of the use of interventions and techniques of major therapeutic\\r\\napproaches. Each item is rated on a 5-point Likert scale.\\r\\n\\r\\nAdditional instruments (session-by-session) for OPM and OPM-F conditions.\\r\\n\\r\\nPre-session (for patients):\\r\\n\\r\\nNotes: Will be administered before EACH session only in the OPM and OPM-F conditions .\\r\\n\\r\\nCORE-10: Clinical Outcomes in routine evaluation.\\r\\n\\r\\nPost -session: (for both therapists and patients):\\r\\n\\r\\nNotes: Will be administered after each session only in the OPM and OPM-F conditions\\r\\n(After the second session).\\r\\n\\r\\nWAI-Session Alliance Inventory; (Version for both therapists and patients).\\r\\n\\r\\nProcedure The study will be conducted subject to the approval of the Institutional Review\\r\\nBoard of the Department of Humanities and Social Sciences, University of Bergamo.\\r\\n\\r\\nBefore proceeding with the completion of the battery of questionnaires, the participant\\r\\nwill be asked to review the informed consent form. The disclosure will outline the\\r\\nfollowing:\\r\\n\\r\\n  -  the nature and purpose of the study;\\r\\n\\r\\n  -  the measures in the study;\\r\\n\\r\\n  -  the duration of the study;\\r\\n\\r\\n  -  the option for participants not to consent to participation and the option to\\r\\n     withdraw from the study at any time;\\r\\n\\r\\n  -  the manner in which the data will be processed, which will be kept confidential, not\\r\\n     being shared with anyone outside the research staff; and\\r\\n\\r\\nStatistical Analysis\\r\\n\\r\\nData Analysis Plan:\\r\\n\\r\\nTo test the primary hypotheses, 3-level hierarchical mixed-effects models will be used\\r\\nwith repeated measures of psychological distress, symptom severity or therapeutic\\r\\nalliance values at level 1 of the model, nested in patients at level 2 and therapists at\\r\\nlevel 3. Study conditions (OPM-F, OPM, TAU) will be coded with \"dummy\" variables and\\r\\nmodeled at level 3. Investigators will use full maximum likelihood estimation and allow\\r\\nall parameters to vary (they will be treated randomly). Data useful for clustering with\\r\\nrespect to digital propensity and skills will be analyzed using a two-step cluster\\r\\nanalysis (hierarchical clustering and K-means). Latent variables will be identified and\\r\\nreduced through a Principal Component Analysis.\\r\\n\\r\\nMissing Data:\\r\\n\\r\\nInvestigators will use post-treatment and follow-up data from all patients discontinuing\\r\\ntreatment when possible. Data analyses will be conducted with the intent to treat sample.\\r\\n(intent to treat, ITT) which appears to be the gold standard for randomized clinical\\r\\ntrials. In ITT analysis, data from all subjects initially enrolled in a clinical trial\\r\\nare included in statistical analyses and analyzed according to the group to which they\\r\\nwere originally assigned, regardless of the treatment (if any) they received. This method\\r\\nallows the researcher to draw accurate (unbiased) conclusions about the effectiveness of\\r\\nan intervention. This method preserves the advantages of randomization, which cannot be\\r\\nassumed when using other methods of analysis. Investigators will evaluate the impact of\\r\\nmissing data with pattern mixing models (PMM). Mixed-effects modeling with maximum\\r\\nlikelihood estimation will estimate reliable parameters with random missing data. If\\r\\nnecessary, investigators will control for significant missing data patterns.'},\n",
       "   'conditionsModule': {'conditions': ['Feedback, Psychological'],\n",
       "    'keywords': ['Routine outcome monitoring (ROM)',\n",
       "     'PRIN-Italy-OutProFeed.',\n",
       "     'Feedback informed therapy (FIT)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 180, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Treatment as usual (TAU)',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'TAU: therapists and patients proceed with psychotherapy as they normally would without\\r\\nreceiving any initial training and using only Mindy as a simplified digital folder.'},\n",
       "     {'label': 'OPM',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Process and outcome monitoring (OPM) in which patients will complete process and outcome\\r\\nmeasures with \"baseline\" feedback related to each psychotherapy session, but therapists\\r\\nwill not receive support with clinical support tools on these measures, will not have\\r\\nspecific training on Feedback Informed Therapy (FIT), and will not receive monthly\\r\\nsupervision, but rather will use the Mindy platform as a medical record',\n",
       "      'interventionNames': ['Behavioral: Feedback and ROM (basic)']},\n",
       "     {'label': 'OPM-F',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Process and outcome monitoring with feedback (OPM-F) in which patients will complete\\r\\nprocess and outcome measures related to each session, and therapists will receive\\r\\nfeedback on patient progress and patient experiences of the therapeutic alliance with\\r\\nspecific training on feedback informed therapy (FIT) and use the Mindy platform with all\\r\\ninformation inherent to feedback and Clinical Support Tools, they will also receive\\r\\nmonthly supervision/coaching (for three months) designed to complete on-going training on\\r\\nFIT and ROM, with practical discussion of the most difficult clinical cases and possible\\r\\nsolutions to be implemented in therapy.',\n",
       "      'interventionNames': ['Behavioral: (Feedback Informed Therapy) with Clinical Support Tools and ah hoc training',\n",
       "       'Behavioral: Feedback and ROM (basic)']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': '(Feedback Informed Therapy) with Clinical Support Tools and ah hoc training',\n",
       "      'description': 'Therapists in the condition (OPM-F) will receive specific training on the procedures and\\r\\ntechniques inherent in feedback informed therapy (FIT); during the intervention phase\\r\\n(lasting 15 sessions) the Clinical Support System in FIT will guide them in the clinical\\r\\napplication of the procedures. In addition, they will receive monthly supervision (for\\r\\nthree months) apt to provide on-going clinical support on FIT and ROM, with practical\\r\\ndiscussion of the most difficult clinical cases and possible solutions to be implemented\\r\\nin therapy.',\n",
       "      'armGroupLabels': ['OPM-F']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Feedback and ROM (basic)',\n",
       "      'description': 'Process and outcome monitoring (OPM) in which patients will complete process and outcome\\r\\nmeasures related to each psychotherapy session but therapists will receive basic feedback\\r\\non these measures',\n",
       "      'armGroupLabels': ['OPM', 'OPM-F']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in Symptom severity (GAD7-PHQ9) in OPM-F,OPM and TAU conditions at T2 (up to 6 months), and follow up (3 months)',\n",
       "      'description': 'Patients whose therapists were in the OPM-F condition will have better results in terms\\r\\nof reduction of symptom severity (GAD7-PHQ9) at the end of treatment (after 15\\r\\nsessions/up to 6 months) and three months after treatment (follow up) than patients of\\r\\ntherapists in the OPM condition and TAU condition.\\r\\n\\r\\nGAD is a 7-item self-report screening instrument for the assessment of generalized\\r\\nanxiety disorder (GAD). Each item is rated on a 4-point Likert scale (0 = \"Not at all\" to\\r\\n3 = \"Almost every day\"), with higher scores reflecting greater severity of GAD.\\r\\n\\r\\nPatient Health Questionnaire is a 9-item self-report instrument that assesses symptoms of\\r\\ndepression. Each item is rated on a 4-point Likert scale (0 = \"Not at all\" to 3 = \"Almost\\r\\nevery day\"), with higher scores indicating greater severity of depression.',\n",
       "      'timeFrame': 'Baseline, T2 (up to 6 months), Follow-up (3 months)'},\n",
       "     {'measure': 'Clinical Outcomes in Routine Evaluation-10 (Change in Session by session)',\n",
       "      'description': 'Patients whose therapists were in the OPM-F condition will have better results in terms\\r\\nof decreasing distress (CORE-10) from session to session than patients of therapists in\\r\\nthe OPM condition and the TAU condition.\\r\\n\\r\\nPatients whose therapists were in the OPM condition will have better results in terms of\\r\\ndecreasing discomfort (CORE-10) from session to session than patients of therapists in\\r\\nthe TAU condition.\\r\\n\\r\\nCORE-10 is a short 10-item measure to explore psychological distress developed for\\r\\noutcome monitoring in clinical settings Items are rated on a 5-point Likert-type scale\\r\\n(from 0 = not at all to 4 = most or all of the time), and higher total scores (i.e., the\\r\\nsum of all items, ranging from 0 to 40) indicate greater distress.',\n",
       "      'timeFrame': 'Session by session (every weeks from baseline to up to 6 months)'},\n",
       "     {'measure': 'Working Alliance Inventory-Short Revised-Client (Change in session by session)',\n",
       "      'description': 'Patients of therapists in the OPM-F condition will report a greater increase in\\r\\ntherapeutic alliance during therapy sessions than patients in the OPM and TAU conditions.\\r\\n\\r\\nPatients of therapists in the OPM condition will report a greater increase in therapeutic\\r\\nalliance during therapy sessions than patients in the TAU conditions.',\n",
       "      'timeFrame': 'Session by session (From baseline to up to 6 months)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Impact of Usability of MINDY platform with Post-Study System Usability Questionnaire (PSSUQ) and Net Promoter Score (NPS) on patient outcomes',\n",
       "      'description': 'Usability will be assessed on patients, following the track of validated technological\\r\\nusability questionnaire (PSSUQ) and analyzed through thematic analysis.',\n",
       "      'timeFrame': 'T2 (up to 6 months) and follow-up (3 months)'},\n",
       "     {'measure': 'Change from baseline of The Reflective Functioning Questionnaire (RFQ)-7',\n",
       "      'description': 'Mentalization will be assessed with RFQ-7, we expect that patients of therapists in the\\r\\nOPM-F condition may have better levels of mentalization at the end of treatment and even\\r\\nat 3 months, compared with OPM and TAU conditions.',\n",
       "      'timeFrame': 'Baseline, T2 (up to 6 months), follow up (3 months)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Terapists with a regular specialisation diploma in psychotherapy recognised by the\\r\\n     MIUR (https://www.miur.it/ElencoSSPWeb/), in activity; and/or specialising in\\r\\n     psychotherapy at least in their third year will be selected.\\r\\n\\r\\nThere will be no restrictions on the type of psychotherapy used by the professionals who\\r\\nwill be recruited (the only criterion for inclusion is that it must be psychotherapy for\\r\\na mental health issue).\\r\\n\\r\\n  -  Patients: Approximately 1500 to 2000 patients will be recruited, 5 new patients per\\r\\n     therapist.\\r\\n\\r\\n  -  New patients seen for less than 3 sessions.\\r\\n\\r\\n  -  Adult patients, 18 years of age or older.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients: - No restrictions on diagnoses except for the following: Psychosis and\\r\\n     neurocognitive disorders, because as pointed out by Barkham and colleagues when\\r\\n     using ROM and FIT the clinical population and context must be considered.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Angelo Compare, Full Professor',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+39 0352052989',\n",
       "      'email': 'angelo.compare@unibg.it'}],\n",
       "    'overallOfficials': [{'name': 'Gianluca Lo Coco, Full Professor',\n",
       "      'affiliation': 'University of Palermo (Italy)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Masella Cristina, Full Professor',\n",
       "      'affiliation': '\"Politecnico\" Milan (Italy)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Giorgio A. Tasca, Full Professor',\n",
       "      'affiliation': 'School of Psychology, University of Ottawa (Canada)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Barbara Poletti, Professor',\n",
       "      'affiliation': 'Scuola di Psicoterapia Integrata (Bergamo) Italy',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Luca Pievani, Dr.',\n",
       "      'affiliation': 'Scuola di Psicoterapia Integrata (Bergamo) Italy',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Antonino Carcione, Professor',\n",
       "      'affiliation': 'Terzocentro di Psicoterapia Cognitiva (Roma) Italy',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Antonino La Tona, Dr.',\n",
       "      'affiliation': 'University of Bergamo (Italy)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Mattia V. Olive, Dr.',\n",
       "      'affiliation': '\"Politecnico\" Milan (Italy)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Agostino Brugnera, Assistant Professor',\n",
       "      'affiliation': 'University of Bergamo',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Gary M. Burlingame, Full Professor',\n",
       "      'affiliation': 'Brigham Young University (Utah)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Kim De Jong, Full Professor',\n",
       "      'affiliation': 'Leiden University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Michael Barkham, Full Professor',\n",
       "      'affiliation': 'University of Sheffield',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Jaime Delgadillo, Full Professor',\n",
       "      'affiliation': 'University of Sheffield',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Bergamo (DSUS)',\n",
       "      'city': 'Bergamo',\n",
       "      'state': 'Ita (bg)',\n",
       "      'zip': '24125',\n",
       "      'country': 'Italy',\n",
       "      'geoPoint': {'lat': 45.69601, 'lon': 9.66721}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '29350997',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Clark DM. Realizing the Mass Public Benefit of Evidence-Based Psychological Therapies: The IAPT Program. Annu Rev Clin Psychol. 2018 May 7;14:159-183. doi: 10.1146/annurev-clinpsy-050817-084833. Epub 2018 Jan 19.'},\n",
       "     {'pmid': '35201811',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Barber J, Resnick SG. Collect, Share, Act: A transtheoretical clinical model for doing measurement-based care in mental health treatment. Psychol Serv. 2023;20(Suppl 2):150-157. doi: 10.1037/ser0000629. Epub 2022 Feb 24. Erratum In: Psychol Serv. 2023;20(Suppl 2):259.'},\n",
       "     {'pmid': '10281188',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Barley SR. Technology as an occasion for structuring: evidence from observations of CT scanners and the social order of radiology departments. Adm Sci Q. 1986 Mar;31(1):78-108.'},\n",
       "     {'pmid': '38086157',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Deisenhofer AK, Barkham M, Beierl ET, Schwartz B, Aafjes-van Doorn K, Beevers CG, Berwian IM, Blackwell SE, Bockting CL, Brakemeier EL, Brown G, Buckman JEJ, Castonguay LG, Cusack CE, Dalgleish T, de Jong K, Delgadillo J, DeRubeis RJ, Driessen E, Ehrenreich-May J, Fisher AJ, Fried EI, Fritz J, Furukawa TA, Gillan CM, Gomez Penedo JM, Hitchcock PF, Hofmann SG, Hollon SD, Jacobson NC, Karlin DR, Lee CT, Levinson CA, Lorenzo-Luaces L, McDanal R, Moggia D, Ng MY, Norris LA, Patel V, Piccirillo ML, Pilling S, Rubel JA, Salazar-de-Pablo G, Schleider JL, Schnurr PP, Schueller SM, Siegle GJ, Uher R, Watkins E, Webb CA, Wiltsey Stirman S, Wynants L, Youn SJ, Zilcha-Mano S, Lutz W, Cohen ZD. Implementing precision methods in personalizing psychological therapies: Barriers and possible ways forward. Behav Res Ther. 2024 Jan;172:104443. doi: 10.1016/j.brat.2023.104443. Epub 2023 Dec 1. No abstract available.'},\n",
       "     {'pmid': '1920064',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Bartholomew K, Horowitz LM. Attachment styles among young adults: a test of a four-category model. J Pers Soc Psychol. 1991 Aug;61(2):226-44. doi: 10.1037//0022-3514.61.2.226.'},\n",
       "     {'pmid': '20566188',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Bickman L. A measurement feedback system (MFS) is necessary to improve mental health outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Oct;47(10):1114-9. doi: 10.1097/CHI.0b013e3181825af8. Epub 2009 Aug 21. No abstract available.'},\n",
       "     {'pmid': '32913809',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Brugnera A, Zarbo C, Farina B, Picardi A, Greco A, Lo Coco G, Tasca GA, Carlucci S, Auteri A, Greco F, Compare A. Psychometric properties of the Italian version of the Experience in Close Relationship Scale 12 (ECR-12): an exploratory structural equation modeling study. Res Psychother. 2019 Dec 20;22(3):392. doi: 10.4081/ripppo.2019.392. eCollection 2019 Dec 19.'},\n",
       "     {'pmid': '29942568',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Chantler T, Paton C, Velardo C, Triantafyllidis A, Shah SA, Stoppani E, Conrad N, Fitzpatrick R, Tarassenko L, Rahimi K. Creating connections - the development of a mobile-health monitoring system for heart failure: Qualitative findings from a usability cohort study. Digit Health. 2016 Oct 10;2:2055207616671461. doi: 10.1177/2055207616671461. eCollection 2016 Jan-Dec.'},\n",
       "     {'pmid': '22036697',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Crits-Christoph P, Ring-Kurtz S, Hamilton JL, Lambert MJ, Gallop R, McClure B, Kulaga A, Rotrosen J. A preliminary study of the effects of individual patient-level feedback in outpatient substance abuse treatment programs. J Subst Abuse Treat. 2012 Apr;42(3):301-9. doi: 10.1016/j.jsat.2011.09.003. Epub 2011 Oct 29.'},\n",
       "     {'pmid': '22468992',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'de Jong K, van Sluis P, Nugter MA, Heiser WJ, Spinhoven P. Understanding the differential impact of outcome monitoring: therapist variables that moderate feedback effects in a randomized clinical trial. Psychother Res. 2012;22(4):464-74. doi: 10.1080/10503307.2012.673023. Epub 2012 Apr 2.'},\n",
       "     {'pmid': '24375536',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Emmelkamp PM, David D, Beckers T, Muris P, Cuijpers P, Lutz W, Andersson G, Araya R, Banos Rivera RM, Barkham M, Berking M, Berger T, Botella C, Carlbring P, Colom F, Essau C, Hermans D, Hofmann SG, Knappe S, Ollendick TH, Raes F, Rief W, Riper H, Van Der Oord S, Vervliet B. Advancing psychotherapy and evidence-based psychological interventions. Int J Methods Psychiatr Res. 2014 Jan;23 Suppl 1(Suppl 1):58-91. doi: 10.1002/mpr.1411.'},\n",
       "     {'pmid': '9635069',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Felitti VJ, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, Koss MP, Marks JS. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 1998 May;14(4):245-58. doi: 10.1016/s0749-3797(98)00017-8.'},\n",
       "     {'pmid': '9866193',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Flett GL, Hewitt PL, Blankstein KR, Gray L. Psychological distress and the frequency of perfectionistic thinking. J Pers Soc Psychol. 1998 Nov;75(5):1363-81. doi: 10.1037//0022-3514.75.5.1363.'},\n",
       "     {'pmid': '8870542',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Howard KI, Moras K, Brill PL, Martinovich Z, Lutz W. Evaluation of psychotherapy. Efficacy, effectiveness, and patient progress. Am Psychol. 1996 Oct;51(10):1059-64. doi: 10.1037//0003-066x.51.10.1059.'},\n",
       "     {'pmid': '36689840',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Jarva E, Oikarinen A, Andersson J, Tomietto M, Kaariainen M, Mikkonen K. Healthcare professionals' digital health competence and its core factors; development and psychometric testing of two instruments. Int J Med Inform. 2023 Mar;171:104995. doi: 10.1016/j.ijmedinf.2023.104995. Epub 2023 Jan 18.\"},\n",
       "     {'pmid': '30115041',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Knapstad M, Nordgreen T, Smith ORF. Prompt mental health care, the Norwegian version of IAPT: clinical outcomes and predictors of change in a multicenter cohort study. BMC Psychiatry. 2018 Aug 16;18(1):260. doi: 10.1186/s12888-018-1838-0.'},\n",
       "     {'pmid': '33909341',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lipner LM, Muran JC, Eubanks CF, Gorman BS, Winston A. Operationalizing alliance rupture-repair events using control chart methods. Clin Psychol Psychother. 2022 Jan;29(1):339-350. doi: 10.1002/cpp.2606. Epub 2021 May 7.'},\n",
       "     {'pmid': '21604904',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Coco GL, Gullo S, Prestano C, Gelso CJ. Relation of the real relationship and the working alliance to the outcome of brief psychotherapy. Psychotherapy (Chic). 2011 Dec;48(4):359-67. doi: 10.1037/a0022426. Epub 2011 May 23. Erratum In: Psychotherapy (Chic). 2012 Jun;49(2):108.'},\n",
       "     {'pmid': '35980735',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Longhini J, Rossettini G, Palese A. Digital Health Competencies Among Health Care Professionals: Systematic Review. J Med Internet Res. 2022 Aug 18;24(8):e36414. doi: 10.2196/36414. Erratum In: J Med Internet Res. 2022 Nov 29;24(11):e43721.'},\n",
       "     {'pmid': '29085540',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'McCoy CE. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. West J Emerg Med. 2017 Oct;18(6):1075-1078. doi: 10.5811/westjem.2017.8.35985. Epub 2017 Sep 18.'},\n",
       "     {'pmid': '20013760',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Munder T, Wilmers F, Leonhart R, Linster HW, Barth J. Working Alliance Inventory-Short Revised (WAI-SR): psychometric properties in outpatients and inpatients. Clin Psychol Psychother. 2010 May-Jun;17(3):231-9. doi: 10.1002/cpp.658.'},\n",
       "     {'pmid': '33151152',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Nazeha N, Pavagadhi D, Kyaw BM, Car J, Jimenez G, Tudor Car L. A Digitally Competent Health Workforce: Scoping Review of Educational Frameworks. J Med Internet Res. 2020 Nov 5;22(11):e22706. doi: 10.2196/22706.'},\n",
       "     {'pmid': '14712543',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Reichheld FF. The one number you need to grow. Harv Bus Rev. 2003 Dec;81(12):46-54, 124.'},\n",
       "     {'pmid': '24000837',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Reese RJ, Slone NC, Miserocchi KM. Using client feedback in psychotherapy from an interpersonal process perspective. Psychotherapy (Chic). 2013 Sep;50(3):288-91. doi: 10.1037/a0032522.'},\n",
       "     {'pmid': '29336228',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Solomonov N, McCarthy KS, Gorman BS, Barber JP. The Multitheoretical List of Therapeutic Interventions - 30 items (MULTI-30). Psychother Res. 2019 Jul;29(5):565-580. doi: 10.1080/10503307.2017.1422216. Epub 2018 Jan 16.'},\n",
       "     {'pmid': '17760317',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Stevens CL, Muran JC, Safran JD, Gorman BS, Winston A. Levels and patterns of the therapeutic alliance in brief psychotherapy. Am J Psychother. 2007;61(2):109-29. doi: 10.1176/appi.psychotherapy.2007.61.2.109.'},\n",
       "     {'pmid': '29044599',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Winkeljohn Black S, Owen J, Chapman N, Lavin K, Drinane JM, Kuo P. Feedback informed treatment: An empirically supported case study of psychodynamic treatment. J Clin Psychol. 2017 Nov;73(11):1499-1509. doi: 10.1002/jclp.22529.'},\n",
       "     {'pmid': '31021113',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wright CV, Goodheart C, Bard D, Bobbitt BL, Butt Z, Lysell K, McKay D, Stephens K. Promoting measurement-based care and quality measure development: The APA mental and behavioral health registry initiative. Psychol Serv. 2020 Aug;17(3):262-270. doi: 10.1037/ser0000347. Epub 2019 Apr 25.'},\n",
       "     {'pmid': '431682',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979 May 31;300(22):1242-5. doi: 10.1056/NEJM197905313002203.'},\n",
       "     {'pmid': '37017222',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'La Tona A, Tagini S, Brugnera A, Poletti B, Aiello EN, Lo Coco G, Del Piccolo L, Compare A. Italian validation of the Clinical Outcomes in Routine Evaluation-10 (CORE-10): a short measure for routine outcome monitoring in clinical practice. Res Psychother. 2023 Apr 4;26(1):671. doi: 10.4081/ripppo.2023.671.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06432387',\n",
       "    'orgStudyIdInfo': {'id': 'CoFA-TAAA'},\n",
       "    'organization': {'fullName': 'University of Thessaly', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair',\n",
       "    'officialTitle': 'Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair (CoFA-TAAA); a Prospective Observational Study',\n",
       "    'acronym': 'CoFA-TAAA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-01-15', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-28',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Elena Arnaoutoglou',\n",
       "     'investigatorTitle': 'Professor of Anaesthesiology',\n",
       "     'investigatorAffiliation': 'University of Thessaly'},\n",
       "    'leadSponsor': {'name': 'University of Thessaly', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study will evaluate the impact of complex thoraco-abdominal aortic aneurysm repair\\r\\nin coagulation during the immediate postoperative period in patients undergoing omplex\\r\\nthoraco-abdominal aortic aneurysm repair.',\n",
       "    'detailedDescription': 'Endovascular aneurysm repair of abdominal aorta activates a significant inflammation\\r\\nreaction and has an impact on coagulation. Platelet activation seems to have a major role\\r\\nin this prothrombotic and hypercoagulable state. In complex thoraco-abdominal aortic\\r\\naneurysm repair the implants are more complexed and the duration of operation longer. The\\r\\nmain hypothesis is that all the above have a greater impact on platelet activation and\\r\\ncoagulation alterations.\\r\\n\\r\\nThe aim of this study is the evaluation of the impact of complex thoraco-abdominal aortic\\r\\naneurysm repair in coagulation during the immediate postoperative period in patients\\r\\nundergoing omplex thoraco-abdominal aortic aneurysm repair.'},\n",
       "   'conditionsModule': {'conditions': ['Thoraco-abdominal Aortic Aneurysm Repair',\n",
       "     'Coagulation Factors Alterations',\n",
       "     'Platelet Activation']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 58, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Patients undergoing complex thoraco-abdominal aortic aneurysm repair',\n",
       "      'description': 'Perioperative laboratory examinations will follow institutional guidelines. These will\\r\\ninclude, but will not be limited to full blood count, conventional coagulation tests,\\r\\nliver function, and kidney function tests. Moreover, for the purpose of this study, the\\r\\nfollowing parameters will also be obtained; vWF, factors VIII and XI, D-dimers,\\r\\nfibrinogen, platelets activation (multiplate), adams-13, anti-Xa and high sensitivity\\r\\ntroponin. All samples will be obtained via puncture from a peripheral vein. Blood samples\\r\\nwill obtained at three time points; preoperatively before induction to GA (01),\\r\\npostoperative day 1 (02) and postoperative day 3rd-4th (03). During hospitalization any\\r\\nmyocardial injury after non cardiac surgery, acute kidney injure and post-implantation\\r\\nsyndrome will be recorded.\\r\\n\\r\\nOf note, at 30 days, 3, 6 and 12 months our patients will undergo an evaluation for any\\r\\nmajor cardiovascular event, implant failure or death of any cause.',\n",
       "      'interventionNames': ['Other: Patients undergoing complex thoraco-abdominal aortic aneurysm repair']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Patients undergoing complex thoraco-abdominal aortic aneurysm repair',\n",
       "      'description': 'Patients undergoing complex thoraco-abdominal aortic aneurysm repair',\n",
       "      'armGroupLabels': ['Patients undergoing complex thoraco-abdominal aortic aneurysm repair']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Coagulation status',\n",
       "      'description': 'Early preoperatively, early and late postoperatively',\n",
       "      'timeFrame': 'Day of surgery, 1st postoperative day, 4-5th postoperative day'},\n",
       "     {'measure': 'Myocardial injury after non cardiac surgery',\n",
       "      'timeFrame': 'Day of surgery, 1st postoperative day, 4-5th postoperative day'},\n",
       "     {'measure': 'Acute kidney injury',\n",
       "      'timeFrame': 'Day of surgery, 1st postoperative day, 4-5th postoperative day'},\n",
       "     {'measure': 'Post-implantation syndrome',\n",
       "      'timeFrame': 'Day of surgery, 1st postoperative day, 4-5th postoperative day'},\n",
       "     {'measure': 'Major cardiovascular events',\n",
       "      'timeFrame': 'Day of surgery, 1st postoperative day, 4-5th postoperative day'},\n",
       "     {'measure': 'Major cardiovascular events, implant failure and death of any cause',\n",
       "      'timeFrame': '30 days, 3, 6, and 12 months postoperatively'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Consecutive patients undergoing complex thoraco-abdominal aortic aneurysm repair in\\r\\n     University Hospital of Larissa, after informed consent will be included.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Refuse to participate\\r\\n\\r\\n  -  Prior surgery within 3 months\\r\\n\\r\\n  -  ASA PS > 3\\r\\n\\r\\n  -  Known medical history of thrombophilia or functional platelet dysfunction',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'All patients will be treated by the same medical team in UHL according to the European\\r\\nSociety for Vascular Surgery (ESVS) guidelines. Preoperatively patients will be treated\\r\\nwith aspirin 100 mg once daily for at least 5 days. Postoperatively in the absence of\\r\\nbleeding patients will receive aspirin 100 mg and in the absence of neurological\\r\\ndysfunction due to spine ischemia they will receive clopidogrel 150 mg and from the next\\r\\nday dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75 mg). If the patient was\\r\\ntreated with anticoagulant agents this will be discontinued preoperative according to\\r\\nACCP guidelines and it will be restarted on the 1st or 2nd postoperative day based on\\r\\nhemostasis. In this case patients will be treated with aspirin 100 mg once daily five\\r\\ndays preoperatively and aspirin will also be continued postoperatively.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Eleni Arnaoutoglou, Prof',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '6974301352',\n",
       "      'phoneExt': '+30',\n",
       "      'email': 'earnaout@gmail.com'},\n",
       "     {'name': 'Maria Ntalouka',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'maria.ntalouka@icloud.com'}],\n",
       "    'overallOfficials': [{'name': 'Eleni Arnaoutoglou, Prof',\n",
       "      'affiliation': 'University of Thessaly',\n",
       "      'role': 'STUDY_CHAIR'}],\n",
       "    'locations': [{'facility': 'University of Thessaly',\n",
       "      'city': 'Larissa',\n",
       "      'zip': '41335',\n",
       "      'country': 'Greece',\n",
       "      'geoPoint': {'lat': 39.63689, 'lon': 22.41761}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000000783',\n",
       "      'term': 'Aneurysm'},\n",
       "     {'id': 'D000001014', 'term': 'Aortic Aneurysm'},\n",
       "     {'id': 'D000017544', 'term': 'Aortic Aneurysm, Abdominal'},\n",
       "     {'id': 'D000094624', 'term': 'Aortic Aneurysm, Thoracoabdominal'},\n",
       "     {'id': 'D000017545', 'term': 'Aortic Aneurysm, Thoracic'}],\n",
       "    'ancestors': [{'id': 'D000014652', 'term': 'Vascular Diseases'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000001018', 'term': 'Aortic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M4113',\n",
       "      'name': 'Aneurysm',\n",
       "      'asFound': 'Aneurysm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4330',\n",
       "      'name': 'Aortic Aneurysm',\n",
       "      'asFound': 'Aortic Aneurysm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19800',\n",
       "      'name': 'Aortic Aneurysm, Abdominal',\n",
       "      'asFound': 'Abdominal Aortic Aneurysm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3070',\n",
       "      'name': 'Aortic Aneurysm, Thoracoabdominal',\n",
       "      'asFound': 'Thoraco-Abdominal Aortic Aneurysm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M19801',\n",
       "      'name': 'Aortic Aneurysm, Thoracic',\n",
       "      'asFound': 'Thoraco-Abdominal Aortic Aneurysm',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4334', 'name': 'Aortic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T66',\n",
       "      'name': 'Abdominal Aortic Aneurysm',\n",
       "      'asFound': 'Abdominal Aortic Aneurysm',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M11110',\n",
       "      'name': 'Liver Extracts',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9581',\n",
       "      'name': 'Heparin, Low-Molecular-Weight',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20153', 'name': 'Dalteparin', 'relevance': 'LOW'},\n",
       "     {'id': 'M203832', 'name': 'Fibrin fragment D', 'relevance': 'LOW'},\n",
       "     {'id': 'M8312', 'name': 'Factor VIII', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hemat', 'name': 'Hematinics'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'FiAg', 'name': 'Fibrinolytic Agents'},\n",
       "     {'abbrev': 'AnCoag', 'name': 'Anticoagulants'},\n",
       "     {'abbrev': 'Coag', 'name': 'Coagulants'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06400888',\n",
       "    'orgStudyIdInfo': {'id': 'M2024117'},\n",
       "    'secondaryIdInfos': [{'id': 'HP2024-03-501004',\n",
       "      'type': 'OTHER_GRANT',\n",
       "      'domain': '2024 Haidian District Health and Wellness Development Research Incubation Program'}],\n",
       "    'organization': {'fullName': 'Peking University Third Hospital',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Needle-Free Subcutaneous Injector and Conventional Intramuscular Injection of Mecobalamin in Diabetes Peripheral Neuropathy',\n",
       "    'officialTitle': 'a Prospective, Randomized, Open-Label, Clinical Trial Study Comparing the Efficacy and Safety for Needle-Free Subcutaneous Injector and Conventional Intramuscular Injection of Mecobalamin in Diabetes Peripheral Neuropathy'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-09',\n",
       "    'studyFirstSubmitQcDate': '2024-05-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Yuanjin Zhang',\n",
       "     'investigatorTitle': 'Chief Physician of Department of Neurology',\n",
       "     'investigatorAffiliation': 'Peking University Third Hospital'},\n",
       "    'leadSponsor': {'name': 'Peking University Third Hospital',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The evaluation for efficacy and safety of needle-free subcutaneous injector and\\r\\nconventional intramuscular injection of mecobalamin for diabetic neuropathy.'},\n",
       "   'conditionsModule': {'conditions': ['Diabetic Peripheral Neuropathy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'needle free subcutaneous injector of mecobalamin',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'interventionNames': ['Other: needle-free subcutaneous injector for Mecbl']},\n",
       "     {'label': 'intramuscular injection of Mecbl',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'interventionNames': ['Other: intramuscular injection of Mecbl']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'needle-free subcutaneous injector for Mecbl',\n",
       "      'description': 'needle-free subcutaneous injector for Mecbl',\n",
       "      'armGroupLabels': ['needle free subcutaneous injector of mecobalamin']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'intramuscular injection of Mecbl',\n",
       "      'description': 'intramuscular injection of Mecbl',\n",
       "      'armGroupLabels': ['intramuscular injection of Mecbl']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'concentration of plasma vitamin B12',\n",
       "      'description': 'The plasma vitamin B12, biomarker for effective active metabolite for neural repair.',\n",
       "      'timeFrame': 'baseline, half an hour, first hour, second hour, 8 weeks'},\n",
       "     {'measure': 'corneal confocal microscopy parameter: inferior whorl length',\n",
       "      'description': 'The corneal nerve fiber length in inferior whorl area.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'corneal confocal microscopy parameter: corneal nerve fiber length',\n",
       "      'description': 'The corneal nerve fiber length per frame.',\n",
       "      'timeFrame': 'baseline, 8 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'neurological function scales score: the modified Toronto clinical neuropathy score (mTCNS)',\n",
       "      'description': 'mTCNS is a valid and reliable scale for staging of mild to moderate diabetic sensorimotor\\r\\npolyneuropathy. Value of 3 or more is recommended for the diagnosis of peripheral\\r\\nneuropathy.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: Norfolk Quality of Life Questionnaire - Diabetic Neuropathy (QOL-DN)',\n",
       "      'description': 'A patient-reported outcomes measure reflecting small fiber, physical functioning/large\\r\\nfiber neuropathy, autonomic nerve function, symptoms, and activities of daily living.\\r\\nRanges from -4 to 136, higher score indicates worse QOL.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: Neuropathy Impairment Score (NIS)',\n",
       "      'description': 'Clinician assessments about cranial nerves and limbs for muscle weakness, sensation loss,\\r\\nand decreased reflexes. ranges from 0 to 244. Higher NIS reflect greater neuropathic\\r\\nimpairment.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: Neuropathy Impairment Score of the lower limbs plus seven tests (NIS(LL)+7 tests)',\n",
       "      'description': 'Neuropathy impairment score of the lower limbs plus seven tests includes muscle weakness,\\r\\nsensation loss, and decreased reflexes. Ranges from 0 to 88. More NIS-LL scores indicate\\r\\ngreater neuropathic impairment.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: Polyneuropathy disability (PND) score',\n",
       "      'description': 'Polyneuropathy disability grades of walking. 0-IV grades were measured. More score is\\r\\nmore severe impairment.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: DNS score',\n",
       "      'description': 'Score items are unsteadiness of gait, burning or aching sensation, pricking sensation and\\r\\nnumbness. A score of one or more denotes the presence of neuropathy.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neurological function scales score: NDS score',\n",
       "      'description': 'Evaluation of pinprick sensation, vibration sensation and temperature sensation. A total\\r\\nof 10 points was adopted. A score of 6 - 8 denotes the presence of moderate DPN, and a\\r\\nscore of 9 - 10 denotes severe DPN.',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neuroelectrophysiological parameter: NCV',\n",
       "      'description': 'Nerve conduction latency',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neuroelectrophysiological parameter: NCV',\n",
       "      'description': 'Nerve conduction velocity',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neuroelectrophysiological parameter: NCV',\n",
       "      'description': 'Nerve conduction wave amplitude',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neuroelectrophysiological parameter: SSR',\n",
       "      'description': 'Velocity of sympathetic skin response',\n",
       "      'timeFrame': 'baseline, 8 weeks'},\n",
       "     {'measure': 'neuroelectrophysiological parameter: SSR',\n",
       "      'description': 'Amplitude of sympathetic skin response',\n",
       "      'timeFrame': 'baseline, 8 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Male or female subjects, age 18-70 years.\\r\\n\\r\\n  2. Participants who have been diagnosed with type 1 or type 2 diabetes for at least 1\\r\\n     year.\\r\\n\\r\\n  3. Meet the diagnosis of peripheral neuropathy according to neuroelectrophysiological\\r\\n     examination.\\r\\n\\r\\n  4. According to the researchers' clinical judgment, blood glucose has been optimally\\r\\n     controlled. The blood glucose was kept as stable as possible during the study. HbA1c\\r\\n     level≤9% prior to screening, the variety is at least less than 2% within the\\r\\n     3-months before enrollment.\\r\\n\\r\\n  5. No history of eye trauma or corneal laser treatment.\\r\\n\\r\\n  6. No history of keratopathy or other intraocular ophthalmic disease.\\r\\n\\r\\n  7. No history of wearing contact lenses.\\r\\n\\r\\n  8. Have not taken medicines that affect corneal metabolism.\\r\\n\\r\\n  9. Did not take Mecbl or α-lipoic acid therapy within 3 months before screening.\\r\\n\\r\\n 10. Women of child bearing age (e.g., non-operative birth control or pausimenia less\\r\\n     than 1 year) must be negative in the gonadotropin pregnancy test (urine) screening\\r\\n     and receive effective contraception during treatment.\\r\\n\\r\\n 11. Signs the informed consent.\\r\\n\\r\\n 12. Subjects are willing and able to comply with the study visit schedule, treatment\\r\\n     plan, laboratory tests and other study procedures.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Have been diagnosed with a malignant tumor in the past 2 years.\\r\\n\\r\\n  2. The presence of other neurological disorders that researchers believe perhaps affect\\r\\n     the evaluation of DPN.\\r\\n\\r\\n  3. The presence of skin diseases in the affected skin areas may affect the evaluation\\r\\n     of DPN and injection according to the researcher's judgment.\\r\\n\\r\\n  4. Amputation of the ends of fingers and toes.\\r\\n\\r\\n  5. Participated in any other trials involving a study or post-marketing drug within 30\\r\\n     days of screening.\\r\\n\\r\\n  6. Subjects with clinically significant or unstable diseases, such as but not limited\\r\\n     to acute cardiovascular diseases, cerebrovascular diseases, liver diseases, kidney\\r\\n     diseases, respiratory diseases, blood diseases, immune system diseases, inflammatory\\r\\n     or rheumatic diseases, uncontrolled infections, symptomatic peripheral vascular\\r\\n     diseases, untreated endocrine diseases, etc.\\r\\n\\r\\n  7. Had donated blood within 30 days of the study treatment commencement (if\\r\\n     applicable); or preparative blood donors during the study or 30 days after the end\\r\\n     of treatment.\\r\\n\\r\\n  8. The WBC < 4000 / mm^2, neutrophils count <1500/mm^2, platelet count <100×109 /mm^2.\\r\\n\\r\\n  9. Clinically significant abnormalities in 12-lead ECG.\\r\\n\\r\\n 10. Subjects received combining transcutaneous electrical nerve stimulation (TENS) or\\r\\n     acupuncture.\\r\\n\\r\\n 11. A history of intolerance or allergy to Mecbl or similar chemical compound.\\r\\n\\r\\n 12. Current or history presence of alcohol and/or other substance abuse within the past\\r\\n     1 year.\\r\\n\\r\\n 13. Other severe acute or chronic medical or psychiatric conditions or laboratory\\r\\n     abnormalities that, in the determination of the investigator, may increase the risk\\r\\n     associated with participating in the trial or using Mecbl, or that may affect the\\r\\n     interpretation of the study results, may render the subject unfit to participate in\\r\\n     the trial.\\r\\n\\r\\n 14. Inability and/or unwillingness to understand and/or comply with the plan.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'}],\n",
       "    'ancestors': [{'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7115',\n",
       "      'name': 'Diabetes Mellitus',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'asFound': 'Peripheral Neuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC18',\n",
       "      'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'T451',\n",
       "      'name': 'Methylcobalamin',\n",
       "      'asFound': 'RET Inhibitor',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'Vi', 'name': 'Vitamins'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05918783',\n",
       "    'orgStudyIdInfo': {'id': 'CLIN2201 LCM101'},\n",
       "    'organization': {'fullName': 'Impact Biotech Ltd', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer',\n",
       "    'officialTitle': 'A Multicenter Open-label Phase 1/1b Study to Evaluate Safety, Feasibility and Early Treatment Effect of Padeliporfin VTP Using Robotic Assisted Bronchoscopy and Cone Beam CT Guidance in Patients With Peripheral Lung Cancer'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-06',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-25',\n",
       "    'studyFirstSubmitQcDate': '2023-06-15',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-06-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-04',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-05', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Impact Biotech Ltd', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': True},\n",
       "   'descriptionModule': {'briefSummary': 'Phase 1/1b, safety, feasibility, and light dose titration study followed by further study\\r\\nof therapeutic ablation effects.\\r\\n\\r\\nPatients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom\\r\\nsurgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days\\r\\nfollowing the VTP procedure.\\r\\n\\r\\nStudy intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation:\\r\\nvascular targeted photodynamic therapy using Padeliporfin photosensitizer.',\n",
       "    'detailedDescription': 'A multicenter, open label, phase 1/1b, safety, feasibility, and light dose titration\\r\\nstudy followed by further study of therapeutic ablation effects.\\r\\n\\r\\nPatients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom\\r\\nsurgical treatment is planned, will be recruited. Patients who are candidates for lung\\r\\nresection will be recruited as a diagnose and treat in the same anaesthesia, protocol;\\r\\nsurgery will be performed at least 5 days and up to 21 days following the VTP procedure.\\r\\n\\r\\nStudy intervention will consist of robotic assisted bronchoscopic Padeliporfin VTP lung\\r\\nablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer, an\\r\\nablation mechanism with efficacy related to immune response post-ablation.'},\n",
       "   'conditionsModule': {'conditions': ['Peripheral Lung Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'interventionModelDescription': 'Part B recruitment will be opened upon completion of Part A light dose escalation.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 36, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Part A',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'will be a monotherapy light dose escalation with single dose of Padeliporfin at light\\r\\nlaser doses of 150, 250 and 400 mW/cm for 20 minutes.\\r\\n\\r\\nPart A will proceed with light dose escalation and will continue until the maximum\\r\\ntolerated light dose (MTD) and/or recommended phase 2 dose (RP2D) is defined.',\n",
       "      'interventionNames': ['Combination Product: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy']},\n",
       "     {'label': 'Part B',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'will be a dose expansion part at MTD/RP2D dose level identified in Part A to further\\r\\nassess the safety, tolerability, and treatment effect of the MTD and/ or RP2D',\n",
       "      'interventionNames': ['Combination Product: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy']}],\n",
       "    'interventions': [{'type': 'COMBINATION_PRODUCT',\n",
       "      'name': 'Padeliporfin Vascular Targeted Photodynamic (VTP) therapy',\n",
       "      'description': 'Bronchoscopy will be performed with robotic assisted approach using standard practices\\r\\nusing general anaesthesia and placement of the optic fiber intratumorally followed by IV\\r\\nadministration of Padeliporfin for 10 min and laser light illumination.',\n",
       "      'armGroupLabels': ['Part A', 'Part B'],\n",
       "      'otherNames': ['Padeliporfin VTP']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety of robotic assisted bronchoscopic Padeliporfin VTP ablation',\n",
       "      'description': 'Incidence of treatment-related adverse events as assessed by CTCAE v5.0',\n",
       "      'timeFrame': 'Day 30'},\n",
       "     {'measure': 'Feasibility of robotic assisted bronchoscopic Padeliporfin VTP treatment',\n",
       "      'description': 'Feasibility of robotic bronchoscopic light fiber delivery into the target lesion as\\r\\nconfirmed by cone beam CT and complete VTP treatment',\n",
       "      'timeFrame': 'Day 1'},\n",
       "     {'measure': 'Evaluate Maximum Tolerated light Dose and/or RP2D of Padeliporfin VTP ablation',\n",
       "      'description': 'Evaluate Maximum Tolerated light Dose and/or RP2D of robotic assisted bronchoscopic\\r\\nPadeliporfin VTP ablation (a vascular targeted photodynamic therapy with Padeliporfin of\\r\\npatients with peripheral stage 1A1/1A2) primary non-small cell lung cancers.',\n",
       "      'timeFrame': 'Day 14'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Evaluation lung surgery feasibility',\n",
       "      'description': 'Number and severity of operative, postoperative adverse events Number and length of any\\r\\ndelays to surgery or surgical cancellations Number of completed surgeries',\n",
       "      'timeFrame': 'Day 5-21'},\n",
       "     {'measure': 'Evaluation of the ablation area',\n",
       "      'description': 'Acute radiographic changes on CT chest imaging obtained two days post Padeliporin VTP\\r\\ntreatment',\n",
       "      'timeFrame': '2 days post Padeliprofin VTP'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Age ≥18\\r\\n\\r\\n  2. Patients with primary lung lesions who are at high risk for primary lung cancer.\\r\\n\\r\\n     2.1.Biopsy with intraoperative confirmation of malignancy using on-site cytology\\r\\n     will be used as final inclusion prior to study treatment.\\r\\n\\r\\n  3. All patients will be approved by a multi-disciplinary team (thoracic surgery,\\r\\n     interventional pulmonology, medical oncology and radiation oncology) as appropriate\\r\\n     for bronchoscopic VTP prior to surgical resection.\\r\\n\\r\\n  4. Tumor size targeted for VTP treatment ≤ 2 cm (Part A) and <3cm (Part B), based on CT\\r\\n     scan, including solid or semi-solid tumors.\\r\\n\\r\\n  5. EBUS mediastinal staging performed intraoperative prior to VTP treatment with rapid\\r\\n     on-site evaluation negative for nodal involvement of malignancy.\\r\\n\\r\\n  6. Tumor is ≥ 2cm from the central bronchial tree (distal 2 cm of the trachea, carina,\\r\\n     and named major lobar bronchi up to their first bifurcation) (Timmerman, 2018).\\r\\n\\r\\n  7. Lung lesion is not contiguous with and ≥ 1 cm from the pleura/fissures.\\r\\n\\r\\n  8. Patient is eligible to undergo bronchoscopy under general anesthesia.\\r\\n\\r\\n  9. Tumor is accessible for Padeliporfin VTP treatment via robotic bronchoscopy\\r\\n\\r\\n 10. ECOG performance score 0-2\\r\\n\\r\\n 11. Estimated life expectancy of ≥3 months\\r\\n\\r\\n 12. Adequate organ system function\\r\\n\\r\\n 13. Negative serum pregnancy test\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patient has a centrally located lung lesion, as defined by RTOG within 2 cm of the\\r\\n     proximal bronchial tree, or within 2 cm of other major mediastinal structure (aorta,\\r\\n     heart, trachea, pericardium, superior vena cava, pulmonary artery, esophagus,\\r\\n     vertebra's body or spinal canal).\\r\\n\\r\\n  2. Patient has a lung lesion located less than 1 cm from the pleura or fissure\\r\\n\\r\\n  3. Patient has a lung cancer lesion >2cm in diameter, for the expansion cohort lesion\\r\\n     >2-3 cm\\r\\n\\r\\n  4. Patient has cytologic or histologic evidence of nodal disease\\r\\n\\r\\n  5. Tumor invades major vessels\\r\\n\\r\\n  6. Prior exposure to VTP or PDT treatments\\r\\n\\r\\n  7. Pregnant or breastfeeding women\\r\\n\\r\\n  8. Receiving any other investigational treatment\\r\\n\\r\\n  9. Co-morbidities:\\r\\n\\r\\n       1. Baseline hypoxia with O2 saturation <92% on 2L NC or more of oxygen\\r\\n\\r\\n       2. New York Heart Association (NYHA) stage III/IV heart failure\\r\\n\\r\\n       3. Unstable coronary artery disease or MI within the last 6 months\\r\\n\\r\\n       4. Uncontrollable clinically serious arrhythmia\\r\\n\\r\\n       5. Decompensated/clinically worsening interstitial lung disease or obstructive\\r\\n          lung disease.\\r\\n\\r\\n       6. Unstable cerebrovascular or peripheral vascular disease\\r\\n\\r\\n       7. Inability to stop anticoagulation or anti-platelet therapy peri-procedure\\r\\n\\r\\n       8. Evidence of clinically active infection requiring systemic (any route)\\r\\n          antibiotic therapy. All prior infections must have resolved following optimal\\r\\n          therapy.\\r\\n\\r\\n       9. Patient has any acute or chronic condition assessed as clinically significant\\r\\n          by Investigator which may preclude bronchoscopy procedure\\r\\n\\r\\n      10. History of medical or psychiatric disease which, in the view of the\\r\\n          investigator, would preclude safe treatment or acceptable study compliance\\r\\n\\r\\n      11. Known severe pulmonary hypertension (mean pulmonary arterial pressure ≥ 50\\r\\n          mmHg)\\r\\n\\r\\n 10. Patient has a cancer diagnosis with active disease requiring further cancer therapy.\\r\\n\\r\\n 11. Patient has had major surgery within the last 4 weeks.\\r\\n\\r\\n 12. Patient has porphyria or hypersensitivity to padeliporfin or porphyrin-like\\r\\n     compounds or to any of its excipients.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008175',\n",
       "      'term': 'Lung Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000012142', 'term': 'Respiratory Tract Neoplasms'},\n",
       "     {'id': 'D000013899', 'term': 'Thoracic Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11172',\n",
       "      'name': 'Lung Neoplasms',\n",
       "      'asFound': 'Lung Tumors',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14979',\n",
       "      'name': 'Respiratory Tract Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16658', 'name': 'Thoracic Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06417983',\n",
       "    'orgStudyIdInfo': {'id': 'Onychomycosis Topical'},\n",
       "    'organization': {'fullName': 'Medical Life Care Planners, LLC',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Topical Application of Essential Oils to Treat Onchomycosis',\n",
       "    'officialTitle': 'Use of Topical Essential Oil Compound to Treat Toe Nail Onychomycosis',\n",
       "    'acronym': 'NailFungus'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-11-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-11-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-23',\n",
       "    'studyFirstSubmitQcDate': '2024-05-15',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Gregory L Smith, MD, MPH',\n",
       "     'investigatorTitle': 'Principal Investigaor',\n",
       "     'investigatorAffiliation': 'Medical Life Care Planners, LLC'},\n",
       "    'leadSponsor': {'name': 'Medical Life Care Planners, LLC',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Patients with documented onychomycosis of one or more toe nails will be treated with a\\r\\ndaily application of a topical lacquer containing several essential oils.',\n",
       "    'detailedDescription': 'The topical lacquer contains the following components:\\r\\n\\r\\nActive ingredients:\\r\\n\\r\\nHydroxypropyl Chitosan OLEOZON(r) - natural, ozonized sunflower oil. Vitamin E Tea Tree\\r\\nOil Cannabidiol\\r\\n\\r\\nVehicle:\\r\\n\\r\\nNanoparticle medium chain triglyceride oil'},\n",
       "   'conditionsModule': {'conditions': ['Onychomycosis of Toenail',\n",
       "     'Fungal Infection',\n",
       "     'Toenail Infection']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'CASE_ONLY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Thickness of the Hyponychium Fungal Infection',\n",
       "      'description': 'Objective change in the thickness of the hyponychium of the most infected nailplate. The\\r\\nhyponycium will be measured with a micometer thickness guage in micrometer gradations at\\r\\nbaseline, 2,5,9 and 12 weeks.',\n",
       "      'timeFrame': '12 weeks'},\n",
       "     {'measure': 'Subject Perceived Improvement in overall toenail infection',\n",
       "      'description': \"Subject's personal perception of improvement of all infected toenails using the OnyCOE-t\\r\\nquestionnaire for patient reported outcomes for toenail onychomycosis at baseline, 2,5 ,9\\r\\nand 12 weeks of treatment.\",\n",
       "      'timeFrame': '12 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nClinician observation consistent with probable onychomycosis of one or more toenails.\\r\\n\\r\\nPositive polymerase chain reaction (PCR) for fungal infection or Positive Periodic Acid\\r\\nSchiff, Biopsy, KOH or Culture for fungal infection -\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nUnwlling to discontinue current anti-fungal medication, oral or topical\\r\\n\\r\\n  -',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'All adult patients presenting to a community podiatry clinic who upon examination are\\r\\nnoted to have podiatrist diagnosed onychomycosis of one or more toenails. Not currently\\r\\nusing topical or oral anti-fungal treatment.',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Andronica Handie, DPM',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '9189944000',\n",
       "      'email': 'disabilityevaluators@gmail.com'},\n",
       "     {'name': 'Gregory L Smith',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '4044514045',\n",
       "      'email': 'DrSmith@NeX-Therapeutics.com'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '26481920',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Flores FC, Beck RC, da Silva Cde B. Essential Oils for Treatment for Onychomycosis: A Mini-Review. Mycopathologia. 2016 Feb;181(1-2):9-15. doi: 10.1007/s11046-015-9957-3. Epub 2015 Oct 19.'},\n",
       "     {'pmid': '28040821',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Halteh P, Scher RK, Lipner SR. Over-the-counter and natural remedies for onychomycosis: do they really work? Cutis. 2016 Nov;98(5):E16-E25.'},\n",
       "     {'pmid': '32076805',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Wang Y, Lipner SR. Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration. Arch Dermatol Res. 2020 Oct;312(8):581-586. doi: 10.1007/s00403-020-02044-7. Epub 2020 Feb 19.'},\n",
       "     {'pmid': '33669627',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Abd Rashed A, Rathi DG, Ahmad Nasir NAH, Abd Rahman AZ. Antifungal Properties of Essential Oils and Their Compounds for Application in Skin Fungal Infections: Conventional and Nonconventional Approaches. Molecules. 2021 Feb 19;26(4):1093. doi: 10.3390/molecules26041093.'},\n",
       "     {'pmid': '25547349',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Ghannoum MA, Long L, Isham N, Bulgheroni A, Setaro M, Caserini M, Palmieri R, Mailland F. Ability of hydroxypropyl chitosan nail lacquer to protect against dermatophyte nail infection. Antimicrob Agents Chemother. 2015 Apr;59(4):1844-8. doi: 10.1128/AAC.04842-14. Epub 2014 Dec 29.'},\n",
       "     {'pmid': '33672633',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Feldman M, Sionov RV, Mechoulam R, Steinberg D. Anti-Biofilm Activity of Cannabidiol against Candida albicans. Microorganisms. 2021 Feb 20;9(2):441. doi: 10.3390/microorganisms9020441.'},\n",
       "     {'pmid': '1303075',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Tong MM, Altman PM, Barnetson RS. Tea tree oil in the treatment of tinea pedis. Australas J Dermatol. 1992;33(3):145-9. doi: 10.1111/j.1440-0960.1992.tb00103.x.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "    'timeFrame': '6 months',\n",
       "    'accessCriteria': 'Researcher with clear need to know',\n",
       "    'url': 'http://nex-therapeutics.com'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007239',\n",
       "      'term': 'Infections'},\n",
       "     {'id': 'D000003141', 'term': 'Communicable Diseases'},\n",
       "     {'id': 'D000009181', 'term': 'Mycoses'},\n",
       "     {'id': 'D000014009', 'term': 'Onychomycosis'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000001423', 'term': 'Bacterial Infections and Mycoses'},\n",
       "     {'id': 'D000014005', 'term': 'Tinea'},\n",
       "     {'id': 'D000003881', 'term': 'Dermatomycoses'},\n",
       "     {'id': 'D000012874', 'term': 'Skin Diseases, Infectious'},\n",
       "     {'id': 'D000009260', 'term': 'Nail Diseases'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12136',\n",
       "      'name': 'Mycoses',\n",
       "      'asFound': 'Fungal Infections',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6368',\n",
       "      'name': 'Communicable Diseases',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16766',\n",
       "      'name': 'Onychomycosis',\n",
       "      'asFound': 'Onychomycosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'M4722', 'name': 'Bacterial Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M4721',\n",
       "      'name': 'Bacterial Infections and Mycoses',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16762', 'name': 'Tinea', 'relevance': 'LOW'},\n",
       "     {'id': 'M7076', 'name': 'Dermatomycoses', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15677', 'name': 'Skin Diseases, Infectious', 'relevance': 'LOW'},\n",
       "     {'id': 'M12211', 'name': 'Nail Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT04742439',\n",
       "    'orgStudyIdInfo': {'id': '00104712'},\n",
       "    'secondaryIdInfos': [{'id': 'P2CHD086844',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/P2CHD086844'}],\n",
       "    'organization': {'fullName': 'Medical University of South Carolina',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Individualizing tDCS Dose',\n",
       "    'officialTitle': 'Testing the Effects of Individualized and 4mA tDCS'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-01',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-04-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2021-02-02',\n",
       "    'studyFirstSubmitQcDate': '2021-02-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2021-02-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-01-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-01-26', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Kevin Caulfield',\n",
       "     'investigatorTitle': 'Research Assistant Professor-Faculty',\n",
       "     'investigatorAffiliation': 'Medical University of South Carolina'},\n",
       "    'leadSponsor': {'name': 'Medical University of South Carolina',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Transcranial direct current stimulation (tDCS) is a noninvasive method of modulating\\r\\nbrain activity and has therapeutic potential in many neurological and psychiatric\\r\\nconditions. However, unlike every current FDA-approved form of brain stimulation, there\\r\\nis no method of individualizing stimulation dose. In this study, a method of\\r\\nindividualizing tDCS dose on behavioral outcomes and whether this could help to improve\\r\\nthe consistency and magnitude of the stimulation effects will be tested.'},\n",
       "   'conditionsModule': {'conditions': ['tDCS', 'Motor Function']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'BASIC_SCIENCE',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Sham stimulation',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'interventionNames': ['Device: Sham transcranial direct current stimulation']},\n",
       "     {'label': 'Individualized stimulation',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Device: Individualized transcranial direct current stimulation']},\n",
       "     {'label': '2mA stimulation',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Device: 2mA transcranial direct current stimulation']},\n",
       "     {'label': '4mA stimulation',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Device: 4mA transcranial direct current stimulation']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Sham transcranial direct current stimulation',\n",
       "      'description': 'Participants will receive 30 seconds of ramp up and down stimulation at the start and end\\r\\nof the 20 minute stimulation period.',\n",
       "      'armGroupLabels': ['Sham stimulation']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'Individualized transcranial direct current stimulation',\n",
       "      'description': 'Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at\\r\\nthe individualized dose (maximum of 4mA).',\n",
       "      'armGroupLabels': ['Individualized stimulation']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': '2mA transcranial direct current stimulation',\n",
       "      'description': 'Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at\\r\\na 2mA dose.',\n",
       "      'armGroupLabels': ['2mA stimulation']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': '4mA transcranial direct current stimulation',\n",
       "      'description': 'Participants will receive 20 minutes of transcranial direct current stimulation (tDCS) at\\r\\na 4mA dose.',\n",
       "      'armGroupLabels': ['4mA stimulation']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Motor Evoked Potential Variance',\n",
       "      'description': 'MEP variance is measured by single pulses of transcranial magnetic stimulation and\\r\\ncontralateral hand electrodes.',\n",
       "      'timeFrame': 'Baseline and post-stimulation (20 minutes apart)'},\n",
       "     {'measure': 'Difference in Motor Evoked Potential Amplitudes from 4mA and 2mA Stimulation',\n",
       "      'description': 'MEP amplitude is measured by single pulses of transcranial magnetic stimulation and\\r\\ncontralateral hand electrodes.',\n",
       "      'timeFrame': 'Baseline and post-stimulation (20 minutes apart)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Healthy volunteers or chronic stroke participants (at least 6 months prior to the\\r\\n     study)\\r\\n\\r\\n  -  No history of epilepsy\\r\\n\\r\\n  -  No metal in the body\\r\\n\\r\\n  -  No contraindications for TMS or MRI scanning\\r\\n\\r\\n  -  Right handed\\r\\n\\r\\n  -  Ability to find motor hotspot and acquire motor evoked potentials\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Metal in the body\\r\\n\\r\\n  -  History of epilepsy or claustrophobia\\r\\n\\r\\n  -  Alcohol or substance abuse or dependence\\r\\n\\r\\n  -  Current treatment for any psychiatric conditions (pharmacological or otherwise)\\r\\n\\r\\n  -  Pregnant or actively breastfeeding',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mark S George',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '8437929888',\n",
       "      'email': 'georgem@musc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Mark S George, MD',\n",
       "      'affiliation': 'Medical University of South Carolina',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Medical University of South Carolina',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Charleston',\n",
       "      'state': 'South Carolina',\n",
       "      'zip': '29425',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kevin A Caulfield',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'caulfiel@musc.edu'}],\n",
       "      'geoPoint': {'lat': 32.77657, 'lon': -79.93092}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'ICF',\n",
       "      'hasProtocol': False,\n",
       "      'hasSap': False,\n",
       "      'hasIcf': True,\n",
       "      'label': 'Informed Consent Form',\n",
       "      'date': '2023-01-19',\n",
       "      'uploadDate': '2023-12-15T13:46',\n",
       "      'filename': 'ICF_000.pdf',\n",
       "      'size': 3039174}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05826015',\n",
       "    'orgStudyIdInfo': {'id': '202306082'},\n",
       "    'organization': {'fullName': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer',\n",
       "    'officialTitle': 'Phase I/IB of AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-01-03', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2034-01-04', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-11',\n",
       "    'studyFirstSubmitQcDate': '2023-04-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-04-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-15',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Washington University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Cancer Institute (NCI)',\n",
       "      'class': 'NIH'},\n",
       "     {'name': 'Aravive, Inc.', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to determine safety and tolerability of AVB-500 when given\\r\\nin combination with paclitaxel in patients with recurrent high-grade uterine cancer.'},\n",
       "   'conditionsModule': {'conditions': ['Recurrent High Grade Uterine Cancer'],\n",
       "    'keywords': ['Batiraxcept',\n",
       "     'AVB-500',\n",
       "     'uterine serous',\n",
       "     'high-grade endometrioid',\n",
       "     'paclitaxel']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 36, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Paclitaxel + AVB-500',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients will receive up to 9 21-day cycles of paclitaxel + AVB-500. Patients will\\r\\nreceive AVB-500 via intravenous (IV) infusion at the assigned dose level on days 1, 8,\\r\\nand 15 of each cycle. Patients will receive IV paclitaxel at a dose of 175 mg/m^2 on day\\r\\n1 of each cycle. After 3 cycles, patients will be assessed for disease response. Patients\\r\\nwho have progression will not continue on treatment. Patients who have a partial response\\r\\nor stable disease will continue on treatment for another 3 cycles of paclitaxel + AVB-500\\r\\nat the assigned dose. Patients will be assessed for response again at the end of 6 cycles\\r\\nand may continue on treatment if they have partial response (PR) or stable disease (SD).\\r\\nUp to 9 cycles of treatment with paclitaxel + AVB-500 may be given. At the end of the 9\\r\\ncycles, patients with a SD or PR can continue on maintenance AVB-500 until progression.\\r\\nPatients with complete response will continue single agent AVB-500 as maintenance therapy\\r\\nuntil progression.',\n",
       "      'interventionNames': ['Drug: Paclitaxel', 'Drug: Batiraxcept']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Paclitaxel',\n",
       "      'description': 'IV over 3 hours',\n",
       "      'armGroupLabels': ['Paclitaxel + AVB-500'],\n",
       "      'otherNames': ['Taxol']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Batiraxcept',\n",
       "      'description': 'IV over 60 minutes',\n",
       "      'armGroupLabels': ['Paclitaxel + AVB-500'],\n",
       "      'otherNames': ['AVB-500']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Frequency and severity of treatment-emergent adverse events',\n",
       "      'description': '-Graded by CTCAE v.5.',\n",
       "      'timeFrame': 'From start of treatment though 30 days after the last dose of AVB-500 (estimated to be 31 weeks)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Serum sAXL and GAS6 ratio',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Pharmacokinetic (PK) parameters (including Cmax) as determined from AVB-500 serum levels',\n",
       "      'timeFrame': 'Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days)'},\n",
       "     {'measure': 'Pharmacokinetic (PK) parameters (including Tmax) as determined from AVB-500 serum levels',\n",
       "      'timeFrame': 'Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days)'},\n",
       "     {'measure': 'Pharmacodynamic effects as determined by changes from baseline in serum GAS6 levels',\n",
       "      'timeFrame': 'Cycle 1 Day 1 pre-infusion, Cycle 1 Day 1 post-infusion, Cycle 1 Day 15 pre-infusion, and subsequent cycles day 1 pre-infusions (each cycle is 21 days)'},\n",
       "     {'measure': 'Overall response rate (ORR)',\n",
       "      'description': '-Defined as the proportion of subjects who have a partial or complete response to therapy',\n",
       "      'timeFrame': 'Through completion of treatment (estimated to be 27 weeks)'},\n",
       "     {'measure': 'Progression-free survival (PFS)',\n",
       "      'description': '-Defined as the time from start of treatment to the first radiologically documented\\r\\ndisease progression, or death, whichever comes first. The alive patients without\\r\\nradiologically documented disease progression are censored at the last follow-up.',\n",
       "      'timeFrame': 'Through completion of follow-up (estimated to be 5 years and 27 weeks)'},\n",
       "     {'measure': 'Recommended Phase 2 dose (RP2D) of AVB-500 in combination with paclitaxel',\n",
       "      'timeFrame': 'Through completion of cycle 1 (cycle=21 days) for all patients (estimated to be 48 months and 3 weeks)'},\n",
       "     {'measure': 'Incidence of anti-drug antibodies (ADA)',\n",
       "      'timeFrame': 'Day 1 of each cycle (cycle-21 days) and end of treatment (estimated to be 27 weeks)'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': '-Defined as the time from start of treatment to death. The alive patients are censored at\\r\\nthe last follow-up.',\n",
       "      'timeFrame': 'Through completion of follow-up (estimated to be 5 years and 27 weeks)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Diagnosis of recurrent, FIGO grade 3 endometrioid, serous, or mixed high grade\\r\\n     uterine or endometrial cancer. Patients must have experienced either prior\\r\\n     progression on a platinum-based therapy or intolerance to platinum. Patients with\\r\\n     dMMR or MSI-H tumors or targetable HER2 alterations are required to have received\\r\\n     prior therapy with appropriate targeted agents.\\r\\n\\r\\n  -  Patients must have disease that cannot be managed by local therapy.\\r\\n\\r\\n  -  Measurable disease by RECIST 1.1\\r\\n\\r\\n  -  Women or transgender men with a uterus who are at least 18 years of age.\\r\\n\\r\\n  -  ECOG performance status ≤ 2\\r\\n\\r\\n  -  Normal bone marrow and organ function as defined below:\\r\\n\\r\\n       -  Absolute neutrophil count ≥ 1.5 K/cumm\\r\\n\\r\\n       -  Platelets ≥ 100 K/cumm\\r\\n\\r\\n       -  Hemoglobin ≥ 9.0 g/dL\\r\\n\\r\\n       -  Total bilirubin ≤ 1.5 x IULN\\r\\n\\r\\n       -  AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN (unless liver metastases are present in which\\r\\n          case AST/ALT must be ≤ 5.0 x IULN)\\r\\n\\r\\n       -  Serum creatinine < 2.0 mg/dL or < 177 µmol/L OR calculated or measured\\r\\n          creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault equation)\\r\\n\\r\\n       -  INR ≤ 1.5 x IULN\\r\\n\\r\\n       -  aPTT ≤ 1.5 x IULN\\r\\n\\r\\n  -  The effects of AVB-500 on the developing human fetus are unknown. For this reason\\r\\n     and because chemotherapeutic agents are known to be teratogenic, patients of\\r\\n     childbearing potential must agree to use adequate contraception (hormonal or barrier\\r\\n     method of birth control, abstinence) prior to study entry and for the duration of\\r\\n     study participation. Should a patient become pregnant or suspect pregnancy while\\r\\n     participating in this study, the treating physician must be informed immediately.\\r\\n\\r\\n  -  Subjects who have received prior treatment with trastuzumab, pembrolizumab, or\\r\\n     dostarlimab can enroll in the study.\\r\\n\\r\\n  -  Ability to understand and willingness to sign an IRB approved written informed\\r\\n     consent document (or that of legally authorized representative, if applicable).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any prior treatment with AVB-500\\r\\n\\r\\n  -  A history of other malignancy with the exception of malignancies for which all\\r\\n     treatment was completed at least 2 years before registration and the patient has no\\r\\n     evidence of disease.\\r\\n\\r\\n  -  Currently receiving any other (non-study) cytotoxic chemotherapy, radiation,\\r\\n     targeted treatment, or immunotherapy within 4 weeks prior of start of study\\r\\n     treatment.\\r\\n\\r\\n  -  Currently receiving any other investigational agents or has received an\\r\\n     investigational agent within 4 weeks of start of study treatment.\\r\\n\\r\\n  -  Known brain metastases. Patients with known brain metastases must be excluded from\\r\\n     this clinical trial because of their poor prognosis and because they often develop\\r\\n     progressive neurologic dysfunction that would confound the evaluation of neurologic\\r\\n     and other adverse events.\\r\\n\\r\\n  -  A history of allergic reactions attributed to compounds of similar chemical or\\r\\n     biologic composition to AVB-500 or other agents used in the study.\\r\\n\\r\\n  -  Abnormal gastrointestinal function, defined as Grade >2 diarrhea, constipation,\\r\\n     nausea, vomiting, or abdominal pain. This includes GI obstruction or bleeding or\\r\\n     signs/symptoms thereof within 3 months of study enrollment. Patients with a history\\r\\n     of abdominal fistula will be considered eligible if the fistula was surgically\\r\\n     repaired or has healed, there has been no evidence of fistula for at least 6 months,\\r\\n     and patient is deemed to be at low risk of recurrent fistula.\\r\\n\\r\\n  -  Significant cardiac disease history including:\\r\\n\\r\\n       -  Clinically significant atrial or ventricular arrhythmias requiring treatment\\r\\n\\r\\n       -  Medically controlled congestive heart failure\\r\\n\\r\\n       -  Significant angina or clinically and/or electrocardiographically documented\\r\\n          myocardial infarction within the past year\\r\\n\\r\\n       -  Clinically significant valvular disease\\r\\n\\r\\n  -  Non-healing wound, ulcer, or bone fracture.\\r\\n\\r\\n  -  Known active hepatitis; ongoing systemic bacterial, fungal, or viral infection.\\r\\n\\r\\n  -  History or evidence upon physical examination of CNS disease, including primary\\r\\n     brain tumor, seizures not controlled with standard medical therapy, or history of\\r\\n     CVA, TIA, or subarachnoid hemorrhage within 6 months of the first date of treatment\\r\\n     on this study.\\r\\n\\r\\n  -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\\r\\n     infection, symptomatic congestive heart failure, unstable angina pectoris, or\\r\\n     cardiac arrhythmia.\\r\\n\\r\\n  -  History of major surgical procedure within 14 days prior to start of study\\r\\n     treatment.\\r\\n\\r\\n  -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative\\r\\n     pregnancy test within 14 days of study entry.\\r\\n\\r\\n  -  Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL\\r\\n     or they have a history of AIDS-defining opportunistic infection within the 12 months\\r\\n     prior to registration. Concurrent treatment with effective ART according to DHHS\\r\\n     treatment guidelines is recommended. Recommend exclusion of specific ART agents\\r\\n     based on predicted drug-drug interactions (i.e. for sensitive CYP3A4 substrates,\\r\\n     concurrent strong CYP3A4 inhibitors (ritonavir and cobicistat) or inducers\\r\\n     (efavirenz) should be contraindicated).',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'David G Mutch, M.D.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '314-362-3181',\n",
       "      'email': 'mutchd@wustl.edu'}],\n",
       "    'overallOfficials': [{'name': 'David G Mutch, M.D.',\n",
       "      'affiliation': 'Washington University School of Medicine',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of California, San Francisco',\n",
       "      'city': 'San Francisco',\n",
       "      'state': 'California',\n",
       "      'zip': '94143',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Katherine Fuh, M.D., Ph.D.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '415-885-5761'},\n",
       "       {'name': 'Katherine Fuh, M.D., Ph.D.',\n",
       "        'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 37.77493, 'lon': -122.41942}},\n",
       "     {'facility': 'Washington University School of Medicine',\n",
       "      'city': 'Saint Louis',\n",
       "      'state': 'Missouri',\n",
       "      'zip': '63110',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'David G Mutch, M.D.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '314-362-3181',\n",
       "        'email': 'mutchd@wustl.edu'},\n",
       "       {'name': 'David G Mutch, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Andrea R Hagemann, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Ian Hagemann, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Lindsay Kuroki, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'L. Stewart Massad, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Carolyn McCourt, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Dineo Khabele, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Matthew A Powell, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Premal Thaker, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Maggie Mullen, M.D.', 'role': 'SUB_INVESTIGATOR'},\n",
       "       {'name': 'Esther Lu, Ph.D.', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.62727, 'lon': -90.19789}},\n",
       "     {'facility': 'University of New Mexico',\n",
       "      'city': 'Albuquerque',\n",
       "      'state': 'New Mexico',\n",
       "      'zip': '87106',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Carolyn Muller, M.D.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '505-272-2111'},\n",
       "       {'name': 'Carolyn Muller, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 35.08449, 'lon': -106.65114}},\n",
       "     {'facility': 'University of Oklahoma',\n",
       "      'city': 'Oklahoma City',\n",
       "      'state': 'Oklahoma',\n",
       "      'zip': '73104',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kathleen Moore, M.D.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '405-271-8707'},\n",
       "       {'name': 'Kathleen Moore, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School\\r\\nof Medicine',\n",
       "      'url': 'http://www.siteman.wustl.edu'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000014594',\n",
       "      'term': 'Uterine Neoplasms'},\n",
       "     {'id': 'D000012008', 'term': 'Recurrence'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000005833', 'term': 'Genital Neoplasms, Female'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000014591', 'term': 'Uterine Diseases'},\n",
       "     {'id': 'D000005831', 'term': 'Genital Diseases, Female'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14850',\n",
       "      'name': 'Recurrence',\n",
       "      'asFound': 'Recurrent',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17342',\n",
       "      'name': 'Uterine Neoplasms',\n",
       "      'asFound': 'Uterine Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'M8945', 'name': 'Genital Neoplasms, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17339', 'name': 'Uterine Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000017239',\n",
       "      'term': 'Paclitaxel'}],\n",
       "    'ancestors': [{'id': 'D000000972',\n",
       "      'term': 'Antineoplastic Agents, Phytogenic'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000050257', 'term': 'Tubulin Modulators'},\n",
       "     {'id': 'D000050256', 'term': 'Antimitotic Agents'},\n",
       "     {'id': 'D000050258', 'term': 'Mitosis Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M19537',\n",
       "      'name': 'Paclitaxel',\n",
       "      'asFound': 'Surgery',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M231', 'name': 'Albumin-Bound Paclitaxel', 'relevance': 'LOW'},\n",
       "     {'id': 'M26197', 'name': 'Tubulin Modulators', 'relevance': 'LOW'},\n",
       "     {'id': 'M26196', 'name': 'Antimitotic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06433115',\n",
       "    'orgStudyIdInfo': {'id': '2097458'},\n",
       "    'secondaryIdInfos': [{'id': '2097458',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'University of Missouri'}],\n",
       "    'organization': {'fullName': 'University of Missouri-Columbia',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effects of Lean Beef Consumption on Cardiometabolic Health and Gut Microbiome',\n",
       "    'officialTitle': 'Effects of Lean Beef Consumption on Cardiometabolic Health and Gut Microbiome'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-29',\n",
       "    'studyFirstSubmitQcDate': '2024-05-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Jaapna Dhillon',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'University of Missouri-Columbia'},\n",
       "    'leadSponsor': {'name': 'University of Missouri-Columbia',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is investigating the benefits of lean beef consumption on cardiometabolic\\r\\nhealth and gut microbiome.',\n",
       "    'detailedDescription': 'The study is a 6-wk randomized, controlled, and parallel arm clinical trial. Participants\\r\\nwill be randomized to consume either lean grain-fed beef, lean grass-fed beef, or\\r\\nplant-based meat for 6 weeks. Outcomes assessed will include metabolic, inflammatory, and\\r\\ngut microbiome markers.'},\n",
       "   'conditionsModule': {'conditions': ['Diet Intervention']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel Assignment',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Single Blind',\n",
       "      'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Lean (93%) Grass-Fed Beef',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The quantity of beef will be adjusted or normalized based on their individual energy\\r\\nrequirements. The specified amount will be 4 oz. per day or 28 ounces per week for\\r\\nparticipants with an energy requirement of 2000 kcal. Participants will consume meals for\\r\\nsix weeks.',\n",
       "      'interventionNames': ['Other: Lean (93%) Grass-Fed Beef']},\n",
       "     {'label': 'Lean (93%) Grain-Fed Beef',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The quantity of beef will be adjusted or normalized based on their individual energy\\r\\nrequirements. The specified amount will be 4 oz. per day or 28 ounces per week for\\r\\nparticipants with an energy requirement of 2000 kcal. Participants will consume meals for\\r\\nsix weeks.',\n",
       "      'interventionNames': ['Other: Lean (93%) Grain-Fed Beef']},\n",
       "     {'label': 'Plant-Based Meat',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Plant-based meat (beyond meat product) would be macronutrient matched to the same\\r\\nquantities of meat prescribed for a given energy level. Participants will consume meals\\r\\nfor six weeks.',\n",
       "      'interventionNames': ['Other: Plant-Based Meat']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Lean (93%) Grass-Fed Beef',\n",
       "      'description': 'The specified amount will be 4 oz. per day or 28 ounces per week for participants with an\\r\\nenergy requirement of 2000 kcal.',\n",
       "      'armGroupLabels': ['Lean (93%) Grass-Fed Beef']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Lean (93%) Grain-Fed Beef',\n",
       "      'description': 'The specified amount will be 4 oz. per day or 28 ounces per week for participants with an\\r\\nenergy requirement of 2000 kcal.',\n",
       "      'armGroupLabels': ['Lean (93%) Grain-Fed Beef']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Plant-Based Meat',\n",
       "      'description': 'Plant-based meat would be macronutrient matched to the same quantities of meat prescribed\\r\\nfor a given energy level.',\n",
       "      'armGroupLabels': ['Plant-Based Meat']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'LDL-C concentrations',\n",
       "      'description': 'Lipid profile',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Interleukin-6 concentrations',\n",
       "      'description': 'Inflammatory marker',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Gut microbial alpha-diversity',\n",
       "      'description': 'Assessed via16S rRNA sequencing',\n",
       "      'timeFrame': 'Baseline, week 6'}],\n",
       "    'secondaryOutcomes': [{'measure': 'HDL-C concentrations',\n",
       "      'description': 'Lipid profile',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Total cholesterol concentrations',\n",
       "      'description': 'Lipid profile',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Triglyceride concentrations',\n",
       "      'description': 'Lipid profile',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Gut microbiome abundance',\n",
       "      'description': '16S rRNA sequencing',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'LPS-binding protein concentration',\n",
       "      'description': 'Intestinal permeability marker',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Glucose concentrations',\n",
       "      'description': 'Blood Glucose',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Insulin concentrations',\n",
       "      'description': 'Insulin',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Body mass',\n",
       "      'description': 'Measured in kg',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': 'Fat mass',\n",
       "      'description': 'Fat mass',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': 'Fat-free mass',\n",
       "      'description': 'Fat-free mass',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': 'Waist circumference',\n",
       "      'description': 'Waist circumference',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': 'Hip circumference',\n",
       "      'description': 'Hip Circumference',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': 'Thigh circumference',\n",
       "      'description': 'Thigh Circumference',\n",
       "      'timeFrame': 'Baseline, week 3, and week 6'},\n",
       "     {'measure': '24 hour appetite ratings',\n",
       "      'description': '24-hour appetite ratings assessed on VAS',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Physical activity scores',\n",
       "      'description': 'Activity assessment using Actigraphs',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Total hours of sleep',\n",
       "      'description': 'Sleep diary',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Palatability rating of foods',\n",
       "      'description': 'Hedonic general labelled magnitude scale (gLMS)',\n",
       "      'timeFrame': 'Baseline, week 3, week 6'},\n",
       "     {'measure': 'Acceptance rating of foods',\n",
       "      'description': '9-point food action rating scale',\n",
       "      'timeFrame': 'Baseline, week 3, week 6'},\n",
       "     {'measure': 'Taste and flavor intensity ratings of foods',\n",
       "      'description': 'Sensory intensity scales',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Gene expression levels',\n",
       "      'description': 'Transcriptomics analyses',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Inflammatory marker concentrations',\n",
       "      'description': 'Inflammatory markers',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Healthy eating index score',\n",
       "      'description': 'NCI diet history questionnaire',\n",
       "      'timeFrame': 'Baseline, week 6'}],\n",
       "    'otherOutcomes': [{'measure': 'Metabolite intensities',\n",
       "      'description': 'Untargeted and targeted metabolomics',\n",
       "      'timeFrame': 'Baseline, week 6'},\n",
       "     {'measure': 'Nutrient intakes',\n",
       "      'description': '24 hours dietary recall',\n",
       "      'timeFrame': 'Baseline, week 3, week 6'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age: 18-45 years of age\\r\\n\\r\\n  -  BMI: 18-35 kg/m2\\r\\n\\r\\n  -  Willingness to consume study foods.\\r\\n\\r\\n  -  Willing to comply with study protocol.\\r\\n\\r\\n  -  Consistent diet and activity patterns for 4 weeks\\r\\n\\r\\n  -  Weight stable (≤5 kg change over the last 3 months)\\r\\n\\r\\n  -  Non-smoker >1 year or more\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Allergies to foods provided in the study\\r\\n\\r\\n  -  Diabetes\\r\\n\\r\\n  -  Gastrointestinal disease and/or bariatric surgery\\r\\n\\r\\n  -  Uncontrolled hypertension and blood pressure ≥ 180/110\\r\\n\\r\\n  -  Illicit drug use\\r\\n\\r\\n  -  Recent consumption of antibiotics\\r\\n\\r\\n  -  Recent start of medications that affect metabolism or appetite.\\r\\n\\r\\n  -  Drug therapy for coronary artery disease, peripheral artery disease, congestive\\r\\n     heart failure, or dyslipidemia\\r\\n\\r\\n  -  Pregnant or lactating individuals\\r\\n\\r\\n  -  Taste or smell disorders',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jaapna Dhillon',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '573-884-2103',\n",
       "      'email': 'jdhillon@missouri.edu'}],\n",
       "    'overallOfficials': [{'name': 'Jaapna Dhillon, PhD',\n",
       "      'affiliation': 'University of Missouri-Columbia',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Missouri-Columbia',\n",
       "      'city': 'Columbia',\n",
       "      'state': 'Missouri',\n",
       "      'zip': '65211',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Jaapna Dhillon',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '573-884-2103',\n",
       "        'email': 'jdhillon@missouri.edu'},\n",
       "       {'name': 'Jaapna Dhillon, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 38.95171, 'lon': -92.33407}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Individual participant data that underlie the results reported here after\\r\\ndeidentification (ie; text, tables, figures, and appendices)',\n",
       "    'infoTypes': ['STUDY_PROTOCOL'],\n",
       "    'timeFrame': 'Immediately following publication. No end date.',\n",
       "    'accessCriteria': 'Data will be deposited in online repositories'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06400017',\n",
       "    'orgStudyIdInfo': {'id': 'JQ23038-2'},\n",
       "    'organization': {'fullName': 'Beijing Tiantan Hospital', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Mechanism and Application of DBS in the Treatment of PD',\n",
       "    'officialTitle': \"Mechanism and Application of Deep Brain Stimulation in the Treatment of Parkinson's Disease\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-11',\n",
       "    'studyFirstSubmitQcDate': '2024-05-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-06', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Beijing Tiantan Hospital', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Tsinghua University', 'class': 'OTHER'},\n",
       "     {'name': \"Boston Children's Hospital\", 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Project name: The mechanism and application of deep brain stimulation in the treatment of\\r\\nParkinson's disease\\r\\n\\r\\nObjective:\\r\\n\\r\\nTo test the hypothesis that electrical stimulation of substantia nigra regulates\\r\\ncognitive dysfunction in Parkinson's disease and to reveal its electrophysiological\\r\\nmechanism.\\r\\n\\r\\nStudy design:\\r\\n\\r\\nThis study is a self-controlled prospective cohort study. By comparing the behavioral\\r\\ncharacteristics of the memory paradigm under microelectrode stimulation during DBS\\r\\noperation and the characteristics of the underlying electrophysiological signals, and the\\r\\nbehavioral characteristics of the memory paradigm and the characteristics of brain\\r\\nnetwork activity under electrical stimulation when DBS is turned on 1 month after\\r\\nsurgery. The regulatory effect of substantia nigra DBS on memory network was analyzed.\\r\\n\\r\\nCases: 60\\r\\n\\r\\nCase selection:\\r\\n\\r\\nInclusion criteria:\\r\\n\\r\\n1)Voluntarily participate in the clinical study and sign the informed consent; 2) Age\\r\\n50-70 years old, gender unlimited; 3) The clinical diagnosis is consistent with typical\\r\\nPD, and the medical history is less than 20 years; 4) Patients who intend to use 3.0T\\r\\nmagnetic resonance compatible dual-channel DBS device (G106R or G106RS, Beijing Pinchi\\r\\nCompany) for bilateral subthalamic nucleus DBS surgery to control PD symptoms; 5) MRI\\r\\nexcluded patients with obvious structural changes; 6) The visual acuity and hearing of\\r\\nthe subjects were basically normal, and the compliance was good, and they could complete\\r\\nthe tasks listed in the experimental scheme in accordance with the standards.\\r\\n\\r\\nExclusion criteria:\\r\\n\\r\\n1)Serious mental, cognitive and psychological disorders, unable to sign informed consent\\r\\nor cooperate with the operation and various tasks; 2) There are contraindications for\\r\\nneurosurgery, such as hydrocephalus, cerebral atrophy, cerebrovascular sequelae, heart\\r\\ndisease and other cardiovascular and cerebrovascular diseases; 3) There are concomitant\\r\\ndiseases that seriously affect health, such as tumors, serious abnormalities of liver and\\r\\nkidney function (indexes more than 3 times normal); 4) There is intracranial space\\r\\noccupation, cerebrovascular disease, mental illness, other neurological diseases,\\r\\nclaustrophobia, or there is an implant in the body, which affects the nuclear magnetic\\r\\nscan; 5) The results of the Mini-Mental State Scale (MMSE) <24 or the Montreal Cognitive\\r\\nAssessment Scale (MoCA) <18 in the preoperative assessment, or the results of other\\r\\nscales indicate the presence of severe dementia.\\r\\n\\r\\ntherapeutic schedule： This study did not change the patient's overall treatment regimen,\\r\\nand only electrical stimulation was tested during and 1 month after DBS surgery\\r\\n\\r\\nEfficacy evaluation:\\r\\n\\r\\nEffectiveness evaluation index (primary efficacy index and secondary efficacy index) :\\r\\naccuracy of memory paradigm, response speed Safety evaluation indicators: blood pressure,\\r\\nheart rate, dual frequency index, patient complaints and symptoms\\r\\n\\r\\nStatistical methods:\\r\\n\\r\\nThe group t test was used to compare the normal distribution between the measurement data\\r\\ngroups. For measurement data with non-normal distribution, Wilcoxon rank sum test was\\r\\nused for comparison between groups.\\r\\n\\r\\nThe study period is January 1, 2024 - December 31, 2026.\",\n",
       "    'detailedDescription': 'Research background The core symptoms of Parkinson\\'s disease (PD) include motor symptoms\\r\\nand non-motor symptoms, among which cognitive dysfunction is the most common and one of\\r\\nthe most overlooked non-motor symptoms in patients with advanced PD. Cross-sectional\\r\\nstudies have shown that up to 40% of PD patients are combined with cognitive dysfunction\\r\\nat the time of diagnosis, which is manifested by functional decline in memory, executive,\\r\\nattention, language, visuospatial ability and other cognitive subfields. Among them, the\\r\\nmemory impairment subtype with episodic memory function decline as the main manifestation\\r\\nis the most common and the fastest progressing. About 10% to 15% of patients with these\\r\\nmanifestations will progress to dementia each year, which is four to six times higher\\r\\nthan the age-matched non-PD population, and more than 80% of patients with PD will\\r\\ndevelop dementia within 10 years of diagnosis of PD. This increasing cognitive and memory\\r\\ndysfunction seriously affects the quality of life of patients and the overall treatment\\r\\neffect, often leading to accelerated deterioration of the disease, bringing a heavy\\r\\nburden to the family and society. It can be seen that in-depth exploration of the\\r\\nformation mechanism of PD cognitive and memory dysfunction and the establishment of\\r\\neffective intervention means have become an important proposition to be solved urgently\\r\\nin the field of PD research.\\r\\n\\r\\nThe applicant\\'s previous study found that deep brain stimulation (DBS) is an effective\\r\\nmeans to treat Parkinson\\'s disease, and low frequency electrical stimulation of the\\r\\nsubstantia nigra can improve episodic memory function in patients with Parkinson\\'s\\r\\ndisease. Therefore, the applicant team intends to further study the regulatory effect and\\r\\nmechanism of substantia nigra electrical stimulation on episodic memory, reveal the\\r\\nmechanism of its improvement of cognitive function from the theoretical level, clarify\\r\\nits regulatory effect on cognitive impairment from the technical level, and verify the\\r\\npotential of its treatment of cognitive impairment from the application level, so as to\\r\\nsolve the major clinical needs in the diagnosis and treatment of PD cognitive impairment.\\r\\nBring the Gospel to 5 million PD patients, and help the construction of Beijing\\r\\nInternational Science and Technology Innovation Center.\\r\\n\\r\\nResearch purpose\\r\\n\\r\\n  1. Main Objective: To verify the hypothesis that electrical stimulation of substantia\\r\\n     nigra can regulate cognitive dysfunction in Parkinson\\'s disease, and to reveal its\\r\\n     electrophysiological mechanism.\\r\\n\\r\\n  2. Secondary objective: To explore the safety and side effects of electrical\\r\\n     stimulation of substantia nigra in regulating cognitive dysfunction.\\r\\n\\r\\nResearch design types, principles and test steps\\r\\n\\r\\n  1. Research design This was a self-controlled prospective cohort study.\\r\\n\\r\\n  2. Sample size and research plan In this study, 60 patients with Parkinson\\'s disease\\r\\n     who met the inclusion and exclusion criteria were selected to undergo MRI compatible\\r\\n     DBS device implantation. By comparing the behavioral characteristics of the memory\\r\\n     paradigm under microelectrode stimulation during DBS operation and the\\r\\n     characteristics of the electrophysiological signals behind it, The behavioral\\r\\n     characteristics of memory paradigm and brain network activity during electrical\\r\\n     stimulation of DBS at 1 month after operation were analyzed, and the regulatory\\r\\n     effect of substantia nigra DBS on memory network was analyzed.\\r\\n\\r\\n  3. Study duration January 1, 2024 - December 31, 2026\\r\\n\\r\\n  4. Use DBS equipment and program control 1) DBS equipment manufacturers DBS equipment:\\r\\n     dual-channel rechargeable Deep brain stimulation pulse generation System (G106R)\\r\\n     compatible with 3.0T magnetic resonance scanning, produced by Beijing Pinchi Medical\\r\\n     Equipment Co., LTD.\\r\\n\\r\\n  2) Parameter setting Contact selection: According to the electrode position in the\\r\\n     image (target reconstruction through CT scan), the electrode located in the\\r\\n     substantia nigra is selected as the negative electrode, the contact near the upper\\r\\n     part of the substantia nigra is selected as the positive electrode, and the bipolar\\r\\n     stimulation mode is selected.\\r\\n\\r\\nStimulation parameters: The frequency was selected as 5/10/20/60/130/150Hz, the pulse\\r\\nwidth remained unchanged at 90μs, the side effects of patients were observed, and the\\r\\nvoltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious\\r\\nstimulation.\\r\\n\\r\\nSide effects: paresthesia, local pain, palpitation, chest tightness, etc. 5. Memory\\r\\nparadigm The episodic memory task paradigm used in this study was designed with the\\r\\nPsychtoolbox (v3.0 version) based on MATLAB2018b(MathWorks, USA). During the operation,\\r\\nthe episodic memory paradigm test was conducted 2-3 times for each subject according to\\r\\nthe situation, and the total duration of the test was no more than 30 minutes for each\\r\\nsubject, or it was stopped at any time according to the subject\\'s will. The paradigm is\\r\\ndivided into two phases, in the memory coding phase, 20 silent episodic memory clips\\r\\n(each about 6 seconds long, including 10 consecutive event clips and 10 jump event clips)\\r\\nare presented in pseudo-random order. Before each video was played, a cross mark (0.5s -\\r\\n1.5s) would appear in the center of the screen to remind subjects to look at the center\\r\\nof the screen and reduce eye movement. After each video was played, in order to ensure\\r\\nparticipants\\' participation in the passive viewing process, participants were asked to\\r\\nanswer questions related to the video (such as determining whether most scenes of the\\r\\nvideo took place \"indoors\" or \"outdoors\"). After the participants memorized and encoded\\r\\n20 short films, they entered the scene recognition stage. At the beginning of the task, a\\r\\ncross mark (0.25s-0.75s) appeared in the center of the screen to remind subjects to pay\\r\\nattention to the task, and then scene pictures were displayed (pictures were from 20\\r\\nfilms played or not played in the memory coding stage). Subjects were asked to judge\\r\\nwhether the scene shown was a selection of short films played in the free memory coding\\r\\nstage. The whole experiment process, the subjects used reactor (RB - 840) answer keys,\\r\\nand the stimulus (video and pictures), and subjects button at the end of your answer by\\r\\ntask related electrical synchronizer C - Pod (Cedrus, Us) sends pulses from the\\r\\nexperimental computer to Neuro Omega to form time stamps (TTL pulses). Time permitting,\\r\\nthe memory encoding and scene recognition phase will be repeated 3-4 times (keeping the\\r\\nsame experimental format but replacing it with different experimental clips and test\\r\\npictures).\\r\\n\\r\\nResearch methods\\r\\n\\r\\n  1. Clinical trials were conducted to verify the regulatory effect of electrical\\r\\n     stimulation of substantia nigra under different stimulation modes on episodic memory\\r\\n     impairment in PD, and to establish the interdependence between the changes in the\\r\\n     firing mode of substantia nigra neurons and the changes in episodic memory function.\\r\\n\\r\\n  1. To evaluate the impact of substantia nigra DBS on episodic memory function of PD\\r\\n     subjects: For PD patients to be treated with bilateral subthalaminal nucleus DBS,\\r\\n     the cognitive memory function, mental behavior symptoms and daily living ability of\\r\\n     the patients were assessed by neuropsychological scale, and those meeting the\\r\\n     criteria were selected to be included in the group. The MRI compatible dual-channel\\r\\n     DBS device was implanted into the subthalamic nucleus as the target. During the\\r\\n     operation, the lowest contact of the DBS electrode was implanted into the substantia\\r\\n     nigra according to the electrophysiological signal, and the remaining contact was\\r\\n     implanted into the subthalamic nucleus. The position of DBS electrode implantation\\r\\n     was reconstructed, and the electrode contacts in or close to the substantia nigra\\r\\n     were selected to perform 24-hour substantia nigra DBS under different parameter\\r\\n     combinations such as high frequency and low frequency. Neuropsychological scale was\\r\\n     used to evaluate the cognitive memory function of patients, and the influence of\\r\\n     substantia nigra DBS under different parameters on the episodic memory function of\\r\\n     PD subjects was analyzed. Then to evaluate the effect of substantia nigra DBS on\\r\\n     episodic memory function of PD subjects.\\r\\n\\r\\n  2. To study the electrophysiological mechanism of the substantia nigra\\'s participation\\r\\n     in episodic memory activities: the experiment of episodic memory task was completed\\r\\n     during DBS surgery, and the multi-mode neural electrophysiological signals of brain\\r\\n     regions such as substantia nigra, subthalamic nucleus, and dorsolateral prefrontal\\r\\n     cortex were recorded synchronously during the process of episodic memory activities,\\r\\n     and the behavioral results (accuracy rate, reaction time, etc.) of the completion of\\r\\n     the episodic memory tasks were calculated; The dynamic activation/inhibition\\r\\n     relationship among the substantia nigra, subthalamic nucleus, dorsolateral\\r\\n     prefrontal cortex and other brain regions was analyzed, and the response sequence\\r\\n     and dynamic changes of the peak potential, local field potential, and cortical\\r\\n     potential under the time-locking relationship were observed, so as to clarify the\\r\\n     mutual driving relationship between the brain regions related to episodic memory\\r\\n     activities. The activity characteristics of neurons in substantia nigra that respond\\r\\n     to episodic memory event boundaries were analyzed, and the relationship between the\\r\\n     change of discharge frequency and the formation process of episodic memory events\\r\\n     was studied, and the significance of the change of activity on episodic memory\\r\\n     events was discussed, so as to analyze the electrophysiological mechanism of various\\r\\n     brain regions involved in episodic memory activities.\\r\\n\\r\\n  3. To determine the key time nodes and dose-effect correspondence of the regulation of\\r\\n     episodic memory formation by electrical stimulation of substantia nigra:\\r\\n     microstimulation or macro stimulation delivered by microelectrode during DBS surgery\\r\\n     can be used to predict the effect or side effects of electrical stimulation, and\\r\\n     then prepare for the implantation of macro electrode, which is a routine operation\\r\\n     in surgery. In this study, the operation of episodic memory paradigm was controlled\\r\\n     by programming, and micro-stimulus or macro-stimulus was given before, during and\\r\\n     after the presentation of stimuli, respectively, to observe the effects of\\r\\n     electrical stimulation with different frequencies, different modes and different\\r\\n     stimulation regions on behavioral performance of episodic memory (accuracy rate,\\r\\n     reaction time, etc.). To establish the dose-effect correspondence between the\\r\\n     relative time node of electrical stimulation, micro-stimulation sites,\\r\\n     micro-stimulation parameters and the result of memory formation, and identify the\\r\\n     key time node of the regulation of episodic memory formation by electrical\\r\\n     stimulation of substantia nigra.\\r\\n\\r\\n  2. Through the study of brain structure and functional connectomics, the optimal\\r\\n     stimulus mode and stimulus parameters of substantia nigra DBS regulating episodic\\r\\n     memory dysfunction were revealed.\\r\\n\\r\\n  1. The influence of substantia nigra DBS on the functional brain network related to\\r\\n     episodic memory was explored by means of functional magnetic resonance imaging\\r\\n     (fMRI) technology: the DBS device implanted in this study was an MRI-compatible\\r\\n     dual-channel DBS device, and the activity of the brain network could be evaluated by\\r\\n     fMRI scanning technology when the device was turned on. In this study, the enrolled\\r\\n     patients completed the fMRI scanning of the resting state and the episodic memory\\r\\n     task state in the substantia nigra DBS state, calculated the behavioral results\\r\\n     (accuracy rate, reaction time, etc.) of the subjects in different groups to complete\\r\\n     the episodic memory task, and analyzed the change characteristics and dynamic\\r\\n     evolution of the dependent signal of blood oxygen level in the fMRI task state. The\\r\\n     brain regions with activation/inhibition of episodic memory task states and their\\r\\n     activation/inhibition relationship in time series were analyzed, and the correlation\\r\\n     between behavioral results and the characteristics of fMRI signal changes in task\\r\\n     states in each group was studied, so as to explore the functional changes of\\r\\n     episodic memory brain network before and after substania nigra DBS in PD patients.\\r\\n\\r\\n  2. Verify the results of animal experiments through brain structural connectomics\\r\\n     studies, and clarify the correlation between the activated tissue of substantia\\r\\n     nigra DBS and the changes in cognitive function: Lead DBS toolkit was used to\\r\\n     calculate substantia nigra DBS stimulation-activated tissue volume (VTA) under\\r\\n     different parameters, and cognitive behavioral evaluation results under different\\r\\n     stimulus parameters were collected, experimental data and patient data of each group\\r\\n     were sorted out. The machine learning toolkit was used to analyze the correlation\\r\\n     and weight between the changes in behavioral results of the subjects\\' episodic\\r\\n     memory and the subgroups (diagnosis, age, disease course, preoperative evaluation\\r\\n     results, imaging indicators, electrophysiological indicators, VTA, fMRI indicators\\r\\n     and other information, etc.), so as to clarify the correlation between DBS activated\\r\\n     tissue of substantia nigra and the changes in episodic memory function. To search\\r\\n     for biomarkers that can predict the changes of episodic memory after DBS, and reveal\\r\\n     the optimal stimulation mode and stimulation parameters of substantia nigra DBS in\\r\\n     regulating cognitive dysfunction\\r\\n\\r\\nConcomitant medication Patients will continue to take Parkinson\\'s disease drugs at\\r\\npreoperative dose (or according to the doctor\\'s advice) during perioperative and\\r\\npostoperative periods, and this experiment will not affect the drug usage and dosage of\\r\\npatients.\\r\\n\\r\\nObservation indicators and inspection time\\r\\n\\r\\n  1. Clinical evaluation: Two evaluations were conducted before surgery and one month\\r\\n     after surgery, including the following contents: 1) general information (age,\\r\\n     gender, age of onset and course of disease); 2) Drug treatment (drug type, dose,\\r\\n     time and side effects); 3) Behavioral assessment: PD patients were evaluated using\\r\\n     the Unified Parkinson\\'s Disease Rating Scale(UPDRS) version 3.0; 4) Neuropsychology:\\r\\n     In this study, multiple neuropsychological scales will be used for comprehensive\\r\\n     assessment of patients, including Mini-mental State Examination (MMSE), the Montreal\\r\\n     Cognitive Assessment Scale (MoCA), the Frontal Lobe Function Rating Scale (FAB), the\\r\\n     Hamilton Depression Rating Scale for Depression(HRSD), and the Hamilton Anxiety\\r\\n     Scale (HRSA).\\r\\n\\r\\n  2. MRI data: 3D T1, T2 axis, T2 crown, BOLD (on and off), DTI sequence. Two times were\\r\\n     collected before surgery and one month after surgery.\\r\\n\\r\\n  3. Memory paradigm test data: This project will start the memory paradigm test after\\r\\n     the microelectrode enters the substania nigra during the DBS operation, and give\\r\\n     electrical stimulation test when some memory stimuli are presented, so as to observe\\r\\n     the baseline memory accuracy rate of subjects and the changes in the recognition\\r\\n     accuracy rate of new/old objects under the state of electrical stimulation. In\\r\\n     addition, when the subjects returned to the hospital one month after the operation,\\r\\n     the memory function of the subjects was evaluated with the memory paradigm in the\\r\\n     magnetic resonance and fMRI environment, and the changes in the fMRI signal and\\r\\n     connectivity of the brain functional areas were observed. Then, the behavioral\\r\\n     characteristics of the memory paradigm and the activity characteristics of the brain\\r\\n     network under the state of electrical stimulation when DBS was turned on were\\r\\n     studied by post-processing analysis technology. The regulatory effect of substantia\\r\\n     nigra DBS on memory network was analyzed. We will monitor blood pressure, heart\\r\\n     rate, dual-frequency index and other indicators when patients complete the normal\\r\\n     form experiment during DBS surgery, and judge whether patients can continue to\\r\\n     complete the experiment according to the patient\\'s chief complaint and symptom\\r\\n     changes. If all indicators change in a negative direction, the experiment will be\\r\\n     terminated timely according to the situation. The safety of using electrical\\r\\n     stimulation of substantia nigra to regulate cognitive function was evaluated\\r\\n     according to the changes of blood pressure, heart rate, dual frequency index,\\r\\n     complaints and symptoms of patients after completing the normal form experiment.\\r\\n\\r\\nFollow-up time Follow-up will be completed at DBS startup 1 month after surgery.\\r\\n\\r\\nClinical evaluation\\r\\n\\r\\n  1. Efficacy evaluation: Changes in the corresponding clinical scales of patients at\\r\\n     each follow-up point are shown in observation indicators and examination time.\\r\\n\\r\\n  2. Safety evaluation: Adverse events were described by the number of adverse events and\\r\\n     the incidence rate, and the incidence rate was tested for significance between\\r\\n     groups. At the same time, the specific manifestation, degree and relationship\\r\\n     between all adverse events and devices were described in detail. Including\\r\\n     surgery-related adverse reactions, stimulus-related adverse reactions and\\r\\n     device-related adverse reactions.\\r\\n\\r\\nKnown and potential risks and benefits of the project, as well as risk disposal plans In\\r\\nthis study, participants will be required to complete a cognitive function test during\\r\\nthe operation, which only requires a simple operation of the keyplate and lasts for about\\r\\n20-30 minutes, during which the operation will be stopped and the surgical incision will\\r\\nbe covered with a sterile towel. Previous results of similar studies conducted in our\\r\\ncenter and other centers show that this testing process does not significantly increase\\r\\nthe degree of infection of the incision. Nor does it significantly increase the overall\\r\\nrisk of surgery; In part of the testing process, we will use a micro-current below 50uA\\r\\nfor electrical stimulation, which is not substantially different from the electrical\\r\\nstimulation used to test the efficacy in surgery, and the intensity is significantly\\r\\nweaker than the efficacy test current. Previous studies have not found that such\\r\\nintensity of the current will induce epilepsy, bleeding, necrosis and other\\r\\ncomplications, and the subjects have not reported obvious subjective discomfort. In\\r\\naddition, this study requires access to your medical information and other privacy, and\\r\\nwhile we are fully prepared to deal with the issue of data disclosure, it does not rule\\r\\nout such a risk. About 1 month after the operation, when the subjects participated in the\\r\\nfollow-up, the changes of cognitive function under electrical stimulation of the\\r\\nsubstania nigra were tested by a professional program control physician. The parameters\\r\\nof electrical stimulation used in the process were all within the safe range, and there\\r\\nwas usually no obvious discomfort, and the effects of electrical stimulation disappeared\\r\\nimmediately after the stimulator was turned off. This project will use an MRI-compatible\\r\\nDBS device that has passed safety testing before it is marketed and generally poses no\\r\\nadditional risk, but because it is still relatively new to the market, it is still\\r\\nprudent to watch for discomfort or other changes during MRI scans. Overall, there was no\\r\\nsignificant increase in preoperative, intraoperative, or postoperative risk.\\r\\n\\r\\nThis study will actively reconstruct the electrode position for patients after DBS, and\\r\\nprovide patients with more accurate and effective program control, which will help\\r\\nimprove the therapeutic effect of DBS surgery. At the same time, this study will provide\\r\\nfollow-up treatment and follow-up help and suggestions for patients, which will help\\r\\npatients improve their experience of medical treatment and treatment. In addition,\\r\\nconsidering that participating in this study will require the cooperation of the subjects\\r\\nduring and after the operation, which may lead to a slight extension of the operation\\r\\ntime, and the need for debugging and corresponding inspection after the operation, the\\r\\nproject team will cooperate with Beijing Pinchi Medical Equipment Co., Ltd. to apply for\\r\\nthe reduction of part of the equipment cost (about 55,000 yuan in total) for you.\\r\\nIncluding 1 DBS electrode (the market price is about 25,000 yuan), 2 electrode locks (the\\r\\nmarket price is 15,000 yuan/piece, a total of about 30,000 yuan); In addition, we will\\r\\nfacilitate your follow-up visit and arrange for your doctor to advise you on follow-up\\r\\ntreatment. Note: The specific content of remission needs to be determined according to\\r\\nthe degree of cooperation of the subjects and the completion of the experiment. All\\r\\nremission will be completed before and after the completion of the 1-month postoperative\\r\\nscan.\\r\\n\\r\\nData preservation The researchers established an independent study number for each\\r\\nsubject, named the corresponding data with the study number, and deleted the patient name\\r\\nand hospital number information from all the data. The study data included behavioral\\r\\ndata in.mat format, CT and MRI data in.dcm format, EEG data in.mpx format and image data\\r\\nin.mp4 format. Keep the original data for 10 years after the completion or termination of\\r\\nthe study.\\r\\n\\r\\nData security inspection Data and safety monitors were set up in this study, all adverse\\r\\nevents were recorded in detail, properly handled and tracked until properly resolved or\\r\\nthe disease was stable, and serious adverse events and unexpected events were reported to\\r\\nthe ethics Committee, competent authorities, sponsors and drug regulatory authorities in\\r\\na timely manner in accordance with relevant systems; The principal investigator conducts\\r\\na cumulative review of all adverse events on a regular basis, and investigator meetings\\r\\nare convened when necessary to assess the risks and benefits of the study.\\r\\n\\r\\nStatistical processing SPSS 22.0 software or SAS9.4 were used for analysis. In bilateral\\r\\ntests, P < 0.05 was considered to have significant differences. Measurement data were\\r\\ndescribed by mean, standard deviation, maximum, minimum, median, 25th and 75th quantile.\\r\\nGroup t test was used to compare the normal distribution measurement data among groups.\\r\\nFor measurement data with non-normal distribution, Wilcoxon Rank Sum test was used for\\r\\ninter-group comparison.\\r\\n\\r\\nEthical considerations The clinical study is conducted only after the protocol is\\r\\napproved by the Ethics Committee before the study begins. Before each subject is enrolled\\r\\nin this study, the investigator has the responsibility to fully introduce to the subject\\r\\nor his legal agent the purpose, procedure and possible risks of this study, as well as\\r\\nrelevant information about alternative treatment, and sign a written informed consent,\\r\\nwhich should let the subject know that they have the right to withdraw from this study at\\r\\nany time, and the informed consent will be retained as a clinical study document for\\r\\nfuture reference. Participants\\' personal information will be protected from disclosure\\r\\nduring the study.\\r\\n\\r\\nConfidentiality of information The subjects\\' medical information will be combined and\\r\\nused to study treatments. All information will be coded and will not contain the\\r\\nsubject\\'s name or any other information that directly identifies the subject. Information\\r\\nthat is not relevant to the study (such as information about previous illnesses,\\r\\ninfectious disease history) will not be provided to other parties.'},\n",
       "   'conditionsModule': {'conditions': [\"Parkinson's Disease and Parkinsonism\"],\n",
       "    'keywords': ['Cognitive dysfunction',\n",
       "     'Electrical stimulation of substantia nigra']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'interventionModelDescription': 'By comparing the behavioral characteristics of the memory paradigm under microelectrode\\r\\nstimulation during DBS operation and the characteristics of the electrophysiological\\r\\nsignals behind it, as well as the behavioral characteristics of the memory paradigm under\\r\\nelectrical stimulation and the characteristics of brain network activity during DBS\\r\\nstartup one month after surgery, we analyzed the regulatory effect of substantia nigra\\r\\nDBS on memory network',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Intraoperative and One month after the operation microelectrode stimulation of DBS',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'By comparing the behavioral characteristics of the memory paradigm under microelectrode\\r\\nstimulation during DBS operation and the characteristics of the electrophysiological\\r\\nsignals behind it, as well as the behavioral characteristics of the memory paradigm under\\r\\nelectrical stimulation and the characteristics of brain network activity during DBS\\r\\nstartup one month after surgery, we analyzed the regulatory effect of substantia nigra\\r\\nDBS on memory network',\n",
       "      'interventionNames': ['Device: microelectrode stimulation of DBS']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'microelectrode stimulation of DBS',\n",
       "      'description': 'Contact selection: According to the electrode position in the image (target\\r\\nreconstruction through CT scan), the electrode located in the substantia nigra is\\r\\nselected as the negative electrode, the contact near the upper part of the substantia\\r\\nnigra is selected as the positive electrode, and the bipolar stimulation mode is\\r\\nselected.\\r\\n\\r\\nStimulation parameters: The frequency was selected as 5/10/20/60/130/150Hz, the pulse\\r\\nwidth remained unchanged at 90μs, the side effects of patients were observed, and the\\r\\nvoltage was slowly increased to 2.0V; The patient voltage was 0 during the spurious\\r\\nstimulation.',\n",
       "      'armGroupLabels': ['Intraoperative and One month after the operation microelectrode stimulation of DBS']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes in recognition accuracy of new/old objects between baseline and under electrical stimulation',\n",
       "      'description': 'In this project, after the microelectrode was inserted into the substantia nigra during\\r\\nDBS surgery, the memory paradigm test was started, and some memory stimuli were presented\\r\\nwith electrical stimulation test at the same time, so as to observe the baseline memory\\r\\naccuracy of the subjects and the changes in the recognition accuracy of new/old objects\\r\\nunder the state of electrical stimulation',\n",
       "      'timeFrame': 'From the middle of DBS surgery to one month after surgery'},\n",
       "     {'measure': 'Changes of fMRI signal and connectivity in brain functional areas',\n",
       "      'description': 'In this study, SPM12 and DPABI were used to preprocess the resting-state fMRI data and\\r\\ncalculate the functional connectivity, locate the location of the dorsolateral prefrontal\\r\\nlobe, establish the resting-state brain network between the substantia nigra and the\\r\\ndorsolateral prefrontal lobe, calculate the functional connectivity between the\\r\\nsubstantia nigra and the dorsolateral prefrontal lobe, and design the surgical path. The\\r\\nmaximum functional connectivity between the dorsolateral prefrontal cortex, substantia\\r\\nnigra and subthalamic nucleus was calculated according to the results of resting-state\\r\\nfMRI. All subjects underwent 7.0T and 3.0T MR Scans before and after surgery,\\r\\nrespectively. Scanning sequences included 3D-T1-weighted images, axial coronal\\r\\nT2-weighted images, 3D-Flair sequences, etc. In addition, all participants completed the\\r\\nresting-state and task-state fMRI scans before and after the operation, and the\\r\\npost-operation task-state fMRI scan was performed with DBS on',\n",
       "      'timeFrame': 'From preoperative to one month postoperative'},\n",
       "     {'measure': 'Multimode neuroelectrophysiological signal recording',\n",
       "      'description': 'In this study, the spike potential and local field potential signals at the location of\\r\\nthe microelectrode tip were recorded simultaneously, and the cortical potential signals\\r\\nof the dorsolateral prefrontal cortex were collected by a custom-made ring electrode to\\r\\nanalyze the spatio-temporal characteristics of the SN and the dorsolateral prefrontal\\r\\ncortex during the formation of episodic memory encoding. The microelectrode recorded\\r\\nmicrovolt electrophysiological signals within 0.2-0.3mm around the microelectrode. The\\r\\nmacroelectrode recorded the surrounding local field potential signal. In this way, the\\r\\nspike potential signal and local field potential signal at the tip of the microelectrode,\\r\\nthe local field potential signal 3mm behind the tip, and the cortical potential signal\\r\\ncould be recorded synchronously.',\n",
       "      'timeFrame': 'During DBS surgery'},\n",
       "     {'measure': 'Mini-mental State Examination Score',\n",
       "      'description': 'The DBS device was implanted at the subthalamic nucleus. According to the\\r\\nelectrophysiological signal during the operation, the lowest contact of the DBS electrode\\r\\nwas implanted into the substantia nigra, and the remaining contacts were implanted into\\r\\nthe subthalamic nucleus. The cognitive memory function of the patients was assessed by\\r\\nMini-mental State Examination before surgery, and then the cognitive memory function of\\r\\nthe patients in no stimulation, low frequency and high frequency substantia nigra DBS\\r\\nstates was assessed by Mini-mental State Examination Score one month after surgery. The\\r\\neffects of substantia nigra DBS with different parameters on the memory function of PD\\r\\nsubjects were analyzed. The scale has a minimum value of 0 and a maximum value of 30,\\r\\nwith higher scores indicating better outcomes.',\n",
       "      'timeFrame': 'From preoperative to one month postoperative'},\n",
       "     {'measure': 'Montreal Cognitive Assessment Score',\n",
       "      'description': 'The DBS device was implanted at the subthalamic nucleus. According to the\\r\\nelectrophysiological signal during the operation, the lowest contact of the DBS electrode\\r\\nwas implanted into the substantia nigra, and the remaining contacts were implanted into\\r\\nthe subthalamic nucleus. The cognitive memory function of the patients was assessed by\\r\\nMontreal Cognitive Assessment before surgery, and then the cognitive memory function of\\r\\nthe patients in no stimulation, low frequency and high frequency substantia nigra DBS\\r\\nstates was assessed by Montreal Cognitive Assessment one month after surgery. The effects\\r\\nof substantia nigra DBS with different parameters on the memory function of PD subjects\\r\\nwere analyzed. The scale has a minimum value of 0 and a maximum value of 30, with higher\\r\\nscores indicating better outcomes.',\n",
       "      'timeFrame': 'From preoperative to one month postoperative'},\n",
       "     {'measure': 'Frontal Lobe Function Rating Scale',\n",
       "      'description': 'The DBS device was implanted at the subthalamic nucleus. According to the\\r\\nelectrophysiological signal during the operation, the lowest contact of the DBS electrode\\r\\nwas implanted into the substantia nigra, and the remaining contacts were implanted into\\r\\nthe subthalamic nucleus. The cognitive memory function of the patients was assessed by\\r\\nFrontal Lobe Function Rating Scale before surgery, and then the cognitive memory function\\r\\nof the patients in no stimulation, low frequency and high frequency substantia nigra DBS\\r\\nstates was assessed by Frontal Lobe Function Rating Scale one month after surgery. The\\r\\neffects of substantia nigra DBS with different parameters on the memory function of PD\\r\\nsubjects were analyzed. The scale has a minimum value of 0 and a maximum value of 18,\\r\\nwith higher scores indicating better outcomes.',\n",
       "      'timeFrame': 'From preoperative to one month postoperative'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Voluntarily participate in the clinical study and sign the informed consent;\\r\\n\\r\\n  -  Age 50-70 years old, gender unlimited;\\r\\n\\r\\n  -  The clinical diagnosis is consistent with typical PD, and the medical history is\\r\\n     less than 20 years;\\r\\n\\r\\n  -  Patients who intend to use 3.0T magnetic resonance compatible dual-channel DBS\\r\\n     device (G106R or G106RS, Beijing Pinchi Company) for bilateral subthalamic nucleus\\r\\n     DBS surgery to control PD symptoms;\\r\\n\\r\\n  -  MRI excluded patients with obvious structural changes;\\r\\n\\r\\n  -  The visual acuity and hearing of the subjects were basically normal, and the\\r\\n     compliance was good, and they could complete the tasks listed in the experimental\\r\\n     scheme in accordance with the standards.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Serious mental, cognitive and psychological disorders, unable to sign informed\\r\\n     consent or cooperate with the operation and various tasks;\\r\\n\\r\\n  -  There are contraindications for neurosurgery, such as hydrocephalus, cerebral\\r\\n     atrophy, cerebrovascular sequelae, heart disease and other cardiovascular and\\r\\n     cerebrovascular diseases;\\r\\n\\r\\n  -  There are concomitant diseases that seriously affect health, such as tumors, serious\\r\\n     abnormalities of liver and kidney function (indexes more than 3 times normal);\\r\\n\\r\\n  -  There is intracranial space occupation, cerebrovascular disease, mental illness,\\r\\n     other neurological diseases, claustrophobia, or there is an implant in the body,\\r\\n     which affects the nuclear magnetic scan;\\r\\n\\r\\n  -  The results of the Mini-Mental State Scale (MMSE) <24 or the Montreal Cognitive\\r\\n     Assessment Scale (MoCA) <18 in the preoperative assessment, or the results of other\\r\\n     scales indicate the presence of severe dementia.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '50 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'lin shi, M.D.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '008615210466780',\n",
       "      'email': 'shilin2015@foxmail.com'}],\n",
       "    'overallOfficials': [{'name': 'lin shi, M.D.',\n",
       "      'affiliation': 'Beijing Tiantan Hospital',\n",
       "      'role': 'STUDY_CHAIR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010300',\n",
       "      'term': 'Parkinson Disease'},\n",
       "     {'id': 'D000020734', 'term': 'Parkinsonian Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001480', 'term': 'Basal Ganglia Diseases'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000009069', 'term': 'Movement Disorders'},\n",
       "     {'id': 'D000080874', 'term': 'Synucleinopathies'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M13213',\n",
       "      'name': 'Parkinson Disease',\n",
       "      'asFound': \"Parkinson's Disease\",\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22494',\n",
       "      'name': 'Parkinsonian Disorders',\n",
       "      'asFound': 'Parkinsonism',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29705', 'name': 'Cognitive Dysfunction', 'relevance': 'LOW'},\n",
       "     {'id': 'M25603', 'name': 'Ganglion Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M16358', 'name': 'Synovial Cyst', 'relevance': 'LOW'},\n",
       "     {'id': 'M4774', 'name': 'Basal Ganglia Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12029', 'name': 'Movement Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M2217', 'name': 'Synucleinopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06398652',\n",
       "    'orgStudyIdInfo': {'id': 'CMAB015-002'},\n",
       "    'organization': {'fullName': 'Taizhou Mabtech Pharmaceutical Co.,Ltd',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis',\n",
       "    'officialTitle': 'Comparative Study of the Efficacy, Safety, and Immunogenicity of CMAB015 and Secukinumab in Adult Patients With Moderate-severe Chronic Plaque Psoriasis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-01',\n",
       "    'studyFirstSubmitQcDate': '2024-05-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Taizhou Mabtech Pharmaceutical Co.,Ltd',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of\\r\\nSecukinumab in patients with moderate-severe chronic plaque psoriasis. It will also learn\\r\\nabout the similarity of CMAB015 and Secukinumab in terms of safety and immunogenicity in\\r\\npatients with moderate-severe chronic plaque psoriasis. The main question it aims to\\r\\nanswer is:\\r\\n\\r\\nIn subjects with moderate to severe plate psoriasis treated with CMAB015, Is the\\r\\nproportion of patients achieving a 75% improvement in PASI (Psoriasis area and severity\\r\\nindex) scores relative to baseline (PASI 75) the same as those treated with Secukinumab?\\r\\n\\r\\nParticipants will:\\r\\n\\r\\nReceive treatment with 300 mg CMAB015 or Secukinumab by subcutaneous injection at weeks\\r\\n0, 1, 2, 3, 4, and 8, followed by every 4 weeks until week 48.\\r\\n\\r\\nVisit the clinic at weeks 0, 1, 2, 3, 4, and 8, followed by every 4 weeks until week 52.\\r\\n\\r\\nBe evaluated with PASI scores, body surface area (BSA) scores and investigator's global\\r\\nassessment (IGA) (mod 2011) scores.\",\n",
       "    'detailedDescription': 'This study was a multicenter, randomized, double-blind, secukinumab controlled, 1:1 ratio\\r\\nparallel grouping, equivalent design. The study treatment period would be 52 weeks,\\r\\nincluding a 12-week induction therapy period and a 40-week maintenance therapy period.\\r\\nThe primary endpoint was the proportion of patients achieving at least a 75% improvement\\r\\nin PASI scores from baseline at 12 weeks, with an equivalence cut-off of ±15%. A total of\\r\\n336 adult patients with moderate-to-severe plaque psoriasis are planned to be enrolled,\\r\\nwith 168 cases in each group. Eligible subjects received 300 mg CMAB015 or Secukinumab\\r\\nsubcutaneous injection. Patients who do not achieve at least a 50% improvement in PASI\\r\\nscores at week 12 would withdraw from the study, and patients who achieve a 50%\\r\\nimprovement continue on maintenance therapy until the last treatment at week 48.\\r\\n\\r\\nThis study is a double-blind design, and a central randomization system woud be used to\\r\\nrandomize subjects. The control factors for randomization are body weight (<60 kg, ≥60\\r\\nkg), prior treatment (prior systemic therapy with no prior biologics, prior systemic\\r\\ntherapy with biologics), concomitant psoriatic arthritis (yes, no), and PK intensive\\r\\nsampling (yes, no).'},\n",
       "   'conditionsModule': {'conditions': ['Psoriasis']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel Assignment',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 336, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Experimental Arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'CMAB015',\n",
       "      'interventionNames': ['Biological: CMAB015']},\n",
       "     {'label': 'Active Comparator Arm',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Secukinumab',\n",
       "      'interventionNames': ['Biological: Secukinumab']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'CMAB015',\n",
       "      'description': 'Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as\\r\\ninduction therapy. Patients who obtain a 75% improvement relative to baseline in PASI\\r\\nscores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain\\r\\ntherapy, until the last treatment at week 48.',\n",
       "      'armGroupLabels': ['Experimental Arm']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'Secukinumab',\n",
       "      'description': 'Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4,\\r\\n8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in\\r\\nPASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as\\r\\nmaintain therapy, until the last treatment at week 48.',\n",
       "      'armGroupLabels': ['Active Comparator Arm'],\n",
       "      'otherNames': ['Cosentyx']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients with PASI 75 at week 12.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75%\\r\\nreduction in PASI scores compared with the Baseline PASI scores.',\n",
       "      'timeFrame': 'week 12'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Proportion of patients with IGA (mod 2011) 0/1 at week 12.',\n",
       "      'description': \"The modified version of Investigator's Global Assessment (IGA) wich was developed in 2011\\r\\n(mod 2011) is a simple instrument providing a subjective evaluation of the overall\\r\\nseverity of psoriasis. Erythema, induration, and scaling of psoriatic lesions are scored\\r\\non a 5-point scale ranging from 0 (none) to 4 (severe) as the following:\\r\\n\\r\\n0=Clear (e.g., no signs of psoriasis, some post-inflammatory hyperpigmentation may be\\r\\npresent) ; 1=Almost clear (e.g., no thickening, normal or pink coloration) ; 2=Mild\\r\\n(e.g., mild thickening, pink to light red coloration) ;3= Moderate (e.g., moderate\\r\\nthickening, dull to bright red) ; 4=Severe (e.g., severe thickening, bright to deep red)\\r\\n.\",\n",
       "      'timeFrame': 'week 12'},\n",
       "     {'measure': 'Proportion of patients with IGA (mod 2011) 0/1 at week 52.',\n",
       "      'description': \"The modified version of Investigator's Global Assessment (IGA) wich was developed in 2011\\r\\n(mod 2011) is a simple instrument providing a subjective evaluation of the overall\\r\\nseverity of psoriasis. Erythema, induration, and scaling of psoriatic lesions are scored\\r\\non a 5-point scale ranging from 0 (none) to 4 (severe) as the following:\\r\\n\\r\\n0=Clear (e.g., no signs of psoriasis, some post-inflammatory hyperpigmentation may be\\r\\npresent) ; 1=Almost clear (e.g., no thickening, normal or pink coloration) ; 2=Mild\\r\\n(e.g., mild thickening, pink to light red coloration) ;3= Moderate (e.g., moderate\\r\\nthickening, dull to bright red) ; 4=Severe (e.g., severe thickening, bright to deep red)\\r\\n.\",\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Proportion of patients with IGA (mod 2011) 0 at week 12.',\n",
       "      'description': \"The modified version of Investigator's Global Assessment (IGA) wich was developed in 2011\\r\\n(mod 2011) is a simple instrument providing a subjective evaluation of the overall\\r\\nseverity of psoriasis. Erythema, induration, and scaling of psoriatic lesions are scored\\r\\non a 5-point scale ranging from 0 (none) to 4 (severe) as the following:\\r\\n\\r\\n0=Clear (e.g., no signs of psoriasis, some post-inflammatory hyperpigmentation may be\\r\\npresent) ; 1=Almost clear (e.g., no thickening, normal or pink coloration) ; 2=Mild\\r\\n(e.g., mild thickening, pink to light red coloration) ;3= Moderate (e.g., moderate\\r\\nthickening, dull to bright red) ; 4=Severe (e.g., severe thickening, bright to deep red)\\r\\n.\",\n",
       "      'timeFrame': 'week 12'},\n",
       "     {'measure': 'Proportion of patients with IGA (mod 2011) 0 at week 52.',\n",
       "      'description': \"The modified version of Investigator's Global Assessment (IGA) wich was developed in 2011\\r\\n(mod 2011) is a simple instrument providing a subjective evaluation of the overall\\r\\nseverity of psoriasis. Erythema, induration, and scaling of psoriatic lesions are scored\\r\\non a 5-point scale ranging from 0 (none) to 4 (severe) as the following:\\r\\n\\r\\n0=Clear (e.g., no signs of psoriasis, some post-inflammatory hyperpigmentation may be\\r\\npresent) ; 1=Almost clear (e.g., no thickening, normal or pink coloration) ; 2=Mild\\r\\n(e.g., mild thickening, pink to light red coloration) ;3= Moderate (e.g., moderate\\r\\nthickening, dull to bright red) ; 4=Severe (e.g., severe thickening, bright to deep red)\\r\\n.\",\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Proportion of patients with PASI 50 at week 12.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 50 is defined as at least a 50%\\r\\nreduction in PASI scores compared with the Baseline PASI scores.',\n",
       "      'timeFrame': 'week 12'},\n",
       "     {'measure': 'Proportion of patients with PASI 75 at week 52.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75%\\r\\nreduction in PASI scores compared with the Baseline PASI scores.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Proportion of patients with PASI 90 at week 12.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90%\\r\\nreduction in PASI scores compared with the Baseline PASI scores.',\n",
       "      'timeFrame': 'week 12'},\n",
       "     {'measure': 'Proportion of patients with PASI 90 at week 52.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90%\\r\\nreduction in PASI scores compared with the Baseline PASI scores.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Proportion of patients with PASI 100 at week 12.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as complete\\r\\nremission.',\n",
       "      'timeFrame': 'week 12'},\n",
       "     {'measure': 'Proportion of patients with PASI 100 at week 52.',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as complete\\r\\nremission..',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Change from baseline in DLQI at week 52',\n",
       "      'description': \"The Dermatology Life Quality Index (DLQI) is the most commonly used dermatology-specific\\r\\nquality of life (QOL) measure in clinical trials of skin diseases. It consists of 10\\r\\nquestions concerning dermatologic patients' perception of the impact of skin diseases on\\r\\ndifferent aspects of their QOL over the last week. The items of the DLQI encompass\\r\\naspects such as symptoms and feelings, daily activities, leisure, work or school,\\r\\npersonal relationships, and the side effects of treatment. Each item is scored on a\\r\\n4-point scale: 0=not at all/not relevant , 1=a little, 2=a lot, and 3=very much. Scores\\r\\nof individual items are added to yield a total score (0-30). A DLQI score of 0 and 1\\r\\nmeans no impact ona patient's QOL whereas a score of 2~5, 6~10, 11~20, and 21~30\\r\\nindicates a small, moderate, large, and an extremely large effect on patient's QOL,\\r\\nrespectively.\",\n",
       "      'timeFrame': 'week 52.'},\n",
       "     {'measure': 'Change from baseline in PASI at week 52',\n",
       "      'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of\\r\\neffect on body surface area of psoriasis and the extension of erythema (reddening),\\r\\ninduration (thickness), desquamation (scaling) of the lesions and area affected as\\r\\nobserved on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates\\r\\nno psoriasis and 72 indicates very severe psoriasis.',\n",
       "      'timeFrame': 'week 52.'},\n",
       "     {'measure': 'Change from baseline in IGA (mod 2011) at week 52',\n",
       "      'description': \"The modified version of Investigator's Global Assessment (IGA) wich was developed in 2011\\r\\n(mod 2011) is a simple instrument providing a subjective evaluation of the overall\\r\\nseverity of psoriasis. Erythema, induration, and scaling of psoriatic lesions are scored\\r\\non a 5-point scale ranging from 0 (none) to 4 (severe) as the following:\\r\\n\\r\\n0=Clear (e.g., no signs of psoriasis, some post-inflammatory hyperpigmentation may be\\r\\npresent) ; 1=Almost clear (e.g., no thickening, normal or pink coloration) ; 2=Mild\\r\\n(e.g., mild thickening, pink to light red coloration) ;3= Moderate (e.g., moderate\\r\\nthickening, dull to bright red) ; 4=Severe (e.g., severe thickening, bright to deep red)\\r\\n.\",\n",
       "      'timeFrame': 'week 52.'},\n",
       "     {'measure': 'Change from baseline in BSA at week 52',\n",
       "      'description': 'Body Surface Area (BSA) score is an important indicator for calculating the overall skin\\r\\nlesion area of psoriasis. BSA ≈1% refers to the area of the skin lesion as the size of a\\r\\npalm, and the estimation of the skin lesion area in this method can roughly assess the\\r\\nseverity of the disease.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Incidence of adverse events',\n",
       "      'description': 'Number of patients reporting at least one adverse event in the study. An adverse event is\\r\\ndefined as any untoward medical occurrence in a clinical trial participant graded\\r\\naccording to the common terminology criteria for adverse events (CTCAE) v.5.0\\r\\ncriteria,including clinically-significant changes in physical examinations, laboratory\\r\\nsafety tests, ECG and vital signs',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Immunogenicity',\n",
       "      'description': 'Percentage of anti-drug antibody and neutralizing antibody in the study. Subjects with a\\r\\npositive antibody response to CMAB015 or Secukinumab were determined to test neutralizing\\r\\nantibody.',\n",
       "      'timeFrame': 'week 52'}],\n",
       "    'otherOutcomes': [{'measure': 'AUC0-t',\n",
       "      'description': 'AUC0-t, the area under the concentration-time curve from time zero to the time of the\\r\\nlast quantifiable concentration, will be analyzed using a non-atrioventricular model.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'AUC0-inf',\n",
       "      'description': 'AUC0-inf, the area under the concentration-time curve from time zero to infinity, will be\\r\\nanalyzed using a non-atrioventricular model.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Half time',\n",
       "      'description': 'Half time will be analyzed using a non-atrioventricular model.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Cmax',\n",
       "      'description': 'Cmax is the maximum concentration.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Tmax',\n",
       "      'description': 'Tmax is the time of the maximum concentration.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Clearance Rate',\n",
       "      'description': 'Clearance rate will be analyzed using a non-atrioventricular model.',\n",
       "      'timeFrame': 'week 52'},\n",
       "     {'measure': 'Apparent Volume of Distribution',\n",
       "      'description': 'Apparent Volume of Distribution will be analyzed using a non-atrioventricular model.',\n",
       "      'timeFrame': 'week 52'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  History of confirmed moderate-severe plaque psoriasis for at least 6 months before\\r\\n     randomization.\\r\\n\\r\\n  -  PASI scores≥12, IGA (mod 2011) scores ≥3 and BSA≥10% at screening and randomization.\\r\\n\\r\\n  -  With indications for phototherapy or systemic therapy.\\r\\n\\r\\n  -  Voluntarily sign informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Presented with pustular psoriasis, erythrodermic psoriasis，guttate psoriasis or\\r\\n     psoriasis triggered by medicine at screening.\\r\\n\\r\\n  -  Active persistent cutaneous inflammatory disease other than psoriasis at\\r\\n     randomization.\\r\\n\\r\\n  -  Treatment with phototherapy, including but not limited to ultraviolet A phototherapy\\r\\n     (with or without psoralen), ultraviolet B phototherapy, or excimer laser within 4\\r\\n     weeks prior to randomization. Patients who are unwilling to avoid excessive UV\\r\\n     exposure within 4 weeks prior to randomization and during this trial.\\r\\n\\r\\n  -  Use of systemic treatment with anti-psoriasis non-biologic agents within 4 weeks\\r\\n     prior to randomization, including but not limited to glucocorticoids, retinoids,\\r\\n     cyclosporine, methotrexate, azathioprine, leflunomide, mycophenolate mofetil,\\r\\n     tofacitinib, apremilast, traditional Chinese medicine/proprietary Chinese medicine,\\r\\n     etc.\\r\\n\\r\\n  -  Intra-articular glucocorticoid injection within 4 weeks or 5 drug half-lives\\r\\n     (whichever is longer) prior to randomization.\\r\\n\\r\\n  -  Topical anti-psoriasis treatment within 2 weeks prior to randomization.\\r\\n\\r\\n  -  Prior treatment with the following biologic agents for the treatment of psoriasis\\r\\n     within the specified time period prior to randomization: ustekinumab<6 months,\\r\\n     Adalimumab, Etanercept, Infliximab, Golimumab, Guselkumab<12 weeks, Rituximab<12\\r\\n     months, or any other biological agent< 5 half lives.\\r\\n\\r\\n  -  Prior treatment with anti-IL-17 antibody or anti-IL-17 receptor antibody.\\r\\n\\r\\n  -  Meets any of the following at screening: haemoglobin<80 g/L, white blood\\r\\n     cell<3×10E9/L, Neutrophils<1.5×10E9/L, platelet<75×10E9/L, alanine aminotransferase\\r\\n     (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin (TBiL)>2 times\\r\\n     the upper limit of normal (ULN), serum creatinine (Scr)>1.5 ULN.\\r\\n\\r\\n  -  History of inflammatory bowel disease or other disease with a high risk of\\r\\n     perforation or other active autoimmune disease.\\r\\n\\r\\n  -  Systemic infection or serious infection requiring hospitalization and/or intravenous\\r\\n     anti-infective therapy within 4 weeks prior to randomization; any active infection\\r\\n     within 2 weeks prior to randomization, with the exception of general upper\\r\\n     respiratory tract infection.\\r\\n\\r\\n  -  Have Received a live vaccine within 12 weeks prior to randomization, or plan to\\r\\n     receive a live vaccine during the study or within 6 months after the last dose.\\r\\n\\r\\n  -  Previously diagnosed or ongoing lymphoproliferative disorders. Malignant tumors\\r\\n     within 5 years prior to screening, excluding squamous cell carcinoma of the skin or\\r\\n     basal cell carcinoma or unflavored cervical cancer that have been cured after\\r\\n     treatment.\\r\\n\\r\\n  -  History of depression and/or any finding of suicidal ideation before randomization.\\r\\n\\r\\n  -  Concomitant progressive or uncontrolled cardiovascular and cerebrovascular diseases,\\r\\n     respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, and\\r\\n     neurological diseases, which are judged by the investigators to be inappropriate for\\r\\n     participation in this study;\\r\\n\\r\\n  -  Positive for any of the followings: hepatitis B virus surface antigen, hepatitis C\\r\\n     virus antibody ,human immunodeficiency virus antibody, treponema pallidum antibody.\\r\\n\\r\\n  -  Latent or active tuberculosis.\\r\\n\\r\\n  -  Allergy to anti-IL-17 antibody active ingredients, excipients or latex.\\r\\n\\r\\n  -  Pregnant or nursing women. Male or female patients who are unwilling to use\\r\\n     effective contraception during the trial and for 5 months after the last dose\\r\\n\\r\\n  -  Participated in other drug clinical trials within 3 months or 5 drug half-lives\\r\\n     (whichever is longer) before screening.\\r\\n\\r\\n  -  Any major surgery within 8 weeks prior to randomization, or planned major surgery\\r\\n     during the study.\\r\\n\\r\\n  -  History of recurrent drug abuse or unprescribed medication, or history of alcohol\\r\\n     abuse.\\r\\n\\r\\n  -  Other conditions judged by the investigator to be inappropriate to participate in\\r\\n     this study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jin h Xu, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '021-52887781',\n",
       "      'email': 'xjhlcsy@163.com'},\n",
       "     {'name': 'Ming x Y',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '021-60129299',\n",
       "      'phoneExt': '8021',\n",
       "      'email': 'mingxia.yu@mabpharm.net'}],\n",
       "    'overallOfficials': [{'name': 'Jin h Xu, PhD',\n",
       "      'affiliation': 'Huashan Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011565',\n",
       "      'term': 'Psoriasis'}],\n",
       "    'ancestors': [{'id': 'D000017444',\n",
       "      'term': 'Skin Diseases, Papulosquamous'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14422',\n",
       "      'name': 'Psoriasis',\n",
       "      'asFound': 'Psoriasis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M19713',\n",
       "      'name': 'Skin Diseases, Papulosquamous',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4854',\n",
       "      'name': 'Benzocaine',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T433', 'name': 'Tannic Acid', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06030037',\n",
       "    'orgStudyIdInfo': {'id': 'HCC 22-077'},\n",
       "    'organization': {'fullName': 'University of Pittsburgh', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma',\n",
       "    'officialTitle': 'Randomized Phase II Study of Pembrolizumab/Lenvatinib With and Without Responder-derived FMT (R-FMT) in Relapsed/Refractory Melanoma'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-09-01',\n",
       "    'studyFirstSubmitQcDate': '2023-09-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-09-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-15', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Diwakar Davar',\n",
       "     'investigatorTitle': 'Assistant Professor of Medicine and a Medical oncologist/hematologist',\n",
       "     'investigatorAffiliation': 'University of Pittsburgh'},\n",
       "    'leadSponsor': {'name': 'Diwakar Davar', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Merck Sharp & Dohme LLC', 'class': 'INDUSTRY'},\n",
       "     {'name': 'Gateway for Cancer Research', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'In this is a randomized phase II study the addition of R-FMT to pembrolizumab /lenvatinib\\r\\nin PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1\\r\\nR/R disease. Patients with PD-1 refractory advanced melanoma are eligible to enroll,\\r\\nexcluding patients with prior lenvatinib (or other TKI) exposure. Intestinal microbiome\\r\\ncomposition mediates response to anti-PD-1 by affecting systemic inflammatory tone.',\n",
       "    'detailedDescription': 'Despite treatment advances, 40-60% of melanoma patients do not respond or fail to respond\\r\\ndurably; and the management of relapsed/refractory (R/R) disease remains an important\\r\\nproblem for the field. The importance of intact immune surveillance function in\\r\\ncontrolling outgrowth of neoplastic transformations has been known for decades.\\r\\nAccumulating evidence shows a correlation between tumor-infiltrating lymphocytes in\\r\\ncancer tissue and favorable prognosis in various malignancies. In particular, the\\r\\npresence of CD8+ T-cells and the ratio of CD8+ effector T cells/FoxP3+ regulatory T-cells\\r\\n(T-regs) correlates with improved prognosis and long-term survival in solid malignancies,\\r\\nsuch as ovarian, colorectal, and pancreatic cancer; hepatocellular carcinoma; malignant\\r\\nmelanoma; and renal cell carcinoma. Tumor-infiltrating lymphocytes can be expanded ex\\r\\nvivo and reinfused, inducing durable objective tumor responses in cancers such as\\r\\nmelanoma. Targeting TAMs (tumor associated macrophages, which are innate immune cells of\\r\\nheterogeneous origins that accumulate within the tumor microenvironment (TME) as tumors\\r\\nprogress and interfere with antitumor T cell mediated responses) via targeted depletion,\\r\\ninhibition of active migration, and/or promotion of activation and differentiation have\\r\\nbeen pursued as therapeutic strategies to increase efficacy of ICI therapy clinically and\\r\\npreclinically. The pembrolizumab/lenvatinib combination has been explored in several\\r\\nclinical settings and been granted approval for two indications including advanced\\r\\nendometrial carcinoma and RCC. In addition to tumor-intrinsic mechanisms supporting\\r\\nresistance to anti-PD-1, the gut microbiome is a major tumor-extrinsic regulator of\\r\\nresponses to anti-PD-1.'},\n",
       "   'conditionsModule': {'conditions': ['PD-1 Refractory Advanced Melanoma'],\n",
       "    'keywords': ['CD8+ T-cells',\n",
       "     'CD8+ effector T cells',\n",
       "     'FoxP3+ regulatory T-cells (T-regs)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 56, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'R-FMT + pembrolizumab/lenvatinib (Arm A)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '  -  Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV\\r\\n     infusion (treatment intervals may be increased due to toxicity as described).\\r\\n\\r\\n  -  Lenvatinib will be administered at 20 mg daily.\\r\\n\\r\\n  -  R-FMT (induction) will be administered at C1D1 and C4D1 via colonoscopy.\\r\\n\\r\\n  -  R-FMT (maintenance) will be repeated every 9 weeks starting with C4D1 via\\r\\n     sigmodoscopy.',\n",
       "      'interventionNames': ['Biological: Responder-Derived Fecal microbiota transplantation (R-FMT',\n",
       "       'Drug: Pembrolizumab',\n",
       "       'Drug: Lenvatinib']},\n",
       "     {'label': 'pembrolizumab/lenvatinib (Arm B)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': '  -  Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV\\r\\n     infusion (treatment intervals may be increased due to toxicity as described).\\r\\n\\r\\n  -  Lenvatinib will be administered at 20 mg daily.',\n",
       "      'interventionNames': ['Drug: Pembrolizumab', 'Drug: Lenvatinib']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'Responder-Derived Fecal microbiota transplantation (R-FMT',\n",
       "      'description': 'R-FMT (induction) via colonoscopy on C1D1 and C3D1. R-FMT (maintenance) via sigmoidoscopy\\r\\nwill be repeated every 9 weeks.',\n",
       "      'armGroupLabels': ['R-FMT + pembrolizumab/lenvatinib (Arm A)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'description': 'Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV\\r\\ninfusion (treatment intervals may be increased due to toxicity)',\n",
       "      'armGroupLabels': ['R-FMT + pembrolizumab/lenvatinib (Arm A)',\n",
       "       'pembrolizumab/lenvatinib (Arm B)']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Lenvatinib',\n",
       "      'description': 'Lenvatinib will be administered at 20 mg daily',\n",
       "      'armGroupLabels': ['R-FMT + pembrolizumab/lenvatinib (Arm A)',\n",
       "       'pembrolizumab/lenvatinib (Arm B)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR) per RECIST v1.1',\n",
       "      'description': 'The proportion of patients with objective response to treatment assessed using Response\\r\\nEvaluation Criteria in Solid Tumors v1.1 (RECIST). Per RECIST v1.1: Complete Response\\r\\n(CR): disappearance of all target lesions. Any pathological lymph nodes (target or\\r\\nnontarget) with reduction in short axis to <10 mm. Partial Response (PR): ≥30% decrease\\r\\nin the sum of diameters of target lesions, taking as reference the baseline sum\\r\\ndiameters.',\n",
       "      'timeFrame': 'Up to 5 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of Adverse Events Related to Treatment',\n",
       "      'description': 'Frequency of Adverse Events (AEs) and/or Serious Adverse Events (SAEs) (specifically\\r\\n≥grade 2 irAEs) related to study treatment, per NCI Common Terminology Criteria for\\r\\nAdverse Events (CTCAE) v5.0.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': 'Objective Response Rate (ORR) per iRECIST',\n",
       "      'description': 'The proportion of patients Complete Response (irCR) or Partial Response (irPR) to\\r\\ntreatment as assessed per iRECIST. irCR: Disappearance of non-nodal lesions. All\\r\\npathologic lymph nodes <10 mm (short axis) (2 consecutive measurements ≥4 weeks apart);\\r\\nirPR:≥30% decrease from baseline (2 consecutive measurements ≥4 weeks apart).\\r\\nDisappearance of all non-nodal lesions. All pathologic lymph nodes <10 mm (Non-Target\\r\\nLesions: Any other than disappearance of all non-nodal lesions and reduction of\\r\\npathologic lymph nodes <10 mm). Baseline tumor burden: sum of single diameters (short\\r\\naxis for nodal lesions, longest diameter for other lesions) for target lesions. In\\r\\nsubsequent scans, the diameters of new measurable lesions are added to the tumor burden.\\r\\nRe-treatment: ≤5 target lesions (=/≠ original lesions) are selected and a new baseline\\r\\ntumor burden will be established. (no distinct iRECIST assessment until radiographic\\r\\nprogression per RECIST 1.1 is observed).',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': '6-month Progression-free Survival',\n",
       "      'description': 'Percentage of patients without disease progression at 6 months after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 6 months'},\n",
       "     {'measure': '1-year Progression-free Survival (PFS)',\n",
       "      'description': 'Percentage of patients without disease progression at 1 year after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': '2-year Progression-free Survival (PFS)',\n",
       "      'description': 'Percentage of patients without disease progression at 2 years after start of treatment,\\r\\nper RECIST v1.1. Progressive Disease (PD): ≥20% increase in the sum of diameters of\\r\\ntarget lesions, taking as reference the smallest sum on study (this includes the baseline\\r\\nsum if that is the smallest on study). The sum must also demonstrate an absolute increase\\r\\nof ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Progression-free Survival (PFS)',\n",
       "      'description': 'The median length of time from initiation of study drug(s) disease progression as defined\\r\\nby RECIST v1.1, or death. Progressive Disease (PD): ≥20% increase in the sum of diameters\\r\\nof target lesions, taking as reference the smallest sum on study (this includes the\\r\\nbaseline sum if that is the smallest on study). The sum must also demonstrate an absolute\\r\\nincrease of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.',\n",
       "      'timeFrame': 'Up to 5 years'},\n",
       "     {'measure': '1-year Overall Survival (OS)',\n",
       "      'description': 'Percentage of patients that are alive at 1 year after start of treatment.',\n",
       "      'timeFrame': 'Up to 1 year'},\n",
       "     {'measure': '2-year Overall Survival (OS)',\n",
       "      'description': 'Percentage of patients that are alive at 2 years after start of treatment.',\n",
       "      'timeFrame': 'Up to 2 years'},\n",
       "     {'measure': 'Overall Survival (OS)',\n",
       "      'description': 'The median length of time that patients remain alive after treatment.',\n",
       "      'timeFrame': 'Up to 5 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patients with cutaneous melanoma or unknown primary melanoma may enroll. Patients\\r\\n     with uveal or mucosal or acral-lentiginous melanoma are excluded.\\r\\n\\r\\n  -  A male participant must agree to use a contraception as detailed in Appendix 3 of\\r\\n     this protocol during the treatment period and for at least 120 days after the last\\r\\n     dose of study treatment and refrain from donating sperm during this period.\\r\\n\\r\\n  -  A female participant is eligible to participate if she is not pregnant (see Appendix\\r\\n     3), not breastfeeding, and at least one of the following conditions applies:\\r\\n\\r\\n  -  Not a woman of childbearing potential (WOCBP) as defined in Appendix 3; OR\\r\\n\\r\\n  -  A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the\\r\\n     treatment period and for at least 120 days after the last dose of study treatment.\\r\\n\\r\\n  -  Participants must have progressed on treatment with an anti-PD(L)1 ICI administered\\r\\n     either as monotherapy or in combination with other checkpoint inhibitors or other\\r\\n     standard/investigational therapies. PD-1 treatment progression is defined by meeting\\r\\n     all the following criteria:\\r\\n\\r\\n  -  Has received at least 2 doses of an approved anti-PD(L)1 ICI administered as a\\r\\n     single agent, in combination with chemotherapy, and/or in combination with other\\r\\n     investigational therapy.\\r\\n\\r\\n  -  Participants who progressed on/within 3 months of adjuvant therapy with anti-PD(L)1\\r\\n     ICI will eligible.\\r\\n\\r\\n  -  Demonstrated disease progression after anti-PD-1/L1 as defined by RECIST v1.1. The\\r\\n     initial evidence of PD is to be confirmed by a second assessment no sooner than 4\\r\\n     weeks from the date of the first documented PD.\\r\\n\\r\\n  -  Progressive disease has been documented within 12 weeks from the last dose of\\r\\n     anti-PD-1/anti-PD-L1 mAb.\\r\\n\\r\\n  -  Patients with CNS disease are eligible if CNS metastases are treated and deemed\\r\\n     stable prior to date of enrollment.\\r\\n\\r\\n  -  Willingness to repeatedly receive FMT administered endoscopically (colonoscopy or\\r\\n     sigmoidoscopy) following necessary bowel preparation pre-procedure.\\r\\n\\r\\n  -  Presence of measurable disease based on RECIST 1.1.\\r\\n\\r\\n  -  Patients need to have at least one measurable lesion and a separate lesion for\\r\\n     biopsy. Patients with only 1 lesion may be enrolled after discussion with\\r\\n     Sponsor-Investigator.\\r\\n\\r\\n  -  Able to provide newly obtained core or excisional biopsy of a tumor lesion not\\r\\n     previously irradiated to undergo tumor biopsy (core, punch, incisional or\\r\\n     excisional).\\r\\n\\r\\n  -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\\r\\n\\r\\n  -  Have adequate organ function as defined in Table 4.1.11-1 below. Specimens must be\\r\\n     collected within 28 days prior to the start of study intervention.\\r\\n\\r\\n  -  Patients who are hepatitis B positive (i.e. HBsAg positive) or have a history of\\r\\n     history of hepatitis B (i.e. HBcAb positive, or history of documented hepatitis B\\r\\n     infection) are eligible if they have received hepatitis B directed antiviral therapy\\r\\n     for at least 4 weeks and have undetectable HBV viral load (HBV DNA) prior to\\r\\n     enrollment\\r\\n\\r\\n  -  Patients who are hepatitis C positive (i.e. HCV antibody reactive) or have a history\\r\\n     of history of hepatitis C (i.e. history of documented hepatitis C infection) are\\r\\n     eligible if they have received and completed hepatitis C directed antiviral therapy\\r\\n     at least 4 weeks and have undetectable HCV viral load (HCV RNA) prior to enrollment\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Diagnosis of non-cutaneous melanoma histologies including mucosal melanoma,\\r\\n     ocular/choroidal melanoma, and acral-lentiginous melanoma.\\r\\n\\r\\n  -  Receipt of prior agent(s) targeting the intestinal microbiome including but not\\r\\n     limited to: FMT, defined bacterial consortia, single bacterial species and/or\\r\\n     microbiota derived peptides.\\r\\n\\r\\n  -  Prior chemotherapy, targeted therapy, and/or small molecule therapy within 2 weeks\\r\\n     (or 4 half lives) prior to study Day 1.\\r\\n\\r\\n  -  Prior therapy with lenvatinib or other systemic anti-angiogenic therapy.\\r\\n\\r\\n  -  Prior radiotherapy within 2 weeks of start of study intervention.\\r\\n\\r\\n  -  Has had major surgery within 3 weeks prior to first dose of study interventions.\\r\\n\\r\\n  -  Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.\\r\\n\\r\\n  -  Has urine protein ≥1 g/24 hours. Note: Participants with proteinuria ≥2+ (≥100\\r\\n     mg/dL) on urine dipstick testing (urinalysis) will undergo 24-hour urine collection\\r\\n     for quantitative assessment of proteinuria.\\r\\n\\r\\n  -  Has a LVEF below the institutional (or local laboratory) normal range, as determined\\r\\n     by multigated acquisition (MUGA) or echocardiogram (TTE).\\r\\n\\r\\n  -  Has radiographic evidence of encasement or invasion of a major blood vessel, or of\\r\\n     intratumoral cavitation.\\r\\n\\r\\n  -  Prolongation of QTcF interval to >480 ms.\\r\\n\\r\\n  -  Has clinically significant cardiovascular disease within 12 months from first dose\\r\\n     of study intervention, including New York Heart Association Class III or IV\\r\\n     congestive heart failure, unstable angina, myocardial infarction, cerebral vascular\\r\\n     accident, or cardiac arrhythmia associated with hemodynamic instability.\\r\\n\\r\\n  -  Gastrointestinal malabsorption or any other condition that might affect the\\r\\n     absorption of lenvatinib\\r\\n\\r\\n  -  Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior\\r\\n     to the first dose of study drug.\\r\\n\\r\\n  -  Presence of an absolute contraindication(s) to FMT administration\\r\\n\\r\\n  -  Toxic megacolon\\r\\n\\r\\n  -  Severe dietary allergies (e.g. shellfish, nuts, seafood)\\r\\n\\r\\n  -  Inflammatory bowel disease\\r\\n\\r\\n  -  Patients who have not adequately recovered (i.e., ≤Grade 1 or at baseline or ≤Grade\\r\\n     2 endocrinopathy) from adverse events (AEs) due to a previously administered agent.\\r\\n\\r\\n  -  A WOCBP who has a positive urine pregnancy test at Screening (see Appendix 3). If\\r\\n     the urine test is positive or cannot be confirmed as negative, a serum pregnancy\\r\\n     test will be required.\\r\\n\\r\\n  -  Has received a live vaccine within 30 days prior to the first dose of study drug\\r\\n     (examples of live vaccines include, but are not limited to, the following: measles,\\r\\n     mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus\\r\\n     Calmette-Guérin (BCG), and typhoid vaccine)\\r\\n\\r\\n  -  Seasonal influenza vaccines for injection are generally killed virus vaccines and\\r\\n     are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live\\r\\n     attenuated vaccines and are not allowed.\\r\\n\\r\\n  -  Has a diagnosis of immunodeficiency, immunosuppression and/or is receiving chronic\\r\\n     systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)\\r\\n     or any other form of immunosuppressive therapy within 14 days prior to the first\\r\\n     dose of study drug.\\r\\n\\r\\n  -  Has active autoimmune disease that has required systemic treatment in the past 2\\r\\n     years (i.e. with use of disease modifying agents, corticosteroids or\\r\\n     immunosuppressive drugs).\\r\\n\\r\\n  -  Concurrent non-hematologic malignancy within 3 years of data of first planned dose\\r\\n     of therapy except for tumors with a negligible risk of metastasis and/or death as\\r\\n     defined below:\\r\\n\\r\\n  -  Adequately treated non-invasive malignancies including but not limited to melanoma\\r\\n     in situ (MIS), cutaneous squamous cell carcinoma (cSCC), in situ cSCC, basal cell\\r\\n     carcinoma (BCC), CIS of cervix, or DCIS/LCIS of breast.\\r\\n\\r\\n  -  Low-risk early-stage prostate adenocarcinoma (T1-T2a N0 M0 and Gleason score ≤6 and\\r\\n     PSA ≤10 ng/mL) for which the management plan is active surveillance, or prostate\\r\\n     adenocarcinoma with biochemical-only recurrence with documented PSA doubling time of\\r\\n     > 12 months for which the management plan is active surveillance.\\r\\n\\r\\n  -  Indolent hematologic malignancies for which the management plan is active\\r\\n     surveillance including but not limited to CLL/indolent lymphoma.\\r\\n\\r\\n  -  Active (i.e., symptomatic or growing) central nervous system (CNS) metastases.\\r\\n\\r\\n  -  Patients with leptomeningeal disease are excluded.\\r\\n\\r\\n  -  Has severe hypersensitivity (≥Grade 3) to anti-PD(L)1 inhibitor.\\r\\n\\r\\n  -  Has a systemic disease that requires systemic pharmacologic doses of corticosteroids\\r\\n     greater than 10 mg daily prednisone (or equivalent).\\r\\n\\r\\n  -  Has a history of interstitial lung disease or active, non-infectious pneumonitis\\r\\n     that required steroids or has current pneumonitis.\\r\\n\\r\\n  -  Any active infection requiring systemic therapy.\\r\\n\\r\\n  -  Active TB (Bacillus Tuberculosis).\\r\\n\\r\\n  -  Active COVID-19 infection and/or exposure to SARS-CoV-2 as defined below:\\r\\n\\r\\n  -  Positive SARS-CoV-2 result on nasopharyngeal and/or stool specimens (by RT-PCR test)\\r\\n\\r\\n  -  Active COVID-19 infection (per CDC guidelines)\\r\\n\\r\\n  -  Exposure to active COVID-19 infected patient (as confirmed using SARS-CoV-2 RT-PCR\\r\\n     test or other approved test) as defined per CDC guidelines.\\r\\n\\r\\n  -  Active human immunodeficiency virus (HIV) infection.\\r\\n\\r\\n  -  Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA)\\r\\n     and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA)\\r\\n     infection.\\r\\n\\r\\n  -  Has a history or current evidence of any condition, therapy, or laboratory\\r\\n     abnormality that mighconfound the results of the study, interfere with the\\r\\n     participant's participation for the full duration of the study, or is not in the\\r\\n     best interest of the participant to participate, in the opinion of the treating\\r\\n     investigator.\\r\\n\\r\\n  -  Has known psychiatric or substance abuse disorders that would interfere with\\r\\n     cooperation with the requirements of the trial.\\r\\n\\r\\n  -  Is pregnant or breastfeeding or expecting to conceive or father children within the\\r\\n     projected duration of the study, starting with the Screening visit through 120 days\\r\\n     after the last dose of trial treatment.\\r\\n\\r\\n  -  Has had an allogenic tissue/solid organ transplant.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Amy Rose, RN',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '412-647-8587',\n",
       "      'email': 'kennaj@upmc.edu'},\n",
       "     {'name': 'Samantha Berton, RN',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '412-647-9967',\n",
       "      'email': 'bertonsf@upmc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Diwakar Davar, MD, PhD',\n",
       "      'affiliation': 'UPMC Hillman Cancer Center',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'UPMC Hillman Cancer Center',\n",
       "      'city': 'Pittsburgh',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '15232',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Amy Rose, RN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '412-647-8587',\n",
       "        'email': 'kennaj@upmc.edu'},\n",
       "       {'name': 'Samantha Berton, RN',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '412-647-9967',\n",
       "        'email': 'bertonsf@upmc.edu'},\n",
       "       {'name': 'Diwakar Davar, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008545',\n",
       "      'term': 'Melanoma'}],\n",
       "    'ancestors': [{'id': 'D000018358', 'term': 'Neuroendocrine Tumors'},\n",
       "     {'id': 'D000017599', 'term': 'Neuroectodermal Tumors'},\n",
       "     {'id': 'D000009373', 'term': 'Neoplasms, Germ Cell and Embryonal'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000009380', 'term': 'Neoplasms, Nerve Tissue'},\n",
       "     {'id': 'D000018326', 'term': 'Nevi and Melanomas'},\n",
       "     {'id': 'D000012878', 'term': 'Skin Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000012871', 'term': 'Skin Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11528',\n",
       "      'name': 'Melanoma',\n",
       "      'asFound': 'Melanoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20495', 'name': 'Neuroendocrine Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20388',\n",
       "      'name': 'Neuroectodermal Tumors, Primitive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12318',\n",
       "      'name': 'Neoplasms, Germ Cell and Embryonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'},\n",
       "     {'id': 'M12448', 'name': 'Nevus, Pigmented', 'relevance': 'LOW'},\n",
       "     {'id': 'M12446', 'name': 'Nevus', 'relevance': 'LOW'},\n",
       "     {'id': 'M20470', 'name': 'Nevi and Melanomas', 'relevance': 'LOW'},\n",
       "     {'id': 'M15681', 'name': 'Skin Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T4091', 'name': 'Neuroendocrine Tumor', 'relevance': 'LOW'},\n",
       "     {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000582435',\n",
       "      'term': 'Pembrolizumab'},\n",
       "     {'id': 'C000531958', 'term': 'Lenvatinib'}],\n",
       "    'ancestors': [{'id': 'D000074322',\n",
       "      'term': 'Antineoplastic Agents, Immunological'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000082082', 'term': 'Immune Checkpoint Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M353738',\n",
       "      'name': 'Lenvatinib',\n",
       "      'asFound': 'Primary care',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M349416',\n",
       "      'name': 'Pembrolizumab',\n",
       "      'asFound': 'Blind',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6403', 'name': 'Complement C3', 'relevance': 'LOW'},\n",
       "     {'id': 'M18459', 'name': 'Complement C3d', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M2342',\n",
       "      'name': 'Immune Checkpoint Inhibitors',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06426485',\n",
       "    'orgStudyIdInfo': {'id': 'LY03005/CT-CHN-408'},\n",
       "    'organization': {'fullName': 'Luye Pharma Group Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets',\n",
       "    'officialTitle': 'A Multicenter, Randomized Withdrawal, Double-blind, Parallel, Placebo-controlled Design Clinical Trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-02-28', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-24',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Luye Pharma Group Ltd.', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled\\r\\ndesign clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to\\r\\nevaluate the long-term efficacy and safety in the treatment of Chinese patients with\\r\\ndepression.'},\n",
       "   'conditionsModule': {'conditions': ['Major Depressive Disorder']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 736, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg or 160 mg group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'orally once a day',\n",
       "      'interventionNames': ['Drug: Toludesvenlafaxine Hydrochloride Sustained-release Tablets']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'orally once a day',\n",
       "      'interventionNames': ['Drug: placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Toludesvenlafaxine Hydrochloride Sustained-release Tablets',\n",
       "      'description': 'orally once a day',\n",
       "      'armGroupLabels': ['Toludesvenlafaxine Hydrochloride Sustained-release Tablets 80 mg or 160 mg group']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'placebo',\n",
       "      'description': 'orally once a day',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Time to relapse.',\n",
       "      'timeFrame': 'from Baseline to week 24'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change From Double-Blind Treatment Period Baseline in Montgomery - Eisberg Depression Rating Scale (MADRS) Total Score;',\n",
       "      'timeFrame': 'from Baseline to week 24'},\n",
       "     {'measure': 'Change from Double-Blind Treatment Period Baseline in Clinical Global Impression Scale - Severity of Illness (CGI-S) score and Clinical Global Impression Scale - Global Improvement (CGI-I) score',\n",
       "      'timeFrame': 'from Baseline to week 24'},\n",
       "     {'measure': 'Change From Double-Blind Treatment Period Baseline in Hamilton Anxiety Rating Scale (HAMA) Total Score.',\n",
       "      'timeFrame': 'from Baseline to week 24'},\n",
       "     {'measure': 'Change From Double-Blind Treatment Period Baseline in the Anhedonia Rating Scale (DARS) Score',\n",
       "      'timeFrame': 'from Baseline to week 24'},\n",
       "     {'measure': 'Change From Double-Blind Treatment Period Baseline in SHEEHAN Disability Scale (SDS) Score',\n",
       "      'timeFrame': 'from Baseline to week 24'},\n",
       "     {'measure': 'Change from Double-Blind Treatment Period Baseline in Digit Symbol Substitution Test (DSST) Score',\n",
       "      'timeFrame': 'from Baseline to week 24]'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. The subject voluntarily signs the informed consent form and is able to comply with\\r\\n     the scheduled visits, treatment plan, laboratory tests and other study procedures;\\r\\n\\r\\n  2. Aged 18 years and above, male or female;\\r\\n\\r\\n  3. Outpatients with the main diagnosis of depression meeting DSM-5 (Diagnostic and\\r\\n     Statistical Manual of Mental Disorders, 5th Edition) diagnostic criteria for\\r\\n     recurrent episodes (without psychotic features) (F33.1/F33.2);\\r\\n\\r\\n  4. MADRS total score ≥ 26 at baseline of screening and open treatment phase.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Patients who meet the criteria of treatment-resistant depression, that is, patients\\r\\n     who have failed to respond to at least two antidepressants with different mechanisms\\r\\n     of action in the case of adequate treatment (at least 8 weeks of treatment at the\\r\\n     maximum recommended therapeutic dose);\\r\\n\\r\\n  2. Known to have a history of allergy to any component of the investigational product\\r\\n     or similar drugs, or allergic constitution (allergic to two or more drugs or food)\\r\\n     and the investigator considers it inappropriate to participate in the trial;\\r\\n\\r\\n  3. Significant suicide attempt (defined as a score of ≥ 4 on item 10 of the MADRS\\r\\n     scale) or suicidal behavior in the past 6 months on the Columbia-Suicide Severity\\r\\n     Rating Scale (C-SSRS) (\"actual attempt\",\"interrupted attempt\", and\"abandoned\\r\\n     attempt\"with any outcome of\"yes\");\\r\\n\\r\\n  4. Other diseases meeting DSM-5 diagnostic criteria, including organic mental\\r\\n     disorders, substance-related and addictive disorders (except nicotine or caffeine),\\r\\n     schizophrenia spectrum and other psychotic disorders, bipolar and related disorders,\\r\\n     substance/drug-induced depressive disorders, depressive disorders due to other\\r\\n     physical/mental diseases, obsessive-compulsive and related disorders, traumatic and\\r\\n     stress-related disorders, dissociative disorders, anorexia nervosa or bulimia,\\r\\n     personality disorders;\\r\\n\\r\\n  5. Previous history of increased intraocular pressure or closed glaucoma;\\r\\n\\r\\n  6. Patients with poorly controlled hypertension [screening or baseline sitting systolic\\r\\n     blood pressure (SBP) ≥ 160 mmHg or sitting diastolic blood pressure (DBP) ≥ 100\\r\\n     mmHg];\\r\\n\\r\\n  7. Total bilirubin (TBIL) value 1.5 times higher than the upper limit of normal, or\\r\\n     alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 times higher\\r\\n     than the upper limit of normal, or creatinine 1.5 times higher than the upper limit\\r\\n     of normal at screening;\\r\\n\\r\\n  8. Female patients who are pregnant or have a positive pregnancy test result, or male\\r\\n     and female subjects of childbearing potential do not agree to use effective\\r\\n     contraception throughout the study and for at least 1 month after discontinuation;\\r\\n\\r\\n  9. Patients who received electroconvulsive therapy (ECT) within 3 months before\\r\\n     screening or currently require ECT according to the investigator\\'s judgment;\\r\\n\\r\\n 10. Patients who have received or are receiving systemic psychotherapy (interpersonal\\r\\n     therapy, dynamic therapy, cognitive behavioral therapy) within 3 months before\\r\\n     screening or currently need systemic psychotherapy according to the investigator\\'s\\r\\n     judgment;\\r\\n\\r\\n 11. Patients who received physical therapy such as transcranial magnetic stimulation\\r\\n     (TMS), deep brain stimulation, vagus nerve stimulation and transcranial electrical\\r\\n     stimulation within 3 months before screening;\\r\\n\\r\\n 12. Patients who received phototherapy within 2 weeks before screening;\\r\\n\\r\\n 13. Patients who have stopped antidepressant drugs for less than 5 half-lives (at least\\r\\n     2 weeks for monoamine oxidase inhibitors (MAOIs) and 1 month for fluoxetine) before\\r\\n     enrollment;\\r\\n\\r\\n 14. Those who have participated in other clinical trials within 1 month before screening\\r\\n     (excluding those who are not eligible after screening and not enrolled);\\r\\n\\r\\n 15. Currently suffering from acute or severe unstable physical illness, or other\\r\\n     conditions that the investigator judges the subject is not suitable for the study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Hongyan Zhang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '13601237138',\n",
       "      'email': 'hongyanzhang@bjmu.edu.cn'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003866',\n",
       "      'term': 'Depressive Disorder'},\n",
       "     {'id': 'D000003865', 'term': 'Depressive Disorder, Major'}],\n",
       "    'ancestors': [{'id': 'D000019964', 'term': 'Mood Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M7058', 'name': 'Depression', 'relevance': 'LOW'},\n",
       "     {'id': 'M7061',\n",
       "      'name': 'Depressive Disorder',\n",
       "      'asFound': 'Depressive Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7060',\n",
       "      'name': 'Depressive Disorder, Major',\n",
       "      'asFound': 'Major Depressive Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21835', 'name': 'Mood Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06334185',\n",
       "    'orgStudyIdInfo': {'id': 'pVax'},\n",
       "    'organization': {'fullName': 'Azienda Ospedaliera di Lecco',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection.',\n",
       "    'officialTitle': 'Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection: a Retrospective Study in Two Lombardy Centers in the Pre-pandemic Phase From 2015 to 2019.',\n",
       "    'acronym': 'pVax'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-20',\n",
       "    'studyFirstSubmitQcDate': '2024-03-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Stefania Piconi',\n",
       "     'investigatorTitle': 'Director of Infectious Diseases Unit',\n",
       "     'investigatorAffiliation': 'Azienda Ospedaliera di Lecco'},\n",
       "    'leadSponsor': {'name': 'Azienda Ospedaliera di Lecco', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'IRCCS Ospedale San Raffaele',\n",
       "      'class': 'OTHER'}]},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Respiratory tract infections are among the leading causes of death worldwide and many of\\r\\nthese infections are preventable through vaccination. One of the most important bacteria\\r\\nfrom an etiological and mortality point of view regarding respiratory and systemic\\r\\ninfections is the gram-positive Streptococcus pneumoniae. Four types of vaccines are\\r\\ncurrently available for this pathogen: three pneumococcal conjugate vaccines (PCV13,\\r\\nPCV15, and PCV20) and one polysaccharide vaccine (PPSV23). In Italy, people over 65 years\\r\\nof age and people suffering from chronic pathologies with effects on the immune system\\r\\nwould be advised to be vaccinated with the pneumococcal conjugate vaccine and with the\\r\\npolysaccharide vaccine as a second dose.\\r\\n\\r\\nHowever, there are no data available in Italy on vaccination coverage in these population\\r\\ncategories and above all the vaccination rates in patients who have a history of an\\r\\nepisode of invasive pneumococcal infection are not known. The aim of the study is to\\r\\nmeasure how many patients are vaccinated for S. pneumoniae after hospitalization for a\\r\\nsystemic pneumococcal infection in order to understand patients' awareness of preventing\\r\\nthis infection after receiving a first diagnosis.\"},\n",
       "   'conditionsModule': {'conditions': ['Invasive Pneumococcal Infection']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'RETROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 320, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of antipneumococcal vaccination in hospitalized patients for invasive pneumococcal infection between 2015 and 2019.',\n",
       "      'timeFrame': 'The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Rate of pneumococcal serotype that caused the invasive infection in patients vaccinated prior to the infectious event',\n",
       "      'timeFrame': 'The information regarding vaccination after the infectious episode will be assessed by consulting the SIAVR portal or the vaccination booklet in a period between at least one month from discharge and up to 06/30/2023.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patients over 18 years old;\\r\\n\\r\\n  -  Patients hospitalized at the Manzoni Hospital in Lecco or at the San Raffaele\\r\\n     Hospital in Milan with invasive pneumococcal infection in the period between\\r\\n     01/01/2015 and 31/12/2019;\\r\\n\\r\\n  -  Presence of a positive culture test for S. pneumoniae on blood cultures and/or\\r\\n     liquor;\\r\\n\\r\\n  -  Patients whose discharge letter or clinical documentation relating to the infectious\\r\\n     episode is available;\\r\\n\\r\\n  -  Patients whose vaccination record can be consulted (on paper or on SIAVR) and whose\\r\\n     vaccination history is available before and after hospitalization.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with positive urinary antigen for S. pneumoniae as the only microbiological\\r\\n     finding;\\r\\n\\r\\n  -  Patients whose vaccination history or vaccination records are not available.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'A retrospective multicenter study is planned on patients admitted to the Alessandro\\r\\nManzoni Hospital in Lecco and the San Raffaele Hospital in Milan with a diagnosis of\\r\\nsystemic pneumococcal infection from 01/01/2015 to 12/31/2019 before the SARS pandemic\\r\\n-CoV-2.\\r\\n\\r\\nAll patients admitted with a diagnosis of invasive pneumococcal infection defined by\\r\\npositive blood or CSF cultures for S. pneumoniae by the microbiology laboratory were\\r\\nenrolled.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Stefania Piconi, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0341-489890',\n",
       "      'email': 's.piconi@asst-lecco.it'},\n",
       "     {'name': 'Silvia Pontiggia',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0341-253678',\n",
       "      'email': 's.pontiggia@asst-lecco.it'}],\n",
       "    'overallOfficials': [{'name': 'Antonella Castagna, Prof',\n",
       "      'affiliation': 'IRCCS Ospedale San Raffaele Turro - Milano Infectious Diseases Unit',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007239',\n",
       "      'term': 'Infections'},\n",
       "     {'id': 'D000003141', 'term': 'Communicable Diseases'},\n",
       "     {'id': 'D000011014', 'term': 'Pneumonia'},\n",
       "     {'id': 'D000011018', 'term': 'Pneumonia, Pneumococcal'},\n",
       "     {'id': 'D000011008', 'term': 'Pneumococcal Infections'}],\n",
       "    'ancestors': [{'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000012141', 'term': 'Respiratory Tract Infections'},\n",
       "     {'id': 'D000008171', 'term': 'Lung Diseases'},\n",
       "     {'id': 'D000012140', 'term': 'Respiratory Tract Diseases'},\n",
       "     {'id': 'D000013290', 'term': 'Streptococcal Infections'},\n",
       "     {'id': 'D000016908', 'term': 'Gram-Positive Bacterial Infections'},\n",
       "     {'id': 'D000001424', 'term': 'Bacterial Infections'},\n",
       "     {'id': 'D000001423', 'term': 'Bacterial Infections and Mycoses'},\n",
       "     {'id': 'D000018410', 'term': 'Pneumonia, Bacterial'}],\n",
       "    'browseLeaves': [{'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6368',\n",
       "      'name': 'Communicable Diseases',\n",
       "      'asFound': 'Infection',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13904',\n",
       "      'name': 'Pneumonia',\n",
       "      'asFound': 'Pneumonia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13908',\n",
       "      'name': 'Pneumonia, Pneumococcal',\n",
       "      'asFound': 'Streptococcus Pneumoniae',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13898',\n",
       "      'name': 'Pneumococcal Infections',\n",
       "      'asFound': 'Pneumococcal Infections',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'M14978',\n",
       "      'name': 'Respiratory Tract Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14977',\n",
       "      'name': 'Respiratory Tract Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16080', 'name': 'Streptococcal Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M4722', 'name': 'Bacterial Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M19252',\n",
       "      'name': 'Gram-Positive Bacterial Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12136', 'name': 'Mycoses', 'relevance': 'LOW'},\n",
       "     {'id': 'M4721',\n",
       "      'name': 'Bacterial Infections and Mycoses',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20529', 'name': 'Pneumonia, Bacterial', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC08',\n",
       "      'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05391841',\n",
       "    'orgStudyIdInfo': {'id': 'AAG-O-H-2123'},\n",
       "    'organization': {'fullName': 'Tetec AG', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee',\n",
       "    'officialTitle': 'Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART Inject for the Treatment of Cartilage Defects in the Knee in Pediatric Patients With Closed Epiphyses',\n",
       "    'acronym': 'NINJA'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-11',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2032-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-04-08',\n",
       "    'studyFirstSubmitQcDate': '2022-05-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-05-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-11-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-11-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Tetec AG', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'Winicker Norimed GmbH', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The study is a prospective, multicenter, single-arm non-interventional study to evaluate\\r\\nthe efficacy, safety and health economics of NOVOCART® Inject in the treatment of\\r\\ncartilage defects of the knee in pediatric patients with radiologically proven closed\\r\\nepiphyseal growth plates.',\n",
       "    'detailedDescription': 'In this non-interventional study NOVOCART® Inject, which is marketed in Germany under a\\r\\nlicense according to Section 4b of the AMG, will be used in routine clinical practice\\r\\naccording to the current authorized Summary of Product Characteristics (SmPC). As stated\\r\\nin this SmPC, NOVOCART® Inject may only be used by physicians who are trained on the\\r\\nproduct. The treatment with NOVOCART® Inject requires two surgeries. During the first\\r\\nsurgery cartilage tissue will be harvested arthroscopically and sent to TETEC AG for\\r\\nNOVOCART® Inject manufacturing, then NOVOCART® Inject will be transplanted during a\\r\\nsecond surgery about 3 to 4 weeks later.\\r\\n\\r\\nAll patients will be followed up for 5 years post NOVOCART® Inject implantation and data\\r\\nwill be collected preoperatively and at 3, 6, 12, 18, 24, 36, 48 and 60 months as\\r\\noutlined at the end of this synopsis.\\r\\n\\r\\nNOVOCART® Inject post treatment rehabilitation should follow the recommendations given in\\r\\nthe SmPC and during product training.\\r\\n\\r\\nThe primary and secondary variables (see below) will be assessed after a follow-up of 24\\r\\nmonth post NOVOCART® Inject implantation (primary analysis).\\r\\n\\r\\nLong-term data will be assessed after an additional 3 years follow-up (follow-up\\r\\nanalysis).\\r\\n\\r\\nThe collected data will be documented using dedicated case report forms (CRFs) which are\\r\\ncreated by TETEC AG.'},\n",
       "   'conditionsModule': {'conditions': ['Cartilage Disease'],\n",
       "    'keywords': ['NOVOCART Inject',\n",
       "     'Cartilage Defect',\n",
       "     'Pediatric Patients',\n",
       "     'Knee',\n",
       "     'Cartilage Injury']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '5 Years',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'DRUG',\n",
       "      'name': 'NOVOCART Inject',\n",
       "      'description': 'Autologous Chondrocyte Implantation'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Responder rate of overall KOOS',\n",
       "      'description': 'The overall Knee injury and Osteoarthritis Outcome Score (KOOS5) responder rate defined\\r\\nas the proportion of patients with ≥ 10 points improvement in the KOOS5 from baseline.',\n",
       "      'timeFrame': '24-months Follow-up'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change of overall KOOS from baseline',\n",
       "      'description': 'Change of overall KOOS from baseline to the 24-month assessment, Knee Injury and\\r\\nOsteoarthritis Outcome Score, score 0-100, higher score shows better outcome',\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': 'Change of the 5 sub-scores of the KOOS from baseline',\n",
       "      'description': 'Change of the 5 sub-scores of the KOOS from baseline to the 24-month assessment, Knee\\r\\nInjury and Osteoarthritis Outcome Score, score 0-100, higher score shows better outcome',\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': 'Change of the IKDC subjective score from baseline',\n",
       "      'description': 'Change from baseline to the 24-month visit in the IKDC subjective score, international\\r\\nknee documentation committee, score 0-100, higher score shows better outcome',\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': \"Change in the IKDC surgeon's part from baseline\",\n",
       "      'description': \"Change from baseline to the 24-month visit in the IKDC surgeon's part. international knee\\r\\ndocumentation committee, score 0-100, higher score shows better outcome\",\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': 'MOCART (MRI imaging)',\n",
       "      'description': 'In vivo performance measured by the assessment of the Magnetic Resonance, Observation of\\r\\nCartilage Repair Tissue (MOCART) score, Magnetic Resonance Observation of Cartilage\\r\\nRepair Tissue, score 0-100, higher score shows better outcome',\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': 'IKDC subjective score responder rate',\n",
       "      'description': 'IKDC subjective score responder rate, defined as the proportion of patients with > 20.5\\r\\npoints improvement in the IKDC subjective score from baseline to the 24-month visit',\n",
       "      'timeFrame': '24-months Follow-up'},\n",
       "     {'measure': 'Proportion of patients with treatment failure',\n",
       "      'description': 'Proportion of patients with treatment failure',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Number of postop physical therapy',\n",
       "      'description': 'Number of postop physical therapy',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Number of postop doctor visits',\n",
       "      'description': 'Number of postop doctor visits',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Days of hospitalisation',\n",
       "      'description': 'Days of hospitalisation',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Work/school status checklist',\n",
       "      'description': 'Work/school status, changes due to injury in work or school status (pupil, worker full or\\r\\npart time, not working, job seeking)',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Days of work/school missed',\n",
       "      'description': 'Days of work/school missed',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Patient satisfaction',\n",
       "      'description': 'Patient questionnaire, 4 questions with 3 answer choices better, same, worse',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Treatment-related adverse reactions (ARs)',\n",
       "      'description': 'Treatment-related adverse reactions (ARs)',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Rate of unplanned re-operations',\n",
       "      'description': 'Rate of unplanned re-operations: all unplanned reoperations and those related to\\r\\nNOVOCART® Inject treatment',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Surgical time',\n",
       "      'description': 'cut-to-suture time',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Length of incision',\n",
       "      'description': 'Length of incision',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'}],\n",
       "    'otherOutcomes': [{'measure': 'Adverse reactions',\n",
       "      'description': 'Continuous assessment of adverse reactions (ARs)',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Number of device deficiencies - trephine',\n",
       "      'description': 'Number of device deficiencies - trephine',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Number of device deficiencies - Application System',\n",
       "      'description': 'Number of device deficiencies - Application System',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'},\n",
       "     {'measure': 'Number of device deficiencies - number of product related issues',\n",
       "      'description': 'Number of device deficiencies - number of product related issues',\n",
       "      'timeFrame': '24-months Follow up, 60-months Follow-up'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Pediatric patients (< 18 years of age at implantation)\\r\\n\\r\\n  -  Closure of the epiphysis adjacent to the biopsy harvest site or the defect to be\\r\\n     treated confirmed by an adequate imaging modality\\r\\n\\r\\n  -  Localized full-thickness cartilage defect (ICRS grade III or IV) of the knee\\r\\n\\r\\n  -  Medicinal indication for NOVOCART® Inject treatment\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nsee NOVOCART Inject SmPC',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'maximumAge': '17 Years',\n",
       "    'stdAges': ['CHILD'],\n",
       "    'studyPopulation': \"Pediatric patients (< 18 years of age) with closed epiphyses who suffer from a\\r\\nfull-thickness cartilage defect of the knee caused by acute or repetitive trauma or by\\r\\nosteochondrosis dissecans and who are scheduled for treatment with NOVOCART Inject SmPC,\\r\\nwhere the therapeutic indications, contraindications, special warnings and precautions\\r\\nfor use are listed in detail. The decision to treat patients with NOVOCART Inject must be\\r\\nmade independently from the patient's participation in the study.\",\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Silvia Rombach, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+49 7121 1626 202',\n",
       "      'email': 'silvia.rombach@tetec-ag.de'}],\n",
       "    'overallOfficials': [{'name': 'Peter Angele, Prof. Dr.',\n",
       "      'affiliation': 'Universitätsklinik Regensburg',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'St. Josefs-Hospital Cloppenburg gemeinnützige GmbH',\n",
       "      'city': 'Cloppenburg',\n",
       "      'zip': '49661',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Boris Baron von Engelhardt, Dr. med.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+494471 16 2008',\n",
       "        'email': 'boris.vonEngelhardt@kh-clp.de'}],\n",
       "      'geoPoint': {'lat': 52.84754, 'lon': 8.045}},\n",
       "     {'facility': 'Universitätsklinikum Freiburg',\n",
       "      'city': 'Freiburg',\n",
       "      'zip': '79119',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Hagen Schmal, Prof. Dr.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+49 761 270-26990',\n",
       "        'email': 'hagen.schmal@uniklinik-freiburg.de'}],\n",
       "      'geoPoint': {'lat': 47.9959, 'lon': 7.85222}},\n",
       "     {'facility': 'OCM Klinik GmbH München',\n",
       "      'city': 'München',\n",
       "      'zip': '81369',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Phillipp Niemeyer, Prof. Dr.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+49 89 206082-0',\n",
       "        'email': 'philipp.niemeyer@ocm-muenchen.de'}],\n",
       "      'geoPoint': {'lat': 48.13743, 'lon': 11.57549}},\n",
       "     {'facility': 'Klinikum rechts der Isar, Technische Universität München',\n",
       "      'city': 'München',\n",
       "      'zip': '81675',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Sebastian Siebenlist, Prof. Dr.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+49(0)89 41405118',\n",
       "        'email': 'sebastian.siebenlist@mri.tum.de'}],\n",
       "      'geoPoint': {'lat': 48.13743, 'lon': 11.57549}},\n",
       "     {'facility': 'Universitätsklinikum Regensburg',\n",
       "      'city': 'Regensburg',\n",
       "      'zip': '93053',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Peter Angele, Prof. Dr.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0941 944-6805',\n",
       "        'email': 'peter.angele@ukr.de'}],\n",
       "      'geoPoint': {'lat': 49.01513, 'lon': 12.10161}},\n",
       "     {'facility': 'Universitätsklinikum Tübingen',\n",
       "      'city': 'Tübingen',\n",
       "      'zip': '72076',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Christian Konrads, PD Dr.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+49 7071 29-68217',\n",
       "        'email': 'Christian.Konrads@med.uni-tuebingen.de'}],\n",
       "      'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002357',\n",
       "      'term': 'Cartilage Diseases'}],\n",
       "    'ancestors': [{'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000003240', 'term': 'Connective Tissue Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M5611',\n",
       "      'name': 'Cartilage Diseases',\n",
       "      'asFound': 'Cartilage Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6464',\n",
       "      'name': 'Connective Tissue Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06290141',\n",
       "    'orgStudyIdInfo': {'id': 'EFC18156'},\n",
       "    'secondaryIdInfos': [{'id': 'U1111-1295-3363',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'ICTRP'},\n",
       "     {'id': '2023-508338-33', 'type': 'REGISTRY', 'domain': 'CTIS'}],\n",
       "    'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)',\n",
       "    'officialTitle': 'A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "    'acronym': 'VITALIZE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-11-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-05-19', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-26',\n",
       "    'studyFirstSubmitQcDate': '2024-02-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-04', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult\\r\\nparticipants with CIDP who are receiving maintenance treatment with IVIg. The study\\r\\nduration will be for a maximum of 109 weeks including screening, treatment phases, and\\r\\nfollow-up.'},\n",
       "   'conditionsModule': {'conditions': ['Chronic Inflammatory Demyelinating Polyneuropathy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Part A is a double-blind treatment period and Part B is an open-label period.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Riliprubart Arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Riliprubart + Placebo IVIg for 24 weeks followed by open-label extension phase with\\r\\nriliprubart for 24 weeks',\n",
       "      'interventionNames': ['Drug: riliprubart',\n",
       "       'Drug: Placebo',\n",
       "       'Drug: IVIg premedication']},\n",
       "     {'label': 'IVIg Arm',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'IVIg (IVIg continuation) + Placebo riliprubart for 24 weeks followed by open-label\\r\\nextension phase with riliprubart for 24 weeks',\n",
       "      'interventionNames': ['Drug: Placebo',\n",
       "       'Drug: riliprubart',\n",
       "       'Drug: IVIg',\n",
       "       'Drug: IVIg premedication']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'riliprubart',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:IV solution',\n",
       "      'armGroupLabels': ['Riliprubart Arm'],\n",
       "      'otherNames': ['SAR445088']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:IV solution',\n",
       "      'armGroupLabels': ['IVIg Arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'riliprubart',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:SC solution',\n",
       "      'armGroupLabels': ['IVIg Arm', 'Riliprubart Arm'],\n",
       "      'otherNames': ['SAR445088']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:SC solution',\n",
       "      'armGroupLabels': ['IVIg Arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'IVIg',\n",
       "      'description': 'Pharmaceutical form:Concentrate for solution for infusion (or any other formulation\\r\\napproved locally)-Route of administration:IV solution',\n",
       "      'armGroupLabels': ['IVIg Arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pharmaceutical form:Placebo to match intravenous immunoglobulin IVIg for IV\\r\\ninfusion-Route of administration:IV solution',\n",
       "      'armGroupLabels': ['Riliprubart Arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'IVIg premedication',\n",
       "      'description': 'Pharmaceutical form:Per respective labels-Route of administration:Per respective labels',\n",
       "      'armGroupLabels': ['IVIg Arm', 'Riliprubart Arm']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of participants experiencing a response',\n",
       "      'description': 'A response is defined as decrease of ≥1 point from baseline in adjusted INCAT disability\\r\\nscore at Week 24',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Percentage of participants randomized to riliprubart who responded during the double-blind period and had a lasting response during the open-label period',\n",
       "      'description': 'Lasting response is defined as a decrease of ≥1 point no in adjusted INCAT disability\\r\\nscore',\n",
       "      'timeFrame': 'Baseline to week 48'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change from baseline in Rasch-built Overall Disability Scale (I-RODS) score',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in adjusted inflammatory neuropathy cause and treatment (INCAT) disability score',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in grip strength (kilopascals, dominant hand)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in Medical Research Council Sum Score (MRC-SS)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in the Rasch-built modified fatigue severity scale (RT-FSS)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Percentage of participants experiencing a relapse',\n",
       "      'description': 'A relapse is defined as increase of ≥1 point from baseline in adjusted INCAT disability\\r\\nscore',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in the EuroQol 5 Dimension, 5-Level Health Scale (EQ-5D-5L)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Number of participants with TEAEs, including SAEs and AESIs',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Number of participants with treatment-emergent ADA in participants treated with riliprubart',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Number of participants with TEAEs, including SAEs and AESIs',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to riliprubart experiencing a relapse',\n",
       "      'description': 'A relapse is defined as an increase of ≥1 point from baseline',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to IVIg continuation experiencing a relapse',\n",
       "      'description': 'A relapse is defined as an increase of ≥1 point from baseline in adjusted INCAT\\r\\ndisability score',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Number of participants and titer of anti-drug antibodies (ADA)',\n",
       "      'timeFrame': 'Baseline to week 109'},\n",
       "     {'measure': 'Change from baseline in I-RODS',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in adjusted INCAT score',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in grip strength (kilopascals; dominant hand)',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in MRC-SS',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in RT-FSS',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in EQ-5D-5L score',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to riliprubart who experience a response during the open-label period without prior response in the double-blind period (delayed response)',\n",
       "      'description': 'A delayed response is defined as a decrease of ≥1 point in adjusted INCAT disability\\r\\nscore',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to IVIg continuation who experience a response',\n",
       "      'description': 'A response is defined as a decrease of ≥1 point in adjusted INCAT disability score',\n",
       "      'timeFrame': 'Week 24 to week 48'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nParticipants are eligible to be included in the study only if all of the following\\r\\ncriteria apply:\\r\\n\\r\\n  -  Participant must have CIDP or possible CIDP criteria, based on European Academy of\\r\\n     Neurology (EAN)/ Peripherial Nerve Society (PNS) Task Force CIDP guidelines, second\\r\\n     revision (2021).\\r\\n\\r\\n  -  Participant must have either typical CIDP, or one of the following 2 CIDP variants:\\r\\n     motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be\\r\\n     confirmed by the study adjudication committee.\\r\\n\\r\\n  -  Participants must have responded to IVIg in the past 5 years. Response must be an\\r\\n     objective clinically meaningful improvement defined by at least one of the\\r\\n     following: ≥1 point decrease in adjusted INCAT score, ≥4 points increase in I-RODS\\r\\n     total score, ≥3 points increase in the MRC-SS, ≥8 kilopascal improvement in mean\\r\\n     grip strength (1 hand), or an equivalent improvement based on information documented\\r\\n     in medical records as per the Investigator\\'s judgment.\\r\\n\\r\\n  -  Participant must be on a stable maintenance dosage of IVIg, defined as no change\\r\\n     greater than 10% in frequency or dose of IVIg within 8 weeks prior to Screening, and\\r\\n     remaining stable until baseline.\\r\\n\\r\\n  -  Participant must have residual disability, defined as an INCAT score of 2 to 9 at\\r\\n     Screening that is confirmed at baseline (a score of 2 should be exclusively from leg\\r\\n     disability component of INCAT).\\r\\n\\r\\n  -  Participant must be receiving treatment with IVIg within a standard maintenance\\r\\n     dosing regimen, defined as per EAN/PNS 2021 CIDP guidelines: 0.4 to 1 g/kg every 2\\r\\n     to 6 weeks.\\r\\n\\r\\n  -  Participants receiving IVIg infusions at home are eligible, as long as IVIg\\r\\n     infusions are switched to a hospital or infusion center setting at least 1 cycle\\r\\n     prior to baseline.\\r\\n\\r\\n  -  Participant must have active disease, defined by a CIDP disease activity score\\r\\n     (CDAS) XE \" CDAS \" \\\\f Abbreviation \\\\t \"CIDP disease activity score\" of ≥2 points at\\r\\n     Screening.\\r\\n\\r\\n  -  Participant must have documented vaccinations against encapsulated bacterial\\r\\n     pathogens given within 5 years of Screening or initiated a minimum of 14 days prior\\r\\n     to first dose of study intervention.\\r\\n\\r\\n  -  All participants must agree to use contraception methods during and after the study\\r\\n     as required.\\r\\n\\r\\n  -  Contraceptive use by men and women participating in the study should be consistent\\r\\n     with local regulations regarding the methods of contraception for those\\r\\n     participating in clinical studies.\\r\\n\\r\\n  -  A male participant is eligible to participate if they agree to the following during\\r\\n     the study intervention period and for at least 55 weeks after the last dose of study\\r\\n     medication.\\r\\n\\r\\n       -  Refrain from donating or cryopreserving sperm.\\r\\n\\r\\nPLUS, either:\\r\\n\\r\\n--Be abstinent from heterosexual intercourse as their preferred and usual lifestyle\\r\\n(abstinent on a long-term and persistent basis) and agree to remain abstinent.\\r\\n\\r\\nOR\\r\\n\\r\\n  -  Must agree to use contraception/barrier as detailed below:\\r\\n\\r\\n       -  A male condom and an additional highly effective contraceptive method\\r\\n          (Contraceptive and barrier guidance per protocol) when having sexual\\r\\n          intercourse with a woman of childbearing potential (WOCBP) who is not currently\\r\\n          pregnant.\\r\\n\\r\\n       -  A female participant is eligible to participate if she is not pregnant or\\r\\n          breastfeeding, and one of the following conditions applies:\\r\\n\\r\\n  -  Is a woman of nonchildbearing potential (WONCBP) as defined by the protocol. OR\\r\\n\\r\\n  -  Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a\\r\\n     failure rate of <1% per year), preferably with low user dependency, as described in\\r\\n     the protocol during the study intervention period (to be effective before starting\\r\\n     the intervention) and for at least 55 weeks after the last administration of study\\r\\n     intervention and agrees not to donate or cryopreserve eggs (ova, oocytes) for the\\r\\n     purpose of reproduction during this period.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nParticipants are excluded from the study if any of the following criteria apply:\\r\\n\\r\\n  -  Polyneuropathy of other causes, including but not limited to hereditary\\r\\n     demyelinating neuropathies, neuropathies secondary to infection or systemic disease,\\r\\n     diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor\\r\\n     neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS XE \" POEMS \"\\r\\n     \\\\f Abbreviation \\\\t \"polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma\\r\\n     cell disorder, skin changes\" syndrome, lumbosacral radiculoplexus neuropathy.\\r\\n\\r\\n  -  Sensory CIDP, distal CIDP and focal CIDP variants.\\r\\n\\r\\n  -  Any other neurological or systemic disease that can cause symptoms and signs\\r\\n     interfering with treatment or outcome assessments.\\r\\n\\r\\n  -  Poorly controlled diabetes (HbA1c XE \" HbA1c \" \\\\f Abbreviation \\\\t \"glycated\\r\\n     hemoglobin\" >7%).\\r\\n\\r\\n  -  Serious infections requiring hospitalization within 30 days prior to Screening, any\\r\\n     active infection requiring treatment during Screening, or presence of a condition\\r\\n     that may predispose the participant to increased risk of infection (eg, medical\\r\\n     history such as known immunodeficiency or history of recurrent infections).\\r\\n\\r\\n  -  Clinical diagnosis of Systemic Lupus Erythematosus (SLE)\\r\\n\\r\\n  -  Sensitivity to any of the study interventions, or components thereof, or drug or\\r\\n     other allergy that, in the opinion of the Investigator, contraindicates\\r\\n     participation in the study. Specifically, history of any hypersensitivity reaction\\r\\n     to riliprubart or its components or of a severe allergic or anaphylactic reaction to\\r\\n     any humanized or murine monoclonal antibody.\\r\\n\\r\\n  -  Any contraindication related to the administration of immunoglobulins (eg\\r\\n     hypersensitivity, chronic kidney disease, thromboembolic diseases or recent\\r\\n     thromboembolic event, known history of IgA XE \" IgA \" \\\\f Abbreviation \\\\t\\r\\n     \"immunoglobulin A\" deficiency at the time of Screening).\\r\\n\\r\\n  -  Any other clinically meaningful medical history or ongoing medical condition (as\\r\\n     determined by the Investigator at Screening) that might impact the benefit-risk\\r\\n     assessment, jeopardize the safety of the participant, or compromise the quality of\\r\\n     the data collected in this study; or history or presence of other significant\\r\\n     concomitant illness that would adversely affect participation in this study, per the\\r\\n     Investigator\\'s judgment.\\r\\n\\r\\n  -  Documented history of attempted suicide over the 6 months prior to the Screening\\r\\n     visit, presence of suicidal ideation of category 4 or 5 on the C-SSRS XE \" C-SSRS \"\\r\\n     \\\\f Abbreviation \\\\t \"Coiumbia-Suicide Severity Rating Scale\" during Screening, OR if\\r\\n     in the Investigator\\'s judgment, the participant is at risk for a suicide attempt.\\r\\n\\r\\n  -  Evidence of CIDP worsening within the 6 weeks following a prior vaccination that, in\\r\\n     the opinion of the Investigator, constituted a relapse.\\r\\n\\r\\n  -  Recent or planned major surgery that could confound the results of the trial or put\\r\\n     the participant at undue risk.\\r\\n\\r\\n  -  Treatment with plasma exchange within 8 weeks prior to Screening.\\r\\n\\r\\n  -  Treatment within 3 months prior to dosing with immunosuppressive/ immunomodulator\\r\\n     medication, or corticosteroids (except ≤20 mg/day of prednisone or equivalent which\\r\\n     is allowed), or prior treatment (at any time) with highly immunosuppressive/\\r\\n     chemotherapeutic medications with sustained effects (eg, mitoxantrone, alemtuzumab,\\r\\n     or cladribine).\\r\\n\\r\\n  -  Prior treatment with riliprubart.\\r\\n\\r\\n  -  Use of any specific complement system inhibitor (eg, eculizumab) within 12 weeks or\\r\\n     5 times the half-life of the product, whichever is longer, prior to Screening.\\r\\n\\r\\n  -  Prior treatment (any time) with total lymphoid irradiation or bone marrow\\r\\n     transplantation.\\r\\n\\r\\n  -  Prior treatment with B-cell depleting agents such as rituximab within 6 months prior\\r\\n     to riliprubart dosing, or before B-cell counts return to normal levels, whichever is\\r\\n     longer.\\r\\n\\r\\n  -  Any vaccination received within 28 days prior to dosing (with few exceptions to be\\r\\n     confirmed at screening).\\r\\n\\r\\n  -  Participation in another clinical trial with an investigational drug or receipt of\\r\\n     an investigational product within 12 weeks or 5 times the half-life of the product\\r\\n     (whichever is longer) prior to Screening.\\r\\n\\r\\n  -  Any Screening laboratory values outside normal limits or abnormal ECG considered in\\r\\n     the Investigator\\'s judgment to be clinically significant in the context of this\\r\\n     trial.\\r\\n\\r\\n  -  Positive result of any of the following tests:\\r\\n\\r\\n       -  HBsAg XE \" HBsAg \" \\\\f Abbreviation \\\\t \"Hepatitis B surface antigen\" .\\r\\n\\r\\n       -  Anti-HBc Ab XE \" HBc Ab \" \\\\f Abbreviation \\\\t \"Hepatitis B core antibodies\" ;\\r\\n          unless anti-HBs Ab XE \" HBs Ab \" \\\\f Abbreviation \\\\t \"Hepatitis B surface\\r\\n          antibody\" are also positive, indicating natural immunity.\\r\\n\\r\\n       -  Anti-HCV XE \" HCV \" \\\\f Abbreviation \\\\t \"Hepatitis C virus\" antibodies.\\r\\n\\r\\n       -  Anti-HIV1 XE \" HIV1\" \\\\f Abbreviation \\\\t \"human immunodeficiency virus 1\" and\\r\\n          anti-HIV2 XE \" HIV2\" \\\\f Abbreviation \\\\t \"human immunodeficiency virus 2\"\\r\\n          antibodies.\\r\\n\\r\\n  -  Pregnancy, defined as a positive result of a highly sensitive urine or serum\\r\\n     pregnancy test, or lactation.\\r\\n\\r\\n  -  Accommodation in an institution because of regulatory or legal order; imprisoned or\\r\\n     legally institutionalized.\\r\\n\\r\\n  -  Participant not suitable for participation, whatever the reason, as judged by the\\r\\n     Investigator, including medical or clinical conditions, or participants potentially\\r\\n     at risk of noncompliance to study procedures.\\r\\n\\r\\n  -  Participants are employees of the clinical study site or other individuals directly\\r\\n     involved in the conduct of the study, or immediate family members of such\\r\\n     individuals XE \" ICH \" \\\\f Abbreviation \\\\t \"Internation Council of Harmonization\" XE\\r\\n     \" GCP \" \\\\f Abbreviation \\\\t \"Good clinical practice\" .\\r\\n\\r\\n  -  Any country-related specific regulation that would prevent the participant from\\r\\n     entering the study as defined by the protocol.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Trial Transparency email recommended (Toll free for US & Canada)',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '800-633-1610',\n",
       "      'phoneExt': 'option 6',\n",
       "      'email': 'Contact-US@sanofi.com'}],\n",
       "    'locations': [{'facility': 'Alabama Neurology Associates Site Number : 8400019',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Birmingham',\n",
       "      'state': 'Alabama',\n",
       "      'zip': '35209',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Qualified researchers may request access to patient level data and related study\\r\\ndocuments including the clinical study report, study protocol with any amendments, blank\\r\\ncase report form, statistical analysis plan, and dataset specifications. Patient level\\r\\ndata will be anonymized and study documents will be redacted to protect the privacy of\\r\\ntrial participants. Further details on Sanofi's data sharing criteria, eligible studies,\\r\\nand process for requesting access can be found at: https://vivli.org\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011115',\n",
       "      'term': 'Polyneuropathies'},\n",
       "     {'id': 'D000020277',\n",
       "      'term': 'Polyradiculoneuropathy, Chronic Inflammatory Demyelinating'}],\n",
       "    'ancestors': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000011129', 'term': 'Polyradiculoneuropathy'},\n",
       "     {'id': 'D000020274', 'term': 'Autoimmune Diseases of the Nervous System'},\n",
       "     {'id': 'D000003711', 'term': 'Demyelinating Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M13999',\n",
       "      'name': 'Polyneuropathies',\n",
       "      'asFound': 'Polyneuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22097',\n",
       "      'name': 'Polyradiculoneuropathy, Chronic Inflammatory Demyelinating',\n",
       "      'asFound': 'Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14013', 'name': 'Polyradiculoneuropathy', 'relevance': 'LOW'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22094',\n",
       "      'name': 'Autoimmune Diseases of the Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6909', 'name': 'Demyelinating Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T1306',\n",
       "      'name': 'Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "      'asFound': 'Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000016756',\n",
       "      'term': 'Immunoglobulins, Intravenous'},\n",
       "     {'id': 'D000005719', 'term': 'gamma-Globulins'},\n",
       "     {'id': 'D000018029', 'term': 'Rho(D) Immune Globulin'}],\n",
       "    'ancestors': [{'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M19117',\n",
       "      'name': 'Immunoglobulins, Intravenous',\n",
       "      'asFound': 'Stretching exercises',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8836',\n",
       "      'name': 'gamma-Globulins',\n",
       "      'asFound': 'Stretching exercises',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20191',\n",
       "      'name': 'Rho(D) Immune Globulin',\n",
       "      'asFound': 'Stretching exercises',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06206941',\n",
       "    'orgStudyIdInfo': {'id': 'STUDY0007957'},\n",
       "    'organization': {'fullName': 'State University of New York at Buffalo',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer',\n",
       "    'officialTitle': 'Assessing Benefits and Harms of Cannabis Use in Patients Treated With Immunotherapy for Cancer: a Prospective Cohort Study',\n",
       "    'acronym': 'IMPACT-C'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-21',\n",
       "    'studyFirstSubmitQcDate': '2024-01-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Rebecca Ashare',\n",
       "     'investigatorTitle': 'Associate Professor',\n",
       "     'investigatorAffiliation': 'State University of New York at Buffalo'},\n",
       "    'leadSponsor': {'name': 'State University of New York at Buffalo',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Thomas Jefferson University',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Oregon Health and Science University', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this research is to assess how patients with cancer being treated with\\r\\nImmune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its\\r\\ntreatment. Patients use a variety of ways to manage symptoms including traditional and\\r\\nalternative treatments including cannabis, acupuncture, etc. This research will have an\\r\\nimportant impact on our knowledge of cancer symptom management, and ultimately improve\\r\\npatient care and safety.\\r\\n\\r\\nParticipants will complete online surveys and 7 days of ecological momentary assessments\\r\\nat 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users\\r\\nsymptoms.',\n",
       "    'detailedDescription': \"Immunotherapy:Prospective Assessment of Cannabis Treatment in Cancer (IMPACT-C) is an\\r\\nobservational study to assess the side effect of cancer patients going through\\r\\nimmunotherapy treatments. The investigators will use a variety of methods to recruit,\\r\\nincluding generating reports of potentially eligible patients from institutional\\r\\nregistries, reviewing Electronic Medical Records (EMR), approaching patients during their\\r\\nregular outpatient visits, taking referrals from oncology teams, and placing study\\r\\nadvertisements at strategic locations of the oncology clinics and Facebook sites. If a\\r\\npotentially eligible patient is interested in the study, the research assistant (RA) will\\r\\nreview the eligibility checklist. The consent form will be written in easy-to-understand\\r\\nEnglish and administered during a regular office visit or virtually via video/phone\\r\\nmeeting, based on patients' convenience and preference. Once informed consent/HIPAA are\\r\\ncompleted and eligibility is confirmed, participants will complete Baseline measures (see\\r\\nMeasurement Table). Those patients that are eligible for the subset of blood draws will\\r\\nreview and sign the amendment.\\r\\n\\r\\nA research assistant (RA) or study staff will collect self-reported data using video or\\r\\nphone calls at all time points; This method has several advantages, including participant\\r\\nconvenience and the RAs' ability to directly enter data into a secure study database,\\r\\nthereby reducing the potential for missing data. Assessments range from 30-60 min per\\r\\ntime point. In person visits can be arranged if technology is limited at the cancer\\r\\ncenters or University.\\r\\n\\r\\nEcological Momentary Assessment (EMA). Daily EMA data will be collected for 7 consecutive\\r\\ndays at each assessment timepoint (total of 49 days) using web link or an application\\r\\n(app) that can be loaded onto the patients' smart phone (significantly reducing patient\\r\\nburden). The week of data collection in measurement months (0, 1, 2, 4, 6, 9 and 12) will\\r\\nbe randomized across participants. Capturing data at various times throughout the month\\r\\nwill allow the investigators to account for potential confounding factors (e.g., patients\\r\\nreceiving income at the beginning of the month). The EMA (mEMA; ilumivu, Inc. Or through\\r\\nREDCap and Mosio), provides flexibility in survey creation, alert scheduling, and\\r\\nmonitoring of participant compliance. The mEMA platforms time stamps all responses to\\r\\nmonitor fidelity, is available for both Android and iphone Oporating System (iOS) phones,\\r\\nand allows recording of responses even when Wi-Fi and cellular signals are lost or turned\\r\\noff (e.g., airplane mode). All de-identified data (linked only to participant ID) are\\r\\nsynchronized with a secure server. EMA training and assessment procedures will follow\\r\\nprior and on-going work of the investigators. During the Baseline call (Month 0),\\r\\nparticipants will be trained on proper use of the EMA and will demonstrate the ability to\\r\\ncomplete both self-initiated assessments (morning assessment) and device-initiated\\r\\nassessments (alerts sent to participant at random times of day). Study staff will\\r\\ncomplete regular check-ins to troubleshoot any difficulties with the EMA. To improve\\r\\nadherence and reduce burden, participants will select a 9-hour period during which EMA\\r\\nprompts occur each day (our pilot work indicated that a 12-hour period was too long as\\r\\nmany patients reported going to bed early and sleeping late).\\r\\n\\r\\nEMA Measures include, Morning Assessment (user initiated, 1/day, duration 3-7 minutes,\\r\\ntimeframe: previous 24 hours) of questions regarding; Cannabis use,Daily use (yes or no)\\r\\nsource, form composition, and quantity, Reason for Cannabis use, Pain, sleep, anxiety,\\r\\nnausea, enjoyment, other (6-item checkboxes),Adverse effects (Dizziness, difficult\\r\\nconcentrating, Impaired memory, Fatigue (4-item checkboxes),Other medications (Opioids,\\r\\nbenzodiazepines, sleep aids, etc.)\\r\\n\\r\\nDevice-initiated Assessments 3 random alarms, 3/day. Every 3 hours over a 9-hour\\r\\nduration: 2-5 min., timeframe: current) of questions on Cannabis use,use since last\\r\\nassessment (yes or no); quantity, form, composition, reason for use (see above), anxiety\\r\\n(2 randomly selected items from the Patient Reported Outcomes Measurement Information\\r\\nSystem (PROMIS), Pain, Enjoyment of Life & General Activity function (PEG) scale, adverse\\r\\neffects (AE).\\r\\n\\r\\nParticipants will be asked to complete the morning assessment for 7 consecutive days,\\r\\nwithin 1 hour of waking. Table 3 shows the items assessed. Device-initiated random\\r\\nassessments will be delivered 3 times per day for 7 consecutive days at each timepoint.\\r\\nThe device-initiated prompts will be delivered over 9 hours, beginning 3 hours after the\\r\\nparticipant's usual wake time and divided into three 3-hour blocks (1 assessment per\\r\\nblock and constrained so that each assessment is at least 1 hour apart).\\r\\n\\r\\nInflammatory marker assay. A subset of 60 patients (30 cannabis users and 30 cannabis\\r\\nnon-users) will have 8 milliliter (ml) blood samples drawn at baseline (prior to\\r\\ninitiation of ICI treatment) and months 2, 6, & 12 to assess changes in inflammatory\\r\\nmarkers. Samples will be collected, processed, and de-identified; serum will be stored\\r\\nlocally. At the time of blood draw, we will assess whether cannabis has been used in the\\r\\npast 72 h. All three recruitment sites collect and store blood samples that can be used\\r\\nfor future research as part of their master protocols. Thus, if we have difficulty\\r\\nenrolling patients prior to the start of treatment, we will have access to these banked\\r\\nsamples. Upon study completion, samples from Oregon Health and Science University and\\r\\nUniversity at Buffalo will be shipped to Sydney Kimmel Cancer Center and analyzed by\\r\\nCo-Investigator Dr. Harshyne's highly experienced immunology lab. Specifically, Luminex\\r\\nmultiplex assays use xMAP bead-based technology to simultaneously detect and quantitate\\r\\nmultiple secreted proteins including cytokines, chemokines, and growth factors in a\\r\\nsingle sample. The Luminex® xMAP® technology uses color-coded beads coupled with\\r\\ntarget-specific antibodies allowing the detection of up to 100 soluble analytes in a\\r\\nsingle 20 ul sample.\\r\\n\\r\\nElectronic Medical Record Data. Each site will collect clinical data from routinely\\r\\nconducted labs within +/- 1 month of the following time points: baseline, 1, 2, 4, 6, 9,\\r\\nand 12 months. Data to be collected will include blood draw lab data that is routinely\\r\\ncollected on all oncology patients during surveillance and survivorship: comprehensive\\r\\nmetabolic panel (CMP; inclusive of renal and liver function as well as blood glucose and\\r\\nalbumin), complete blood count (CBC) with differential and all applicable tumor markers\\r\\nassociated with the cancer type for each patient. Additionally, any acute, unplanned\\r\\nhospitalizations or Emergency Room visits will be noted, inclusive of the reason for\\r\\nadmission. All radiographic scans done +/- 1 month of the time point will be recorded\\r\\nwith specific notation of progression or regression of disease documented in report.\\r\\n\\r\\nThe data sources in this study include repeated assessments using EMA, monthly assessment\\r\\nof Patient Reported Outcomes (PROs), patients' EMR, for cancer progression and blood\\r\\nsamples for inflammatory markers.\\r\\n\\r\\nThe investigator's goal was to use widely validated common data elements while minimizing\\r\\npatient burden. Thus, the investigators chose psychometrically equivalent brief measures\\r\\nwhen they were available. Investigators also decreased the administration frequency of\\r\\nmeasures that did not make sense as serial measures. Investigators quantified completion\\r\\ntime based on literature or our previous experience with the measure.\\r\\n\\r\\nAim 1. Assess benefits and harms of cannabis use over 12-months. Primary outcomes will be\\r\\nfrom EMA data; monthly surveys are secondary.\\r\\n\\r\\nAim 1a (Benefits): Pain. The 3-item PEG scale (Pain, Enjoyment of life, General activity)\\r\\nwas chosen for its brevity and validity. PEG scale has been recommended by the Centers\\r\\nfor Disease Control and Prevention (CDC) to assess pain and function and recommended by\\r\\nthe Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group that\\r\\nsets the standards of measurement in pain research. A 30% improvement or difference is\\r\\nconsidered clinically meaningful. Anxiety. The PROMIS Anxiety (SF4a) will be used to\\r\\nassess anxiety via EMA. These 4 items are also included in the 8-item version used in\\r\\nmonthly surveys. Sleep. The PROMIS Sleep Disturbance (SF4a) will be used to assess\\r\\nperceptions of sleep quality, perceived difficulties and concerns with falling or staying\\r\\nasleep, and perceptions of satisfaction with sleep. Additional PROs, considered\\r\\nexploratory, are collected during monthly surveys.\\r\\n\\r\\nAim 1b (Harms): The presence of the following 4 adverse effects will be assessed via EMA:\\r\\ndizziness, difficulty concentrating, impaired memory, and fatigue. These items were\\r\\nchosen because these are the most common adverse effects of cannabis, common in cancer\\r\\nand its treatments and our pilot data. The Adverse Reactions to Cannabis Scale (ARCS)\\r\\nassesses for the presence of each reaction while using cannabis (yes/no) and for each\\r\\nendorsed reaction, how distressing it was using a 5-point Likert scale (0=Not at all to\\r\\n4=Severely distressing). Adverse Effects of ICIs including the identification, grading,\\r\\nand recommendations for managing immune-related and other ICI treatment-related AEs will\\r\\nbe extracted from the EMR.8-item Cannabis Use Disorders Identification Test-R\\r\\n(CUDIT-R)(past 6 months) assesses consumption, cannabis related problems, dependence, and\\r\\npsychological consequences. CUDIT-R is secondary because it only applies to patients who\\r\\nuse cannabis. Additional outcomes, considered exploratory, are collected during monthly\\r\\nsurveys.\\r\\n\\r\\nAim 2. Test whether cannabis use over time moderates the associations between a measure\\r\\nof neighborhood disadvantage (Area Deprivation Index) and benefits and harms in Aim 1.\\r\\nThe investigators use the Area Deprivation Index (ADI) as a composite indicator of Social\\r\\nDisparity of Health (SDoH). Created by the Health Resources & Services Administration,\\r\\nand adapted and validated to the Census Block Group neighborhood level, the ADI is a\\r\\nwidely used measure ranking neighborhoods based on socioeconomic disadvantage. Its\\r\\ncomposite score combines key indicators of socioeconomic status, such as income,\\r\\neducation, employment, and housing quality, and is weighted and standardized to create an\\r\\noverall score for each neighborhood (0-100 percentile), with higher scores indicating a\\r\\nhigher degree of disadvantage. Across studies, including studies with persons with\\r\\ncancer, ADI has informed health delivery, access, and policy outcomes, especially for the\\r\\nmost disadvantaged neighborhoods. Rationale for ADI: While the investigators considered\\r\\nfocusing mainly on race and ethnicity or other measures of socioeconomic disadvantage\\r\\n(e.g., Distressed Community Index), we chose ADI for these reasons: (1) ADI has a greater\\r\\nnumber of SDoH input variables to inform outcomes;(2) Although we will account for\\r\\nself-reported race and ethnicity in our analyses to identify race-based disparities,\\r\\ninvestigators propose ADI as it is based on a broader set of SDoH variables that are\\r\\nrelevant to our study including neighborhood characteristics that have been associated\\r\\nwith access to cannabis dispensaries and other types of health and social access; (3) ADI\\r\\nemploys area-level indicators of Social Economic Status (SES) at a small geographic scale\\r\\n(9-digit census tracts vs 5-digit zip code in DCI); and (4) investigators opted not to\\r\\nuse individual SES as neighborhood disadvantage has been independently associated with\\r\\npoor health outcomes, regardless of an individual's SES. Data suggest that individuals\\r\\nfrom low-income backgrounds residing in relatively affluent neighborhoods may exhibit\\r\\nbetter health outcomes than those living in disadvantaged neighborhoods.\\r\\n\\r\\nAim 3 (Exploratory). For a subset of patients (n=60) scheduled to receive ICI therapy as\\r\\na first-line cancer treatment for non-skin solid malignancies, investigators will\\r\\nlongitudinally explore whether cannabis use is associated with markers of (a) disease\\r\\nresponse or progression; (b) clinical outcomes (Table 5); and (c) key immunological\\r\\nmarkers from baseline (prior to initiation of ICI treatment) and over 12-months. Most\\r\\ndata for Aim 3 will be extracted from the EMR (Table 5). Inflammation assays will be\\r\\nconducted.\"},\n",
       "   'conditionsModule': {'conditions': ['Cancer']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'ECOLOGIC_OR_COMMUNITY',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood'},\n",
       "    'enrollmentInfo': {'count': 450, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cannabis User',\n",
       "      'description': 'Cancer patients being treated with immunotherapy and using cannabis'},\n",
       "     {'label': 'Cannabis non-user',\n",
       "      'description': 'Cancer patients being treated with immunotherapy and not using cannabis'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient Reported Outcomes Measurement Information System: Pain interference',\n",
       "      'description': 'Pain interference with daily life and enjoyment on a 5 item scale of not at all to very\\r\\nmuch. Higher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Patient Reported Outcomes Measurement Information System: Sleep',\n",
       "      'description': 'PROMISE sleep disturbance on a 5 item scale of not at all to very much. Higher score\\r\\nindicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Patient Reported Outcomes Measurement Information System:Anxiety',\n",
       "      'description': 'Anxiety on a 5 item scale of never to always. Higher score indicates worse outcome.\\r\\nHigher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Adverse reaction of Cannabis',\n",
       "      'description': 'Adverse reaction to Cannabis Scale of present side effects and 5 item scale of how\\r\\ndistressing the symptoms were experienced. Higher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Cannabis Use Disorder Identification Test',\n",
       "      'description': 'Cannabis Use Disorder Identification Test (CUDIT), the usage of cannabis and 5 item scale\\r\\nof never to daily or almost daily. Higher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Patient Reported Outcomes Measurement Information System: Depression',\n",
       "      'description': 'Emotional Distress-Depression on a 5 item scale of never to always, level of sexual\\r\\nactivity, emotional well-being, functional well-being and additional concerns on a 5 item\\r\\nscale not at all to very much. Higher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Patient Reported Outcomes Measurement Information System: Cognitive Function',\n",
       "      'description': 'Cognitive Function-Abilities on a 5 item scal not at all to very much. Higher score\\r\\nindicates better outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Patient Reported Outcomes Measurement Information System: Fatigue',\n",
       "      'description': 'Level of fatigue on a 5 item scale of never to always. Higher score indicates worse\\r\\noutcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Quality of Life with cancer',\n",
       "      'description': 'Functional Assessment of Cancer Therapy-General. Physical well-being, Social/Family Well\\r\\nbeing on a 5 item scale of not at all to very much. Higher score indicates worse outcome.',\n",
       "      'timeFrame': '0,1,2,4,6,9 and 12 months'},\n",
       "     {'measure': 'Area Deprivation Index',\n",
       "      'description': 'Test cannabis use association with Area Deprivation Index (ADI) and the benefits and\\r\\nharms. The Area Deprivation Index Its composite score combines key indicators of\\r\\nsocioeconomic status, such as income, education, employment, and housing quality, and is\\r\\nweighted and standardized to create an overall score for each neighborhood (0-100\\r\\npercentile), with higher scores indicating a higher degree of disadvantage.',\n",
       "      'timeFrame': '0, 2, 6, and 12'}],\n",
       "    'otherOutcomes': [{'measure': 'Immunological markers',\n",
       "      'description': 'Blood draws to test inflammatory markers. Luminex multiplex assays use xMAP bead-based\\r\\ntechnology to simultaneously detect and quantitate multiple secreted proteins including\\r\\ncytokines, chemokines, and growth factors in a single sample. The Luminex® xMAP®\\r\\ntechnology uses color-coded beads coupled with target-specific antibodies allowing the\\r\\ndetection of up to 100 soluble analytes in a single 20 ul sample.',\n",
       "      'timeFrame': '0, 2, 6 and 12 month'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  adult age of 21 years or older\\r\\n\\r\\n  -  cancer diagnosis and planning or using immunotherapy treatment,\\r\\n\\r\\n  -  pain and spend less than 50% in bed or chair\\r\\n\\r\\n  -  fluent in english language\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  use synthetic cannabis or only use Cannabidiol (CBD)\\r\\n\\r\\n  -  non users but used in the past 3 months\\r\\n\\r\\n  -  prior immunotherapy, Patients receiving immunosuppressants or organ transplant\\r\\n     recipients.\\r\\n\\r\\n  -  Patients within 6 months of Hospice care.\\r\\n\\r\\n  -  Pain that limits movement to more than 50% of their day in bed or chair',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '21 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Adult cancer patients that are treated or plan to be treated with immunotherapy.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Rebecca L Ashare, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '716-829-6273',\n",
       "      'email': 'rlashare@buffalo.edu'},\n",
       "     {'name': 'Colleen K Kilanowski, MS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '716-829-5977',\n",
       "      'email': 'ckk@buffalo.edu'}],\n",
       "    'locations': [{'facility': 'Oregon Health and Science University',\n",
       "      'city': 'Portland',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97239',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Shannon Nugent, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '503-220-8262',\n",
       "        'email': 'nugent@ohsu.edu'},\n",
       "       {'name': 'Felipe Rubim, MS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '503-220-8262',\n",
       "        'phoneExt': '53846',\n",
       "        'email': 'felipe.rubim@va.gov'}],\n",
       "      'geoPoint': {'lat': 45.52345, 'lon': -122.67621}},\n",
       "     {'facility': 'Thomas Jefferson University',\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19107',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Brooke Worster, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '215-955-1888',\n",
       "        'email': 'Brooke.Worster@jefferson.edu'}],\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'browseLeaves': [{'id': 'M5449',\n",
       "      'name': 'Marijuana Abuse',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC25',\n",
       "      'name': 'Substance Related Disorders'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M2853',\n",
       "      'name': 'Immunomodulating Agents',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06396000',\n",
       "    'orgStudyIdInfo': {'id': 'FARPSPP'},\n",
       "    'organization': {'fullName': 'Tongji Hospital', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Factors Analysis Related to Prolonged Stay in the Pediatric Post-Anesthesia Care Unit(PACU)',\n",
       "    'officialTitle': 'Prolonged Stay in the Pediatric PACU',\n",
       "    'acronym': 'PACU'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-03-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-23',\n",
       "    'studyFirstSubmitQcDate': '2024-04-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-01',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Saiqiang Guo',\n",
       "     'investigatorTitle': 'Senior nurse',\n",
       "     'investigatorAffiliation': 'Tongji Hospital'},\n",
       "    'leadSponsor': {'name': 'Saiqiang Guo', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to determine which factors contribute to prolonged stay of\\r\\nchildren in the PACU.',\n",
       "    'detailedDescription': \"Studying the factors associated with prolonged stay of children in the PACU is of great\\r\\nsignificance to the medical team, as it can improve the quality and speed of anesthesia\\r\\nrecovery, not only in line with the concept of accelerated rehabilitation surgery, but\\r\\nalso through intervention and optimization of specific factors to improve the efficiency\\r\\nof children's postoperative discharge from the PACU, reduce the incidence of\\r\\ncomplications, lower medical costs, and increase patient and family satisfaction.\\r\\nTherefore, this study aims to explore the factors associated with prolonged stay of\\r\\nchildren in the PACU through retrospective analysis.\"},\n",
       "   'conditionsModule': {'conditions': ['Anesthesia; Adverse Effect'],\n",
       "    'keywords': ['Post-anesthesia care unit', 'Risk factors', 'Pediatrics']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'RETROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 10000, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Anesthesia Plan Selection',\n",
       "      'description': 'Anesthesia options include general anesthesia, combined anesthesia, pure intravenous\\r\\nanesthesia, and nerve block anesthesia.',\n",
       "      'timeFrame': 'Day 1'},\n",
       "     {'measure': 'Pain Score',\n",
       "      'description': 'Evaluate pain using the Visual Analog Scale (VAS): 0 points: no pain; 1-3 points: mild\\r\\npain; 4-6 points: moderate pain; 7-10 points: severe pain.',\n",
       "      'timeFrame': 'Day 1'},\n",
       "     {'measure': 'Complications in PACU',\n",
       "      'description': 'Nausea, vomiting, chills, pain, agitation',\n",
       "      'timeFrame': 'Day 1'},\n",
       "     {'measure': 'American Society of Anesthesiologists（ASA）',\n",
       "      'description': 'ASA I: Patients in good health, without systemic disease. ASA II: Patients with mild\\r\\nsystemic disease, not significantly limiting daily activity.\\r\\n\\r\\nASA III: Patients with severe systemic disease, with definite functional limitation.\\r\\n\\r\\nASA IV: Patients with severe systemic disease that is a constant threat to life.\\r\\n\\r\\nASA V: Moribund patients who are not expected to survive without the operation. ASA VI:\\r\\nBrain-dead patients whose organs are being removed for donation.',\n",
       "      'timeFrame': 'Day 1'},\n",
       "     {'measure': 'The medication usage in PACU',\n",
       "      'description': 'Morphine, Propofol, Ketorolac, Fentanyl',\n",
       "      'timeFrame': 'Day 1'}],\n",
       "    'secondaryOutcomes': [{'measure': 'The use of PCA（Patient-Controlled Analgesia）in PACU',\n",
       "      'description': 'PCA usage statistics，yes or no',\n",
       "      'timeFrame': 'Day 1'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Children aged 0-18 years old; Child entering the Pediatric Post-Anesthesia Care.\\r\\n\\r\\n  -  Emergency surgery; Pediatric patients with incomplete medical history; Pediatric\\r\\n     patients requiring postoperative ICU care; Pediatric patients with preoperative\\r\\n     altered consciousness; Neurological disorders; Severe liver, kidney, lung, and heart\\r\\n     diseases.',\n",
       "    'sex': 'ALL',\n",
       "    'maximumAge': '18 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT'],\n",
       "    'studyPopulation': 'Pediatric patient entering the Pediatric Post-Anesthesia Care.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M4107',\n",
       "      'name': 'Anesthetics',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06360952',\n",
       "    'orgStudyIdInfo': {'id': 'T23-03'},\n",
       "    'organization': {'fullName': 'Tasso Inc.', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC',\n",
       "    'officialTitle': 'A Comparator Study of a Tasso Device to Traditional Venous Blood Sampling Methods for Complete Blood Count (CBC) With 5-part Differential in Patients With Leukemia, Lymphoma, and/or Other Blood Cell Disorders'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-02',\n",
       "    'studyFirstSubmitQcDate': '2024-04-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-11', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-20',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Tasso Inc.', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'The Leukemia and Lymphoma Society',\n",
       "      'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': True,\n",
       "    'isUnapprovedDevice': True,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'This study will evaluate the feasibility of using capillary blood samples collected with\\r\\nthe Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or\\r\\nother blood cell disorders.\\r\\n\\r\\nThis investigation will include a minimum of 40 sample sets from unique patients.',\n",
       "    'detailedDescription': 'This study will evaluate the feasibility of using capillary blood samples collected with\\r\\nthe Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or\\r\\nother blood cell disorders.\\r\\n\\r\\nThis investigation will include a minimum of 40 sample sets from unique patients.\\r\\n\\r\\nThe primary aim of this study is to demonstrate the agreement between capillary blood\\r\\ncollected using the Tasso device and venous blood collected in a K2EDTA (dipotassium\\r\\nethylenediaminetetraacetic acid) tube according to established sampling procedures for\\r\\nquantification of WBC and ANC as part of a standard CBC panel with 5-part differential.\\r\\n\\r\\nThe secondary aim of the study is to demonstrate the agreement between Tasso device and\\r\\nvenous samples for the measurement of additional analytes evaluated as part of a standard\\r\\nCBC panel with 5-part differential, including PLTs, HGB, RBC, Hct, MCV, lymphocytes,\\r\\nmonocytes, eosinophils, and basophils.\\r\\n\\r\\nAn exploratory aim of this research is to evaluate patient acceptance of the Tasso device\\r\\nin a diseased population.\\r\\n\\r\\nAdverse Events (AEs) occurring up to 24 hours after use of the Tasso device will be\\r\\nevaluated.\\r\\n\\r\\nPatient response to using the Tasso device will be collected via simple survey.'},\n",
       "   'conditionsModule': {'conditions': ['Leukopenia',\n",
       "     'Leukocytosis',\n",
       "     'Neutropenia'],\n",
       "    'keywords': ['leukocytosis', 'neutropenia', 'leukopenia', 'CBC', 'Tasso']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'leukopenia',\n",
       "      'description': 'Participants that have abnormal laboratory results for leukopenia. Participants will be\\r\\nassigned to all cohorts they have abnormal laboratory results for.',\n",
       "      'interventionNames': ['Device: Tasso+ CBC']},\n",
       "     {'label': 'leukocytosis',\n",
       "      'description': 'Participants that have abnormal laboratory results for leukocytosis. Participants will be\\r\\nassigned to all cohorts they have abnormal laboratory results for.',\n",
       "      'interventionNames': ['Device: Tasso+ CBC']},\n",
       "     {'label': 'neutropenia',\n",
       "      'description': 'Participants that have abnormal laboratory results for neutropenia. Participants will be\\r\\nassigned to all cohorts they have abnormal laboratory results for.',\n",
       "      'interventionNames': ['Device: Tasso+ CBC']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Tasso+ CBC',\n",
       "      'description': 'Novel blood collection device',\n",
       "      'armGroupLabels': ['leukocytosis', 'leukopenia', 'neutropenia']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Agreement between capillary and venous blood in the measurement of White Blood Cells and Absolute Neutrophil Count',\n",
       "      'description': 'To demonstrate agreement between capillary blood collected using the Tasso device and\\r\\ntraditional venous blood collected using standard methods for measurement of white blood\\r\\ncells (WBCs), and absolute neutrophils count (ANC) as part of a CBC analysis with 5-part\\r\\ndifferential.',\n",
       "      'timeFrame': 'Day 1'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Agreement between capillary and venous blood in the measurement of secondary biomarkers',\n",
       "      'description': 'To demonstrate agreement between capillary blood collected using the Tasso device and\\r\\ntraditional venous blood collected using standard methods for measurement of remaining\\r\\nCBC components including platelets (PLTs), hemoglobin (HGB), red blood cells (RBCs),\\r\\nhematocrit (Hct), and mean corpuscular volume (MCV), as well as differential\\r\\nquantification of lymphocytes, monocytes, eosinophils, and basophils.',\n",
       "      'timeFrame': 'Day 1'}],\n",
       "    'otherOutcomes': [{'measure': 'Patient acceptance of Tasso device',\n",
       "      'description': \"To evaluate patient acceptance of the Tasso device in a diseased population via survey\\r\\nresponses. Survey responses will consist of a series of questions referencing the\\r\\nparticipant perception of the experience with the Tasso device using The Satisfaction\\r\\nScale under the parameters of 1 through 5 (1 - Strongly Disagree through 5 - Strongly\\r\\nAgree) and other questions asking for participant preference in regards to the means of\\r\\nsample collection and location (ex. Venipuncture versus Tasso, self-collected at home or\\r\\npreformed at a doctor's office or clinic).\",\n",
       "      'timeFrame': 'Day 1'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Willing and able to provide written (or electronic) informed consent prior to study\\r\\n     entry\\r\\n\\r\\n  2. At least 18 years of age\\r\\n\\r\\n  3. Requiring a CBC blood test as part of the patient's standard of care\\r\\n\\r\\n  4. Have abnormal laboratory results of either leukopenia, leukocytosis or neutropenia.\\r\\n\\r\\n  5. Normal skin integrity and healthy skin appearance around the capillary collection\\r\\n     site (upper arm/shoulder area on at least one side)\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Unable to give full and free consent to participate in a study due to limited\\r\\n     capacity or risk of undue influence or coercion (including but not limited to\\r\\n     children, prisoners, individuals with diminished decision-making capacity,\\r\\n     illiterate or educationally disadvantaged populations) or any other individual who\\r\\n     is unable to give full and free consent in the judgement of the investigator\\r\\n\\r\\n  2. At the determination of the treating physician, unsuitable for enrollment due to\\r\\n     severe immunocompromised status or other comorbidities.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Patients with known blood cancers and/or blood cell disorders resulting in abnormal\\r\\nlaboratory results for either leukopenia, leukocytosis or neutropenia will be recruited\\r\\nand enrolled into this study',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Shivani Surati',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(919) 966-7597',\n",
       "      'email': 'Shivani_Surati@med.unc.edu'}],\n",
       "    'overallOfficials': [{'name': 'Erwin Berthier, Phd',\n",
       "      'affiliation': 'Tasso Inc.',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Lineberger Comprehensive Cancer Center',\n",
       "      'city': 'Chapel Hill',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27599',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009503',\n",
       "      'term': 'Neutropenia'},\n",
       "     {'id': 'D000007970', 'term': 'Leukopenia'},\n",
       "     {'id': 'D000007964', 'term': 'Leukocytosis'}],\n",
       "    'ancestors': [{'id': 'D000000380', 'term': 'Agranulocytosis'},\n",
       "     {'id': 'D000095542', 'term': 'Cytopenia'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'},\n",
       "     {'id': 'D000007960', 'term': 'Leukocyte Disorders'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M11220', 'name': 'Lymphoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M10945', 'name': 'Leukemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M12443',\n",
       "      'name': 'Neutropenia',\n",
       "      'asFound': 'Neutropenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10973',\n",
       "      'name': 'Leukopenia',\n",
       "      'asFound': 'Leukopenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10967',\n",
       "      'name': 'Leukocytosis',\n",
       "      'asFound': 'Leukocytosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M3730', 'name': 'Agranulocytosis', 'relevance': 'LOW'},\n",
       "     {'id': 'M3170', 'name': 'Cytopenia', 'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10963', 'name': 'Leukocyte Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'T3543', 'name': 'Lymphosarcoma', 'relevance': 'LOW'},\n",
       "     {'id': 'T2606',\n",
       "      'name': 'Granulocytopenia',\n",
       "      'asFound': 'Neutropenia',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06332170',\n",
       "    'orgStudyIdInfo': {'id': 'HS-20093-103'},\n",
       "    'organization': {'fullName': 'Hansoh BioMedical R&D Company',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors',\n",
       "    'officialTitle': 'ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-18',\n",
       "    'studyFirstSubmitQcDate': '2024-03-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-25',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-27', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Hansoh BioMedical R&D Company',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds\\r\\nto B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study\\r\\nare to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of\\r\\nHS-20093 in combination with other anti-cancer agents in patients with advanced solid\\r\\ntumor patients.',\n",
       "    'detailedDescription': 'This is a phase 1, open-label, multi-center, dose-escalation and expansion, phase 1 study\\r\\nin Chinses subjects with advanced solid tumors. This study is in design allowing\\r\\nassessment of safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093\\r\\nin combination with other anti-cancer agents.\\r\\n\\r\\nA total of 5 combination-treatments will be carried out in 3 cohorts. The target\\r\\npopulation of dose escalation part is patients have progressed on or intolerant to\\r\\navailable standard therapies, and the dose expansion part will enroll patients who have\\r\\nnot received prior treatment for advanced/metastatic disease.\\r\\n\\r\\nAll patients will be carefully followed for adverse events during the study treatment and\\r\\nfor 90 days after the last dose of study drug. Subjects will be permitted to continue\\r\\ntherapy with assessments for progression if the product is well tolerated and sustained\\r\\nclinical benefit exists.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 610, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1a',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-20093 and Adebrelimab',\n",
       "      'interventionNames': ['Drug: HS-20093', 'Drug: Adebrelimab']},\n",
       "     {'label': 'Cohort 1b',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-20093, Adebrelimab and Cisplatin/ Carboplatin',\n",
       "      'interventionNames': ['Drug: HS-20093',\n",
       "       'Drug: Adebrelimab',\n",
       "       'Drug: Cisplatin/ Carboplatin']},\n",
       "     {'label': 'Cohort 2a',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-20093 and Cetuximab',\n",
       "      'interventionNames': ['Drug: HS-20093', 'Drug: Cetuximab']},\n",
       "     {'label': 'Cohort 2b',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-20093, Cetuximab and Cisplatin/ Carboplatin',\n",
       "      'interventionNames': ['Drug: HS-20093',\n",
       "       'Drug: Cisplatin/ Carboplatin',\n",
       "       'Drug: Cetuximab']},\n",
       "     {'label': 'Cohort 3a',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-20093 and Enzalutamide',\n",
       "      'interventionNames': ['Drug: HS-20093', 'Drug: Enzalutamide']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HS-20093',\n",
       "      'description': 'administered as an IV infusion',\n",
       "      'armGroupLabels': ['Cohort 1a',\n",
       "       'Cohort 1b',\n",
       "       'Cohort 2a',\n",
       "       'Cohort 2b',\n",
       "       'Cohort 3a']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Adebrelimab',\n",
       "      'description': 'administered as an IV infusion',\n",
       "      'armGroupLabels': ['Cohort 1a', 'Cohort 1b']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cisplatin/ Carboplatin',\n",
       "      'description': 'administered as an IV infusion',\n",
       "      'armGroupLabels': ['Cohort 1b', 'Cohort 2b']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cetuximab',\n",
       "      'description': 'administered as an IV infusion',\n",
       "      'armGroupLabels': ['Cohort 2a', 'Cohort 2b']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Enzalutamide',\n",
       "      'description': '160mg once daily (QD) orally',\n",
       "      'armGroupLabels': ['Cohort 3a']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose (MTD) for combination-treatments',\n",
       "      'description': 'To determine the MTD for further evaluation of HS-20093 with other anti-cancer agents in\\r\\nsubjects with advanced solid tumors',\n",
       "      'timeFrame': 'Up to day 21 from the first dose'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence and severity of adverse events (AEs)',\n",
       "      'description': \"AE assessed by investigator exclusively related to subject's underlying disease or\\r\\nmedical condition [graded according to the NCI Common Terminology Criteria for Adverse\\r\\nEvents (CTCAE), Version 5.0]. Any untoward medical occurrence in a clinical study\\r\\nparticipant, whether or not considered related to the medicinal product. Incidence and\\r\\nseverity of AEs are assessed according to vital signs, laboratory variables, physical\\r\\nexamination, electrocardiogram, etc.\",\n",
       "      'timeFrame': 'From the first dose through 90 days post end of treatment'},\n",
       "     {'measure': 'Objective response rate (ORR) determined by investigators',\n",
       "      'description': 'Objective tumor response for target lesions will be assessed by imaging/measurement\\r\\ncompared with the overall tumor burden at baseline. ORR is evaluated by the number of\\r\\nparticipants with best overall response of CR and PR (Confirmed CR/PR assessment require\\r\\nat least 1 repeat). For prostate cancer patients, ORR is determined by investigators\\r\\naccording to RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3).',\n",
       "      'timeFrame': 'From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Disease control rate (DCR) determined by investigators',\n",
       "      'description': 'Objective tumor response for target lesions will be assessed by imaging/measurement\\r\\ncompared with the overall tumor burden at baseline. DCR was evaluated by the number of\\r\\nparticipants with best overall response of CR, PR and stable disease (SD) [Confirmed\\r\\nCR/PR assessment require at least one repeat (≥4 weeks); SD shall be assessed at least 5\\r\\nweeks after the first dose]. For prostate cancer patients, DCR is determined by\\r\\ninvestigators according to RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3).',\n",
       "      'timeFrame': 'From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Duration of response (DoR) determined by investigators',\n",
       "      'description': 'DoR was defined as the period from the first occurrence of CR or PR to PD or death from\\r\\nany cause. If no PD or death after CR/PR, the cut-off date of progression-free survival\\r\\n(PFS) would be used [Confirmed CR/PR assessment require at least one repeat (≥4 weeks)].\\r\\nFor prostate cancer patients, DoR is determined by investigators according to RECIST 1.1\\r\\nand Prostate Cancer Working Group 3 (PCWG3).',\n",
       "      'timeFrame': 'From the first dose up to PD or death, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Progression-free survival (PFS) determined by investigators according to RECIST 1.1',\n",
       "      'description': 'PFS was defined as the time from random assignment or first dose to PD or death from any\\r\\ncause.',\n",
       "      'timeFrame': 'From the first dose up to PD or death, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'OS was defined as the time from random assignment or first dose to death from any cause.',\n",
       "      'timeFrame': 'From the first dose up to death, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Radiographic progression-free survival (rPFS) determined by investigators according to RECIST 1.1 and PCWG3',\n",
       "      'description': 'For prostate cancer patients, the rPFS is defined as the time from random assignment or\\r\\nfirst dose to the date of first documented PD per PCWG3 or death from any cause,\\r\\nwhichever occurs first.',\n",
       "      'timeFrame': 'From the first dose up to PD or death from study, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Time to PSA progression (TTPP)',\n",
       "      'description': 'In participants with a decrease in PSA from baseline: ≥ 25% increase and an absolute\\r\\nincrease of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second\\r\\nvalue obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline: ≥\\r\\n25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12\\r\\nweeks.',\n",
       "      'timeFrame': 'From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Prostate-specific cancer antigen (PSA) response rate',\n",
       "      'description': 'PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3\\r\\nweeks after the first documented reduction in PSA of ≥ 50%.',\n",
       "      'timeFrame': 'From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Time to first subsequent therapy (TFST)',\n",
       "      'description': 'TFST was defined as the time from random assignment or first dose to the imitation of\\r\\nsubsequent therapy or death.',\n",
       "      'timeFrame': 'From the first dose up to the imitation of subsequent therapy or death, whichever came first, assessed up to 24 months'},\n",
       "     {'measure': 'Observed maximum plasma concentration (Cmax) of HS-20093advanced solid tumor',\n",
       "      'description': 'Cmax will be obtained after administration of the first dose of HS-20093',\n",
       "      'timeFrame': 'From pre-dose to study completion, assessed up to 24 months'},\n",
       "     {'measure': 'Time to reach maximum plasma concentration (Tmax) of HS-20093',\n",
       "      'description': 'Tmax will be obtained after administration of the first dose of HS-20093',\n",
       "      'timeFrame': 'From pre-dose to study completion, assessed up to 24 months'},\n",
       "     {'measure': 'Terminal half-life (T1/2) of HS-20093 following the first dose',\n",
       "      'description': 'T1/2 will be obtained after administration of the first dose of HS-20093',\n",
       "      'timeFrame': 'From pre-dose to study completion, assessed up to 24 months'},\n",
       "     {'measure': 'Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093',\n",
       "      'description': 'Area under the plasma concentration versus time curve from time zero to the last sampling\\r\\ntime when the concentration was no less than the lower limit of quantification (LLQ).\\r\\nAUC0-t was calculated according to the mixed log-linear trapezoidal rule.',\n",
       "      'timeFrame': 'From pre-dose to study completion, assessed up to 24 months'},\n",
       "     {'measure': 'Percentage of participants with antibodies to HS-20093 in serum',\n",
       "      'description': 'Serum samples were collected for the determination of anti-drug antibody (ADA) at\\r\\ndesignated time points.',\n",
       "      'timeFrame': 'From pre-dose to study completion, assessed up to 24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  At least age of 18 years at screening;\\r\\n\\r\\n  -  Histologically or cytologically confirmed, locally advanced or metastatic solid\\r\\n     tumors\\r\\n\\r\\n       1. Dose escalation part will enroll advanced solid tumor for which standard\\r\\n          treatment has proven ineffective or unavailable or intolerable.\\r\\n\\r\\n       2. Dose expansion part will enroll patients who have not received prior treatment\\r\\n          for advanced/metastatic disease.\\r\\n\\r\\n  -  least one extra-cranial measurable lesion according to RECIST 1\\r\\n\\r\\n  -  Agree to provide fresh or archival tumor tissue\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0~1\\r\\n\\r\\n  -  Life expectancy >= 12 weeks\\r\\n\\r\\n  -  Agree to use medically accepted methods of contraception\\r\\n\\r\\n  -  Men or women should be using adequate contraceptive measures throughout the study;\\r\\n\\r\\n  -  Females subjects must not be pregnant at screening or have evidence of\\r\\n     non-childbearing potential\\r\\n\\r\\n  -  Signed and dated Informed Consent Form\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any of the following would exclude the subject from participation in the study:\\r\\n\\r\\ntreatment with any of the following: Previous or current treatment with B7-H3 targeted\\r\\ntherapy Intolerable for any PD-L1 inhibitor, cetuximab, enzalutamide and cisplatin/\\r\\ncarboplatin Cytotoxic chemotherapy, investigational agents and anticancer drugs within 14\\r\\ndays prior to the first scheduled dose of HS-20093 Prior treatment with a monoclonal\\r\\nantibody within 28 days prior to the first scheduled dose of HS-20093 Radiotherapy with a\\r\\nlimited field of radiation for palliation within 2 weeks, or patients received more than\\r\\n30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to\\r\\nthe first scheduled dose of HS-20093 Major surgery within 4 weeks prior to the first\\r\\nscheduled dose of HS-20093\\r\\n\\r\\n  -  Subjects with previous or concurrent malignancies\\r\\n\\r\\n  -  Inadequate bone marrow reserve or organ dysfunction\\r\\n\\r\\n  -  Evidence of cardiovascular risk\\r\\n\\r\\n  -  Evidence of current severe or uncontrolled systemic diseases\\r\\n\\r\\n  -  Evidence of mucosal or internal bleeding within 1 month prior to the first scheduled\\r\\n     dose of HS-20093\\r\\n\\r\\n  -  Known active infection requiring antibodies treatment within 2 weeks, or severe\\r\\n     infection within 4 weeks prior to the first scheduled dose of HS-20093\\r\\n\\r\\n  -  Subjects with current infectious diseases\\r\\n\\r\\n  -  History of neuropathy or mental disorders\\r\\n\\r\\n  -  Pregnant or lactating female\\r\\n\\r\\n  -  History of severe hypersensitivity reaction, severe infusion reaction or\\r\\n     idiosyncrasy to drugs chemically related to HS-20093 or any of the components of\\r\\n     HS-20093\\r\\n\\r\\n  -  Unlikely to comply with study procedures, restrictions, and requirements in the\\r\\n     opinion of the investigator\\r\\n\\r\\n  -  Any disease or condition that, in the opinion of the investigator, would compromise\\r\\n     subject safety or interfere with study assessments',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000016190',\n",
       "      'term': 'Carboplatin'},\n",
       "     {'id': 'D000068818', 'term': 'Cetuximab'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000074322', 'term': 'Antineoplastic Agents, Immunological'}],\n",
       "    'browseLeaves': [{'id': 'M18650',\n",
       "      'name': 'Carboplatin',\n",
       "      'asFound': 'System',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M315',\n",
       "      'name': 'Cetuximab',\n",
       "      'asFound': 'Solid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'},\n",
       "     {'id': 'M1346',\n",
       "      'name': 'Antineoplastic Agents, Immunological',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06415175',\n",
       "    'orgStudyIdInfo': {'id': 'OBS18427'},\n",
       "    'secondaryIdInfos': [{'id': 'U1111-1306-7579',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'ICTRP'}],\n",
       "    'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain',\n",
       "    'officialTitle': 'Prospective, Observational, Longitudinal Study in Paediatric Patients With AD, Treated With Dupilumab in Spain',\n",
       "    'acronym': 'PROADAP'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-10',\n",
       "    'studyFirstSubmitQcDate': '2024-05-10',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-10',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'Regeneron Pharmaceuticals',\n",
       "      'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False},\n",
       "   'descriptionModule': {'briefSummary': \"This is a multicentre, prospective, non-interventional study that aims to describe the\\r\\ntreatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in\\r\\nSpain: patients' characteristics, disease characteristics, prior treatments for and\\r\\ntreatment prescription modalities. As well as to document the real-world effectiveness\\r\\nand safety of dupilumab during the two years of follow up. No diagnostic or therapeutic\\r\\nintervention outside of routine clinical practice will be applied.\"},\n",
       "   'conditionsModule': {'conditions': ['Atopic Dermatitis'],\n",
       "    'keywords': ['Pediatric']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Dupilumab',\n",
       "      'description': \"The information will be collected during consultation as part of the patient's usual\\r\\nfollow-up.\",\n",
       "      'interventionNames': ['Drug: Dupilumab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Dupilumab',\n",
       "      'description': 'This study will not administer any treatment, only observe the treatment as prescribed in\\r\\nreal world-clinical practice.',\n",
       "      'armGroupLabels': ['Dupilumab']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Demographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Gender',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Characteristic of pediatric patients initiating treatment with dupilumab for Severe AD:Body mass index (BMI)',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Medical history characteristics of pediatric patients initiating treatment with dupilumab for Severe AD',\n",
       "      'description': 'Including course of AD, recent AD treatment history, family history.',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Medical history of atopic comorbidities',\n",
       "      'description': 'Selected atopic comorbidities over time will be reported.',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Medical history of non-atopic diseases',\n",
       "      'timeFrame': 'At baseline'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Description of real-world treatment patterns: Dupilumab dosage',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns: Dupilumab frequency of administration',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns: Dupilumab reason for discontinuation',\n",
       "      'description': 'Reason for discontinuation will be reported if applicable.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns (other treatments): Other type of treatment',\n",
       "      'description': 'In case of receiving other treatments for AD, topical or systemic.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns (other treatments): Name of treatment',\n",
       "      'description': 'In case of receiving other treatments for AD, topical or systemic.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns (other treatments): Duration of treatment',\n",
       "      'description': 'In case of receiving other treatments for AD, topical or systemic.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Description of real-world treatment patterns (other treatments): Reason for discontinuation (if applicable)',\n",
       "      'description': 'In case of receiving other treatments for AD, topical or systemic. Reason for\\r\\ndiscontinuation will be reported if applicable.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': \"Participant-caregiver assessment: Change from baseline in the Children's Dermatology Life Quality Index score\",\n",
       "      'description': \"The Children's Dermatology Life Quality Index (cDLQI) it is a 10-item questionnaire that\\r\\nassesses six different aspects that may affect quality of life, including symptoms and\\r\\nfeelings, daily activities, leisure, work and school performance, personal relationships,\\r\\nand treatment. Each of the 10 questions is scored from 0 (not at all) to 3 (very much)\\r\\nand the overall cDLQI is calculated by summing the score of each question, resulting in a\\r\\ntotal score between 0-30. The higher the score, the more quality of life is impaired.\",\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': \"Participant-caregiver assessment: Change from baseline in the Infant's Dermatology Life Quality Index score\",\n",
       "      'description': 'The Infant Dermatology Quality of Life Index (iDLQI) contains 10 questions and a response\\r\\nscale divided into four boxes. Each box gives a point between 0 and 3. The lower number\\r\\nis understood as the most positive for the participant.\\r\\n\\r\\nThe index is filled out by a parent to a participating child between the ages of 0 to 5\\r\\nyears.\\r\\n\\r\\nPoints from each question are added together and the end-sum represents the score. The\\r\\nsum score can be between 0 and 30. The higher the score the worse the assumed quality of\\r\\nlife.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Participant-caregiver assessment: Change from baseline in the Dermatitis Family Impact (DFI) questionnaire',\n",
       "      'description': 'The DFI is a 10-item disease specific questionnaire assessing the impact of having a\\r\\nchild with AD on family Quality of Life (QoL). The DFI questions are scored ranging from\\r\\n0 to 3, and the total DFI score ranges from 0 to 30. The time frame of reference is the\\r\\npast week, and a higher DFI score indicates greater impairment in family QoL as affected\\r\\nby AD.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': \"Participant-caregiver assessment: Change from baseline in the patient's Worst Itch Numerical Rating Scale (WI-NRS)\",\n",
       "      'description': 'WI-NRS is a validated measure of itch severity. Patients will be asked daily to rate the\\r\\nintensity of their worst pruritus (itch) over the past 24 hours, using a 11-point scale\\r\\nranging from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate more\\r\\nseverity.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': \"Caregiver assessment: Change from baseline in the patient's Worst Itch Scale Numerical Rating Scale (WSI-NRS)\",\n",
       "      'description': 'The WSI-NRS is a single-item caregiver-reported. The caregivers describe their child\\r\\n\"scratch\" or \"itch\" in the AD-affected area by using numeric response options (0: no\\r\\nscratching/itching to 10: worst scratching/itching). Higher scores indicate more\\r\\nseverity.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Physician assessment: Change from baseline in the eczema severity using the Eczema Area and Severity Index (EASI)',\n",
       "      'description': 'The EASI is calculated by summing 4 separate scores of the (1) head/neck, (2) upper\\r\\nextremities, (3) trunk, and (4) lower extremities. For each of the 4 anatomical regions,\\r\\nthe score formula is SxAxM [\"S\" is the congregate score from the severity of 4 signs:\\r\\nerythema, oedema/papulation, excoriation, and lichenification graded on a discrete scale\\r\\nfrom 0 to 3, where 0 = absent, 1 = mild, 2 = moderate, and 3 = severe, giving S a maximum\\r\\nof 12. \"A\" represents the area to which AD affects the body, yielding a maximum of 6\\r\\npoints: 0 = 0%, 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, and 6 =\\r\\n90-100%. \"M\" is a multiplier, which is 0.1, 0.2, 0.3, and 0.4, respectively, for the\\r\\nregion affected in those ≥8 years and 0.2, 0.2, 0.3, and 0.3, respectively, for those <8\\r\\nyears. The final EASI score is calculated based on the sum of the scores from the 4\\r\\nanatomical regions. A higher score means higher AD severity. Scores range from 0 (no\\r\\ndisease) to 72 (maximal disease severity).',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Physician assessment: Percent change from beseline in the Body Surface Area (BSA) (%) affected by AD',\n",
       "      'description': 'BSA affected by AD disease will be assessed for each major section of the body (head,\\r\\nneck, anterior trunk, back, upper limbs, lower limbs, and genitals). It will be reported\\r\\nas a percentage of all major body sections combined.',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': \"Physician assessment: Change in Proportion of patients with Validated Investigator's Global Assessment (IGA)\",\n",
       "      'description': 'The IGA is an Investigator-completed assessment scale used to determine severity of AD\\r\\nand clinical response to treatment. It is based on a 5-point scale, ranging from 0\\r\\n(clear) to 4 (severe).',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Physician assessment: Change from baseline in Biomarkers',\n",
       "      'description': 'Biomarker analysis will be performed, if available, in routine clinical practice and at\\r\\nroutine visits',\n",
       "      'timeFrame': 'From baseline up to 24 months'},\n",
       "     {'measure': 'Number of Adverse Events (AE) / Serious Adverse Events (SAE) / Adverse Event of Special Interest (AESI)',\n",
       "      'description': 'The number of events and the percentage of patients who had at least one event will be\\r\\ndescribed.',\n",
       "      'timeFrame': 'From date of signed ICF, up to 24 months'},\n",
       "     {'measure': 'Health Care Resource Utilization (HCRU) Questionnaire',\n",
       "      'description': 'Health care resource utilization may include hospitalizations (including length of stay),\\r\\noutpatient visits, urgent care or emergency room visits.',\n",
       "      'timeFrame': 'From baseline up to 24 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Male or female aged 6 months to 11 years old at baseline.\\r\\n\\r\\n  -  Patients with severe Atopic dermatitis (AD) according to the investigator's\\r\\n     assessment.\\r\\n\\r\\n  -  Patients initiating dupilumab (in those patients initiated retrospectively 2 months\\r\\n     before the start of the study, the baseline information must be correctly filled out\\r\\n     in the medical records).\\r\\n\\r\\n  -  Signed informed consent by the parent/legally acceptable representative and assent\\r\\n     by the patient appropriate to the patient's age.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients who are participating in an interventional clinical trial that modifies\\r\\n     patient care.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '6 Months',\n",
       "    'maximumAge': '11 Years',\n",
       "    'stdAges': ['CHILD'],\n",
       "    'studyPopulation': 'Patients aged 6 months to 11 years old at baseline and initiating Dupilumab for their\\r\\nSevere Atopic dermatitis (AD) in Spain.',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Trial Transparency email recommended (Toll free for US & Canada)',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '800-633-1610',\n",
       "      'phoneExt': 'option 6',\n",
       "      'email': 'Contact-us@sanofi.com'}],\n",
       "    'overallOfficials': [{'name': 'Clinical Sciences & Operations',\n",
       "      'affiliation': 'Sanofi',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Qualified researchers may request access to patient level data and related study\\r\\ndocuments including the clinical study report, study protocol with any amendments, blank\\r\\ncase report form, statistical analysis plan, and dataset specifications. Patient level\\r\\ndata will be anonymized and study documents will be redacted to protect the privacy of\\r\\ntrial participants. Further details on Sanofi's data sharing criteria, eligible studies,\\r\\nand process for requesting access can be found at: https://vivli.org\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003876',\n",
       "      'term': 'Dermatitis, Atopic'},\n",
       "     {'id': 'D000003872', 'term': 'Dermatitis'},\n",
       "     {'id': 'D000004485', 'term': 'Eczema'}],\n",
       "    'ancestors': [{'id': 'D000012871', 'term': 'Skin Diseases'},\n",
       "     {'id': 'D000012873', 'term': 'Skin Diseases, Genetic'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000017443', 'term': 'Skin Diseases, Eczematous'},\n",
       "     {'id': 'D000006969', 'term': 'Hypersensitivity, Immediate'},\n",
       "     {'id': 'D000006967', 'term': 'Hypersensitivity'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7067',\n",
       "      'name': 'Dermatitis',\n",
       "      'asFound': 'Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7071',\n",
       "      'name': 'Dermatitis, Atopic',\n",
       "      'asFound': 'Atopic Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7655',\n",
       "      'name': 'Eczema',\n",
       "      'asFound': 'Atopic Dermatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15674', 'name': 'Skin Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15676', 'name': 'Skin Diseases, Genetic', 'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M19712', 'name': 'Skin Diseases, Eczematous', 'relevance': 'LOW'},\n",
       "     {'id': 'M10018', 'name': 'Hypersensitivity', 'relevance': 'LOW'},\n",
       "     {'id': 'M10020',\n",
       "      'name': 'Hypersensitivity, Immediate',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06422988',\n",
       "    'orgStudyIdInfo': {'id': 'IRAS323099'},\n",
       "    'organization': {'fullName': 'Imperial College London', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Do Probiotics Reduce The Risk Of Severe Necrotising Enterocolitis (NEC) In Infants Born Before 32 Weeks Gestation?',\n",
       "    'officialTitle': 'Do Probiotics Reduce The Risk Of Severe Necrotising Enterocolitis (NEC) In Infants Born Before 32 Weeks Gestation? An Observational Study Using Routinely Collected Data.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'ENROLLING_BY_INVITATION',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-07-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-24',\n",
       "    'studyFirstSubmitQcDate': '2024-05-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-18',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Cheryl Battersby',\n",
       "     'investigatorTitle': 'Clinical Senior Lecturer',\n",
       "     'investigatorAffiliation': 'Imperial College London'},\n",
       "    'leadSponsor': {'name': 'Imperial College London', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University of Nottingham', 'class': 'OTHER'},\n",
       "     {'name': 'Newcastle University', 'class': 'OTHER'},\n",
       "     {'name': 'Queen Mary University of London', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Necrotising enterocolitis (NEC) is one of the leading causes of mortality and morbidity\\r\\nin very preterm infants. This study aims to determine whether NEC rates are different\\r\\nbetween infants who receive probiotics versus infants who do not receive probiotics. The\\r\\nstudy has a retrospective cohort design and will utilise routinely collected data from\\r\\nthe UK National Neonatal Research Database (NNRD). The cohort will comprise all infants\\r\\nborn before 32 weeks gestation and cared for in neonatal units in England and Wales\\r\\nbetween 2016 and 2022. A propensity score matched approach will be used to conduct two\\r\\ncomparisons: i) the risk of necrotising enterocolitis (NEC) between who do and those who\\r\\ndo not receive probiotics in the first 14 days of life ii) the risk of NEC between babies\\r\\nwho receive the two most common probiotic products used in UK units, (Labinic and\\r\\nProprems).'},\n",
       "   'conditionsModule': {'conditions': ['Enterocolitis, Necrotizing'],\n",
       "    'keywords': ['Probiotics']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'RETROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 48000, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Exposed to probiotics',\n",
       "      'description': 'Receipt of any probiotic in the first 14 days of life. Probiotics to include: Labinic,\\r\\nProprems probiotic, Acidophillus, Bifidobacterium, Bio-kult, Infloran, LB2.\\r\\n\\r\\nTo address potential recording error, infants whose NNRD records show minimal (one day)\\r\\nof probiotic exposure will only be classed as exposed if they are cared for in a\\r\\nprobiotic unit. Probiotic units are defined as:\\r\\n\\r\\n  -  units who have confirmed that a guideline was in place to provide probiotics to\\r\\n     infants born before 32 weeks gestation and that the guideline was in place at any\\r\\n     point in the year that the infant was born OR\\r\\n\\r\\n  -  units where more than 50% of the infants eligible to be part of the cohort received\\r\\n     probiotics in the six months after the infant was born.',\n",
       "      'interventionNames': ['Dietary Supplement: Probiotics']},\n",
       "     {'label': 'No probiotic exposure',\n",
       "      'description': 'Did not receive any probiotic in the first 14 days of life.',\n",
       "      'interventionNames': ['Dietary Supplement: Probiotics']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Probiotics',\n",
       "      'description': 'Any exposure to probiotics in first 14 days of life',\n",
       "      'armGroupLabels': ['Exposed to probiotics', 'No probiotic exposure'],\n",
       "      'otherNames': ['Labinic',\n",
       "       'Proprems',\n",
       "       'Acidophillus',\n",
       "       'Bifidobacterium',\n",
       "       'Bio-kult',\n",
       "       'Infloran',\n",
       "       'LB2']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Severe necrotising enterocolitis (NEC)',\n",
       "      'description': 'NEC confirmed at surgery or postmortem or listed as a cause of death',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Necrotising enterocolitis (NNAP definition)',\n",
       "      'description': 'NEC diagnosed at postmortem or NEC diagnosed during surgery or NEC diagnosed using\\r\\nclinical and radiographic features (where the infant has at least one clinical feature\\r\\n(bilious gastric aspirate or emesis, abdominal distension, occult, gross blood in stool)\\r\\nand at least one radiographic feature (pneumatosis, hepato-biliary gas,\\r\\npneumoperitoneum)).',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Pragmatically defined NEC',\n",
       "      'description': 'Infants who had a recorded diagnosis of necrotising enterocolitis and received at least 5\\r\\nconsecutive days of antibiotics whilst also nil by mouth',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Late onset sepsis',\n",
       "      'description': 'HQIP NNAP case definition',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Pragmatically defined late onset sepsis',\n",
       "      'description': 'Growth of any organisms that appear in the NNAP lists of \"Clearly pathogenic organisms\"\\r\\nand \"Other organisms\"',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Survival to discharge home',\n",
       "      'timeFrame': 'On date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Survival without severe NEC or late onset sepsis (LOS)',\n",
       "      'description': 'LOS is defined according to the Healthcare Quality Improvement Partnership (HQIP)\\r\\nNational Neonatal Audit Programme (NNAP) case definition i.e. blood stream or\\r\\ncerebrospinal fluid confirmed pure growth in culture after first three days of life',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Survival without any NEC',\n",
       "      'description': 'NEC is defined as per the NNAP definition',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Brain injury',\n",
       "      'description': 'Either left or right grade 3 or higher intra-ventricular haemorrhage or cystic\\r\\nperiventricular leukomalacia',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Treated retinopathy of prematurity',\n",
       "      'description': 'Defined as cryotherapy, laser therapy or injection of anti-vascular endothelial growth\\r\\nfactor therapy for ROP in either or both eyes',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Stage of retinopathy of prematurity',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Bronchopulmonary dysplasia',\n",
       "      'description': 'Defined as any respiratory or ventilatory support or supplemental oxygen at 36 weeks\\r\\npostmenstrual age',\n",
       "      'timeFrame': '36 weeks postmenstrual age'},\n",
       "     {'measure': 'Severe bronchopulmonary dysplasia',\n",
       "      'description': 'Defined as ventilation via endotracheal tube or trachestomy, and excluding non-invasive\\r\\nsupport or CPAP, at 36 weeks postmenstrual age',\n",
       "      'timeFrame': '36 weeks postmenstrual age'},\n",
       "     {'measure': 'Length of stay',\n",
       "      'description': 'Number of days between first neonatal unit admission and final neonatal unit discharge\\r\\nfor surviving infants',\n",
       "      'timeFrame': 'From date of birth until the date of discharge from final neonatal unit, assessed up to 24 months'},\n",
       "     {'measure': 'Time to full feeds',\n",
       "      'description': 'Defined as the number of days until an infant is recorded as not requiring any parenteral\\r\\nnutrition or fluid (i.e. no parenteral nutrition or intravenous dextrose)',\n",
       "      'timeFrame': 'Before discharge from final neonatal unit'},\n",
       "     {'measure': 'Growth',\n",
       "      'description': 'Weight for post-menstrual age standard deviation score',\n",
       "      'timeFrame': '36 weeks corrected gestational age'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Eligible infants must have been born at less than 32 weeks gestation and be cared\\r\\n     for in a English or Welsh unit which contributes data to the National Neonatal\\r\\n     Research Database (this includes all NHS neonatal units in England and Wales).\\r\\n\\r\\n  -  Infants born in the period January 1st, 2016, to December 31st, 2022 (7 years) will\\r\\n     be included.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  They have missing data for any of: gestational age at birth, birth weight, year of\\r\\n     birth and date of death (for those that died).\\r\\n\\r\\n  -  Their NNRD record does not include details of their first admission or begins after\\r\\n     Day 3 of life.\\r\\n\\r\\n  -  The absolute value of their recorded birthweight for gestational age z score exceeds\\r\\n     4 or is missing.\\r\\n\\r\\n  -  They die in the first two postnatal days of life.\\r\\n\\r\\n  -  They have a major congenital abnormality',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'maximumAge': '32 Weeks',\n",
       "    'stdAges': ['CHILD'],\n",
       "    'studyPopulation': 'Infants born very preterm i.e. before 32 weeks gestation',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Imperial College',\n",
       "      'city': 'London',\n",
       "      'zip': 'SW10 9NH',\n",
       "      'country': 'United Kingdom',\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED',\n",
       "    'description': 'Study protocol available now. Analysis code will be available after publication of\\r\\nresults.'}},\n",
       "  'documentSection': {'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP',\n",
       "      'hasProtocol': True,\n",
       "      'hasSap': True,\n",
       "      'hasIcf': False,\n",
       "      'label': 'Study Protocol and Statistical Analysis Plan',\n",
       "      'date': '2024-04-12',\n",
       "      'uploadDate': '2024-04-23T05:17',\n",
       "      'filename': 'Prot_SAP_000.pdf',\n",
       "      'size': 1459636}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000004760',\n",
       "      'term': 'Enterocolitis'},\n",
       "     {'id': 'D000020345', 'term': 'Enterocolitis, Necrotizing'}],\n",
       "    'ancestors': [{'id': 'D000005759', 'term': 'Gastroenteritis'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M7922',\n",
       "      'name': 'Enterocolitis',\n",
       "      'asFound': 'Enterocolitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22151',\n",
       "      'name': 'Enterocolitis, Necrotizing',\n",
       "      'asFound': 'Enterocolitis, Necrotizing',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8875', 'name': 'Gastroenteritis', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T4055',\n",
       "      'name': 'Necrotizing Enterocolitis',\n",
       "      'asFound': 'Enterocolitis, Necrotizing',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'T367',\n",
       "      'name': 'Bifidobacterium',\n",
       "      'asFound': 'Neonates',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'Ot', 'name': 'Other Dietary Supplements'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06425978',\n",
       "    'orgStudyIdInfo': {'id': 'FSD-CEL-2023-11'},\n",
       "    'secondaryIdInfos': [{'id': '2023-507200-31-00', 'type': 'CTIS'}],\n",
       "    'organization': {'fullName': 'Institut Universitari Dexeus',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit',\n",
       "    'officialTitle': 'The Efficacy of the Use of Cellular Matrix / A-CP-HA Kit (Combination of Autologous Platelet-rich Plasma and Non-cross-linked Hyaluronic Acid) Compared to Local Estrogen Therapy (Blissel, Estriol 50 Micrograms/g Vaginal Gel) in Women With Genitourinary Syndrome of Menopause. A Randomized Controlled Trial, With a Second Blind Observer.',\n",
       "    'acronym': 'CellularMatrix'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-08', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-17',\n",
       "    'studyFirstSubmitQcDate': '2024-05-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-17',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Fundación Santiago Dexeus Font',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Regen Lab SA', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is a randomized, controlled, non-inferiority trial, that will be performed on\\r\\n192 women on Menopause (absence of menstruation for at least 12 months), with diagnostic\\r\\nof genitourinary syndrome of menopause (SGM) and a vaginal health index <15 points, that\\r\\nare sexually active.\\r\\n\\r\\nPatients will be randomized 1:1, equal number assigned to each of the two treatment\\r\\ngroups, to receive treatment with two dose of Cellular Matrix / A-CP-HA Kit (a\\r\\ncombination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid)\\r\\nseparated for a month, and control group that will receive the standard treatment for\\r\\nSGM, local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel).\\r\\n\\r\\nBoth groups will be follow-up for 3 and 6 month afther treatment, a blind observer will\\r\\nassess the application of the validated scale (VHIS, VHI), and the investigators will do\\r\\nthe FSD, symptom record, maturation index, follow-up photography and evaluation of\\r\\nadverse events and treatment compliance and adherence.',\n",
       "    'detailedDescription': 'This study is a randomized, controlled, non-inferiority trial, with a second blind\\r\\nobserver, comparing effectiveness of the use of Cellular Matrix / A-CP-HA Kit (a\\r\\ncombination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid) to\\r\\nthe standard line of treatment, local estrogen therapy (Blissel, estriol 50 micrograms/g\\r\\nvaginal gel) in women with genitourinary syndrome of menopause (SGM). Duration of the\\r\\nstudy estimated is 24 months.\\r\\n\\r\\nA total of 192 menopausal women, with absence of menstruation for at least 12 months, ≤70\\r\\nyears old, that are sexually active and who report symptoms and signs of SGM, with a\\r\\nvaginal health index <15 points. Patients will be excluded if are in treatment with\\r\\nsystemic or local hormonal treatment in the last 3 months, Tamoxifen or Aromatase\\r\\ninhibitor treatments. Vulvovaginal pathologies (condyloma, vaginal intraepithelial\\r\\nneoplasia, vaginal carcinoma, lichen sclerosus, lichen planus, history of radiation,\\r\\nhistory of cervical cancer, other gynecologic cancer, or pelvic radiation, or active\\r\\ngenital infection (eg. g., bacterial vaginosis, genital herpes, candida).\\r\\nContraindication for vaginal estrogen therapy. Women with thrombocytopenia or coagulation\\r\\ndisorders, systemic infections, STDs, cancer of any type in recent treatment, connective\\r\\ntissue diseases. Women who have had pelvic surgery within 6 months.\\r\\n\\r\\nPatients will be randomized 1:1, equal number assigned to each of the two treatment\\r\\ngroups, to receive treatment with two dose of Cellular Matrix / A-CP-HA Kit (a\\r\\ncombination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid),\\r\\nseparated for a month, and control group that will receive the standard treatment for\\r\\nSGM, local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel).\\r\\n\\r\\nPatients will interviewed about their medical history, age of menopause, symptoms related\\r\\nand history of treatments. Evaluation of the Vaginal Health Index (VHIS), Vulvar Health\\r\\nIndex (VHI), vaginal pH, and vaginal maturation index (vaginal cytology). The intensity\\r\\nof VVA symptoms (vaginal burning, vaginal itching, vaginal dryness, dyspareunia and\\r\\ndysuria) will be measured using a 5-cm visual analog scale (VAS), and a valuation of\\r\\nFemale Sexual Distress (FSD) score. Photographic monitoring during all phases of the\\r\\nprocedure. Routine laboratory test serology will requested for both groups (valid up to 3\\r\\nmonths).\\r\\n\\r\\nBoth groups will be follow-up for 3 and 6 month afther treatment, a blind observer will\\r\\nassess the application of the validated scale (VHIS, VHI), and the investigators will do\\r\\nthe FSD, symptom record, maturation index, follow-up photography and evaluation of\\r\\nadverse events and treatment compliance and adherence.'},\n",
       "   'conditionsModule': {'conditions': ['Genitourinary Syndrome of Menopause']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 192, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cellular Matrix / A-CP-HA Kit',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': '(a combination of autologous platelet-rich plasma and non-cross-linked hyaluronic acid)\\r\\nis a sterile tube designed for use in the preparation of a mixture of PRP and hyaluronic\\r\\nacid, tube is under vacuum allowing the withdrawal of 6 ml of blood and contains: 2 ml of\\r\\nhyaluronic acid gel (20mg/ml, 40 mg per tube) in phosphate buffer. Not crosslinked,\\r\\nhyaluronic acid is obtained from bacterial fermentation, 3 g of inert cell-selector gel,\\r\\nand 0.6 ml of anticoagulant (sodium citrate 4%). Centrifuged at 1,500 g, 3,000 rpm for 5\\r\\nmin. Platelet recovery of more than 70%, granulocyte depletion of 94.3% and red blood\\r\\ncells of 99.5% are achieved.',\n",
       "      'interventionNames': ['Drug: Cellular Matrix / A-CP-HA Kit']},\n",
       "     {'label': 'Local estrogen therapy',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Blissel, estriol 50 micrograms/g vaginal gel',\n",
       "      'interventionNames': ['Drug: Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Cellular Matrix / A-CP-HA Kit',\n",
       "      'description': 'For infiltration, a prior preparation of the region with anesthetic cream is performed,\\r\\nprocaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal\\r\\nintroitus. Occlusion of the area with plastic film is performed for 20 minutes. After\\r\\nasepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using\\r\\nthe technique of superficial \"point-to-point\" mesotherapy microinjections, in the\\r\\nvestibule and the first 3 cm of the posterior wall of the vagina.',\n",
       "      'armGroupLabels': ['Cellular Matrix / A-CP-HA Kit']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)',\n",
       "      'description': 'Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row,\\r\\nthen two times a week for 24 weeks (6 months). Application instructions will be explained\\r\\nto the patients. The gel should be applied in the vagina using an applicator with the\\r\\nmarked dose, the full applicator should be inserted into the vagina and emptied,\\r\\npreferably at night.',\n",
       "      'armGroupLabels': ['Local estrogen therapy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of patients with improved symptomatology.',\n",
       "      'description': 'Improvement is defined as having a higher score than the baseline in the Vaginal Health\\r\\nIndex (VHIS)',\n",
       "      'timeFrame': 'at 6 months after treatment'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Healing percentage',\n",
       "      'description': 'defined as percentage of patients scoring ≥ 15 in the VHIS',\n",
       "      'timeFrame': 'at 6 months after treatment'},\n",
       "     {'measure': 'Evolution of Vaginal Health Index',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'},\n",
       "     {'measure': 'Evolution of Vulvar Health Index',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'},\n",
       "     {'measure': 'Evolution of vaginal pH',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'},\n",
       "     {'measure': 'Evolution of Vaginal maturation index (vaginal cytology)',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'},\n",
       "     {'measure': 'Evolution of intensity of VVA symptoms (vaginal burning, vaginal itching, vaginal dryness, dyspareunia, and dysuria)',\n",
       "      'description': 'measured using a 5-cm visual analog scale (VAS)',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'},\n",
       "     {'measure': 'Incidence of adverse events and serious adverse events',\n",
       "      'timeFrame': 'at 3-months and 6-months follow-up'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Women ≤70 years old\\r\\n\\r\\n  -  Women that are sexually active\\r\\n\\r\\n  -  Women who report symptoms and signs of SGM, with a vaginal health index (VHIS -\\r\\n     Bachmann score) < 15 points.\\r\\n\\r\\n  -  Women who understand the Spanish language\\r\\n\\r\\n  -  Willing to participate in the study and sign informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Systemic or local hormonal treatment in the last 3 months\\r\\n\\r\\n  -  Tamoxifen or Aromatase inhibitor treatments\\r\\n\\r\\n  -  Vulvovaginal pathologies (condyloma, vaginal intraepithelial neoplasia, vaginal\\r\\n     carcinoma, lichen sclerosus, lichen planus, history of radiation, history of\\r\\n     cervical cancer, other gynecologic cancer, or pelvic radiation, or active genital\\r\\n     infection (eg. g., bacterial vaginosis, genital herpes, candida) Contraindication\\r\\n     for vaginal estrogen therapy\\r\\n\\r\\n  -  Women with thrombocytopenia or coagulation disorders, systemic infections, STDs,\\r\\n     cancer of any type in recent treatment, connective tissue diseases.\\r\\n\\r\\n  -  Women who have had pelvic surgery within 6 months.\\r\\n\\r\\n  -  Women who are unwilling or unable to give informed consent and/or do not comply with\\r\\n     the study requirements.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Antonella de Ponte Davi, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0034932274700',\n",
       "      'email': 'ANTPON@dexeus.com'},\n",
       "     {'name': 'Ignacio Rodríguez, MSc',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0034932274700',\n",
       "      'phoneExt': '22029',\n",
       "      'email': 'nacrod@dexeus.com'}],\n",
       "    'locations': [{'facility': 'Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus',\n",
       "      'city': 'Barcelona',\n",
       "      'zip': '08037',\n",
       "      'country': 'Spain',\n",
       "      'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'Related Info',\n",
       "      'url': 'http://www.dexeus.com'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000013577',\n",
       "      'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T6036',\n",
       "      'name': 'Menopause',\n",
       "      'asFound': 'Menopause',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000004967',\n",
       "      'term': 'Estrogens'}],\n",
       "    'ancestors': [{'id': 'D000006728', 'term': 'Hormones'},\n",
       "     {'id': 'D000006730',\n",
       "      'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M9878',\n",
       "      'name': 'Hyaluronic Acid',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M11014', 'name': 'Lidocaine', 'relevance': 'LOW'},\n",
       "     {'id': 'M8116',\n",
       "      'name': 'Estrogens',\n",
       "      'asFound': 'Nasal spray',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4244', 'name': 'Anticoagulants', 'relevance': 'LOW'},\n",
       "     {'id': 'M21320', 'name': 'Citric Acid', 'relevance': 'LOW'},\n",
       "     {'id': 'M1837', 'name': 'Sodium Citrate', 'relevance': 'LOW'},\n",
       "     {'id': 'M14216', 'name': 'Procaine', 'relevance': 'LOW'},\n",
       "     {'id': 'M1801',\n",
       "      'name': 'Lidocaine, Prilocaine Drug Combination',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "     {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'T382', 'name': 'Citrate', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'AnArAg', 'name': 'Anti-Arrhythmia Agents'},\n",
       "     {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'},\n",
       "     {'abbrev': 'AnCoag', 'name': 'Anticoagulants'},\n",
       "     {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06386978',\n",
       "    'orgStudyIdInfo': {'id': '2024/209'},\n",
       "    'organization': {'fullName': 'TC Erciyes University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Analgesic Efficacy of Transvers Abdominis Plane Block and Transversalis Fascia Plane Block in Cesarean Section',\n",
       "    'officialTitle': 'Examination of the Postoperative Analgesic Efficacy of Transvers Abdominis Plane Block and Transversalis Fascia Plane Block in Cesarean Section Surgeries Performed Under Spinal Anesthesia'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-15',\n",
       "    'studyFirstSubmitQcDate': '2024-04-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Kudret Dogru',\n",
       "     'investigatorTitle': 'Prof. Dr.',\n",
       "     'investigatorAffiliation': 'TC Erciyes University'},\n",
       "    'leadSponsor': {'name': 'TC Erciyes University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study was designed as a prospective, randomized observational clinical trial.\\r\\n\\r\\nA total of 90 adult women were included in the study performed elective cesarean section.\\r\\n\\r\\nAfter excluding patients, the care of 90 was included and 3 of these amounts were\\r\\nreserved.\\r\\n\\r\\nTAP Block Group (n=30,Group 1): Spinal Anesthesia + TAP block ; TFP Block group\\r\\n(n=30,Group 2): Spinal Anesthesia + TFP block ; Control group (n=30,Group 3); Spinal\\r\\nAnesthesia + No block;',\n",
       "    'detailedDescription': 'This study was designed as a prospective, randomized observational clinical trial.\\r\\nErciyes University Clinical Research Ethics Board 2024/209.\\r\\n\\r\\nAll participants in the study were adults and their information was confirmed in writing.\\r\\nPreoperative anesthesia assessment was made by an anesthetic injection, cesarean section\\r\\nsurgeries for 90 women were planned to be performed on elective conditions among those\\r\\nregistered between May 2024 and May 2025. ASA score, anesthesia method, age, weight,\\r\\nheight, TAP block group (Group I) or TFP block group (Group II), Control group (Group\\r\\nIII) :\\r\\n\\r\\nDuration of spinal anesthesia, time of first analgesic request, total analgesic\\r\\nconsumption for 24-48 hours, VAS score, additional analgesics, patient satisfaction,\\r\\npossible postoperative bleeding, vomiting, heat retention and other interruptions were\\r\\nrecorded in the patients.\\r\\n\\r\\nThose who were allergic to local anesthetics, steroid treatment areas, ASA III, ASA IV\\r\\nand ASA V, patients under the age of 18, preeclampsia, eclampsia, placenta percreta and\\r\\naccreta complications and emergency hospitals were excluded from the study. After\\r\\nexcluding patients, the care of 90 was included and 3 of these amounts were reserved.\\r\\n\\r\\nTAP Block Group (n=30,Group 1): Spinal Anesthesia + TAP block ; TFP Block group\\r\\n(n=30,Group 2): Spinal Anesthesia + TFP block ; Control group (n=30,Group 3): Spinal\\r\\nAnesthesia + No block; At the end of the surgery, TAP (Transverse Abdominis Plane Block)\\r\\nBlock or TFP (Transversalis Fascia Plane Block) block was performed under aseptic\\r\\nconditions under ultrasonography guidance.\\r\\n\\r\\nTAP (Transverse Abdominis Plane Block) Block for Group 1 patients and TFP (Transversalis\\r\\nFascia Plane Block) block for Group 2 patients on both sides after negative aspiration,\\r\\nwith 20 ml 0.25% bupivacaine (Marcaine®, Astra-Zeneca, Turkey) under ultrasonography\\r\\nguidance. It was done under aseptic conditions.\\r\\n\\r\\nPatients who did not accept both blocks were included in Group 3 (Control group).\\r\\n\\r\\nAll patients were trained on visual analog score (VAS) by the anesthesia assistant during\\r\\nthe preoperative evaluation. VAS used for pain assessment, a 10 cm long horizontal line\\r\\nwas used.\\r\\n\\r\\nFrom 0= (no pain) to 10= (most severe pain).\\r\\n\\r\\nPCA morphine administration to all patients: The hourly limit was set as 4 mg, and the\\r\\nrepeat limit was set as 10 minutes. If the 1 mg IV morphine bolus dose was not\\r\\nsufficient, it was planned to repeat it after 10 minutes, and if it was still not\\r\\nsufficient, paracetamol and diclofenac were planned to be administered.'},\n",
       "   'conditionsModule': {'conditions': ['Obstetric'],\n",
       "    'keywords': ['ceserean section',\n",
       "     'transverse abdominis plane block',\n",
       "     'transversalis facia plane block']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'TAP Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'TAP (Transverse Abdominis Plane Block) Block was performed in Group 1 patients after\\r\\nnegative aspiration on both sides, under aseptic conditions with bupivacaine under\\r\\nultrasonography guidance.',\n",
       "      'interventionNames': ['Procedure: Transverse Facia Plane Block (TAP Block)']},\n",
       "     {'label': 'TFP Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'TFP (Transversalis facia plane block ) Block was performed in Group 2 patients after\\r\\nnegative aspiration on both sides, under aseptic conditions with bupivacaine under\\r\\nultrasonography guidance.',\n",
       "      'interventionNames': ['Procedure: Transversalis Facia Plane Block (TFP Block)']},\n",
       "     {'label': 'Control Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients in the Third group will be considered the control group and no block will be\\r\\nperformed',\n",
       "      'interventionNames': ['Procedure: Control']}],\n",
       "    'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Transverse Facia Plane Block (TAP Block)',\n",
       "      'description': 'Spinal Anesthesia + TAP block',\n",
       "      'armGroupLabels': ['TAP Group']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Transversalis Facia Plane Block (TFP Block)',\n",
       "      'description': 'Spinal Anesthesia + TFP block',\n",
       "      'armGroupLabels': ['TFP Group']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Control',\n",
       "      'description': 'Spinal anesthesia + No block',\n",
       "      'armGroupLabels': ['Control Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'VAS score evaluation',\n",
       "      'description': \"A research asistant, bilinded to the group allocation, interviewedpatients and collected\\r\\ndata in the24 hours postoperative period. Verbal Analog Pain Scale Score value will be\\r\\nthe lowerst 0 and the highest 10. All the highest value, the patient's pain is at its\\r\\nmaximum and whether higher scores mean worse outcome.\",\n",
       "      'timeFrame': '1st, 6th, 12nd, 24 hours at rest, in the first 24hr first day of postoperative period.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'time until the first analgesic request',\n",
       "      'description': 'These were the time until the first analgesic request, the number of patients requiring\\r\\nadditional analgesics, the general dose of additional analgesic consumption and\\r\\ncomplications.',\n",
       "      'timeFrame': '1st, 6th, 12nd, 24 hours at rest, in the first 24hr first day of postoperative period'}],\n",
       "    'otherOutcomes': [{'measure': 'Satisfaction/Dissatisfaction',\n",
       "      'description': 'A scale of Satisfaction/Dissatisfaction was used to evaluate the patient satisfaction\\r\\nrate.',\n",
       "      'timeFrame': '1st, 6th, 12nd, 24 hours at rest, in the first 24hr first day of postoperative period'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  ASA I and ASA II,\\r\\n\\r\\n  -  Pregnant patients accepting spinal anesthesia and procedure\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Those who are allergic to local anesthetics,\\r\\n\\r\\n  -  Those receiving steroid treatment,\\r\\n\\r\\n  -  ASA III, ASA IV and ASA V,\\r\\n\\r\\n  -  Patients under the age of 18,\\r\\n\\r\\n  -  Patients with preeclampsia,\\r\\n\\r\\n  -  Eclampsia,\\r\\n\\r\\n  -  Placenta percreta and accreta and its complications,\\r\\n\\r\\n  -  Emergency patients.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '49 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Kudret Dogru, prof.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '905334735112',\n",
       "      'email': 'kdogru@erciyes.edu.tr'},\n",
       "     {'name': 'Sibel Pehlivan, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '905052532919',\n",
       "      'email': 'sibelpehlivan@erciyes.edu.tr'}],\n",
       "    'overallOfficials': [{'name': 'Kudret Dogru, Prof.',\n",
       "      'affiliation': 'TC Erciyes University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Erciyes University',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Kayseri',\n",
       "      'zip': '38039',\n",
       "      'country': 'Turkey',\n",
       "      'contacts': [{'name': 'Kudret Dogru, Prof',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+905334735112',\n",
       "        'email': 'kdogru@erciyes.edu.tr'},\n",
       "       {'name': 'Sibel Pehlivan, Asssoc Prof.',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+905052532919',\n",
       "        'email': 'sibelpehlivan@erciyes.edu.tr'}],\n",
       "      'geoPoint': {'lat': 38.73222, 'lon': 35.48528}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '26240550',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Srivastava U, Verma S, Singh TK, Gupta A, Saxsena A, Jagar KD, Gupta M. Efficacy of trans abdominis plane block for post cesarean delivery analgesia: A double-blind, randomized trial. Saudi J Anaesth. 2015 Jul-Sep;9(3):298-302. doi: 10.4103/1658-354X.154732.'},\n",
       "     {'pmid': '32412986',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Aydin ME, Bedir Z, Yayik AM, Celik EC, Ates I, Ahiskalioglu EO, Ahiskalioglu A. Subarachnoid block and ultrasound-guided transversalis fascia plane block for caesarean section: A randomised, double-blind, placebo-controlled trial. Eur J Anaesthesiol. 2020 Sep;37(9):765-772. doi: 10.1097/EJA.0000000000001222.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M5315',\n",
       "      'name': 'Bupivacaine',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05958875',\n",
       "    'orgStudyIdInfo': {'id': '2023-506602-39-00 (EU CT#)'},\n",
       "    'organization': {'fullName': 'UMC Utrecht', 'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'officialTitle': 'A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'acronym': 'INTENSIFY SZ'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-06-30',\n",
       "    'studyFirstSubmitQcDate': '2023-07-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-07-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr. Inge Winter',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'UMC Utrecht'},\n",
       "    'leadSponsor': {'name': 'Dr. Inge Winter', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Universität Münster', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Schizophrenia (SZ) affects approximately 4.5 million people across the European Union\\r\\n(EU) and is associated with annual healthcare and societal costs of 29 billion Euros. The\\r\\nimpact on the daily life of patients is huge, ranging from frequent relapses and\\r\\nhospitalisations, the inability to maintain a job or continue scholing, to a low quality\\r\\nof life, impaired cognitive functioning, suicidal ideation and an increase morbidity\\r\\nrate, next to the large burden for carers 1. When diagnosed with schizophrenia or related\\r\\ndisorder, patients are commonly prescribed antipsychotics. One-third of the schizophrenia\\r\\npatients are regarded treatment-resistant (TR), meaning that at least two antipsychotic\\r\\ntrials have failed. Typically, clozapine is prescribed for TR patients, which is\\r\\neffective for approximately 40% of patients. Clozapine is among the most effective\\r\\ntreatments, with the lowest all-cause mortality. Although it is among the most effective\\r\\nantipsychotics, it is generally not used earlier in the illness course due to a small\\r\\nrisk of severe neutropenia/agranulocytosis, which is why patients treated with clozapine\\r\\nare intensely monitored. However, this small risk outweighs the burden of not receiving\\r\\nan effective treatment.\\r\\n\\r\\nSince clozapine is among the most effective treatments, this leads to the research\\r\\nquestion whether earlier initiation of third-line treatment ('early intensified'\\r\\npharmacological treatment; EIPT) would be more beneficial than the current second-line\\r\\ntreatments (treatment as usual; TAU). If this is indeed the case, this could lead to the\\r\\nprevention of unnecessary trials of ineffective treatments, hospitalisations, and\\r\\nrecommendations for adaptations of worldwide guidelines as well as a reduction of\\r\\nhealthcare and societal costs The INTENSIFY-Schizophrenia trial is part of the larger\\r\\nHorizon 2021 project Psych-STRATA, with the central goal of paving the way for a shift\\r\\ntowards a treatment decision-making process tailored for the individual at risk for\\r\\ntreatment resistance. To that end, the inestigators aim to establish evidence-based\\r\\ncriteria to make decisions of early intense treatment in individuals at risk for\\r\\ntreatment resistance across the major psychiatric disorders of schizophrenia, bipolar\\r\\ndisorder and major depression. The current protocol focuses on the sample of\\r\\nschizophrenia patients.\",\n",
       "    'detailedDescription': \"Rationale Schizophrenia (SZ) affects approximately 4.5 million people across the European\\r\\nUnion (EU) and is associated with annual healthcare and societal costs of 29 billion\\r\\nEuros. The impact on the daily life of patients is huge, ranging from frequent relapses\\r\\nand hospitalisations, the inability to maintain a job or continue scholing, to a low\\r\\nquality of life, impaired cognitive functioning, suicidal ideation and an increase\\r\\nmorbidity rate, next to the large burden for carers. When diagnosed with schizophrenia or\\r\\nrelated disorder, patients are commonly prescribed antipsychotics. One-third of the\\r\\nschizophrenia patients are regarded treatment-resistant (TR), meaning that at least two\\r\\nantipsychotic trials have failed. Typically, clozapine is prescribed for TR patients,\\r\\nwhich is effective for approximately 40% of patients. Clozapine is among the most\\r\\neffective treatments, with the lowest all-cause mortality. Although it is among the most\\r\\neffective antipsychotics, it is generally not used earlier in the illness course due to a\\r\\nsmall risk of severe neutropenia/agranulocytosis, which is why patients treated with\\r\\nclozapine are intensely monitored. However, this small risk outweighs the burden of not\\r\\nreceiving an effective treatment.\\r\\n\\r\\nSince clozapine is among the most effective treatments, this leads to the research\\r\\nquestion whether earlier initiation of third-line treatment ('early intensified'\\r\\npharmacological treatment; EIPT) would be more beneficial than the current second-line\\r\\ntreatments (treatment as usual; TAU). If this is indeed the case, this could lead to the\\r\\nprevention of unnecessary trials of ineffective treatments, hospitalisations, and\\r\\nrecommendations for adaptations of worldwide guidelines as well as a reduction of\\r\\nhealthcare and societal costs The INTENSIFY-Schizophrenia trial is part of the larger\\r\\nHorizon 2021 project Psych-STRATA, with the central goal of paving the way for a shift\\r\\ntowards a treatment decision-making process tailored for the individual at risk for\\r\\ntreatment resistance. To that end, the investigators aim to establish evidence-based\\r\\ncriteria to make decisions of early intense treatment in individuals at risk for\\r\\ntreatment resistance across the major psychiatric disorders of schizophrenia, bipolar\\r\\ndisorder and major depression. The current protocol focuses on the sample of\\r\\nschizophrenia patients.\\r\\n\\r\\nObjective The primary objective is to compare the treatment response, expressed as mean\\r\\nchange in symptom severity as measured through the Positive And Negative Syndrome Scale\\r\\n(PANSS) under an early-intensified pharmacological treatment to that under treatment as\\r\\nusual, in subjects who had a first-time treatment failure on their first-line treatment\\r\\nfor schizophrenia, schizoaffective or schizophreniform disorder.\\r\\n\\r\\nMain trial endpoints Mean change in symptom severity total score from baseline (visit 2)\\r\\nto end of treatment (visit 4) between the two treatment arms (EIPT vs. TAU). This is\\r\\nmeasured using PANSS.\\r\\n\\r\\nSecondary trial objectives\\r\\n\\r\\n  1. To compare changes in PANSS subscale scores (positive, negative and general) between\\r\\n     the two treatment arms.\\r\\n\\r\\n  2. To compare changes in severity and improvement in global functioning assessed by the\\r\\n     Clinical Global Impression Scale (CGI) between the two treatment arms.\\r\\n\\r\\n  3. To compare changes in the levels of depression and anxiety between treatment arms.\\r\\n\\r\\n  4. To compare changes in quality of life and functioning measures between treatment\\r\\n     arms.\\r\\n\\r\\n  5. To compare changes in cognitive performance between treatment arms.\\r\\n\\r\\n  6. To compare the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\n     remission at visit 4.\\r\\n\\r\\n  7. To compare presence of side effects between treatment arms.\\r\\n\\r\\n  8. To compare use of concomitant medication between treatment arms.\\r\\n\\r\\n  9. To compare premature discontinuation (timing and reason) between treatment arms.\\r\\n\\r\\n 10. To compare changes in suicidal ideation between treatment arms.\\r\\n\\r\\nTrial design The clinical study is an international, multicenter controlled, randomised,\\r\\nopen label trial (with blinded raters), with a treatment duration of six weeks.\\r\\n\\r\\nTrial population The aim is to recruit 418 subjects with schizophrenia, schizoaffective\\r\\ndisorder or schizophreniform disorder. Male and female subjects, in- and out-patients,\\r\\nwithin the age range of 18 to 70 years old are eligible for participation. The main\\r\\nexclusion criteria are defined to protect the wellbeing of subjects, e.g. being pregnant\\r\\nor breastfeeding, subjects with previous failure on clozapine, meeting any\\r\\ncontraindications, or participants with a known intolerance to clozapine.\\r\\n\\r\\nInterventions Subjects are randomised to treatment as usual (second-line treatment) or to\\r\\nthe early-intensified pharmacological treatment (third-line treatment; clozapine).\\r\\n\\r\\nEthical considerations relating to the clinical trial including the expected benefit to\\r\\nthe individual subject or group of subjects represented by the trial subjects as well as\\r\\nthe nature and extent of burden and risks All medications studied in the current trial\\r\\nare widely used (alone or in combination) in clinical practice and side effect profiles\\r\\nare well established. In the current study, clinical practice is mimicked as much as\\r\\npossible to maximize generalizability and for feasibility purposes. To this end,\\r\\nSummaries of Product Characteristics (SmPCs) are followed with regards to\\r\\ncontraindications (implemented as exclusion criterion), safety measures and prohibited\\r\\ncomedications. Site visits and assessments are kept to a minimum to keep subject burden\\r\\nat an acceptable level, while meeting the objectives of the study. Blood samples for\\r\\nbiomarker analyses are only collected when subjects provide consent; safety measures are\\r\\nperformed as part of clinical routine.\\r\\n\\r\\nOverall, the risks are similar to daily clinical practice; the only difference relative\\r\\nto clinical practice is the application of early-intensified pharmacological treatment\\r\\nearlier in the illness. Still, these intense treatment options are also commonly\\r\\nprescribed by clinicians. There are no indications in existing literature or clinical\\r\\npractice that the earlier introduction of these medications poses a safety risk when used\\r\\nin an earlier illness phase than indicated in the SmPC.\\r\\n\\r\\nA benefit of the study is that if it indeed turns out that the clozapine is associated\\r\\nwith more symptom improvement compared to treatment as usual, future patients have to go\\r\\nthrough less trial and error, which results in a reduced burden (higher quality of life,\\r\\nless unemployment, less hospitalisations) for patients and carers as well as lower\\r\\nsocietal and healthcare costs.\\r\\n\\r\\nIMPORTANT: the study was submitted to the European authorities before (see NCT05603104)\\r\\nand they requested to split this study into 3 studies (1 for each diagnostic category).\\r\\nWe have done this and created 3 new ClinicalTrials.gov studies as well, from which this\\r\\nis one for schizophrenia. For the BD study it is NCT05973786 and for MDD NCT05973851. The\\r\\nsite in the UK (London) followed the advice and will submit 3 separate protocols and are\\r\\ntherefore included in the current record. However, Israel already submitted this as one\\r\\nprotocol. Therefore, we keep the old clinicaltrials.gov number for Israel (NCT05603104).\"},\n",
       "   'conditionsModule': {'conditions': ['Schizophrenia and Related Disorders',\n",
       "     'Early Treatment-Resistance'],\n",
       "    'keywords': ['Schizophrenia',\n",
       "     'Schizoaffective disorder',\n",
       "     'Schizophreniform disorder',\n",
       "     'Clozapine',\n",
       "     'Treatment as usual',\n",
       "     'Early treatment-Resistance']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified\\r\\npharmacological treatment (EIPT).',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Open label, except for the assessors of the primary outcome',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 418, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Schizophrenia early intensified treatment (EIPT): Switch to clozapine',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"Subject with schizophrenia, randomized to EIPT: Switch to clozapine. Brand, dosage,\\r\\nfrequency and duration up to the investigator's discretion\",\n",
       "      'interventionNames': ['Drug: Clozapine']},\n",
       "     {'label': 'Schizophrenia treatment as usual (TAU): second-line antispychotic',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': \"Subject with schizophrenia or related disorder randomized to TAU: switch to second-line\\r\\nantispychotic. Compound, brand, dosage, frequency and duration up to the investigator's\\r\\ndiscretion (in accordance with SmPC)\",\n",
       "      'interventionNames': ['Drug: Second-line Antipsychotics (treatment as usual)']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Clozapine',\n",
       "      'description': 'Participants are randomized to clozapine or second-line antipsychotics. When randomised\\r\\nto clozapine, they will receive clozapine for six weeks.',\n",
       "      'armGroupLabels': ['Schizophrenia early intensified treatment (EIPT): Switch to clozapine'],\n",
       "      'otherNames': ['ATC code: N05AH02']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Second-line Antipsychotics (treatment as usual)',\n",
       "      'description': 'Participants are randomized to clozapine or second-line antipsychotics. When randomized\\r\\nto second-line antipsychotics, this means participants will receive treatment as usual.\\r\\nThe physician has the choice to administer any second-line antipsychotic. More\\r\\nspecification is not possible, as this is a choice the physician makes with the\\r\\nparticipant based on the characteristic and preference of the participant (in line with\\r\\nstandard clinical practice).',\n",
       "      'armGroupLabels': ['Schizophrenia treatment as usual (TAU): second-line antispychotic']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in symptom severity on Positive and Negative Syndrome Scale',\n",
       "      'description': 'Change in symptom severity (EIPT vs. TAU) total score from baseline (visit 2) to end of\\r\\ntreatment (visit 4). This is measured using the Positive And Negative Syndrome Scale.\\r\\nMinimum score is 30, maimum score 210. A bigger mean change means a better outcome.',\n",
       "      'timeFrame': '6 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Compare symptomatic remission.',\n",
       "      'description': 'Comparison of the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\nremission at visit 4. Remission is defined as meeting all the Positive and Negative\\r\\nSyndrome Scale modified Andreasen criteria (Low scores (≤3) P1. Delusions; P3.\\r\\nHallucinatory behavior; P2. Conceptual disorganization; N1. Blunted affect; N4.\\r\\nPassive/apathetic social withdrawal; N6. Lack of spontaneity and flow of conversation;\\r\\nG5. Mannerisms/posturing; G9. Unusual thought content. There is no minimum or maximum\\r\\nscore; either a participants meets the criteria or not (dichotomous outcome).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in PANSS subscale scores (positive, negative and general) between the two treatment arms.',\n",
       "      'description': 'To compare changes in Positive and Negative Syndrome Scale subscale scores (positive\\r\\n(mimumum score 7, maximum score 49), negative (minimum score 7, maximum score 49) and\\r\\ngeneral( (minimum score 16, maximum score 112)) between the two treatment arms over the\\r\\nsix-week treatment period (visit 2 versus visit 4). Lower scores mean better outcomes.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare changes in the levels of depression and anxiety',\n",
       "      'description': 'To compare changes in the levels of depression and anxiety as assessed with the Hospital\\r\\nAnxiety and Depression Scale between the two treatment arms (EIPT/TAU) over the six week\\r\\ntreatment period (visit 2 versus visit 4). Lower scores mean less depression and anxiety.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in cognitive performance as measured through the Trail Making Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Trail Making Test\\r\\nbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit\\r\\n4). A lower time to complete the test means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes cognitive performance as measured through the Digit Symbol Substitution Test',\n",
       "      'description': 'To compare changes cognitive performance as measured through the Digit Symbol\\r\\nSubstitution Test between the two treatment arms over the six weeks treatment period\\r\\n(visit 2 versus visit 4). A higher scores means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Rey Auditory Verbal\\r\\nLearning Test between the two treatment arms over the six weeks treatment period (visit 2\\r\\nversus visit 4). Higher scores means better cognitive performance. There are several\\r\\nscores to calculate: RAVLT Immediate score: the sum of scores from 5 first trials (Trials\\r\\n1 to 5).\\r\\n\\r\\nRAVLT Learning score: the score of Trial 5 minus the score of Trial 1. RAVLT Forgetting:\\r\\nthe score of Trial 5 minus score of the delayed recall. RAVLT Percent Forgetting score:\\r\\nRAVLT Forgetting divided by the score of Trial 5.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in subjective cognitive performance as measured through the Perceived Deficits Questionnaire',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Perceived Deficits\\r\\nQuestionnaire between the two treatment arms over the six weeks treatment period (visit 2\\r\\nversus visit 4). A higher scores means worse subjective cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in functioning on the Leuven Afective and Pleasure Scale',\n",
       "      'description': 'To compare changes in the functioning measure, Leuven Afective and Pleasure Scale,\\r\\nbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit\\r\\n4). A higher scores means worse functioning. Minimum score: 0, Maximum score: 160',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in functioning on the Sheehan Disability Scale',\n",
       "      'description': 'To compare changes in the functioning measure,Sheehan Disability Scale, between the two\\r\\ntreatment arms over the six weeks treatment period (visit 2 versus visit 4). A higher\\r\\nscores means worse functioning. Minimum score: 0, maximum score 30.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in quality of life measure, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form',\n",
       "      'description': 'To compare changes in quality of life measure, Quality of Life Enjoyment and Satisfaction\\r\\nQuestionnaire Short Form between the two treatment arms over the six weeks treatment\\r\\nperiod (visit 2 versus visit 4). A higher scores means better quality of life. Minimum\\r\\nscore: 16, maximum score: 80.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in quality of life measure, Quality of Life Scale -100, subscale inner tension',\n",
       "      'description': \"To compare changes in quality of life measure, Quality of Life Scale -100, subscale inner\\r\\ntension between the two treatment arms over the six weeks treatment period (visit 2\\r\\nversus visit 4). This is a dichotomous scale (unsatisfactory or satisfactory). More\\r\\n'satisfatory' answers means higher quality of life.\",\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare presence of side effects between the two treatment arms.',\n",
       "      'description': 'To compare presence of side effects as measured through General Assessment of Side\\r\\nEffects Scale and reported spontaneously between the two treatment arms (EIPT/TAU) over\\r\\nthe six week treatment period (visit 2 versus visit 4). Higher scores means more side\\r\\neffects. Minimum score: 0 side effects, maximum score: 38 side effects.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the use of concomitant medication between the two treatment arms.',\n",
       "      'description': 'To compare use of concomitant medication between the two treatment arms (EIPT/TAU) over\\r\\nthe six week treatment period (visit 2 versus visit 4).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the difference in number of participants (EIPT vs. TAU) that prematurely discontinuate the study (stopping before visit 4 while started medication at visit 2',\n",
       "      'description': 'To compare the difference in number of participants (EIPT vs. TAU) that prematurely\\r\\ndiscontinuate the study (stopping before visit 4 while started medication at visit 2',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare mean changes in symptom severity on the Clinical Global Impression Scale, Severity',\n",
       "      'description': 'To compare changes in symptom severity on the Clinical Global Impression scale (Severity)\\r\\nbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit\\r\\n4). A higher score on CGI-S means worse symptom severity. Minimum score: 1, maximum\\r\\nscore: 7',\n",
       "      'timeFrame': '6 weeks.'},\n",
       "     {'measure': 'To compare mean changes in symptom severity on the Clinical Global Impression Scale, Improvement',\n",
       "      'description': 'To compare changes in improvement on the Clinical Global Impression scale (Improvement)\\r\\nbetween the two treatment arms over the six weeks treatment period (visit 2 versus visit\\r\\n4). A higher score on CGI-I means more improvement. Minimum score: 1, maximum score: 7',\n",
       "      'timeFrame': '6 weeks.'},\n",
       "     {'measure': 'To compare the reasons for premature discontinuation (EIPT vs. TAU) (stopping before visit 4 while started medication at visit 2',\n",
       "      'description': 'To compare the difference in reasons for premature discontinuation between the treatment\\r\\narms over the treatment period.',\n",
       "      'timeFrame': '6 weeks.'},\n",
       "     {'measure': 'To compare changes in suicidal ideation between treatment arms.',\n",
       "      'description': \"Changes from baseline (visit 2) on Module B 'Suicidality' of the Mini International\\r\\nNeuropsychiatric Interview (v7.0.2) at V4 between the two treatment arms. A score of 1-8\\r\\npoints on this module means that the suicide risk is low, scores 9-16 means a moderate\\r\\nrisk and 17 points or higher means that there is a high risk. The minimum score is 0 and\\r\\nthe maximum score is 154.\",\n",
       "      'timeFrame': '6 weeks.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. In- or out patients, at least 18 years of age up until 70.\\r\\n\\r\\n  2. Being willing and able to provide written informed consent. Having a legal guardian\\r\\n     to cosign is allowed. Informed consent will be signed at visit 1, before any study\\r\\n     procedure.\\r\\n\\r\\n  3. Female subjects of child bearing potential must use effective contraception during\\r\\n     the trial as per the requirements of the applicable SmPCs and should have a negative\\r\\n     pregnancy test at visit 1 (protocol section 8.2).\\r\\n\\r\\n  4. Meeting diagnostic criteria for a primary diagnosis of schizophrenia,\\r\\n     schizoaffective disorder, or schizophreniform disorder, according to DSM-5. The\\r\\n     primary diagnosis will be confirmed by the Mini International Neuropsychiatric\\r\\n     Interview (MINI v7.0.2).\\r\\n\\r\\n  5. Subject currently experiences his/her first treatment failure due to lack of\\r\\n     efficacy; this treatment is a first-line pharmacotherapeutic agent for the primary\\r\\n     DSM-5 diagnosis, and was prescribed for at least 4 weeks within the dose range as\\r\\n     specified in the Summary of Product Characteristics (SmPCs).\\r\\n\\r\\n  6. Subject has failed on current psychopharmacological treatment of current episode of\\r\\n     SZ, as confirmed by a CGI-I ≥3.\\r\\n\\r\\n  7. Subject and clinician intend to change pharmacotherapeutic treatment.\\r\\n\\r\\n  8. A minimum symptom severity threshold needs to be present (moderate level; see below)\\r\\n     and subject needs to experience functional impairment.\\r\\n\\r\\n       -  The minimum symptom severity threshold is at least 2 PANSS positive or negative\\r\\n          items with a score of 4, or at least one PANSS positive or negative item with a\\r\\n          score of 5.\\r\\n\\r\\n       -  Functional impairment is defined as a score of 5 or higher on any of the three\\r\\n          scales of the Sheehan Disability Scale (SDS).\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Being pregnant or breastfeeding.\\r\\n\\r\\n  2. Subject has used clozapine in the past.\\r\\n\\r\\n  3. Subject has a known intolerance to clozapine or to all TAU medication options.\\r\\n\\r\\n  4. Meeting any of the contraindications of clozapine or to all TAU medication options,\\r\\n     as specified within the applicable SmPC.\\r\\n\\r\\n  5. Subject has participated in another clinical trial in which the subject received an\\r\\n     experimental or investigational drug or agent within 30 days before visit 1.\\r\\n\\r\\n  6. Subject currently uses more than the allowed psychotropic concomitant medication and\\r\\n     needs to stay on this medication during the study.\\r\\n\\r\\n  7. Subject experiences any other significant disease or disorder which, in the opinion\\r\\n     of the investigator, may either put the subjects at risk because of participation in\\r\\n     the trial, or may influence the result of the trial, or the subject's ability to\\r\\n     participate in the trial.\\r\\n\\r\\n  8. Moderate or high suicidal ideation within the last 2 weeks, defined as a score of 9\\r\\n     or higher on Module B (Suicidality) of the Mini International Neuropsychiatric\\r\\n     Interview (MINI v7.0.2)\\r\\n\\r\\n  9. Subject meets criteria for current substance use disorder, as confirmed by the Mini\\r\\n     International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is\\r\\n     allowed, as well as mild alcohol and/or cannabis use disorder (as defined by MINI\\r\\n     v7.0.2). Moderate and severe alcohol and/or cannabis use disorder are not allowed.\\r\\n\\r\\n 10. Subjects have not been committed to an institution by virtue of an order issued\\r\\n     either by the judicial or the administrative authorities.\\r\\n\\r\\n 11. Subjects who meet the modified Andreasen criteria for remission.\\r\\n\\r\\n 12. Subjects that have any clinically significant abnormal values on the local\\r\\n     laboratory test (especially ANC/WBC and liver values), electrocardiogram (ECG) or\\r\\n     physician examinations.\\r\\n\\r\\n 13. Subjects dependent on the sponsor, investigator or trial site must be excluded from\\r\\n     participation in advance\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Inge Winter, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'i.winter@umcutrecht.nl'},\n",
       "     {'name': 'Cynthia Okhuijsen-Pfeifer, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'c.pfeifer@umcutrecht.nl'}],\n",
       "    'locations': [{'facility': 'Medical University Innsbruck',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Innsbruck',\n",
       "      'country': 'Austria',\n",
       "      'contacts': [{'name': 'Alex Hofer, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'a.hofer@i-med.ac.at'}],\n",
       "      'geoPoint': {'lat': 47.26266, 'lon': 11.39454}},\n",
       "     {'facility': 'Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Bielefeld',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Martin Driessen, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'martin.driessen@evkb.de'}],\n",
       "      'geoPoint': {'lat': 52.03333, 'lon': 8.53333}},\n",
       "     {'facility': 'University Hospital Frankfurt am Main - Goethe University',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Frankfurt am Main',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Andreas Reif, MD,PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'andreas.reif@kgu.de'}],\n",
       "      'geoPoint': {'lat': 50.11552, 'lon': 8.68417}},\n",
       "     {'facility': 'Klinik für Psychiatrie und Psychotherapie der Universitätsmedizin Mainz',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Mainz',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Klaus Lieb',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'klaus.lieb@lir-mainz.de'}],\n",
       "      'geoPoint': {'lat': 49.98419, 'lon': 8.2791}},\n",
       "     {'facility': 'Westfälische Wilhelms-Universität Münster',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Münster',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Bernhard Baune',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Bernhard.Baune@ukmuenster.de'}],\n",
       "      'geoPoint': {'lat': 51.96236, 'lon': 7.62571}},\n",
       "     {'facility': 'Universita degli Studi di Brescia',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Brescia',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Antonio Vita, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'antonio.vita@unibs.it'}],\n",
       "      'geoPoint': {'lat': 45.53558, 'lon': 10.21472}},\n",
       "     {'facility': 'University of Cagliari',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Cagliari',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Mirko Manchia, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'mirkomanchia@unica.it'}],\n",
       "      'geoPoint': {'lat': 39.23054, 'lon': 9.11917}},\n",
       "     {'facility': 'Università degli studi della Campania Luigi Vanvitelli',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Naples',\n",
       "      'zip': '80138',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Armida Mucci, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'armida.mucci@gmail.com'}],\n",
       "      'geoPoint': {'lat': 40.85216, 'lon': 14.26811}},\n",
       "     {'facility': 'Azienda Ospedaliero-Universitaria \"Città della Salute e della Scienza di Torino\"',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Turin',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Paola Rocca, MD,PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'paola.rocca@unito.it'}],\n",
       "      'geoPoint': {'lat': 45.07049, 'lon': 7.68682}},\n",
       "     {'facility': 'Fundació Clínic per a la Recerca Biomèdica',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Barcelona',\n",
       "      'country': 'Spain',\n",
       "      'contacts': [{'name': 'Eduard Vieta, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'EVIETA@clinic.cat'}],\n",
       "      'geoPoint': {'lat': 41.38879, 'lon': 2.15899}},\n",
       "     {'facility': \"King's College London, Psychiatry & Cognitive Neuroscience\",\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'London',\n",
       "      'zip': 'SE5 8AF',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Howes Oliver, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'oliver.howes@kcl.ac.uk'},\n",
       "       {'name': 'Allan Young, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'allan.young@kcl.ac.uk'}],\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'CSR']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000012559',\n",
       "      'term': 'Schizophrenia'}],\n",
       "    'ancestors': [{'id': 'D000019967',\n",
       "      'term': 'Schizophrenia Spectrum and Other Psychotic Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M15376',\n",
       "      'name': 'Schizophrenia',\n",
       "      'asFound': 'Schizophrenia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M21838',\n",
       "      'name': 'Schizophrenia Spectrum and Other Psychotic Disorders',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000014150',\n",
       "      'term': 'Antipsychotic Agents'},\n",
       "     {'id': 'D000003024', 'term': 'Clozapine'}],\n",
       "    'ancestors': [{'id': 'D000014149', 'term': 'Tranquilizing Agents'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000011619', 'term': 'Psychotropic Drugs'},\n",
       "     {'id': 'D000012702', 'term': 'Serotonin Antagonists'},\n",
       "     {'id': 'D000018490', 'term': 'Serotonin Agents'},\n",
       "     {'id': 'D000018377', 'term': 'Neurotransmitter Agents'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000018756', 'term': 'GABA Antagonists'},\n",
       "     {'id': 'D000018682', 'term': 'GABA Agents'}],\n",
       "    'browseLeaves': [{'id': 'M6254',\n",
       "      'name': 'Clozapine',\n",
       "      'asFound': 'Capsaicin',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16904',\n",
       "      'name': 'Antipsychotic Agents',\n",
       "      'asFound': 'Orange',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14474', 'name': 'Psychotropic Drugs', 'relevance': 'LOW'},\n",
       "     {'id': 'M15512', 'name': 'Serotonin', 'relevance': 'LOW'},\n",
       "     {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'CNSDep',\n",
       "      'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06098742',\n",
       "    'orgStudyIdInfo': {'id': 'ANT-05-01-2022'},\n",
       "    'organization': {'fullName': 'Valenta Pharm JSC', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers',\n",
       "    'officialTitle': 'An Open-label, Randomized, Crossover Study to Investigate the Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-10',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-10-20', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-09-20', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-19',\n",
       "    'studyFirstSubmitQcDate': '2023-10-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-24', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-28',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Valenta Pharm JSC', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence\\r\\n(bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg\\r\\nchewable tablets in healthy volunteers.'},\n",
       "   'conditionsModule': {'conditions': ['Heartburn',\n",
       "     'Acid-dependent Diseases of the Gastrointestinal Tract',\n",
       "     'Symptomatic Treatment of Gastric and Duodenal Ulcers']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'CROSSOVER',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'TR-sequence (T-test drug, R-reference drug)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Group 1 (25 volunteers, TR sequence) will take 2 sachets of Antareit 800 mg/10 ml oral\\r\\nsuspension 2 h prior to food intake in Period 1 and 2 tablets of Riopan 800 mg chewable\\r\\ntablets 2 h prior to food intake in Period 2',\n",
       "      'interventionNames': ['Drug: Antareit']},\n",
       "     {'label': 'RT-sequence',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Group 2 (25 volunteers, RT sequence) will take 2 tablets of Riopan 800 mg chewable\\r\\ntablets 2 h prior to food intake in Period 1 and 2 sachets of Antareit 800 mg/10 ml oral\\r\\nsuspension 2 h prior to food intake in Period 2',\n",
       "      'interventionNames': ['Drug: Antareit']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Antareit',\n",
       "      'description': 'A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake',\n",
       "      'armGroupLabels': ['RT-sequence',\n",
       "       'TR-sequence (T-test drug, R-reference drug)']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Pharmacodynamics - AUCpH - Area under the curve potential of hydrogen',\n",
       "      'description': 'Area under the pharmacodynamic pH-time curve',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics - time percentage during which the intragastric pH value will exceed 4.0',\n",
       "      'description': 'PH - potential of hydrogen',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics- рНmaximum',\n",
       "      'description': 'maximum potential of hydrogen',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics- рНmin',\n",
       "      'description': 'minimum potential of hydrogen',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics - average pH value',\n",
       "      'description': 'root mean square',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics - time percentage during which the intragastric pH value will exceed 3.0',\n",
       "      'description': 'During which the intragastric pH value will exceed 3.0',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics - median time when the pH was above 3.0',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'},\n",
       "     {'measure': 'Pharmacodynamics - median time when the pH was above 4.0',\n",
       "      'timeFrame': 'From 0 to 1 hour (Day 1 and Day 8)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Safety and Tolerability: adverse event (AE) number and frequency',\n",
       "      'description': 'Number and frequency of adverse events (AEs) or serious AEs (SAEs)',\n",
       "      'timeFrame': 'From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)'},\n",
       "     {'measure': 'Safety and Tolerability: serious adverse event (SAE) number and frequency',\n",
       "      'description': 'Number and frequency of serious AEs (SAEs)',\n",
       "      'timeFrame': 'From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)'},\n",
       "     {'measure': 'Safety and Tolerability: volunteer complaints',\n",
       "      'timeFrame': 'From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)'},\n",
       "     {'measure': 'Safety and Tolerability: physical examination results',\n",
       "      'description': 'Physical examination will be conducted to identify normal and abnormal physical\\r\\ncharacteristics of volunteers in accordance with the planned examination and will include\\r\\nan assessment of the Condition of the cardiovascular, respiratory, digestive, endocrine,\\r\\nmusculoskeletal, nervous, sensory systems, skin/visible mucous membranes',\n",
       "      'timeFrame': 'Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 15)'},\n",
       "     {'measure': 'Safety and Tolerability: vital signs',\n",
       "      'description': 'systolic blood pressure (SBP),diastolic blood pressure (DBP), heart rate (HR), body\\r\\ntemperature',\n",
       "      'timeFrame': 'Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 15)'},\n",
       "     {'measure': 'Safety and Tolerability: 12-lead electrocardiogram (ECG)',\n",
       "      'description': '12-lead ECG (I, II, III, aVR -enhanced unipolar abduction from the right arm , aVL -\\r\\nenhanced unipolar abduction from the left arm , aVF - enhanced unipolar abduction from\\r\\nthe left legб V1-V6) taken while lying down: heart rate (beats per minute), PQ interval\\r\\n(is the period, measured in milliseconds, that extends from the beginning of the P wave\\r\\n(the onset of atrial depolarization) until the beginning of the QRS complex), QRS complex\\r\\n(The QRS complex is the combination of three of the graphical deflections seen on a\\r\\ntypical electrocardiogram), corrected QT interval (distance from the beginning of the QRS\\r\\ncomplex to the end of the T wave)',\n",
       "      'timeFrame': 'Screening, Day 9'},\n",
       "     {'measure': 'Safety and Tolerability: clinical blood test',\n",
       "      'description': 'hemoglobin, hematocrit, Red blood cell count, Platelet count, Leukocyte count,\\r\\nerythrocyte sedimentation rate, Leukocyte formula (myelocytes, band neutrophils,\\r\\nsegmented neutrophils, eosinophils, basophils, monocytes, lymphocytes)',\n",
       "      'timeFrame': 'Screening, Day 2, Day 9'},\n",
       "     {'measure': 'Safety and Tolerability: blood chemistry',\n",
       "      'description': 'Glucose concentration, Total cholesterol concentration, Total protein concentration,\\r\\nTotal bilirubin concentration, Creatinine concentration, Alkaline phosphatase activity,\\r\\nalanine transaminase and aspartate transaminase activity',\n",
       "      'timeFrame': 'Screening, Day 2, Day 9'},\n",
       "     {'measure': 'Safety and Tolerability: urinalysis',\n",
       "      'description': 'Relative density, Color, Transparency, pH, Protein concentration, Glucose concentration,\\r\\nRed blood cell content, White blood cell content, Epithelial cell content, Presence of\\r\\ncasts, Presence of mucus, Presence of bacteria.',\n",
       "      'timeFrame': 'Screening, Day 2, Day 9'},\n",
       "     {'measure': 'Safety and Tolerability: urinalysis (microscopy)',\n",
       "      'description': 'Microscopy of urine sediment is performed if it is present.',\n",
       "      'timeFrame': 'Screening, Day 2, Day 9'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Voluntary and handwritten informed consent form signed by a healthy volunteer to\\r\\n     participate in the study prior to any of the study procedures;\\r\\n\\r\\n  2. Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive);\\r\\n\\r\\n  3. Verified diagnosis \"healthy\" (without abnormal findings in the protocol-defined\\r\\n     clinical, laboratory, and instrumental test data);\\r\\n\\r\\n  4. pH according to hourly pH-metry in the screening period, carried out at least 3\\r\\n     hours after the last meal, is completely in the range from 1 to 3 inclusive\\r\\n     throughout the entire astronomical hour of measurement;\\r\\n\\r\\n  5. Blood pressure (BP) levels: 100 to 139 mm Hg, inclusive (systolic, SBP), 60 to 89 mm\\r\\n     Hg, inclusive (diastolic, DBP);\\r\\n\\r\\n  6. Heart rate (HR) of 60 to 90 bpm, inclusive;\\r\\n\\r\\n  7. Body mass index (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, where the body weight range is\\r\\n     ≥ 55 kg for men and ≥ 45 kg for women;\\r\\n\\r\\n  8. Non-smoking healthy volunteers (who have never smoked or gave up smoking more than 6\\r\\n     months prior to the Screening);\\r\\n\\r\\n  9. Consent to use adequate methods of contraception throughout the study and for 30\\r\\n     days after completion; for women of preserved reproductive potential, a negative\\r\\n     urine pregnancy test result;\\r\\n\\r\\n 10. The volunteers must have adequate behavior and coherent speech.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. A history of allergy;\\r\\n\\r\\n  2. History of drug intolerance to the active and/or excipients included in the study\\r\\n     drugs;\\r\\n\\r\\n  3. History of drug intolerance of or hypersensitivity/allergic reactions to lidocaine,\\r\\n     xylocaine or other topical anesthetics which will be used at the trial site for\\r\\n     anesthesia during esophagogastroduodenoscopy (EGD) and insertion of the probe for\\r\\n     the pH measurements;\\r\\n\\r\\n  4. Chronic diseases of the circulatory, lymphatic, respiratory, nervous, endocrine,\\r\\n     gastrointestinal, musculoskeletal, integumentary, immune, urogenital, and\\r\\n     hematopoietic systems;\\r\\n\\r\\n  5. Esophageal, gastric, and/or duodenal diseases based on EGC performed at screening\\r\\n     and based on the medical history; a history of esophageal, gastric, and/or duodenal\\r\\n     surgery;\\r\\n\\r\\n  6. Diseases/conditions which, in the opinion of the investigator, may affect the pH\\r\\n     measurement results;\\r\\n\\r\\n  7. Acute infectious diseases less than 4 weeks prior to screening;\\r\\n\\r\\n  8. Use of antacids (including sodium bicarbonate solution)/H2 antagonists 24 h prior to\\r\\n     the Screening Visit;\\r\\n\\r\\n  9. Use of proton pump inhibitors 72 h prior to the Screening Visit;\\r\\n\\r\\n 10. Use of (including use of a single dose) steroids and/or other ulcerogenic drug\\r\\n     (e.g., nonsteriodal anti-inflammatory drugs [NSAID]) less than 4 weeks prior to the\\r\\n     Screening Visit;\\r\\n\\r\\n 11. Regular use of any medicinal products, including prescription only and OTC\\r\\n     (Over-the-counter) drugs and dietary supplements within 2 weeks prior to the\\r\\n     Screening Visit;\\r\\n\\r\\n 12. Blood or plasma donation less than 3 months prior to the Screening Visit;\\r\\n\\r\\n 13. Use of hormonal contraceptives (in women) less than 2 months prior to the Screening\\r\\n     Visit;\\r\\n\\r\\n 14. Pregnancy or breastfeeding; a positive pregnancy test for women of childbearing\\r\\n     potential;\\r\\n\\r\\n 15. Participation in another clinical trial less than 3 months prior to screening or\\r\\n     simultaneously with this study;\\r\\n\\r\\n 16. Use of more than 10 units of alcohol (1 unit of alcohol is equivalent to 330 ml of\\r\\n     beer, 150 ml of wine or 40 ml of spirits) a week within a month prior to the\\r\\n     enrollment in the study or history data of alcohol/drug dependence or drug abuse.\\r\\n\\r\\n 17. Positive antibody blood test for HIV-1 and HIV-2, Treponema pallidum antigen,\\r\\n     hepatitis B surface antigen (HBsAg), or hepatitis C virus antigen;\\r\\n\\r\\n 18. Positive urine test for narcotic substances or strong drugs;\\r\\n\\r\\n 19. Positive test for alcohol vapor in exhaled breath or a positive alcohol saliva test;\\r\\n\\r\\n 20. Deviated septum/nasal obstruction preventing the placement of the pH probe;\\r\\n\\r\\n 21. Medical history of chronic constipation;\\r\\n\\r\\n 22. Medical history of severe maxillofacial injuries;\\r\\n\\r\\n 23. Expected admission to hospital during this study for any reason, except for\\r\\n     hospitalization provided for by this protocol;\\r\\n\\r\\n 24. Impossibility or failure to comply with the protocol, undergo protocol-defined\\r\\n     procedures, or adhere to the diet or activity regime;\\r\\n\\r\\n 25. Positive SARS-CoV-2 (severe acute respiratory syndrome related coronavirus)\\r\\n     (COVID-19) rapid test;\\r\\n\\r\\n 26. Other circumstances which in the opinion of the investigator prevent a volunteer\\r\\n     from being included in the study or may result in premature drop-out from the study.\\r\\n\\r\\nWithdrawal criteria:\\r\\n\\r\\n  1. The volunteer\\'s refusal to further participate in the study;\\r\\n\\r\\n  2. Failure of the volunteer to comply with the rules of participation in the study\\r\\n     (skipping study procedures, independent use of drugs prohibited in the study,\\r\\n     violation of dietary and lifestyle restrictions, etc.);\\r\\n\\r\\n  3. Taking prohibited therapy;\\r\\n\\r\\n  4. Occurrence of causes/occurrence during the study of situations that threaten the\\r\\n     safety of the volunteer, including severe AEs;\\r\\n\\r\\n  5. Volunteers selected to participate in the study in violation of the\\r\\n     inclusion/non-inclusion criteria;\\r\\n\\r\\n  6. Violation of the rules for conducting pH measurements or the occurrence of\\r\\n     conditions that required early termination of pH measurements (vomiting, nosebleeds,\\r\\n     etc.);\\r\\n\\r\\n  7. Missing a dose of the study drug/comparator drug during any period of the study for\\r\\n     any reason;\\r\\n\\r\\n  8. Positive urine test for narcotics and powerful drugs;\\r\\n\\r\\n  9. Positive breath alcohol vapor test or alcohol in saliva;\\r\\n\\r\\n 10. Positive pregnancy test in women;\\r\\n\\r\\n 11. Positive test for COVID-19;\\r\\n\\r\\n 12. The occurrence in the course of the study of other reasons that prevent the study\\r\\n     according to the protocol.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Llc \"Certa Clinic\"',\n",
       "      'city': 'Moscow',\n",
       "      'zip': '109235',\n",
       "      'country': 'Russian Federation',\n",
       "      'contacts': [{'name': 'Alexander S Goncharov, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+7 (495) 121 07 05',\n",
       "        'email': 'info@certa-clinic.ru'}],\n",
       "      'geoPoint': {'lat': 55.75222, 'lon': 37.61556}},\n",
       "     {'facility': 'Limited Liability Company \"Research Center Eco-Safety\"',\n",
       "      'city': 'Saint Petersburg',\n",
       "      'zip': '196143',\n",
       "      'country': 'Russian Federation',\n",
       "      'contacts': [{'name': 'Konstantin Zakharov, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+7 921 950 29 91',\n",
       "        'email': 'konstantin.zakharov@mail.ru'}],\n",
       "      'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000004381',\n",
       "      'term': 'Duodenal Ulcer'},\n",
       "     {'id': 'D000006356', 'term': 'Heartburn'}],\n",
       "    'ancestors': [{'id': 'D000012817',\n",
       "      'term': 'Signs and Symptoms, Digestive'},\n",
       "     {'id': 'D000010437', 'term': 'Peptic Ulcer'},\n",
       "     {'id': 'D000004378', 'term': 'Duodenal Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000013272', 'term': 'Stomach Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M17206', 'name': 'Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M9444',\n",
       "      'name': 'Heartburn',\n",
       "      'asFound': 'Heartburn',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7555',\n",
       "      'name': 'Duodenal Ulcer',\n",
       "      'asFound': 'Duodenal Ulcer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15622',\n",
       "      'name': 'Signs and Symptoms, Digestive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M13348', 'name': 'Peptic Ulcer', 'relevance': 'LOW'},\n",
       "     {'id': 'M7552', 'name': 'Duodenal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M16062', 'name': 'Stomach Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M225612',\n",
       "      'name': 'Magaldrate',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06350006',\n",
       "    'orgStudyIdInfo': {'id': 'SHR-A1904-301'},\n",
       "    'organization': {'fullName': 'Shanghai Hengrui Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor',\n",
       "    'officialTitle': 'A Phase Ib/III Study of SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-12-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2028-12-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-01',\n",
       "    'studyFirstSubmitQcDate': '2024-04-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-05', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-25',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Shanghai Hengrui Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study consists of two research phases:\\r\\n\\r\\nPhase Ib (includes dose escalation phase and efficacy extension phase): To explore the\\r\\nsafety, tolerability and initial efficacy of SHR-A1904 in the treatment of\\r\\nCLDN18.2-positive advanced solid tumors, and to determine the recommended dose and\\r\\nrecommended population for the Phase III combination study.\\r\\n\\r\\nPhase III: A randomized, double-blind, multicenter clinical study of SHR-1904 combined\\r\\nwith chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for\\r\\nCLDN18.2-positive advanced solid tumors.'},\n",
       "   'conditionsModule': {'conditions': ['Cldn18.2-positive Advanced Solid Tumor']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This study is a multicenter Phase Ib/III clinical study. Phase Ib consists of two phases,\\r\\nIB-A for dose escalation and IB-B for efficacy extension. The Phase III multi-center,\\r\\nrandomized controlled, double-blind study was designed to evaluate the efficacy and\\r\\nsafety of SHR-A1904 combined chemotherapy and immunotherapy versus chemotherapy combined\\r\\nimmunotherapy in first-line treatment of CLDN18.2-positive solid tumors patients.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 924, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'SHR-A1904 combined with Adebrelimab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SHR-A1904+ Adebrelimab',\n",
       "      'interventionNames': ['Drug: SHR-A1904; Adebrelimab']},\n",
       "     {'label': 'SHR-A1904 combined with CAPOX and Adebrelimab',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SHR-A1904+ CAPOX+ Adebrelimab',\n",
       "      'interventionNames': ['Drug: SHR-A1904; CAPOX; Adebrelimab']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'SHR-A1904; Adebrelimab',\n",
       "      'description': 'SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab',\n",
       "      'armGroupLabels': ['SHR-A1904 combined with Adebrelimab']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'SHR-A1904; CAPOX; Adebrelimab',\n",
       "      'description': 'SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)',\n",
       "      'armGroupLabels': ['SHR-A1904 combined with CAPOX and Adebrelimab']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and severity of AE',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'Up to follow-up period, approximately 24 months'},\n",
       "     {'measure': 'Dose Limiting Toxicity (DLT)',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Maximal Tolerable Dose (MTD)',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Phase III Recommended Dose (RP3D)',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria',\n",
       "      'description': 'Phase 3',\n",
       "      'timeFrame': 'approximately 36 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'SHR-A1904 toxin binding antibody',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'SHR-A1904 Total antibody',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb)',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Expression level of CLDN18.2 in tumor tissues',\n",
       "      'description': 'Phase 1b',\n",
       "      'timeFrame': 'approximately 24 months'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'Phase 3',\n",
       "      'timeFrame': 'approximately 36 months'},\n",
       "     {'measure': 'Incidence and severity of AE',\n",
       "      'description': 'Phase 3',\n",
       "      'timeFrame': 'approximately 36 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Age 18 to 75 years old (including boundary values);\\r\\n\\r\\n  2. Volunteer to participate in this clinical study and sign informed consent;\\r\\n\\r\\n  3. ECOG score 0-1;\\r\\n\\r\\n  4. Expected survival ≥3 months;\\r\\n\\r\\n  5. Pathologically confirmed locally advanced unresectable or metastatic solid tumors;\\r\\n\\r\\n  6. positive CLDN18.2 expression in tumor tissue;\\r\\n\\r\\n  7. There is at least one measurable lesion that meets the RECIST 1.1 criteria;\\r\\n\\r\\n  8. Adequate bone marrow and organ function.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Plan to receive any other antitumor therapy during this trial; Received other\\r\\n     investigational drugs or treatments that are not on the market within 4 weeks prior\\r\\n     to the first administration; Anti-tumor therapy, such as chemotherapy, radiotherapy,\\r\\n     biotherapy, targeted therapy or immunotherapy, was received within 4 weeks before\\r\\n     the first administration of the study drug. Palliative radiotherapy or local therapy\\r\\n     within 2 weeks before the first administration of the study drug; Had major surgery\\r\\n     other than diagnosis or biopsy within the 4 weeks prior to the first administration\\r\\n     or randomization and required elective surgery during the trial.\\r\\n\\r\\n  2. Stage III: HER2 expression in tumor tissue is positive.\\r\\n\\r\\n  3. The adverse reactions of previous anti-tumor therapy has not recovered to NCI-CTCAE\\r\\n     v5.0 grade≤ 1.\\r\\n\\r\\n  4. Has ≥ grade 2 peripheral sensory neuropathy.\\r\\n\\r\\n  5. Has an allergic reaction to any of the components treated in this study, or are\\r\\n     allergic to humanized monoclonal antibody products.\\r\\n\\r\\n  6. Has a history or current history of meningeal metastasis; or active brain\\r\\n     metastases.\\r\\n\\r\\n  7. Presence of dysphagia or other factors affecting the use of oral medications.\\r\\n\\r\\n  8. Additional malignancy within the five years prior to the first administration or\\r\\n     randomization.\\r\\n\\r\\n  9. Has an active autoimmune disease or a history of autoimmune disease.\\r\\n\\r\\n 10. Received systemic use of corticosteroids or other immunosuppressants for\\r\\n     immunosuppressive effects within 14 days prior to the first administration or\\r\\n     randomization.\\r\\n\\r\\n 11. Has a history of clinically significant lung disease.\\r\\n\\r\\n 12. Has serosal effusion ≥ grade 3 (based on NCI CTCAE5.0 criteria).\\r\\n\\r\\n 13. There was an active infection requiring systemic treatment within 2 weeks prior to\\r\\n     the first administration or randomization.\\r\\n\\r\\n 14. A history of immunodeficiency, including a positive HIV test; Presence of active\\r\\n     hepatitis B or hepatitis C.\\r\\n\\r\\n 15. People who have previously received allogeneic hematopoietic stem cell\\r\\n     transplantation or organ transplantation.\\r\\n\\r\\n 16. Has severe cardiovascular and cerebrovascular diseases.\\r\\n\\r\\n 17. Gastrointestinal perforation and/or gastrointestinal fistula within the last 6\\r\\n     months prior to the first administration or randomization; Active gastrointestinal\\r\\n     bleeding occurred 3 months before the first administration or randomization.\\r\\n\\r\\n 18. In the investigator's judgment, the subjects has other factors that could have\\r\\n     affected the study results or led to the forced termination of the study.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Wei Shi',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0518-82342973',\n",
       "      'email': 'wei.shi@hengrui.com'},\n",
       "     {'name': 'Di Zong',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '0518-82342973',\n",
       "      'email': 'di.zong@hengrui.com'}],\n",
       "    'locations': [{'facility': 'Sun Yat-sen University Cancer Center',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Guangzhou',\n",
       "      'state': 'Guangdong',\n",
       "      'zip': '510060',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Ruihua Xu', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M377',\n",
       "      'name': 'Capecitabine',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M1674', 'name': 'Oxaliplatin', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06427252',\n",
       "    'orgStudyIdInfo': {'id': 'GHIST24'},\n",
       "    'organization': {'fullName': 'The First Affiliated Hospital with Nanjing Medical University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM',\n",
       "    'officialTitle': 'The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of Gastric or Esophagogastric Junctional Cancer With Peritoneal Metastasis: A Prospective, Multicenter Phase II Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-19',\n",
       "    'studyFirstSubmitQcDate': '2024-05-19',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-23', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'The First Affiliated Hospital with Nanjing Medical University',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'Gastric cancer (GC) with peritoneal metastasis has a poor prognosis and short survival.\\r\\nIn recent years, heat intraperitoneal perfusion chemotherapy (HIPEC) has gained better\\r\\nefficacy in the treatment of peritoneal metastases of many malignant tumors, including GC\\r\\nwith peritoneal metastasis. The use of immune checkpoint inhibitors (ICIs) in the\\r\\ntreatment of advanced GC has made significant progress in recent years. And studies\\r\\nshowed that patients who were responded to immunotherapy combined with chemotherapy as\\r\\nthe first-line treatment were able to achieve significant survival benefit after radical\\r\\nresection. However, whether HIPEC combined with immunotherapy for peritoneal metastatic\\r\\ngastric cancer improves the R0 resection rate and prolongs survival time is currently\\r\\nunclear. Therefore, we conducted this prospective multicenter clinical trial to explore\\r\\nthe effective dose and safety of the combination of systemic chemotherapy, HIPEC,\\r\\nanti-PD-1 and anti-HER-2 therapy, which will provide a clinical basis for the treatment\\r\\nof advanced GC.',\n",
       "    'detailedDescription': 'Gastric cancer (GC) is the 5th most common malignant tumor worldwide, and it causes the\\r\\n4th most tumor-related deaths among all malignant tumors. China is a large country with\\r\\n40% of the total number of GC cases worldwide. Despite the advances in medical detection\\r\\nmethods, most of the GC patients in China are in the advanced stage at the time of\\r\\ndiagnosis, in which peritoneal metastasis is one of the common metastatic patterns of\\r\\nadvanced GC, and the presence of peritoneal metastasis accounts for about 46% of patients\\r\\nwith distant metastasis detected at the first diagnosis. The prognosis of GC patients\\r\\nwith peritoneal metastasis is extremely poor, and compared with other metastatic organs,\\r\\npatients with stage IV GC with peritoneal metastasis have a worse prognosis and shorter\\r\\nsurvival.\\r\\n\\r\\nThe treatment of peritoneal metastasis of GC has been based on systemic chemotherapy with\\r\\nreference to advanced GC, but it is difficult for traditional chemotherapeutic agents to\\r\\nreach the peritoneal lesions due to the existence of blood-peritoneal barrier. In recent\\r\\nyears, heat intraperitoneal perfusion chemotherapy (HIPEC) has gained better efficacy in\\r\\nthe treatment of peritoneal metastases of many malignant tumors, including GC.HIPEC\\r\\nallows chemotherapeutic drugs to act directly on tumor tissues while reducing the impact\\r\\non other parts of the body; the warming effect is synergistic with the antitumor effects\\r\\nof chemotherapeutic drugs and helps the drugs to act more efficiently on the\\r\\nintraperitoneal tumor cells; moreover, the chemotherapeutic drugs are absorbed through\\r\\nthe peritoneum and then enter the liver via the portal vein route, which is beneficial to\\r\\npreventing liver metastasis. HIPEC currently has four applications and indications in the\\r\\nclinic: firstly, palliative application to improve the quality of life for GC abdominal\\r\\nmetastasis with a large amount of carcinomatous ascites; secondly, therapeutic\\r\\napplication of radical gastric cancer surgery + cytoreductive surgery + HIPEC for the\\r\\ntreatment of GC; third, prophylactic application, radical gastric cancer surgery +\\r\\nperitoneal hyperthermia chemotherapy, targeting people with high risk of peritoneal\\r\\nrecurrence, especially patients with T3-4 or positive lymph nodes; fourth, neoadjuvant\\r\\napplication, neoadjuvant chemotherapy combined with peritoneal hyperthermia chemotherapy\\r\\nbefore radical gastric cancer treatment, in order to reduce the risk of peritoneal\\r\\nimplantation of gastric cancer and to increase the possibility of radical surgery.\\r\\nHowever, there is a lack of high-level evidence-based medical evidence on the efficacy\\r\\nand safety of HIPEC as a translational treatment for GC with peritoneal metastasis.\\r\\n\\r\\nThe use of immune checkpoint inhibitors (ICIs) in the treatment of advanced GC has made\\r\\nsignificant progress in recent years. The KEYNOTE series of studies evaluated the safety\\r\\nand efficacy of PD-L1 antibody as a first-line treatment for advanced GC, among which the\\r\\nresults of KEYNOTE-859 confirmed that the combination of Pembrolizumab and chemotherapy\\r\\nis expected to be a HER-2 negative advanced gastric/esophagogastric junctional cancer\\r\\nfirst-line treatment option. A recent retrospective study by Chinese scholars\\r\\ndemonstrated that patients with stage IV GC who were responded to the immunotherapy\\r\\ncombined with chemotherapy as the first-line treatment were able to achieve significant\\r\\nsurvival benefit after radical resection. However, whether HIPEC combined with\\r\\nimmunotherapy for peritoneal metastatic gastric cancer improves the R0 resection rate and\\r\\nprolongs survival time is currently unclear.\\r\\n\\r\\nTherefore, we conducted this prospective multicenter clinical trial trying to combine the\\r\\nspecificity of HIPEC for peritoneal metastases with immunotherapy for advanced GC, aiming\\r\\nto evaluate the efficacy and feasibility of multimodal treatment regimens, such as HIPEC\\r\\nin combination with immunotherapy, for the transformative treatment of peritoneal\\r\\nmetastases of GC or EJ junctional cancer and to explore the effective dose and safety of\\r\\nthe combination of systemic chemotherapy, HIPEC, anti-PD-1 and anti-HER-2 therapy, which\\r\\nwill provide a clinical basis for the treatment of advanced GC.'},\n",
       "   'conditionsModule': {'conditions': ['Gastric Cancer, Metastatic'],\n",
       "    'keywords': ['gastric cancer',\n",
       "     'peritoneal metastasis',\n",
       "     'HIPEC',\n",
       "     'immunotherapy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'HIPEC plus PD-1 plus SOX therapy',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HIPEC treatment (paclitaxel, at 43°C for 60 min) was performed on the 1st day after the\\r\\nfirst exploratory laparotomy and on the third day after the radical surgery for a total\\r\\nof 2-3 times (total amount of paclitaxel was 175 mg/m2 ). Systemic therapy was started 3\\r\\nweeks after HIPEC. Systemic therapy including: Tirilizumab: 200 mg, Q3W; oxaliplatin:\\r\\n130mg/m2, Q3W; Herceptin: loading dose of 8 mg/kg followed by 6 mg/kg Q3W. Tegeo: Oral\\r\\nadministration: 40 mg per dose for BSA <1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60\\r\\nmg per dose for BSA ≥1.5, twice daily for each treatment cycle Q3W; After 2-6 weeks,\\r\\nlaparoscopic exploration was performed, PCI score was calculated, and radical surgery was\\r\\nperformed in patients who were eligible for radical surgery. Postoperative HIPEC was\\r\\nperformed twice.',\n",
       "      'interventionNames': ['Drug: HIPEC', 'Drug: Systemic therapy']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HIPEC',\n",
       "      'description': 'In the experimental group, HIPEC treatment (paclitaxel, 3000 ml of physiological saline\\r\\nat 43°C for 60 min) was performed on the first day after the first exploratory laparotomy\\r\\nand on the third day after the radical surgery for a total of 2-3 times (total amount of\\r\\npaclitaxel was 175 mg/m2 ), with an interval of not more than 72 h. Intravenous systemic\\r\\ntherapy was started 3 weeks after the completion of HIPEC treatment. systemic therapy.',\n",
       "      'armGroupLabels': ['HIPEC plus PD-1 plus SOX therapy']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Systemic therapy',\n",
       "      'description': '  1. Tirilizumab: 200 mg, i.v., D1, Q3W;\\r\\n\\r\\n  2. oxaliplatin: 130mg/m2, i.v., D1, Q3W;\\r\\n\\r\\n  3. Herceptin: a tri-weekly dosing regimen with an initial loading dose of 8 mg/kg\\r\\n     followed by 6 mg/kg Q3W.\\r\\n\\r\\n  4. Tegeo: Oral administration: 40 mg per dose for BSA <1.25, 50 mg per dose for BSA\\r\\n     1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle\\r\\n     D1-D14, Q3W;',\n",
       "      'armGroupLabels': ['HIPEC plus PD-1 plus SOX therapy']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival',\n",
       "      'description': 'The proportion of patients still alive at one year from the start of patient enrollment\\r\\nwas calculated as a percentage of all patients. Deaths from all causes were included in\\r\\nthe calculation of overall survival. The OS of patients who did not reach the one-year\\r\\nloss to follow-up was counted as data censored at the time of last confirmed survival\\r\\nbefore the loss to follow-up, i.e., only the time point of last known survival was\\r\\ncounted in the number of survivors.',\n",
       "      'timeFrame': '1 year'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Progression-free Survival',\n",
       "      'description': 'Percentage of all patients who did not experience disease progression or death within one\\r\\nyear from the start of patient enrollment. If disease progression is indicated by\\r\\nimaging, the date of disease progression will be the time of the imaging exam that\\r\\nclearly confirms disease progression. If disease progression was diagnosed by other\\r\\nclinical modalities, the date of diagnosis will be used as the date of disease\\r\\nprogression. Patients who discontinued the trial (without follow-up imaging) for reasons\\r\\nother than disease progression and patients who received post-trial therapy will have the\\r\\ntime of discontinuation of the trial or the time of initiation of post-trial therapy as\\r\\nthe data censored. New onset of other tumors is not considered a disease progression\\r\\nevent and is also not censored as data.',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Completeness of cytoreduction score',\n",
       "      'description': 'CC-0 indicates no residual tumor visible to the naked eye, CC-1 indicates residual tumor\\r\\nwith a maximum diameter of <2.5 mm, CC-2 indicates residual tumor with a diameter of more\\r\\nthan 2.5 mm but <25 mm, and CC-3 indicates residual tumor with a diameter of ≥25 mm. CC-0\\r\\nand CC-1 are usually classified as complete cytoreduction.',\n",
       "      'timeFrame': '1 year'},\n",
       "     {'measure': 'Objective Response Rate',\n",
       "      'description': 'Refers to the proportion of patients whose tumors shrank to a certain level and remained\\r\\nthere for a certain period of time, and includes both CR (Complete Response) and PR\\r\\n(Partial Response) cases. Objective tumor remission was assessed using the Solid Tumor\\r\\nRemission Assessment Criteria (RECIST 1.1 criteria). Patients had to be accompanied by\\r\\nmeasurable tumor lesions at baseline, and the efficacy assessment criteria were\\r\\nclassified as Complete Response (CR), Partial Response (PR), Stable Disease (SD), and\\r\\nProgressed Disease (PD) according to the RECIST 1.1 criteria. Disease (PD).',\n",
       "      'timeFrame': '1 year'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. patients with a pathologically confirmed primary diagnosis of\\r\\n     gastric/esophagogastric junctional cancer who have not undergone chemotherapy,\\r\\n     radiotherapy, or other antitumor therapy prior to the start of the clinical trial;\\r\\n\\r\\n  2. age 18 to 75 years Eastern Coorperative Oncology Group (ECOG): 0 to 1 points;\\r\\n\\r\\n  3. diagnosis of metastatic adenocarcinoma of the peritoneum [peritoneal cancer index\\r\\n     (PCI) ≤ 20 points] with or without ascites (beyond the pelvis but not reaching full\\r\\n     abdominal ascites) by laparoscopic exploration;\\r\\n\\r\\n  4. Voluntarily sign the informed consent form.\\r\\n\\r\\n  5. good cardiac function for resection with curative intent. If clinically indicated,\\r\\n     patients with underlying ischemic, valvular heart disease or other severe heart\\r\\n     disease should be evaluated preoperatively by a cardiologist;\\r\\n\\r\\n  6. normal function of major organs and subjects are required to meet the following\\r\\n     laboratory criteria: 1) Absolute neutrophil count (ANC) ≥ 1.5x109/L in the last 14\\r\\n     days without granulocyte colony-stimulating factor (GCSF); 2) Platelets ≥ 100 x\\r\\n     109/L in the absence of blood transfusion in the last 14 days; 3) Hemoglobin > 9\\r\\n     g/dL without transfusion or erythropoietin use in the last 14 days; 4) Total\\r\\n     bilirubin ≤ 1.5 x upper limit of normal (ULN); enrollment is also allowed if total\\r\\n     bilirubin > 1.5 x ULN but direct bilirubin ≤ ULN; 5) Aspartate aminotransferase\\r\\n     (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.\\r\\n\\r\\n  6) Blood creatinine ≤1.5×ULN and creatinine clearance (calculated using the\\r\\n     Cockcroft-Gault formula) ≥60 ml/min; 7) good coagulation function, defined as\\r\\n     International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 x ULN; 8) Normal\\r\\n     thyroid function, defined as thyrotropin (TSH) within the normal range. If baseline\\r\\n     TSH is outside the normal range, subjects may also be enrolled if total T3 (or FT3)\\r\\n     and FT4 are within the normal range; 9) Cardiac enzyme profiles within the normal\\r\\n     range (enrollment will be allowed if the investigator determines that the laboratory\\r\\n     abnormality is not of clinical significance); 7) Thyroid function: thyroid\\r\\n     stimulating hormone (TSH) and free thyroxine (FT3/FT4) in the normal range or mildly\\r\\n     abnormal without clinical significance; 8. weight of 40 kg or more (including 40\\r\\n     kg), or BMI > 18.5; 9. female patients must meet:\\r\\n\\r\\n  -  Menopausal (defined as absence of menstruation for at least 1 year with no confirmed\\r\\n     cause other than menopause) status, or surgically sterilized (removal of ovaries\\r\\n     and/or uterus), or patients of childbearing potential must also meet the following\\r\\n     requirements:\\r\\n\\r\\n  -  Pregnancy test within 7 days prior to first dose must be negative;\\r\\n\\r\\n  -  Agree to use contraception with an annual failure rate of < 1% or remain abstinent\\r\\n     (avoid heterosexual intercourse) (at least 120 days from signing the informed\\r\\n     consent form until at least 9 months after the last dose of the test drug and at\\r\\n     least 9 months after the procedure (contraceptive methods with an annual failure\\r\\n     rate of < 1% include bilateral tubal ligation, male sterilization, proper use of\\r\\n     hormonal contraceptives that suppress ovulation, hormone-releasing intrauterine\\r\\n     contraceptives, and copper-containing intrauterine devices). .;\\r\\n\\r\\n  -  No breastfeeding is allowed. 10. The subject reads and fully understands the patient\\r\\n     instructions and signs the informed consent form.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. the patient has a previous (within 5 years) or concurrent other malignant tumor;\\r\\n\\r\\n  2. patients who are preparing for or have previously received organ or bone marrow\\r\\n     transplantation;\\r\\n\\r\\n  3. have had a blood transfusion within 2 weeks prior to the first dose, or have a\\r\\n     history of bleeding, and any bleeding event with a severity rating of 3 or more on\\r\\n     the CTCAE 4.0 within 4 weeks prior to screening;\\r\\n\\r\\n  4. abnormal coagulation with bleeding tendency (INR in the absence of anticoagulants at\\r\\n     normal values > 1.5); patients treated with anticoagulants or vitamin K antagonists\\r\\n     such as warfarin, heparin, or their analogues; the use of low-dose warfarin (1 mg\\r\\n     orally once daily) for prophylactic purposes is permitted, provided the\\r\\n     International Normalized Ratio of the prothrombinogen time (INR) is ≤ 1.5, or\\r\\n     Small-dose aspirin (no more than 100 mg daily);\\r\\n\\r\\n  5. an actinic/venous thrombotic event within 6 months prior to screening, such as\\r\\n     cerebrovascular accident (including transient ischemic attack), deep vein thrombosis\\r\\n     (except for venous thrombosis due to intravenous cannulation for pre-chemotherapy,\\r\\n     which has resolved in the judgment of the investigator), and pulmonary embolism;\\r\\n\\r\\n  6. myocardial infarction, poorly controlled arrhythmia (including QTc interval ≥ 450 ms\\r\\n     in men and ≥ 470 ms in women) within 6 months prior to the first dose (QTc interval\\r\\n     is calculated using the Fridericia formula);\\r\\n\\r\\n  7. the presence of NYHA class III-IV cardiac insufficiency or cardiac ultrasound: LVEF\\r\\n     (left ventricular ejection fraction) <50%;\\r\\n\\r\\n  8. urine protein ≥++ and confirmed 24-hour urine protein quantification >1.0 g;\\r\\n\\r\\n  9. have multiple factors that interfere with oral administration of medications (e.g.,\\r\\n     inability to swallow, chronic diarrhea, and intestinal obstruction)\\r\\n\\r\\n 10. pleural effusion with clinical symptoms requiring clinical intervention;\\r\\n\\r\\n 11. human immunodeficiency virus (HIV) infection;\\r\\n\\r\\n 12. active tuberculosis;\\r\\n\\r\\n 13. long-standing unhealed wounds or incompletely healed fractures;\\r\\n\\r\\n 14. patients with pre-existing and current interstitial pneumonitis, pneumoconiosis,\\r\\n     radiation pneumonitis, drug-associated pneumonitis, and severely impaired lung\\r\\n     function that may interfere with the detection and management of suspected\\r\\n     drug-associated pulmonary toxicity\\r\\n\\r\\n 15. the presence of a known active or suspected autoimmune disease, except those who are\\r\\n     in a stable state of that disease at the time of enrollment (not requiring systemic\\r\\n     immunosuppressive therapy);\\r\\n\\r\\n 16. a history of severe chronic autoimmune disease, such as systemic lupus\\r\\n     erythematosus; a history of inflammatory bowel disease, such as ulcerative\\r\\n     enteritis, Crohn's disease, or chronic diarrheal disease, such as irritable bowel\\r\\n     syndrome; a history of tuberculosis or tuberculosis; a history of active hepatitis\\r\\n     B, hepatitis C, or HIV; or well-controlled non-severe immune disorders, such as\\r\\n     dermatitis, arthritis, or psoriasis, may be eligible. .. Hepatitis B virus titers <\\r\\n     500copy/ml may be enrolled;\\r\\n\\r\\n 17. patients requiring treatment with systemic corticosteroids (> 10 mg/day prednisone\\r\\n     efficacy dose) or other immunosuppressive drugs within 14 days prior to the first\\r\\n     dose or during the study period. However, enrollment is permitted if patients are\\r\\n     allowed to use topical topical or inhaled steroids, or adrenal hormone replacement\\r\\n     therapy at doses ≤ 10 mg/day prednisone efficacy dose in the absence of active\\r\\n     autoimmune disease;\\r\\n\\r\\n 18. any active infection requiring systemic administration of anti-infective therapy\\r\\n     within 14 days prior to the first dose; except for prophylactic antibiotic therapy\\r\\n     (e.g., for the prevention of urinary tract infections or chronic obstructive\\r\\n     pulmonary disease);\\r\\n\\r\\n 19. treatment with a live vaccine within 28 days prior to the first dose; except\\r\\n     inactivated viral vaccines for seasonal influenza;\\r\\n\\r\\n 20. prior treatment with antibodies/drugs targeting immune checkpoints, e.g., PD-1,\\r\\n     PD-L1, CTLA-4 inhibitors, etc;\\r\\n\\r\\n 21. have received treatment with immunologically-affecting related drugs or medical\\r\\n     technologies (including but not limited to the following: thymopentin, thymofacine,\\r\\n     interferon, CAR-T therapy, etc.) within 6 months prior to the first dose of the drug\\r\\n\\r\\n 22. is receiving treatment in another clinical study or is scheduled to begin treatment\\r\\n     in this study less than 1 month from the end of treatment in the previous clinical\\r\\n     study;\\r\\n\\r\\n 23. has a known history of allergy or intolerance to any study medication or its\\r\\n     components\\r\\n\\r\\n 24. patients with a history of alcoholism, drug abuse, and substance abuse. Patients who\\r\\n     have stopped drinking alcohol may be enrolled;\\r\\n\\r\\n 25. patients with non-compliance with medical advice, non-adherence to prescribed\\r\\n     medication, or incomplete information that may affect the judgment of efficacy or\\r\\n     safety;\\r\\n\\r\\n 26. pregnant or lactating female patients;\\r\\n\\r\\n 27. patients with conditions that may increase the risk of study participation and study\\r\\n     medication, or other severe, acute, and chronic conditions that, in the judgment of\\r\\n     the investigator, make participation in a clinical study unsuitable.\\r\\n\\r\\n 28. other conditions that, in the judgment of the investigator, make them unsuitable for\\r\\n     this clinical trial.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '75 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Fengyuan Li, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+8617366065271',\n",
       "      'email': '491275128@qq.com'},\n",
       "     {'name': 'Yigang Zhang, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+8615996341965',\n",
       "      'email': 'zhangyg0021@163.com'}],\n",
       "    'overallOfficials': [{'name': 'Zekuan Xu, PhD',\n",
       "      'affiliation': 'The First Affiliated Hospital with Nanjing Medical University',\n",
       "      'role': 'STUDY_CHAIR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000013274',\n",
       "      'term': 'Stomach Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000005770', 'term': 'Gastrointestinal Neoplasms'},\n",
       "     {'id': 'D000004067', 'term': 'Digestive System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000013272', 'term': 'Stomach Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M12307',\n",
       "      'name': 'Neoplasm Metastasis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M16064',\n",
       "      'name': 'Stomach Neoplasms',\n",
       "      'asFound': 'Gastric Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8886', 'name': 'Gastrointestinal Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7256', 'name': 'Digestive System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M16062', 'name': 'Stomach Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T5486', 'name': 'Stomach Cancer', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M19537',\n",
       "      'name': 'Paclitaxel',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M231', 'name': 'Albumin-Bound Paclitaxel', 'relevance': 'LOW'},\n",
       "     {'id': 'M2853', 'name': 'Immunomodulating Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M1674', 'name': 'Oxaliplatin', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06162299',\n",
       "    'orgStudyIdInfo': {'id': 'YS-101'},\n",
       "    'organization': {'fullName': 'Yisheng Biopharma (Singapore) Pte. Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Phase I, The Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002',\n",
       "    'officialTitle': 'A Phase I, Double-blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 in the Treatment of Chronic Hepatitis B (CHB) Infection in Adults ≥ 18 Years Old'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-11',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-11-22',\n",
       "    'studyFirstSubmitQcDate': '2023-11-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-12-08', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-02',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-03', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Yisheng Biopharma (Singapore) Pte. Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose\\r\\nescalating study to evaluate the safety, immunogenicity and preliminary efficacy of the\\r\\nYSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating\\r\\ndoses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.',\n",
       "    'detailedDescription': 'This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose\\r\\nescalating study to evaluate the safety, immunogenicity and preliminary efficacy of the\\r\\nYSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating\\r\\ndoses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.\\r\\nEnrollment in the study will sequentially start from the low dose 0.5mL as Group A, then\\r\\nto the mid-dose 1.0mL as Group B and lastly to the high dose of 2.0mL as Group C. Each\\r\\ngroup will have 16 patients enrolled. The first 4 enrollees in Group A will be sentinel\\r\\npatients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or\\r\\nplacebo (Table 3). As there is no comparable equivalent to YS-HBV-002 available in the\\r\\nmarket, the placebo of normal saline solution to be injected intramuscularly will serve\\r\\nas the control in this trial. The next 12 enrollees in Group A will be the main patients\\r\\nand will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo. The\\r\\nvaccination regimen will be 1 IM injection every 3 days in the deltoid muscle,\\r\\nalternately for approximately 6 weeks. A total of 14 injections will be administered to\\r\\neach patient.'},\n",
       "   'conditionsModule': {'conditions': ['Chronic Hepatitis b'],\n",
       "    'keywords': ['PIKA Adjuvant']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 48, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Low dose 0.5mL',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Group A ：The first 4 enrollees in Group A will be sentinel patients and will be allocated\\r\\nat a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The\\r\\nnext 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to\\r\\nreceive 0.5mL of either YS-HBV-002 or placebo.',\n",
       "      'interventionNames': ['Biological: YS-HBV-002']},\n",
       "     {'label': 'Mid-dose 1.0mL',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Group B ：The first 4 enrollees in Group B will be sentinel patients and will be allocated\\r\\nat a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The\\r\\nnext 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to\\r\\nreceive 1.0mL of either YS-HBV-002 or placebo.',\n",
       "      'interventionNames': ['Biological: YS-HBV-002']},\n",
       "     {'label': 'High dose 2.0mL',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Group C ：The first 4 enrollees in Group C will be sentinel patients and will be allocated\\r\\nat a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The\\r\\nnext 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to\\r\\nreceive 2.0mL of either YS-HBV-002 or placebo.',\n",
       "      'interventionNames': ['Biological: YS-HBV-002']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'YS-HBV-002',\n",
       "      'description': 'YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant',\n",
       "      'armGroupLabels': ['High dose 2.0mL',\n",
       "       'Low dose 0.5mL',\n",
       "       'Mid-dose 1.0mL']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of AEs within 30 minutes after vaccination.',\n",
       "      'description': 'To assess the safety and tolerability',\n",
       "      'timeFrame': '30 minutes post each vaccination'},\n",
       "     {'measure': 'Incidence of solicited local reactions within 7 days after each vaccination.',\n",
       "      'description': 'To assess the safety and tolerability',\n",
       "      'timeFrame': '7 days post each vaccination'},\n",
       "     {'measure': 'Incidence of solicited systemic reactions from first vaccination to 7 days after the last vaccination (D1 to D46).',\n",
       "      'description': 'To assess the safety and tolerability',\n",
       "      'timeFrame': 'From Day1 to Day46'},\n",
       "     {'measure': 'Incidence of unsolicited AEs, serious adverse events (SAEs) including suspected unexpected serious adverse reactions (SUSARs), adverse events of special interest (AESIs), and AEs leading to withdrawals throughout the study period',\n",
       "      'description': 'To assess the safety and tolerability',\n",
       "      'timeFrame': 'From Day1 to Day 90'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Proportion of patients showing reduction in HBV DNA using PCR for each dose from baseline to the end of the study and at specified timepoints.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'Change in mean log10 of HBV DNA from baseline to end of study and at each specified timepoint.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study at each specified timepoint.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'Change in serum levels of HBeAg, HBcAg, and HBsAg from baseline to end of study and at each specified timepoint.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'Proportion of patients with loss (defined as lower limit of quantitation [LLOQ]) or decline in HBsAg, HBcAg, and HBeAg from baseline to the end of the study and at each specified timepoint.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'GMTs of antibodies against HBsAg, HBcAg and HBeAg at baseline and at pre-defined post-vaccination timepoints.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'},\n",
       "     {'measure': 'Seroconversion rates of antibodies against HBsAg, HBcAg, and HBeAg.',\n",
       "      'description': 'To evaluate the preliminary efficacy, immunogenicity and determine the appropriate dose',\n",
       "      'timeFrame': 'Day0， Day16， Day34， Day60， Day90'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Age ≥ 18 years during screening\\r\\n\\r\\n  2. Body Mass Index (BMI) of 18.5-30 kg/m2\\r\\n\\r\\n  3. Diagnosed or laboratory confirmed to have CHB\\r\\n\\r\\n       1. Have CHB infection for at least 6 months\\r\\n\\r\\n       2. HBsAg titer ≥ 1000 IU/mL\\r\\n\\r\\n       3. HBV DNA ≥ 2000 IU/mL\\r\\n\\r\\n       4. Serum alanine amino transferase (ALT) and aspartate aminotransferase (AST) ≤ 2\\r\\n          × upper limit of normal (ULN)\\r\\n\\r\\n  4. Able to provide informed consent\\r\\n\\r\\n  5. Able and willing to comply with all study procedures throughout the study period of\\r\\n     approximately 3 months\\r\\n\\r\\n  6. For female subjects with childbearing potential: must agree to avoid pregnancy\\r\\n     throughout the study period of approximately 3 months. Women physically capable of\\r\\n     pregnancy (not sterilized and still menstruating or within 1 year of the last menses\\r\\n     if menopausal) in sexual relationships with men must use an acceptable method of\\r\\n     avoiding pregnancy during this period. Acceptable methods on avoiding pregnancy\\r\\n     include: a sterile sexual partner, sexual abstinence (not engaging in sexual\\r\\n     intercourse), hormonal contraceptives (oral, injection, transdermal patch, or\\r\\n     implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or\\r\\n     diaphragm with a spermicide.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Pregnant or breastfeeding or intending to become pregnant within the projected\\r\\n     duration of the trial\\r\\n\\r\\n  2. Transient elastography at screening revealing a FibroScan value of ≥ 9 kPa or a\\r\\n     previous liver biopsy evidencing hepatic fibrosis at or within 24 months prior to\\r\\n     vaccination\\r\\n\\r\\n  3. Patients with hepatitis caused by other etiologies\\r\\n\\r\\n  4. History of or manifestations of liver decompensation (e.g., Child-Pugh Class B or C,\\r\\n     or ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial\\r\\n     peritonitis, etc....)\\r\\n\\r\\n  5. Currently participating in or has participated in a study with an IP within 30 days\\r\\n     preceding Day 0\\r\\n\\r\\n  6. Fever (axillary temperature ≥ 37.8 ℃)\\r\\n\\r\\n  7. Subjects with abnormal indicators of blood biochemistry and other routine blood\\r\\n     tests deemed clinically significant by the investigator\\r\\n\\r\\n  8. History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin\\r\\n     eczema, dyspnea, angioneurotic edema, or allergic abdominal pain) or allergy to any\\r\\n     of the components of YS-HBV-002\\r\\n\\r\\n  9. Any history of anaphylaxis or angioedema after any vaccination\\r\\n\\r\\n 10. Allergy to kanamycin and aminoglycosides\\r\\n\\r\\n 11. Past or family history of convulsion, epilepsy, encephalopathy, or mental illness\\r\\n\\r\\n 12. Diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma,\\r\\n     leukemia, or other autoimmune diseases\\r\\n\\r\\n 13. History of coagulation dysfunction (e.g., coagulation factor deficiency, coagulation\\r\\n     disease)\\r\\n\\r\\n 14. Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding\\r\\n     inclusion, contraindicating IM vaccination based on the investigator's judgement\\r\\n\\r\\n 15. Vaccinated with live attenuated vaccine within 1 month, or other\\r\\n     vaccine/non-COVID-19 vaccine within 14 days prior to vaccination\\r\\n\\r\\n 16. Receiving immunotherapy or inhibitor therapy (consistently oral or infusion for more\\r\\n     than 14 days) within 3 months prior to vaccination\\r\\n\\r\\n 17. Received systemic immunosuppressants within 4 months prior to vaccination or\\r\\n     anticipating the need for immunosuppressant at any time during participation in the\\r\\n     study. Topical or inhaled treatment is allowed if not used within 14 days prior to\\r\\n     vaccination\\r\\n\\r\\n 18. Have received antiviral therapy for chronic hepatitis but have stopped for less than\\r\\n     30 days or plan to take antiviral therapy during the study\\r\\n\\r\\n 19. Received blood products within 3 months before vaccine administration\\r\\n\\r\\n 20. History of alcohol or drug abuse within the past 2 years\\r\\n\\r\\n 21. Any condition that, in the opinion of the investigator, would pose a health risk to\\r\\n     the patient if enrolled or could interfere with evaluation of the study vaccine or\\r\\n     interpretation of study results.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Maricris Trillana',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+63917 5855628',\n",
       "      'email': 'maricris.trillana@yishengbio.com'},\n",
       "     {'name': 'Renan Lim',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+63 917 897 2958',\n",
       "      'email': 'renan.lim@yishengbio.com'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000006509',\n",
       "      'term': 'Hepatitis B'},\n",
       "     {'id': 'D000019694', 'term': 'Hepatitis B, Chronic'},\n",
       "     {'id': 'D000006505', 'term': 'Hepatitis'},\n",
       "     {'id': 'D000006521', 'term': 'Hepatitis, Chronic'}],\n",
       "    'ancestors': [{'id': 'D000008107', 'term': 'Liver Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000006525', 'term': 'Hepatitis, Viral, Human'},\n",
       "     {'id': 'D000014777', 'term': 'Virus Diseases'},\n",
       "     {'id': 'D000007239', 'term': 'Infections'},\n",
       "     {'id': 'D000086982', 'term': 'Blood-Borne Infections'},\n",
       "     {'id': 'D000003141', 'term': 'Communicable Diseases'},\n",
       "     {'id': 'D000018347', 'term': 'Hepadnaviridae Infections'},\n",
       "     {'id': 'D000004266', 'term': 'DNA Virus Infections'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9592', 'name': 'Hepatitis A', 'relevance': 'LOW'},\n",
       "     {'id': 'M9591',\n",
       "      'name': 'Hepatitis',\n",
       "      'asFound': 'Hepatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9595',\n",
       "      'name': 'Hepatitis B',\n",
       "      'asFound': 'Hepatitis B',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21609',\n",
       "      'name': 'Hepatitis B, Chronic',\n",
       "      'asFound': 'Chronic Hepatitis B',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9607',\n",
       "      'name': 'Hepatitis, Chronic',\n",
       "      'asFound': 'Chronic Hepatitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11107', 'name': 'Liver Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9610', 'name': 'Hepatitis, Viral, Human', 'relevance': 'LOW'},\n",
       "     {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2593', 'name': 'Blood-Borne Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M20487', 'name': 'Hepadnaviridae Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M7442', 'name': 'DNA Virus Infections', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360',\n",
       "      'name': 'Vaccines',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06414993',\n",
       "    'orgStudyIdInfo': {'id': 'R34DA057639',\n",
       "     'type': 'NIH',\n",
       "     'link': 'https://reporter.nih.gov/quickSearch/R34DA057639'},\n",
       "    'secondaryIdInfos': [{'id': 'R34DA057639',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/R34DA057639'}],\n",
       "    'organization': {'fullName': 'Chestnut Health Systems', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Leveraging Parents and Peers to Increase Recovery Capital in Emerging Adults',\n",
       "    'officialTitle': 'Leveraging Parents and Peer Recovery Supports to Increase Recovery Capital in Emerging Adults With Polysubstance Use: Feasibility, Acceptability, and Scaling up of Launch',\n",
       "    'acronym': 'Launch'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-15', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-15', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-07',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Tess Drazdowski',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Chestnut Health Systems'},\n",
       "    'leadSponsor': {'name': 'Chestnut Health Systems', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Institute on Drug Abuse (NIDA)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Emerging adults (EAs; aged 18-26) are the highest-risk population for poly-substance use\\r\\n(misuse of more than one drug), compared to all other age groups and are the least-served\\r\\npopulation for substance use services. The overarching purpose of this pilot study is to\\r\\nassess whether an innovative services package, Launch, can reasonably work (is feasible)\\r\\nand whether providers and participants like it (acceptability). Launch works with both\\r\\nEAs and a supportive parent (or parental figure) and delivers peer recovery support\\r\\nservices (PRSS) to EAs while helping parents use an effective, evidence-based program\\r\\ncalled contingency management, adapted for EAs, at home with their EA child. This study\\r\\nwill also lay the groundwork for a future large-scale trial of Launch services.',\n",
       "    'detailedDescription': \"The objective of the study is to investigate a scalable service that can be used in rural\\r\\ncommunities called Launch. Launch is an innovative adaptation of current evidence-based\\r\\nservices for Emerging Adults (EAs), ages 18-26 years old with polysubstance use\\r\\n(poly-SU); with a particular emphasis on increasing their recovery capital. Recovery\\r\\ncapital is the resources available to promote substance use recovery (e.g.,\\r\\nvocational/educational skills, recovery-supportive community). Launch leverages (1)\\r\\nparents of EAs and (2) peer recovery support services (PRSS), while ensuring services are\\r\\nequitable and scalable by using digital technology and existing substance use services\\r\\ninfrastructure. Participants will be 48 families that include an EA struggling with\\r\\npoly-SU and a parent or parental figure supportive of their EA child's recovery journey.\\r\\nFamilies will be randomized to one of three conditions detailed further in the attached\\r\\nmaterials that include either: (1) Virtual Parent Contingency Management for Emerging\\r\\nAdults (CM-EA) Coach for parents only, (2) In-Person PRSS for EAs only, or (3) a\\r\\ncombination of Virtual Parent CM-EA Coach for parents and In-Person PRSS for EAs.\\r\\nQuantitative and qualitative measures will assess the feasibility and acceptability of\\r\\nLaunch. Additionally, payors/providers of substance use services will be interviewed in\\r\\nthis study with the aim of improving future uptake and implementation of the service\\r\\nshould it be deemed effective.\\r\\n\\r\\nThe aims of the study are as follows:\\r\\n\\r\\n  1. Adapt and evaluate the Launch parent coach and PRSS training protocols/adherence\\r\\n     tools.\\r\\n\\r\\n  2. Assess the feasibility and acceptability of (a) a virtual study protocol for\\r\\n     recruiting, assessing, and retaining parents and EAs and (b) Launch components.\\r\\n\\r\\n  3. Determine from payors and providers the data needed for future funding and delivery\\r\\n     of Launch, as well as develop a site recruitment pool for a rigorous R01 trial.\"},\n",
       "   'conditionsModule': {'conditions': ['Polysubstance Drug Use (Indiscriminate Drug Use)'],\n",
       "    'keywords': ['Contingency management',\n",
       "     'Emerging adults',\n",
       "     'Polysubstance use',\n",
       "     'Peer recovery support services']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 48, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Contingency Management for Emerging Adults (CM-EA) Only',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The parents in this group will receive CM-EA delivered virtually by a parent coach\\r\\napproximately weekly (20-40 minute sessions) for 6 months.',\n",
       "      'interventionNames': ['Behavioral: Contingency Management for Emerging Adults (CM-EA)']},\n",
       "     {'label': 'Standard Peer Recovery Support Services (PRSS)+Vocational/Educational (V/E) Skill Building',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'The EAs in this group will receive PRSS+Vocational/Educational (V/E) Skill Building\\r\\ndelivered by peer workers in-person in the local community approximately weekly (1 hour\\r\\nsessions) for 6 months.',\n",
       "      'interventionNames': ['Behavioral: Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services']},\n",
       "     {'label': 'CM-EA and PRSS+V/E',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Families receive both CM-EA and PRSS + V/E as described above.',\n",
       "      'interventionNames': ['Behavioral: Contingency Management for Emerging Adults (CM-EA)',\n",
       "       'Behavioral: Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Contingency Management for Emerging Adults (CM-EA)',\n",
       "      'description': \"After CM-EA is introduced, a contingency contract is developed between a parent and\\r\\nemerging adult (EA) that provides EAs with rewards for negative drug screens and\\r\\ncompletion of developmentally appropriate goals to build recovery capital, along with\\r\\ndisincentives for positive screens or engaging in inappropriate behaviors. Concurrently,\\r\\nparents are taught to conduct random urine drug screens. Additionally, parents are\\r\\ntrained to complete functional analyses in collaboration with their EA to identify the\\r\\nEA's triggers for poly-substance use and negative behaviors. Individualized triggers are\\r\\ntargeted via self-management planning and drug refusal skills training. At the end of\\r\\nCM-EA, plans are made with the family for sustaining abstinence and improvements in other\\r\\nbehaviors.\",\n",
       "      'armGroupLabels': ['CM-EA and PRSS+V/E',\n",
       "       'Contingency Management for Emerging Adults (CM-EA) Only']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services',\n",
       "      'description': \"Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation,\\r\\nemployment). After needs are identified, a peer worker addresses needs through\\r\\ninformational resources and community referrals and engages clients in positive\\r\\nrecreational activities offering advice, hope and empowerment to encourage steps toward a\\r\\nreduction in substance use and eventual abstinence. When desired, peer workers also link\\r\\nclients to a broader recovery peer community. In addition, the peer worker will dedicate\\r\\ntime to increasing recovery capital via improving skills related to V/E advancement using\\r\\na workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health\\r\\nProviders, for which peer workers will be trained.\",\n",
       "      'armGroupLabels': ['CM-EA and PRSS+V/E',\n",
       "       'Standard Peer Recovery Support Services (PRSS)+Vocational/Educational (V/E) Skill Building']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Levels of Emerging Adult Perceptions of Acceptability of the Launch Intervention (measured at 6 months).',\n",
       "      'description': 'Levels of acceptability of the Launch intervention, such as if participants like the\\r\\nintervention, as reported by emerging adults on the Acceptability of Intervention\\r\\nMeasure. Scores range from 4-20. Higher scores indicate higher levels of intervention\\r\\nacceptability.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Parent Perceptions of Acceptability of the Launch Intervention (measured at 6 months).',\n",
       "      'description': 'Levels of acceptability of the Launch intervention, such as if participants like the\\r\\nintervention, as reported by parents on the Acceptability of Intervention Measure. Scores\\r\\nrange from 4-20. Higher scores indicate higher levels of intervention acceptability.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Perceptions of Launch Intervention Appropriateness (measured 6 months).',\n",
       "      'description': 'Levels of Launch intervention appropriateness, such as if the intervention is a good\\r\\nmatch, as reported by emerging adults on the Intervention Appropriateness Measure. Scores\\r\\nrange from 4-20. Higher scores indicate higher levels of intervention appropriateness.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Parent Perceptions of Launch Intervention Appropriateness (measured 6 months).',\n",
       "      'description': 'Levels of Launch intervention appropriateness, such as if the intervention is a good\\r\\nmatch, as reported by parents on the Intervention Appropriateness Measure. Scores range\\r\\nfrom 4-20. Higher scores indicate higher levels of intervention appropriateness.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Perceptions of Feasibility of the Launch Intervention (measured at 6 months).',\n",
       "      'description': 'Levels of Launch intervention feasibility, such as if the intervention is easy to use, as\\r\\nreported by emerging adults on the Feasibility of Intervention Measure. Scores range from\\r\\n4-20. Higher scores indicate higher levels of intervention feasibility.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Parent Perceptions of Feasibility of the Launch Intervention (measured at 6 months).',\n",
       "      'description': 'Levels of Launch intervention feasibility, such as if the intervention is easy to use, as\\r\\nreported by parents on the Feasibility of Intervention Measure. Scores range from 4-20.\\r\\nHigher scores indicate higher levels of intervention feasibility.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Client Satisfaction with Launch Services (measured at 6 months).',\n",
       "      'description': 'Levels of satisfaction with the Launch services reported by emerging adult clients on the\\r\\nClient Satisfaction Questionnaire 8-item scale adapted to reflect receipt of Launch\\r\\nservices.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Parent Client Satisfaction with Launch Services (measured at 6 months).',\n",
       "      'description': 'Levels of satisfaction with the Launch services reported by parent clients on the Client\\r\\nSatisfaction Questionnaire 8-item scale (CSQ-8) adapted to reflect receipt of Launch\\r\\nservices.',\n",
       "      'timeFrame': '6 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Substance Use Disorders (measured at 0 and 6 months).',\n",
       "      'description': 'Frequency of substance use disorders reported by emerging adults on the Diagnostic and\\r\\nStatistical Manual of Mental Illnesses Version 5 (DSM-5) Substance Use Checklist for the\\r\\nfollowing substance categories: alcohol, cannabis, hallucinogens, inhalants, opioids,\\r\\nsedatives/hypnotics/anxiolytics, stimulants, and an \"other\" category.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Substance Use and Problems (measured at 0 and 6 months).',\n",
       "      'description': 'Frequency of substance use and substance-related problems reported by emerging adults on\\r\\nthe Global Appraisal of Individual Needs (GAIN) and (Justice Community Opioid Innovation\\r\\nNetwork (JCOIN) Core Measures for the past 30 days.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Polysubstance Use (measured at 0 and 6 months).',\n",
       "      'description': 'Frequency of polysubstance use reported by emerging adults on the Polysubstance Use\\r\\nAssessment Tool.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Quality of Life (measured at 0 and 6 months).',\n",
       "      'description': 'Levels of quality of life reported by emerging adults on the Patient-Reported Outcomes\\r\\nMeasurement Information System (PROMIS)-29+2 Profile V2.1, a 31-item measure of quality\\r\\nof life across 7 domains: physical function, anxiety, depression, fatigue, sleep\\r\\ndisturbance, social participation, pain interference, pain intensity, and cognitive\\r\\nfunction.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Service Utilization (measured at 0 and 6 months).',\n",
       "      'description': 'Frequency of service utilization in the past 30 days reported by emerging adults on the\\r\\nJCOIN Core Measures Service Utilization Scale, higher score indicate more service\\r\\nutilization.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Abstinence Self Efficacy (measured at 0 and 6 months).',\n",
       "      'description': 'Levels of abstinence self-efficacy reported by emerging adults on the Abstinence Self\\r\\nEfficacy Scale, higher scores indicate higher abstinence self efficacy.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Emerging Adult Recovery Capital (measured at 0 and 6 months).',\n",
       "      'description': 'Levels of recovery capital as reported by emerging adult clients on the Emerging Adult\\r\\nRecovery Capital Scale, an emerging adult-specific measure under development by members\\r\\nof the study team and collaborators, higher scores indicate higher recovery capital.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Changes from baseline to 6 months post-baseline in Recovery Capital (measured at 0 and 6 months).',\n",
       "      'description': 'Levels of recovery capital as reported by emerging adult clients on the Brief Assessment\\r\\nof Recovery Capital (BARC-10); higher scores indicate higher levels of recovery capital.',\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Client Quality of Relationship with Peer Worker (measured at 6 months).',\n",
       "      'description': \"Levels of the quality of the relationship between the emerging adult client and the peer\\r\\nworker as reported by emerging adults on the Dual Role Relationship Inventory adapted to\\r\\nassess emerging adults' perceptions of their relationship with their peer worker (among\\r\\nemerging adults assigned to work with a peer worker).\",\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Client Quality of Relationship with Parent (measured at 0 and 6 months).',\n",
       "      'description': \"Levels of the quality of the relationship between the emerging adult client and their\\r\\nparent as reported by emerging adults on the Dual Role Relationship Inventory adapted to\\r\\nassess emerging adults' perceptions of their relationship with their parent.\",\n",
       "      'timeFrame': 'Baseline to 6 months'},\n",
       "     {'measure': 'Levels of Emerging Adult Session Attendance with Peer Worker (measured weekly from baseline to 6 months).',\n",
       "      'description': 'Frequency of emerging adult attendance at their peer worker sessions (e.g., attended, no\\r\\nshow, rescheduled) as reported by the peer worker.',\n",
       "      'timeFrame': 'Duration of services until 6 months after baseline'},\n",
       "     {'measure': 'Levels of Parent Session Attendance with CM-EA Parent Coach (measured weekly from baseline to 6 months).',\n",
       "      'description': 'Frequency of parent attendance at their CM-EA parent coach sessions (e.g., attended, no\\r\\nshow, rescheduled) as reported by the parent coach.',\n",
       "      'timeFrame': 'Duration of services until 6 months after baseline'},\n",
       "     {'measure': 'Attitudes at 6 months post-baseline in Emerging Adult Attitudes Toward the Services Provided, Research Protocol, and Parent/Emerging Adult Relationship (measured at 6 months).',\n",
       "      'description': 'Emerging adult attitudes toward the Launch services program, including their perceptions\\r\\nof the acceptability, appropriateness, and feasibility of Launch as well as the research\\r\\nprotocol, and impact of services on themselves and their relationship with their parents\\r\\nas measured during qualitative interviews with emerging adults.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Attitudes at 6 months post-baseline in Parent Attitudes Toward the Services Provided, Research Protocol, and Parent/Emerging Adult Relationship (measured at 6 months).',\n",
       "      'description': 'Parent attitudes toward the Launch services program, including their perceptions of the\\r\\nacceptability, appropriateness, and feasibility of Launch as well as the research\\r\\nprotocol, and impact of services on their emerging adult child and their relationship\\r\\nwith their emerging adult child as measured during qualitative interviews with parents.',\n",
       "      'timeFrame': '6 months'},\n",
       "     {'measure': 'Attitudes at end of services in Peer Worker Attitudes Toward the Services Provided, Impacts on Emerging Adult Clients, and Services Improvement (measured at 6 months).',\n",
       "      'description': 'Peer worker attitudes toward the Launch services program, including their perceptions of\\r\\nthe acceptability, appropriateness, and feasibility of Launch, the impact of services on\\r\\ntheir emerging adult clients, and suggestions for services improvement as measured during\\r\\nqualitative interviews with peer workers.',\n",
       "      'timeFrame': 'From date of consent until the date of two months past last client session completed, assessed up to 2 years'},\n",
       "     {'measure': 'Attitudes at end of services in Parent Coach Attitudes Toward the Services Provided, Impacts on Parent Clients, and Services Improvement (measured at 6 months).',\n",
       "      'description': 'Parent coach attitudes toward the Launch services program, including their perceptions of\\r\\nthe acceptability, appropriateness, and feasibility of Launch, the impact of services on\\r\\ntheir parent clients, and suggestions for services improvement as measured during\\r\\nqualitative interviews with parent coaches.',\n",
       "      'timeFrame': 'From date of consent until the date of two months past last client session completed, assessed up to 2 years'},\n",
       "     {'measure': 'Changes from baseline to end fo services in Peer Worker Services and Vocational/Educational Activity Completion (measured monthly throughout services duration).',\n",
       "      'description': 'Frequency of peer worker completion of vocational/educational coaching activities\\r\\nreported by peer workers coaches on the Session Checklist and session tape coding.',\n",
       "      'timeFrame': 'Duration of services, after each session with an emerging adult until 6 months after baseline'},\n",
       "     {'measure': 'Changes from baseline to end fo services in Parent Contingency Management for Emerging Adults (CM-EA) Adherence (measured monthly throughout services duration).',\n",
       "      'description': 'Adherence to CM-EA practices by parents reported by parent coaches as measured using the\\r\\nCM-Therapist Adherence Measure (CM-TAM) (Self-report version and Tape Coding version).',\n",
       "      'timeFrame': 'Duration of services, after each session with a parent until 6 months after baseline'},\n",
       "     {'measure': 'Descriptions of Economic-Related Information for Future Large-Scale Study from Payors/Providers of Recovery Services (measured once at any point during the study period).',\n",
       "      'description': 'Payors and providers of recovery services will report via qualitative interviews on what\\r\\nkinds of participant-level outcomes or economic-related information they would want to\\r\\nknow about as the result of a future large-scale study, selection of appropriate\\r\\ncomparators for the future cost-effectiveness analysis, and potential recruitment sites\\r\\nfor a future large-scale study of Launch.',\n",
       "      'timeFrame': 'Up to 2 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'This study has four different participants: (1) Emerging Adult (EA)/Parent Pairs, (2)\\r\\nPeer Workers, (3) Parent Coaches, and (4) Payors/Providers of Recovery Services.\\r\\n\\r\\n  1. Emerging Adult (EA)/Parent Pairs\\r\\n\\r\\n     Inclusion Criteria:\\r\\n\\r\\n       -  EA (aged 18-26) who reports (1) misuse of opioids and/or stimulants and at\\r\\n          least one other substance in the same week during the past 30 days, (2) at\\r\\n          least one SU disorder reported by EA or parent as assessed via the DSM-V\\r\\n          Checklist, and (3) has a supportive parent willing to be virtually coached to\\r\\n          deliver CM-EA. Participating \"parents\" can include any supportive adult who is\\r\\n          in a financially supportive caregiving role for the EA and has the desire and\\r\\n          ability to implement the CM-EA program\\r\\n\\r\\n     Exclusion Criteria:\\r\\n\\r\\n       -  Only EAs that present with unstable conditions requiring intensive treatment,\\r\\n          such as hospital interventions, will be excluded from the sample. Examples of\\r\\n          these conditions include participant reports of active suicidal or homicidal\\r\\n          intentions or requests for medically supervised detox services.\\r\\n\\r\\n  2. Peer Workers\\r\\n\\r\\n     Inclusion Criteria:\\r\\n\\r\\n       -  Certified peer worker (aged 18+) willing to be trained in\\r\\n          vocational/educational skill building and participate in research protocols\\r\\n          with study-enrolled emerging adult clients.\\r\\n\\r\\n     Exclusion Criteria:\\r\\n\\r\\n       -  None\\r\\n\\r\\n  3. Parent Coaches\\r\\n\\r\\n     Inclusion Criteria:\\r\\n\\r\\n       -  Individual (18+) with a background in clinical work willing to be trained in\\r\\n          Contingency Management for Emerging Adults (CM-EA) and participate in research\\r\\n          protocols with study-enrolled parent clients.\\r\\n\\r\\n     Exclusion Criteria:\\r\\n\\r\\n       -  None\\r\\n\\r\\n  4. .Payors/Providers of Recovery Services\\r\\n\\r\\nInclusion Criteria:\\r\\n\\r\\n  -  Individual (18+) who works at an administrative level at an organization that\\r\\n     provides or pays for recovery services that would potentially fund or otherwise\\r\\n     support the implementation of Launch services willing to be interviewed.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  None',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Tess K Drazdowski, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '309-451-7755',\n",
       "      'email': 'tkdrazdowski@chestnut.org'}],\n",
       "    'overallOfficials': [{'name': 'Tess K Drazdowski, PhD',\n",
       "      'affiliation': 'Chestnut Health Systems',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Chestnut Health Systems',\n",
       "      'city': 'Eugene',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97401',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Tess K Drazdowski, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '309-451-7755',\n",
       "        'email': 'tkdrazdowski@chestnut.org'},\n",
       "       {'name': 'Ashli J Sheidow, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'ajsheidow@chestnut.org'},\n",
       "       {'name': 'Tess K Drazdowski, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 44.05207, 'lon': -123.08675}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Attendance data, client satisfaction data, and EA outcomes data will be shared.\\r\\nParticipants will be assigned a unique identifier to allow linking across data files.\\r\\n\\r\\nThese data will be stored in an electronic file format (e.g., csv), accessible to\\r\\nstandard analytic software (e.g., Excel, SAS) and will undergo formatting and quality\\r\\nassurances prior to sharing. Data dictionaries and codebooks, detailing variable-level\\r\\ninformation also will be shared.\\r\\n\\r\\nThe PI agrees to deposit and maintain the data, and any secondary analysis of data prior\\r\\nto depositing data into the NAHDAP or similar repository. The PI understands that NAHDAP\\r\\nand similar repositories have data access policies and procedures consistent with NIH and\\r\\nthe Helping End Addiction Long-term (HEAL) Initiative data sharing policies. HEAL data\\r\\nstewards will ensure that data are available to the HEAL Ecosystem after deposit.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'ICF'],\n",
       "    'timeFrame': 'Data will be shared upon acceptance of the data for publication or within six months\\r\\nafter the completion of the 6-month follow-up assessments, whichever is earlier.',\n",
       "    'accessCriteria': 'Information on where the data will be available and how to access the data will be\\r\\nincluded in any publications and presentations that the study team authors using these\\r\\ndata. The repositories (e.g., NAHDAP), HEAL Data Ecosystem, and funding sources will be\\r\\nacknowledged in any publications and presentations. Repositories such as the NAHDAP have\\r\\npolicies and procedures in place that will provide data access to qualified researchers,\\r\\nfully consistent with NIH data sharing policies and applicable laws and regulations.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06395428',\n",
       "    'orgStudyIdInfo': {'id': 'WMed-2024-1032'},\n",
       "    'organization': {'fullName': 'Western Michigan University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department',\n",
       "    'officialTitle': 'Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-04-15', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-04-15', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-01',\n",
       "    'studyFirstSubmitQcDate': '2024-04-29',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-02', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Western Michigan University School of Medicine',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Bronson Methodist Hospital',\n",
       "      'class': 'UNKNOWN'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'Single center, double-blind, randomized, controlled trial in patients who present to the\\r\\nemergency department (ED) with a chief complaint of back pain. A total of 150 patients\\r\\nage 18-65 presenting to the emergency department with chief complaint of backpain will be\\r\\nenrolled from April 2024 - April 2025. Patients will be randomized and symptom levels\\r\\nwill be recorded at 30, 60, 90, minutes. Follow-up will be performed by telephone at 24\\r\\nhours.'},\n",
       "   'conditionsModule': {'conditions': ['Back Pain', 'Chronic Pain'],\n",
       "    'keywords': ['Haloperidol', 'Chronic Pain', 'Back Pain']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This is a single-center prospective randomized double-blinded non-inferiority trial with\\r\\npotential assessment of superiority comparing haloperidol to ketorolac for the treatment\\r\\nof back pain.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'maskingDescription': 'Treatment allocations will be revealed only after study completion, unless there is\\r\\nconcern for a serious adverse event in which case treatment team and patient will be\\r\\nunblinded. Interim analysis will be performed at 34 participants to evaluate for\\r\\neffectiveness and power',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Haloperidol',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Haloperidol 5 mg IM haloperidol',\n",
       "      'interventionNames': ['Drug: Haloperidol']},\n",
       "     {'label': 'Ketoralac',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Ketoralac 30 mg IM',\n",
       "      'interventionNames': ['Drug: Ketorolac Tromethamine']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Haloperidol',\n",
       "      'description': 'Intramuscular injection of drug',\n",
       "      'armGroupLabels': ['Haloperidol'],\n",
       "      'otherNames': ['Haldol']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Ketorolac Tromethamine',\n",
       "      'description': 'Intramuscular injection of drug',\n",
       "      'armGroupLabels': ['Ketoralac'],\n",
       "      'otherNames': ['Toradol']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Visual Analog Scale (VAS)',\n",
       "      'description': 'Mean change in visual analog scale (VAS) of self-rated nausea severity',\n",
       "      'timeFrame': '30, 60, and 90 minutes after drug administration'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Length of stay after enrollment',\n",
       "      'description': \"Mean length of stay in minutes between the 2 groups will be assessed with a student's t\\r\\ntest to assess for significant difference between groups\",\n",
       "      'timeFrame': '24 hours'},\n",
       "     {'measure': 'Need for rescue medications',\n",
       "      'description': 'Need for rescue medications will be a Boolean variable recorded in redcaps that will be\\r\\nqualitatively assessed to compare the number of patients in each group requiring rescue\\r\\nmedication.',\n",
       "      'timeFrame': '30, 60, and 90 minutes after drug administration'},\n",
       "     {'measure': 'Patient Satisfaction',\n",
       "      'description': 'This will be assessed based on the follow-up question \"would you receive this treatment\\r\\nagain?\" on the follow-up phone call. Number of patients in each group that answer yes to\\r\\nthis question will be qualitatively discussed in the results.',\n",
       "      'timeFrame': '24 hours after enrollment up to 1 week'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age 18 - 65 years old\\r\\n\\r\\n  -  Presenting to the Bronson ED with a chief complaint of acute, non-traumatic back\\r\\n     pain\\r\\n\\r\\n  -  VAS score >5 cm\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Back pain due to traumatic injury\\r\\n\\r\\n  -  Experiencing saddle anesthesia\\r\\n\\r\\n  -  Has bowel or bladder dysfunction\\r\\n\\r\\n  -  Has an abnormal neurological exam\\r\\n\\r\\n  -  Requires imaging in ED\\r\\n\\r\\n  -  Has a Glascow coma score <15\\r\\n\\r\\n  -  Has one or more abnormal vital signs:\\r\\n\\r\\nHR>120, SBP>180 or <90, temperature >38°, O2 saturation<92%\\r\\n\\r\\n  -  Has an allergy to ketorolac or haloperidol\\r\\n\\r\\n  -  Has a known diagnosis of Lewy Body Dementia\\r\\n\\r\\n  -  Has a known diagnosis of glaucoma.\\r\\n\\r\\n  -  Is known to be pregnant or breastfeeding\\r\\n\\r\\n  -  Is a prisoner or ward of the state\\r\\n\\r\\n  -  Is unable to consent for themselves/ non-english speaking\\r\\n\\r\\n  -  In the opinion of the attending physician or investigator the patient should not\\r\\n     participate in the research',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Jessica McCoy, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '269-337-6600',\n",
       "      'email': 'jessica.mccoy@wmed.edu'},\n",
       "     {'name': 'Katharine Mitchell, MA',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '269-341-8364',\n",
       "      'email': 'mitckath@bronsonhg.org'}],\n",
       "    'overallOfficials': [{'name': 'Jessica McCoy, MD',\n",
       "      'affiliation': 'Western Michigan University Homer Stryker M.D. School of Medicine',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '12167140',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002 Jun;42(6):515-8. doi: 10.1046/j.1526-4610.2002.02126.x.'},\n",
       "     {'pmid': '32402480',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'McCoy JJ, Aldy K, Arnall E, Petersen J. Treatment of Headache in the Emergency Department: Haloperidol in the Acute Setting (THE-HA Study): A Randomized Clinical Trial. J Emerg Med. 2020 Jul;59(1):12-20. doi: 10.1016/j.jemermed.2020.04.018. Epub 2020 May 10.'},\n",
       "     {'pmid': '17306626',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Todd KH, Ducharme J, Choiniere M, Crandall CS, Fosnocht DE, Homel P, Tanabe P; PEMI Study Group. Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study. J Pain. 2007 Jun;8(6):460-6. doi: 10.1016/j.jpain.2006.12.005. Epub 2007 Feb 15.'},\n",
       "     {'pmid': '28376873',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Edwards J, Hayden J, Asbridge M, Gregoire B, Magee K. Prevalence of low back pain in emergency settings: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017 Apr 4;18(1):143. doi: 10.1186/s12891-017-1511-7.'},\n",
       "     {'pmid': '26802501',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Kea B, Fu R, Lowe RA, Sun BC. Interpreting the National Hospital Ambulatory Medical Care Survey: United States Emergency Department Opioid Prescribing, 2006-2010. Acad Emerg Med. 2016 Feb;23(2):159-65. doi: 10.1111/acem.12862. Epub 2016 Jan 23.'},\n",
       "     {'pmid': '25534654',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Hoppe JA, Kim H, Heard K. Association of emergency department opioid initiation with recurrent opioid use. Ann Emerg Med. 2015 May;65(5):493-499.e4. doi: 10.1016/j.annemergmed.2014.11.015. Epub 2014 Dec 18.'},\n",
       "     {'pmid': '28797652',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Ruhm CJ. Geographic Variation in Opioid and Heroin Involved Drug Poisoning Mortality Rates. Am J Prev Med. 2017 Dec;53(6):745-753. doi: 10.1016/j.amepre.2017.06.009. Epub 2017 Aug 7.'},\n",
       "     {'pmid': '33805916',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Bertrand S, Meynet G, Taffe P, Della Santa V, Fishman D, Fournier Y, Frochaux V, Ribordy V, Rutschmann OT, Hugli O. Opiophobia in Emergency Department Healthcare Providers: A Survey in Western Switzerland. J Clin Med. 2021 Mar 25;10(7):1353. doi: 10.3390/jcm10071353.'},\n",
       "     {'pmid': '21119516',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Gueant S, Taleb A, Borel-Kuhner J, Cauterman M, Raphael M, Nathan G, Ricard-Hibon A. Quality of pain management in the emergency department: results of a multicentre prospective study. Eur J Anaesthesiol. 2011 Feb;28(2):97-105. doi: 10.1097/EJA.0b013e3283418fb0.'},\n",
       "     {'pmid': '29709398',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Duncan RW, Smith KL, Maguire M, Stader DE 3rd. Alternatives to opioids for pain management in the emergency department decreases opioid usage and maintains patient satisfaction. Am J Emerg Med. 2019 Jan;37(1):38-44. doi: 10.1016/j.ajem.2018.04.043. Epub 2018 Apr 22.'},\n",
       "     {'pmid': '35636044',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Rech MA, Griggs C, Lovett S, Motov S. Acute pain management in the Emergency Department: Use of multimodal and non-opioid analgesic treatment strategies. Am J Emerg Med. 2022 Aug;58:57-65. doi: 10.1016/j.ajem.2022.05.022. Epub 2022 May 22.'},\n",
       "     {'pmid': '19093703',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68(18):2611-32. doi: 10.2165/0003495-200868180-00007.'},\n",
       "     {'pmid': '12629531',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003 Mar;28(3):519-26. doi: 10.1038/sj.npp.1300027.'},\n",
       "     {'pmid': '11495717',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage. 2001 Aug;22(2):704-8. doi: 10.1016/s0885-3924(01)00302-5.'},\n",
       "     {'pmid': '20226624',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage. 2010 Apr;39(4):768-78. doi: 10.1016/j.jpainsymman.2009.09.008. Epub 2010 Mar 11.'},\n",
       "     {'pmid': '28052951',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Inayat F, Virk HU, Ullah W, Hussain Q. Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome? BMJ Case Rep. 2017 Jan 4;2017:bcr2016218239. doi: 10.1136/bcr-2016-218239.'},\n",
       "     {'pmid': '33193995',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Cowling M, Covington S, Roehmer C, Musey P. Characterizing the role of haloperidol for analgesia in the Emergency Department. J Pain Manag. 2019;12(2):141-146.'}],\n",
       "    'seeAlsoLinks': [{'label': 'Haloperidol by Patriot Pharmaceuticals LLC / Johnson & Johnson Research & Development,\\r\\nLLC / Janssen Pharmaceutica NV / Janssen Pharmaceutica, NV HALOPERIDOL injection.',\n",
       "      'url': 'https://fda.report/DailyMed/c9d0d515-adb7-4f93-8363-0f11771321c9'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': \"The subject's info collected as part of the research, even if identifiers are removed,\\r\\nwill not be used or distributed for future research studies.\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001416',\n",
       "      'term': 'Back Pain'},\n",
       "     {'id': 'D000004630', 'term': 'Emergencies'},\n",
       "     {'id': 'D000059350', 'term': 'Chronic Pain'}],\n",
       "    'ancestors': [{'id': 'D000010146', 'term': 'Pain'},\n",
       "     {'id': 'D000009461', 'term': 'Neurologic Manifestations'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M7796',\n",
       "      'name': 'Emergencies',\n",
       "      'asFound': 'Emergency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4714',\n",
       "      'name': 'Back Pain',\n",
       "      'asFound': 'Back Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29442',\n",
       "      'name': 'Chronic Pain',\n",
       "      'asFound': 'Chronic Pain',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'},\n",
       "     {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000020910',\n",
       "      'term': 'Ketorolac'},\n",
       "     {'id': 'D000020911', 'term': 'Ketorolac Tromethamine'},\n",
       "     {'id': 'D000006220', 'term': 'Haloperidol'},\n",
       "     {'id': 'C000033563', 'term': 'Haloperidol decanoate'}],\n",
       "    'ancestors': [{'id': 'D000000894',\n",
       "      'term': 'Anti-Inflammatory Agents, Non-Steroidal'},\n",
       "     {'id': 'D000018712', 'term': 'Analgesics, Non-Narcotic'},\n",
       "     {'id': 'D000000700', 'term': 'Analgesics'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000893', 'term': 'Anti-Inflammatory Agents'},\n",
       "     {'id': 'D000018501', 'term': 'Antirheumatic Agents'},\n",
       "     {'id': 'D000016861', 'term': 'Cyclooxygenase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000932', 'term': 'Antiemetics'},\n",
       "     {'id': 'D000001337', 'term': 'Autonomic Agents'},\n",
       "     {'id': 'D000005765', 'term': 'Gastrointestinal Agents'},\n",
       "     {'id': 'D000014150', 'term': 'Antipsychotic Agents'},\n",
       "     {'id': 'D000014149', 'term': 'Tranquilizing Agents'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000011619', 'term': 'Psychotropic Drugs'},\n",
       "     {'id': 'D000018492', 'term': 'Dopamine Antagonists'},\n",
       "     {'id': 'D000015259', 'term': 'Dopamine Agents'},\n",
       "     {'id': 'D000018377', 'term': 'Neurotransmitter Agents'},\n",
       "     {'id': 'D000018726', 'term': 'Anti-Dyskinesia Agents'}],\n",
       "    'browseLeaves': [{'id': 'M9312',\n",
       "      'name': 'Haloperidol',\n",
       "      'asFound': 'Window',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M215475',\n",
       "      'name': 'Haloperidol decanoate',\n",
       "      'asFound': 'Window',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22645',\n",
       "      'name': 'Ketorolac',\n",
       "      'asFound': 'Kg/day',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22646',\n",
       "      'name': 'Ketorolac Tromethamine',\n",
       "      'asFound': 'Lopinavir',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4217', 'name': 'Anti-Inflammatory Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4218',\n",
       "      'name': 'Anti-Inflammatory Agents, Non-Steroidal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'},\n",
       "     {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'},\n",
       "     {'id': 'M20604', 'name': 'Antirheumatic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M19209', 'name': 'Cyclooxygenase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4251', 'name': 'Antiemetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M16904', 'name': 'Antipsychotic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M14474', 'name': 'Psychotropic Drugs', 'relevance': 'LOW'},\n",
       "     {'id': 'M7473', 'name': 'Dopamine', 'relevance': 'LOW'},\n",
       "     {'id': 'M20596', 'name': 'Dopamine Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M17962', 'name': 'Dopamine Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'AnDyAg', 'name': 'Anti-Dyskinesia Agents'},\n",
       "     {'abbrev': 'AnEm', 'name': 'Antiemetics'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "     {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'},\n",
       "     {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'CaAg', 'name': 'Cardiotonic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06401811',\n",
       "    'orgStudyIdInfo': {'id': 'KSU.'},\n",
       "    'organization': {'fullName': 'Kahramanmaras Sutcu Imam University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': \"Reliability, Validity, and Responsiveness of the Turkish Version of Eating Assessment Tool-10 for Patients With Primer Sjögren's Syndrome\",\n",
       "    'officialTitle': \"Reliability, Validity, and Responsiveness of the Turkish Version of Eating Assessment Tool-10 for Patients With Primer Sjögren's Syndrome\"},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-11-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-02',\n",
       "    'studyFirstSubmitQcDate': '2024-05-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-07', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-02',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Nazli Elif Nacar',\n",
       "     'investigatorTitle': 'Lecturer',\n",
       "     'investigatorAffiliation': 'Kahramanmaras Sutcu Imam University'},\n",
       "    'leadSponsor': {'name': 'Kahramanmaras Sutcu Imam University',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Evaluations will be made by researchers following the guidance of individuals with\\r\\nprimary Sjögren's Syndrome who receive diagnosis, routine medical care, and treatment\\r\\nmanagement.\\r\\n\\r\\nIn addition, for the reliability of the Turkish Eating Assessment Tool-10, the Turkish\\r\\nEating Assessment Tool-10 will be repeated on patients at least one-fifth of the number\\r\\nof individuals included, after one week.\\r\\n\\r\\nFor the sensitivity of the scale, an exercise that is routinely applied in the\\r\\nRheumatological Rehabilitation Unit of Hacettepe University Faculty of Physical Therapy\\r\\nand Rehabilitation will be invited and after 3 months, the same evaluations as applied in\\r\\nthe first measurement will be made again on individuals at least one-fifth of the number\\r\\nof individuals included.\"},\n",
       "   'conditionsModule': {'conditions': [\"Sjogren's Syndrome\"],\n",
       "    'keywords': [\"Primer Sjogren's Syndrome\", 'swallowing disorder']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '3 Months',\n",
       "    'designInfo': {'observationalModel': 'OTHER',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Turkish Eating Assessment Tool',\n",
       "      'description': 'Turkish Eating Assessment Tool-10 is a survey consisting of 10 questions with a Likert\\r\\nscale between 0 and 4 (0 = no problem, 4 = severe problem). The total score is calculated\\r\\nout of 40 points by finding the sum of the answers given by individuals to each question.\\r\\nA score of 3 or more in the survey is considered abnormal. A score of 16 or above is\\r\\nconsidered a suspicion of aspiration. Turkish validity and reliability were tested by\\r\\nauthors in 2016.',\n",
       "      'timeFrame': 'Baseline-first week-third month'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Yale Swallow Protocol',\n",
       "      'description': \"Yale Swallow Protocol is a reliable screening test performed under expert supervision to\\r\\ndetermine the risk of aspiration at an early stage. The protocol has three main\\r\\ncomponents. These are exclusion criteria, a short cognitive test, and oral mechanism, and\\r\\ndrinking 3 oz (90 cc) water directly from the glass or with a straw. Risk factors are\\r\\nexamined in the 1st and 2nd stages to determine the patients to whom the test can be\\r\\napplied. Patients who complete step 1 and are not contraindicated for testing proceed to\\r\\nthe short cognitive testing phase. Patients who pass the short cognitive test and oral\\r\\nmechanism stages can proceed to the third stage, which is drinking 90 cc of water. The 90\\r\\ncc water swallow challenge protocol is a simple assessment that can be used by many\\r\\nqualified healthcare professionals to identify aspiration risk because it is easy to\\r\\nperform, highly reliable, cost-effective, and clinically validated.Patients showing these\\r\\nfindings are recorded as 'failing' the test.\",\n",
       "      'timeFrame': 'Baseline-third month'}],\n",
       "    'otherOutcomes': [{'measure': 'Test of Mastication and Swallowing Solids',\n",
       "      'description': \"In our study, the Test of Mastication and Swallowing Solids (TOMASS) will be used. The\\r\\ntest evaluates how many bites the individual takes to eat a biscuit while sitting\\r\\nupright, how many chewing cycles he makes, how many times he swallows it, and how long\\r\\nthe total time is from biting to swallowing. Video recording will be taken during the\\r\\ntest. The number of bites, number of chewing cycles, number of swallows and total time\\r\\nwill be calculated on the video. Individuals will be asked to eat the biscuit normally\\r\\nwhile sitting on a chair in an upright position with the throat visible. Meanwhile, video\\r\\nrecording will be taken from the individuals' front view, showing their mouth and neck.\\r\\nThe evaluation of the test will then be made by the evaluator. Videos will be stored in\\r\\nfolders on an encrypted computer and only the work team will have access.\",\n",
       "      'timeFrame': 'Baseline-third month'},\n",
       "     {'measure': 'Dysphagia limit',\n",
       "      'description': 'While evaluating dysphagia, individuals are given 5, 10, 15, 20, 25, 30, 35, 40 and 45 mL\\r\\nvolumes of liquid, respectively, with a graduated syringe and are asked to swallow the\\r\\nliquid. The maximum amount of fluid that the thyroid cartilage can swallow during a\\r\\nsingle movement is determined. The normal dysphagia limit in healthy individuals is more\\r\\nthan 20 mL. If a person can swallow 20 mL normally, the dysphagia limit is normal.',\n",
       "      'timeFrame': 'Baseline-third month'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Patients diagnosed with Primary Sjögren's Syndrome\\r\\n\\r\\n  -  18 years or older\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Patients with Secondary Sjögren's Syndrome,\\r\\n\\r\\n  -  Patients who are diagnosed with other uncontrolled/clinically important diseases\\r\\n     (chronic obstructive pulmonary disease, congestive heart failure, endocrine system\\r\\n     diseases, neurological, psychological diseases, etc.),\\r\\n\\r\\n  -  Individuals who do not agree to participate in the study and do not give written\\r\\n     consent will be excluded from the study.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': \"Patients with primer Sjogren's Syndrome diagnosed by a rheumatologist.\",\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Nazli Elif Nacar, MSc',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+903443004085',\n",
       "      'email': 'nelifnacar@ksu.edu.tr'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000012859',\n",
       "      'term': \"Sjogren's Syndrome\"},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000001172', 'term': 'Arthritis, Rheumatoid'},\n",
       "     {'id': 'D000001168', 'term': 'Arthritis'},\n",
       "     {'id': 'D000007592', 'term': 'Joint Diseases'},\n",
       "     {'id': 'D000009140', 'term': 'Musculoskeletal Diseases'},\n",
       "     {'id': 'D000012216', 'term': 'Rheumatic Diseases'},\n",
       "     {'id': 'D000014987', 'term': 'Xerostomia'},\n",
       "     {'id': 'D000012466', 'term': 'Salivary Gland Diseases'},\n",
       "     {'id': 'D000009059', 'term': 'Mouth Diseases'},\n",
       "     {'id': 'D000009057', 'term': 'Stomatognathic Diseases'},\n",
       "     {'id': 'D000015352', 'term': 'Dry Eye Syndromes'},\n",
       "     {'id': 'D000007766', 'term': 'Lacrimal Apparatus Diseases'},\n",
       "     {'id': 'D000005128', 'term': 'Eye Diseases'},\n",
       "     {'id': 'D000003240', 'term': 'Connective Tissue Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15664',\n",
       "      'name': \"Sjogren's Syndrome\",\n",
       "      'asFound': \"Sjogren's Syndrome\",\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6882', 'name': 'Deglutition Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4476', 'name': 'Arthritis', 'relevance': 'LOW'},\n",
       "     {'id': 'M4480', 'name': 'Arthritis, Rheumatoid', 'relevance': 'LOW'},\n",
       "     {'id': 'M10621', 'name': 'Joint Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15045', 'name': 'Rheumatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6323', 'name': 'Collagen Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17724', 'name': 'Xerostomia', 'relevance': 'LOW'},\n",
       "     {'id': 'M15285', 'name': 'Salivary Gland Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12019', 'name': 'Mouth Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M18040', 'name': 'Dry Eye Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'M10664',\n",
       "      'name': 'Keratoconjunctivitis Sicca',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M10786',\n",
       "      'name': 'Lacrimal Apparatus Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6464', 'name': 'Connective Tissue Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'},\n",
       "     {'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'BC11', 'name': 'Eye Diseases'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC09', 'name': 'Ear, Nose, and Throat Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05888311',\n",
       "    'orgStudyIdInfo': {'id': 'EF 184B'},\n",
       "    'organization': {'fullName': 'Eurofarma Laboratorios S.A.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Evaluation of the Protection of a Liquid Bandage',\n",
       "    'officialTitle': 'Randomized, Open Clinical Study to Evaluate the Protective Potential of a Liquid Bandage Based on Liquid Elastic Collodion Versus no Treatment'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-08-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-05-04',\n",
       "    'studyFirstSubmitQcDate': '2023-06-01',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-06-05', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Eurofarma Laboratorios S.A.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This study was designed with the objective of evaluating the protection potential\\r\\nprovided by the experimental product (Liquid Bandage) by evaluating its barrier formation\\r\\ncapacity. Once the product's ability to form a barrier is confirmed, its ability to\\r\\nprotect against small skin injuries, such as small cuts and bruises, blisters and cracks,\\r\\nis confirmed. The barrier formation also guarantees protection against the formation of\\r\\ncalluses.\"},\n",
       "   'conditionsModule': {'conditions': ['Skin Care'],\n",
       "    'keywords': ['effectiveness', 'Contact test']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': \"Visit 1, demographic data and medical history will be obtained. Visit 2, two areas will\\r\\nbe demarcated on the participant's forearm, with activated charcoal applied to both\\r\\nareas. The bandage will be applied to the corresponding area, with photos captured in\\r\\nboth the treated and control areas. After 12 hours, new photos of the areas will be\\r\\ntaken. The bandage will be reapplied to the treated area and the occurrence of adverse\\r\\nevents will be assessed. For the first 25 participants, two areas will also be demarcated\\r\\non the contralateral forearm, with activated charcoal applied to both areas. The bandage\\r\\nwill be applied to the corresponding area, with photos taken of both areas. 4 washes of\\r\\nthe areas of the contralateral forearm will be carried out at intervals of 30 minutes.\\r\\nAfter each wash, new photos will be taken. Visit 3, new photos will be obtained of the\\r\\ntreatment and control areas 24 hours after the first application of the bandage. The\\r\\noccurrence of adverse events will be checked.\",\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Liquid bandage',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Will receive the application of the experimental product (liquid bandage) on the area\\r\\nwith activated carbon at the beginning (T0) and at the end of visit 1 (T12).',\n",
       "      'interventionNames': ['Device: Liquid bandage',\n",
       "       'Other: Activated carbon']},\n",
       "     {'label': 'Control area',\n",
       "      'type': 'OTHER',\n",
       "      'description': 'will not receive the experimental product over activated carbon.',\n",
       "      'interventionNames': ['Other: Activated carbon']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Liquid bandage',\n",
       "      'description': 'Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms,\\r\\nwith activated carbon applied to both areas. An area to be treated with the experimental\\r\\nproduct will be determined by randomization.',\n",
       "      'armGroupLabels': ['Liquid bandage']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Activated carbon',\n",
       "      'description': 'Two areas measuring 3.0 cm x 3.0 cm will be randomly demarcated on one of your forearms,\\r\\nwith activated carbon applied to both areas. An untreated area (control area) will be\\r\\ndetermined by randomization.',\n",
       "      'armGroupLabels': ['Control area', 'Liquid bandage']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Average variation in color change in relation to the control area 12 hours after application of the experimental product.',\n",
       "      'description': 'Primary efficacy analyzes (barrier formation 12 hours after product application) will be\\r\\nbased on the intention-to-treat population, which includes all randomized participants\\r\\nwho have data up to at least 12 hours after product application.',\n",
       "      'timeFrame': '12 hours'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Average variation in color change in relation to the control area in 01 washes after applying the experimental product.',\n",
       "      'description': 'Secondary efficacy analyzes (resistance to water barrier formation up to 24 hours after\\r\\nproduct application) will be based on the per-protocol population, which include all\\r\\nrandomized participants who present data for all study assessment times without major\\r\\nprotocol violations.',\n",
       "      'timeFrame': '1 hours'},\n",
       "     {'measure': 'Average variation in color change in relation to the control area in 02 washes after applying the experimental product.',\n",
       "      'description': 'Secondary efficacy analyzes (resistance to water barrier formation up to 24 hours after\\r\\nproduct application) will be based on the per-protocol population, which include all\\r\\nrandomized participants who present data for all study assessment times without major\\r\\nprotocol violations.',\n",
       "      'timeFrame': '2 hours'},\n",
       "     {'measure': 'Average variation in color change in relation to the control area in 03 washes after applying the experimental product.',\n",
       "      'description': 'Secondary efficacy analyzes (resistance to water barrier formation up to 24 hours after\\r\\nproduct application) will be based on the per-protocol population, which include all\\r\\nrandomized participants who present data for all study assessment times without major\\r\\nprotocol violations.',\n",
       "      'timeFrame': '3 hours'},\n",
       "     {'measure': 'Average variation in color change in relation to the control area in 04 washes after applying the experimental product.',\n",
       "      'description': 'Secondary efficacy analyzes (resistance to water barrier formation up to 24 hours after\\r\\nproduct application) will be based on the per-protocol population, which include all\\r\\nrandomized participants who present data for all study assessment times without major\\r\\nprotocol violations.',\n",
       "      'timeFrame': '4 hours'}],\n",
       "    'otherOutcomes': [{'measure': 'Incidence of adverse event and treatment discontinuations due to adverse event.',\n",
       "      'description': 'The safety assessment will be based on the safety population, which includes all\\r\\nrandomized research participants who receive the first application of the investigational\\r\\nproduct and who perform at least one safety assessment after randomization',\n",
       "      'timeFrame': '12 hours'},\n",
       "     {'measure': 'Incidence of adverse event and treatment discontinuations due to adverse event.',\n",
       "      'description': 'The safety assessment will be based on the safety population, which includes all\\r\\nrandomized research participants who receive the first application of the investigational\\r\\nproduct and who perform at least one safety assessment after randomization',\n",
       "      'timeFrame': '24 hours'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria\\r\\n\\r\\n  -  Age between 18 and 70 years old.\\r\\n\\r\\n  -  Presence of intact skin in the test region (right forearm and left forearm for\\r\\n     selected participants).\\r\\n\\r\\n  -  Agreement to adhere to the study procedures and requirements and attend the\\r\\n     institute on the days and times determined for the assessments.\\r\\n\\r\\n  -  Signing of the Informed Consent Form (ICF) and the Image Disclosure Consent Form\\r\\n     (IDCF) before carrying out any study procedure.\\r\\n\\r\\nExclusion Criteria\\r\\n\\r\\n  -  Diagnosis of skin diseases such as vitiligo, psoriasis, atopic dermatitis.\\r\\n\\r\\n  -  Diagnosis of immunological insufficiency.\\r\\n\\r\\n  -  Use of systemic corticosteroids or immunosuppressants.\\r\\n\\r\\n  -  Diagnosis of type 1 diabetes mellitus or insulin-dependent diabetes or presence of\\r\\n     complications resulting from diabetes (such as retinopathy, nephropathy,\\r\\n     neuropathy), presence of diabetes-related dermatoses (such as plantar ulcers, lipoid\\r\\n     necrobiosis, granuloma annulare, opportunistic infections), history of episodes of\\r\\n     hypoglycemia, diabetic ketoacidosis and/or hyperosmolar coma .',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Gleyce Lima',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 5090 8411',\n",
       "      'phoneExt': '8411',\n",
       "      'email': 'gleyce.lima@eurofarma.com'},\n",
       "     {'name': 'Luiza Terranova',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '55 11 5090 8421',\n",
       "      'email': 'luiza.terranova@eurofarma.com'}],\n",
       "    'locations': [{'facility': 'Eurofarma Laboratorios S.A',\n",
       "      'city': 'São Paulo',\n",
       "      'zip': '06696-000',\n",
       "      'country': 'Brazil',\n",
       "      'contacts': [{'name': 'Gleyce Lima',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '55 11 5090 8411',\n",
       "        'phoneExt': '8411',\n",
       "        'email': 'gleyce.lima@eurofarma.com'},\n",
       "       {'name': 'Luiza Terranova',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '55 1 15090 8421',\n",
       "        'email': 'luiza.terranova@eurofarma.com'}],\n",
       "      'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000002606',\n",
       "      'term': 'Charcoal'}],\n",
       "    'ancestors': [{'id': 'D000000931', 'term': 'Antidotes'},\n",
       "     {'id': 'D000020011', 'term': 'Protective Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M5852',\n",
       "      'name': 'Charcoal',\n",
       "      'asFound': 'Iliopubic eminence',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4250', 'name': 'Antidotes', 'relevance': 'LOW'},\n",
       "     {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06216093',\n",
       "    'orgStudyIdInfo': {'id': 'EuRSV_101'},\n",
       "    'organization': {'fullName': 'EuBiologics Co.,Ltd', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years',\n",
       "    'officialTitle': 'Phase I, Randomized, Observer-blind, Placebo-control, Parallel-group, first-in Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years',\n",
       "    'acronym': 'EuRSV'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-03-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-01-02',\n",
       "    'studyFirstSubmitQcDate': '2024-01-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-22', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'EuBiologics Co.,Ltd', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy\\r\\nadults aged 19 to 80 years who have voluntarily given written consent to participate in\\r\\nthis study.'},\n",
       "   'conditionsModule': {'conditions': ['Respiratory Syncytial Virus Infections',\n",
       "     'Respiratory Syncytial Virus (RSV)'],\n",
       "    'keywords': ['EuRSV', 'RSV', 'Respiratory Syncytial Virus']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'RSV-1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Biological: EuRSV']},\n",
       "     {'label': 'RSV-2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Biological: EuRSV']},\n",
       "     {'label': 'Normal Saline',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'interventionNames': ['Other: Placebo Comparator']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'EuRSV',\n",
       "      'description': 'Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.',\n",
       "      'armGroupLabels': ['RSV-1', 'RSV-2']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Placebo Comparator',\n",
       "      'description': 'Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.',\n",
       "      'armGroupLabels': ['Normal Saline']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Occurrence of solicited adverse events',\n",
       "      'description': 'local and systemic AEs',\n",
       "      'timeFrame': 'within 7 days post vaccination'},\n",
       "     {'measure': 'Occurrence of immediate adverse events',\n",
       "      'description': 'local and systemic AEs',\n",
       "      'timeFrame': 'within 30 minutes post vaccination'},\n",
       "     {'measure': 'Occurrence of unsolicited adverse events',\n",
       "      'description': 'local and systemic AEs',\n",
       "      'timeFrame': 'within 52 weeks post vaccination'},\n",
       "     {'measure': 'Occurrence of serious adverse events',\n",
       "      'description': 'local and systemic AEs',\n",
       "      'timeFrame': 'within 52 weeks post vaccination'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Healthy adult men and women who meet the age criteria below\\r\\n\\r\\n  2. Have a body mass index (BMI) of at least 18 Kg/m^2 and no more than 30 Kg/m^2 at the\\r\\n     screening visit\\r\\n\\r\\n  3. Women and men of childbearing potential who agree to use a highly effective method\\r\\n     of contraception* for the duration of the study (up to 3 months after the last dose\\r\\n     of study medication)\\r\\n\\r\\n  4. Agree to refrain from donating blood and transfusions (whole blood, plasma\\r\\n     components, platelet components, platelet-plasma components) for the duration of the\\r\\n     study.\\r\\n\\r\\n  5. After receiving and understanding a detailed explanation of this clinical trial,\\r\\n     voluntarily decide to participate and give written consent.\\r\\n\\r\\n  6. For women of childbearing potential, a negative pregnancy test prior to receiving\\r\\n     the investigational drug.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Clinically significant abnormalities on clinical laboratory tests, electrocardiogram\\r\\n     (ECG), or chest x-ray at screening.\\r\\n\\r\\n  2. Positive hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) test\\r\\n     results at screening.\\r\\n\\r\\n  3. Have had clinically significant symptoms of respiratory illness within 14 days prior\\r\\n     to the first dose of investigational product (e.g., cough, sore throat, dyspnea,\\r\\n     wheezing, or nocturnal awakenings due to respiratory symptoms).\\r\\n\\r\\n  4. Active pulmonary infection within 14 days prior to the first dose of investigational\\r\\n     medicinal product, or any other significant infectious disease that, in the opinion\\r\\n     of the investigator, would render the subject ineligible for participation in the\\r\\n     study.\\r\\n\\r\\n  5. Have had an acute febrile illness of 38 celsius degrees or greater within 3 days\\r\\n     prior to the first dose of investigational drug\\r\\n\\r\\n  6. Have any of the following conditions, or any serious medical or neuropsychiatric\\r\\n     condition that, in the opinion of the investigator, would make them ineligible to\\r\\n     participate in this study\\r\\n\\r\\n  7. History of allergic reactions or hypersensitivity to any of the components of the\\r\\n     investigational drug.\\r\\n\\r\\n  8. History of serious adverse events, serious allergic reactions, or serious\\r\\n     hypersensitivity reactions related to vaccination.\\r\\n\\r\\n  9. History of platelet-related or hemorrhagic disease (such as major venous and/or\\r\\n     arterial thrombosis with thrombocytopenia), or history of excessive bleeding or\\r\\n     bruising after intramuscular injection or venipuncture, or receiving anticoagulant\\r\\n     therapy (except that patients may participate if they are using low-dose\\r\\n     anticoagulants (e.g., aspirin <100 mg/day) as determined by the investigator).\\r\\n\\r\\n 10. History of systemic urticaria within 5 years prior to the first dose of\\r\\n     investigational drug.\\r\\n\\r\\n 11. Have a history of hereditary or idiopathic angioneurotic edema\\r\\n\\r\\n 12. History of organ or bone marrow transplantation\\r\\n\\r\\n 13. Suspected history of drug abuse or alcohol abuse within 6 months prior to the first\\r\\n     dose of investigational medication.\\r\\n\\r\\n 14. History of respiratory syncytial virus (RSV) vaccination or participation in an RSV\\r\\n     vaccine clinical trial\\r\\n\\r\\n 15. Treatment with immunosuppressive or immunomodulatory agents or chronic steroid use\\r\\n     within 6 months prior to the first dose of investigational product.\\r\\n\\r\\n 16. History of dependent use of antipsychotics or narcotic analgesics within 6 months\\r\\n     prior to the first dose of study medication, or psychiatric or social conditions\\r\\n     that, in the opinion of the investigator, would make it difficult to comply with the\\r\\n     procedures of this study.\\r\\n\\r\\n 17. Received any other investigational drug or received an investigational medical\\r\\n     device within 6 months of the screening visit.\\r\\n\\r\\n 18. Treatment with immunoglobulins or blood-derived products within 3 months prior to\\r\\n     the first dose of investigational medicinal product or planned treatment during the\\r\\n     study period\\r\\n\\r\\n 19. Have received or plan to receive any other vaccine within 4 weeks prior to or after\\r\\n     each dose of investigational product.\\r\\n\\r\\n 20. Pregnant or lactating women\\r\\n\\r\\n 21. For any other reason deemed by the investigator to be unsuitable as a patient in\\r\\n     this study',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '19 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Howard Her',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+82-00-000-0000',\n",
       "      'email': 'hher@eubiologics.com'}],\n",
       "    'locations': [{'facility': 'Univsersity Hospital',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Seoul',\n",
       "      'country': 'Korea, Republic of',\n",
       "      'contacts': [{'name': 'Y.H. Woo',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'kughirb@kumc.or.kr'}],\n",
       "      'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000018357',\n",
       "      'term': 'Respiratory Syncytial Virus Infections'}],\n",
       "    'ancestors': [{'id': 'D000014777', 'term': 'Virus Diseases'},\n",
       "     {'id': 'D000007239', 'term': 'Infections'},\n",
       "     {'id': 'D000018186', 'term': 'Pneumovirus Infections'},\n",
       "     {'id': 'D000018184', 'term': 'Paramyxoviridae Infections'},\n",
       "     {'id': 'D000018701', 'term': 'Mononegavirales Infections'},\n",
       "     {'id': 'D000012327', 'term': 'RNA Virus Infections'}],\n",
       "    'browseLeaves': [{'id': 'M10283',\n",
       "      'name': 'Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M20494',\n",
       "      'name': 'Respiratory Syncytial Virus Infections',\n",
       "      'asFound': 'Respiratory Syncytial Virus Infections',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M20330',\n",
       "      'name': 'Paramyxoviridae Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20778',\n",
       "      'name': 'Mononegavirales Infections',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05853211',\n",
       "    'orgStudyIdInfo': {'id': '2023PI022'},\n",
       "    'organization': {'fullName': 'Central Hospital, Nancy, France',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Therapeutic Effects of Class II Elastics on Aligners in Different Vertical Skelettal Patterns',\n",
       "    'officialTitle': 'Therapeutic Effects of Class II Elastics on Aligners in Different Vertical Skelettal Patterns in Adult Patients: Retrospective Study.'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-13',\n",
       "    'studyFirstSubmitQcDate': '2023-05-08',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-10', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-30', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'VANDE VANNET Bart',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'Central Hospital, Nancy, France'},\n",
       "    'leadSponsor': {'name': 'Central Hospital, Nancy, France',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The objective is to compare the dento-alveolar therapeutic effects of wearing class II\\r\\ninter-arch traction elastics on aligners versus multi-brackets in an adult population.\\r\\nThe principal hypothesis is no significant difference in therapeutic effects of using\\r\\ninter-arch elastics on aligners versus multi-brackets.',\n",
       "    'detailedDescription': 'It is a non-interventional research involving the human person, research on existing data\\r\\nand / samples in the field of dentofacial orthopedics. This study analyzes the effects of\\r\\nrubber bands when combined with aligners in adult patients. This is a comparative\\r\\nretrospective study of radiographs and casts before and after orthodontic treatment. The\\r\\npatients studied are in Angle class II and adults. Two groups are analysed: patients\\r\\ntreated with fixed (vestibular multi-attachment) and removable (Invisalign-type aligners)\\r\\nappliances.'},\n",
       "   'conditionsModule': {'conditions': ['Malocclusion, Angle Class II'],\n",
       "    'keywords': ['aligner',\n",
       "     'inter-arch elastic',\n",
       "     'orthodontic',\n",
       "     'class II malocclusion',\n",
       "     'adult',\n",
       "     'clear aligner',\n",
       "     'orthodontic appliance',\n",
       "     'Invisalign',\n",
       "     'class II elastics',\n",
       "     'angle class II malocclusion']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'OTHER',\n",
       "     'timePerspective': 'RETROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Clear aligner',\n",
       "      'description': 'Patient with class II malocclusion, treated with class II elastics on aligners',\n",
       "      'interventionNames': ['Combination Product: Aligner and inter-arch elastics']},\n",
       "     {'label': 'Fixed appliance',\n",
       "      'description': 'Patient with class II malocclusion, treated with class II elastics on fixed appliance'}],\n",
       "    'interventions': [{'type': 'COMBINATION_PRODUCT',\n",
       "      'name': 'Aligner and inter-arch elastics',\n",
       "      'description': 'Correction of class II malocclusion by class II elastics on clear aligners',\n",
       "      'armGroupLabels': ['Clear aligner']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in IMPA Mandibular incisor angle (degrees)',\n",
       "      'description': 'Angle between the mandibular plane and the lower incisor axis: position of the lower\\r\\nincisor in relation to the mandible',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months.'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Sex',\n",
       "      'description': 'Sex',\n",
       "      'timeFrame': '1 month'},\n",
       "     {'measure': 'Duration of treatment',\n",
       "      'description': 'Treatment time duration in month',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Change in interproximal dental size',\n",
       "      'description': 'Interproximal size in mm',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in skeletal sagittal pattern ANB angle',\n",
       "      'description': 'Cephalometric measurements : angle between A, Na (nasion) and B in degrees',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in skeletal sagittal pattern Ao-Bo',\n",
       "      'description': 'Cephalometric measurements : mesure in mm between Ao and Bo',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in skeletal vertical pattern : FMA',\n",
       "      'description': 'Cephalometric measurements : angle in degrees between franckfort plan and mandibular\\r\\nplan.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in skeletal vertical pattern : Sn Gogn',\n",
       "      'description': 'Cephalometric measurements : angle in degrees between SN and GoGn',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in faciale anterior height',\n",
       "      'description': 'Cephalometric measurements of faciale anterior height',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in faciale posterior height',\n",
       "      'description': 'Cephalometric measurements of faciale posterior height',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in index Faciale height',\n",
       "      'description': 'Cephalometric measurements, index HFP (faciale posterior heigth)/ HFA (faciale anterior\\r\\nheight)',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in nterincisal angle',\n",
       "      'description': 'Cephalometric measurements : measurement between manxillary and mandibular incisors.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in plan of occlusion',\n",
       "      'description': 'Cephalometric measurements : angle between SN and Op',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Age at the beginning of treatment',\n",
       "      'description': 'Age',\n",
       "      'timeFrame': '1 month'},\n",
       "     {'measure': 'Age at the end of treatment',\n",
       "      'description': 'Age',\n",
       "      'timeFrame': '24 months'},\n",
       "     {'measure': 'Change in von Spee curve',\n",
       "      'description': 'Measurements on impressions : it is the average of the distance between the highest point\\r\\nof the deepest cusp and the occlusal plane.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in overall crowding',\n",
       "      'description': 'Measurements on impressions : comparison of the sum of the mesiodistal diameters of 35 to\\r\\n45 and the arch perimeter from the mesial face of 36 to the mesial face of 46.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in overjet',\n",
       "      'description': 'Measurements on impressions : in mm',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in overbite',\n",
       "      'description': 'Measurements on impressions : in mm',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in arch length',\n",
       "      'description': 'Measurements on impressions : distance between inter incisal point and mesiale face of 6.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'CHange in class II quantity',\n",
       "      'description': 'Measurements on impressions : inter canine and inter molar relations',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in space required',\n",
       "      'description': 'Measurements on impressions : sum of all mesiodistal diameter.',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in inter canine distance',\n",
       "      'description': 'Measurements on impressions : distance between the canine in mm',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in inter premolar distance',\n",
       "      'description': 'Measurements on impressions : distance between the premolars',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'},\n",
       "     {'measure': 'Change in inter molar distance',\n",
       "      'description': 'Measurements on impressions : distance between the molars',\n",
       "      'timeFrame': 'First : just before the beginning of treatment; Second : just after the end of orthodontic treatment. An average of 18 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  CVM stage 5 on lateral teleradiography (end of growth)\\r\\n\\r\\n  -  Angle Class II\\r\\n\\r\\n  -  Treatments with rubber bands for inter-arch traction\\r\\n\\r\\n  -  End of treatment in class I\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Incomplete data\\r\\n\\r\\n  -  Treatment with extractions, mini-screws, mini-plate or ortho-surgical treatment\\r\\n\\r\\n  -  Dental agenesis (excluding wisdom teeth)\\r\\n\\r\\n  -  Cranial-facial syndromes',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '13 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Adult with class II malocclusion treated with class II elastics',\n",
       "    'samplingMethod': 'PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Bart VANDE VANNET, Phd',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+32496284339',\n",
       "      'email': 'bart.vande-vannet@univ-lorraine.fr'},\n",
       "     {'name': 'Lou DEON',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+33685327891',\n",
       "      'email': 'loudeon@yahoo.fr'}],\n",
       "    'overallOfficials': [{'name': 'Bart VANDE VANNET',\n",
       "      'affiliation': 'Central Hospital, Nancy, France',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'DEON',\n",
       "      'city': 'Nancy',\n",
       "      'state': 'Lorraine',\n",
       "      'zip': '54000',\n",
       "      'country': 'France',\n",
       "      'contacts': [{'name': 'Lou DEON, Student',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+33685327891',\n",
       "        'email': 'loudeon@yahoo.fr'}],\n",
       "      'geoPoint': {'lat': 48.68439, 'lon': 6.18496}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '23452973',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Janson G, Sathler R, Fernandes TM, Branco NC, Freitas MR. Correction of Class II malocclusion with Class II elastics: a systematic review. Am J Orthod Dentofacial Orthop. 2013 Mar;143(3):383-92. doi: 10.1016/j.ajodo.2012.10.015.'},\n",
       "     {'pmid': '31651082',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Robertson L, Kaur H, Fagundes NCF, Romanyk D, Major P, Flores Mir C. Effectiveness of clear aligner therapy for orthodontic treatment: A systematic review. Orthod Craniofac Res. 2020 May;23(2):133-142. doi: 10.1111/ocr.12353. Epub 2019 Nov 13.'},\n",
       "     {'pmid': '28547915',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Zheng M, Liu R, Ni Z, Yu Z. Efficiency, effectiveness and treatment stability of clear aligners: A systematic review and meta-analysis. Orthod Craniofac Res. 2017 Aug;20(3):127-133. doi: 10.1111/ocr.12177. Epub 2017 May 26.'},\n",
       "     {'pmid': '30171391',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Lombardo L, Colonna A, Carlucci A, Oliverio T, Siciliani G. Class II subdivision correction with clear aligners using intermaxilary elastics. Prog Orthod. 2018 Sep 1;19(1):32. doi: 10.1186/s40510-018-0221-5.'},\n",
       "     {'pmid': '34013659',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Dianiskova S, Rongo R, Buono R, Franchi L, Michelotti A, D'Anto V. Treatment of mild Class II malocclusion in growing patients with clear aligners versus fixed multibracket therapy: A retrospective study. Orthod Craniofac Res. 2022 Feb;25(1):96-102. doi: 10.1111/ocr.12500. Epub 2021 May 31.\"},\n",
       "     {'pmid': '26636248',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Duncan LO, Piedade L, Lekic M, Cunha RS, Wiltshire WA. Changes in mandibular incisor position and arch form resulting from Invisalign correction of the crowded dentition treated nonextraction. Angle Orthod. 2016 Jul;86(4):577-83. doi: 10.2319/042415-280.1. Epub 2015 Dec 4.'},\n",
       "     {'pmid': '35015923',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Amm E, El Amm C, Vaden J. Effect of Class II elastics on different mandibular arch preparation stabilized with aligners and stainless-steel wires: A FEM study. Orthod Craniofac Res. 2022 Nov;25(4):520-529. doi: 10.1111/ocr.12564. Epub 2022 Jan 27.'},\n",
       "     {'pmid': '36555949',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': \"Rongo R, Dianiskova S, Spiezia A, Bucci R, Michelotti A, D'Anto V. Class II Malocclusion in Adult Patients: What Are the Effects of the Intermaxillary Elastics with Clear Aligners? A Retrospective Single Center One-Group Longitudinal Study. J Clin Med. 2022 Dec 9;11(24):7333. doi: 10.3390/jcm11247333.\"},\n",
       "     {'pmid': '32291482',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Deregibus A, Tallone L, Rossini G, Parrini S, Piancino M, Castroflorio T. Morphometric analysis of dental arch form changes in class II patients treated with clear aligners. J Orofac Orthop. 2020 Jul;81(4):229-238. doi: 10.1007/s00056-020-00224-8. Epub 2020 Apr 14. Erratum In: J Orofac Orthop. 2020 Nov;81(6):447.'},\n",
       "     {'pmid': '36456944',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Liu X, Cheng Y, Qin W, Fang S, Wang W, Ma Y, Jin Z. Effects of upper-molar distalization using clear aligners in combination with Class II elastics: a three-dimensional finite element analysis. BMC Oral Health. 2022 Dec 1;22(1):546. doi: 10.1186/s12903-022-02526-2.'},\n",
       "     {'pmid': '12169031',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Baccetti T, Franchi L, McNamara JA Jr. An improved version of the cervical vertebral maturation (CVM) method for the assessment of mandibular growth. Angle Orthod. 2002 Aug;72(4):316-23. doi: 10.1043/0003-3219(2002)0722.0.CO;2.'},\n",
       "     {'pmid': '18774080',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Marshall SD, Caspersen M, Hardinger RR, Franciscus RG, Aquilino SA, Southard TE. Development of the curve of Spee. Am J Orthod Dentofacial Orthop. 2008 Sep;134(3):344-52. doi: 10.1016/j.ajodo.2006.10.037.'},\n",
       "     {'pmid': '34479824',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Fawaz P, Amm E, Khoury E. The curve of Spee and its levelling in different vertical skeletal patterns: A 3D set-up study. Int Orthod. 2021 Dec;19(4):659-668. doi: 10.1016/j.ortho.2021.08.003. Epub 2021 Aug 31.'},\n",
       "     {'pmid': '35361187',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Adel SM, Vaid NR, El-Harouni N, Kassem H, Zaher AR. Digital model superimpositions: are different software algorithms equally accurate in quantifying linear tooth movements? BMC Oral Health. 2022 Mar 31;22(1):103. doi: 10.1186/s12903-022-02129-x.'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008310',\n",
       "      'term': 'Malocclusion'},\n",
       "     {'id': 'D000008312', 'term': 'Malocclusion, Angle Class II'},\n",
       "     {'id': 'D000057887', 'term': 'Overbite'}],\n",
       "    'ancestors': [{'id': 'D000014076', 'term': 'Tooth Diseases'},\n",
       "     {'id': 'D000009057', 'term': 'Stomatognathic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M28896',\n",
       "      'name': 'Overbite',\n",
       "      'asFound': 'Malocclusion, Angle Class II',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11303',\n",
       "      'name': 'Malocclusion, Angle Class II',\n",
       "      'asFound': 'Malocclusion, Angle Class II',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11301',\n",
       "      'name': 'Malocclusion',\n",
       "      'asFound': 'Malocclusion',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M16831', 'name': 'Tooth Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12017', 'name': 'Stomatognathic Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06430411',\n",
       "    'orgStudyIdInfo': {'id': '1336/2022'},\n",
       "    'organization': {'fullName': 'Medical University of Vienna',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study',\n",
       "    'officialTitle': 'Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study',\n",
       "    'acronym': 'OLIGOMET'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2031-01-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2031-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-02',\n",
       "    'studyFirstSubmitQcDate': '2024-05-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr. Pawel G. Rajwa',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Medical University of Vienna'},\n",
       "    'leadSponsor': {'name': 'Medical University of Vienna', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'IRCCS Ospedale San Raffaele',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'University Hospital of Cologne', 'class': 'OTHER'},\n",
       "     {'name': 'St. Antonius Hospital', 'class': 'OTHER'},\n",
       "     {'name': 'Istituto Europeo di Oncologia', 'class': 'OTHER'},\n",
       "     {'name': 'University Hospital, Udine, Italy', 'class': 'OTHER'},\n",
       "     {'name': 'Azienda Ospedaliera San Giovanni Battista', 'class': 'OTHER'},\n",
       "     {'name': 'Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Lund University', 'class': 'OTHER'},\n",
       "     {'name': 'Medical University of Warsaw', 'class': 'OTHER'},\n",
       "     {'name': 'Ziekenhuis Netwerk Antwerpen (ZNA)', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'PSMA-PET/CT or PSMA-PET/MRI are more accurate imaging modalities compared to CT/BS; in\\r\\napproximately 10-20% of high-risk patients diagnosed using conventional imaging PSMA-PET\\r\\nup-stages the disease. Therefore a substantial proportion of high-risk patients\\r\\npreviously considered as non-metastatic are expected to be diagnosed with oligometastatic\\r\\ndisease. While standard treatment pathways exist for patients with non-metastatic or\\r\\noligometastatic disease confirmed using conventional imaging, less is known about the\\r\\noptimal management of patients with oligometastatic prostate cancer on PSMA-PET.\\r\\n\\r\\nCurrently, data on the safety, effectiveness and oncologic outcomes of local therapies in\\r\\noligometastatic patients diagnosed using PSMA-PET have been poorly reported so far. Thus,\\r\\nthere is a need for a prospectively maintained database to collect real-world clinical\\r\\ndata to produce high-quality research on the optimal management in oligometastatic\\r\\nprostate cancer who underwent PSMA-PET for primary staging and subsequent local therapy.\\r\\nThis database will allow centers to retro- and prospectively collect data to facilitate\\r\\nanalysis and assessment of the outcomes of oligometastatic patients managed with local\\r\\ntherapy.',\n",
       "    'detailedDescription': \"The Emerging Role of PSMA-PET in Prostate Cancer Imaging\\r\\n\\r\\nPSMA-PET, in conjunction with CT or MRI, has significantly enhanced the precision of\\r\\nprostate cancer staging. Traditional imaging modalities, such as CT or BS, often fail to\\r\\naccurately determine the disease's extent. In contrast, PSMA-PET offers a more precise\\r\\ndiagnostic alternative, especially in identifying oligometastatic cases among high-risk\\r\\nprostate cancer patients. Remarkably, 10-20% of patients with unfavorable prostate cancer\\r\\ninitially classified as non-metastatic through conventional imaging are reclassified as\\r\\noligometastatic when reassessed with PSMA-PET. This reclassification is pivotal, possibly\\r\\ninfluencing treatment decisions and prognostic outcomes.\\r\\n\\r\\nThe Need for a Focused Study\\r\\n\\r\\nOligometastatic prostate cancer represents an intermediate stage between localized and\\r\\nsystemic disease, reflecting an early phase in metastatic progression. These tumors not\\r\\nonly exhibit unique biological characteristics but also constitute a distinct clinical\\r\\nentity, offering possibilities for long-term control or even cure. Numerous studies\\r\\ndemonstrated benefits from combining local and metastasis-directed therapies with\\r\\nsystemic treatment in oligometastatic prostate cancer patients diagnosed with\\r\\nconventional imaging. However, despite diagnostic advancements and the evolving uptake of\\r\\nPSMA-PET, substantial gaps persist in the understanding of optimal management for\\r\\noligometastatic prostate cancer identified with next-generation imaging.\\r\\n\\r\\nDue to the diagnostics advancements and dynamically changing treatment landscape with\\r\\nvarious local, systemic, and metastasis-directed therapies, this topic requires a\\r\\nprospective multicenter registry. To address this, the investigators have initiated this\\r\\nprospective cohort study focusing on the efficacy and safety of local therapies in\\r\\noligometastatic prostate cancer patients diagnosed with PSMA-PET, performed under the\\r\\numbrella of EAU Young Academic Urologists (YAU) Prostate Cancer Working Group.\\r\\n\\r\\nStudy Design and Objectives\\r\\n\\r\\nThis multicenter, prospective observational cohort study aims primarily to evaluate time\\r\\nto castration-resistance, clinical and radiological progression-free survival in patients\\r\\nwith oligometastatic prostate cancer identified using PSMA-PET. Secondary objectives\\r\\ninclude assessing complications of local therapies, pathological, functional, and\\r\\noncologic outcomes among others.\\r\\n\\r\\nEligible patients are those diagnosed with primary oligometastatic prostate cancer with\\r\\nPSMA-PET and treated with local therapies such as radical prostatectomy or radiation. The\\r\\noligometastatic state is defined as cM1a and/or cM1b with ≤5 bone metastases and/or M1c\\r\\nwith ≤3 lung lesions, with or without cN positivity. Key exclusion criteria include the\\r\\npresence of visceral metastases (other than lungs) or neoadjuvant therapy before initial\\r\\nPSMA-PET assessment.\\r\\n\\r\\nThe study aims to answer pivotal questions about oncological, functional, and safety\\r\\noutcomes after local treatment in oligometastatic prostate cancer patients on PSMA-PET.\\r\\nFurthermore, the goal is to report treatment strategies for this disease state in this\\r\\ndynamically changing field, and to identify factors predicting improved outcomes.\\r\\n\\r\\nData Collection and Management\\r\\n\\r\\nData will be meticulously collected and managed using the Castor electronic case report\\r\\nform platform, provided by the European Association of Urology Foundation for Urological\\r\\nResearch, ensuring pseudonymization and security. With the study starting in 2024, the\\r\\ninvestigators aim to collect data until end of 2030.\\r\\n\\r\\nEstimated Impact of the Study\\r\\n\\r\\nThis study is anticipated to substantially contribute to the understanding of\\r\\noligometastatic prostate cancer and the role of PSMA-PET in its diagnosis and management.\\r\\nIn a recent multicenter EAU-YAU study closely related to OLIGOMET project, the\\r\\ninvestigators have shown that patients with oligometastatic prostate cancer diagnosed\\r\\nwith PSMA-PET and treated with radical prostatectomy have overall favorable oncologic\\r\\noutcomes. Nevertheless, a portion of these patients still faced a risk of early\\r\\nprogression, emphasizing the need for multimodal therapy. The study illustrated the lack\\r\\nof evidence and precise clinical guidance in this distinct disease stage; there existed\\r\\nsignificant heterogeneity in the treatment approach among participating tertiary referral\\r\\ncenters, with the majority of patients receiving multimodal therapy.\\r\\n\\r\\nWhile the combination of radiation and systemic therapy can be considered the current\\r\\nstandard of care in oligometastatic patients on conventional imaging, the preferred\\r\\nmanagement of patients with a small metastatic burden on PSMA-PET remains unknown.\\r\\nTherefore, the investigators believe that evaluating the effectiveness of local therapies\\r\\nin patients diagnosed with next-generation imaging can pave the way for personalized, and\\r\\neffective treatment strategies of oligometastatic disease in the future. Moreover, the\\r\\nuse of PSMA-PET may allow for early identification and intervention, potentially altering\\r\\nthe natural history of the disease and improving oncologic control. Finally, the\\r\\ninvestigators expect that by understanding the role of combination therapies and\\r\\nidentifying predictive factors to guide treatment selection, could lead to extended\\r\\nsurvival and improved quality of life of patients.\"},\n",
       "   'conditionsModule': {'conditions': ['Prostate Cancer Metastatic',\n",
       "     'Prostate Cancer Metastatic to Bone',\n",
       "     'Prostate Cancer',\n",
       "     'Prostate Neoplasm',\n",
       "     'Oligometastatic Disease',\n",
       "     'Oligometastasis'],\n",
       "    'keywords': ['prostate',\n",
       "     'oligometastatic',\n",
       "     'oligometastasis',\n",
       "     'oligomet',\n",
       "     'prostatectomy',\n",
       "     'irradiation',\n",
       "     'abiraterone',\n",
       "     'enzalutamide',\n",
       "     'darolutamide',\n",
       "     'apalutamide',\n",
       "     'androgen deprivation therapy',\n",
       "     'ADT',\n",
       "     'docetaxel',\n",
       "     'PSMA PET']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': True,\n",
       "    'targetDuration': '5 Years',\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'PROCEDURE',\n",
       "      'name': 'Radical prostatectomy',\n",
       "      'description': 'Removal of the prostate and seminal vesicles.'},\n",
       "     {'type': 'RADIATION',\n",
       "      'name': 'Prostate irradiation',\n",
       "      'description': 'Radiation therapy of the prostate.'},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Surgical metastasectomy',\n",
       "      'description': 'Surgical removal of metastases.'},\n",
       "     {'type': 'RADIATION',\n",
       "      'name': 'Irradiation of metastases',\n",
       "      'description': 'Radiation therapy of metastases.'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Abiraterone acetate',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Enzalutamide',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Darolutamide',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Apalutamide',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Docetaxel',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Lutetium-PSMA',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Androgen deprivation treatment',\n",
       "      'description': 'Administered as part of multimodal treatment for oligometastatic prostate cancer'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Radiographic progression-free survival (rPFS)',\n",
       "      'description': 'Defined as increase in size of existing lesion or appearance of new lesion (on any\\r\\nsubsequent follow-up imaging modality used for baseline assessment), or death.',\n",
       "      'timeFrame': 'From date of diagnosis until the date of first documented radiographic progression or date of death from any cause, whichever came first, assessed up to 100 months'},\n",
       "     {'measure': 'Clinical progression-free survival (cPFS)',\n",
       "      'description': 'Defined as new prostate cancer-related symptom, radiographic progression, initiation of\\r\\nnew treatment, or death.',\n",
       "      'timeFrame': 'From date of diagnosis until the date of first documented clinical progression or date of death from any cause, whichever came first, assessed up to 100 months'},\n",
       "     {'measure': 'Castration resistance-free survival (CRPC-FS)',\n",
       "      'description': 'Castration resistance is defined as: castrate serum testosterone <50ng/dL or 1.7nmol/L,\\r\\nplus either biochemical progression (three consecutive rises in PSA at least one week\\r\\napart resulting in two 50% increases over the nadir, and a PSA > 2ng/mL) or radiographic\\r\\nprogression (> 2 new bone lesions or a new soft tissue lesion).',\n",
       "      'timeFrame': 'From date of diagnosis until the date of castration resistance or date of death from any cause, whichever came first, assessed up to 100 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Local therapy complications',\n",
       "      'description': 'Local therapy complications are assessed using Clavien-Dindo classification for radical\\r\\nprostatectomy and RTOG/EORTC Radiation Toxicity Grading for radiation therapy.',\n",
       "      'timeFrame': 'From the time of local therapy to 30 days after treatment.'},\n",
       "     {'measure': 'Pathological response to systemic therapy',\n",
       "      'description': 'Change of pathological stage',\n",
       "      'timeFrame': 'Measured immediately after the surgery'},\n",
       "     {'measure': 'Imaging response to systemic therapy',\n",
       "      'description': 'Defined as prostate cancer downstaging and/or decrease in number of metastasis lesions\\r\\ndue to the effect of systemic therapy.\\r\\n\\r\\nTime Frame:\\r\\n\\r\\nMeasured from the administration of systemic treatment until the end of treatment,\\r\\nassessed up to 100 months',\n",
       "      'timeFrame': 'Measured from the administration of systemic treatment until the end of treatment, assessed up to 100 months'},\n",
       "     {'measure': 'Functional outcomes - continence',\n",
       "      'description': 'Defined as continence rate (no incontinence 0 pads/24h, mild 1 pads/24h, moderate 2-3\\r\\npads/24h, severe >3 pads/24h).',\n",
       "      'timeFrame': '6 months, 1, 2, and 3 years after local therapy.'},\n",
       "     {'measure': 'Functional outcomes - potency',\n",
       "      'description': 'Defined as potency (potent ( IIEF-EF=>22), inpotent (IIEF-EF <22)',\n",
       "      'timeFrame': '6 months, 1, 2, and 3 years after local therapy.'},\n",
       "     {'measure': 'Cancer-specific survival',\n",
       "      'description': 'Time from oligometastasis diagnosis to death from prostate cancer.',\n",
       "      'timeFrame': 'From date of diagnosis until the date of death from prostate cancer, assessed up to 100 months'},\n",
       "     {'measure': 'Overall survival',\n",
       "      'description': 'Time from oligometastasis diagnosis to death of any cause.',\n",
       "      'timeFrame': 'From date of diagnosis until the date of death from any cause, assessed up to 100 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Oligometastatic prostate cancer diagnosed using PSMA PET defined as cM1a and/or cM1b\\r\\n     with ≤5 osseous metastases and/or M1c with ≤3 lung lesions, with or without cN\\r\\n     positivity.\\r\\n\\r\\n  -  Oligometastatic prostate cancer treated with primary local therapy such as radical\\r\\n     prostatectomy or radiation therapy.\\r\\n\\r\\n  -  Any Gleason Score, any cT stage, any PSA\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Visceral metastases (apart from lungs).\\r\\n\\r\\n  -  Neoadjuvant therapy prior to first PSMA PET.\\r\\n\\r\\n  -  Non-metastatic prostate cancer.\\r\\n\\r\\n  -  Patients who did not undergo imaging before local treatment.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Oligometastatic prostate cancer patients treated with local therapy across Europe.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Tamás Fazekas, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+36-70-611-8524',\n",
       "      'email': 'fazekastamas192@gmail.com'},\n",
       "     {'name': 'Pawel G Rajwa, MD PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+48-604-090-416',\n",
       "      'email': 'pawelgrajwa@gmail.com'}],\n",
       "    'overallOfficials': [{'name': 'Shahrokh F Shariat, MD PhD DDsc',\n",
       "      'affiliation': 'Medical University of Vienna',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Pawel G Rajwa, MD PhD',\n",
       "      'affiliation': 'Medical University of Vienna',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011471',\n",
       "      'term': 'Prostatic Neoplasms'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'}],\n",
       "    'ancestors': [{'id': 'D000005834', 'term': 'Genital Neoplasms, Male'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000005832', 'term': 'Genital Diseases, Male'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000011469', 'term': 'Prostatic Diseases'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M14335',\n",
       "      'name': 'Prostatic Neoplasms',\n",
       "      'asFound': 'Prostate Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8946', 'name': 'Genital Neoplasms, Male', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8944', 'name': 'Genital Diseases, Male', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14333', 'name': 'Prostatic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000077143',\n",
       "      'term': 'Docetaxel'},\n",
       "     {'id': 'D000069501', 'term': 'Abiraterone Acetate'},\n",
       "     {'id': 'D000000728', 'term': 'Androgens'}],\n",
       "    'ancestors': [{'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000050257', 'term': 'Tubulin Modulators'},\n",
       "     {'id': 'D000050256', 'term': 'Antimitotic Agents'},\n",
       "     {'id': 'D000050258', 'term': 'Mitosis Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000065088', 'term': 'Steroid Synthesis Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000006727', 'term': 'Hormone Antagonists'},\n",
       "     {'id': 'D000006730',\n",
       "      'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000065607', 'term': 'Cytochrome P-450 Enzyme Inhibitors'},\n",
       "     {'id': 'D000006728', 'term': 'Hormones'}],\n",
       "    'browseLeaves': [{'id': 'M4059',\n",
       "      'name': 'Androgens',\n",
       "      'asFound': 'Assistance',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1668',\n",
       "      'name': 'Docetaxel',\n",
       "      'asFound': 'Physical',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M451',\n",
       "      'name': 'Abiraterone Acetate',\n",
       "      'asFound': 'Website',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26197', 'name': 'Tubulin Modulators', 'relevance': 'LOW'},\n",
       "     {'id': 'M26196', 'name': 'Antimitotic Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'},\n",
       "     {'id': 'M9788', 'name': 'Hormone Antagonists', 'relevance': 'LOW'},\n",
       "     {'id': 'M30537',\n",
       "      'name': 'Cytochrome P-450 Enzyme Inhibitors',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05554393',\n",
       "    'orgStudyIdInfo': {'id': 'NCI-2022-07534'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2022-07534',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'MM1YA-CTG01',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'Canadian Cancer Trials Group'},\n",
       "     {'id': 'MM1YA-CTG01', 'type': 'OTHER', 'domain': 'CTEP'},\n",
       "     {'id': 'U10CA180863',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/U10CA180863'}],\n",
       "    'organization': {'fullName': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'},\n",
       "    'briefTitle': 'Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)',\n",
       "    'officialTitle': 'A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-02',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-09-22',\n",
       "    'studyFirstSubmitQcDate': '2022-09-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-09-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'National Cancer Institute (NCI)',\n",
       "     'class': 'NIH'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus\\r\\ncytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the\\r\\ntreatment of younger patients with intermediate risk acute myeloid leukemia (AML).\\r\\nCytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid\\r\\n(DNA) replication and repair and can slow or stop the growth of cancer cells.\\r\\nDaunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA\\r\\nrepair, and it may kill cancer cells. Venetoclax is in a class of medications called\\r\\nB-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking\\r\\nBcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts\\r\\nwith DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding\\r\\nvenetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work\\r\\nbetter than the usual treatment of cytarabine with daunorubicin alone. To decide if they\\r\\nare better, the study doctors are looking to see if venetoclax increases the rate of\\r\\nelimination of AML in participants by 20% or more compared to the usual approach.',\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVE:\\r\\n\\r\\nI. To compare the rates of undetectable measurable residual disease (MRD) in patients who\\r\\nachieve a complete remission/complete remission with incomplete count recovery (CR/CRi)\\r\\nafter induction therapy with 7 +3 (cytarabine + daunorubicin hydrochloride\\r\\n[daunorubicin]) versus (vs.) azacitidine + venetoclax vs. 7+3 + venetoclax.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. To estimate the frequency and severity of toxicities with each of the regimens.\\r\\n\\r\\nII. To estimate complete remission (CR) rates (with and without MRD), complete remission\\r\\nwith incomplete count recovery (CRi) (with and without MRD) rates, event-free survival\\r\\n(EFS), relapse-free survival (RFS), and overall survival (OS) with each of the regimens.\\r\\n\\r\\nTERTIARY OBJECTIVES:\\r\\n\\r\\nI. To evaluate response to therapy received according to genomic findings. II. To\\r\\nevaluate MRD kinetics by following patients with detectable MRD through Tier 2 and\\r\\nbeyond.\\r\\n\\r\\nIII. To evaluate longer term outcomes by treatment arm, genomics, MRD outcome, and other\\r\\nfeatures as patients receive additional myeloMATCH therapies to generate testable\\r\\nhypotheses for more precise patient selection for these therapies.\\r\\n\\r\\nOUTLINE: Patients are randomized to 1 of 3 arms.\\r\\n\\r\\nARM I: Patients receive daunorubicin intravenously (IV), cytarabine IV, and venetoclax\\r\\norally (PO) on study and undergo bone marrow aspiration and collection of blood samples\\r\\non study and as clinically indicated.\\r\\n\\r\\nARM II: Patients receive azacitidine IV or subcutaneously (SC) and venetoclax PO on study\\r\\nand undergo bone marrow aspiration and collection of blood samples on study and as\\r\\nclinically indicated.\\r\\n\\r\\nARM III: Patients receive daunorubicin IV and cytarabine IV on study and undergo bone\\r\\nmarrow aspiration and collection of blood samples on study and as clinically indicated.'},\n",
       "   'conditionsModule': {'conditions': ['Acute Myeloid Leukemia']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 153, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive daunorubicin IV, cytarabine IV, and venetoclax PO on study and undergo\\r\\nbone marrow aspiration and collection of blood samples on study and as clinically\\r\\nindicated.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspirate',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'ARM II (azacitidine, venetoclax)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive azacitidine IV or SC and venetoclax PO on study and undergo bone marrow\\r\\naspiration and collection of blood samples on study and as clinically indicated.',\n",
       "      'interventionNames': ['Drug: Azacitidine',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspirate',\n",
       "       'Drug: Venetoclax']},\n",
       "     {'label': 'ARM III (daunorubicin, cytarabine)',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Patients receive daunorubicin IV and cytarabine IV on study and undergo bone marrow\\r\\naspiration and collection of blood samples on study and as clinically indicated.',\n",
       "      'interventionNames': ['Procedure: Biospecimen Collection',\n",
       "       'Procedure: Bone Marrow Aspirate',\n",
       "       'Drug: Cytarabine',\n",
       "       'Drug: Daunorubicin Hydrochloride']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Azacitidine',\n",
       "      'description': 'Given IV or SC',\n",
       "      'armGroupLabels': ['ARM II (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['5 AZC',\n",
       "       '5-AC',\n",
       "       '5-Azacitidine',\n",
       "       '5-Azacytidine',\n",
       "       '5-AZC',\n",
       "       'Azacytidine',\n",
       "       'Azacytidine, 5-',\n",
       "       'Ladakamycin',\n",
       "       'Mylosar',\n",
       "       'U-18496',\n",
       "       'Vidaza']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo collection of blood samples',\n",
       "      'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'ARM II (azacitidine, venetoclax)',\n",
       "       'ARM III (daunorubicin, cytarabine)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Bone Marrow Aspirate',\n",
       "      'description': 'Undergo bone marrow aspiration',\n",
       "      'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'ARM II (azacitidine, venetoclax)',\n",
       "       'ARM III (daunorubicin, cytarabine)'],\n",
       "      'otherNames': ['BONE MARROW, LIQUID', 'Human Bone Marrow Aspirate']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Cytarabine',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'ARM III (daunorubicin, cytarabine)'],\n",
       "      'otherNames': ['.beta.-Cytosine arabinoside',\n",
       "       '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-.beta.-D-Arabinofuranosylcytosine',\n",
       "       '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone',\n",
       "       '1-Beta-D-arabinofuranosylcytosine',\n",
       "       '1.beta.-D-Arabinofuranosylcytosine',\n",
       "       '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-',\n",
       "       '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-',\n",
       "       'Alexan',\n",
       "       'Ara-C',\n",
       "       'ARA-cell',\n",
       "       'Arabine',\n",
       "       'Arabinofuranosylcytosine',\n",
       "       'Arabinosylcytosine',\n",
       "       'Aracytidine',\n",
       "       'Aracytin',\n",
       "       'Aracytine',\n",
       "       'Beta-Cytosine Arabinoside',\n",
       "       'CHX-3311',\n",
       "       'Cytarabinum',\n",
       "       'Cytarbel',\n",
       "       'Cytosar',\n",
       "       'Cytosine Arabinoside',\n",
       "       'Cytosine-.beta.-arabinoside',\n",
       "       'Cytosine-beta-arabinoside',\n",
       "       'Erpalfa',\n",
       "       'Starasid',\n",
       "       'Tarabine PFS',\n",
       "       'U 19920',\n",
       "       'U-19920',\n",
       "       'Udicil',\n",
       "       'WR-28453']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Daunorubicin Hydrochloride',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'ARM III (daunorubicin, cytarabine)'],\n",
       "      'otherNames': ['Cerubidin',\n",
       "       'Cerubidine',\n",
       "       'Cloridrato de Daunorubicina',\n",
       "       'Daunoblastin',\n",
       "       'Daunoblastina',\n",
       "       'Daunoblastine',\n",
       "       'Daunomycin Hydrochloride',\n",
       "       'Daunomycin, hydrochloride',\n",
       "       'Daunorubicin.HCl',\n",
       "       'Daunorubicini Hydrochloridum',\n",
       "       'FI-6339',\n",
       "       'Ondena',\n",
       "       'RP-13057',\n",
       "       'Rubidomycin Hydrochloride',\n",
       "       'Rubilem']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Venetoclax',\n",
       "      'description': 'Given PO',\n",
       "      'armGroupLabels': ['ARM I (daunorubicin, cytarabine, venetoclax)',\n",
       "       'ARM II (azacitidine, venetoclax)'],\n",
       "      'otherNames': ['ABT-0199',\n",
       "       'ABT-199',\n",
       "       'ABT199',\n",
       "       'GDC-0199',\n",
       "       'RG7601',\n",
       "       'Venclexta',\n",
       "       'Venclyxto']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Measurable residual disease (MRD) undetectable complete remission (CR)',\n",
       "      'description': 'Will assess after one induction cycle with or without the addition of venetoclax or two\\r\\ncycles of venetoclax and azacitidine. The MRD negative CR will be assessed using European\\r\\nLeukemiaNet (ELN) 2017 criteria [Döhner 2017]. The analysis population for the primary\\r\\noutcome will be all randomized patients with the intent to treat (ITT) population. The\\r\\nMRD undetectable CR rate will be the number of patients with MRD undetectable CR divided\\r\\nby the total number of patients. The differences of MRD undetectable CR rates between the\\r\\nexperimental groups and the control group will be estimated and the corresponding\\r\\none-sided 80% confidence limit will be calculated using Normal distribution\\r\\napproximation. MRD non-evaluable patients will be considered as MRD positive.',\n",
       "      'timeFrame': 'Up to 2 cycles (56 days)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Frequency and severity of toxicities with each of the regimens',\n",
       "      'description': \"All patients who have received at least one dose of study treatment will be included in\\r\\nthe safety analysis. Adverse events will be graded using the Common Terminology Criteria\\r\\nfor Adverse Events (CTCAE) version 5.0. The incidence of adverse events will be\\r\\nsummarized by type severity and relationship to the study drugs. A Fisher's exact test\\r\\nwill be used to compare toxicities between the two arms, if needed.\",\n",
       "      'timeFrame': 'Up to 10 years'},\n",
       "     {'measure': 'Complete remission (CR) rates',\n",
       "      'description': 'Will be assessed per 2017 ELN guidelines and will be tabulated. Exact 95% confidence\\r\\nintervals will be calculated.',\n",
       "      'timeFrame': 'Up to 2 cycles (56 days)'},\n",
       "     {'measure': 'Complete remission with incomplete count recovery (CRi)',\n",
       "      'description': 'Will be assessed with and without MRD. Will be assessed per 2017 ELN guidelines and will\\r\\nbe tabulated. Exact 95% confidence intervals will be calculated.',\n",
       "      'timeFrame': 'Up to 2 cycles (56 days)'},\n",
       "     {'measure': 'Event-free survival (EFS)',\n",
       "      'description': 'Patients not known to have any of these events are censored on the date of last contact.\\r\\nWill be described by the Kaplan-Meier estimate, and log-rank tests will be used to test\\r\\nthe difference between each experimental arms to the control arms.',\n",
       "      'timeFrame': 'From the date of randomization to the first: date of primary refractory disease; date of progressive disease; date off protocol therapy without CR or CRi; date of relapse from CR or CRi, or death from any cause, assessed up to 10 years'},\n",
       "     {'measure': 'Relapse-free survival (RFS)',\n",
       "      'description': 'Will be calculated for participants who have achieved a CR or CRi. For patients who have\\r\\nnot relapsed or died, will be censored on the date of the last disease assessment. Will\\r\\nbe described by the Kaplan-Meier estimate, and log-rank tests will be used to test the\\r\\ndifference between each experimental arms to the control arms.',\n",
       "      'timeFrame': 'From the time of CR or CRi, until the relapse from CR or CRi, or death from any cause, assessed up to 10 years'},\n",
       "     {'measure': 'Overall survival (OS)',\n",
       "      'description': 'For patients who did not die, overall survival time will be censored at the time of last\\r\\nknown alive (LKA) date. Will be described by the Kaplan-Meier estimate, and log-rank\\r\\ntests will be used to test the difference between each experimental arms to the control\\r\\narms.',\n",
       "      'timeFrame': 'From randomization to the time of death from any cause, assessed up to 10 years'},\n",
       "     {'measure': 'Responses to therapy received relative to genomic findings',\n",
       "      'description': 'Will evaluate to gain insights toward more precise patient selection for optimal\\r\\noutcomes.',\n",
       "      'timeFrame': 'Up to 10 years'}],\n",
       "    'otherOutcomes': [{'measure': 'Comparative analysis by molecular characteristics',\n",
       "      'timeFrame': 'Up to 10 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Patient must have enrolled onto MYELOMATCH and must have been given a treatment\\r\\n     assignment to MyeloMATCH to MM1YA-CTG01 based on the presence of an actionable\\r\\n     mutation as defined in MYELOMATCH\\r\\n\\r\\n  -  Participants must have been registered to master screening and re-assessment\\r\\n     protocol (myeloMATCH MSRP) prior to consenting to this study. Participants must have\\r\\n     been assigned to this clinical trial, via MATCHBox, prior to registration to this\\r\\n     study. Participants must have agreed to have specimens submitted for translational\\r\\n     medicine (MRD) and must be offered the opportunity to submit biosamples for banking\\r\\n     for future research as per the myeloMATCH MSRP\\r\\n\\r\\n       -  Note: Pre-enrollment/diagnosis labs must have already been performed under the\\r\\n          MSRP\\r\\n\\r\\n  -  Previously untreated, de novo acute myeloid leukemia (AML) defined by > 20%\\r\\n     myeloblasts in the peripheral blood or bone marrow (refer to the 2016 updated World\\r\\n     Health Organization [WHO] classification of myeloid neoplasms and acute leukemia)\\r\\n     excluding all the following categories of AML:\\r\\n\\r\\n       -  Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion\\r\\n          16(p13.1;q22), t(16;16)(p13.1;q22); CBFB-MYH11\\r\\n\\r\\n       -  CEBPA biallelic mutations\\r\\n\\r\\n       -  NPM1 mutation\\r\\n\\r\\n       -  AML with PML-RARalpha\\r\\n\\r\\n       -  AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1,\\r\\n          11q23/KMT2 rearrangements\\r\\n\\r\\n       -  AML with FLT3-ITD or FLT3-TKD mutations\\r\\n\\r\\n       -  Therapy related AML, or AML following a diagnosis of myelodysplasia or\\r\\n          myeloproliferative neoplasm Participants with central nervous system (CNS)\\r\\n          disease are eligible for this trial and will be treated according to\\r\\n          institutional guidelines with intrathecal chemotherapy for this aspect of their\\r\\n          disease\\r\\n\\r\\n  -  Age 18-59 years at time of induction therapy\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) performance status =< 3\\r\\n\\r\\n  -  Total bilirubin =< 2 x institutional upper limit of normal (ULN) (must be done\\r\\n     within 7 days of enrollment)\\r\\n\\r\\n  -  Aspartate aminotransferase (AST) (serum glutamate pyruvate transaminase [SGPT]) +/or\\r\\n     alanine aminotransferase (ALT) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 3\\r\\n     × institutional ULN (must be done within 7 days of enrollment)\\r\\n\\r\\n  -  Cardiac ejection fraction >= 50% (echocardiography or multigated acquisition scan\\r\\n     [MUGA]) (must be done within 7 days of enrollment)\\r\\n\\r\\n  -  Calculated creatinine clearance >= 30 mL/min/ 1.73m^2; Clearance to be calculated\\r\\n     using Cockcroft formula (must be done within 7 days of enrollment)\\r\\n\\r\\n  -  White blood cells (WBC) must be < 25 x 10^9/L. Hydroxyurea and leukapheresis are\\r\\n     permitted to control the WBC prior to enrollment and initiation of protocol-defined\\r\\n     therapy but must be stopped within 24 hours of initiation of protocol therapy\\r\\n\\r\\n  -  Patients with a prior or concurrent malignancy whose natural history or treatment\\r\\n     does not have the potential to interfere with the safety or efficacy assessment of\\r\\n     the investigational regimen are eligible for this trial\\r\\n\\r\\n  -  Patients with known history or current symptoms of cardiac disease, or history of\\r\\n     treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac\\r\\n     function using the New York Heart Association Functional Classification. To be\\r\\n     eligible for this trial, patients should be class 2B or better\\r\\n\\r\\n  -  Women/men of childbearing potential must have agreed to use a highly effective\\r\\n     contraceptive method while on treatment and for 6 months after stopping study drug.\\r\\n     A woman is considered to be of \"childbearing potential\" if she has had menses at any\\r\\n     time in the preceding 12 consecutive months. In addition to routine contraceptive\\r\\n     methods, \"effective contraception\" also includes heterosexual celibacy and surgery\\r\\n     intended to prevent pregnancy (or with a side-effect of pregnancy prevention)\\r\\n     defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or\\r\\n     vasectomy/vasectomized partner. However, if at any point a previously celibate\\r\\n     patient chooses to become heterosexually active during the time period for use of\\r\\n     contraceptive measures outlined in the protocol, he/she is responsible for beginning\\r\\n     contraceptive measures.\\r\\n\\r\\nWomen of childbearing potential will have a pregnancy test to determine eligibility as\\r\\npart of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if\\r\\na false-positive is suspected. Patient will be considered eligible if an ultrasound is\\r\\nnegative for pregnancy\\r\\n\\r\\n  -  Patient consent must be appropriately obtained in accordance with applicable local\\r\\n     and regulatory requirements. Each patient must sign a consent form prior to\\r\\n     enrollment in the trial to document their willingness to participate\\r\\n\\r\\n  -  Patients must be accessible for treatment, response assessment and follow up.\\r\\n     Patients enrolled on this trial must be treated and followed at the participating\\r\\n     centre. Investigators must assure themselves the patients enrolled on this trial\\r\\n     will be available for complete documentation of the treatment, adverse events, and\\r\\n     follow-up.\\r\\n\\r\\nPatients must agree to return to their primary care facility for any adverse events which\\r\\nmay occur through the course of the trial\\r\\n\\r\\n  -  In accordance with Canadian Cancer Trials Group (CCTG) policy, protocol treatment is\\r\\n     to begin within 7 working days of patient enrollment\\r\\n\\r\\n  -  Participants receiving strong or moderate CYP3A inhibitors must agree to discontinue\\r\\n     use at least 48 hours prior to start of study treatment if assigned to arm 1 or 2\\r\\n\\r\\n  -  Patients with known human immunodeficiency virus (HIV) infection who are on\\r\\n     effective anti-retroviral therapy and have undetectable viral load within 6 months\\r\\n     of enrollment are eligible for this trial\\r\\n\\r\\n  -  Participants with evidence of chronic hepatitis B virus (HBV) infection must have\\r\\n     undetectable HBV viral load within 28 days of enrollment. Patients need to be on\\r\\n     suppressive therapy, if indicated\\r\\n\\r\\n  -  Patients with a history of hepatitis C virus (HCV) infection who have been treated\\r\\n     and cured are eligible. Patients who with active HCV infection who are currently\\r\\n     being treated must have an undetectable HCV viral load within 28 days of enrollment\\r\\n     to be eligible\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Prior therapy for AML except for hydroxyurea and leukapheresis to control blood\\r\\n     counts. The use of all-trans retinoic acid (ATRA) is permitted until a diagnosis of\\r\\n     acute promyelocytic leukemia, if suspected, is ruled out\\r\\n\\r\\n  -  Patients who are receiving any other investigational agents\\r\\n\\r\\n  -  History of allergic reactions attributed to compounds of similar chemical or\\r\\n     biologic composition to cytarabine, daunorubicin, azacitidine, venetoclax\\r\\n\\r\\n  -  Pregnant women are excluded from this study because venetoclax, cytarabine and\\r\\n     azacitidine have the potential for teratogenic or abortifacient effects. Because\\r\\n     there is an unknown but potential risk for adverse events in nursing infants\\r\\n     secondary to treatment of the mother with venetoclax, cytarabine and azacitidine\\r\\n     breastfeeding should be discontinued if the mother is treated with venetoclax,\\r\\n     cytarabine and azacitidine. These potential risks may also apply to other agents\\r\\n     used in this study\\r\\n\\r\\n  -  Patients with isolated myeloid sarcoma are not eligible\\r\\n\\r\\n  -  Any other serious intercurrent illness, life threatening condition, organ system\\r\\n     dysfunction, or medical condition judged by the local investigator to compromise the\\r\\n     subject\\'s safety (for example):\\r\\n\\r\\n       -  Active, uncontrolled bacterial, fungal, or viral infection',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '59 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Mary L Savoie',\n",
       "      'affiliation': 'Canadian Cancer Trials Group',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how\\r\\nclinical trial data is shared, access the link to the NIH data sharing policy page.',\n",
       "    'url': 'https://grants.nih.gov/policy/sharing.htm'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007938',\n",
       "      'term': 'Leukemia'},\n",
       "     {'id': 'D000007951', 'term': 'Leukemia, Myeloid'},\n",
       "     {'id': 'D000015470', 'term': 'Leukemia, Myeloid, Acute'}],\n",
       "    'ancestors': [{'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000006402', 'term': 'Hematologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M10945',\n",
       "      'name': 'Leukemia',\n",
       "      'asFound': 'Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10955',\n",
       "      'name': 'Leukemia, Myeloid',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18127',\n",
       "      'name': 'Leukemia, Myeloid, Acute',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20497', 'name': 'Neoplasm, Residual', 'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9490', 'name': 'Hematologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T3995',\n",
       "      'name': 'Myeloid Leukemia',\n",
       "      'asFound': 'Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T182',\n",
       "      'name': 'Acute Myeloid Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T188',\n",
       "      'name': 'Acute Non Lymphoblastic Leukemia',\n",
       "      'asFound': 'Acute Myeloid Leukemia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC15', 'name': 'Blood and Lymph Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000003561',\n",
       "      'term': 'Cytarabine'},\n",
       "     {'id': 'D000001374', 'term': 'Azacitidine'},\n",
       "     {'id': 'C000579720', 'term': 'Venetoclax'},\n",
       "     {'id': 'D000003630', 'term': 'Daunorubicin'}],\n",
       "    'ancestors': [{'id': 'D000000964',\n",
       "      'term': 'Antimetabolites, Antineoplastic'},\n",
       "     {'id': 'D000000963', 'term': 'Antimetabolites'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000000998', 'term': 'Antiviral Agents'},\n",
       "     {'id': 'D000000890', 'term': 'Anti-Infective Agents'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000000903', 'term': 'Antibiotics, Antineoplastic'},\n",
       "     {'id': 'D000059005', 'term': 'Topoisomerase II Inhibitors'},\n",
       "     {'id': 'D000059003', 'term': 'Topoisomerase Inhibitors'}],\n",
       "    'browseLeaves': [{'id': 'M6766',\n",
       "      'name': 'Cytarabine',\n",
       "      'asFound': 'School',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M249656',\n",
       "      'name': 'Venetoclax',\n",
       "      'asFound': 'Hepatocellular Carcinoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4673',\n",
       "      'name': 'Azacitidine',\n",
       "      'asFound': 'Frequency',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6832',\n",
       "      'name': 'Daunorubicin',\n",
       "      'asFound': 'Characterized',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'},\n",
       "     {'id': 'M4314', 'name': 'Antiviral Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M4224',\n",
       "      'name': 'Antibiotics, Antitubercular',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05151211',\n",
       "    'orgStudyIdInfo': {'id': 'Gulnergiz'},\n",
       "    'organization': {'fullName': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis',\n",
       "    'officialTitle': 'Investigation of the Use of 1 Minute Sit to Stand Test to Evaluate Physical Capacity and Effort-Related Desaturation in Individuals With Amyotrophic Lateral Sclerosis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-12',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-03-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2021-11-13',\n",
       "    'studyFirstSubmitQcDate': '2021-11-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2021-12-09', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-12-05',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-12-07', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Ayse Asena Yekdaneh',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'Istanbul University - Cerrahpasa (IUC)'},\n",
       "    'leadSponsor': {'name': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of this study is to investigate the usability of the 1 Minute Sit to Stand Test\\r\\n(1 MSTS) in evaluating physical capacity and effort-related desaturation in individuals\\r\\nwith Amyotrophic Lateral Sclerosis (ALS). In this context, patients diagnosed with ALS\\r\\nwho meet the inclusion criteria will be included in the study. For the physical capacity\\r\\nassessment of patients with ALS at different ambulatory levels included in this study, a\\r\\n6 minutes walking test (6 MWT) and a 1 MSTS will be applied. Before and at the end of the\\r\\ntest, the severity of dyspnea and leg fatigue of the patients will be determined by the\\r\\nModified Borg Scale; effort-induced desaturation and heart rate by fingertip pulse\\r\\noximetry; peripheral muscle strength (for the quadriceps femoris muscle) will be\\r\\nevaluated with a hand held dynamometer. When the studies are examined, it has been\\r\\ndetermined that the 6 MWT is relatively difficult to tolerate in individuals with ALS, it\\r\\nmay be difficult to provide the necessary space and equipment for the test, and a\\r\\nshorter, easy-to-apply, and practical evaluation method that can be used instead of this\\r\\ntest in the clinic is needed. As a result of this study, the usability of the 1 MSTS in\\r\\nindividuals with ambulatory ALS in evaluating physical capacity and desaturation due to\\r\\neffort will be revealed.'},\n",
       "   'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'],\n",
       "    'keywords': ['Amyotrophic Lateral Sclerosis',\n",
       "     'Physical capacity',\n",
       "     'Desaturation',\n",
       "     'Dyspne']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'CROSS_SECTIONAL'},\n",
       "    'enrollmentInfo': {'count': 35, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Validity and Reliability Group',\n",
       "      'description': 'In order to evaluate the usability of the 1 MSTS, the validity and reliability of the\\r\\ntest will be examined. In order to determine its validity in assessing physical capacity,\\r\\nthe correlation of 1 minute sit up and 6 MWT and quadriceps muscle strength; In order to\\r\\ndetermine its validity in the evaluation of effort-induced desaturation, the correlation\\r\\nbetween the change in oxygen saturation and heart rate parameters before and after the 6\\r\\nMWT and the change before and after the 1 MSTS test will be examined. In order to\\r\\ndetermine the reliability of the 1 MSTS, a re-test will be performed and 1 MSTS will be\\r\\napplied again after 1 week and the intraclass correlation coefficient will be checked.'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'ALS Functional Rating Scale (ALSFRS)',\n",
       "      'description': 'ALSFRS, which is used to evaluate the functional status of individuals with ALS, is a\\r\\nscale consisting of 12 parameters: speech, salivation, swallowing, handwriting, feeding,\\r\\ndressing and self-care, turning and covering in bed, walking, climbing stairs, dyspnea,\\r\\northopnea and respiratory failure. And evaluated out of a total of 48 points. Each\\r\\nquestion is scored between 0 and 4 points. While the functionally normal patient gets\\r\\nfour points, the scores decrease from four depending on the functional deterioration and\\r\\nzero point is given to the worst functional condition. In this study, the functional\\r\\nlevels of the participants will be evaluated with this scale.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': '1 Minute Sit to Stand Test (1MSTS)',\n",
       "      'description': '1MSTS will be administered using an armless chair (height = 43 cm). Participants will be\\r\\nasked to sit and stand as quickly and safely as possible for one minute from the time the\\r\\ntime starts. The number of times to get out of the chair completed in one minute will be\\r\\ncounted and recorded as the test result. In this study, the functionality of the\\r\\nparticipants will be evaluated with this test.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': '6 Minutes Walking Test (6MWT)',\n",
       "      'description': 'The 6MWT is a submaximal exercise test used to evaluate aerobic capacity and endurance.\\r\\nThe distance traveled during the test is used as an outcome measure to determine physical\\r\\ncapacity. In this context, an area of 30 meters long will be determined with cones, and\\r\\nthe participants will be asked to walk the maximum distance they can walk between two\\r\\ncones for six minutes. At the end of each minute, a standardized notification will be\\r\\ngiven, reminding the remaining time and instructing to continue. After six minutes, the\\r\\ntotal distance walked will be recorded in meters. The greater the distance walked, the\\r\\ngreater the test result. In this study, the physical capacity of the participants will be\\r\\nevaluated with this test.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': 'Modified Borg Scale (MBS)',\n",
       "      'description': 'It will be used to evaluate dyspnea and lower extremity muscle fatigue of individuals\\r\\nwith ALS before and after the 6 minute walking test and 1 minute sit to stand test. MBS\\r\\nis a scale that is frequently used to evaluate the severity of dyspnea on exertion and\\r\\nseverity of dyspnea at rest. It consists of ten items describing the severity of dyspnea\\r\\naccording to their degrees.It is similarly used to determine lower extremity fatigue;\\r\\nzero indicates no fatigue in the lower extremities, while the person experiencing maximal\\r\\nfatigue gets 10 points.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': 'Heart Rate Measurement',\n",
       "      'description': 'Before and after the 6 minute walking test and 1 minute sit to stand test, heart rate of\\r\\nthe participants will be evaluated with by pulse oximetry. A pulse oximeter is a small,\\r\\nlightweight device used to monitor the amount of oxygen carried in the body and also\\r\\nheart rate. Heart rate, is the number of times the heart beats per minute. A normal\\r\\nresting heart rate should be between 60 to 100 beats per minute. Lower than 60 and higher\\r\\nthan 100 can indicate heart rate anomaly.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': 'Quadriceps Muscle Strength',\n",
       "      'description': 'Quadriceps muscle strength will be evaluated bilaterally using a hand held dynamometer.\\r\\nMeasurements were to be repeated 2 times in the manual muscle test position and with\\r\\nadequate rest intervals, with the highest value recorded in pounds (lbs). In this study,\\r\\nthe quadriceps muscle strength of the participants will be evaluated with this test.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': 'Dyspnea ALS 15 (DALS-15)',\n",
       "      'description': 'The DALS-15 is a one-dimensional scale developed to assess shortness of breath in ALS\\r\\npatients. It can be applied very quickly and easily. The questionnaire consists of 15\\r\\nquestions that the patient can easily answer on their own. The patient expresses his/her\\r\\ncondition in the last 2 weeks using a 3-point Likert scale (0=never, 1=occasionally, and\\r\\n2=often). The total score ranges from 0 (no dyspnea) to a maximum of 30 (severe dyspnea).\\r\\nThe higher the score, the greater the severity of dyspnea. In this study, the shortness\\r\\nof breath status of the participants will be evaluated with this scale.',\n",
       "      'timeFrame': 'Time Frame: Baseline'},\n",
       "     {'measure': 'Oxygen Saturation Measurement (SpO2 Measurement)',\n",
       "      'description': 'Before and after the 6 minute walking test and 1 minute sit to stand test, the SpO2 of\\r\\nthe participants will be evaluated with by pulse oximetry. A pulse oximeter is a small,\\r\\nlight weight device used to monitor the amount of oxygen carried in the body and also\\r\\nheart rate. This non invasive tool will be attached painlessly to paticipants fingertip,\\r\\nsending two wave lengths of light through the finger to measure paticipants heart rate\\r\\nand how much oxygen is in the system. An oxygen saturation level of 95 percent is\\r\\nconsidered typical for most healthy people. Lower than this percent can indicate low\\r\\nlevel of oxygen in the blood.',\n",
       "      'timeFrame': 'Time Frame: Baseline'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Diagnosed with ALS\\r\\n\\r\\n  -  18 years and over\\r\\n\\r\\n  -  Ambulatory\\r\\n\\r\\n  -  Volunteer to participate in the study\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Having a comorbidity that may affect the results of the study (orthopedic,\\r\\n     cardiopulmonary, orthopedic, psychiatric, etc.)\\r\\n\\r\\n  -  Not willing to participate in the study',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'Individuals with ALS who come to Bakırköy Psychiatric Hospital, Neurology Clinic and meet\\r\\nthe inclusion criteria',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Asena Yekdaneh, Pt., MSc.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '000000000000',\n",
       "      'email': 'asenayekdaneh@gmail.com'}],\n",
       "    'overallOfficials': [{'name': 'Gökşen KURAN ASLAN, Asst. Prof.',\n",
       "      'affiliation': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "      'role': 'STUDY_DIRECTOR'},\n",
       "     {'name': 'İrem Kurt, Pt., MSc.',\n",
       "      'affiliation': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Tuğba Akgüller, Pt., MSc.',\n",
       "      'affiliation': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Feray Güngör, Pt., MSc.',\n",
       "      'affiliation': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "     {'name': 'Nazlı Güngör, Pt., MSc.',\n",
       "      'affiliation': 'Istanbul University - Cerrahpasa (IUC)',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Istanbul University-Cerrahpasa',\n",
       "      'city': 'Istanbul',\n",
       "      'country': 'Turkey',\n",
       "      'contacts': [{'name': 'Gökşen Kuran Aslan, Asst. Prof.',\n",
       "        'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000016472',\n",
       "      'term': 'Motor Neuron Disease'},\n",
       "     {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'},\n",
       "     {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000013118', 'term': 'Spinal Cord Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'},\n",
       "     {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M15415',\n",
       "      'name': 'Sclerosis',\n",
       "      'asFound': 'Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M18879',\n",
       "      'name': 'Motor Neuron Disease',\n",
       "      'asFound': 'Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4024',\n",
       "      'name': 'Amyotrophic Lateral Sclerosis',\n",
       "      'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'},\n",
       "     {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'T349',\n",
       "      'name': 'Amyotrophic Lateral Sclerosis',\n",
       "      'asFound': 'Amyotrophic Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4699',\n",
       "      'name': 'Primary Lateral Sclerosis',\n",
       "      'asFound': 'Lateral Sclerosis',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M11982',\n",
       "      'name': 'Morphine',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06147011',\n",
       "    'orgStudyIdInfo': {'id': 'FJUH111215-2'},\n",
       "    'organization': {'fullName': 'Fu Jen Catholic University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': '3D Thyroid Education Model for Student',\n",
       "    'officialTitle': 'Development of 3D Printing High-Fidelity Thyroid Fine Needle Aspiration Exam Medical Education Model to Facilitate Student Learning and Practice'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-12',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-07-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-11-20',\n",
       "    'studyFirstSubmitQcDate': '2023-11-20',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-27', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2023-12-05',\n",
       "    'lastUpdatePostDateStruct': {'date': '2023-12-12', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Ke-Yun, Chao',\n",
       "     'investigatorTitle': 'Group leader of Respiratory Therapists',\n",
       "     'investigatorAffiliation': 'Fu Jen Catholic University'},\n",
       "    'leadSponsor': {'name': 'Fu Jen Catholic University', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of our study is to develop a high-fidelity thyroid education model, that can\\r\\nbe utilized for medical students/ PGY doctors/ residents training. This model can help\\r\\nthem better understand the structure of thyroid, learn about what are thyroid nodules,\\r\\nand practice thyroid fine needle aspiration examination with the model. The investigators\\r\\nwould also evaluate the efficacy of using this model in student teaching.',\n",
       "    'detailedDescription': \"Background： Thyroid nodular disorder is prevalent in Endocrine clinics, and while thyroid\\r\\nfine needle aspiration examination is crucial for evaluating nodules, conveying the\\r\\nprocedure to students is challenging. The investigators propose a high-fidelity 3D model\\r\\nto enhance education, especially for hands-on practice. Our study aims to assess the\\r\\nmodel's education efficacy.\\r\\n\\r\\nStudy Design： This is a prospective study.\\r\\n\\r\\nMethods： In our study, 3D scanning and 3D printing technology will be used to create the\\r\\nthyroid high-fidelity model. The investigators plan to choose 3D printing materials that\\r\\nenable the practice of thyroid fine needle aspiration produce with No.22 or No.23\\r\\nneedles.\\r\\n\\r\\nEffect： The investigators hope to assist students understand the structure of thyroid and\\r\\nthyroid nodules better. And students will be able to practice thyroid fine needle\\r\\naspiration examination with the 3D high-fidelity model. The outcome of our study may be\\r\\nutilized in medical schools or hospitals to facilitate student education.\\r\\n\\r\\nKey words： 3D printing; medical education model; high-fidelity simulation; thyroid; fine\\r\\nneedle aspiration\"},\n",
       "   'conditionsModule': {'conditions': ['Satisfaction, Personal'],\n",
       "    'keywords': ['3D printing',\n",
       "     'medical education model',\n",
       "     'high-fidelity simulation',\n",
       "     'thyroid',\n",
       "     'fine needle aspiration']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': '3D medical education model group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Received a regular learning plus 3D printing model',\n",
       "      'interventionNames': ['Other: 3D printed educational model']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': '3D printed educational model',\n",
       "      'description': 'Slide-based presention plus 3D printed thyroid fine needle aspiration model',\n",
       "      'armGroupLabels': ['3D medical education model group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Patient education effectiveness questionnaire',\n",
       "      'description': 'higher means a better outcome',\n",
       "      'timeFrame': 'immediately after the intervention'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Medical students, medical interns, PGY physicians, and resident physicians training\\r\\n     at Fu Jen Catholic University Hospital\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Refused to participate in the study',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '20 Years',\n",
       "    'maximumAge': '80 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Ke-Yun Chao, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+886905301879',\n",
       "      'email': 'C00152@mail.fjuh.fju.edu.tw'}],\n",
       "    'overallOfficials': [{'name': 'Ke-Yun Chao, PhD',\n",
       "      'affiliation': 'Fu Jen Catholic University Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Fu Jen Catholic University Hospital, Fu Jen Catholic University',\n",
       "      'city': 'New Taipei City',\n",
       "      'zip': '24352',\n",
       "      'country': 'Taiwan',\n",
       "      'geoPoint': {'lat': 25.01111, 'lon': 121.44583}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000013959',\n",
       "      'term': 'Thyroid Diseases'}],\n",
       "    'ancestors': [{'id': 'D000004700', 'term': 'Endocrine System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M16718',\n",
       "      'name': 'Thyroid Diseases',\n",
       "      'asFound': 'Thyroid',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC19',\n",
       "      'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06433505',\n",
       "    'orgStudyIdInfo': {'id': 'CA071-1005'},\n",
       "    'organization': {'fullName': 'Celgene', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants',\n",
       "    'officialTitle': 'A Phase 1, Open-label, Two-Part Study to Evaluate the Pharmacokinetics, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-23', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-09-23', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-23',\n",
       "    'studyFirstSubmitQcDate': '2024-05-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-23',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-29', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Celgene', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The objective of this study is to assess the pharmacokinetics (PK) and absolute\\r\\nbioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and\\r\\nextent of elimination, and mass balance of BMS-986365.'},\n",
       "   'conditionsModule': {'conditions': ['Healthy Volunteers'],\n",
       "    'keywords': ['BMS-986365',\n",
       "     'Pharmacokinetics',\n",
       "     'Absolute Bioavailability',\n",
       "     'Healthy Male Volunteers',\n",
       "     'CC-94676',\n",
       "     'ADME']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'SEQUENTIAL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Part A',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: BMS-986365', 'Drug: [14C] BMS-986365']},\n",
       "     {'label': 'Part B - Arm 1',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: [14C] BMS-986409 + BMS-986410']},\n",
       "     {'label': 'Part B - Arm 2',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'interventionNames': ['Drug: [14C] BMS-986410 + BMS-986409']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'BMS-986365',\n",
       "      'description': 'Specified dose on specified days',\n",
       "      'armGroupLabels': ['Part A']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': '[14C] BMS-986365',\n",
       "      'description': 'Specified dose on specified days.',\n",
       "      'armGroupLabels': ['Part A']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': '[14C] BMS-986409 + BMS-986410',\n",
       "      'description': 'Specified dose on specified days',\n",
       "      'armGroupLabels': ['Part B - Arm 1']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': '[14C] BMS-986410 + BMS-986409',\n",
       "      'description': 'Specified dose on specified days',\n",
       "      'armGroupLabels': ['Part B - Arm 2']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum observed concentration (Cmax)',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Time of maximum observed concentration (Tmax)',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC (INF))',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Apparent terminal plasma half-life (T-HALF)',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Total body clearance (CLT)',\n",
       "      'description': 'Part A',\n",
       "      'timeFrame': 'Up to Day 15'},\n",
       "     {'measure': 'Apparent total body clearance (CLT/F)',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Mean residence time (MRT)',\n",
       "      'description': 'Part A',\n",
       "      'timeFrame': 'Up to Day 15'},\n",
       "     {'measure': 'Apparent volume of distribution (Vz)',\n",
       "      'description': 'Part A',\n",
       "      'timeFrame': 'Up to Day 15'},\n",
       "     {'measure': 'Apparent volume of distribution (Vz/F)',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Absolute bioavailability (F)',\n",
       "      'description': 'Part A',\n",
       "      'timeFrame': 'Up to Day 15'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Number of participants with Adverse Events',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with Serious Adverse Events',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with AEs leading to discontinuation',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with Vital sign abnormalities',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with electrocardiogram (ECG) abnormalities',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with physical examination abnormalities',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'},\n",
       "     {'measure': 'Number of participants with clinical laboratory abnormalities',\n",
       "      'description': 'Part A and B',\n",
       "      'timeFrame': 'Up to Day 60'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Healthy male participants as determined by no clinically significant deviations from\\r\\n     normal in medical history, physical examination, 12-lead ECGs, or clinical\\r\\n     laboratory determinations, as determined by the investigator\\r\\n\\r\\n  -  Participants will require a left ventricular ejection fraction of > 50% at\\r\\n     screening.\\r\\n\\r\\n  -  Body mass index of 18.0 to 32.0 kg/m2, inclusive, at screening. Body mass index =\\r\\n     weight(kg)/(height [m])2.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Any current or recent significant acute or chronic illness.\\r\\n\\r\\n  -  Participants with a prior history of heart failure, ischemic heart diseases, serious\\r\\n     cardiac arrythmias, or prolonged QTcF interval (> 450 ms) at screening.\\r\\n\\r\\n  -  Current or recent (within 3 months of intervention administration) gastrointestinal\\r\\n     disease that could affect the absorption of study drug including cholecystectomy.\\r\\n     Mild gastroesophageal reflux (even if managed with avoidance of food triggers) is\\r\\n     exclusionary.\\r\\n\\r\\n  -  History of allergy to BMS-986365 or related compounds.\\r\\n\\r\\nOther protocol-defined Inclusion/Exclusion criteria apply.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'MALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '60 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'BMS Study Connect Contact Center www.BMSStudyConnect.com',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '855-907-3286',\n",
       "      'email': 'Clinical.Trials@bms.com'},\n",
       "     {'name': 'First line of the email MUST contain the NCT# and Site #.',\n",
       "      'role': 'CONTACT'}],\n",
       "    'overallOfficials': [{'name': 'Bristol-Myers Squibb',\n",
       "      'affiliation': 'Bristol-Myers Squibb',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Local Institution - 0001',\n",
       "      'city': 'Madison',\n",
       "      'state': 'Wisconsin',\n",
       "      'zip': '53704',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site 0001', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 43.07305, 'lon': -89.40123}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'BMS Clinical Trial Information',\n",
       "      'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html'},\n",
       "     {'label': 'BMS Clinical Trial Patient Recruiting',\n",
       "      'url': 'https://www.BMSStudyConnect.com'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06290128',\n",
       "    'orgStudyIdInfo': {'id': 'EFC17236'},\n",
       "    'secondaryIdInfos': [{'id': 'U1111-1295-5755',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'ICTRP'},\n",
       "     {'id': '2023-506503-26', 'type': 'REGISTRY', 'domain': 'CTIS'}],\n",
       "    'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work',\n",
       "    'officialTitle': 'A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "    'acronym': 'MOBILIZE'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-02-03', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-10-12', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-02-26',\n",
       "    'studyFirstSubmitQcDate': '2024-02-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-04', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-01', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in\\r\\nadult participants with CIDP whose disease is refractory to standard of care. The study\\r\\nduration will be for a maximum of 109 weeks including screening, treatment phases, and\\r\\nfollow-up.'},\n",
       "   'conditionsModule': {'conditions': ['Chronic Inflammatory Demyelinating Polyradiculoneuropathy',\n",
       "     'Polyneuropathy, Inflammatory Demyelinating, Chronic'],\n",
       "    'keywords': ['Autoimmune Diseases, Neurologic',\n",
       "     'Autoimmune Disorders, Nervous System',\n",
       "     'Peripheral Nerves Disease',\n",
       "     'Nervous System Diseases',\n",
       "     'Neurologic Disorders',\n",
       "     'Neurological Disorders',\n",
       "     'Complement Inhibitor',\n",
       "     'Complement Inhibitors']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'This is a double-blind treatment in part A and open-label treatment in Part B.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 140, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Riliprubart Arm',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24\\r\\nweeks',\n",
       "      'interventionNames': ['Drug: Riliprubart', 'Drug: Placebo']},\n",
       "     {'label': 'Placebo Arm',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Placebo for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks',\n",
       "      'interventionNames': ['Drug: Riliprubart', 'Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Riliprubart',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:IV Infusion',\n",
       "      'armGroupLabels': ['Placebo Arm', 'Riliprubart Arm'],\n",
       "      'otherNames': ['SAR445088']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:IV Infusion',\n",
       "      'armGroupLabels': ['Placebo Arm', 'Riliprubart Arm']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Riliprubart',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:SC Injection',\n",
       "      'armGroupLabels': ['Placebo Arm', 'Riliprubart Arm'],\n",
       "      'otherNames': ['SAR445088']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Pharmaceutical form:Solution-Route of administration:SC Injection',\n",
       "      'armGroupLabels': ['Placebo Arm', 'Riliprubart Arm']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of participants refractory to standard of care (SOC) experiencing a response',\n",
       "      'description': 'A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT\\r\\ndisability score at Week 24.',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Percentage of participants randomized to riliprubart with lasting response',\n",
       "      'description': 'Lasting response is defined as no increase in adjusted INCAT disability score after\\r\\nexperiencing a response in the first 24 weeks.',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to placebo who experience a response',\n",
       "      'description': 'A response is defined as a decrease of ≥1 point in adjusted INCAT disability score from\\r\\nWeek 24 to Week 48.',\n",
       "      'timeFrame': 'Week 24 to week 48'},\n",
       "     {'measure': 'Percentage of participants randomized to riliprubart who experience a response',\n",
       "      'description': 'A response is defined as a decrease of ≥1 point in adjusted INCAT disability score\\r\\nwithout prior response in first 24 weeks, from Week 24 to Week 48.',\n",
       "      'timeFrame': 'Week 24 to week 48'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Change from baseline in Inflammatory Raschbuilt Overall Disability Scale (IRODS) score',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in adjusted inflammatory neuropathy cause and treatment (INCAT) disability score',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in grip strength (kilopascals; dominant hand)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in Medical Research Council Sum Score (MRCSS)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Percentage of participants refractory to immunoglobulins experiencing a response',\n",
       "      'description': 'A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT\\r\\ndisability score at Week 24',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in the EuroQol 5 Dimension, 5Level Health Scale (EQ5D5L)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Change from baseline in the Rasch-built modified fatigue severity scale (RT-FSS)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Number of participants with treatmentemergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Incidence and titer of anti-riliprubart antibodies (ADA)',\n",
       "      'timeFrame': 'Baseline to week 24'},\n",
       "     {'measure': 'Number of participants with TEAEs, including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)',\n",
       "      'timeFrame': 'Week 24 to week 109'},\n",
       "     {'measure': 'Incidence and titer of anti-riliprubart antibodies',\n",
       "      'timeFrame': 'Week 24 to week 109'},\n",
       "     {'measure': 'Change from baseline in I RODS score',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in adjusted INCAT score',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in grip strength (kilopascals; dominant hand)',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in MRC-SS',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in EQ-5D-5L score',\n",
       "      'timeFrame': 'Baseline to week 48'},\n",
       "     {'measure': 'Change from baseline in RT-FSS',\n",
       "      'timeFrame': 'Baseline to week 48'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\nParticipants are eligible to be included in the study only if all of the following\\r\\ncriteria apply:\\r\\n\\r\\n  -  Participant must have CIDP or possible CIDP criteria, based on European Academy of\\r\\n     Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second\\r\\n     revision (2021).\\r\\n\\r\\n  -  Participant must have either typical CIDP, or one of the following two CIDP\\r\\n     variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome).\\r\\n     Diagnosis must be confirmed by the adjudication committee.\\r\\n\\r\\n  -  Participant must be refractory to either immunoglobulin therapy or corticosteroid\\r\\n     therapy, as defined below.\\r\\n\\r\\n       -  Immunoglobulinrefractory subgroup: Historic evidence of failure or inadequate\\r\\n          response to immunoglobulin therapy prior to screening, defined as no clinically\\r\\n          meaningful improvement or persistent INCAT score ≥2 after a minimum of:\\r\\n\\r\\n            -  One dose of IVIg of 2 g/kg, followed by a second dose of 2 g/kg or two\\r\\n               doses of 1 g/kg, with a separation of approximately 3 weeks between doses\\r\\n               (each dose can be divided over 2 to 5 days), as indicated in the EAN/PNS\\r\\n               2021 guidelines OR\\r\\n\\r\\n            -  SCIg maintenance therapy with at least 0.2 g/kg weekly for 5 weeks\\r\\n\\r\\n       -  Corticosteroidrefractory subgroup:\\r\\n\\r\\nHistoric evidence of failure or inadequate response to corticosteroid therapy prior to\\r\\nscreening, defined as no clinically meaningful improvement or persistent INCAT score ≥2\\r\\nafter a minimum of 12 weeks of corticosteroid therapy. Corticosteroid regimen can be\\r\\ndaily oral prednisone/prednisolone, at least 60 mg, equivalent to methylprednisolone 48\\r\\nmg, tapered over 6 to 8 months, or alternative regimens, e.g. pulsed high-dose\\r\\ncorticosteroid treatment (40 mg/day oral dexamethasone or 500 mg/day IV\\r\\nmethylprednisolone, each daily for 4 days per month for 6 months), as indicated in the\\r\\nEAN/PNS 2021 guidelines A clinically meaningful improvement is defined as one or more of\\r\\nthe following:\\r\\n\\r\\n  -  A ≥1 point decrease in adjusted INCAT disability score\\r\\n\\r\\n  -  An increase in IRODS total score ≥4 points\\r\\n\\r\\n  -  An increase in MRC Sum score ≥3 points\\r\\n\\r\\n  -  An improvement in hand grip strength of ≥8 kilopascals or\\r\\n\\r\\n  -  Equivalent improvement based on information from medical records and per the\\r\\n     Investigator's judgment\\r\\n\\r\\n     -Participant has an adjusted INCAT score of 2 to 9\\r\\n\\r\\n       -  (a score of 2 should be exclusively from the leg disability component of\\r\\n          INCAT).\\r\\n\\r\\n            -  Any allowed immunosuppressant drugs (azathioprine, cyclosporine, or\\r\\n               mycophenolate mofetil) have been taken for ≥6 months at a stable dose for\\r\\n               ≥3 months prior to Screening\\r\\n\\r\\n            -  Participant may be receiving low-dose oral corticosteroids (≤20 mg/day of\\r\\n               prednisone [or equivalent dose for other oral corticosteroids]), but only\\r\\n               if taken at a stable dose for ≥3 months prior to Screening\\r\\n\\r\\n            -  Participant must have active disease, defined by a CIDP disease activity\\r\\n               score (CDAS) of ≥ 2 points at Screening\\r\\n\\r\\n            -  Participant must have documented vaccinations against encapsulated\\r\\n               bacterial pathogens given within 5 years of screening or initiated a\\r\\n               minimum of 14 days prior to first dose of study intervention\\r\\n\\r\\n            -  All participants must agree to use contraception methods during and after\\r\\n               the study as required.\\r\\n\\r\\n            -  Contraceptive use by men and women participating in the study should be\\r\\n               consistent with local regulations regarding the methods of contraception\\r\\n               for those participating in clinical studies.\\r\\n\\r\\n       -  Male participants are eligible to participate if they agree to the following\\r\\n          during the study intervention period and for at least 55 weeks after the last\\r\\n          dose of study medication:\\r\\n\\r\\n  -  Refrain from donating or cryopreserving sperm PLUS\\r\\n\\r\\n  -  Be abstinent from heterosexual intercourse as their preferred and usual lifestyle\\r\\n     (abstinent on a long term and persistent basis) and agree to remain abstinent OR\\r\\n\\r\\n  -  Must agree to use contraception/barrier as detailed below:\\r\\n\\r\\n     ---- A male condom and an additional highly effective contraceptive method as\\r\\n     described in the protocol.\\r\\n\\r\\n     -- A female participant is eligible to participate if she is not pregnant or\\r\\n     breastfeeding, and one of the following conditions applies:\\r\\n\\r\\n  -  Is a woman of nonchildbearing potential (WONCBP) as defined by the protocol OR\\r\\n\\r\\n  -  Is a woman of childbearing potential (WOCBP) and agrees to use a contraceptive\\r\\n     method that is highly effective (with a failure rate of <1% per year), preferably\\r\\n     with low user dependency, as described in Appendix 10.4 Contraception and barrier\\r\\n     guidance during the study intervention period (to be effective before starting the\\r\\n     intervention) and for at least 55 weeks after the last administration of study\\r\\n     intervention and agrees not to donate or cryopreserve eggs (ova, oocytes) for the\\r\\n     purpose of reproduction during this period.\\r\\n\\r\\nExclusion Criteria: Participants are excluded from the study if any of the following\\r\\ncriteria apply:\\r\\n\\r\\n  -  Polyneuropathy of other causes, including but not limited to: hereditary\\r\\n     demyelinating neuropathies, neuropathies secondary to infection or systemic disease,\\r\\n     diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor\\r\\n     neuropathy, polyneuropathy related to Immunoglobulin M (IgM) monoclonal gammopathy,\\r\\n     POEMS syndrome, and lumbosacral radiculoplexus neuropathy.\\r\\n\\r\\n  -  Sensory CIDP, Distal CIDP and focal CIDP variants.\\r\\n\\r\\n  -  Any other neurological or systemic disease that can cause symptoms and signs\\r\\n     interfering with treatment or outcome assessments\\r\\n\\r\\n  -  Poorly controlled diabetes (HbA1c >7%)\\r\\n\\r\\n  -  Serious infections requiring hospitalization within 30 days prior to Screening and\\r\\n     any active infection requiring treatment during screening or presence of a condition\\r\\n     that may predispose the participant to increased risk of infection (eg, medical\\r\\n     history such as known immunodeficiency or history of recurrent infections)\\r\\n\\r\\n  -  Clinical diagnosis of Systemic Lupus Erythematosus (SLE)\\r\\n\\r\\n  -  Sensitivity to any of the study interventions, or components thereof, or drug or\\r\\n     other allergy that, in the opinion of the Investigator, contraindicates\\r\\n     participation in the study. Specifically, history of any hypersensitivity reaction\\r\\n     to riliprubart or its components or of a severe allergic or anaphylactic reaction to\\r\\n     any humanized or murine monoclonal antibody.\\r\\n\\r\\n  -  Any other clinically meaningful medical history or ongoing medical condition (as\\r\\n     determined by the Investigator at Screening) that might impact benefitrisk\\r\\n     assessment, jeopardize the safety of the participant, or compromise the quality of\\r\\n     the data collected in this study; or history or presence of other significant\\r\\n     concomitant illness that would adversely affect participation in this study, per\\r\\n     Investigator's judgment.\\r\\n\\r\\n  -  Documented history of attempted suicide over the 6 months prior to the Screening\\r\\n     visit, presence of suicidal ideation of category 4 or 5 on CSSRS during screening,\\r\\n     OR if in the Investigator's judgment, the participant is at risk for a suicide\\r\\n     attempt.\\r\\n\\r\\n  -  Evidence of CIDP worsening within the 6 weeks following a prior vaccination that, in\\r\\n     the opinion of the Investigator, constituted a relapse\\r\\n\\r\\n  -  Recent or planned major surgery that could confound the results of the trial or put\\r\\n     the participant at undue risk\\r\\n\\r\\n  -  Participant has received immunoglobulins (IVIg or SCIg) within 8 weeks prior to\\r\\n     Screening\\r\\n\\r\\n  -  Treatment with plasma exchange within the 8 weeks prior to Screening\\r\\n\\r\\n  -  Prior treatment with riliprubart\\r\\n\\r\\n  -  Prior treatment with (any time) with highly immunosuppressive/chemotherapeutic\\r\\n     medications with sustained effects, eg, mitoxantrone, alemtuzumab, cladribine\\r\\n\\r\\n  -  Prior treatment (any time) with total lymphoid irradiation or bone marrow\\r\\n     transplantation\\r\\n\\r\\n  -  Prior treatment with Bcelldepleting agents such as rituximab within 6 months prior\\r\\n     to riliprubart dosing, or before Bcell counts return to normal levels, whichever is\\r\\n     longer\\r\\n\\r\\n  -  Use of any specific complement system inhibitor (eg, eculizumab) within 12 weeks or\\r\\n     5 times the halflife of the product, whichever is longer, prior to Screening\\r\\n\\r\\n  -  Treatment within 6 months prior to dosing with immunosuppressive/ chemotherapeutic\\r\\n     medications, such as cyclophosphamide, methotrexate, tacrolimus, interferon, or\\r\\n     tumor necrosis factor (TNF)α inhibitors. Certain immunosuppressants commonly used in\\r\\n     CIDP (azathioprine, cyclosporine, or mycophenolate mofetil) are allowed, as\\r\\n     indicated under inclusion criterion.\\r\\n\\r\\n  -  Any vaccination received within 28 days prior to dosing (with few exceptions to be\\r\\n     confirmed at screening)\\r\\n\\r\\n  -  Participation in another clinical trial with an investigational drug or receipt of\\r\\n     an investigational product within 12 weeks or 5 times the halflife of the product,\\r\\n     whichever is longer, prior to Screening\\r\\n\\r\\n  -  Any screening laboratory values outside normal limits or abnormal ECG considered in\\r\\n     the Investigator's judgment to be clinically significant in the context of this\\r\\n     trial.\\r\\n\\r\\n  -  Positive result of any of the following tests:\\r\\n\\r\\n       -  hepatitis B surface antigen (HBsAg)\\r\\n\\r\\n       -  antihepatitis B core antibodies (anti-HBc Ab) (unless anti-hepatitis B surface\\r\\n          antibodies [antiHBs Ab] are also positive, indicating natural immunity)\\r\\n\\r\\n       -  antihepatitis C virus (antiHCV) antibodies\\r\\n\\r\\n       -  antihuman immunodeficiency virus 1 and 2 (antiHIV1 and antiHIV2) antibodies\\r\\n\\r\\n  -  Pregnancy, defined as a positive result of a highly sensitive urine or serum\\r\\n     pregnancy test, or lactation\\r\\n\\r\\n  -  Accommodation in an institution because of regulatory or legal order; eg, imprisoned\\r\\n     or legally institutionalized\\r\\n\\r\\n  -  Participant not suitable for participation, whatever the reason, as judged by the\\r\\n     Investigator, including medical or clinical conditions, or potential risk for\\r\\n     noncompliance to study procedures\\r\\n\\r\\n  -  Participants are employees at the clinical study site or other individuals directly\\r\\n     involved in the conduct of the study, or immediate family member of such individuals\\r\\n\\r\\n  -  Any country related specific regulation that would prevent the participant from\\r\\n     entering the study\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Trial Transparency email recommended (Toll free for US & Canada)',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '800-633-1610',\n",
       "      'phoneExt': 'option 6',\n",
       "      'email': 'Contact-US@sanofi.com'}],\n",
       "    'locations': [{'facility': 'Alabama Neurology Associates Site Number : 8400019',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Birmingham',\n",
       "      'state': 'Alabama',\n",
       "      'zip': '35209',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Qualified researchers may request access to patient level data and related study\\r\\ndocuments including the clinical study report, study protocol with any amendments, blank\\r\\ncase report form, statistical analysis plan, and dataset specifications. Patient level\\r\\ndata will be anonymized and study documents will be redacted to protect the privacy of\\r\\ntrial participants. Further details on Sanofi's data sharing criteria, eligible studies,\\r\\nand process for requesting access can be found at: https://vivli.org\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000011115',\n",
       "      'term': 'Polyneuropathies'},\n",
       "     {'id': 'D000020277',\n",
       "      'term': 'Polyradiculoneuropathy, Chronic Inflammatory Demyelinating'},\n",
       "     {'id': 'D000011129', 'term': 'Polyradiculoneuropathy'}],\n",
       "    'ancestors': [{'id': 'D000010523',\n",
       "      'term': 'Peripheral Nervous System Diseases'},\n",
       "     {'id': 'D000009468', 'term': 'Neuromuscular Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000020274', 'term': 'Autoimmune Diseases of the Nervous System'},\n",
       "     {'id': 'D000003711', 'term': 'Demyelinating Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M4629',\n",
       "      'name': 'Autoimmune Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M13432',\n",
       "      'name': 'Peripheral Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M13999',\n",
       "      'name': 'Polyneuropathies',\n",
       "      'asFound': 'Polyneuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M14013',\n",
       "      'name': 'Polyradiculoneuropathy',\n",
       "      'asFound': 'Polyradiculoneuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M22097',\n",
       "      'name': 'Polyradiculoneuropathy, Chronic Inflammatory Demyelinating',\n",
       "      'asFound': 'Chronic Inflammatory Demyelinating Polyradiculoneuropathy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M22094',\n",
       "      'name': 'Autoimmune Diseases of the Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6909', 'name': 'Demyelinating Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'asFound': 'Chronic',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1306',\n",
       "      'name': 'Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "      'asFound': 'Chronic Inflammatory Demyelinating Polyneuropathy',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M21860',\n",
       "      'name': 'Pharmaceutical Solutions',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M6392',\n",
       "      'name': 'Complement System Proteins',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06436547',\n",
       "    'orgStudyIdInfo': {'id': '2024-112-002'},\n",
       "    'organization': {'fullName': 'Xuanwu Hospital, Beijing', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)',\n",
       "    'officialTitle': 'The Efficacy and Safety of Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Bilateral Hippocampal Sclerosis: A Prospective, Single-Arm Trial'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-07-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-07-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-24',\n",
       "    'studyFirstSubmitQcDate': '2024-05-30',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-30',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Liankun_Ren',\n",
       "     'investigatorTitle': 'Professor',\n",
       "     'investigatorAffiliation': 'Xuanwu Hospital, Beijing'},\n",
       "    'leadSponsor': {'name': 'Xuanwu Hospital, Beijing', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The primary objective of this research is to study the efficacy and safety of deep brain\\r\\nstimulation (DBS) of Subiculum as adjunctive therapy for reducing the frequency of\\r\\nseizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis',\n",
       "    'detailedDescription': 'This project aims to include 6 participants, and evaluate the effectiveness and safety of\\r\\nbilateral hippocampal subcortical stimulation in patients with temporal lobe epilepsy and\\r\\nbilateral hippocampal sclerosis through A prospective, interventional, unblinded,\\r\\nsingle-arm clinical trial. It is expected to provide new therapeutic options for patients\\r\\nwith temporal lobe epilepsy and bilateral hippocampal sclerosis with alternative\\r\\ntreatment options.'},\n",
       "   'conditionsModule': {'conditions': ['Epilepsy, Drug Resistant'],\n",
       "    'keywords': ['Deep Brain Stimulation',\n",
       "     'Drug Resistant Epilepsy',\n",
       "     'Subiculum',\n",
       "     'Temporal lobe epilepsy with bilateral hippocampal sclerosis',\n",
       "     'neuromodulation']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 6, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'subiculum-DBS group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'participants will undergo subiculum-DBS ON with the individual stimulation parameters\\r\\ndetermined in the parameter determination period, then continue to receive stimulation\\r\\nfor the remainder of the study.',\n",
       "      'interventionNames': ['Device: Subiculum-DBS ON']}],\n",
       "    'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'Subiculum-DBS ON',\n",
       "      'description': 'The surgical intervention named deep brain stimulation is a well-established\\r\\nneurosurgical treatment for drug-resistant epilepsy.The targets used in this study are\\r\\nbiliteral subiculum.The devices used for intervention have been approved by Chinese\\r\\nNational Medical Products Administration (CFDA). The postoperative drug dosage adjustment\\r\\ndepends on the efficacy of DBS and the judgment of the epilepsy specialist.',\n",
       "      'armGroupLabels': ['subiculum-DBS group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Seizure frequency (SF28)',\n",
       "      'description': 'Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28\\r\\nis calculated as follows, where D=total number of days for which seizure information is\\r\\ncollected for the specific 28-day interval:\\r\\n\\r\\nSF28=(Total number of seizures in D days/D)*28. In addition, the baseline seizure\\r\\nfrequency is defined as mean of 3-month SF28 in the baseline period. The seizure\\r\\nfrequency in double-blind phase is defined as SF28 per month during the double-blind\\r\\nperiod. Percent change in seizure frequency=100*(double-blind SF28-baseline\\r\\nSF28)/baseline SF28.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Seizure Responder Rate',\n",
       "      'description': 'The proportion of patients with a ≥ 50% reduction from Baseline in seizure frequency.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'},\n",
       "     {'measure': 'Life quality evaluation',\n",
       "      'description': 'Percentage change from baseline in Quality of Life in Epilepsy-31 inventory (QOLIE-31)\\r\\nscore.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'},\n",
       "     {'measure': 'Cognitive function evaluation (MMSE)',\n",
       "      'description': 'Percentage change from baseline in Mini-Mental State Examination (MMSE) score.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'},\n",
       "     {'measure': 'Cognitive function evaluation (MoCA)',\n",
       "      'description': 'Percentage change from baseline in Montreal Cognitive Assessment (MoCA) score.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'},\n",
       "     {'measure': 'Adverse Events',\n",
       "      'description': 'Rate of adverse events which were judged to be study-related throughout the study.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'},\n",
       "     {'measure': 'Incidence of Sudden Unexpected Death in Epilepsy (SUDEP)',\n",
       "      'description': 'The number presented is for Definite and Probable SUDEP. The rate is calculated per 1000\\r\\nsubject years of follow-up.',\n",
       "      'timeFrame': 'Up to 1 year after subculum-DBS'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Participants are between the ages of 14 -65 years of age\\r\\n\\r\\n  -  Refractory to anti-seizure medications (ASMs).\\r\\n\\r\\n  -  After comprehensive preoperative evaluation, patients who are considered unsuitable\\r\\n     for or refuse resection surgery, or those for whom the effects of epileptic focus\\r\\n     resection and thermocoagulation surgery are not satisfactory.\\r\\n\\r\\n  -  Participants must have had a non-invasive video-EEG monitoring revealing seizure\\r\\n     semiology and ictal EEG consistent with bilateral Temporal Lobe Epilepsy\\r\\n\\r\\n  -  Biliteral hippocampal atrophy on MRI T1 imaging with increased ipsilateral mesial\\r\\n     signal on T2 imaging\\r\\n\\r\\n  -  Informed consent signed.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;\\r\\n\\r\\n  -  Psychogenic non-epileptic seizures within 12 months;\\r\\n\\r\\n  -  Presence of implanted electrical stimulation medical device anywhere in the body\\r\\n     (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any\\r\\n     metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal\\r\\n     nerve stimulators are allowed if the parameter remains stable for at least 3 months\\r\\n     prior to the screening visit;\\r\\n\\r\\n  -  Risk factors that would put the participant at risk for intraoperative or\\r\\n     postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for\\r\\n     chronic anticoagulation or antiplatelet aggregation medications;\\r\\n\\r\\n  -  IQ < 55 or severe cognitive dysfunction, unable to complete the study;\\r\\n\\r\\n  -  Diagnosed with a progressive neurological disorder (including progressive\\r\\n     Rasmussen's encephalitis, etc.);\\r\\n\\r\\n  -  Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression\\r\\n     (admission to a psychiatric specialty/hospital within 5 years or any suicidal or\\r\\n     self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\\r\\n\\r\\n  -  Diagnosed with other serious physical disorders, internal diseases or severe\\r\\n     abnormalities in liver or kidney function;\\r\\n\\r\\n  -  Pregnant, or planning to pregnant within 2 years;\\r\\n\\r\\n  -  Participation in another clinical study within 3 months;\\r\\n\\r\\n  -  Not suitable for enrollment as assessed by the multidisciplinary team of the center.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '14 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Liankun Ren, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 13681576621',\n",
       "      'email': 'renlk2022@outlook.com'}],\n",
       "    'overallOfficials': [{'name': 'Liankun Ren, MD',\n",
       "      'affiliation': 'Xuanwu Hospital, Beijing',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Xuanwu Hospital,Capital Medical University',\n",
       "      'city': 'Beijing',\n",
       "      'state': 'Beijing',\n",
       "      'zip': '100053',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Liankun Ren, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+86 13681576621',\n",
       "        'email': 'renlk2022@outlook.com'},\n",
       "       {'name': 'Liankun Ren, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000004827',\n",
       "      'term': 'Epilepsy'},\n",
       "     {'id': 'D000004833', 'term': 'Epilepsy, Temporal Lobe'},\n",
       "     {'id': 'D000092223', 'term': 'Hippocampal Sclerosis'},\n",
       "     {'id': 'D000069279', 'term': 'Drug Resistant Epilepsy'},\n",
       "     {'id': 'D000012598', 'term': 'Sclerosis'}],\n",
       "    'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000004828', 'term': 'Epilepsies, Partial'},\n",
       "     {'id': 'D000073376', 'term': 'Epileptic Syndromes'},\n",
       "     {'id': 'D000065703',\n",
       "      'term': 'Malformations of Cortical Development, Group I'},\n",
       "     {'id': 'D000054220', 'term': 'Malformations of Cortical Development'},\n",
       "     {'id': 'D000009421', 'term': 'Nervous System Malformations'},\n",
       "     {'id': 'D000000013', 'term': 'Congenital Abnormalities'}],\n",
       "    'browseLeaves': [{'id': 'M7983',\n",
       "      'name': 'Epilepsy',\n",
       "      'asFound': 'Epilepsy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7989',\n",
       "      'name': 'Epilepsy, Temporal Lobe',\n",
       "      'asFound': 'Temporal Lobe Epilepsy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M2908',\n",
       "      'name': 'Hippocampal Sclerosis',\n",
       "      'asFound': 'Hippocampal Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M369',\n",
       "      'name': 'Drug Resistant Epilepsy',\n",
       "      'asFound': 'Epilepsy, Drug Resistant',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M15415',\n",
       "      'name': 'Sclerosis',\n",
       "      'asFound': 'Sclerosis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7984', 'name': 'Epilepsies, Partial', 'relevance': 'LOW'},\n",
       "     {'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'},\n",
       "     {'id': 'M1165', 'name': 'Epileptic Syndromes', 'relevance': 'LOW'},\n",
       "     {'id': 'M12', 'name': 'Congenital Abnormalities', 'relevance': 'LOW'},\n",
       "     {'id': 'M27589',\n",
       "      'name': 'Malformations of Cortical Development',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12365',\n",
       "      'name': 'Nervous System Malformations',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06363851',\n",
       "    'orgStudyIdInfo': {'id': 'Kylo-11-I-C01'},\n",
       "    'organization': {'fullName': 'Kylonova (Xiamen) Biopharma co., LTD.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Single-ascending Dose Study of Kylo-11 in Healthy Subjects',\n",
       "    'officialTitle': 'A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-11 in Healthy Subjects'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-11-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-09',\n",
       "    'studyFirstSubmitQcDate': '2024-04-09',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Kylonova (Xiamen) Biopharma co., LTD.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending\\r\\ndose study in healthy volunteers. Kylo-11 will be evaluated in approximately 60 subjects\\r\\nto assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.'},\n",
       "   'conditionsModule': {'conditions': ['Cardiovascular Diseases']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'TRIPLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Kylo-11',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Single ascending doses of Kylo-11 administered subcutaneously (SC).',\n",
       "      'interventionNames': ['Drug: Kylo-11']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Administered SC.',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Kylo-11',\n",
       "      'description': 'Administered SC.',\n",
       "      'armGroupLabels': ['Kylo-11']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Administered SC.',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of adverse events',\n",
       "      'timeFrame': 'up to Week 24'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of adverse events',\n",
       "      'timeFrame': 'up to week 48'},\n",
       "     {'measure': 'Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax)',\n",
       "      'timeFrame': 'up to Week 48'},\n",
       "     {'measure': 'PK parameter of time of maximum observed concentration (Tmax)',\n",
       "      'timeFrame': 'up to Week 48'},\n",
       "     {'measure': 'PK parameter of area under the concentration time curve (AUC)',\n",
       "      'timeFrame': 'up to Week 48'},\n",
       "     {'measure': 'Change in serum Lp(a) over time',\n",
       "      'timeFrame': 'up to Week 48'},\n",
       "     {'measure': 'Percent change in serum Lp(a) over time',\n",
       "      'timeFrame': 'up to Week 48'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Men and women aged 18 to 55 years old, inclusive;\\r\\n\\r\\n  -  Body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive;\\r\\n\\r\\n  -  Protocol-defined elevated serum Lp(a) level;\\r\\n\\r\\n  -  Female subjects must not be able to get pregnant and male subjects must agree to\\r\\n     adhere to contraception restrictions;\\r\\n\\r\\n  -  Willing to comply with protocol required visits and assessments, and provide written\\r\\n     informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  History or evidence of a clinically significant disorder, condition or disease;\\r\\n\\r\\n  -  Received an investigational drug, vaccine or device within 3 months before dosing;\\r\\n\\r\\n  -  History of evidence of malignant tumor or Gilbert syndrome;\\r\\n\\r\\n  -  Positive screen of Hepatitis B surface antigen, hepatitis C virus, human\\r\\n     immunodeficiency virus or syphilis infection;\\r\\n\\r\\n  -  History of alcohol abuse within 12 months before dosing;\\r\\n\\r\\n  -  History of drug abuse within 3 months before screening;\\r\\n\\r\\n  -  History of blood donations or blood loss of 400 ml and more within 3 months before\\r\\n     dosing;\\r\\n\\r\\n  -  History of stroke or myocardial infarction within 6 months before sceening;\\r\\n\\r\\n  -  Pregnant or breast-feeding women;\\r\\n\\r\\n  -  Other exclusion criteria applied per protocol.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '55 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Qinsheng Zhang',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86-021-58217380',\n",
       "      'email': 'zhangqsh@hygieiapharma.com'}],\n",
       "    'locations': [{'facility': 'Chengdu Xinhua Hospital',\n",
       "      'city': 'Chengdu',\n",
       "      'state': 'Sichuan',\n",
       "      'zip': '610000',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Xiaolan Yong', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000002318',\n",
       "      'term': 'Cardiovascular Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06413147',\n",
       "    'orgStudyIdInfo': {'id': 'yinchunlin_PFO safety'},\n",
       "    'organization': {'fullName': 'Xuanwu Hospital, Beijing', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Long-term Procedural and Device Related Complications of PFO Closure',\n",
       "    'officialTitle': 'Long-term Procedural and Device Related Complications of PFO Closure'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2029-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-08',\n",
       "    'studyFirstSubmitQcDate': '2024-05-13',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-14', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'yinchunlin',\n",
       "     'investigatorTitle': 'Xuanwu Hospital, Capital Medical University',\n",
       "     'investigatorAffiliation': 'Xuanwu Hospital, Beijing'},\n",
       "    'leadSponsor': {'name': 'Xuanwu Hospital, Beijing', 'class': 'OTHER'}},\n",
       "   'descriptionModule': {'briefSummary': 'We aimed to explore: (1）long-term complications of PFO closure; (2) antiplate or\\r\\nanticoagulation use after PFO closure.'},\n",
       "   'conditionsModule': {'conditions': ['Patent Foramen Ovale']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'interventions': [{'type': 'DEVICE',\n",
       "      'name': 'PFO closure',\n",
       "      'description': 'Surgery of PFO closure'}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'ischemic stroke, Hemorrhagic stroke or transient ischemic attack',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'}],\n",
       "    'secondaryOutcomes': [{'measure': 'atrial fibrillation',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'},\n",
       "     {'measure': 'Hemorrhage related to the use of antithrombotic drugs',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'},\n",
       "     {'measure': 'residual leaks',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'},\n",
       "     {'measure': 'death',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'},\n",
       "     {'measure': 'open-heart surgery',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'},\n",
       "     {'measure': 'Other severe events related to PFO closure',\n",
       "      'timeFrame': '1 month, 6 months, 1 year, 3 years, 5 years'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  All patients who underwent PFO closure\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Unable to complete or adhere to the study',\n",
       "    'sex': 'ALL',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'All patients who underwent PFO closure and willing to participate in this study.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Chunlin Yin',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '13552566227',\n",
       "      'email': 'yinclmail@163.com'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000054092',\n",
       "      'term': 'Foramen Ovale, Patent'}],\n",
       "    'ancestors': [{'id': 'D000006344', 'term': 'Heart Septal Defects, Atrial'},\n",
       "     {'id': 'D000006343', 'term': 'Heart Septal Defects'},\n",
       "     {'id': 'D000006330', 'term': 'Heart Defects, Congenital'},\n",
       "     {'id': 'D000018376', 'term': 'Cardiovascular Abnormalities'},\n",
       "     {'id': 'D000002318', 'term': 'Cardiovascular Diseases'},\n",
       "     {'id': 'D000006331', 'term': 'Heart Diseases'},\n",
       "     {'id': 'D000000013', 'term': 'Congenital Abnormalities'}],\n",
       "    'browseLeaves': [{'id': 'M27570',\n",
       "      'name': 'Foramen Ovale, Patent',\n",
       "      'asFound': 'Patent Foramen Ovale',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9431', 'name': 'Heart Septal Defects', 'relevance': 'LOW'},\n",
       "     {'id': 'M9432',\n",
       "      'name': 'Heart Septal Defects, Atrial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9418', 'name': 'Heart Defects, Congenital', 'relevance': 'LOW'},\n",
       "     {'id': 'M12', 'name': 'Congenital Abnormalities', 'relevance': 'LOW'},\n",
       "     {'id': 'M20503',\n",
       "      'name': 'Cardiovascular Abnormalities',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06315751',\n",
       "    'orgStudyIdInfo': {'id': 'NOE-TTS-201'},\n",
       "    'organization': {'fullName': 'Noema Pharma AG', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Efficacy and Safety of Gemlapodect in Adults and Adolescents With Tourette Syndrome',\n",
       "    'officialTitle': 'A Double-blind, Placebo-controlled, Phase 2b, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodect in Adult and Adolescent Patients With Tourette Syndrome',\n",
       "    'acronym': 'Allevia2'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-03',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-06',\n",
       "    'studyFirstSubmitQcDate': '2024-03-12',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-03-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Noema Pharma AG', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on\\r\\nreducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will\\r\\nbe enrolled after a sentinel cohort of adults is complete.',\n",
       "    'detailedDescription': 'Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic\\r\\neffect for the treatment of tics associated with Tourette Syndrome (TS). This is a\\r\\nmulti-center, double-blind, parallel-arm, placebo-controlled study in patients with TS.\\r\\nFollowing screening to confirm eligibility and to wash-out previous TS medication during\\r\\na 14-day placebo run-in, patients will be randomized 1:1 on Day 1 to receive gemlapodect\\r\\nor placebo once daily for 12 weeks.'},\n",
       "   'conditionsModule': {'conditions': ['Tourette Syndrome']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 180, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Gemlapodect',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Escalating doses of NOE-105 capsules',\n",
       "      'interventionNames': ['Drug: Gemlapodect']},\n",
       "     {'label': 'Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Escalating doses of matching placebo',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Gemlapodect',\n",
       "      'description': 'Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic\\r\\neffect for the treatment of tics associated with TS. Administered in the form of oral\\r\\ncapsules.',\n",
       "      'armGroupLabels': ['Gemlapodect'],\n",
       "      'otherNames': ['NOE-105']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Administered in the form of oral capsules with inert ingredients.',\n",
       "      'armGroupLabels': ['Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in tic severity score on the Revised Yale Global Tic Scoring Scale (YGTSS-R)',\n",
       "      'description': 'YGTSS-R is a clinician rated score that evaluates number, frequency, intensity,\\r\\ncomplexity and interference of motor and phonic tics with a total score ranging from 0 to\\r\\n50, with 50 being the most severe and 0 being no tics. Change in YGTSS-R total tic scores\\r\\nfrom baseline (randomization) to D85 for gemlapodect as compared to placebo.\\r\\n\\r\\nThe primary estimand is the difference in means between gemlapodect and placebo for the\\r\\nchange in the TTS of the YGTSS-R from baseline (randomization) to D85, in the target\\r\\npatient population of adult and adolescent patients with TS, regardless of whether or not\\r\\ndose reduction, suspension, or treatment discontinuation occurred due to events\\r\\nattributable to treatment, and regardless of change in background medication (dose and\\r\\nproduct) while under treatment, but in the absence of any new treatment started after\\r\\ndiscontinuation of investigational intervention',\n",
       "      'timeFrame': '85 days'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Impact on patient functioning',\n",
       "      'description': 'Change in Sheehan Disability Scale from baseline (randomization) to D85 for gemlapodect\\r\\nas compared to placebo',\n",
       "      'timeFrame': '85 days'},\n",
       "     {'measure': 'Change in PUTS',\n",
       "      'description': 'Change in premonitory urge for tics scale from baseline (randomization) to D85 for\\r\\ngemlapodect as compared to placebo',\n",
       "      'timeFrame': '85 days'},\n",
       "     {'measure': 'Safety and Tolerability of gemlapodect',\n",
       "      'description': 'The Incidence and severity of adverse events, including serious adverse events and\\r\\nadverse events of special interest',\n",
       "      'timeFrame': '85 days'},\n",
       "     {'measure': 'Assessment of suicidality and suicidal ideation',\n",
       "      'description': 'Change in Columbia suicide severity rating scale (C-SSRS) subscale from\\r\\nbaseline(randomization) to D85 for gemlapodect as compared to placebo. The C-SSRS\\r\\nsupports suicide risk assessment through a series of simple, plain-language questions to\\r\\nassesses suicidal ideation and suicidal behavior.',\n",
       "      'timeFrame': '85 days'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Initially, patients aged 18 years onwards, at the time of signing the ICF form.\\r\\n     Adolescents aged 12 years and older at the time of signing the ICF/informed assent\\r\\n     form will be eligible for inclusion after completion of a sentinel cohort of adults\\r\\n\\r\\n  2. Moderate to severe Tourette Syndrome as defined by DSM-5 diagnostic criteria and\\r\\n     TS-CGI-S ≥ 4.\\r\\n\\r\\n  3. Treatment naive or previously treated patients in need of treatment alternative as\\r\\n     per investigators judgement.\\r\\n\\r\\n  4. Patients must discontinue all medications used to treat TS for at least 14 days\\r\\n     prior to randomization. Other psychotropic drugs, including stimulants, will be\\r\\n     allowed provided they have been stable for at least 30 days prior to randomization\\r\\n     and are expected to remain stable for the duration of the study.\\r\\n\\r\\n  5. BMI within the range 18 to 35 kg/m2 (inclusive).\\r\\n\\r\\n  6. Women of childbearing potential should only be included after a confirmed menstrual\\r\\n     period and a negative highly sensitive urine or serum pregnancy test. Contraceptive\\r\\n     use should be consistent with local regulations regarding the methods of\\r\\n     contraception for those participating in clinical studies.\\r\\n\\r\\n  7. Capable of giving signed informed consent or consent from their legal\\r\\n     representative.\\r\\n\\r\\n  8. Fluency in the language of the investigator, study staff, and the ICF/informed\\r\\n     assent form when applicable.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Any medical condition which, in the opinion of the investigator, could interfere\\r\\n     with study procedures including but not limited to functional tic-like disorder,\\r\\n     secondary tic symptoms accompanied by late-onset tics, Huntington's chorea,\\r\\n     malignant TS, neuroacanthocytosis, mental retardation as defined by the\\r\\n     investigator, and autism.\\r\\n\\r\\n  2. Current diagnosis of severe anxiety, bipolar disorder, schizophrenia, or major\\r\\n     depressive disorder (MDD). Patients with MDD on selective serotonin reuptake\\r\\n     inhibitors treatment stable for greater than or equal to 1 month can participate in\\r\\n     the study.\\r\\n\\r\\n  3. A history of severe traumatic brain injury or stroke.\\r\\n\\r\\n  4. Any unstable medical conditions, severe symptoms, or clinically significant\\r\\n     abnormalities on screening test/examinations, including uncontrolled seizure\\r\\n     disorders, which, in the investigator's judgment, will put them at a risk of major\\r\\n     AE during this trial, or will interfere with safety and efficacy assessments.\\r\\n\\r\\n  5. Are undergoing active CBT (including but not limited to comprehensive behavioral\\r\\n     intervention for tics, exposure and response prevention, relaxation training) during\\r\\n     the last 28 days before the planned date of randomization and until the end of the\\r\\n     trial. Patients willing to discontinue their CBT over this period are eligible to\\r\\n     the study.\\r\\n\\r\\n  6. Known DSM-5 diagnosis of substance abuse or dependence.\\r\\n\\r\\n  7. Active suicidal ideation or behavior, as assessed by the C-SSRS\\r\\n\\r\\n  8. Use of prescribed or recreational cannabinoids during the study are prohibited.\\r\\n     Prescribed cannabinoids include Epidiolex® (cannabidiol), Marinol® /Syndros®\\r\\n     (dronabinol), and Cesamet® (nabilone). These medications will be discontinued during\\r\\n     the Screening period. Recreational cannabinoids, regardless of their form of intake,\\r\\n     which include tetrahydrocannabinol and/or cannabidiol, are prohibited.\\r\\n\\r\\n  9. Strong inhibitors of CYP3A4 are prohibited; commonly used strong inhibitors of\\r\\n     CYP3A4 are limited to systemic oral antibiotics (e.g., clarithromycin,\\r\\n     telithromycin), systemic, oral antifungals (eg, itraconazole, ketoconazole), and\\r\\n     antivirals (eg, atazanavir, darunavir, indinavir).\\r\\n\\r\\n 10. Neurostimulation/deep brain stimulation for TS.\\r\\n\\r\\n 11. Participation in another clinical study with a study intervention administered in\\r\\n     the last 30 days.\\r\\n\\r\\n 12. Patients with a known hypersensitivity to gemlapodect or any of the excipients of\\r\\n     the product\\r\\n\\r\\n 13. Positive urine drug screen for cannabis, cocaine, or nonprescribed opiates.\\r\\n\\r\\n 14. The person is an employee or family member of an employee of the Sponsor,\\r\\n     Investigator, or study site personnel..\\r\\n\\r\\n 15. Judgment by the investigator that the patient should not participate in the study if\\r\\n     the patient is unlikely to comply with study procedures, restrictions, and\\r\\n     requirements.\\r\\n\\r\\n 16. Previous randomization in the present study.\\r\\n\\r\\n 17. The person is currently committed to an institution by virtue of an order issued\\r\\n     either by the judicial or the administrative authorities\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '12 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Noema Pharma',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': 'please contact via email',\n",
       "      'email': 'clinicaltrials@noemapharma.com'}],\n",
       "    'overallOfficials': [{'name': 'Clinical Director, MD',\n",
       "      'affiliation': 'Noema Pharma AG',\n",
       "      'role': 'STUDY_DIRECTOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005879',\n",
       "      'term': 'Tourette Syndrome'},\n",
       "     {'id': 'D000013577', 'term': 'Syndrome'}],\n",
       "    'ancestors': [{'id': 'D000004194', 'term': 'Disease'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000001480', 'term': 'Basal Ganglia Diseases'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000013981', 'term': 'Tic Disorders'},\n",
       "     {'id': 'D000009069', 'term': 'Movement Disorders'},\n",
       "     {'id': 'D000020271',\n",
       "      'term': 'Heredodegenerative Disorders, Nervous System'},\n",
       "     {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'},\n",
       "     {'id': 'D000030342', 'term': 'Genetic Diseases, Inborn'},\n",
       "     {'id': 'D000065886', 'term': 'Neurodevelopmental Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M16355',\n",
       "      'name': 'Syndrome',\n",
       "      'asFound': 'Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8991',\n",
       "      'name': 'Tourette Syndrome',\n",
       "      'asFound': 'Tourette Syndrome',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M25603', 'name': 'Ganglion Cysts', 'relevance': 'LOW'},\n",
       "     {'id': 'M16358', 'name': 'Synovial Cyst', 'relevance': 'LOW'},\n",
       "     {'id': 'M4774', 'name': 'Basal Ganglia Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22132', 'name': 'Tics', 'relevance': 'LOW'},\n",
       "     {'id': 'M16739', 'name': 'Tic Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M12029', 'name': 'Movement Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M22092',\n",
       "      'name': 'Heredodegenerative Disorders, Nervous System',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21558',\n",
       "      'name': 'Neurodegenerative Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M23686', 'name': 'Genetic Diseases, Inborn', 'relevance': 'LOW'},\n",
       "     {'id': 'M30644',\n",
       "      'name': 'Neurodevelopmental Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC16',\n",
       "      'name': 'Diseases and Abnormalities at or Before Birth'},\n",
       "     {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05973851',\n",
       "    'orgStudyIdInfo': {'id': '2023-506617-21-00 (EU CT#)'},\n",
       "    'organization': {'fullName': 'UMC Utrecht', 'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'officialTitle': 'A Randomised, Controlled Trial to Investigate the Effect of a Sixweek Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.',\n",
       "    'acronym': 'INTENSIFY MDD'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-07-25',\n",
       "    'studyFirstSubmitQcDate': '2023-07-25',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-08-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-13',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr. Inge Winter',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'UMC Utrecht'},\n",
       "    'leadSponsor': {'name': 'Dr. Inge Winter', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Universität Münster', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Over 28 million people suffer from current depressive disorder in the European Union.\\r\\nMajor depressive disorder (MDD) is one of the most common psychiatric illnesses. The\\r\\nsymptoms cause clinically significant distress or impairment in social, occupational, and\\r\\nother important areas of functioning. To treat MDD, there are several antidepressants\\r\\navailable and prescribing medication is a process of trial-and-error. Guidelines do not\\r\\nexplicitly advise on the order in which antidepressant medication should be prescribed.\\r\\nThe choice of antidepressant should be tailored to the patient, while involving the\\r\\npatient in the decision-making process. In general, the choice for the first- and\\r\\nsecond-line treatment will be a second-generation antidepressant. Recently, esketamine\\r\\nnasal spray (intranasal (IN) administration) was approved for patients with\\r\\ntreatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two\\r\\nantidepressants in sufficient duration and adequate dose without sufficient effect. TRD\\r\\nis associated with a negative impact on quality of life, higher risk for hospitalisations\\r\\nand suicide, comorbidities, poorer social and occupational functioning and a high carer\\r\\nburden. The efficacy of intranasal use of esketamine has been demonstrated in MDD\\r\\nsubjects with treatment-resistant symptoms but also in subjects with non-treatment\\r\\nresistant depression, and is approved by the FDA and EMA as a third-line treatment.\\r\\nBesides the registered esketamine nasal spray, which is not available in all countries to\\r\\nall patients because of the high costs, off-label utilization of (es)ketamine infusions\\r\\n(IV) is growing extensively over time to treat TRD. Research conducted so far indicates\\r\\nan unequivocal initial substantial response to (es)ketamine IV in MDD populations,\\r\\nregardless of whether or not patients suffer from treatment resistant MDD. However, until\\r\\nnow, there has not been a study investigating this in a sufficiently large population.\\r\\nThis may be a unique opportunity to potentially prevent patients progressing into a\\r\\ntreatment resistant illness stage. The potential implications of the results of the\\r\\ncurrent study are the prevention of unnecessary trials of ineffective treatments,\\r\\nreducing subject burden substantially, as well as a reduction of healthcare and societal\\r\\ncosts.',\n",
       "    'detailedDescription': 'Rationale Over 28 million people suffer from current depressive disorder in the European\\r\\nUnion. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.\\r\\nThe symptoms cause clinically significant distress or impairment in social, occupational,\\r\\nand other important areas of functioning. To treat MDD, there are several antidepressants\\r\\navailable and prescribing medication is a process of trial-and-error. Guidelines do not\\r\\nexplicitly advise on the order in which antidepressant medication should be prescribed.\\r\\nThe choice of antidepressant should be tailored to the patient, while involving the\\r\\npatient in the decision-making process. In general, the choice for the first- and\\r\\nsecond-line treatment will be a second-generation antidepressant. Recently, esketamine\\r\\nnasal spray (intranasal (IN) administration) was approved for patients with\\r\\ntreatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two\\r\\nantidepressants in sufficient duration and adequate dose without sufficient effect. TRD\\r\\nis associated with a negative impact on quality of life, higher risk for hospitalisations\\r\\nand suicide, comorbidities, poorer social and occupational functioning and a high carer\\r\\nburden. The efficacy of intranasal use of esketamine has been demonstrated in MDD\\r\\nsubjects with treatment-resistant symptoms but also in subjects with non-treatment\\r\\nresistant depression, and is approved by the FDA and EMA as a third-line treatment.\\r\\nBesides the registered esketamine nasal spray, which is not available in all countries to\\r\\nall patients because of the high costs, off-label utilization of (es)ketamine infusions\\r\\n(IV) is growing extensively over time to treat TRD. Research conducted so far indicates\\r\\nan unequivocal initial substantial response to (es)ketamine IV in MDD populations,\\r\\nregardless of whether or not patients suffer from treatment resistant MDD. However, until\\r\\nnow, there has not been a study investigating this in a sufficiently large population.\\r\\nThis may be a unique opportunity to potentially prevent patients progressing into a\\r\\ntreatment resistant illness stage. The potential implications of the results of the\\r\\ncurrent study are the prevention of unnecessary trials of ineffective treatments,\\r\\nreducing subject burden substantially, as well as a reduction of healthcare and societal\\r\\ncosts.\\r\\n\\r\\nObjective The primary objective is to compare the treatment response (baseline; visit 2\\r\\nvs. end of treatment; visit 4), expressed as symptom severity at six weeks and changes in\\r\\nsymptom severity from baseline, as measured through the Montgomery-Åsberg Depression\\r\\nRating Scale (MADRS) under an early-intensified pharmacological treatment to that under\\r\\ntreatment as usual, in subjects who had a first-time treatment failure of first-line\\r\\ntreatment during the current episode of MDD.\\r\\n\\r\\nMain trial endpoints Change in symptom severity total score from baseline (visit 2) to\\r\\nend of treatment (visit 4). This is measured using MADRS.\\r\\n\\r\\nSecondary trial endpoints\\r\\n\\r\\n  1. To compare changes in severity and improvement in global functioning assessed by the\\r\\n     Clinical Global Impression Scale (CGI) between the two treatment arms.\\r\\n\\r\\n  2. To compare changes in the levels of depression and anxiety between treatment arms.\\r\\n\\r\\n  3. To compare changes in quality of life and functioning measures between treatment\\r\\n     arms.\\r\\n\\r\\n  4. To compare changes in cognitive performance between treatment arms.\\r\\n\\r\\n  5. To compare the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\n     remission at visit 4.\\r\\n\\r\\n  6. To compare presence of side effects between treatment arms.\\r\\n\\r\\n  7. To compare use of concomitant medication between treatment arms.\\r\\n\\r\\n  8. To compare premature discontinuation (timing and reason) between treatment arms.\\r\\n\\r\\n  9. To compare changes in suicidal ideation between treatment arms.\\r\\n\\r\\nTrial design The clinical study is an international, multicenter controlled, randomised,\\r\\nopen label trial (with blinded raters), with a treatment duration of four weeks.\\r\\n\\r\\nTrial population The aim is to recruit 418 subjects with major depressive disorder,\\r\\nwithout psychotic features. Male and female subjects, in- and out-patients, within the\\r\\nage range of 18 to 65 years old are eligible for participation. The main exclusion\\r\\ncriteria are defined to protect the wellbeing of subjects, e.g. being pregnant or\\r\\nbreastfeeding, subjects with previous failure on (es)ketamine, meeting any\\r\\ncontraindications, or participants with a known intolerance to (es)ketamine.\\r\\n\\r\\nInterventions\\r\\n\\r\\nSubjects are randomised to treatment as usual (second-line treatment) or to the\\r\\nearly-intensified pharmacological treatment (third-line treatment). Treatment per can be\\r\\nfound in the table below:\\r\\n\\r\\nTable 1. Overview of treatment randomisation per study sample. MDD sample Treatment as\\r\\nUsual (TAU) Switch to second-line antidepressant Early-Intensified Pharmacological\\r\\nTreatment (EIPT) Oral antidepressant plus esketamine nasal spray or esketamine IV or\\r\\nketamine IV\\r\\n\\r\\nEthical considerations relating to the clinical trial including the expected benefit to\\r\\nthe individual subject or group of subjects represented by the trial subjects as well as\\r\\nthe nature and extent of burden and risks In the current study, clinical practice is\\r\\nmimicked as much as possible to maximize generalizability and for feasibility purposes.\\r\\nTo this end, Summaries of Product Characteristics (SmPCs) are followed with regards to\\r\\ncontraindications (implemented as exclusion criterion), safety measures and allowed\\r\\ncombinations with other medications. Site visits and assessments are kept to a minimum to\\r\\nkeep subject burden at an acceptable level, while meeting the objectives of the study.\\r\\nBlood samples for biomarker analyses are only collected when subjects provide consent;\\r\\nsafety measures are performed as part of clinical routine.\\r\\n\\r\\nUse of both EIPT and TAU medications implies that there is a risk of side effects. For\\r\\nTAU, these side effects are well-known, and would be no different from regular clinical\\r\\npractice. For EIPT, there are acute psychotropic effects of (es)ketamine which are\\r\\nconsidered side effects for this study, such as anxiety, delusional thoughts,\\r\\ndissociation and hallucinations (see IMPDs). In addition, increased blood pressure and\\r\\nheart rate, as well as dizziness and nausea are reported. These acute effect are\\r\\ntransient and after 2 hours completely dissipated. Therefore, an observation period of 2\\r\\nhours after every administration is implemented to monitor this closely. The potential\\r\\nside effects of all treatments are well-known and will be monitored during the study with\\r\\na standardized side-effect scale (GASE), spontaneous reporting and the local standard\\r\\nprocedure regarding other measures such as laboratory tests, physical examinations, ECGs.\\r\\nThe results will be captured (as data) and reviewed for tolerability. Most of the tests\\r\\nthat will be done as part of standard clinical care (lab tests, ECG, physical\\r\\nexamination) for EIPT are also part of TAU.\\r\\n\\r\\nA benefit of the study is that while ensuring that the tolerability and additional burden\\r\\nremains acceptable, the investigators expect that the larger effect in reducing symptom\\r\\nseverity will justify the increase in burden relative to the TAU group. When participants\\r\\nare treated with the intense treatment in earlier stage of the illness (less trial and\\r\\nerror before moving on to this treatment option), this is expected to result in a reduced\\r\\nburden of disease for subjects, expressed as less relapses, lower all-cause mortality,\\r\\nhospitalisations and job losses and improved quality of life, in addition to lower\\r\\nsocietal and healthcare costs as well as preventing patients from turning into a\\r\\ntreatment-resistant treatment phase. Last, an advantage of participation could be that\\r\\nsubjects will be more thoroughly followed and examined, and that therefore effects and\\r\\nside effects are measured and managed better.\\r\\n\\r\\nIMPORTANT: the study was submitted to the European authorities before (see NCT05603104)\\r\\nand they requested to split this study into 3 studies (1 for each diagnostic category).\\r\\nThe investigators have done this and created 3 new ClinicalTrials.gov studies as well,\\r\\nfrom which this is one for major depressive disorder. The ClinicalTrial.gov numbers for\\r\\nthe other studies are NCT05958875 for INTENSIFY SZ and NCT05973786 for INTENSIFY BD. The\\r\\nsite in the UK (London) followed the advice and will submit 3 separate protocols and are\\r\\ntherefore included in the current record. However, Israel already submitted this as one\\r\\nprotocol. Therefore, the investigators keep the old clinicaltrials.gov number for Israel\\r\\n(NCT05603104).'},\n",
       "   'conditionsModule': {'conditions': ['Major Depressive Disorder',\n",
       "     'Treatment Resistant Depression'],\n",
       "    'keywords': ['Major Depressive Disorder',\n",
       "     'Treatment as usual',\n",
       "     'Early treatment-resistance']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE3'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified\\r\\npharmacological treatment (EIPT).',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Open label, except for the assessors of the primary outcome',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 418, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': \"Major depressive disorder randomized to EIPT: Switch to second-line antidepressant +\\r\\nesketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage,\\r\\nfrequency and duration up to the investigator's discretion (in accordance with SmPC).\\r\\n\\r\\nEsketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that\\r\\nincreases can be made with 28 mg per increase (up to 84 mg per week). This decision is up\\r\\nto the investigator's discretion (in accordance with SmPC).\\r\\n\\r\\n(Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the\\r\\ninvestigator's discretion (in accordance with SmPC).\",\n",
       "      'interventionNames': ['Drug: Esketamine Nasal Product',\n",
       "       'Drug: Ketamine Hydrochloride',\n",
       "       'Drug: Esketamine hydrochloride']},\n",
       "     {'label': 'Major Depressive Disorder TAU: second-line antidepressant',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Subject with major depressive disorder, randomized to TAU: switch to second-line\\r\\nantidepressant. When randomized to second-line anti-depressants, this means participants\\r\\nwill receive treatment as usual. The physician has the choice to administer any\\r\\nsecond-line anti-depressant. More specification is not possible, as this is a choice the\\r\\nphysician makes with the participant based on the characteristic and preference of the\\r\\nparticipant (in line with standard clinical practice).',\n",
       "      'interventionNames': ['Drug: Second-line Antidepressants']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Esketamine Nasal Product',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray'],\n",
       "      'otherNames': ['ATC code: N06AB10']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Ketamine Hydrochloride',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray'],\n",
       "      'otherNames': ['N01AX03']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Esketamine hydrochloride',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray'],\n",
       "      'otherNames': ['N015X14']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Second-line Antidepressants',\n",
       "      'description': 'See arm description',\n",
       "      'armGroupLabels': ['Major Depressive Disorder TAU: second-line antidepressant']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Comparing the change in symptom severity on Montgomery Asberg Depression Rating Scale',\n",
       "      'description': 'Change in symptom severity (EIPT vs. TAU) total score from baseline (visit 2) to end of\\r\\ntreatment (visit 4). This is measured using the Montgomery Asberg Depression Rating\\r\\nScale. Minimum score is 0, maximum score 60. A bigger mean change means a better outcome',\n",
       "      'timeFrame': '6 weeks'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Compare proportion of participants that is in symptomatic remission',\n",
       "      'description': 'Comparison of the proportion of participants (EIPT vs. TAU) that is in symptomatic\\r\\nremission at visit 4. Remission is defined as a Montgomery Asberg Depression Rating scale\\r\\nscore of ≤ 12.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the change in the severity and improvement CGI-S sub-scores',\n",
       "      'description': 'To compare changes in the severity sub-score of the Clinical Global Impression Scale (CGI\\r\\n2) between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2\\r\\nversus visit 4). Higher scores indicate higher illness severity. Minimum score: 1,\\r\\nmaximum score: 7',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the change in the severity and improvement CGI-I sub-scores',\n",
       "      'description': 'To compare changes in the total improvement sub-score of the Clinical Global Impression\\r\\nScale (CGI 2) between the two treatment arms (EIPT/TAU) over the four week treatment\\r\\nperiod (visit 2 versus visit 4). A higher score means lower treatment improvement.\\r\\nMinimum score: 1, maximum score: 7',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'Compare the changes in the levels of depression and anxiety',\n",
       "      'description': 'To compare changes in the levels of depression and anxiety as assessed with the Hospital\\r\\nAnxiety and Depression Scale between the two treatment arms (EIPT/TAU) over the four week\\r\\ntreatment period (visit 2 versus visit 4). Lower scores mean less depression and anxiety.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in cognitive performance as measured through the Trail Making Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Trail Making Test\\r\\nbetween the two treatment arms over the four weeks treatment period (visit 2 versus visit\\r\\n4). A lower time to complete the test means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Rey Auditory Verbal\\r\\nLearning Test between the two treatment arms over the four weeks treatment period (visit\\r\\n2 versus visit 4). A higher scores means better cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in subjective cognitive performance as measured through the Perceived Deficits Questionnaire',\n",
       "      'description': 'To compare changes in cognitive performance as measured through the Perceived Deficits\\r\\nQuestionnaire between the two treatment arms over the four weeks treatment period (visit\\r\\n2 versus visit 4). A higher scores means worse subjective cognitive performance.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in functioning on the Leuven Affective and Pleasure Scale',\n",
       "      'description': 'To compare changes in the functioning measure, Leuven Affective and Pleasure Scale,\\r\\nbetween the two treatment arms over the four weeks treatment period (visit 2 versus visit\\r\\n4). A higher scores means worse functioning. Minimum score: 0, Maximum score: 160',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in functioning on the Sheehan Disability Scale',\n",
       "      'description': 'To comparechanges in the functioning measure,Sheehan Disability Scale, between the two\\r\\ntreatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher\\r\\nscores means worse functioning. Minimum score: 0, maximum score 30.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes in quality of life measure, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form',\n",
       "      'description': 'To compare changes in quality of life measure, Quality of Life Enjoyment and Satisfaction\\r\\nQuestionnaire Short Form between the two treatment arms over the four weeks treatment\\r\\nperiod (visit 2 versus visit 4). A higher scores means better quality of life. Minimum\\r\\nscore: 16, maximum score: 80.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the changes of participants in quality of life measure, Quality of Life Scale -100, subscale inner tension',\n",
       "      'description': \"To compare changes in quality of life measure, Quality of Life Scale -100, subscale inner\\r\\ntension between the two treatment arms over the four weeks treatment period (visit 2\\r\\nversus visit 4). This is a dichotomous scale (unsatisfactory or satisfactory). More\\r\\n'satisfactory' answers means higher quality of life.\",\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the frequency of occurrence of side effects between the two treatment arms.',\n",
       "      'description': 'To compare presence of side effects as measured through General Assessment of Side\\r\\nEffects Scale and reported spontaneously between the two treatment arms (EIPT/TAU) over\\r\\nthe four week treatment period (visit 2 versus visit 4). Higher scores means more side\\r\\neffects. Minimum score: 0 side effects, maximum score: 38 side effects.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the proportion of participants using concomitant medication between the two treatment arms.',\n",
       "      'description': 'To compare use of concomitant medication between the two treatment arms (EIPT/TAU) over\\r\\nthe four week treatment period (visit 2 versus visit 4) effects.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the proportion of participants who prematurely discontinue between the two treatment arms.',\n",
       "      'description': 'To compare premature discontinuation between the two treatment arms (EIPT/TAU) over the\\r\\nfour week treatment period (visit 2 versus visit 4).',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare the reason of participants that prematurely discontinue the study between the two treatment arms.',\n",
       "      'description': 'To compare the difference in reason of participants that prematurely discontinue the\\r\\nstudy between the two treatment arms.',\n",
       "      'timeFrame': '6 weeks'},\n",
       "     {'measure': 'To compare changes in suicidal ideation between treatment arms.',\n",
       "      'description': \"Changes from baseline (visit 2) on Module B 'Suicidality' of the Mini International\\r\\nNeuropsychiatric Interview (v7.0.2) at V4 between the two treatment arms. A score of 1-8\\r\\npoints on this module means that the suicide risk is low, scores 9-16 means a moderate\\r\\nrisk and 17 points or higher means that there is a high risk. The minimum score is 0 and\\r\\nthe maximum score is 154.\",\n",
       "      'timeFrame': '6 weeks.'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. In- or outpatients, at least 18 years of age up until 65.\\r\\n\\r\\n  2. Being willing and able to provide written informed consent. Having a legal guardian\\r\\n     to cosign is allowed. Informed consent will be signed at visit 1, before any study\\r\\n     procedure.\\r\\n\\r\\n  3. Female subjects of child bearing potential must use effective contraception during\\r\\n     the trial as per the requirements of the applicable SmPCs and should have a negative\\r\\n     pregnancy test at visit 1 (section 8.2.1).\\r\\n\\r\\n  4. Meeting diagnostic criteria for a primary diagnosis of major depressive disorder\\r\\n     (without psychotic features), according to DSM-5. The primary diagnosis will be\\r\\n     confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2).\\r\\n\\r\\n  5. Subject currently experiences his/her first treatment failure due to lack of\\r\\n     efficacy; this treatment is a first-line pharmacotherapeutic agent for the primary\\r\\n     DSM-5 diagnosis, and was prescribed for at least 4 weeks within the dose range as\\r\\n     specified in the Summary of Product Characteristics (SmPCs).\\r\\n\\r\\n  6. Subject has failed on current psychopharmacological treatment of current episode of\\r\\n     MDD, as confirmed by a CGI-I ≥3.\\r\\n\\r\\n  7. Subject and clinician intend to change pharmacotherapeutic treatment.\\r\\n\\r\\n  8. A minimum symptom severity threshold needs to be present (moderate level; see below)\\r\\n     and subject needs to experience functional impairment.\\r\\n\\r\\n       -  The minimum symptom severity threshold is a score of ≥20 on the Montgomery\\r\\n          Åsberg Depression Rating Scale (MADRS)\\r\\n\\r\\n       -  Functional impairment is defined as a score of 5 or higher on any of the three\\r\\n          scales of the Sheehan Disability Scale (SDS).\\r\\n\\r\\nExclusion criteria:\\r\\n\\r\\n  1. Being pregnant or breastfeeding.\\r\\n\\r\\n  2. Subject has used (es)ketamine previously for the treatment of depressive symptoms.\\r\\n\\r\\n  3. Subject has a known intolerance to (es)ketamine or to all TAU medication.\\r\\n\\r\\n  4. Meeting any of the contraindications for (es)ketamine, or to all TAU medication\\r\\n     options, as specified within the applicable SmPC, supported by clinically\\r\\n     significant abnormal values on local laboratory tests, electrocardiogram (ECG) or\\r\\n     physical examinations.\\r\\n\\r\\n  5. Subject has participated in another clinical trial in which the subject received an\\r\\n     experimental or investigational drug or agent within 30 days before visit 1.\\r\\n\\r\\n  6. Subject currently uses more than the allowed psychotropic concomitant medication and\\r\\n     needs to stay on this medication during the study.\\r\\n\\r\\n  7. Subject experiences any other significant disease or disorder which, in the opinion\\r\\n     of the investigator, may either put the subjects at risk because of participation in\\r\\n     the trial, or may influence the result of the trial, or the subject's ability to\\r\\n     participate in the trial.\\r\\n\\r\\n  8. Moderate or high suicidal ideation within the last 2 weeks, defined as a score of 9\\r\\n     or higher on Module B (Suicidality) of the Mini International Neuropsychiatric\\r\\n     Interview (MINI v7.0.2)\\r\\n\\r\\n  9. Subject meets criteria for current substance use disorder, as confirmed by the Mini\\r\\n     International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is\\r\\n     allowed, as well as mild alcohol and/or cannabis use disorder (as defined by MINI\\r\\n     v7.0.2). Moderate and severe alcohol and/or cannabis use disorder are not allowed.\\r\\n\\r\\n 10. Subjects have not been committed to an institution by virtue of an order issued\\r\\n     either by the judicial or the administrative authorities.\\r\\n\\r\\n 11. Subjects dependent on the sponsor, investigator or trial site must be excluded from\\r\\n     participation in advance.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Inge Winter, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'i.winter@umcutrecht.nl'},\n",
       "     {'name': 'Cynthia Okhuijsen-Pfeifer, Dr.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+31875553227',\n",
       "      'email': 'c.pfeifer@umcutrecht.nl'}],\n",
       "    'locations': [{'facility': 'Medical University Innsbruck',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Innsbruck',\n",
       "      'country': 'Austria',\n",
       "      'contacts': [{'name': 'Alex Hofer, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'a.hofer@i-med.ac.at'}],\n",
       "      'geoPoint': {'lat': 47.26266, 'lon': 11.39454}},\n",
       "     {'facility': 'Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Bielefeld',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Martin Driessen, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'martin.driessen@evkb.de'}],\n",
       "      'geoPoint': {'lat': 52.03333, 'lon': 8.53333}},\n",
       "     {'facility': 'University Hospital Frankfurt am Main - Goethe University',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Frankfurt am Main',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Andreas Reif, MD,PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'andreas.reif@kgu.de'}],\n",
       "      'geoPoint': {'lat': 50.11552, 'lon': 8.68417}},\n",
       "     {'facility': 'Westfälische Wilhelms-Universität Münster',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Münster',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Bernhard Baune',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'Bernhard.Baune@ukmuenster.de'}],\n",
       "      'geoPoint': {'lat': 51.96236, 'lon': 7.62571}},\n",
       "     {'facility': 'Universita degli Studi di Brescia',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Brescia',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Antonio Vita, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'antonio.vita@unibs.it'}],\n",
       "      'geoPoint': {'lat': 45.53558, 'lon': 10.21472}},\n",
       "     {'facility': 'University of Cagliari',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Cagliari',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Mirko Manchia, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'mirkomanchia@unica.it'}],\n",
       "      'geoPoint': {'lat': 39.23054, 'lon': 9.11917}},\n",
       "     {'facility': 'Università degli studi della Campania Luigi Vanvitelli',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Naples',\n",
       "      'zip': '80138',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Armida Mucci, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'armida.mucci@gmail.com'}],\n",
       "      'geoPoint': {'lat': 40.85216, 'lon': 14.26811}},\n",
       "     {'facility': 'Azienda Ospedaliero-Universitaria \"Città della Salute e della Scienza di Torino\"',\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'Turin',\n",
       "      'country': 'Italy',\n",
       "      'contacts': [{'name': 'Paola Rocca, MD,PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'paola.rocca@unito.it'}],\n",
       "      'geoPoint': {'lat': 45.07049, 'lon': 7.68682}},\n",
       "     {'facility': 'Fundació Clínic per a la Recerca Biomèdica',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Barcelona',\n",
       "      'country': 'Spain',\n",
       "      'contacts': [{'name': 'Eduard Vieta, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'EVIETA@clinic.cat'}],\n",
       "      'geoPoint': {'lat': 41.38879, 'lon': 2.15899}},\n",
       "     {'facility': \"King's College London, Psychiatry & Cognitive Neuroscience\",\n",
       "      'status': 'NOT_YET_RECRUITING',\n",
       "      'city': 'London',\n",
       "      'zip': 'SE5 8AF',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Howes Oliver, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'oliver.howes@kcl.ac.uk'},\n",
       "       {'name': 'Allan Young, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'allan.young@kcl.ac.uk'}],\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'CSR']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003863',\n",
       "      'term': 'Depression'},\n",
       "     {'id': 'D000003866', 'term': 'Depressive Disorder'},\n",
       "     {'id': 'D000003865', 'term': 'Depressive Disorder, Major'},\n",
       "     {'id': 'D000061218', 'term': 'Depressive Disorder, Treatment-Resistant'}],\n",
       "    'ancestors': [{'id': 'D000001526', 'term': 'Behavioral Symptoms'},\n",
       "     {'id': 'D000019964', 'term': 'Mood Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M7058',\n",
       "      'name': 'Depression',\n",
       "      'asFound': 'Depressive Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7061',\n",
       "      'name': 'Depressive Disorder',\n",
       "      'asFound': 'Depressive Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7060',\n",
       "      'name': 'Depressive Disorder, Major',\n",
       "      'asFound': 'Major Depressive Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M29783',\n",
       "      'name': 'Depressive Disorder, Treatment-Resistant',\n",
       "      'asFound': 'Treatment Resistant Depression',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4818', 'name': 'Behavioral Symptoms', 'relevance': 'LOW'},\n",
       "     {'id': 'M21835', 'name': 'Mood Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000007649',\n",
       "      'term': 'Ketamine'},\n",
       "     {'id': 'C000629870', 'term': 'Esketamine'},\n",
       "     {'id': 'D000000928', 'term': 'Antidepressive Agents'}],\n",
       "    'ancestors': [{'id': 'D000000700', 'term': 'Analgesics'},\n",
       "     {'id': 'D000018689', 'term': 'Sensory System Agents'},\n",
       "     {'id': 'D000018373', 'term': 'Peripheral Nervous System Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000778', 'term': 'Anesthetics, Dissociative'},\n",
       "     {'id': 'D000018686', 'term': 'Anesthetics, Intravenous'},\n",
       "     {'id': 'D000018681', 'term': 'Anesthetics, General'},\n",
       "     {'id': 'D000000777', 'term': 'Anesthetics'},\n",
       "     {'id': 'D000002492', 'term': 'Central Nervous System Depressants'},\n",
       "     {'id': 'D000018691', 'term': 'Excitatory Amino Acid Antagonists'},\n",
       "     {'id': 'D000018683', 'term': 'Excitatory Amino Acid Agents'},\n",
       "     {'id': 'D000018377', 'term': 'Neurotransmitter Agents'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000011619', 'term': 'Psychotropic Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M271980',\n",
       "      'name': 'Esketamine',\n",
       "      'asFound': 'Days per week',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10674',\n",
       "      'name': 'Ketamine',\n",
       "      'asFound': 'Read',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4247',\n",
       "      'name': 'Antidepressive Agents',\n",
       "      'asFound': 'Hysterectomy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4107', 'name': 'Anesthetics', 'relevance': 'LOW'},\n",
       "     {'id': 'M4108', 'name': 'Anesthetics, Dissociative', 'relevance': 'LOW'},\n",
       "     {'id': 'M20766', 'name': 'Anesthetics, Intravenous', 'relevance': 'LOW'},\n",
       "     {'id': 'M20761', 'name': 'Anesthetics, General', 'relevance': 'LOW'},\n",
       "     {'id': 'M20771',\n",
       "      'name': 'Excitatory Amino Acid Antagonists',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M14474', 'name': 'Psychotropic Drugs', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'PsychDr', 'name': 'Psychotropic Drugs'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Analg', 'name': 'Analgesics'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06111547',\n",
       "    'orgStudyIdInfo': {'id': 'TAK-279-1005'},\n",
       "    'organization': {'fullName': 'Takeda', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of TAK-279 in Healthy Chinese Adults',\n",
       "    'officialTitle': 'A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese Subjects'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-12', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-12', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-27',\n",
       "    'studyFirstSubmitQcDate': '2023-10-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Takeda', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The main aim of this study is to find out how the body of a healthy Chinese adult\\r\\nprocesses TAK-279 (pharmacokinetics). Other aims are to learn about side effects and how\\r\\nwell TAK-279 is tolerated when given to healthy Chinese Adults. Participants will receive\\r\\neither TAK-279 or a placebo on Day 1 and from Day 6 to Day 19. Blood samples will be\\r\\ntaken at different timepoints throughout the study participation. Participants will need\\r\\nto adhere to certain lifestyle restrictions during the study. This also includes eating\\r\\nand drinking restrictions.\\r\\n\\r\\nDuring the study, participants will need to stay at the clinic for 25 days.'},\n",
       "   'conditionsModule': {'conditions': ['Healthy Volunteers']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'OTHER',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 24, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cohort 1: TAK-279 30 mg',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive a single dose of TAK-279 30 milligram (mg) oral tablet on Day 1\\r\\nfollowed by Day 6 to Day 19 once daily under fasted condition.',\n",
       "      'interventionNames': ['Drug: TAK-279']},\n",
       "     {'label': 'Cohort 2: TAK-279 60 mg',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive a dose of TAK-279 60 mg (2*30mg) oral tablets on Day 1 followed\\r\\nby Day 6 to Day 19 once daily under fasted condition.',\n",
       "      'interventionNames': ['Drug: TAK-279']},\n",
       "     {'label': 'Cohort 1 and 2: Placebo 30 mg or 60 mg',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Participants will receive TAK-279 30 mg or 60 mg (2*30mg) matching placebo oral tablets\\r\\non Day 1 followed by Day 6 to Day 19 once daily under fasted condition.',\n",
       "      'interventionNames': ['Drug: Placebo']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'TAK-279',\n",
       "      'description': 'TAK-279 oral tablet.',\n",
       "      'armGroupLabels': ['Cohort 1: TAK-279 30 mg',\n",
       "       'Cohort 2: TAK-279 60 mg']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'TAK-279 30 mg or 60 mg (2*30mg) matching placebo tablet.',\n",
       "      'armGroupLabels': ['Cohort 1 and 2: Placebo 30 mg or 60 mg']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Area Under the Concentration Time Curve From Time 0 to the Time t (AUC0-t) of TAK-279',\n",
       "      'description': 'AUC0-t of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Area Under the Concentration-time Curve From Time 0 To Infinity (AUC0-inf) of TAK-279',\n",
       "      'description': 'AUC0-inf of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Maximum Observed Plasma Concentration (Cmax) of TAK-279',\n",
       "      'description': 'Cmax of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of TAK-279',\n",
       "      'description': 'AUCtau of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of TAK-279',\n",
       "      'description': 'Cmax,ss of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESI)',\n",
       "      'description': 'Number of participants with TEAEs, serious TEAEs and AESI will be reported.',\n",
       "      'timeFrame': 'From start of study drug administration up to follow-up (up to Day 36)'},\n",
       "     {'measure': 'Number of Participants With Clinically Significant Changes in 12-Lead Electrocardiogram (ECG), Vital Signs and Clinical Laboratory Parameters',\n",
       "      'description': \"Number of participants with clinically significant changes in ECG, vital signs, and\\r\\nclinical laboratory parameters will be assessed. Clinical significance of ECG, vital\\r\\nsigns, and clinical laboratory parameters will be determined at the investigator's\\r\\ndiscretion.\",\n",
       "      'timeFrame': 'From start of study drug administration up to follow-up (up to Day 36)'},\n",
       "     {'measure': 'Area Under the Plasma Concentration-Time Curve From Time 0 To the Time 24 Hours (AUC0-24) of TAK-279',\n",
       "      'description': 'AUC0-24 of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post-dose'},\n",
       "     {'measure': 'Terminal Elimination Rate Constant (Lambda z) of TAK-279 at Day 1 and Day 19',\n",
       "      'description': 'Lambda z of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1 and Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Terminal phase half-life (t1/2) of TAK-279 at Day 1 and Day 19',\n",
       "      'description': 't1/2 of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1 and Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Apparent Clearance (CL/F) of TAK-279',\n",
       "      'description': 'CL/F of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of TAK-279',\n",
       "      'description': 'Vz/F of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Time to Reach Peak Plasma Concentration (Tmax) of TAK-279',\n",
       "      'description': 'Tmax of TAK-279 in plasma will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Minimum Plasma Concentration (Cmin) of TAK-279',\n",
       "      'description': 'Cmin of TAK-279 will be assessed.',\n",
       "      'timeFrame': 'Day 1: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Trough Concentration (Ctrough) of TAK-279',\n",
       "      'description': 'Ctrough of TAK-279 will be assessed.',\n",
       "      'timeFrame': 'Pre-dose on Day 17, Day 18 and Day 19'},\n",
       "     {'measure': 'Time to Reach the Maximum Plasma Concentration at Steady State (Tmax,ss) of TAK-279',\n",
       "      'description': 'Tmax,ss of TAK-279 will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Total Body Drug Clearance at Steady State (CLss/F) of TAK-279',\n",
       "      'description': 'CLss/F of TAK-279 will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Apparent Volume of Distribution at Steady State (Vss/F) of TAK-279',\n",
       "      'description': 'Vss/F of TAK-279 will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Average Plasma Concentration (Cavg) for TAK-279',\n",
       "      'description': 'Cavg of TAK-279 will be assessed, calculated as AUC(tau)/tau. Tau is defined as length of\\r\\ndosing interval.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Percent peak-to-trough fluctuation (%FLUC) of TAK-279',\n",
       "      'description': 'Percent peak-to-trough fluctuation will be assessed, calculated as\\r\\n100%*([Cmax,ss-Ctrough]/Cavg) will be assessed.',\n",
       "      'timeFrame': 'Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Accumulation Ratio for Cmax (RA, Cmax) of TAK-279',\n",
       "      'description': 'Accumulation ratio calculated from Cmax,ss at steady state and Cmax indicated a single\\r\\ndose will be assessed.',\n",
       "      'timeFrame': 'Day 1 and Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'},\n",
       "     {'measure': 'Accumulation Ratio for AUCtau (RA, AUCtau) of TAK-279',\n",
       "      'description': 'Accumulation ratio calculated from AUCtau at steady state and AUC0-24 indicated a single\\r\\ndose will be assessed.',\n",
       "      'timeFrame': 'Day 1 and Day 19: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion criteria:\\r\\n\\r\\n  -  Participant is willing to participate and is capable of giving informed consent.\\r\\n\\r\\n  -  Healthy, male or female participants of Chinese descent 18 to 45 years of age,\\r\\n     inclusive, at the time of informed consent.\\r\\n\\r\\n  -  Female participants meets the following contraception requirements: A surgically\\r\\n     sterile female participant; or a female participant of nonchildbearing potential\\r\\n     with laboratory confirmation of postmenopausal status (that is follicle-stimulating\\r\\n     hormone levels greater than [>] 40 milli-international units per milliliter\\r\\n     [mIU/mL]); or, if sexually active with a non-sterilized male partner, a female\\r\\n     participant who agrees to use a highly effective method of contraception from the\\r\\n     signing of informed consent throughout the duration of the study and for 10 days\\r\\n     after the last dose. Male participants must agree to comply with effective\\r\\n     contraceptive requirements.\\r\\n\\r\\n  -  Body mass index greater than or equal to (>=) 18.0 kilogram per meter square\\r\\n     (kg/m^2) and less than or equal to (<=) 28.0 kg/m^2 at the screening visit.\\r\\n\\r\\n  -  Medically healthy with no clinically significant medical history, physical\\r\\n     examination, laboratory profiles, vital signs, or electrocardiograms [ECGs], as\\r\\n     deemed by the principal investigator (PI) or designee, including the following:\\r\\n\\r\\n       -  Seated blood pressure (BP) (systolic BP/diastolic BP) >=90/50 millimeters of\\r\\n          mercury (mmHg) and <=140/90 mmHg at the screening visit.\\r\\n\\r\\n       -  Seated heart rate or pulse is >=50 beats per minute (bpm) and <=100 bpm at the\\r\\n          screening visit.\\r\\n\\r\\n       -  ECG findings are considered normal or not clinically significant by the PI or\\r\\n          designee at the screening visit.\\r\\n\\r\\n  -  Participant must be willing and able to understand and fully comply with all study\\r\\n     procedures and must be available for the duration of the study.\\r\\n\\r\\nExclusion criteria:\\r\\n\\r\\n  -  Site personnel or their family.\\r\\n\\r\\n  -  History or presence of clinically significant medical or psychiatric condition or\\r\\n     disease.\\r\\n\\r\\n  -  History of any illness or condition that might confound the results of the study or\\r\\n     poses an additional risk to the participant by their participation in the study.\\r\\n\\r\\n  -  History of allergy to study drug or any of its components.\\r\\n\\r\\n  -  History of stomach or intestinal surgery or resection that would potentially alter\\r\\n     absorption and/or excretion of orally administered drugs (uncomplicated appendectomy\\r\\n     and hernia repair will be allowed).\\r\\n\\r\\n  -  Clinical laboratory values at the time of screening or at check-in:\\r\\n\\r\\n       -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) >1.5 * the upper\\r\\n          limit normal (ULN).\\r\\n\\r\\n       -  Creatine phosphokinase (CPK) > the ULN.\\r\\n\\r\\n       -  Hemoglobin <11.0 grams per deciliter (g/dL) (<110.0 gram per liter [g/L]).\\r\\n\\r\\n       -  Absolute neutrophil count <1.8*10^9/liters (L) (<1800 per cubic millimeter\\r\\n          [/mm^3]).\\r\\n\\r\\n       -  Absolute lymphocyte count <0.8*10^9/L (<800/mm^3).\\r\\n\\r\\n       -  Platelet count <100*10^9/L (<100,000/mm^3).\\r\\n\\r\\n  -  A participant with out-of-range values may have the test repeated once at each time\\r\\n     point (screening or check-in) and the participant may be enrolled if the repeated\\r\\n     values are within protocol-specified ranges.\\r\\n\\r\\n  -  Ingestion of Seville orange- or grapefruit-containing foods or beverages within 7\\r\\n     days prior to check-in.\\r\\n\\r\\n  -  History of alcohol abuse or drug/chemical abuse within 2 years prior to check-in.\\r\\n\\r\\n  -  Continuous smoker who has used nicotine- or tobacco-containing products within 1\\r\\n     month prior to the first dosing based on participant self-reporting.\\r\\n\\r\\n  -  Female participants who have a positive pregnancy test result at the screening visit\\r\\n     or at check-in, are planning to become pregnant during the study or are lactating.\\r\\n\\r\\n  -  Positive results for urine drug test at the screening visit or at check-in.\\r\\n\\r\\n  -  Herpes infections:\\r\\n\\r\\n       -  Participants has active herpes virus infection, including herpes zoster or\\r\\n          herpes simplex 1 and 2 (demonstrated on physical examination and/or medical\\r\\n          history) at screening or check-in.\\r\\n\\r\\n       -  Participants has a history of serious herpetic infection that includes any\\r\\n          episode of disseminated disease, multi-dermatomal herpes zoster virus, herpes\\r\\n          encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2\\r\\n          episodes within 2 years).\\r\\n\\r\\n  -  Positive results for non-herpetic viral diseases at the screening visit:\\r\\n\\r\\n       -  Participant has presence of hepatitis C virus (HCV) antibody or a positive\\r\\n          confirmatory test result for HCV RNA (Ribonucleic acid) test or polymerase\\r\\n          chain reaction (PCR).\\r\\n\\r\\n       -  Participant has presence of positive result for hepatitis B surface antigen,\\r\\n          presence of hepatitis B virus deoxyribonucleic acid, or positive anti-hepatitis\\r\\n          B core antibody without concurrent positive hepatitis B surface antibody.\\r\\n\\r\\n  -  Participant has positive results for human immunodeficiency virus.\\r\\n\\r\\n  -  Positive results for Tuberculosis (TB) at the screening visit:\\r\\n\\r\\n       -  The participant has a history of active TB infection, regardless of treatment\\r\\n          status.\\r\\n\\r\\n       -  The participant has signs or symptoms of active TB (including but not limited\\r\\n          to chronic fever, chronic productive cough, night sweats, or weight loss) as\\r\\n          judged by the investigator.\\r\\n\\r\\n       -  The participant has evidence of latent TB as evidenced by a positive\\r\\n          QuantiFERON-TB Gold (QFT) result or tuberculosis-specific enzyme-linked\\r\\n          immunospot assay (T-Spot) OR 2 indeterminant QFT results or 2 borderline T-Spot\\r\\n          results.\\r\\n\\r\\n       -  The participant has had any imaging study during or 6 months prior to\\r\\n          screening, including x-ray, chest computed tomography, magnetic resonance\\r\\n          imaging, or other chest imaging suggesting evidence of current active or a\\r\\n          history of TB.\\r\\n\\r\\n  -  Positive result for Coronavirus disease 2019 (COVID-19) PCR test at the screening\\r\\n     visit.\\r\\n\\r\\n  -  Prior and concomitant therapy:\\r\\n\\r\\n       -  Participants who received a live or live-attenuated vaccine in the 60 days\\r\\n          prior to study drug administration. Administration of nonlive-attenuated\\r\\n          vaccines or boosters for COVID-19 (for example [eg,] RNA-based vaccines,\\r\\n          inactivated adenovirus-based vaccines, protein-based vaccines) in the 14 days\\r\\n          prior to first dosing. The study site should follow local guidelines related to\\r\\n          COVID-19.\\r\\n\\r\\n       -  Use or intent to use any medications/products known to alter drug absorption,\\r\\n          metabolism, or elimination processes, including CYP3A4 and/or P-glycoprotein\\r\\n          (P-gp) inhibitors or inducers and St. John's wort, within 30 days prior to\\r\\n          check-in.\\r\\n\\r\\n       -  Use or intent to use any prescription medications/products or over-the-counter\\r\\n          (OTC) medications within 14 days prior to check-in.\\r\\n\\r\\n       -  Use or intent to use any nonprescription medications/products including\\r\\n          phyto-therapeutic/herbal/plant-derived preparations within 14 days prior to\\r\\n          check-in\\r\\n\\r\\n  -  Donation of blood or significant blood loss within 56 days prior to study drug\\r\\n     administration. Plasma donation within 7 days prior to the first dosing.\\r\\n\\r\\n  -  Participation in another clinical study and having received its study drug within 30\\r\\n     days or 5 elimination half-lives prior to study drug administration. The 30-day or 5\\r\\n     elimination half-lives window will be derived from the date of the last blood\\r\\n     collection or dosing, whichever is later, in the previous study to Day 1 of the\\r\\n     current study.\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '45 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Takeda Contact',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+1-877-825-3327',\n",
       "      'email': 'medinfoUS@takeda.com'}],\n",
       "    'overallOfficials': [{'name': 'Study Director',\n",
       "      'affiliation': 'Takeda',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Huashan Hospital Fudan University',\n",
       "      'city': 'Shanghai',\n",
       "      'zip': '201100',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Site Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '021-52888045',\n",
       "        'email': 'Zhangj_fudan@163.com'},\n",
       "       {'name': 'Jing Zhang, Dr.', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'To obtain more information about this study, click this link',\n",
       "      'url': 'https://clinicaltrials.takeda.com/study-detail/878f1c20e19f46a5?idFilter=%5B%22TAK-279-1005%22%5D'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Takeda provides access to the de-identified individual participant data (IPD) for\\r\\neligible studies to aid qualified researchers in addressing legitimate scientific\\r\\nobjectives (Takeda's data sharing commitment is available on\\r\\nhttps://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be\\r\\nprovided in a secure research environment following approval of a data sharing request,\\r\\nand under the terms of a data sharing agreement.\",\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "    'accessCriteria': 'IPD from eligible studies will be shared with qualified researchers according to the\\r\\ncriteria and process described on https://vivli.org/ourmember/takeda/. For approved\\r\\nrequests, the researchers will be provided access to anonymized data (to respect patient\\r\\nprivacy in line with applicable laws and regulations) and with information necessary to\\r\\naddress the research objectives under the terms of a data sharing agreement.',\n",
       "    'url': 'https://vivli.org/ourmember/takeda/'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06095128',\n",
       "    'orgStudyIdInfo': {'id': 'Vedolizumab-4054'},\n",
       "    'organization': {'fullName': 'Takeda', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)',\n",
       "    'officialTitle': 'An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-07-09', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2027-07-09', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-18',\n",
       "    'studyFirstSubmitQcDate': '2023-10-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-10-23', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-24',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-28', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Takeda', 'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': True},\n",
       "   'descriptionModule': {'briefSummary': 'The main aim of this study is to learn about the effect of treatment with vedolizumab IV\\r\\n(vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative\\r\\ncolitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the\\r\\ndouble treatment.\\r\\n\\r\\nAll participants will receive vedolizumab together with tofacitinib for 8 weeks and will\\r\\nbe checked for response. Participants who show a response to the treatment after 8 weeks\\r\\nwill be treated with vedolizumab alone for an additional 44 weeks.\\r\\n\\r\\nEach participant will be followed up for at least 26 weeks after the last dose of\\r\\nvedolizumab.',\n",
       "    'detailedDescription': 'The drugs being tested in this study are called Vedolizumab and Tofacitinib. Vedolizumab\\r\\nand Tofacitinib dual targeted therapy is being tested to treat people with moderate to\\r\\nsevere ulcerative colitis (UC) who have experienced inadequate response, loss of response\\r\\nor intolerance to no more than 2 prior tumor necrosis factor (TNF) antagonists. This\\r\\nstudy will look at the clinical remission in people who take Vedolizumab and Tofacitinib\\r\\ndual targeted therapy.\\r\\n\\r\\nThe study will enroll approximately 65 patients. All the participants will be enrolled in\\r\\na single treatment group to receive dual targeted treatment with Vedolizumab and\\r\\nTofacitinib for the first 8 weeks:\\r\\n\\r\\nVedolizumab 300 mg + Tofacitinib 10 mg\\r\\n\\r\\nOnly those participants who show a clinical response at Week 8 will transition to\\r\\nVedolizumab monotherapy for 44 weeks.\\r\\n\\r\\nThis multi-center trial will be conducted in the United States and Canada. The overall\\r\\nduration of the study is up to 76 weeks. Participants will be followed up for 26 weeks\\r\\nafter the last dose of the study drug for safety.'},\n",
       "   'conditionsModule': {'conditions': ['Ulcerative Colitis'],\n",
       "    'keywords': ['Drug Therapy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE4'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 65, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Vedolizumab 300 mg + Tofacitinib 10 mg',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive Vedolizumab 300 mg , intravenous (IV) infusion, at Week 0, Week\\r\\n2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to\\r\\nWeek 8. Participants with clinical response at Week 8 will transition to receive\\r\\nvedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46.',\n",
       "      'interventionNames': ['Drug: Vedolizumab', 'Drug: Tofacitinib']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Vedolizumab',\n",
       "      'description': 'Vedolizumab IV infusions',\n",
       "      'armGroupLabels': ['Vedolizumab 300 mg + Tofacitinib 10 mg'],\n",
       "      'otherNames': ['Entyvio', 'MLN0002']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Tofacitinib',\n",
       "      'description': 'Tofacitinib Tablets',\n",
       "      'armGroupLabels': ['Vedolizumab 300 mg + Tofacitinib 10 mg'],\n",
       "      'otherNames': ['Xeljanz', 'CP-690', 'CP-550']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score',\n",
       "      'description': \"Clinical remission based on complete Mayo Score is where a participant achieves complete\\r\\nMayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic\\r\\nScore includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index\\r\\n(PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3\\r\\npoints) where 0=none and 3=severe disease and summed to give a total disease activity\\r\\nscore (range, 0-12), with higher scores representing more severe disease activity.\",\n",
       "      'timeFrame': 'At Week 8'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving Clinical Remission at Week 52 Based on Complete Mayo Score',\n",
       "      'description': \"Clinical remission based on complete Mayo Score is where a participant achieves complete\\r\\nMayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic\\r\\nScore includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index\\r\\n(PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3\\r\\npoints) where 0=none and 3=severe disease and summed to give a total disease activity\\r\\nscore (range, 0-12), with higher scores representing more severe disease activity\",\n",
       "      'timeFrame': 'At Week 52'},\n",
       "     {'measure': 'Percentage of Participants Achieving Clinical Remission at Weeks 8, 14, and 26 Based on Partial Mayo Score',\n",
       "      'description': 'Clinical remission based on complete Mayo Score is where a participant achieves complete\\r\\nMayo Score ≤2 points with no individual subscore >1. Partial Mayo Score consists of 3\\r\\nvariables of the Mayo Clinic Score: stool frequency, rectal bleeding and PGA. Each\\r\\nvariable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease.\\r\\nThese scores are summed to give a total score range of 0 to 9 where higher scores\\r\\nindicate maximum disease activity..',\n",
       "      'timeFrame': 'At Weeks 8, 14 and 26'},\n",
       "     {'measure': 'Percentage of Participants Achieving Clinical Response at Weeks 2, 6, 8, 14, 26 and 52 Based on Complete or Partial Mayo Score',\n",
       "      'description': 'Clinical response based on complete Mayo Score is where a participant achieves a\\r\\nreduction in complete Mayo score of ≥3 points and ≥30% from Baseline or a partial Mayo\\r\\nscore of ≥2 points and ≥25% from baseline, if the complete Mayo score was not performed\\r\\nat the visit with an accompanying decrease in rectal bleeding subscore of ≥1 point or\\r\\nabsolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4\\r\\nvariables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a\\r\\n4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total\\r\\ndisease activity score (range, 0-12), with higher scores representing more severe disease\\r\\nactivity.',\n",
       "      'timeFrame': 'At Weeks 2, 6, 8, 14, 26, and 52'},\n",
       "     {'measure': 'Percentage of Participants Achieving Clinical Remission at Week 8 and Week 52 Based on Modified Mayo Score',\n",
       "      'description': 'Clinical remission based on modified Mayo Score is where a participant achieves component\\r\\nmodified Mayo score of ≤2 with modified MES ≤1, rectal bleeding = 0, and stool frequency\\r\\n≤1. Modified Mayo Score consists of 3 variables: stool frequency, rectal bleeding and\\r\\nMES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe\\r\\ndisease. These scores are summed to give a total score range of 0 to 9 where higher\\r\\nscores indicate maximum disease activity.',\n",
       "      'timeFrame': 'At Weeks 8 and 52'},\n",
       "     {'measure': 'Percentage of Participants With Durable Clinical Remission at Week 8 and Week 52',\n",
       "      'description': 'Durable clinical remission is defined as the clinical remission at Week 8 and Week 52.\\r\\nClinical remission is defined as complete Mayo Score of ≤2 points and no individual\\r\\nsubscore >1 point at Weeks 8 and 52. The complete Mayo Clinic Score includes 4 variables:\\r\\nStool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point\\r\\nscale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease\\r\\nactivity score (range, 0-12), with higher scores representing more severe disease\\r\\nactivity.',\n",
       "      'timeFrame': 'At Week 8 and Week 52'},\n",
       "     {'measure': 'Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 8',\n",
       "      'description': 'Clinical remission is defined as complete Mayo Score of ≤2 points and no individual\\r\\nsubscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool\\r\\nfrequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale\\r\\n(0-3 points) where 0=none and 3=severe disease and summed to give a total disease\\r\\nactivity score (range, 0-12), with higher scores representing more severe disease\\r\\nactivity.',\n",
       "      'timeFrame': 'At Week 8'},\n",
       "     {'measure': 'Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 8',\n",
       "      'description': 'Corticosteroid-free clinical remission is where a participant achieves\\r\\ncorticosteroid-free clinical remission at Week 8. Clinical remission is defined as\\r\\ncomplete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The\\r\\ncomplete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA\\r\\nand MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and\\r\\n3=severe disease and summed to give a total disease activity score (range, 0-12), with\\r\\nhigher scores representing more severe disease activity.',\n",
       "      'timeFrame': 'At Week 8'},\n",
       "     {'measure': 'Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 52',\n",
       "      'description': 'Clinical remission is defined as complete Mayo Score of ≤2 points and no individual\\r\\nsubscore >1 point at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool\\r\\nfrequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale\\r\\n(0-3 points) where 0=none and 3=severe disease and summed to give a total disease\\r\\nactivity score (range, 0-12), with higher scores representing more severe disease\\r\\nactivity.',\n",
       "      'timeFrame': 'At Week 52'},\n",
       "     {'measure': 'Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 52',\n",
       "      'description': 'Corticosteroid-free clinical remission is where a participant achieves\\r\\ncorticosteroid-free clinical remission at Week 52, and was off corticosteroids at least 3\\r\\nmonths prior to Week 52. Clinical remission is defined as complete Mayo Score of ≤2\\r\\npoints and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score\\r\\nincludes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is\\r\\nscored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to\\r\\ngive a total disease activity score (range, 0-12), with higher scores representing more\\r\\nsevere disease activity.',\n",
       "      'timeFrame': 'At Week 52'},\n",
       "     {'measure': 'Percentage of Participants Achieving Clinical Response at Week 8',\n",
       "      'description': 'Clinical response based on complete Mayo Score is where a participant achieves a\\r\\nreduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying\\r\\ndecrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of\\r\\n≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal\\r\\nbleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where\\r\\n0=none and 3=severe disease and summed to give a total disease activity score (range,\\r\\n0-12), with higher scores representing more severe disease activity.',\n",
       "      'timeFrame': 'At Week 8'},\n",
       "     {'measure': 'Percentage of Participants With Mucosal Healing Based on MES at Week 52',\n",
       "      'description': 'Mucosal healing is defined as MES ≤1 point at Week 52. MES is a subscale of the Mayo\\r\\nscore, an instrument designed to measure disease activity of UC. The subscale is graded\\r\\nfrom 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa,\\r\\n1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked\\r\\nerythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous\\r\\nbleeding, ulceration). Higher scores indicate more severe disease.',\n",
       "      'timeFrame': 'At Week 52'},\n",
       "     {'measure': 'Percentage of Participants With Histological Remission Based on Geboes Score at Week 52',\n",
       "      'description': 'Histological remission is defined as Geboes score <2 at Week 52. The Geboes score is a\\r\\nhistological grading system for assessing histological disease activity in UC. The Geboes\\r\\nscore evaluates 7 histological features. It consists of 6 grades (0-6). Each of the\\r\\ngrades is divided into subgrades, based on the severity of tissue abnormalities or the\\r\\nextent of inflammatory cell infiltration. The Geboes score ranges from 0.0 to 5.4, and\\r\\nhigher grades are indicative of more severe disease activity.',\n",
       "      'timeFrame': 'At Week 52'},\n",
       "     {'measure': 'Change in C-Reactive Protein Levels (CRP) From Baseline',\n",
       "      'description': 'CRP is a useful marker of inflammation in participants with inflammatory bowel disease\\r\\n(IBD). In participants with UC, elevated CRP has been associated with severe clinical\\r\\nactivity',\n",
       "      'timeFrame': 'Baseline to Weeks 2, 6, 8, 14, 26, 42 and 52'},\n",
       "     {'measure': 'Change in Fecal Calprotectin Concentrations From Baseline',\n",
       "      'description': 'Fecal calprotectin is a biomarker for intestinal inflammatory activity.',\n",
       "      'timeFrame': 'Baseline to Weeks 2, 6, 8, 14, 26, 42 and 52'},\n",
       "     {'measure': 'Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline',\n",
       "      'description': 'The IBDQ is an instrument used to assess quality of life in adult participants with\\r\\ninflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related\\r\\nQuality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social\\r\\nFunction (5 items), and Systemic Function (5 items). Participants are asked to recall\\r\\nsymptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert\\r\\nscale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from\\r\\neach domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting\\r\\nworse HRQOL. A positive change from Baseline indicates improvement.',\n",
       "      'timeFrame': 'At Weeks 8, 26 and 52'},\n",
       "     {'measure': 'Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline',\n",
       "      'description': 'The FACIT-F is a validated, 13-item questionnaire to assess fatigue in participants with\\r\\na variety of chronic illnesses, including participants with IBD. Items are rated on a\\r\\n5-point Likert scale and the total score ranges from 0 to 52 with lower scores\\r\\nrepresenting greater fatigue.',\n",
       "      'timeFrame': 'At Weeks 8, 26 and 52'},\n",
       "     {'measure': 'Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)',\n",
       "      'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally\\r\\nassociated with the use of the study intervention, whether or not the occurrence is\\r\\nconsidered related to the study intervention.',\n",
       "      'timeFrame': 'Up to 76 Weeks'},\n",
       "     {'measure': 'Number of Participants With Clinically Significant Change in Vital Signs From Baseline',\n",
       "      'description': 'Vital signs will include body temperature, respiratory rate, blood pressure (resting more\\r\\nthan 5 minutes), and pulse (resting more than 5 minutes).',\n",
       "      'timeFrame': 'Up to 76 Weeks'},\n",
       "     {'measure': 'Number of Participants With Clinically Significant Physical Examination Findings',\n",
       "      'description': 'A baseline physical examination (defined as the assessment before first dose of study\\r\\nmedication) will consist of the following body systems: general appearance; HEENT (head,\\r\\neyes, ears, nose, and throat); cardiovascular system; respiratory system;\\r\\ngastrointestinal system; dermatologic system; extremities; musculoskeletal system;\\r\\nnervous system; lymph nodes; and other. All subsequent physical examinations will assess\\r\\nclinically significant changes from the assessment prior to first dose examination.',\n",
       "      'timeFrame': 'At Baseline and From Week 14 to Week 72'},\n",
       "     {'measure': 'Number of Participants With Markedly Abnormal Laboratory Values',\n",
       "      'description': 'Standard laboratory tests will include clinical chemistry, hematology, coagulation and\\r\\nurinalysis.',\n",
       "      'timeFrame': 'Up to Week 76'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  1. Has a confirmed diagnosis of UC established at least 3 months prior to screening, by\\r\\n     clinical and endoscopic evidence and corroborated by a histopathology report.\\r\\n\\r\\n  2. Has moderately to severely active UC as determined by a complete Mayo score\\r\\n     [including physician's global assessment (PGA)] of 6 to 12 with a rectal bleeding\\r\\n     subscore ≥>1 and a centrally assessed endoscopic subscore ≥2 at screening.\\r\\n\\r\\n  3. Has evidence of UC extending proximally to the rectum [≥15 centimeter (cm) of\\r\\n     involved colon].\\r\\n\\r\\n  4. Participants with extensive colitis or pancolitis of >8 years duration or left sided\\r\\n     colitis >12 years duration must have documented evidence that a surveillance\\r\\n     colonoscopy was performed within 12 months of the initial screening visit.\\r\\n\\r\\n  5. Participants with a family history of colorectal cancer, personal history of\\r\\n     increased colorectal cancer risk, age >50 years, or other known risk factors must be\\r\\n     up to date on colorectal cancer surveillance.\\r\\n\\r\\n  6. Has demonstrated an inadequate response to, loss of response to, or intolerance to\\r\\n     no more than 2 TNF antagonists.\\r\\n\\r\\n  7. If using corticosteroids must be on a stable dose of oral corticosteroids up to a\\r\\n     maximum of 20 milligrams per day (mg/day) of prednisone or equivalent for at least 4\\r\\n     weeks prior to screening endoscopy and must be willing to follow a mandatory taper\\r\\n     of corticosteroids from enrollment.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nGastrointestinal Exclusion criteria:\\r\\n\\r\\n  1. Has any of the following UC-related complications:\\r\\n\\r\\n       1. Acute severe UC.\\r\\n\\r\\n       2. The participant has had extensive colonic resection, subtotal or total\\r\\n          colectomy.\\r\\n\\r\\n       3. The participant has clinical evidence of abdominal abscess or toxic megacolon.\\r\\n\\r\\n       4. The participant has had ileostomy, colostomy, or known fixed symptomatic\\r\\n          stenosis of the intestine.\\r\\n\\r\\n       5. Short bowel syndrome.\\r\\n\\r\\n  2. Has Crohn's colitis, indeterminate colitis, ischemic colitis, nonsteroidal\\r\\n     anti-inflammatory drug (NSAID) induced colitis, idiopathic colitis (i.e, colitis not\\r\\n     consistent with UC), radiation colitis, microscopic colitis, colonic mucosal\\r\\n     dysplasia, or untreated bile acid malabsorption.\\r\\n\\r\\n  3. Has uncontrolled primary sclerosing cholangitis.\\r\\n\\r\\nInfectious Disease Exclusion Criteria:\\r\\n\\r\\n  1. Has any evidence of an active infection during screening.\\r\\n\\r\\n  2. Has active or latent tuberculosis (TB), regardless of treatment history, as\\r\\n     evidenced by any of the following:\\r\\n\\r\\n     a. History of TB. b. A diagnostic TB test performed during screening that is\\r\\n     positive, as defined by: i. A positive QuantiFERON test or 2 successive\\r\\n     indeterminate QuantiFERON tests or ii. A tuberculin skin test reaction ≥10 mm (≥5 mm\\r\\n     in subjects receiving the equivalent of >15 mg/day prednisone).\\r\\n\\r\\n  3. A positive test for hepatitis B virus (HBV).\\r\\n\\r\\n  4. A positive test for hepatitis C virus (HCV).\\r\\n\\r\\n  5. Evidence of, or treatment for, Clostridium difficile infection or other intestinal\\r\\n     pathogen within 28 days prior to first dose of study treatment.\\r\\n\\r\\n  7. Evidence of active Cytomegalovirus (CMV) infection at screening.\\r\\n\\r\\nMedication exclusion criteria:\\r\\n\\r\\n  1. Has received immunomodulators (eg, 6-mercaptopurine, azathioprine, and methotrexate)\\r\\n     within 4 weeks prior to first dose or immunosuppressants (eg, cyclosporine,\\r\\n     tacrolimus) within 8 weeks prior to first dose.\\r\\n\\r\\n  2. Any medicinal product, herbal medication, or natural health product which might\\r\\n     interfere with cytochrome P450 genotype 3A4 (CYP3A4) within 2 weeks prior to\\r\\n     enrollment.\\r\\n\\r\\n  3. Has received any of the following medical therapies for UC:\\r\\n\\r\\n       1. IV antibiotics within 8 weeks prior to enrollment.\\r\\n\\r\\n       2. Any rectal therapy for treatment of UC within 2 weeks prior to screening\\r\\n          endoscopy.\\r\\n\\r\\n       3. NSAIDs as long-term treatment, defined as use for at least 4 days a week each\\r\\n          month (>100 milligrams (mg) daily or acetaminophen and aspirin >325 mg daily.)\\r\\n\\r\\n  4. Has received a live virus or live bacterial vaccine within 4 weeks prior to\\r\\n     enrollment, or planned vaccination during the study and for 12 weeks after last\\r\\n     dose.\\r\\n\\r\\nGeneral Exclusion Criteria:\\r\\n\\r\\n  1. Has any of the following cardiovascular or thrombotic conditions:\\r\\n\\r\\n       1. Recent (within past 6 months) cerebrovascular accident, myocardial infarction,\\r\\n          or coronary stenting.\\r\\n\\r\\n       2. Recent (within past 6 months) moderate to severe congestive heart failure (New\\r\\n          York Heart Association class III or IV).\\r\\n\\r\\n       3. Prior history of thrombotic events, including deep vein thrombosis and\\r\\n          pulmonary embolism.\\r\\n\\r\\n       4. Known inherited conditions that predispose to hypercoagulability.\\r\\n\\r\\n  2. History of lymphoproliferative disease, including lymphoma, or signs and symptoms\\r\\n     suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or\\r\\n     splenomegaly.\\r\\n\\r\\n  3. A surgical procedure requiring general anesthesia within 3 months prior to screening\\r\\n     or is planning to undergo major surgery during the study period.\\r\\n\\r\\n  4. Any investigational procedure ≤4 weeks prior to screening.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Takeda Contact',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+1-877-825-3327',\n",
       "      'email': 'medinfoUS@takeda.com'}],\n",
       "    'overallOfficials': [{'name': 'Study Director',\n",
       "      'affiliation': 'Takeda',\n",
       "      'role': 'STUDY_DIRECTOR'}],\n",
       "    'locations': [{'facility': 'Cedars Sinai Medical Center',\n",
       "      'city': 'Los Angeles',\n",
       "      'state': 'California',\n",
       "      'zip': '90048',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Site Contact',\n",
       "        'role': 'CONTACT',\n",
       "        'email': 'andres.yarur@cshs.org'},\n",
       "       {'name': 'Andres Yarur', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'To obtain more information about this study, click this link',\n",
       "      'url': 'https://clinicaltrials.takeda.com/study-detail/bfc3d28999a04bba?idFilter=%5B%22Vedolizumab-4054%22%5D'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"Takeda provides access to the de-identified individual participant data (IPD) for\\r\\neligible studies to aid qualified researchers in addressing legitimate scientific\\r\\nobjectives (Takeda's data sharing commitment is available on\\r\\nhttps://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be\\r\\nprovided in a secure research environment following approval of a data sharing request,\\r\\nand under the terms of a data sharing agreement.\",\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'],\n",
       "    'accessCriteria': 'IPD from eligible studies will be shared with qualified researchers according to the\\r\\ncriteria and process described on https://vivli.org/ourmember/takeda/. For approved\\r\\nrequests, the researchers will be provided access to anonymized data (to respect patient\\r\\nprivacy in line with applicable laws and regulations) and with information necessary to\\r\\naddress the research objectives under the terms of a data sharing agreement.',\n",
       "    'url': 'https://vivli.org/ourmember/takeda/'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003092',\n",
       "      'term': 'Colitis'},\n",
       "     {'id': 'D000003093', 'term': 'Colitis, Ulcerative'},\n",
       "     {'id': 'D000014456', 'term': 'Ulcer'}],\n",
       "    'ancestors': [{'id': 'D000005759', 'term': 'Gastroenteritis'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000003108', 'term': 'Colonic Diseases'},\n",
       "     {'id': 'D000007410', 'term': 'Intestinal Diseases'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'},\n",
       "     {'id': 'D000015212', 'term': 'Inflammatory Bowel Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M17206',\n",
       "      'name': 'Ulcer',\n",
       "      'asFound': 'Ulcerative',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6320',\n",
       "      'name': 'Colitis',\n",
       "      'asFound': 'Colitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6321',\n",
       "      'name': 'Colitis, Ulcerative',\n",
       "      'asFound': 'Ulcerative Colitis',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8875', 'name': 'Gastroenteritis', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6336', 'name': 'Colonic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10444', 'name': 'Intestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M17917',\n",
       "      'name': 'Inflammatory Bowel Diseases',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'C000543529',\n",
       "      'term': 'Vedolizumab'},\n",
       "     {'id': 'C000479163', 'term': 'Tofacitinib'}],\n",
       "    'ancestors': [{'id': 'D000075242', 'term': 'Janus Kinase Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000005765', 'term': 'Gastrointestinal Agents'}],\n",
       "    'browseLeaves': [{'id': 'M258018',\n",
       "      'name': 'Tofacitinib',\n",
       "      'asFound': 'Burn',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M288641',\n",
       "      'name': 'Vedolizumab',\n",
       "      'asFound': 'Management Program',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1474', 'name': 'Janus Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M8881', 'name': 'Gastrointestinal Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06320405',\n",
       "    'orgStudyIdInfo': {'id': 'STUDY00025940'},\n",
       "    'secondaryIdInfos': [{'id': 'NCI-2024-01397',\n",
       "      'type': 'REGISTRY',\n",
       "      'domain': 'CTRP (Clinical Trial Reporting Program)'},\n",
       "     {'id': 'STUDY00025940',\n",
       "      'type': 'OTHER',\n",
       "      'domain': 'OHSU Knight Cancer Institute'}],\n",
       "    'organization': {'fullName': 'OHSU Knight Cancer Institute',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors',\n",
       "    'officialTitle': 'A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2027-04-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-04-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-03-05',\n",
       "    'studyFirstSubmitQcDate': '2024-03-13',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-03-20', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Shivaani Kummar',\n",
       "     'investigatorTitle': 'Principal Investigator',\n",
       "     'investigatorAffiliation': 'OHSU Knight Cancer Institute'},\n",
       "    'leadSponsor': {'name': 'OHSU Knight Cancer Institute', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Oregon Health and Science University',\n",
       "      'class': 'OTHER'},\n",
       "     {'name': 'Incyte Corporation', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in\\r\\ncombination with retifanlimab and paclitaxel for the treatment of patients with a solid\\r\\ntumor that may have spread from where it first started to nearby tissue, lymph nodes, or\\r\\ndistant parts of the body (advanced) or that has spread from where it first started\\r\\n(primary site) to other places in the body (metastatic). Axatilimab is a monoclonal\\r\\nantibody that may interfere with the ability of tumor cells to grow and spread.\\r\\nImmunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's\\r\\nimmune system attack the cancer, and may interfere with the ability of tumor cells to\\r\\ngrow and spread. Paclitaxel is in a class of medications called antimicrotubule agents.\\r\\nIt stops cancer cells from growing and dividing and may kill them. Giving axatilimab in\\r\\ncombination with retifanlimab and paclitaxel may be safe, tolerable and/or effective in\\r\\ntreating patients with advanced or metastatic solid tumors.\",\n",
       "    'detailedDescription': 'PRIMARY OBJECTIVES:\\r\\n\\r\\nI. Phase Ib: Determine the safety and tolerability of the combination of axatilimab,\\r\\nretifanlimab, and paclitaxel in patients with advanced solid tumors.\\r\\n\\r\\nII. Phase II: Determine the efficacy of the combination of axatilimab, retifanlimab, and\\r\\npaclitaxel in patients with advanced solid tumors.\\r\\n\\r\\nSECONDARY OBJECTIVES:\\r\\n\\r\\nI. Determine the safety and tolerability of the combination of axatilimab, retifanlimab,\\r\\nand paclitaxel in patients with advanced solid tumors treated in phase II.\\r\\n\\r\\nII. Explore treatment related changes in the tumor microenvironment (TME) following\\r\\ntreatment with the combination of axatilimab, retifanlimab, and paclitaxel in advanced\\r\\nsolid tumors.\\r\\n\\r\\nIII. Assess predictive biomarkers of response in peripheral blood.\\r\\n\\r\\nOUTLINE:\\r\\n\\r\\nPatients receive axatilimab intravenously (IV) over 30 minutes on day -8, prior to cycle\\r\\n1. Beginning in cycle 1 day 1, patients receive axatilimab IV over 30 minutes on days 8\\r\\nand 21 of each cycle, retifanlimab IV over 30-60 minutes on day 1 of each cycle, and\\r\\npaclitaxel IV over 60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28\\r\\ndays in the absence of disease progression or unacceptable toxicity. Patients also\\r\\nundergo tumor biopsy, computed tomography (CT) scan, and blood sample collection at\\r\\nscreening and on study and may undergo magnetic resonance imaging (MRI) and/or positron\\r\\nemission tomography (PET) scan at screening and on study.\\r\\n\\r\\nAfter completion of study treatment, patients are followed up at 30 and 90 days.'},\n",
       "   'conditionsModule': {'conditions': ['Advanced Malignant Solid Neoplasm',\n",
       "     'Metastatic Malignant Solid Neoplasm',\n",
       "     'Recurrent Malignant Solid Neoplasm',\n",
       "     'Refractory Malignant Solid Neoplasm']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1', 'PHASE2'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 38, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Treatment (axatilimab, retifanlimab, paclitaxel)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients receive axatilimab IV over 30 minutes on day -8, prior to cycle 1. Beginning in\\r\\ncycle 1 day 1, patients receive axatilimab IV over 30 minutes on days 8 and 21 of each\\r\\ncycle, retifanlimab IV over 30-60 minutes on day 1 of each cycle, and paclitaxel IV over\\r\\n60 minutes on days 1, 8, and 15 of each cycle. Cycles repeat every 28 days in the absence\\r\\nof disease progression or unacceptable toxicity. Patients also undergo tumor biopsy, CT\\r\\nscan, and blood sample collection at screening and on study and may undergo MRI and/or\\r\\nPET scan at screening and on study.',\n",
       "      'interventionNames': ['Biological: Axatilimab',\n",
       "       'Procedure: Biopsy',\n",
       "       'Procedure: Biospecimen Collection',\n",
       "       'Procedure: Computed Tomography',\n",
       "       'Procedure: Magnetic Resonance Imaging',\n",
       "       'Drug: Paclitaxel',\n",
       "       'Procedure: Positron Emission Tomography',\n",
       "       'Biological: Retifanlimab']}],\n",
       "    'interventions': [{'type': 'BIOLOGICAL',\n",
       "      'name': 'Axatilimab',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['Anti-M-CSFR Monoclonal Antibody SNDX-6352',\n",
       "       'SNDX 6352',\n",
       "       'SNDX-6352',\n",
       "       'SNDX6352',\n",
       "       'UCB6352']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biopsy',\n",
       "      'description': 'Undergo tumor biopsy',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['BIOPSY_TYPE', 'Bx']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Biospecimen Collection',\n",
       "      'description': 'Undergo blood sample collection',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['Biological Sample Collection',\n",
       "       'Biospecimen Collected',\n",
       "       'Specimen Collection']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Computed Tomography',\n",
       "      'description': 'Undergo CT scan',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['CAT',\n",
       "       'CAT Scan',\n",
       "       'Computed Axial Tomography',\n",
       "       'Computerized Axial Tomography',\n",
       "       'Computerized axial tomography (procedure)',\n",
       "       'Computerized Tomography',\n",
       "       'CT',\n",
       "       'CT Scan',\n",
       "       'tomography']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Magnetic Resonance Imaging',\n",
       "      'description': 'Undergo MRI',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['Magnetic Resonance',\n",
       "       'Magnetic resonance imaging (procedure)',\n",
       "       'Magnetic Resonance Imaging Scan',\n",
       "       'Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance',\n",
       "       'MR',\n",
       "       'MR Imaging',\n",
       "       'MRI',\n",
       "       'MRI Scan',\n",
       "       'MRIs',\n",
       "       'NMR Imaging',\n",
       "       'NMRI',\n",
       "       'Nuclear Magnetic Resonance Imaging',\n",
       "       'sMRI',\n",
       "       'Structural MRI']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Paclitaxel',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['Anzatax',\n",
       "       'Asotax',\n",
       "       'Bristaxol',\n",
       "       'Praxel',\n",
       "       'Taxol',\n",
       "       'Taxol Konzentrat']},\n",
       "     {'type': 'PROCEDURE',\n",
       "      'name': 'Positron Emission Tomography',\n",
       "      'description': 'Undergo PET scan',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['Medical Imaging, Positron Emission Tomography',\n",
       "       'PET',\n",
       "       'PET Scan',\n",
       "       'Positron emission tomography (procedure)',\n",
       "       'Positron Emission Tomography Scan',\n",
       "       'Positron-Emission Tomography',\n",
       "       'proton magnetic resonance spectroscopic imaging',\n",
       "       'PT']},\n",
       "     {'type': 'BIOLOGICAL',\n",
       "      'name': 'Retifanlimab',\n",
       "      'description': 'Given IV',\n",
       "      'armGroupLabels': ['Treatment (axatilimab, retifanlimab, paclitaxel)'],\n",
       "      'otherNames': ['INCMGA 0012',\n",
       "       'INCMGA-0012',\n",
       "       'INCMGA00012',\n",
       "       'INCMGA0012',\n",
       "       'MGA 012',\n",
       "       'MGA-012',\n",
       "       'MGA012',\n",
       "       'Retifanlimab-dlwr',\n",
       "       'Zynyz']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of dose limiting toxicities (phase Ib)',\n",
       "      'description': 'Will be coded by system organ class, MedDRA preferred term, and severity grade using\\r\\nCommon Terminology Criteria for Adverse Events (version 5.0).',\n",
       "      'timeFrame': 'From the first dose of axatilimab (day -8) to the end of cycle 1 (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'},\n",
       "     {'measure': 'Recommended phase 2 dose of the study drug combination (phase Ib)',\n",
       "      'timeFrame': 'From the first dose of axatilimab (day -8) to the end of cycle 1 (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'},\n",
       "     {'measure': 'Clinical benefit rate (phase Ib/II)',\n",
       "      'description': 'Defined as percentage of participants with complete response or partial response\\r\\nconfirmed by scans at least 4 weeks apart, or stable disease for > 4 months. Will be\\r\\nreported with exact 95% confidence interval.',\n",
       "      'timeFrame': 'From screening assessment to the end of cycle 6 assessment (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Incidence of ≥ grade 3 toxicities possibly or definitely related to study drugs',\n",
       "      'description': 'Will be categorized and tabulated for reporting. The analyses for reporting may include\\r\\ndescriptive statistical analyses of the overall set of phase II adverse events.',\n",
       "      'timeFrame': 'From the first dose of axatilimab (day -8) to 90 days after the end of treatment visit (an average of 6 months)'},\n",
       "     {'measure': 'Changes in immune cell composition and functionality',\n",
       "      'description': 'Will be characterized in peripheral blood using flow cytometry (FC) and candidate protein\\r\\nbiomarkers will be identified in tumor tissue using multiplexed immunohistochemistry.\\r\\nChanges in immune cell composition and functionality at the biopsy during cycle 2 will be\\r\\nassessed by paired t-test.',\n",
       "      'timeFrame': 'From screening until cycle 2 day 1 biopsy (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'},\n",
       "     {'measure': 'Change in immune cell population',\n",
       "      'description': 'To assess predictive biomarkers of response in peripheral blood, changes in immune cell\\r\\npopulations in peripheral blood, including reduced presence of CD14dimCD16+ monocytes and\\r\\nincreased presence of CD8+ T effector memory subsets, at the end of the study between\\r\\nresponders and non-responders will be assessed using repeated measures of analysis of\\r\\ncovariance over time to accommodate a longitudinal nature of peripheral blood draws for\\r\\nflow cytometry.',\n",
       "      'timeFrame': 'From screening to end of treatment visit (an average of 6 months)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Ability to comprehend the investigational nature of the study and provide informed\\r\\n     consent. Written informed consent must be obtained prior to any study specific\\r\\n     procedures or interventions\\r\\n\\r\\n  -  Age ≥ 18 years at the time of consent. All participants, irrespective of their\\r\\n     gender, gender identity, race, and ethnicity, will be included\\r\\n\\r\\n  -  Certified, documented diagnosis of a metastatic solid tumor based on pathology\\r\\n     review\\r\\n\\r\\n  -  Presence of at least one lesion that is measurable per Response Evaluation Criteria\\r\\n     in Solid Tumors (RECIST) 1.1 and another lesion that is amenable to tumor biopsy\\r\\n\\r\\n  -  Relapsed from, or refractory to, standard of care (SOC) systemic therapy known to\\r\\n     prolong survival or if, in the opinion of the primary treating oncologist, a\\r\\n     clinical trial is the best option for the next line of treatment based on response\\r\\n     and/or tolerability to available therapies\\r\\n\\r\\n  -  Investigational therapy is permitted after a wash-out period of 5 half-lives (if\\r\\n     known), or 28 days, whichever is shorter, prior to study day -8. Prior use of an\\r\\n     investigational agent for imaging, such as T cell imaging, is permitted\\r\\n\\r\\n  -  Prior treatment with taxanes. A wash-out of period of ≥ 3 months prior to day -8\\r\\n     must be met for enrollment. Prior anti PD-1/PD-L1 therapy is allowed, but not\\r\\n     required\\r\\n\\r\\n  -  Eastern Cooperative Oncology Group (ECOG) status (performance status [PS]) of 0-1\\r\\n\\r\\n  -  Life expectancy of greater than 12 weeks according to certified physician review\\r\\n\\r\\n  -  Hemoglobin (Hb) ≥ 8.5 g/dL\\r\\n\\r\\n  -  Leukocytes ≥ 3,000/mcL\\r\\n\\r\\n  -  Absolute neutrophil count (ANC) ≥ 1,500/mcL\\r\\n\\r\\n  -  Platelets ≥ 100K/cc mL\\r\\n\\r\\n       -  Values must be obtained without transfusion within 2 weeks\\r\\n\\r\\n  -  Serum creatinine (sCr) < 1.5 x upper limit of normal (ULN) or creatinine clearance\\r\\n     (CrCl) ≥ 50 mL/min (calculated with the Cockcroft-Gault formula) for participants\\r\\n     with creatinine (sCr) levels above institutional normal\\r\\n\\r\\n  -  Total bilirubin < 1.5 x upper limit of normal (ULN)\\r\\n\\r\\n       -  With the exception of documented Gilbert's syndrome or similar conditions, at\\r\\n          the discretion of the principal investigator (PI). Clinical chemistry testing\\r\\n          may be adjusted, as clinically indicated\\r\\n\\r\\n  -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or\\r\\n     alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x\\r\\n     ULN\\r\\n\\r\\n  -  Patients with known history or current symptoms of cardiac disease, or history of\\r\\n     treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac\\r\\n     function using the New York Heart Association (NYHA) Functional Classification. To\\r\\n     be eligible for this trial, patients should be class 2B or better\\r\\n\\r\\n  -  Corrected QT interval Fridericia's formula (QTcF) of < 480 ms on a 12 lead\\r\\n     electrocardiogram (EKG), except for participants with atrioventricular pacemakers or\\r\\n     other conditions (e.g., right bundle branch block) that render the QT measurement\\r\\n     invalid\\r\\n\\r\\n  -  Willingness to modify concomitant drug regimens, at the recommendation and\\r\\n     discretion of pharmacy services, including the use of known substrates or inhibitors\\r\\n     of CYP2C8 and CYP3A4\\r\\n\\r\\n  -  Physiologic maintenance doses of corticosteroids (≤ 10 mg/day of prednisone or\\r\\n     equivalent) are permitted. Examples include: Asthma treatment; topical ocular,\\r\\n     intra-articular, or intranasal steroids with minimal systemic absorption; and brief\\r\\n     courses of corticosteroids for prophylaxis\\r\\n\\r\\n  -  Patients with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL are eligible regardless of\\r\\n     HIV serology\\r\\n\\r\\n       -  HIV-infected patients on effective anti-retroviral therapy with undetectable\\r\\n          viral load within 6 months of enrollment are eligible\\r\\n\\r\\n       -  In the case of ongoing treatment with antiretroviral therapy (ART), medication\\r\\n          adjustment may be necessary for the duration of treatment. A wash-out period\\r\\n          may be necessary, at the recommendation of the institutional research pharmacy\\r\\n          service (RPS)\\r\\n\\r\\n  -  Evidence of chronic hepatitis B virus (HBV) infection (i.e., hepatitis B surface\\r\\n     antigen [HBsAg]-positive, undetectable or low HBV deoxyribonucleic acid [DNA], and\\r\\n     normal ALT) in the absence of HBV therapy, or serologic evidence of a resolved prior\\r\\n     HBV infection (i.e., HBsAg-negative and hepatitis B virus core antibody\\r\\n     [anti-HBc]-positive) is permitted\\r\\n\\r\\n  -  History of hepatitis C virus (HCV) infection is permitted given prior curative\\r\\n     treatment or undetectable HCV viral load by serology or polymerase chain reaction\\r\\n     (PCR) testing\\r\\n\\r\\n       -  Patient who are HCV antibody (Ab) seropositive but HCV ribonucleic acid (RNA)\\r\\n          negative due to prior treatment or natural resolution are eligible\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Secondary malignancy with documented diagnosis by a treating physician < 3 years\\r\\n     prior to study day -8. The following criteria also apply:\\r\\n\\r\\n       -  New or progressive brain metastases. Patients with brain metastases not\\r\\n          requiring immediate central nervous system (CNS) specific treatment or stable\\r\\n          for at least 4 weeks prior to study day -8 are eligible at the discretion of\\r\\n          the investigator given that neurologic symptoms are resolved.\\r\\n\\r\\n       -  Patients with active leptomeningeal disease are not eligible\\r\\n\\r\\n  -  Palliative radiation therapy administered within 1 week prior to study day -8, Note:\\r\\n     Participants must have recovered from all radiation-related toxicities (to grade < 1\\r\\n     or baseline), must not require corticosteroids for this purpose, and must not have\\r\\n     had radiation pneumonitis\\r\\n\\r\\n  -  Immunization with a live vaccine within 28 days prior to study day -8\\r\\n\\r\\n  -  History of organ transplantation, including hematopoietic stem cell transplantation\\r\\n     (HSCT)\\r\\n\\r\\n  -  Clinical evidence of interstitial lung disease or active non-infectious pneumonia\\r\\n\\r\\n  -  Active autoimmune disease requiring systemic immunosuppression in excess of\\r\\n     physiologic maintenance doses of corticosteroids (≤ 10 mg/day of prednisone or\\r\\n     equivalent is permitted)\\r\\n\\r\\n  -  Prior National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events\\r\\n     (CTCAE) grade ≥ 3 immune-related adverse event (irAE) that required systemic\\r\\n     immunosuppression (endocrinopathies managed by stable doses of supplements and/or\\r\\n     corticosteroids ≤ 10 mg/day are permitted)\\r\\n\\r\\n  -  Unresolved toxicities (resolution required to grade 1 or baseline) from prior\\r\\n     anticancer therapies. The following exceptions apply:\\r\\n\\r\\n       -  Alopecia, lymphopenia, grade 2 neuropathy (if not resulting in functional\\r\\n          deficit), and grade 1 (no supplementation required) or grade 2 endocrinopathies\\r\\n          (stable on supplements)\\r\\n\\r\\n  -  Prior allergy or severe hypersensitivity reaction to axatilimab, retifanlimab,\\r\\n     paclitaxel, cremaphor-containing agents, and/or components of the drug formulations\\r\\n\\r\\n  -  Active infection requiring systemic antibiotic therapy\\r\\n\\r\\n  -  Persons of childbearing potential (PCBP) who are pregnant (i.e., positive pregnancy\\r\\n     test within 7 days prior to study day -8) or breastfeeding are not eligible.\\r\\n\\r\\n       -  The effects of the investigational regimen on the developing human fetus are\\r\\n          unknown. For this reason, persons of reproductive potential must agree to use a\\r\\n          highly effective form of contraception, starting with the time of consent to 4\\r\\n          months after the last dose of retifanlimab or 90 days after the last dose of\\r\\n          axatilimab, whichever is longer\\r\\n\\r\\n       -  Sperm-producing participants must not donate sperm throughout the study period\\r\\n          and for 90 days post completion of study treatment\\r\\n\\r\\n  -  Uncontrolled, intercurrent illness and psychiatric illness/social situations that\\r\\n     would limit compliance with study requirements, at the discretion of the\\r\\n     investigator\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'overallOfficials': [{'name': 'Shivaani Kummar',\n",
       "      'affiliation': 'OHSU Knight Cancer Institute',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'OHSU Knight Cancer Institute',\n",
       "      'status': 'RECRUITING',\n",
       "      'city': 'Portland',\n",
       "      'state': 'Oregon',\n",
       "      'zip': '97239',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Shivaani Kummar',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '503-494-6594',\n",
       "        'email': 'kummar@ohsu.edu'},\n",
       "       {'name': 'Shivaani Kummar', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000009369',\n",
       "      'term': 'Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M14850',\n",
       "      'name': 'Recurrence',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC23',\n",
       "      'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000017239',\n",
       "      'term': 'Paclitaxel'},\n",
       "     {'id': 'D000068196', 'term': 'Albumin-Bound Paclitaxel'}],\n",
       "    'ancestors': [{'id': 'D000000972',\n",
       "      'term': 'Antineoplastic Agents, Phytogenic'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'},\n",
       "     {'id': 'D000050257', 'term': 'Tubulin Modulators'},\n",
       "     {'id': 'D000050256', 'term': 'Antimitotic Agents'},\n",
       "     {'id': 'D000050258', 'term': 'Mitosis Modulators'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'}],\n",
       "    'browseLeaves': [{'id': 'M4225', 'name': 'Antibodies', 'relevance': 'LOW'},\n",
       "     {'id': 'M4230', 'name': 'Antibodies, Monoclonal', 'relevance': 'LOW'},\n",
       "     {'id': 'M19537',\n",
       "      'name': 'Paclitaxel',\n",
       "      'asFound': 'Treating',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M231',\n",
       "      'name': 'Albumin-Bound Paclitaxel',\n",
       "      'asFound': 'Treating',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10184', 'name': 'Immunoglobulins', 'relevance': 'LOW'},\n",
       "     {'id': 'M11901', 'name': 'Mitoguazone', 'relevance': 'LOW'},\n",
       "     {'id': 'M26197', 'name': 'Tubulin Modulators', 'relevance': 'LOW'},\n",
       "     {'id': 'M26196', 'name': 'Antimitotic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06415877',\n",
       "    'orgStudyIdInfo': {'id': '1111111'},\n",
       "    'organization': {'fullName': 'Osmaniye Korkut Ata University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'The Effect of the Modified Simulation Model on Self-Efficacy, Anxiety, and Academic Motivation in Episiotomy Training',\n",
       "    'officialTitle': 'The Effect of the Modified Simulation Model on Self-Efficacy, Anxiety, and Academic Motivation in Episiotomy Training',\n",
       "    'acronym': 'Episiotomy'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-06-20', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-09',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Emine Yıldırım',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'Osmaniye Korkut Ata University'},\n",
       "    'leadSponsor': {'name': 'Emine Yıldırım', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'It was planned as a randomized controlled study to determine the effect of the modified\\r\\nsimulation model on self-efficacy, anxiety and academic motivation in episiotomy\\r\\ntraining. It will be held online with students from the midwifery department of Osmaniye\\r\\nKorkut Ata University.'},\n",
       "   'conditionsModule': {'conditions': ['Episiotomy', 'Anxiety', 'Simulation'],\n",
       "    'keywords': ['episiotomy', 'anxiety', 'simulation']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'BASIC_SCIENCE',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'beef tongue stitched',\n",
       "      'interventionNames': ['Other: Episio Training']},\n",
       "     {'label': 'sham comparator',\n",
       "      'type': 'SHAM_COMPARATOR',\n",
       "      'description': 'episio model',\n",
       "      'interventionNames': ['Other: Episio Training']},\n",
       "     {'label': 'experimental group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'modified tripe coated veal',\n",
       "      'interventionNames': ['Other: Episio Training']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Episio Training',\n",
       "      'description': 'episio repair training',\n",
       "      'armGroupLabels': ['experimental group',\n",
       "       'placebo',\n",
       "       'sham comparator']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'self-efficacy',\n",
       "      'description': 'questionnaire',\n",
       "      'timeFrame': '1 week'}],\n",
       "    'secondaryOutcomes': [{'measure': 'academic motivation',\n",
       "      'description': 'questionnaire',\n",
       "      'timeFrame': '1 week'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Midwifery student\\r\\n\\r\\n  -  volunteers\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  involuntary',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001008',\n",
       "      'term': 'Anxiety Disorders'}],\n",
       "    'ancestors': [{'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M4324',\n",
       "      'name': 'Anxiety Disorders',\n",
       "      'asFound': 'Anxiety',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06188754',\n",
       "    'orgStudyIdInfo': {'id': 'Healthy Lifestyles 01'},\n",
       "    'organization': {'fullName': 'University of California, Berkeley',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Healthy Lifestyles for Bipolar Disorder',\n",
       "    'officialTitle': 'Time-restricted Eating vs. Mediterranean Diet as Adjunctive Interventions for Bipolar Disorder',\n",
       "    'acronym': 'HL'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-01-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2029-01-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-12-18',\n",
       "    'studyFirstSubmitQcDate': '2023-12-18',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-01-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-12',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-16', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'University of California, Berkeley',\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University College, London', 'class': 'OTHER'},\n",
       "     {'name': 'Swinburne University of Technology', 'class': 'OTHER'},\n",
       "     {'name': 'Deakin University', 'class': 'OTHER'},\n",
       "     {'name': 'University of British Columbia', 'class': 'OTHER'},\n",
       "     {'name': 'Salk Institute for Biological Studies', 'class': 'OTHER'},\n",
       "     {'name': 'Wellcome Trust', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to compare the effects of two different healthy\\r\\nlifestyles on outcomes for those with bipolar disorder. The goals are to understand the\\r\\nacceptability of time-restricted eating and the mediterranean diet for those who are\\r\\nalready receiving medication treatment for bipolar disorder, and to consider how these\\r\\ntwo food plans predict changes in manic symptoms, depressive symptoms, and Quality of\\r\\nLife. Participants will complete daily measures of eating, sleep and mood for two weeks,\\r\\nand then will be assigned to follow one of the two food plans for eight weeks. The\\r\\ninvestigators will measure symptoms and Quality of Life at baseline and during and after\\r\\nthe food plan.',\n",
       "    'detailedDescription': 'The investigators will conduct a randomized controlled trial (RCT) to examine the effects\\r\\nof time-restricted eating as compared to the mediterranean diet. In time-restricted\\r\\neating (TRE), participants will be asked to limit their food intake to a period of 10\\r\\nhours per day. In the mediterranean diet, participants will be asked to follow a food\\r\\nplan that emphasizes vegetables, fruit, whole grains, and olive oil as central dietary\\r\\ncomponents. The investigators aim to test both food plans as additions to standard\\r\\nmedication approaches in bipolar disorder. Participants who are receiving medical\\r\\ntreatment for bipolar disorder and who report at least some sleep or circadian problems\\r\\nwill complete baseline measures and then will be randomly assigned to TRE or the\\r\\nmediterranean diet for 8 weeks, and then will complete measures of symptoms, Quality of\\r\\nLife, and possible treatment mechanisms at the end of treatment and at 3, 6 and 12 months\\r\\nafter the intervention. If successful, this work will provide a novel, easily implemented\\r\\nand highly acceptable intervention for BD.'},\n",
       "   'conditionsModule': {'conditions': ['Time Restricted Eating',\n",
       "     'Diet, Mediterranean'],\n",
       "    'keywords': ['bipolar disorder', 'sleep', 'circadian rhythm']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Participants will be randomly assigned to take part in either time-restricted eating or\\r\\nthe Mediterranean diet.',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Outcomes will be assessed by an interviewer who is unaware of treatment condition.',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Time Restricted Eating (TRE) for 8 weeks',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive an intro to TRE and then throughout 8 weeks they will receive\\r\\nbrief online psychoeducation several times per week with optional weekly coaching\\r\\nsessions. TRE involves restricting the window of eating to 10 hours/ day, most typically\\r\\nby avoiding eating in the first 1-2 hours after awakening and in the 2-4 before sleep.\\r\\nThose with an eating window > 14 hours will be asked to restrict their eating to 12 hours\\r\\nin the first week, then 10 hours in week 2. To select the period, investigators will ask\\r\\nSs to review baseline logs to consider sleep, eating, family meals and social commitment\\r\\nschedules, and any special energy demands, such as exercise. During the eating window, no\\r\\nrestrictions are placed on the type or quantity of food consumed. The investigators will\\r\\ninstruct participants to follow their habitual diet within their 10-hour eating window\\r\\nand to aim to consume the same number of calories per day as they did at baseline.',\n",
       "      'interventionNames': ['Behavioral: Time restricted eating']},\n",
       "     {'label': 'Mediterranean diet for 8 weeks',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Participants will receive a several page introduction to the mediterranean diet, and then\\r\\nwill receive support throughout the 8 week intervention to follow this food plan,\\r\\nincluding brief online psychoeducation that will be sent several times per week, and\\r\\noptional weekly coaching sessions.\\r\\n\\r\\nThe mediterranean diet is a plan for healthy eating based on how people eat in the\\r\\nmediterranean region. Individuals will be encouraged to consume vegetables (6\\r\\nservings/day), fruits (2-4 servings/day), whole grains (daily), legumes (3-4 times per\\r\\nweek), nuts (.5 oz per day), and oily fish (2 servings/week). Participants will be\\r\\nencouraged to choose lean meats and other sources of protein over red meat and processed\\r\\nmeats. Sweets, refined cereals, alcohol, and wine or alcohol will be labelled as extras,\\r\\nand participants will be encouraged to limit consumption of extras.',\n",
       "      'interventionNames': ['Behavioral: Mediterranean diet']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Time restricted eating',\n",
       "      'description': 'Limiting food intake to 10 hours per day',\n",
       "      'armGroupLabels': ['Time Restricted Eating (TRE) for 8 weeks'],\n",
       "      'otherNames': ['intermittent fasting']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Mediterranean diet',\n",
       "      'description': 'Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and\\r\\nthe use of olive oil.',\n",
       "      'armGroupLabels': ['Mediterranean diet for 8 weeks']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Acceptability',\n",
       "      'description': 'Participant self-ratings of the acceptability of the intervention: The primary index of\\r\\nacceptability will be the percentage of individuals who endorse that they agree or\\r\\nstrongly agree that they would recommend the food plan to a friend. This single item has\\r\\nbeen used in previous trials of bipolar disorder. Higher agreement will be considered a\\r\\npositive outcome.',\n",
       "      'timeFrame': 'immediately post-treatment (10 weeks after enrollment)'},\n",
       "     {'measure': 'Adherence to time-restricted eating',\n",
       "      'description': 'Adherence will be scored based on the time of their first and final calorie consumption\\r\\neach day during the 8 week intervention. The investigators will select entries from the\\r\\ntime interval that contains 95% of intake events. Following standards in other US and\\r\\nEuropean studies of TRE, the investigators will focus on days in which participants\\r\\nadequately logged (e.g., entered at least two intake events, covering at least a 5 hour\\r\\nwindow), and will calculate the percentage of days in which individuals met the eating\\r\\nwindow goal. High adherence will be defined as meeting this standard on at least 78% of\\r\\ndays logged. As supplemental data, the investigators will report the percentage of days\\r\\nlogged, and the percentage of days in which individuals logged adequately and followed\\r\\nthe planned window.',\n",
       "      'timeFrame': 'Average number of daily food logs showing adherence across the 8-week intervention'},\n",
       "     {'measure': 'Adherence to Mediterranean Diet',\n",
       "      'description': 'Adherence will be scored based on a Food Frequency Questionnaire that we developed for\\r\\nthis study. We will score this using the Adherence to the Mediterranean Diet scoring\\r\\nsystem (AMed), which provides up to 9 points based on above-median consumption of\\r\\nbeneficial foods (e.g., fruits and vegetables) and below median consumption of \"extras\"\\r\\nsuch as alcohol. Higher scores reflect better adherence to the mediterranean diet.',\n",
       "      'timeFrame': 'Average number of food logs showing adherence at or above the median for 2 days at the mid-point of treatment (week 6) and at the end of treatment (week 10)'},\n",
       "     {'measure': 'Mania',\n",
       "      'description': 'Decline in Young Mania Rating Scale (YMRS) total scores, completed by a blind rater',\n",
       "      'timeFrame': 'Lower YMRS at the end of intervention (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Depression',\n",
       "      'description': 'Decline in Montgomery Asberg Depression Scale (MADRS) total scores, completed by a blind\\r\\nrater',\n",
       "      'timeFrame': 'Lower MADRS at the end of intervention (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Self-rated Quality of Life (QOL)',\n",
       "      'description': 'Higher scores on the self-rated Brief Quality of Life in Bipolar Disorder (QoL.BD) at\\r\\n3-months post intervention as compared to baseline',\n",
       "      'timeFrame': 'Scores at 3-months post-intervention (22 weeks after study entry) as compared to baseline'},\n",
       "     {'measure': 'Mania at follow-up',\n",
       "      'description': 'Sustained lower YMRS scores across follow-up',\n",
       "      'timeFrame': 'YMRS scores will be lower at 3, 6, 12 month post-intervention follow-ups as compared to baseline'},\n",
       "     {'measure': 'Depression at follow-up',\n",
       "      'description': 'Sustained lower MADRS scores across follow-up',\n",
       "      'timeFrame': 'MADRS scores will be lower at 3, 6, 12 month post-intervention follow-ups as compared to baseline'},\n",
       "     {'measure': 'QOL at follow-up',\n",
       "      'description': 'Sustained higher QOL.BD scores',\n",
       "      'timeFrame': 'QOL.BD scores will be higher at 6- and 12-month post-intervention follow-ups as compared to baseline'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Self-rated mania',\n",
       "      'description': 'Lower Patient Health Questionnaire (PHQ) Mania scores at post-intervention (10 weeks) and\\r\\nat 1.5, 3, 6, and 12 month follow-ups post-intervention',\n",
       "      'timeFrame': 'at post-intervention (10 weeks) and at 1.5, 3, 6, and 12 month follow-ups post-intervention, as compared to baseline'},\n",
       "     {'measure': 'Self-rated depression',\n",
       "      'description': 'Lower Patient Health Questionnaire (PHQ) Depression scores at post-intervention (10\\r\\nweeks) and at 1.5, 3, 6, and 12 month follow-ups post-intervention',\n",
       "      'timeFrame': 'at post-intervention (10 weeks) and at 1.5, 3, 6, and 12 month follow-ups post-intervention, as compared to baseline'},\n",
       "     {'measure': 'Sleep hygiene behaviors',\n",
       "      'description': 'Lower scores on the Sleep Household Environment and In-Bed Behaviors at end-of-treatment\\r\\n(10 weeks) as compared to baseline',\n",
       "      'timeFrame': 'post-intervention (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Weekly change in mania severity',\n",
       "      'description': 'Lower Longitudinal Interval Follow-up Evaluation (LIFE) weekly Mania scores\\r\\npost-treatment as compared to those at baseline. The investigators will administer the\\r\\nLIFE interview at 3, 6, and 12-months after the intervention, and interviewers will\\r\\nrecord a mania severity rating for each week, to cover the time from the end of\\r\\nintervention until one year after the intervention ends.',\n",
       "      'timeFrame': 'Weekly scores from the end of the intervention through one-year post-intervention follow-up'},\n",
       "     {'measure': 'Sleep disturbance and sleep impairment',\n",
       "      'description': 'Lower scores on the Patient Outcomes Reporting Information System (PROMIS) sleep\\r\\ndisturbance and sleep impairment scores at post-treatment (10 weeks) as compared to\\r\\nbaseline',\n",
       "      'timeFrame': 'post-treatment (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Sleep mid-point variability (Munich Chronotype Questionnaire; MCTQ)',\n",
       "      'description': 'MCTQ scores will show a smaller proportion of individuals with either early or delayed\\r\\nchronotype (as reflected in standard scoring for the MCTQ) at post-treatment as compared\\r\\nto baseline',\n",
       "      'timeFrame': 'post-treatment (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Regularity of daily routines (Brief Social Rhythm Questionnaire)',\n",
       "      'description': 'Lower Brief Social Rhythm Questionnaire scores (less irregularity) at post-treatment as\\r\\ncompared to baseline',\n",
       "      'timeFrame': 'post-treatment (10 weeks) as compared to baseline'},\n",
       "     {'measure': 'Daily emotional lability as assessed using ecological momentary assessment',\n",
       "      'description': 'Lower mean square of successive difference of negative affect scores within derived from\\r\\nthe ecological momentary assessments at the mid-point of treatment (6 weeks) as compared\\r\\nto baseline. Participants will be asked to complete negative affect ratings several times\\r\\nper day for 8 days, at the baseline and mid-point of treatment. The investigators will\\r\\ncalculate scores to examine the degree of negative affect variability for each day, and\\r\\nthen take the average across 8 days at baseline and at treatment mid-point.',\n",
       "      'timeFrame': 'mid-point of treatment (6 weeks post study entry) as compared to baseline'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  meets diagnostic criteria for bipolar I disorder or bipolar II disorder (but not\\r\\n     cyclothymia, BD Not otherwise specified or BD due to another medical condition)\\r\\n\\r\\n  -  current sleep (insomnia, hypersomnolence) or circadian sleep-wake (delayed phase,\\r\\n     advanced phase, irregular sleep-wake, non-24-hour sleep-wake-type) concerns\\r\\n     indicated by endorsement of at least some sleep or circadian-related impairment\\r\\n     across the screening self-reports or interview\\r\\n\\r\\n       -  Living in an English-speaking country (and one that we have expertise in\\r\\n          research procedures and diet)\\r\\n\\r\\n       -  Has been speaking English for at least 10 years.\\r\\n\\r\\n       -  Receiving medical care for BD (referrals will be provided for those who would\\r\\n          like to begin care)\\r\\n\\r\\n       -  Mood-stabilizing medication regimens stable for at least one month\\r\\n\\r\\n       -  < 5 kg weight change in the past 3 months\\r\\n\\r\\n       -  Currently eating ≥ 12 hours per day at least twice per week\\r\\n\\r\\n       -  Able to operate the camera function and respond to web-based surveys by phone\\r\\n          (loaner phones will be provided as needed)\\r\\n\\r\\n       -  Not engaged in current shift work or have other responsibilities such as\\r\\n          providing care that would chronically disrupt their sleep (i.e., > 3 h between\\r\\n          22:00 and 05:00 h for at least 1 day/week)\\r\\n\\r\\n       -  Able to complete 7 days of dietary logs adequately (e.g., at least 2 entries\\r\\n          per day, covering at least a 5-hour eating window) during the baseline period\\r\\n\\r\\n       -  Able to complete screening and baseline questionnaires adequately (e.g., not\\r\\n          failing more than 1 attention check item with instructed responding; responding\\r\\n          to standard multiple-choice items in a mean of < 2 seconds per item). Where\\r\\n          individuals respond to more than 14 items in a row with the same response, we\\r\\n          will manually review for possible invalidity.\\r\\n\\r\\nExclusion criteria include the following:\\r\\n\\r\\n  -  Current episode of depression, hypomania or mania, or psychosis (assessed by the\\r\\n     Mini International Neuropsychiatric Interview; MINI), Participants with acute mood\\r\\n     disorder episodes will be encouraged to seek treatment and to consider the study\\r\\n     when symptoms have remitted.\\r\\n\\r\\n  -  Eating disorder diagnosis (by self-report of treatment or diagnosis at any point\\r\\n     during their life, Short Eating Disorder Examination Questionnaire (EDE-QS) scores\\r\\n     above clinical concern thresholds for eating disorders, or MINI interview of\\r\\n     symptoms during adulthood)\\r\\n\\r\\n  -  Past 3-month alcohol use disorder or substance use disorder (assessed by MINI)\\r\\n\\r\\n  -  Active suicidal ideation coupled with plan, intent or attempt history as assessed by\\r\\n     Columbia Suicide Severity Rating Scale\\r\\n\\r\\n  -  Conditions that would interfere with ability to take part in the intervention,\\r\\n     including pregnancy, breastfeeding, uncorrected hypo or hyperthyroidism,\\r\\n     gastrointestinal conditions impairing nutrient absorption\\r\\n\\r\\n  -  Medications contraindicated for fasting: clozapine, glucose-lowering medications,\\r\\n     diabetes-related injections, medications requiring food early morning or late\\r\\n     evening, corticosteroids; medications such as semaglutide will not be an exclusion\\r\\n     criteria\\r\\n\\r\\n  -  Cognitive deficits as noted during the initial interview or as indicated by low\\r\\n     performance on the Orientation Memory Concentration Test (OMC < 9)',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '65 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Sheri L Johnson, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(510) 519-4305',\n",
       "      'email': 'calmprogram@berkeley.edu'},\n",
       "     {'name': 'Nandini Rajgopal, BS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(510) 519-4305',\n",
       "      'email': 'calmprogram@berkeley.edu'}],\n",
       "    'overallOfficials': [{'name': 'Sheri L Johnson, PhD',\n",
       "      'affiliation': 'University of California, Berkeley',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of California',\n",
       "      'city': 'Berkeley',\n",
       "      'state': 'California',\n",
       "      'zip': '94720',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 37.87159, 'lon': -122.27275}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': 'Measures, data, and analysis scripts will be shared through Open Science Foundation.',\n",
       "    'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'ANALYTIC_CODE'],\n",
       "    'timeFrame': 'De-identified data will be shared within one year after data collection ends.',\n",
       "    'accessCriteria': 'Data will be available publically through Open Science Foundation upon request. We will\\r\\nalso comply with Wellcome Trust guidance for data sharing.'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000001714',\n",
       "      'term': 'Bipolar Disorder'}],\n",
       "    'ancestors': [{'id': 'D000068105',\n",
       "      'term': 'Bipolar and Related Disorders'},\n",
       "     {'id': 'D000019964', 'term': 'Mood Disorders'},\n",
       "     {'id': 'D000001523', 'term': 'Mental Disorders'}],\n",
       "    'browseLeaves': [{'id': 'M4996',\n",
       "      'name': 'Bipolar Disorder',\n",
       "      'asFound': 'Bipolar Disorder',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M226',\n",
       "      'name': 'Bipolar and Related Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M21835', 'name': 'Mood Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXM',\n",
       "      'name': 'Behaviors and Mental Disorders'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M3777',\n",
       "      'name': 'Ethanol',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T242', 'name': 'Olive', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419751',\n",
       "    'orgStudyIdInfo': {'id': '2023-ZX067'},\n",
       "    'organization': {'fullName': 'China National Center for Cardiovascular Diseases',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'briefTitle': 'the Effects of Different Exercise on Vascular Health',\n",
       "    'officialTitle': 'Research on the Effect of Lifestyle Intervention Combined With Wearable Devices Based on Different Exercise on Vascular Health'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-14',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'China National Center for Cardiovascular Diseases',\n",
       "     'class': 'OTHER_GOV'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'To explore the effect of smart app and wearable-based lifestyle intervention management\\r\\non vascular health, comparing different exercise with the improvement of vascular\\r\\narterial stiffness. The accuracy and consistency evaluation of smart wearable devices in\\r\\nscreening for vascular health risks were also discussed.',\n",
       "    'detailedDescription': 'This study intends to carry out a randomized controlled trial to dynamically monitor a\\r\\nvariety of cardiovascular parameters in people with high risk of vascular health, using\\r\\nwearable devices and artificial intelligence-assisted health management platform, and\\r\\nprovide intelligent lifestyle intervention programs with different exercise.By observing\\r\\nthe improvement of vascular health in the study population, the management effect of\\r\\nintelligent lifestyle intervention on high-risk groups of vascular health was evaluated.\\r\\nIt is expected that through comprehensive lifestyle intervention based on smart wearable\\r\\ndevices, early prevention and control of arteriosclerosis can be achieved, the level of\\r\\nhospital health management will be improved, and more physical health and health economic\\r\\nbenefits will be obtained.'},\n",
       "   'conditionsModule': {'conditions': ['Mind-body Exercise',\n",
       "     'Vascular Health',\n",
       "     'M-health',\n",
       "     'Cardiac Rehabilitation'],\n",
       "    'keywords': ['m-health',\n",
       "     'mind-body exercise',\n",
       "     'cardiac rehabilitation',\n",
       "     'arterial stiffness']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}},\n",
       "    'enrollmentInfo': {'count': 216, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Control',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'Study participants were given training on dietary patterns, regular monitoring and\\r\\nfollow-up through apps and wearable devices, and no forced exercise measures were\\r\\nperformed.'},\n",
       "     {'label': 'Combined Exercise Group',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Study participants were given training on dietary patterns, regular monitoring and\\r\\nfollow-up through apps and wearable devices.Based on the status of the study participants\\r\\nand the results of the cardiopulmonary exercise test, the investigators prescribe\\r\\nmoderate-intensity aerobic exercise combined with resistance exercise',\n",
       "      'interventionNames': ['Behavioral: Regular exercise']},\n",
       "     {'label': 'Mind-body Exercise Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Study participants were given training on dietary patterns, regular monitoring and\\r\\nfollow-up through apps and wearable devices.A standardized Baduanjin exercise program\\r\\nconsists of eight postures, each training time is about 30 minutes (including 10 min\\r\\nwarm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12\\r\\nweeks.',\n",
       "      'interventionNames': ['Behavioral: Baduanjin']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Regular exercise',\n",
       "      'description': \"Based on the study participant's status and exercise assessment, the investigators\\r\\nprescribe moderate-intensity aerobic exercise combined with resistance exercise. Before\\r\\neach exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic\\r\\nexercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the\\r\\nsame time, choose non-consecutive 3 days of resistance training in 5 aerobic training\\r\\nsessions to increase resistance training (choose 1~2 muscle groups each time, 4~5\\r\\nmovements, repeat each action 8~12 times, repeat 2~3 sets)\",\n",
       "      'armGroupLabels': ['Combined Exercise Group']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Baduanjin',\n",
       "      'description': 'A professional therapist instructed the participants to learn and train Baduanjin before\\r\\nthe intervention, and a standardized Baduanjin exercise program included eight postures,\\r\\neach training time was about 50 minutes (including 10 min of warm-up, 2 times of\\r\\nBaduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks',\n",
       "      'armGroupLabels': ['Mind-body Exercise Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Cervical femoral pulse wave velocity（cfPWV）',\n",
       "      'description': 'The cardio-cerebrovascular and aortic function detector (Campura, France, model: Complior\\r\\nAnalyse) was used to measure cfPWV, and the study participants were in a supine position,\\r\\nlying flat on the pillow, with their palms up on their sides of the body, so that their\\r\\nwhole body was relaxed and rested for about 3 minutes. PWV can reflect arterial\\r\\nstiffness, and the European Society of Cardiology recommends cfPWV >10 m/s as the\\r\\ndefinitive threshold for assessing arterial functional changes in hypertension.We\\r\\nmonitored cfPWV at baseline,3,6,9 months of the study.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Brachi-ankle pulse wave velocity（baPWV）',\n",
       "      'description': 'The blood pressure of the limbs is measured with the Omron arteriosclerosis detector, and\\r\\nthe pulse conduction velocity (baPWV) and ankle-brachial index (ABI) are calculated to\\r\\nautomatically evaluate the degree of arteriosclerosis and blood vessel blockage. Positive\\r\\ncriteria for baPWV: ≥1400 cm/s or baPWV% ≥ 19% is arteriosclerosis. Lower extremity\\r\\nvascular occlusion (ABI positive criteria): ≤0.9 for peripheral arterial stenosis and\\r\\n≤0.5 for possible peripheral arterial occlusion.We monitored baPWV at baseline,3,6,9\\r\\nmonths of the study.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'blood pressure',\n",
       "      'description': 'Blood pressure indicator: systolic blood pressure and diastolic blood pressure.We\\r\\nmonitored blood pressure at baseline,3,6,9 months of the study.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'body weight',\n",
       "      'description': 'Using bioelectrical impedance analysis to monitor body weight,weight and height will be\\r\\ncombined to report BMI in kg/m^2.We monitored body composition at baseline,3,6,9 months\\r\\nof the study.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'Lipid metabolism parameters: TC(mmol/L), TG(mmol/L), HDL-C(mmol/L), LDL-C(mmol/L)',\n",
       "      'description': 'Lipid metabolism indicators: total cholesterol , triglyceride , high density lipoprotein\\r\\ncholesterol, low density lipoprotein cholesterol.We monitored lipid metabolism parameters\\r\\nat baseline,3,6,9 months of the study.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'Physical fitness',\n",
       "      'description': 'The measurement of muscle strength, balance and flexibility is completed by the\\r\\nrehabilitation therapist, mainly including: (1) upper limb muscle strength test (dumbbell\\r\\narm curl test); (2) Lower limb muscle strength test (chair standing and sitting test);\\r\\n(3) balance ability test; (4) Lower limb flexibility assessment (chair sitting body\\r\\nforward bending test); (5) Upper limb flexibility assessment (two-hand dorsum extension\\r\\ntest). Participants were observed for changes at baseline, 3,6,9 months.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'Vascular Health Index',\n",
       "      'description': 'The PWV was analyzed by the smart watch through ECG (electrocardiogram) and PPG\\r\\n(photoplethysmography) sensors to evaluate the degree of vascular elasticity, and the\\r\\nvascular health index and evaluation were obtained, and the results were divided into\\r\\nlow-risk, medium-risk, and high-risk.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'},\n",
       "     {'measure': 'Application adherence',\n",
       "      'description': 'Study participants who received remote lifestyle interventions through the app, completed\\r\\nall exercise training content per week, or clocked in ≥ exercise 3 times were considered\\r\\nto have good compliance; Those who check in < exercise 3 times a week are considered to\\r\\nhave poor compliance.',\n",
       "      'timeFrame': 'baseline,3months,6months,9 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  1. Age: ≥ 18 years old and < 60 years old;\\r\\n\\r\\n  2. cfPWV>10m/s;\\r\\n\\r\\n  3. Those who have 1 intelligent communication device and can use it proficiently\\r\\n     (Android mobile phone is preferred);\\r\\n\\r\\n  4. People who have lived and/or worked relatively steadily in the past 6 months;\\r\\n\\r\\n  5. Signed informed consent.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  1. Moderate to severe obesity (≥30kg/m^2);\\r\\n\\r\\n  2. Acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic\\r\\n     stenosis and other serious circulatory respiratory diseases and acute cardiovascular\\r\\n     and cerebrovascular diseases;\\r\\n\\r\\n  3. severe essential hypertension (systolic blood pressure ≥180mmHg and/or diastolic\\r\\n     blood pressure ≥110mmHg) or poorly controlled essential hypertension;\\r\\n\\r\\n  4. Patients with secondary hypertension, acute hypertension, subacute hypertension and\\r\\n     hypertensive encephalopathy;\\r\\n\\r\\n  5. Significant arrhythmia (atrial fibrillation, etc.);\\r\\n\\r\\n  6. Patients with atherosclerotic cardiovascular diseases, such as coronary heart\\r\\n     disease, severe peripheral atherosclerotic diseases, etc.;\\r\\n\\r\\n  7. Type 1 diabetes, uncontrolled type 2 diabetes or other diseases affecting\\r\\n     carbohydrate metabolism;\\r\\n\\r\\n  8. Severe stenosis of the carotid and/or femoral arteries (resulting in significant\\r\\n     abnormalities in the blood flow spectrum); Those who have anatomical abnormalities\\r\\n     of the aorta and major branches and cannot complete PWV detection;\\r\\n\\r\\n  9. Cancer and other major comorbidities affecting arterial blood pressure;\\r\\n\\r\\n 10. Those who are unable to exercise due to fractures, joint instability and other\\r\\n     physical diseases or diseases affecting the locomotor system;\\r\\n\\r\\n 11. Those who have involuntary physical movements due to mental illness, epilepsy or\\r\\n     other diseases;\\r\\n\\r\\n 12. Those who have a pacemaker installed;\\r\\n\\r\\n 13. Pregnant/trying to conceive;\\r\\n\\r\\n 14. Patients with allergies, limb trauma or skin diseases who cannot cooperate with the\\r\\n     completion of ABI and baPWV index examinations;\\r\\n\\r\\n 15. Those who have undergone or plan to have bariatric surgery in the next 12 months;\\r\\n\\r\\n 16. Those who have participated in other clinical studies in the past 3 months;\\r\\n\\r\\n 17. Refusal to sign informed consent.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '60 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Yifan Wu',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '01088398069',\n",
       "      'email': 'wuyifan1127@126.com'}],\n",
       "    'overallOfficials': [{'name': 'Xue Feng',\n",
       "      'affiliation': 'Fuwai Hospital',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05818254',\n",
       "    'orgStudyIdInfo': {'id': 'Pro00112931'},\n",
       "    'secondaryIdInfos': [{'id': '1R01AR082673',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/1R01AR082673'}],\n",
       "    'organization': {'fullName': 'Duke University', 'class': 'OTHER'},\n",
       "    'briefTitle': 'The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB',\n",
       "    'officialTitle': 'The HOP-STEP (Healthy Outcomes in Pregnancy With SLE Through Education of Providers) Intervention: Improving Maternal Health in Women With Lupus Through Improved Pregnancy Prevention and Planning sIRB',\n",
       "    'acronym': 'HOP-STEPsIRB'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-03-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-05',\n",
       "    'studyFirstSubmitQcDate': '2023-04-17',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-04-18', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Duke University', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University of Chicago', 'class': 'OTHER'},\n",
       "     {'name': 'National Institutes of Health (NIH)', 'class': 'NIH'},\n",
       "     {'name': 'National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'While the HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of\\r\\nProviders) program has been demonstrated to be effective in improving provider\\r\\nconfidence, increasing contraception documentation, and facilitating equitable pregnancy\\r\\nplanning care in a single sub-specialty clinic here at Duke, the delivery of HOP-STEP may\\r\\nneed to be changed to increase its fit with the local context at the University of\\r\\nChicago Medical Center (UCMC) and subsequent locations. Thus, the investigators will now\\r\\nfit the intervention into a high-minority, high-poverty academic rheumatology center, and\\r\\nlater pilot it through a randomized trial to identify and overcome existing barriers to\\r\\nequitable pregnancy prevention and planning at another institution (The University of\\r\\nChicago Medical Center). The objective of this study is to prepare for a multi-center\\r\\ntrial of the HOP-STEP intervention by fitting and then piloting its implementation and\\r\\nmeasuring its potential impact on maternal outcomes.',\n",
       "    'detailedDescription': 'The study creates opportunities for SLE (systemic lupus erythematosus) patients seeking\\r\\nreproductive care by restructuring the rheumatology clinic environment. Specifically\\r\\nthrough:\\r\\n\\r\\nAim 1: Fit the implementation of the HOP-STEP Intervention to the local Rheumatology\\r\\nspecialty clinic context with key stakeholder input.\\r\\n\\r\\nAim 2: Evaluation of a pilot trial of the HOP-STEP Intervention. At the completion of\\r\\nthis study, the investigators will know how to equitably implement and study the HOP-STEP\\r\\nIntervention within an academic rheumatology setting that cares for a high-minority,\\r\\nhigh-poverty population of women with SLE.'},\n",
       "   'conditionsModule': {'conditions': ['Systemic Lupus Erythematosus',\n",
       "     'Contraception'],\n",
       "    'keywords': ['Family Planning', 'SLE', 'Contraception']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Routine Care Providers',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Care Providers in this arm will continue seeing patients as normal in clinic.',\n",
       "      'interventionNames': ['Behavioral: Routine Care']},\n",
       "     {'label': 'HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Providers',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HOP-STEP providers will inquire and document their patients about contraceptive usage and\\r\\npregnancy interest, then provide personalized guidance on family planning.',\n",
       "      'interventionNames': ['Behavioral: HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Intervention',\n",
       "      'description': 'The HOP-STEP Intervention is simple with 3-steps: (1) ascertain and document current\\r\\npregnancy intention and contraceptive use, (2) patient and provider collaboratively\\r\\narrive at her optimal contraceptive and/or pregnancy plan using a Decision Guide directed\\r\\nconversation, and (3) create a warm handoff with a patient-specific SLE risk assessment\\r\\nand guideline-aligned recommendations.',\n",
       "      'armGroupLabels': ['HOP-STEP (Healthy Outcomes in Pregnancy with SLE Through Education of Providers) Providers']},\n",
       "     {'type': 'BEHAVIORAL',\n",
       "      'name': 'Routine Care',\n",
       "      'description': 'Providers will continue to provide reproductive healthcare in their current manner.',\n",
       "      'armGroupLabels': ['Routine Care Providers']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Contraception Documentation',\n",
       "      'description': \"Yes/No: Documentation of contraception use during patient visit; includes if the provider\\r\\ndocuments that the patient does not use any contraception. This is extracted from the\\r\\npatient's medical record and is part of the HOP-STEP intervention. This will also be\\r\\nanalyzed by patient-level characteristics: race, age, teratogen use. Denominator: all\\r\\neligible patients.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Reach: Pregnancy intention documentation',\n",
       "      'description': \"Yes/No: Documentation of the patient's pregnancy intention during patient visit. This is\\r\\nextracted from the patient's medical record and is part of the HOP-STEP intervention.\\r\\nThis will also be analyzed by patient-level characteristics: race, age, teratogen use.\\r\\nDenominator: all eligible patients.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Reach: Contraceptive Counseling',\n",
       "      'description': 'Yes/No: Documentation of any contraceptive counseling during patient visit. Denominator:\\r\\nall eligible patients.',\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Reach: Pregnancy planning',\n",
       "      'description': \"Yes/No: Documentation of any pregnancy planning during patient visit. Denominator: all\\r\\neligible patients.\\r\\n\\r\\nThis is extracted from the patient's medical record. This will also be analyzed by\\r\\npatient-level characteristics: race, age, teratogen use.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Effectiveness: ACR-aligned contraception',\n",
       "      'description': \"Yes/No: documentation of use of contraception aligned with ACR RHG a rheumatology clinic\\r\\nvisit within 6 months of a visit in the Intervention Period. ACR RHG guidelines\\r\\nrecommend:\\r\\n\\r\\n  1. Any woman with SLE: avoid estrogen-containing patch;\\r\\n\\r\\n  2. Those with prior blood clot, positive antiphospholipid antibodies, or nephrotic\\r\\n     syndrome: avoid contraceptives that increase thrombotic risk (pills with estrogen,\\r\\n     ring, patch, or depot-medroxyprogesterone);\\r\\n\\r\\n  3. Those with highly active SLE: avoid contraceptives that contain estrogen (pills with\\r\\n     estrogen, ring, patch); and\\r\\n\\r\\n  4. Those not medically ready for pregnancy: effective or highly effective\\r\\n     contraception. Denominator: Eligible patients excluding pregnant women or women who\\r\\n     have a documented pregnancy intention AND are medically optimized for pregnancy.\\r\\n     This will be coded based on information extracted from the patient's medical record.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Effectiveness: Effective and/or highly effective contraception',\n",
       "      'description': \"Yes/No: documentation of use of an effective or highly effective contraception at a\\r\\nRheumatology clinic visit in the Intervention Period. Effective and highly effective\\r\\ncontraception includes hormonal contraception, long-acting reversible contraception, and\\r\\npermanent contraception or the physical inability to get pregnant (menopause,\\r\\nhysterectomy, oophorectomy). Denominator: Eligible patients excluding pregnant women or\\r\\nwomen who have a documented pregnancy intention AND are medically optimized for\\r\\npregnancy. This is extracted from the patient's medical record.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Effectiveness: Change from no contraception or ineffective contraception to effective and/or highly effective contraception',\n",
       "      'description': \"Yes/No: documentation of use of an effective or highly effective contraception at any\\r\\nRheumatology clinic visit within 6 months of a visit in the Intervention Period.\\r\\nDenominator: Eligible non-pregnant women who have documentation of either no\\r\\ncontraceptive use or low efficacy contraception at a prior rheumatology visit in the\\r\\nIntervention Period. Women without contraception documentation are excluded from this\\r\\nanalysis. Effective and highly effective contraception includes hormonal contraception,\\r\\nlong-acting reversible contraception, and permanent contraception or the physical\\r\\ninability to get pregnant (menopause, hysterectomy, oophorectomy). Low Efficacy\\r\\nContraception includes condom, diaphragm, sponge, cervical cap, spermicide, fertility\\r\\nawareness, withdrawal method. This is extracted from the patient's medical record.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Effectiveness: Pregnancy when women is medically optimized for pregnancy',\n",
       "      'description': \"Yes/No: conception is aligned with ACR recommendations. Denominator: All pregnancies\\r\\nconceived within 6 months of a rheumatology visit in the Intervention Period.\\r\\n\\r\\nMedically optimized for pregnancy is defined as meeting all 3 criteria:\\r\\n\\r\\n  1. Urine protein:creatinine ratio measured within 3 months before or after conception\\r\\n     and with <1g of proteinuria\\r\\n\\r\\n  2. Not taking any rheumatic teratogens at conception (mycophenolate or mycophenolic\\r\\n     acid, methotrexate, leflunamide, cyclophosphamide, thalidomide or lenalidomide)\\r\\n\\r\\n  3. Continued pregnancy-compatible SLE medications after conception (most commonly\\r\\n     prednisone, hydroxychloroquine, and/or azathioprine; also tacrolimus, cyclosporin,\\r\\n     and/or colchicine) This is extracted from the patient's medical record.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Adoption: Providers that ever complete the HOP-STEP intervention',\n",
       "      'description': \"Yes/No: provider that has documentation of completing the whole HOP-STEP intervention\\r\\nwith one or more of their patients. Completing the whole HOP-STEP Intervention is defined\\r\\nas documenting all three components of the intervention: current contraception, pregnancy\\r\\nintention, and ACR-aligned contraception and/or pregnancy planning counseling. This is\\r\\nextracted from the provider's patients' medical records and will also be examined by the\\r\\nprovider's race, age, gender, and proportion of SLE patients within a provider's\\r\\npractice.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': \"Degree of Adoption: Providers' completion of the HOP-STEP intervention\",\n",
       "      'description': \"Per provider, the number of eligible patients who received the whole HOP-STEP\\r\\nIntervention at one or more of their visits. Denominator: eligible patients cared for by\\r\\nthe provider during the Intervention Period. This is extracted from the provider's\\r\\npatients' medical records and will also be examined by the provider's race, age, gender,\\r\\nand proportion of SLE patients within a provider's practice.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Fidelity to the ACR RHG contraception recommendations',\n",
       "      'description': \"Yes/No: contraception recommendations aligned with the ACR RHG. Denominator: eligible\\r\\npatients who received any contraception recommendation. This is extracted from the\\r\\npatient's medical record. This will also be analyzed by patient-level characteristics:\\r\\nrace, age, teratogen use.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'Fidelity to the ACR RHG pregnancy medications recommendations',\n",
       "      'description': \"Yes/No: pregnancy planning recommendations aligned with the ACR RHG. Denominator:\\r\\neligible patients who received any pregnancy planning. This is extracted from the\\r\\npatient's medical record.\",\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'},\n",
       "     {'measure': 'FRAME system to document local changes to the Implementation',\n",
       "      'description': '1.) when and how a change is made, 2.) whether the change was planned or not, 3.) who\\r\\ndetermined that the change could be made, 4.) what the change was, 5.) where within the\\r\\ndelivery the change was made, 6.) the type of content- or context-level change, 7.) the\\r\\ndegree that the change is consistent with intervention fidelity, and 8.) the reasons for\\r\\nthe change, including intended impact on equity of reach, adoption, effectiveness, and/or\\r\\nmaintenance of the HOP-STEP intervention.',\n",
       "      'timeFrame': 'Intervention Period, up to 12 months'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  adult and/or pediatric clinical rheumatology providers within UCMC clinics',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Dana Burshell, MPH',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '5042512799',\n",
       "      'email': 'dana.burshell@duke.edu'},\n",
       "     {'name': 'Megan A Reaves, MS',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '9196602272',\n",
       "      'email': 'megan.reaves@duke.edu'}],\n",
       "    'overallOfficials': [{'name': 'Megan E Clowse, MD',\n",
       "      'affiliation': 'Duke University',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'University of Chicago Medical Center',\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60637',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Cuoghi Edens, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '773-702-6119',\n",
       "        'email': 'cedens@bsd.uchicago.edu'},\n",
       "       {'name': 'Cuoghi Edens, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}]},\n",
       "   'referencesModule': {'seeAlsoLinks': [{'label': 'HOP-STEP website',\n",
       "      'url': 'http://lupuspregnancy.org/'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000008180',\n",
       "      'term': 'Lupus Erythematosus, Systemic'}],\n",
       "    'ancestors': [{'id': 'D000003240', 'term': 'Connective Tissue Diseases'},\n",
       "     {'id': 'D000001327', 'term': 'Autoimmune Diseases'},\n",
       "     {'id': 'D000007154', 'term': 'Immune System Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M11177',\n",
       "      'name': 'Lupus Erythematosus, Systemic',\n",
       "      'asFound': 'Systemic Lupus Erythematosus',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M6464', 'name': 'Connective Tissue Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC17',\n",
       "      'name': 'Skin and Connective Tissue Diseases'},\n",
       "     {'abbrev': 'BC20', 'name': 'Immune System Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M6494',\n",
       "      'name': 'Contraceptive Agents',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T187', 'name': 'Hops', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Repr',\n",
       "      'name': 'Reproductive Control Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06142461',\n",
       "    'orgStudyIdInfo': {'id': 'HPV-PJ-01'},\n",
       "    'secondaryIdInfos': [{'id': '1R44CA261326-01A1',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/1R44CA261326-01A1'}],\n",
       "    'organization': {'fullName': 'PharmaJet, Inc.', 'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System',\n",
       "    'officialTitle': 'Safety and Immunogenicity of Human Papillomavirus Quadrivalent Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'WITHDRAWN',\n",
       "    'whyStopped': 'Change in landscape of HPV treatment',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-12-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-04-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-11-16',\n",
       "    'studyFirstSubmitQcDate': '2023-11-16',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-21', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-24', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'PharmaJet, Inc.', 'class': 'INDUSTRY'},\n",
       "    'collaborators': [{'name': 'National Institutes of Health (NIH)',\n",
       "      'class': 'NIH'},\n",
       "     {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False,\n",
       "    'isUsExport': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to evaluate the safety and immunogenicity of an HPV\\r\\nVaccine (Gardasil) delivered by intramuscular needle-free injection and intradermal\\r\\nneedle-free injection. The main question it aims to answer is:\\r\\n\\r\\n  -  Is intramuscular and intradermal needle-free injection of Gardasil safe?\\r\\n\\r\\n  -  Does intramuscular and intradermal needle-free vaccination with Gardasil illicit an\\r\\n     immune response?\\r\\n\\r\\nParticipants will:\\r\\n\\r\\n  -  Receive Gardasil by intramuscular needle-free injection, intradermal needle-free\\r\\n     injection, or needle and syringe injection.\\r\\n\\r\\n  -  Provide blood samples\\r\\n\\r\\n  -  Complete physical exams\\r\\n\\r\\n  -  Complete diaries'},\n",
       "   'conditionsModule': {'conditions': ['Vaccine Reaction']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': 'Open-label vaccination. Serology samples for immunogenicity assessment are blinded.',\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': '1: Intradermal needle-free injection',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Fractional dose (2 x 0.1 mL injections) intradermal administration of Gardasil® using\\r\\nPharmaJet Tropis® Needle-Free Injection System.',\n",
       "      'interventionNames': ['Drug: Gardasil',\n",
       "       'Device: PharmaJet Tropis® Needle-Free Injection System']},\n",
       "     {'label': '2: Intramuscular needle-free injection',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Full dose (0.5 mL injection) intramuscular administration of Gardasil® using PharmaJet\\r\\nStratis® Needle-Free Injection System',\n",
       "      'interventionNames': ['Drug: Gardasil',\n",
       "       'Device: PharmaJet Stratis® Needle-Free Injection System']},\n",
       "     {'label': '3: Needle and syringe',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Full dose (0.5 mL injection) intramuscular administration of Gardasil® using needle and\\r\\nsyringe',\n",
       "      'interventionNames': ['Drug: Gardasil']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Gardasil',\n",
       "      'description': 'Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant\\r\\nPre-filled syringe, 0.5mL dose volume',\n",
       "      'armGroupLabels': ['3: Needle and syringe'],\n",
       "      'otherNames': ['Gardasil PFS, 0.5mL']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Gardasil',\n",
       "      'description': 'Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant\\r\\nNeedle-free intramuscular injection, 0.5mL dose volume',\n",
       "      'armGroupLabels': ['2: Intramuscular needle-free injection'],\n",
       "      'otherNames': ['Gardasil vial, 0.5mL']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Gardasil',\n",
       "      'description': 'Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant\\r\\nNeedle-free intradermal injection, 0.2mL dose volume',\n",
       "      'armGroupLabels': ['1: Intradermal needle-free injection'],\n",
       "      'otherNames': ['Gardasil vial, 0.2mL']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'PharmaJet Stratis® Needle-Free Injection System',\n",
       "      'description': '0.5mL dose injection',\n",
       "      'armGroupLabels': ['2: Intramuscular needle-free injection'],\n",
       "      'otherNames': ['Stratis']},\n",
       "     {'type': 'DEVICE',\n",
       "      'name': 'PharmaJet Tropis® Needle-Free Injection System',\n",
       "      'description': '0.1mL dose injection',\n",
       "      'armGroupLabels': ['1: Intradermal needle-free injection'],\n",
       "      'otherNames': ['Tropis']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Safety of fractional dose intradermal administration of Gardasil using PharmaJet Tropis® Needle-Free Injection System',\n",
       "      'timeFrame': 'Day 0 through Day 210'},\n",
       "     {'measure': 'Immunogenicity of fractional dose intradermal administration of Gardasil using PharmaJet Tropis® Needle-Free Injection System',\n",
       "      'timeFrame': '28 days following each vaccination'},\n",
       "     {'measure': 'Safety of full dose intramuscular administration of Gardasil using PharmaJet Stratis® Needle-Free Injection System',\n",
       "      'timeFrame': 'Day 0 through Day 210'},\n",
       "     {'measure': 'Immunogenicity of full dose intramuscular administration of Gardasil using PharmaJet Stratis® Needle-Free Injection System',\n",
       "      'timeFrame': '28 days following each vaccination'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Non-inferior immunogenicity of intradermal administration of Gardasil using PharmaJet Tropis® Needle-Free Injection System compared to full dose intramuscular administration of Gardasil using needle and syringe',\n",
       "      'timeFrame': '28 days following each vaccination'},\n",
       "     {'measure': 'Non-inferior immunogenicity of intramuscular administration of Gardasil using PharmaJet Stratis® Needle-Free Injection System compared to full dose intramuscular administration of Gardasil using needle and syringe',\n",
       "      'timeFrame': '28 days following each vaccination'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Female between the age of 12 years and 13 years, inclusive. (Female 7th grade junior\\r\\n     high school students in Indonesia)\\r\\n\\r\\n  -  Clinically healthy, as established by medical history and physical examination\\r\\n     before entering the study.\\r\\n\\r\\n  -  Not pregnant at the time of vaccination.\\r\\n\\r\\n  -  Able to provide informed consent and assent.\\r\\n\\r\\n  -  Able to comply with the study.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Previous vaccination against HPV.\\r\\n\\r\\n  -  Use of any investigational or non-registered product (drug or vaccine) other than\\r\\n     the study vaccine within 30 days prior to study enrollment, or planned use during\\r\\n     the study period.\\r\\n\\r\\n  -  Administration of any vaccine within 30 days prior the study enrollment, or within\\r\\n     30 days of study vaccination visits.\\r\\n\\r\\n  -  Chronic administration of immunosuppressants or other immune-modifying drugs within\\r\\n     six months prior to the study enrollment, or planned use during the study period.\\r\\n\\r\\n  -  Any medically diagnosed or suspected immunodeficient condition based on medical\\r\\n     history and physical examination.\\r\\n\\r\\n  -  History of allergic disease, suspected allergy, or reactions likely to be\\r\\n     exacerbated by any component of vaccine, including yeast.\\r\\n\\r\\n  -  History of chronic condition(s) requiring treatment such as cancer, chronic\\r\\n     hepatitis or kidney disease(s), diabetes, autoimmune disease. Participants with\\r\\n     medically stable, well controlled autoimmune disease may be permitted.\\r\\n\\r\\n  -  Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular\\r\\n     injection.\\r\\n\\r\\n  -  Received immunoglobulins and/or blood product within 90 days preceding enrollment,\\r\\n     or planned use during the study period.\\r\\n\\r\\n  -  Acute disease at the time of enrollment. Acute disease is defined as the presence of\\r\\n     a moderate or severe illness with or without fever. All vaccines can be administered\\r\\n     to persons with a minor illness such as diarrhea, mild upper respiratory infection\\r\\n     with or without low-grade febrile illness, i.e., axillary temperature <37.5°C.\\r\\n\\r\\n  -  Any condition that may interfere with ability to comply with trial procedures, as\\r\\n     assessed by the Investigator.',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'genderBased': True,\n",
       "    'minimumAge': '12 Years',\n",
       "    'maximumAge': '13 Years',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'locations': [{'facility': 'Universitas Padjadjaran',\n",
       "      'city': 'Bandung',\n",
       "      'country': 'Indonesia',\n",
       "      'geoPoint': {'lat': -6.92222, 'lon': 107.60694}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360',\n",
       "      'name': 'Vaccines',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06383897',\n",
       "    'orgStudyIdInfo': {'id': 'HS-10398-101'},\n",
       "    'organization': {'fullName': 'Jiangsu Hansoh Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'},\n",
       "    'briefTitle': 'Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction',\n",
       "    'officialTitle': 'A Randomized, Double-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and the Impact of Food on Pharmacokinetics of HS-10398 in Healthy Participants, and a Clinical Trial to Assess the Pharmacokinetic Characteristics of HS-10398 in Participants With Kidney Dysfunction'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-01-31', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-01-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-06-20',\n",
       "    'studyFirstSubmitQcDate': '2024-04-22',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-25', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-22',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-25', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Jiangsu Hansoh Pharmaceutical Co., Ltd.',\n",
       "     'class': 'INDUSTRY'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'A randomized, double-blind, placebo-controlled, dose-escalation clinical trial to\\r\\nevaluate the safety, tolerability, pharmacokinetic characteristics, and the impact of\\r\\nfood on pharmacokinetics of oral HS-10398 in Chinese healthy participants, and a clinical\\r\\ntrial to assess the pharmacokinetic characteristics of oral HS-10398 in Chinese\\r\\nparticipants with kidney dysfunction',\n",
       "    'detailedDescription': 'This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled,\\r\\ndose-escalation clinical trial. The primary objective is to evaluate the safety,\\r\\ntolerability, and pharmacokinetic characteristics of single and multiple oral doses of\\r\\nHS-10398 in Chinese healthy participants. The secondary objective is to assess the impact\\r\\nof food on the pharmacokinetics of single oral doses of HS-10398 in Chinese healthy\\r\\nparticipants, as well as to evaluate the pharmacokinetic characteristics of oral HS-10398\\r\\nin Chinese participants with kidney dysfunction.'},\n",
       "   'conditionsModule': {'conditions': ['Healthy'],\n",
       "    'keywords': ['HS-10398', 'Phase 1', 'Healthy']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE1'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'DOUBLE',\n",
       "      'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}},\n",
       "    'enrollmentInfo': {'count': 116, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Cohort1：HS-10398',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'SAD： HS-10398 capsule',\n",
       "      'interventionNames': ['Drug: HS-10398']},\n",
       "     {'label': 'Cohort2：HS-10398 Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'SAD：HS-10398 capsule placebo',\n",
       "      'interventionNames': ['Drug: HS-10398 Placebo']},\n",
       "     {'label': 'Cohort3：HS-10398',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'MAD： HS-10398 capsule',\n",
       "      'interventionNames': ['Drug: HS-10398']},\n",
       "     {'label': 'Cohort4：HS-10398 Placebo',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'MAD：HS-10398 capsule placebo',\n",
       "      'interventionNames': ['Drug: HS-10398 Placebo']},\n",
       "     {'label': 'Cohort5：HS-10398',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney\\r\\nDysfunction',\n",
       "      'interventionNames': ['Drug: HS-10398']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'HS-10398',\n",
       "      'description': 'SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day\\r\\n1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or\\r\\ntwice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1\\r\\nin Participants With Kidney Dysfunction',\n",
       "      'armGroupLabels': ['Cohort1：HS-10398',\n",
       "       'Cohort3：HS-10398',\n",
       "       'Cohort5：HS-10398']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'HS-10398 Placebo',\n",
       "      'description': 'SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally\\r\\nonce on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be\\r\\nadministered orally once or twice from Day 1 to Day 14',\n",
       "      'armGroupLabels': ['Cohort2：HS-10398 Placebo',\n",
       "       'Cohort4：HS-10398 Placebo']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence and severity of adverse events (AEs)',\n",
       "      'description': 'The definition of adverse event [AE] is any untoward medical occurrence in a patient or\\r\\nclinical study participant, temporally associated with the use of study intervention,\\r\\nwhether or not considered related to the study intervention.',\n",
       "      'timeFrame': 'From screening to day 15'},\n",
       "     {'measure': 'Serious adverse events (SAEs)',\n",
       "      'description': 'The definition of serious adverse event [SAE] is any untoward medical occurrence at any\\r\\ndose that results in death; is life threatening; requires inpatient hospitalization or\\r\\nprolongation of existing hospitalization; results in persistent disability/incapacity;\\r\\nresults in congenital anomaly/birth defect.',\n",
       "      'timeFrame': 'From screening to day 15'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Observed maximum plasma concentration (Cmax)',\n",
       "      'description': 'Cmax will be obtained following administration of a single oral dose of HS-10398',\n",
       "      'timeFrame': 'up to 216 hours after dosing'},\n",
       "     {'measure': 'Time to reach maximum plasma concentration (Tmax)',\n",
       "      'description': 'Tmax will be obtained following administration of a single oral dose of HS-10398',\n",
       "      'timeFrame': 'up to 216 hours after dosing'},\n",
       "     {'measure': 'Elimination Halflife (T1/2)',\n",
       "      'description': 'Elimination Halflife (T1/2) is the time measured for the concentration to decrease by one\\r\\nhalf which will be obtained following administration of a single oral dose of HS-10398',\n",
       "      'timeFrame': 'up to 216 hours after dosing'},\n",
       "     {'measure': 'Apparent clearance（CL/F）',\n",
       "      'description': 'CL/F will be obtained following administration of a single oral dose of HS-10398',\n",
       "      'timeFrame': 'up to 216 hours after dosing'},\n",
       "     {'measure': 'Apparent Volume of Distribution（Vd/F）',\n",
       "      'description': 'Vd/F will be obtained following administration of a single oral dose of HS-10398',\n",
       "      'timeFrame': 'up to 216 hours after dosing'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\n  -  Healthy participants aged from 18 to 64 years\\r\\n\\r\\n  -  Subjects need to fully understand the research content and process, as well as\\r\\n     possible adverse reactions, and voluntarily signed Informed Consent Form\\r\\n\\r\\n  -  Males' weight should be ≥ 50kg, and females' weight should be ≥ 45kg. Body mass\\r\\n     index (BMI), calculated as weight/height^2 (kg/m^2), should be controlled within the\\r\\n     range of 19 to 28, including the critical value\\r\\n\\r\\n  -  Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection is\\r\\n     required prior to the start of study treatment. If the patient has not been\\r\\n     previously vaccinated, or if a booster is required, vaccine should be given\\r\\n     according to local regulations at least 2 weeks prior to first study drug\\r\\n     administration\\r\\n\\r\\n  -  Participants with Kidney Dysfunction must have met the following additional criteria\\r\\n     to be enrolled in this study：Patients with chronic kidney disease (defined as the\\r\\n     presence of any markers of kidney damage or an estimated glomerular filtration rate\\r\\n     (eGFR) persistently less than 90 mL/min/1.73m² for more than 3 months), and with an\\r\\n     estimated glomerular filtration rate (eGFR) at screening and baseline assessments\\r\\n     (with a minimum interval of 3 days between screening and baseline assessments)\\r\\n     meeting the criteria of 60≤eGFR<90 mL/min/1.73m².\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Has a history of chronic or serious disease from neuropsychiatric system,\\r\\n     cardiovascular system, urinary system, digestive system, respiratory system,\\r\\n     skeletal muscle system, metabolic endocrine system, skin disease, blood system,\\r\\n     immune system or tumor\\r\\n\\r\\n  -  Has taken any drugs, including prescription drugs, over-the-counter drugs, herbal\\r\\n     preparations, some health products or inhibitor/inducer of CYP3A4/5 or CYP2C8 or any\\r\\n     medications that inhibit P-glycoprotein transporters., within 2 weeks (or 5\\r\\n     half-lives) before screening and throughout the study period\\r\\n\\r\\n  -  Has clinically significant ECG abnormalities, such as QT interval corrected\\r\\n     according to Fridericia formula(QTcF), >450 ms (males), >470 ms (females)\\r\\n\\r\\n  -  Has participated in another clinical trial involving drugs or medical devices within\\r\\n     the month prior to screening and received investigational drugs or used medical\\r\\n     devices, or within 5 half-lives of the investigational drugs from another trial at\\r\\n     the time of screening, whichever is longer\\r\\n\\r\\n  -  Unable to abstain from smoking and alcohol.\\r\\n\\r\\n  -  History of drug dependence or substance abuse\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '64 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Yu Cao, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+86 18661809090',\n",
       "      'email': 'caoyu1767@126.com'}],\n",
       "    'locations': [{'facility': 'The Affiliated Hospital of Qingdao University',\n",
       "      'city': 'Qingdao',\n",
       "      'country': 'China',\n",
       "      'contacts': [{'name': 'Xiaolei Zhang',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0532-82912611',\n",
       "        'email': 'qingyilunli@126.com'}],\n",
       "      'geoPoint': {'lat': 36.06488, 'lon': 120.38042}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05603897',\n",
       "    'orgStudyIdInfo': {'id': '20220558'},\n",
       "    'organization': {'fullName': 'University of Miami', 'class': 'OTHER'},\n",
       "    'briefTitle': 'Non-standardized vs. Standardized Screening for Dysphagia',\n",
       "    'officialTitle': 'Utility of Non-standardized Clinical Swallow Evaluation vs. Standardized Swallow Evaluation to Identify the Presence of Dysphagia and Risk for Aspiration in Patients Post-ischemic Stroke in Acute Inpatient Rehabilitation'},\n",
       "   'statusModule': {'statusVerifiedDate': '2023-10',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-01-04', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-01-04', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2022-10-28',\n",
       "    'studyFirstSubmitQcDate': '2022-10-28',\n",
       "    'studyFirstPostDateStruct': {'date': '2022-11-03', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-02-05',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-02-06', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Gemayaret Alvarez',\n",
       "     'investigatorTitle': 'Attending Physician',\n",
       "     'investigatorAffiliation': 'University of Miami'},\n",
       "    'leadSponsor': {'name': 'University of Miami', 'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The purpose of this study is to compare two different screening tests for detecting\\r\\ndysphagia (difficulty swallowing) as well as the risk for aspiration (silent swallowing\\r\\nof liquids/solids into the lungs) in patients after an ischemic stroke (when a blood clot\\r\\nblocks or narrows an artery leading to the brain).'},\n",
       "   'conditionsModule': {'conditions': ['Dysphagia'],\n",
       "    'keywords': ['difficulty swallowing']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'primaryPurpose': 'SCREENING',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Mann Assessment of Swallowing Ability (MASA) Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants in this group will receive the MASA dysphagia screening once upon admission\\r\\nto inpatient rehabilitation for approximately 20 minutes.',\n",
       "      'interventionNames': ['Other: Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)']},\n",
       "     {'label': 'Non-standardized clinical swallow evaluation Group',\n",
       "      'type': 'OTHER',\n",
       "      'description': 'Participants in this group will receive standard of care treatment (dysphagia screening\\r\\nonce upon admission to inpatient rehabilitation using a non-standardized clinical swallow\\r\\nevaluation for approximately 15 minutes).',\n",
       "      'interventionNames': ['Other: Non-standardized clinical swallow evaluation']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)',\n",
       "      'description': 'Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for\\r\\napproximately 20 minutes during initial speech language pathology evaluation. The MASA\\r\\nwill be administered at bedside as a cognitive/speech language evaluation as well as\\r\\noropharyngeal function examination.',\n",
       "      'armGroupLabels': ['Mann Assessment of Swallowing Ability (MASA) Group']},\n",
       "     {'type': 'OTHER',\n",
       "      'name': 'Non-standardized clinical swallow evaluation',\n",
       "      'description': 'Participants will receive current standard of care for dysphagia screening and treatment.',\n",
       "      'armGroupLabels': ['Non-standardized clinical swallow evaluation Group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Dysphagia measured by MASA',\n",
       "      'description': \"The MASA is a 24-item clinical test that evaluates swallowing in the order in which\\r\\nswallowing phases occur. Each item is quantitatively scored using either a 5-point or\\r\\n10-point score at the end of which a total score out of 200 is summed up. The MASA takes\\r\\napproximately 15-20 minutes to perform and can then be repeated during a patient's\\r\\nclinical course to monitor for recovery.\",\n",
       "      'timeFrame': 'Up to 20 minutes'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Adults ≥ 18 years old\\r\\n\\r\\n  -  Patients admitted to Lynn Rehabilitation Center with an admitting diagnosis\\r\\n     consistent with acute ischemic stroke within the past 1 month\\r\\n\\r\\n  -  Patients able to provide informed, written consent. If patients are not cognitively\\r\\n     able to give informed consent, then consent will be obtained from patient proxy in\\r\\n     person or over the phone\\r\\n\\r\\n  -  Able to read and comprehend verbal instruction in English and/or Spanish\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Adults > 80 years old\\r\\n\\r\\n  -  Pregnant women\\r\\n\\r\\n  -  Prisoners\\r\\n\\r\\n  -  Those with a prior history of dysphagia\\r\\n\\r\\n  -  Those with any diagnoses that include acute intracranial hemorrhage, subdural\\r\\n     hematoma, subarachnoid hemorrhage, traumatic brain injury',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Gemayaret Alvarez, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '305-585-9420',\n",
       "      'email': 'g.alvarez3@med.miami.edu'},\n",
       "     {'name': 'Claudia Santesteban-bidot, M.S.',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '305-585-9449',\n",
       "      'email': 'claudia.santesteban@jhsmiami.org'}],\n",
       "    'overallOfficials': [{'name': 'Gemayaret Alvarez, MD',\n",
       "      'affiliation': 'University of Miami',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': 'Lynn Rehabilitation Center / University of Miami',\n",
       "      'city': 'Miami',\n",
       "      'state': 'Florida',\n",
       "      'zip': '33136',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Oliver Acosta, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '305-585-9420',\n",
       "        'email': 'oliver.acosta@jhsmiami.org'},\n",
       "       {'name': 'Claudia Santesteban-bidot, MS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '305-585-9449',\n",
       "        'email': 'claudia.santesteban@jhsmiami.org'},\n",
       "       {'name': 'Oliver Acosta, MD', 'role': 'PRINCIPAL_INVESTIGATOR'},\n",
       "       {'name': 'Gemayaret Alvarez, MD', 'role': 'SUB_INVESTIGATOR'}],\n",
       "      'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000003680',\n",
       "      'term': 'Deglutition Disorders'}],\n",
       "    'ancestors': [{'id': 'D000004935', 'term': 'Esophageal Diseases'},\n",
       "     {'id': 'D000005767', 'term': 'Gastrointestinal Diseases'},\n",
       "     {'id': 'D000004066', 'term': 'Digestive System Diseases'},\n",
       "     {'id': 'D000010608', 'term': 'Pharyngeal Diseases'},\n",
       "     {'id': 'D000010038', 'term': 'Otorhinolaryngologic Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M22306', 'name': 'Stroke', 'relevance': 'LOW'},\n",
       "     {'id': 'M2400', 'name': 'Ischemic Stroke', 'relevance': 'LOW'},\n",
       "     {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'},\n",
       "     {'id': 'M6882',\n",
       "      'name': 'Deglutition Disorders',\n",
       "      'asFound': 'Dysphagia',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M8085', 'name': 'Esophageal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8883', 'name': 'Gastrointestinal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M7255', 'name': 'Digestive System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M13515', 'name': 'Pharyngeal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M12961',\n",
       "      'name': 'Otorhinolaryngologic Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T170',\n",
       "      'name': 'Acute Graft Versus Host Disease',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'BC06', 'name': 'Digestive System Diseases'},\n",
       "     {'abbrev': 'BC09', 'name': 'Ear, Nose, and Throat Diseases'},\n",
       "     {'abbrev': 'BC07', 'name': 'Mouth and Tooth Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06434805',\n",
       "    'orgStudyIdInfo': {'id': 'HE-NHS2024/02'},\n",
       "    'organization': {'fullName': 'Hong Kong Metropolitan University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'An Education Initiative to Reduce Stigma Towards Sex Workers and Sexual Minorities Among Nursing Students',\n",
       "    'officialTitle': 'An Education Initiative to Reduce Stigma Towards Sex Workers and Sexual Minorities Among Nursing Students: a Pilot Study'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-18',\n",
       "    'studyFirstSubmitQcDate': '2024-05-23',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-30', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-29',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Dr Polly MA Haixia',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'Hong Kong Metropolitan University'},\n",
       "    'leadSponsor': {'name': 'Hong Kong Metropolitan University',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"Background: Sex workers and sexual minorities (SWSM) often encounter barriers when\\r\\naccessing healthcare services due to social stigma and discrimination. In Hong Kong,\\r\\nstigma and prejudice exist among nurses and nursing students toward SWSM.\\r\\n\\r\\nAims: This education initiative aims to improve the knowledge, attitudes, and clinical\\r\\ncompetence of nursing students in caring for SWSM.\\r\\n\\r\\nMethods: This pilot study will employ a one-group pre-and post-test design. Convenience\\r\\nsampling will be used to recruit 52 nursing students from the clinical phase of the\\r\\nBachelor of Nursing program at the School of Nursing and Health Studies of Hong Kong\\r\\nMetropolitan University, as well as nursing students from other local universities. The\\r\\nintervention will consist of a four-session one-day workshop based on social cognitive\\r\\ntheory and interpersonal contact theory. The workshop will cover various topics,\\r\\nincluding terminologies, human rights, stigma and discrimination in healthcare settings,\\r\\ncontact with SWSM, and skills building. The primary outcome measure will include\\r\\nparticipants' attitudes toward SWSM. Secondary outcome measures included their knowledge\\r\\nand clinical competence. These outcome measurements will be assessed at baseline (T0) and\\r\\nafter the intervention (T1) and three months follow up (T2). Additionally, focus group\\r\\ndiscussions will be carried out to explore participants' experiences of the intervention.\\r\\n\\r\\nDiscussion: Findings from this study could contribute to the existing knowledge on stigma\\r\\nsurrounding SWSM in Hong Kong and its impact on healthcare. The intervention is expected\\r\\nto increase the knowledge, attitudes, and skills of nursing students in providing care\\r\\nfor SWSM. By promoting non-judgmental and equitable care, the research aims to contribute\\r\\nto the overall well-being and health outcomes of SWSM. These results will inform future\\r\\nnursing education curricula and clinical practice, facilitating the development of more\\r\\ninclusive and patient-centered care for marginalized populations in Hong Kong and beyond.\"},\n",
       "   'conditionsModule': {'conditions': ['Stigmatization',\n",
       "     'Sex Work',\n",
       "     'Homosexuality',\n",
       "     'Transgenderism'],\n",
       "    'keywords': ['gender and sexual minority',\n",
       "     'sex workers',\n",
       "     'cultural competency',\n",
       "     'nursing students']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'NA',\n",
       "     'interventionModel': 'SINGLE_GROUP',\n",
       "     'interventionModelDescription': 'A single group with outcome assessments will be taken at baseline, post-intervention, and\\r\\nat 3-month follow-up.',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 52, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Education workshop',\n",
       "      'type': 'OTHER',\n",
       "      'description': 'This is a one-day workshop with four sessions.',\n",
       "      'interventionNames': ['Other: sex workers and sexual minorities education workshop']}],\n",
       "    'interventions': [{'type': 'OTHER',\n",
       "      'name': 'sex workers and sexual minorities education workshop',\n",
       "      'description': 'The participants will receive a one-day workshop (four sessions). The generic content\\r\\naims at enhancing the understanding of sexual orientation, gender identities, social\\r\\nstigma, sex work and sexual orientation and human rights (session 1), the lived\\r\\nexperience of SWSM (session 2), the content specifically related to the medical and\\r\\nhealthcare field, including be familiar with the professional and ethical obligations\\r\\n(session 3), the skills that can be adopted when providing services to SWSM (session 4).',\n",
       "      'armGroupLabels': ['Education workshop']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Attitudes toward lesbians and gay men scale (ATLG)',\n",
       "      'description': 'The Attitudes Toward Lesbians and Gay Men Scale (ATLG) is an instrument designed to\\r\\nmeasure the attitudes of heterosexuals toward lesbians and gay men. It consists of 20\\r\\nitems, the first 10 about lesbians and the next 10 about gay men, and can be used as a\\r\\nsingle scale or two distinct subscales. Items are scored using a 4-point Likert scale,\\r\\nfrom 1 (strongly disagree) to 4 (strongly agree). The total score range for both the\\r\\nlesbian and gay subscale is from 10 to 40. The ATLG was validated in Hong Kong.',\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'},\n",
       "     {'measure': 'Genderism and Transphobia Scale (GTS)',\n",
       "      'description': 'The Genderism and Transphobia Scale (GTS) is a questionnaire consisting of 32 items\\r\\nmeasuring cognitive, behavioral, and affective dimensions of genderism, transphobia, and\\r\\ngender-bashing. The statements are rated on a 7-point Likert scale (1 = strongly agree to\\r\\n7 = strongly disagree), with higher scores denoting strong negative feelings and\\r\\nbehaviors toward transgender individuals. The GTS was validated in Hong Kong and included\\r\\nan additional item 33, and the total score ranges from 33 to 231.',\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'},\n",
       "     {'measure': 'Attitudes Toward sex workers with HIV and sexually transmitted diseases (STDs)',\n",
       "      'description': \"The scale will measure nursing students' attitudes towards sex workers, which was adopted\\r\\nfrom a scale developed by Melby et al. (1992) to determine nurses' attitudes towards\\r\\nprostitutes (Melby et al., 1992). The scale on nursing students' attitudes was comprised\\r\\nof eight items on attitude, with three related to morals, two to control, and three to\\r\\nsympathy. A 5-point Likert-type scale was used, with 1 = strongly disagree, and 5 =\\r\\nstrongly agree. Negative items (items 2 and 7) will be reversely coded, with higher score\\r\\nrepresenting positive attitudes. The total score ranges from 8 to 40.\",\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'}],\n",
       "    'secondaryOutcomes': [{'measure': 'LGBT development of clinical skills scale (LGBT-DOCSS)',\n",
       "      'description': \"LGBT-DOCSS will be used to assess nursing students' clinical skills in caring for sexual\\r\\nminorities. It includes 18 items crossing three domains: clinical preparedness,\\r\\nattitudinal attitudes, and basic knowledge. A 7-point Likert-type scale was used, with 1\\r\\n= not at all true, 4 = somewhat true, and 7 = total true. The total score ranges from 18\\r\\nto 126. Higher scores are indicative of higher levels of clinical preparedness and\\r\\nrudimentary knowledge and less prejudicial attitudinal awareness regarding LGBT\\r\\nclients/patients. LGBT-DOCSS was back-and-forth translated by the research team.\",\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'},\n",
       "     {'measure': 'Sex worker development of clinical skills scale (SW-DOCSS)',\n",
       "      'description': \"Sex worker development of clinical skills scale (SW-DOCSS) is developed based on\\r\\nLGBT-DOCSS. It will be used to assess nursing students' clinical skills in caring for\\r\\nsexual minorities. It includes 10 items crossing three domains: clinical preparedness,\\r\\nattitudinal attitudes, and basic knowledge. A 7-point Likert-type scale was used, with 1\\r\\n= not at all true, 4 = somewhat true, and 7 = total true. The total score ranges from 10\\r\\nto 70. Higher scores are indicative of higher levels of clinical preparedness and\\r\\nrudimentary knowledge and less prejudicial attitudinal awareness regarding sex worker\\r\\nclients/patients. A pilot test will be conducted to establish the reliability of the\\r\\nSW-DOCSS.\",\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'},\n",
       "     {'measure': 'Self-developed questionnaire regarding knowledge of sex workers and sexual minorities',\n",
       "      'description': \"The measurement of nursing students' knowledge of sex workers and sexual minorities is\\r\\ndeveloped from previous studies. It includes 14 items, where students will be asked to\\r\\nrate each statement as either right or wrong. The total score ranges from 0 to 14, with a\\r\\nhigher score indicating more accurate knowledge of sex workers and sexual minorities.\",\n",
       "      'timeFrame': 'baseline, immediately after the intervention, 3-months post-intervention'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  aged 18 years of age or above;\\r\\n\\r\\n  -  studying in the clinical phase (i.e., year 3 to year 5);\\r\\n\\r\\n  -  are able to speak, read, and write Cantonese or Putonghua;\\r\\n\\r\\n  -  are willing to participate in the study and share their experience of the education\\r\\n     initiative with the research group;\\r\\n\\r\\n  -  have informed consent to participate in the study.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Those who have completed a similar workshop or discussion of sex workers and sexual\\r\\n     minorities in previous nursing education will be excluded from this study.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '50 Years',\n",
       "    'stdAges': ['ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Haixia Ma, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '39702990',\n",
       "      'email': 'phxma@hkmu.edu.hk'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO',\n",
       "    'description': \"Participants' privacy, confidentiality, and voluntary participation of the study will be\\r\\nensured. Participants' information will be kept in a password-protected computer. Only\\r\\nthe research team could access the original data.\"}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06033651',\n",
       "    'orgStudyIdInfo': {'id': 'version 1 27/6/2023'},\n",
       "    'organization': {'fullName': 'Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust',\n",
       "     'class': 'OTHER_GOV'},\n",
       "    'briefTitle': 'Long Term Follow up of the Titanium Modular Revision Hip System, With Review of Metal Ion Levels',\n",
       "    'officialTitle': 'Long Term Follow up of the Titanium Modular Revision Hip System, With Review of Metal Ion Levels',\n",
       "    'acronym': 'TinT10'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2025-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-08-29',\n",
       "    'studyFirstSubmitQcDate': '2023-09-11',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-09-13', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-09',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-10', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust',\n",
       "     'class': 'OTHER_GOV'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'Patients are to be approached to attend clinic who have been identified as being\\r\\nimplanted with either a Lima Corporate Delta Revision TT, Delta One TT or the Delta\\r\\nMultihole Systems hip systems between 2011 and 2013, a minimum of 10 years since hip\\r\\nsurgery. They will be x-rayed (AP pelvis and a lateral view) and a blood test will be\\r\\ntaken and sent to a lab in Surrey to check titanium levels.',\n",
       "    'detailedDescription': \"Since its popularisation in the 1960's, Hip replacements have become one of the NHS's\\r\\nhighest volume procedures. Unfortunately, hip replacements can fail with on average 8,500\\r\\nrevision hip replacements being performed each year pre-covid. Often this is very complex\\r\\nwith destruction of the normal anatomy leaving surgeons with a significant challenge in\\r\\nensuring appropriate positioning of the socket within the confines of the patient's\\r\\nanatomy.\\r\\n\\r\\nThe Lima Corporate Delta Revision TT, Delta One TT and Delta Multihole Systems are\\r\\ndesigned to help surgeons with this very problem by providing the option of a 'face\\r\\nchanger' allowing surgeons to place a socket within a socket.\\r\\n\\r\\nTo allow for this function, the 'face changer' must connect with the acetabular cup\\r\\n(socket). Through research, it is widely known that when metals interact within the body,\\r\\nthey can cause wear and shedding of metal debris. This process is known as metallosis and\\r\\ncan result in metal ions being released into the surrounding bone and tissues as well as\\r\\nbeing absorbed into the blood stream.\\r\\n\\r\\nThe risk of this is highest when there is significant movement between the components\\r\\n(such as in metal-on-metal hip replacements). It is less of an issue at other interfaces\\r\\nwhich are not intended to allow movement between them. That said, our hypothesis is that\\r\\nthe increase in the number of interfaces which gives us the flexibility we need, may\\r\\nincrease the release of free metal ions in the blood stream. The aim of this study is to\\r\\ntherefore identify if this is in fact the case and if so, whether the increase in ions is\\r\\nsufficient for surgeons to bear in mind.\"},\n",
       "   'conditionsModule': {'conditions': ['Hip Surgery']},\n",
       "   'designModule': {'studyType': 'OBSERVATIONAL',\n",
       "    'patientRegistry': False,\n",
       "    'designInfo': {'observationalModel': 'COHORT',\n",
       "     'timePerspective': 'PROSPECTIVE'},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Only 1 arm for the study',\n",
       "      'description': 'All participants shall receive the same treatment.',\n",
       "      'interventionNames': ['Radiation: x-ray']}],\n",
       "    'interventions': [{'type': 'RADIATION',\n",
       "      'name': 'x-ray',\n",
       "      'description': 'A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.',\n",
       "      'armGroupLabels': ['Only 1 arm for the study'],\n",
       "      'otherNames': ['blood sample']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'The survivourship of the modular acetabular hip system at 10 years post-op',\n",
       "      'description': 'By looking at titanium ion blood levels and pelvis x-rays, this gives an indication of\\r\\nwhether the device is loosening and failing in this particular hip system.',\n",
       "      'timeFrame': 'Once blood results are back from the specialist assessment laboratory (approximately 3 weeks post clinic visit).'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\nAll adult patients who had Lima Corporate modular titanium acetabular component implants\\r\\nimplanted between 2012 and 2013.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nDeceased patients Patients who have undergone a subsequent acetabular revision Patients\\r\\nthat lack capacity Prisoners in the custody of HM Prison service or who are offenders\\r\\nsupervised by the probation service in England or Wales.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT'],\n",
       "    'studyPopulation': 'All adult patients who had Lima Corporate modular titanium acetabular component implants\\r\\nimplanted between 2012 and 2013.',\n",
       "    'samplingMethod': 'NON_PROBABILITY_SAMPLE'},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Julie Steen',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+441691404418',\n",
       "      'phoneExt': '4418',\n",
       "      'email': 'julie.steen@nhs.net'},\n",
       "     {'name': 'Thomas Banks',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '+441691404418',\n",
       "      'email': 'thomas.banks3@nhs.net'}],\n",
       "    'overallOfficials': [{'name': 'Robin Banerjee',\n",
       "      'affiliation': 'The Robert Jones and Agnes Hunt Orthopaedic Hospital Foundation Trust',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'referencesModule': {'references': [{'pmid': '36516281',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Ben-Shlomo Y, Blom A, Boulton C, Brittain R, Clark E, Dawson-Bowling S, Deere K, Esler C, Espinoza O, Evans J, Goldberg A, Gregson C, Howard P, Jameson S, Jennison T, Judge A, Lawrence S, Lenguerrand E, Marques E, McCormack V, Newell C, Pegg D, Penfold C, Porter M, Price A, Reed M, Rees J, Royall M, Sayers A, Stonadge J, Swanson M, Taylor D, Toms A, Watts A, Whitehouse M, Wilkinson M, Wilton T, Young E. The National Joint Registry 19th Annual Report 2022 [Internet]. London: National Joint Registry; 2022 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK587525/'},\n",
       "     {'pmid': '9865472',\n",
       "      'type': 'BACKGROUND',\n",
       "      'citation': 'Liu TK, Liu SH, Chang CH, Yang RS. Concentration of metal elements in the blood and urine in the patients with cementless total knee arthroplasty. Tohoku J Exp Med. 1998 Aug;185(4):253-62. doi: 10.1620/tjem.185.253.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06111651',\n",
       "    'orgStudyIdInfo': {'id': 'Pro00124236'},\n",
       "    'secondaryIdInfos': [{'id': '5P20GM130420',\n",
       "      'type': 'NIH',\n",
       "      'link': 'https://reporter.nih.gov/quickSearch/5P20GM130420'}],\n",
       "    'organization': {'fullName': 'University of South Carolina',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Family-Based Prevention With Black and Latinx Children',\n",
       "    'officialTitle': 'Family-Based Prevention to Promote the Social-Emotional Functioning and Healthy Lifestyle Behaviors of Black & Latinx Children'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-02-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-10-26',\n",
       "    'studyFirstSubmitQcDate': '2023-10-26',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-11-01', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-19',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-22', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR',\n",
       "     'investigatorFullName': 'Daniel Cooper',\n",
       "     'investigatorTitle': 'Assistant Professor',\n",
       "     'investigatorAffiliation': 'University of South Carolina'},\n",
       "    'leadSponsor': {'name': 'University of South Carolina', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'National Institute of General Medical Sciences (NIGMS)',\n",
       "      'class': 'NIH'}]},\n",
       "   'oversightModule': {'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The main objective of this project is to test whether providing parenting support, with\\r\\nan added emphasis on ethnic-racial socialization and healthy lifestyle behaviors,\\r\\nimproves the social-emotional functioning and healthy lifestyle behaviors of Black and\\r\\nLatinx children.',\n",
       "    'detailedDescription': \"This pilot project is novel in that it (a) interweaves positive parenting practices,\\r\\nethnic-racial socialization, and healthy lifestyle behaviors into a prevention program\\r\\nfor Black and Latinx families, and (b) targets preschool-aged children using a brief,\\r\\nuniversal prevention approach, which increases potential for dissemination and\\r\\nscalability. The guiding hypothesis is that incorporating these components into a\\r\\nparenting intervention will lead to improvements in children's health as compared to a\\r\\ncontrol condition. A type 1 hybrid effectiveness-implementation design is used to\\r\\nsimultaneously test intervention effectiveness while also gathering information on\\r\\nintervention delivery to inform future implementation trials. The specific aims are to:\\r\\n(a) test the preliminary effects of a preventive intervention on the social-emotional\\r\\nfunctioning and healthy lifestyle behaviors of Black and Latinx children, (b) identify\\r\\nthe preliminary effects of the intervention on parenting outcomes, and (c) examine\\r\\npotential barriers and facilitators to intervention delivery.\"},\n",
       "   'conditionsModule': {'conditions': ['Child Behavior', 'Health Behavior'],\n",
       "    'keywords': ['parent training',\n",
       "     'randomized controlled trial',\n",
       "     'pilot study',\n",
       "     'child development',\n",
       "     'implementation trial',\n",
       "     'prevention']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'PREVENTION',\n",
       "     'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Intervention',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'parents will participate in a multicomponent parenting intervention',\n",
       "      'interventionNames': ['Behavioral: Parenting Intervention']},\n",
       "     {'label': 'Control',\n",
       "      'type': 'NO_INTERVENTION',\n",
       "      'description': 'parents will receive information about healthy eating habits'}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Parenting Intervention',\n",
       "      'description': 'parent training program with an added emphasis on ethnic-racial socialization and healthy\\r\\nlifestyle behaviors',\n",
       "      'armGroupLabels': ['Intervention']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'child social-emotional functioning',\n",
       "      'description': 'Parent-reported assessment of various positive and negative child behaviors. Likert scale\\r\\nvalues range from 0 to 2, with higher values typically indicating greater dysfunctional\\r\\nbehavior.',\n",
       "      'timeFrame': 'pre (weeks 0-2) and post intervention (weeks 6-8)'},\n",
       "     {'measure': 'child physical activity',\n",
       "      'description': 'Time spent sedentary and in light, moderate, and vigorous physical activity each day will\\r\\nbe collected using a waterproof accelerometer. Validated methods will be used to identify\\r\\nvalid days and derive activity intensities.',\n",
       "      'timeFrame': 'pre (weeks 0-2) and post intervention (weeks 6-8)'},\n",
       "     {'measure': 'child sleep',\n",
       "      'description': 'Child average nightly sleep duration and quality will be calculated from data obtained\\r\\nusing a waterproof accelerometer.',\n",
       "      'timeFrame': 'pre (weeks 0-2) and post intervention (weeks 6-8)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'parenting practices',\n",
       "      'description': 'Parent-reported measure of different dimensions of parenting (e.g., harsh parenting,\\r\\npermissive parenting). Likert scale values range from 1 to 7, with higher values\\r\\nindicating greater dysfunctional parenting.',\n",
       "      'timeFrame': 'pre (weeks 0-2) and post intervention (weeks 6-8)'},\n",
       "     {'measure': 'ethnic-racial socialization practices',\n",
       "      'description': 'Parent-reported measure of attitudes about and use of various ethnic-racial socialization\\r\\npractices. Likert scale values range from 1 to 5, with higher values indicating more\\r\\npositive ethnic-racial socialization attitudes and practices.',\n",
       "      'timeFrame': 'pre (weeks 0-2) and post intervention (weeks 6-8)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\r\\n\\r\\nEligible children will:\\r\\n\\r\\n  -  be between the ages of 3-6 years\\r\\n\\r\\n  -  identify as Black/African American or Latinx/Hispanic\\r\\n\\r\\n  -  have a parent or caregiver willing to participate in the intervention that: (a)\\r\\n     lives in the same household as the child ≥50% of the time, (b) has primary\\r\\n     responsibility for the child, and (c) speaks English or Spanish.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\nConsistent with typical methods associated with a universal prevention approach, there\\r\\nare minimal exclusion criteria. Children will be excluded who:\\r\\n\\r\\n  -  have a cognitive/psychological condition that limits the child's ability to\\r\\n     communicate\\r\\n\\r\\n  -  have a physical health condition that limits the child's ability to be physically\\r\\n     active\",\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '3 Years',\n",
       "    'maximumAge': '6 Years',\n",
       "    'stdAges': ['CHILD']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Daniel K Cooper, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '803-777-4137',\n",
       "      'email': 'dc47@mailbox.sc.edu'},\n",
       "     {'name': 'Ellen R Siceloff, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'email': 'SICELOFE@mailbox.sc.edu'}],\n",
       "    'locations': [{'facility': 'University of South Carolina',\n",
       "      'city': 'Columbia',\n",
       "      'state': 'South Carolina',\n",
       "      'zip': '29208',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Daniel K Cooper, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '803-777-4137',\n",
       "        'email': 'dc47@mailbox.sc.edu'}],\n",
       "      'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT05843253',\n",
       "    'orgStudyIdInfo': {'id': 'TarGeT-A'},\n",
       "    'organization': {'fullName': \"Nationwide Children's Hospital\",\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Study of Ribociclib and Everolimus in HGG and DIPG',\n",
       "    'officialTitle': 'PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-04',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2028-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2034-05-30', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2023-04-20',\n",
       "    'studyFirstSubmitQcDate': '2023-05-02',\n",
       "    'studyFirstPostDateStruct': {'date': '2023-05-06', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-04-11',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-04-12', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': \"Nationwide Children's Hospital\",\n",
       "     'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'Novartis', 'class': 'INDUSTRY'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': True,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The goal of this study is to determine the efficacy of the study drugs ribociclib and\\r\\neverolimus to treat pediatric and young adult patients newly diagnosed with a high-grade\\r\\nglioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle,\\r\\nPI3K/mTOR) that these drugs target.\\r\\n\\r\\nThe main question the study aims to answer is whether the combination of ribociclib and\\r\\neverolimus can prolong the life of patients diagnosed with HGG, including DIPG.',\n",
       "    'detailedDescription': 'This is a multicenter, international, phase II study of post-radiotherapy (RT)\\r\\ncombination of ribociclib and everolimus to treat pediatric, adolescent, and young adult\\r\\npatients newly diagnosed with HGG and DIPG that harbor alterations of the cell cycle\\r\\nand/or PI3K/mTOR pathways to assess treatment efficacy (Part 2). The study will include a\\r\\nfeasibility cohort (Part 1) to identify the dose of ribociclib PfOS (Powder for Oral\\r\\nSuspension) that is safe and tolerable in combination with everolimus. Efficacy for Part\\r\\n2 study will be defined by progression-free survival (PFS; HGG [stratum A]) and Overall\\r\\nSurvival (OS; DIPG [stratum B]), with key longitudinal biomarker correlatives. Outcomes\\r\\namong patients with primary thalamic, spinal cord, and/or secondary (radiation related)\\r\\nHGG (strata C) will be descriptively analyzed. Objective radiographic response rates and\\r\\nagent-specific toxicities will also be assessed, with a feasibility cohort to determine\\r\\nthe recommended phase II dose (RP2D) of the combination of ribociclib and everolimus in\\r\\npatients with metastatic disease who received upfront craniospinal irradiation (stratum\\r\\nD).\\r\\n\\r\\nProtocol therapy with the maintenance combination of ribociclib and everolimus must begin\\r\\nno later than 35 calendar days post-completion of RT. The earliest patients can begin\\r\\nprotocol treatment is 28 calendar days post-completion of RT. Each cycle will be 28 days\\r\\nin duration and treatment can continue up to a total of 26 cycles. Ribociclib will be\\r\\ngiven orally once daily for 3 weeks (days 1-21), with one week off. Everolimus will be\\r\\ngiven orally daily continuously (days 1-28).'},\n",
       "   'conditionsModule': {'conditions': ['High Grade Glioma',\n",
       "     'Diffuse Intrinsic Pontine Glioma',\n",
       "     'Anaplastic Astrocytoma',\n",
       "     'Glioblastoma',\n",
       "     'Glioblastoma Multiforme',\n",
       "     'Diffuse Midline Glioma, H3 K27M-Mutant',\n",
       "     'Metastatic Brain Tumor',\n",
       "     'WHO Grade III Glioma',\n",
       "     'WHO Grade IV Glioma']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['PHASE2'],\n",
       "    'designInfo': {'allocation': 'NON_RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Ribociclib and Everolimus',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Stratum A (n=40)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients with localized, intracranial, non-pontine, and non-thalamic HGG (who do not meet\\r\\ncriteria for strata B, C, or D).',\n",
       "      'interventionNames': ['Drug: Ribociclib', 'Drug: Everolimus']},\n",
       "     {'label': 'Stratum B (n=40)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients with DIPG, defined as a tumor with pontine epicenter and diffuse involvement of\\r\\nat least 2/3 of the pons, with histopathology consistent with diffuse WHO grade 2-4\\r\\nglioma (e.g., diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, H3K27-altered\\r\\ndiffuse midline glioma).',\n",
       "      'interventionNames': ['Drug: Ribociclib', 'Drug: Everolimus']},\n",
       "     {'label': 'Stratum C (n=6-12)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients with primary thalamic, spinal cord, and/or secondary (radiation-related) HGG.',\n",
       "      'interventionNames': ['Drug: Ribociclib', 'Drug: Everolimus']},\n",
       "     {'label': 'Stratum D (n=6-12)',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients with metastatic/disseminated HGG, multifocal HGG, and/or gliomatosis cerebri who\\r\\nreceived craniospinal irradiation.',\n",
       "      'interventionNames': ['Drug: Ribociclib', 'Drug: Everolimus']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Ribociclib',\n",
       "      'description': 'Ribociclib PO qd on days 1-21',\n",
       "      'armGroupLabels': ['Stratum A (n=40)',\n",
       "       'Stratum B (n=40)',\n",
       "       'Stratum C (n=6-12)',\n",
       "       'Stratum D (n=6-12)'],\n",
       "      'otherNames': ['Kisqali']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Everolimus',\n",
       "      'description': 'Everolimus PO qd on days 1-28',\n",
       "      'armGroupLabels': ['Stratum A (n=40)',\n",
       "       'Stratum B (n=40)',\n",
       "       'Stratum C (n=6-12)',\n",
       "       'Stratum D (n=6-12)'],\n",
       "      'otherNames': ['Afinitor']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Progression-Free Survival (PFS) in HGG (Part 2, Stratum A)',\n",
       "      'description': 'To assess the efficacy of ribociclib and everolimus in pediatric and young adult patients\\r\\nnewly diagnosed with HGG by estimating the distribution of PFS compared to\\r\\nmolecularly-stratified and matched historical controls.',\n",
       "      'timeFrame': 'From date on treatment until date of Progressive Disease or death due to any cause or date of last follow-up, assessed up to 60 months'},\n",
       "     {'measure': 'Overall Survival (OS) in DIPG (Part 2, Stratum B)',\n",
       "      'description': 'To assess the efficacy of ribociclib and everolimus in pediatric and young adult patients\\r\\nnewly diagnosed with DIPG by estimating the distribution of OS compared to\\r\\nmolecularly-stratified and matched historical controls.',\n",
       "      'timeFrame': 'From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months'},\n",
       "     {'measure': 'Establish MTD and RP2D of ribociclib and everolimus (Part 2, Stratum D)',\n",
       "      'description': 'To identify the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of the\\r\\ncombination of ribociclib and everolimus given to patients with metastatic HGG who have\\r\\nreceived craniospinal irradiation CSI.',\n",
       "      'timeFrame': 'Completion of Cycle 1 (28 days)'},\n",
       "     {'measure': 'Number of participants with ribociclib and everolimus-related adverse events as assessed by CTCAE v5.0 (Part 1- initial feasibility study)',\n",
       "      'description': 'Identify the safe dose of ribociclib powder for oral solution (PfOS) formulation in\\r\\ncombination with everolimus that is feasible in pediatric patients with newly-diagnosed\\r\\nHGG, including DIPG, with cell cycle and/or PI3K/mTOR pathway alterations. This will be\\r\\nachieved by calculating the number of participants with, as well as frequency and\\r\\nseverity of, ribociclib and everolimus-related Adverse Events as assessed by CTCAE v5.0\\r\\nin the first 6-12 patients enrolled',\n",
       "      'timeFrame': 'Completion of Cycle 1 (28 days)'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Overall Survival in HGG',\n",
       "      'description': 'Determine distribution of OS for pediatric and young adult patients newly-diagnosed with\\r\\nHGG which harbor cell cycle and/or PI3K/mTOR pathway alterations treated with post-RT\\r\\nribociclib and everolimus.',\n",
       "      'timeFrame': 'From date on treatment until date of death due to any cause or date of last follow-up, assessed up to 60 months'},\n",
       "     {'measure': 'Objective Response Rate (ORR) in HGG',\n",
       "      'description': 'Evaluate the radiographic objective response rate (ORR) defined as complete response (CR)\\r\\n+ partial response (PR) in pediatric and young adult patients newly diagnosed with HGG\\r\\ntreated with the combination of ribociclib and everolimus.',\n",
       "      'timeFrame': 'From Day 1 of protocol treatment through 30 days following end of protocol treatment'},\n",
       "     {'measure': 'Objective Response Rate (ORR) in DIPG',\n",
       "      'description': 'Evaluate the radiographic objective response rate (ORR) defined as complete response (CR)\\r\\n+ partial response (PR) in pediatric and young adult patients newly diagnosed with DIPG\\r\\ntreated with the combination of ribociclib and everolimus.',\n",
       "      'timeFrame': 'From Day 1 of protocol treatment through 30 days following end of protocol treatment'},\n",
       "     {'measure': 'Number of participants with ribociclib and everolimus-related adverse events as assessed by CTCAE v5.0',\n",
       "      'description': 'Assess and further characterize the safety and toxicity of post-RT combination of\\r\\nribociclib and everolimus in pediatric and young adult patients newly diagnosed with HGG,\\r\\nincluding DIPG. This will be achieved by calculating the number of participants with, as\\r\\nwell as frequency and severity of, ribociclib and everolimus-related Adverse Events as\\r\\nassessed by CTCAE v5.0.',\n",
       "      'timeFrame': 'From Day 1 of protocol treatment through 30 days following end of protocol treatment'},\n",
       "     {'measure': 'Evaluate Health-Related Quality of Life Outcomes',\n",
       "      'description': 'Evaluate health-related quality of life outcomes of pediatric and young adult patients\\r\\nnewly-diagnosed with HGG, including DIPG, treated with combination of ribociclib and\\r\\neverolimus, by patient and/or parent reporting at key timepoints in therapy using the\\r\\npatient reported outcomes measurement information system (PROMIS) survey.',\n",
       "      'timeFrame': 'At the end of Cycles 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 (each cycle is 28 days)'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': \"TarGeT-A study strata definitions Part1: Initial Feasibility Study for the combination of\\r\\nribociclib PfOS formulation with everolimus: Enrollment on this cohort will be limited to\\r\\npatients aged <21 years with primary intracranial localized HGG and DIPG\\r\\n\\r\\nPart 2\\r\\n\\r\\n  -  Stratum A: Patients with localized, intracranial, non-pontine, and non-thalamic HGG\\r\\n     (who do not meet criteria for strata C-D)\\r\\n\\r\\n  -  Stratum B: Patients with DIPG\\r\\n\\r\\n  -  Stratum C: Patients with primary thalamic, spinal cord, and/or\\r\\n     secondary/radiation-related HGG.\\r\\n\\r\\n  -  Stratum D: Patients with metastatic/disseminated HGG, multifocal HGG, and/or\\r\\n     gliomatosis cerebri who received CSI.\\r\\n\\r\\nInclusion Criteria:\\r\\n\\r\\n  1. Inclusion criteria already met to enroll on TarGeT-SCR (central molecular and\\r\\n     histopathologic screening) based on:\\r\\n\\r\\n     1.1) Age: patients must be ≥12 months and ≤39 years of age at the time of enrollment\\r\\n     on TarGeT-SCR. For the Part 1 Initial Feasibility Cohort only: patients must be <21\\r\\n     years of age at the time of enrollment on this protocol.\\r\\n\\r\\n     1.2) Diagnosis: patients with newly-diagnosed HGG, including DIPG are eligible. All\\r\\n     patients must have tumor tissue from diagnostic biopsy or resection, without\\r\\n     exceptions. The diagnosis of HGG, including DIPG, must have been confirmed through\\r\\n     TarGeT-SCR:\\r\\n\\r\\n       -  For the diagnosis of DIPG, patients must have a tumor with pontine epicenter\\r\\n          and diffuse involvement of at least 2/3 of the pons, with histopathology,\\r\\n          consistent with diffuse WHO grade 2-4 glioma\\r\\n\\r\\n       -  All other HGGs must be WHO grade 3 or 4.\\r\\n\\r\\n     1.3) Disease status: There are no disease status requirements for enrollment\\r\\n\\r\\n       -  Patients without measurable disease are eligible.\\r\\n\\r\\n       -  Patients with metastatic or multifocal disease or gliomatosis cerebri who\\r\\n          received upfront CSI are eligible\\r\\n\\r\\n       -  Patients with a primary spinal HGG are eligible\\r\\n\\r\\n       -  Patients with secondary, radiation-related HGG are eligible.\\r\\n\\r\\n  2. Inclusion criteria for assignment to TarGeT-A, for all strata:\\r\\n\\r\\n2.1) Presence of at least one relevant actionable somatic alteration, detailed here:\\r\\n\\r\\n  -  Pathogenic alterations presumed to cause activation of cell cycle:\\r\\n\\r\\n  -  Amplification of CDK4 or CDK6\\r\\n\\r\\n  -  Deletion of CDKN2A, CDKN2B, or CDKN2C\\r\\n\\r\\n  -  Amplification of CCND1 or CCND2\\r\\n\\r\\n  -  Pathogenic alterations presumed to cause activation of the PI3K/mTOR pathway:\\r\\n\\r\\n  -  Deletion or mutation of PTEN\\r\\n\\r\\n  -  Mutation or amplification of PIK3CA\\r\\n\\r\\n  -  Mutation of PIK3R1\\r\\n\\r\\n  -  Patients with evidence of homozygous (biallelic) RB1 loss by sequencing are excluded\\r\\n     from this treatment protocol (TarGeT-A).\\r\\n\\r\\n  -  Patients whose tumors harbor other alterations suspected to activate the cell cycle\\r\\n     and/or PI3K/mTOR pathway could potentially also be eligible, but only following\\r\\n     consensus recommendation by the international multidisciplinary molecular screening\\r\\n     committee.\\r\\n\\r\\n2.2) Performance Level: Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50\\r\\nfor patients ≤ 16 years of ag. Patients who are unable to walk because of paralysis, but\\r\\nwho are up in a wheelchair, will be considered ambulatory for the purpose of assessing\\r\\nthe performance score.\\r\\n\\r\\n2.3) Prior Therapy for HGG:\\r\\n\\r\\n  -  Surgery, RT, dexamethasone are permissible. Temozolomide administered concurrently\\r\\n     with RT is permissible but discouraged. No other prior anticancer therapy for HGG\\r\\n     will be allowed.\\r\\n\\r\\n  -  Patients must have received photon or proton RT.\\r\\n\\r\\n  -  Patients must have started RT within 31 calendar days of initial diagnosis defined\\r\\n     as the date of diagnostic biopsy or resection. If a patient underwent 2 upfront\\r\\n     surgeries (e.g., biopsy then resection or debulking), this is the date of the second\\r\\n     surgery.\\r\\n\\r\\n  -  RT delivered via photon or proton beam, must have been administered at a standard\\r\\n     dose including (54 Gy in 30 fractions for DIPG, 59.4 Gy in 33 fractions or 54-60 Gy\\r\\n     in 30 fractions for other HGG), 45 Gy-50.4 Gy for primary spinal disease, and/or 36\\r\\n     Gy-39.6 Gy craniospinal for patients with spinal or leptomeningeal metastatic\\r\\n     disease with supplemental boost to 45-54 Gy for metastasis within the thecal sac and\\r\\n     54 Gy-60 Gy for intracranial metastasis). Any variances in the radiotherapy dose\\r\\n     within 10% of the standard doses outlined above will be discussed with the\\r\\n     Sponsor-Investigator to confirm eligibility prior to study enrollment.\\r\\n\\r\\n  -  Patients must enroll and start treatment No later than 35 calendar days\\r\\n     post-completion of RT. The earliest patients can begin protocol treatment is 28\\r\\n     calendar days post-completion of RT.\\r\\n\\r\\n2.4) Organ Function Requirements\\r\\n\\r\\n2.4.1) Adequate Bone Marrow Function Defined as:\\r\\n\\r\\n  -  Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3\\r\\n\\r\\n  -  Platelet count ≥ 100,000/mm3 (transfusion independent, defined as not receiving\\r\\n     platelet transfusions for at least 7 days prior to enrollment)\\r\\n\\r\\n  -  Hemoglobin >8 g/dL (may be transfused)\\r\\n\\r\\n2.4.2) Adequate Renal Function Defined as:\\r\\n\\r\\n  -  Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 OR\\r\\n\\r\\n  -  Maximum serum creatinine based on (Schwartz et al. J. Peds, 106:522, 1985)\\r\\n     age/gender as follows: 1 to < 2 years=0.6 mg/dL for males and females; 2 to < 6\\r\\n     years=0.8 mg/dL for males and females; 6 to < 10 years= 1.0 mg/dL for males and\\r\\n     females; 10 to < 13 years=1.2 mg/dL for males and females. 13 to < 16 years=1.5\\r\\n     mg/dL for males and 1.4 mg/dL for females.\\r\\n\\r\\n2.4.3) Adequate Liver Function Defined as:\\r\\n\\r\\n  -  Total bilirubin must be ≤ 1.5 times institutional upper limit of normal for age\\r\\n\\r\\n  -  AST(SGOT)/ALT(SGPT) ≤ 3 times institutional upper limit of normal\\r\\n\\r\\n  -  Serum albumin ≥ 2g/dL\\r\\n\\r\\n2.4.4) Adequate Cardiac Function Defined as:\\r\\n\\r\\n  -  Ejection fraction of ≥ 50% by echocardiogram\\r\\n\\r\\n  -  QTc ≤ 450 msec (by Bazett formula)\\r\\n\\r\\n2.4.5) Adequate Neurologic Function Defined as: Patients with seizure disorder may be\\r\\nenrolled if well-controlled on anticonvulsants that are not strong inducers or inhibitors\\r\\nof CYP3A4/5.\\r\\n\\r\\n2.4.6) Adequate Pulmonary Function Defined as: No evidence of dyspnea at rest, and a\\r\\npulse oximetry >94% on room air if there is clinical indication for determination.\\r\\n\\r\\n2.5) Informed Consent: All patients and/or their parents or legally authorized\\r\\nrepresentatives must sign a written informed consent. Assent, when appropriate, will be\\r\\nobtained according to institutional guidelines\\r\\n\\r\\n2.6) Contraception: Male and female patients of childbearing potential must be willing to\\r\\nuse a highly effective contraception method.\\r\\n\\r\\nExclusion Criteria\\r\\n\\r\\n  1. Pregnant or Breast-Feeding Pregnant or breast-feeding women will not be entered on\\r\\n     this study due to known potential risks of fetal and teratogenic adverse events as\\r\\n     seen in animal/human studies. Pregnancy tests must be obtained in girls who are\\r\\n     post-menarchal. Patients of childbearing or child fathering potential must agree to\\r\\n     use at least one highly effective method of contraception while being treated on\\r\\n     this study and for 3 months after completing therapy. A woman is considered of\\r\\n     childbearing potential if she is fertile, following menarche and until becoming\\r\\n     post-menopausal unless permanently sterile. A postmenopausal state is defined as no\\r\\n     menses for 12 months without an alternative medical cause. A high follicle\\r\\n     stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a\\r\\n     post-menopausal state in women not using hormonal contraception or hormonal\\r\\n     replacement therapy. However, in the absence of 12 months of amenorrhea, a single\\r\\n     FSH measurement is insufficient. A man is considered fertile after puberty unless\\r\\n     permanently sterile by bilateral orchidectomy. Male participants should refrain from\\r\\n     sperm donation throughout the duration of treatment and for 3 months after\\r\\n     completion of therapy\\r\\n\\r\\n     A highly effective contraception method is defined as one that results in a low\\r\\n     failure rate (<1% per year) when used consistently and correctly. The following are\\r\\n     considered highly effective contraception methods:\\r\\n\\r\\n       -  Combined estrogen and progesterone containing hormonal contraception associated\\r\\n          with inhibition of ovulation.\\r\\n\\r\\n       -  Progesterone-only hormonal contraception associated with inhibition of\\r\\n          ovulation.\\r\\n\\r\\n       -  Intra Uterine Device (IUD)\\r\\n\\r\\n       -  Intra Uterine hormone releasing system\\r\\n\\r\\n       -  Bilateral tubal occlusion\\r\\n\\r\\n       -  Vasectomized partner\\r\\n\\r\\n       -  Sexual abstinence (avoiding having heterosexual intercourse) The following\\r\\n          contraceptive measures are NOT considered effective\\r\\n\\r\\n       -  Progesterone-only hormonal contraception (birth control pill) that that does\\r\\n          NOT stop ovulation\\r\\n\\r\\n       -  Male or female condom with or without spermicide\\r\\n\\r\\n       -  Cap, diaphragm or sponge with spermicide\\r\\n\\r\\n  2. Concomitant Medications\\r\\n\\r\\n       -  Patients receiving corticosteroids are eligible. The use of corticosteroids\\r\\n          must be reported.\\r\\n\\r\\n       -  Patients who are currently receiving another investigational drug are not\\r\\n          eligible.\\r\\n\\r\\n       -  Patients who are currently receiving other anti-cancer agents are not eligible,\\r\\n          with the exception of temozolomide given concurrently with RT only.\\r\\n\\r\\n       -  Patients who are receiving enzyme inducing anticonvulsants that are strong\\r\\n          inducers or inhibitors of CYP3A4/5 are not eligible.\\r\\n\\r\\n       -  Patients who are receiving strong inducers or inhibitors of CYP3A4/5 are not\\r\\n          eligible and should be avoided from 14 days prior to enrollment to the end of\\r\\n          the study.\\r\\n\\r\\n       -  Patients who are receiving medications known to prolong QTc interval are not\\r\\n          eligible.\\r\\n\\r\\n       -  Patients who are receiving therapeutic anticoagulation with warfarin or other\\r\\n          coumadin-derived anticoagulants are not eligible. Therapy with heparin, low\\r\\n          molecular weight heparin (LMWH), or fondaparinux is allowed as long as the\\r\\n          patient has adequate coagulation defined as aPTT < 1.5Xs ULN and INR < 1.5.\\r\\n\\r\\n  3. Patients who have an uncontrolled infection are not eligible.\\r\\n\\r\\n  4. Patients who, in the opinion of the investigator, may not be able to comply with the\\r\\n     safety monitoring requirements of the study are not eligible.\\r\\n\\r\\n  5. Patients with known clinically significant active malabsorption syndrome or other\\r\\n     condition that could affect absorption are not eligible.\\r\\n\\r\\n  6. Patients with prior or ongoing clinically significant medical or psychiatric\\r\\n     condition that, in the investigator's opinion, could affect the safety of the\\r\\n     subject, or could impair the assessment of study results are not eligible.\",\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '12 Months',\n",
       "    'maximumAge': '39 Years',\n",
       "    'stdAges': ['CHILD', 'ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Leonie Mikael, PhD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '16147223284',\n",
       "      'email': 'leonie.mikael@nationwidechildrens.org'}],\n",
       "    'overallOfficials': [{'name': 'Margot Lazow, MD',\n",
       "      'affiliation': \"Nationwide Children's Hospital\",\n",
       "      'role': 'STUDY_CHAIR'},\n",
       "     {'name': 'Maryam Fouladi, MD',\n",
       "      'affiliation': \"Nationwide Children's Hospital\",\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}],\n",
       "    'locations': [{'facility': \"Children's Hospital Colorado\",\n",
       "      'city': 'Aurora',\n",
       "      'state': 'Colorado',\n",
       "      'zip': '80045',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kathleen Dorris, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '720-777-8314',\n",
       "        'email': 'kathleen.dorris@childrenscolorado.org'}],\n",
       "      'geoPoint': {'lat': 39.72943, 'lon': -104.83192}},\n",
       "     {'facility': \"Children's National Medical Center\",\n",
       "      'city': 'Washington',\n",
       "      'state': 'District of Columbia',\n",
       "      'zip': '20010',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Eugene Hwang, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '202-476-5046',\n",
       "        'email': 'ehwang@childrensnational.org'}],\n",
       "      'geoPoint': {'lat': 38.89511, 'lon': -77.03637}},\n",
       "     {'facility': \"Ann & Robert H. Lurie Children's Hospital of Chicago\",\n",
       "      'city': 'Chicago',\n",
       "      'state': 'Illinois',\n",
       "      'zip': '60611',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Ashley Plant, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '312-227-4090',\n",
       "        'email': 'Aplant@luriechildrens.org'}],\n",
       "      'geoPoint': {'lat': 41.85003, 'lon': -87.65005}},\n",
       "     {'facility': 'Dana-Farber Cancer Institute',\n",
       "      'city': 'Boston',\n",
       "      'state': 'Massachusetts',\n",
       "      'zip': '02215',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Susan Chi, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '617-632-4386',\n",
       "        'email': 'Susan_chi@dfci.harvard.edu'}],\n",
       "      'geoPoint': {'lat': 42.35843, 'lon': -71.05977}},\n",
       "     {'facility': 'Duke University Health System',\n",
       "      'city': 'Durham',\n",
       "      'state': 'North Carolina',\n",
       "      'zip': '27708',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'David Ashley, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '919-681-3824',\n",
       "        'email': 'david.ashley@duke.edu'}],\n",
       "      'geoPoint': {'lat': 35.99403, 'lon': -78.89862}},\n",
       "     {'facility': \"Cincinnati Children's Hospital Medical Center\",\n",
       "      'city': 'Cincinnati',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '45229',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Peter de Blank, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '513-517-2068',\n",
       "        'email': 'Peter.deBlank@cchmc.org'}],\n",
       "      'geoPoint': {'lat': 39.12713, 'lon': -84.51435}},\n",
       "     {'facility': \"Nationwide Children's Hospital\",\n",
       "      'city': 'Columbus',\n",
       "      'state': 'Ohio',\n",
       "      'zip': '43235',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Maryam Fouladi, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '614-722-5758',\n",
       "        'email': 'Maryam.fouladi@nationwidechildrens.org'}],\n",
       "      'geoPoint': {'lat': 39.96118, 'lon': -82.99879}},\n",
       "     {'facility': \"Children's Hospital of Philadelphia\",\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19104',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Michael J Fisher, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '215-590-5188',\n",
       "        'email': 'fisherm@email.chop.edu'}],\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}},\n",
       "     {'facility': \"Texas Children's Hospital\",\n",
       "      'city': 'Houston',\n",
       "      'state': 'Texas',\n",
       "      'zip': '77030',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Patricia Baxter, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '832-824-4681',\n",
       "        'email': 'pabaxter@txch.org'}],\n",
       "      'geoPoint': {'lat': 29.76328, 'lon': -95.36327}},\n",
       "     {'facility': \"Seattle Children's Hospital\",\n",
       "      'city': 'Seattle',\n",
       "      'state': 'Washington',\n",
       "      'zip': '98105',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Sarah Leary, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '206-987-2106',\n",
       "        'email': 'sarah.leary@seattlechildrens.org'}],\n",
       "      'geoPoint': {'lat': 47.60621, 'lon': -122.33207}},\n",
       "     {'facility': \"Sydney Children's Hospital\",\n",
       "      'city': 'Randwick',\n",
       "      'state': 'New South Wales',\n",
       "      'zip': '2031',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'David Ziegler, MBBS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61293821730',\n",
       "        'email': 'd.ziegler@unsw.edu.au'}],\n",
       "      'geoPoint': {'lat': -33.91439, 'lon': 151.24895}},\n",
       "     {'facility': \"Queensland Children's Hospital\",\n",
       "      'city': 'South Brisbane',\n",
       "      'state': 'Queensland',\n",
       "      'zip': '4101',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'Tim Hassall, MBBS',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61730683593',\n",
       "        'email': 'tim.hassall@health.qld.gov.au'}],\n",
       "      'geoPoint': {'lat': -27.48034, 'lon': 153.02049}},\n",
       "     {'facility': \"Perth Children's Hospital\",\n",
       "      'city': 'Perth',\n",
       "      'state': 'Western Australia',\n",
       "      'zip': '6000',\n",
       "      'country': 'Australia',\n",
       "      'contacts': [{'name': 'Nick Gottardo, MBChB',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '+61864560241',\n",
       "        'email': 'nick.gottardo@health.wa.gov.au'}],\n",
       "      'geoPoint': {'lat': -31.95224, 'lon': 115.8614}},\n",
       "     {'facility': 'The Hospital for Sick Children (SickKids)',\n",
       "      'city': 'Toronto',\n",
       "      'state': 'Ontario',\n",
       "      'zip': 'M5G1X8',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Eric Bouffet, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '4168137457',\n",
       "        'email': 'eric.bouffet@sickkids.ca'}],\n",
       "      'geoPoint': {'lat': 43.70011, 'lon': -79.4163}},\n",
       "     {'facility': \"Montreal Children's Hospital\",\n",
       "      'city': 'Montréal',\n",
       "      'state': 'Quebec',\n",
       "      'zip': 'H4A3J1',\n",
       "      'country': 'Canada',\n",
       "      'contacts': [{'name': 'Genevieve Legault, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '5144124400',\n",
       "        'phoneExt': '60497',\n",
       "        'email': 'Genevieve.legault4@mcgill.ca'}],\n",
       "      'geoPoint': {'lat': 45.50884, 'lon': -73.58781}},\n",
       "     {'facility': \"Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)\",\n",
       "      'city': 'Heidelberg',\n",
       "      'state': 'Baden-Württemberg',\n",
       "      'zip': '69120',\n",
       "      'country': 'Germany',\n",
       "      'contacts': [{'name': 'Olaf Witt, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '0496221423570',\n",
       "        'email': 'o.witt@kitz-heidelberg.de'}],\n",
       "      'geoPoint': {'lat': 49.40768, 'lon': 8.69079}},\n",
       "     {'facility': 'Princess Máxima Center',\n",
       "      'city': 'Utrecht',\n",
       "      'zip': '3720',\n",
       "      'country': 'Netherlands',\n",
       "      'contacts': [{'name': 'Jasper van der Lugt, MD, PhD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '31 6 18559694',\n",
       "        'email': 'D.G.vanVuurden@prinsesmaximacentrum.nl'}],\n",
       "      'geoPoint': {'lat': 52.09083, 'lon': 5.12222}},\n",
       "     {'facility': 'Great Ormond Street Hospital',\n",
       "      'city': 'London',\n",
       "      'zip': 'WC1N 3JH',\n",
       "      'country': 'United Kingdom',\n",
       "      'contacts': [{'name': 'Darren Hargrave, MD',\n",
       "        'role': 'CONTACT',\n",
       "        'phone': '02078138525',\n",
       "        'email': 'darren.hargrave@nhs.net'}],\n",
       "      'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000005909',\n",
       "      'term': 'Glioblastoma'},\n",
       "     {'id': 'D000005910', 'term': 'Glioma'},\n",
       "     {'id': 'D000001254', 'term': 'Astrocytoma'},\n",
       "     {'id': 'D000080443', 'term': 'Diffuse Intrinsic Pontine Glioma'}],\n",
       "    'ancestors': [{'id': 'D000018302', 'term': 'Neoplasms, Neuroepithelial'},\n",
       "     {'id': 'D000017599', 'term': 'Neuroectodermal Tumors'},\n",
       "     {'id': 'D000009373', 'term': 'Neoplasms, Germ Cell and Embryonal'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009380', 'term': 'Neoplasms, Nerve Tissue'},\n",
       "     {'id': 'D000001932', 'term': 'Brain Neoplasms'},\n",
       "     {'id': 'D000016543', 'term': 'Central Nervous System Neoplasms'},\n",
       "     {'id': 'D000009423', 'term': 'Nervous System Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000001927', 'term': 'Brain Diseases'},\n",
       "     {'id': 'D000002493', 'term': 'Central Nervous System Diseases'},\n",
       "     {'id': 'D000009422', 'term': 'Nervous System Diseases'},\n",
       "     {'id': 'D000020295', 'term': 'Brain Stem Neoplasms'},\n",
       "     {'id': 'D000015192', 'term': 'Infratentorial Neoplasms'}],\n",
       "    'browseLeaves': [{'id': 'M9019',\n",
       "      'name': 'Glioblastoma',\n",
       "      'asFound': 'Glioblastoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M9020',\n",
       "      'name': 'Glioma',\n",
       "      'asFound': 'Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5209', 'name': 'Brain Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M2159',\n",
       "      'name': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'asFound': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M4561',\n",
       "      'name': 'Astrocytoma',\n",
       "      'asFound': 'Anaplastic Astrocytoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M20446',\n",
       "      'name': 'Neoplasms, Neuroepithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M19845', 'name': 'Neuroectodermal Tumors', 'relevance': 'LOW'},\n",
       "     {'id': 'M20388',\n",
       "      'name': 'Neuroectodermal Tumors, Primitive',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12318',\n",
       "      'name': 'Neoplasms, Germ Cell and Embryonal',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12325', 'name': 'Neoplasms, Nerve Tissue', 'relevance': 'LOW'},\n",
       "     {'id': 'M18937',\n",
       "      'name': 'Central Nervous System Neoplasms',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12367', 'name': 'Nervous System Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M5742',\n",
       "      'name': 'Central Nervous System Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M22108', 'name': 'Brain Stem Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M17898', 'name': 'Infratentorial Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'T2518',\n",
       "      'name': 'Glioblastoma',\n",
       "      'asFound': 'Glioblastoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T2519',\n",
       "      'name': 'Glioma',\n",
       "      'asFound': 'Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T1865',\n",
       "      'name': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'asFound': 'Diffuse Intrinsic Pontine Glioma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T364',\n",
       "      'name': 'Anaplastic Astrocytoma',\n",
       "      'asFound': 'Anaplastic Astrocytoma',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4092', 'name': 'Neuroepithelioma', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC10', 'name': 'Nervous System Diseases'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000068338',\n",
       "      'term': 'Everolimus'}],\n",
       "    'ancestors': [{'id': 'D000091203', 'term': 'MTOR Inhibitors'},\n",
       "     {'id': 'D000047428', 'term': 'Protein Kinase Inhibitors'},\n",
       "     {'id': 'D000004791', 'term': 'Enzyme Inhibitors'},\n",
       "     {'id': 'D000045504',\n",
       "      'term': 'Molecular Mechanisms of Pharmacological Action'},\n",
       "     {'id': 'D000007166', 'term': 'Immunosuppressive Agents'},\n",
       "     {'id': 'D000007155', 'term': 'Immunologic Factors'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'},\n",
       "     {'id': 'D000000970', 'term': 'Antineoplastic Agents'}],\n",
       "    'browseLeaves': [{'id': 'M255',\n",
       "      'name': 'Everolimus',\n",
       "      'asFound': 'Criteria',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M21960', 'name': 'Sirolimus', 'relevance': 'LOW'},\n",
       "     {'id': 'M353695', 'name': 'Temsirolimus', 'relevance': 'LOW'},\n",
       "     {'id': 'M2827', 'name': 'MTOR Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M25820', 'name': 'Protein Kinase Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'},\n",
       "     {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'},\n",
       "     {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06419777',\n",
       "    'orgStudyIdInfo': {'id': 'iRISID-2024-2999'},\n",
       "    'organization': {'fullName': 'Thomas Jefferson University',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes',\n",
       "    'officialTitle': 'Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Glucometer Use - A Randomized Control Trial (START1)',\n",
       "    'acronym': 'START 1'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-09',\n",
       "    'studyFirstSubmitQcDate': '2024-05-14',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-14',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Thomas Jefferson University', 'class': 'OTHER'},\n",
       "    'collaborators': [{'name': 'University of Rochester', 'class': 'OTHER'}]},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The aim of our study is to compare neonatal and maternal outcomes using different\\r\\nthresholds for the initiation and titration of pharmacotherapy for gestational diabetes\\r\\n(GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is\\r\\ndefined as two abnormal values or more over a one-week period (two fasting values\\r\\nelevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial\\r\\nvalue elevated), whereas the permissive threshold is defined as 50% of values elevated\\r\\nover 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall\\r\\nvalues).',\n",
       "    'detailedDescription': 'Pregnancy is a state of insulin resistance to ensure that the growing fetus has ample\\r\\nnutrition. Gestational Diabetes (GDM) develops in pregnant patients with pancreatic\\r\\ndysfunction that leads to impairment of glucose tolerance.\\r\\n\\r\\nVarious studies have examined the benefit of treatment for GDM, including the 2005\\r\\nAustralian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) and the 2009 Landon\\r\\net al randomized controlled trials. These studies found that treatment was associated\\r\\nwith a significant reduction in newborn complications of perinatal death, shoulder\\r\\ndystocia, large for gestational age infants, cesarean delivery, and birth trauma. The\\r\\nspecific threshold value for initiation and up-titration of medical therapy is unknown.\\r\\nLack of evidence leads to a wide variation in clinical practice of pharmacological\\r\\ninitiation and titration for GDM. A systematic review and meta-analysis by Caissutti in\\r\\n2019 analyzed criteria for initiating pharmacotherapy for GDM and noted the following: 12\\r\\nof 15 trials initiated pharmacotherapy after 1-2 abnormal values over 1-2 weeks, 2\\r\\nstudies initiated pharmacotherapy after 50% of overall values were abnormal, and 1 study\\r\\ninitiated pharmacotherapy after 30% of overall values were abnormal. However, there have\\r\\nbeen no randomized controlled trials of head-to-head comparison of different thresholds.\\r\\n\\r\\nThe aim of our study is to compare neonatal and maternal outcomes using different\\r\\nthresholds for the initiation and titration of pharmacotherapy for gestational diabetes.\\r\\nOur goal is to compare a strict and relaxed threshold. The strict threshold is defined as\\r\\ntwo abnormal values or more over a one week period (two fasting values elevated, two of\\r\\nthe same post prandial values elevated, or 1 fasting and 1 post prandial value elevated),\\r\\nwhereas the relaxed threshold is defined as 50% of values elevated over 1 week (50% of\\r\\noverall fasting values, 50% of postprandial values, or 50% of overall values).'},\n",
       "   'conditionsModule': {'conditions': ['Gestational Diabetes',\n",
       "     'Pregnancy Related'],\n",
       "    'keywords': ['gestational diabetes',\n",
       "     'pregnancy',\n",
       "     'insulin',\n",
       "     'Initiation of medication']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'TREATMENT',\n",
       "     'maskingInfo': {'masking': 'NONE'}},\n",
       "    'enrollmentInfo': {'count': 430, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Strict Arm',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The strict threshold is defined as two abnormal values or more over a one-week period\\r\\n(two fasting values elevated, two of the same post prandial values elevated, or 1 fasting\\r\\nand 1 post prandial value elevated)',\n",
       "      'interventionNames': ['Drug: Insulin']},\n",
       "     {'label': 'Permissive',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'The permissive threshold is defined as 50% of values elevated over 1 week (50% of overall\\r\\nfasting values, 50% of postprandial values, or 50% of overall values).',\n",
       "      'interventionNames': ['Drug: Insulin']}],\n",
       "    'interventions': [{'type': 'DRUG',\n",
       "      'name': 'Insulin',\n",
       "      'description': 'Insulin will be used in gestational diabetics to control blood glucose levels',\n",
       "      'armGroupLabels': ['Permissive', 'Strict Arm'],\n",
       "      'otherNames': ['Lantus', 'Lispro', 'NPH', 'Levemir', 'Humalog']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Neonatal Composite Outcome',\n",
       "      'description': 'neonatal composite including the following measures: large for gestational age (LGA) of\\r\\nneonate defined as birth weight >90th percentile for gestational age using the Fenton\\r\\ngrowth chart, hypoglycemia o defined as glucose <40 mg/dL <48 hours after birth or\\r\\nglucose, hyperbilirubinemia, stillbirth or neonatal death, birth trauma',\n",
       "      'timeFrame': 'First 28 days of birth'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Neonatal Outcome: Gestational Age of Birth',\n",
       "      'description': 'Gestational age at delivery in weeks and days',\n",
       "      'timeFrame': 'Delivery Time'},\n",
       "     {'measure': 'Neonatal Outcome: APGAR Score',\n",
       "      'description': 'Scoring system provided a standardized assessment for infants after delivery from 0-10',\n",
       "      'timeFrame': 'At 1 minute of life and at 5 min of life'},\n",
       "     {'measure': 'Neonatal Outcome: Birthweight',\n",
       "      'description': 'Birthweight in grams, Macrosomia (birthweight >4000g, Small for gestational age (<10th\\r\\npercentile based on Fenton Growth Charts)',\n",
       "      'timeFrame': 'Delivery Time'},\n",
       "     {'measure': 'Neonatal Outcome: Brachial Plexus Injury',\n",
       "      'description': 'Brachial plexus nerves in neonate are torn, stretched, or compressed at delivery',\n",
       "      'timeFrame': 'Delivery Time'},\n",
       "     {'measure': 'Neonatal Outcome: Respiratory distress',\n",
       "      'description': 'Breathing difficulties after birth requiring supplemental oxygen, mask, intubation,\\r\\nand/or surfactant',\n",
       "      'timeFrame': 'Within first 24 hours after delivery'},\n",
       "     {'measure': 'Neonatal Outcome: Admission to Neonatal intensive Care Unit',\n",
       "      'description': 'Admission to neonatal intensive care unit (NICU)',\n",
       "      'timeFrame': 'From delivery to discharge from NICU'},\n",
       "     {'measure': 'Maternal Outcomes: Maternal hypoglycemia',\n",
       "      'description': 'Maternal episode of hypoglycemia < 60 mg/dL throughout the pregnancy',\n",
       "      'timeFrame': 'Initiation of insulin to delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Shoulder Dystocia',\n",
       "      'description': \"An obstetric emergency where the anterior fetal shoulder becomes stuck on the maternal\\r\\npubic symphysis, delaying the birth of the baby's body.\",\n",
       "      'timeFrame': 'At Delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Obstetric anal sphincter injury (OASIS)',\n",
       "      'description': '3rd degree and 4th degree perineal injuries',\n",
       "      'timeFrame': 'At Delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Operative Delivery',\n",
       "      'description': 'Vacuum-assisted and Forcep-assisted vaginal Delivery',\n",
       "      'timeFrame': 'At Delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Cesarean Delivery',\n",
       "      'description': 'Cesarean birth',\n",
       "      'timeFrame': 'At Delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Postpartum hemorrhage',\n",
       "      'description': 'Defined as cumulative blood loss ≥1000 mL, or bleeding associated with signs/symptoms of\\r\\nhypovolemia within 24 hours of the birth process',\n",
       "      'timeFrame': 'Within 24 hours of delivery'},\n",
       "     {'measure': 'Maternal Outcomes: Hypertensive Disorders of Pregnancy',\n",
       "      'description': 'Hypertensive disorders of pregnancy: gestational hypertension, Preeclampsia without\\r\\nsevere features, Pre-eclampsia with severe features, severe range blood pressures defined\\r\\nas (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg),\\r\\nsymptoms of central nervous dysfunction, thrombocytopenia with Platelet count <100,000\\r\\nplatelets/microL, hepatic abnormalities, kidney impairment, and or pulmonary edema',\n",
       "      'timeFrame': 'From gestational age of 20 weeks during pregnancy to 6 weeks postpartum'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Live, non-anomalous fetus\\r\\n\\r\\n  -  Literacy in English, Spanish, Mandarin, or Arabic\\r\\n\\r\\n  -  Patients are also required to provide consent, demonstrate an understanding of the\\r\\n     purpose of the study, and agree to the study protocol.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  <18 years at EDD\\r\\n\\r\\n  -  pre-existing diabetes or diagnosis of GDM before 24 weeks\\r\\n\\r\\n  -  multi-fetal gestation\\r\\n\\r\\n  -  known major fetal anomaly\\r\\n\\r\\n  -  known allergy to insulin\\r\\n\\r\\n  -  chronic maternal corticosteroid use\\r\\n\\r\\n  -  diagnosis of GDM based on finger sticks alone\\r\\n\\r\\n  -  patients who have contraindication to oral glucose tolerance test\\r\\n\\r\\n  -  a primary language other than English, Spanish, Mandarin, or Arabic',\n",
       "    'healthyVolunteers': True,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Kavisha Khanuja, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '215-955-5000',\n",
       "      'email': 'kxk334@jefferson.edu'},\n",
       "     {'name': 'Rodney McLaren Jr, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '215-955-5000',\n",
       "      'email': 'rodney.mclaren@jefferson.edu'}],\n",
       "    'locations': [{'facility': 'University of Rochester Medical Center',\n",
       "      'city': 'Rochester',\n",
       "      'state': 'New York',\n",
       "      'zip': '14642',\n",
       "      'country': 'United States',\n",
       "      'geoPoint': {'lat': 43.15478, 'lon': -77.61556}},\n",
       "     {'facility': 'Thomas Jefferson University',\n",
       "      'city': 'Philadelphia',\n",
       "      'state': 'Pennsylvania',\n",
       "      'zip': '19107',\n",
       "      'country': 'United States',\n",
       "      'contacts': [{'name': 'Kavisha Khanuja, MD', 'role': 'CONTACT'},\n",
       "       {'name': 'Rodney McLaren, MD', 'role': 'CONTACT'}],\n",
       "      'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}]},\n",
       "   'referencesModule': {'references': [{'pmid': '31424780',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Quintanilla Rodriguez BS, Mahdy H. Gestational Diabetes. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK545196/'},\n",
       "     {'pmid': '21288502',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol. 2011 Jun;204(6):479-87. doi: 10.1016/j.ajog.2010.11.039. Epub 2011 Feb 2.'},\n",
       "     {'pmid': '35877134',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Gregory EC, Ely DM. Trends and Characteristics in Gestational Diabetes: United States, 2016-2020. Natl Vital Stat Rep. 2022 Jul;71(3):1-15.'},\n",
       "     {'pmid': '21078733',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Metzger BE, Persson B, Lowe LP, Dyer AR, Cruickshank JK, Deerochanawong C, Halliday HL, Hennis AJ, Liley H, Ng PC, Coustan DR, Hadden DR, Hod M, Oats JJ, Trimble ER; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome study: neonatal glycemia. Pediatrics. 2010 Dec;126(6):e1545-52. doi: 10.1542/peds.2009-2257. Epub 2010 Nov 15.'},\n",
       "     {'pmid': '29370047',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018 Feb;131(2):e49-e64. doi: 10.1097/AOG.0000000000002501.'},\n",
       "     {'pmid': '15951574',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. doi: 10.1056/NEJMoa042973. Epub 2005 Jun 12.'},\n",
       "     {'pmid': '19797280',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009 Oct 1;361(14):1339-48. doi: 10.1056/NEJMoa0902430.'},\n",
       "     {'pmid': '23712381',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013 Jul 16;159(2):123-9. doi: 10.7326/0003-4819-159-2-201307160-00661.'},\n",
       "     {'pmid': '34000260',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Davitt C, Flynn KE, Harrison RK, Pan A, Palatnik A. Current practices in gestational diabetes mellitus diagnosis and management in the United States: survey of maternal-fetal medicine specialists. Am J Obstet Gynecol. 2021 Aug;225(2):203-204. doi: 10.1016/j.ajog.2021.04.263. Epub 2021 May 14. No abstract available.'},\n",
       "     {'pmid': '29125636',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Caissutti C, Saccone G, Ciardulli A, Berghella V. Very tight vs. tight control: what should be the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy? Evidence from randomized controlled trials. Acta Obstet Gynecol Scand. 2018 Mar;97(3):235-247. doi: 10.1111/aogs.13257. Epub 2017 Dec 14.'},\n",
       "     {'pmid': '33308193',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Harrison RK, Cruz M, Wong A, Davitt C, Palatnik A. The timing of initiation of pharmacotherapy for women with gestational diabetes mellitus. BMC Pregnancy Childbirth. 2020 Dec 11;20(1):773. doi: 10.1186/s12884-020-03449-y.'},\n",
       "     {'pmid': '8598962',\n",
       "      'type': 'RESULT',\n",
       "      'citation': \"Landy HJ, Gomez-Marin O, O'Sullivan MJ. Diagnosing gestational diabetes mellitus: use of a glucose screen without administering the glucose tolerance test. Obstet Gynecol. 1996 Mar;87(3):395-400. doi: 10.1016/0029-7844(95)00460-2.\"},\n",
       "     {'pmid': '27054932',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Harper LM, Mele L, Landon MB, Carpenter MW, Ramin SM, Reddy UM, Casey B, Wapner RJ, Varner MW, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Caritis SN, Sorokin Y, Peaceman AM, Tolosa JE; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Carpenter-Coustan Compared With National Diabetes Data Group Criteria for Diagnosing Gestational Diabetes. Obstet Gynecol. 2016 May;127(5):893-898. doi: 10.1097/AOG.0000000000001383.'},\n",
       "     {'pmid': '27182178',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Blum AK. Insulin Use in Pregnancy: An Update. Diabetes Spectr. 2016 May;29(2):92-7. doi: 10.2337/diaspect.29.2.92. Erratum In: Diabetes Spectr. 2016 Aug;29(3):191.'},\n",
       "     {'pmid': '23601190',\n",
       "      'type': 'RESULT',\n",
       "      'citation': 'Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 2013 Apr 20;13:59. doi: 10.1186/1471-2431-13-59.'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'NO'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000016640',\n",
       "      'term': 'Diabetes, Gestational'},\n",
       "     {'id': 'D000003920', 'term': 'Diabetes Mellitus'}],\n",
       "    'ancestors': [{'id': 'D000044882', 'term': 'Glucose Metabolism Disorders'},\n",
       "     {'id': 'D000008659', 'term': 'Metabolic Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000011248', 'term': 'Pregnancy Complications'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'}],\n",
       "    'browseLeaves': [{'id': 'M19012',\n",
       "      'name': 'Diabetes, Gestational',\n",
       "      'asFound': 'Gestational Diabetes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M7115',\n",
       "      'name': 'Diabetes Mellitus',\n",
       "      'asFound': 'Diabetes',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M25403',\n",
       "      'name': 'Glucose Metabolism Disorders',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'}]},\n",
       "   'interventionBrowseModule': {'meshes': [{'id': 'D000007328',\n",
       "      'term': 'Insulin'},\n",
       "     {'id': 'D000061268', 'term': 'Insulin Lispro'},\n",
       "     {'id': 'D000069057', 'term': 'Insulin Detemir'}],\n",
       "    'ancestors': [{'id': 'D000007004', 'term': 'Hypoglycemic Agents'},\n",
       "     {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}],\n",
       "    'browseLeaves': [{'id': 'M10365',\n",
       "      'name': 'Insulin',\n",
       "      'asFound': 'Day 1',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'},\n",
       "     {'id': 'M29802',\n",
       "      'name': 'Insulin Lispro',\n",
       "      'asFound': 'Spectroscopy',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M349',\n",
       "      'name': 'Insulin Detemir',\n",
       "      'asFound': 'Military',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M347', 'name': 'Insulin Glargine', 'relevance': 'LOW'},\n",
       "     {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06438445',\n",
       "    'orgStudyIdInfo': {'id': 'Interventional'},\n",
       "    'organization': {'fullName': 'Universidade Federal Fluminense',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Effects of Royal Jelly Supplementation in Chronic Kidney Disease',\n",
       "    'officialTitle': 'Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2024-12-05', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-05-27',\n",
       "    'studyFirstSubmitQcDate': '2024-05-27',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'},\n",
       "    'lastUpdateSubmitDate': '2024-05-27',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-31', 'type': 'ESTIMATED'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Universidade Federal Fluminense',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': False,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': 'The objective of this study is to evaluate the effects of royal jelly on inflammation and\\r\\ncellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).',\n",
       "    'detailedDescription': 'Royal jelly is a substance produced in the hypopharyngeal glands of bees that operate\\r\\nyoung, and rich in bioactive compounds such as polyphenols, free fatty acids and\\r\\nexclusive peptides capable of mitigating inflammation and premature aging (genomic\\r\\ninstability, mitochondrial dysfunction, shortening of telomeres) existing in patients\\r\\nwith chronic kidney disease (CKD) on hemodialysis. However, to date there are no studies\\r\\nevaluating the effects of royal jelly on such complications in patients with RDC.\\r\\nObjectives: To evaluate the effects of royal jelly on inflammation and cellular\\r\\nsenescence in patients with CKD. Methods: Clinical, longitudinal, randomized study, with\\r\\nwashout and crossover period. Patients with CKD on HD received 140 mL bottles containing\\r\\npropolis and turmeric, and were instructed to take 10 mL/day (dosing cup), containing a\\r\\ndose equivalent to 110 mg/day of standardized green propolis extract (EPP-AF) plus 130 mg\\r\\nof curcuminoids/day or placebo for 8 weeks. After this supplementation, patients will\\r\\nenter the washout period (8 weeks) and after this period, the intervention group will\\r\\nreceive placebo and vice versa. The collection of biological material (blood and feces)\\r\\nwill be done before and after each study period. The mRNA expression of the transcription\\r\\nfactors Nrf2 and NF-κB, as well as their target genes, antioxidant enzymes, inflammatory\\r\\ncytokines and the expression of genes and proteins that modulate the protein will be\\r\\nevaluated using rtPCR, western blotting and assay methods. multiplex. Uremic toxins from\\r\\nthe intestinal microbiota such as indoxyl sulfate (IS), p-cresyl sulfate (p-CS) and\\r\\nIndole-3-acetic acid (IAA) will be confirmed by HPLC and plasma lipopolysaccharide (LPS)\\r\\nlevels will be analyzed by ELISA. The determination of antioxidant capacity will be\\r\\ndetermined by the FRAP, ORAC AND DPPH methods. The analysis of the composition of the\\r\\nintestinal microbiota will be evaluated by high-throughput sequencing of the V4-V5 region\\r\\nof the 16S ribosomal RNA gene. Nutritional status and dietary intake will also be\\r\\nassessed.'},\n",
       "   'conditionsModule': {'conditions': ['Kidney Failure, Chronic',\n",
       "     'Oxidative Stress',\n",
       "     'Hemodialysis'],\n",
       "    'keywords': ['Cellular Senescence',\n",
       "     'Renal Dialysis',\n",
       "     'Renal Insufficiency, Chronic',\n",
       "     'Oxidative Stress']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'primaryPurpose': 'HEALTH_SERVICES_RESEARCH',\n",
       "     'maskingInfo': {'masking': 'QUADRUPLE',\n",
       "      'whoMasked': ['PARTICIPANT',\n",
       "       'CARE_PROVIDER',\n",
       "       'INVESTIGATOR',\n",
       "       'OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Real Jelly Group',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Patients with chronic kidney disease on hemodialysis will receive capsules containing\\r\\n500mg of royal jelly/day for two months.',\n",
       "      'interventionNames': ['Dietary Supplement: Real Jelly']},\n",
       "     {'label': 'Placebo group',\n",
       "      'type': 'PLACEBO_COMPARATOR',\n",
       "      'description': 'Patients with chronic kidney disease on hemodialysis will receive capsules containing\\r\\n500mg of placebo/ day for two months.',\n",
       "      'interventionNames': ['Dietary Supplement: Placebo']}],\n",
       "    'interventions': [{'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Real Jelly',\n",
       "      'description': 'Participants will receive 500mg of royal jelly capsules per day for two months.',\n",
       "      'armGroupLabels': ['Real Jelly Group']},\n",
       "     {'type': 'DIETARY_SUPPLEMENT',\n",
       "      'name': 'Placebo',\n",
       "      'description': 'Participants will receive 500mg of placebo capsules per day for two months.',\n",
       "      'armGroupLabels': ['Placebo group']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in inflammatory biomarkers',\n",
       "      'description': 'The mRNA levels of Nrf2, Keap1, Bach1, NLPR3, NF-kB, HO-1, NQO1, p14, p16, p21 and p53 as\\r\\nwell as VCAM, ICAM and E-selectin and TLR-4, TNFR and AhR receptors will be evaluated\\r\\nfrom peripheral blood mononuclear cells.',\n",
       "      'timeFrame': '6 weeks'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  patients with CKD undergoing hemodialysis for more than 6 months\\r\\n\\r\\n  -  patients with arteriovenous fistula (AVF) as vascular access.\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  pregnant,\\r\\n\\r\\n  -  lactating,\\r\\n\\r\\n  -  smoker\\r\\n\\r\\n  -  patients using antibiotics and antioxidant supplements in the last three months\\r\\n\\r\\n  -  patients with autoimmune and infectious diseases,\\r\\n\\r\\n  -  patients with cancer, liver disease, and AIDS',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'ALL',\n",
       "    'minimumAge': '18 Years',\n",
       "    'maximumAge': '70 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Denise Mafra',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '21985683003',\n",
       "      'email': 'dmafra30@gmail.com'}],\n",
       "    'locations': [{'facility': 'Denise Mafra',\n",
       "      'city': 'Rio de Janeiro',\n",
       "      'state': 'RJ',\n",
       "      'zip': '22260050',\n",
       "      'country': 'Brazil',\n",
       "      'geoPoint': {'lat': -22.90278, 'lon': -43.2075}}]}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000007674',\n",
       "      'term': 'Kidney Diseases'},\n",
       "     {'id': 'D000051436', 'term': 'Renal Insufficiency, Chronic'},\n",
       "     {'id': 'D000051437', 'term': 'Renal Insufficiency'},\n",
       "     {'id': 'D000007676', 'term': 'Kidney Failure, Chronic'}],\n",
       "    'ancestors': [{'id': 'D000014570', 'term': 'Urologic Diseases'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000052801', 'term': 'Male Urogenital Diseases'},\n",
       "     {'id': 'D000002908', 'term': 'Chronic Disease'},\n",
       "     {'id': 'D000020969', 'term': 'Disease Attributes'},\n",
       "     {'id': 'D000010335', 'term': 'Pathologic Processes'}],\n",
       "    'browseLeaves': [{'id': 'M10698',\n",
       "      'name': 'Kidney Diseases',\n",
       "      'asFound': 'Kidney Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26717',\n",
       "      'name': 'Renal Insufficiency, Chronic',\n",
       "      'asFound': 'Chronic Kidney Disease',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M26718',\n",
       "      'name': 'Renal Insufficiency',\n",
       "      'asFound': 'Kidney Failure',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10699',\n",
       "      'name': 'Kidney Failure, Chronic',\n",
       "      'asFound': 'Kidney Failure, Chronic',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M10293', 'name': 'Inflammation', 'relevance': 'LOW'},\n",
       "     {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'},\n",
       "     {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'},\n",
       "     {'id': 'T1303',\n",
       "      'name': 'Chronic Graft Versus Host Disease',\n",
       "      'asFound': 'Chronic',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]},\n",
       "   'interventionBrowseModule': {'browseLeaves': [{'id': 'M14295',\n",
       "      'name': 'Propolis',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T364', 'name': 'Bee Products', 'relevance': 'LOW'}],\n",
       "    'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'},\n",
       "     {'abbrev': 'All', 'name': 'All Drugs and Chemicals'},\n",
       "     {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}},\n",
       "  'hasResults': False},\n",
       " {'protocolSection': {'identificationModule': {'nctId': 'NCT06386887',\n",
       "    'orgStudyIdInfo': {'id': 'CASE1824'},\n",
       "    'organization': {'fullName': 'Case Comprehensive Cancer Center',\n",
       "     'class': 'OTHER'},\n",
       "    'briefTitle': 'Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer',\n",
       "    'officialTitle': 'The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer'},\n",
       "   'statusModule': {'statusVerifiedDate': '2024-05',\n",
       "    'overallStatus': 'NOT_YET_RECRUITING',\n",
       "    'expandedAccessInfo': {'hasExpandedAccess': False},\n",
       "    'startDateStruct': {'date': '2024-05-30', 'type': 'ESTIMATED'},\n",
       "    'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'},\n",
       "    'completionDateStruct': {'date': '2026-01-01', 'type': 'ESTIMATED'},\n",
       "    'studyFirstSubmitDate': '2024-04-15',\n",
       "    'studyFirstSubmitQcDate': '2024-04-24',\n",
       "    'studyFirstPostDateStruct': {'date': '2024-04-26', 'type': 'ACTUAL'},\n",
       "    'lastUpdateSubmitDate': '2024-05-16',\n",
       "    'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}},\n",
       "   'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'},\n",
       "    'leadSponsor': {'name': 'Case Comprehensive Cancer Center',\n",
       "     'class': 'OTHER'}},\n",
       "   'oversightModule': {'oversightHasDmc': True,\n",
       "    'isFdaRegulatedDrug': False,\n",
       "    'isFdaRegulatedDevice': False},\n",
       "   'descriptionModule': {'briefSummary': \"The goal of this clinical trial is to see if timed fasting (periods of time that you\\r\\ndon't eat) in participants who are receiving chemotherapy prior to surgery is achievable,\\r\\nsafe and can improve quality of life, symptoms and outcomes (results) compared to\\r\\nparticipants who receive standard dietary recommendations in individuals being treated\\r\\nfor epithelial ovarian cancer . The main questions it aims to answer are:\\r\\n\\r\\n  -  Is it feasible to use intermittent fasting during neoadjuvant chemotherapy?\\r\\n\\r\\n  -  Is it safe to use intermittent fasting during neoadjuvant chemotherapy?\\r\\n\\r\\n  -  Do participants find it acceptable to use intermittent fasting during neoadjuvant\\r\\n     chemotherapy?\\r\\n\\r\\nResearchers will compare participants who receive standard dietary recommendations to see\\r\\nwhich method is more achievable, safe, and able to improve quality of life, symptoms and\\r\\noutcomes.\\r\\n\\r\\nParticipants will:\\r\\n\\r\\n  -  Receive either the fasting intervention (schedule of times when you do not eat) or\\r\\n     standard diet recommendations for 6-9 weeks prior to your surgery starting with the\\r\\n     second cycle of chemotherapy.\\r\\n\\r\\n  -  All participants will be asked to complete chemotherapy and surgery, cancer imaging,\\r\\n     baseline screening tests, nutritional assessments, food diaries, blood tests, and\\r\\n     surveys about wellbeing.\\r\\n\\r\\n  -  Participants in the intervention group will be asked to follow a fasting schedule\\r\\n     that consists of not eating for 16 hours a day followed by normal eating for the\\r\\n     remaining 8 hours of the day for 5 days in a row followed by 2 days of regular\\r\\n     eating each week.\",\n",
       "    'detailedDescription': 'The quality of diet can affect the biology of cancer. For example, evidence implies a\\r\\nhigh fat/ Western diet may impose adverse events on ovarian cancer outcomes, and the\\r\\npotential that the gut microbiome alterations secondary to dietary changes may impact\\r\\ntumor responsiveness to treatment and outcomes. This study seeks to clarify the effect of\\r\\ndietary intervention on the tumor and gut microbiome and ovarian cancer biology. The\\r\\nobjectives of this study include:\\r\\n\\r\\n  -  Primary: To test the feasibility and safety of IF during neoadjuvant chemotherapy\\r\\n     (including effects on body composition)\\r\\n\\r\\n  -  Secondary: To measure the effects of IF on participant reported outcomes,\\r\\n     chemotherapy toxicity and quality of life.\\r\\n\\r\\n  -  Exploratory: To test the effect of IF on pathologic response, systemic inflammatory\\r\\n     and immune responses, microbial diversity and metabolic pathway alterations.'},\n",
       "   'conditionsModule': {'conditions': ['Epithelial Ovarian Cancer'],\n",
       "    'keywords': ['Short term fasting',\n",
       "     'Intermittent fasting',\n",
       "     'Intermittent energy restriction (IER)',\n",
       "     'Fasting mimicking diet (FMD)']},\n",
       "   'designModule': {'studyType': 'INTERVENTIONAL',\n",
       "    'phases': ['NA'],\n",
       "    'designInfo': {'allocation': 'RANDOMIZED',\n",
       "     'interventionModel': 'PARALLEL',\n",
       "     'interventionModelDescription': 'Two arm, randomized, controlled study.',\n",
       "     'primaryPurpose': 'SUPPORTIVE_CARE',\n",
       "     'maskingInfo': {'masking': 'SINGLE',\n",
       "      'maskingDescription': \"Participants' cross-sectional skeletal muscle areas will be measured. Measurements will\\r\\nbe performed on CT scans obtained within 4-6 weeks of treatment initiation (with a 7-day\\r\\nscreening window) by a fellowship-trained, experienced radiologist and imaging specialist\\r\\nin consensus who will be blinded to participant clinical variables and treatment.\",\n",
       "      'whoMasked': ['OUTCOMES_ASSESSOR']}},\n",
       "    'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}},\n",
       "   'armsInterventionsModule': {'armGroups': [{'label': 'Intermittent Fasting',\n",
       "      'type': 'EXPERIMENTAL',\n",
       "      'description': 'Participants will receive 16 hours of fasting, 8 hour regular feeding for 5 days a week\\r\\nstarting 2 days prior to chemotherapy.',\n",
       "      'interventionNames': ['Behavioral: Intermittent Fasting',\n",
       "       'Drug: Neoadjuvant chemotherapy']},\n",
       "     {'label': 'Standard of Care',\n",
       "      'type': 'ACTIVE_COMPARATOR',\n",
       "      'description': 'Participants will receive standard of care dietary recommendations and will provide a\\r\\n3-day diet diary at study enrollment and during cycles 2 and 3.',\n",
       "      'interventionNames': ['Drug: Neoadjuvant chemotherapy']}],\n",
       "    'interventions': [{'type': 'BEHAVIORAL',\n",
       "      'name': 'Intermittent Fasting',\n",
       "      'description': 'Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16\\r\\nhours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum\\r\\nfeeding for 2 days has been proposed. With this type of intervention, there are no\\r\\ndietary restrictions to the type or quality of food and it decreased daily energy intake\\r\\nby 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of\\r\\ncontinuous fasting per day for 5 days a week. This will be started 2 days prior to\\r\\nchemotherapy (cycle 2).',\n",
       "      'armGroupLabels': ['Intermittent Fasting'],\n",
       "      'otherNames': ['Time restricted eating']},\n",
       "     {'type': 'DRUG',\n",
       "      'name': 'Neoadjuvant chemotherapy',\n",
       "      'description': 'Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for\\r\\n3 to 4 cycles per routine care. As chemotherapy is not part of this research study,\\r\\nparticipants will begin standard chemotherapy as decided by their physician.',\n",
       "      'armGroupLabels': ['Intermittent Fasting', 'Standard of Care']}]},\n",
       "   'outcomesModule': {'primaryOutcomes': [{'measure': 'Intermittent fasting compliance as measured by serum glucose laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (serum glucose) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Day 1 of cycle 1 (each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by ketone laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (ketone) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Day 1 of cycle 1 (each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by IGF-1 laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (IGF-1) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Day 1 of cycle 1 (each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by insulin laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (insulin) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Day 1 of cycle 1 (each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by serum glucose laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (serum glucose) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by ketone laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (ketone) prior to each chemotherapy. which will be measured\\r\\nby metabolic laboratory tests (serum glucose, ketone, IGF-1, and insulin) prior to each\\r\\nchemotherapy.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by IGF-1 laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (IGF-1) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by insulin laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (insulin) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by serum glucose laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (serum glucose) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by ketone laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (ketone) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by IGF-1 laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (IGF-1) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by insulin laboratory testing',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby metabolic laboratory tests (insulin) prior to each chemotherapy.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by self-reported assessment',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby a self-reported compliance checklist assessment.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by self-reported assessment',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\nby a self-reported compliance checklist assessment.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by food diary',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\na 3-food diary submitted during each dietitian in person visit.',\n",
       "      'timeFrame': 'Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by food diary',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\na 3-food diary submitted during each dietitian in person visit.',\n",
       "      'timeFrame': 'Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Intermittent fasting compliance as measured by food diary',\n",
       "      'description': 'Participants will be assessed for intermittent fasting compliance which will be measured\\r\\na 3-food diary submitted during each dietitian in person visit.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'Pre body composition',\n",
       "      'description': 'Pre- and post- treatment body composition will be assessed by Computed Tomography scans.',\n",
       "      'timeFrame': 'Baseline'},\n",
       "     {'measure': 'Post body composition',\n",
       "      'description': 'Pre- and post- treatment body composition will be assessed by Computed Tomography scans.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'}],\n",
       "    'secondaryOutcomes': [{'measure': 'Chemotherapy related toxicity at Cycle 2',\n",
       "      'description': 'Participants will undergo evaluation of chemotherapy related toxicity (according to\\r\\nCommon Terminology Criteria for Adverse Events [CTCAE version 5.0]).',\n",
       "      'timeFrame': 'Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Chemotherapy related toxicity at Cycle 3',\n",
       "      'description': 'Participants will undergo evaluation of chemotherapy related toxicity (according to\\r\\nCommon Terminology Criteria for Adverse Events [CTCAE version 5.0]).',\n",
       "      'timeFrame': 'Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Chemotherapy related toxicity at Cycle 4',\n",
       "      'description': 'Participants that undergo an additional cycle of chemotherapy will undergo evaluation of\\r\\nchemotherapy related toxicity (according to Common Terminology Criteria for Adverse\\r\\nEvents [CTCAE version 5.0]).',\n",
       "      'timeFrame': 'Week 9 (At day 1 of cycle 4; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'Chemotherapy related toxicity at post treatment',\n",
       "      'description': 'Participants will undergo evaluation of chemotherapy related toxicity (according to\\r\\nCommon Terminology Criteria for Adverse Events [CTCAE version 5.0]),',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'ESAS Score at Enrollment',\n",
       "      'description': 'Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS) at\\r\\nenrollment. The ESAS assesses pain, tiredness, nausea, depression, anxiety, drowsiness,\\r\\nappetite, wellbeing, and shortness of breath. Responses are scored to produce a physical\\r\\ncomponent summary and a mental component summary on a scale from 0 to 100, with higher\\r\\nscores indicative of better functional status.',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'ESAS Score at Cycle 2',\n",
       "      'description': 'Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS\\r\\nassesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing,\\r\\nand shortness of breath. Responses are scored to produce a physical component summary and\\r\\na mental component summary on a scale from 0 to 100, with higher scores indicative of\\r\\nbetter functional status.',\n",
       "      'timeFrame': 'Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'ESAS Score at Cycle 3',\n",
       "      'description': 'Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS\\r\\nassesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing,\\r\\nand shortness of breath. Responses are scored to produce a physical component summary and\\r\\na mental component summary on a scale from 0 to 100, with higher scores indicative of\\r\\nbetter functional status.',\n",
       "      'timeFrame': 'Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'ESAS Score at Post Treatment',\n",
       "      'description': 'Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS\\r\\nassesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing,\\r\\nand shortness of breath. Responses are scored to produce a physical component summary and\\r\\na mental component summary on a scale from 0 to 100, with higher scores indicative of\\r\\nbetter functional status.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'SF-125 Score at Baseline',\n",
       "      'description': 'Participants will complete Study Short Form-12 Health Survey (SF-125) at enrollment. The\\r\\nSF-12 measures physical and mental health status. Responses are scored to produce a\\r\\nphysical component summary and a mental component summary on a scale from 0 to 100, with\\r\\nhigher scores indicative of better functional status.',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'SF-125 Score at Cycle 2',\n",
       "      'description': 'Participants will complete Study Short Form-12 Health Survey (SF-125) day 1 cycle 2. The\\r\\nSF-12 measures physical and mental health status. Responses are scored to produce a\\r\\nphysical component summary and a mental component summary on a scale from 0 to 100, with\\r\\nhigher scores indicative of better functional status.',\n",
       "      'timeFrame': 'Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'SF-125 Score at Cycle 3',\n",
       "      'description': 'Participants will complete Study Short Form-12 Health Survey (SF-125) day 1 cycle 3. The\\r\\nSF-12 measures physical and mental health status. Responses are scored to produce a\\r\\nphysical component summary and a mental component summary on a scale from 0 to 100, with\\r\\nhigher scores indicative of better functional status.',\n",
       "      'timeFrame': 'Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'SF-125 Score at Post Treatment',\n",
       "      'description': 'Participants will complete Study Short Form-12 Health Survey (SF-125) post treatment. The\\r\\nSF-12 measures physical and mental health status. Responses are scored to produce a\\r\\nphysical component summary and a mental component summary on a scale from 0 to 100, with\\r\\nhigher scores indicative of better functional status.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'Pre Quality of Life (QLQ-C30) Score at Baseline',\n",
       "      'description': 'Quality of life questionnaires will be distributed at enrollment and will be compared\\r\\nbetween IF and control groups. Quality of life will be measured by Quality of life will\\r\\nbe measured with the European Organization for Research and Treatment of Cancer (EORTC)\\r\\nQuality of Life Questionnaire (QLQ-C30). EORTC QLQ-C30 is a 30 item questionnaire. Higher\\r\\nscore represents a higher (\"better\") level of functioning, or a higher (\"worse\") level of\\r\\nsymptoms.',\n",
       "      'timeFrame': 'At baseline'},\n",
       "     {'measure': 'Post Quality of Life (QLQ-C30) Score Post Treatment',\n",
       "      'description': 'Quality of life questionnaires will be distributed at enrollment and will be compared\\r\\nbetween IF and control groups. Quality of life will be measured by Quality of life will\\r\\nbe measured with the European Organization for Research and Treatment of Cancer (EORTC)\\r\\nQuality of Life Questionnaire (QLQ-C30). EORTC QLQ-C30 is a 30 item questionnaire. Higher\\r\\nscore represents a higher (\"better\") level of functioning, or a higher (\"worse\") level of\\r\\nsymptoms.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'Pre Functional Assessment (FACT-O) Score at Baseline',\n",
       "      'description': 'Functional Assessment of Cancer Therapy- Ovarian (FACT-O) will be administered post\\r\\ntreatment and will be compared between IF and control groups. FACT-O is a 39 item\\r\\nquestionnaire with a 5 point Likert-type scale. Scores range from 0-156. The higher the\\r\\nscore, the better the quality of life.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'Post Functional Assessment (FACT-O) Score Post Treatment',\n",
       "      'description': 'Functional Assessment of Cancer Therapy- Ovarian (FACT-O) will be administered at\\r\\nenrollment and will be compared between IF and control groups. FACT-O is a 39 item\\r\\nquestionnaire with a 5 point Likert-type scale. Scores range from 0-156. The higher the\\r\\nscore, the better the quality of life.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'},\n",
       "     {'measure': 'AIM Survey Score at Cycle 2',\n",
       "      'description': 'Acceptability of intervention Measure (AIM) questionnaire will be administered IF\\r\\nparticipants. AIM has 4 item psychometric assessment times measuring acceptability of\\r\\nintervention. Scale values range from 1 to 5. Overall scores that are lower indicating\\r\\nlower acceptability, and higher scores indicating greater acceptability, appropriateness,\\r\\nand feasibility.',\n",
       "      'timeFrame': 'Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'AIM Survey Score at Cycle 3',\n",
       "      'description': 'Acceptability of intervention Measure (AIM) questionnaire will be administered IF\\r\\nparticipants. AIM has 4 item psychometric assessment times measuring acceptability of\\r\\nintervention. Scale values range from 1 to 5. Overall scores that are lower indicating\\r\\nlower acceptability, and higher scores indicating greater acceptability, appropriateness,\\r\\nand feasibility.',\n",
       "      'timeFrame': 'Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)'},\n",
       "     {'measure': 'AIM Survey Score at Post Treatment',\n",
       "      'description': 'Acceptability of intervention Measure (AIM) questionnaire will be administered IF\\r\\nparticipants. AIM has 4 item psychometric assessment times measuring acceptability of\\r\\nintervention. Scale values range from 1 to 5. Overall scores that are lower indicating\\r\\nlower acceptability, and higher scores indicating greater acceptability, appropriateness,\\r\\nand feasibility.',\n",
       "      'timeFrame': 'Up to 12 weeks post intervention'}]},\n",
       "   'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\r\\n\\r\\n  -  Age 18 years and above\\r\\n\\r\\n  -  Participants with confirmed diagnosis of epithelial ovarian cancer (EOC) by internal\\r\\n     cytologic or histologic evaluation (including fallopian tube and primary peritoneal\\r\\n     cancer)\\r\\n\\r\\n  -  Participant who had undergone laparoscopic evaluation or laparotomy for diagnosis\\r\\n     but did not proceed with surgical debulking\\r\\n\\r\\n  -  Participants with stage III or IV EOC planned to undergo NACT or already receiving\\r\\n     NACT (cycle 1)\\r\\n\\r\\n  -  Any invasive ovarian cancer histology\\r\\n\\r\\n  -  Normal cognitive function\\r\\n\\r\\nExclusion Criteria:\\r\\n\\r\\n  -  Age <18 years\\r\\n\\r\\n  -  Malignant complete or partial bowel obstruction confirmed on imaging.\\r\\n\\r\\n  -  Participants unable to provide informed consent.\\r\\n\\r\\n  -  BMI <18\\r\\n\\r\\n  -  Participants diagnosed with severe malnutrition as assessed by study dietitian\\r\\n\\r\\n  -  Type I diabetes on insulin\\r\\n\\r\\n  -  Absence of pretreatment CT abdomen and pelvis imaging or >4-6 weeks between imaging\\r\\n     and cycle 1 of chemotherapy.',\n",
       "    'healthyVolunteers': False,\n",
       "    'sex': 'FEMALE',\n",
       "    'minimumAge': '18 Years',\n",
       "    'stdAges': ['ADULT', 'OLDER_ADULT']},\n",
       "   'contactsLocationsModule': {'centralContacts': [{'name': 'Mariam AlHilli, MD',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '(216) 445-8090',\n",
       "      'email': 'ALHILLM@ccf.org'},\n",
       "     {'name': 'Jackie Ludwig',\n",
       "      'role': 'CONTACT',\n",
       "      'phone': '216 390-2492',\n",
       "      'email': 'ludwigj@ccf.org'}],\n",
       "    'overallOfficials': [{'name': 'Mariam AlHilli, MD',\n",
       "      'affiliation': 'The Cleveland Clinic',\n",
       "      'role': 'PRINCIPAL_INVESTIGATOR'}]},\n",
       "   'ipdSharingStatementModule': {'ipdSharing': 'YES',\n",
       "    'description': \"All collected participant data will be shared through publication including clinical\\r\\ndata, laboratory results, CT data, qualitative data (questionnaire's) in additional,\\r\\nmolecular data, histologic data, treatment response after statistical analysis. All data\\r\\nwill be shared without participant identifiers.\",\n",
       "    'timeFrame': 'Anticipated 6-2025 - indefinitely through publication of data'}},\n",
       "  'derivedSection': {'miscInfoModule': {'versionHolder': '2024-05-31'},\n",
       "   'conditionBrowseModule': {'meshes': [{'id': 'D000010051',\n",
       "      'term': 'Ovarian Neoplasms'},\n",
       "     {'id': 'D000077216', 'term': 'Carcinoma, Ovarian Epithelial'}],\n",
       "    'ancestors': [{'id': 'D000004701', 'term': 'Endocrine Gland Neoplasms'},\n",
       "     {'id': 'D000009371', 'term': 'Neoplasms by Site'},\n",
       "     {'id': 'D000009369', 'term': 'Neoplasms'},\n",
       "     {'id': 'D000010049', 'term': 'Ovarian Diseases'},\n",
       "     {'id': 'D000000291', 'term': 'Adnexal Diseases'},\n",
       "     {'id': 'D000005831', 'term': 'Genital Diseases, Female'},\n",
       "     {'id': 'D000052776', 'term': 'Female Urogenital Diseases'},\n",
       "     {'id': 'D000005261',\n",
       "      'term': 'Female Urogenital Diseases and Pregnancy Complications'},\n",
       "     {'id': 'D000091642', 'term': 'Urogenital Diseases'},\n",
       "     {'id': 'D000005833', 'term': 'Genital Neoplasms, Female'},\n",
       "     {'id': 'D000014565', 'term': 'Urogenital Neoplasms'},\n",
       "     {'id': 'D000091662', 'term': 'Genital Diseases'},\n",
       "     {'id': 'D000004700', 'term': 'Endocrine System Diseases'},\n",
       "     {'id': 'D000006058', 'term': 'Gonadal Disorders'},\n",
       "     {'id': 'D000002277', 'term': 'Carcinoma'},\n",
       "     {'id': 'D000009375', 'term': 'Neoplasms, Glandular and Epithelial'},\n",
       "     {'id': 'D000009370', 'term': 'Neoplasms by Histologic Type'}],\n",
       "    'browseLeaves': [{'id': 'M12974',\n",
       "      'name': 'Ovarian Neoplasms',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M1704',\n",
       "      'name': 'Carcinoma, Ovarian Epithelial',\n",
       "      'asFound': 'Epithelial Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'},\n",
       "     {'id': 'M7863', 'name': 'Endocrine Gland Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M12972', 'name': 'Ovarian Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M3643', 'name': 'Adnexal Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M27093',\n",
       "      'name': 'Female Urogenital Diseases',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'},\n",
       "     {'id': 'M8399',\n",
       "      'name': 'Female Urogenital Diseases and Pregnancy Complications',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M8945', 'name': 'Genital Neoplasms, Female', 'relevance': 'LOW'},\n",
       "     {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'},\n",
       "     {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'},\n",
       "     {'id': 'M9163', 'name': 'Gonadal Disorders', 'relevance': 'LOW'},\n",
       "     {'id': 'M12320',\n",
       "      'name': 'Neoplasms, Glandular and Epithelial',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'M12315',\n",
       "      'name': 'Neoplasms by Histologic Type',\n",
       "      'relevance': 'LOW'},\n",
       "     {'id': 'T4352',\n",
       "      'name': 'Ovarian Cancer',\n",
       "      'asFound': 'Ovarian Cancer',\n",
       "      'relevance': 'HIGH'},\n",
       "     {'id': 'T4354',\n",
       "      'name': 'Ovarian Epithelial Cancer',\n",
       "      'asFound': 'Epithelial Ovarian Cancer',\n",
       "      'relevance': 'HIGH'}],\n",
       "    'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'},\n",
       "     {'abbrev': 'BXS',\n",
       "      'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'},\n",
       "     {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'},\n",
       "     {'abbrev': 'All', 'name': 'All Conditions'},\n",
       "     {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}},\n",
       "  'hasResults': False}]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "last_five_years"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Given the comprehensive list of fields available in the ClinicalTrials.gov dataset, we can derive valuable insights for a competitor benchmark analysis. We'll focus on key areas like:\n",
    "\n",
    "- Sponsor Activity: Identify the most active sponsors, their areas of focus (therapeutic areas), and trends in their trial initiations over time.\n",
    "- Study Designs and Phases: Analyze the distribution of study designs (e.g., randomized, observational) and phases (Phase 1, 2, 3) to understand industry trends and competitor strategies.\n",
    "- Therapeutic Areas: Determine the most common therapeutic areas being investigated, highlighting potential areas of high competition or unmet medical needs.\n",
    "- Collaboration Patterns: Examine collaborations between sponsors and other organizations (e.g., academic institutions) to identify potential partnership opportunities or competitive alliances.\n",
    "- Geographic Distribution: Analyze the geographic locations of trial sites to understand where competitors are focusing their research efforts.\n",
    "\n",
    "First it is crucial to identify what is meant by \"Top Sponsor\"\n",
    "\n",
    "In the context of this task, \"top sponsors\" likely refers to the organizations or entities that have initiated (sponsored) the highest number of clinical studies/trials within the specified time frame (the last 5 years).  This metric could be used to identify the most active players in the clinical research landscape, and the insights gained could be valuable for a competitor benchmark analysis.\n",
    "\n",
    "However, there could be some ambiguity in this term. Depending on the specific goals of the competitor benchmark analysis, \"top sponsors\" could also be interpreted in other ways:\n",
    "\n",
    "- Sponsors with the largest trials: Instead of focusing on the number of trials, this interpretation would prioritize sponsors that have initiated trials with the largest number of participants. This could be a relevant metric if the goal is to understand which sponsors are investing in the most extensive research efforts.\n",
    "- Sponsors with the most successful trials: This interpretation would focus on sponsors whose trials have achieved the most positive outcomes, such as FDA approval or publication in major medical journals. This could be a valuable metric if the goal is to identify sponsors with a track record of success in clinical research.\n",
    "\n",
    "Study Populations\n",
    "\n",
    "Therefore we identify 3 study populations:\n",
    "\n",
    "- a) Sponsors with the highest number of trials\n",
    "- b) Sponsors with the largest trials\n",
    "- c) Sponsors with the most successful trials\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
